<SEC-DOCUMENT>0001628280-22-007698.txt : 20220329
<SEC-HEADER>0001628280-22-007698.hdr.sgml : 20220329
<ACCEPTANCE-DATETIME>20220329161333
ACCESSION NUMBER:		0001628280-22-007698
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220329
DATE AS OF CHANGE:		20220329

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		22780923

	BUSINESS ADDRESS:	
		STREET 1:		800 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		650-272-6269

	MAIL ADDRESS:	
		STREET 1:		800 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>advm-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:1a8e5b7c-bca3-4165-b4c0-12c52c6244d9,g:f2d923c2-de02-4da0-a578-7d0cd54aca4d,d:4967880cb16f4a6c939e04bb1dfb040a--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:advm="http://www.adverum.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8wLTEtMS0xLTEyODIy_561d6547-6c3f-4eef-bf28-e4026f8f18c4">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8xLTEtMS0xLTEyODIy_893cb665-b51d-4322-80ba-418d21b97896">2021</ix:nonNumeric><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8yLTEtMS0xLTEyODIy_b42a1d16-5d48-44b4-9db3-4b9a66d80a7a">FY</ix:nonNumeric><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8zLTEtMS0xLTEyODIy_febceb44-b147-4d94-a6d2-5d644a168014">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="i9fac97c217604a89ac8040860830763c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ie4f9e3e52f534877a4e117ef7bb0f6f1_I20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MjY_6080290b-1a2f-4c6f-9319-23bad6204282">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cfd24eb4d89453dbcb821bb7fb4079c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i10ee18cbd41f41fb8035ae70d3ac055b_I20220318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2c917411737449d0a88f9f35170ed838_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53f24fd80d7847a4a109b4930dfa58dd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61bf30013d1447db830bbcf1c0f8e693_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bf0483faf9c4578af16fb35b2fa264f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6e133ae95f4549b3dced0eb367c851_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3feb10512c544b2be5df43808067ffd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1545d1dd80f34ac3aef307e7cbbb2e71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac60871d0b6541e7b3972cd6bb0b694b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a914f1d116d433589863bd5a9a0f6a0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e120d0535d8453791e0f2c600950d30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib98193b039da41878e8829babfad3291_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ca06aba1d444f9692c01566cac96dbe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795d1398d0ed477da363e54fb41ee0b7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ebd7da8b96a4cedad752dba138eb1b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie798bce7c7694970a7f83c3c90201b15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c53c953f5be42b2a5877734d774a767_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c7935b84f04449fac206a423055e6aa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>advm:segment</xbrli:measure></xbrli:unit><xbrli:context id="i9fac97c217604a89ac8040860830763c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib014e00f9b8e44bb9cec4471e9b7458e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d8be49b7bbf4251910929fc132243a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198713b3bc694250846e3c8d7a262676_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e36a17528e246b0ab9dcbede5458fb4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9878b1af9a524eeeaa9c8427214abf99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc2e87b6775540219d86de876645d890_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11aa3c6438434617967b1b14ac83e990_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03259c961d784a7f9273e4d83977e07b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f9e3e52f534877a4e117ef7bb0f6f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd8584c0ea5b463ca366376a46eac4d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9538a71ff1d424989f80b9467a6a448_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3388e01ba0cd4c2bb002f33d9f0729df_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c6315f35b6402d86b1167231385890_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6311b039ae14140ac682b123ba2e20b_D20211101-20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c50a8ce1839401ebdedd41b23664dc7_I20211101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe35d41e331443d948be3c7be2e9ec8_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd7de60f78ff4ca4b73e44e0bed3fb91_I20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64eef970c89427db31b4a0fad29b6a3_I20211026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00fd997b49304a6fb48d58e552aeb8ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4bfec030c89344d68297b3d5723d72af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ebc23bbab6a4b809a58be9b27bc6683_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b342bb0ce1b4ddfbb1fc42da05b8954_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d7cb21878274c689e6a89f1c23e59d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd25a4e655954753968ec44adaaed1c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76e6ddf942cd490c98176b6a38c05c9c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3a06d6569a4f0eb845ce032f5207f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01fe6f2e1c640889f794f6d0cb75b01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i299d93d81b8442fea229100cbe836c75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4372ddfd6eaf4ebdab2698da6339e4ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i966d761db5484ddc9c6cc7e401bba8fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i151723aa80f341a8952a483bb904ee20_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandSeventeenInducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if01574c0aec8441ebcd6ced712437994_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0712c015900b4ee29ae1903994ae8913_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a91a547f88e4a6a81c47e8971ea1f72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18936e5d4e5454ab245e22276a0fb26_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1974c638bb5e4a5990d928e7aecd0c6d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c8c42cfe214c2e915d20a2db5f37ae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675005a96bf84236b0181223cfe2bf55_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55d4e6f877b540b484ca25983cbe7bad_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id078bd5264c44f8d85cbc656e1a30010_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aa1a08442284607a20e7c4f8d0e72b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8988b116ae244c71b22a0159529f37af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i637b2d0774af4daf84893a36dbbffb39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1fca633f724372ab4c9e5aea494549_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31af55d22bfb48c4b7cc961ba70d0f12_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf93b275abc44ef8fb8c54d925edaa0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09580173048e4c7ca33b47016c7728b2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4828bf008756429682ad64a18e6f626a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98df46a84d42486094eb52256840d178_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f92a2c752147398b0b7cb89424a66d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec59229ab7074b74bd212f356c86ea60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92372011da0b4b8d9b3ff9c9bc63cda2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a4cbf761c8a4a17a861b8bf1844e0a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c00f24526d4abea5fca0722e1248a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f8ae5b4a0644993bf5b58e572c9d713_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2ca53fed51a445cbea0844f267402e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib61d35f9c1b7487797a8b6521663d206_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e8bd338962449c9e2411b96b08c1be_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44fcf3a223a1481794c8de42a0377a7a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb6a75db0aa4095bfd093ce5e08bfd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzQ3_b02b7c06-a27d-454d-8d7d-a38545fc1197">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6YThmYTkyMmE0NmQ0NGI1NWIyYzBmNDFlYmQxYjdlZTgvdGFibGVyYW5nZTphOGZhOTIyYTQ2ZDQ0YjU1YjJjMGY0MWViZDFiN2VlOF8wLTAtMS0xLTEyODIy_5c623336-a701-4b76-8185-9252c7888288">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8yNzc_f11b686d-26b1-495a-90b0-d06c3dba7e6e"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8yNzc_a3f7e91a-ecee-4c71-9a72-3c4125ac7d27">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6NWYzNjliYWFhMDRhNDg1NGE5ZTMzYzY0YzRiODhjZWQvdGFibGVyYW5nZTo1ZjM2OWJhYWEwNGE0ODU0YTllMzNjNjRjNGI4OGNlZF8wLTAtMS0xLTEyODIy_fe8f4d3f-9941-49b0-ba93-1d6c6e342584">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYw_2ddf4a96-ab21-4931-8309-62ef17f6569e">001-36579</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:23pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzQ4_337e9429-23cd-4101-81c8-ee36933f8695">Adverum Biotechnologies, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZGIzOTg3NjA2YWYwNDRlYmEwZDIzNjA1MzAzYTMxN2QvdGFibGVyYW5nZTpkYjM5ODc2MDZhZjA0NGViYTBkMjM2MDUzMDNhMzE3ZF8wLTAtMS0xLTEyODIy_e385d4c6-155c-4b30-bea5-cd794f8645da">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZGIzOTg3NjA2YWYwNDRlYmEwZDIzNjA1MzAzYTMxN2QvdGFibGVyYW5nZTpkYjM5ODc2MDZhZjA0NGViYTBkMjM2MDUzMDNhMzE3ZF8wLTEtMS0xLTEyODIy_aa7e217d-ff6c-4372-9622-07139ce287cb">20-5258327</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYx_4103d87d-8bf3-4375-a725-478565d3a0e0">800 Saginaw Drive</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYy_965c48e9-2de0-410d-88c2-53b912223d73">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzU1_e791a271-0966-4c60-9864-4ab6c20fe50c">California</ix:nonNumeric> <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzQ5_80142aa4-69c5-4daf-b3a9-f1461ee12e1a">94063</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzUw_36c0a931-d191-4046-ac2d-a007ba2b5735">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzUz_739b7902-e6b8-4de6-8791-61c5279b4e52">656-9323</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:110%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.301%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6Mjg2YzgxYjNmNWMwNDkzN2FmYTUwZWNiNTlhODYxZmYvdGFibGVyYW5nZToyODZjODFiM2Y1YzA0OTM3YWZhNTBlY2I1OWE4NjFmZl8xLTAtMS0xLTEyODIy_867a0d8f-bbff-41b1-a329-1f6acb065a40">Common Stock, par value $0.0001&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6Mjg2YzgxYjNmNWMwNDkzN2FmYTUwZWNiNTlhODYxZmYvdGFibGVyYW5nZToyODZjODFiM2Y1YzA0OTM3YWZhNTBlY2I1OWE4NjFmZl8xLTItMS0xLTEyODIy_be5a93a1-9c8d-426c-8161-7cde46644adb">ADVM</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6Mjg2YzgxYjNmNWMwNDkzN2FmYTUwZWNiNTlhODYxZmYvdGFibGVyYW5nZToyODZjODFiM2Y1YzA0OTM3YWZhNTBlY2I1OWE4NjFmZl8xLTQtMS0xLTEyODIy_69a9e5dd-651c-4857-91c2-55942ad0ec6d">Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_______________________________________________________________________________</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzE5_504b74b0-e525-4cc8-a849-ab1902b30fb5">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzU2_651b5ecc-4ab6-4915-8d01-f6706aba08ce">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzU3_0f4cb005-1d3b-46b0-8e88-fa2a6c842c46">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYz_b1ec8047-0df2-4078-9b48-4ffa9400b45a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:19.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.354%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6MzZmMzIyZjkwZjI1NGFkYzgxYzNjMzRhMjVjYTg3NDgvdGFibGVyYW5nZTozNmYzMjJmOTBmMjU0YWRjODFjM2MzNGEyNWNhODc0OF8xLTAtMS0xLTE1Njc2_5d5c9648-cd05-4258-80e3-1ae9464a915f">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6MzZmMzIyZjkwZjI1NGFkYzgxYzNjMzRhMjVjYTg3NDgvdGFibGVyYW5nZTozNmYzMjJmOTBmMjU0YWRjODFjM2MzNGEyNWNhODc0OF8xLTMtMS0xLTEyODIy_78313d01-0675-418f-aad7-9cea17993cac">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6MzZmMzIyZjkwZjI1NGFkYzgxYzNjMzRhMjVjYTg3NDgvdGFibGVyYW5nZTozNmYzMjJmOTBmMjU0YWRjODFjM2MzNGEyNWNhODc0OF8yLTMtMS0xLTEyODIy_9109db3e-4bad-449f-b7fb-80a8b35e7283">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzIx_8f73ee7f-20cf-402b-bf3d-8fae2caa1759">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzIz_6f4163f9-5744-4669-a21d-d83f24b6316b">x</ix:nonNumeric></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of June 30, 2021, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="i6cfd24eb4d89453dbcb821bb7fb4079c_I20210630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8zMzgy_b975ec8a-ec54-46f6-aff8-c82423ed942f">320.3</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market on June 30, 2021 of $3.50 per share.&#160;Shares of the registrant&#8217;s common stock held by each officer and director and each person known to the registrant to be affiliated with an officer or director have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of March&#160;18, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i10ee18cbd41f41fb8035ae70d3ac055b_I20220318" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8zODQ4_4442360a-b4bc-40cf-b552-6cfca7179f5e">98,750,717</ix:nonFraction>&#160;shares of common stock, par value $0.0001&#160;par value, outstanding.</span></div><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzI0_3102a100-0670-488a-b633-897018fd74b5" escape="true"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the definitive proxy statement (the Proxy Statement) for the 2022 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K. If the Proxy Statement is not filed by May 2, 2022, then the registrant will file an amendment to this Form 10-K on Form 10-K/A to include the Part III information in this Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Auditor Firm ID:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZjM2MDAyZmUzNjk3NDlkM2I1ZjNiYzU5MjQwYjQ1NmUvdGFibGVyYW5nZTpmMzYwMDJmZTM2OTc0OWQzYjVmM2JjNTkyNDBiNDU2ZV8wLTEtMS0xLTE5MjAz_cc8c786c-81e0-423f-b9cc-5a25105aaa04">42</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Auditor Name:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZjM2MDAyZmUzNjk3NDlkM2I1ZjNiYzU5MjQwYjQ1NmUvdGFibGVyYW5nZTpmMzYwMDJmZTM2OTc0OWQzYjVmM2JjNTkyNDBiNDU2ZV8wLTMtMS0xLTE5MjA1_24877110-0839-4f4c-a8de-042fb99ed384">Ernst &amp; Young, LLP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Auditor Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZjM2MDAyZmUzNjk3NDlkM2I1ZjNiYzU5MjQwYjQ1NmUvdGFibGVyYW5nZTpmMzYwMDJmZTM2OTc0OWQzYjVmM2JjNTkyNDBiNDU2ZV8wLTUtMS0xLTE5MjA3_77b14bed-58be-44e1-abb9-45890d8cb817">San Jose , California, USA</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.757%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_16">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_16">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_19">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_19">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_22">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_22">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_22">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_52">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_52">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_52">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_55">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_55">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_55">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_58">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_58">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_58">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_61">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_61">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_61">69</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_64">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_64">70</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_67">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_67">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_67">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_79">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_76">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_76">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_82">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_82">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_82">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_109">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_109">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_112">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_112">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_112">78</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_187">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_187">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_187">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_190">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_190">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_190">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_193">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_193">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_193">99</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_1797">Disclosure Regarding Foreign Jurisdiction</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_1797">s</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_1797"> that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_1797">99</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_196">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_196">100</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_199">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_199">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_199">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_202">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_202">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_202">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_205">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_205">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_205">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_208">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_208">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_208">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_211">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_211">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_211">100</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_214">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_214">101</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_217">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_217">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_217">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_220">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_220">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_220">104</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_223">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_223">105</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this report, unless otherwise stated or the context otherwise indicates, references to &#8220;Adverum,&#8221; &#8220;Adverum Biotechnologies,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Adverum Biotechnologies, Inc., a Delaware corporation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum, the Adverum logo and other trademarks or service marks of Adverum that may appear in this Annual Report on Form 10-K are the property of Adverum. This Annual Report on Form 10-K contains additional trade names, trademarks, and service marks of other companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum does not intend its use or display of other companies&#8217; trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of Adverum by, these other companies, and all such third-party trade names, trademarks, and service marks are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to advance our viral vector manufacturing and delivery capabilities;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing or likelihood of regulatory submissions, designations and approvals;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our plans to explore potential applications of our gene therapy platform in other indications in ocular and rare diseases;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectations regarding the clinical effectiveness of our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the pricing and reimbursement of our product candidates, if approved;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our expectation regarding the potential market sizes for our product candidates;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intellectual property position;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential benefits of our strategic collaborations and our ability to enter into strategic arrangements;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments and projections relating to our competitors and our industry;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our estimates regarding expenses, future revenue, our financial position, capital requirements, uses of cash and needs for additional financing and the period for which our cash resources will be sufficient to meet our operating requirements; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the safety, efficacy and projected development timeline and commercial potential of any product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed in &#8220;Risk Factors Summary&#8221; below and under the heading &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any forward-looking statement in this Annual Report on Form 10-K reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, industry and future growth. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report on Form 10-K may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_13"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTORS SUMMARY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in common stock involves numerous risks, including the risks described in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K. Below are some of these risks, any one of which could materially adversely affect our business, financial condition, results of operations, and prospects. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to our at-the-market sales agreement, licensing or collaboration arrangements, or acquisitions, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure or perceived failure to comply with existing or future laws, regulations, contracts, self-regulatory schemes, standards, and other obligations related to privacy, data protection, and data security (including security incidents) could harm our business.  Our compliance or the actual or perceived failure to comply with such obligations could increase the costs of our services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART 1.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Business</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. We develop gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector discovery, nonclinical and clinical development, and pre-commercial planning. In addition, we have in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;GMP&#8221;) quality control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, ADVM-022, is a single, in-office intravitreal (&#8220;IVT&#8221;) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (&#8220;VEGF&#8221;) injections. ADVM-022 utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and capable of transducing retinal cells after an in-office IVT injection. This product is intended to improve both real-world vision and quality of life outcomes for patients. ADVM-022 is currently being developed for the treatment of patients with wet age-related macular degeneration (&#8220;wet AMD&#8221;) who are responsive to anti-VEGF therapy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. Age-related macular degeneration (&#8220;AMD&#8221;) is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for ADVM-022 for the treatment of wet AMD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, we initiated the OPTIC trial, designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. We completed enrollment for OPTIC in July 2020 and continue to regularly present updated efficacy, aflibercept protein expression and safety data from the trial out to 2 years and have initiated an extension study to continue to follow our patients for an additional 3 years.  To date, we have seen strong signals of therapeutic efficacy in OPTIC in both the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) and 2 x 10&#94;11 vg/eye (&#8220;2E11&#8221;) doses, with dose-dependent adeno-associated virus (&#8220;AAV&#8221;) associated ocular inflammation that has been responsive to topical corticosteroid therapy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonclinical studies have indicated that a 6 x 10&#94;10 vg/eye (&#8220;6E10&#8221;) dose is expected to achieve therapeutic levels of aflibercept. We are planning to evaluate ADVM-022 at the previously studied 2E11 dose and the new lower 6E10 dose with new enhanced prophylactic steroid regimens, which we anticipate will include local steroids and a combination of local and systemic steroids, in a future Phase 2 clinical trial in wet AMD. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, we initiated the INFINITY trial, a multi-center, Phase 2, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with diabetic macular edema (&#8220;DME&#8221;). A dose limiting toxicity at the 6E11 dose in this diabetic population was identified in April of 2021. Consequently, we are no longer pursing ADVM-022 for DME or at the 6E11 dose in wet AMD. We have not seen similar patient safety concerns in either the 2E11 dose in any of our patients in the INFINITY or OPTIC trials or the 6E11 dose in the OPTIC trial. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunogenicity to AAV therapy has been broadly reported to be associated both with systemic and with ocular gene therapies. Based on an extensive evaluation of data from all of our subjects treated with ADVM-022 and all of our nonclinical data by internal and external experts, we believe new enhanced prophylactic steroid regimens, which we anticipate will include local steroids and a combination of local and systemic steroids, will allow us to minimize inflammation in our trial subjects going forward. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance ADVM-022 for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8.  In January 2022, we announced the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by mutations in either the L or the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM and to our knowledge, no other therapies to treat BCM are in development. We are collaborating with the families of patients affected with BCM to help advance our therapies.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations and financial condition for the year ended December 31, 2021 were not significantly impacted by the COVID-19 pandemic. However, the full extent to which the COVID-19 pandemic will directly or indirectly impact these areas in the future is unknown at this time and will depend on future developments that are unpredictable. We are actively monitoring and managing our response and assessing actual and potential impacts to these areas. Please refer to the &#8220;Risk Factors&#8221; section for further discussion of the risks we face as a result of the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are continuously evaluating and addressing potential impacts of the COVID-19 pandemic on our operations. To date, we have experienced limited impact due to COVID-19 on our operations. Our offices, laboratories, clinical trial sites, contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations, and other collaborators and partners are located in jurisdictions where quarantines, executive orders, previous shelter-in-place orders, other public health orders, guidelines, and other similar orders and restrictions intended to control the spread of the disease have been put in place by governmental authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health and safety of our employees and their families and doing our part to slow the community spread of COVID-19. In mid-March 2020, we implemented a number of actions, including a work-from-home policy for employees whose jobs do not require them to be onsite, allowing for flexible work schedules, restricting in-person meetings, and limiting onsite activities to only the most time-critical or necessary operational activities. We have maintained certain essential in-person laboratory functions in order to advance key research and development initiatives, supported by the implementation of updated onsite procedures. We believe these measures and others have allowed us to mitigate, but not eliminate, the effects and risks on our on-site operations posed by the COVID-19 pandemic.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of the COVID-19 pandemic on our ongoing and planned clinical trials is uncertain and subject to change. To date, we believe we have experienced limited impact due to COVID-19 on our ongoing clinical programs, including the OPTIC and INFINITY clinical trials. We are working closely with our clinical trial sites to monitor and attempt to address or limit the potential negative impacts of the evolving COVID-19 outbreak and the emergence of COVID-19 variants on patient safety, continued participation and follow-up of patients already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity. Despite these efforts, we are unsure as to whether the COVID-19 pandemic will significantly impact future trial enrollment or completion of our current or planned clinical studies.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact on Supply Chain and Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not yet experienced significant disruptions to our supply chain and manufacturing as a result of the COVID-19 pandemic, we cannot be certain that this trend will continue. Based on current information, we believe that our partners in our supply chain have been and will continue to serve us continuously during the COVID-19 pandemic. However, certain of these partners including our bulk drug substance and drug product suppliers have prioritized and allocated more resources and capacity to supply drug product or raw materials to other companies engaged in the study and/or supply of potential treatments or vaccinations for COVID-19 and its variants, which could result in supply interruptions for us. To mitigate against future potential delays in product supply, we are continuously implementing additional measures to address potential risks as we identify them, including securing additional supplies and manufacturing capacity reserve, which have resulted in additional expenses and may result in other additional expenses in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strengths</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have the capabilities, resources, and expertise to enable Adverum to become a leading gene therapy company. These strengths include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry-leading development capabilities in AAV ocular gene therapy and AAV product optimization, including cassette engineering and vectorizing antibodies;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deep understanding of how immunogenicity impacts ocular gene therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a pipeline of gene therapy product candidates targeting the treatment of ocular and rare diseases;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-house gene therapy manufacturing expertise, specifically in scalable process development, assay development, and GMP quality control; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maturing a portfolio of proprietary vectors with specific ocular cell tropism;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a robust patent portfolio; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an experienced leadership team with expertise in ophthalmology, gene therapy, drug development, regulatory approval and commercialization.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to discover, develop, and commercialize novel gene therapies with the potential to treat patients living with ocular and rare diseases. The key elements of our strategy to achieve this goal are to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Target large patient populations impacted by wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  There are approximately 20 million individuals worldwide living with wet AMD, and the incidence of new cases is expected to continue to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  We estimate that the standard-of-care anti-VEGF therapies used to treat wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy generated in excess of $13 billion worldwide in sales in 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Develop a single intravitreal injection gene therapy treatment to relieve the burden of frequent, chronic injections and improve real-world vision and quality of life outcomes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gene therapies are designed as a single, in-office IVT injection therapy to address the unmet needs of patients with ocular and rare diseases. The current standards of care for wet AMD and other chronic diseases require frequent injections for the duration of the disease. As an example, for wet AMD, a current standard-of-care treatment requires patients to receive IVT injections of anti-VEGF protein every 4-12 weeks. We believe that durable treatment to reduce injection frequency and improve long term visual outcomes is the largest unmet need for wet AMD patients and their caregivers. Lifetime need for frequent injections burdens patients, caregivers, healthcare providers and healthcare systems. Real world evidence shows reduction in patients&#8217; vision over time associated with insufficient treatment, and the persistence of macular fluid between anti-VEGF injections, including as a result of poor adherence to the frequent injection regimen. Furthermore, frequent bolus anti-VEGF injections result in fluctuations in macular fluid that have been shown to have negative impacts on visual outcomes over time. A gene therapy administered as a single, in-office IVT injection has the potential to deliver long-term efficacy, reduce the burden of frequent anti-VEGF injections, minimize macular fluid and macular fluid fluctuation and improve vision outcomes for patients. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pursue indications with well-defined clinical and regulatory paths where possible, to mitigate the development risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In wet AMD, we have selected an indication that has prior clinical validation, including established endpoints, standard-of-care administration methods, and defined regulatory paths. In wet AMD, aflibercept is an approved standard-of-care IVT injection treatment, and ADVM&#8209;022 utilizes our proprietary vector, AAV.7m8, designed to provide a codon optimized cassette of aflibercept through a single IVT injection.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advance our pipeline by moving our early-stage research assets into our development pipeline and leverage our industry-leading capabilities in AAV vector and cassette optimization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Integrating our AAV engineering, cassette optimization and innovation together with our manufacturing expertise, we have the capability to generate high-quality recombinant AAV products. Expand our understanding of AAV-induced inflammation and the intersection of ocular and systemic inflammatory responses to generate optimal prophylaxis strategies and best in class IVT products. We believe that this knowledge, together with ongoing discovery of improved ubiquitous and cell-specific promoters will improve our ability to create optimized AAV cassettes for ocular gene therapy. We plan to use this expertise to expand our pipeline and manage the life cycle of our novel gene therapies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Collaborate with partners to leverage our industry-leading AAV vector expertise and ocular vector development and product delivery capabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We explore opportunities to work collaboratively with potential new partners that may benefit from our capabilities and expertise in AAV vector development. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand our process development capabilities to support late-stage clinical trials and commercialization. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing process is based on the Baculovirus/Sf9 production system, which has been used for a number of vaccines and recombinant protein therapies approved by the FDA and European Medicines Agency (&#8220;EMA&#8221;), and is capable of producing large quantities of AAVs. Our strategy is to develop scalable processes to transfer to our global GMP contract manufacturers, providing a flexible manufacturing strategy to support a potentially global supply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gene Therapy Background</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy is a powerful treatment modality to address disease biology in a targeted and efficient way. With gene therapy, patients receive vectors encoding therapeutic genes, expressing a therapeutic protein or the functional version of a mutated protein. Instead of dosing patients with proteins or other therapies repeatedly over a long period, gene therapy offers the possibility of dosing once to achieve long-term, durable benefits. Once a patient&#8217;s cells are transduced with a gene, the cells are potentially able to continue to produce the therapeutic protein for years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to existing classes of protein or biologic therapies such as monoclonal antibodies and drug-antibody conjugates, gene therapy has taken a number of years to evolve from a research tool into a viable and compelling treatment modality. There have been several recent advances in gene therapy, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Substantial clinical data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Positive data from gene therapy clinical trials have been reported in a variety of indications, including hemophilia, spinal muscular atrophy, Sanfilippo syndrome, ornithine transcarbamylase deficiency, glycogen storage disease type 1a, sickle cell disease, Parkinson&#8217;s disease, and Duchenne muscular dystrophy, as well as several ocular diseases including biallelic RPE65 mutation-associated retinal dystrophy, choroideremia, Leber&#8217;s hereditary optic neuropathy, and X&#8209;linked retinitis pigmentosa.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Significant investment by biopharmaceutical companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The modality of gene therapy has received significant interest and investments by biopharmaceutical companies. Large, global biopharmaceutical companies, such as Astellas Pharma Inc., Biogen Idec Inc., Bristol-Myers Squib, CSL Behring, Daiichi Sankyo, Hoffmann-La Roche Ltd., Johnson &amp; Johnson, Novartis, and Regeneron have increased their investment in the gene therapy field. Additionally, pure-play gene therapy companies, such as 4D Molecular Therapeutics, Akouos Therapeutics, Passage Bio, REGENXBIO Inc., Rocket Pharmaceuticals, Sangamo Therapeutics, Sarepta Therapeutics, Sio Gene Therapies, Solid Biosciences, Taysha Gene Therapies, and uniQure N.V. have attracted recent investment in this growing field.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Approval of cell and gene therapy products by regulatory authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The FDA and EC have approved several cell and gene therapy products, including three AAV vector-based gene therapy products, two of which are currently being marketed. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Novel AAV Vector Optimization System</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our next-generation discovery platform is based on vectors derived from AAV, which is a small, non-pathogenic virus, which carry a therapeutic DNA instead of the viral genes. The resulting vector is used to deliver a gene into a desired cell population, which when expressed, can provide sustained protein production. We believe AAV vectors offer numerous advantages over other viral and non-viral vector technologies used for gene therapy. These advantages, highlighted below, have the potential to allow AAVs to be safe, to be applicable for a variety of indications, and to exhibit long-term efficacy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Highly-efficient transfer of DNA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV vectors offer highly-efficient transfer of DNA to the patient.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Non-pathogenic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Naturally occurring and recombinant AAV are not known to cause disease in humans.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Non-replicating.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Naturally occurring AAV is incapable of replication without co-infection of a helper virus such as adenovirus, herpes virus, or others. Recombinant AAV vectors used in our product candidates lack additional genes making them even less capable of replication.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Long-term expression.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Once incorporated into the host cell, AAV vectors can continue to drive expression of a therapeutic protein for years, making AAV-based gene therapy a compelling treatment modality for diseases requiring frequent chronic treatment regimens.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Low-integrating potential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Recombinant AAV vector genomes remain mainly as a stable non-integrating episomes, mitigating safety concerns associated with genomic integration.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Low inflammatory potential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Compared to other vectors used in direct gene therapy approaches, AAV vectors elicit relatively mild inflammatory reactions that may be mitigated with adequate steroid prophylaxis.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Ability to transduce non-dividing cells.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AAV vectors can efficiently transduce non-dividing cells or slow-dividing cells such as retinal cells and hepatocytes, which allow production of the therapeutic protein at the site of the disease (wet AMD) or its natural organ of production (C1-Esterase Inhibitor).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Approval of cell and gene therapy products by regulatory authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The FDA and EC have approved three AAV vector-based gene therapy products, two of which are currently being marketed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AAV-derived vectors are a leading vector used in gene therapy. According to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Gene Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, AAV has been used in over 260 clinical trials as of January 2021. As effective as existing AAV vectors are in gene therapy, we believe there are opportunities for improvement. Naturally occurring AAV variants have evolved with particular characteristics, some of which remain and pose limitations to their use in gene therapy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To create next-generation vectors, we use a multi-step process known as directed evolution. Our directed evolution technology uses a library of engineered AAV capsid genes, which exhibit different properties and capabilities than naturally occurring AAVs. Once we have created an initial pool of millions of different AAVs, we screen the AAVs in the pool for novel properties, e.g., specific transduction of a particular cell type. Once capsids with desirable properties are identified, those capsids are screened to create a smaller pool of optimized vectors which are further screened until we have identified a select number of engineered AAVs with the characteristics we seek.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing a pipeline of novel gene therapy product candidates designed to treat ocular and rare diseases. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ocular Diseases</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVM-022, Our Single Intravitreal Injection Gene Therapy Candidate for Treating</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Wet AMD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVM&#8209;022 is our clinical-stage gene therapy product candidate being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AAV.7m8 capsid was engineered from AAV2 by directed evolution to efficiently transduce retinal cells following a routine intravitreal injection. The vector carries a vector genome (&#8220;vg&#8221;) encoding a codon-optimized cDNA of the aflibercept protein, a current standard of care in wet AMD, under the control of a strong, ubiquitous expression cassette.</span></div><div style="margin-top:6pt"><img src="advm-20211231_g1.gif" alt="advm-20211231_g1.gif" style="height:353px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IVT, intravitreal </span></div><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Grish&#229;nin, R et al. Mol Ther 2019;27:118&#8211;29</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe IVT injection of gene therapy offers substantial advantages compared to subretinal surgical administration of gene therapy, for the treatment of wet AMD:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IVT injection is a simple procedure performed during an office visit, and is the mode of administration for current standard-of-care therapies to treat patients with wet AMD; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In comparison, a surgical setting is required for subretinal injections, with the attendant risks associated with intraocular surgery and vitrectomy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ADVM&#8209;022 for Treatment of Wet AMD</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market for Treating Patients with Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Age-related macular degeneration is a progressive disease affecting the retinal cells in the macula, the region of the retina at the back of the eye responsible for central vision. Disease progression results in the death of retinal cells and the gradual loss of vision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD, also known as neovascular AMD or nAMD, is an advanced form of AMD, affecting approximately 10% of patients living with AMD. In patients with wet AMD, the growth of abnormal blood vessels begin to invade the space between layers of cells in the retina. These new blood vessels are often leaky, which results in fluid and blood in the retina and causes vision loss.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wet AMD is a leading cause of blindness in patients over 65 years of age, with a prevalence of approximately 20 million individuals worldwide living with wet AMD. The incidence of new cases of wet AMD is expected to grow significantly worldwide as populations age. AMD is expected to impact 288 million people worldwide by 2040, with wet AMD accounting for approximately ten percent of those cases.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current standard-of-care therapy for wet AMD is chronic and frequent anti-VEGF IVT injections. These are effective but typically require eye injections every 4-12 weeks in order to maintain vision. Real-world evidence shows that this regimen can be difficult to adhere to for patients, caregivers, and healthcare systems, leading to undertreatment associated with persistent macular fluid as well as fluctuations of macular fluid, all resulting in loss of vision over time. We estimate that the standard-of-care anti-VEGF therapies used to treat wet AMD and other chronic retinal conditions that respond to anti-VEGF therapy generated in excess of $13 billion worldwide in sales in 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advancing the Clinical Development of ADVM&#8209;022 for Wet AMD</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated the ADVM&#8209;022 phase 1 clinical trial entitled &#8220;An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration (&#8220;the OPTIC trial&#8221;) with the first subject dosed in November 2018. We received Fast Track designation from the FDA for ADVM&#8209;022 for wet AMD in September&#160;2018.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OPTIC trial is designed as a multi-center, open-label, phase 1, dose-ranging safety trial of ADVM-022 in subjects with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Subjects in OPTIC are treatment-experienced, and previously required frequent anti&#8209;VEGF injections to manage their wet AMD and to maintain functional vision.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In OPTIC, subjects were dosed with a single IVT injection of ADVM-022. Subjects in cohort 1 (n=6) were treated with a 6E11 dose of ADVM-022. Patients in cohort 2 (n=6) were treated with a three-fold 2E11 dose of ADVM-022. Subjects in cohorts 1 and 2 received a 13-day tapering course of prophylactic oral steroids following ADVM-022 administration. Subjects in cohort 3 (n=9) were treated with a 2E11 dose of ADVM-022, and subjects in cohort 4 (n=9) were treated with a 6E11 dose of ADVM-022. Subjects in cohorts 3 and 4 received a 6&#8209;week tapering course of prophylactic topical steroids in place of the oral steroids.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the trial is the safety and tolerability of ADVM-022 after a single IVT administration. Secondary endpoints include changes in best-corrected visual acuity (BCVA), measurement of central subfield thickness (&#8220;CST&#8221;, a measure of retinal thickness), as well as mean number of anti-VEGF supplemental injections and percentage of patients needing anti-VEGF supplemental injections. Each patient enrolled will be followed for a total of two years in OPTIC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><img src="advm-20211231_g2.gif" alt="advm-20211231_g2.gif" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In OPTIC, ADVM-022 continues to show robust treatment response from both doses. Subjects who received 6E11 of ADVM-022, Cohorts 1 and 4, experienced a 97% reduction in annualized anti-VEGF injections and 80% remained supplemental anti-VEGF injection free with median follow up of 60 weeks. Subjects who received 2E11 of ADVM-022, Cohorts 2 and 3, experienced an 83% reduction in annualized anti-VEGF injections and 53% remained supplemental anti-VEGF injection free with median follow up of 88 weeks. Patients completing two years in OPTIC are being enrolled into an extension trial to be followed for up to five years. ADVM-022 continues to be well tolerated with a favorable safety profile at both doses. </span></div><div style="margin-top:6pt"><img src="advm-20211231_g3.gif" alt="advm-20211231_g3.gif" style="height:361px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Six subjects were diagnosed &lt;1 year prior to ADVM-022 injection: one each in Cohorts 1, 2 and 3, three in Cohort 4. Cohort 2, Subject 1 death due to cardiopulmonary arrest due to hypoxia; Cohort 2, Subject 6 death due to lung malignancy; Incomplete prior data for Cohort 4, Subject 2. Cohort 4, Subject 4 had a port delivery system (PDS) implanted 3 years prior to Screening (explanted 1.5 years later); Cohort 4, Subject 5 received in a clinical trial not yet unmasked (NCT03790852); IVT, intravitreal injection. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to regulatory review, we are finalizing the design for a Phase 2 trial of ADVM-022 in wet-AMD investigating 2E11  and 6E10 doses, with new enhanced prophylactic steroid regimens, which we anticipate will include local steroids and a combination of local and systemic steroids. The trial is expected to enroll approximately 72 subjects and evaluate similar endpoints to the Phase 1 OPTIC trial in wet AMD. This study design is based on extensive analysis conducted by our clinical development team and incorporates feedback from our scientific advisory board and key retina, uveitis and gene therapy experts. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">IND Amendment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to file an investigational new drug (&#8220;IND&#8221;) amendment in the first half of 2022 and engage with the FDA with the aim of securing agreement to proceed with the Phase 2 trial study. We anticipate completing this process by mid-2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Phase 2 Initiation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We are beginning preparations for the Phase 2 trial of ADVM-022 in wet AMD, with the intention of dosing the first subject in the third quarter of 2022. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Fully Resourced</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe our cash position is sufficient to fund our operations, including its development plans for ADVM-022, into 2024.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Programs</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonclinical Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADVM-062 (AAV.7m8-L-opsin) is a novel gene therapy product candidate being developed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy (&#8220;BCM&#8221;) via a single IVT injection. ADVM-062 utilizes Adverum&#8217;s propriety vector capsid, AAV.7m8. In January 2022, we announced the FDA granted Orphan Drug Designation to ADVM-062.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BCM affects approximately 1 to 9 in 100,000 males, worldwide. This X-linked recessive hereditary condition is caused by mutations in either the L or the M opsin gene(s) and can manifest in loss of visual acuity, photosensitivity, myopia and infantile nystagmus that can persist into adulthood. Consequently, individuals with BCM have visual impairments to important aspects of daily living such as facial recognition, learning, reading, and daylight vision. Currently, there is no cure for BCM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to ADVM-022 and ADMV-062, we are currently utilizing our industry-leading development capabilities for our AAV-based directed evolution platform and are conducting observational studies. We are in the early stages of nonclinical development for additional product candidates that we may advance in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Program Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed to GenSight rights to use AAV.7m8 for GS030 gene therapy encoding channelrhodopsin protein. GenSight is conducting a phase 1/2 trial in retinitis pigmentosa in the U.S., France, and U.K., which began in October 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance ADVM-022 for wet AMD, we are continuing to develop our manufacturing expertise for ongoing supply. We maintain control of key aspects of the manufacturing process, specifically in scalable process development, assay development, and GMP quality controls. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AAV vector manufacturing process is based on the Baculovirus Expression Vector System (&#8220;BEVS&#8221;), which has been used in a number of FDA- and EC-approved products. This approach is well suited for the production of large quantities of AAVs, as it takes advantage of the efficiency of viral infection coupled with the high density and scalability of insect cells grown in serum-free suspension cultures. Compared to the mammalian cell-based approaches commonly used in the field, our manufacturing process is designed to produce higher yields of vectors per manufacturing campaign in a cost-effective manner.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AAV manufacturing method is industrialized, highly scalable and ready for adaptation for commercial stage. We believe our process provides the following advantages over competing systems:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Industrial-scale biologics production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system can produce quantities of product required at commercial stage by incorporating scalable, well-established process steps used throughout the industry for biologic products.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Safety advantages.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system does not use mammalian cell cultures or tumorigenic cell lines, and the DNA sequences used to allow AAV vector production are inactive in mammalian cells, which lowers the risk of off-target expression from our products in humans.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">High yield and low cost.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Because of its scalability, our BEVS system may allow the production of large quantities of AAV vectors, up to the 2000-liter scale. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">High purity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our BEVS system coupled with our proprietary downstream purification process produces a highly pure drug substance.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Precedent regulatory framework.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Glybera, an AAV-based gene therapy authorized by the EC, and several other vaccines and recombinant protein therapies have been approved using a manufacturing process similar to our BEVS technology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our products are manufactured using cell banks and a scalable process developed internally that is transferred to approved Contract Manufacturing Organizations (&#8220;CMOs&#8221;). These CMOs produce investigational drugs under GMP conditions to support our clinical trials. High quality raw materials are purchased from various suppliers and are used throughout the manufacturing process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate new raw material suppliers, as well as additional CMOs, in order to provide manufacturing flexibility. As we prepare for larger, late-stage clinical trials and potential commercialization, we have expanded our in-house process development capabilities, allowing us to develop larger-scale processes for transfer to our global GMP contract manufacturers. We leverage GMP contract manufacturer partnerships for flexible clinical and future commercial supply. This strategy capitalizes on our internal AAV manufacturing expertise while providing both security, expandability and flexibility as we prepare to potentially deliver one of the first gene therapies for large indications.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is characterized by intense and dynamic competition to develop new proprietary technologies and therapies and a strong emphasis on intellectual property. We believe that our single administration, intravitreal approach for the treatment of wet AMD, our AAV-based directed evolution platform, our nonclinical and clinical development experience, our gene therapy manufacturing experience and our expertise in the field of gene therapy provide us with competitive advantages. However, we face actual or potential competition from various sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as from academic institutions, governmental agencies, and public and private research institutions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gene therapy ADVM&#8209;022 for wet AMD utilizes a proprietary vector and is administered through a single intravitreal injection and will compete with a variety of therapies currently marketed and in development, including biologics, small molecules, long-acting delivery devices and gene therapy. The key factors that contribute to success of any approved product include safety profile, efficacy, durability, mode of administration and cost of goods. Existing anti-VEGF therapies are well-established therapies and are widely accepted by physicians, patients and third-party payers as the standard-of-care treatment of patients with wet AMD. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We know of a significant number of product candidates in development or recently approved for chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD, and we group them into four main categories:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">biosimilar anti-VEGFs (e.g., FYB201);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">bispecific / combination / add-on therapy for efficacy or durability improvement (e.g., Vabysmo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">faricimab</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and OPT-302);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">next-generation anti-VEGF for durability improvement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-acting delivery device / gene therapy to lower treatment frequency (e.g., Susvimo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ranibizumab port delivery system) and RGX-314).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several other companies with marketed products or products in development for the treatment of chronic retinal conditions that respond to anti-VEGF therapy, including wet AMD. These companies include 4D Molecular Therapeutics, Bayer, Graybug Vision, Hoffmann-La Roche Ltd., Kodiak Sciences, Novartis, Opthea, Regeneron and REGENXBIO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies, as well as competitors we may face, either alone or with their partners, for our other product candidates, may have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments, and commercializing those treatments. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance. Our competitors&#8217; treatments may be more effective, or more effectively marketed and sold, than any treatment we may commercialize and may render our treatments obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our treatments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. We expect any treatments that we develop and commercialize to compete on the basis of, among other things, efficacy, safety, convenience of administration and delivery, price, the level of generic competition and the availability of reimbursement from government and other third-party payers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">License and Collaboration Agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">University of California</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AAV.7m8 License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In June 2013, we entered into an exclusive worldwide sublicensable license agreement with the Regents of University of California (&#8220;Regents&#8221;) to certain intellectual property related to improved AAV vectors, including the AAV.7m8 capsid. Under this license agreement, we are obligated to make certain de minimis license payments, certain milestone payments totaling up to $1.0 million upon reaching certain stages of development of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the licensed products for a first indication, and totaling up to $0.5 million for each subsequent indication for which licensed products are developed, for up to a maximum of two additional indications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are obligated to pay Regents royalties on sales of licensed products in the low single-digits, subject to adjustments and minimum thresholds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, this agreement will be in effect on a country-by-country, licensed product-by-licensed product basis until the expiration of the last claim of the licensed intellectual property covering the manufacture, use, or sale of such product in such country. We may terminate this agreement in whole or in party by giving Regents 30 days&#8217; prior written notice. Regents may terminate this agreement for breach by us that remains uncured for 60 days, if we become insolvent, if we directly or through a third-party file a claim that a licensed patent right is invalid or unenforceable, or if we fail to meet or extend the date for meeting certain diligence milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GenSight</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2014, we entered into an agreement with GenSight, in which we granted GenSight a non-exclusive license to our proprietary AAV.7m8 vector to develop gene therapy products to deliver certain therapeutic transgenes. Under the agreement, we are eligible to receive development, regulatory and commercial milestones. Also, we are eligible to receive low to mid-single digit royalties on sales of GenSight&#8217;s licensed products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GenSight is currently developing GS030, a gene therapy encoding channelrhodopsin protein which incorporates the AAV.7m8 capsid. GenSight is conducting a phase 1/2 trial with GS030 to treat retinitis pigmentosa in the U.S., France, and the U.K., which began in October 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into an agreement with Lexeo Therapeutics, pursuant to which we granted Lexeo an exclusive license to the intellectual property rights, pre-clinical data and know how associated with our Friedrich&#8217;s Ataxia program. Under the agreement, we are eligible to receive development and commercial milestones and royalties related to sales of a product containing our licensed rights. Lexeo is currently developing LX2006, an adeno-associated virus mediated treatment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Virovek</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2011, we entered into an agreement with Virovek, Inc. (&#8220;Virovek&#8221;), in which we received a non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing AAV. Under the agreement, Virovek is entitled to certain license payments and low-single digit royalty payments. This license with Virovek continues in effect until expiration of the last-to-expire patent.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy that may be important for the development of our business. Additionally, we may rely on regulatory protection afforded through orphan drug designations, data exclusivity, market exclusivity, and patent term extensions where available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; obtain regulatory exclusivity and operate without infringing the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents or trade secrets that cover these activities. In some cases, these rights may need to be enforced by third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect to any of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our commercial products and methods of manufacturing the same.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or license more than 140 issued patents which are still in force, including more than twenty-five issued U.S. patents and five European patents validated in more than eighty countries, as well as more than 190 patent applications pending in the U.S. and foreign jurisdictions. These numbers include more than thirty patents and forty pending applications filed by or on behalf of universities which have granted us exclusive license rights to the technology. Our policy is to file patent applications to protect technology, inventions and improvements to inventions that are commercially important to the development of our business. We seek patent protection in the U.S. and abroad for a variety of technologies, including research tools and methods, AAV-based biological products, methods for treating diseases of interest and methods for manufacturing our AAV-based products. We also intend to seek patent protection or rely upon trade secret rights to protect other technologies that may be used to discover and validate targets and that may be used to identify and develop novel biological products. We seek protection, in part, through confidentiality and proprietary information agreements. We are a party to various other license agreements that give us rights to use specific technologies in our research and development.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Company-owned Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own four patent families that are directed to AAV-based compositions and methods for treating or preventing eye diseases associated with neovascularization. Patents and applications in the first of these families relate to compositions and methods for the AAV-based delivery of anti-VEGF proteins, for use in treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, in patients who respond to anti-VEGF protein therapy. Fourteen patents in this family have issued in the U.S., elsewhere in North America, and the Asia/Pacific region, and nineteen corresponding applications are pending in the U.S., elsewhere in North America, Europe, and Asia. Patents in this family are generally expected to expire in 2033, subject to possible patent term adjustments and patent term extensions. Patents and applications in the second of these families relate to AAV gene therapy for the treatment of neovascular diseases of the eye, including wet AMD and diabetic retinopathy, using the AAV.7m8 vector to deliver aflibercept. One issued European patent is validated in thirty-seven countries, one patent is issued in Asia, and at least eighteen corresponding applications are pending in the U.S., elsewhere in North America, Europe, and Asia.  Patents in this family are generally expected to expire in 2037, subject to possible patent term adjustment and patent term extensions. The third of these families contains pending U.S. and corresponding foreign applications to AAV gene therapy for the treatment of neovascular diseases of the eye, including wet AMD and diabetic retinopathy, using the AAV.7m8 vector to deliver ranibizumab.   Patents that may eventually issue from this patent family, if any, are generally expected to expire in 2037, subject to possible patent term adjustments and patent term extensions.  The fourth family contains eight pending applications including two pending PCT applications and corresponding national applications in the U.S., Asia, and South America, and is directed to methods of treating neovascular diseases of the eye, including wet AMD and diabetic retinopathy, with AAV.7m8-aflibercept. Patents that may eventually issue from this family, if any, are generally expected to expire in 2039 to 2040 subject to possible patent term adjustments and patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own ten patent families that are directed to various aspects of our proprietary technology platform. Fourteen patents in these families have issued patents in the U.S., Europe, and Asia, including one issued European patent validated in six countries, as well as at least seventy-five pending applications, including PCT applications or national phase applications in the U.S., elsewhere in North America, Europe, and Asia. Patents that may eventually issue from these families, if any, are generally expected to expire between 2035 and 2040, subject to possible patent term extensions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensed Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained both exclusive and non-exclusive licenses to patents directed to both compositions of matter and methods of use and to other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have exclusively licensed several families of patents and patent applications that relate to variant rAAV virions having desirable characteristics, such as increased infectivity, as well as novel methods to screen for such variants.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One patent family directed to improved rAAV virions that we have exclusively licensed in the ocular field includes ten granted patents in the U.S., elsewhere in North America and Europe, including one European patent validated in three countries, as well as two pending patent applications in the U.S. The patents in this family are projected to expire between 2024 and 2029 in the U.S. and in 2024 elsewhere, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another patent family directed to improved rAAV virions that we have exclusively licensed includes three granted U.S. patents and a pending U.S. patent application that are expected to expire in 2031, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third patent family that we have exclusively licensed includes claims directed to the novel AAV.7m8 vector, which allows delivery of transgenes to the retina via intravitreal injection, and which we utilize in our product candidate ADVM&#8209;022. This family includes at least fifty issued patents in the U.S., elsewhere in North America, Europe, Asia, and the Pacific, including a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European patent validated in thirty-seven countries.  Seventeen corresponding applications are pending in the U.S. and elsewhere in North America, Europe, Asia and the Pacific. Patents that issue from this patent family are generally expected to expire in 2032, subject to possible patent term extensions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also non-exclusively licensed rights to a patent family related to the Baculovirus/SF9 production system that includes eight issued patents in the U.S., Europe, and Asia, including a European patent validated in three countries. These patents are expected to expire in 2027.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed a family of patent applications related to gene therapy treatments for HAE, C1-esterase deficiency, which includes three issued patents in the U.S. and Asia, and twelve pending U.S. and foreign applications. Patents that grant from this patent family are generally expected to expire in 2036, subject to possible patent term extensions and adjustments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusively licensed a family of patents and applications related to the treatment of cardiomyopathy associated with Friedreich&#8217;s Ataxia. This family includes two granted U.S. patents and fourteen pending applications in the U.S. and elsewhere in North America, Europe, Asia, and the Pacific. Patents that grant from this patent family are generally expected to expire in 2033, subject to possible patent term extensions and adjustments.  In January 2021, we granted an exclusive (even as to us) sublicense to this patent family, which does not relate to ADVM-022, to Lexeo Therapeutics.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade Secret Protection</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some circumstances we may rely on trade secrets to protect aspects of our technology and product candidates, including aspects for which we do not obtain patent protection. We seek to protect our trade secrets and confidential information, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our confidential information and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., biological products, including gene therapy products, are primarily regulated under the Federal Food, Drug, and Cosmetic Act (&#8220;FD&amp;C Act&#8221;) and the Public Health Service Act (&#8220;PHSA&#8221;), as well as corresponding implementing regulations promulgated by the FDA. These laws and regulations govern, among other things, the testing, manufacturing, safety, purity, potency, efficacy, labeling, packaging, storage, distribution, record keeping, reporting, advertising and promotion, export and import of biologics products. Prior to conducting human clinical testing of our gene therapy products, we must submit an investigational new drug application (&#8220;IND&#8221;) to the FDA, and the IND must be cleared by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the FDA, the Center for Biologics Evaluation and Research (&#8220;CBER&#8221;) regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Tissues and Advanced Therapies (&#8220;OTAT&#8221;). The FDA has also established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has published a growing body of guidance documents on topics relevant to the development of our product candidates, including, among other things, gene therapy products developed for retinal disorders, rare diseases; patient-focused drug development, nonclinical testing of gene therapy products; CMC information requirements for gene therapy; and observation of subjects involved in gene therapy studies for delayed adverse events. All of these guidance documents are intended to facilitate the industry&#8217;s development of gene therapy products. Guidance documents provide the FDA&#8217;s current thinking about a particular subject, but are not legally binding on either the FDA or the regulated industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before our product candidates may be marketed in the U.S. generally involves the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Completion of nonclinical laboratory tests, including evaluations of product chemistry, formulations, and toxicity and animal studies in accordance with current Good Laboratory Practice (&#8220;GLP&#8221;), regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission of an IND to the FDA, which must be cleared before human clinical trials may begin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by the independent institutional review board (&#8220;IRB&#8221;) of each clinical protocol and each clinical trial site before the trial may be initiated at that site;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approval by the institutional biosafety committee (&#8220;IBC&#8221;) of each clinical trial site, which assesses the safety of research involving, among other things, recombinant DNA, and identifies any potential risks to public health or the environment;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generation of substantial evidence from human clinical trials, conducted in accordance with Good Clinical Practice (&#8220;GCP&#8221;) regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and potency of the biologic product for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Submission to the FDA of a BLA for marketing approval that demonstrates adequate efficacy and acceptable safety profile of the biological product based on results of nonclinical testing and clinical trials, as well as providing information on the chemistry, manufacturing and controls to ensure product identity, purity, potency and quality, as well as proposed labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Satisfactory completion of an FDA inspection of each manufacturing facility at which the biologic product is produced, to assure that the product is produced in compliance with GMP, regulations, and any additional requirements made by the agency to assure that the methods and controls used during manufacturing are adequate to preserve the biological product&#8217;s safety, identity, strength, quality, purity, and potency;Successful completion of FDA audit(s) of the nonclinical and clinical trial sites and the clinical study sponsor that generated the data in support of the BLA;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successful completion of the advisory committee review, if the FDA convenes an advisory committee; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment of user fees and FDA review and licensure of the BLA prior to any commercial marketing, sale or shipment of the product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biological product candidate, including a gene therapy product, in humans, the product candidate enters the nonclinical testing stage. Nonclinical tests include animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the nonclinical tests must comply with federal regulations and requirements, including GLPs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical tests, together with manufacturing information, such as laboratory evaluation of product chemistry, formulation, and stability, as well as any available clinical data or literature and a proposed clinical trial protocol, are submitted as part of an IND to the FDA. Some nonclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions relating to the content of the IND during the review period or places the clinical study on a clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding concerns before the IND goes into effect and the clinical trial begins. The FDA can impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold on an IND, clinical trials may not commence or proceed without FDA authorization, and then only under terms authorized by the FDA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve administering of the investigational biological product candidate to human subjects under the supervision of qualified investigators, who are generally physicians not employed by or under the study sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, the parameters to be used in monitoring subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur, and the effectiveness criteria to be used. Each protocol must be submitted to the FDA as part of the IND. An independent IRB, and IBC, at each institution where the clinical trial will be conducted must also review and approve the plan for any clinical trial before it can begin at that institution, and the IRB must monitor the clinical trial until it is completed. For certain types of research, including research involving recombinant DNA, the IBC will also assess the safety of the research and identify any potential risk to public health or the environment, until the research is completed. Clinical testing also must satisfy GCP requirements, including the requirements for informed consent from all subjects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical research performed in the United States in support of a BLA must be authorized in advance by the FDA as described above. However, a sponsor who wishes to conduct a clinical trial outside the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the FDA will accept a well-designed, well-conducted, non-IND foreign clinical trial as support for a BLA if (i) the clinical trial was conducted in accordance with GCP as further detailed in the regulation, including review and approval by an independent ethics committee, and (ii) if the FDA is able to validate the data from the clinical trial through an onsite inspection, if necessary. In addition, when an applicant submits data from a foreign clinical trial not conducted under an IND to support a BLA, the FDA requires a description of the actions the applicant took to ensure that the research conformed to GCP. Further, additional requirements apply when a sponsor intends to base marketing approval of a new drug solely on foreign clinical data.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are typically conducted in three sequential phases, which may overlap or be combined.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 studies are typically closely monitored and may be conducted in patients or healthy volunteer subjects. These studies are designed to determine the metabolism and pharmacologic actions of the drug in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. During Phase 1, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase 2 studies. Phase 1 studies also include studies of drug metabolism, structure-activity relationships, and mechanism of action in humans, as well as studies in which investigational drugs are used as research tools to explore biological phenomena or disease processes. In the case of some product candidates for severe or life-threatening diseases, the initial human testing is often conducted in patients. Phase 1 clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2 clinical trials are typically conducted in a larger subject population than Phase 1 trials to evaluate dosage tolerance and appropriate dosage, identify possible adverse effects and safety risks, and to preliminarily evaluate the efficacy of the product candidate for specific targeted indications. For Phase 2 clinical trials in gene therapy, although the subject population may be larger than the Phase 1 trials, the subject population may still remain relatively limited.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trials are typically conducted when Phase 2 clinical trials demonstrate that a dose range of the biological product candidate is effective and has an acceptable safety profile. Phase 3 clinical trials are generally undertaken with large numbers of subjects, to provide substantial evidence of clinical efficacy, and to further test for safety in an expanded and diverse subject population at multiple, geographically-dispersed clinical trial sites. Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a product candidate.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional data from the treatment of patients in the intended therapeutic indication, particularly for long-term safety.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for any serious and unexpected adverse event that occurs during the study, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the clinical protocol or Investigator&#8217;s Brochure, as well as any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human subjects from the product candidate. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor's initial receipt of the information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the biological product has been associated with unexpected serious harm to patients. Similar rules govern the conduct of clinical trials in the European Economic Area (&#8220;EEA&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the U.S., the various phases of nonclinical and clinical research in the European Union are subject to significant regulatory controls. Previously, in the European Union, pursuant to the EU Clinical Trials Directive 2001/20/EC, a clinical trial application had to be submitted to each country&#8217;s national regulatory authority in which the clinical trial was to take place, together with an independent ethics committee, much like the FDA and IRB, respectively. Although the Directive sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive in a manner that is often not uniform. This led to variations in the rules governing the conduct of clinical trials in the individual EU Member States. In 2014, a new Clinical Trials Regulation 536/2014, replacing the current Directive, was adopted. The new Regulation is directly applicable in all EU Member States (without national implementation) and entered into application on 31 January 2022. The new Regulation seeks to simplify and streamline the approval of clinical trials in the European Union. Pursuant to the Regulation, the sponsor shall submit a single application for approval of a clinical trial via the EMA's Clinical Trials Information System, or CTIS, which will cover all regulatory and ethics assessments from the member states concerned. Any submissions made from January 31, 2023 onwards must be made through CTIS and all trials authorized pursuant to the Directive that are still ongoing on January 31, 2025 must be made through CTIS. Once the CTA is approved in accordance with a member state's requirements, clinical trial development may proceed. Approval and monitoring of clinical trials in the European Union is, as it was under the Directive, the responsibility of individual member states, but compared to the position prior to the applicability of the Clinical Trials Regulation there is likely to be more collaboration, information-sharing, and decision-making between member states. The new Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements, such as mandatory submission of a summary of the clinical trial results to a new EU database. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the National Institutes of Health (&#8220;NIH&#8221;) developed a publicly accessible database, the Genetic Modification Clinical Research Information System, designed to facilitate safety reporting. The database includes information on gene transfer studies and serves as an electronic tool to facilitate the reporting and analysis of adverse events on these clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. The FDA has issued various guidance documents regarding gene therapies, which outline additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper nonclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. Further, the FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for up to 5-years for nonintegrating vectors such as AAV vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The responsible party for an applicable clinical trial must register the clinical trial in Phase 2 or later on the ClinicalTrials.gov website, including the registry of new, on-going, and completed clinical trials of drugs, biologics, and device products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics License Applications</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical studies and clinical trial(s), together with detailed information on the quality of the product, are submitted to the FDA in the form of a BLA requesting approval to market the product for one or more specified indications. The submission of a BLA must be accompanied by a substantial user fee unless a waiver applies, and is subject to a sixty-day filing review period to determine if the application is sufficiently complete to permit substantive review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the FDA has a performance goal to review applications within 6 months from successful filing of the application for priority reviews or 10 months for standard reviews. The review timeline begins upon the FDA&#8217;s acceptance of the original application submission for filing, no later than 60 calendar days from the date the FDA receives the application. In some instances, the review process and the PDUFA goal date may be extended depending on the information required in order for the FDA reviewers to complete their review of the BLA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The FDA may deny licensure of a BLA by issuing a complete response letter if the applicable statutory and regulatory criteria are not satisfied, and may require additional clinical data or an additional Phase 3 clinical trial. Even if a product receives licensure, the licensure may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited or subject to Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;), which could restrict the commercial value of the product. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the FDA licenses a BLA, or supplement thereto, the FDA may withdraw the licensure if ongoing regulatory requirements are not met or if safety problems are identified after the product reaches the market. Even where a withdrawal is not required, the FDA still may seize existing inventory of such product or require a recall of product already on the market. In addition, the FDA may require testing, including Phase 4 clinical trials and surveillance programs to monitor the effect of licensed biologics that have been commercialized. The FDA has the authority to prevent or limit further marketing of a biologic based on the results of these post-marketing programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics may be marketed only for the FDA approved indications and in accordance with the provisions of the approved labeling. Further, if there are any modifications to the product, including changes in indications, labeling, or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the sponsor to develop additional data or conduct additional nonclinical studies and clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before licensing a BLA, the FDA will inspect the facilities at which the biologic is manufactured and will not license the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements. The FDA may also inspect the site(s) at which the clinical trials were conducted to assess their GCP compliance and will not approve the product unless compliance with the IND study requirements and GCP requirements is satisfactory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After approval, certain changes to the approved product, such as adding new indications, manufacturing changes, or additional labeling claims are subject to further FDA review and approval. Depending on the nature of the change proposed, a BLA supplement must be filed and approved before the change may be implemented. For many proposed post-approval changes to a BLA that include new efficacy data, the FDA intends to review and act on the supplemental application within 10 months of receipt. As with new BLAs, the review process is often significantly extended by FDA requests for additional information or clarification.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biological product approved under section 351(a) of the PHSA (a &#8220;reference product&#8221;) can receive 12 years of marketing exclusivity, four years of which constitute data exclusivity. In other words, no biosimilar application that cites the reference product can be submitted to the FDA until four years after approval of the reference product, and no biosimilar application that cites the reference product can be approved during the full 12-year period. These exclusivity provisions only apply to biosimilars&#8212;companies that rely on their own data and file a full BLA may be approved earlier than 12 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EEA (which is comprised of 27 Member States of the EU plus Norway, Iceland, and Liechtenstein), medicinal products can only be commercialized after a related Marketing Authorization, or MA, has been granted. Marketing authorization for medicinal products can be obtained through several different procedures. These are through a centralized, mutual recognition procedure, decentralized procedure, or national procedure (if marketing authorization is sought for a single EU Member State). The centralized procedure allows a company to submit a single application to the EMA. If a related positive opinion is provided by the EMA, the EC will grant a centralized marketing authorization that is valid in all 27 EU Member States and three of the four European Free Trade Associations, or EFTA, countries (Norway, Iceland, and Liechtenstein) all of whom make up the EEA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, advance therapy medicinal products such as gene therapy, orphan medicinal products, regenerative medicinal products, and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance that is not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or for which grant of centralized marketing authorization is in the interest of patients at EU level in the EU.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized authorization procedure permits companies to file identical applications for authorization to several EU Member States simultaneously for a medicinal product that has not yet been authorized in any EU Member State. The competent authority of a single EU Member State, the reference member state, is appointed to review the application and provide an assessment report. The competent authorities of the other EU Member States, the concerned member states, are subsequently required to grant marketing authorization for their territories on the basis of this assessment. The only exception to this is where an EU Member State considers that there are concerns of potential serious risk to public health related to authorization of the product. In these circumstances, the matter is submitted to the Heads of Medicines Agencies, or Co-ordination Group for Mutual Recognition and Decentralised procedures - Human, for review. The mutual recognition procedure allows companies that have a medicinal product already authorized in one EU Member State to apply for this authorization to be recognized by the competent authorities in other EU Member States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, biological products authorized according to the centralized authorization procedure are entitled to eight years&#8217; data exclusivity and 10 years&#8217; market exclusivity. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedure for approval of biosimilars following expiry of exclusivity differs from that for generic medicinal products. Developers of biosimilars must demonstrate through comprehensive comparability studies with the &#8220;reference&#8221; biological medicine that their biosimilar product is highly similar to the reference medicine, notwithstanding natural variability inherent to all biological medicines and that there are no clinically meaningful differences between the biosimilar and the reference medicine in terms of safety, quality and efficacy.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expedited Development and Review Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has provided guidance to sponsors developing regenerative medicine therapies for serious or life-threatening diseases or conditions, with recommendations on the expedited development and review of these therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fast track designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for fast track designation, a product candidate must be intended to treat a serious condition and address an unmet medical need. Advantages of fast track designation include the possibility for a rolling review, eligibility for priority review, and the ability to have greater interactions with the FDA. In addition, under the Fast Track program and the FDA&#8217;s accelerated approval regulations, the FDA may approve a biologic product based on a surrogate endpoint. A surrogate endpoint is a measurement of laboratory or clinical signs of a disease or conditions that substitutes for a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more easily or more rapidly than clinical endpoints. A biologic product candidate approved using a surrogate endpoint is subject to rigorous post-marketing compliance requirements, including the completion of post-approval clinical trials to confirm the beneficial effect on a clinical endpoint. Failure to conduct or to confirm a clinical benefit during these required trials may result in FDA withdrawal of the approved biologic product from the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product submitted to the FDA for marketing approval, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation, priority review designation, and accelerated approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough therapy designation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for the breakthrough therapy program, a product candidate must be intended to treat a serious condition, and have preliminary clinical data indicating that it provides a substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program; intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross&#8209;disciplinary review; and rolling review.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regenerative medicine advanced therapy (&#8220;RMAT&#8221;) designation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To qualify for the RMAT designation, a product candidate must be a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition, and there must be preliminary clinical evidence that the candidate has the potential to address the unmet medical need. The FDA has indicated that gene therapies may qualify as regenerative medicine therapies. Advantages of RMAT designation include early interactions with the FDA to discuss any potential surrogate or intermediate endpoints and address potential ways to support accelerated approval and satisfy post-approval requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority review. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product, including those that receive fast track, breakthrough therapy, or RMAT designations, may be eligible for priority review, if the product meets the criteria for priority review at the time the BLA is submitted. If priority review is granted, the FDA has a 6-month goal for reviewing the marketing application or efficacy supplement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accelerated approval. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug or biologic products with evidence showing that they provide meaningful therapeutic benefit over existing treatments for serious or life&#8209;threatening illnesses may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of clinical data establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit. As a condition of approval, the FDA may require that a sponsor conduct post&#8209;marketing clinical trials.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation (&#8220;ODD&#8221;)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biological product intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or if there is no reasonable expectation that the cost of developing and making the product available in the U.S. will be recovered from sales of the product.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ODD must be requested before submitting a BLA. ODD does not affect the regulatory review and approval process. However, if a product that has orphan designation subsequently receives the first BLA applicant to receive FDA approval for that product for the disease or condition for which it has such designation, that product is entitled to a seven-year exclusive marketing period in the U.S. for that product in the approved indication. During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market the same drug or biological product for the same indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Among the other benefits of ODD are tax credits for certain research and a waiver of the user fee. In September 2021, the FDA finalized Guidance For Industry on determining &#8220;sameness&#8221; for gene therapy products for purposes of orphan drug exclusivity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, orphan drug designation may be granted to products that can be used to treat life-threatening diseases or chronically debilitating conditions with an incidence of no more than five in 10,000 people or that, for economic reasons, would be unlikely to be developed without incentives. Medicinal products for which orphan designation has been granted are entitled to a range of benefits during the development and regulatory review process and to ten years of exclusivity in all EU member states upon approval. As in the U.S., a similar medicinal product with the same orphan indication may be approved, notwithstanding orphan product exclusivity, if the exclusivity holder gives consent or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if the similar product is deemed safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity granted in relation to the original orphan medicinal product may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any biologics manufactured or distributed by us or our collaborators pursuant to FDA or EU and other governmental authorities&#8217; approvals would be subject to continuing regulation by the FDA, the EMA and other governmental authorities, including recordkeeping requirements and reporting of adverse experiences associated with the product. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, or equivalent EU and other governmental authorities and are subject to periodic unannounced inspections by the FDA, certain state agencies and EU and other governmental authorities for compliance with ongoing regulatory requirements, including GMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the GMP regulations and other ongoing FDA, EU or other governmental authorities&#8217; regulatory requirements. If we or our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA, EMA, EU Member State or other governmental authorities may halt our clinical trials, require us to recall a product from distribution or withdraw approval of the BLA for that biologic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. For example, under the FDA&#8217;s current interpretation of the relevant laws, in proactively promoting a biologic, a company generally can make only those substantiated claims relating to safety and efficacy that are for indications approved by the FDA and that are otherwise consistent with the FDA-approved label for the biologic. Claims must be truthful and non-misleading. Failure to comply with these requirements can result in fines, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians may prescribe legally available biologics for uses that are not described in the product&#8217;s labeling and that differ from those tested by the sponsor and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. If the FDA finds that we have promoted off-label use of any product that is eventually approved, sanctions could include refusal to approve pending applications, withdrawal of an approval, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the advertising and promotion of pharmaceutical products are subject to laws governing promotion of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that promotional materials and advertising in relation to medicinal products comply with the product&#8217;s Summary of Product Characteristics, or SmPC, as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the SmPC is considered off-label and is prohibited in the EU. Other relevant laws at EU level and in the individual EU member states also apply to the advertising and promotion of medicinal products, including laws that prohibit the direct-to-consumer advertising of prescription-only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care professionals. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative measures, fines and imprisonment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Privacy Laws</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may process personal or sensitive information.  Accordingly, we are subject to numerous privacy, data protection, and data security obligations, including federal, state, local, and foreign laws, regulations, guidance, and industry standards. Many of these laws and regulations are constantly evolving and differ from or conflict with each other in significant ways and may not have the same effect, which complicates compliance efforts and may increase our exposure to regulatory enforcement action, sanctions, and litigation. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU General Data Protection Regulation (&#8220;EU GDPR&#8221;) and the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) are examples of the increasingly stringent and evolving regulatory frameworks related to personal information processing that may increase our compliance obligations and exposure for any noncompliance.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU GDPR took effect in the EU in 2018 and imposes comprehensive privacy, data protection, and data security obligations on businesses with stringent penalties for noncompliance. The EU GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal information in connection with the offering of goods or services to data subjects in the EEA or the monitoring of the behavior of data subjects in the EEA. Similarly, Brazil recently enacted the General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais or &#8220;LGPD&#8221;) (Law No. 13,709/2018), which broadly regulates the processing of personal information in a manner comparable to the EU GDPR and allows for substantial penalties for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA imposes obligations on covered businesses to provide specific disclosures related to a business&#8217;s collecting, using, and disclosing personal information and to respond to certain requests from California residents related to their personal information (for example, requests to know of the business&#8217;s personal information processing activities, to delete the individual&#8217;s personal information, and to opt out of certain personal information disclosures). Also, the CCPA provides for civil penalties and a private right of action for data breaches which may include an award of statutory damages. In addition, the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), effective January 1, 2023, will expand the CCPA. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, establish restrictions on personal information retention, expand the types of data breaches that are subject to the CCPA&#8217;s private right of action, and establish a new California Privacy Protection Agency to implement and enforce the new law. In addition, several states within the United States have enacted or proposed privacy, data protection, and data security laws.  For example, Virginia recently passed the Consumer Data Protection Act, and Colorado passed the Colorado Privacy Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their implementing regulations (collectively, &#8220;HIPAA&#8221;) imposes requirements on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain and transmit individually identifiable health information for or on behalf of a covered entity relating to the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Healthcare Laws and Regulations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we obtain regulatory approval for any of our product candidates, we may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments in which we conduct our business. These laws may impact, among other things, our research activities, as well as our proposed sales, marketing, and education programs. The laws that may affect our ability to operate include:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or order of any health care item or service for which payment may be made, in whole or in part, by federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary managers on the other. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Law constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor, or for which no exception or safe harbor is available, may be subject to scrutiny;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the United States Attorney General or as a qui tam action by a private individual (a whistleblower) in the name of the government and the individual, and the whistleblower may share in any monetary recovery. Many pharmaceutical and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing activities, including: providing free product to customers with the expectation that the customers would bill federal programs for the product; providing sham consulting fees, grants, free travel and other benefits to physicians to induce them to prescribe the company&#8217;s products; and inflating prices reported to private price publication services, which are used to set drug payment rates under government healthcare programs. In addition, the government has pursued civil False Claims Act cases against a number of pharmaceutical companies for causing false claims to be submitted as a result of the marketing of their products for unapproved, and thus non-reimbursable, uses. Because of the threat of treble damages and mandatory penalties per false or fraudulent claim or statement, healthcare and pharmaceutical companies often resolve allegations without admissions of liability for significant and material amounts. Pharmaceutical and other healthcare companies also are subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) information related to direct and indirect payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Outside the U.S., interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products, which is prohibited in the EU, is governed by the national anti-bribery laws of the EU member states. Violation of these laws could result in substantial fines and imprisonment. Certain EU member states, or industry codes of conduct, require that payments made to physicians be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her competent professional organization, and/or the competent authorities of the individual EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to significant penalties, including civil, criminal, and administrative penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs (such as Medicare and Medicaid), imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security, and fraud laws may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the pharmaceutical and biotechnology industry have received increased public and governmental scrutiny for the cost of drugs. In particular, U.S. federal prosecutors have issued subpoenas to pharmaceutical companies seeking information about drug pricing practices and the U.S. Senate is investigating several pharmaceutical companies relating to drug price increases and pricing practices. If we obtain regulatory approval of any of our product candidates, our revenue and future profitability could be negatively affected if these inquiries were to result in legislative or regulatory proposals that limit our ability to increase the prices of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of gene therapy products. In the U.S. and other countries, sales of any products for which we receive marketing approval will depend in part on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payer will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drugs for a particular indication. Moreover, a payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. A number of gene or cell therapy products have been approved over the past several years by the FDA. For example, although CMS has approved coverage for Chimeric Antigen Receptor T-cell therapies, such as Yescarta and Kymriah, and has established reimbursement methods for these therapies, these policies could be changed in the future. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the United States, even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act, contains provisions that may reduce the profitability of drug products, including, for example, by increasing the minimum rebates owed by manufacturers under the Medicaid Drug Rebate Program, extending the rebate program to individuals enrolled in Medicaid managed care plans, addressing a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and imposing annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Adoption of government controls and other measures, and tightening of restrictive policies in jurisdictions with existing controls and other measures, could limit coverage of or payments for pharmaceuticals, or affect rebates or other price concessions owed on such products. Certain provisions of the Affordable Care Act have been subject to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judicial challenges as well as efforts to repeal, replace, or otherwise modify them or to alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act, enacted on December 22, 2017, eliminated the tax-based payment for individuals who fail to maintain minimum essential coverage under section 5000A of the Internal Revenue Code of 1986, commonly referred to as the individual mandate, effective January 1, 2019. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argue the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. It is unclear how efforts to repeal, replace or otherwise modify, or invalidate, the Affordable Care Act or its implementing regulations, or portions thereof, as well as health care reform measures of the Biden administration, will affect our business. On January 28, 2021, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, it is unclear whether such legislative changes, regulatory changes, or judicial challenges related to the Affordable Care Act, or other health care reform measures will also have an impact on biologic product exclusivity, or the biosimilar product licensure pathway established under the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which was enacted as part of the Affordable Care Act.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect through 2031 unless additional congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020, through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been increasing legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. For example, on November 20, 2020, CMS issued an interim final rule to implement a &#8220;Most Favored Nation&#8221; demonstration project to test Medicare Part B reimbursement of certain separately payable drugs and biologicals based on international reference prices. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. Additionally, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles. It is possible that the Affordable Care Act, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare financing, more rigorous coverage criteria, and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from commercial payers. Coverage policies and reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Further, it is possible that additional governmental action could be taken in response to the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to what is occurring in the U.S., political, economic and regulatory developments outside of the U.S. are also subjecting the healthcare industry to fundamental changes and challenges. Pressure by governments and other stakeholders on prices and reimbursement levels continue to exist. In various EU member states, we expect to be subject to continuous cost-cutting measures, such as lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative. Health technology assessment (&#8220;HTA&#8221;) of medicinal products is becoming an increasingly </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common part of the pricing and reimbursement procedures in some EU member states, including countries representing major markets. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally compares attributes of individual medicinal products, as compared with other treatment options available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU member states. On January 31, 2018, the EC adopted a proposal for an HTA regulation intended to boost cooperation among EU member states in assessing health technologies, including new medicinal products. The HTA regulation, which aims to harmonize the clinical benefit assessment of HTA across the EEA, will apply from January 12, 2025. The HTA regulation provides that EU member states will be able to use common HTA tools, methodologies, and procedures across the EU. Individual EU member states will continue to be responsible for assessing nonclinical (e.g., economic, social and ethical) aspects of health technologies, and making decisions on pricing and reimbursement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The making available or placing on the EU market of unauthorized medicinal products is generally prohibited. However, the competent authorities of the EU member states may exceptionally and temporarily allow and reimburse the supply of such unauthorized products, either on a named patient basis or through a compassionate use process, to individual patients or a group of patients with a chronically or seriously debilitating disease or whose disease is considered to be life-threatening, and who cannot be treated satisfactorily by an authorized medicinal product. Such reimbursement may no longer be available if authorization for named patient or compassionate use programs expire or is terminated or if marketing authorization is granted for the product. In some EU member states, authorization and reimbursement policies may also delay commercialization of our products, or may adversely affect our ability to sell our products on a profitable basis. After initial price and reimbursement approvals, reductions in prices and changes in reimbursement levels can be triggered by multiple factors, including reference pricing systems and publication of discounts by third party payers or authorities in other countries. In the EU, prices can be reduced further by parallel distribution and parallel trade, or arbitrage between low-priced and high-priced EU member states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of adequate government reimbursement for our products may also be subject to regulatory changes and controls.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the U.S., we or our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our future drugs. Whether or not we obtain FDA approval for a drug, we or our collaborators must obtain approval from the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing of the drug in those countries. Many countries outside of the U.S. have a similar process that requires the submission of a clinical study application much like the IND prior to the commencement of human clinical studies. To obtain regulatory approval of a biological medicinal product under European Union (&#8220;EU&#8221;) regulatory systems, we must submit a marketing authorization application. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the EU and the U.S., we or our collaborators will be subject to a variety of foreign regulations governing clinical trials and commercial distribution of our future products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Testing and Approval of Pharmaceutical Products in the EU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The EU and many individual countries have regulatory structures similar to the U.S. for conducting nonclinical and clinical testing and applying for marketing approval or authorization, although specifics may vary widely from country to country. Clinical trials in the EU must be conducted in accordance with the requirements of the EU Clinical Trials Directive, as implemented in national law by individual EU member states, or in accordance with the EU Clinical Trials Regulation which became applicable on January 13, 2022, and applicable good clinical practice standards. In the EU, there are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on a country-by-country basis. There is a &#8220;centralized&#8221; procedure allowing submission of a single marketing authorization application to the European Medicines Agency, or EMA. If the EMA issues a positive opinion, the EC will grant a centralized marketing authorization that is valid in all EU member states and three of the four European Free Trade Association countries (Iceland, Liechtenstein and Norway). The centralized procedure is mandatory for certain medicinal products, including orphan medicinal products and biotechnology-derived medicinal products, and optional for others. There is also a &#8220;decentralized&#8221; procedure allowing companies to file identical applications to several EU member states simultaneously for product candidates that have not yet been authorized in any EU member state and a &#8220;mutual recognition&#8221; procedure allowing companies that have a product already authorized in one EU member state to apply for that authorization to be recognized by the competent authorities in other EU member states.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum timeframe for the evaluation of an application in the EU under the centralized procedure is 210 days, subject to certain exceptions and clock stops. An initial marketing authorization granted in the EU is valid for five years, with renewal </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to reevaluation of the risk-benefit profile of the product. Once renewed, the authorization is usually valid for an unlimited period unless the national competent authority or the EC decides on justified grounds to proceed with one additional five-year renewal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, if an applicant can demonstrate that comprehensive data on the efficacy and safety of the product under normal conditions of use cannot be provided due to certain specified objective and verifiable reasons, products may be granted marketing authorization &#8220;under exceptional circumstances.&#8221; A marketing authorization granted under exceptional circumstances is valid for five years, subject to an annual reassessment of conditions imposed by the EC.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK&#8217;s withdrawal from the EU on January 31, 2020, commonly referred to as Brexit, has created significant uncertainty concerning the extent to which the UK and the EU regulatory environments may diverge in the future. Any such divergence may lead to increased costs and administrative burden. On December 24, 2020, the EU and UK reached an agreement in principle on the framework for their future relationship, the EU-UK Trade and Cooperation Agreement. The Agreement formally entered into force on May 1, 2021. The Agreement primarily focuses on ensuring free trade between the EU and the UK in relation to goods, including medicinal products. Although the body of the Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to continue to accept EU batch testing and batch release, two years notice will be provided of any changes to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the EC. The UK Medicines and Healthcare products Regulatory Agency is the UK competent authority for the regulation and authorizations or medicinal products in the UK.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Manufacture of Medicinal Products in the EU</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the EU, a manufacturing authorization from the national regulatory authority of the member state in which the manufacturing of medicinal products is carried out is required to manufacture medicinal products. The manufacturing authorization holder must comply with various requirements set out in applicable EU laws, regulations and guidance. These requirements include compliance with EU GMP standards when manufacturing products and their APIs, including APIs manufactured outside of the EU with the intention of importing them into the EU. In addition to inspection reports, manufacturers and marketing authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in cases of non-compliance with the EU or EU member states&#8217; requirements applicable to manufacturing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Data Exclusivity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  In the EU, innovative medicinal products that are subject to marketing authorization on the basis of a full dossier qualify for eight years&#8217; data exclusivity upon marketing authorization and an additional two years&#8217; market exclusivity. Data exclusivity prevents regulatory authorities in the EU from referencing the innovator&#8217;s data to assess a generic application or biosimilar application for eight years from the date of authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced. However, the generic product or biosimilar products cannot be marketed in the EU for a further two years thereafter. The overall ten-year period may be extended for a further year to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Data exclusivity periods are currently the same in Great Britain as in the EU. However, following Brexit, the UK could change the duration of data exclusivity periods under its national legislation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, Health and Safety Regulation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state and local environmental, health and safety (&#8220;EHS&#8221;) laws and regulations relating to, among other matters, safe working conditions, product stewardship, environmental protection, and handling or disposition of products, including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous materials, medical waste, and infectious materials. Some of these laws and regulations also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with the applicable permits, we could face substantial fines or possible revocation of our permits or limitations on our ability to conduct our operations. Certain of our development and manufacturing activities involve use of hazardous materials, and we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. However, we cannot ensure that EHS liabilities will not develop in the future. EHS laws and regulations are complex, change frequently and have tended to become more stringent over time. Although the costs to comply with applicable laws and regulations, including requirements in the European Union relating to the restriction of use of hazardous substances in products, have not been material, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December 31, 2021, we had approximately 188 full-time employees. Of these employees, 27 hold Ph.D. or M.D. degrees, 131 are engaged in research and development, and 57 are engaged in business development, finance, legal, human resources, facilities, information technology, and general management and administration. We also engage temporary employees and consultants. Our employees are not represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. Our employee engagement is highly favorable, which we attribute to our shared mission of transforming the lives of those affected by ocular and rare diseases and has led to our being named a Top Workplaces 2021 by Bay Area New Group</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our employees are one of our most valuable assets and are essential to our success. We have been purposeful in our efforts to hire, develop and retain diverse talent as well as create an inclusive culture. We are investing in the creation of a work environment that values the health, safety and wellness of our team, and where our employees are inspired to deliver their best every day. All employees are responsible for upholding the Adverum Code of Business Conduct and Ethics, as well as complying with our Employee Handbook, which together form the foundation of our policies and practices. We continue to expand our systems to track key human capital metrics such as demographics, diversity, compensation and benefits, and engagement.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity and Inclusion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to diversity, equity and inclusion (&#8220;DEI&#8221;) across all aspects of our company, including hiring, promotion and development practices. As of December 31, 2021, racial and ethnic minorities represented 68% of our employee base.  52.7% of our workforce were women and 43.8% of our positions at director-level and above were held by women.]Our employees bring diversity to our workplace across many critical categories, and we believe our company is stronger as a result of our diverse experiences and backgrounds. We are committed to creating and maintaining a diverse, inclusive and safe work environment where our employees can bring their best selves to work each day. We continue to implement employee-led resource groups (&#8220;ERGs&#8221;) and to assemble DEI-related resources for our employees.  We currently have two ERGs that represent and support two diverse communities in our workforce: SOAR - Supporting Women of All Ranks ERG, providing support and mentorship for our female workforce, including guidance on career advancement and the LGBTQ+ - Pride ERG, working to foster an inclusive workplace culture that supports our LGBTQ+ workforce. These ERGs mentor, foster, encourage and inspire employees in all stages of their careers by providing access to senior leadership, peer groups, mentoring and other valuable resources to help them pursue their career ambitions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to our employees starts with benefit and compensation programs that value their contributions and offer physical, financial and personal health programs to them and their families. We strive to provide pay, benefits and services that are competitive to market and create incentives to attract and retain employees. Our compensation package includes market-competitive pay, broad-based stock grants and bonuses, healthcare and retirement benefits, and paid time off. We also offer an Employee Stock Purchase Program through which employees can purchase company stock at a discounted price, and offer stipends to cover expenses associated with working from home and the use of personal devices for work purposes. Additionally, we continue to advance transparency in our pay and representation data by complying with all applicable statutory filing requirements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Communication and Engagement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe that Adverum&#8217;s success depends on our employees understanding how their work contributes to the company&#8217;s overall strategy. We strive to foster open and direct communication, and seek to empower our employees to be our greatest ambassadors. We use a variety of channels to facilitate this exchange of information, including quarterly business updates from the senior management team; regular all hands meetings, open forums and company-wide written communications; postings on our company intranet; and employee engagement surveys. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Wellness and Safety</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee safety and well-being is of paramount importance to us, particularly in light of COVID-19. In response to the pandemic, we have taken extra precautions to reduce the risk of virus exposure for our employees. We provide protective equipment for our employees working on site, have implemented new safety protocols and procedures, and provide access for weekly COVID-19 testing. We have also established a governance structure to ensure timely communication and decision making. For our remote employees, we provide productivity and collaboration tools and resources, allow flexible schedules and support their information technology needs. We also regularly promote employee assistance programs to support our employees&#8217; physical, financial and mental well-being.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Available Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in 2006 under the name &#8220;Avalanche Biotechnologies, Inc.&#8221; We completed the initial public offering of our common stock in August 2014. On May 11, 2016, upon the completion of our acquisition of Annapurna Therapeutics SAS, we changed our name to &#8220;Adverum Biotechnologies, Inc.&#8221; Our common stock is currently listed on The Nasdaq Global Market under the symbol &#8220;ADVM.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 800 Saginaw Drive, Redwood City, CA 94063, and our telephone number is (650) 656&#8209;9323. Our website address is www.adverum.com. We make available on our website, free of charge, our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding our filings at www.sec.gov. The information found on our website is not incorporated by reference into this Annual Report on Form 10-K or any other report we file with or furnish to the SEC.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_22"></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects. Further, the current coronavirus (&#8220;COVID-19&#8221;) pandemic and actions taken to address the pandemic may exacerbate the risks described below.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years or longer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs for at least twelve months from the date of this filing. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into 2024. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials and expected investments into our manufacturing capabilities, and changing circumstances beyond our control may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned through collaboration agreements and public or private financings. If we run low on capital and are unable to successfully raise additional funds on terms acceptable to us, we may need to significantly curtail some or all of our development activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require substantial future capital in order to complete the nonclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or ongoing clinical trials of our product candidates could cause an increase in our spending levels, as would other corporate activities, such as expenses related to manufacturing supply of our product candidates. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the type, number, scope, progress, expansion costs, results of and timing of any future nonclinical studies and clinical trials of any of our product candidates which we are pursuing or may choose to pursue in the future;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), including any additional clinical trials or nonclinical studies the FDA or other regulatory authorities outside the U.S. may require evaluating the safety of our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including internal and external commercial manufacturing;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing sales and marketing capabilities and enhanced internal controls over financial reporting;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain partnering arrangements for development; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain funding on a timely basis, we will be unable to complete any future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are in the early stages of development and will require substantial nonclinical and/or clinical development and testing, manufacturing process improvement and validation, bridging studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful completion of nonclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers or developing our own manufacturing capabilities that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing market share while competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA or marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (&#8220;EMA&#8221;) and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development has inherent risk. Our lead product candidate, ADVM-022 for the treatment of wet age-related macular degeneration (&#8220;wet AMD&#8221;) uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may experience unexpected results in clinical trials in the future, such as the dose-limiting toxicity at the 6 x 10&#94;11 vg/eye (&#8220;6E11&#8221;) dose tested in the INFINITY trial in diabetic macular edema (&#8220;DME&#8221;) patients. Although we will be bound by the generally applicable laws governing grant of approval, the fact that our product is a gene therapy and the broad patient population that it is intended to treat means that the safety and efficacy of our product and the related clinical data will be under increased scrutiny by competent authorities. There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors are safe and effective for use in their target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of serious complications or side effects that outweigh the therapeutic benefit in connection with or during use of our product candidates, either in nonclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of nonclinical studies and clinical trials, animal models and patients may experience changes in their health, including illnesses, injuries and discomforts. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. In addition, patients may not comply with the requirements of the study, such as missing physician visits or not taking eye drops as prescribed, which may result in changes to their health or vision that are then attributed to the product candidate. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. For example, a dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial in DME patients resulted in our announcement on July 22, 2021 that we were discontinuing development of ADVM-022 for the DME indication. It is possible that as we test ADVM-022 and other product candidates, in current and future clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, including the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that one or more of our product candidates causes serious or life-threatening side effects, or side effects that outweigh the therapeutic benefit of the product candidate, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a patient experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate in order to understand the safety of our product candidates. The patients we enroll in our clinical trials for our current product candidates are generally less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the patients enrolled in our wet AMD trials are often geriatric and have other health conditions unrelated to wet AMD. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a patient in any of these or subsequent trials was related to ADVM-022, nor can we assure you that the FDA or other regulatory authorities outside the U.S. responsible for reviewing the safety of ADVM-022 will agree with our determination. If a patient in one of our clinical trials experiences a negative health event, and that event is misattributed to ADVM-022, the trial and other trials of ADVM-022 may be placed on clinical hold, and regulatory approval of ADVM-022 may be delayed or denied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if a patient enrolled in one of our clinical trials experiences a negative health event, they may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because patients we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC that enroll a small number of patients, this risk is increased.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates built on adeno-associated viral vector (&#8220;AAV&#8221;) vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, ocular inflammation is a known side effect of ADVM-022 administration, but the duration of inflammation caused by ADVM-022, our ability to manage that inflammation using steroids or other anti-inflammatory or immunomodulatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. If we are unable to manage this inflammation appropriately, the FDA or other regulatory authorities outside the U.S. may not approve ADVM-022. Even if we achieve marketing approval, doctors may not prescribe, and patients may not use, ADVM-022 or our other product candidates if they deem the levels or risk of inflammation to be unacceptable. Further, patients treated with ADVM-022 could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies in the future. In addition, patients previously treated with or exposed to other AAV-based gene therapies could develop antibodies against AAV.7m8 and/or the aflibercept protein, which could reduce or eliminate the effectiveness of ADVM-022 or could cause unanticipated adverse reactions to ADVM-022. Studies have also found that intravenous delivery of certain AAV vectors at high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any protein or injection of gene therapies that express a therapeutic protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to intravitreal injection, such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our lead product candidate, ADVM-022, is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though EYLEA&#174; (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed as a gene therapy treatment modality. If such side effects are serious or life-threatening, the development of our product candidate and future product candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The results of nonclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology. Promising nonclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a nonclinical model, including non-human primate models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. Success in nonclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through nonclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may only become apparent when the candidate is tested in human patients suffering from the relevant disease. Furthermore, the initiation of future trials for a product candidate, such as our planned Phase 2 clinical trial for ADVM-022 in wet AMD to explore additional doses with new enhanced prophylactic steroid regimens, which we anticipate will include local steroids and a combination of local and systemic steroids, will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, the FDA and/or other regulatory authorities outside the U.S. may still conclude that the product candidate has not demonstrated a beneficial risk/benefit profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on our gene therapy platform and our future success depends on the successful development of product candidates based on this platform. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible, and scalable manufacturing process or transferring that process to external commercial manufacturing sites, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the clinical trial requirements of the FDA, EMA and other regulatory authorities outside the U.S. and the criteria these regulators may use to determine the quality, safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other product types, which are better known or more extensively studied to date. The FDA only recently approved the first in vivo gene therapies, LUXTURNA&#174; and ZOLGENSMA&#174;, and FDA approvals of gene therapy products to date have been generally for rare diseases with limited treatment options. Because we are targeting a broad population of patients with wet AMD, the benefit-risk profile of ADVM-022 may be subject to greater scrutiny by regulatory authorities. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory authorities have more substantial experience.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, before a clinical trial can begin to enroll at a site, each clinical site's Institutional Review Board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess appropriateness to conduct the clinical trial at that site. In addition, adverse events in clinical trials of gene therapy products conducted by others may cause the FDA or other regulatory authorities outside the U.S. to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change chemistry, manufacturing, and controls requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so or the consultations take longer than we expect, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in our clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating and patient&#8217;s safety concerns over participating in a clinical trial, including during a pandemic. We will be required to identify and enroll a sufficient number of patients for any clinical trials for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of rare diseases, a relatively small number of individuals in the U.S. (fewer than 200,000) are impacted, and therefore, there is a limited patient pool from which to draw for clinical trials. Enrollment of eligible patients with rare or orphan diseases may be limited or slower than we anticipate in light of the small patient populations involved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek initial marketing approval of our product candidates in the U.S. and/or Europe and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or the EMA or other regulatory authorities outside the U.S. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if patients and investigators are unwilling to participate in our gene therapy studies because of the dose-limiting toxicity at the 6E11 dose tested in the INFINITY trial, or because of negative publicity from other adverse events in the biotechnology or gene therapy industries or inadequate results in our nonclinical studies or clinical trials or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, or conduct of clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an AAV delivery system, with which host integration has been less of a concern. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may choose not to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nonclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities outside the U.S. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable regulatory authorities outside the U.S. can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities outside the U.S. that a product candidate is safe and effective for any indication;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S. or the other regulatory authorities outside the U.S.;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our interpretation of data from nonclinical studies or clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in the manufacturing processes, analytical testing, our facilities, or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable regulatory authorities outside the U.S. in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues or further patient follow up occurs and more patient data become available. For example, although we have periodically announced interim data from patients in our OPTIC trial, which showed all ADVM-022 related adverse events as mild to moderate in severity, there is no guarantee that in the future, we will not have more severe drug- or treatment-related adverse events in patients treated with ADVM-022, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of patients are enrolled with different dosages and other treatment conditions under our protocol. These different doses, populations, and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of supplemental injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fast Track designation for ADVM&#8209;022 may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that ADVM&#8209;022 will receive marketing approval in the United States.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received Fast Track designation for ADVM&#8209;022 in September 2018 for the treatment of wet AMD. The FDA may grant Fast Track designation to a drug that is intended to treat a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical needs. The FDA provides opportunities for frequent interactions with the review team for a Fast Track product, including pre-investigational new drug application (&#8220;IND&#8221;) meetings, end-of-phase 1 meetings, and end-of-phase 2 meetings with the FDA to discuss study design, extent of safety data required to support approval, dose-response concerns, and use of biomarkers. A Fast Track product may also be eligible for rolling review, where the FDA reviews portions of a marketing application before the sponsor submits the complete application.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, Fast Track designation for ADVM&#8209;022 may not result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, the FDA may rescind the Fast Track designation for ADVM&#8209;022 if FDA later determines that ADVM&#8209;022 no longer meets the qualifying criteria for Fast Track designation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to successfully develop and maintain robust and reliable manufacturing processes for our product candidates, we may be unable to advance clinical trials or licensure applications and may be forced to delay or terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of commercially viable manufacturing processes typically is very difficult to achieve, is often very expensive and may require extended periods of time. As we develop, seek to optimize, and operate the ADVM-022 manufacturing process, we will likely face technical and scientific challenges, considerable capital costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical manufacturing campaigns or process validation campaigns. For example, all Good Manufacturing Practices (&#8220;GMP&#8221;) activities at our Redwood City facility, and external manufacturing, testing, and distribution partners are subject to significant health authority regulation with respect to manufacturing and testing our product candidates. If we are unable to satisfy these regulatory requirements, or if we are unable to solve the technical, scientific, and other challenges described above, we may be unable to manufacture a sufficient supply of our product candidates for our clinical trials and may be forced to delay or terminate our development programs. Additionally, changes in manufacturing processes (including cell lines), equipment or facilities (including moving manufacturing or testing from one of our facilities to another one of our facilities or a third-party facility, or from a third-party facility to one of our facilities) may require us to conduct additional studies to demonstrate comparability in order to receive regulatory approval of any manufacturing modifications. As a result, we could experience manufacturing delays that prevent us from completing our clinical studies in a timely manner, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may revise the process that we used to manufacture ADVM-022 for our Phase 1 clinical trial. Before we use a revised process in future clinical trials, we must submit analytical comparability data to the FDA to demonstrate that the process changes have not altered ADVM-022 in a manner that undermines the applicability of the clinical data from our Phase 1 clinical trial. If the FDA does not find our analytical comparability data sufficient, the FDA could place our IND on clinical hold until we conduct additional nonclinical or clinical comparability studies demonstrating that the ADVM-022 manufactured by our revised process and our previous process are materially equivalent, which could substantially delay the development process. If we make further changes to the manufacturing process of ADVM-022 in the future, the FDA may require additional comparability studies. For example, the FDA could require additional comparability studies to demonstrate that ADVM-022 manufactured in its current facilities is comparable to ADVM-022 manufactured at future commercial supply sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether any required comparability studies will begin as planned, will need to be restructured or will be completed on schedule, or at all. If the results of these comparability studies are not positive or are only modestly positive or if there are safety concerns, we may be delayed in obtaining marketing approval for ADVM-022 or not obtain marketing approval at all. Our product development costs also will increase if we experience delays in testing or regulatory approvals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to produce sufficient quantities of our products at acceptable costs, we may be unable to meet clinical or potential commercial demand, lose potential revenue, have reduced margins, or be forced to terminate a program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the complexity of manufacturing our products, we may not be able to manufacture sufficient quantities to meet clinical or potential commercial demand. Our inability to produce enough of a product meeting all release acceptance criteria at acceptable costs may cause us to be unable to meet clinical or potential commercial demand, to lose potential revenue, to have reduced margins, or to be forced to discontinue such product.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop, seek to optimize and operate the ADVM-022 manufacturing process, we will likely face technical and scientific challenges, considerable costs, and potential difficulty in recruiting and hiring experienced, qualified personnel. There may also be unexpected technical or operational issues during clinical or commercial manufacturing campaigns. As a result, we could experience manufacturing delays that prevent us from commercializing ADVM-022, if approved, on a profitable basis, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our manufacturing processes will subject us to a variety of U.S. federal, state and local laws and regulations governing the use, generation, manufacture, storage, handling and disposal of hazardous materials and wastes resulting from their use, as well as comparable legislation and regulations outside of the U.S. We will incur significant costs in complying with these laws and regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene therapy products are novel and complex and have only in limited cases been manufactured at scales sufficient for pivotal trials and commercialization. Few pharmaceutical contract manufacturers specialize in gene therapy products and those that do are still developing appropriate processes and facilities for large-scale production. In addition, certain of our contract manufacturing partners are currently committed to COVID-19 vaccine and therapeutics production projects, including those funded by the U.S. government, leading to increased competition for a limited number of contract manufacturing slots. If we are unable to secure adequate manufacturing capacity from our contract manufacturing partners, or if our currently contracted slots are cancelled or delayed in order to prioritize COVID-19 projects, we may be unable to produce sufficient quantities of our product candidates for our development programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain, and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product used in clinical trials or approved for commercial sale must be manufactured and tested in accordance with GMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GMP regulations enforced by the FDA through its facilities inspection program as well as other regulations enforced by other regulatory authorities outside the U.S. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with GMP regulations to the satisfaction of the FDA or other regulatory authorities outside the U.S. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. If the facility does not pass a pre-approval plant inspection, the FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect our manufacturing facilities or those of our third-party contractors involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authorities outside the U.S. determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in laws and governmental policies may have an effect on regulations. For example, on January 31, 2020, the United Kingdom (&#8220;UK&#8221;) withdrew from the European Union (&#8220;EU&#8221;), commonly referred to as Brexit. Pursuant to the formal withdrawal arrangements agreed between the UK and the EU, the UK was subject to a transition period until December 31, 2020, or the Transition Period, during which EU rules continued to apply. The UK-EU Trade and Cooperation Deal, which has applied since the end of the Transition Period, provides for tariff-free trade of goods, but not services, between the UK and the EU, but there may however be additional non-tariff costs which did not exist prior to the end of the Transition Period. Further, should the UK diverge from the EU from a regulatory perspective in relation to medical products, tariffs could be put into place in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the body of the UK-EU Trade and Cooperation Agreement includes general terms which apply to medicinal products, greater detail on sector-specific issues is provided in an Annex to the Agreement. The Annex provides a framework for the recognition of GMP inspections and for the exchange and acceptance of official GMP documents. The regime does not, however, extended to procedures such as batch release certification. Among the changes that will now occur are that Great Britain (England, Scotland and Wales) will be treated as a third country. Northern Ireland will, with regard to EU regulations, continue to follow the EU regulatory rules. As part of the UK-EU Trade and Cooperation Agreement, the EU and the UK will recognize GMP inspections carried out by the other Party and the acceptance of official GMP documents issued by the other Party. The UK-EU Trade and Cooperation Agreement also encourages, although it does not oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual recognition are batch testing and batch release. The UK has unilaterally agreed to continue to accept EU batch testing and batch release, two years notice will be provided of any change to such a policy. However, the EU continues to apply EU laws that require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in the UK must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great Britain will have a separate regulatory submission process, approval process and a separate national MA. Northern Ireland will, however, continue to be covered by the marketing authorizations granted by the European Commission (&#8220;EC&#8221;).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the immediate term, there are currently delays on cross-border trade between the UK and the EU as businesses and governmental bodies adapt to the new arrangements. We and our contract vendors currently rely on other contractors based in the UK. The end of the Transition Period and implementation of new governmental policies associated with Brexit may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time, inspect our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our third-party contractors fail to maintain regulatory compliance, the FDA or other regulatory authorities outside the U.S. can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, revocation of a pre-existing approval, injunction, seizure of product, or other civil or criminal penalties or closing one or more manufacturing or testing facilities. As a result, our business, financial condition and results of operations may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. Alternative contractors could need to be qualified through a BLA supplement which could result in further delay. The regulatory authorities may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Changing contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Due to the complexity of manufacturing our product candidates, we may not be able to manufacture sufficient quantities to support our clinical trials. Delays in manufacture and supply by our contract manufacturing partners as a result of the COVID-19 pandemic may also cause delays in their ability to supply the amount of our product that we have ordered and on which we have based our expected development timelines. Our inability to produce enough of a product candidate at acceptable costs may result in the delay or termination of development programs. In addition, focus by certain of our contract manufacturing partners on manufacturing activities related to the COVID-19 pandemic may cause delays in their ability to supply our product or reductions in the amount of product they are able to supply.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error, or transportation or storage conditions of the product. Even minor deviations from prescribed manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our contract manufacturers must comply with the FDA&#8217;s GMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable regulatory authorities in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow GMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging, storage, or distribution of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We continue to develop the manufacturing process for late-stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, process development, assay development, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to independently conduct all aspects of our vector production, product manufacturing, product testing, protocol development, protocol performance, and research. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements with these third parties and if we do enter into agreements with these third parties, any of these third parties may not be successful at fulfilling their contractual obligations or may choose to terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for vector production, process development, assay development, product manufacturing, product testing, protocol development, protocol performance, and research activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our nonclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vector production, product manufacturing, and product testing are conducted in accordance with applicable GMP requirements and other applicable regulatory requirements; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other research, process development, and assay development are conducted in accordance with applicable industry and regulatory standards and norms</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any of which we may not be able to do.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to rely on third-party manufacturers, which entails risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced control as a result of using third-party manufacturers for some or all aspects of manufacturing activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer or supplier, or their commitments to COVID-19 vaccine and therapeutics production projects that may reduce available manufacturing capacity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct some nonclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct all aspects of our nonclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct nonclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer those patients to another qualified clinical trial site.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities outside the U.S. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to conduct research and to develop and manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that they become known </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, academic institution that we collaborate with often require rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patent applications may not result in any patents being issued;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">result in costly litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divert the time and attention of our technical personnel and management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cause development delays;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, we have received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. While we do not believe Virovek has the right to terminate the agreement, if it were terminated, we may be unable to obtain a new license to Virovek technology on commercially reasonable terms, if at all. If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California, Cornell University, and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Hatch-Waxman exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded to us, if any, may not be commercially meaningful.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates. Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension&#8212;and no guarantee any such extension would confer patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;). Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, the Hatch-Waxman Act permits a patent restoration term of up to five years beyond the normal expiration of the patent, which is limited to the approved product or approved indication. In the United States, patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval; only one patent may be extended; and extension is available for only those claims covering the approved drug, a method for using it, or a method for manufacturing it. Similar extensions of patent term are available in Europe and other jurisdictions. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation by the regulatory authorities in the EU of applicable EU regulations governing data and market exclusivity may impact our entitlement to data and market exclusivity. The revisions to the orphan drug legislation in the EU and the EU rules governing Supplementary Protection Certificates that are currently being discussed may also impact our entitlement to this exclusivity. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some intellectual property that we have in-licensed may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property rights we have licensed, including certain rights related to our proprietary AAV.7m8 capsid, were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability, or that of our sublicensees, to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sublicensing of patent and other rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our diligence obligations under the license agreement, what activities satisfy those diligence obligations, and to what extent those obligations are relieved or delayed by external factors beyond our control, such as the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of our payment obligations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our rights upon termination of such agreement; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final marketing approval for our product candidates by the FDA or other regulatory authorities outside the U.S. for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we are able to successfully complete our clinical trials and submit a BLA, and/or an MAA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory authorities will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in policies from the FDA or other regulatory authorities outside the U.S. during the period of product development, clinical trials and FDA regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of clinical efficacy, including duration of efficacy, and safety compared to other more-established products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of our targeted patient population and other limitations or warnings contained in any labeling approved for our products by the FDA or other applicable regulatory authorities outside the U.S., including the possible inclusion of a &#8220;black box warning&#8221; from the FDA or other applicable regulatory authorities outside the U.S. alerting health care providers to potential serious side effects associated with using a product or the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of new therapeutic options by health care providers and their patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new procedures or methods of treatment that may be more effective in treating or may reduce the incidences of wet AMD, or other conditions that our product candidates are intended to treat;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost-effectiveness;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable publicity relating to the product candidate; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products and defend and enforce our intellectual property rights relating to our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering a gene encoding a therapeutic antibody fragment similar to ranibizumab (LUCENTIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the treatment of wet AMD and diabetic retinopathy, which competes for the same patients, study site resources, and personnel as ADVM-022. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New developments, including the development of other biotechnology and gene therapy technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, LUCENTIS and EYLEA are currently available in the U.S. for treatment of wet AMD. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, ADVM-022 for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long-acting delivery devices and gene therapy. LUCENTIS and EYLEA are anti-VEGF therapies that are well established and widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of wet AMD. There are several other companies with marketed products or products in development for the treatment of wet AMD, including 4D Molecular Therapeutics, Bayer, Graybug Vision, Hoffmann-La Roche Ltd., Kodiak Sciences, Novartis, Opthea, Regeneron and REGENXBIO.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities outside the U.S. for compliance with GMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or withdraw regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">institute import holds;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a REMS plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA and other regulatory authorities outside the U.S. strictly regulate the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the competent regulatory authority as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and regulatory and enforcement authorities outside the U.S. actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit under its health plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the United States, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for one such product, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payers in the United States, even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain regulatory approvals. Our product candidates may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans. or, if they do, the level of payment may not be sufficient to allow the company to sell its products at a profit. The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;Affordable Care Act&#8221;), was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of the Affordable Care Act have been subject to executive, Congressional, and judicial challenges as well as efforts to repeal, replace, or otherwise modify them or alter their interpretation and implementation. For example, the Tax Cuts and Jobs Act of 2017 included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, on June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including, among others, policies that undermine protections for people with pre-existing conditions, demonstrations and waivers under Medicaid and the Affordable Care Act that may reduce coverage or undermine the programs thereunder, including work requirements, and policies that make it more difficult to access health benefits through Medicaid or the Affordable Care Act. Additional legislative changes, regulatory changes, and judicial challenges related to the Affordable Care Act remain possible. Any such changes could affect the number of individuals with health coverage. It is possible that the Affordable Care Act, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. For example, on August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, will stay in effect through 2031 unless additional congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020, through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Further, Congress is considering additional health reform measures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. The Biden administration expressed its intent to pursue certain policy initiatives to reduce drug prices. For example, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, Health and Human Services (&#8220;HHS&#8221;) released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. No legislation or administrative actions have been finalized to implement these principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional governmental action could be taken in response to the COVID-19 pandemic, and that such action could affect our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we can initiate clinical trials in the U.S. for our product candidates, we need to submit the results of nonclinical testing to the FDA, along with other information including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. We may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary nonclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA may require us to conduct additional nonclinical testing for any product candidate before it allows us to initiate clinical testing under any IND, or at any stage of clinical development based on concerns that arise as the clinical program progresses or if significant manufacturing change are made to the product during the program, which may lead to additional delays and increase the costs of our nonclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any clinical trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities outside the U.S. failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities outside the U.S. to temporarily or permanently shut down due to violations of GMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process, or in the manufacturing facilities in which our product candidates are made;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection or analysis in a timely and accurate manner;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inspections of clinical trial sites by the FDA or other regulatory authorities outside the U.S., or the finding of regulatory violations by the FDA or other regulatory authorities outside the U.S., or an IRB that require us to undertake corrective action, result in suspension or termination of one or more clinical sites or the imposition of a clinical hold on the IND or that prohibit us from using some or all of the data in support of our marketing applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities outside the U.S. for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">one or more IRBs refusing to approve, suspending or terminating the trial at a clinical site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product development costs will increase if we have delays in testing or approval of any of our product candidates, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of our clinical trials, or if we, the FDA or other regulatory authorities outside the U.S., the IRB, other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the market for our product candidate, if approved, in the treatment of wet AMD or any other indication we seek to treat is smaller than we believe it is, or if our product candidate is approved with limitations that reduce the market size, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are advancing the development of ADVM-022 for the treatment of wet AMD, a disease we believe to be the most common cause of vision loss in adults over the age of 50 in developed countries. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate (including in our rare disease programs), we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with ADVM-022 or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effort to identify patients with diseases we seek to treat is in early stages as we conduct the OPTIC trial of ADVM-022 for the treatment of wet AMD, and we cannot accurately predict the number of patients for whom treatment might be possible or whether the FDA or other regulatory authorities may approve indications for ADVM-022 that are more limited than we expect due to efficacy or safety concerns. For example, some patients have neutralizing antibodies at titer levels that may prevent them from benefiting from ADVM-022. If this patient population is larger than we estimate, the market for ADVM-022 may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic steroid treatment will be required to manage inflammation associated with treatment with ADVM-022, and certain patients cannot be treated with prophylactic steroids. If this proportion of patient population is larger than we estimate, the market for ADVM-022 may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, even if we obtain significant market share for any of our rare disease programs, because the potential target population is very small, we may never achieve profitability despite obtaining such significant market share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, because the target patient population for any of our rare disease programs is relatively small, the pricing and reimbursement of these product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any of our product candidates targeting such rare disease will be adversely affected. The manner and level at which reimbursement is provided for services related to this product candidate (e.g., for administration of such product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates targeting such rare disease.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into development or other strategic collaborations with biotechnology and pharmaceutical companies in the past and may do so again in the future. Research activities under our collaboration agreements are subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments may impose price controls, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, including Member States of the European Economic Area (&#8220;EEA&#8221;), the pricing of prescription pharmaceuticals is subject to governmental control. Additional countries may adopt similar approaches to the pricing of prescription drugs. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. There can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after coverage and reimbursement have been obtained. Reference pricing used by various countries and parallel distribution, or arbitrage between low-priced and high-priced countries, can further reduce prices. Publication of discounts by third-party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no sales, marketing or distribution capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, or distribution capabilities. If any of our product candidates ultimately receive regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to attract and build an effective marketing department or sales force;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our direct sales and marketing efforts may not be successful.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events, such as the dose-limiting toxicity at the 6E11 dose tested in our INFINITY trial, remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, ADVM&#8209;022 expresses the aflibercept protein, which is also the active component in EYLEA. If safety or efficacy issues occur relating to EYLEA, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused us to modify our business practices (including adhering to the previous &#8220;shelter-in-place&#8221; orders and other public health orders, limiting employee travel, and cancelling physical participation in meetings, events and conferences), and we may take further actions that may be required by government authorities or that we determine are in the best interests of our employees, customers, and business partners. We are uncertain that such measures will be sufficient to mitigate the risks posed by the virus and its variants or otherwise be satisfactory to government authorities and how long we will be required to continue these measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating under the previous &#8220;shelter-in-place&#8221; orders and other public health orders has made it more challenging and time-consuming for us to conduct certain of our operations. The effects of operating under the previous &#8220;shelter-in-place&#8221; and other public health orders may continue to negatively impact productivity, disrupt our operations and negatively impact our business and financial condition, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Separately, an increased reliance by us and the companies with which we do business on information technology systems may increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic may also affect our current and planned trials and development programs, possibly affecting our timelines for commercialization. We and our CROs and contract manufacturing organizations (&#8220;CMOs&#8221;) may face disruptions that may affect our ability to conduct and timely complete ongoing clinical trials including disruptions in procuring items that are essential for our development activities, such as materials used in the manufacturing of ADVM-022. We and our CROs and CMOs, as well as clinical trial sites, may face disruptions that affect our ongoing clinical trials arising from staffing disruptions and limitations on our activities and the activities of our CROs and CMOs, and delays in the ability to obtain necessary institutional review board or other necessary site approvals or delays in site initiations or site monitoring visits, as well as other delays at clinical trial sites. We may also face limitations on enrollment and patients withdrawing from our clinical trials or not complying with the protocol procedures, which could delay completion of our clinical trials or adversely affect the data generated by our clinical trials. The previous shelter-in-place orders, or other public health orders and the current general reluctance of people to make in-person visits to healthcare providers for treatment of non-life-threatening ailments may make initiating clinical trial sites, identifying potential patients and enrolling them in our clinical trials, retaining any such patients, ensuring that such patients comply with treatment protocols, and collecting sufficient trial data to progress our clinical programs more difficult. For example, patient concerns related to COVID-19 caused some of our OPTIC trial patients to miss scheduled appointments for fear of contracting the virus which, if this were to be repeated over longer periods of time, could impact our ability to collect data we need. Additionally, our ability to recruit and retain patients and principal investigators and site staff who believe they have heightened risks if exposed to COVID-19 may be limited which may adversely impact our clinical trial operations. The response to the COVID-19 pandemic also could redirect resources with respect to regulatory and intellectual property matters in a way that could adversely impact our ability to progress regulatory approvals and protect our intellectual property. In addition, we may face impediments to regulatory meetings and approvals due to measures that are intended to limit in-person interactions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, due to the limited ability to access our facilities and our reliance on outside vendors who may be similarly affected, our development programs may not proceed along the timelines we previously anticipated. We rely on third-party research facilities, manufacturers, suppliers, and other service providers from other countries and from different parts of the U.S. to provide services and resources necessary to support our research and development plans, to produce our product candidates, and support our clinical trials. Our ability to obtain this necessary support or supplies could be disrupted, or the cost of this support or these supplies could increase, if the operations of these suppliers or service providers, or national and international supply chains, including transportation carriers and transportation hubs, are affected by the COVID-19 pandemic. In addition, if our relationships with our manufacturers, service providers, suppliers, or other vendors are terminated, materially altered, or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative manufacturers, service providers, suppliers, or other vendors or do so on commercially reasonable terms or in a timely or cost-effective manner. Further, we may be subject to the inability or unwillingness of clinical investigators or patients to follow our research protocols as a result of the COVID-19 pandemic. As a result, delays could occur which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. The COVID-19 pandemic may also affect the operations of the FDA or other health regulatory authorities outside the U.S., which could result in delays of meetings, reviews and approvals, including with respect to our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19 and the emergence of new variants, which have caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are taking steps to mitigate all of these effects, the occurrence of any of these disruptions, including of our own operations, could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic continues to impact our business, results of operations, and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the duration and spread or any future resurgence of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the COVID-19 outbreak has subsided, we may experience materially adverse impacts to our business as a result of its global human and economic impact, or as a result of our actions taken and not taken as mitigation measures during the COVID-19 pandemic.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our information technology systems or data, or those of third parties upon which we rely, are or were compromised, we could adverse consequences resulting from such compromise, including but not limited to regulatory investigations or actions; litigation; significant fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; material disruption of our product development programs; and other adverse consequences. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of our business, we and other third parties on which we rely collect, receive, use, process, generate, transfer, make accessible, protect, secure, dispose of, transmit, share, and store sensitive, confidential, and proprietary information, including personal information (such as health-related information and medical information), intellectual property, trade secrets, research and development information, financial information, and other business information. We may rely upon third-party service providers and technologies to operate critical business systems to process sensitive information in a variety of contexts, including, without limitation, encryption and authentication technology, employee email, and other functions. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. We may share or receive sensitive, confidential, and proprietary information with or from third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase.  These threats are becoming increasingly difficult to detect. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation-states, and nation-state-supported actors. We and the third parties upon which we rely may be subject to a variety of evolving threats, including but not limited to social-engineering attacks (including through phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks (such as credential stuffing), personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, telecommunications failures, and other similar threats. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology or the third-party information technology systems that support us and our services. The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy. We use third parties for our business, may share personal information with them, and rely on them to manufacture our product candidates and conduct clinical trials, and similar events relating to their systems could also have a material adverse effect on our business. Despite the implementation of security measures to protect against unauthorized access or disclosure, we and our CROs, contractors, consultants, collaborators, and other related third parties are vulnerable to damage or attacks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ransomware attacks, including by organized criminal threat actors, nation-states, and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions in our operations, disruptions of clinical trials, loss of data and income, reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or regulations prohibiting payments. Further, the COVID-19 pandemic and remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption. A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information. A security incident or other interruption could result in delays to the development and commercialization of our product candidates, disruption of our programs, negative publicity and financial loss. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents.  Certain privacy, data protection, and data security obligations may require us to implement and maintain specific security measures, industry-standard or reasonable security measures to protect our information technology systems and sensitive information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems (including our products), our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. While we are not aware of any such material system failure, accident, or any other security incident to date, any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable privacy, data protection, and data security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal information); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A security incident could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business, delay or impede the development of our products, and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed. In addition, there can be no assurance that we will promptly detect any such disruption or security incident, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy, data protection, and data security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy, data protection, and data security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable state and federal healthcare laws and regulations, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including research and marketing, in the pharmaceutical industry. These laws include anti-kickback, false claims, and healthcare professional payment transparency laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering, arranging for, or recommending the purchase, lease or order of any healthcare item or service for which payment may be made, in whole or in part, under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices may be subject to scrutiny if they do not qualify for an exception or safe harbor. Liability may be established under the federal Anti-Kickback Statute without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. Pharmaceutical and other healthcare companies have faced enforcement actions under the federal civil False Claims Act for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for allegedly causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses. In addition, a claim can be deemed to be false due to failure to comply with legal or regulatory requirements material to the government&#8217;s payment decision. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false claim or statement. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments and other transfers of value made by them to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), certain other healthcare professionals (such as a physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states and localities also mandate implementation of commercial compliance programs, restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs, impose restrictions on drug manufacturer marketing practices, require the tracking and reporting of gifts, compensation and other remuneration to physicians and/or require the registration of pharmaceutical sales representatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decline in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold $10 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to evolving and increasingly stringent obligations related to privacy, data protection, and data security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; interruption of our clinical trials; and other adverse business consequences. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share sensitive, proprietary, and confidential information, including personal information, business data, trade secrets, intellectual property, and data we collect about trial participants in connection with clinical trials. Our processing activities subject us to numerous privacy, data protection, and data security obligations, such as laws, regulations, guidance, industry standards, external and internal policies, contracts, and other obligations that govern processing of personal information by us or on our behalf, including information that we collect or will collect about patients and healthcare providers in connection with clinical trials. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous privacy, data protection, and data security laws and regulations, including those relating to data breach notification and consumer protection. The legislative and regulatory landscape for privacy, data protection, and data security continues to evolve, and there has been an increasing focus on privacy, data protection, and data security issues which may affect our business. Many of these laws differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Federal regulators, state attorneys general, and plaintiffs&#8217; attorneys, including class action attorneys, have been and will likely continue to be active in this space. For example, HIPAA, as amended by HITECH, imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services for them involving individually identifiable health information, as well as their covered subcontractors. We may obtain health information from third parties, such as research institutions, that are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to penalties if we, our affiliates, or our agents obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States have begun to introduce comprehensive privacy, data protection, and data security laws and regulations. For example, California enacted the CCPA, which took effect on January 1, 2020. These obligations include, but are not limited to, providing specific disclosures in privacy notices and affording California residents certain rights related to their personal information.  The CCPA allows for statutory fines for noncompliance (up to $7,500 per violation). Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase compliance costs and potential liability with respect to other personal information we maintain about California residents. Additionally, the CCPA will be expanded substantially on January 1, 2023, when the CPRA becomes fully operative. The CPRA will, among other things, give California residents the ability to limit use of certain sensitive personal information, expand the types of data breaches subject to the CCPA&#8217;s private right of action, and establish a new California Privacy Protection Agency to implement and enforce the new law. Other states have enacted privacy, data protection, and data security laws. For example, Virginia recently enacted a comprehensive privacy, data protection, and data security law, the Consumer Data Protection Act, and Colorado similarly enacted the Colorado Privacy Act, both laws of which will become effective in 2023 and share similarities with but differ from the CCPA and CPRA. The obligations to comply with the CCPA and other evolving legislation may require us, among other things, to update our notices and develop new processes internally and with our partners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, an increasing number of laws, regulations, and industry standards apply to privacy, data protection, and data security. For example, the EU GDPR, the United Kingdom&#8217;s GDPR (&#8220;UK GDPR&#8221;), Brazil&#8217;s LGPD, and China&#8217;s Personal Information Protection Law (&#8220;PIPL&#8221;) impose strict requirements for processing personal information. The processing of sensitive personal information, such as physical health condition and medical information, may impose heightened compliance burdens under the EU GDPR and is a topic of active interest among foreign regulators. The EU GDPR and UK GDPR confer a private right of action to data subjects and consumer associations, the right to lodge complaints with supervisory authorities, the right to seek judicial remedies, and the right to obtain compensation for damages. The obligations under the EU GDPR and UK GDPR may be onerous and adversely affect our business, financial condition, results of operations and prospects. Compliance with the EU GDPR and UK GDPR is a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with any European activities. In the event we enroll subjects in our ongoing or future clinical trials in Europe, we may be subject to additional privacy, data protection, and data security restrictions, including restrictions relating to the collection, use, storage, transfer, and other processing of personal information, including personal health data, regarding individuals in Europe as governed by the EU GDPR and UK GDPR. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal information transfer laws, which could make it more difficult to transfer information across jurisdictions (such as transferring or receiving personal information that originates in the EU or in other foreign jurisdictions). Existing mechanisms that facilitate cross-border personal information transfers may change or be invalidated. For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal information to countries outside the EEA that the EC does not consider to provide an adequate level of data privacy and security, such as the United States. The EC released a set of Standard Contractual Clauses (&#8220;SCCs&#8221;), which is a valid mechanism to transfer personal information outside of the EEA. In addition, Switzerland and the UK similarly restrict personal information transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal information protection, and certain countries outside Europe (e.g. Russia, China, Brazil) have also passed or are considering laws requiring local data residency or otherwise impeding the transfer of personal information across borders, any of which could increase the cost and complexity of doing business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot implement a valid mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal information from Europe or other jurisdictions. In the event that we expand our operations abroad, the inability to import personal information to the United States could significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trials in Europe or elsewhere, limiting our ability to collaborate with contract research organizations, service providers, contractors, and other companies subject to such cross-border data transfer or localization laws, or requiring us to increase our personal information processing capabilities and infrastructure in foreign jurisdictions at significant expense. European privacy, data protection, and data security laws may decrease demand for our products and services if affected customers seek alternatives that do not involve such transfers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the UK&#8217;s departure from the EU, has created uncertainty with regard to data protection regulation in the UK. In particular, it is unclear how data transfers to and from the UK will be regulated. On June 28, 2021, the EC issued an adequacy decision under the EU GDPR which allows transfers of personal information from the EEA to the UK to continue without restriction for a period of four years ending June 27, 2025. If the adequacy decision is withdrawn or not renewed, transfers of personal information from the EEA to the UK will require a valid transfer mechanism and companies making such transfers may be required to implement new processes and put new agreements in place to continue making such transfers. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations related to privacy, data protection, and data security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires significant resources and may necessitate changes to our information technologies, systems, and practices and to those of any third parties that process personal information on our behalf.  In addition, these obligations may require us to change our business model. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. Any failure or perceived failure by us or our partners, CROs, CMOs, collaborators, and other related third parties to comply with privacy, data protection, and data security obligations, we may face significant consequences. These consequences may include, but are not limited to, government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-related claims); additional reporting requirements and/or oversight; bans on processing personal information; orders to destroy or not use personal information; and imprisonment of company officials (for example, under HIPAA). Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, clinical trials); inability to process personal information or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or revision or restructuring of our operations.  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our development partners, third-party manufacturer and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and any of our future development partners or CROs are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal and state health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid, and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legislation enacted on December 22, 2017, known as the Tax Cuts &amp; Jobs Act (&#8220;TCJA&#8221;) enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. In addition, in response to the COVID-19 pandemic, the CARES Act was signed into law in March 2020. The CARES Act modifies certain of the changes made by the TCJA. Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, and the deductibility of expenses under the TCJA, as amended by the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. For example, proposals have been made in Congress (which have not yet been enacted) that would make various changes to the federal income tax laws applicable to corporations.  In addition, it is uncertain if and to what extent various states will conform to the TCJA, as amended by the CARES Act, or any newly enacted federal tax legislation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the TCJA, federal NOLs incurred in taxable years beginning after 2017 and in future years may be carried forward indefinitely, but the deductibility of such federal NOLs for taxable years beginning after 2020 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. In connection with our acquisition of Annapurna in May 2016, we determined that certain NOLs and research and developments tax credits for both federal and state purposes were severely limited and therefore we removed a significant amount of NOLs and research and development tax credits from our deferred tax assets. In addition, we may have experienced an ownership change as a result of the February 2018 underwritten public offering of our common stock, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the amount of the NOLs and research credit carryforwards presented in our financial statements could be limited and may expire unutilized. In addition, state suspensions of the ability to use NOLs, and research credits such as California&#8217;s June 2020 temporary suspension and limitation on use of such attributes, may limit our ability to use our NOLs and research credits to offset state taxable income and taxes.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll and dose patients in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct additional nonclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of any clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the U.S. and foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in manufacturing adequate supply of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity relating to the gene therapy market generally, including with respect to other products and potential products in such markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our stock by insiders and stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the continuing effects of the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, pursuant to our at-the-market sales agreement, licensing or collaboration arrangements, or acquisitions, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants and debt financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limitation of the removal of directors by the stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a staggered board of directors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been subject to securities class action lawsuits in the past, and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management&#8217;s time and attention from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we and certain of our former officers were involved in purported securities class action lawsuits, which have since been settled. The purported securities class action lawsuits asserted that the defendants violated the Exchange Act and the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and alleged that the defendants who are no longer at Adverum made materially false and misleading statements and omitted allegedly material information related to, among other things, the Phase 2a clinical trial for AVA&#8209;101, a program which was discontinued in 2015, and the prospects of AVA-101. We settled these lawsuits for $13.0 million, of which $1.0 million we contributed to cover our indemnification obligations to the underwriters, and the remainder was contributed by our insurers. Any future litigation of this type could result in payment of damages or settlement fees and diversion of management&#8217;s attention and resources, any of which could adversely impact our business. Monitoring and defending against legal actions are time-consuming for our management and detracts from our ability to focus fully on our business activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or addition of cohorts to clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">nature and terms of stock-based compensation grants; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">derivative instruments recorded at fair value.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation and bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a breach of fiduciary duty;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us arising under the Delaware General Corporation Law; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim against us that is governed by the internal-affairs doctrine.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated bylaws provide</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our certificate of incorporation and bylaws. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These exclusive forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find either exclusive-forum provision in our certificate of incorporation or bylaws to be inapplicable or unenforceable in an action, we may incur </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional costs associated with resolving the dispute in other jurisdictions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all of </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could seriously harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Red</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">wood City, California, consisting of approximately 120,000 square feet of office, laboratory, and process development space under a lease that will expire in December 2031.  We also occupy approximately 21,000 square feet of laboratory and support space under a sublease that will expire in June 2022.</span></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our facilities are adequate and suita</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ble for our current needs. </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;ADVM&#8221;.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 18, 2022, we had approximately 17 holders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Reserved</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_82"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion of our financial condition and results of operations in conjunction with the financial statements and the related notes included elsewhere in this Annual Report on Form 10-K. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this Annual Report on Form 10-K, particularly in &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221;</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_1806"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of December&#160;31, 2021, we had an accumulated deficit of $648.1 million. We expect to incur substantial expenses and increasing losses from operations in the foreseeable future as we continue our research and development efforts, advance our product candidates through nonclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we may in the future generate revenue from a variety of sources, including license fees, milestone and research and development payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved, to date we have not generated any revenue from product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party CROs to carry out our clinical development and we do not have a sales organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial and increasing expenditures in the foreseeable future for the development and potential commercialization of our product candidates. We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through nonclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had $305.2&#160;million in cash, cash equivalents and short-term investments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash, cash equivalents and short-term investments are sufficient to fund operations into 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized $7.5 million of license revenue during the year ended December&#160;31, 2021. We did not recognize any revenue during the year ended December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate nonclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage nonclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We anticipate increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net primarily comprises interest income on our cash equivalents and investments in marketable securities.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Judgments and Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. We base our estimates on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued and Prepaid Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate our accrued and prepaid research and development expenses as of each balance sheet date. This process involves reviewing contracts and purchase orders, reviewing the terms of our license agreements, communicating with our applicable personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. Expenses that are paid in advance of performance are deferred as a prepaid expense and expensed as the services are provided.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Examples of estimated accrued research and development expenses include fees to:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">contract manufacturers in connection with the production of clinical trial materials;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">CROs and other service providers in connection with clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">investigative sites in connection with clinical studies;</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">vendors in connection with nonclinical development activities; and</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">services providers for professional service fees such as consulting and related services.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our understanding of the status and timing of services performed relative to the actual status and timing may vary and may result in our reporting changes in estimates in any particular period. To date, there have been no material differences from our estimates to the amount actually incurred. However, due to the nature of these estimates, we cannot assure you that we will not adjust our estimates in the future as we become aware of additional information about the status or conduct of our clinical studies or other research activities. For the years ended December&#160;31, 2021 and 2020, there were no material changes from our estimates of accrued research and development expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for leases under Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) (&#8220;Topic 842&#8221;) effective  January 1, 2019. For our long-term operating leases, we recognize a right-of-use asset and a lease liability on our consolidated balance sheets. The lease liability is determined as the present value of future lease payments reduced by lease incentives, if any, using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, we estimate our credit rating, adjust the credit rating for the nature of the collateral, and benchmark the borrowing rate against observable yields on comparable securities with a similar term. We base the right-of-use lease asset on the lease liability adjusted for any prepaid or deferred rent. We determine the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the carrying value of amortizable long&#8209;lived assets, whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values. For example, in connection with the early termination of a lease in 2021, we tested the recoverability of the carrying amount of the asset group. The carrying amount of the asset group, consisting of right-of-use assets and leasehold improvements, related to the lease termination exceeded our anticipated undiscounted cash flows. As a result of our evaluation, we recorded an impairment charge of $1.1 million, which includes $0.8 million associated with the right-of-use assets and $0.3 million associated with leasehold improvements, for the year ended December&#160;31, 2021. The assets indicated as impaired were written down to the estimated fair value, which was determined using the terms of the termination and sublease agreements. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation costs related to stock-based awards granted to employees based on the estimated fair value of the awards on the date of grant. We estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black&#8209;Scholes valuation model for stock options, and using intrinsic value, which is the closing price of our common stock on the grant date for the restricted stock units (&#8220;RSUs&#8221;). The fair value of performance stock units (&#8220;PSU&#8221;) is estimated based on the closing sale price of our common stock on the date of grant. Expense recognition of PSU commences when the associated performance-based criteria are determined to be probable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the grant-date fair value of the stock-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to assist us in determining the fair value of our stock options, which includes our employee stock purchase plan. The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the expected volatility on our historical stock price volatility. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We derive the expected term using the &#8220;simplified&#8221; method that determines the expected term as the average of the time-to-vesting and the contractual life of the options. The expected term of the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) rights equals to the six-month look-back period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We base the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have never paid any dividends and do not plan to pay dividends in the foreseeable future, and, therefore, used an expected dividend yield of zero in the valuation model.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize deferred income taxes for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. We periodically evaluate the positive and negative evidence bearing upon realizability of our deferred tax assets. Based upon the weight of available evidence, which includes our historical operating performance, reported cumulative net losses since inception and difficulty in accurately forecasting our future results, we maintained a full valuation allowance on the net deferred tax assets as of December&#160;31, 2021 and 2020 of approximately $154.7&#160;million and $94.6&#160;million, respectively. We intend to maintain a full valuation allowance on the federal, state and foreign deferred tax assets until sufficient positive evidence exists to support reversal of the valuation allowance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $393.4&#160;million to offset future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2021, we also had U.S. state NOL carryforwards of approximately $227.1&#160;million to offset future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2021, we also had approximately $50.1&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record unrecognized tax benefits as liabilities and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available. As of December 31, 2021, the total amount of unrecognized tax benefits that would affect our effective tax rate, if recognized, is $1.1 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to recognize interest and penalties related to income taxes as a component of income tax expense. We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, we accrued $257,000 interest and penalties related to uncertain tax positions. There are no ongoing examinations by tax authorities at this time. </span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Results of Operations for the Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,641&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146,122)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,950)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,172)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(975)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,393)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,147)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (provision)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,507)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,033)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $7.5 million license revenue for the year ended December&#160;31, 2021 was related to an upfront payment received in January 2021 upon execution of a license agreement entered with Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;). We recognized no revenue for the year ended December&#160;31, 2020. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased $15.9 million to $89.2 million for the year ended December&#160;31, 2021 from $73.3&#160;million for the year ended December&#160;31, 2020. This overall increase was primarily related to a $10.3&#160;million increase in personnel-associated costs including salaries, stock-based compensation expense, and bonus mainly driven by headcount increase from 114 employees as of December&#160;31, 2020 to 133 employees as of December&#160;31, 2021, a $5.1&#160;million increase in facilities costs as we entered into new leases during the year, a $2.2 million increase in other research and development services, a $2.0 million increase in expenses for consultants and contractors and a $1.0 million in clinical trials-related expenses; partially offset by a decrease of $5.4 million in material productions and bioanalytics expenses due to timing of cost incurred related to product candidate ADVM-022 and earlier-stage research programs. Stock-based compensation expense included in research and development expenses was $8.9 million for the year ended December&#160;31, 2021, compared to $7.1&#160;million for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, our research and development activities were attributable to our wet AMD, DME, rare disease programs and earlier-stage research programs. We expect that research and development expenses will increase in future periods as we continue to invest in advancing our gene therapy product candidate ADVM-022 and earlier-stage research programs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased $19.8 million to $64.4 million for the year ended December&#160;31, 2021 from $44.6&#160;million for the year ended December&#160;31, 2020, primarily related to an increase of $7.3 million in personnel-associated costs including higher salaries and stock-based compensation expense as a result of higher average headcount during 2021. The overall increase also reflects increase of $6.0 million in professional services mainly for investor relations and legal fees in connection with our proxy contest ended in May 2021, $2.9&#160;million in taxes, insurances, and license fees primarily due to state taxes on revenue and increase in insurance premiums, $2.3 million in rent and facilities related expenses for new leases that commenced in 2021, and $1.1 million of impairment charges for long-lived assets related to a leased facility terminated in November 2021. Stock-based compensation expense included in general and administrative expenses was $16.3 million for the year ended December&#160;31, 2021, compared to $13.3 million for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that general and administrative expenses will increase in future periods as we continue to support advancing our gene therapy programs. We anticipate increased expenses related to audit, legal, finance and investor functions to support our organizational growth.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $1.0 million in net other income for the year ended December&#160;31, 2021 as compared to 2020 was primarily due to a decrease in interest earned on lower average balances of our short-term investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized no income tax provision for the year ended December&#160;31, 2021. We recognized an income tax provision of $1.1&#160;million for the year ended December&#160;31, 2020 related to foreign operations. </span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity, Capital Resources and Plan of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not generated positive cash flow or net income from operations since our inception and as of December&#160;31, 2021, we had an accumulated deficit of $648.1 million. As of December&#160;31, 2021, we had $305.2 million in cash, cash equivalents and short-term investments. compared to $429.7 million as of December&#160;31, 2020. We believe that our existing cash and cash equivalents and short-term investments as of December&#160;31, 2021 will be sufficient to fund our operations and meet our existing contractual obligations and other cash requirements into 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we sold an aggregate of 10,925,000 shares of our common stock for $140.8 million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we sold an aggregate of 16,675,000 shares of our common stock for $203.5 million in net proceeds after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs, and expenses to build out our new facility. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned nonclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing, costs and results of nonclinical studies and any clinical trials for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to expand our research and development activities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of progress and cost of our commercialization of our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to implement additional infrastructure and internal systems;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to hire additional personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of the COVID-19 pandemic on our business, results of operations, and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the primary sources and uses of cash for each of the periods presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107,831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,291)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280,167)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,725)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,473)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Used in Operating Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, net cash used in operating activities was $107.8&#160;million, primarily as a result of net loss of $145.5&#160;million due to the continued activities developing our product candidates, partially offset by $33.6&#160;million of non-cash charges mainly related to $25.2&#160;million of stock-based compensation expense, $4.6&#160;million of depreciation and amortization expenses, $2.8&#160;million of amortization of premium on marketable securities, and $1.1&#160;million of impairment of long-lived assets, and $4.1&#160;million of net decrease in cash from changes in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, net cash used in operating activities was $79.3 million, primarily as a result of net loss of $117.5 million due to the continued activities developing our product candidates, partially offset by $25.5 million of non-cash charges mainly related to $20.4 million of stock-based compensation expense and $4.2 million of depreciation and amortization expenses, and $12.7 million of net increase in cash from changes in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December&#160;31, 2021 consisted of $93.8&#160;million of net maturities and sales of marketable securities, partially offset by $15.1&#160;million of purchases of property and equipment primarily related to the new facilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the year ended December 31, 2020 consisted of $268.3 million of net purchases of marketable securities and $11.8 million of purchases of property and equipment primarily related to the new facility.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Provided by Financing Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December&#160;31, 2021 consisted of $1.7&#160;million of net proceeds from the sale of our common stock, and $0.9&#160;million in proceeds from employee stock purchase plan, partially offset by  $0.2&#160;million repayment of loans.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2020 consisted of $344.3 million of net proceeds from the sale of our common stock, $12.7 million of net proceeds from the exercise of stock options, and $1.1 million in proceeds from employee stock purchase plan, partially offset by $2.0 million in taxes paid relating to net share settlement of restricted stock units and repayment of loans.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in Regulation S-K, Item 303(a)(4)(ii).</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data.</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_115"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:91.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_118">Report of Independent Registered Public Accounting Firm (PCAOB ID</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_118"> No.</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_118"> 42)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_118">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_121">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_121">81</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_124">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_124">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_127">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_127">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_130">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_130">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4967880cb16f4a6c939e04bb1dfb040a_133">85</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stockholders and Board of Directors of Adverum Biotechnologies, Inc. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Accrued research and development expenses &#8211; clinical and manufacturing costs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recorded research and development expenses of $89.2 million for the year ended December 31, 2021. As described in Note 2, research and development costs are expensed as incurred. Research and development costs include fees paid to contract research organizations that conduct certain research and development activities on the Company&#8217;s behalf and contract manufacturing organizations in connection with the production of materials for clinical trials.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Auditing the Company&#8217;s research and development expenses for contract research organizations and contract manufacturing organizations and related accruals was challenging due to the complex nature of evaluating the completeness and accuracy of the expenses and accruals.  Research and development expenses are recognized as the services are being performed by the vendors, which requires management to accurately monitor the activity at the vendors to determine the extent of unbilled services performed during the reporting period.</span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.655%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the completeness and accuracy of the contract research organization and contract manufacturing organization expenses and related accruals, our audit procedures included, among others, testing a sample of research and development expenses recorded during the period and evaluating the timing, amount and project coding of the expense recognition, testing a sample of cash disbursements after period end to assess the completeness of the expense recognition, and confirming with a sample of vendors the progress of activities under research and development contracts at period end.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;29, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzQtMS0xLTEtMTI4MjI_dc1d563c-b432-4009-bac2-aec4e745e93e">34,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzQtMy0xLTEtMTI4MjI_04ea039a-0010-42e5-8e0d-56d0daa6c3e9">62,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzUtMS0xLTEtMTI4MjI_0a1cf308-3589-42a9-829f-55b7c06949cd">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzUtMy0xLTEtMTI4MjI_7893e2f2-4c09-4f75-a11f-76149fa8baa4">367,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease incentive receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMS0xLTEtMTU3NTA_6de6d34d-69cf-4053-8603-f8fcbebeb590">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMy0xLTEtMTU3NTA_dd4a15b5-0ec9-43aa-9f91-75eba36c8885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMS0xLTEtMTI4MjI_46a349a7-ee65-45c6-b4e8-aa90969fac3b">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMy0xLTEtMTI4MjI_14bc9c7d-ef8d-42c6-b762-7583437ca340">4,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzctMS0xLTEtMTI4MjI_94476017-42af-444a-85d6-7bbee528c1df">317,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzctMy0xLTEtMTI4MjI_cd6d4f9c-7fff-47a8-a31a-40fc40e2fd44">434,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzgtMS0xLTEtMTI4MjI_4144bb98-094d-4863-bdae-a694b570b4dc">86,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzgtMy0xLTEtMTI4MjI_4543a681-7ce5-4214-857f-d034610f2310">19,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzktMS0xLTEtMTI4MjI_561d3ad7-4fce-4951-9e8d-0a495f55eed1">33,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzktMy0xLTEtMTI4MjI_8567f168-6b7d-4123-b9a0-eb605d955623">27,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEwLTEtMS0xLTEyODIy_bd03081a-d4e8-4708-829c-90f7459acb56">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEwLTMtMS0xLTEyODIy_03cff55e-7fba-42a9-a867-89fe6ccff82c">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred rent receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTEtMS0xLTE1NzYz_1ad7a18e-3ca4-4efd-b185-1ea31129b8e5">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredRentReceivablesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTMtMS0xLTE1NzYz_da5a7799-5f43-4bba-91d3-4df058e31968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposit and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzExLTEtMS0xLTEyODIy_3b6ce8b6-c6fd-4005-ba9c-fc772e785d9d">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzExLTMtMS0xLTEyODIy_2621589e-97b3-4d28-aad0-227352d4864b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTEtMS0xLTEyODIy_f71f09b7-60aa-4eef-a27b-66207b823592">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTMtMS0xLTEyODIy_8bbfbe52-8302-4a01-b7a5-ed58552acfa9">482,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE1LTEtMS0xLTEyODIy_63ec4d9b-7a91-4796-8e49-fa021b474aa4">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE1LTMtMS0xLTEyODIy_4db83509-5a30-4b80-9ebf-6bfc6e1b4d36">2,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE2LTEtMS0xLTEyODIy_321b5940-7732-49fb-9cbb-45f5404984e4">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE2LTMtMS0xLTEyODIy_05cdfa5d-8d08-49ec-a047-56b7987d4797">13,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE3LTEtMS0xLTEyODIy_73a078c4-7af8-4ce2-9e76-9faa08ac3a05">1,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE3LTMtMS0xLTEyODIy_08fe20f5-e255-4fb7-b877-f3207a105de5">4,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE5LTEtMS0xLTEyODIy_748b4f88-7518-432c-aa64-ac7280916229">21,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE5LTMtMS0xLTEyODIy_21f9468c-6de4-478c-af43-fee6cb27b41c">20,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzIzLTEtMS0xLTEyODIy_b3c02568-50fe-44ee-b58f-12634db825b9">101,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzIzLTMtMS0xLTEyODIy_9c82d54b-7506-47d3-9bbc-dd2a9728e8a5">26,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI0LTEtMS0xLTEyODIy_2bcb9b2e-e05d-4524-9c53-47400fc74601">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI0LTMtMS0xLTEyODIy_e18b1e00-9df4-4eff-9eee-6496092129c0">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI1LTEtMS0xLTEyODIy_29993085-17bd-4328-9d2b-7afe0dd138e3">123,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI1LTMtMS0xLTEyODIy_a27fa64c-cde7-46d7-9f20-7e1448c7a145">48,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI2LTEtMS0xLTEyODIy_09f8991d-5c7b-4a8c-b520-5e69db4e1b72"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI2LTMtMS0xLTEyODIy_79300e15-5fd8-45d7-ae2f-b22b9a036653"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMjE_92589c27-0cf8-4b9c-9d1a-6a05d11e54f7"><ix:nonFraction unitRef="usdPerShare" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMjE_cde2385e-a233-4a82-8156-b179acb7b9d4">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMzU_6c2d51a1-f222-4193-a616-59c1d05825ce"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMzU_c204284c-5e11-4962-9e38-85ba7a4bdca5">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_8a279201-a6b1-4e58-9d4b-e667f375d829"><ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_a97ae0c5-b1ce-43d4-b48f-7b350f6a5579"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_d42c1e6a-f7ef-4bf1-84c1-e219320cf4ab"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_e22c7b95-4980-4f74-80c6-471425d7859c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTEtMS0xLTEyODIy_182245b3-8707-4d15-9ba5-79c3fb976308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTMtMS0xLTEyODIy_7baa4e38-62e6-47e9-8a64-d981c05b0725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMTg_63c24965-ecc1-4a43-b937-f82e4e34eb67"><ix:nonFraction unitRef="usdPerShare" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMTg_7a391002-04ab-4ba4-a6b2-ab289b27d92e">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMzI_6b512d5c-8671-4ef2-a18e-de6ff135085a"><ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMzI_c97aa4a0-967d-4ac5-9eb6-11cb795d59e3">300,000</ix:nonFraction></ix:nonFraction> shares authorized at December 31, 2021: <ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfNzU_1537102d-1de0-4027-b286-49e4de6a2977"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfNzU_d5db6653-cebd-4eb8-a479-e960ea5ca4a7">98,381</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfODI_16a25e9c-103a-4c3a-b4e6-9114e5a3629a"><ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfODI_6ba69aa0-409d-4d48-bcca-63c1e345dcc7">97,549</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2021 and 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTEtMS0xLTEyODIy_2ac0ea1c-0521-4919-b25e-f37f7d287be6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTMtMS0xLTEyODIy_b7636ef8-2cfc-4a17-8b45-f20066fad274">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMwLTEtMS0xLTEyODIy_e248d8a9-8faf-40d0-a668-30376bc4a47a">964,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMwLTMtMS0xLTEyODIy_30055abe-f07b-4558-beb7-2a0479754981">937,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMxLTEtMS0xLTEyODIy_caf863d3-66c4-48d8-a8b7-0cbace3585da">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMxLTMtMS0xLTEyODIy_a8003503-0e8f-4933-9ce1-a7ff31b0ceb7">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMyLTEtMS0xLTEyODIy_5eef177b-f434-4a74-93b0-6c9f70b36d5e">648,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMyLTMtMS0xLTEyODIy_5c881b65-5db8-4370-80d0-57773c94a75a">502,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMzLTEtMS0xLTEyODIy_36b385f9-51e7-42e8-aa3b-a03c884d5f80">316,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMzLTMtMS0xLTEyODIy_0f109174-919c-4755-8185-026d19bcd5e0">434,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzM0LTEtMS0xLTEyODIy_ab42e534-330a-45ac-9771-8e0a637a06e0">439,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzM0LTMtMS0xLTEyODIy_13a57686-fd40-425c-8ce7-3ac1303580ca">482,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration and license revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzItMS0xLTEtMTI4MjI_092fc672-5157-4805-bce0-c22320a29e8e">7,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzItMy0xLTEtMTI4MjI_f30ceaba-4449-4e4b-8fa3-c96833dff21c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzQtMS0xLTEtMTI4MjI_9623b860-7c6d-4320-a433-61850f911194">89,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzQtMy0xLTEtMTI4MjI_5883c185-452e-45e9-802b-47a2ca907be9">73,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzUtMS0xLTEtMTI4MjI_b75c0ad8-bece-4f37-8c23-1ca704e3515f">64,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzUtMy0xLTEtMTI4MjI_515f8d7d-aa41-4362-825e-b16789af9b16">44,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzctMS0xLTEtMTI4MjI_69604615-4adc-4f65-8a93-7ec43222dd99">153,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzctMy0xLTEtMTI4MjI_e698b85e-23ce-4032-9bd8-e8b70d729bd0">117,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzgtMS0xLTEtMTI4MjI_4516e530-e8d8-4c72-b499-e1c2a39dd0fe">146,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzgtMy0xLTEtMTI4MjI_d1bb9253-2faa-4137-be39-34b06baaf835">117,950</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEwLTEtMS0xLTEyODIy_db7289d0-5020-402f-b17f-d6273851fb39">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEwLTMtMS0xLTEyODIy_49c670b1-ae51-427f-a22e-3e00729d7e7d">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzExLTEtMS0xLTEyODIy_ba361672-a7b3-42b9-8a98-1b1284462286">145,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzExLTMtMS0xLTEyODIy_1e391b7c-fd2c-46ed-97de-d95f27dbc29a">116,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEyLTEtMS0xLTEyODIy_894a5d4a-5e8f-46c6-9294-01cbba7a61af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEyLTMtMS0xLTEyODIy_31d6accd-9b49-4cbc-bb01-cdd633aab999">1,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEzLTEtMS0xLTEyODIy_24450372-5775-46aa-a8a6-b29e59b8e4ab">145,540</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEzLTMtMS0xLTEyODIy_ff848af2-0936-4c63-8ff5-ade06698418e">117,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain (loss) on marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE1LTEtMS0xLTEyODIy_ced8ddc4-76d4-4e23-b542-7388ffb2e0a1">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE1LTMtMS0xLTEyODIy_bf843ecd-9b6a-4437-9cf7-137587f02b48">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE2LTEtMS0xLTEyODIy_a2802a2f-8a65-47e7-bcc8-d42e84e677d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE2LTMtMS0xLTEyODIy_752add41-248c-401a-9c8b-c5f23afd2e3b">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE3LTEtMS0xLTEyODIy_29bbeaea-0d67-4479-8954-cbd8edff7256">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE3LTMtMS0xLTEyODIy_9ad082c1-1ae1-46d7-976a-5b30e9a2317a">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE4LTEtMS0xLTEyODIy_3b8d3223-c563-461b-8a97-6926b58042dc">145,993</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE4LTMtMS0xLTEyODIy_1a58edbd-4e6c-4fe6-9dfe-4901e04e32c9">117,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTEtMS0xLTEyODIy_ab008883-6d57-4e33-93f5-cc71baed5234"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTEtMS0xLTEyODIy_be9b58ef-5844-4a29-a3ec-bb8d2d0bd9c8">1.48</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTMtMS0xLTEyODIy_1d95a106-0e87-4817-b25d-5c145c0b6cf0"><ix:nonFraction unitRef="usdPerShare" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTMtMS0xLTEyODIy_acc0c24b-a84c-4b53-b8b0-faab544ff66e">1.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding-basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTEtMS0xLTEyODIy_63193338-0002-4aa5-b92f-283b8a675105"><ix:nonFraction unitRef="shares" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTEtMS0xLTEyODIy_92d9f286-30fb-4cfc-bcb6-1aa2ea311dc7">98,039</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTMtMS0xLTEyODIy_74ddbb7c-43d8-4c45-86bd-e2be81b4cd6a"><ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTMtMS0xLTEyODIy_7d5270ad-e5c2-471e-9865-7014df7aa238">85,146</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.800%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.428%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">COMMON STOCK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ADDITIONAL<br/>PAID-IN<br/>CAPITAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ACCUMULATED<br/>OTHER<br/>COMPREHENSIVE<br/>INCOME (LOSS)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ACCUMULATED<br/>DEFICIT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TOTAL<br/>STOCKHOLDERS'<br/>EQUITY</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53f24fd80d7847a4a109b4930dfa58dd_I20191231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTEtMS0xLTEyODIy_d46cc972-74ce-4732-a132-f7c7555dbd2d">67,329</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53f24fd80d7847a4a109b4930dfa58dd_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTMtMS0xLTEyODIy_f420393c-6242-46cf-8f6c-5f35858ea125">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61bf30013d1447db830bbcf1c0f8e693_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTUtMS0xLTEyODIy_63f1e994-e8ca-4094-8930-f5c894df3bed">560,704</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bf0483faf9c4578af16fb35b2fa264f_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTctMS0xLTEyODIy_5c4bc5ba-1933-43a6-a1d5-0e567ef64f77">725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d6e133ae95f4549b3dced0eb367c851_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTktMS0xLTEyODIy_3eece75d-24bf-4d64-961e-e4c386b9bf06">385,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTExLTEtMS0xMjgyMg_8b60d829-c461-4ebf-95e8-89970c766fd0">174,957</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTAtMS0xLTEyODIyL3RleHRyZWdpb246MDA1NDE3MTk4MTAyNGRhZWIxZGFmMDA5NjQyZDIzOTdfMTA5OTUxMTYyNzgzNA_d874fbba-4298-4e86-800e-cd6911fdb08f">676</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTEtMS0xLTEyODIy_118340de-69e7-4aa6-9ce2-bf4a8010b590">27,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTMtMS0xLTEyODIy_95506d4a-8545-4540-a700-05c7a1dda5ea">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTUtMS0xLTEyODIy_c7d1cae6-4fa0-4c8f-908f-a7544f08d016">344,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTExLTEtMS0xMjgyMg_1bb14df3-2deb-4bbd-9c69-db26aeb7aee8">344,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI3LTUtMS0xLTEyODIy_1bfa470d-5586-4813-b7e0-5396741fd27b">20,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI3LTExLTEtMS0xMjgyMg_aba30313-b5a2-4c1a-98d8-8da9bef60e04">20,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI4LTEtMS0xLTEyODIy_b8b89bca-53df-4367-ae8d-57213b180e95">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI4LTUtMS0xLTEyODIy_c3eac6a7-e485-4ac9-87fb-dda74d3c7932">12,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI4LTExLTEtMS0xMjgyMg_5ffe4ae0-b032-47ae-ae10-32edbaa4e12f">12,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon net exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="advm:WarrantsIssuedDuringPeriodShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI5LTEtMS0xLTEyODIy_2157f8cb-ccf9-4f6c-8eec-57e510310f90">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMwLTEtMS0xLTEyODIy_b42893cb-6dc3-4bea-bd9c-86d4ddc6755b">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMwLTUtMS0xLTEyODIy_0cc4b119-f25a-4528-abbe-da0319ac49de">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMwLTExLTEtMS0xMjgyMg_79ee72e0-6c25-4845-803e-0ec7c79b1e58">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMxLTEtMS0xLTEyODIy_fa635a3d-3353-4db0-aa65-9f256ae7c051">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock surrendered for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMyLTEtMS0xLTEyODIy_9809fa86-aa78-4153-bb53-d5150c32160d">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMyLTUtMS0xLTEyODIy_36847f8d-9cb7-4fcf-b458-9143c44e3eb8">2,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMyLTExLTEtMS0xMjgyMg_dd9eafc5-dcab-4156-b167-97b3a10376bf">2,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMzLTctMS0xLTEyODIy_8819f26d-f5bf-48d5-b90b-162cb952dfeb">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMzLTExLTEtMS0xMjgyMg_453a5c58-f8ee-4792-91b8-c6a410f0a2a8">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM0LTctMS0xLTEyODIy_a96a6aee-b3c9-402d-a700-9df70f61649d">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM0LTExLTEtMS0xMjgyMg_5c2ceddc-1486-4c0b-8d7f-5f7bd66ec721">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM1LTctMS0xLTEyODIy_dfe00ad0-5d48-4970-85f3-ecdfd97a7963">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM1LTExLTEtMS0xMjgyMg_5b52781b-3aca-4676-b138-57e8800de9b8">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3feb10512c544b2be5df43808067ffd_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM2LTktMS0xLTEyODIy_cf6ac7e2-8c5c-46d3-8499-9523de54732c">117,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM2LTExLTEtMS0xMjgyMg_44e36ed3-361b-44be-94f4-ffd8c427d0df">117,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1545d1dd80f34ac3aef307e7cbbb2e71_I20201231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTEtMS0xLTEyODIy_486fda6d-f59d-44a7-8d08-eaa66b7d364d">97,549</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1545d1dd80f34ac3aef307e7cbbb2e71_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTMtMS0xLTEyODIy_3ea5d65b-fc97-4098-ac11-1436d3830def">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac60871d0b6541e7b3972cd6bb0b694b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTUtMS0xLTEyODIy_c8f86a5f-9c83-4491-859a-c98117d1ed41">937,134</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a914f1d116d433589863bd5a9a0f6a0_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTctMS0xLTEyODIy_607f7a20-8d2c-49e8-9058-0b00bb30e7ab">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1e120d0535d8453791e0f2c600950d30_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTktMS0xLTEyODIy_fca42634-7999-4911-92e5-5bd37c16c14b">502,536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTExLTEtMS0xMjgyMg_a193d648-ae51-4f71-8f93-1ccca550dae2">434,347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTAtMS0xLTEzOTU2L3RleHRyZWdpb246ZDgwYjRmOTc4YzVhNGM4ZDk0ODEwMDM2OGI4NzUwZTBfMTA5OTUxMTYyNzgzNQ_aa639da8-28a1-4813-9fef-8eac43410bde">9</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTEtMS0xLTEzOTc4_4ecdb3c7-2f47-4bf5-a528-de12b476788b">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTMtMS0xLTEzOTc4_177dddad-10bd-4b1b-b2f7-2bdc4ad804bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTUtMS0xLTEzOTc4_eb22619d-052e-4ac8-82f7-35f4c1739fdd">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTExLTEtMS0xNTI1OQ_b3c56a73-b513-457c-a848-897321cc723b">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM5LTUtMS0xLTEzOTc4_7372c512-90f8-466c-b345-f570844b434a">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM5LTExLTEtMS0xNTI1NA_59627a40-c848-4891-9eba-9dd572ef3afe">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQwLTEtMS0xLTEzOTg4_a25d8fa6-6e3c-4fa0-abd3-77843aeb6819">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQwLTUtMS0xLTEzOTg4_ba37ce53-c575-4d85-8209-edc37b6520cf">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQwLTExLTEtMS0xNTI1Ng_1fab05ae-0355-4df0-9308-2046dd7a5230">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQxLTEtMS0xLTEzOTg4_8fc8d01f-2979-448c-8826-a7f35d3dcd0a">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQxLTUtMS0xLTEzOTg4_9c6369c9-6a65-41a6-a224-d6a43403cd91">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQxLTExLTEtMS0xNTI2Mw_0252c555-e149-4672-9e99-d8cf87c034fd">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock issued upon release of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQyLTEtMS0xLTEzOTg4_2088d83b-21f7-4cca-8bb3-6d3afca5b605">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca06aba1d444f9692c01566cac96dbe_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ0LTctMS0xLTEzOTk1_b2575ced-5323-4f25-86c3-8e863aea24fa">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQzLTExLTEtMS0xNTI2Ng_65076af4-bfe9-423f-9161-934396caed14">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ca06aba1d444f9692c01566cac96dbe_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ1LTctMS0xLTEzOTk1_faaab420-8795-4b30-9df6-b42427da6f9b">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ0LTExLTEtMS0xNTI3MA_072494d7-8155-4e99-909a-69713ad847b6">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i795d1398d0ed477da363e54fb41ee0b7_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTktMS0xLTEzOTk1_2606c809-0427-4d63-966b-400011e93ab8">145,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ1LTExLTEtMS0xNTI1Mg_7df8b94f-1ed0-454a-8296-bc0353eb9d08">145,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ebd7da8b96a4cedad752dba138eb1b7_I20211231" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTEtMS0xLTE1MjUw_09bcadf8-1e99-4be0-b00c-71f448ee246e">98,381</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ebd7da8b96a4cedad752dba138eb1b7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTMtMS0xLTE1MjUw_f72ddd07-a2be-4cdb-aae8-0ba46a5dbe74">10</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie798bce7c7694970a7f83c3c90201b15_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTUtMS0xLTE1MjUw_8aa9c25b-2062-4190-b99e-5ede21d8340a">964,965</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c53c953f5be42b2a5877734d774a767_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTctMS0xLTE1MjUw_21f19f40-900e-47f5-a2e4-41c98faeaa6e">714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c7935b84f04449fac206a423055e6aa_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTktMS0xLTE1MjUw_6db1e1d3-f06e-4abe-a093-776f5b3db10e">648,076</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTExLTEtMS0xNTI1MA_fcf02893-69bf-4177-8e35-afd0355d895f">316,185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMtMS0xLTEtMTI4MjI_ee00e988-a8eb-4885-a1d6-8024796fbce2">145,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMtMy0xLTEtMTI4MjI_b274bdb5-f58e-4fe4-839c-d4707c7e57b5">117,507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUtMS0xLTEtMTI4MjI_ae5f197f-a6a1-4d9e-88a9-73d23161a046">4,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUtMy0xLTEtMTI4MjI_67e75c0a-ae77-4892-9a70-097992662e7b">4,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzYtMS0xLTEtMTI4MjI_20740af1-5fb6-427c-bedf-c1cb94f7f481">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzYtMy0xLTEtMTI4MjI_ce7de134-b0ba-45c0-b8cb-9590074cd170">20,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of premium and discounts on marketable securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzctMS0xLTEtMTI4MjI_426e051a-a448-4c97-8f84-a15bda6adf06">2,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzctMy0xLTEtMTI4MjI_a289547e-c4e1-4efa-8de8-e6b4bec96191">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accreted interest on BPI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:AccretionExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzgtMS0xLTEtMTI4MjI_6af34d34-fc8c-4300-83fc-dc750a762581">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzgtMy0xLTEtMTI4MjI_9a4f714b-5eb4-4e5d-a8e7-ecd4d5001d43">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzktMS0xLTEtMTI4MjI_2bbae4e4-738e-4cfb-a59e-8616619322b9">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzktMy0xLTEtMTI4MjI_aecf8050-623c-43df-b997-8387f74ffafb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency remeasurement loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEwLTEtMS0xLTEyODIy_245fb61d-392b-4201-a860-552d7a13cd11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEwLTMtMS0xLTEyODIy_c18ad148-f786-43e1-8cd7-7fa0b84c0506">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzExLTEtMS0xLTEyODIy_e0fa5cf7-6e9d-4bc4-a2df-1a361d95c79e">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzExLTMtMS0xLTEyODIy_8fc0881b-5db0-4664-8650-d7a51c150756">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEzLTEtMS0xLTEyODIy_d1b13314-64a9-4e25-8313-92280d23ba44">2,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEzLTMtMS0xLTEyODIy_8780ed40-2939-4bb3-8c75-c69e6ca2798a">5,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deposit and other long-term assets and deferred rent receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE0LTEtMS0xLTEyODIy_dd23321e-234d-407a-8c3c-5709f03f0ec3">990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE0LTMtMS0xLTEyODIy_90b2ad98-2b8b-418b-876d-4a75a569475c">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE1LTEtMS0xLTEyODIy_42b677c4-a348-498f-81a8-4d749a409890">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE1LTMtMS0xLTEyODIy_17fd03b5-231d-4083-adb1-9857f9910d47">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE2LTEtMS0xLTEyODIy_3c06e0bf-14dc-4c4d-8072-a6c3ca09012c">1,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE2LTMtMS0xLTEyODIy_34e0f133-ca62-4081-abe2-b7a973d70083">1,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses, other current and non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE3LTEtMS0xLTEyODIy_6dced81b-ea40-4644-a5ef-f7a319d24e55">3,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE3LTMtMS0xLTEyODIy_be734f7b-e1bc-40ee-b05f-ce94cb8c08c6">4,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIwLTEtMS0xLTEyODIy_fdcb0480-758d-4d6f-933a-e68a948569fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIwLTMtMS0xLTEyODIy_0717073d-58d4-450b-a5d4-b055b48fb8be">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIxLTEtMS0xLTEyODIy_ac3dda6e-6bb7-4010-bec0-477b5bb36c77">2,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIxLTMtMS0xLTEyODIy_3840dca7-b467-4f6d-9d46-d5dc96dda60e">1,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIzLTEtMS0xLTEyODIy_dfe92e85-2ac8-4859-abcd-0e0497d1c8dd">107,831</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIzLTMtMS0xLTEyODIy_8bbb9ac1-0cdb-4985-b0dc-861770e0e5ef">79,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI2LTEtMS0xLTEyODIy_bf1705e8-912d-4709-ba3c-e79f88be2c86">407,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI2LTMtMS0xLTEyODIy_40054ff9-ef39-4cfa-a3c4-0b329eacef06">570,386</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI3LTEtMS0xLTEyODIy_4aac2c28-26f5-4230-a58c-90163eda0d8c">492,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI3LTMtMS0xLTEyODIy_6e6cdc43-65a3-4598-b6c0-a48dd6e808e0">295,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI4LTEtMS0xLTEyODIy_421938ef-e2ff-466e-9d7a-3fecf3c7fc9d">8,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI4LTMtMS0xLTEyODIy_63a02b91-32ee-4ea2-b0de-d6bfdaa8373f">6,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI5LTEtMS0xLTEyODIy_491b08a2-d5b0-4464-b365-18738248c40c">15,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI5LTMtMS0xLTEyODIy_4edffdec-6898-4a25-a48a-7cb726d7fd2f">11,844</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) by provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMwLTEtMS0xLTEyODIy_20ec0fa7-3391-4cd0-b799-5e873545e91c">78,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMwLTMtMS0xLTEyODIy_2a78c25e-edbd-4784-81f1-8595e1a587d3">280,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMzLTEtMS0xLTEyODIy_57204ce5-e0cf-4416-b5ad-c755f7c5ed2e">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMzLTMtMS0xLTEyODIy_3679905d-bcbe-496b-8265-a69b291c8800">344,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM1LTEtMS0xLTEyODIy_33ad23a3-063b-4aa9-b41f-e4ffbc8d9ee3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM1LTMtMS0xLTEyODIy_804a3809-d318-4be8-a570-232f2c8481e4">12,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM2LTEtMS0xLTEyODIy_8009ab9a-05cf-4570-81de-0eedf5a55d9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM2LTMtMS0xLTEyODIy_0a9693b7-54ce-472c-820a-315408d8ad4a">2,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM3LTEtMS0xLTEyODIy_ee072b38-d06a-4daf-9c43-36d9b9aa24ab">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM3LTMtMS0xLTEyODIy_23f2a20e-64ad-4fae-80ea-c5c1b07c0a13">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of BPI loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM4LTEtMS0xLTEyODIy_2bfebd58-f959-4072-af47-1e1bb7781d81">240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM4LTMtMS0xLTEyODIy_af68ffa2-d915-4e6d-8314-36e007d61f86">61</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQwLTEtMS0xLTEyODIy_c49c827f-2a1d-40ac-90b8-9522322897d1">2,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQwLTMtMS0xLTEyODIy_6f15be49-17ee-47ce-bc7e-3ecc7bf17844">355,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQxLTEtMS0xLTEyODIy_65e12912-19cf-4f88-ac16-2b83ab8b26e5">26,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQxLTMtMS0xLTEyODIy_28012148-be01-4bae-b878-b02313949cc7">3,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQyLTEtMS0xLTEyODIy_d1909de5-329b-429f-92f6-9aa26358b9a8">63,423</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQyLTMtMS0xLTEyODIy_c90d63d5-2d4c-4e0b-921e-c9627391796a">66,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQzLTEtMS0xLTEyODIy_b3c8a5b9-e3f1-4c4d-bed5-d8a6c49076ec">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQzLTMtMS0xLTEyODIy_0ec076a6-bb96-4655-b735-f44b167a66f4">63,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ1LTEtMS0xLTIxMDAw_dc1d563c-b432-4009-bac2-aec4e745e93e">34,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ1LTMtMS0xLTIxMDAw_04ea039a-0010-42e5-8e0d-56d0daa6c3e9">62,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTEtMS0xLTIxMDA2_bd03081a-d4e8-4708-829c-90f7459acb56">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTMtMS0xLTIxMDA2_03cff55e-7fba-42a9-a867-89fe6ccff82c">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTEtMS0xLTIxNzQ4_af7bf2a1-8b76-43d6-aa15-4b607192e993">36,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTMtMS0xLTIxNzQ4_1e5f91b2-de81-4a09-921a-2c82d9021478">63,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of noncash investing information</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTEtMS0xLTE1Njcy_59976b3f-bff1-4cd4-a6e9-a5336280f221">84,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTMtMS0xLTE1Njcy_c1472db4-a00e-432b-b93c-9a624db7df2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease in right-of-use asset and lease liability due to termination</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUwLTEtMS0xLTIyMzM5_d80a608c-adfc-478b-a103-7e9cff267f91">15,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUwLTMtMS0xLTIyMzQx_18efa9ee-d3ec-48c3-9063-82fdf225ad27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Remeasurement of right-of-use asset on lease modification</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="advm:RemeasurementOfRightOfUseAssetOnLeaseModification" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTEtMS0xLTE1OTEw_df8d2e3c-834b-4424-9551-071ed346e4a9">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="advm:RemeasurementOfRightOfUseAssetOnLeaseModification" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTMtMS0xLTE2Mjcy_1f4d1e18-a24d-4893-bce1-de9ce303bf97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets in accounts payable and current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTEtMS0xLTEyODIy_e35094ed-2695-4993-8d28-6d193c6d37bf">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTMtMS0xLTEyODIy_8c70ab09-2f91-43b5-948d-eefa09f4ce6c">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzYvZnJhZzo5NTUzOGM4NTA4YTE0OTU2OTBjYmM1ZDI2ZjQ4NjJlNS90ZXh0cmVnaW9uOjk1NTM4Yzg1MDhhMTQ5NTY5MGNiYzVkMjZmNDg2MmU1XzE1Mzk_71a23d22-9fbd-4b0a-a285-a8a6767b727b" continuedAt="ie0f6e845ca564259b8882523299ccf1d" escape="true">Description of the business </ix:nonNumeric></span></div><ix:continuation id="ie0f6e845ca564259b8882523299ccf1d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzYvZnJhZzo5NTUzOGM4NTA4YTE0OTU2OTBjYmM1ZDI2ZjQ4NjJlNS90ZXh0cmVnaW9uOjk1NTM4Yzg1MDhhMTQ5NTY5MGNiYzVkMjZmNDg2MmU1XzEyODc_76d8f869-7ac4-499d-88ad-bdd7e81ddffa">648.1</ix:nonFraction> million as of December&#160;31, 2021. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2021, the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzYvZnJhZzo5NTUzOGM4NTA4YTE0OTU2OTBjYmM1ZDI2ZjQ4NjJlNS90ZXh0cmVnaW9uOjk1NTM4Yzg1MDhhMTQ5NTY5MGNiYzVkMjZmNDg2MmU1XzEwOTk1MTE2MzE1MDE_6e37af3c-80ee-4484-95e4-caa820fb2777">305.2</ix:nonFraction> million, which the Company believes will be sufficient to fund its operations into 2024.</span></div></ix:continuation><div id="i4967880cb16f4a6c939e04bb1dfb040a_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU3_390a3a38-096c-49ba-b818-0a73fb08fdc9" continuedAt="ie146ecff2c8e4d5e9322ea994a69025c" escape="true">Summary of significant accounting policies</ix:nonNumeric></span></div><ix:continuation id="ie146ecff2c8e4d5e9322ea994a69025c" continuedAt="iffd93758d51b4785ac621f9423da0328"><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ2_8b22a139-6433-4842-99d4-f79f483836f1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQz_fe81363c-7afe-42d5-89c7-0a768bdb2d57" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUw_73c12836-e8de-4968-9617-a7b6ee962ecc" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU4_3b2d6a56-00ad-47ff-8266-91aed176bc19" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></ix:nonNumeric></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ0_7463ab4d-cf33-4249-93b5-2d4d7400cca4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="iffd93758d51b4785ac621f9423da0328" continuedAt="i9faf56c75e29473fb71fd79e27fcdd4b"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUx_7580f705-d7b5-47db-83f9-aa052b328d4e" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#8217;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODM4_fd6537a6-d525-42f5-8262-2fcd49490e59" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as <ix:nonFraction unitRef="segment" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzUyODI_3c8c5bea-abd1-43ad-b55e-e38a72997431"><ix:nonFraction unitRef="segment" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzUyODI_4cd3aa99-95d8-4a5f-b72c-0cc4fb6c4325">one</ix:nonFraction></ix:nonFraction> reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODM5_055e81c9-6aa4-41ef-9b08-bb04b0f4cbb8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support the growth.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUy_a58edd33-4ac9-432a-9dbd-6b61559df9b2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb">three</span> to <ix:nonNumeric contextRef="ib014e00f9b8e44bb9cec4471e9b7458e_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDc_7007e1e7-8bf6-4b59-89fa-3250fd294ef2">five years</ix:nonNumeric>. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></ix:nonNumeric></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUz_ab22bd1c-e9a7-4b56-aae5-eac49c7af628" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets and Purchased Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates the carrying value of amortizable long&#8209;lived assets, whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#8217;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within general and administrative expense in the consolidated statements of operations and comprehensive loss an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzQ5NDc4MDIzNDc2Mjg_de772fe9-6751-49f5-93fb-4461dbaceb1a">1.1</ix:nonFraction>&#160;million, which includes $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzQ5NDc4MDIzNDc2Mjk_a299ca19-ffcd-4621-b4fe-3a2914356e2e">0.8</ix:nonFraction>&#160;million associated with the write down of right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfLeasehold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzQ5NDc4MDIzNDc2Mjc_2c7df3c3-2804-4ed7-883a-507dbce1b23a">0.3</ix:nonFraction>&#160;million associated with write down of leasehold improvements, net of accumulated depreciation, for the year ended December&#160;31, 2021. There were <ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzg0ODU_b8544f4f-13a7-405a-98bc-0f4277314528">no</ix:nonFraction> impairment indicators noted for the Company&#8217;s long-lived assets, fixed assets, for the year ended December&#160;31, 2020.</span></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="i9faf56c75e29473fb71fd79e27fcdd4b" continuedAt="ibe3b610757d04b70bd408bc461458a25"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU0_1f957101-0eb9-4c93-ae52-b4d73b967eb7" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, management estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The Company bases the right-of-use asset on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQw_321d953e-df42-4d29-8df9-aaee599c5d3d" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQx_058bfb92-c60d-49c6-b5ef-0ca34cc427b2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. There have been no significant changes from the Company&#8217;s original estimates in any of the periods presented.</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQy_95867d4e-6fc0-4411-b057-73ac8622c6c1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ3_c6b86799-728c-4296-b805-9e5c4fde0631" continuedAt="ife830dcd9041441ca29b2093ddd5cebb" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and using intrinsic value, which is the closing price of its common stock on the date of the grant, for the restricted stock units (&#8220;RSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="ibe3b610757d04b70bd408bc461458a25"><ix:continuation id="ife830dcd9041441ca29b2093ddd5cebb"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div></ix:continuation><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ4_0ed4a209-ece3-4d9b-af65-7f52cf26ce4e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2021 and 2020, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU1_4e885a66-ef28-4958-a870-3c9e466e6f68" continuedAt="ia9f5bcd492e146848a51c1bee19d012d" escape="true">Comprehensive Loss</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia9f5bcd492e146848a51c1bee19d012d">&#8212;Comprehensive loss comprises net loss and other comprehensive income. Other comprehensive income consists of foreign currency translation adjustments and unrealized gain on marketable securities.</ix:continuation> </span></div><div style="margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ5_83e1fa27-d48d-4781-8e5f-e28635d3e5ce" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, restricted stock units (&#8220;RSUs&#8221;), employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU2_f5dade94-b57b-4b62-aaaa-f839f35c9e86" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326, but does not expect the effect of adoption to be material.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzMwOTg_6afcbe4f-8c20-495c-a889-79c2ce01085d" continuedAt="iecf2f977792b4a9ba52d3593890e003c" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="iecf2f977792b4a9ba52d3593890e003c" continuedAt="ied0116a95c0b414c843b8d2dd9c241d9"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="ied0116a95c0b414c843b8d2dd9c241d9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bond and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzMxMDA_7ba81c79-26ff-4d3f-95bf-6168463cbccd" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtMS0xLTEtMTI4MjI_0a7b770a-6ee7-481c-ae4e-93e8b19ba265">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtMy0xLTEtMTI4MjI_ad863967-088a-456d-a630-76b8e7d6bc3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtNS0xLTEtMTI4MjI_6809f781-8056-4984-960e-be37b8f9afaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtNy0xLTEtMTI4MjI_6acc22e0-aee6-4642-95eb-8918cd6dca7b">10,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtMS0xLTEtMTI4MjI_04063e8b-bb61-4cfd-88c3-a89b8063b20b">62,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtMy0xLTEtMTI4MjI_6cb608b9-f271-4b7d-9105-f5440df0ae9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtNS0xLTEtMTI4MjI_78740e38-754c-4475-855f-f2fcee8cf910">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtNy0xLTEtMTI4MjI_63f8cbb2-ad8c-4b15-be42-77a411038b0a">62,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198713b3bc694250846e3c8d7a262676_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtMS0xLTEtMTI4MjI_731b0d94-528d-41ee-beb8-a27924f93721">177,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198713b3bc694250846e3c8d7a262676_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtMy0xLTEtMTI4MjI_73d684c8-19a0-46aa-8773-db5e95916e84">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i198713b3bc694250846e3c8d7a262676_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtNS0xLTEtMTI4MjI_baf316b7-c8c7-4078-85ce-1f571e501636">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i198713b3bc694250846e3c8d7a262676_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtNy0xLTEtMTI4MjI_cd143f1f-c984-49cc-aeb0-23a9285ab604">177,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctMS0xLTEtMTI4MjI_3995775a-ae4c-46fd-ab01-5a614c8ac842">47,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctMy0xLTEtMTI4MjI_d93c12a0-0363-41a1-9dd2-cc4f6bb0206a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctNS0xLTEtMTI4MjI_e88f1609-af6e-4bf6-8b35-aa31c8788bd8">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctNy0xLTEtMTI4MjI_f7f328fd-06e7-48d3-b0bf-d27de2b51ecc">47,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtMS0xLTEtMTI4MjI_45e017fd-cc92-4ebc-9ec6-6223f7bba271">297,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtMy0xLTEtMTI4MjI_ff7c4a20-bd1d-4528-a359-385854b1d482">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtNS0xLTEtMTI4MjI_f5e452c1-e3fe-436e-acc6-96b115ef59ef">318</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtNy0xLTEtMTI4MjI_7232aca0-139d-4f08-8c10-aceafe8f8ec9">296,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktMS0xLTEtMTI4MjI_4f2b3693-e5c7-45f4-8d2e-e5a9dee29a5f">25,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktMy0xLTEtMTI4MjI_dfc9c62a-b420-47fb-9c69-a7c53655d11b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktNS0xLTEtMTI4MjI_1b580407-c7fe-4ba4-a15a-c44cb5507fe4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktNy0xLTEtMTI4MjI_852e03a6-7a2a-4b8c-aef7-8e90518bbb0b">25,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTEtMS0xLTEyODIy_f5e2ca06-d7bd-4279-8c93-c215cf5b2c03">271,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTMtMS0xLTEyODIy_de4af58f-33f9-48e9-839f-fe8011f5c196">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTUtMS0xLTEyODIy_0abafecf-e5ec-4017-8a99-03085156c19e">317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTctMS0xLTEyODIy_7165b43c-a6b0-474b-b2a3-f19618bebe1f">270,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2e87b6775540219d86de876645d890_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtMS0xLTEtMTI4MjI_5669547d-923a-4c49-9e35-5bf9b3935925">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2e87b6775540219d86de876645d890_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtMy0xLTEtMTI4MjI_1ac4fbea-5ab1-46f0-8aa2-defc6fbf27fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2e87b6775540219d86de876645d890_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtNS0xLTEtMTI4MjI_a0bb3ca6-6053-4ecf-86de-e604838de894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc2e87b6775540219d86de876645d890_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtNy0xLTEtMTI4MjI_cfdc882b-e301-489e-9528-5b8a7f33fcf5">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtMS0xLTEtMTI4MjI_8092fbef-1812-4210-aebd-8e7b4eef4cba">328,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtMy0xLTEtMTI4MjI_8ae03b02-20ed-4881-b259-2ecd176c14e3">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtNS0xLTEtMTI4MjI_63f33522-221f-4dca-b188-4e4fc83a05c2">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtNy0xLTEtMTI4MjI_f9f66de1-e03e-4db5-92d8-d1ef67ef1bd5">328,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtMS0xLTEtMTI4MjI_21e57aa8-b94f-4b08-95e8-cc471fd8a1fc">97,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtMy0xLTEtMTI4MjI_0ce0f6f9-3f4a-4dc5-9036-d08644ee0b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtNS0xLTEtMTI4MjI_c202a757-8872-4947-8462-5aeee92611b0">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtNy0xLTEtMTI4MjI_82596efd-cdee-4b9f-9a4c-5747bd8a436d">97,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtMS0xLTEtMTI4MjI_5704e878-c512-4a42-b1b2-3eb18b0f7221">426,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtMy0xLTEtMTI4MjI_b1fb639e-1c30-461e-9a2f-85b15620fa20">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtNS0xLTEtMTI4MjI_9423c7eb-4b30-4654-a17f-e72893164ce6">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtNy0xLTEtMTI4MjI_f2143245-080a-44b9-964a-d057aeba84f1">426,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:CashAndCashEquivalentAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktMS0xLTEtMTI4MjI_be7c14f4-31e3-4cb4-9094-713de0a02370">58,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktMy0xLTEtMTI4MjI_c46b4ff4-5702-4852-9a84-d6e4f65d41bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktNS0xLTEtMTI4MjI_7f4605b3-a33d-4f53-8c6b-42ce28b7c548">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktNy0xLTEtMTI4MjI_d8476a19-1cfa-4832-8801-3e95c558a80e">58,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTEtMS0xLTEyODIy_e91db49a-e56e-4971-905b-391b14063501">367,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTMtMS0xLTEyODIy_6d34efef-bee0-4626-a075-35ce14b2ed69">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTUtMS0xLTEyODIy_413d2bf2-c948-45a8-b1c6-5e0bb1e191bd">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTctMS0xLTEyODIy_06d49733-a1e3-46f9-a4b2-fb3e56b96f30">367,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#8217;s consolidated balance sheet. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of December&#160;31, 2021 were temporary in nature and none were in continuous loss position for 12 months or more. Management concluded that <ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI3NjY_e8cc5fb6-ccfc-41af-9c9d-cfddcbb661b1">none</ix:nonFraction> of the Company&#8217;s marketable securities were other-than-temporarily impaired as of December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-5" name="advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI4NjU_daee709c-1d84-432d-9d71-4a7a6898b71c">47.0</ix:nonFraction> million of marketable securities had remaining maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MjY_6080290b-1a2f-4c6f-9319-23bad6204282">one</span> and <ix:nonNumeric contextRef="ibd8584c0ea5b463ca366376a46eac4d1_I20211231" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MzM_33db667e-f8e6-4dc5-b5fb-d0f7c1b17821">two years</ix:nonNumeric>. The remainder of the marketable securities have a remaining maturity of one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers within the hierarchy during the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company performed an impairment test to measure certain right-of-use assets and leasehold improvements at fair value. The assets are measured at fair value on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable, by comparing the sum of the estimated future undiscounted cash flows to the carrying amount of the assets. Refer to Note 5, Leases for additional information.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3OTQ_241e5d74-e1f3-42f3-9d35-32cbd047cda6" continuedAt="id05730bb7b2b4a509a12afb4b5dd34c0" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="id05730bb7b2b4a509a12afb4b5dd34c0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic9538a71ff1d424989f80b9467a6a448_D20210125-20210125" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3ODI_9c33559c-4177-4b76-ba3e-d1eddd18e54b">7.5</ix:nonFraction>&#160;million. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the initial transaction price is the $<ix:nonFraction unitRef="usd" contextRef="i3388e01ba0cd4c2bb002f33d9f0729df_D20210125-20210125" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3Njg_54cf4e93-55e1-431f-a7cd-6b69149ccffb">7.5</ix:nonFraction>&#160;million the Company received for the license granted. As described above, the arrangement provides for additional payments to the Company when certain development and commercial milestones are achieved. Because these milestone payments are not within the control of the Company and are not considered probable of being achieved until the events occur, the Company did not include them in the transaction price. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i15c6315f35b6402d86b1167231385890_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3NDA_a7745e88-43dc-4358-862c-7079fbabd95c">7.5</ix:nonFraction>&#160;million was allocated to a combined performance obligation that was fulfilled during the three months ended March 31, 2021. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3NTQ_c60573fa-a027-42a1-8f27-a0f1e6c288bc">7.5</ix:nonFraction>&#160;million of license revenue during year ended December&#160;31, 2021.</span></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwODg_e83cbc9b-12b1-4a7d-badc-60456951a3ad" continuedAt="id8c6e24168db4ec492d4b82b1fdebe30" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="id8c6e24168db4ec492d4b82b1fdebe30" continuedAt="ib9a3fc8ffacb46b2b8cfe1ebaa83e8e7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Redwood City</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has a lease for facilities in Redwood City, which provides a total of tenant improvement allowances of up to $<ix:nonFraction unitRef="usd" contextRef="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231" decimals="-5" name="advm:LesseeOperatingLeaseLeaseholdImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzIxOTkwMjMyNjczNTk_65c6ba37-1434-4870-9497-47113802e550">10.2</ix:nonFraction>&#160;million. Related to the Redwood City lease, the Company provided the landlord with a letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231" decimals="-5" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2NDA2MDA_b130124e-09c3-4c01-8ba2-36e229fa82a5">2.5</ix:nonFraction>&#160;million, which is classified as restricted cash under long term assets on the Company's consolidated balance sheets.  The Redwood City lease expires in December 2031, with an option to extend for a period of <ix:nonNumeric contextRef="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzk4OTU2MDQ2Njc0ODc_314ed2cf-a5e9-4cd4-938e-bfcd3adff41e">eight years</ix:nonNumeric>. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2021, the Company entered into an amendment to terminate the lease of one of its Redwood City premises under the existing lease and paid a termination fee of $<ix:nonFraction unitRef="usd" contextRef="ib6311b039ae14140ac682b123ba2e20b_D20211101-20211101" decimals="-5" name="advm:LesseeOperatingLeaseLeaseTerminationFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzQ5NDc4MDIzMzQzNDA_741334a3-ad7e-494d-8fe2-a08fd197bc1a">0.4</ix:nonFraction>&#160;million. Concurrently, the Company entered into an agreement to sublease a portion of such premises at $<ix:nonFraction unitRef="usd" contextRef="i6c50a8ce1839401ebdedd41b23664dc7_I20211101" decimals="-5" name="advm:OperatingLeaseMonthlyCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzY1OTcwNjk3NzYxODA_54f52684-c8f6-40d2-b3f3-a0c0d10945ef">0.1</ix:nonFraction>&#160;million monthly base rent. The sublease will expire on March&#160;31, 2022 and may be extended on a month to month basis until June 30, 2022. For short-term leases the Company does not recognize the right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease termination resulted in the requirement to test the recoverability of the carrying amount of the asset group. The carrying amount of the asset group, consisting of right-of-use assets and leasehold improvements, relating to the lease termination exceeds the Company's anticipated undiscounted cash flows. Accordingly, the Company reviewed the related right-of-use assets and leasehold improvements for impairment. As a result of the evaluation, the Company recorded an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzY1OTcwNjk3NzYxOTU_f0442595-ab2b-44da-9f7e-c3196198ca64">1.1</ix:nonFraction>&#160;million, which includes $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzQ5NDc4MDIzMzQzNjg_735864e6-0c62-47ac-9d66-62107b82e864">0.8</ix:nonFraction>&#160;million associated with the right-of-use assets and $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:ImpairmentOfLeasehold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzY1OTcwNjk3NzYyMTA_e5feb753-908b-4812-bd31-bec074abf1f9">0.3</ix:nonFraction>&#160;million associated with leasehold improvements, for the year ended December&#160;31, 2021. The assets indicated as impaired were written down to the estimated fair value, which was determined using the terms of the termination and sublease agreements. In connection with the termination of this lease, the Company derecognized the corresponding operating lease right-of-use asset and liability balances from the consolidated balance sheet</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with <ix:nonFraction unitRef="segment" contextRef="i6fe35d41e331443d948be3c7be2e9ec8_D20210108-20210108" decimals="INF" name="advm:LesseeOperatingLeaseNumberOfRenewalContracts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzk4OTU2MDQ2NTk1OTA_435613af-eda7-4188-9f46-bf50fe3acc4d">two</ix:nonFraction> options to extend the lease term for a period of <ix:nonNumeric contextRef="icd7de60f78ff4ca4b73e44e0bed3fb91_I20210108" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzk4OTU2MDQ2NTk2MDc_5a05de05-69b4-4dac-9584-a9bddb4724bc">five years</ix:nonNumeric> each. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the North Carolina property through October 2037, the remainder of the lease term. The remainder of the tenant improvement allowance under the original lease of approximately $<ix:nonFraction unitRef="usd" contextRef="ie64eef970c89427db31b4a0fad29b6a3_I20211026" decimals="-5" name="advm:LesseeOperatingLeaseLeaseholdImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzE2NDkyNjc0NTkyNDg_39eff524-3814-44d4-80c0-372a8ede6a8a">22.7</ix:nonFraction>&#160;million was transferred to the subtenant. This change in the Company&#8217;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability on the modification date. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="ib9a3fc8ffacb46b2b8cfe1ebaa83e8e7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted-average remaining lease term was <ix:nonNumeric contextRef="i00fd997b49304a6fb48d58e552aeb8ba_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2Mzc0MDY_9d317bb0-8850-4d7d-8cdc-1710deff86d1">11.7</ix:nonNumeric> years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#8220;IBR&#8221;) was <ix:nonFraction unitRef="number" contextRef="i00fd997b49304a6fb48d58e552aeb8ba_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2Mzc0MTM_9085f9c7-dab3-48c2-8095-60c4337cba9d">9.4</ix:nonFraction>%. IBR is an estimated rate of interest used to determine present value of future lease payments in order to measure lease liability, which rate is what the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the IBR, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. </span></div><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwODk_64d91d1f-66e2-48c5-b408-f623485de4cc" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzItMi0xLTEtMTI4MjI_519019d4-6196-4e8d-9cac-cb2fefeb9b30">6,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzItNC0xLTEtMTUyMDc_e6e62827-2055-4631-8393-56588b8177ad">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzMtMi0xLTEtMTI4MjI_ba93b982-cd61-4e24-8b8f-dd286633ffd1">13,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzMtNC0xLTEtMTUyMDc_8ce16eb0-e791-4e17-9ae6-d444319fe5b8">5,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzQtMi0xLTEtMTI4MjI_f3281d2d-4266-45a3-8e4e-f239da913ae5">14,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzQtNC0xLTEtMTUyMDc_de396c05-8632-4b36-879d-547fc16d3e96">6,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzUtMi0xLTEtMTI4MjI_7449ed17-b646-4018-9c3a-7bfc5e21580a">14,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzUtNC0xLTEtMTUyMDc_8a82e604-a19d-4fcb-a99e-1df8c58faba6">6,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzYtMi0xLTEtMTI4MjI_6fb2a9ec-b3b2-4843-840d-a8478679fb49">15,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzYtNC0xLTEtMTUyMDc_cd461aed-1727-42a3-9096-b7a9dfd40630">6,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzctMi0xLTEtMTI4MjI_be911a92-2772-48d8-8452-fda82363f45d">133,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzctNC0xLTEtMTUyMDc_55312ce4-eb10-4eed-83ca-9754603ceec8">82,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzgtMi0xLTEtMTI4MjI_0f6134e9-1031-4d81-b129-4ef75209714a">198,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzgtNC0xLTEtMTUyMDc_59af616a-4180-4775-8773-9f6e109db387">107,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzktMi0xLTEtMTI4MjI_48bd3598-92ff-4513-81ed-7f362cf9bd12">91,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:TenantImprovements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzEwLTItMS0xLTE2MTI2_c6dc1a22-437b-42ab-9b8c-b6bd7a9ee23c">9,577</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Lease incentive receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:IncentiveToLessee" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzExLTItMS0xLTE2MDgy_6de6d34d-69cf-4053-8603-f8fcbebeb590">5,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzEwLTItMS0xLTEyODIy_5c224545-a7ae-44a2-8ced-fcbd33191d1a">102,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the years ended December&#160;31, 2021, and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY2MTQ_171c5132-c52c-4c21-809f-2f348dd786af">12.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY2MTk_36050570-7a7e-4678-8915-754618bc1216">5.8</ix:nonFraction>&#160;million, respectively, which includes variable lease costs for utilities, parking, maintenance, and real estate taxes. Variable lease expenses for the years ended December&#160;31, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY4MDM_1087d0bb-7e25-4805-971c-351ba12ba8e1">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY4MTE_9f4169ff-d5e0-4bbc-8f73-0349ca3fd661">1.5</ix:nonFraction> million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzE2NDkyNjc0NjA3MTY_2baa85c8-8f47-4780-8543-1f5600a8ac43">5.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzE2NDkyNjc0NjA4Nzk_4ecceccd-fe24-4d2d-9a26-fde0031650e3">4.2</ix:nonFraction>&#160;million, respectively. Sublease income was $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2Mzc0MzY_c8f0cc5f-9e71-4f30-8d30-38a050abf81f">1.2</ix:nonFraction>&#160;million for the year ended December&#160;31, 2021, which was classified as a reduction in rent expense.</span></div></ix:continuation><div id="i4967880cb16f4a6c939e04bb1dfb040a_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90ZXh0cmVnaW9uOjFkZjA3MjdjMjE0YjQ2NjBhNDczNjM1YzljOTFhZjFhXzM0Mw_c26f8237-59cc-42a6-b4c0-077034f4ed95" continuedAt="idb5abc432a2e4469b0988b95c2debc19" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="idb5abc432a2e4469b0988b95c2debc19" continuedAt="if8f47d6de6c04c3fb9b7a6dd65a44eb0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90ZXh0cmVnaW9uOjFkZjA3MjdjMjE0YjQ2NjBhNDczNjM1YzljOTFhZjFhXzM0NA_bf751dd4-d89d-4cf1-b340-c702221b715c" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bfec030c89344d68297b3d5723d72af_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzMtMS0xLTEtMTI4MjI_6016ba11-02f0-44c2-9493-1a93c9c3b4d4">1,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ebc23bbab6a4b809a58be9b27bc6683_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzMtMy0xLTEtMTI4MjI_13dde35c-40ad-42b5-a113-2151f758d0c4">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b342bb0ce1b4ddfbb1fc42da05b8954_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzQtMS0xLTEtMTI4MjI_1c218455-30bc-4488-8e3d-c6251c0e77d2">12,778</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7cb21878274c689e6a89f1c23e59d1_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzQtMy0xLTEtMTI4MjI_5c192ef5-8b50-4e23-8b1a-44e41c98b311">9,354</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd25a4e655954753968ec44adaaed1c5_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzUtMS0xLTEtMTI4MjI_dc4c0884-32bb-4fe4-9027-e2cf2206ebd3">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76e6ddf942cd490c98176b6a38c05c9c_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzUtMy0xLTEtMTI4MjI_b3c27c60-7df7-47db-8f86-82a547b4cd43">1,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3a06d6569a4f0eb845ce032f5207f1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzYtMS0xLTEtMTI4MjI_99a09057-88af-4d7b-81f5-3e59cf399c44">26,701</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01fe6f2e1c640889f794f6d0cb75b01_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzYtMy0xLTEtMTI4MjI_74b2056c-67ea-4aa0-86f6-c4c509b30a76">24,631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i299d93d81b8442fea229100cbe836c75_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzctMS0xLTEtMTI4MjI_8f9bfcaf-30af-4b25-80e6-097f75e1c269">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4372ddfd6eaf4ebdab2698da6339e4ba_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzctMy0xLTEtMTI4MjI_1228eae8-6ce7-461e-a0bb-0d99059184da">1,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzgtMS0xLTEtMTI4MjI_8e9f1073-aa5f-428a-8559-6a454aaf642b">46,234</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzgtMy0xLTEtMTI4MjI_b2962500-3de7-473e-8c29-ff7603770c63">37,797</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzktMS0xLTEtMTI4MjI_86c8bb7e-ae68-4cca-8c04-f982a086277c">13,174</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzktMy0xLTEtMTI4MjI_8ba7519a-313a-48a6-8e86-7762464cfdce">10,072</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzEwLTEtMS0xLTEyODIy_b110ead3-ecbd-4fae-b2dc-1200ff138759">33,060</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzEwLTMtMS0xLTEyODIy_a1b20c94-b4d1-47f8-9b0b-c54df79a652e">27,725</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="if8f47d6de6c04c3fb9b7a6dd65a44eb0"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90ZXh0cmVnaW9uOjFkZjA3MjdjMjE0YjQ2NjBhNDczNjM1YzljOTFhZjFhXzM0NQ_e6f9fa8a-604a-462f-8bdc-559865abfad6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzMtMS0xLTEtMTI4MjI_444448bf-27f4-4f46-82d3-483b73b4af42">9,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AccruedEmployeeBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzMtMy0xLTEtMTI4MjI_b4250f69-a979-436b-9c4c-720486f0b25d">8,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzQtMS0xLTEtMTI4MjI_4844fc33-8f2a-4c66-aa4c-e491bbbd5257">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzQtMy0xLTEtMTI4MjI_4878c86f-411e-49e2-8759-7af321b2fedd">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:AccruedNonclinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzUtMS0xLTEtMTI4MjI_d63deb1a-09b2-41dc-84ff-33d51898763b">2,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:AccruedNonclinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzUtMy0xLTEtMTI4MjI_91364fce-b403-4db1-9258-0c5865b86d42">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:AccruedClinicalAndDevelopmentProcessCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzYtMS0xLTEtMTI4MjI_39281d43-f68d-4a8f-8080-df284d6db6af">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:AccruedClinicalAndDevelopmentProcessCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzYtMy0xLTEtMTI4MjI_350bd534-0b95-4848-a455-592d87bc46a3">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMS0xLTEtMTY5ODE_53172c38-ffdc-41ad-963a-f06cbc704acb">1,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMy0xLTEtMTY5ODE_a5fc4085-968e-4dad-8ebb-e8f73290638a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMS0xLTEtMTI4MjI_c09a737e-a21a-4719-8326-99d4135d0594">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMy0xLTEtMTI4MjI_370c2fef-8559-4dd6-8b94-917a3ed126a0">1,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzgtMS0xLTEtMTI4MjI_db9b8c9a-6e99-4b92-80b0-9cfe1d72864c">18,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:AccruedExpensesAndOtherCurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzgtMy0xLTEtMTI4MjI_4fdb2296-25a0-46f4-a57a-ad31fc0689d4">13,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTcvZnJhZzozNGRjMGZlMjRjZTk0ZTE0OWFmODM5MTIxOWZlOGUwMC90ZXh0cmVnaW9uOjM0ZGMwZmUyNGNlOTRlMTQ5YWY4MzkxMjE5ZmU4ZTAwXzE3Nzc_6bc93552-1626-4bb1-aaa0-10d44a10c1c2" continuedAt="i6c676d78e37c4ca58fa95189668a3ff8" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i6c676d78e37c4ca58fa95189668a3ff8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. Through December&#160;31, 2021, none of the goals had been achieved under the license agreements and <ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="INF" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTcvZnJhZzozNGRjMGZlMjRjZTk0ZTE0OWFmODM5MTIxOWZlOGUwMC90ZXh0cmVnaW9uOjM0ZGMwZmUyNGNlOTRlMTQ5YWY4MzkxMjE5ZmU4ZTAwXzM1Mg_bc03a38c-3939-4095-968f-c1f5b322f99c">no</ix:nonFraction> milestones were accrued or payable. Because the achievement of these milestones is not fixed and determinable, such commitments have not been included on the Company&#8217;s consolidated balance sheets.</span></div></ix:continuation><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODQ_12ea0ab9-2621-45d9-b512-19e071fa5ac1" continuedAt="i47381e7109e047d68b882913869aeb64" escape="true">Stock Plans</ix:nonNumeric></span></div><ix:continuation id="i47381e7109e047d68b882913869aeb64" continuedAt="i3a4c05746dc94bb398b63ee3fa04431a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#8220;2006 Plan&#8221;). The 2006 Plan allowed for the granting of incentive stock options (&#8220;ISOs&#8221;) and non-qualified stock options (&#8220;NSOs&#8221;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs were granted to the employees and consultants. In July 2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (<ix:nonFraction unitRef="number" contextRef="i966d761db5484ddc9c6cc7e401bba8fb_D20210101-20211231" decimals="INF" name="advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2Xzk5MA_1eca8da3-811d-4252-be57-50c9d6ce0843">4</ix:nonFraction>%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company adopted the 2017 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Company reserved <ix:nonFraction unitRef="shares" contextRef="i151723aa80f341a8952a483bb904ee20_I20171031" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzEyNjQ_c40b2688-e5ff-4abb-a71f-3e92a347f678">600,000</ix:nonFraction> shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2021, a total of <ix:nonFraction unitRef="shares" contextRef="if01574c0aec8441ebcd6ced712437994_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzE4NTI_d3d78a3a-843d-471c-b306-e675efe79623">33,965,569</ix:nonFraction> shares of common stock were reserved for issuance and <ix:nonFraction unitRef="shares" contextRef="if01574c0aec8441ebcd6ced712437994_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzE5MDk_de4e04f9-164f-415b-bb0c-2be251d86d9d">5,717,148</ix:nonFraction> shares were available for future grants under the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to <ix:nonNumeric contextRef="i0712c015900b4ee29ae1903994ae8913_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIwNzc_3a9011b2-81db-4362-8f78-13007f7b0512">10</ix:nonNumeric> years and at prices no less than <ix:nonFraction unitRef="number" contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIxMDc_e093561d-05cc-4f2a-a138-133713069e81">100</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a <ix:nonFraction unitRef="number" contextRef="i9a91a547f88e4a6a81c47e8971ea1f72_D20210101-20211231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIyODg_5ea80912-4454-431d-b49e-8f610efebaeb">10</ix:nonFraction>% stockholder may not be less than <ix:nonFraction unitRef="number" contextRef="i9a91a547f88e4a6a81c47e8971ea1f72_D20210101-20211231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIzMjQ_f83e4969-980c-4475-a738-c5e6dd8fe25a">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over <ix:nonNumeric contextRef="ic18936e5d4e5454ab245e22276a0fb26_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzI0NzI_3b95e5ec-fbea-4fa3-a2c9-52338b8054b6">four years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="i3a4c05746dc94bb398b63ee3fa04431a" continuedAt="i8204ae37401b4a9f9dd0b51ebdce7484"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODU_588eedb6-b15e-45d3-8085-cc87e93b564b" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtMS0xLTEtMTI4MjI_3ed3b925-946b-4bde-8fbc-1b29a94fe30a">8,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtMy0xLTEtMTI4MjI_aaa968ce-b951-476f-81d1-e558b63803a6">7.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1974c638bb5e4a5990d928e7aecd0c6d_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtNS0xLTEtMTI4MjI_a9ed3f30-b172-4b39-aff7-6a743e88a076">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtNy0xLTEtMTI4MjI_1370e4e6-01c1-4cc4-9fb6-bd2b3d42d750">48,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzYtMS0xLTEtMTI4MjI_75b0655e-a2ec-4232-a5bc-8c153428f098">4,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzYtMy0xLTEtMTI4MjI_e51898fa-0e3c-4d2e-ad63-6e7fbe527026">18.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzctMS0xLTEtMTI4MjI_7bb0cf34-cd6f-402e-89ee-eca810591efb">2,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzctMy0xLTEtMTI4MjI_d9796a6e-3b6e-41f2-a04d-0365fa6ed0ec">6.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzgtMS0xLTEtMTI4MjI_0be314a3-41a2-4d75-b58d-2a716517504e">646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzgtMy0xLTEtMTI4MjI_f1e4107e-d1bb-4273-83e7-290e58cb95a0">10.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktMS0xLTEtMTI4MjI_ea5b8023-eeb8-4b55-84ad-6ed5ce937122">10,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktMy0xLTEtMTI4MjI_1b4e4573-2857-4d31-ba03-48152b8e2738">11.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktNS0xLTEtMTI4MjI_d125d389-13ee-4b96-a6a6-decd41c5a96a">8.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktNy0xLTEtMTI4MjI_0b347400-875e-4e6d-8bc4-a7e7eec5364b">31,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEwLTEtMS0xLTEyODIy_86530402-61ce-4ed0-ad57-63ec33c40871">8,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEwLTMtMS0xLTEyODIy_98e78974-41b1-45cd-805c-be5ed97d275e">7.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzExLTEtMS0xLTEyODIy_d19030ce-9b5b-49dd-aed0-c36787677f62">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzExLTMtMS0xLTEyODIy_a06bc957-69b6-4186-9ae3-18884b38dfdb">5.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEyLTEtMS0xLTEyODIy_aaf401b8-7566-4358-bb33-13c500a3ba14">5,366</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEyLTMtMS0xLTEyODIy_7721c2b0-94e5-4239-b1b4-44e71be6aee7">10.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTEtMS0xLTEyODIy_e7d7c412-d9b1-4261-9f21-3b326b3152ed">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTMtMS0xLTEyODIy_6d6774c8-82e7-4028-8679-c0f5ab94f653">9.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTUtMS0xLTEyODIy_eb1c2d5b-24e8-49ab-a743-e4254ea0bc83">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTctMS0xLTEyODIy_b806153d-a689-4638-97ff-7f8a5a6d4d7a">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTEtMS0xLTEyODIy_4d7c9e5c-f55d-4a38-8d9f-4a3d24a359c8">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTMtMS0xLTEyODIy_4525b700-f2cf-4e20-88a4-db6793b8ae22">9.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTUtMS0xLTEyODIy_84130ad7-5d15-4677-b3a9-fee84ef0cffc">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTctMS0xLTEyODIy_f1312b9a-b2ef-417d-b24d-cca65aba9c4f">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTEtMS0xLTEyODIy_a69ea41d-3775-4d1e-a6ff-27a37c0fd9ca">5,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTMtMS0xLTEyODIy_89d9722d-b521-4280-9ea6-313f8e226ee0">10.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTUtMS0xLTEyODIy_ec5899de-6379-49db-8bf3-bc77093b4356">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTctMS0xLTEyODIy_09ceeb00-9d68-4158-929e-d9d0917b7e58">145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzI4NzE_470ac090-5a58-4a8c-903b-d9459801d73d">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzI4Nzg_0227244b-7ce7-46ae-beaf-3da5c487f621">20.8</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODY_d149a787-2988-40ee-8fa3-8d2030770813" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtMS0xLTEtMTI4MjI_7984be1f-89aa-41d6-9c68-528d68bde137">91</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtMy0xLTEtMTI4MjI_d1aeed21-32a8-4b60-b631-03d87930b03e">87</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtNy0xLTEtMTI4MjI_811cb7fe-f40b-4b23-a136-07f399c4145b">122</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtOS0xLTEtMTI4MjI_d22bceeb-9ffc-4507-a5f1-6227262bf1c8">89</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtMS0xLTEtMTI4MjI_085e89cf-16b7-44de-8223-f452e6ed3ef8">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtMy0xLTEtMTI4MjI_3177bb9f-b832-476d-bd28-495b2c611ed3">6.0</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtNy0xLTEtMTI4MjI_959c7f56-3f7c-445a-abfe-0630d1c98857">1.21</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtOS0xLTEtMTI4MjI_55a1a675-e37d-4d65-9529-0c7020d94205">0.5</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtMS0xLTEtMTI4MjI_47c56ada-94a6-42e6-9cc5-a6500cf0a364">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtMy0xLTEtMTI4MjI_3305987d-2201-4bd8-b95c-b498020827e6">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtNy0xLTEtMTI4MjI_490d40d1-37bb-4895-aa83-51319adff70a">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtOS0xLTEtMTI4MjI_35fbcded-990b-4f57-8c65-ad58c1483231">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtMS0xLTEtMTI4MjI_23c30c42-2ed7-4d76-a622-53ef2e9d07d3">1.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtMy0xLTEtMTI4MjI_18f053f8-67f6-455c-bcb5-bcc432f09b68">0.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtNy0xLTEtMTI4MjI_b9ee4023-9a4a-4793-9a39-afadebe23d1b">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtOS0xLTEtMTI4MjI_b4b2faff-c6ae-4214-a8dd-21c61b087a47">0.1</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December&#160;31, 2021 and 2020 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMxNjY_8dc3807e-aa2a-413b-8ab7-09319832b9a0">5.18</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMxNjk_deb5cb3c-5698-4c73-a74a-c62b5e5879be">13.39</ix:nonFraction>, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMyMTQ_9de713fb-7339-403e-b8d1-b2a79019710b">43.1</ix:nonFraction> million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMzNTk_0c528a72-0a46-4a66-aa4e-aae4e0a16e68">2.9</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#8217;s common stock on the grant date. RSUs granted to employees generally vest over a <ix:nonNumeric contextRef="id1c8c42cfe214c2e915d20a2db5f37ae_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzM2NTA_57e861b8-7c64-4c6e-9c06-8f4a939ea6c9">2</ix:nonNumeric>&#8211;<ix:nonNumeric contextRef="i675005a96bf84236b0181223cfe2bf55_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODc_615d8921-bee9-4b2e-8329-02680c98abe4">4</ix:nonNumeric> year period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="i8204ae37401b4a9f9dd0b51ebdce7484"><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODg_18d20e1f-5450-49b0-85b2-4a305369a0fb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55d4e6f877b540b484ca25983cbe7bad_I20191231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzUtMS0xLTEtMTI4MjI_73367f06-d3bd-4b22-9397-3e0a7fb68981">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55d4e6f877b540b484ca25983cbe7bad_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzUtMy0xLTEtMTI4MjI_f2b2e6ad-c50c-433e-af12-ae544ca4510d">4.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id078bd5264c44f8d85cbc656e1a30010_D20190101-20191231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzUtNS0xLTEtMTI4MjI_ef0ea141-a816-42ff-97b8-16144dd1d641">0.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzYtMS0xLTEtMTI4MjI_4f00eb4f-47c8-4936-ab60-a880abc7c88f">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzYtMy0xLTEtMTI4MjI_7aff34f9-2d5f-4c2d-9e0b-09335c7296f6">15.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzctMS0xLTEtMTI4MjI_257b5a07-da2c-427b-90e2-3765317f1733">590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzctMy0xLTEtMTI4MjI_5ebbaf8a-a805-4b67-bbce-55525655ff6e">4.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzgtMS0xLTEtMTI4MjI_b85802dd-1ebd-4de6-825c-b1391a4b0a8c">96</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzgtMy0xLTEtMTI4MjI_d08a7463-9ef4-4f96-aa6c-42d14ed87459">7.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1aa1a08442284607a20e7c4f8d0e72b5_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzktMS0xLTEtMTI4MjI_2f20e749-5a11-4e11-bf85-77bfef348682">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1aa1a08442284607a20e7c4f8d0e72b5_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzktMy0xLTEtMTI4MjI_7286e8b3-2f8e-4401-9b02-c45dbac1952b">6.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzktNS0xLTEtMTI4MjI_516fe4b9-b812-435f-8f80-42d2cfd003f6">0.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEwLTEtMS0xLTEyODIy_7a7237c6-cc61-4463-98e7-c22caedd82ca">2,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEwLTMtMS0xLTEyODIy_7e7614bf-f924-43b8-b877-3c0f2c6d7ef7">3.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzExLTEtMS0xLTEyODIy_eb471b97-3be1-4dd3-80d9-2be15fb927bd">305</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzExLTMtMS0xLTEyODIy_03ddac94-2bc6-4500-805d-0b572ab467fd">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEyLTEtMS0xLTEyODIy_55ab413b-198b-4a27-90df-ff090693ead3">694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEyLTMtMS0xLTEyODIy_c1975c6a-f06b-4957-b6c8-62c107ac1710">5.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8988b116ae244c71b22a0159529f37af_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEzLTEtMS0xLTEyODIy_ab15e0ea-f3e6-486e-941f-8a1c002a163c">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8988b116ae244c71b22a0159529f37af_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEzLTMtMS0xLTEyODIy_8ac32c51-387a-4fd9-924c-9a6be71fdee9">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEzLTUtMS0xLTEyODIy_6f0081a4-f434-451a-ad15-6feaf6524d6c">1.44</ix:nonNumeric></span></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the year ended December&#160;31, 2021 include <ix:nonFraction unitRef="shares" contextRef="i637b2d0774af4daf84893a36dbbffb39_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzE1OTQyOTE4NjA4OTAx_60176a0e-44c9-4e7a-b925-fe3a92a452dd">1.3</ix:nonFraction>&#160;million shares of performance units with both performance and service vesting conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020 total fair value of RSUs vested was $<ix:nonFraction unitRef="usd" contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzM5Nzk_379734e8-5cb7-4c6a-8ccf-2b51cc3c8fdc">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzM5ODM_2adb86e3-b0b0-44ef-b582-c2f942e79f28">2.7</ix:nonFraction>&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i8988b116ae244c71b22a0159529f37af_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQyMTU_f76e3b92-1920-4ece-858c-5591547afada">4.5</ix:nonFraction>&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQzNDU_8133b190-5eab-4730-b622-b241cbc8903d">1.8</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The Company reserved <ix:nonFraction unitRef="shares" contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ0ODM_fedc5e65-4002-402f-94e0-8b89f0c4fe6c">208,833</ix:nonFraction>&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (<ix:nonFraction unitRef="number" contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ3MDA_17fc6ba2-07be-4a0f-9eab-25d9d8f54720">1</ix:nonFraction>%)&#160;of the number of the Company&#8217;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. During the year ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="i31af55d22bfb48c4b7cc961ba70d0f12_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ4ODI_16b462db-990c-401e-beb1-8d9e570aa63c">397,763</ix:nonFraction> shares were issued under the ESPP. As of December&#160;31, 2021, a total of <ix:nonFraction unitRef="shares" contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ5NDE_ae5e3875-8f26-4e3d-866b-73795729d186">2,130,542</ix:nonFraction> shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2021, there was $<ix:nonFraction unitRef="usd" contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzUwMzg_d2a9ac75-71ce-4a51-b0b3-90d5e5836fb0">1.9</ix:nonFraction>&#160;million of unrecognized compensation cost related to the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Recognized in the Consolidated Statement of Operations and Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODk_6b08e46a-55b1-4fec-aa7a-cd92b9a231e3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdf93b275abc44ef8fb8c54d925edaa0_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzMtMS0xLTEtMTI4MjI_7f55aac1-1caa-4af9-b68b-2b6de766a0b8">8,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09580173048e4c7ca33b47016c7728b2_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzMtMy0xLTEtMTI4MjI_0660d043-d574-4f97-9177-e8b7300c9e08">7,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4828bf008756429682ad64a18e6f626a_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzQtMS0xLTEtMTI4MjI_61652bf5-f175-4d5f-aa45-40f32c7596cd">16,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98df46a84d42486094eb52256840d178_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzQtMy0xLTEtMTI4MjI_90e4a0fe-8f6d-48ff-bdd9-1ceabb5695f2">13,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzUtMS0xLTEtMTI4MjI_f6a0a73a-62ef-4308-a34b-484e1ca58487">25,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzUtMy0xLTEtMTI4MjI_30f1cf18-d35d-4879-9928-97a448371b5f">20,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzUzNzQ_dd57e8c8-b128-441f-bb5a-976d9966748f">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:StockOptionPlanExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzUzNzg_e5b9d07c-f6fe-4d45-8685-c9f58900bfe2">0.3</ix:nonFraction>&#160;million,  respectively of stock&#8209;based compensation expense as a result of the modification of the vesting and exercisability of stock awards associated with the departure of its executives and directors.</span></div></ix:continuation><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjkvZnJhZzpmNzAyYjc2YWY1N2M0YTVmYmNhYWMyMzg5NmM5OTVhMi90ZXh0cmVnaW9uOmY3MDJiNzZhZjU3YzRhNWZiY2FhYzIzODk2Yzk5NWEyXzQ0Mg_6738de86-ba56-4d2e-b146-8658b06c7e05" continuedAt="i657f47ec83e74a809dc862d0a743029b" escape="true">401(k) Savings Plan</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i657f47ec83e74a809dc862d0a743029b">The Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjkvZnJhZzpmNzAyYjc2YWY1N2M0YTVmYmNhYWMyMzg5NmM5OTVhMi90ZXh0cmVnaW9uOmY3MDJiNzZhZjU3YzRhNWZiY2FhYzIzODk2Yzk5NWEyXzQxNg_55e28170-3897-4d7f-a000-c3124c6aea96">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjkvZnJhZzpmNzAyYjc2YWY1N2M0YTVmYmNhYWMyMzg5NmM5OTVhMi90ZXh0cmVnaW9uOmY3MDJiNzZhZjU3YzRhNWZiY2FhYzIzODk2Yzk5NWEyXzQyMA_bbea4a6a-f579-41fd-9cd3-920c2c694ed5">0.7</ix:nonFraction> million, respectively.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTM_475f9725-e93b-439e-bd64-e8df8b2c72c7" continuedAt="i271eed0429e34b03800aac189c040ab1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i271eed0429e34b03800aac189c040ab1" continuedAt="i34b0c840c53f457b827b1905ff2e2dce"><div style="margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzY1OTcwNjk3NzIwNDk_1fb50a50-841f-4f69-8438-34a609f616e0" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzMtMS0xLTEtMjE4NzM_a6f713f1-0c6a-4512-a25b-4c3cdac16b25">145,375</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzMtMy0xLTEtMjE4NzM_4cf83cff-71a4-4646-aaf1-b09db14d8145">110,327</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzQtMS0xLTEtMjE4NzM_6d119bce-8a01-42ae-8667-53a1287f7b9b">165</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzQtMy0xLTEtMjE4NzM_d350216d-12c4-4da9-bdbf-f5773d92b288">6,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzUtMS0xLTEtMjE4NzM_0faa1123-9714-4ce2-9b6d-fa53d04b8001">145,540</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzUtMy0xLTEtMjE4NzM_a1f7c7e3-b20f-4620-82ee-f5e7ac1a10ac">116,393</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTY_836cc436-d0f1-4e31-8c56-004d63fbcba2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax provision (benefit) were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzYtMS0xLTEtMTI4MjI_c166bc9e-91b1-4f6a-ae68-cb1d5e3fe9df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzYtMy0xLTEtMTI4MjI_daa030a9-2808-4e57-b390-0e77d8e66443">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzctMS0xLTEtMTI4MjI_b775dab5-ae21-4f04-b742-daaa15b0b256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzctMy0xLTEtMTI4MjI_2f5bc4be-a383-4b69-9796-5e9c562e7104">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzExLTEtMS0xLTEyODIy_e474ba4e-1d55-42cb-a411-b4e70d29449c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzExLTMtMS0xLTEyODIy_9a0e56fa-a5ae-4f05-9d68-911acba58868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEyLTEtMS0xLTEyODIy_dafac520-7fed-444f-b03c-4f641b6a8201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEyLTMtMS0xLTEyODIy_df647580-3b6d-47dc-b8a2-39f68be9ecaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEzLTEtMS0xLTEyODIy_b1dd5d31-e011-4137-8ef9-307b4ec4acd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEzLTMtMS0xLTEyODIy_0aa5b422-d87c-4df9-b866-3886e254c20a">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:6pt;margin-top:12pt"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTg_bc90aebe-ef06-46df-a14f-a451770b3f75" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for the years ended December&#160;31, 2021 and 2020 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzMtMS0xLTEtMTI4MjI_983d3bf5-c08f-4488-912e-de4a93db16a4">30,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzMtMy0xLTEtMTI4MjI_060d9f4b-7d1d-46c3-8269-6fea00153008">24,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzQtMS0xLTEtMTI4MjI_653b4672-836d-4956-86a8-7206edb0c14e">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzQtMy0xLTEtMTI4MjI_84aa00d5-e68d-495b-9b47-13a9d4a8f06f">2,787</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzUtMS0xLTEtMTI4MjI_0bd59723-81eb-491a-9403-e2d0105d57fa">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzUtMy0xLTEtMTI4MjI_4e6b8a4c-6a11-475c-8f5b-9455c5b56bd8">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzctMS0xLTEtMTI4MjI_277538e9-0924-403c-b394-130a5c9b22fd">2,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzctMy0xLTEtMTI4MjI_d09eb55b-5770-41d4-91fe-bf60caa64622">3,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzgtMS0xLTEtMTI4MjI_b359db48-fd95-4b88-8d33-c770b22fb966">41,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzgtMy0xLTEtMTI4MjI_e4a449f6-dcd4-41c3-a724-f2d67d9216fe">24,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzktMS0xLTEtMTI4MjI_93802d69-a21c-49e7-b35f-29ef056293a4">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzktMy0xLTEtMTI4MjI_4e6db391-f082-49c0-b8e7-de4fb9a6371e">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEwLTEtMS0xLTEyODIy_f081f3eb-2df5-4eae-ad15-a348439a2e64">9,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEwLTMtMS0xLTEyODIy_8c0e111a-c5a5-46e9-8bac-889d102f6c41">2,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="advm:IncomeTaxReconciliationChangeInStateUncertainTaxPosition" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzExLTEtMS0xLTEyODIy_599b0b7e-5d26-41ce-a5eb-fe1d22c85f3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="advm:IncomeTaxReconciliationChangeInStateUncertainTaxPosition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzExLTMtMS0xLTEyODIy_5c500eaa-dd42-456d-a770-480763036fd4">2,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEyLTEtMS0xLTIxODQ1_d6a2f24a-1af4-4227-a7ce-31dcaf854e2f">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEyLTMtMS0xLTIxODQ1_9e64391a-8fa5-4ff8-9a07-2268a3c1d8f7">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEzLTEtMS0xLTEyODIy_989263a5-9d68-4156-8f2e-d800e6a1ab70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEzLTMtMS0xLTEyODIy_4967f440-1d1a-4f9d-9dcb-dd0742c8a6e1">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><ix:continuation id="i34b0c840c53f457b827b1905ff2e2dce" continuedAt="icd866be7235b4952904ee3f51e03bbbb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTk_4af7f49d-90e2-4cff-9f2f-2273e954978a" continuedAt="ida019810778849d0a369b904dcf192cb" escape="true">The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:</ix:nonNumeric></span><ix:continuation id="ida019810778849d0a369b904dcf192cb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzQtMS0xLTEtMTI4MjI_a9a75f0b-350c-4c15-95d5-3478c8d1b666">111,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzQtMy0xLTEtMTI4MjI_6b8e8261-b167-4817-b660-c943484b0801">74,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzUtMS0xLTEtMTI4MjI_3454fe82-6568-4805-a9e0-dfc036904916">2,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzUtMy0xLTEtMTI4MjI_8cfbbd9c-ea12-4c28-9f85-1e896f9a10bf">1,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzYtMS0xLTEtMTI4MjI_17c498c5-e45a-48a8-ab31-c2965bef4106">16,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzYtMy0xLTEtMTI4MjI_88bd5699-08fe-41e0-8cc1-89b75cfd5d1a">11,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzctMS0xLTEtMTI4MjI_e5f5ffaa-5dc9-4560-9805-215c713dd89b">9,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzctMy0xLTEtMTI4MjI_9531b2e3-991f-412d-b8fd-886f643700c5">5,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEwLTEtMS0xLTEyODIy_48944cb6-c4a0-4e5a-923c-11d96d90bf46">1,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEwLTMtMS0xLTEyODIy_11e690dc-61b4-4d4a-8b98-4b7b3f6180a2">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="advm:DeferredTaxAssetsLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzExLTEtMS0xLTEyODIy_4f95fe00-ebc1-494e-9834-eef291fa1360">24,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="advm:DeferredTaxAssetsLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzExLTMtMS0xLTEyODIy_bac8b7f2-0efd-4927-bee3-0629128c3788">6,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTEtMS0xLTE5Mzc3_29040ecb-4db1-4a67-a20a-085a749f4b58">9,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTMtMS0xLTE5Mzc3_12fa8a62-7e65-41a9-9591-4ed74abf1197">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTEtMS0xLTEyODIy_92b6a485-4987-4ab0-a6b7-7b40babdc88b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTMtMS0xLTEyODIy_6d739621-81d5-4c48-98bf-608dbf529bd6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEzLTEtMS0xLTEyODIy_60536c58-cd86-4fd5-8a60-6a9228d455b6">176,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEzLTMtMS0xLTEyODIy_145b93d8-29c4-4eec-a9c5-f307943491ff">99,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE0LTEtMS0xLTEyODIy_5878bb64-b1eb-4ffa-b588-cfb2a255022a">154,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE0LTMtMS0xLTEyODIy_7468a712-102c-494e-ac9b-ed99255ddd3e">94,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE1LTEtMS0xLTEyODIy_b9a4371d-e6fb-4ef3-8bed-8123eb7f0a2c">21,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE1LTMtMS0xLTEyODIy_2fc8f638-2581-417b-8796-8f1adda6ddc0">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE4LTEtMS0xLTEyODIy_5b8f53db-5c92-403c-8848-53d5ae25b329">20,227</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE4LTMtMS0xLTEyODIy_afb6b3f6-3057-423e-885f-dfc53083fb44">4,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE5LTEtMS0xLTEyODIy_227684dd-c587-409e-a206-2f07ff9cc660">1,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE5LTMtMS0xLTEyODIy_2b6d2aa4-85f9-4372-89b7-e78e175ef1df">1,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIxLTEtMS0xLTEyODIy_f640b66c-874c-45c9-9ed4-7cd43ec699e3">21,607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIxLTMtMS0xLTEyODIy_1b9b1599-a006-471b-82c9-dd4d470b1e65">5,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIzLTEtMS0xLTEyODIy_7de26d33-eb39-4e5f-93eb-0985e71981fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIzLTMtMS0xLTEyODIy_ddf15534-5938-456a-bfbb-92ade903cdc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased approximately $<ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzExODY_d6b36e58-eb18-49da-8a1e-e1fc888454b1">60.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzExOTM_54fd242c-228e-4419-8d75-19cc5be74dbb">28.4</ix:nonFraction>&#160;million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had U.S. federal net operating losses (&#8220;NOLs&#8221;) carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="if6f92a2c752147398b0b7cb89424a66d_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzEzNDQ_9f0b080e-830a-4db6-825a-3be79ebc48d6">393.4</ix:nonFraction>&#160;million to offset any future federal income. Approximately $<ix:nonFraction unitRef="usd" contextRef="if6f92a2c752147398b0b7cb89424a66d_I20211231" decimals="-5" name="advm:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzEzOTg_aba4e4ea-4073-4674-8acf-88178a1f40c4">57.3</ix:nonFraction>&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2021, the Company also had U.S. state NOL carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="iec59229ab7074b74bd212f356c86ea60_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE0OTA_2f3a256e-9da7-4b0b-895e-de95dccb5495">227.1</ix:nonFraction>&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2021, the Company also had approximately $<ix:nonFraction unitRef="usd" contextRef="i92372011da0b4b8d9b3ff9c9bc63cda2_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE1OTA_cb60c49b-26c6-4321-b9b6-fa1ac401ec48">50.1</ix:nonFraction>&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had federal research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i7a4cbf761c8a4a17a861b8bf1844e0a5_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE4Mjk_dbef6fe0-d8a9-4568-8357-105df7f3ff74">13.6</ix:nonFraction>&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2021, the Company had state credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i78c00f24526d4abea5fca0722e1248a5_I20211231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE5NTU_692700da-d33e-481c-9243-87144204a772">12.3</ix:nonFraction>&#160;million available to reduce future tax liabilities which do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><ix:continuation id="icd866be7235b4952904ee3f51e03bbbb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has total unrecognized tax benefits as of December&#160;31, 2021 and 2020 of approximately $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzM0NTQ_70deb7e5-bac6-49a6-945f-4b07825d2fb9">21.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzM0NjE_ee0bcf5a-6a5a-460c-b193-2b85c8112a7f">8.7</ix:nonFraction>&#160;million, respectively. As of December 31, 2021, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate, if recognized, is $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQ5NDc4MDIzMzAxMjU_735e949a-4216-4c31-8d20-1a54369d7789">1.1</ix:nonFraction>&#160;million. The Company does not anticipate a significant change to its unrecognized tax benefits over the next twelve months. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTI_35fff19a-5925-474c-bb84-5af04f3a29f5" continuedAt="i1aaabec9e51c4e36837cd8a4a6042def" escape="true">A&#160;reconciliation of the unrecognized tax benefits is as follows:</ix:nonNumeric></span><ix:continuation id="i1aaabec9e51c4e36837cd8a4a6042def"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzMtMS0xLTEtMTI4MjI_1dacee05-a4f4-4255-ba0d-2eade3b74be8">8,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzMtMy0xLTEtMTI4MjI_deb5d370-c3d5-45f7-8368-2d53577c8983">3,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) related to prior year tax provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzQtMS0xLTEtMTI4MjI_a0c3f3f8-a7c6-432a-8f05-8ab50ce70482">10,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzQtMy0xLTEtMTI4MjI_eb6c0c0d-497d-41a0-b0b9-a856f1569422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to current year tax provisions</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzUtMS0xLTEtMTI4MjI_5a8a47f8-27f6-402c-93d1-a1c80cba21de">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzUtMy0xLTEtMTI4MjI_cb5c3e16-0c98-4a50-94e2-e4c7677a3ab9">5,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzYtMS0xLTEtMTI4MjI_bec9b60c-1819-4452-9732-bd61bf1623d1">21,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzYtMy0xLTEtMTI4MjI_c223f8a1-8898-4325-962c-6a0318fd144d">8,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, the Company accrued interest and penalties related to uncertain tax positions of $<ix:nonFraction unitRef="usd" contextRef="i2c917411737449d0a88f9f35170ed838_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQ5NDc4MDIzMjkzMDE_37cad620-3943-4e2c-b5e6-21a1ca39a687"><ix:nonFraction unitRef="usd" contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQ5NDc4MDIzMjkzMDE_afc7700b-7a59-42d5-b82b-43af74fa33c3">257,000</ix:nonFraction></ix:nonFraction>. There are no ongoing examinations by taxing authorities at this time.</span></div></ix:continuation><div id="i4967880cb16f4a6c939e04bb1dfb040a_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90ZXh0cmVnaW9uOmUzZmU5ZjNhNmYxNjQyNGVhMjE0MGUxM2Q1NDNlZDE2XzI3MA_73c6f2d1-7025-4df5-ba09-73ad4ed0bc50" continuedAt="i8c814e9152ff4138a43a6b85511dfa6d" escape="true">Net Loss per Share</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i8c814e9152ff4138a43a6b85511dfa6d"><ix:nonNumeric contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90ZXh0cmVnaW9uOmUzZmU5ZjNhNmYxNjQyNGVhMjE0MGUxM2Q1NDNlZDE2XzI3MQ_00889fb5-c684-4c5a-be11-282bc0a125b3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2f8ae5b4a0644993bf5b58e572c9d713_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzMtMS0xLTEtMTI4MjI_3a087768-a1f3-4004-bc32-26158fcac40d">13,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2ca53fed51a445cbea0844f267402e5_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzMtMy0xLTEtMTI4MjI_cb4fb63d-32cb-4d34-aea8-ae846654f2af">10,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d35f9c1b7487797a8b6521663d206_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzQtMS0xLTEtMTI4MjI_163ed9bd-c3b8-43f7-a2e0-c80e49d87827">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19e8bd338962449c9e2411b96b08c1be_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzQtMy0xLTEtMTI4MjI_aea5212a-9c99-41f2-8b56-5ee536caf5ef">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i44fcf3a223a1481794c8de42a0377a7a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzUtMS0xLTEtMTI4MjI_7b6c1f11-326c-4d33-b678-13d1b774e463">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfb6a75db0aa4095bfd093ce5e08bfd1_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzUtMy0xLTEtMTI4MjI_284aa7e6-76df-459b-9725-d5c43ad11de3">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzctMS0xLTEtMTI4MjI_4a2d9bbe-67b7-468f-8895-8beb69d88cd2">15,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzctMy0xLTEtMTI4MjI_e8537633-8a73-4355-9da7-b4d1c42c763c">10,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_187"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_190"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including Laurent Fisher, our Chief Executive Officer and Rupert D'Souza, our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December&#160;31, 2021. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Annual Report on Form 10-K. In the course of this evaluation, we sought to identify any material weaknesses in our disclosure controls and procedures to determine whether we had identified any acts of fraud involving personnel who have a significant role in our disclosure controls and procedures, and to confirm that necessary corrective action, including process improvements, was taken. This type of evaluation is done quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that as of December&#160;31, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i)&#160;recorded, processed, summarized and reported as and when required and (ii)&#160;accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed our internal control over financial reporting as of December&#160;31, 2021, the end of our fiscal year. Management based its assessment on criteria established in &#8220;Internal Control&#8212;Integrated Framework (2013)&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management's assessment included evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment. This assessment is supported by testing and monitoring performed by our internal accounting and finance organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our assessment, management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2021. The results of management's assessment were reviewed with the Audit Committee.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2021 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures and our internal controls will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been or will be detected. As these inherent limitations are known features of the financial reporting process, it is possible to design into the process safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. While our Chief Executive Officer and Chief Financial Officer concluded that, as of December&#160;31, 2021, the design of our disclosure controls and procedures, as defined in Rule 13a-15(e) under the Exchange Act, was effective, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_193"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">None</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_1797"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Not applicable</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_199"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission pursuant to Regulation 14A in connection with our 2021 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), which is expected to be filed not later than 120 days after the end of our fiscal year ended December 31, 2021, under the headings &#8220;Executive Officers,&#8221; &#8220;Election of Directors,&#8221; &#8220;Corporate Governance,&#8221; and &#8220;Delinquent Section 16(a) Reports,&#8221; and is incorporated herein by reference.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on the Corporate Governance section of our website, which is located at www.adverum.com. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for our principal executive officer, principal financial officer, principal accounting officer, controller or persons performing similar functions, or any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form 8-K. </span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_202"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Executive Compensation&#8221; and &#8220;Non-employee Director Compensation,&#8221; and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_205"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information,&#8221; and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_208"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the headings &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Corporate Governance,&#8221; and is incorporated herein by reference.</span></div><div><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_211"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item will be contained in the Proxy Statement under the heading &#8220;Ratification of Selection of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_217"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The financial statements schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Consolidated Financial Statements in Item 8 of this Annual Report on Form 10-K. No financial statement schedules are provided because the information called for is not required or is shown in the consolidated financial statements or related notes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) The following exhibits are included herein or incorporated by reference:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 9, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312520182655/d917807dex31.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reference is made to Exhibits </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> through </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312516588027/d130217dex32.htm">3.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021003623/advm-20201231xexx42.htm">Description of Common Stock</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1A&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex109_293.htm">License Agreement between AAVLife and Inserm Transfert, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex109_293.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex109_293.htm">July 4, 2014.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1B&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex1010_292.htm">Amendment No. 1 to License Agreement between AAVLife and Inserm Transfert, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex1010_292.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459016023738/advm-ex1010_292.htm">October&#160;5,&#160;2015.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 9, 2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm">Exclusive License Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm"> between</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm">Avalanche</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm"> Biotechnol</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm">ogies, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm"> and the Regents of the University of California, dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm"> as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1046_908.htm"> June 17, 2013.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 6, 2019</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm">License Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm">between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm">Avalanche </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm"> Biotechnologies, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm"> and Virovek, Inc., dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm"> as of</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1047_912.htm"> October 12, 2011.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 6, 2019</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">Lease </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">Adverum </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">Biotechnologies</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm"> and HCP LS Redwood City, LLC</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018020510/advm-ex102_101.htm">dated as of June 28, 2018</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex101firstamendment-health.htm">First Lease Amendment between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of April 19, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4C</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xex104c.htm">Second </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xex104c.htm">Amendment to </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xex104c.htm">Lease</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xex104c.htm"> (Partial Lease Termination) between Adverum Biotechnologies, Inc. and HCP LS Redwood City, LLC, dated as of November 1, 2021. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx104d.htm">Sublease Agreement between Adverum Biotechnologies, Inc. and Revolution Medicines, Inc., dated as of November 1, 2021. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex105leasenor.htm">Lease Agreement between Adverum NC, LLC (a wholly owned subsidiary of the Company) and ARE-NC REGION NO. 21, LLC, dated as of January 8, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx105b.htm">Sublease Agreement between Adverum NC, LLC and Jaguar Gene Therapy, LLC, dated as of October 26, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit1092017induceme.htm">2017 Inducement Plan, as amended and restated</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">001-36579</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312517307248/d463313dex992.htm">Form of Stock Option Grant Notice and Option Agreement under the 2017 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-220894</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312517307248/d463313dex993.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2017 Inducement Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-220894</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019006536/advm-ex1016_910.htm">Adverum Biotechnologies, Inc. 2014 Employee Stock Purchase Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit1082014eip.htm">Adverum Biotechnologies, Inc. 2014 Equity Incentive Award Plan, as amended and restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018004560/advm-ex1014_1087.htm">Form of Stock Option Grant Notice and Stock Option Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-197133</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459018004560/advm-ex1016_1089.htm">Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2014 Equity Incentive </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 6, 2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8D(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312514280644/d729335dex1018.htm">Form of Restricted Stock Award Grant Notice and Restricted Stock Award Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-197133</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 25, 2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8E(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx108e.htm">Form of Performance Stock Unit Award Grant Notice and Performance Stock Unit Award Agreement under the 2014 Equity Incentive Award Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx109.htm">Form of Change in Control </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx109.htm">and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx109.htm">Severance Agreement for executive officers other than the chief executive officer.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020008534/advm-20200331xex101.htm">Form of Indemnification Agreement for directors and executive officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.11A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex106nonxempl.htm">Non-Employee Director Compensation Policy, effective March 31, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(#)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex107nonxempl.htm">Non-Employee Director Compensation Policy, effective May 5, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit103leonepatters.htm">Amended and Restated Employment Agreement between Adverum Biotechnologies, Inc. and Leone Patterson, dated as of June 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit105leonepatters.htm">Amended and Restated Change in Control and Severance Agreement between Adverum Biotechnologies, Inc. and Leone Patterson, dated as of June 23, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.12C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex102pattersonconsultingag.htm">Consulting Agreement between Adverum Biotechnologies, Inc. and Leone Patterson, dated as of June 24, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">between Adverum Biotechnologies, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">Thomas Leung</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">February 27, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019017203/advm-ex101_157.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 8, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex103tleungse.htm">Separation Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex103tleungse.htm">and General Release of Claims </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex103tleungse.htm">between Adverum Biotechnologies, Inc. and Thomas Leung, dated as of February 2, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.13C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021009293/advm-20210331ex104tleungco.htm">Consulting Agreement between Adverum Biotechnologies, Inc. and Thomas Leung, dated as of February 2, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020008534/advm-20200331xex102.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Angela Thedinga, dated as of July 26, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020008534/advm-20200331xex103.htm">Promotion Letter between Adverum Biotechnologies, Inc. and Angela Thedinga, dated as of February 21, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 28, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14C(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021021777/advm-20210930ex101thedinga.htm">Separation Agreement and General Release of Claims between Adverum Biotechnologies, Inc. and Angela Thedinga, dated as of October 1, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.14D(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021021777/advm-20210930ex102thedinga.htm">Consulting Agreement between Adverum Biotechnologies, Inc. and Angela Thedinga, dated as of October 1, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex103clark_juliexofferlett.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Julie Clark, dated as of April 2, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.15B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex104promotionletterjuliec.htm">Promotion Letter between Adverum Biotechnologies, Inc. and Julie Clark, dated as of May 22, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.16(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828021015877/ex106offerletterchrisderes.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Chris DeRespino, dated as of February 1, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17A(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm"> between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">Adverum B</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">iotechnol</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">ogies, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">Laurent Fischer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">June 11, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit101laurentfisch.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.17B(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">Change</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> in Control and Severance Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> between</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> Adverum Biotechnol</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">ogies, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">Laure</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">n</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">t Fischer</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">dated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">as</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm"> of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000162828020012332/exhibit102laurentfisch.htm">June 11, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 10, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.18(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">Employment Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm"> between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">Adverum Biotechnologies, Inc. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">and Peter Sopar</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">kar, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">October 11, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459019041787/advm-ex102_241.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-36579</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 7, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.19(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1019.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Brigit Riley, dated as of May 21, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.20(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1020.htm">Employment Agreement between Adverum Biotechnologies, Inc. and Rupert D'Souza, dated as of November 12, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.21(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">Employment Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">between Adverum Biotechnologies, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">Setareh Seyedkazemi</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">De</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">cember 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1021.htm">, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">Employment Agreement </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">between Adverum Biotechnologies, Inc. and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">Richard Beckman</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">December 3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">0</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx1022.htm">, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx211.htm">List of subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_223">Power of Attorney (included on signature page hereto)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx312.htm">Certification of Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FILE NUMBER</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">FORM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx321.htm">Certification of Principal Executive Officer pursuant to 18&#160;U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="advm-20211231xexx322.htm">Certification of Principal Financial and Accounting Officer pursuant to 18&#160;U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page of the Company's Annual Report on Form 10-K has been formatted in Inline XBRL.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been filed separately with the SEC.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;This certification attached to this Annual Report on Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div><div style="padding-left:54pt"><span><br/></span></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_220"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i4967880cb16f4a6c939e04bb1dfb040a_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4967880cb16f4a6c939e04bb1dfb040a_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;29, 2022 </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.305%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Laurent Fischer, M.D.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rupert D'Souza</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rupert D'Souza, Ph.D.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Principal Accounting Officer)</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Power of Attorney</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints Laurent Fischer and Rupert D'Souza, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this annual report on Form&#160;10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.481%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Laurent Fischer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rupert D'Souza</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rupert D'Souza, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Patrick Machado</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patrick Machado, J.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Soo Hong</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soo Hong, M.B.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Lupher</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Lupher, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rabia Gurses Ozden</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rabia Gurses Ozden, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Scopa</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Scopa, J.D., M.B.A.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dawn Svoronos</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Reed Tuckson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reed Tuckson, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Whitcup</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 29, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Whitcup, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>advm-20211231xex104c.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3a67a96602c444f2be98677f1a56d9f5_33"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EXHIBIT 10.4C</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">SECOND AMENDMENT TO LEASE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">(PARTIAL LEASE TERMINATION)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Second Amendment to Lease (Partial Lease Termination) (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is entered into as of the 1st day of November, 2021, by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HCP LS REDWOOD CITY, LLC, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">R E C I T A L S &#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:20.81pt">Landlord and Tenant are parties to that certain Lease dated June 28, 2018 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Original Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), as amended by that certain First Amendment to Lease dated April 19, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and together with the Original Lease, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), whereby Tenant leases approximately 161,087 rentable square feet of space (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RSF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), consisting of (i) all of the rentable area (containing 41,445 RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">800 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in the building located at 800 Saginaw Drive, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">800 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), (ii) all of the rentable area (containing 39,967 RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">900 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in the building located at 900 Saginaw Drive, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">900 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), and (iii) all of the rentable area (containing 79,675 RSF RSF) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">100 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in the building located at 100 Cardinal Way, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">100 Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:21.42pt">Tenant and Landlord desire to enter into this Second Amendment in order to terminate the Lease with respect to the 800 Premises only and to release one another from their respective obligations thereunder, except as otherwise provided herein.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A G R E E M E N T &#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing recitals and the conditions and the covenants hereinafter contained, and for other consideration hereinafter set forth, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree as follows.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Capitalized Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. All capitalized terms when used herein shall have the same meaning as is given such terms in the Lease unless expressly superseded by the terms of this Second Amendment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Termination of the Lease of 800 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Landlord and Tenant hereby agree that conditioned upon the performance by the parties of the provisions of this Second Amendment, the Lease, with respect to the 800 Premises only, shall terminate and be of no further force or effect as of 11&#58;59 P.M. on November 6, 2021(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">800 Termination Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). Accordingly, effective as of 11&#58;59 P.M. Pacific Daylight Time on the 800 Termination Date, (i) the 800 Premises shall no longer be considered a part of the Premises, and Landlord and Tenant shall be relieved of their respective obligations under the Lease with respect to the 800 Premises, except those obligations under the Lease which relate to the term of Tenant&#8217;s lease of the 800 Premises prior to the 800 Termination Date and which specifically survive the expiration of the Lease (unless otherwise set forth elsewhere in this Second Amendment) (including, without limitation, Tenant&#8217;s payment of reconciliation of Direct Expenses) and Landlord shall have all the rights and remedies with respect to such obligations as set forth in the Lease, and (ii) the &#8220;Premises&#8221; shall consist only of the 900 Premises and the 100 Premises, and the &#8220;Building&#8221; shall mean only the 900 Building and the 100 Building.   Nothing contained herein shall relieve Landlord or Tenant of their respective obligations with respect to the 900 Premises or the 100 Premises.  In the event that Tenant retains possession of the 800 Premises or any part thereof after the 800 Termination Date, then the provisions of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Article 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the Original Lease shall apply.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-1-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Surrender of 800 Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Tenant hereby agrees to vacate the 800 Premises and surrender and deliver exclusive possession of the 800 Premises to Landlord on or before the 800 Termination Date and Landlord hereby agrees to accept the 800 Premises, in its condition as of the date hereof as full satisfaction of Tenant&#8217;s repair, maintenance and surrender obligations under the Lease except that the 800 Premises other than the Retained Premises shall be in vacant broom clean condition, and holes patched and painted to match nearby areas. Notwithstanding the foregoing, Landlord acknowledges that Tenant shall remain in the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">) floor portion of the 800 Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Retained Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) pursuant to a sublease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) with Revolution Medicines, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Third Party Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and that certain furniture, fixtures and equipment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Furniture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) will remain in the 800 Premises after transfer of possession of the 800 Premises to the Third Party Tenant. Tenant&#8217;s possession of the Retained Premises and the presence of such Furniture shall not be considered a holdover or other violation of the Lease or this Second Amendment.  Landlord hereby acknowledges that Tenant shall not be required to remove or restore any of the alterations and improvements existing in or serving the 800 Premises as of the date of this Second Amendment (including the Pad, Pad Equipment, Rooftop Equipment, or Lines serving the 800 Premises).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Consideration to Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In consideration for Landlord&#8217;s execution of this Second Amendment, Tenant shall deliver to Landlord upon execution of this Second Amendment the sum of $400,000.00 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">800 Termination Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Representations of Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Tenant represents and warrants to Landlord that (a)&#160;Tenant has not heretofore assigned or sublet all or any portion of its interest in the 800 Premises&#59; (b)&#160;intentionally omitted&#59; (c)&#160;Tenant has the full right, legal power and actual authority to enter into this Second Amendment and to terminate the Lease with respect to the 800 Premises without the consent of any person, firm or entity&#59; and (d) Tenant has the full right, legal power and actual authority to bind Tenant to the terms and conditions hereof.  Tenant further represents and warrants to Landlord that as of the date hereof there are no, and as of the 800 Termination Date there shall not be any, mechanic&#8217;s liens or other liens encumbering all or any portion of the 800 Premises, by virtue of any act or omission on the part of Tenant, its predecessors, contractors, agents, employees, successors or assigns.  Notwithstanding the termination of the Lease with respect to the 800 Premises and the release of liability provided for herein, the representations and warranties set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> shall survive the 800 Termination Date and Tenant shall be liable to Landlord for any inaccuracy or any breach thereof.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Each of Landlord and Tenant represents and warrants to the other that it has (a) the full right, legal power and actual authority to enter into this Second Amendment and to terminate the Lease with respect to the 800 Premises without the consent of any person, firm or entity&#59; and (b) the full right, legal power and actual authority to bind itself to the terms and conditions hereof. Landlord represents and warrants that there is no mortgage or deed of trust encumbering the 800 Premises and Landlord has the full right, legal power and actual authority to enter into this Second Amendment and to terminate the Lease with respect to the 800 Premises without the consent of any person, firm or entity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Remainder of Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Notwithstanding anything to the contrary herein, and for the avoidance of doubt, all terms of the Lease with respect to the 900 Premises and the 100 Premises shall (i) not be affected by this Second Amendment or the termination of the Lease with respect to the 800 Premises, and (ii) shall remain in full force and effect, including but not limited to Tenant&#8217;s extension rights set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. of the Original Lease and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> of the First Amendment with respect to the 900 Premises and the 100 Premises and Tenant&#8217;s right to use the Existing EV Spaces serving the 100 Premises and the 900 Premises pursuant to the terms of the Lease. From and after the 800 Termination Date and so long as Tenant is in occupancy of the Retained Premises pursuant to the Sublease, Tenant shall continue to have the right to use those Existing EV Spaces serving the 800 Premises shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">800 EV Spaces</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) in connection with the Retained Premises, provided that Tenant&#8217;s use thereof shall be non-exclusive following the 800 Termination Date and used in common </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">with the Third Party Tenant, and following expiration of the Sublease, Tenant shall have no right to use such 800 EV Spaces. In addition, Tenant shall have the right to use, in common with the occupants of the 800 Premises, the Patio Area. Landlord shall maintain the Patio Area to the same extent as if it were a Common Area and Tenant shall have no further obligation to maintain the Patio Area.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Disposition of Personal Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  In the event that Tenant does not remove any of its personal property, equipment and signage (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Personal Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) from the 800 Premises, other than the Furniture and Tenant&#8217;s Personal Property in the Retained Premises, prior to such 800 Termination Date, Tenant acknowledges that Landlord shall be entitled, but shall not be obligated, to dispose of said Personal Property in any manner it deems fit, and charge the cost of such disposal to Tenant Tenant hereby waives any rights it may have to notice under California Civil Code sections 1980 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">et seq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. with respect to such Personal Property.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:27.75pt;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Should any dispute arise between the parties hereto or their legal representatives, successors and assigns concerning any provision of this Second Amendment or the rights and duties of any person in relation thereto, the party prevailing in such dispute shall be entitled, in addition to such other relief that may be granted, to recover reasonable attorneys&#8217; fees and legal costs in connection with such dispute.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Second Amendment shall be governed and construed under the laws of the State of California.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Counterparts&#59; Signatures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Second Amendment may be executed in counterparts, each of which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement.  The parties hereto consent and agree that this Second Amendment may be signed and&#47;or transmitted by facsimile, e-mail of a .pdf document or using electronic signature technology (e.g., via DocuSign or similar electronic signature technology), and that such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party&#8217;s handwritten signature.  The parties&#8217; further consent and agree that (1) to the extent a party signs this Second Amendment using electronic signature technology, by clicking &#8220;SIGN&#8221;, such party is signing this Second Amendment electronically, and (2) the electronic signatures appearing on this Second Amendment shall be treated, for purposes of validity, enforceability and admissibility, the same as handwritten signatures.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  This Second Amendment shall inure to the benefit of, and shall be binding upon, the parties hereto and their respective legal representatives, successors and assigns.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Time of the Essence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Time is of the essence of this Second Amendment and the provisions contained herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  Landlord and Tenant hereby agree to execute such further documents or instruments as may be necessary or appropriate to carry out the intention of this Second Amendment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:22.25pt;text-decoration:underline">Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  The parties have read this Second Amendment and mutual release as contained herein, and on the advice of counsel they have freely and voluntarily entered into this Second Amendment.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#91;SIGNATURES APPEAR ON THE FOLLOWING PAGE&#93;</font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Landlord and Tenant have executed this Second Amendment as of the day and year first above written.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8220;LANDLORD&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">HCP LS REDWOOD CITY, LLC,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a Delaware limited liability company</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Scott Bohn&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Name&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">cott Bohn&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Its&#58; S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">enior Vice President&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">&#8220;TENANT&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">ADVERUM BIOTECHNOLOGIES, INC.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a Delaware corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Laurent Fischer&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Laurent Fischer&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Its&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">CEO&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; </font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:18pt"><font><br></font></div><div style="margin-top:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Reviewed by ADVM Legal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration:underline">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160; &#160; &#160; &#160;&#160; &#160; &#160;</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div></div></div><div id="i3a67a96602c444f2be98677f1a56d9f5_38"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">EXHIBIT A </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:107%;text-decoration:underline">800 EV SPACES</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="image.jpg" src="image.jpg" style="height:544px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">EXHIBIT A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">-1-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4D
<SEQUENCE>3
<FILENAME>advm-20211231xexx104d.htm
<DESCRIPTION>EX-10.4D
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6e74eb007a8c4fa18397deb58285e018_33"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 10.4D</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBLEASE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(REDWOOD CITY, CALIFORNIA)</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS SUBLEASE (this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8220;Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is entered into as of November 1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), by and between REVOLUTION MEDICINES, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sublandlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Subtenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Sublandlord and Subtenant may each be referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;, and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">RECITALS</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Sublease is made with reference to the following recitals of essential facts&#58;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.        Sublandlord, as tenant, and HCP LS REDWOOD CITY, LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Master Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as landlord, are parties to that certain Lease dated as of January 15, 2015 (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Master Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), as amended by that certain First Amendment to Lease date September 16, 2016, that certain Second Amendment to Lease dated April 17, 2020, and that certain Third Amendment to Lease dated November&#160;1, 2021 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Sublandlord leases from Master Landlord certain space including, in part, all of the building commonly known as 800 Saginaw Drive, Redwood City, California (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), containing approximately 41,445 rentable square feet, as more particularly described in the Master Lease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Master Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms used, but not defined, herein have the meanings set forth in the Master Lease, a copy of which has been previously provided to Subtenant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.        Subtenant is or was party to that certain Lease dated June 28, 2018, between Subtenant, as tenant, and Master Landlord, as landlord (as amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Adverum Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), pursuant to which Subtenant leased certain space including, in part, the Building.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.        Substantially concurrently herewith, Subtenant and Master Landlord have or will terminate the Adverum Lease as to the Building (the &#8220;Adverum Lease Termination&#8221;), and Master Landlord has or will lease the Building to Sublandlord pursuant to the Third Amendment (the execution and delivery of the Third Amendment by Master Landlord and Sublandlord is referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Third Amendment Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.        Subject to the terms and conditions of this Sublease and the occurrence of the Adverum Lease Termination and Third Amendment Execution, Sublandlord desires to sublease to Subtenant, and Subtenant desires to sublease from Sublandlord, that certain portion of the Master Premises comprising approximately 20,723 rentable square feet, located on the first floor of the Building, as depicted in Exhibit A attached hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Subleased Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">E.         Sublandlord may continue to lease and&#47;or occupy that portion of the Master Premises which does not contain the Subleased Premises (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Reserved Premises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) during the Sublease Term (as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">AGREEMENT</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">RECITALS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The foregoing recitals are hereby incorporated into this Sublease by this reference as if fully set forth herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">SUBLEASED PREMISES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sublandlord hereby subleases to Subtenant, and Subtenant hereby subleases from Sublandlord, the Subleased Premises. Additionally, Subtenant is hereby granted the nonexclusive right to use the common areas of the Building as reasonably necessary for the Subtenant&#8217;s continued use of the Subleased Premises for the uses permitted under this Sublease to the extent of Sublandlord&#8217;s rights to use of the same pursuant to the Master Lease, in common with other tenants in the Building (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Common Areas</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), each throughout the Sublease Term (as defined in Section 3).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">SUBLEASE TERM.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Commencement Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The term of this Sublease (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sublease Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall commence upon the later to occur of&#58; (a) Master Landlord&#8217;s execution of the Landlord&#8217;s Consent (as defined below), (b) the Adverum Lease Termination, and (c) Third Amendment Execution (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Commencement Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and shall expire on the Expiration Date (as defined in Section 3.2).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Expiration Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Unless earlier terminated under any provision of the Master Lease or this Sublease, the Sublease Term shall expire on March 31, 2022 (as may be extended by the MTM Period, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Subtenant may, upon written notice to Sublandlord given no later than March 1, 2022, extend the Sublease Term on a month-to-month basis, until no later than June 30, 2022 (the time period between April 1, 2022 and June 30, 2022 is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">MTM Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). During the MTM Period, Subtenant may terminate this Sublease on thirty (30) days prior notice to Sublandlord&#59; provided that, on June 30, 2022, the Sublease Term shall automatically expire without the requirement that either Party provide such prior notice. For the avoidance of doubt, Subtenant has no right to extend the Sublease Term beyond June 30, 2022.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt;text-decoration:underline">Possession</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Parties acknowledge that, as of the Effective Date, Subtenant is already in possession of the Subleased Premises. Accordingly, Sublandlord shall not be required to deliver possession of the Subleased Premises to Subtenant. Within five (5) business days following the Effective Date, Subtenant shall deliver to Sublandlord&#58; (a) the first full month&#8217;s Base Rent (as defined in Section 4), (b) the Security Deposit (as defined in Section 8), and (c) subject to the consent of Master Landlord, the certificate(s) of insurance evidencing that Subtenant carries the insurance required of the Subtenant under Adverum Lease (which insurance policies shall also name Sublandlord as additional insured).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">BASE RENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Beginning on the Commencement Date, Subtenant shall pay base rent to Sublandlord in the following amounts during the following periods (each payment, a monthly installment of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Base Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58;</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Time Period</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Monthly Installment<br>of Base Rent</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Monthly Base <br>Rental Rate Per</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Rentable Square <br>Foot</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Commencement Date<br>&#160;to March 31, 2022</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-1.2pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">$111,904.20</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$5.40</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">April 1, 2022 to <br>June 30, 2022*</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;text-indent:-1.2pt;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$111,904.20</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">$5.40</font></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*If applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">EXPENSE REIMBURSEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to paying Base Rent, beginning on the Commencement Date, Subtenant shall pay to Sublandlord, as additional rent, Subtenant&#8217;s Share of Direct Expenses (as defined in the Master Lease) on a monthly basis throughout the Sublease Term. As used in this Sublease, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Subtenant&#8217;s Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means 50% (which is the ratio that the rentable square footage of the Subleased Premises bears to the rentable square footage of the Master Premises). Sublandlord shall promptly forward to Subtenant all Estimate Statements and Statements (as each term is defined in the Master Lease) for the Master Premises that Sublandlord receives from Master Landlord. If Sublandlord receives a credit for overpayment of Direct Expenses attributable to the Master Premises (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Direct Expense Credit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to Section 4.4.1 of the Master Lease, Subtenant shall receive a credit against the next installment of Rent due under this Sublease in an amount equal to Subtenant&#8217;s Share multiplied by the total Direct Expense Credit or, if the Sublease Term has ended, Sublandlord shall pay such amount to Subtenant within thirty (30) days of Sublandlord&#8217;s receipt of the Direct Expense Credit. If Sublandlord makes a payment to Master Landlord due to an underpayment of Direct Expenses attributable to the Master Premises (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Direct Expense Shortfall</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) pursuant to Section 4.4.1 of the Master Lease, Subtenant shall pay Sublandlord an amount equal to Subtenant&#8217;s Share multiplied by the total Direct Expense Shortfall together with the next installment of Rent due or, if the Sublease Term has ended, Subtenant shall pay such amount to Sublandlord within thirty (30) days of Subtenant&#8217;s receipt of an invoice therefor. Subtenant shall not have the right to audit Direct Expenses.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">PAYMENT OF RENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Base Rent, Subtenant&#8217;s Share of Direct Expenses, and any other amounts payable by Subtenant in connection with this Sublease are referred to in this Sublease as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Rent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. Rent shall be due and payable to Sublandlord without prior written notice or demand, in advance, without deduction or offset, in lawful money of the United States of America, on or before the first day of each calendar month during the Sublease Term. Rent shall be payable at Sublandlord&#8217;s address set forth herein, or at such other place as Sublandlord may designate in writing to Subtenant. Rent for any period during this Sublease Term that is less than one (1) month shall be prorated based on a thirty (30) day month. Subtenant shall pay Rent for the first full month of the Sublease term upon Subtenant&#8217;s execution of this Sublease. Section 25 of the Master Lease shall apply to any late payment of Rent by Subtenant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">RESERVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">SECURITY DEPOSIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant shall deposit with Sublandlord on or before the Effective Date the sum of One Hundred Eleven Thousand Nine Hundred Four and 20&#47;100 Dollars ($111,904.20) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Security Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which Sublandlord will hold as security for Subtenant&#8217;s faithful performance of all of the terms, covenants and conditions of this Sublease to be kept and performed by Subtenant during the period commencing on the Effective Date and ending upon the expiration or termination of Subtenant&#8217;s obligations under this Sublease. If an Event of Default (as defined in Section 22) occurs with respect to any provision of this Sublease, including any provision relating to the payment of Rent, then Sublandlord may, but is not required to, use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to compensate Sublandlord for any other loss or damage that Sublandlord may suffer by reason of Subtenant&#8217;s default. If Sublandlord so uses or applies any portion of the Security Deposit, then Subtenant shall, within ten (10) days following demand therefor, deposit cash with Sublandlord in an amount sufficient to restore the Security Deposit to its original amount, and Subtenant&#8217;s failure to do so shall be a material breach of this Lease. Sublandlord shall return to Subtenant the Security Deposit, less any portion thereof which Sublandlord may have or withhold as permitted by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, within thirty (30) days after the expiration of the Sublease Term by lapse of time, termination of the Master Lease through no default of Subtenant or by the mutual, written agreement of Sublandlord and Subtenant. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the expiration or earlier termination of this Sublease. SUBTENANT HEREBY WAIVES THE REQUIREMENTS OF SECTION 1950.7 OF THE CALIFORNIA CIVIL CODE, AS THE SAME MAY BE AMENDED FROM TIME TO TIME.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">CONDITION OF SUBLEASED PREMISES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant (a) acknowledges that Subtenant currently occupies, and prior to this Sublease occupied, the Subleased Premises, and (b) accepts the Subleased Premises in their current &#8220;as is&#8221; condition with all faults. Subtenant hereby waives all warranties, whether express or implied (including warranties of merchantability or fitness for a particular purpose), with respect to the Subleased Premises or any furniture, fixtures and equipment located therein. Except as expressly set forth in this Sublease, Sublandlord makes no representation or warranty of any kind with respect to the Subleased Premises, and Subtenant shall have full responsibility for making any desired repairs, installations, alterations or additions to the Subleased Premises. Any installations, alterations or additions which Subtenant desires to make to the Subleased Premises shall be subject to the prior written approval of both Master Landlord and Sublandlord and shall otherwise be constructed in accordance with all of the terms and conditions of the Master Lease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">QUIET ENJOYMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant shall peacefully have, hold and enjoy the Subleased Premises during the Sublease Term, subject to the terms and conditions of this Sublease and termination of the Master Lease, provided that there is not a default by Subtenant beyond applicable notice and cure periods.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">USE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant may use the Subleased Premises solely for the uses permissible under the Master Lease, and for no other use. Subtenant&#8217;s use of the Subleased Premises must at all times comply with the requirements of the Master Lease, and Subtenant shall not use the Subleased Premises in a manner that is in any way inconsistent with the Master Lease, or that might cause Sublandlord to be in breach of the Master Lease. Notwithstanding the foregoing, should Master Landlord agree to the Adverum Operating Terms, in the case of a conflict between </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the terms of this Section 11 and the Adverum Operating Terms, the Adverum Operating Terms shall control.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">COMPLIANCE WITH LAWS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant shall, at its sole cost and expense, promptly comply with all laws, ordinances and regulations with respect to Subtenant&#8217;s use, occupancy or improvement of the Subleased Premises (as amended, together with the regulations promulgated pursuant thereto) (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; provided, however, Subtenant shall not be required to perform or pay for any improvements with respect to the construction of improvements to cause the Subleased Premises to comply with Applicable Laws except those incurred as a result of Subtenant&#8217;s (a) specific use and occupancy of the Subleased Premises, (b) obtaining any permit or license with respect to the Subleased Premises, or (c) making any installations, additions or alterations to the Subleased Premises during the Sublease Term.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">COMPLIANCE WITH MASTER LEASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Subtenant Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant covenants that it will occupy the Subleased Premises in accordance with all of the terms and conditions of the Master Lease as they apply to the Subleased Premises and will not suffer to be done or omit to do any act which may result in a violation of or a default under any of the terms and conditions of the Master Lease, or render Sublandlord liable for any damage, charge or expense thereunder. Subtenant further covenants and agrees to indemnify Sublandlord against and hold Sublandlord harmless from any claim, demand, action, proceeding, suit, liability, loss, judgment, expense (including reasonable attorneys&#8217; fees) and damages of any kind or nature whatsoever (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) arising out of, by reason of, or resulting from, Subtenant&#8217;s failure to perform or observe any of the terms and conditions of the Master Lease applicable to the Subleased Premises. Notwithstanding the foregoing or anything to the contrary in this Sublease, but subject to Master Landlord&#8217;s agreement hereto, it shall not be a violation of this Sublease for Subtenant to use and operate, and Subtenant may use and operate in, the Subleased Premises in the same manner permitted under and in accordance with the terms and conditions of the Adverum Lease (including but not limited to the Permitted Use thereunder and Subtenant&#8217;s use of Hazardous Materials), and Subtenant may continue to use the Pad Equipment, Rooftop Equipment and the Generator serving the Building to the same extent &#8220;Tenant&#8221; was so authorized under the Adverum Lease&#59; provided, that, to the extent such equipment services the building generally and not the Subleased Premises only, Sublandlord may utilize such equipment in a manner that does not disrupt Subtenant&#8217;s use thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Adverum Operating Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Sublandlord Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sublandlord covenants that it will maintain the Master Lease during the entire Sublease Term, subject, however, to any earlier termination of the Master Lease without the fault of Sublandlord, and to comply with or perform or cause to be performed Sublandlord&#8217;s obligations with respect to the Reserved Premises and with any obligations with respect to the Subleased Premises not assumed by Subtenant hereunder. Sublandlord hereby covenants (1) not to voluntarily surrender the Master Lease to Master Landlord as to the Subleased Premises (except in connection with Sublandlord&#8217;s right to terminate the Master Lease following a casualty or condemnation event), and (2) not enter into any amendment or other agreement with respect to the Master Lease which will prevent or adversely affect Subtenant&#8217;s use of the Subleased Premises in accordance with the terms of this Sublease, increase Subtenant&#8217;s obligations or decrease Subtenant&#8217;s rights under this Sublease, </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">shorten the term of this Sublease or increase the rental or any other sums Subtenant is required to pay under this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Subordination of Sublease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Sublease is subject and subordinate to the Master Lease in all respects. If the Master Lease is terminated for any reason whatsoever, then this Sublease shall automatically terminate as if it expired by its terms (unless assumed by Master Landlord) and in such event neither Sublandlord nor Master Landlord shall have any liability whatsoever to Subtenant as a result of such termination, except that Sublandlord shall be liable to Subtenant for any such termination arising as a result of Sublandlord&#8217;s default under the Master Lease. Sublandlord shall use commercially reasonable efforts to cause the Master Landlord to perform its obligations under the Master Lease, and shall cooperate with Subtenant in its efforts to obtain such performance, but under no circumstance shall Sublandlord be otherwise responsible or liable in any way for, Master Landlord&#8217;s failure to, (a) perform any acts required to be completed by Master Landlord under the Master Lease, (b) supply any item, including, but not limited to, any utility or service to the Subleased Premises required to be supplied by Master Landlord under the Master Lease, or (c) complete any work or maintenance in the Subleased Premises, the Building or the Master Premises required to be completed by Master Landlord under the Master Lease&#59; and no such failure will in any way excuse Subtenant&#8217;s performance under this Sublease or entitle Subtenant to any abatement of Rent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Consents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any consent is required of Master Landlord for any action of &#8220;Tenant&#8221; under the Master Lease, then such consent shall be required from both Master Landlord and Sublandlord for such action under this Sublease. Any consent or approval requested from Sublandlord in accordance with this Sublease shall be deemed reasonably withheld if Master Landlord withholds its consent or approval.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the expiration or earlier termination of this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">UTILITIES&#59; SERVICES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Sublandlord shall have no obligation to provide to the Subleased Premises with any services or utilities (including without limitation telephone or internet services). Notwithstanding the foregoing, to the extent that utilities serving the Subleased Premises (excluding telephone and internet) are not separately metered, Sublandlord shall establish an account for such utilities and Subtenant shall pay to Sublandlord, as additional rent hereunder, Subtenant&#8217;s Share of the cost of such utilities (such utilities are referred to herein as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Sublandlord-Provided Utilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). Sublandlord shall not be responsible or liable in any way for any failure or interruption, for any reason whatsoever, of the services, utilities or facilities that may or should be appurtenant or supplied to the Subleased Premises, and no such failure will in any way excuse Subtenant&#8217;s performance under this Sublease or entitle Subtenant to any abatement of Rent, unless such failure is a result of Sublandlord&#8217;s gross negligence or willful misconduct, or Sublandlord&#8217;s default under the Master Lease, in which event Subtenant may contract directly with Master Landlord to restore such interrupted utilities and services. Subtenant shall pay to Sublandlord as Rent hereunder any and all sums which Sublandlord may be required to pay to Master Landlord or any service provider arising out of excess consumption by Subtenant or a request by Subtenant for additional building services (e.g., charges associated with after-hours HVAC usage and over-standard electrical charges). Notwithstanding anything to the contrary in this Sublease or the Master Lease, Subtenant agrees that Sublandlord shall not be </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">required to perform any of the covenants, agreements or obligations of Master Landlord under the Master Lease and, insofar as any of the covenants, agreements and obligations of Sublandlord hereunder are required to be performed under the Master Lease by Master Landlord, Sublandlord&#8217;s obligation shall be to use commercially reasonable efforts to cause Master Landlord to so perform (but Sublandlord shall not be required to file a legal action to so enforce such matter). Notwithstanding the foregoing, should Sublandlord&#8217;s negligent acts or willful misconduct result in any interruption, cessation or disturbance in the provision of Subtenant-Provided Utilities to the Subleased Premises that materially impairs Subtenant&#8217;s use and occupancy of the Subleased Premises, such that Subtenant is prevented from using, and does not use the Subleased Premises or any portion thereof, for more than three (3) consecutive days, commencing on the fourth (4th) day after the commencement of such interruption, cessation or disturbance, the Rent payable hereunder by Subtenant shall abate during such time that Subtenant continues to be so prevented from using, and does not use, the Subleased Premises or a portion thereof, in the proportion that the square feet of the portion of the Subleased Premises that Subtenant is prevented from using, and does not use, bears to the total square feet of the Subleased Premises&#59; provided, however, that Subtenant shall not be entitled to abatement or reduction of Rent to the extent the matters described in this sentence above arise out of or results from a matter outside of Sublandlord&#8217;s reasonable control. To the extent Subtenant shall be entitled to abatement of Rent because of a damage or destruction or a taking pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section&#160;29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> below, then the terms of the immediately prior sentence shall not be applicable.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">MAINTENANCE.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subtenant shall perform all maintenance and repairs in the Subleased Premises to maintain the Premises in its existing condition which Sublandlord is required to perform under the Master Lease&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, however, that, at Sublandlord&#8217;s option, or if Subtenant fails to make such repairs, Sublandlord may, but need not, make such repairs and replacements, and Subtenant shall pay Sublandlord&#8217;s costs or expenses, arising from Sublandlord&#8217;s involvement with such repairs and replacements upon being billed for same. Notwithstanding the foregoing, Sublandlord shall be responsible for the maintenance and repair of all common areas and shared Building systems pursuant to the terms of the Master Lease. Sublandlord and Subtenant shall reasonably cooperate in transferring such responsibilities from Subtenant to Sublandlord, including, without limitation, transferring any maintenance contracts to Sublandlord, promptly following the Commencement Date. Subtenant shall be responsible for payment to Sublandlord of Subtenant&#8217;s Share of the actual, out-of-pocket costs incurred by Sublandlord in so maintaining and repairing the common areas and shared Building systems, which costs Subtenant shall pay as additional rent within thirty (30) days of its receipt of invoices and reasonable supporting documentation for such costs from Sublandlord.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">ASSIGNMENT AND SUBLETTING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant shall not assign, mortgage, hypothecate, encumber or otherwise transfer this Sublease or sub-sublease (which term shall be deemed to include the granting of concessions and licenses and the like) the whole or any part of the Subleased Premises, including by operation of law (any of the foregoing, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), without in each case first obtaining the prior written consent of Sublandlord, not to be unreasonably withheld. No Assignment shall relieve Subtenant of any liability under this Sublease. Consent to any such Assignment shall not operate as a waiver of the necessity for consent to any subsequent Assignment. In connection with each request for an Assignment, Subtenant shall pay Sublandlord&#8217;s reasonable cost of processing such Assignment, including </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">attorneys&#8217; fees, and any fees or costs payable under the Master Lease, upon demand of Sublandlord (not to exceed the actual cost charged to Sublandlord by Master Landlord to review the request, plus up to $3,000 for Sublandlord&#8217;s review costs). Any assignee or subtenant shall assume all of Subtenant&#8217;s obligations under this Sublease and be jointly and severally liable with Subtenant hereunder. Any Assignment hereunder must comply with the Master Lease, including, without limitation, the obtaining of any required consent of Master Landlord.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">INDEMNITY&#47; INSURANCE</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">By Subtenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subtenant shall, except to the extent caused by Sublandlord&#8217;s or Master Landlord&#8217;s gross negligence or willful misconduct, indemnify, protect, defend and hold  harmless Master Landlord and Sublandlord and their affiliates, agents, partners and lenders, from and against any and all Claims arising out of, involving, or in connection with, (a) the use or occupancy of the Subleased Premises by Subtenant, (b) the acts or omissions of Subtenant or any of Subtenant&#8217;s invitees, agents or employees, (c) any breach of this Sublease by Subtenant, and (d) any violation of Applicable Laws caused by Subtenant. If any action or proceeding is brought against Master Landlord or Sublandlord by reason of any of the foregoing matters, Subtenant shall upon notice defend the same at Subtenant&#8217;s expense by counsel reasonably satisfactory to Master Landlord and Sublandlord.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">By Sublandlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sublandlord shall, except to the extent caused by Subtenant&#8217;s gross negligence or willful misconduct, indemnify, protect, defend and hold harmless Subtenant and its affiliates, agents, partners and lenders, from and against any and all Claims arising out of, involving, or in connection with, (a) Sublandlord&#8217;s gross negligence or willful misconduct, (b) any breach of this Sublease by Sublandlord, and (c) Sublandlord&#8217;s use and occupancy of the Reserved Premises. If any action or proceeding is brought against Subtenant by reason of any of the foregoing matters, Sublandlord shall upon notice defend the same at Sublandlord&#8217;s expense by counsel reasonably satisfactory to Subtenant.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Surviva</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">l.  The indemnities in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the expiration or earlier termination of this Sublease.1</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">Insurance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Subject to Master Landlord&#8217;s consent, Subtenant shall continue to maintain the insurance coverage in such form and amounts as satisfies Subtenant&#8217;s obligations under the Adverum Lease which shall be in full satisfaction of Subtenant&#8217;s insurance obligations under this Sublease&#59; provided, that, Subtenant shall name Sublandlord as an additional insured to the commercial general liability policy maintained thereunder. Notwithstanding anything to the contrary in this Lease the waiver and releases set forth in Section 10.5 of the Master Lease shall apply as between Sublandlord and Subtenant as, &#8220;Landlord&#8221; and &#8220;Tenant&#8221; respectively.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">EXEMPTION OF SUBLANDLORD FROM LIABILITY&#59; WAIVERS.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Unless caused by Sublandlord&#8217;s gross negligence or willful misconduct, Sublandlord shall not be liable for injury or damage to the goods, wares, merchandise, or other property of Subtenant, Subtenant&#8217;s employees, contractors, invitees, customers, or any other person in or about the Master Premises, whether such damage or injury is caused by or results from fire, steam, electricity, gas, water or rain, or from the breakage, leakage, obstruction or other defects of pipes, fire sprinklers, wires, appliances, plumbing, air conditioning or lighting fixtures, or from any </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other cause, whether said injury or damage results from conditions arising from the Master Premises or from any other source or place, and regardless of whether the cause of damage or injury or the means of repairing the same is accessible. Notwithstanding anything to the contrary in this Sublease or the Master Lease, in no event whatsoever shall Sublandlord or Subtenant be liable for injury to the other&#8217;s business or for any loss of income or profit therefrom.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">DAMAGE AND DESTRUCTION&#59; CONDEMNATION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In no event shall Sublandlord have any obligation to Subtenant to restore the Subleased Premises or the Master Premises if damaged, destroyed or condemned as described in Section 11 or Section 13 of the Master Lease. To the extent any damage, destruction or casualty loss occurs in the Master Premises or Subleased Premises which entitles Sublandlord to terminate the Master Lease, Sublandlord may terminate the Master Lease (in which event this Sublease shall automatically terminate) without liability to Subtenant. With respect to damage, destruction or condemnation (as described in Section 11 and Section 13 of the Master Lease), Subtenant shall receive an abatement of Rent under this Sublease to the extent Sublandlord receives an abatement of rent under the Master Lease with respect to the Subleased Premises. In the case of a casualty or condemnation, Subtenant shall have the same right to terminate this Sublease as &#8220;Tenant&#8221; under the Master Lease with respect to the Premises as if the Subleased Premises were the &#8220;Premises&#8221; thereunder.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">BROKERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Sublandlord and Subtenant hereby represent and warrant to each other that they have had no dealings with any real estate broker or agent in connection with the negotiation of this Sublease, and that they know of no real estate broker or agent who is entitled to a commission in connection with this Sublease other than Colliers on behalf of Tenant (the &#8220;Broker&#8221;). Each Party agrees to indemnify and defend the other Party against and hold the other Party harmless for, from and against any and all Claims with respect to any leasing commission or equivalent compensation alleged to be owing on account of the indemnifying Party&#8217;s dealings with any real estate broker or agent other than the Broker. The indemnities in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the expiration or termination of this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">NOTICES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any notice, demand or request required or desired to be given under this Sublease to Sublandlord or Subtenant shall be in writing via (a) personal delivery, (b) First Class U.S. Mail, return receipt requested, or (c) FedEx or other reputable overnight carrier, or (d) email (but only if a hard copy is sent within one (1) business day thereafter by one of the methods in the foregoing sections (a) through (c)), and shall be addressed to the address of the Party to be served, as set forth in this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Either Party may from time to time, by written notice to the other Party in accordance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, designate a different address than that set forth below for the purpose of notice. Upon receipt of any notice from Master Landlord, Subtenant shall promptly deliver a copy of such notice to Sublandlord in accordance with the terms and conditions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notices shall be deemed delivered (a) upon receipt, if personally delivered, or (b) three (3) business days after mailing, if mailed as set forth above. Notwithstanding the foregoing, all notices given to Master Lessor under the Master Lease shall be considered delivered only when delivered in accordance with the Master Lease.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Sublandlord&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Subtenant&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Revolution Medicines, Inc. <br>700 Saginaw Drive <br>Redwood City, CA 94063 <br>Attn&#58; General Counsel <br>Email&#58; legal&#64;revmed.com</font></td><td colspan="3" style="padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Adverum Biotechnologies, Inc. <br>800 Saginaw Drive, First Floor <br>Redwood City, CA 94063 <br>Attn&#58; Chief Financial Officer <br>Email&#58;___________________</font></td></tr></table></div><div style="margin-top:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">DEFAULT.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">By Subtenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The occurrence of any of the following events (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall constitute a material default and breach of this Sublease by Subtenant&#58; (a) Subtenant&#8217;s failure to pay Rent, where such failure shall continue for a period of three (3) days following Subtenant&#8217;s receipt of written notice thereof from Sublandlord&#59; provided, however, that any such notice shall be in lieu of, and not in addition to, any notice required under California Code of Civil Procedure, Section 1161, (b) the occurrence of a material default or breach of the Master Lease beyond applicable notice and cure periods contained therein due to Subtenant&#8217;s acts or omissions, or (c) the occurrence of any of the events described in Section 19.1 of the Master Lease. Upon any Event of Default under this Sublease, Sublandlord shall have all of the remedies available to Master Landlord pursuant to the Master Lease as applied to this Sublease, including without limitation the remedies enumerated in Section 19.2 of the Master Lease. All of Sublandlord&#8217;s rights and remedies herein enumerated or incorporated by reference above are cumulative, and none will exclude any other right or remedy allowed by law or in equity.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12pt;text-decoration:underline">By Sublandlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that Sublandlord (i) defaults in the performance or observance of any of Sublandlord&#8217;s remaining obligations under the Master Lease, or (ii) fails to perform Sublessor&#8217;s stated obligations under this Sublease and such failure continues for thirty (30) days following written notice thereof from Subtenant, or (iii) fails to enforce, for Subtenant&#8217;s benefit, Master Landlord&#8217;s obligations under the Master Lease (to the extent expressly required by this Sublease), then Subtenant shall give Sublandlord notice specifying in what manner Sublandlord has defaulted, and if such default shall not be cured by Sublandlord within thirty (30) days thereafter (except that if such default cannot be cured within said thirty (30) day period, this period shall be extended for an additional reasonable time, provided that Sublandlord commences to cure such default within such thirty (30) day period and proceeds diligently thereafter to effect such cure as quickly as possible), then Subtenant shall be entitled to cure such default and promptly collect from Sublandlord Subtenant&#8217;s reasonable expenses in so doing (including, without limitation, reasonable attorneys&#8217; fees and court costs).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">SURRENDER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  On the expiration or earlier termination of this Sublease, Subtenant shall, at its sole cost and expense, surrender and deliver up the Subleased Premises to Sublandlord, in the same condition as of the Commencement Date, normal wear and tear, casualty damage, and Sublandlord&#8217;s and Master Landlord&#8217;s obligations excepted, and shall remove Tenant&#8217;s Signage with respect to the Building and perform the obligations of Subtenant under Section 15.3 of the Adverum Lease, which Section 15.3 is incorporated herein by reference solely for purposes of this sentence. Unless Sublandlord otherwise agrees in writing, all </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">alterations, additions or improvements affixed to the Subleased Premises shall be surrendered with the Subleased Premises at the expiration of the Sublease Term, except that, subject to the rights of Master Landlord under the Master Lease, Sublandlord may, by notice to Subtenant at the time of its consent thereto, require Subtenant to remove by the Expiration Date, or sooner termination of this Sublease, all or any alterations, decorations, fixtures, additions, improvements and the like installed after the Commencement Date either by Subtenant or by Sublandlord for Subtenant&#8217;s benefit, and to repair any damage to the Subleased Premises arising from the removal&#59; provided, however, that Subtenant shall not be required to remove any leasehold improvements existing in the Subleased Premises as of the Effective Date. For the purpose of providing clarity, the items identified in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Schedule 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> are Subtenant&#8217;s personal property and may be removed by Subtenant at any time during the Sublease Term.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">HOLDOVER.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  If Subtenant fails to surrender the Subleased Premises in accordance with the terms and conditions of this Sublease on or before the Expiration Date or earlier termination of this Sublease, such tenancy shall be from month-to-month only, at a rental rate for the first two (2) months that is 150% of the monthly Rent payable under this Sublease immediately prior to termination or expiration of this Sublease, and thereafter at a rate of 200% of the monthly Rent applicable prior to such holdover tenancy, and shall not constitute a renewal or extension of this Sublease. Notwithstanding any provision to the contrary contained in this Sublease, (i) Sublandlord expressly reserves the right to require Subtenant to surrender possession of the Subleased Premises upon the expiration of the Sublease Term or upon the earlier termination hereof and the right to assert any remedy at law or in equity to evict Subtenant or collect damages in connection with any such holding over, and (ii) should Subtenant holdover more than 30 days after the Expiration Date (or the end of the MTM Period), then, Subtenant shall indemnify, defend and hold Sublandlord harmless from and against any and all Claims incurred or suffered by Sublandlord by reason of Subtenant&#8217;s failure to surrender the Subleased Premises on the expiration or earlier termination of this Sublease in accordance with the provisions of this Sublease, including without limitation one hundred percent (100%) of all holdover rent and other costs charged to Sublandlord pursuant to the Master Lease as a result of Subtenant&#8217;s holdover. The provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Section 24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall survive the expiration or earlier termination of this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">PARKING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  During the Sublease Term, Subtenant shall have non-exclusive use on a first come, first served basis of 50% of the parking rights allocated to Tenant under the Master Lease, in accordance with Section 28 of the Master Lease. Subtenant&#8217;s right to use the parking space is expressly conditioned upon Subtenant&#8217;s compliance with all reasonable rules and regulations respecting parking established from time to time by Master Landlord.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">SIGNAGE.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Subtenant is not entitled to any signage in or on the Building or the Master Premises without the prior written consent of Sublandlord and Master Landlord. Notwithstanding the foregoing, subject to Master Landlord&#8217;s consent, Subtenant may maintain its current signage with respect to the Building, which Subtenant shall remove no later than the expiration of this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">GOVERNING LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The terms and provisions of this Sublease shall be construed in accordance with and governed by the laws of the State of California.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">PARTIAL INVALIDITY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any term, provision or condition contained in this Sublease shall, to any extent, be invalid or unenforceable, the remainder of this Sublease, or the application of such term, provision or condition to persons or circumstances other than those with respect to which it is invalid or unenforceable, shall not be affected thereby, and each and every other term, provision and condition of this Sublease shall be valid and enforceable to the fullest extent possible permitted by law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">ATTORNEYS&#8217; FEES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If either Party commences litigation against the other Party in connection with this Sublease, for damages for the breach hereof or otherwise for enforcement of any remedy hereunder, the prevailing Party shall be entitled to recover from the other Party such costs and reasonable attorneys&#8217; fees as may have been incurred, including any and all costs incurred in enforcing, perfecting and executing such judgment.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">COUNTERPARTS AND ELECTRONIC SIGNATURES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Sublease may be executed in counterparts, each of which shall be deemed an original, but such counterparts, when taken together, shall constitute one agreement. This Sublease may be executed by a Party&#8217;s signature transmitted by email, and copies of this Sublease executed and delivered by means of emailed signatures shall have the same force and effect as copies hereof executed and delivered with original signatures. All Parties hereto may rely upon emailed signatures (including signatures in Portable Document Format or via Docusign) as if such signatures were originals. All Parties hereto agree that an emailed signature page may be introduced into evidence in any proceeding arising out of or related to this Sublease as if it were an original signature page.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">ENTIRE AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Sublease, together with the Master Lease as incorporated or referenced herein, constitutes the entire agreement and complete understanding of the Parties with respect to the matters set forth herein and merges and supersedes all prior, oral and written, agreements and understandings, and all contemporaneous oral agreements and understandings, of any nature whatsoever with respect to such subject matter.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">CONTINGENCIES.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  The effectiveness of this Sublease is subject to and contingent upon (a) Master Landlord&#8217;s execution of a written consent to this Sublease in a form reasonably acceptable to the Parties hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Landlord Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), &#91;which shall include Master Landlord&#8217;s agreement (i) to the &#91;Adverum Operating Terms&#93; (and that Subtenant&#8217;s operations in accordance with the same shall not be a violation of the Master Lease), (ii) that Subtenant&#8217;s insurance under Section 17.4 shall satisfy the terms of the Master Lease, above (iii) Subtenant&#8217;s continue right to maintain signage as set forth in Section 26, above, and (iv) that the waiver and release set forth in Section 10.5 of the Master Lease shall apply as between Master Landlord and Subtenant&#93;, (b) the Adverum Lease Termination, and (c) Third Amendment Execution (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). In the event the Contingencies are not satisfied within ten (10) days following the Effective Date, either Party may terminate this Sublease upon written notice to the other Party after the expiration of such ten (10) days period, but before the Contingencies are satisfied. If this Sublease is so terminated, Sublandlord shall promptly return any prepaid Rent and the Security Deposit to Subtenant.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Signature page follows&#93;</font></div><div style="margin-top:12pt;text-indent:36pt"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, Sublandlord and Subtenant have executed this Sublease as of the date and year set forth above.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SUBLANDLORD&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Revolution Medicines, Inc.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a Delaware corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Mark A Goldsmith&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Nam</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline"> Mark A. Goldsmith&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">SUBTENANT&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a Delaware corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">By</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Laurent Fischer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Nam</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline"> Laurent Fischer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Title</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">&#58; CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">MAH</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subleased Premises</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Schedule 1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Subtenant&#8217;s Personal Property</font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify;text-indent:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Equipment Type</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Manufacturer</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Model&#47;Cat#</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Location</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Autoclave</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Primus</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PEB361255-48</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:-0.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Glasswash 1116A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RO&#47;DI Water System</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rephile</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">RLIG0IHOO</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Glasswash 1116A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prefiltration System</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rephile</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LABKT1000</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Glasswash 1116A</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">High Density Rack System</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Metro</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Warehouse 1131</font></div></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5B
<SEQUENCE>4
<FILENAME>advm-20211231xexx105b.htm
<DESCRIPTION>EX-10.5B
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2053ae33ada642e1abbca42bfd19cdab_33"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EXHIBIT 10.5B</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">THIS AGREEMENT OF SUBLEASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (&#8220;Sublease&#8221;) made as of the 26th day of October, 2021, by and between ADVERUM NC, LLC (&#8220;Sublandlord&#8221;) and JAGUAR GENE THERAPY, LLC (&#8220;Subtenant&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">WITNESSETH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Sublandlord has leased the Premises (as hereinafter defined) from ARE-NC REGION NO. 21, LLC (the &#8220;Landlord&#8221;) pursuant to a certain Lease Agreement dated January 8, 2021, as amended by that certain First Amendment to Lease Agreement dated April 15, 2021 (as amended, the &#8220;Prime Lease&#8221;), which is incorporated herein by reference and which is attached hereto as Exhibit A.  Sublandlord is referred to as the &#8220;Tenant&#8221; in the Prime Lease&#59; and</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the premises subleased hereby contain approximately 173,820 rentable square feet and constitute the entirety of that certain building located at 14 TW Alexander Drive, Durham, North Carolina, and known as the &#8220;Building.&#8221;  The space subleased hereby is the same space leased to the Sublandlord under the Prime Lease and is hereinafter referred to as the &#8220;Premises.&#8221;  The parties desire by this Sublease to establish the terms and conditions upon which Subtenant will sublet the Premises from Sublandlord&#59; and</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, in consideration of the mutual covenants and premises herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt">Except for Sections 4(b), 39, 40, 42(u) of, and Exhibit J to the Prime Lease (provided that such exclusions shall not prohibit Subtenant from exercising such rights that Landlord granted to Subtenant pursuant to Landlord&#8217;s consent to this Sublease as set forth in the Consent to Sublease and Second Amendment to Lease dated October 26, 2021 (the &#8220;Sublease Consent&#8221;) obtained pursuant to Section 12 hereof), or as otherwise herein provided, as between Sublandlord and Subtenant, all of the terms, provisions, covenants and conditions contained in the Prime Lease are made a part of this Sublease, Sublandlord being substituted for &#8220;Landlord&#8221; and Subtenant for &#8220;Tenant,&#8221; it being understood that such rights and obligations of Tenant as are contained in the same, and as the same relate to the Premises, during the term of this subletting, are hereby granted to or imposed on Subtenant in the same manner as if Subtenant had been Tenant in same.  Notwithstanding the foregoing, this Sublease shall not release Sublandlord from any existing or future duty, obligation or liability to Landlord under the Prime Lease, nor shall this Sublease change, modify, or amend the Prime Lease in any manner, and in the event of any conflict between the terms of the Prime Lease and this Sublease as between Landlord and Sublandlord, the express terms of the Prime Lease shall prevail.  In the event of a conflict between the terms of the Prime Lease and this Sublease as between Sublandlord and Subtenant, the terms of this Sublease shall govern and control.  In the event of a conflict between the terms of the Sublease Consent and this Sublease as between Sublandlord and Subtenant, the terms of the Sublease Consent shall govern and control.  Sublandlord agrees that Subtenant shall be entitled to receive all services Sublandlord is entitled to receive from Landlord pursuant to the Prime Lease, and Subtenant agrees that Sublandlord shall not be responsible for providing the same.  Subtenant expressly acknowledges that Sublandlord is not responsible for complying with any terms of the Prime Lease which, by their nature, are the sole obligations of the Landlord </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">thereunder.  Sublandlord agrees that any request received by Landlord from Subtenant for additional or modified services or Landlord&#8217;s approval with respect to any matter for which Landlord&#8217;s approval is required under the Prime Lease, including without limitation, Exhibit C (Work Letter) to the Prime Lease as such Exhibit C is amended and restated by Exhibit B to the Sublease Consent (the &#8220;Revised Work Letter&#8221;), shall be deemed a request made by and from Sublandlord and shall be deemed approved by Sublandlord when delivered to Landlord, provided the notice requesting such consent is made pursuant to the terms of the Sublease Consent.  </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subject to the terms of this Sublease and the Sublease Consent, Sublandlord acknowledges and agrees that Subtenant&#8217;s representative shall act pursuant to the terms of the Sublease Consent and as Sublandlord&#8217;s representative under the Revised Work Letter and shall have the limited right to act as Sublandlord to comply with Sublandlord&#8217;s obligations as &#8220;Tenant&#8221; as expressly stated under the Revised Work Letter and to receive the benefit of Sublandlord&#8217;s rights as &#8220;Tenant&#8221; under the Revised Work Letter and the Prime Lease as provided for in the Sublease Consent and herein.  Upon receiving Subtenant&#8217;s written request, Sublandlord shall notify Landlord of Subtenant&#8217;s change in its representative to act as Sublandlord&#8217;s representative under the Revised Work Letter.  Sublandlord shall use commercially reasonable efforts and take such further actions and assurances to enable Subtenant to receive all the rights and benefits of &#8220;Tenant&#8221; under the Revised Work Letter. Notwithstanding the foregoing, Subtenant is not being appointed as an agent for or given the authority to act as an agent of Sublandlord. Subtenant&#8217;s rights and authority to act as a representative of Sublandlord are strictly limited to those set forth in this Sublease, the Sublease Consent and the Revised Work Letter and Subtenant is not granted any express or implied authority to act on behalf of Sublandlord except as expressly set forth therein. Subtenant does not have the authority to and cannot bind Sublandlord to modifications or waivers to the terms and conditions of the Prime Lease, Sublease Consent or Revised Work Letter. Subtenant must exercise its limited authority and act in such role and capacity in a prudent and reasonable manner. In the event that Subtenant is unclear as to the scope and extent of its authority to take certain action as Sublandlord&#8217;s representative, Subtenant shall promptly request written clarification from Sublandlord prior to taking any such action. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subtenant acknowledges that there is no privity of contract as between Landlord and Subtenant which would entitle Subtenant to directly enforce the Landlord&#8217;s obligations under the Prime Lease. Sublandlord covenants and agrees, upon written request of Subtenant, to use commercially reasonable efforts to cause Landlord to observe and perform such obligations, provided that if Landlord&#8217;s failure to observe or perform such obligations materially impairs Subtenant&#8217;s ability to use or operate in the Premises, at Subtenant&#8217;s reasonable request and pursuant to its reasonable direction, Sublandlord shall bring legal or other form of dispute resolution to enforce any remedies that Sublandlord has at law or in equity.  Provided that the cause of Landlord&#8217;s default is not Sublandlord&#8217;s default hereunder, Subtenant shall reimburse Sublandlord for its costs related to such enforcement and Subtenant shall indemnify, defend and hold harmless Sublandlord from and against, any and all claims, damages, judgments, suits, causes of actions, losses, liabilities, and expenses, including, without limitation, attorneys&#8217; fees and court costs to the extent arising or resulting from Sublandlord pursuing such legal or other dispute resolution action.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Sublandlord hereby subleases the Premises to Subtenant, on the same terms and conditions upon which said Premises were leased to Sublandlord under the Prime Lease, the same as if all the terms and conditions of the Prime Lease were fully set forth herein, except as otherwise expressly set forth herein.  During the term of this Sublease, and except as set forth to the contrary herein or in the Sublease Consent, Subtenant hereby assumes and agrees to make all payments as hereinafter set forth and perform and fulfill all obligations, covenants and agreements of Sublandlord under the Prime Lease, with respect to the Premises, from and after the date hereof in the same manner as if Subtenant had executed the Prime Lease as tenant on the date hereof.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, Subtenant acknowledges that Sublandlord is in the process of preparing and submitting invoices for its design and construction work to date, for reimbursement from the Tenant Improvement Allowance if approved in accordance with and subject to the terms and conditions of the Lease (in the approximate amount of not more than $2,733,653.00).  As such, the Tenant Improvement Allowance available for Subtenant&#8217;s use shall be reduced by the amount so disbursed by Landlord to Sublandlord but such available amount shall be not less than $20,732,047.00, which is in addition to the Additional Tenant Improvement Allowance and the Warm Shell Improvement Allowance.  Sublandlord shall reasonably cooperate with Subtenant to obtain or to have any building permits or other governmental approvals required for Subtenant&#8217;s construction assigned to Subtenant.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As an inducement to Subtenant to enter into this Sublease, Sublandlord represents and warrants with respect to the Premises that the following statements are true&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;The Prime Lease is in full force and effect, and the copy attached hereto as Exhibit A is a true and complete copy thereof.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;The Commencement Date of the Prime Lease was April 23, 2021 and the Expiration Date of the Prime Lease is October 31, 2037.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;To Sublandlord's actual knowledge, there exists under the Prime Lease no default by either party or event of default by either party, nor has there occurred any event which, with the giving of notice or passage of time or both, could constitute such a default or event of default by either party.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Sublandlord has not received any written notice that the Premises or any portion thereof are in violation of applicable laws.</font></div><div style="margin-top:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;There are no oral modifications to the Prime Lease and Landlord and Sublandlord do not have any agreements regarding the Premises except for the Prime Lease.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;Sublandlord has not assigned its interest in the Prime Lease or subleased or otherwise permitted any other parties to occupy any part of the Premises.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;Landlord is currently the &#8220;Landlord&#8221; (as such term is defined under the Prime Lease).</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;Sublandlord is currently the &#8220;Tenant&#8221; (as such term is defined under the Prime Lease).</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;The only reports or other documents that Sublandlord has in its possession regarding the environmental condition of the Premises are&#58; </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">that certain Phase 1 Environmental Site Assessment dated August 2020 and prepared by Ranboll US Corporation&#59; </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">that certain Limited Hazardous Materials Clearance Report dated May 17, 2021 and prepared by Froehling and Robertson, Inc.&#59; </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">that certain Limited Hazardous Materials Survey Report (first floor pipe risers) dated August 12, 2021 prepared by Michael J. Krupa, CIEC Industrial Hygiene Project Manager, Froehling &#38; Robertson, Inc.&#59; </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">that certain Limited Moisture and Microbial Eval Report dated July 7, 2021, prepared by Froehling and Robertson, Inc.&#59; </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">that certain General Mold Remediation Guidelines dated July 7, 2021, prepared by Froehling and Robertson, Inc.&#59; and </font></div><div style="padding-left:126pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">that certain Limited Hazardous Materials Survey Report (Sub-Slab Holding Tank Testing) ARE-14 TW Alexander IH Sub-Slab Report dated March 29, 2021, prepared by Freohling and Robertson, Inc.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(x)&#160;&#160;&#160;&#160;Except for the Prime Lease, the Sublease and the Sublease Consent and the agreement regarding demolition with DPR to be assigned by Sublandlord to Subtenant, Sublandlord is not a party to any agreement, including, without limitation, construction, engineering or design agreements, that will be binding on the Premises or Subtenant after the date of this Sublease.</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The term of this Sublease (the &#8220;Term&#8221;) shall commence as of the later of (i) the date which is the first business day after all parties hereto have executed this Sublease and Landlord has consented to this Sublease in writing, or (ii)  the date on which Sublandlord transfers possession of the Premises to Subtenant (the &#8220;Sublease Commencement Date&#8221;), and shall expire on the 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> day of October, 2037 at 5&#58;00 p.m. (the &#8220;Expiration Date&#8221;), unless sooner terminated in accordance with the terms of this Sublease, including a termination of the Prime Lease.  Subtenant expressly acknowledges that no rights to other space owned or leased by Landlord or Sublandlord (including specifically any right of first refusal), is granted to Subtenant hereunder, nor shall Subtenant be entitled to exercise any such or similar rights afforded under the Prime Lease.  Sublandlord covenants and agrees that, during the Term of this Sublease, Sublandlord shall not take any action that would cause a default by Sublandlord under the Prime Lease and Sublandlord shall not terminate or extend the term of or enter into any material amendments to or material modifications of the Prime Lease or enter into any amendments to or modifications of the Prime Lease that would increase Subtenant&#8217;s obligations or impair its rights hereunder or agree to any new alterations or improvements to the Premises, without the prior written consent of Subtenant (not to be unreasonably withheld, conditioned, or delayed).  Furthermore, Sublandlord shall not agree to any new covenants, conditions, restrictions, easements or other encumbrances against the Premises without the prior written consent of Subtenant.  Sublandlord covenants and agrees to fully and faithfully perform the terms and conditions of the Prime Lease and this Sublease on its part to be performed.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Commencing on the Sublease Commencement Date, subject to the terms of the Sublease Consent and any credits, abatements, offsets, reductions or other concessions pursuant to the terms of the Prime Lease, Subtenant shall pay base annual rent (&#8220;Base Rent&#8221;) directly to the Landlord according to the same schedule, and in the same amounts, as listed in the Prime Lease.  Except as set forth in Section 23 herein, below, Subtenant shall not be responsible for any rent payable to Landlord by Sublandlord for the period of time prior to the Sublease Commencement Date.  In the event that the Sublease commences on a day other than the first (1st) day of the month or expires or terminates on a day other than the last day of such month, the Rent payable during such month shall be prorated with Subtenant only responsible for the portion of such month falling within the Term.  All payments requiring proration shall be prorated on the basis of the number of days in the pertinent calendar month or year, as applicable.  All rent and other amounts due under this Sublease shall be paid without demand or notice and without any setoff or deduction whatsoever.  All charges, costs and sums required to be paid by Subtenant to Sublandlord hereunder in addition to Base Rent shall be deemed additional rent (&#8220;Additional Rent&#8221;), and Base Rent and Additional Rent shall hereinafter be collectively called &#8220;Rent.&#8221;  Any portion of such Additional Rent which is payable under the terms of the Prime Lease to Landlord shall by paid by Subtenant directly to Landlord in accordance with the terms of the Sublease Consent.  In the event that any Rent is payable to Sublandlord hereunder, such Rent shall be paid to or upon the order of Sublandlord (or directly to Landlord, if so directed by Sublandlord) at the following address&#58; 100 Cardinal Way, Redwood City, CA 94063 Attn&#58; Chief Financial Officer.  Sublandlord shall have the right to change the Sublandlord&#8217;s address by giving advance written notice thereof to Subtenant. All payments of Rent shall be made in immediately available, lawful money of the United States.  In the event that Subtenant is not able to enforce the audit and review rights under the Prime Lease related to Operating Expenses, Sublandlord shall do so at Subtenant&#8217;s direction pursuant to the terms of the Prime Lease and Subtenant shall reimburse Sublandlord for its out of pocket third party costs related thereto.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As of the Sublease Commencement Date, Subtenant shall also be responsible for all Additional Rent (including, without limitation, Operating Expenses)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">required of Sublandlord as Tenant under the Prime Lease. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary contained herein, in the event that pursuant to the Prime Lease, Sublandlord actually receives an abatement, reduction, reimbursement, offset or other credit against rent payable under the Prime Lease, including, without limitation, related to an interruption in any services or utilities required to be provided by Landlord under the Prime Lease or related to a failure of Landlord to perform any maintenance and repair obligations of Landlord under the Prime Lease, Sublandlord shall provide Subtenant with such amounts to be applied against rent payable hereunder.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt">Subtenant will not assign this Sublease in whole or in part, nor sublet all or any part of the Premises, without the written consent of Sublandlord, which consent shall not be unreasonably withheld, conditioned or delayed, and (ii) if required by the terms of the Prime Lease, the prior written consent of Landlord.  </font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, provided that (i) Subtenant is not in default hereunder beyond any applicable notice and cure period provided for herein and (ii) Subtenant obtains Landlord's prior written consent thereto (unless, in connection with the Sublease Consent, Landlord has previously agreed to permit the following without its consent), Subtenant shall have the right, without the prior consent of Sublandlord, to assign this Sublease or sublet all or any portion of the Premises or transfer any interest in Subtenant to (1) any successor to Subtenant resulting from a merger, consolidation, spin-off, membership interest or other ownership interest sale or sale of all or substantially all of Subtenant's assets, but only in the event Subtenant is the surviving entity, or if Subtenant is not the surviving entity, the successor subtenant has substantially the same or better long-term debt rating or equivalent financial capacity as Subtenant immediately prior thereto (as reasonably confirmed by Sublandlord and Landlord in writing), or (2) to a parent, subsidiary or to any corporation or other entity that controls, or is controlled by, or is under common control with Subtenant (in any such case, a &#34;Permitted Transferee&#34;) provided that&#58; (A) such Permitted Transferee assumes in writing (or by operation of law succeeds to) all of Subtenant's obligations hereunder with respect to the Sublease or portion thereof covered by the applicable sublease, and (B) Subtenant, if Subtenant survives the transaction, remains liable to Sublandlord and Landlord for the performance of all terms and conditions of this Sublease, including the payment of Rent hereunder. Sublandlord shall be notified of such sublease or assignment and be given a copy of such sublease or assignment prior to or within (5) business days after such transfer.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt">All notices required or permitted by any provision of the Prime Lease or this Sublease shall be sent via certified mail, return receipt requested or via personal or overnight courier delivery (with proof of delivery requested) and shall be directed to Landlord at the address for notice as set forth in the Prime Lease.  Other notices required or permitted by any provision of the Prime Lease or this Sublease shall be directed as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.987%"><tr><td style="width:1.0%"></td><td style="width:7.785%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.172%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Sublandlord&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">100 Cardinal Way<br>Redwood City, CA 94063<br>Attention&#58; Legal Department</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Smith, Anderson, Blount, Dorsett,<br>Mitchell &#38; Jernigan, L.L.P.<br>Post Office Box 2611<br>Raleigh, North Carolina 27602-2611<br>Attention&#58; Wayne K. Maiorano, Esq. </font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">overnight delivery address</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2300 Wells Fargo Capitol Center</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">150 Fayetteville Street</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Raleigh, North Carolina 27601</font></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.500%"><tr><td style="width:1.0%"></td><td style="width:8.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.930%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If to Subtenant&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Jaguar Gene Therapy, LLC</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">150 N. Field Drive</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Suite 300</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Lake Forest, IL 60521</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Attention&#58;  Chief Legal Officer</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">with a copy to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Benesch Friedlander Coplan &#38; Aronoff LLP<br>71 South Wacker Drive, Suite 1600<br>Chicago, IL 60606<br>Attention&#58;  Michael J. Klein</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Either party may, at any time or from time to time, designate in writing a substitute address for the above set forth, and thereafter notice shall be directed to such substitute address.  Sublandlord shall provide (within five (5) business days after receipt) Subtenant with copies of any notices that Sublandlord receives from Landlord under the Lease.</font></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">This Sublease, and all rights hereunder, are in full respects subordinate to the Prime Lease. In the event the Prime Lease terminates for any reason during the Term, this Sublease shall simultaneously terminate unless, and except to the extent, otherwise provided in the Sublease Consent. Nothing contained in this Sublease shall be construed to create privity of estate or contract between Subtenant and the Landlord except for the agreements of Subtenant hereunder which are intended to benefit the Landlord (e.g. Sections 10, 12 and 22 hereof) as to which Landlord shall be deemed a third-party beneficiary hereunder and except for those agreements between Landlord and Subtenant expressly contained in the Sublease Consent.  Except as expressly provided in the Sublease Consent, Landlord shall have no obligations to Subtenant under the Sublease and the Prime Lease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Subtenant hereby agrees to execute such other necessary documents and instruments as Sublandlord may hereafter reasonably request in order to effectuate the provisions of the Sublease.  Sublandlord hereby agrees to execute such other necessary documents and instruments as Subtenant may hereafter reasonably request in order to effectuate the provisions of the Sublease.  </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Except as expressly provided for in the Sublease Consent, the Sublease Consent shall not be construed as relieving Sublandlord from the requirement of obtaining Landlord&#8217;s consent to any further subleasing or assignment of the Prime Lease, or of creating any rights in Subtenant against Landlord as a result of the Sublease Consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">Except as otherwise provided for herein and the Prime Lease, Subtenant acknowledges and agrees that the Premises are being conveyed on an &#8220;as is&#8221; basis, and that Sublandlord hereby makes no representation or warranty whatsoever, including specifically the condition thereof or their fitness for a particular purpose, provided that the foregoing shall not be deemed to be a waiver by Subtenant of any of Sublandlord&#8217;s obligations herein or the condition in which Landlord is required to construct Landlord&#8217;s Work or deliver the Premises.  Subtenant shall not alter the Premises without first obtaining Sublandlord&#8217;s written approval for such alteration, provided that if Landlord consents to such alterations then Sublandlord shall be deemed to have consented to such alterations also.  Subtenant acknowledges that alterations are </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">further subject to the consent of Landlord and Subtenant shall be responsible for obtaining such consent&#59; provided, however, Sublandlord shall reasonably cooperate and work with Subtenant to obtain the consent of the Landlord.  Except as otherwise agreed upon at the time any such consent is given, all alterations shall remain upon the Premises and shall be incorporated in and made a part of the Premises as completed.  Subtenant shall be responsible, at its sole cost and expense, for all conditions of Landlord&#8217;s consent to any alterations, including without limitation any restoration and&#47;or removal obligations.  Subtenant shall not be required to remove and&#47;or restore any improvements or other alterations which were either (a) constructed or installed prior to the Sublease Commencement Date, (b) which were approved by Landlord prior to the Sublease Commencement Date or (c) which are not required to be removed pursuant to the terms of the Prime Lease or the Sublease Consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Subtenant shall be liable for, and shall indemnify, defend and hold Sublandlord and Landlord harmless from and against, any and all claims, damages, judgments, suits, causes of actions, losses, liabilities, and expenses, including, without limitation, attorneys&#8217; fees and court costs to the extent arising or resulting from (a) the negligence or willful misconduct of Subtenant or any of Subtenant&#8217;s agents, employees, subtenants, assignees, licensees, contractors, or invitees as to injuries to persons or damage to property occurring in or about the Premises, including without limitation, arising from or as a result of the performance of the Tenant Improvements under the Amended and Restated Work Letter, (b) the default by Subtenant of any obligation on Subtenant&#8217;s part to be performed under the terms of this Sublease, the Sublease Consent or the Amended and Restated Work Letter attached to the Sublease Consent as Exhibit B, and (c) Subtenant exceeding its authority to act in Sublandlord&#8217;s name except as otherwise expressly permitted under this Sublease, the Sublease Consent or the Amended and Restated Work Letter&#59; provided, however, Subtenant&#8217;s indemnity shall not apply or extend to any such damage or injury to the extent the same are&#58;  (i)  the result of the gross negligence or willful misconduct of Sublandlord (or Landlord, in the case of Landlord&#8217;s indemnity), or Sublandlord&#8217;s (or Landlord&#8217;s, in the case of Landlord&#8217;s indemnity) employees, agents or contractors, or (ii) paid to Sublandlord (or Landlord, in the case of Landlord&#8217;s indemnity) out of the proceeds of any policy of insurance required hereunder.  In case any action or proceeding is brought against Sublandlord or Landlord by reason of Subtenant&#8217;s indemnification obligation set forth in this section, Subtenant, upon notice from Sublandlord or Landlord shall defend the same at Subtenant&#8217;s expense.  The terms and provisions of this section shall survive the termination or expiration of this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Notwithstanding any provision contained in this Sublease to the contrary, should either party institute any legal proceeding against the other for breach of any provision herein contained and prevail in such action, such other party shall reimburse the prevailing party for the cost of expenses of such prevailing party, including, without limitation, its reasonable attorneys&#8217; fees actually incurred at standard and reasonable billing rates.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">This Sublease and all provisions contained herein are contingent upon the written approval of Landlord, pursuant to a separate written agreement entered into by Landlord, Sublandlord, and Subtenant, which form of agreement shall be reasonably acceptable to Sublandlord and Subtenant.  Notwithstanding the foregoing, Sublandlord and Subtenant acknowledge and agree that the Sublease Consent shall be in the form attached hereto as Exhibit B and made a part hereof. Promptly following mutual agreement by Sublandlord and Subtenant as to the final form of this Sublease, Sublandlord shall use diligent, good faith efforts to obtain </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Landlord's consent to this Sublease, and Sublandlord shall provide notice of Sublandlord's receipt of such Sublease Consent promptly following Sublandlord's receipt of the same. Sublandlord and Subtenant shall each be  responsible for paying fifty percent (50%) of any fees and&#47;or charges imposed by Landlord (including, without limitation, payment or reimbursement of Landlord's attorneys' fees or any other out-of-pocket costs incurred by Landlord, if applicable) in connection with Sublandlord's request for and negotiation of the Sublease Consent.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Upon full execution, said Sublease Consent shall be incorporated by reference into, and made a part of, this Sublease.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">None of the covenants, terms or conditions of this Sublease to be kept and performed by either party, shall in any manner be altered, waived, modified, changed or abandoned except by a written instrument, duly signed and delivered by the other party.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">If any term or provision of this Sublease shall to any extent be held invalid or unenforceable, the remaining terms and provisions of this Sublease shall not be affected thereby, but each term and provision of this Sublease shall be valid and shall be enforced to the fullest extent permitted by law.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">All of the covenants, agreements, conditions and undertakings contained in this Sublease shall extend and inure to and be binding upon the heirs, executors, administrators, successors and permitted assigns of the respective parties hereto.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Sublandlord and Subtenant warrant to the other that neither of them has had any dealings with any broker or agent in connection with the transactions contemplated hereby.  Sublandlord and Subtenant covenant to pay, hold harmless and indemnify the other from and against any and all costs, expenses or liability for any compensation, commissions and charges claimed by any other broker or agent, with respect to the transactions contemplated hereby or the negotiation thereof and arising by virtue of the acts of the indemnifying party.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">No waiver by any party hereto of any breach by the other party hereto of any term, covenant, condition, or agreement herein and no failure by any party hereto to exercise any right or remedy in respect of any breach hereunder, shall constitute a waiver or relinquishment for the future of any such term, covenant, condition, or agreement or of any subsequent breach or of any such term, covenant, condition or agreement.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">This Sublease constitutes the entire agreement among the parties hereto with respect to the subject matter hereof and this Sublease supersedes all prior oral or written agreements, commitments, or understandings with respect to the matters provided for herein.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">This Sublease may be executed in multiple counterparts, each of which may be deemed to be an original.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Sublandlord acknowledges and agrees that Subtenant shall be entitled to such signage rights as are permitted by the Landlord, in Landlord&#8217;s sole discretion (provided that Sublandlord will not withhold its consent to any such signage rights specifically provided in the Prime Lease, so long as Landlord agrees to same in its consent to this Sublease).  Subtenant shall be responsible, at its sole cost and expense, for all conditions of Landlord&#8217;s consent to any signage, including without limitation any restoration and&#47;or removal obligations.</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Whenever Sublandlord is required in the Prime Lease to furnish insurance to Landlord, Subtenant agrees to furnish such insurance in the same amounts naming Sublandlord and Landlord as additional insureds with waivers of subrogation in favor of Landlord and Sublandlord, as provided in the Prime Lease.  The policies shall not be cancelled upon less than thirty (30) days prior written notice to Sublandlord.  Subtenant will deliver certificates of insurance to Sublandlord (on forms reasonably in accordance with the requirements of the Prime Lease).</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">In accordance with the Prime Lease, Sublandlord paid to Landlord the Base Rent payment for the first full calendar month for which Base Rent will become due after the Rent Commencement Date, in the amount of $463,520.00 (&#8220;Initial Rent Payment&#8221;). Within five (5) business days of execution of this Sublease, Subtenant shall pay to Sublandlord $463,520.00 in full reimbursement of the Initial Rent Payment. Further, within five (5) business days of execution of this Sublease, Subtenant shall provide to and for the benefit of Sublandlord a security deposit in an amount equal to one hundred percent (100%) of the amount required of Sublandlord as Tenant under the Prime Lease, which security deposit shall be deposited by Subtenant pursuant to the written direction of Sublandlord.   In addition, such security deposit shall be reduced in accordance with the reduction of the Security Deposit as defined in and in accordance with the terms of the Prime Lease. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Whenever the consent of Landlord shall be required pursuant to the Prime Lease with respect to any proposed action by Subtenant hereunder, Sublandlord covenants and agrees to use commercially reasonable efforts to obtain such consent on behalf of Subtenant. So long as Subtenant is not in default beyond the expiration of applicable notice and cure periods hereunder, Sublandlord further covenants and agrees not to voluntarily terminate the Prime Lease without the prior written consent of Subtenant, which consent may be granted or withheld by Subtenant in its sole discretion.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt">Neither Sublandlord nor Subtenant shall issue or make any public announcement, press release or other public disclosure regarding this Sublease or its subject matter or the Subtenant without the other party&#8217;s prior consent (not to be unreasonably withheld, conditioned, or delayed), except for such disclosure that is required by law, the rules of a stock exchange on which the securities of the Sublandlord are listed or as required to comply with Sublandlord&#8217;s rights and obligations herein.  Subject to the requirements of law and governmental authorities, the parties shall cooperate in good faith regarding their approval of the issuance of initial press releases or governmental disclosures.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">&#91;Signature Page(s) Follow&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, each party hereto has duly executed this Sublease as of and on the day and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.511%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBLANDLORD&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADVERUM NC, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Laurent Fischer </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">CEO</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2021-10-25  &#124;  11&#58;20&#58;12 PDT</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SUBTENANT&#58; </font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">JAGUAR GENE THERAPY, LLC</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Andrew Knudten</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Name&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Andrew Knudten</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COO</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10&#47;26&#47;2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center;text-indent:216pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit A</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(Prime Lease)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;attached&#93;</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit B</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">(Agreed form of Consent)</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;attached&#93;</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8E
<SEQUENCE>5
<FILENAME>advm-20211231xexx108e.htm
<DESCRIPTION>EX-10.8E
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i36ff072158204c7e9fe102285c1434ea_33"></div><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EXHIBIT 10.8E</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2014 EQUITY INCENTIVE AWARD PLAN </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE STOCK UNIT AWARD GRANT NOTICE </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverum Biotechnologies, Inc., a Delaware corporation, (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), pursuant to its 2014 Equity Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), hereby grants to the holder listed below (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), an award of performance-based restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Each vested Performance Stock Unit represents the right to receive, in accordance with the Performance Stock Unit Award Agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), one share of Common Stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). This award of Performance Stock Units is subject to all of the terms and conditions set forth herein and in the Agreement and the Plan, each of which are incorporated herein by reference. Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Performance Stock Unit Award Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the Agreement. </font></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:60.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.726%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Participant&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Grant Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total Number of PSUs&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Vesting Schedule&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Exhibit B.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Termination&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Exhibit A.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By his or her signature and the Company&#8217;s signature below, the Participant agrees to be bound by the terms and conditions of the Plan, the Agreement and this Grant Notice. The Participant has reviewed the Agreement, the Plan and this Grant Notice in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Grant Notice and fully understands all provisions of this Grant Notice, the Agreement and the Plan. The Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions arising under the Plan, this Grant Notice or the Agreement. In addition, by signing below, the Participant also agrees that the Company, in its sole discretion, may satisfy any withholding obligations in accordance with Section 2.6(b) of the Agreement by (i) withholding shares of Common Stock otherwise issuable to the Participant upon vesting of the PSUs, (ii) instructing a broker on the Participant&#8217;s behalf to sell shares of Common Stock otherwise issuable to the Participant upon vesting of the PSUs and submit the proceeds of such sale to the Company, or (iii) using any other method permitted by Section 2.6(b) of the Agreement or the Plan.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.272%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.277%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ADVERUM BIOTECHNOLOGIES, INC.&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PARTICIPANT&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Print Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Print Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">800 Saginaw Drive</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Address&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Redwood City, CA 94063</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT A </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TO PERFORMANCE STOCK UNIT AWARD GRANT NOTICE </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE STOCK UNIT AWARD AGREEMENT </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Performance Stock Unit Award Grant Notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to which this Performance Stock Unit Award Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is attached, Adverum Biotechnologies, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), has granted to the Participant the number of performance-based restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) set forth in the Grant Notice under the Company&#8217;s 2014 Equity Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Each vested Performance Stock Unit represents the right to receive one share of Common Stock (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and Grant Notice. </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Incorporation of Terms of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The PSUs are subject to the terms and conditions of the Plan, which are incorporated herein by reference. In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control. </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRANT OF PERFORMANCE STOCK UNITS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to the Grant Notice and upon the terms and conditions set forth in the Plan and this Agreement, effective as of the Grant Date set forth in the Grant Notice, the Company hereby grants to the Participant an award of PSUs under the Plan in consideration of the Participant&#8217;s past and&#47;or continued employment with or service to the Company or any Affiliates and for other good and valuable consideration. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Unsecured Obligation to PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless and until the PSUs have vested in the manner set forth in Article 2 hereof, the Participant will have no right to receive Common Stock under any such PSUs. Prior to actual payment of any vested PSUs, such PSUs will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to Section 2.5 hereof, the PSUs shall vest and become nonforfeitable with respect to the applicable portion thereof according to the vesting schedule set forth in the Grant Notice (rounding down to the nearest whole Share). </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consideration to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In consideration of the grant of the award of PSUs pursuant hereto, the Participant agrees to render faithful and efficient services to the Company or any Affiliate. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Forfeiture, Termination and Cancellation Upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any contrary provision of this Agreement or the Plan, except as set forth on Exhibit B to the Grant Notice, upon the Participant&#8217;s Termination of Service for any or no reason, all Performance Stock Units which have not vested prior to or in connection with such Termination of Service (after taking into consideration any accelerated vesting which may occur in connection with such Termination of Service (if any)) shall thereupon automatically be forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration by the Company, and the Participant, or the Participant&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights hereunder. Except as set forth on Exhibit B to the Grant Notice, no portion of the PSUs which has not become vested as of the date on which the Participant incurs a Termination of Service shall thereafter become vested. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Issuance of Common Stock upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) As soon as administratively practicable following the vesting of any Performance Stock Units pursuant to Section 2.3 hereof, but in no event later than sixty (60) days after such vesting date (for the avoidance of doubt, this deadline is intended to comply with the &#8220;short term deferral&#8221; exemption from Section 409A of the Code), the Company shall deliver to the Participant (or any transferee permitted under Section 3.2 hereof) a number of Shares (either by delivering one or more certificates for such Shares or by entering such Shares in book entry form, as determined by the Company in its sole discretion) equal to the number of PSUs subject to this Award that vest on the applicable vesting date, unless such PSUs terminate prior to the given vesting date pursuant to Section 2.5 hereof. Notwithstanding the foregoing, in the event Shares cannot be issued pursuant to Section 12.4 of the Plan, the Shares shall be issued pursuant to the preceding sentence as soon as administratively practicable after the Administrator determines that Shares can again be issued in accordance with such Section. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) As set forth in Section 12.2 of the Plan, the Company shall have the authority and the right to deduct or withhold, or to require the Participant to remit to the Company, an amount sufficient to satisfy all applicable federal, state and local taxes required by law to be withheld with respect to any taxable event arising in connection with the Performance Stock Units. The Company shall not be obligated to deliver any new certificate representing Shares to the Participant or the Participant&#8217;s legal representative or enter such Shares in book entry form unless and until the Participant or the Participant&#8217;s legal representative shall have paid or otherwise satisfied in full the amount of all federal, state and local taxes applicable to the taxable income of the Participant resulting from the grant or vesting of the Performance Stock Units or the issuance of Shares.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conditions to Delivery of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Shares deliverable hereunder may be either previously authorized but unissued Shares, treasury Shares or issued Shares which have then been reacquired by the Company. Such Shares shall be fully paid and nonassessable. The Company shall not be required to issue or deliver any certificates or make any book entries evidencing Shares deliverable hereunder prior to fulfillment of the conditions set forth in Section 12.4 of the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The holder of the PSUs shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the PSUs and any Shares underlying the PSUs and deliverable hereunder unless and until such Shares shall have been issued by the Company and held of record by such holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company). No adjustment shall be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14.2 of the Plan. </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III. </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER PROVISIONS </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules. All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon the Participant, the Company and all other interested persons. No member of the Administrator or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the PSUs. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PSUs Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The PSUs shall be subject to the restrictions on transferability set forth in Section 12.3 of the Plan&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that this Section 3.2 notwithstanding, with the consent of the Administrator, the PSUs may be transferred to one or more Permitted Transferees, subject to and in accordance with Section 12.3 of the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tax Consultation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Participant understands that the Participant may suffer adverse tax consequences in connection with the PSUs granted pursuant to this Agreement (and the Shares issuable with respect thereto). The Participant represents that the Participant has consulted with any tax consultants the Participant deems advisable in </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the PSUs and the issuance of Shares with respect thereto and that the Participant is not relying on the Company for any tax advice. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the limitation on the transferability of the PSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Adjustments Upon Specified Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Administrator may accelerate the vesting of the PSUs in such circumstances as it, in its sole discretion, may determine. The Participant acknowledges that the PSUs are subject to adjustment, modification and termination in certain events as provided in this Agreement and Section 14.2 of the Plan. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of the Secretary of the Company at the Company&#8217;s principal office, and any notice to be given to the Participant shall be addressed to the Participant at the Participant&#8217;s last address reflected on the Company&#8217;s records. By a notice given pursuant to this Section 3.6, either party may hereafter designate a different address for notices to be given to that party. Any notice shall be deemed duly given when sent via email or when sent by certified mail (return receipt requested) and deposited (with postage prepaid) in a post office or branch post office regularly maintained by the United States Postal Service. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Participant&#8217;s Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If the Shares issuable hereunder have not been registered under the Securities Act or any applicable state laws on an effective registration statement at the time of such issuance, the Participant shall, if required by the Company, concurrently with such issuance, make such written representations as are deemed necessary or appropriate by the Company and&#47;or its counsel. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Participant acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any other Applicable Law. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the PSUs are granted, only in such a manner as to conform to Applicable Law. To the extent permitted by Applicable Law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such Applicable Law. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Administrator or the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, except as may otherwise be provided by the Plan, no amendment, modification, suspension or termination of this Agreement shall adversely affect the PSUs in any material way without the prior written consent of the Participant. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon the Participant and his or her heirs, executors, administrators, successors and assigns. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any other provision of the Plan or this Agreement, if the Participant is subject to Section 16 of the Exchange Act, then the Plan, the PSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule. To the extent permitted by Applicable Law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Not a Contract of Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Nothing in this Agreement or in the Plan shall confer upon Participant any right to continue to serve as an employee or other service provider of the Company or any of its Affiliates or interfere with or restrict in any way with the right of the Company or any of its Affiliates, which rights are hereby expressly reserved, to discharge or to terminate for any reason whatsoever, with or without cause, the services of the Participant&#8217;s at any time. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Plan, the Grant Notice and this Agreement (including all Exhibits thereto, if any) constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and the Participant with respect to the subject matter hereof. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.16 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Award is not intended to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). However, notwithstanding any other provision of the Plan, the Grant Notice or this Agreement, if at any time the Administrator determines that this Award (or any portion thereof) may be subject to Section 409A, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Participant or any other person for failure to do so) to adopt such amendments to the Plan, the Grant Notice or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate for this Award either to be exempt from the application of Section 409A or to comply with the requirements of Section 409A. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.17 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limitation on Participant&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Participation in the Plan confers no rights or interests other than as herein provided. This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust. Neither the Plan nor any underlying program, in and of itself, has any assets. The Participant shall have only the rights of a general unsecured creditor of the Company and its Affiliates with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to PSUs, as and when payable hereunder. </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT B</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This award of PSUs shall vest as follows&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Vesting Conditions</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;To be specified for each specific grant&#93;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;To be specified for each specific grant&#93;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#91;To be specified for each specific grant&#93;</font></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent an PSU has not vested in accordance with the provisions above, such PSU shall be forfeited immediately following the third anniversary of the date of grant.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Provisions</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing&#58;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Early achievement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; &#91;To be specified for each specific grant&#93;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; &#91;To be specified for each specific grant&#93;</font></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Non-CIC-related termination of service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; &#91;To be specified for each specific grant&#93;</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>advm-20211231xexx109.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8feb23217d3a4099a6ac08d72c8ab257_33"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT 10.9</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHANGE IN CONTROL AND SEVERANCE AGREEMENT</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Change in Control and Severance Agreement (the &#8220;Agreement&#8221;) is made and entered into by and between &#91;_____________________&#93; (&#8220;Executive&#8221;) and Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;), effective as of the latest date set forth by the signatures of the parties hereto below (the &#8220;Effective Date&#8221;).</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">It is expected that the Company from time to time will consider the possibility of an acquisition by another company or other change in control.  The Board of Directors of the Company (the &#8220;Board&#8221;) recognizes that such consideration as well as the possibility of an involuntary termination or reduction in responsibility can be a distraction to Executive and can cause Executive to consider alternative employment opportunities.  The Board has determined that it is in the best interests of the Company and its stockholders to assure that the Company will have the continued dedication and objectivity of Executive, notwithstanding the possibility, threat or occurrence of such an event.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">The Board believes that it is in the best interests of the Company and its stockholders to provide Executive with an incentive to continue Executive&#8217;s employment and to motivate Executive to maximize the value of the Company upon a Change in Control (as defined below) for the benefit of its stockholders.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25pt">The Board believes that it is imperative to provide Executive with severance benefits upon certain terminations of Executive&#8217;s service to the Company that enhance Executive&#8217;s financial security and provide incentive and encouragement to Executive to remain with the Company notwithstanding the possibility of such an event.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.34pt">Certain capitalized terms used in this Agreement are defined in Section 7 below.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The parties hereto agree as follows&#58;</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Term of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall become effective as of the Effective Date and terminate upon the date that all obligations of the parties hereto with respect to this Agreement have been satisfied.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company and Executive acknowledge that Executive&#8217;s employment is and shall continue to be &#8220;at-will,&#8221; as defined under applicable law.  If Executive&#8217;s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided by this Agreement.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Covered Termination Other Than During a Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Executive experiences a Covered Termination other than during a Change in Control Period, and if Executive delivers to the Company a general release of all claims against the Company and its affiliates that becomes effective and irrevocable within sixty (60) days, or such shorter period of time specified by the Company, following such Covered Termination (a &#8220;Release of Claims&#8221;), then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following&#58;</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall be entitled to receive an amount equal to nine (9) months of Executive&#8217;s Base Salary, payable in substantially equal installments in accordance with the Company&#8217;s normal payroll policies, less applicable withholdings&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that no payments under this Section 3(a) shall be made prior to the first payroll date occurring on or after the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day following the date of the Covered Termination (such payroll date, the &#8220;First Payroll Date&#8221;), and any amounts otherwise payable prior to the First Payroll Date shall be paid on the First Payroll Date without interest thereon.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Continued Healthcare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;), the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive&#8217;s covered dependents through the earlier of (i) nine (9) months following the date of Executive&#8217;s termination of employment and (ii) the date Executive and Executive&#8217;s covered dependents, if any, become eligible for healthcare coverage under another employer&#8217;s plan(s).  Notwithstanding the foregoing, (i) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A of the Code under Treasury Regulation Section 1.409A-1(a)(5), or (ii) the Company is otherwise unable to continue to cover Executive under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.  After the Company ceases to pay premiums pursuant to this Section 3(b), Executive may, if eligible, elect to continue healthcare coverage at Executive&#8217;s expense in accordance the provisions of COBRA.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Covered Termination During a Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Executive experiences a Covered Termination during a Change in Control Period, and if Executive delivers to the Company a Release of Claims that becomes effective and irrevocable within sixty (60) days, or such shorter period of time specified by the Company, following such Covered Termination, then in addition to any accrued but unpaid salary, bonus, vacation and expense reimbursement payable in accordance with applicable law, the Company shall provide Executive with the following&#58;</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive shall be entitled to receive an amount equal to the sum of&#58; (i) twelve (12) months of Executive&#8217;s Base Salary at the rate in effect immediately before the date of the Covered Termination. Such amount shall be payable in a cash lump sum, less applicable withholdings, on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day after the date of the Covered Termination.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each outstanding equity award, including, without limitation, each stock option and restricted stock award, held by Executive shall automatically become vested and, if applicable, exercisable and any forfeiture restrictions or rights of repurchase thereon shall immediately lapse, in each case, with respect to one-hundred percent (100%) of the unvested shares of Company common stock subject to such equity award.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Continued Healthcare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Executive elects to receive continued healthcare coverage pursuant to the provisions of COBRA, the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive&#8217;s covered dependents through the earlier of (i) twelve (12) months following the date of Executive&#8217;s termination of employment and (ii) the date Executive and Executive&#8217;s covered dependents, if any, become eligible for healthcare coverage under another employer&#8217;s plan(s).  Notwithstanding the foregoing, (i) if any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the period of continuation coverage to be, exempt from the application of Section 409A of the Code under Treasury Regulation Section 1.409A-1(a)(5), or (ii) the Company is otherwise unable to continue to cover Executive under its group health plans without penalty under applicable law (including without limitation, Section 2716 of the Public Health Service Act), then, in either case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments.  After the Company ceases to pay premiums pursuant to this Section 4(c), Executive may, if eligible, elect to continue healthcare coverage at Executive&#8217;s expense in accordance the provisions of COBRA.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Other Terminations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If Executive&#8217;s service with the Company is terminated by the Company or by Executive for any or no reason other than as a Covered Termination, then Executive shall not be entitled to any benefits hereunder other than accrued but unpaid salary, bonus, vacation and expense reimbursement in accordance with applicable law and to elect any continued healthcare coverage as may be required under COBRA or similar state law.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Limitation on Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding anything in this Agreement to the contrary, if any payment or distribution Executive would receive pursuant to this Agreement or otherwise (&#8220;Payment&#8221;) would (a) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and (b) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;Excise Tax&#8221;), then such Payment shall either be (i) delivered in full, or (ii) delivered as to such lesser extent which would result in no portion of such Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt by Executive on an after-tax basis, of the largest payment, notwithstanding that all or some portion the Payment may be taxable under Section 4999 of the Code.  The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations.  The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder.  The accounting firm shall provide its calculations to the Company and Executive within fifteen (15) calendar days after the date on which Executive&#8217;s right to a Payment is triggered (if requested at that time by the Company or Executive) or such other time as requested by the Company or Executive.  Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Company and Executive.  Any reduction in payments and&#47;or benefits pursuant to this </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6 will occur in the following order&#58;  (1) reduction of cash payments&#59; (2) cancellation of accelerated vesting of equity awards other than stock options&#59; (3) cancellation of accelerated vesting of stock options&#59; and (4) reduction of other benefits payable to Executive.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Definition of Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The following terms referred to in this Agreement shall have the following meanings&#58;</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;Base Salary&#8221; means Executive&#8217;s annual base salary in effect immediately prior to Executive&#8217;s termination (disregarding any reduction in base salary that would give rise to Executive&#8217;s right to a Constructive Termination).</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;Cause&#8221; will be determined in the sole discretion of the Board and will mean misconduct, including&#58; (i) the Executive&#8217;s commission or the attempted commission of or participation in any crime involving fraud, dishonesty or moral turpitude that results in (or might have reasonably resulted in) material harm to the business of the Company&#59; (ii) intentional and material damage to the Company&#8217;s property and&#47;or misappropriation of Company funds&#59; (iii) conduct that constitutes gross insubordination, incompetence or habitual neglect of duties that results in (or might have reasonably resulted in) material harm to the business of the Company that has not been cured within 30 days after written notice from the Executive&#8217;s immediate supervisor or in the case of the chief executive officer, from the Board&#59; or (iv) material breach of the Proprietary Information Agreement (as defined below). </font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;Change in Control&#8221; shall mean the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following events&#58;</font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.69pt">A transaction or series of transactions (other than an offering of Common Stock to the general public through a registration statement filed with the Securities and Exchange Commission) whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections 13(d) and 14(d)(2) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)) (other than the Company, any of its subsidiaries, an employee benefit plan maintained by the Company or any of its subsidiaries or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition&#59; or</font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.36pt">During any period of two consecutive years, individuals who, at the beginning of such period, constitute the Board together with any new director(s) (other than a director designated by a person who shall have entered into an agreement with the Company to effect a transaction described in Section 7(c)(i) or 7(c)(ii)) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds of the directors then still in office</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:1.69pt;vertical-align:baseline">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">who either were directors at the beginning of the two-year period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof&#59; or</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.03pt">The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x) a merger, consolidation, reorganization, or business combination or (y) a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z) the acquisition of assets or stock of another entity, in each case other than a transaction&#58;  (A) which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Company or the person that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company (the Company or such person, the &#8220;Successor Entity&#8221;)) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction, and (B) after which no person or group beneficially owns voting securities representing 50% or more of the combined voting power of the Successor Entity&#59; provided, however, that no person or group shall be treated for purposes of this clause (B) as beneficially owning 50% or more of the combined voting power of the Successor Entity solely as a result of the voting power held in the Company prior to the consummation of the transaction&#59; or </font></div><div style="margin-top:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18.69pt">The Company&#8217;s stockholders approve a liquidation or dissolution of the Company.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, in no event shall a transaction constitute a Change in Control unless such transaction also constitutes a &#8220;change in control event&#8221; within the meaning of Section 409A of the Code and the Treasury regulations promulgated thereunder.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;Change in Control Period&#8221; means the period of time beginning three (3) months prior to and ending twelve (12) months following the closing date of a Change in Control.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Constructive Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;Constructive Termination&#8221; means any of the following actions taken without Cause by the Company or a successor corporation or entity without Executive&#8217;s consent&#58;  (i) substantial reduction of Executive&#8217;s rate of compensation&#59; (ii) material reduction in Executive&#8217;s duties, provided, however, that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; unless Executive&#8217;s new duties are substantially reduced from the prior duties&#59; (iii) failure or refusal of a successor to the Company to assume the Company&#8217;s obligations under this Agreement in the event of a Change in Control&#59; (iv) relocation of Executive&#8217;s principal place of employment or service to a place greater than 50 miles from the Executive&#8217;s then current principal place of employment or service. Notwithstanding the foregoing, a resignation shall not constitute a &#8220;Constructive Termination&#8221; unless the event or condition giving rise to such resignation continues more than thirty (30) days following Executive&#8217;s written notice of such condition provided to the Company within ninety (90) days of the first occurrence of such event or condition and such resignation is effective within thirty (30) days following the end of such notice period.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Covered Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  &#8220;Covered Termination&#8221; shall mean Executive&#8217;s Constructive Termination or the termination of Executive&#8217;s employment by the Company other than for Cause.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Company&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any successor to the Company (whether direct or indirect and whether by purchase, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#8217;s business and&#47;or assets shall assume the obligations under this Agreement and agree expressly to perform the obligations under this Agreement in the same manner and to the same extent as the Company would be required to perform such obligations in the absence of a succession.  For all purposes under this Agreement, the term &#8220;Company&#8221; shall include any successor to the Company&#8217;s business and&#47;or assets which executes and delivers the assumption agreement described in this Section 8(a) or which becomes bound by the terms of this Agreement by operation of law.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Executive&#8217;s Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The terms of this Agreement and all rights of Executive hereunder shall inure to the benefit of, and be enforceable by, Executive&#8217;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally delivered or one day following mailing via Federal Express or similar overnight courier service.  In the case of Executive, mailed notices shall be addressed to Executive at Executive&#8217;s home address that the Company has on file for Executive.  In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Legal Department. </font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Confidentiality&#59; Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Nothing herein modifies, supersedes, voids or otherwise alters Executive&#8217;s pre-existing contractual obligations set forth in the Employee Proprietary Information and Invention Assignment Agreement (&#8220;Proprietary Information Agreement&#8221;) entered into between Executive and the Company.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Interference with Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Consistent with Executive&#8217;s obligations under the Proprietary Information Agreement, Executive shall not for a period of one (1) year following Executive&#8217;s termination of employment for any reason, directly or indirectly solicit, induce, recruit or encourage any officer, director, employee, independent contractor or consultant of the Company who was employed by or affiliated with the Company at the time of termination to leave the Company or terminate his or her employment or relationship with the Company. Executive agrees not to make, publish or communicate at any time to any person or entity or in any public forum any defamatory or disparaging remarks, comments or statements concerning the Company or its businesses, or any of its employees, officers, and existing and prospective customers, suppliers, investors and other associated third parties. Executive agrees not to use the Company&#8217;s Proprietary Information (as defined in Executive&#8217;s Proprietary Information Agreement) to directly or indirectly interrupt, disturb or interfere with the Company&#8217;s relationships with any customer, vendor, supplier, licensor, investor, consultant, independent contractor or other business partner, or to compete unfairly with the Company. </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Survival of Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The provisions of this Section 10 shall survive the termination or expiration of the applicable Executive&#8217;s employment with the Company and shall be fully enforceable thereafter.  If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 10 is excessive in duration or scope or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To ensure the timely and economical resolution of disputes that arise in connection with this Agreement, Executive and the Company agree that any and all disputes, claims, or causes of action arising from or relating to the enforcement, breach, performance or interpretation of this Agreement, Executive's employment, or the termination of Executive's employment, shall be resolved to the fullest extent permitted by law by final, binding and confidential arbitration, by a single arbitrator, in San Mateo County, California, conducted by Judicial Arbitration and Mediation Services, Inc. (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) under the applicable JAMS employment rules. By agreeing to this arbitration procedure, both Executive and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. The arbitrator shall&#58; (i) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (ii) issue a written arbitration decision, to include the arbitrator's essential findings and conclusions and a statement of the award. The arbitrator shall be authorized to award any or all remedies that Executive or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS' arbitration fees in excess of the amount of court fees that would be required if the dispute were decided in a court of law. Nothing in this Agreement is intended to prevent either Executive or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Notwithstanding the foregoing, Executive and the Company each have the right to resolve any issue or dispute over intellectual property rights by Court action instead of arbitration.</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21pt;text-decoration:underline">Miscellaneous Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  </font></div><div style="margin-top:12pt;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:29.19pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The payments and benefits under this Agreement are intended to qualify for exemptions from the application of Section 409A of the Code, and this Agreement will be construed to the greatest extent possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section 409A of the Code to the extent necessary to avoid adverse taxation under Section 409A of the Code.</font></div><div style="margin-top:12pt;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:25.86pt;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provision to the contrary in this Agreement, no amount deemed deferred compensation subject to Section 409A of the Code shall be payable pursuant to Sections 3 or 4 unless Executive&#8217;s termination of employment constitutes a &#8220;separation from service&#8221; with the Company within the meaning of Section 409A of the Code and the Department of Treasury regulations and other guidance promulgated thereunder (&#8220;Separation from Service&#8221;) and, except as provided under Section 11(a)(iii) of this Agreement, any such amount shall not be paid, or in the case of installments, commence payment, until the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day following Executive&#8217;s Separation from Service.  </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any installment payments that would have been made to Executive during the sixty (60) day period immediately following Executive&#8217;s Separation from Service but for the preceding sentence shall be paid to Executive on the sixtieth (60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) day following Executive&#8217;s Separation from Service and the remaining payments shall be made as provided in this Agreement.</font></div><div style="margin-top:12pt;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.53pt;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provision to the contrary in this Agreement, if Executive is deemed at the time of his or her separation from service to be a &#8220;specified employee&#8221; for purposes of Section 409A(a)(2)(B)(i) of the Code, to the extent delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of Executive&#8217;s benefits shall not be provided to Executive prior to the earlier of (a) the expiration of the six (6)-month period measured from the date of the Executive&#8217;s Separation from Service or (b) the date of Executive&#8217;s death.  Upon the first business day following the expiration of the applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this Section 11(a)(iii) shall be paid in a lump sum to Executive, and any remaining payments due under this Agreement shall be paid as otherwise provided herein.</font></div><div style="margin-top:12pt;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:23.19pt;text-decoration:underline">Installment Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  Each installment payment payable under this Agreement will be treated as a separate payment for purposes of Section 409A of the Code.</font></div><div style="margin-top:12pt;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.52pt;text-decoration:underline">Expense Reimbursements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the extent that any reimbursements payable pursuant to this Agreement are subject to the provisions of Section 409A of the Code, any such reimbursements payable to Executive pursuant to this Agreement shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and Executive&#8217;s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver or discharge is agreed to in writing and signed by Executive and by an authorized officer of the Company (other than Executive).  No waiver by either party of any breach of, or of compliance with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Whole Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, the Offer Letter, and Executive&#8217;s Proprietary Information Agreement represent the entire understanding of the parties hereto with respect to the subject matter hereof and supersede all prior arrangements and understandings regarding same.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt;text-decoration:underline">Choice of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of California.</font></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:24.03pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-top:12pt;text-indent:39.59pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company by its duly authorized officer, as of the day and year set forth below.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.617%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">ADVERUM BIOTECHNOLOGIES, INC.</font></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;____________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;__________________________________</font></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE </font></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_______________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;Name of Executive&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;__________________________________</font></div></td></tr></table></div><div style="margin-top:12pt;padding-left:216pt"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>7
<FILENAME>advm-20211231xexx1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i523d7a9e7df2451e9c0fc84059d0849e_33"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><img alt="advmlogo.jpg" src="advmlogo.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 10.19</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">May 21, 2021</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Brigit Riley</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Address&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58; Employment Offer, Chief Scientific Officer</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Brigit, </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I am pleased to offer you a position with Adverum Technologies, Inc. (the &#8220;Company&#8221;) as Chief Scientific Officer, reporting to the Chief Executive Officer, Laurent Fischer, M.D.  You will work at our office located in Redwood City, CA. Of course, the Company may change your position, duties, and work location from time to time in its discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you decide to join us, this letter agreement (the &#8220;Agreement&#8221;) memorializes your compensation and other employment terms. These terms will become effective on the date you join the Company (the &#8220;Hire Date&#8221;).   </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Compensation and Benefits.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Base Compensation&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your base salary will be $450,000 annually ($18,750) per pay period), subject to payroll deductions and all required withholdings, reflecting your full-time employment with the Company. Your salary will be paid in accordance with the Company&#8217;s standard payroll schedule (currently the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and last calendar day of each month).  As an exempt salaried employee, you will be expected to work the Company&#8217;s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Bonus&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for each calendar year starting with 2021 you will be eligible to earn an annual performance bonus with a target bonus amount equal to 40% of your base salary (as of January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the bonus year). Your annual bonus for the calendar year in which you were hired will not be prorated based on your Hire Date and will be based on your base salary on your Hire Date.  Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year, as well as such other criteria deemed relevant by the Company. Bonus payments will be in the form of cash and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors or its Compensation Committee. Any cash bonus payments will be less payroll deductions and all required withholdings. The bonus is not earned until paid (that is, you must be employed by the Company on the date the bonus is paid in order to be entitled to receive the bonus) and no pro-rated amount will be paid if your employment terminates for any reason prior to the payment date. </font></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i523d7a9e7df2451e9c0fc84059d0849e_67"></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Equity Award&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For each calendar year starting with the year after you have completed one year of service, you may be eligible for a discretionary annual equity grant, provided that you are actively employed with the Company through and including the date of such annual equity grant.  Whether any discretionary annual equity grant is granted, and the terms of any such equity grant, is entirely at the discretion of the Company&#8217;s Board of Directors or its Compensation Committee.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a regular, full time employee, you will be eligible to participate in the Company&#8217;s employee benefits programs in accordance with the terms, conditions and limitations of the benefit plans, including health, dental and vision plans, retirement, paid time off, and other benefits, to the extent such plans have been established by the Company. Our employee benefits are described in the Benefits Booklet. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All forms of compensation referred to in this Agreement are subject to all applicable taxes, withholding and any other deductions required by applicable law.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may change compensation and benefits from time to time in its discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;New Hire Equity Grant.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company grant you options to purchase 450,000 shares of the Company&#8217;s common stock with an exercise price per share equal to the closing price of the common stock on the date of grant (the &#8220;Option&#8221;). The Option will be granted pursuant to the Company&#8217;s 2017 Inducement Plan as an inducement grant. The option will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date,  25% of the shares of common stock subject to the award of the Option shall vest on the first anniversary of the vesting commencement date (your Hire Date)  and 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option shall be subject to the other terms and conditions set forth in the Company&#8217;s 2017 Inducement Plan and the Company&#8217;s standard form of Nonstatutory Stock Option Agreement.  You should consult with your own tax advisor concerning the risks associated with accepting the Option.  </font></div><div style="margin-top:12pt"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Confidentiality and Proprietary Information Obligations.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Company Policies and Proprietary Information Agreement. As a condition of employment, you will be required to sign the employee Proprietary Information and Invention Assignment Agreement (the &#8220;PIIAA&#8221;) attached hereto as Exhibit A, which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Similarly, you agree not to bring any third-</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will in no way utilize any such information.  You agree to honor all obligations to former employers during your employment with the Company. </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Adverse or Outside Business Activities. Throughout your employment with the Company, you may engage in civic, academic teaching and lectures, and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. You may not engage in other employment or undertake any other commercial business activities unless you obtain the prior written consent of the Company&#8217;s CEO. The Company may rescind its consent to your service as a director of all other corporations or participation in other business or public activities, if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s reputational or business interests or conflict with your duties to the Company. In addition, throughout the term of your employment with the Company, you agree not to, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, executive, partner, employee, principal, agent, representative, consultant, licensor, licensee or otherwise with, any business or enterprise engaged in any business which is competitive with or which is reasonably anticipated to be competitive with the Company&#8217;s business&#59; provided, however, that you may purchase or otherwise acquire up to (but not more than) 1% of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. You hereby represent and warrant that you have disclosed previously to the Company all other employment or other commercial business activities that you already undertake, or intend to undertake (to the extent currently known by you), during your period of employment with the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;No Conflicts.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By signing this Agreement you hereby represent to the Company that, except as previously disclosed to the Company&#58; (a) your employment with the Company is not prohibited under any employment agreement or other contractual arrangement&#59; and (b) you do not know of any conflicts which would restrict your employment with the Company. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company, and that you are presently in compliance with such contracts, if any.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Reserved. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;At Will Employment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company is excited about your joining as a full time, regular, exempt employee and looks forward to a beneficial and productive relationship.  Nevertheless, your employment relationship with the Company will be an &#8220;at-will&#8221; arrangement and is for no specific period. This means that </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">either you or the Company may terminate your employment at any time, with or without cause, and with or without advance notice. This &#8220;at-will&#8221; employment relationship cannot be changed except in a written agreement approved by the Company and signed by you and by a duly authorized officer of the Company. We request that, in the event of resignation, you give the Company at least two weeks notice. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1.&#160;&#160;&#160;&#160;Conditions of employment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This offer is contingent upon a satisfactory reference check and satisfactory proof of your right to work in the United States.  If the Company informs you that you are required to complete a background check, this offer is contingent upon satisfactory clearance of such background check. You agree to assist as needed and to complete any documentation at the Company&#8217;s request to meet these conditions. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2. &#160;&#160;&#160;&#160;Dispute Resolution.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS&#8217; then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.  This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration (collectively, the &#8220;Excluded Claims&#8221;).  In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.  You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator.  Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator.  The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written statement </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3. &#160;&#160;&#160;&#160;Succession and assignment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is personal to you and shall not be assigned by you. Any purported assignment by you shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4.&#160;&#160;&#160;&#160;Enforceability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.5.&#160;&#160;&#160;&#160;Governing law and jurisdiction.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.6.&#160;&#160;&#160;&#160;Headings and captions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.7.&#160;&#160;&#160;&#160;No construction against drafter.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any ambiguity in this Agreement shall not be construed against either party as the drafter. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.8.&#160;&#160;&#160;&#160;Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.9.&#160;&#160;&#160;&#160;Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.10&#160;&#160;&#160;&#160;Entire agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, together with your PIIAA (Exhibit A) and the Change of Control and Severance Agreement (Exhibit B) forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this Agreement supersede any other agreements or promises made to you by anyone concerning your employment terms, including, but not limited to, any representations made during your recruitment, interviews or pre employment negotiations, whether written or oral.</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:58.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Acknowledgement of Full Understanding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please sign and date this letter, and the attached Change of Control Agreement and the Proprietary Information and Invention Assignment Agreement, and return them to me by the close of business on May 21, 2021 in order to confirm your acceptance of our offer and agreement to these employment terms. This offer of employment will terminate if it is not accepted, signed and returned by the specified date. If you accept our offer, your first day of employment will be no later than June 1, 2021.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We look forward to a favorable reply and a productive and enjoyable work relationship with you.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Laurent Fischer, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Laurent Fischer, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Understood and Accepted&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; B. Riley</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Brigit Riley</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Date&#58; 2021-05-21  &#124;  13&#58;45&#58;31 PDT</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>8
<FILENAME>advm-20211231xexx1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4d92190582674f6d9ab231f844bf0c61_33"></div><div style="min-height:85.5pt;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><img alt="advmlogo.jpg" src="advmlogo.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.20</font></div><div style="margin-top:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">November 11, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rupert D&#8217;Souza </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Address&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58; Employment Offer, Chief Financial Officer</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Rupert,</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I am pleased to offer you a position with Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;) as Chief Financial Officer, reporting to the Chief Executive Officer, Laurent Fischer, M.D. You will work at our office located in Redwood City, CA. Of course, the Company may change your position, duties, and work location from time to time in its discretion.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you decide to join us, this letter agreement (the &#8220;Agreement&#8221;) memorializes your compensation and other employment terms. These terms will become effective on the date you join the Company (the &#8220;Hire Date&#8221;).</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27pt">Compensation and Benefits.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Base Compensation&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your base salary will be $425,000.00 annually ($17,708.34 per pay period), subject to payroll deductions and all required withholdings, reflecting your full-time employment with the Company. Your salary will be paid in accordance with the Company&#8217;s standard payroll schedule (currently the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and last calendar day of each month). As an exempt salaried employee, you will be expected to work the Company&#8217;s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Bonus&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for each calendar year starting with 2021 you will be eligible to earn an annual performance bonus with a target bonus amount equal to 40% of your base salary (as of January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the bonus year). Your annual bonus for the calendar year in which you were hired will not be prorated based on your Hire Date and will be based on your base salary on your Hire Date. Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year, as well as such other criteria deemed relevant by the Company. Bonus payments will be in the form of cash and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors or its Compensation Committee. Any cash bonus payments will be less payroll </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i4d92190582674f6d9ab231f844bf0c61_68"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">deductions and all required withholdings. The bonus is not earned until paid (that is, you must be employed by the Company on the date the bonus is paid in order to be entitled to receive the bonus) and no pro- rated amount will be paid if your employment terminates for any reason prior to the payment date.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Equity Award&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For each calendar year starting with the year after you have completed one year of service, you may be eligible for a discretionary annual equity grant, provided that you are actively employed with the Company through and including the date of such annual equity grant. Whether any discretionary annual equity grant is granted, and the terms of any such equity grant, is entirely at the discretion of the Company&#8217;s Board of Directors or its Compensation Committee.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a regular, full time employee, you will be eligible to participate in the Company&#8217;s employee benefits programs in accordance with the terms, conditions and limitations of the benefit plans, including health, dental and vision plans, retirement, paid time off, and other benefits, to the extent such plans have been established by the Company. Our employee benefits are described in the Benefits Booklet.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All forms of compensation referred to in this Agreement are subject to all applicable taxes, withholding and any other deductions required by applicable law.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may change compensation and benefits from time to time in its discretion.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;New Hire Equity Grant.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company grant you options to purchase 400,000 shares of the Company&#8217;s common stock with an exercise price per share equal to the closing price of the common stock on the date of grant (the &#8220;Option&#8221;). The Option will be granted pursuant to the Company&#8217;s 2017 Inducement Plan as an inducement grant. The option will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date, 25% of the shares of common stock subject to the award of the Option shall vest on the first anniversary of the vesting commencement date (your Hire Date) and 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option shall be subject to the other terms and conditions set forth in the Company&#8217;s 2017 Inducement Plan and the Company&#8217;s standard form of Nonstatutory Stock Option Agreement. You should consult with your own tax advisor concerning the risks associated with accepting the Option.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;Confidentiality and Proprietary Information Obligations.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Company Policies and Proprietary Information Agreement. As a condition of employment, you will be required to sign the employee Proprietary Information </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and Invention Assignment Agreement (the &#8220;PIIAA&#8221;) attached hereto as Exhibit&#160;A, which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will in no way utilize any such information. You agree to honor all obligations to former employers during your employment with the Company.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Adverse or Outside Business Activities. Throughout your employment with the Company, you may engage in civic, academic teaching and lectures, and not-for- profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. You may not engage in other employment or undertake any other commercial business activities unless you obtain the prior written consent of the Company&#8217;s CEO. The Company may rescind its consent to your service as a director of all other corporations or participation in other business or public activities, if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s reputational or business interests or conflict with your duties to the Company. In addition, throughout the term of your employment with the Company, you agree not to, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, executive, partner, employee, principal, agent, representative, consultant, licensor, licensee or otherwise with, any business or enterprise engaged in any business which is competitive with or which is reasonably anticipated to be competitive with the Company&#8217;s business&#59; provided, however, that you may purchase or otherwise acquire up to (but not more than) 1% of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. You hereby represent and warrant that you have disclosed previously to the Company all other employment or other commercial business activities that you already undertake, or intend to undertake (to the extent currently known by you), during your period of employment with the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;No Conflicts.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By signing this Agreement you hereby represent to the Company that, except as previously disclosed to the Company&#58; (a) your employment with the Company is not prohibited under any employment agreement or other contractual arrangement&#59; and (b) you do not know of any conflicts which would restrict your employment with the Company. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company, and that you are presently in compliance with such contracts, if any.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Reserved.</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;At Will Employment.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company is excited about your joining as a full time, regular, exempt employee and looks forward to a beneficial and productive relationship. Nevertheless, your employment relationship with the Company will be an &#8220;at-will&#8221; arrangement and is for no specific period. This means that either you or the Company may terminate your employment at any time, with or without cause, and with or without advance notice. This &#8220;at-will&#8221; employment relationship cannot be changed except in a written agreement approved by the Company and signed by you and by a duly authorized officer of the Company. We request that, in the event of resignation, you give the Company at least two weeks notice. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;Miscellaneous.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Conditions of employment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This offer is contingent upon a satisfactory reference check and satisfactory proof of your right to work in the United States. If the Company informs you that you are required to complete a background check, this offer is contingent upon satisfactory clearance of such background check. You agree to assist as needed and to complete any documentation at the Company&#8217;s request to meet these conditions.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Dispute Resolution. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS&#8217; then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration (collectively, the &#8220;Excluded Claims&#8221;).  In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">publicly filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Succession and assignment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is personal to you and shall not be assigned by you. Any purported assignment by you shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Enforceability. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Governing law and jurisdiction. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Headings and captions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">No construction against drafter. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any ambiguity in this Agreement shall not be construed against either party as the drafter.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Waiver. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21pt">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes.</font></div><div style="text-indent:54pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:15pt">Entire agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, together with your PIIAA (Exhibit A) and the Change of Control and Severance Agreement (Exhibit B) forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this Agreement supersede any other agreements or promises made to you by anyone concerning your employment terms, including, but not limited to, any representations made during your recruitment, interviews or pre employment negotiations, whether written or oral.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;Acknowledgement of Full Understanding. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please sign and date this letter, and the attached Change of Control Agreement and the Proprietary Information and Invention Assignment Agreement, and return them to me by the close of business on November 12, 2021 in order to confirm your acceptance of our offer and agreement to these employment terms. This offer of employment will terminate if it is not accepted, signed and returned by the specified date. If you accept our offer, your first day of employment will be no later than December 6, 2021.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We look forward to a favorable reply and a productive and enjoyable work relationship with you.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely, </font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.&#58;</font></div><div><font><br></font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Laurent Fischer, M.D.</font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Laurent Fischer, M.D.</font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Understood and Accepted&#58;</font></div><div style="text-indent:4.5pt"><font><br></font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Rupert D&#8217;Souza</font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Rupert D&#8217;Souza</font></div><div style="text-indent:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; 2021-11-12  &#124;  08&#58;48&#58;44 PST</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>9
<FILENAME>advm-20211231xexx1021.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i07b77a670bad43479a821434b8cc4ce3_33"></div><div style="min-height:67.5pt;width:100%"><div style="text-align:center"><img alt="advmlogoa.jpg" src="advmlogoa.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 10.21</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">December 3, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Setareh Seyedkazemi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Address&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58; Employment Offer, Chief Development Officer </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Setareh,</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I am pleased to offer you a position with Adverum Technologies, Inc. (the &#8220;Company&#8221;) as Chief Development Officer, reporting to the Chief Executive Officer, Laurent Fischer, M.D.  You will work at our office located in Redwood City, CA. Of course, the Company may change your position, duties, and work location from time to time in its discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you decide to join us, this letter agreement (the &#8220;Agreement&#8221;) memorializes your compensation and other employment terms. These terms will become effective on the date you join the Company (the &#8220;Hire Date&#8221;). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Compensation and Benefits.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Base Compensation&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your base salary will be $465,000.000 annually ($19,375.00 per pay period), subject to payroll deductions and all required withholdings, reflecting your full-time employment with the Company. Your salary will be paid in accordance with the Company&#8217;s standard payroll schedule (currently the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and last calendar day of each month).  As an exempt salaried employee, you will be expected to work the Company&#8217;s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Bonus&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for each calendar year starting with 2022 you will be eligible to earn an annual performance bonus with a target bonus amount equal to 40% of your base salary (as of January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the bonus year). Your annual bonus for the calendar year in which you were hired will be prorated based on your Hire Date, so long as you joined the Company prior to October 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of that year. If you joined on or after October 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, you will not be eligible for a bonus for that year.  Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year, as well as such other criteria deemed relevant by the Company. Bonus payments will be in the form of cash and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors or its Compensation Committee. Any cash bonus payments will be less payroll deductions and all required withholdings. The bonus is not earned until paid (that is, you must be employed by the</font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i07b77a670bad43479a821434b8cc4ce3_86"></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Company on the date the bonus is paid in order to be entitled to receive the bonus) and no pro-rated amount will be paid if your employment terminates for any reason prior to the payment date. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Equity Award&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For each calendar year starting with the year after you complete one full year of service, you may be eligible for a discretionary annual equity grant, provided that you are actively employed with the Company through and including the date of such annual equity grant.  Whether any discretionary annual equity grant is granted, and the terms of any such equity grant, is entirely at the discretion of the Company&#8217;s Board of Directors or its Compensation Committee. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signing Bonus&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A one-time signing bonus of $170,000.00 will be advanced within the first 30 days of your employment and will be subject to payroll deductions and all required withholdings (the &#8220;Signing&#47;Retention Bonus&#8221;). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, during this critical time for the Company you will be eligible for the Incentive Program Bonus, as we work to get our first patient into the clinic in 2022. The program includes a Cash Bonus of $30,000.00 contingent upon the first patient being dosed with ADVM-022 in a Phase 2 study in 2022. To receive this cash bonus, you will need to remain employed with Adverum through the date of the first patient dosing described above.  This incentive program bonus will be payable within 30 days of the goal being attained and subject to payroll deductions and all required withholdings.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a regular, full time employee, you will be eligible to participate in the Company&#8217;s employee benefits programs in accordance with the terms, conditions and limitations of the benefit plans, including health, dental and vision plans, retirement, paid time off, and other benefits, to the extent such plans have been established by the Company. Our employee benefits are described in the Benefits Booklet. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All forms of compensation referred to in this Agreement are subject to all applicable taxes, withholding and any other deductions required by applicable law.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may change compensation and benefits from time to time in its discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;New Hire Equity Grants.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Options</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company grant you options to purchase 425,000 shares of the Company&#8217;s common stock with an exercise price per share equal to the closing price of the common stock on the date of grant (the &#8220;Option&#8221;). The Option will be granted pursuant to the Company&#8217;s 2017 Inducement </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Plan as an inducement grant. The option will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date,  25% of the shares of common stock subject to the award of the Option shall vest on the first anniversary of the vesting commencement date (your Hire Date)  and 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option shall be subject to the other terms and conditions set forth in the Company&#8217;s 2017 Inducement Plan and the Company&#8217;s standard form of Nonstatutory Stock Option Agreement.  You should consult with your own tax advisor concerning the risks associated with accepting the Option.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Stock Units</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company award you 100,000 Performance Sock Units (&#8220;PSUs&#8221;) under the Company&#8217;s 2014 Equity Incentive Award Plan, as set forth in the form of PSU award agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The PSU award shall be subject to the terms and conditions set forth in the Company&#8217;s 2014 Equity Incentive Award Plan and the Company&#8217;s PSU Award Agreement.  You should consult with your own tax advisor concerning the risks associated with accepting the PSU award.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;Confidentiality and Proprietary Information Obligations.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Company Policies and Proprietary Information Agreement. As a condition of employment, you will be required to sign the employee Proprietary Information and Invention Assignment Agreement (the &#8220;PIIAA&#8221;) attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will in no way utilize any such information.  You agree to honor all obligations to former employers during your employment with the Company. </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Adverse or Outside Business Activities. Throughout your employment with the Company, you may engage in civic, academic teaching and lectures, and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. You may not engage in other employment or undertake any other commercial business activities unless you obtain the prior written consent of the Company&#8217;s CEO. The Company may rescind its consent to your service as a director of all other corporations or participation in other business or public activities, if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s reputational or business interests or conflict with your duties to the Company. In addition, throughout the term of your employment with the Company, you agree not to, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, finance or </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, executive, partner, employee, principal, agent, representative, consultant, licensor, licensee or otherwise with, any business or enterprise engaged in any business which is competitive with or which is reasonably anticipated to be competitive with the Company&#8217;s business&#59; provided, however, that you may purchase or otherwise acquire up to (but not more than) 1% of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. You hereby represent and warrant that you have disclosed previously to the Company all other employment or other commercial business activities that you already undertake, or intend to undertake (to the extent currently known by you), during your period of employment with the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. &#160;&#160;&#160;&#160;No Conflicts.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By signing this Agreement you hereby represent to the Company that, except as previously disclosed to the Company&#58; (a) your employment with the Company is not prohibited under any employment agreement or other contractual arrangement&#59; and (b) you do not know of any conflicts which would restrict your employment with the Company. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company, and that you are presently in compliance with such contracts, if any.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;Reserved. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;At Will Employment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company is excited about your joining as a full time, regular, exempt employee and looks forward to a beneficial and productive relationship.  Nevertheless, your employment relationship with the Company will be an &#8220;at-will&#8221; arrangement and is for no specific period. This means that either you or the Company may terminate your employment at any time, with or without cause, and with or without advance notice. This &#8220;at-will&#8221; employment relationship cannot be changed except in a written agreement approved by the Company and signed by you and by a duly authorized officer of the Company. We request that, in the event of resignation, you give the Company at least two weeks notice. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1.&#160;&#160;&#160;&#160;Conditions of employment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This offer is contingent upon a satisfactory reference check and satisfactory proof of your right to work in the United States.  If the Company informs you that you are required to complete a background check, this offer is contingent upon satisfactory clearance of such background check. You agree to assist as needed and to complete any documentation at the Company&#8217;s request to meet these conditions. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2. &#160;&#160;&#160;&#160;Dispute Resolution.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS&#8217; then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.  This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration (collectively, the &#8220;Excluded Claims&#8221;).  In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.  You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator.  Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator.  The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3. &#160;&#160;&#160;&#160;Succession and assignment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is personal to you and shall not be assigned by you. Any purported assignment by you shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns. </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4.&#160;&#160;&#160;&#160;Enforceability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.5.&#160;&#160;&#160;&#160;Governing law and jurisdiction.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.6. &#160;&#160;&#160;&#160;Headings and captions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.7.&#160;&#160;&#160;&#160;No construction against drafter.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any ambiguity in this Agreement shall not be construed against either party as the drafter. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.8. &#160;&#160;&#160;&#160;Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.10&#160;&#160;&#160;&#160;Entire agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, together with the Change of Control and Severance Agreement (Exhibit A) and your PIIAA (Exhibit C), forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this Agreement supersede any other agreements or promises made to you by anyone concerning your employment terms, including, but not limited to, any representations made during your recruitment, interviews or pre employment negotiations, whether written or oral.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;Acknowledgement of Full Understanding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please sign and date this letter, and the attached Change of Control Agreement and the Proprietary Information and Invention Assignment Agreement and return them to me by the close of business on December 3, 2021 in order to confirm your acceptance of our offer and agreement to these employment terms. This offer of employment will terminate if it is not accepted, signed and returned by the specified date. If you accept our offer, your first day of employment will be no later than January 6, 2022</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We look forward to a favorable reply and a productive and enjoyable work relationship with you.</font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:67.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverum Biotechnologies, Inc.&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Laurent Fischer, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Laurent Fischer, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Understood and Accepted&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Setareh Seyedkazemi</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Setareh Seyedkazemi</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; 2021-12-03  &#124;  20&#58;47&#58;40 PST</font></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>10
<FILENAME>advm-20211231xexx1022.htm
<DESCRIPTION>EX-10.22
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if97132dbc5de4e12a004096f3031319d_33"></div><div style="min-height:63pt;width:100%"><div style="text-align:center"><img alt="advmlogob.jpg" src="advmlogob.jpg" style="height:56px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 10.22</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">December 29, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Richard Beckman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Address&#93;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Re&#58; Employment Offer, Chief Medical Officer</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Richard,</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I am pleased to offer you a position with Adverum Technologies, Inc. (the &#8220;Company&#8221;) as Chief Medical Officer, reporting to the Chief Executive Officer, Laurent Fischer, M.D.  Although you will be based out of our office located in Redwood City, California, this is a remote role so you will maintain your residence in &#91;address on file&#93; and telecommute. Our Telecommuting Policy is attached at Exhibit A. You acknowledge that your position as Chief Medical Officer, and associated responsibilities may sometimes require you be present in the Redwood City office. The details of your telecommuting arrangement, in particular the frequency of travel to Redwood City, will be as arranged between you and your manager taking into account the duties and responsibilities of your role consistent with the Company&#8217;s Telecommuting Policy at Exhibit A. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you decide to join us, this letter agreement (the &#8220;Agreement&#8221;) memorializes your compensation and other employment terms. These terms will become effective on the date you join the Company (the &#8220;Hire Date&#8221;). </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;Compensation and Benefits.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Base Compensation&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Your base salary will be $465,000.00 annually ($19,375.00 per pay period), subject to payroll deductions and all required withholdings, reflecting your full-time employment with the Company. Your salary will be paid in accordance with the Company&#8217;s standard payroll schedule (currently the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and last calendar day of each month).  As an exempt salaried employee, you will be expected to work the Company&#8217;s normal business hours as well as additional hours as required by the nature of your work assignments, and you will not be eligible for overtime compensation.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Bonus&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, for each calendar year starting with 2022 you will be eligible to earn an annual performance bonus with a target bonus amount equal to 40% of your base salary (as of January 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the bonus year). Your annual bonus for the calendar year in which you were hired will be prorated based on your Hire Date, so long as you joined the Company prior to October 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of that year. If you joined on or after October 1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, you will not be eligible for a bonus for that year.  Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year, as well as such</font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="if97132dbc5de4e12a004096f3031319d_71"></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other criteria deemed relevant by the Company. Bonus payments will be in the form of cash and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors or its Compensation Committee. Any cash bonus payments will be less payroll deductions and all required withholdings. The bonus is not earned until paid (that is, you must be employed by the Company on the date the bonus is paid in order to be entitled to receive the bonus) and no pro-rated amount will be paid if your employment terminates for any reason prior to the payment date. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Annual Equity Award&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For each calendar year starting with the year after you complete one full year of service, you may be eligible for a discretionary annual equity grant, provided that you are actively employed with the Company through and including the date of such annual equity grant.  Whether any discretionary annual equity grant is granted, and the terms of any such equity grant, is entirely at the discretion of the Company&#8217;s Board of Directors or its Compensation Committee. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signing Bonus&#58;</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A one-time signing bonus of $150,000.00 will be advanced within the first 30 days of your employment and will be subject to payroll deductions and all required withholdings (the &#8220;Signing&#47;Retention Bonus&#8221;). The Company will advance you the Signing&#47;Retention Bonus, prior to its being earned, within 30 days after your Hire Date.  You will earn the Signing&#47;Retention Bonus if you remain continuously employed with the Company for 12 months after your Hire Date.  If your employment with the Company ends for any reason, other than death or disability, prior to you completing 12 months of employment, you agree to repay, within 30 days of your last day of employment with the Company, the entire Sign-On&#47;Retention Payment paid to you by the Company in advance of becoming earned.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Benefits</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a regular, full time employee, you will be eligible to participate in the Company&#8217;s employee benefits programs in accordance with the terms, conditions and limitations of the benefit plans, including health, dental and vision plans, retirement, paid time off, and other benefits, to the extent such plans have been established by the Company. Our employee benefits are described in the Benefits Booklet. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All forms of compensation referred to in this Agreement are subject to all applicable taxes, withholding and any other deductions required by applicable law.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company may change compensation and benefits from time to time in its discretion.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;New Hire Equity Grants.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Options</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company grant you options to purchase 485,000 shares of the Company&#8217;s common stock </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with an exercise price per share equal to the closing price of the common stock on the date of grant (the &#8220;Option&#8221;). The Option will be granted pursuant to the Company&#8217;s 2017 Inducement Plan as an inducement grant. The option will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date,  25% of the shares of common stock subject to the award of the Option shall vest on the first anniversary of the vesting commencement date (your Hire Date)  and 1&#47;48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option shall be subject to the other terms and conditions set forth in the Company&#8217;s 2017 Inducement Plan and the Company&#8217;s standard form of Nonstatutory Stock Option Agreement.  You should consult with your own tax advisor concerning the risks associated with accepting the Option.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Performance Stock Units</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if you join the Company, it will be recommended at the first meeting of the Company&#8217;s Board of Directors or its Compensation Committee following your Hire Date, that the Company award you 100,000 Performance Sock Units (&#8220;PSUs&#8221;) under the Company&#8217;s 2014 Equity Incentive Award Plan, as set forth in the form of PSU award agreement attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The PSU award shall be subject to the terms and conditions set forth in the Company&#8217;s 2014 Equity Incentive Award Plan and the Company&#8217;s PSU Award Agreement.  You should consult with your own tax advisor concerning the risks associated with accepting the PSU award.  </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. &#160;&#160;&#160;&#160;Confidentiality and Proprietary Information Obligations.</font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">Company Policies and Proprietary Information Agreement. As a condition of employment, you will be required to sign the employee Proprietary Information and Invention Assignment Agreement (the &#8220;PIIAA&#8221;) attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit&#160;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, which requires, among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of Company proprietary information. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer, and that in performing your duties for the Company you will in no way utilize any such information.  You agree to honor all obligations to former employers during your employment with the Company. </font></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Adverse or Outside Business Activities. Throughout your employment with the Company, you may engage in civic, academic teaching and lectures, and not-for-profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. You may not engage in other employment or undertake any other commercial business activities unless you obtain the prior written consent of the Company&#8217;s CEO. The Company may rescind its consent to your service as a director of all other corporations or participation in other business or public activities, if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s reputational or business interests or conflict with your duties to the Company. In addition, throughout the term of your employment </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">with the Company, you agree not to, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, executive, partner, employee, principal, agent, representative, consultant, licensor, licensee or otherwise with, any business or enterprise engaged in any business which is competitive with or which is reasonably anticipated to be competitive with the Company&#8217;s business&#59; provided, however, that you may purchase or otherwise acquire up to (but not more than) 1% of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. You hereby represent and warrant that you have disclosed previously to the Company all other employment or other commercial business activities that you already undertake, or intend to undertake (to the extent currently known by you), during your period of employment with the Company.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;No Conflicts.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By signing this Agreement you hereby represent to the Company that, except as previously disclosed to the Company&#58; (a) your employment with the Company is not prohibited under any employment agreement or other contractual arrangement&#59; and (b) you do not know of any conflicts which would restrict your employment with the Company. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company, and that you are presently in compliance with such contracts, if any.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. &#160;&#160;&#160;&#160;Reserved. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;At Will Employment.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company is excited about your joining as a full time, regular, exempt employee and looks forward to a beneficial and productive relationship.  Nevertheless, your employment relationship with the Company will be an &#8220;at-will&#8221; arrangement and is for no specific period. This means that either you or the Company may terminate your employment at any time, with or without cause, and with or without advance notice. This &#8220;at-will&#8221; employment relationship cannot be changed except in a written agreement approved by the Company and signed by you and by a duly authorized officer of the Company. We request that, in the event of resignation, you give the Company at least two weeks notice. You should note that the Company may modify job titles, salaries and benefits from time to time as it deems necessary.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;Miscellaneous.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.1.&#160;&#160;&#160;&#160;Conditions of employment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This offer is contingent upon a satisfactory reference check and satisfactory proof of your right to work in the United States.  If the Company informs you that you are required to complete a background check, this offer is contingent upon satisfactory clearance of such background check. You agree to assist as needed and to complete any documentation at the Company&#8217;s request to meet these conditions. </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.2.&#160;&#160;&#160;&#160;Dispute Resolution.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To ensure the rapid and economical resolution of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment with the Company, or the termination of your employment, shall be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167; 1-16, to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS or its successor, under JAMS&#8217; then applicable rules and procedures for employment disputes before a single arbitrator (available upon request and also currently available at </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">You acknowledge that by agreeing to this arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity.  The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding.  To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration.  This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration (collectively, the &#8220;Excluded Claims&#8221;).  In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration.  You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator.  Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator.  The arbitrator shall&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law&#59; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing in this letter agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.3. &#160;&#160;&#160;&#160;Succession and assignment.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement is personal to you and shall not be assigned by you. Any purported assignment by you shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or </font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.4. &#160;&#160;&#160;&#160;Enforceability.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.5. &#160;&#160;&#160;&#160;Governing law and jurisdiction.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.6. &#160;&#160;&#160;&#160;Headings and captions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.7. &#160;&#160;&#160;&#160;No construction against drafter.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any ambiguity in this Agreement shall not be construed against either party as the drafter. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.8. &#160;&#160;&#160;&#160;Waiver.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.9. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Counterparts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> This letter may be delivered and executed via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law) or other transmission method and shall be deemed to have been duly and validly delivered and executed and be valid and effective for all purposes. </font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.10&#160;&#160;&#160;&#160;Entire agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement, together with the Change of Control and Severance Agreement (Exhibit A) and your PIIAA (Exhibit C), forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this Agreement supersede any other agreements or promises made to you by anyone concerning your employment terms, including, but not limited to, any representations made during your recruitment, interviews or pre employment negotiations, whether written or oral.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;Acknowledgement of Full Understanding.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT. </font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please sign and date this letter, and the attached Change of Control Agreement and the Proprietary Information and Invention Assignment Agreement and return them to me by the close of business on December 31, 2021 in order to confirm your acceptance of our offer and agreement to these employment terms. This offer of employment will terminate if it is not accepted, signed and returned by the specified date. If you accept our offer, your first day of employment will be no later than February 7, 2022.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We look forward to a favorable reply and a productive and enjoyable work relationship with you.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Sincerely, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Adverum Biotechnologies, Inc.&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Laurent Fischer, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Laurent Fischer, M.D.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Understood and Accepted&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#47;s&#47; Richard Beckman</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">_________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Richard Beckman</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Date&#58; 2021-12-30  &#124;  13&#58;30&#58;41 PST</font></div><div><font><br></font></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>11
<FILENAME>advm-20211231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8dcd8cc9d894403089b44cc79f117256_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SUBSIDIARIES OF ADVERUM BIOTECHNOLOGIES, INC.</font></div><div style="margin-top:18pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Country of Incorporation</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avalanche Australia PTY LTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annapurna Therapeutics, LTD</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adverum NC, LLC</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Carolina, USA</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>advm-20211231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6765c3f1ab58455d9a1b7d62f90a3a84_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit  23.1</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:105%">We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-223894, 333-218465, 333-211439, 333-203398, 333-199296, 333-230138, 333-233135, 333-220894, 333-237136, 333-243761, and 333-253727) of our report dated March 29, 2022, with respect to the consolidated financial statements of Adverum Biotechnologies Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Jose, California</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 29, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>13
<FILENAME>advm-20211231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2b24e93df11b41049596443448b4f429_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Laurent Fischer, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Form 10-K of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;29, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>14
<FILENAME>advm-20211231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icbac2fc210f94169a37e40ac73900fc7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Rupert D'Souza, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this Form 10-K of Adverum Biotechnologies, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:47.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;29, 2022</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rupert D'Souza</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rupert D'Souza, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>15
<FILENAME>advm-20211231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i9dd2b5a8c0cd4b659c0526853e352aba_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Laurent Fischer, as President and Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;29, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Laurent Fischer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laurent Fischer, M.D.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>16
<FILENAME>advm-20211231xexx322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i57708afb09604083b67e26ad74f4cad5_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of Adverum Biotechnologies, Inc. for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Rupert D'Souza, as Chief Financial Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;29, 2022</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Rupert D'Souza</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rupert D'Souza, Ph.D.<br>Chief Financial Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>17
<FILENAME>advm-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1a8e5b7c-bca3-4165-b4c0-12c52c6244d9,g:f2d923c2-de02-4da0-a578-7d0cd54aca4d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20211231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.adverum.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.adverum.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1004006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.adverum.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusiness" roleURI="http://www.adverum.com/role/DescriptionoftheBusiness">
        <link:definition>2101101 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionoftheBusinessAdditionalInformationDetail" roleURI="http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Description of the Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Summaryofsignificantaccountingpolicies" roleURI="http://www.adverum.com/role/Summaryofsignificantaccountingpolicies">
        <link:definition>2103102 - Disclosure - Summary of significant accounting policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofsignificantaccountingpoliciesAdditionalInformationDetail" roleURI="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail">
        <link:definition>2405402 - Disclosure - Summary of significant accounting policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>2106103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>2307301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail">
        <link:definition>2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>2409404 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.adverum.com/role/Revenue">
        <link:definition>2110104 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueAdditionalInformationDetail" roleURI="http://www.adverum.com/role/RevenueAdditionalInformationDetail">
        <link:definition>2411405 - Disclosure - Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.adverum.com/role/Leases">
        <link:definition>2112105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.adverum.com/role/LeasesTables">
        <link:definition>2313302 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalInformationDetail" roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetail">
        <link:definition>2414406 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail" roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail">
        <link:definition>2415407 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>2116106 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>2317303 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2418408 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail">
        <link:definition>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.adverum.com/role/CommitmentsandContingencies">
        <link:definition>2120107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.adverum.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlans" roleURI="http://www.adverum.com/role/StockPlans">
        <link:definition>2122108 - Disclosure - Stock Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansTables" roleURI="http://www.adverum.com/role/StockPlansTables">
        <link:definition>2323304 - Disclosure - Stock Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansAdditionalInformationDetail" roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetail">
        <link:definition>2424411 - Disclosure - Stock Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansSummaryofStockOptionsActivityDetail" roleURI="http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail">
        <link:definition>2425412 - Disclosure - Stock Plans - Summary of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail" roleURI="http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail">
        <link:definition>2426413 - Disclosure - Stock Plans - Schedule of Stock Purchase Plan Valuation Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansSummaryofRestrictedStockUnitsActivityDetail" roleURI="http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail">
        <link:definition>2427414 - Disclosure - Stock Plans - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockPlansStockBasedCompensationExpenseDetail" roleURI="http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail">
        <link:definition>2428415 - Disclosure - Stock Plans - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kSavingsPlan" roleURI="http://www.adverum.com/role/A401kSavingsPlan">
        <link:definition>2129109 - Disclosure - 401(k) Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kSavingsPlanAdditionalInformationDetail" roleURI="http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetail">
        <link:definition>2430416 - Disclosure - 401(k) Savings Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.adverum.com/role/IncomeTaxes">
        <link:definition>2131110 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.adverum.com/role/IncomeTaxesTables">
        <link:definition>2332305 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail">
        <link:definition>2433417 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails">
        <link:definition>2434418 - Disclosure - Income Taxes- Schedule of Components of Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail">
        <link:definition>2435419 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsDetail" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail">
        <link:definition>2436420 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2437421 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail" roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail">
        <link:definition>2438422 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>2139111 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>2340306 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" roleURI="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail">
        <link:definition>2441423 - Disclosure - Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_TwoThousandSeventeenInducementPlanMember" abstract="true" name="TwoThousandSeventeenInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_AccruedNonclinicalCostsCurrent" abstract="false" name="AccruedNonclinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandAndFourteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_WarrantsIssuedDuringPeriodShares" abstract="false" name="WarrantsIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="advm_LexeoTherapeuticsIncMember" abstract="true" name="LexeoTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseLeaseTerminationFee" abstract="false" name="LesseeOperatingLeaseLeaseTerminationFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" abstract="false" name="IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="advm_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseNumberOfRenewalContracts" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalContracts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="advm_DeferredTaxAssetsLeaseObligation" abstract="false" name="DeferredTaxAssetsLeaseObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" abstract="false" name="DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" abstract="false" name="ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_StockOptionsAndRestrictedStockUnitsMember" abstract="true" name="StockOptionsAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" abstract="false" name="AccruedClinicalAndDevelopmentProcessCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TerminatedLeaseMember" abstract="true" name="TerminatedLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_RemeasurementOfRightOfUseAssetOnLeaseModification" abstract="false" name="RemeasurementOfRightOfUseAssetOnLeaseModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonQualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" abstract="false" name="OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TwoThousandFourteenPlanAndInducementPlanMember" abstract="true" name="TwoThousandFourteenPlanAndInducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_TwoThousandAndFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandAndFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_OperatingLeaseMonthlyCost" abstract="false" name="OperatingLeaseMonthlyCost" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" abstract="false" name="IncomeTaxReconciliationChangeInStateUncertainTaxPosition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" abstract="false" name="LesseeOperatingLeaseLeaseholdImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>18
<FILENAME>advm-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1a8e5b7c-bca3-4165-b4c0-12c52c6244d9,g:f2d923c2-de02-4da0-a578-7d0cd54aca4d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_87382320-ef73-4a20-bb8b-96762042079e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ad6cea25-1db4-42e8-9acc-4c75e406541f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87382320-ef73-4a20-bb8b-96762042079e" xlink:to="loc_us-gaap_Liabilities_ad6cea25-1db4-42e8-9acc-4c75e406541f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_82fa86c5-7033-49a4-9bf3-94d400b07422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_87382320-ef73-4a20-bb8b-96762042079e" xlink:to="loc_us-gaap_StockholdersEquity_82fa86c5-7033-49a4-9bf3-94d400b07422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_474dce4f-d8f5-401e-9f17-60f2a7cf5643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9121e88-d63e-4a5d-9c9b-e123b732f7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_474dce4f-d8f5-401e-9f17-60f2a7cf5643" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c9121e88-d63e-4a5d-9c9b-e123b732f7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_3c832dd9-924b-437b-9b19-d25026783721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_474dce4f-d8f5-401e-9f17-60f2a7cf5643" xlink:to="loc_us-gaap_ShortTermInvestments_3c832dd9-924b-437b-9b19-d25026783721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_b6fb50f1-3a76-4549-b67a-a07befbf80ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_474dce4f-d8f5-401e-9f17-60f2a7cf5643" xlink:to="loc_us-gaap_IncentiveToLessee_b6fb50f1-3a76-4549-b67a-a07befbf80ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da8e985f-65e8-4866-b154-c849c9fc7ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_474dce4f-d8f5-401e-9f17-60f2a7cf5643" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da8e985f-65e8-4866-b154-c849c9fc7ce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a68bc53-faad-4a3f-a2df-a82c9a05447c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_73d4f0ff-3d65-40b0-903c-51b01f3e4511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a68bc53-faad-4a3f-a2df-a82c9a05447c" xlink:to="loc_us-gaap_LiabilitiesCurrent_73d4f0ff-3d65-40b0-903c-51b01f3e4511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb44628f-35b9-4df8-bf55-393f3bf11101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a68bc53-faad-4a3f-a2df-a82c9a05447c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb44628f-35b9-4df8-bf55-393f3bf11101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0f134ffe-cd0b-48b2-8aea-35944c997801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_9a68bc53-faad-4a3f-a2df-a82c9a05447c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0f134ffe-cd0b-48b2-8aea-35944c997801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_290fb02a-f0a4-492b-9976-bc379baa893e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3ca14e72-0643-4d23-b54e-606300765e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_290fb02a-f0a4-492b-9976-bc379baa893e" xlink:to="loc_us-gaap_AccountsPayableCurrent_3ca14e72-0643-4d23-b54e-606300765e1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ca2e11b1-675c-4856-9524-b4c1d8ba9d1f" xlink:href="advm-20211231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_290fb02a-f0a4-492b-9976-bc379baa893e" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_ca2e11b1-675c-4856-9524-b4c1d8ba9d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_82a5c580-7ba5-4796-930a-b0df8d44e889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_290fb02a-f0a4-492b-9976-bc379baa893e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_82a5c580-7ba5-4796-930a-b0df8d44e889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_77ae0775-01e0-4e3b-9d15-1d126bd2be0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:to="loc_us-gaap_AssetsCurrent_77ae0775-01e0-4e3b-9d15-1d126bd2be0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf7496a2-b9ed-4563-bb7b-de7f2f18766a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bf7496a2-b9ed-4563-bb7b-de7f2f18766a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f2eecd64-5224-4fa1-a363-a61165f463d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f2eecd64-5224-4fa1-a363-a61165f463d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4d604aa0-5836-419a-be6b-2a370496f6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4d604aa0-5836-419a-be6b-2a370496f6ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_ec702e3d-4294-4240-aef7-4dac92aa16d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_ec702e3d-4294-4240-aef7-4dac92aa16d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c3224af9-1691-44c7-b25c-9f5ccf7143b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_37598be8-ed9f-4aba-b0c7-29a3a7a6d238" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c3224af9-1691-44c7-b25c-9f5ccf7143b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ec0f11ea-ebb3-4f53-98ff-a5fd1d4d0a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:to="loc_us-gaap_PreferredStockValue_ec0f11ea-ebb3-4f53-98ff-a5fd1d4d0a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_157e0cf9-0588-41ee-b822-7e3bb867f218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:to="loc_us-gaap_CommonStockValue_157e0cf9-0588-41ee-b822-7e3bb867f218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_45976c97-f56e-4fc0-ba9e-c15fea16eb6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_45976c97-f56e-4fc0-ba9e-c15fea16eb6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66a792c2-2c10-47f9-b77f-a979d8fe8d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_66a792c2-2c10-47f9-b77f-a979d8fe8d5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dde526cd-08a2-4f3c-810b-97513043ed72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dde526cd-08a2-4f3c-810b-97513043ed72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_55441aa8-e1c5-4a23-8a5e-01121d9feca1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a099dfce-5938-409f-a122-808ecdd1e0da" xlink:to="loc_us-gaap_CommitmentsAndContingencies_55441aa8-e1c5-4a23-8a5e-01121d9feca1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ca37d095-4c44-4338-a696-0b6ff78a3f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cca7896b-70dd-4c04-8f03-1d6bebb9d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ca37d095-4c44-4338-a696-0b6ff78a3f62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cca7896b-70dd-4c04-8f03-1d6bebb9d2d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9d7c3091-50cb-42e5-a73e-9121526052ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_ca37d095-4c44-4338-a696-0b6ff78a3f62" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9d7c3091-50cb-42e5-a73e-9121526052ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5e3fbd7-de0c-4dfb-aa2d-9a9f4eaaabc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa9204fc-0671-46ce-9ef2-cc2d6f6d5334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a5e3fbd7-de0c-4dfb-aa2d-9a9f4eaaabc5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa9204fc-0671-46ce-9ef2-cc2d6f6d5334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a45dc613-0095-4404-8203-cca5de4e6018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a5e3fbd7-de0c-4dfb-aa2d-9a9f4eaaabc5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a45dc613-0095-4404-8203-cca5de4e6018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_805670a3-effc-49c5-81db-93da01faa8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_58ea54f2-0723-45b1-b846-77c519538f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_805670a3-effc-49c5-81db-93da01faa8d5" xlink:to="loc_us-gaap_OperatingIncomeLoss_58ea54f2-0723-45b1-b846-77c519538f45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4d8c3a6c-cf55-485f-94fc-002e7e2075f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_805670a3-effc-49c5-81db-93da01faa8d5" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4d8c3a6c-cf55-485f-94fc-002e7e2075f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0af05a4-87b9-4f18-8644-2c8bec560c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6e8e3b8b-1dea-41c0-9b59-3dfcce17dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0af05a4-87b9-4f18-8644-2c8bec560c94" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_6e8e3b8b-1dea-41c0-9b59-3dfcce17dd60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_e3a73af4-967e-49b9-bb1a-f6065611beef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0af05a4-87b9-4f18-8644-2c8bec560c94" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_e3a73af4-967e-49b9-bb1a-f6065611beef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_29281974-2e3c-4271-83f0-8ef6469ca079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0af05a4-87b9-4f18-8644-2c8bec560c94" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_29281974-2e3c-4271-83f0-8ef6469ca079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d65dcf15-fe88-4d28-bd19-df2284ffd964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e0af05a4-87b9-4f18-8644-2c8bec560c94" xlink:to="loc_us-gaap_NetIncomeLoss_d65dcf15-fe88-4d28-bd19-df2284ffd964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fe09ad71-ac08-4bfe-87c6-0265062d5f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da73a319-3910-4ee1-ab4f-ac5ecb257611" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fe09ad71-ac08-4bfe-87c6-0265062d5f6f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da73a319-3910-4ee1-ab4f-ac5ecb257611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_db664c10-aae4-4081-bc0b-c0393fb29f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fe09ad71-ac08-4bfe-87c6-0265062d5f6f" xlink:to="loc_us-gaap_OperatingExpenses_db664c10-aae4-4081-bc0b-c0393fb29f4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_062aabb2-5cf5-4209-8674-1854245d60a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a6be0b19-44fd-4039-b43f-5b5d4929a0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_062aabb2-5cf5-4209-8674-1854245d60a3" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_a6be0b19-44fd-4039-b43f-5b5d4929a0a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ece860f0-8702-4d9c-8208-73b64fa9b798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_062aabb2-5cf5-4209-8674-1854245d60a3" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_ece860f0-8702-4d9c-8208-73b64fa9b798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09988457-a9bb-412c-b4f3-18a06ac285f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_062aabb2-5cf5-4209-8674-1854245d60a3" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_09988457-a9bb-412c-b4f3-18a06ac285f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_54a934d7-8746-4160-ae56-5e2276d7f5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_062aabb2-5cf5-4209-8674-1854245d60a3" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_54a934d7-8746-4160-ae56-5e2276d7f5cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_489047d1-23aa-4c2e-95e5-ef88aae431f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22ae4691-19ac-4ef6-a309-4b8c60e972c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_489047d1-23aa-4c2e-95e5-ef88aae431f0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_22ae4691-19ac-4ef6-a309-4b8c60e972c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7af4d234-d310-4944-b417-7fd2e98dfd1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_489047d1-23aa-4c2e-95e5-ef88aae431f0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7af4d234-d310-4944-b417-7fd2e98dfd1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dba91863-cdd9-47c2-b7d3-60f9c68ce23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_489047d1-23aa-4c2e-95e5-ef88aae431f0" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dba91863-cdd9-47c2-b7d3-60f9c68ce23e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_20405275-41f6-4834-b2a9-7f31ad3e1ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_489047d1-23aa-4c2e-95e5-ef88aae431f0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_20405275-41f6-4834-b2a9-7f31ad3e1ce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_a0e304c2-a3fb-4f2f-b776-873891137fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_489047d1-23aa-4c2e-95e5-ef88aae431f0" xlink:to="loc_us-gaap_RepaymentsOfDebt_a0e304c2-a3fb-4f2f-b776-873891137fcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_d683b0a0-243a-4d89-afe1-c2638d6f542b" xlink:href="advm-20211231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_d683b0a0-243a-4d89-afe1-c2638d6f542b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_65465c63-229d-44ca-85f5-5b1b1070d077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_AssetImpairmentCharges_65465c63-229d-44ca-85f5-5b1b1070d077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_99865b62-c9ec-4797-a507-631cee743053" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_99865b62-c9ec-4797-a507-631cee743053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bba975a3-a3d0-4de2-8b81-2711d4592a37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_bba975a3-a3d0-4de2-8b81-2711d4592a37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_72240394-4b75-41e2-89e9-3fc4e3a49fbf" xlink:href="advm-20211231.xsd#advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_72240394-4b75-41e2-89e9-3fc4e3a49fbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_97f423dc-c717-4095-8daf-0743ff99b420" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_DepreciationAndAmortization_97f423dc-c717-4095-8daf-0743ff99b420" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_84d51b08-54e4-406d-8384-b66ee2a1be14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_84d51b08-54e4-406d-8384-b66ee2a1be14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d89e011b-9041-4cf5-9688-9e98a4012403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d89e011b-9041-4cf5-9688-9e98a4012403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_925ba18f-81e5-499c-8c24-558d3388c83a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_925ba18f-81e5-499c-8c24-558d3388c83a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e949ee67-b87d-4b3b-9623-4397c21e6254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e949ee67-b87d-4b3b-9623-4397c21e6254" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_643101e4-3698-4ca4-b090-d9272cb04a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_ShareBasedCompensation_643101e4-3698-4ca4-b090-d9272cb04a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c66e4a3b-64f8-44b6-8f30-f94b1496a604" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c66e4a3b-64f8-44b6-8f30-f94b1496a604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e76bc38-4f7d-4929-baa9-0903a92c96ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_NetIncomeLoss_3e76bc38-4f7d-4929-baa9-0903a92c96ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_36ffa8eb-ebf8-4d01-aed8-009b5ea7461f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_AccretionExpense_36ffa8eb-ebf8-4d01-aed8-009b5ea7461f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecf2d81d-5027-4050-8423-ed4afb182643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_72fd683a-dabc-4953-9328-333528d371d5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ecf2d81d-5027-4050-8423-ed4afb182643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e055f4-b0cd-449b-8557-434026ef7828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4b274fc4-7813-4bb2-a105-38d93ced1af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e055f4-b0cd-449b-8557-434026ef7828" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4b274fc4-7813-4bb2-a105-38d93ced1af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e86b775-dda1-403e-bf4d-4a71de88024c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e055f4-b0cd-449b-8557-434026ef7828" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2e86b775-dda1-403e-bf4d-4a71de88024c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe506f66-e387-44a6-9683-ba13588f01d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d0e055f4-b0cd-449b-8557-434026ef7828" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fe506f66-e387-44a6-9683-ba13588f01d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7c2d91ae-1097-4613-8f41-d5163efb6241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_7eef5bfd-f791-4e47-aa94-12ea473eba42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7c2d91ae-1097-4613-8f41-d5163efb6241" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_7eef5bfd-f791-4e47-aa94-12ea473eba42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d2c028b-4ed2-49b6-a68b-ce8442790f09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_7c2d91ae-1097-4613-8f41-d5163efb6241" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7d2c028b-4ed2-49b6-a68b-ce8442790f09" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1534fc51-285d-4429-8b02-6d5e2d849c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff8626e1-cfab-41ec-b30e-296b1b1f46e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1534fc51-285d-4429-8b02-6d5e2d849c4d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ff8626e1-cfab-41ec-b30e-296b1b1f46e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fb3a0d1b-fa87-42c8-9c18-44a612277717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1534fc51-285d-4429-8b02-6d5e2d849c4d" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fb3a0d1b-fa87-42c8-9c18-44a612277717" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5344e98-708c-4509-88f0-2b3f868ac9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1534fc51-285d-4429-8b02-6d5e2d849c4d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5344e98-708c-4509-88f0-2b3f868ac9b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_7349a369-7840-4ae4-bb62-2a0c3cdb4d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_7349a369-7840-4ae4-bb62-2a0c3cdb4d1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_242c2a5b-d5c7-4524-962e-7321afd783e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_242c2a5b-d5c7-4524-962e-7321afd783e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_09707520-f57b-4bfd-9339-cc3ed665cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_09707520-f57b-4bfd-9339-cc3ed665cbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_28faae7d-1d47-417a-88e4-419704df750a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_28faae7d-1d47-417a-88e4-419704df750a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_50f7d76a-09be-49a9-8f88-620e76d5c369" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_50f7d76a-09be-49a9-8f88-620e76d5c369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f4daf9c8-5223-4cb3-a0da-d94937d3acc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_b5f92745-47cd-40ec-a2d7-b2b5b5afc545" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_f4daf9c8-5223-4cb3-a0da-d94937d3acc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4a3017b7-d91e-433e-9bbb-c8678b5aa7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4a3017b7-d91e-433e-9bbb-c8678b5aa7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c8c15fe6-b3e2-42ce-a37f-b8f564565a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c8c15fe6-b3e2-42ce-a37f-b8f564565a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e5525074-96b3-4545-8695-e1ac7528985a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e5525074-96b3-4545-8695-e1ac7528985a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16ff9b34-30ee-43e4-ace0-ed7d650ef8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_16ff9b34-30ee-43e4-ace0-ed7d650ef8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fba35610-39ab-4d86-a87f-50ee7854dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_fba35610-39ab-4d86-a87f-50ee7854dd10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a65339cd-fd86-41fb-b8f5-802682f15b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0a77aab3-8e41-4110-88dc-558d4ab1d97b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a65339cd-fd86-41fb-b8f5-802682f15b5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c5e7497c-3f36-42bf-85ba-eedef46b938a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ec6f6c83-38ea-4918-a080-760bb466f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c5e7497c-3f36-42bf-85ba-eedef46b938a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_ec6f6c83-38ea-4918-a080-760bb466f8fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2fcf4be2-9d81-4720-ab55-8ef59ef2ef30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c5e7497c-3f36-42bf-85ba-eedef46b938a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2fcf4be2-9d81-4720-ab55-8ef59ef2ef30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:href="advm-20211231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c28134b8-912d-4ffd-bfea-4d339a1e8de1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c28134b8-912d-4ffd-bfea-4d339a1e8de1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_064aa218-8459-49bd-9b81-2dc4b07dc8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:to="loc_us-gaap_TaxesPayableCurrent_064aa218-8459-49bd-9b81-2dc4b07dc8e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_714a178a-9df5-4e11-8912-12d0b12b4d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_714a178a-9df5-4e11-8912-12d0b12b4d40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalCostsCurrent_705f0020-bbc3-49f5-9480-f9eb1e7faf41" xlink:href="advm-20211231.xsd#advm_AccruedNonclinicalCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:to="loc_advm_AccruedNonclinicalCostsCurrent_705f0020-bbc3-49f5-9480-f9eb1e7faf41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_6d579ec8-1ed8-48b0-a311-8a31038d12d8" xlink:href="advm-20211231.xsd#advm_AccruedClinicalAndDevelopmentProcessCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:to="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_6d579ec8-1ed8-48b0-a311-8a31038d12d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_76ec8f4b-7ed8-4808-886e-1c8af5fefd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_4242e79e-2b3f-4684-a564-191d5e2dddaf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_76ec8f4b-7ed8-4808-886e-1c8af5fefd14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f88f12-41f1-4276-ac16-4a26196effb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e2dbc558-c895-4c2f-a690-2c0bc695923c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f88f12-41f1-4276-ac16-4a26196effb3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e2dbc558-c895-4c2f-a690-2c0bc695923c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a2c05045-a23e-4d3c-8963-f00e665368e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f88f12-41f1-4276-ac16-4a26196effb3" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a2c05045-a23e-4d3c-8963-f00e665368e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8b288195-674b-4a78-b06f-8a6632d765c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_35b9db25-3160-44f0-b951-8599d2bb68ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8b288195-674b-4a78-b06f-8a6632d765c1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_35b9db25-3160-44f0-b951-8599d2bb68ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b766a2d5-6406-4b9d-bbac-65583b55ece2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8b288195-674b-4a78-b06f-8a6632d765c1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b766a2d5-6406-4b9d-bbac-65583b55ece2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8a9f90e8-1415-4ef8-96a9-7e30f6653c30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c4c4e6a6-02cc-48c9-af9b-af2dba2fd67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8a9f90e8-1415-4ef8-96a9-7e30f6653c30" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c4c4e6a6-02cc-48c9-af9b-af2dba2fd67c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b08fa53-c409-4b4f-ad78-24c40a08df0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7251db1d-4ef3-46ac-974e-d26bd70132cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7b08fa53-c409-4b4f-ad78-24c40a08df0f" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7251db1d-4ef3-46ac-974e-d26bd70132cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_565f1228-29cc-43f0-b039-e47f4e3af136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_565f1228-29cc-43f0-b039-e47f4e3af136" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_15527fef-065f-487d-b417-44331558ba5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_15527fef-065f-487d-b417-44331558ba5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_11a4e856-8c94-4c68-9076-c1f2081dab8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_11a4e856-8c94-4c68-9076-c1f2081dab8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1499357d-4756-4a73-9ba7-b494e38f04b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_1499357d-4756-4a73-9ba7-b494e38f04b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_06d42562-5353-4a4c-9a0f-038c6e843d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_06d42562-5353-4a4c-9a0f-038c6e843d0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_07d8dbdc-0f7c-4761-9b6d-db2a2e972d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_07d8dbdc-0f7c-4761-9b6d-db2a2e972d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b99e154c-c20a-4d05-9571-03f6f5329df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b99e154c-c20a-4d05-9571-03f6f5329df0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_9c54a861-1d84-47af-8670-5ce2e2821e66" xlink:href="advm-20211231.xsd#advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_9c54a861-1d84-47af-8670-5ce2e2821e66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_07ce70fa-6ab3-4abd-aefa-30d94a45705b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_09be164e-0bac-4bbf-9a77-cb1d3d12aac3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_07ce70fa-6ab3-4abd-aefa-30d94a45705b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2191e084-960c-45fc-854e-efe8bd62fc51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8a72615e-aa6c-43b9-b6ef-e6b18cdded42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2191e084-960c-45fc-854e-efe8bd62fc51" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8a72615e-aa6c-43b9-b6ef-e6b18cdded42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fcd82a1b-1ffc-487f-a5f1-0e479156c161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2191e084-960c-45fc-854e-efe8bd62fc51" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fcd82a1b-1ffc-487f-a5f1-0e479156c161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_dcece1a4-6714-49e1-a9a5-484bb4527e03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5e77a10d-d2ab-42e8-bb2f-c774be37f3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_dcece1a4-6714-49e1-a9a5-484bb4527e03" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_5e77a10d-d2ab-42e8-bb2f-c774be37f3f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c7fdb80c-2de5-4abd-9bf2-088b3d94ef08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_dcece1a4-6714-49e1-a9a5-484bb4527e03" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c7fdb80c-2de5-4abd-9bf2-088b3d94ef08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e9b01811-6fad-4d65-97e5-dcd1760b2ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_e9b01811-6fad-4d65-97e5-dcd1760b2ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_cf3ee2aa-3a7d-439a-ba77-4ecf530fadc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_cf3ee2aa-3a7d-439a-ba77-4ecf530fadc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6c692269-a06f-4365-a950-d9f2a3cf3700" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6c692269-a06f-4365-a950-d9f2a3cf3700" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7093951b-f920-4416-9d04-459b061deec7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_7093951b-f920-4416-9d04-459b061deec7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_73af82a0-6c60-4f86-b0f3-4867e94cf488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_73af82a0-6c60-4f86-b0f3-4867e94cf488" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_167310d7-a993-4a6f-8370-925ad718fd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_167310d7-a993-4a6f-8370-925ad718fd6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation_6e97a1ec-6a4d-42a1-b976-56aa4bd3e3bd" xlink:href="advm-20211231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_advm_DeferredTaxAssetsLeaseObligation_6e97a1ec-6a4d-42a1-b976-56aa4bd3e3bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_fce3d331-a0ab-48a3-8dda-173bc248162d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_9246a6cf-a430-45d0-9e6f-0402ed1bc896" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_fce3d331-a0ab-48a3-8dda-173bc248162d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d64dfc3c-1573-42de-ba59-2dcb7b61997b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_23e335da-bd50-4a12-86d8-047503072f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d64dfc3c-1573-42de-ba59-2dcb7b61997b" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_23e335da-bd50-4a12-86d8-047503072f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8c767e58-53a1-43bc-8144-3fc87913f7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d64dfc3c-1573-42de-ba59-2dcb7b61997b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8c767e58-53a1-43bc-8144-3fc87913f7e7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>19
<FILENAME>advm-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1a8e5b7c-bca3-4165-b4c0-12c52c6244d9,g:f2d923c2-de02-4da0-a578-7d0cd54aca4d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i783c9e56d5154e49b8fac7484f3086ad_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_42479319-3cec-4a07-a992-a76dcd29736f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_42479319-3cec-4a07-a992-a76dcd29736f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3eff0023-88c8-4388-9b93-40679f64adcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_SharesOutstanding_3eff0023-88c8-4388-9b93-40679f64adcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_494105da-3dc5-4203-a3a9-479a01ba88f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockholdersEquity_494105da-3dc5-4203-a3a9-479a01ba88f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b9b4264-983e-4c4e-8478-65b95b8c5909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b9b4264-983e-4c4e-8478-65b95b8c5909" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_56fbfb6b-3e72-4ff6-ac15-d63c0717c6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_56fbfb6b-3e72-4ff6-ac15-d63c0717c6bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d96b26fe-e00f-46dd-a668-782ed777eea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d96b26fe-e00f-46dd-a668-782ed777eea6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb883abc-0a52-4897-b49d-14a799be2954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb883abc-0a52-4897-b49d-14a799be2954" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82e478c9-948e-4cf9-90f8-7e43337b11e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82e478c9-948e-4cf9-90f8-7e43337b11e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_WarrantsIssuedDuringPeriodShares_d1706820-dc91-459b-83d3-9e24b309a24d" xlink:href="advm-20211231.xsd#advm_WarrantsIssuedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_advm_WarrantsIssuedDuringPeriodShares_d1706820-dc91-459b-83d3-9e24b309a24d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3af52b2-e19d-4c37-8fbf-07e855640c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3af52b2-e19d-4c37-8fbf-07e855640c33" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6a8b83cc-6f4d-4e6e-b505-60731635fbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6a8b83cc-6f4d-4e6e-b505-60731635fbff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e839ce65-f70f-4929-96bf-9ef01f6ce747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e839ce65-f70f-4929-96bf-9ef01f6ce747" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f6f6f238-90fe-4fd3-b6ec-db75c24594ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f6f6f238-90fe-4fd3-b6ec-db75c24594ce" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8986cfab-128c-4f39-852e-09ab46fef209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8986cfab-128c-4f39-852e-09ab46fef209" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3ad6b5dc-3da3-4dab-a2ba-32d9a5088ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3ad6b5dc-3da3-4dab-a2ba-32d9a5088ecd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_f6203acb-ea5f-4236-871f-0ac23f9f39c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_f6203acb-ea5f-4236-871f-0ac23f9f39c3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8ff0dd53-f78d-43cf-9b7b-5f18b0af523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8ff0dd53-f78d-43cf-9b7b-5f18b0af523c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2cc0fffd-0b8b-4836-b958-42256d322aab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_NetIncomeLoss_2cc0fffd-0b8b-4836-b958-42256d322aab" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f8949f4a-5fe1-45af-ae0e-7a6a8f63dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0d43517-63d3-479a-a666-104f02a7e0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_42479319-3cec-4a07-a992-a76dcd29736f" xlink:to="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ebeb0c0c-aefc-426e-90c1-b76e86745ef2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:to="loc_us-gaap_EquityComponentDomain_ebeb0c0c-aefc-426e-90c1-b76e86745ef2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:to="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34292a37-feee-409d-93a1-731f750836d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_CommonStockMember_34292a37-feee-409d-93a1-731f750836d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a8abe938-eb21-43ea-836f-618b5d01f8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a8abe938-eb21-43ea-836f-618b5d01f8cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ff4851-6fe2-4603-8eb8-661ad500277d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ff4851-6fe2-4603-8eb8-661ad500277d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d202812a-5859-476a-b5ee-46b95c9d247c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_RetainedEarningsMember_d202812a-5859-476a-b5ee-46b95c9d247c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail" xlink:type="extended" id="i4fa3146d3b0b4eb8931f0bbb497e6fe8_SummaryofsignificantaccountingpoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:href="advm-20211231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f4a27f8e-f069-4286-9817-3e0d225112ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_NumberOfReportableSegments_f4a27f8e-f069-4286-9817-3e0d225112ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f57f7147-0501-4d8b-9a5b-38977265af34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f57f7147-0501-4d8b-9a5b-38977265af34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_67e41ed9-ab15-4090-b797-5cfb691dea24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_67e41ed9-ab15-4090-b797-5cfb691dea24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e1e0d572-75e0-4882-941a-fb3d4c455aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_AssetImpairmentCharges_e1e0d572-75e0-4882-941a-fb3d4c455aa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_7686fbc3-3224-4e3f-853b-5f3f912d55a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_7686fbc3-3224-4e3f-853b-5f3f912d55a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_79ea2b3d-0e93-4ddc-9585-1a9d511b32f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_79ea2b3d-0e93-4ddc-9585-1a9d511b32f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:href="advm-20211231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:to="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:to="loc_srt_RangeMember_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:to="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3aa5b04-8ff7-435c-a189-aaa6fb34a43b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:to="loc_srt_MinimumMember_c3aa5b04-8ff7-435c-a189-aaa6fb34a43b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d8abd97-a438-42ef-b947-a86987ef221b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:to="loc_srt_MaximumMember_8d8abd97-a438-42ef-b947-a86987ef221b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended" id="i59ac30e4dd6e4aac915f996588016bb9_FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3d362ac-7284-4b91-8908-4f7531582ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3d362ac-7284-4b91-8908-4f7531582ee0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_14dc4207-c937-46dd-b54b-27cb9ccf05c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_14dc4207-c937-46dd-b54b-27cb9ccf05c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3802242-5f66-47b4-a5fa-6095a26f95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3802242-5f66-47b4-a5fa-6095a26f95bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f26cfff9-4a91-4d4c-8608-35185b0d2e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f26cfff9-4a91-4d4c-8608-35185b0d2e39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_35429373-a999-4a94-9dda-7ab3417ebee9" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_35429373-a999-4a94-9dda-7ab3417ebee9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_d25b9e59-59fb-4bff-9ff6-52d13c811211" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_d25b9e59-59fb-4bff-9ff6-52d13c811211" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_f41c0774-91d2-4c21-b49e-374464b8312b" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_f41c0774-91d2-4c21-b49e-374464b8312b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b4d2d8c-3ee2-425d-9a4c-9a5bf4ecab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b4d2d8c-3ee2-425d-9a4c-9a5bf4ecab9b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31856509-5e4e-426b-b577-5ccc04cc8432_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_31856509-5e4e-426b-b577-5ccc04cc8432_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4c152e40-f842-4f44-b57f-fd03ca6d5c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4c152e40-f842-4f44-b57f-fd03ca6d5c9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9f5eac7e-bc64-4e54-a666-cf3ad355f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9f5eac7e-bc64-4e54-a666-cf3ad355f3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127f47f8-5bb9-4862-8509-43143965e010_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_127f47f8-5bb9-4862-8509-43143965e010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_695607fc-371f-43a0-9dcf-dc16e1e16b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_695607fc-371f-43a0-9dcf-dc16e1e16b6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_8a8e6045-3536-404c-aa59-384341e76d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_8a8e6045-3536-404c-aa59-384341e76d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fe83c5dd-1a12-4909-9610-98a1f557b910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_CommercialPaperMember_fe83c5dd-1a12-4909-9610-98a1f557b910" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e19e5545-3a95-466d-886b-32578153fa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e19e5545-3a95-466d-886b-32578153fa3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_692a6224-69b9-4ddf-910f-25ba88c7877e" xlink:href="advm-20211231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_692a6224-69b9-4ddf-910f-25ba88c7877e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="extended" id="i3fa8f88889894c79b0fe95884892381d_FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_2bd30ac1-b54c-4989-b34e-4fc1fd21dc20" xlink:href="advm-20211231.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_2bd30ac1-b54c-4989-b34e-4fc1fd21dc20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_a6f4ea66-9928-4271-a68e-f849c8d3214b" xlink:href="advm-20211231.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_a6f4ea66-9928-4271-a68e-f849c8d3214b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_0e7faa67-423b-4c95-908b-d78ecf0256a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_0e7faa67-423b-4c95-908b-d78ecf0256a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:to="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d7ff406e-f710-4126-b031-89f410af8af1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:to="loc_srt_RangeMember_d7ff406e-f710-4126-b031-89f410af8af1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:to="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cc961d23-ef0b-4670-bbc6-eaae5835de00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:to="loc_srt_MinimumMember_cc961d23-ef0b-4670-bbc6-eaae5835de00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_de2eb7d9-a693-4010-9d72-9c8c4a5232f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:to="loc_srt_MaximumMember_de2eb7d9-a693-4010-9d72-9c8c4a5232f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RevenueAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#RevenueAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RevenueAdditionalInformationDetail" xlink:type="extended" id="i20953ab6332b43c398e094b9137dba5f_RevenueAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a1733372-f8d9-4330-b87f-aaf32fcb5069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e8fef9-4266-471f-87ce-9da0ba75e44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a1733372-f8d9-4330-b87f-aaf32fcb5069" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e8fef9-4266-471f-87ce-9da0ba75e44a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a1733372-f8d9-4330-b87f-aaf32fcb5069" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:to="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d830569f-ff8f-4f1a-8ed1-da481570d8ad_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d830569f-ff8f-4f1a-8ed1-da481570d8ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81e35a40-1de0-4878-8bf8-e99189706ba8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81e35a40-1de0-4878-8bf8-e99189706ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_a3a0736d-ac9e-4a9b-8c6b-1479c9f142d7" xlink:href="advm-20211231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81e35a40-1de0-4878-8bf8-e99189706ba8" xlink:to="loc_advm_LexeoTherapeuticsIncMember_a3a0736d-ac9e-4a9b-8c6b-1479c9f142d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_60599cff-6db5-4758-ba73-2567a4c53c37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_60599cff-6db5-4758-ba73-2567a4c53c37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b5ab3ca2-494e-4aaa-a2c5-8ccd39ad676b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b5ab3ca2-494e-4aaa-a2c5-8ccd39ad676b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#LeasesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetail" xlink:type="extended" id="i80d337f888804e33a1362fbb92ac84d7_LeasesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e7ae6e82-6d04-414e-9d01-d5ce0afcbb8e" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e7ae6e82-6d04-414e-9d01-d5ce0afcbb8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_84f30582-4a18-407f-8c66-bcf3178ac505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_84f30582-4a18-407f-8c66-bcf3178ac505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f04350de-39ce-4291-8ebf-c3bbf55536dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f04350de-39ce-4291-8ebf-c3bbf55536dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_e9937704-34dd-4319-ae5a-4f462e8bb29c" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseLeaseTerminationFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_e9937704-34dd-4319-ae5a-4f462e8bb29c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseMonthlyCost_fa7209bf-b53c-4565-8292-2118e6d5040b" xlink:href="advm-20211231.xsd#advm_OperatingLeaseMonthlyCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_OperatingLeaseMonthlyCost_fa7209bf-b53c-4565-8292-2118e6d5040b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0ee6d702-a194-4610-b0f0-12ca6ce122b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_AssetImpairmentCharges_0ee6d702-a194-4610-b0f0-12ca6ce122b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_4d4dcc7a-3efd-49fa-83cd-a5b5c83e33e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_4d4dcc7a-3efd-49fa-83cd-a5b5c83e33e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_08da221f-7893-45cc-8392-228033ed5bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_08da221f-7893-45cc-8392-228033ed5bc2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_f806231e-5020-48cb-b165-b598e97f1917" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_f806231e-5020-48cb-b165-b598e97f1917" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6f7715f1-f289-402c-884f-345b61762e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6f7715f1-f289-402c-884f-345b61762e32" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_486e5960-0bd9-4ce7-aa10-655de373f601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_486e5960-0bd9-4ce7-aa10-655de373f601" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0185b2ea-0501-420c-b798-aa56f5fbb1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseExpense_0185b2ea-0501-420c-b798-aa56f5fbb1ef" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e6dea1d2-e617-477e-90ad-373be9bd3759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_VariableLeaseCost_e6dea1d2-e617-477e-90ad-373be9bd3759" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_46dd1c04-a87b-4071-a46f-843502ee0b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeasePayments_46dd1c04-a87b-4071-a46f-843502ee0b65" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_5d55cbf7-9504-488e-a067-d82c8ed2a629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_SubleaseIncome_5d55cbf7-9504-488e-a067-d82c8ed2a629" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9d341a9-d905-4e82-954d-6c8ebc18e524_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a9d341a9-d905-4e82-954d-6c8ebc18e524_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_93766304-c5b9-4e7d-8191-5f0431dd4b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:to="loc_us-gaap_BuildingMember_93766304-c5b9-4e7d-8191-5f0431dd4b55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_28e27a36-e1bb-439a-bcc8-539994ff69f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:to="loc_us-gaap_ManufacturingFacilityMember_28e27a36-e1bb-439a-bcc8-539994ff69f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:to="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_977d1ce1-b4e8-404e-96ba-acd4a20c6c51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:to="loc_us-gaap_LeaseContractualTermDomain_977d1ce1-b4e8-404e-96ba-acd4a20c6c51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f7e7a7e0-baea-4000-accb-a45707ba9ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f7e7a7e0-baea-4000-accb-a45707ba9ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TerminatedLeaseMember_2a2c4c7c-1327-4a82-ba10-4ec46421ad41" xlink:href="advm-20211231.xsd#advm_TerminatedLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f7e7a7e0-baea-4000-accb-a45707ba9ae6" xlink:to="loc_advm_TerminatedLeaseMember_2a2c4c7c-1327-4a82-ba10-4ec46421ad41" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i774c445efa0d4b8ebafb132506765ec0_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc78d4c-b3ec-4586-91f0-6da30749546e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc78d4c-b3ec-4586-91f0-6da30749546e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_db25c38a-b83f-47d4-aa4d-e4f86a43439f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_db25c38a-b83f-47d4-aa4d-e4f86a43439f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a2f2c38-3c70-4e5c-a2b7-1540d7ef615c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a2f2c38-3c70-4e5c-a2b7-1540d7ef615c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f5e8d1e-6d60-4063-9a33-b003022d7808_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2f5e8d1e-6d60-4063-9a33-b003022d7808_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e58b1d8d-f8a5-4e0d-84e3-f8732649f172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_ComputerEquipmentMember_e58b1d8d-f8a5-4e0d-84e3-f8732649f172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c91e44c6-1f25-49f0-a7ff-0f36740f3ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_EquipmentMember_c91e44c6-1f25-49f0-a7ff-0f36740f3ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_49d2a882-e3f1-4d5b-bc02-b2a2b5d08a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_49d2a882-e3f1-4d5b-bc02-b2a2b5d08a2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b92c7c47-17a7-4fc8-bbdc-b85ae902c8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b92c7c47-17a7-4fc8-bbdc-b85ae902c8c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_70b426bd-69e1-4d0c-ae15-a2f961d2249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_ConstructionInProgressMember_70b426bd-69e1-4d0c-ae15-a2f961d2249c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansAdditionalInformationDetail" xlink:type="extended" id="i436b017797c64d2e8068c1f3f23be441_StockPlansAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_13e3ee64-52f3-4557-a761-50e10dc8bf7b" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_13e3ee64-52f3-4557-a761-50e10dc8bf7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3ae92794-5def-4a10-91d0-1a4a0163e232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3ae92794-5def-4a10-91d0-1a4a0163e232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2142f939-d5d0-4ddd-8740-76ede8cdc855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2142f939-d5d0-4ddd-8740-76ede8cdc855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_57d62d97-a31c-4d74-85db-c046ce209e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_57d62d97-a31c-4d74-85db-c046ce209e00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc4dcd3d-560b-473b-96d9-1334fd4d42ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc4dcd3d-560b-473b-96d9-1334fd4d42ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_69b5196c-f072-4f08-9bb0-5f34a0cb57c2" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_69b5196c-f072-4f08-9bb0-5f34a0cb57c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_53b3d754-3a3d-4d7d-a8c0-6b0698d1c61f" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_53b3d754-3a3d-4d7d-a8c0-6b0698d1c61f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e4dfbe6-abd7-4f22-98b4-17775d81e64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e4dfbe6-abd7-4f22-98b4-17775d81e64b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e5bc5b4-16d8-4637-8cb3-e54221ed0224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e5bc5b4-16d8-4637-8cb3-e54221ed0224" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fb45ea6c-e995-4c3e-80bf-025c03b9e0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fb45ea6c-e995-4c3e-80bf-025c03b9e0a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6782aa6c-9b6b-4a0c-b246-99cb3bfc82b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6782aa6c-9b6b-4a0c-b246-99cb3bfc82b1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67eaffbf-ea7a-4b88-9f61-720f44db9660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67eaffbf-ea7a-4b88-9f61-720f44db9660" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69f06af7-f2f3-420e-8c57-4bdde8ade766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69f06af7-f2f3-420e-8c57-4bdde8ade766" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e7249a6e-59f0-4f85-98c6-9ff3fbd7f1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e7249a6e-59f0-4f85-98c6-9ff3fbd7f1c5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4b3c04f8-8c11-43f0-9f56-fd32e606043a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4b3c04f8-8c11-43f0-9f56-fd32e606043a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_39b36811-813d-47de-9bed-38b9bac95c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_39b36811-813d-47de-9bed-38b9bac95c1c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_9cd66f9c-9b2e-4b34-a7d9-9fe174884a48" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_9cd66f9c-9b2e-4b34-a7d9-9fe174884a48" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_397e521a-ec21-49b0-8d90-6c35243959ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_397e521a-ec21-49b0-8d90-6c35243959ea" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_7d6c4a97-7e3d-47ec-aca8-031e01bae543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_StockOptionPlanExpense_7d6c4a97-7e3d-47ec-aca8-031e01bae543" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1ad915b7-7806-4693-afdd-859152453d73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:to="loc_us-gaap_PlanNameDomain_1ad915b7-7806-4693-afdd-859152453d73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:to="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_139deee9-a3d9-4277-902c-6d0245993e8a" xlink:href="advm-20211231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_139deee9-a3d9-4277-902c-6d0245993e8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember_bb4278bf-1730-41e0-99e4-aa3309e67c20" xlink:href="advm-20211231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandSeventeenInducementPlanMember_bb4278bf-1730-41e0-99e4-aa3309e67c20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_62da556f-5905-467c-8446-287c43db2388" xlink:href="advm-20211231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_62da556f-5905-467c-8446-287c43db2388" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_81076fc6-113a-4c0f-a790-f5ed44689323" xlink:href="advm-20211231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_81076fc6-113a-4c0f-a790-f5ed44689323" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92f75639-f9cd-47f7-886b-347778015605_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92f75639-f9cd-47f7-886b-347778015605_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember_e298bf0c-e8a1-4883-8929-f7b0116e35eb" xlink:href="advm-20211231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_advm_StockOptionsAndRestrictedStockUnitsMember_e298bf0c-e8a1-4883-8929-f7b0116e35eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9605c5bb-8494-4fbc-81fc-14a9d7bac2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_StockCompensationPlanMember_9605c5bb-8494-4fbc-81fc-14a9d7bac2a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f276739b-7b4c-43ef-8ddf-cb207b202137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f276739b-7b4c-43ef-8ddf-cb207b202137" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_5600b538-f0bf-4605-a980-abd7755bdc60" xlink:href="advm-20211231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_5600b538-f0bf-4605-a980-abd7755bdc60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8841555a-fa24-4af9-85fb-f180cb5326b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8841555a-fa24-4af9-85fb-f180cb5326b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5932ac66-9198-4da3-a078-bafa0d565893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_PerformanceSharesMember_5932ac66-9198-4da3-a078-bafa0d565893" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_472de4fc-226c-492c-9398-b77694ee04a9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:to="loc_srt_RangeMember_472de4fc-226c-492c-9398-b77694ee04a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:to="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b967afc-249c-4632-a281-ed467419a064" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:to="loc_srt_MinimumMember_9b967afc-249c-4632-a281-ed467419a064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a0ee98ad-72f1-4e19-ae0d-5bd372ec0b3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:to="loc_srt_MaximumMember_a0ee98ad-72f1-4e19-ae0d-5bd372ec0b3c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail" xlink:type="extended" id="ia19e59d13ad94eb7bcc698a4ffa25e47_StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5fdb8783-38df-4e4c-8a6e-4be3cb5cf7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5fdb8783-38df-4e4c-8a6e-4be3cb5cf7c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7b0cee7-7c85-44ac-bda2-e53f562f3159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7b0cee7-7c85-44ac-bda2-e53f562f3159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_460c8742-1466-4990-8b07-fb1c0315de5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_460c8742-1466-4990-8b07-fb1c0315de5a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1de0446f-bbf7-4dd2-b5e5-ca977c062ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1de0446f-bbf7-4dd2-b5e5-ca977c062ef9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:to="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a305df61-f0ac-4784-b1a7-8f1f87213cd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a305df61-f0ac-4784-b1a7-8f1f87213cd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7b8b29af-4734-4cee-b068-f264d0bd7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7b8b29af-4734-4cee-b068-f264d0bd7ed4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_22050ee3-9677-48ec-97db-43bccc6a9df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:to="loc_us-gaap_EmployeeStockMember_22050ee3-9677-48ec-97db-43bccc6a9df7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended" id="i362f52184b584342a67cd197b30a7d7e_StockPlansSummaryofRestrictedStockUnitsActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_faa1316e-02c4-431b-aa53-772e7940e864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_faa1316e-02c4-431b-aa53-772e7940e864" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a6272a74-5fdc-4588-a8ea-a37c8b65bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a6272a74-5fdc-4588-a8ea-a37c8b65bc6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fd8f7ee1-9e10-4fe4-98d5-c957fd564d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fd8f7ee1-9e10-4fe4-98d5-c957fd564d13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ded1b63-482c-43b2-bf98-d45866cecb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ded1b63-482c-43b2-bf98-d45866cecb12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55562694-2a6f-49b6-828e-086d879bd5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8c67a70-1bac-4a7e-9e02-651ff3bc80bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8c67a70-1bac-4a7e-9e02-651ff3bc80bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f77679a-748b-47eb-a7b7-315692c7f612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f77679a-748b-47eb-a7b7-315692c7f612" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b02cbf7e-1875-432e-a725-506e490b38d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b02cbf7e-1875-432e-a725-506e490b38d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a224b97d-8935-4723-be50-f566798883b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a224b97d-8935-4723-be50-f566798883b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16c492f4-0a56-4c8b-90d1-c74549c9af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bf9902b5-ebcd-4229-a11c-f8deafce448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bf9902b5-ebcd-4229-a11c-f8deafce448f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92d2eefa-145b-4efe-908b-3740b97d5986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bf9902b5-ebcd-4229-a11c-f8deafce448f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92d2eefa-145b-4efe-908b-3740b97d5986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:to="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16209eab-73bf-478b-a047-41048017ed91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_16209eab-73bf-478b-a047-41048017ed91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44830091-ffd7-41de-89b5-0054a4cc779b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44830091-ffd7-41de-89b5-0054a4cc779b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0d05efc4-61f8-4da1-9ef4-28d8d56e18ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44830091-ffd7-41de-89b5-0054a4cc779b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0d05efc4-61f8-4da1-9ef4-28d8d56e18ba" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail" xlink:type="extended" id="i41813621b6094a8f87eba644ad9bdf75_StockPlansStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee592a06-4a57-4a5d-b16d-99cd8a7d3c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b90270b-7c4d-45c4-9d54-3bfd16a47120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee592a06-4a57-4a5d-b16d-99cd8a7d3c9b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b90270b-7c4d-45c4-9d54-3bfd16a47120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee592a06-4a57-4a5d-b16d-99cd8a7d3c9b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_62a3f00f-21b3-4654-9652-cff7fb5a860b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_62a3f00f-21b3-4654-9652-cff7fb5a860b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebcda3aa-9f6e-41f6-807e-5b465f725137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebcda3aa-9f6e-41f6-807e-5b465f725137" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8b4cf5e8-314e-44df-95c1-90217035d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8b4cf5e8-314e-44df-95c1-90217035d0a8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="ifd6f9533e7d24ed39fb3bfe32f72ec4b_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:href="advm-20211231.xsd#advm_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc52262a-f43d-408a-b15d-87c3eb477afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc52262a-f43d-408a-b15d-87c3eb477afe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f04ba04b-8f3b-481b-a5ed-d814553a486d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f04ba04b-8f3b-481b-a5ed-d814553a486d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e87ae889-05ab-40e0-aa1f-0c67f7b2093e" xlink:href="advm-20211231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e87ae889-05ab-40e0-aa1f-0c67f7b2093e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ec02337c-63bd-46b0-85fb-c2268a98f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ec02337c-63bd-46b0-85fb-c2268a98f3e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fcb6fb3e-3415-40a0-95a9-94542348b15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fcb6fb3e-3415-40a0-95a9-94542348b15a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f41be3d7-d3e3-4e79-a958-7e96bfa924ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f41be3d7-d3e3-4e79-a958-7e96bfa924ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ee197aa9-6485-48e9-a322-18c091803587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ee197aa9-6485-48e9-a322-18c091803587" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:href="advm-20211231.xsd#advm_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_58bc0a3d-b9cd-4050-9280-d7d4ff72a703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:to="loc_us-gaap_DomesticCountryMember_58bc0a3d-b9cd-4050-9280-d7d4ff72a703" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1b765dbf-a1e6-4d0c-8202-d9264bb645eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1b765dbf-a1e6-4d0c-8202-d9264bb645eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_90fe098b-28cc-4887-b39b-fe7edc8df2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:to="loc_us-gaap_ForeignCountryMember_90fe098b-28cc-4887-b39b-fe7edc8df2c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_585f796c-c202-4830-b715-95f51293f3e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_585f796c-c202-4830-b715-95f51293f3e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e318c529-1173-4f4c-8264-efe7053562f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e318c529-1173-4f4c-8264-efe7053562f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_94fc60a2-970e-4e16-95ca-189b6599103a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_e318c529-1173-4f4c-8264-efe7053562f0" xlink:to="loc_us-gaap_ResearchMember_94fc60a2-970e-4e16-95ca-189b6599103a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" xlink:type="extended" id="i37c94e2c230e4b4caa47f5034071a143_NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3a2a184f-3ab9-4fe2-b0f0-d849879588b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35127b65-87a7-4239-8864-535e4956e824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3a2a184f-3ab9-4fe2-b0f0-d849879588b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35127b65-87a7-4239-8864-535e4956e824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3a2a184f-3ab9-4fe2-b0f0-d849879588b5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54cebb8b-2004-4734-89d6-88e9655a7f35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_54cebb8b-2004-4734-89d6-88e9655a7f35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_84d461af-14dc-4c36-b644-a17dbf02c673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_84d461af-14dc-4c36-b644-a17dbf02c673" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8b6fc554-dffb-489d-a948-184c39278de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8b6fc554-dffb-489d-a948-184c39278de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5600e2de-530c-46a9-87b7-70671f766835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:to="loc_us-gaap_EmployeeStockMember_5600e2de-530c-46a9-87b7-70671f766835" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>20
<FILENAME>advm-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1a8e5b7c-bca3-4165-b4c0-12c52c6244d9,g:f2d923c2-de02-4da0-a578-7d0cd54aca4d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ce8b3b1a-71a5-46a5-a96e-3b658c909916_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c5ca57c1-856a-4bb2-b749-4c86ced7f098_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d0454874-d5c1-4ecc-8089-92b3b1528033_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_8da9d350-b727-46d8-bd73-0300788cbede_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1198b7f4-5fb4-4fa9-81eb-fcde049395dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_c2a98b71-84bd-4a32-837b-a856008185ca_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3e814818-2b52-4e75-8ffb-7ff7af245c3a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9cae4677-fc87-4002-9cb8-91e04d17a63f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_31117610-a195-47ae-9907-011fff82ae1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c136bbfb-654e-47a4-95e7-4d1680a1b198_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_288005a7-b07e-417b-9195-6a0a524f8489_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f13cd61d-fd4c-4b26-b9b8-9ad288f189e5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_01a77c2a-b3d7-49e9-a8d4-3a2c8ec5f482_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_e6644680-0a68-4732-8f75-5b9ec006d0c8_terseLabel_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities with remaining maturities between one and two years</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_label_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_documentation_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:href="advm-20211231.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:to="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7360a2a6-7a97-44bf-ad44-afab58bc43ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_dd0a7ced-3fad-4aea-89e1-8d442afa4d07_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_74421181-9020-4daf-a461-df333c3e0d93_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cfd4fcce-fe45-47f4-91ee-8c338ca1db3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6fccdc8c-3576-4d2b-97ed-6f553a95f901_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d5556f63-b694-40a8-b425-81f17469945e_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_932f4d50-45b5-4ee6-ae75-c1f5518b314d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59a8f31c-fb40-4bdf-9b89-49ea181f47f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e9dd2708-e302-4d1d-9d16-7df101bdec27_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6de2cbdb-f6d1-4ec0-a27d-aa73e19526ae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_5672c943-7286-408e-a834-8dcba6edda67_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_702951d6-bafd-4b40-a388-9d90d82dac87_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_21601e5b-47f9-45b6-a1b7-904caa924a5a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_9b86bf39-406a-46ef-960c-cdac75154c0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_343acb4e-164e-4988-8883-4536a90fa1e4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f98a5b57-11c7-4a7e-8291-44e6bc98db21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_dc8019f9-ae4a-42c1-b4e6-b86c4378fa4e_terseLabel_en-US" xlink:label="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of right-of-use asset on lease modification</link:label>
    <link:label id="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_label_en-US" xlink:label="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Right-Of-Use Asset On Lease Modification</link:label>
    <link:label id="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_documentation_en-US" xlink:label="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement Of Right-Of-Use Asset On Lease Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:href="advm-20211231.xsd#advm_RemeasurementOfRightOfUseAssetOnLeaseModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:to="lab_advm_RemeasurementOfRightOfUseAssetOnLeaseModification" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_3e0a1131-955d-4367-ae70-97614d9982a8_terseLabel_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Plan</link:label>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_label_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Seventeen Inducement Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandSeventeenInducementPlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand seventeen inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember" xlink:href="advm-20211231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandSeventeenInducementPlanMember" xlink:to="lab_advm_TwoThousandSeventeenInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b6ee80d5-0016-4bc7-98d7-5d920d10e0dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_34737f27-dea0-463d-ba9b-bdcf7161cea9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of leasehold</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLeasehold_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLeasehold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Leasehold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLeasehold" xlink:to="lab_us-gaap_ImpairmentOfLeasehold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c221d44c-5a8c-4a27-868c-fd2ad1805aa3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_8b88fb31-b3f4-4bbf-ac3c-31efc9816d3e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) related to prior year tax provisions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e41482d0-2468-46d6-8cd7-44745404b29b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_1a37ea00-96f7-49c4-911c-78bf7b1a38c1_terseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Operating Lease Right Of Use Assets</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in operating lease right-of-use assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:href="advm-20211231.xsd#advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:to="lab_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_e5cd21e8-2549-44e6-8f9a-77ca84edad51_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_80005bcb-971b-4b32-9400-bd5c4128c20a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_17c0b3e2-dc6e-4d0f-9a1a-ac12d864257f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average IBR</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_5d260df3-070f-46d0-9603-583cdedd94b6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_9ed29609-7eee-4ffb-b007-02a0a6ccb007_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ba5ca158-345f-4f46-b18d-aff06836e2a9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9c8d9009-edde-49ee-90aa-245f076ca1dc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_fd58afac-a5ce-4472-b782-4499d1e86dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair values of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e3eb05c2-022f-41df-8c6a-d4a9228af1ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c0ff30da-2388-4d00-9548-352f87f4eef4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_8c223fce-e19d-461a-802e-f50526d67f42_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b445a1d0-d3e7-48f2-8710-d7a23bac4567_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9f56d847-83dd-40c9-8951-67c7b2f8d4cc_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_65727582-3d9b-4bbc-859c-cbaf35b030ce_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_f1149be9-6f8f-4496-84b3-ad32d06b964f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contract Life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9818dab7-8209-4e48-835d-00f8f3a79137_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_456b881e-ccda-4988-953a-80eb98795420_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_cf3be274-397e-4de5-8f49-1d4ccf4dfe27_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_54027c00-fc7b-47f6-9768-3e450ad12132_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of performance units both performance and service vesting conditions (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e42b3388-ec05-4321-ab43-c4c50df5cbf3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_64f76247-d04e-4ae6-9258-a79f09d99fcb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_59fbbe0b-9afb-47d8-9cf5-a86253e973a7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a43aa062-d089-4f91-969a-ac70e7c55258_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cd2c2352-2574-4363-bacb-1cdf6210bac5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1d491086-fc52-4ac7-aacc-23e04368a9c1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12220462-6b98-40ed-8fac-5342673eb023_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_b5dc0d54-3df2-4fd4-b71b-6e2fe7bc5b4e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_f1e3ac6d-9c5a-4dd7-988c-491403e0e33d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ced8cdc5-69a2-494f-832d-f7339db289c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_068605f6-4d18-40f7-9d6b-3318d6a087d4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3ff95df5-94e9-4c12-be1e-944ba970d2a0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets in accounts payable and current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cc10f55e-6d01-43b1-9033-38b2f3889bc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_26156546-cc68-40a3-a888-6b20e108a36a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_1f0446c2-e7d6-4005-9538-fe653013232a_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_e571dda6-7990-49d3-b4f5-9c6917bc241e_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock surrendered for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e08aa00a-084e-4e4b-ba06-e199c6fbb8e4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_149162b2-de57-41e3-a658-34b4545534f9_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:to="lab_advm_LesseeOperatingLeaseNumberOfRenewalContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_de654a37-9fb9-4888-afc7-94b45e60105e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_9198da87-6d13-4fe9-8334-175cc606876c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_622238c7-5a1a-47d9-8c95-ae296f437b7b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_410bc482-9548-470a-91e6-5b99db5dd8b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_d70c9764-61a1-4840-b9c7-9478ebc398e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6c92cc6d-b134-48ee-ae40-5076aa196137_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_58615d6f-d9f6-4f5c-aeed-26e9614faf00_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_26e96f8b-329e-4262-8410-9a40c0128ce8_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5aa1250d-e856-4ead-90dc-d4d8e9b13a9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c3a1bf23-630d-4958-be5d-117c13c16492_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_WarrantsIssuedDuringPeriodShares_b4bc1dfd-fe9a-4e79-a91b-7bb391985553_terseLabel_en-US" xlink:label="lab_advm_WarrantsIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon net exercise of warrants (in shares)</link:label>
    <link:label id="lab_advm_WarrantsIssuedDuringPeriodShares_label_en-US" xlink:label="lab_advm_WarrantsIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued During Period, Shares</link:label>
    <link:label id="lab_advm_WarrantsIssuedDuringPeriodShares_documentation_en-US" xlink:label="lab_advm_WarrantsIssuedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_WarrantsIssuedDuringPeriodShares" xlink:href="advm-20211231.xsd#advm_WarrantsIssuedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_WarrantsIssuedDuringPeriodShares" xlink:to="lab_advm_WarrantsIssuedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_e3b101f1-9d03-4cc7-9e96-8283a634b56b_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time share based payment charge related to cancellation of unvested stock option of CEO and directors</link:label>
    <link:label id="lab_us-gaap_StockOptionPlanExpense_label_en-US" xlink:label="lab_us-gaap_StockOptionPlanExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock or Unit Option Plan Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionPlanExpense" xlink:to="lab_us-gaap_StockOptionPlanExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ca2946ed-19fe-43be-8c2d-7921d9c6df6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1e550de5-ae15-46ff-be9d-ba07bf044f2d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_de72a4dd-52a2-4308-a149-9953dc64f52d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_929b5a5f-f871-44a9-b1c5-a4275defcdf6_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock surrendered for taxes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9e677e02-91f7-4ff4-b493-c0fc61412a26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_3ad00855-30c1-48ad-b2e0-3ac8ab91b30d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_badccf50-e06f-492e-851c-b7fc916fe53a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_9114513b-f5c4-4bb1-bc62-e0ffdee0fd24_terseLabel_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options and Restricted Stock Units</link:label>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_advm_StockOptionsAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:href="advm-20211231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:to="lab_advm_StockOptionsAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_293d0ee7-0b1c-4bb1-9b76-25640b9d46e4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6bafbc8c-7237-4c91-ad2a-e81775269fd3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_ad134acb-3235-47e1-a79c-dc130be08f87_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_a309a840-0446-4d5b-bd5b-7e11843513aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_f4465852-a764-48be-b2ea-4d0f9a315002_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_b0782983-6422-4dfc-bcf4-e7ddeb8bf48f_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvement allowance</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leasehold Improvement Allowance</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Leasehold Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:to="lab_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_708757fb-7ce1-4804-a327-0fe43b5d43c2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_03c99930-84bc-4e50-8294-5829829561c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_26f92f1d-8c47-45f7-b09d-240a5c71cbef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_de73842f-b38f-4b79-9d31-162691df872a_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e90279d5-a5f2-4fb8-8531-fc561b227bd4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_5b88c754-0e24-45ad-a55d-ad1e5ee46072_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_bfc48bdb-c59e-43ab-8cc0-c8c0c6b2e3b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_06460c9e-ccae-4cbf-9523-2996c8b44555_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase related to current year tax provisions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_02e6204c-e5ae-49e8-9340-469b634b52a5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_856d4b20-c895-4858-bf32-d0649b6249fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_22fb6f7f-71b7-4239-8331-c3ebafc3ea76_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_426dabbd-8fa5-4aeb-bc77-38b64b6a9523_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b3d69758-0888-4443-bb17-b73123981802_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_99cce40a-bb09-4ef7-952b-e1fa50930c84_terseLabel_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)</link:label>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_label_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options [Member]</link:label>
    <link:label id="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options And Non-Qualified Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:href="advm-20211231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:to="lab_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5f605e57-3a68-4bb6-9136-9e016e7430ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_91b75496-5d5f-4f1e-b415-f091f894391f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_673f69f2-6a3d-422e-a615-73eb2615c808_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in shares issued</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Increase Decrease In Number Of Shares Issued Percentage</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e86aa970-7bd9-4814-9e1e-33edcb917ea4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b9d225b-c73e-40e6-94fe-c75f9f7aa3ed_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8ec6a976-e1ea-4f11-8abb-1a5fe1d121a9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, if recognized would effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_41c4084c-3794-4a37-b8ba-4643b4994091_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2d30daea-0d07-46ad-bfff-d4a351743e97_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_b968193e-b063-4b30-8bbb-50ef7ddb4914_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ebc5b96c-8d2d-489d-aa39-b39c31854390_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2910015f-9b43-4c36-8e37-93d97c159666_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_9ff0080f-c8db-43f3-aa45-cc81683ef60f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a013b02f-e56c-4736-b136-fffa3a1d044b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fc696446-c96d-47be-989e-83ea4c8d04e2_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2b95464c-0831-47b8-a9fe-6f7dd707bf53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_26fbefa8-a7dd-4413-8ba0-43b44688f43c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_0aebf174-d94e-4fd9-93a6-b9f31c82d98c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f9547ca4-dd82-4b96-ba9d-8d7237fad152_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits as of the beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_28a86c14-41cd-4003-b6a9-d3742017b6ae_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits as of the end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b4618b0e-6c25-4f51-bbf3-a8eac69769ff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_fda29740-da02-43b3-b1e5-2283f76a5fd6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_4e109ad5-b3ca-4ca3-85b9-547b749cf1c5_verboseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d56eda57-e5ab-4d0d-85ac-d0c89174187b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_169d2946-28b1-481d-8d1a-63f9fa0b7349_terseLabel_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan And Inducement Plan</link:label>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_label_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Plan And Inducement Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fourteen plan and inducement plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:href="advm-20211231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:to="lab_advm_TwoThousandFourteenPlanAndInducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_38cd4adf-0c7c-4c42-bc69-899d1c3b3bbe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_6811f8e6-89b0-4cac-9526-035bb10536e0_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_acb277b5-3dc0-47f8-a917-0952b785bab7_terseLabel_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_label_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc [Member]</link:label>
    <link:label id="lab_advm_LexeoTherapeuticsIncMember_documentation_en-US" xlink:label="lab_advm_LexeoTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexeo Therapeutics, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember" xlink:href="advm-20211231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LexeoTherapeuticsIncMember" xlink:to="lab_advm_LexeoTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_c9ede472-b847-40d5-9794-e50a353ed408_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_70a62a86-709b-46dd-8e11-a46a5e87a4e8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_cea90c06-e301-4604-96f7-2774edc73010_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd4c05b6-2bde-4322-837c-91f29be89764_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_bf848e21-b6aa-4e21-a545-676588fb1c24_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_3ad6f95f-6a31-469a-83a7-301fc36e4953_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_b7cf8044-27d0-456e-9ce9-2fe6840cf406_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_b46ade08-5fc1-4412-bd0b-3cf3fe46eafe_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_f9da169e-2523-48f9-a2f6-8271d4bfa204_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_18c802a7-d84f-4afd-8a73-53159f755413_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Provision (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_51dfd4e6-2b3e-4702-b5a8-376f3a1e075b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_47ccd3b8-c353-40e9-9a95-b7db043d7662_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_635f8d52-6ed7-46d3-a852-10b5a7006be5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_680bbbd1-8c53-4e26-b87e-98e5da57b4f5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest or penalties related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_410a1566-2beb-4023-8ee5-e0dafd5b7b26_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7a96a23f-e956-47ae-9ff6-1949939dfdb2_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce2b418f-66c7-4aa6-a528-6ac8dacd014e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_6cc89a32-d96e-4207-ade4-3cf1f352d67c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_77411d03-3c15-424f-80ef-3afdde9811b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_d0f981d9-f5e1-4397-8389-c273bc33bee0_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d869631d-ebe9-424e-82ae-b529b8fa6561_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TenantImprovements_9d3d124c-7400-4ea2-9bb1-8f67b7d6c24f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Tenant improvement allowance</link:label>
    <link:label id="lab_us-gaap_TenantImprovements_label_en-US" xlink:label="lab_us-gaap_TenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TenantImprovements" xlink:to="lab_us-gaap_TenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_08a4f137-03cb-443e-88a4-67564499b037_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_28dbb54a-9e2f-4763-8971-873849dc2bf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7ee7f480-ff46-4173-9178-b53284554e9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2021: 98,381 and 97,549 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_11030d10-8590-4ef8-8841-9b908cdd9d6d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d359b7d2-b049-43fb-b1f4-ab02810998ff_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_b399bdba-4154-45fe-a4ed-ff2c4cb4058f_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_label_en-US" xlink:label="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Change In State Uncertain Tax Position</link:label>
    <link:label id="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_documentation_en-US" xlink:label="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation change in state uncertain tax position.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" xlink:href="advm-20211231.xsd#advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" xlink:to="lab_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_31e0e7de-6172-430a-84cb-ab6f49391328_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation, weighted-average period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a63e8dae-dd38-4d8d-9078-d0b410f79966_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_58daaa27-4f4b-49e6-96ca-4f74b62fa871_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_bc266312-ad4b-4e24-b92c-bca1595d19d8_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ff620bef-24ec-4a44-9f32-04190bea069c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3b32eec6-0e42-40f7-9bd1-13c14806ebaf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6085ce10-af11-425e-9001-6e846cf04f1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b8d24497-6af8-43e3-9190-2b886785addb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_e72171e2-2971-43c0-82f0-379865581c83_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b325222d-bb60-4d17-bae7-9da9c5acea41_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Option Issued Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_046d2964-3038-4401-a230-d1b4f4fc450f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7dae7524-293a-4943-868b-ee0509fb140d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_91b18256-ce61-440f-b75b-d98ac374238a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_228240ca-7bac-46eb-bf03-5d1768302ecb_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9fb1f9af-62b1-4193-a2c6-c6dab34505a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1800e282-fd0e-49a1-b5b0-663442ca3a39_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Present value adjustments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_bbe42977-468d-4c22-98d3-67e07ef6e92e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_eea16d12-ad63-4dd7-84fd-927585ab64b0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_18373e0a-4644-4324-9395-8a14f1ab0f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3673f976-1a33-4339-952b-d83e11cd5a05_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_993f38bd-8bf1-4195-a450-a35b8abda6eb_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Savings Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_25d79e14-0391-4e07-b1be-f42408e8c964_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_5af8cbfe-800d-4632-abce-5888c7399df2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_15b3375d-91f2-45cd-ba01-ef8c038e506e_terseLabel_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Award Plan</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:href="advm-20211231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:to="lab_advm_TwoThousandAndFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_e1d307c0-34a7-4328-925c-c2ada8d0ecd4_terseLabel_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="advm-20211231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_advm_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d55d7dd3-ca75-41c2-9c10-6b9af654533f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_8aa935be-5923-478f-aeb9-424c1882f732_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Payment Receivable</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_62cd6da1-ea90-4dfc-87eb-1bf1316f6a55_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1ff18546-229b-406f-b738-0e0d2c27d79b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_dc557360-623d-4d1e-9a2d-bef6cdb5f41d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_142633d7-6802-4b48-bac0-9f41700172e1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_7a33342a-8073-4613-bca8-04844c37c71e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3f923d84-4c2c-47ae-bbd0-9cbdb12ab6ae_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_0a2cef45-98df-4257-8d4f-62c6143a16e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bb84368d-f4d3-44b7-8fb5-695038788de5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_2b93486a-b5f5-491d-8a91-85b9afb68b71_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution by company</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_fa5e22d7-3b8e-409d-b25e-4a8ff1ba3661_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0e6c8b33-0bb2-450a-904a-084f913bd2eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5b363fce-5170-46d6-a3d3-b0edb38f67e6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a7fc1279-fa88-4710-b2c2-d537e9234b9e_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_72cc237c-fba3-4ac3-ac1a-44066ed86b24_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4b95eeda-b87c-48ee-88b9-486003807914_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_1b015f2b-357a-4100-9db7-ac46d7b48f9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_054960ad-cc5f-42af-a908-efcb3f680aa3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6c39bc73-d5a6-42c8-9251-7b17a0a07462_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_9c7cef5e-de14-41f1-8259-381e4e37d2bc_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of BPI loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedNonclinicalCostsCurrent_b4d2dcf8-f96a-4e50-b469-432e8cde9643_terseLabel_en-US" xlink:label="lab_advm_AccruedNonclinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued nonclinical costs</link:label>
    <link:label id="lab_advm_AccruedNonclinicalCostsCurrent_label_en-US" xlink:label="lab_advm_AccruedNonclinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Nonclinical Costs, Current</link:label>
    <link:label id="lab_advm_AccruedNonclinicalCostsCurrent_documentation_en-US" xlink:label="lab_advm_AccruedNonclinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalCostsCurrent" xlink:href="advm-20211231.xsd#advm_AccruedNonclinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedNonclinicalCostsCurrent" xlink:to="lab_advm_AccruedNonclinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3e2aee09-71c1-4922-add7-827f7d6f2fb1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses, other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_def082cb-6d6a-45d9-9397-06d8082aabab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3d50bc12-d700-4ffd-83da-d326eff3a66b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_b137c48d-bfe6-433a-980c-ae521432a4f9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7ddd0474-0fea-42fa-b71f-d754805b58e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_77ddba98-5dbf-4747-98d7-0d1093779a94_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and short-term investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20211231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncentiveToLessee_3a060220-3e07-4ca7-8a84-2a92cf32ff8c_terseLabel_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Lease incentive receivable</link:label>
    <link:label id="lab_us-gaap_IncentiveToLessee_label_en-US" xlink:label="lab_us-gaap_IncentiveToLessee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive to Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncentiveToLessee" xlink:to="lab_us-gaap_IncentiveToLessee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5a68f8a5-5730-4dc7-af46-60ea53a68ef4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0485d3c8-bd79-4d4a-850b-0644a821d576_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_832e9fbc-2545-4f49-b580-2534e031d352_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_38325551-357e-4452-b429-fc377b3e2fdd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_5943a0c9-87e3-46c6-a9e6-d789f31dd498_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_a6535c1b-c792-4334-a736-f0458fb2276b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3b5bbf99-0b89-4ec0-b36f-e2c88a431a6b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4a1dd630-ca65-441e-a603-e9eaf7f11501_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9dcef621-175e-4f57-b166-a297a7f9ee67_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8fbd884c-f38e-4945-b774-e09f671ab021_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_3f417d3f-ae7d-43f7-a99d-b510b7b60a4b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_edc41ad7-efef-437b-b197-4163da969cb8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Undiscounted Future Lease Payments under Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9d249654-976f-4c74-a677-c2e667c77e8b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_ad2f9563-0134-4d2c-a3a1-534425e0e42f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_7ce5c351-2580-4912-8fd5-9a1266456ef0_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_52bc8239-7201-4a3f-b7d3-a6b4ed7a1273_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_32f160d8-1248-4c20-bf20-bd37fa55b8aa_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8762b099-3b7e-491b-8eec-4d4abe83c851_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_2356dc59-7fb9-48d3-b1a1-5ca5b67c81e2_terseLabel_en-US" xlink:label="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in right-of-use asset and lease liability due to termination</link:label>
    <link:label id="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_label_en-US" xlink:label="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination</link:label>
    <link:label id="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_documentation_en-US" xlink:label="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:href="advm-20211231.xsd#advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:to="lab_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fbd88829-5738-401c-8ae0-82740d182035_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_41aaed9e-5959-4070-8bf9-6c14c23b982c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_3896064a-d840-4e53-a42c-f1c2c9a66891_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9452d207-93f4-43b5-94ee-036071af8adb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_68aa0d51-4ce3-4eb5-9f76-3ce9526888a4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_04f5ce75-6156-49cc-9496-b0654cd039f5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_5922dcd8-650f-469d-8a16-9e36f05b6f85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_4bff8940-691e-4092-b24b-5253f74f2d88_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk and Other Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_38f2e6fd-43ed-4715-84b4-9c220296ec16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_4be620fa-a74f-4780-8f1b-995fc4a32cc5_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_32018a48-0b05-42fd-a630-eb31d42ec859_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_b5ccdfb6-bd15-4216-b059-c6915c890d50_negatedLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other long-term assets and deferred rent receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deposits and other noncurrent assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:href="advm-20211231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:to="lab_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_255ae235-a990-4e8b-a05f-5b12d30e612d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of internal reorganization</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0a62b7ad-144a-4f82-ae55-05197622e0cf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7088a4a2-d1c3-48e0-bc29-675bf0359960_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_1981611a-daad-4947-9679-b1fc19946f53_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_5358157d-4d04-4d43-bd19-ea9023429c35_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c967bbe3-e59d-4367-b9b8-2cf4d80cf2b6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_31002216-d587-4917-a606-995063ea21b5_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8ac24098-daa4-4cbb-8cf1-c21adc6d6a06_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_845050b1-96a4-4770-b2db-3f47bf4fdd09_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_38fb34e2-792d-4306-97a2-25fa93fb2cb4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f84b3868-8327-4fd4-b206-a8378d26a515_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_60e5844f-1e0a-49a0-a016-631177eb86c8_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5cead943-2932-4af7-8923-457201b838b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_20ab45bf-983c-475a-be09-9bda0654c823_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3fbed066-b580-4b6e-abf3-307f484c7b5c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_d5d40b18-e080-492c-9ece-345b720ce5a1_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant stockholder threshold ownership percentage</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6d8773f6-3f1e-4f1c-8560-4dcc3e9e10d1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionExpense_247fe41f-90ca-4405-82f5-6c8580506dfc_terseLabel_en-US" xlink:label="lab_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accreted interest on BPI</link:label>
    <link:label id="lab_us-gaap_AccretionExpense_label_en-US" xlink:label="lab_us-gaap_AccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense" xlink:to="lab_us-gaap_AccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_adae7131-32e3-47ee-813b-7a8da80d39af_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_c3e37608-c548-4b92-8bef-c4c361d062fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dc46f6e5-f643-456a-8077-19c5a2a02a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled/forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d0a9dd92-68d2-43d6-b518-d0b6fc7a13d8_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_980b783d-938c-4d5e-bcb1-9360abb6669c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7d87ccbc-3960-4173-8a3f-fa28bb8df917_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_29585c82-811f-42b0-8d00-aaa05963d48d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_8cd3b3dd-c574-4302-98fa-2e99ac4a7888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e98166fb-bf48-4344-ae0f-789d66977929_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_08beda67-5197-4cfb-95a8-0dcc714a805f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ee402e9b-000c-49f2-9439-e5c6559ea92c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5efe49b9-ed99-4856-bb6c-b3f8fddd2644_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_d6b5b083-7822-4fab-aedd-249d574a7c09_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e714b2d6-9835-4536-8878-6f5e23cd12b1_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_66026256-d81e-47fc-97ea-a60277be212c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_f0287f71-1c91-4f41-94e0-ad99495a0d6d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5c478043-d519-40d9-b41c-31fc78308bd8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bb87d586-3588-4015-be73-88b8874afca4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_99172d1d-f118-48b7-94f3-2925cdbb76bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00d8a4b4-a176-48c6-a6c6-7528194b074f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_85cda524-7b27-46f1-824d-150b8e3e8018_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8b0ec8e3-debd-4c64-8ece-8d9ffafa7c00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a6fef103-4361-4cb1-9eb9-cc8a9b1ef224_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_e8a85c81-fbef-4d32-9f13-3cc62181f694_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in valuation allowance due to net operating loss</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f0601ce2-ce69-44f8-a766-9e3a0134c17e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_84de3787-40f8-4149-8216-fb57af2153a6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense related to awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e88244b-96f9-4063-873c-b36f44692e29_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_ad5e7fd4-dfae-468f-ba69-753294084f3d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_bfc23b66-ee94-4a88-ac35-546e889f8f38_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_6524ebda-3f0b-40f3-a416-9ecaaee3eba2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_d428f17d-9b14-4efa-bb28-e79abbaf6ff0_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d6014983-8e2e-4dbb-a9ba-25b3e3b6d63e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_27c7b402-5167-4555-8479-bbfbff74d58f_terseLabel_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand And Fourteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand and fourteen employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:href="advm-20211231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:to="lab_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6ae64333-5f7f-4cc9-a4a0-d373ed876563_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair values of options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_ade16c17-ab4a-4b3f-bf28-17e9fbd1022a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0436a6ca-a566-4122-8509-3c993a47da27_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ec993b05-ba74-4a53-893f-14881b25e8f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_9fb49331-6157-4793-8fe1-0350da6721da_terseLabel_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards subject to expiration</link:label>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label id="lab_advm_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="advm-20211231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_advm_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_c69bac04-c964-46de-a979-1a92f008c65b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals, reserve and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_b69a71b2-9de2-42f9-8e06-be2a5e306a5d_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OperatingLeaseMonthlyCost_2f213583-3d3d-4f3c-b77d-2b28fdfb6759_terseLabel_en-US" xlink:label="lab_advm_OperatingLeaseMonthlyCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, monthly cost</link:label>
    <link:label id="lab_advm_OperatingLeaseMonthlyCost_label_en-US" xlink:label="lab_advm_OperatingLeaseMonthlyCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Cost</link:label>
    <link:label id="lab_advm_OperatingLeaseMonthlyCost_documentation_en-US" xlink:label="lab_advm_OperatingLeaseMonthlyCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseMonthlyCost" xlink:href="advm-20211231.xsd#advm_OperatingLeaseMonthlyCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OperatingLeaseMonthlyCost" xlink:to="lab_advm_OperatingLeaseMonthlyCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ef9c292-a906-48ab-bba3-6a5a49ddd1ef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_64e8fbe6-0f92-43be-aede-399b1093f53e_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic tax authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxesTable_8dc29b13-98d1-4f24-8c85-68dc3d34b857_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_advm_IncomeTaxesTable_label_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_advm_IncomeTaxesTable_documentation_en-US" xlink:label="lab_advm_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable" xlink:href="advm-20211231.xsd#advm_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxesTable" xlink:to="lab_advm_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_84489068-b39d-4b0d-a737-ce1323911641_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_56b2f572-c24b-45fc-a95d-ae8673d9397f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fe558a31-6cdc-40c7-b531-387611767471_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee55e592-db90-467d-8958-841c2034cdbb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f216ff08-a01a-4cf4-8d26-e77f595a9b2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_04aa2a9d-a87d-4540-90f7-227dfeaa9d78_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_0debaaf5-50cd-4b3b-99de-08d3da42637e_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20211231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_ffc11ba2-a569-4437-b7e8-31a9a210e660_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b1d71ebd-e90c-4c97-863d-a0aa8d0daf67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0258aa60-f2c9-480a-bf04-3d4a362ab1a9_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_61272117-99ac-4328-938b-6232d2417ec9_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_78fcb70b-81ad-4bd7-9c1b-58c44a6e43d1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_39c73dfc-1438-43a7-a765-76ec5f1b4a4c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_feb05e8f-e831-4705-829f-5bfd2cab7a08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_42ae9b50-f1d4-403a-a3db-6402cf7385ae_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_db7aac1d-0353-4aa2-a613-b2dad4e4c0a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c15f7685-3e65-4d0a-bdf9-a469e806bc48_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_aa85c6f3-e924-4472-bd13-1c9ad2051e3e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_a9df79d4-ff25-4ef3-a583-520e27994777_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7cbcadf0-c137-42d0-a7b9-ecaaa1d5471d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_42cdab35-8b8c-43ef-818a-c8920a46e425_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fff1cbb3-8193-484b-aa6f-ad9d81f0fc5b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_bb15644a-009a-403d-aa3c-2ef0ee392c15_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1d44db35-0a6f-4d33-be0f-d5158b22b8a4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_b56f55fb-1d0c-4e9a-81b0-1252ca73247c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_493be910-1db5-469c-ad90-e713b0b442d2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0c00576f-2554-4009-a965-1738d02a16a6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_2a603619-2f3a-4ffe-9ced-560ab0465f65_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_eaef8cbe-e675-449b-8f70-e155f6f56784_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_15734bb4-b001-4a56-bf51-971ab1700ec9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_58f23df7-47ed-4b1b-be64-3711d7a6df9c_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, amortized cost basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_7e6e8f29-667b-4885-bca0-cbae12cadb42_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f86e3c88-2968-47fb-88e7-cb36040c488f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_f3c3acf8-54a2-49d8-b437-cbd67986a2c3_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6dba4fb1-cae4-4a40-a0fc-bd1cd5664beb_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_dd1fc4f2-5fff-4066-b9fe-8949edf16053_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_278f2d10-c21d-4589-b7c0-9da7b66fe5b4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_1e92ef33-17b6-4ed2-b4ec-e2fdd13d53d5_terseLabel_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_advm_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:href="advm-20211231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_advm_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_f2bd7952-e411-4404-8e32-2edcff839877_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_0ae019c4-e4be-4a1d-812e-da0a4f4f31b0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_98cd12dd-1744-43b1-bdf6-9a6d8b5777d1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5b6da815-03ec-4915-8acf-6ce5e7e21133_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_598da839-1365-4276-b107-2a6d507c68f8_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State credit carryforwards</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncomeTaxesLineItems_af00dc41-d9fa-415c-992b-7a82a6e2ad84_terseLabel_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_advm_IncomeTaxesLineItems_label_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_advm_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_advm_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems" xlink:href="advm-20211231.xsd#advm_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncomeTaxesLineItems" xlink:to="lab_advm_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_e1cd254b-5d46-458c-a2a0-edfc0ad65aac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_746b99b6-273d-42ea-9e76-8a89043851fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_6022643a-fb45-4613-9a5c-6065e6dfc8fe_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_8ecfa2c8-8677-4489-b77d-e66efbd7b964_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f11e326-e5b9-4fce-81af-b86f4467d280_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4f232323-3cc1-4df2-8834-645937c669aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (In years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_aadbb03b-3829-4f85-9295-8db9158a3c6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted to employees and non-employees vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a696a2e1-5861-4281-ba19-81ecbba9e4af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7fc73a54-dcfa-405d-8070-26d74c48c129_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d5e0da10-2d7b-4619-8e34-9f183a2cdbe8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_05f953eb-073c-4340-a110-4460c3380bd0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_e4554165-43f9-4452-8d33-9de5825cf482_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_32020ade-a781-4246-9c60-f9879194ef98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d56fcf2b-962e-4e0c-8326-5819ab1a101e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_04399719-81f2-41b5-834c-adf70c378bf6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_3b625d3b-985e-43f2-9425-88cb018f91f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0708990-415a-44ee-afdb-6311d6f3715d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_85f2870d-02b0-4eb1-b1d5-c47072a4fdd5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b1e4087f-07e0-4fd5-b122-b56f68745325_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_fc087288-02e5-4dd8-abbb-997ebf137998_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_44f1ad6f-d2f8-4559-869b-3984fee90fe5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_defe29df-90d3-43f4-8701-3f849fbf0688_verboseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c197d7f6-5035-4225-bf3b-38d3915f4835_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2492be7b-236a-45b3-935a-5c6e499dcde5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_68b95639-a772-4815-9dd5-807136199470_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_e53102e1-0fa2-41e0-a98a-d21ad1e95649_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_30e8853e-7052-4ca5-8760-824b22b40726_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash investing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_babae902-77c1-4895-b84c-ac41f2063e63_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e1eba31a-a73a-4886-a96b-3f9af97df482_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e871657e-4f2b-4603-88a9-d38608c13b95_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_b97c9854-9ff6-4bb7-bcba-5e1c04c79e78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plans</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_fbc45cc9-e864-4abb-a63a-4b175e4909c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a2468004-df00-44cd-8ba5-4182f8a6e6d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e0934f87-7325-494e-ac14-cbd8346b5562_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_275cc365-462a-4672-a8ce-58fad76b8e94_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_b0c5c34f-26d1-42e0-8262-f3318a54261e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_c8d7a10e-16dc-4306-b11f-e0fcca00b8c4_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award price as a percentage of grant date fair value, minimum</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_ae3b262f-d052-4fba-ae7e-5d6529716980_terseLabel_en-US" xlink:label="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_label_en-US" xlink:label="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical And Development Process Costs Current</link:label>
    <link:label id="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_documentation_en-US" xlink:label="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and development process costs current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:href="advm-20211231.xsd#advm_AccruedClinicalAndDevelopmentProcessCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:to="lab_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_5c54ce69-8c8c-429c-a2ac-579552debcc4_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_ab8c51a8-a421-4eef-9b8f-5d92c2f0d57f_terseLabel_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities other-than-temporarily impaired</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_label_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporary Impaired Investments Available For Sale Securities</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impaired investments available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:href="advm-20211231.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:to="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TerminatedLeaseMember_478b4be0-39cb-4d06-9529-f4b4a8a04e5c_terseLabel_en-US" xlink:label="lab_advm_TerminatedLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Lease</link:label>
    <link:label id="lab_advm_TerminatedLeaseMember_label_en-US" xlink:label="lab_advm_TerminatedLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Lease [Member]</link:label>
    <link:label id="lab_advm_TerminatedLeaseMember_documentation_en-US" xlink:label="lab_advm_TerminatedLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terminated Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TerminatedLeaseMember" xlink:href="advm-20211231.xsd#advm_TerminatedLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TerminatedLeaseMember" xlink:to="lab_advm_TerminatedLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_139be512-fa54-4e3d-a268-583f6d6fb23c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_69ad70ec-bd08-4899-adb4-9a54967c165d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_f38751c4-41f8-4c91-8686-e54700f32561_terseLabel_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease obligation</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_label_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Lease Obligation</link:label>
    <link:label id="lab_advm_DeferredTaxAssetsLeaseObligation_documentation_en-US" xlink:label="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets lease obligation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation" xlink:href="advm-20211231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DeferredTaxAssetsLeaseObligation" xlink:to="lab_advm_DeferredTaxAssetsLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_f7de28a3-944b-42ce-a28d-91dcdb9eda31_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets and Purchased Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_11857153-0736-4588-a5c5-ee4557f609fc_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_3f0caa5c-b77b-46a9-bc3f-6e2df4329e85_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_27c4ac66-d717-4649-a66a-c32208da5c84_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d8b6ae7c-d252-4dd7-944a-7fa8f11faa3a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c092f235-5547-4e82-8883-5ef07ec6e3cb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9c63b56f-0dc6-425e-81f9-e58c3976d711_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium and discounts on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8454559c-951b-426b-ae9d-61ff54727621_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8408df81-5ee4-4561-9164-ac3cf6c7f027_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_21bb1f9e-3fe1-4c1c-b3f2-e9474d0c197c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_e686e829-60de-446e-95a8-aabde3fd8bf2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_92163505-b99e-4f9f-ba47-f51793992651_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9d9f11cc-aa31-408a-bd46-a7acbbe10a09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_03ec3371-6ce8-43bb-9bc8-5d16eeaccbec_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_54819b1f-168a-40d7-9f2d-1681ce2eab0c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_25fc8da5-02a8-4a5f-b981-04942b2af479_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares available for future grant (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_10064934-b71e-4ebf-95b0-b27241943f17_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_fa8bea31-8626-48c0-a5c9-8d828ab8050f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d8a5abe9-0e60-401d-bdb0-c564a1609538_negatedLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AuditInformationAbstract_label_en-US" xlink:label="lab_advm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_advm_AuditInformationAbstract_documentation_en-US" xlink:label="lab_advm_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AuditInformationAbstract" xlink:href="advm-20211231.xsd#advm_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AuditInformationAbstract" xlink:to="lab_advm_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8590883a-8b6b-4a6a-8f5c-154781825c99_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_55ae35fb-9a43-494c-a70e-3149252591d6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e443b8eb-56fe-439d-a8eb-5b0fe2c13fe0_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4553f2e-5e9e-4283-9dab-77c7909990ab_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_6f8dae5c-6630-44d3-8a09-81d30b636a6e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7a680ef3-e2cc-4c64-956e-6834d96c3211_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_59921752-d14c-4618-b522-dbc3f5a99eda_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_17c28d81-c8ea-40ce-9b6a-11b050ef5652_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d3120ed6-9d1f-468b-b7f8-7648e10963f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d4de2930-6157-4d41-8e66-92f8a29de9fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_037f6dde-363c-40d6-9d1c-2565f410acfd_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_077e3568-1938-476f-8a97-0f6e3bd3be4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_2b50d0ab-e8fb-4a0f-8c05-caf0cebbd9b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b2106a3-0f02-4a28-a0bd-42c3fd433f15_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) by provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d25b9e6f-2fa5-4c78-8013-5fccf66c28cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5ab65d78-28c1-408e-a506-1061f4f5603b_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_f2d39608-c091-4766-985a-b2c406ab7de5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e1982153-5e8a-490f-8fab-e4d647776305_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1089f6c3-364a-42a8-9367-47d4c9ab9849_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_0660e788-6400-4ce4-b84b-2e51bf4437be_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2c80080-259d-4ab0-bc76-77c82fffb86d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9d7c9420-2647-4774-9d82-26f016c8591e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_45d1c192-b87f-4e46-9c3e-ad6777b61219_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_4793042b-1845-465d-9ba7-236cb9602765_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d4f624b3-1e11-4233-aefe-b3b828d2c638_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_059b4efb-49ab-42c5-9b6c-b3fdc01c3ef2_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_363ba7d9-b98d-450e-948f-7e7bfac9612a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7054a8ef-b7fa-4560-8257-5f8f3e0be91f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_3e723570-17f8-4f68-bc03-9380bcec15c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d4356ed8-46e1-40b6-a51d-b9353c52c2b8_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_01da6d95-3f5b-44bd-a559-1b923fe25b07_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_99b28add-9902-4614-bb08-c5c34437bd67_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseTerminationFee_429e01f1-10c0-4b75-9532-d0042deaf4ed_terseLabel_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease termination fees</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseTerminationFee_label_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Fee</link:label>
    <link:label id="lab_advm_LesseeOperatingLeaseLeaseTerminationFee_documentation_en-US" xlink:label="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseLeaseTerminationFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:to="lab_advm_LesseeOperatingLeaseLeaseTerminationFee" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4aedbab4-1e2f-42cc-948b-7d55e58180c3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_f5758720-6d99-4d87-8318-36bdc64f6c5a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent receivable</link:label>
    <link:label id="lab_us-gaap_DeferredRentReceivablesNet_label_en-US" xlink:label="lab_us-gaap_DeferredRentReceivablesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Receivables, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentReceivablesNet" xlink:to="lab_us-gaap_DeferredRentReceivablesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_6eeca2f6-06c4-4b70-8a22-b38c540a998a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_b96db66b-329b-4d3b-9738-c0c64ca3176d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_28a241b0-9db7-400a-80b4-339a6f4c2c13_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_18d62be1-063e-4359-93dd-dbbf1e23dd81_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_6bba8663-0745-425f-b0d4-cc6c1153d1cc_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_64e1ecac-7e0b-4c10-bc5f-62f456dd5f70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_6fea78c5-8b0a-4336-aba6-5face9fa5f4f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_96cef857-3ebf-4817-9378-e325299ff394_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_724eb5eb-243a-42ea-bec1-dd83153b1239_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_2f1ac924-349f-45e3-be9f-f32f6b400832_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_96466a76-c2dc-46b7-8b76-f443ee87174a_terseLabel_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Facility</link:label>
    <link:label id="lab_us-gaap_ManufacturingFacilityMember_label_en-US" xlink:label="lab_us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManufacturingFacilityMember" xlink:to="lab_us-gaap_ManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_497ed817-6aa8-4dd7-8574-280422112301_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual increase in number of shares available for future issuance</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement Increase In Number Of Shares Reserved For Issuance Percentage Under Plan</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:to="lab_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_39bc38af-2790-48e3-9680-0316ab0467aa_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f6688f96-6e23-4819-b05e-adefacf3d111_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_a1be50ab-5eab-4e74-a7c8-b1c6562540da_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>21
<FILENAME>advm-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:1a8e5b7c-bca3-4165-b4c0-12c52c6244d9,g:f2d923c2-de02-4da0-a578-7d0cd54aca4d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20211231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c104989c-e656-4484-8738-884ff93a83ef" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentType_c104989c-e656-4484-8738-884ff93a83ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_bcc98a00-2bf0-403c-95df-632ba4ac4ac4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentAnnualReport_bcc98a00-2bf0-403c-95df-632ba4ac4ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_740f692a-13b3-49d4-8168-63d535591e80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentPeriodEndDate_740f692a-13b3-49d4-8168-63d535591e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_94e968be-0783-4578-b5f3-ac9e573c14cd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_CurrentFiscalYearEndDate_94e968be-0783-4578-b5f3-ac9e573c14cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8d5445c4-a387-47a1-a6e8-a399921eff51" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentTransitionReport_8d5445c4-a387-47a1-a6e8-a399921eff51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eb12e306-485d-4826-9ec8-c29a0589bcb0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityFileNumber_eb12e306-485d-4826-9ec8-c29a0589bcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1e181f7b-d5a8-4912-9a38-6a8fa97b18e0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityRegistrantName_1e181f7b-d5a8-4912-9a38-6a8fa97b18e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_17e5ffe6-9400-45bd-b137-41d3931cb24f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_17e5ffe6-9400-45bd-b137-41d3931cb24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_66d0a94e-937b-498d-8b51-aaecef511eaa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityTaxIdentificationNumber_66d0a94e-937b-498d-8b51-aaecef511eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e776b2cc-c191-4462-b635-d096aa43222c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityAddressAddressLine1_e776b2cc-c191-4462-b635-d096aa43222c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae9a13cb-02e9-4f3e-b58a-ea28ae61276c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityAddressCityOrTown_ae9a13cb-02e9-4f3e-b58a-ea28ae61276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8430b566-11e1-4557-b6b2-4ac168b39db3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityAddressStateOrProvince_8430b566-11e1-4557-b6b2-4ac168b39db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_dae32a76-83d9-4e91-a108-0cdb229bb61c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityAddressPostalZipCode_dae32a76-83d9-4e91-a108-0cdb229bb61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d449941d-012a-4ec5-b8ff-5c035576a202" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_CityAreaCode_d449941d-012a-4ec5-b8ff-5c035576a202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_87bc818b-88a8-47c1-afd4-fcdbd6735639" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_LocalPhoneNumber_87bc818b-88a8-47c1-afd4-fcdbd6735639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_947538ed-9e39-483f-8654-303824415424" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_Security12bTitle_947538ed-9e39-483f-8654-303824415424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_be8a83b8-fbcd-4637-bd87-8f99cda32678" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_TradingSymbol_be8a83b8-fbcd-4637-bd87-8f99cda32678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e336d320-9196-476f-a17c-848d37348b42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_SecurityExchangeName_e336d320-9196-476f-a17c-848d37348b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a8cbcce5-211a-4c94-a3ef-218344e6b907" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a8cbcce5-211a-4c94-a3ef-218344e6b907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_b14a70d8-d55d-4797-af36-c1847e555a55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityVoluntaryFilers_b14a70d8-d55d-4797-af36-c1847e555a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ec635af6-e8cf-4068-90c1-48049020e2f2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityCurrentReportingStatus_ec635af6-e8cf-4068-90c1-48049020e2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_678abe6a-1a6c-4fbc-91f8-c95f9fd39177" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityInteractiveDataCurrent_678abe6a-1a6c-4fbc-91f8-c95f9fd39177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e665ac85-a74f-4df7-b0ae-bb7f2fbe6751" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityFilerCategory_e665ac85-a74f-4df7-b0ae-bb7f2fbe6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3c46d8c2-b060-4a6b-a663-83bafe3af7f0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntitySmallBusiness_3c46d8c2-b060-4a6b-a663-83bafe3af7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b5751115-d5b4-4bc2-85ed-ca53f9a1e955" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityEmergingGrowthCompany_b5751115-d5b4-4bc2-85ed-ca53f9a1e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_d26ff8ff-9fc0-4b2d-8a9d-30284513bac7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_IcfrAuditorAttestationFlag_d26ff8ff-9fc0-4b2d-8a9d-30284513bac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6155a9b6-3dd2-48af-818d-b0e658f3b715" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityShellCompany_6155a9b6-3dd2-48af-818d-b0e658f3b715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_9d7e25dc-084b-426b-9871-0988f0a0c76e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityPublicFloat_9d7e25dc-084b-426b-9871-0988f0a0c76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ddad3722-6b2b-4450-988a-687733475bd1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ddad3722-6b2b-4450-988a-687733475bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_8a811a98-b3a9-4d99-a9cb-95d4e48d4700" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_8a811a98-b3a9-4d99-a9cb-95d4e48d4700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1caac845-e30d-4d42-a4f0-8018e1982bb6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_AmendmentFlag_1caac845-e30d-4d42-a4f0-8018e1982bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_02497cb9-ee23-47b2-9719-600eaaebb830" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentFiscalYearFocus_02497cb9-ee23-47b2-9719-600eaaebb830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5dcf087f-0028-492c-b61b-bb0c08c9d2bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5dcf087f-0028-492c-b61b-bb0c08c9d2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f2fa4a6d-509f-48af-b4fb-104bb8778360" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6299cf73-dd95-4a2c-ad0a-c6cb174e23e7" xlink:to="loc_dei_EntityCentralIndexKey_f2fa4a6d-509f-48af-b4fb-104bb8778360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/AuditInformation" xlink:type="simple" xlink:href="advm-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AuditInformationAbstract_decc2a92-bc5d-4ca1-a232-d7b502e3ce69" xlink:href="advm-20211231.xsd#advm_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_01234e47-6cc1-433c-befc-3c3fdc7571df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_decc2a92-bc5d-4ca1-a232-d7b502e3ce69" xlink:to="loc_dei_AuditorFirmId_01234e47-6cc1-433c-befc-3c3fdc7571df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_7f428a3a-4f08-45c4-a9fb-3c00ec62fe19" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_decc2a92-bc5d-4ca1-a232-d7b502e3ce69" xlink:to="loc_dei_AuditorName_7f428a3a-4f08-45c4-a9fb-3c00ec62fe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_9f3353f2-0d90-47f1-b19e-4308c2a6ded3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_AuditInformationAbstract_decc2a92-bc5d-4ca1-a232-d7b502e3ce69" xlink:to="loc_dei_AuditorLocation_9f3353f2-0d90-47f1-b19e-4308c2a6ded3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49cd2f94-b745-440d-b7d1-b563bf02d6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49cd2f94-b745-440d-b7d1-b563bf02d6d1" xlink:to="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f74eea05-7741-458a-afe7-939e557b2cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f74eea05-7741-458a-afe7-939e557b2cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_66533915-3303-45e1-bf92-a18d518d08f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:to="loc_us-gaap_ShortTermInvestments_66533915-3303-45e1-bf92-a18d518d08f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_73b8c23f-2557-481c-b9f3-8ae2abf1bb10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:to="loc_us-gaap_IncentiveToLessee_73b8c23f-2557-481c-b9f3-8ae2abf1bb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c203a2e-296e-47e4-94c2-1b29992c25af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c203a2e-296e-47e4-94c2-1b29992c25af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a4572b24-a3ae-45f6-93fe-d12b6762723d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_631f5140-2d09-4daf-b7c7-73c2579365a8" xlink:to="loc_us-gaap_AssetsCurrent_a4572b24-a3ae-45f6-93fe-d12b6762723d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f34a2727-72e2-4141-bafe-cae337659c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f34a2727-72e2-4141-bafe-cae337659c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5a017ec7-23e9-4a31-93eb-c3e6d7c6f59b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5a017ec7-23e9-4a31-93eb-c3e6d7c6f59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_91ffd30d-6580-44b5-95a9-1adc1fb0e7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_91ffd30d-6580-44b5-95a9-1adc1fb0e7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRentReceivablesNet_e8304bd2-6df3-40eb-963a-0ac987b3c525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentReceivablesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_DeferredRentReceivablesNet_e8304bd2-6df3-40eb-963a-0ac987b3c525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0521c481-5e80-41b7-b344-2ff939dba10a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0521c481-5e80-41b7-b344-2ff939dba10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b0d59859-94a2-499d-ad05-3d1bb3603d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_15618cd5-5219-4b36-90e9-d0114cf72134" xlink:to="loc_us-gaap_Assets_b0d59859-94a2-499d-ad05-3d1bb3603d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a4b4d1ba-e4a9-4523-8841-40e09f75f425" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49cd2f94-b745-440d-b7d1-b563bf02d6d1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a4b4d1ba-e4a9-4523-8841-40e09f75f425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9686d4db-e972-4b55-b602-c66f9bb891a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a4b4d1ba-e4a9-4523-8841-40e09f75f425" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9686d4db-e972-4b55-b602-c66f9bb891a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e95507e3-effa-42a2-b076-a1b86639ab68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9686d4db-e972-4b55-b602-c66f9bb891a1" xlink:to="loc_us-gaap_AccountsPayableCurrent_e95507e3-effa-42a2-b076-a1b86639ab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_edf54ec2-e810-4a6f-b229-62ff1fd9b4a0" xlink:href="advm-20211231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9686d4db-e972-4b55-b602-c66f9bb891a1" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_edf54ec2-e810-4a6f-b229-62ff1fd9b4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d3b596e-1102-4a5d-9593-bfd5a6af7105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9686d4db-e972-4b55-b602-c66f9bb891a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7d3b596e-1102-4a5d-9593-bfd5a6af7105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3d4cc125-a0f8-4fa3-86c6-375668211268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9686d4db-e972-4b55-b602-c66f9bb891a1" xlink:to="loc_us-gaap_LiabilitiesCurrent_3d4cc125-a0f8-4fa3-86c6-375668211268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_f9e1c54b-96c1-49e2-8d41-3108479e572d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a4b4d1ba-e4a9-4523-8841-40e09f75f425" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_f9e1c54b-96c1-49e2-8d41-3108479e572d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2989e793-1d77-49ef-9362-537d010a5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f9e1c54b-96c1-49e2-8d41-3108479e572d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2989e793-1d77-49ef-9362-537d010a5d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_30a1a117-7839-434e-b54b-b089061c7f01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f9e1c54b-96c1-49e2-8d41-3108479e572d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_30a1a117-7839-434e-b54b-b089061c7f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bea589f9-327c-4842-a9d8-23ab386b14c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f9e1c54b-96c1-49e2-8d41-3108479e572d" xlink:to="loc_us-gaap_Liabilities_bea589f9-327c-4842-a9d8-23ab386b14c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_91f10e07-cb4f-44c2-bdb5-3412ccb62c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_f9e1c54b-96c1-49e2-8d41-3108479e572d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_91f10e07-cb4f-44c2-bdb5-3412ccb62c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a4b4d1ba-e4a9-4523-8841-40e09f75f425" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_09f39ee1-34eb-4d95-919b-232a3486c3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:to="loc_us-gaap_PreferredStockValue_09f39ee1-34eb-4d95-919b-232a3486c3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_76b9aa57-68d6-4133-a4af-e7e780a7e5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:to="loc_us-gaap_CommonStockValue_76b9aa57-68d6-4133-a4af-e7e780a7e5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b149bdac-57e3-4a58-81ab-1347d6848f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b149bdac-57e3-4a58-81ab-1347d6848f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c7a948f-ac02-4029-a549-7e5ea8c89b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5c7a948f-ac02-4029-a549-7e5ea8c89b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab9c50a5-c541-493d-b1e1-f4cdd6374f93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab9c50a5-c541-493d-b1e1-f4cdd6374f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ad6174d-6695-48b1-ba93-2f7a7d058e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9ed2621a-fecc-4b74-abe0-aefdf076cf7a" xlink:to="loc_us-gaap_StockholdersEquity_5ad6174d-6695-48b1-ba93-2f7a7d058e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2649b47-d86d-438c-9722-7c8bb9a272d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a4b4d1ba-e4a9-4523-8841-40e09f75f425" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d2649b47-d86d-438c-9722-7c8bb9a272d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cceaff3d-f167-491f-913d-d489e060d630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cceaff3d-f167-491f-913d-d489e060d630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_5c23ee1c-5b88-465e-9f45-44ef2dfe7ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_5c23ee1c-5b88-465e-9f45-44ef2dfe7ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f5ab7703-da59-4d0d-8019-32c5c2a0e39a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f5ab7703-da59-4d0d-8019-32c5c2a0e39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_77fa3fda-c837-42a4-ab0e-ce37d7e2ff07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_77fa3fda-c837-42a4-ab0e-ce37d7e2ff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fbb0d9c9-d228-43aa-811e-a65bf8f45557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fbb0d9c9-d228-43aa-811e-a65bf8f45557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d8e6ecfe-62e8-4baa-8a4b-32bd48c53a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d8e6ecfe-62e8-4baa-8a4b-32bd48c53a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_bc8c9386-e92d-4d37-b9e4-d825b5d0e437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_CommonStockSharesIssued_bc8c9386-e92d-4d37-b9e4-d825b5d0e437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8ae88b2b-c889-4645-85e5-aa90e0724859" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4a414177-7f88-417f-8679-09a72f405911" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8ae88b2b-c889-4645-85e5-aa90e0724859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7db0d1f4-6dc8-4ca7-bc0e-4d4d9399af47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7db0d1f4-6dc8-4ca7-bc0e-4d4d9399af47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_f14ba7a9-390e-40d1-966d-708cb591080b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_f14ba7a9-390e-40d1-966d-708cb591080b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0ae4580c-3f8a-4300-803f-084139fdc6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f14ba7a9-390e-40d1-966d-708cb591080b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0ae4580c-3f8a-4300-803f-084139fdc6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_841d7e9c-0662-42d4-81aa-c87b7648b747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f14ba7a9-390e-40d1-966d-708cb591080b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_841d7e9c-0662-42d4-81aa-c87b7648b747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_995e1a60-5272-4765-b52d-9ea84e7e5cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_f14ba7a9-390e-40d1-966d-708cb591080b" xlink:to="loc_us-gaap_OperatingExpenses_995e1a60-5272-4765-b52d-9ea84e7e5cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_58414d51-20e5-459f-8c63-bb4a10a15a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_OperatingIncomeLoss_58414d51-20e5-459f-8c63-bb4a10a15a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_f0acb13e-09ed-4444-89a4-d316f9a38f10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_f0acb13e-09ed-4444-89a4-d316f9a38f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_094d2277-bd24-45c7-92a3-d88c8606c277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_094d2277-bd24-45c7-92a3-d88c8606c277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b46b3a31-9cde-488e-858c-1c24e1cb1b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b46b3a31-9cde-488e-858c-1c24e1cb1b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a56f9ff7-6caf-4704-ac80-d95c704682e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_NetIncomeLoss_a56f9ff7-6caf-4704-ac80-d95c704682e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_730a40b3-3a8a-49e2-87ea-53e39d54cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_730a40b3-3a8a-49e2-87ea-53e39d54cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b25d6854-ced8-43c1-a349-f6ef61706878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_730a40b3-3a8a-49e2-87ea-53e39d54cce4" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_b25d6854-ced8-43c1-a349-f6ef61706878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_8b3f2b08-0e37-42a9-84fd-f808b840efbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_730a40b3-3a8a-49e2-87ea-53e39d54cce4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_8b3f2b08-0e37-42a9-84fd-f808b840efbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_ad3db153-b9e3-4cfd-a816-eb415a9c93ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_730a40b3-3a8a-49e2-87ea-53e39d54cce4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_ad3db153-b9e3-4cfd-a816-eb415a9c93ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_88ac1918-1b3f-4215-b210-037378c3bc63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_730a40b3-3a8a-49e2-87ea-53e39d54cce4" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_88ac1918-1b3f-4215-b210-037378c3bc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_af0b8e80-7800-4113-8799-aa54b61c8ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_EarningsPerShareBasic_af0b8e80-7800-4113-8799-aa54b61c8ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_255bcade-dada-4687-9150-480504d70019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_255bcade-dada-4687-9150-480504d70019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9d32d10-872e-46f2-91b2-81d4a6b080da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9d32d10-872e-46f2-91b2-81d4a6b080da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a31599fc-32ac-430a-8800-111d54f7c41d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6ad100c7-adbf-4773-9e52-2745f66aad0e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a31599fc-32ac-430a-8800-111d54f7c41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6673cf6-ef21-4e5c-9ee9-e671d4aa0e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d6673cf6-ef21-4e5c-9ee9-e671d4aa0e0d" xlink:to="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ebeb0c0c-aefc-426e-90c1-b76e86745ef2" xlink:to="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_34292a37-feee-409d-93a1-731f750836d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_CommonStockMember_34292a37-feee-409d-93a1-731f750836d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a8abe938-eb21-43ea-836f-618b5d01f8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a8abe938-eb21-43ea-836f-618b5d01f8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ff4851-6fe2-4603-8eb8-661ad500277d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_19ff4851-6fe2-4603-8eb8-661ad500277d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d202812a-5859-476a-b5ee-46b95c9d247c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5dc4a9df-6a24-4225-9623-abf49b0bbc4a" xlink:to="loc_us-gaap_RetainedEarningsMember_d202812a-5859-476a-b5ee-46b95c9d247c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_42479319-3cec-4a07-a992-a76dcd29736f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_55846864-b668-455d-afae-d2ad7924ecf3" xlink:to="loc_us-gaap_StatementLineItems_42479319-3cec-4a07-a992-a76dcd29736f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_42479319-3cec-4a07-a992-a76dcd29736f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_3eff0023-88c8-4388-9b93-40679f64adcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_SharesOutstanding_3eff0023-88c8-4388-9b93-40679f64adcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_494105da-3dc5-4203-a3a9-479a01ba88f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockholdersEquity_494105da-3dc5-4203-a3a9-479a01ba88f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b9b4264-983e-4c4e-8478-65b95b8c5909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_4b9b4264-983e-4c4e-8478-65b95b8c5909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_56fbfb6b-3e72-4ff6-ac15-d63c0717c6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_56fbfb6b-3e72-4ff6-ac15-d63c0717c6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d96b26fe-e00f-46dd-a668-782ed777eea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_d96b26fe-e00f-46dd-a668-782ed777eea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb883abc-0a52-4897-b49d-14a799be2954" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb883abc-0a52-4897-b49d-14a799be2954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82e478c9-948e-4cf9-90f8-7e43337b11e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_82e478c9-948e-4cf9-90f8-7e43337b11e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_WarrantsIssuedDuringPeriodShares_d1706820-dc91-459b-83d3-9e24b309a24d" xlink:href="advm-20211231.xsd#advm_WarrantsIssuedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_advm_WarrantsIssuedDuringPeriodShares_d1706820-dc91-459b-83d3-9e24b309a24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3af52b2-e19d-4c37-8fbf-07e855640c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_a3af52b2-e19d-4c37-8fbf-07e855640c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6a8b83cc-6f4d-4e6e-b505-60731635fbff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6a8b83cc-6f4d-4e6e-b505-60731635fbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e839ce65-f70f-4929-96bf-9ef01f6ce747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e839ce65-f70f-4929-96bf-9ef01f6ce747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f6f6f238-90fe-4fd3-b6ec-db75c24594ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_f6f6f238-90fe-4fd3-b6ec-db75c24594ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8986cfab-128c-4f39-852e-09ab46fef209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8986cfab-128c-4f39-852e-09ab46fef209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3ad6b5dc-3da3-4dab-a2ba-32d9a5088ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_3ad6b5dc-3da3-4dab-a2ba-32d9a5088ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_f6203acb-ea5f-4236-871f-0ac23f9f39c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_f6203acb-ea5f-4236-871f-0ac23f9f39c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8ff0dd53-f78d-43cf-9b7b-5f18b0af523c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_8ff0dd53-f78d-43cf-9b7b-5f18b0af523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2cc0fffd-0b8b-4836-b958-42256d322aab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_NetIncomeLoss_2cc0fffd-0b8b-4836-b958-42256d322aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_f8949f4a-5fe1-45af-ae0e-7a6a8f63dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_SharesOutstanding_f8949f4a-5fe1-45af-ae0e-7a6a8f63dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0d43517-63d3-479a-a666-104f02a7e0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e55e0377-ba4f-48db-bdcd-ea6962b20586" xlink:to="loc_us-gaap_StockholdersEquity_f0d43517-63d3-479a-a666-104f02a7e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0c7773ba-28d3-4ba9-9851-266742ae1b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c3d9cb03-cbcf-4d7a-94b1-b9091d108de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0c7773ba-28d3-4ba9-9851-266742ae1b1d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c3d9cb03-cbcf-4d7a-94b1-b9091d108de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20211231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73ec074-7fdb-45ba-b0ab-0f109bde046c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73ec074-7fdb-45ba-b0ab-0f109bde046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a6ed68a-cb0c-4677-8a94-3899d3a70f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73ec074-7fdb-45ba-b0ab-0f109bde046c" xlink:to="loc_us-gaap_NetIncomeLoss_8a6ed68a-cb0c-4677-8a94-3899d3a70f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73ec074-7fdb-45ba-b0ab-0f109bde046c" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e8875e6d-973f-4bb1-9ffa-e737983872d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_DepreciationAndAmortization_e8875e6d-973f-4bb1-9ffa-e737983872d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_27d41f97-4e23-4ff3-93b7-b4c884732f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_ShareBasedCompensation_27d41f97-4e23-4ff3-93b7-b4c884732f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_054e65e6-0054-48ed-9be4-5439f7c12aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_054e65e6-0054-48ed-9be4-5439f7c12aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionExpense_aaa4407d-7181-48a1-8352-692af1622111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_AccretionExpense_aaa4407d-7181-48a1-8352-692af1622111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_d32f595c-8a10-49eb-9f4d-36ec72a6359e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_AssetImpairmentCharges_d32f595c-8a10-49eb-9f4d-36ec72a6359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_be233ee1-4457-4a5e-bd6f-547f43733c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_be233ee1-4457-4a5e-bd6f-547f43733c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_efd291bc-6748-4ed3-92ce-7424c5937d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8592c50-81a5-473c-b6e1-ae4f72f981b5" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_efd291bc-6748-4ed3-92ce-7424c5937d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73ec074-7fdb-45ba-b0ab-0f109bde046c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_891b6e17-5327-4f19-b476-7f5a187afa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_891b6e17-5327-4f19-b476-7f5a187afa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_dcc0c6c0-27ef-479d-9c17-a9d186030990" xlink:href="advm-20211231.xsd#advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable_dcc0c6c0-27ef-479d-9c17-a9d186030990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_718c4e71-8d82-437b-a816-376aa6158d46" xlink:href="advm-20211231.xsd#advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets_718c4e71-8d82-437b-a816-376aa6158d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3dae04a3-6757-40e1-aa5f-dd89b0989030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3dae04a3-6757-40e1-aa5f-dd89b0989030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21d85c77-b2e6-4f23-bebb-f7b1646ce2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_21d85c77-b2e6-4f23-bebb-f7b1646ce2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f1687e36-1ea5-4395-8bb8-c09050e5b085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_f1687e36-1ea5-4395-8bb8-c09050e5b085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_83f1a149-c9de-442e-84c2-55377e262382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_545df58a-7bba-4561-9436-b331ab6facfe" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_83f1a149-c9de-442e-84c2-55377e262382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3c8ceaf-5e80-4676-bb49-49f3c5354006" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b73ec074-7fdb-45ba-b0ab-0f109bde046c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b3c8ceaf-5e80-4676-bb49-49f3c5354006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_adb299bd-302b-4dec-b1f5-635708d94a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_adb299bd-302b-4dec-b1f5-635708d94a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_efbf0e80-49b5-4809-90f2-16111a6c3d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_efbf0e80-49b5-4809-90f2-16111a6c3d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_981856d0-b126-44a8-baa7-f7d7207417f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_981856d0-b126-44a8-baa7-f7d7207417f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_261485dc-4a0d-40c9-bafa-652e70d69c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_261485dc-4a0d-40c9-bafa-652e70d69c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b702784-06d8-4c58-94c6-e2356825ea25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1263e58b-a7ab-4c06-a3e6-4f293c769069" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5b702784-06d8-4c58-94c6-e2356825ea25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_99c1cbed-3777-44c8-93b1-170e701816ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_99c1cbed-3777-44c8-93b1-170e701816ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_843442b5-c724-4d16-b40e-9d063e6c80cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_843442b5-c724-4d16-b40e-9d063e6c80cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_88d62009-4a49-4633-9be0-c74f7088b65c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_88d62009-4a49-4633-9be0-c74f7088b65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4108710c-024d-4543-925f-6370ba459af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_4108710c-024d-4543-925f-6370ba459af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_eec4617e-71b5-419e-ba61-f6ef38de2c77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:to="loc_us-gaap_RepaymentsOfDebt_eec4617e-71b5-419e-ba61-f6ef38de2c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b276c2d9-f539-4275-ae37-dd2c0cfa401e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_77a5794d-678b-477a-94e0-b29db8a27843" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b276c2d9-f539-4275-ae37-dd2c0cfa401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72868499-ba8a-450e-8632-921d2d8e7114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_72868499-ba8a-450e-8632-921d2d8e7114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_24616eba-24d4-4e8c-828f-35904a3882e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_24616eba-24d4-4e8c-828f-35904a3882e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3efe65dc-1066-426c-a87b-61284738321c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3efe65dc-1066-426c-a87b-61284738321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e3db8fc-0db5-4ebc-b945-75ed3b30be42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e3db8fc-0db5-4ebc-b945-75ed3b30be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_efaa15d8-27cd-4328-8798-2465ac62f508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_efaa15d8-27cd-4328-8798-2465ac62f508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_82378bef-38d8-4803-847f-ab6783c554da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_82378bef-38d8-4803-847f-ab6783c554da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_01bae6a3-1a77-4bd5-9cda-98e93e14c212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3d97d0f8-ef66-4ffd-9dff-23a8e8b1d3b2" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_01bae6a3-1a77-4bd5-9cda-98e93e14c212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9d32b848-619c-43b7-805d-62500bf15625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_01bae6a3-1a77-4bd5-9cda-98e93e14c212" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_9d32b848-619c-43b7-805d-62500bf15625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_aff908f0-c722-4383-a846-b170d05addd2" xlink:href="advm-20211231.xsd#advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_01bae6a3-1a77-4bd5-9cda-98e93e14c212" xlink:to="loc_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination_aff908f0-c722-4383-a846-b170d05addd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_8e5e4d22-afd1-41d3-8f18-906caea835c3" xlink:href="advm-20211231.xsd#advm_RemeasurementOfRightOfUseAssetOnLeaseModification"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_01bae6a3-1a77-4bd5-9cda-98e93e14c212" xlink:to="loc_advm_RemeasurementOfRightOfUseAssetOnLeaseModification_8e5e4d22-afd1-41d3-8f18-906caea835c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_16a83427-9a72-4e08-9259-08d7e6f9c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_01bae6a3-1a77-4bd5-9cda-98e93e14c212" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_16a83427-9a72-4e08-9259-08d7e6f9c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/DescriptionoftheBusiness" xlink:type="simple" xlink:href="advm-20211231.xsd#DescriptionoftheBusiness"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/DescriptionoftheBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7580a76e-e9a3-4b89-91f4-dafdfe2fc06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_770f4802-e9b2-4f10-b7e2-78b237c7101c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7580a76e-e9a3-4b89-91f4-dafdfe2fc06a" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_770f4802-e9b2-4f10-b7e2-78b237c7101c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#DescriptionoftheBusinessAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cda77591-dad2-4c73-be18-f66c6668fcae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3b4ccdb3-bd41-47f8-bbf6-6110e604b749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cda77591-dad2-4c73-be18-f66c6668fcae" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3b4ccdb3-bd41-47f8-bbf6-6110e604b749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2c95345-2243-4a06-a916-db0d31b689e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cda77591-dad2-4c73-be18-f66c6668fcae" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_a2c95345-2243-4a06-a916-db0d31b689e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Summaryofsignificantaccountingpolicies" xlink:type="simple" xlink:href="advm-20211231.xsd#Summaryofsignificantaccountingpolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Summaryofsignificantaccountingpolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ae2854fb-7199-469a-a645-b8b2f4ef57ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_44efc478-c1d0-4414-821e-c30d00b31939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ae2854fb-7199-469a-a645-b8b2f4ef57ca" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_44efc478-c1d0-4414-821e-c30d00b31939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="simple" xlink:href="advm-20211231.xsd#SummaryofsignificantaccountingpoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_dfbcbb24-6e55-4b12-9614-927e9db58376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_dfbcbb24-6e55-4b12-9614-927e9db58376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_1ca15574-d2c8-419a-b853-01094ba8be89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_UseOfEstimates_1ca15574-d2c8-419a-b853-01094ba8be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9fccb6d0-eeae-47a5-8b39-9aad8c9bca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9fccb6d0-eeae-47a5-8b39-9aad8c9bca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_def90cda-b78d-4480-a070-2493deefb82a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_def90cda-b78d-4480-a070-2493deefb82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_030658f4-e7d0-4310-9b34-2be013d99060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_030658f4-e7d0-4310-9b34-2be013d99060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_158335f0-2016-4766-99bc-f5fa3a739e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_158335f0-2016-4766-99bc-f5fa3a739e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_34324364-82f3-41a3-9fa1-4d32a2b5b70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_34324364-82f3-41a3-9fa1-4d32a2b5b70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_65014aca-6488-4185-891e-f545cd1ba760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_65014aca-6488-4185-891e-f545cd1ba760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d8ae4c6e-61f9-418e-a7f1-04afdff84dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_d8ae4c6e-61f9-418e-a7f1-04afdff84dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_c079fe53-8a86-4c8c-9961-1b2ef06fb304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_c079fe53-8a86-4c8c-9961-1b2ef06fb304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_15814ef5-ca8e-4ee5-ad00-f14574ad0219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_15814ef5-ca8e-4ee5-ad00-f14574ad0219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1baba349-b431-4e01-a1cc-dc5fc4615854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_1baba349-b431-4e01-a1cc-dc5fc4615854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f266af48-7534-4a0b-a853-dd3339940e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_f266af48-7534-4a0b-a853-dd3339940e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_778399f1-4175-41cb-b8ee-3af96da4a049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_778399f1-4175-41cb-b8ee-3af96da4a049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c95afc0a-ac92-4e44-9583-9ae89c16e21f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c95afc0a-ac92-4e44-9583-9ae89c16e21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_4ca73391-d5f9-4a6d-aa98-eafec53365d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_4ca73391-d5f9-4a6d-aa98-eafec53365d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_3e8ba1f3-0ac4-403e-a668-186d08145d34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_3e8ba1f3-0ac4-403e-a668-186d08145d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_041c5f11-a902-4762-ab0d-c3ac71f0f675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_041c5f11-a902-4762-ab0d-c3ac71f0f675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d1ffb980-f611-41fe-b37e-4ebbf09a0cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3227d4f6-f0d8-4c9f-bf53-5121a53b5fb9" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d1ffb980-f611-41fe-b37e-4ebbf09a0cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ea4f22eb-0c50-42ae-b233-1a9978de720f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:href="advm-20211231.xsd#advm_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ea4f22eb-0c50-42ae-b233-1a9978de720f" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:to="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c23122c-ce42-4cf3-9e6b-ba62ad4387fa" xlink:to="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c3aa5b04-8ff7-435c-a189-aaa6fb34a43b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:to="loc_srt_MinimumMember_c3aa5b04-8ff7-435c-a189-aaa6fb34a43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8d8abd97-a438-42ef-b947-a86987ef221b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_828dac80-c3b8-4f37-b503-f75233afdd3e" xlink:to="loc_srt_MaximumMember_8d8abd97-a438-42ef-b947-a86987ef221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:href="advm-20211231.xsd#advm_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesTable_8ebb60ab-7977-4ba7-ae8a-781d4fda2f03" xlink:to="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_f4a27f8e-f069-4286-9817-3e0d225112ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_NumberOfReportableSegments_f4a27f8e-f069-4286-9817-3e0d225112ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_f57f7147-0501-4d8b-9a5b-38977265af34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_NumberOfOperatingSegments_f57f7147-0501-4d8b-9a5b-38977265af34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_67e41ed9-ab15-4090-b797-5cfb691dea24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_67e41ed9-ab15-4090-b797-5cfb691dea24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e1e0d572-75e0-4882-941a-fb3d4c455aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_AssetImpairmentCharges_e1e0d572-75e0-4882-941a-fb3d4c455aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_7686fbc3-3224-4e3f-853b-5f3f912d55a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_7686fbc3-3224-4e3f-853b-5f3f912d55a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_79ea2b3d-0e93-4ddc-9585-1a9d511b32f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_SummaryOfSignificantAccountingPoliciesLineItems_9ae9fb55-ebf3-4a26-9b82-09a383edcedf" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_79ea2b3d-0e93-4ddc-9585-1a9d511b32f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_07cf2d87-51a2-4f30-96d8-35ebf59809eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_7bbb8211-16b1-465a-b324-f89bc56c5d25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_07cf2d87-51a2-4f30-96d8-35ebf59809eb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_7bbb8211-16b1-465a-b324-f89bc56c5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_992cfc5c-620f-4e37-8dd6-5b93b3cc0efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a81820f6-5e92-4d50-9776-7b93fb69a46e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_992cfc5c-620f-4e37-8dd6-5b93b3cc0efe" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_a81820f6-5e92-4d50-9776-7b93fb69a46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bcbb8145-3146-4c39-9260-b538f79e8dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bcbb8145-3146-4c39-9260-b538f79e8dd3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31856509-5e4e-426b-b577-5ccc04cc8432" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4c152e40-f842-4f44-b57f-fd03ca6d5c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4c152e40-f842-4f44-b57f-fd03ca6d5c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9f5eac7e-bc64-4e54-a666-cf3ad355f3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d527d8ad-9491-4bee-a24d-7840ae2af1f5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9f5eac7e-bc64-4e54-a666-cf3ad355f3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_127f47f8-5bb9-4862-8509-43143965e010" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_695607fc-371f-43a0-9dcf-dc16e1e16b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_MoneyMarketFundsMember_695607fc-371f-43a0-9dcf-dc16e1e16b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_8a8e6045-3536-404c-aa59-384341e76d87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_8a8e6045-3536-404c-aa59-384341e76d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fe83c5dd-1a12-4909-9610-98a1f557b910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_CommercialPaperMember_fe83c5dd-1a12-4909-9610-98a1f557b910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_e19e5545-3a95-466d-886b-32578153fa3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_e19e5545-3a95-466d-886b-32578153fa3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_692a6224-69b9-4ddf-910f-25ba88c7877e" xlink:href="advm-20211231.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e7309e16-58d2-428b-858b-dfbedb7d32c1" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_692a6224-69b9-4ddf-910f-25ba88c7877e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_9c2c7299-2381-4f96-8301-9973077853c9" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3d362ac-7284-4b91-8908-4f7531582ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3d362ac-7284-4b91-8908-4f7531582ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_14dc4207-c937-46dd-b54b-27cb9ccf05c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_14dc4207-c937-46dd-b54b-27cb9ccf05c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3802242-5f66-47b4-a5fa-6095a26f95bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d3802242-5f66-47b4-a5fa-6095a26f95bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f26cfff9-4a91-4d4c-8608-35185b0d2e39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f26cfff9-4a91-4d4c-8608-35185b0d2e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_35429373-a999-4a94-9dda-7ab3417ebee9" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_35429373-a999-4a94-9dda-7ab3417ebee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_d25b9e59-59fb-4bff-9ff6-52d13c811211" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_d25b9e59-59fb-4bff-9ff6-52d13c811211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_f41c0774-91d2-4c21-b49e-374464b8312b" xlink:href="advm-20211231.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_f41c0774-91d2-4c21-b49e-374464b8312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b4d2d8c-3ee2-425d-9a4c-9a5bf4ecab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4ab0b194-7fbe-40fd-81d2-3a8316855568" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9b4d2d8c-3ee2-425d-9a4c-9a5bf4ecab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_425723f6-9cae-4daa-8cff-95063a6bb735" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_425723f6-9cae-4daa-8cff-95063a6bb735" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:to="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d7ff406e-f710-4126-b031-89f410af8af1" xlink:to="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_cc961d23-ef0b-4670-bbc6-eaae5835de00" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:to="loc_srt_MinimumMember_cc961d23-ef0b-4670-bbc6-eaae5835de00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_de2eb7d9-a693-4010-9d72-9c8c4a5232f7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a6726398-4548-43da-8dd0-acb5b873a904" xlink:to="loc_srt_MaximumMember_de2eb7d9-a693-4010-9d72-9c8c4a5232f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0372c104-9b99-4ed6-ad47-ab2349a69602" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_2bd30ac1-b54c-4989-b34e-4fc1fd21dc20" xlink:href="advm-20211231.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_2bd30ac1-b54c-4989-b34e-4fc1fd21dc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_a6f4ea66-9928-4271-a68e-f849c8d3214b" xlink:href="advm-20211231.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_a6f4ea66-9928-4271-a68e-f849c8d3214b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_0e7faa67-423b-4c95-908b-d78ecf0256a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6879f67c-18e8-42fb-bf43-5d97c70f6fa1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_0e7faa67-423b-4c95-908b-d78ecf0256a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Revenue" xlink:type="simple" xlink:href="advm-20211231.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9fd9c954-d49f-4477-851e-20eb0d622bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_14a090ee-ccc3-454e-b4fd-638174886ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9fd9c954-d49f-4477-851e-20eb0d622bee" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_14a090ee-ccc3-454e-b4fd-638174886ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RevenueAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#RevenueAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RevenueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7415ec6f-4e8b-4bdf-9f59-1bbec1d691f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7415ec6f-4e8b-4bdf-9f59-1bbec1d691f7" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:to="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81e35a40-1de0-4878-8bf8-e99189706ba8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d830569f-ff8f-4f1a-8ed1-da481570d8ad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81e35a40-1de0-4878-8bf8-e99189706ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LexeoTherapeuticsIncMember_a3a0736d-ac9e-4a9b-8c6b-1479c9f142d7" xlink:href="advm-20211231.xsd#advm_LexeoTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81e35a40-1de0-4878-8bf8-e99189706ba8" xlink:to="loc_advm_LexeoTherapeuticsIncMember_a3a0736d-ac9e-4a9b-8c6b-1479c9f142d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b5ab3ca2-494e-4aaa-a2c5-8ccd39ad676b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_60599cff-6db5-4758-ba73-2567a4c53c37" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b5ab3ca2-494e-4aaa-a2c5-8ccd39ad676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a1733372-f8d9-4330-b87f-aaf32fcb5069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a1a2f2ae-ab36-4b9e-827d-c89d05ca8eb9" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a1733372-f8d9-4330-b87f-aaf32fcb5069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e8fef9-4266-471f-87ce-9da0ba75e44a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a1733372-f8d9-4330-b87f-aaf32fcb5069" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21e8fef9-4266-471f-87ce-9da0ba75e44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/Leases" xlink:type="simple" xlink:href="advm-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ddd0f65f-ebf5-4e53-b8b3-47f4f7a2ef95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8742f70f-7e44-4da9-a792-0347cf03aaac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ddd0f65f-ebf5-4e53-b8b3-47f4f7a2ef95" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8742f70f-7e44-4da9-a792-0347cf03aaac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesTables" xlink:type="simple" xlink:href="advm-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3d05d7c2-bf1b-4bf1-a0cb-e8abaa520957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d6f2ad00-256e-43a4-80a6-bae82a5e1bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3d05d7c2-bf1b-4bf1-a0cb-e8abaa520957" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d6f2ad00-256e-43a4-80a6-bae82a5e1bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#LeasesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d40fbb01-efea-445b-bcbf-5646601dd085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d40fbb01-efea-445b-bcbf-5646601dd085" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9d341a9-d905-4e82-954d-6c8ebc18e524" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_93766304-c5b9-4e7d-8191-5f0431dd4b55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:to="loc_us-gaap_BuildingMember_93766304-c5b9-4e7d-8191-5f0431dd4b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManufacturingFacilityMember_28e27a36-e1bb-439a-bcc8-539994ff69f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManufacturingFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_30a0e0cc-2351-43e2-8e89-0e5eca132b9e" xlink:to="loc_us-gaap_ManufacturingFacilityMember_28e27a36-e1bb-439a-bcc8-539994ff69f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:to="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_f7e7a7e0-baea-4000-accb-a45707ba9ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_977d1ce1-b4e8-404e-96ba-acd4a20c6c51" xlink:to="loc_us-gaap_LeaseContractualTermDomain_f7e7a7e0-baea-4000-accb-a45707ba9ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TerminatedLeaseMember_2a2c4c7c-1327-4a82-ba10-4ec46421ad41" xlink:href="advm-20211231.xsd#advm_TerminatedLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_f7e7a7e0-baea-4000-accb-a45707ba9ae6" xlink:to="loc_advm_TerminatedLeaseMember_2a2c4c7c-1327-4a82-ba10-4ec46421ad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6173d883-d422-4960-8fef-fe16345f87fb" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e7ae6e82-6d04-414e-9d01-d5ce0afcbb8e" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseLeaseholdImprovementAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance_e7ae6e82-6d04-414e-9d01-d5ce0afcbb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_84f30582-4a18-407f-8c66-bcf3178ac505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_84f30582-4a18-407f-8c66-bcf3178ac505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f04350de-39ce-4291-8ebf-c3bbf55536dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f04350de-39ce-4291-8ebf-c3bbf55536dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_e9937704-34dd-4319-ae5a-4f462e8bb29c" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseLeaseTerminationFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_LesseeOperatingLeaseLeaseTerminationFee_e9937704-34dd-4319-ae5a-4f462e8bb29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLeaseMonthlyCost_fa7209bf-b53c-4565-8292-2118e6d5040b" xlink:href="advm-20211231.xsd#advm_OperatingLeaseMonthlyCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_OperatingLeaseMonthlyCost_fa7209bf-b53c-4565-8292-2118e6d5040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0ee6d702-a194-4610-b0f0-12ca6ce122b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_AssetImpairmentCharges_0ee6d702-a194-4610-b0f0-12ca6ce122b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_4d4dcc7a-3efd-49fa-83cd-a5b5c83e33e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_4d4dcc7a-3efd-49fa-83cd-a5b5c83e33e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLeasehold_08da221f-7893-45cc-8392-228033ed5bc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLeasehold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_ImpairmentOfLeasehold_08da221f-7893-45cc-8392-228033ed5bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_f806231e-5020-48cb-b165-b598e97f1917" xlink:href="advm-20211231.xsd#advm_LesseeOperatingLeaseNumberOfRenewalContracts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_advm_LesseeOperatingLeaseNumberOfRenewalContracts_f806231e-5020-48cb-b165-b598e97f1917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6f7715f1-f289-402c-884f-345b61762e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6f7715f1-f289-402c-884f-345b61762e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_486e5960-0bd9-4ce7-aa10-655de373f601" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_486e5960-0bd9-4ce7-aa10-655de373f601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0185b2ea-0501-420c-b798-aa56f5fbb1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeaseExpense_0185b2ea-0501-420c-b798-aa56f5fbb1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e6dea1d2-e617-477e-90ad-373be9bd3759" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_VariableLeaseCost_e6dea1d2-e617-477e-90ad-373be9bd3759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_46dd1c04-a87b-4071-a46f-843502ee0b65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_OperatingLeasePayments_46dd1c04-a87b-4071-a46f-843502ee0b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_5d55cbf7-9504-488e-a067-d82c8ed2a629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_0e79ade8-6091-4c9b-b679-8edf381a61a7" xlink:to="loc_us-gaap_SubleaseIncome_5d55cbf7-9504-488e-a067-d82c8ed2a629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5a183330-0594-4244-a6bc-bec2cdd72e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a183330-0594-4244-a6bc-bec2cdd72e26" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_13e647c9-1555-4817-a6d9-e0bf110933ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_13e647c9-1555-4817-a6d9-e0bf110933ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c9d2e86d-ce41-4660-8a14-0b8a1da411c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_c9d2e86d-ce41-4660-8a14-0b8a1da411c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b0229c69-0d52-422f-9c8d-f9664cfbfd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b0229c69-0d52-422f-9c8d-f9664cfbfd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e097caad-ba79-4b03-8bfa-44b783f7a065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e097caad-ba79-4b03-8bfa-44b783f7a065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4dfc712f-fe96-4318-b153-12860f921d35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4dfc712f-fe96-4318-b153-12860f921d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7d00a8ad-88c5-4ef1-97c6-3da9acb5ab92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7d00a8ad-88c5-4ef1-97c6-3da9acb5ab92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04d998be-ea08-48af-a222-d46becc7040a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04d998be-ea08-48af-a222-d46becc7040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_00a1c104-4370-49bf-b646-23b63d12eecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_00a1c104-4370-49bf-b646-23b63d12eecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TenantImprovements_27dc88f9-b1a0-4da5-90e7-128874ba4c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_TenantImprovements_27dc88f9-b1a0-4da5-90e7-128874ba4c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncentiveToLessee_c6343081-1809-43c2-8103-063d0b7f8ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncentiveToLessee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_IncentiveToLessee_c6343081-1809-43c2-8103-063d0b7f8ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d0afbf83-7c69-41b1-9c4c-70f3bc6ee6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_6632104d-e531-49d8-b20d-8ee3bc7834c4" xlink:to="loc_us-gaap_OperatingLeaseLiability_d0afbf83-7c69-41b1-9c4c-70f3bc6ee6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a183330-0594-4244-a6bc-bec2cdd72e26" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e55fc505-e00e-43ae-944f-cef5a7773548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_e55fc505-e00e-43ae-944f-cef5a7773548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_cc1fff2e-dbfc-4126-8af8-a71c5e613da2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_cc1fff2e-dbfc-4126-8af8-a71c5e613da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_5e565c37-0e07-4dc9-92c2-376a0f414e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_5e565c37-0e07-4dc9-92c2-376a0f414e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_d62bc108-18c6-439d-991d-a996eb987037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_d62bc108-18c6-439d-991d-a996eb987037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_139889f2-ef82-41c8-b143-06226e994883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_139889f2-ef82-41c8-b143-06226e994883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_dcb87d14-0d7b-47c7-a891-3b4ee870d6d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_dcb87d14-0d7b-47c7-a891-3b4ee870d6d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5aca3520-812b-4616-90ea-074780fdd19c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract_201b8be6-cfae-45d3-9e88-245d90d07277" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_5aca3520-812b-4616-90ea-074780fdd19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c817d5ee-0b57-42c7-a60b-314a9b201238" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_712e958b-6a0a-45ab-be1f-97eeebe33e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c817d5ee-0b57-42c7-a60b-314a9b201238" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_712e958b-6a0a-45ab-be1f-97eeebe33e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d98964d3-0121-480a-a614-dc130be17a22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2d754791-1309-4ecc-8eeb-ce08d9976089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d98964d3-0121-480a-a614-dc130be17a22" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2d754791-1309-4ecc-8eeb-ce08d9976089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ca9690e1-375b-4774-a372-d81f4177d1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d98964d3-0121-480a-a614-dc130be17a22" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ca9690e1-375b-4774-a372-d81f4177d1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ce68f9a0-896f-43c8-94b4-0e83b31404a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ce68f9a0-896f-43c8-94b4-0e83b31404a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2f5e8d1e-6d60-4063-9a33-b003022d7808" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_e58b1d8d-f8a5-4e0d-84e3-f8732649f172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_ComputerEquipmentMember_e58b1d8d-f8a5-4e0d-84e3-f8732649f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_c91e44c6-1f25-49f0-a7ff-0f36740f3ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_EquipmentMember_c91e44c6-1f25-49f0-a7ff-0f36740f3ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_49d2a882-e3f1-4d5b-bc02-b2a2b5d08a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_49d2a882-e3f1-4d5b-bc02-b2a2b5d08a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_b92c7c47-17a7-4fc8-bbdc-b85ae902c8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_b92c7c47-17a7-4fc8-bbdc-b85ae902c8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_70b426bd-69e1-4d0c-ae15-a2f961d2249c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7ba6d978-2d05-49c6-9fad-7ba6a50831ee" xlink:to="loc_us-gaap_ConstructionInProgressMember_70b426bd-69e1-4d0c-ae15-a2f961d2249c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d907ab4d-86b0-49bb-961b-932efac3a380" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc78d4c-b3ec-4586-91f0-6da30749546e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_5bc78d4c-b3ec-4586-91f0-6da30749546e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_db25c38a-b83f-47d4-aa4d-e4f86a43439f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_db25c38a-b83f-47d4-aa4d-e4f86a43439f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3a2f2c38-3c70-4e5c-a2b7-1540d7ef615c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_920e19ed-5d8e-42c1-90fb-a0c321296d03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3a2f2c38-3c70-4e5c-a2b7-1540d7ef615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e67d2edc-21af-4a7f-be39-3715f143eae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_e67d2edc-21af-4a7f-be39-3715f143eae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8e3df472-11b0-4213-aea0-8cdbc72ecfce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8e3df472-11b0-4213-aea0-8cdbc72ecfce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedNonclinicalCostsCurrent_8a72ca1f-55b9-4b30-9bca-3cb3d6110881" xlink:href="advm-20211231.xsd#advm_AccruedNonclinicalCostsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_advm_AccruedNonclinicalCostsCurrent_8a72ca1f-55b9-4b30-9bca-3cb3d6110881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_f8288ab6-b31e-4fe4-b9a1-26adbecc4446" xlink:href="advm-20211231.xsd#advm_AccruedClinicalAndDevelopmentProcessCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent_f8288ab6-b31e-4fe4-b9a1-26adbecc4446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_c5934ac8-e0da-4527-a487-31685c17d289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_us-gaap_TaxesPayableCurrent_c5934ac8-e0da-4527-a487-31685c17d289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d76cef47-940e-4396-9856-f291c3688a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d76cef47-940e-4396-9856-f291c3688a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_24e0db90-3b76-4148-b6be-04b2abacb9ed" xlink:href="advm-20211231.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ffb8dc2d-5fc6-4b80-b852-5b76b70b3714" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_24e0db90-3b76-4148-b6be-04b2abacb9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="advm-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e82ae41b-4e95-4e6a-9f26-855f62131059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b5a32c94-9fea-4d08-8a81-e92d7cdaa31a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e82ae41b-4e95-4e6a-9f26-855f62131059" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b5a32c94-9fea-4d08-8a81-e92d7cdaa31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="advm-20211231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_683a3a62-f817-4c29-9a9c-9d9f6e98f176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_3111de26-845d-4081-acb3-bd189e93bb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_683a3a62-f817-4c29-9a9c-9d9f6e98f176" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_3111de26-845d-4081-acb3-bd189e93bb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlans" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlans"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46937350-0695-4a23-b15f-d496b84e20bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e88f6c8f-2564-410d-9417-79eec48f559c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_46937350-0695-4a23-b15f-d496b84e20bb" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_e88f6c8f-2564-410d-9417-79eec48f559c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansTables" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c70ad051-59d5-416b-9c71-5ebb54456254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e8d2be28-5d24-4738-af20-81fe639409f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c70ad051-59d5-416b-9c71-5ebb54456254" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e8d2be28-5d24-4738-af20-81fe639409f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4ab78d82-68f2-429a-ba2a-02dd1feeebec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c70ad051-59d5-416b-9c71-5ebb54456254" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4ab78d82-68f2-429a-ba2a-02dd1feeebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4d3fbd67-10a7-4dc3-a5fc-d46c91d279eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c70ad051-59d5-416b-9c71-5ebb54456254" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_4d3fbd67-10a7-4dc3-a5fc-d46c91d279eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_023ccd9e-9574-49ee-ba97-ebef66c0c651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c70ad051-59d5-416b-9c71-5ebb54456254" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_023ccd9e-9574-49ee-ba97-ebef66c0c651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0afc920d-6a86-4f9e-bad3-241cf3fd41a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0afc920d-6a86-4f9e-bad3-241cf3fd41a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1ad915b7-7806-4693-afdd-859152453d73" xlink:to="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_139deee9-a3d9-4277-902c-6d0245993e8a" xlink:href="advm-20211231.xsd#advm_TwoThousandAndFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandAndFourteenEquityIncentivePlanMember_139deee9-a3d9-4277-902c-6d0245993e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandSeventeenInducementPlanMember_bb4278bf-1730-41e0-99e4-aa3309e67c20" xlink:href="advm-20211231.xsd#advm_TwoThousandSeventeenInducementPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandSeventeenInducementPlanMember_bb4278bf-1730-41e0-99e4-aa3309e67c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_62da556f-5905-467c-8446-287c43db2388" xlink:href="advm-20211231.xsd#advm_TwoThousandFourteenPlanAndInducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandFourteenPlanAndInducementPlanMember_62da556f-5905-467c-8446-287c43db2388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_81076fc6-113a-4c0f-a790-f5ed44689323" xlink:href="advm-20211231.xsd#advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_6204fbf2-ee2e-442c-9459-e1646d20f040" xlink:to="loc_advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember_81076fc6-113a-4c0f-a790-f5ed44689323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_92f75639-f9cd-47f7-886b-347778015605" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockOptionsAndRestrictedStockUnitsMember_e298bf0c-e8a1-4883-8929-f7b0116e35eb" xlink:href="advm-20211231.xsd#advm_StockOptionsAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_advm_StockOptionsAndRestrictedStockUnitsMember_e298bf0c-e8a1-4883-8929-f7b0116e35eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9605c5bb-8494-4fbc-81fc-14a9d7bac2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_StockCompensationPlanMember_9605c5bb-8494-4fbc-81fc-14a9d7bac2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f276739b-7b4c-43ef-8ddf-cb207b202137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f276739b-7b4c-43ef-8ddf-cb207b202137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_5600b538-f0bf-4605-a980-abd7755bdc60" xlink:href="advm-20211231.xsd#advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember_5600b538-f0bf-4605-a980-abd7755bdc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8841555a-fa24-4af9-85fb-f180cb5326b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8841555a-fa24-4af9-85fb-f180cb5326b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_5932ac66-9198-4da3-a078-bafa0d565893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792f3623-ac21-4b01-b7e9-bf98a500d490" xlink:to="loc_us-gaap_PerformanceSharesMember_5932ac66-9198-4da3-a078-bafa0d565893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_472de4fc-226c-492c-9398-b77694ee04a9" xlink:to="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9b967afc-249c-4632-a281-ed467419a064" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:to="loc_srt_MinimumMember_9b967afc-249c-4632-a281-ed467419a064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a0ee98ad-72f1-4e19-ae0d-5bd372ec0b3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6e7a8039-47e9-4db3-afaa-e12b244c89cb" xlink:to="loc_srt_MaximumMember_a0ee98ad-72f1-4e19-ae0d-5bd372ec0b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e44b3d38-daef-4a8f-84ba-78b87dc7159f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_13e3ee64-52f3-4557-a761-50e10dc8bf7b" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan_13e3ee64-52f3-4557-a761-50e10dc8bf7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3ae92794-5def-4a10-91d0-1a4a0163e232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3ae92794-5def-4a10-91d0-1a4a0163e232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2142f939-d5d0-4ddd-8740-76ede8cdc855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_2142f939-d5d0-4ddd-8740-76ede8cdc855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_57d62d97-a31c-4d74-85db-c046ce209e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_57d62d97-a31c-4d74-85db-c046ce209e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc4dcd3d-560b-473b-96d9-1334fd4d42ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_cc4dcd3d-560b-473b-96d9-1334fd4d42ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_69b5196c-f072-4f08-9bb0-5f34a0cb57c2" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum_69b5196c-f072-4f08-9bb0-5f34a0cb57c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_53b3d754-3a3d-4d7d-a8c0-6b0698d1c61f" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold_53b3d754-3a3d-4d7d-a8c0-6b0698d1c61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e4dfbe6-abd7-4f22-98b4-17775d81e64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_4e4dfbe6-abd7-4f22-98b4-17775d81e64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e5bc5b4-16d8-4637-8cb3-e54221ed0224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5e5bc5b4-16d8-4637-8cb3-e54221ed0224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fb45ea6c-e995-4c3e-80bf-025c03b9e0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_fb45ea6c-e995-4c3e-80bf-025c03b9e0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6782aa6c-9b6b-4a0c-b246-99cb3bfc82b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6782aa6c-9b6b-4a0c-b246-99cb3bfc82b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67eaffbf-ea7a-4b88-9f61-720f44db9660" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_67eaffbf-ea7a-4b88-9f61-720f44db9660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69f06af7-f2f3-420e-8c57-4bdde8ade766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69f06af7-f2f3-420e-8c57-4bdde8ade766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e7249a6e-59f0-4f85-98c6-9ff3fbd7f1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e7249a6e-59f0-4f85-98c6-9ff3fbd7f1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4b3c04f8-8c11-43f0-9f56-fd32e606043a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_4b3c04f8-8c11-43f0-9f56-fd32e606043a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_39b36811-813d-47de-9bed-38b9bac95c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_39b36811-813d-47de-9bed-38b9bac95c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_9cd66f9c-9b2e-4b34-a7d9-9fe174884a48" xlink:href="advm-20211231.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage_9cd66f9c-9b2e-4b34-a7d9-9fe174884a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_397e521a-ec21-49b0-8d90-6c35243959ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_397e521a-ec21-49b0-8d90-6c35243959ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionPlanExpense_7d6c4a97-7e3d-47ec-aca8-031e01bae543" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionPlanExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0bbae9ec-4bb0-4fc2-8683-d5958686f8c3" xlink:to="loc_us-gaap_StockOptionPlanExpense_7d6c4a97-7e3d-47ec-aca8-031e01bae543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansSummaryofStockOptionsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45f04b33-edaf-4f8f-85b6-f582cc683b13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_45f04b33-edaf-4f8f-85b6-f582cc683b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b3e79b4d-c85b-423f-a671-5a4f73168664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b3e79b4d-c85b-423f-a671-5a4f73168664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a56f5c02-39c2-4dfd-8633-d093b66a1de3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a56f5c02-39c2-4dfd-8633-d093b66a1de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_992c26df-85d0-409b-bc50-ce6d400a908a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_992c26df-85d0-409b-bc50-ce6d400a908a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f5136393-6856-4940-b7b3-0e50fe37827d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7c1d716d-b914-4271-a76a-2349cd74288a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f5136393-6856-4940-b7b3-0e50fe37827d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_87bc3e97-c38b-47b9-a607-41b914b43db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_87bc3e97-c38b-47b9-a607-41b914b43db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62243e6d-96c7-44a2-ac97-834b2e73d686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_62243e6d-96c7-44a2-ac97-834b2e73d686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d29a9dd0-3393-4fa1-923c-6cce70e7a71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d29a9dd0-3393-4fa1-923c-6cce70e7a71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_afee1664-fa9e-4686-aa60-f86826398b76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_afee1664-fa9e-4686-aa60-f86826398b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761f5ca0-b826-4d2a-88fa-9129d6cc1506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_761f5ca0-b826-4d2a-88fa-9129d6cc1506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3b3d15e3-22d5-4ea2-9a70-890d4838819b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3b3d15e3-22d5-4ea2-9a70-890d4838819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5498931e-a61b-4cf6-b9df-78310e8b1dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6349f24b-c8e7-43f2-ac0f-1cda5c00db49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5498931e-a61b-4cf6-b9df-78310e8b1dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_69e16e28-e818-49d5-a340-0c69fe188449" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_69e16e28-e818-49d5-a340-0c69fe188449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_10038de0-e596-4912-8e83-a5160b5167c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_10038de0-e596-4912-8e83-a5160b5167c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ce3625e-a7dc-4852-b7ac-6beb1bd8528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ce3625e-a7dc-4852-b7ac-6beb1bd8528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c0754122-567c-4751-b2bf-dcc359f569c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ce3625e-a7dc-4852-b7ac-6beb1bd8528d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c0754122-567c-4751-b2bf-dcc359f569c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3284af43-5096-4d93-8dfc-3c178a4130ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ce3625e-a7dc-4852-b7ac-6beb1bd8528d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_3284af43-5096-4d93-8dfc-3c178a4130ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a83a3d5d-a38f-4692-a938-536fa2427852" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1ce3625e-a7dc-4852-b7ac-6beb1bd8528d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a83a3d5d-a38f-4692-a938-536fa2427852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9c488156-0a63-4185-8960-3b35eadc2228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9c488156-0a63-4185-8960-3b35eadc2228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_164d468c-6b89-4637-bfe2-023d060d67e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_164d468c-6b89-4637-bfe2-023d060d67e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2130bdef-7dd0-4487-90c2-36180b71fdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_09cc2a99-9451-42ad-9c94-c737d67d8c3e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2130bdef-7dd0-4487-90c2-36180b71fdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9695165c-133c-43a9-862e-d7d467af7f86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9695165c-133c-43a9-862e-d7d467af7f86" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:to="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a305df61-f0ac-4784-b1a7-8f1f87213cd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7b8b29af-4734-4cee-b068-f264d0bd7ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7b8b29af-4734-4cee-b068-f264d0bd7ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_22050ee3-9677-48ec-97db-43bccc6a9df7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c4d7d64-0e2b-4943-a6d9-c5337e722efd" xlink:to="loc_us-gaap_EmployeeStockMember_22050ee3-9677-48ec-97db-43bccc6a9df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0675ac36-26db-4a5e-b4b5-91bf87fb6dbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5fdb8783-38df-4e4c-8a6e-4be3cb5cf7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5fdb8783-38df-4e4c-8a6e-4be3cb5cf7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7b0cee7-7c85-44ac-bda2-e53f562f3159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c7b0cee7-7c85-44ac-bda2-e53f562f3159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_460c8742-1466-4990-8b07-fb1c0315de5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_460c8742-1466-4990-8b07-fb1c0315de5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1de0446f-bbf7-4dd2-b5e5-ca977c062ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80586bb6-9cb2-45ba-9b0d-e25502ae26c2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1de0446f-bbf7-4dd2-b5e5-ca977c062ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_300c4764-d88f-404d-9e66-c790dba707ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_300c4764-d88f-404d-9e66-c790dba707ef" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:to="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44830091-ffd7-41de-89b5-0054a4cc779b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_16209eab-73bf-478b-a047-41048017ed91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44830091-ffd7-41de-89b5-0054a4cc779b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_0d05efc4-61f8-4da1-9ef4-28d8d56e18ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44830091-ffd7-41de-89b5-0054a4cc779b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_0d05efc4-61f8-4da1-9ef4-28d8d56e18ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_acfbe73d-7555-4ae2-bd1e-ca8289013403" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_faa1316e-02c4-431b-aa53-772e7940e864" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_faa1316e-02c4-431b-aa53-772e7940e864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a6272a74-5fdc-4588-a8ea-a37c8b65bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a6272a74-5fdc-4588-a8ea-a37c8b65bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fd8f7ee1-9e10-4fe4-98d5-c957fd564d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_fd8f7ee1-9e10-4fe4-98d5-c957fd564d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ded1b63-482c-43b2-bf98-d45866cecb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0ded1b63-482c-43b2-bf98-d45866cecb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55562694-2a6f-49b6-828e-086d879bd5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_528f429a-6fe5-4780-86a6-b31a21276f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_55562694-2a6f-49b6-828e-086d879bd5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8c67a70-1bac-4a7e-9e02-651ff3bc80bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8c67a70-1bac-4a7e-9e02-651ff3bc80bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f77679a-748b-47eb-a7b7-315692c7f612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2f77679a-748b-47eb-a7b7-315692c7f612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b02cbf7e-1875-432e-a725-506e490b38d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_b02cbf7e-1875-432e-a725-506e490b38d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a224b97d-8935-4723-be50-f566798883b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a224b97d-8935-4723-be50-f566798883b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16c492f4-0a56-4c8b-90d1-c74549c9af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8a6bb4ec-4b2b-4323-b61f-718ddc819d6e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_16c492f4-0a56-4c8b-90d1-c74549c9af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bf9902b5-ebcd-4229-a11c-f8deafce448f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7bb61ab2-9cf9-4269-a629-23eecc29bf3c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bf9902b5-ebcd-4229-a11c-f8deafce448f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92d2eefa-145b-4efe-908b-3740b97d5986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_bf9902b5-ebcd-4229-a11c-f8deafce448f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_92d2eefa-145b-4efe-908b-3740b97d5986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#StockPlansStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_805c782e-4650-4cf6-9419-e16aeedc547c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_805c782e-4650-4cf6-9419-e16aeedc547c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_62a3f00f-21b3-4654-9652-cff7fb5a860b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebcda3aa-9f6e-41f6-807e-5b465f725137" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ebcda3aa-9f6e-41f6-807e-5b465f725137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8b4cf5e8-314e-44df-95c1-90217035d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_fcd26408-4279-44a0-80af-80e706d13ac1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_8b4cf5e8-314e-44df-95c1-90217035d0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee592a06-4a57-4a5d-b16d-99cd8a7d3c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_162ce99c-7226-42bc-bb49-b90eca9fbda4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee592a06-4a57-4a5d-b16d-99cd8a7d3c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b90270b-7c4d-45c4-9d54-3bfd16a47120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ee592a06-4a57-4a5d-b16d-99cd8a7d3c9b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b90270b-7c4d-45c4-9d54-3bfd16a47120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/A401kSavingsPlan" xlink:type="simple" xlink:href="advm-20211231.xsd#A401kSavingsPlan"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/A401kSavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_10c339c9-b328-40fa-acf4-27f36050a370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_f240ed70-1f71-4b32-a50b-020cf7eb2cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_10c339c9-b328-40fa-acf4-27f36050a370" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock_f240ed70-1f71-4b32-a50b-020cf7eb2cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#A401kSavingsPlanAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_730ecc90-e62d-42de-aec5-39eb5d0ae161" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_58499d05-96b6-491b-9c0b-fcef9d38587e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_730ecc90-e62d-42de-aec5-39eb5d0ae161" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_58499d05-96b6-491b-9c0b-fcef9d38587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxes" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bd6f22fa-c730-4c3b-b255-489d357eb075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_db57d03b-549c-4c98-8c3f-901231ea28c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bd6f22fa-c730-4c3b-b255-489d357eb075" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_db57d03b-549c-4c98-8c3f-901231ea28c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7158655f-1f8a-4569-bbcb-70ad04f1c94e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a11169f0-34d3-4c7a-929a-57648eed66b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7158655f-1f8a-4569-bbcb-70ad04f1c94e" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_a11169f0-34d3-4c7a-929a-57648eed66b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b1a7c041-8114-4790-98de-5eb0ae98fef5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7158655f-1f8a-4569-bbcb-70ad04f1c94e" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b1a7c041-8114-4790-98de-5eb0ae98fef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cd4b39c5-108b-42e7-94da-9ac2a35c4e11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7158655f-1f8a-4569-bbcb-70ad04f1c94e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cd4b39c5-108b-42e7-94da-9ac2a35c4e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bb0d44b7-5de0-4871-ab2f-9104f2a63f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7158655f-1f8a-4569-bbcb-70ad04f1c94e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bb0d44b7-5de0-4871-ab2f-9104f2a63f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0a4c1c30-ec69-4ed9-948c-48152fecdbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7158655f-1f8a-4569-bbcb-70ad04f1c94e" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_0a4c1c30-ec69-4ed9-948c-48152fecdbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d34a6e10-e04c-4750-9d23-6651a85069b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_12c46759-a1f9-4688-8543-3b4a3b9f480f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d34a6e10-e04c-4750-9d23-6651a85069b4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_12c46759-a1f9-4688-8543-3b4a3b9f480f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_19162f1a-d463-42e3-9a0c-bfdae56ce61f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d34a6e10-e04c-4750-9d23-6651a85069b4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_19162f1a-d463-42e3-9a0c-bfdae56ce61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd08beb7-edf3-4cf8-9a64-53bc3f824b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d34a6e10-e04c-4750-9d23-6651a85069b4" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bd08beb7-edf3-4cf8-9a64-53bc3f824b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6fc3c13c-8f07-4105-abc9-c1badecade44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e03131e0-492c-452a-ab03-a455bab88dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6fc3c13c-8f07-4105-abc9-c1badecade44" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e03131e0-492c-452a-ab03-a455bab88dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0b97a7be-990d-4435-a398-79df417c1c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e03131e0-492c-452a-ab03-a455bab88dcc" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_0b97a7be-990d-4435-a398-79df417c1c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d24b323e-94af-4141-9704-020cab8906fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_e03131e0-492c-452a-ab03-a455bab88dcc" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d24b323e-94af-4141-9704-020cab8906fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5df71a7a-bc54-4cfb-b7b2-4d4de88126de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6fc3c13c-8f07-4105-abc9-c1badecade44" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5df71a7a-bc54-4cfb-b7b2-4d4de88126de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6be53b0e-1e66-4587-833c-5c80fdb4fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5df71a7a-bc54-4cfb-b7b2-4d4de88126de" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6be53b0e-1e66-4587-833c-5c80fdb4fd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0a890cf8-158a-4e65-bfde-50710eb15029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5df71a7a-bc54-4cfb-b7b2-4d4de88126de" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0a890cf8-158a-4e65-bfde-50710eb15029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_759da298-11e7-4920-85fd-2f0a4d74865f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6fc3c13c-8f07-4105-abc9-c1badecade44" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_759da298-11e7-4920-85fd-2f0a4d74865f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_88c8c681-f35c-41cc-9a9b-cc733b81ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_88c8c681-f35c-41cc-9a9b-cc733b81ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a969fc5f-03cf-4c60-9396-cfc1b60a6be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_a969fc5f-03cf-4c60-9396-cfc1b60a6be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2dcded1f-ec98-491e-adf2-674357228881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_2dcded1f-ec98-491e-adf2-674357228881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4d11dc1e-206c-4c27-9533-70e832dcc00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4d11dc1e-206c-4c27-9533-70e832dcc00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3095879d-eed1-4ad7-ab93-5d2eeea32697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_3095879d-eed1-4ad7-ab93-5d2eeea32697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_cbacefdd-e52d-411d-89fb-b754d154c4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_cbacefdd-e52d-411d-89fb-b754d154c4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_f77898f9-3e15-486b-bdba-07625c089fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges_f77898f9-3e15-486b-bdba-07625c089fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_72b724cb-54a5-49b8-b9c2-f151949bc7fa" xlink:href="advm-20211231.xsd#advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition_72b724cb-54a5-49b8-b9c2-f151949bc7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_506c700d-0bf8-4dc4-b4c7-6b5020d47c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_506c700d-0bf8-4dc4-b4c7-6b5020d47c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4d470168-ff39-4972-b9fb-17c97f462a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8989d0ce-6051-4448-b5e5-a2504160f65f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4d470168-ff39-4972-b9fb-17c97f462a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_69612c68-f9ec-4284-ba11-c4e9367690eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69612c68-f9ec-4284-ba11-c4e9367690eb" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bcfe322a-9962-4328-8600-f8231d301380" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bcfe322a-9962-4328-8600-f8231d301380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_18fa079f-de28-4dc5-a72b-59f4d32930d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_18fa079f-de28-4dc5-a72b-59f4d32930d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fcf90b8a-fa1a-47df-8d7f-d3d8c01c6981" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fcf90b8a-fa1a-47df-8d7f-d3d8c01c6981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0412061b-789d-43b5-83ff-4142b93e4469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0412061b-789d-43b5-83ff-4142b93e4469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6ff314fa-423f-406d-a0ee-ff9de0760ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6ff314fa-423f-406d-a0ee-ff9de0760ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DeferredTaxAssetsLeaseObligation_e4373b59-bfa8-4a66-9000-2e952da0f485" xlink:href="advm-20211231.xsd#advm_DeferredTaxAssetsLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_advm_DeferredTaxAssetsLeaseObligation_e4373b59-bfa8-4a66-9000-2e952da0f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ab93d0bf-6077-4192-9b6d-409f6a11d1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_ab93d0bf-6077-4192-9b6d-409f6a11d1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_176d4e33-b1ea-4480-b050-e9de34adb0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_176d4e33-b1ea-4480-b050-e9de34adb0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_47760b7b-b01c-4c78-af63-13416fa9e361" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_47760b7b-b01c-4c78-af63-13416fa9e361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b45870dd-bb5e-4e7e-abfc-1a3a4f06e3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b45870dd-bb5e-4e7e-abfc-1a3a4f06e3c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_87ddfcc0-d8da-4ed3-b46e-527c173910ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_4f7be259-60cd-4581-a2db-9c35ff90a575" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_87ddfcc0-d8da-4ed3-b46e-527c173910ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c9290637-ef5a-4376-8017-b56e3626c299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69612c68-f9ec-4284-ba11-c4e9367690eb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c9290637-ef5a-4376-8017-b56e3626c299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bedc1eed-58b5-4e9a-9c68-dc7b4a2698c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c9290637-ef5a-4376-8017-b56e3626c299" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_bedc1eed-58b5-4e9a-9c68-dc7b4a2698c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_313329cc-089c-49eb-9788-03408908fc70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c9290637-ef5a-4376-8017-b56e3626c299" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_313329cc-089c-49eb-9788-03408908fc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_def3faa3-f420-4827-bac7-c8a10d7401c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c9290637-ef5a-4376-8017-b56e3626c299" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_def3faa3-f420-4827-bac7-c8a10d7401c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8726eac3-0c44-4c61-9aa5-8cd7465e2467" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_69612c68-f9ec-4284-ba11-c4e9367690eb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8726eac3-0c44-4c61-9aa5-8cd7465e2467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6f485454-4409-4583-bdda-b464ed7dcf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:href="advm-20211231.xsd#advm_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6f485454-4409-4583-bdda-b464ed7dcf96" xlink:to="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_a0be6dc0-6ee8-43a7-931e-f14ac6d5dd41" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_58bc0a3d-b9cd-4050-9280-d7d4ff72a703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:to="loc_us-gaap_DomesticCountryMember_58bc0a3d-b9cd-4050-9280-d7d4ff72a703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1b765dbf-a1e6-4d0c-8202-d9264bb645eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1b765dbf-a1e6-4d0c-8202-d9264bb645eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_90fe098b-28cc-4887-b39b-fe7edc8df2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_89d2c7f1-814b-44b8-a479-9ba5bd4284bc" xlink:to="loc_us-gaap_ForeignCountryMember_90fe098b-28cc-4887-b39b-fe7edc8df2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_e318c529-1173-4f4c-8264-efe7053562f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_585f796c-c202-4830-b715-95f51293f3e9" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_e318c529-1173-4f4c-8264-efe7053562f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_94fc60a2-970e-4e16-95ca-189b6599103a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_e318c529-1173-4f4c-8264-efe7053562f0" xlink:to="loc_us-gaap_ResearchMember_94fc60a2-970e-4e16-95ca-189b6599103a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:href="advm-20211231.xsd#advm_IncomeTaxesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesTable_9722bdf5-64ab-4806-92fc-f736e666f3a6" xlink:to="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc52262a-f43d-408a-b15d-87c3eb477afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_bc52262a-f43d-408a-b15d-87c3eb477afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f04ba04b-8f3b-481b-a5ed-d814553a486d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_OperatingLossCarryforwards_f04ba04b-8f3b-481b-a5ed-d814553a486d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e87ae889-05ab-40e0-aa1f-0c67f7b2093e" xlink:href="advm-20211231.xsd#advm_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_advm_OperatingLossCarryforwardsSubjectToExpiration_e87ae889-05ab-40e0-aa1f-0c67f7b2093e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ec02337c-63bd-46b0-85fb-c2268a98f3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ec02337c-63bd-46b0-85fb-c2268a98f3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_fcb6fb3e-3415-40a0-95a9-94542348b15a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_fcb6fb3e-3415-40a0-95a9-94542348b15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f41be3d7-d3e3-4e79-a958-7e96bfa924ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f41be3d7-d3e3-4e79-a958-7e96bfa924ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ee197aa9-6485-48e9-a322-18c091803587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_advm_IncomeTaxesLineItems_75dbc832-8978-4386-bc77-13823bc07d48" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ee197aa9-6485-48e9-a322-18c091803587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_881c17cf-c605-4f41-99eb-1c2d03b7e229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_917fe086-c2f6-4762-aae7-d1eab31ae48a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_881c17cf-c605-4f41-99eb-1c2d03b7e229" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_917fe086-c2f6-4762-aae7-d1eab31ae48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6f4e0e87-026c-4726-9468-80badaad44ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_917fe086-c2f6-4762-aae7-d1eab31ae48a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6f4e0e87-026c-4726-9468-80badaad44ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_bd408595-651d-4dd9-867c-cfe15eff963e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_917fe086-c2f6-4762-aae7-d1eab31ae48a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_bd408595-651d-4dd9-867c-cfe15eff963e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_58eff469-4128-4a78-8840-673f95601e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_917fe086-c2f6-4762-aae7-d1eab31ae48a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_58eff469-4128-4a78-8840-673f95601e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_170d7ad8-b33c-4e2b-bd8f-ed3a90044b91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_917fe086-c2f6-4762-aae7-d1eab31ae48a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_170d7ad8-b33c-4e2b-bd8f-ed3a90044b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20211231.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0c833763-9dbd-4b74-b3b4-413807676534" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_f11d6690-439e-46cd-b1ed-2921e1715971" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0c833763-9dbd-4b74-b3b4-413807676534" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_f11d6690-439e-46cd-b1ed-2921e1715971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20211231.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_77afb0ee-12de-49e1-bb07-d83f7b5300c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_745dab8a-5a20-47c4-baa9-9e96ff0d14e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_77afb0ee-12de-49e1-bb07-d83f7b5300c1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_745dab8a-5a20-47c4-baa9-9e96ff0d14e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" xlink:type="simple" xlink:href="advm-20211231.xsd#NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4ad619ed-ac15-4bbd-8786-ad3eaa156d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4ad619ed-ac15-4bbd-8786-ad3eaa156d96" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_54cebb8b-2004-4734-89d6-88e9655a7f35" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_84d461af-14dc-4c36-b644-a17dbf02c673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_84d461af-14dc-4c36-b644-a17dbf02c673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8b6fc554-dffb-489d-a948-184c39278de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8b6fc554-dffb-489d-a948-184c39278de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_5600e2de-530c-46a9-87b7-70671f766835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_757ea68a-e097-4feb-ae77-12413473c6f7" xlink:to="loc_us-gaap_EmployeeStockMember_5600e2de-530c-46a9-87b7-70671f766835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3a2a184f-3ab9-4fe2-b0f0-d849879588b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_794748d1-7835-4163-a334-31cfd7b2e973" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3a2a184f-3ab9-4fe2-b0f0-d849879588b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35127b65-87a7-4239-8864-535e4956e824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3a2a184f-3ab9-4fe2-b0f0-d849879588b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_35127b65-87a7-4239-8864-535e4956e824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>advm-20211231_g1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20211231_g1.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MPX.9N+8A ATRB%P:"#2 0#0+/5@AA @<X  ./V2RC$&:N(B 0S@\^(9 #B(
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M^@L U;1JB= 'FTH9_ J PL?G-+$TJ- 3ZBQ? @EHFQ+V?) Q,XAC C_-\:@
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MV<ZMVM*MV\IMW>;MW=HMW/(MWNZMWO9MX/ZMX *NX18NXA*NXOHMXP8N!?A
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M-H96^M9O^TY"_-+U_:ZK7'^LYXHK_M;@>,X;;H&@$8ZS<XYFVAEP$0"O VP
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M8C,V*^K%19:XP1R+19]Y;:9Y3>V3J9RT>;=<*8,.OP$EQW>.9W*/SS=LDWI
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M#(;&81RV&I!&8/I":)>E&)R5&89W81 (@0U7: +G61WX&)*G+P,E>(<F#
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M!_>1!5.37,J04,N"/ F>R.>4_SWKE @ !\<8%6EB(RS4 ,3@E+D6ISN'APX
ML,8H9ROR<D/KN"$CC06)2Q%K?#E7ECAK% L;?-AHAXYJ7 A13 B:=,_WA4P7
M;$%7=%,'NL=$3$DE*9LB ^RANBWQLM\&$G8XD,!EL4,1A82*?/.'J#<Q?X]+
MO$;!5BM2KR>5F=5B5YJSM&TC8LZ19WT!#7"@ IQE>%$*0(_UI 8$G(VVI..*
MDJPIFP!%K9ZXB1X9G-PKKH37H\H* &]@6OXG-B9T)[WZ!FFP<T[YIK+81<K
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MK>?KW!*XY$E.B7RCDHX1SRPOZW1Q%WTQ%:V735!#$0H<K^X-Y]1,9WX>BZ
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MA.,WB/-&=)R(".K#Q.G#.MN@OSK"=K+"U+K#-Y$-4 " +MFF>6F]F@.S1Y1
M6]K_IB3AF!S:%^TBC'SQJ5UR"Y^JP GTH8!,AI];"MHS)LYYP62@/620,G98
M)C&(A) 4 ZF2D5AK$L]YR&W3G7>Y%Y=$2:RH+G2*!B,X@IHT@CN @SNP@SL(
M(?2+!DTH@C=# !RH#+SZPQ+! 4V AD9#O^C@FT;+A!QX#=!81I"SPOP*BBQ,
M1ZZ,$#NJFOYHL 020P7I2O'[E7VPF^@8E@8I/VML)+,TRTU++==B+Z+ PZ%
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M J<J8T[L Y=;L_5OCIYL,-ZF$YUE=BCC)M"$Q"7C_9GFQ!7F>R$/Y.8D4#@
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M#3(84?MG:D8UL/2E;>OZ]^.??X,-U3\?L?0(I""VFA][VJ>_ SXK6I<*G$E
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MF%FAV?E%^I$.Y]#0>L4=DT")G4G)N_4+2? +OMU;5\$&:7P;F*@5?TD"Y^'
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MBZ>%2=IOA0Y^]V$XP9 Y*0?OQ$0CS!5"]"- 0*$/U%B#_U[L"/XE(ZZ33^S
MC$<OO#!H].Y@<DP!5>% 0B0$#0Q $BXA$G8AV[(-=K/:"/B+CR-!$KAZ%X3!
M#8"W6A#LS:(B+WZ@?^AB&:IU3^(@!R%JLO I*M*F6(HE6?[K+9!D!@=+1-#
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M\,F^6^BC1S?#R-+>71F5.*H22#([!K (&7BB/6D[&$PJ;+*P)%=.W,,F(.@
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M,XV$>9(:R[OL&J"GC+YFR' $,K=*==<B?K=ECLU67=:JK/M W48@S/L0W4<
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M9,JB>[*)_>1B4@%9)1FIW$<^12VAA G%"4;(P;PR_R:F])G%8V9QG[$2)I&
M 0X %HI][Q)?H2$P'?_-M719YHV?*;C2;QD97NX+F<I!FP+IIAI WS3"&-Y'
M;WX3G'WD#P W: YQ)A'4&*1=->3[^M910XRJ D ,&UX-_AXH!E.MAFYH6,&3
MT$#O?<QSPG+#6W4J$-$GK\<_X0RG.6.,Y/70V#4!16@[3W?Y]>SXR)C/O&O
MDV+L.&ZA',"GC3/O9'FJ!SR.$ZCF#21Y<>Z- U:F\G<6:NY/\5JM/"+AC)#=
MZQ-=#Z^0DE.B?KU!XS>JK6M5T94\V-(-OBBJ7#V1:V# O"R93T8Z!1%-I??
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MI_WI#^H->.]F:=JBAVH]S7B)#_\U=]PIC]J<K]RNT^JLCC4Q]MJO;A:QO7(
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MK.8U[T,\%'@B=PA;+(UU;#EWW<YVG -3OKQT+BH=K%^K2&>LA(*)@='$?L
MU"&&U88=3.N1OG:!AL^\4'"LF8H)!<<9R]#+TJE!P\#R99L/)O6'XK*$; !6
MU$NH]88W9'5;;\@8M^:KB%\U#!B85AQ0F&(94E367/^<TN50;*]_?59=239H
M!V+EUQIS<U)6MI0^%<V0G(*LS2*+QN@1HT\ 8&1H]93?_GQ[*'J\(X(F CTS
MMA-1W>8>S-Y3N4S,L]I1 X !*O^G*PFQ]VK'#68P?RG,+347F+_T)=<V5/ H
MT:W@"-^MENA+W8@G7$OWK>3"#\Y+@1\\XUU[PTWVH0^A\#>9#(U(@"MZ<M3-
M3W0)'?/[W"1SALZ/(P'^,(-+-RF)=MG"U_1PZ18\S5BA!,'>?.8T5Y)NSL$<
M=*U[^=%7KO.3YX3F+[_FSC&,OILXLR>H93/8P]XKE/U/B_^SV*!S6MA3T+59
MIA T2\O^9[Q*\5C&T=8;.+68H?+]U6J=S0=1_?<S4/J$3XVA:3R3 Q^ .JUK
M)6K #K-55S]ZJVB5=:@?C9O%!..KEP_A5F%P@#?$M==ZM<OI_TJRFVJL[@!$
MZ11K:G;_/\,][F;/BN!2AA1U,D4C4!N(S/X8V4#>+&>VW"QG!YJ[J=41 'Z<
MF2V=7Q1]YDZ.BU3^M:>?.YWE:D)BHZYPX4M?WZZWOOTF?WW-KTG<:E+\Z!\N
MQK?6_O;>-N#@A^25UO_+]N,2O),C__T!27.A7_VI7[_E5G"QUP;DUS+HPWZA
MUD\@ "@46(8=1"BDQ(2)Q,V1B=%-6 5669=]((5QG3)I& B"8)&EH,JQW I:
M6,Y9V(+%W-%-H#* PH\Q5"A05#/U'$<8G35YBD:%3CB%4Z2DBC)<X$%H@JJ\
M3\JA7 GNX)-I8 ^2H ON( 9&6)&=H$4)W=.QCA6:W#Y @]B-_R$9/H48J5U?
M%=NQW!FPN9T:ON':*4<;"E;J*8L4[9HFA $ * *CL=58;95;A56XG $:3)IH
MG 9F^ #CG0%9#=6C>95BZ-"W+,9:.<9: 9&L=9YMH)7E<94-Q9H.G8$*W$ F
M[)JO!=NQH%T;TH7K95')M")@H9Y=2)&<M50"N=[(R)U>0-L9#80B,<6(W9N]
M]0=1O%'S^03T7$129 +U6,0>45: G)% ^>(DB&&$3&.D<)\:*4WO9"-2D!OS
M1<676 W:"*#&<1PO:9+#>4V'K.,Z[A]MG6/!<5*%[!8HU=;%Y1_[Q5<[5D!]
MW6, ?LA[_9OY%63]T:,^:AS\0=S6@/]<,7U=&%;-YM0@0H33!5K*GRP#*'09
M*,#31B+$1Q+#1UH4$HID$H*D,VVD,UUD1RJ#$I[D$4*$2K:D2-;81LHD.7UD
M.+FDUJ7D>7RD1OZD@YV*T<T$,_U)F&VA0C64C\U$2\[*1FY83Q[$)AQ$5.YD
MSA5E@:#!%M;8"A(#$E:E5(JD3RJ#6/YDE74D3EK*32*A1:)E3=9@6=)@#,9@
M1=Y$58*D2-!@5-H@3\8E$K8D @!%&1:F82(%V6G,%&71'*:=L&E1744079D%
M=]S9*S;;Q<3A6331*>P:'"2:X^W=P!056;':MP"BK$V>'QH5!PU,5PV,6OU=
M(,*FXWV55PG_(JD%C.;E2R5*GN;E&AHDD7$D"QK:WF(N6^U]1;7<615)IG'*
M(K-81QLBUF%6YT=)#1E.R#T69,/9XVY=W(E$5SVRUU2 4GC"7SZ2YS[V(W6E
M)SV"I]8PY'92$D)6TCGR'_B=YSF.IW<2H'TE9'M2" /VES6.E@16F:=TI8<]
M)5"B1U1.Q 7FX$0\9152)%'>1(.2((:>BDK6(-9E)(8:Q$W:W(B"H$Z:I8?R
MI(J&TTA:I9RT9$O^B4D"60V:)$6*9'J<)(Y:E(6R*(XAF!)^9$C6:(&4Q!&&
MX%/*Z)!"'<Z-Y$@BH8AJX85"Z1,RF*=LI U>()9*)4@^X8Y>:/KD_^AY] 1A
M6J>9CF$%B$>P09!>L46>R=UBRF'L00NP@8SM18R=Z@4MLI1T+,-5%(<FO(%P
M<-4F5EY9(<Q66>)AH)I1'>I1N::C&I$DTN:BIB; <%59"57GZ<NF%I5:Y29J
M/AH.'14,! #I%4<H]-H55=&J*ELL1B<#N:KKI1X"P06;TI['4$O;U5E>B-&9
M_BK^/$C828@_EN,&O-][&BL\#J1VT>?DZ.="'B!"OE]!'J#YQ:.R.MQVFB=[
M;6NUSE^S_J.X J1!=IS <=(Z;L ;6(I00"1G<=:94>1%(J&63JBGI,>+FJ04
M+JDR^26,^AB#96140H0S*6F4$FS 0E-Z^/\E5MHK>G3I3EH*$B(H!FKHE[UH
MP5[HTZ4D#++$P'HLP)X$P6*I528HP@;E@X6"J2PLDJZ$^<RD3+[L6DJH,SD3
MP"[L@OEE51;#2-(H6%H@3L9DSO6<R3)8EI:.$NJKDN*D1N(D1P$KU*89!?S*
M8_)IH.6%K+K4G$5G&V9'+<+=UCY,8^:97P#JM@" HHDJYHT:PH JH3[:6E$>
MOX1J;@[,I"(JI"&5;H;JWH80PFQJHAY&KH6!!05&H<&B<R9N*GH'3OD53MDA
MU[XA7ET'Y1:;*?Q*!42MYD8%=HZA]^5C08Y-?8GN?(YK_K%GL=[7/%9KN2XD
M*'4(M/9?ZD8K)^G_I[?B#>SBKK/NEKG^'RZE7\!%E[:F:8!&%_"6IX7P4P/^
MQ%%(),6R98XN&$M:94HHZ<,*;5X^F(RZZ)"R;(-&;U!:Z,B^;$KPK/F :)?Z
MY5$"[7GXZ(YV)(O::%6VZ Z^)/SRY(A*[%W^"5).:,G:X%[2Z)^,J,V")%E2
MY/;NI*D<:95)J,\N*0VB98 )J84*Z>P,[9#R;,6.8- F+47F:U FJ)(&6--R
M*,6J)1@^X^:N<*[\ %4TD9LVQ]BNU"S6:@"%;0-5KN16[5[ HK0 JJ"J "0<
M%5HU*EI]E5OE+1$[:@AMZJ/^71'[)J0)G@;E)A)3WA.7E1+[W:%"JB)4_\0;
M"*<I]!IE<A$=HE2P#8NKWL5=K?'LW<6LZG"<.N><58NY^  +YW%2""O8_<0C
MI2[OHJ?6<!+P%FLAZR[Q1I?H(K)N+;(B5TAXVE<]<JOM^F/=C"XD#Q<N\2?J
MLA]WONY_<JL_4K(DWU<DB[)N7?+K3K(A2S+KJBN[NNM0 (4R.("-;J2$,K#Z
M0NC#]B_U_FR)GBB9[+),!B4*TRC)7N2$HM/$_J4-MNA-/C/"BJ]!^*A;&J5%
MY:7_)FR0GDK#,@J6%C#]6FA.>HJ,1FF$47""$JF+PJ0!;S/U1H1:0C"7Y>]8
MEC."^F7)HD>]"O"1;N0 :]T^VRB1'G.4_N5YY/]@!&,I]#J "NLQ1#L%$?P*
MV[FJGZEQ#&,,7ZPA'6.F7MBI=EBT8=G59![;2;WJ580"-*3JH=4!#@2 #=!F
M5\WTIC*QX\G:%>>FJV7QJ.8M)[HF%GM5IG8Q( (5I-VF%D,:)*Q']I2B7/DI
M26WM')HQVNGBG\T4='Y'Q;AI KW>1LL=*$QM$40T65M;.+)9/="#>HYR^C57
MN0Y@(F=R)&=R0K9U(O?C*C]R/P*H(<\?0A(R)>\CZ1*O(:-R[ 9H76,KW>!U
M)^NGZ5ZR7&_ 3@9%@9[1Y@"P#G[I_&+HSY8LS2K3!?8O1HYE1S+TPX+SA0%L
M0',DSK).OEJ4FOBE!D?_[/7Z,T#W7$;&+%%*,V[?I9B.:%6"I3_?1"[?Z%_.
M:WJ$ME2B4W"[)#S=<\_*-D)769"N[XA.X)".Y&I7\X.5=@C::(096,9B-VI#
M1'"GLW&SI7'K:$);RN;(<EG'-U' @7C 07.^,672<$<79U5S]5S-\$L!.,5T
MK7*&S'%T)A[6!Q@L\:,>519'@@XY.&TJ,:3R-%#/=%(O<88#E6]*^"Y0,81O
MN*SE&BG:07&8@DJC\6.R:1S+Z=8BYW/6Z@XOKE?C567:A1W\RAO(MQYW+ILY
MDM6D'W?J[EP_LGCZ8^VJ)_(:8'?*[OD1-BGC;NDZ,B:K\NF.)RW%(RC[%BZ=
M_W(KB[*X&OECR[65,^1>KZ>Z8L3()<5/5,V9#6&-EJ0R.RPZ;>__JJAZ_TEQ
M9[8Q _..!G3$2N5."BR./G.-!B7_\B2A7XI4AG9,?JR)VNB,RJ4^PY.CPS-V
M.S-'6J&@_Z3Y"NUZZ[,YL[,^KS9=*O1)^BM!P[-YAR!/.G $%_I:MF^*VC;^
M(K"KVWE(WC9F._=&GK=)5CJ(QJQ#\[BQ&\4;3"T<6*V*TRJ-NP5T$IMC8J9R
M=O09S^G<^7=6*%%@2$\:"$<8S+1OXC12%[6$=R(6T^81:_%."W4GFCNE)G6H
MOGM9A0$,Q$ :%.Y3+]O'.&;ETND6>5$$C?1+Y55_)PRGM,LX<R1[!<#!L3__
M_$=9S>MR^7Q.!5M+^>PBKR<3.61#.5M',B:/C<@SLO$2.99;.<E_)R(7.20+
M.3^*Z\IC?)FK7\<;+Y@C,F0C[\0?LB98SCXL U/4\L@J93B99&[?-OY^J97>
MM@XFO:';N9C:J((9NCE7,X_>H'2?1U(F^G>[NM''.45%,Y?&+-7#)-?KX(O2
M.F]WMU"RMHXZ>MG#Y*3K^FBWO;U2?:8[O47I<]DS+ +7F)Y3U)=M(=(;?=KC
M:'=/.MGS\XHFO>80@SXT(,3S>%A30!$ O..^^%<WT*K&. [_56!-KK"U.+-P
MIJ$5QV<>@ HHFH1KL16[/H>;)NP[.$X#M5)7N%!G_WB'NS[FM;Z#AX$!P, 8
MU$%<*=%*%WS 7_L3]1E??"VU;]&RY%6-:WM^G[2!P^FN1D,13"TH3+[W]\KE
M!/G."[GJ(CDKFS]A$_;(JW_+'R_OON[ZBSS[TY+YTS_NJO]=L_]=MW]S>3E
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M'HEDDDHNR6233CX)99123DEEE59>B6666F[)99=>HJ4, &).XI0R:(@I9I@
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M4C4J,OADE,6*@C6/!L2CPT4FM^-&52C"!O2D/&F7,AR:EZ*>%GDI3FARI;*
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M'%=B\#GKI462G;][<KS4-)55'#:_4C!:E(_/'*FODVT,UFR%4\5O;0#=$RC
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M$&[J;0_+"'&6%JR02<\ 8BB6RP8& \<EQ'4KN('KOO8M -#0AAWK50U)%08
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>0C>ZTITN=:MKW>MB-[O:W2YWN^O=[X(WO*<-"  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>advm-20211231_g2.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20211231_g2.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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MH@G1L S[D(NY& V@8 0/%@VZ&(S"N ^\Z(L&H0S#F(S)N P#(8QPT$5&  K
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M(L8:1SIY#=NM%>NR%ZM_+_MWD69V-3M6R=67RD"6H""E<4H0.;F7X8B77CF
MX[F:PZ&H0W&M<'JK&T"TP4BE_Z8Z$ H)"GL)H\XJ$-<JE[&(E3R1D]4Z<:1G
M@9CZ?;95J[E8K_=*E441I#AEE@*!KD)JM@)1FM)**'HZMP/AH7 Z)XB)M$5@
M!U(*HFD)&V [J7K6;/>IB]" I(6[M\%:'+,)%(AK<\,YC%8[$%))E52J$SVJ
MJF=; 7\+5IUG?_5'?[R'H22&?^/W?O/7NM!II_B)E#QAHLL CQ5@!PKYLXZK
MGI7[H*BFN*^6HK-[?J@+?[![NLG;?LN+O,4'3Z-97-FJK\-HC&D"L6G[)A^Y
M&\.(N\@!M@>GL02AD(_ZM,(8M@9HI<'X!L4AC&TZ$-@[=O/'A<9*DJJV>Y!J
M:AO:G_]#@9A8.A#JBYOC:ZEQ.9>(^;.EZQH!G(L+_(X*8:R_N[:86Q#&^JLX
M$;#-6AT]T\!+X(QO>W_%@9CF&GN821-IRC0-O)H\&K*%%2TFJIA*@<&@D!6*
M^I4)O $5'"T_M[\WS,,^3+J,QK69]L-U6<1G>\2U%X$$&XP+RH'R>HQ:"7SA
M)\'8^J,!)\7'*\7BV\- G,1>S,5&_,5$C,1@3,: 4FP-^C[",8R=]@8C:1#Z
M4+Q2<<*W<;3QJ+066</!P:Q57+9:6Y0[PZ)#&<46NG7&=< P)L9_IH8I"X'C
MF:/M6J!4[+3^Z6Y!RL4),YY,*HRF,%<T,9O<Z+W)^9 YFI/_G6P<UTJF)LL:
MX\F0G(QWS^J.[TN[:M? ")P3+/J-&4N;$Q&ME5NE;+RJ3#R :G$TIIRL2CG&
MBAS&F$QQV;FQRTS&RES&!K+"MOJEBYN+3W&M4)IN1&?-VHQG;Q=US]IVX+P/
M=0 =T[S.74S-[LS.S,S.$/9YT6NP:<<5=)PY"OD&:1*T@^:^*<NLZ*L;*WO.
MC7L<T<J+O4AJ-A&_K;&UU*F2]HN8T9 P#MTS1J"/]0##Z%K%;[RB1<MYGRS'
M$HR0+LFF66MG6SO "VFINZR+'P4*.5F-3%.3L[S#3RG(=^F^C,L:LFJBA&N^
M"\D<)MJ6OY'3PEB1.2D0T8BO,UP0_TQ;F!%MJ\-J'-+)%>YHO];IGMHUQ\*X
MF-Q6 =*X#- @M%M]S=14>;#1RC;6&N1[H_58$^X8CJ4IM4]A!] @HKNX#+I\
M-.ZX 6_ C7S]Q^DH&S)-C;,\)_@J$((;C&5]J@21T5G]OL)C!-"0DX_=48>]
MBP2YLFG]U30CU02!HP:QTAP+GN+8C6T*&X@,0)N]BW'ZP4\[TSOK&GI:G#O1
MV-3HK^I:B:R(B;]MBJJ(BAU%H4)9A5>8W+/I?P+1P%I= =N+)YP,8NAJ"H=(
MO+J8SIJKQV;1>CJ!O1)K:!40QP]YT!L@MZYAVD:AIZ!0OS;!HH+RQ!5*WME[
MVL2(P1")S?\OS<!#(8R^O(LO"L@XD=KC*LP/.<+RN< D>:VAN=Z%6=ADPHU0
M&[$E&HS_^M!QO892H>"$?<W"LY-YV]O8V[T#00_#'!T[P:*<>M8$>IJ\7&SG
MV[4NKHMJ*[-9:N$001/.'=DQWM]1^YA].QM 3HP(H==I.\':2<"K0> 82=#=
M6 1\J]6VK9(J/-H/"</($=7W+8S:S8##V+D_:1/H+14.[>/%">22'+<XGMY#
MCK1 H>5CVM?G79-1J9.QK80_"(-)&(5+N.<B77.0!\() ]!PX8X2:Q/,6@=B
MU>-BU=JSL<4ZS6G8!A0-/*9/W6U3_9 #@9CT8!78NS-#/HSA3<7_;D[%R9P3
MH*G8ND@/H<Z2)MN_P=B1"[S)+R[4N:@, *N3YHW=RNCJEPG=;&H3A(X;';W
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M(R)HJ\G"Z!'KP]&8&%;?_)^9(\?2R2].824J9</:8SUT3!R,R@WLB#TD";?
M =*(D3W\#,&D>R1J-<&8&*NSD#.X> ,Z__T,P$B<]J(76(L+ P4K5^TV@+T]
ME!C7N(@)-X01$IQ6N]#825&YX+)4X23.&!W9D\7":4S91Z5"&./5W_1(W#C%
M-+V+5D.?&GRC^\E.@C,TPZC/2_V+=(5$Z\DJ H+5Q:"RO5L.C"N_-!U&:#HO
M-)J^D4LQ &E$SH*\?%Q#^NR[B3B%U&.YUT2?8U0*T8F_[ZH?"RNH$[/$4@*>
M&)NO6+$,Y*"XO_C8*@TU\4G =>3*%SVKQ2F"@BT,#$3$>;+"M47%C L_O*2/
M0@RW*54?3A' 0N0WMMND 537_]#.K#F_5:79HRJ,SO7<FP":(>Q98@60IQ()
M)AO=N"@F )V?B__CE)_=6DA\,I\Z7:?]J\=CSG'#U$/%2;T]G/Y8H1KC.IB\
MV>64/.%=E,L;H-=E$'[E47%T-/[<HY-C$*V *I4](X?5(T^C50 -%\W0#Y]"
M"N2[S.'JT'QEQ[RE#)5R) F+-/NP$,C=5L,0T@B+I#%D"J@17@^1CZ+!N_\S
M%-7*&,))'>#4R/#S)0\)QT1C%Y-27 ZZU2RT+!O2V81LW6QK$3BXUSQ=''CZ
MW5$KT8C!#@^92A2^,F6 51?]&/W*#^E%DDN*#AB!SJ%80%!,VA)>TFF#D=]8
MBL =7,W@Q5(\#M6]T_EPJ\RH,^J\"I]-"@B.8/Q54<J!D66HQ4V+%F;_0^)N
M4C<+7C<N-,A?C%_C-6.XJD!4DSS#33TD Z91>8-3P)15LM0**$3*0UD*0: ;
M1*/?6Q3V')2@1.,+)B)H@%86+K?X/!07561$-BQ9:N03D<_['"B"3+84/:HB
M]E!5';VYH3U=?4VK<M[%<.0$L0/M>+WHS3L8*R+_TQLK]CYBXTWO9<%,-+WC
M&!0-32^O;3\1O3"M'67WF!80E#>730RXX,+TBQB+P<U1)N4$KI[''.3/G+F]
M<<W.+8_VRPCOO(CW8%!\.>65 >*P##D("2<%<>;W +7\U#CF.F<I6P9Q#L@J
M6H8? @7:K1&.@ _S2![96]DJ4BRK@ ^Z2@F[_SF10!P=H1AE06Y>A?C:Y@43
M=3ZW;1H-9?CFTCD>_D4+: "5@?Z?3!/&JNTEVKK@(FNWXT1I4G-4&+OE-P[7
MY!1$N-O"\(&[Z3W5O9546914-[8J(VZM3UU(XBTWH2Y>1\- D?5=Y>V7,&9J
MG/VZ$FSC',4KX>3502QC,C9F!:[4?Y[>%_NE2+V[4TVWF\9)0]6ER_IJWCTA
ML!%CK>["^)TN-9FWJHY9ND9(#<[JK?/I+[['9";DNUY4L$Y9DVXQ.(3# QY)
M,B8R?FR]N&QCI%;@MIYFPZ9LP%9IG!WI*&M&GF;KOA+JO@;.XZ0^QQ+9S*Y"
M[R$11:WCC\KKY*UJ-O\NM#,B"AGL;--^PB%48]NN:>K]XJ(>ZO7U:F;^Z=C.
MZM^D5.1])2..5-_6J^3>Z=T>Z88Y/;YNQMS^Z]L&MBO<VT5D;E]T4['58(;4
M.Y9U[N 5:]:6Z;E^5^L6;L5&3JYN[Z .SE/CL;_X0?E>,:H^[<6>1,]>4:(V
M[)@6\,M>[34NSO@&Z;$DSIAC:48%;8(>[_$6XP2?)].U,95F:LMZVM$N[^_I
MCVD!S27<;T<E/0]?;;&>Z7O!;!*'\'8;ZYPV6;F<</B&;)@>[1$N:<6..>4<
M/:A.[\%3:H.4[IC5;;=&U,+"I?RSSIB6:KKV0G\K1<C^7733Z9=&<EHZWNXG
M9O$2Y^ZESJ9 V7$4!UH*K^LQMG';&_'=U7"5'?(V=W$NU^S-[N3X_S;QV&[9
MY3WO&!?(.\<QD@YM\NYJR=;ID+YP%Y^7):Z>\%S9)^_=Y'7JLW[J)O?S@T3O
M#FUPL#9<,0/J\$9*M9;L/E=.[F5.5\KS>*SQ%G]M*@_O/D_P/7=KBP14QGYQ
M3(?PF39S)I]4 H_T%_?4RK;P,S[LM#9RTJXRN&#0,"?O7X<R7-]'#A=R_^9>
MPI;V' =:4*<Z]2;I)W=J9V_R3K]NYO5OW-Y=T899@KSE\W[:)11LO5:W_'9*
M^IKL_CZ]9L_SJ)[R;4_T>59C=TOW[*9IJ9[N^;;J/"YP;U=V5P?T&Y]FI#9X
MA %J@NGQ$2_W/Y?UAI?B%H?X+-QW,X]P:O^/\8S_17V,;#17;AVW=!FWO4_]
M[*> 55$?X]KR'[.^<UP7=C1.<>N$[RA,<R]W5TK/=]N><OEZ[.6E<RN'VVL_
M>II?],I&=9-M^%'/=P9LN@#G:31'>>&%=,MN;)$V>H]G;^".12QD;M0.=D6G
M>D/]Y\X^\I.?:H)?[HZG^)'?;&AO^@@CX?E&GT+T96YG>M&N>C=V]/5-/9#7
M[K23]3,^=1SW[K;U=ZLFD:Q:5VNR]V%?^^$]_%TO_(*G/K1$. D/>Z(_=8)G
M>E^OVN$N]'@7>8$<\O:>>&R??-?7[,[G^YXF/\F^2DVI\@+_]B"O>5V_ZD^_
M\BX7>\T3>MF.<X?_-_YPW>M/#VRP%_AZ+VMS'_[MD_GT1GO5YG@M5_IWG?1_
MN?B;MWR2)_IYP_<==^E51^M,?W:3OON_WFX;MW7@\Q:$FDH9T_G/I\BZQO?X
M(FN8!8@*&S8('#BPH,&$!Q4R1,APX4.##@52?#B1(,2"&A=63%C184:.$3=Z
M5 @28\F3(562;.C2HD24)B.^O/A19DR:+3NJA!GS9$^$&UN.%%DS),2D.(T2
MS=GQ9U*@49WF%'E1:=69&(<6I8DTJU2H1J<VO;KT+-.C-U^>)=DTJ]BM<DO.
M%8K2KM>\*;5:Q=I5IUZ^,/&Z?.N6[<R@4_E>-7L7,$NZ;=-&?JP4Y,VW_W[G
MPJ4:U_/>P'41]USI]RG@I:C_ZEWKN'-JGC[#?A9;FC96KCAU4R7*>S-GX&B+
M1BX-M;)DWZK'#BY\6>9OK8W3(IY-]ZEQI+([KP[N,_1MZ*D7?UWN73#8TUY?
M5YU./;#RKW8=H\X^'#WAG<R_K]^LV7IHHA&&GG7;N9:;>&P=:)YAINU6'H.0
MQ29=<\!AUYYD:&V76'*@90AA:Q;VQJ&'EA&HWF26=5<>;=DU.!I_?3WXV%KC
M,7?8?PY>5YN)7=G$V'VPG5==AST&]UMF1BHIUXO=&8=<A%(]::.1FA5'H8C?
MR899?R66I>2*[V&XFF)Y3?GEC%C"F!Z8HE&V'_]Y0IK'YH8JS@F?CV/IE^*5
M23JWXV%%<LGDB52Z&"-Q<+THV* \!FI;A3L"F2-KXDV98I?Q24ECEN')2>1^
MO*U(J:2DD6?@404^Q^>':L4)VY5!DMHFH42&.1J7BD57IZ>%"J=FB:"6JJ.)
MN T[(K+<#4>FA@J&^FN Q):)7[3$'OLGIX!:NN20N0JXJHTXPFEFLY/AU6B0
M"6);ZZX(MCJMMR&.^FV+]UG)+I#9UNK9K2BZYZZBOZ)[GI/0@J>G<%NJJ1NS
MF9IJ+<1O'NE=O^M*>J&T!@.8:I>(1E@NQ\_2!Z*,L:H*8IT6ITPBN/I6V6-^
M]J9ZX:,9LK<PIO7Y^B-^A0.SN&RU=NK*VH8-P^HP@(?RZ.:]\4)*:\DV\R<N
MP4 ;>Z?"8U9ZM+%.[[NMH$B_65EX9Z;++=,Q+C@DIISI[%S7'R]-]=7F?CHM
MM<?Y][#*>RF=)8E9^]TJR,T>6/#7YQ8+\W.>_FA6W8P&WE^L]EVKG;"82RZG
MR9LOIYSE_WFGZ5[%"(M>\Z"7:NYNQ2N+Z6'H1B^^<HUA19>TT!N/"^5GN V(
MMJRLRZWUIS('JBFVL@,^-=Q[AV@X@K=W6.;A$"I?*,:_5QKFV\*F7CSRHMMI
M+9J%NRUP](2O?O'E>3+_N=1GL_Q7Z"TKRS;]H"G\VJ6(FTUHV0CTO8'QCU_S
MBQ;>TJ0WAIT(;WT"7GRJ<[,UV6^"44N4V.*WMKCP[H 8:EOU\*2W!JZ*9YX3
M4J-JM+Z[89!HUM.8QTC5O=4]ZE\5F@_)<F0?KORN:&Z"TW0&2*5L^6Q\)9P<
MFP[6P8G%#X4  ]6M<#BZ]Y6O7V1['0V]=S0B"H]6/#35]VYH1/_UD8N#XPI6
MS<BUJ!L![4,F=&.4)+<G.OWP?'\:6;JHEC=T*6YH :-C\-IT.Q5:[C_MZA:T
M2M<<Z:WK7B14X(QHQC5JQ>MQ'(H@6>Z8.Z\A<7K/&R+8^#;"GFE+?DZ<&=LF
MV+K&J;%]B(JBU'8(/_$1<'FBJIH=P67#OPU-C^CKU?F:9$I?Y4M" :,>&;V$
M+TQ2;DFR8^ 40[E%*3+Q@$NL8+B<A2OQ?=!?MIQE@ KIO"<6$(*_=&$:@Y5,
M1W(/1HR\Y O[9L/T#"AV**I-.SUVPDAM#9]G1-L&W>E/5SHSD%IRT#Q5Z,UZ
M[@U)QD2<::")RSEVL6!AK*8D.VG!9#;_$7LC1&;]A%A)8JI+C "$I^M0U=&G
M3<AHJM,@!4WZQ!_*,D$;A2G+0->RD0)2?CZCZ!M):<R@C8B=GDQB(G>70_NY
M"I47-"%/.V; 828+B,W[HWK2R4H)/BN2;$2H4!67LZ9VDG@DA5PIS;=!VKV/
MJ!1C8<B81REFKO18P+Q303^))P>RSZN,RQC^^CJAV>GUIXN;ZLZHJD@\CJQV
M_)0/L,3I,L\Q,$G>FM56>177?N[TA#H<(UY%B<51 LME 8Q<9W&HT(&J,XC&
M*VG:]MG7A(;UG^6BYC[G23QALK!NJM1G;*_X6 %&UK1%TF4U.<O$QNHNB=!,
MV?&>YTB4'8RK_\PL(N/6RBG><LZ%PTI@=6LI/?&2+'V%+6X;<T=*H.I5FYO2
M)NQ VU.DUM&*)[UIS%A%R)]A<Y)MR^5'PT;/ABZ/A'Z4*"2_!4[AX1=X7%P3
M)AGYVW4ZM;PAPZ/=8 BE-'X)I/,3U_Y:6%K!W;-X"6:JK;X*4:RVEJGU8[$2
M*:F^!I<SDZ:;5WL_B=9].?1='--JM1R'U_X%\V0U]C%%FSOCHOJ5R!8C''O&
MBT D)KFJ4C6BD\M(7Q;K-IY7)FEB1:0?G5XTMD>,KF]A*\?ROO.1Q=3D;LWX
MUQXNDEL8EJ93,TI?/Y+V9@TNZ]=,G+W>B8ETN,/S2KU6Y3/^"\W8G+JKFQ-7
M2CZ"&9V+J2'FNG=32WO34*\;=#/I^&+^KKFKLDPI],S7VTXUK\O)O9Z?\Q?(
MZ*+XTT\[L@\9NMD;2UID?7%M5CF:,#B3>-,BAO1?ARWD=G%RA4O6LH\_N-A7
M4_AE>X4CQ/CZW5+Y;LF@+M^7X<OGX/87E[&TVZ8WO+0L[E+6!IV3GWP)WF&'
MN\GK"R"#*WUJZG9WDWL^,5%]><3!'?.@D[6R.:]*QCTQ%^$$#RE,[UQ3:HM0
MRHK_A&]7,Q<TGFEV>-D<\#95_>!N;HM9=/5O? 5KT9]Q4GN9+AQCQ\EQV 9U
M8[KV,LREBED8+TB*;+4UJN(&OE>U4=VHJS5@/V[H?#W3IUKNL(VA&O5^=W.0
M<D88@OVT1Y"G>\M>';>JKRE/D4-:N#777U[K>MISQO3.GI41**E3NM5N=Z90
MIJ)Q ?Y*029;[T(.^)LAOK7P'7?(H2ZQ4MWW]";2&< O/7%  _]Q0B\PVB#F
M)E4)NO"^#;CLB"4Y<ER.X#6?_.^'SS#4/^MTQ*<7[D2/^S#O.F)H[QC([98I
M3E]F:!SSLT&H?CR0"T[YP\ZJQ^@]<^$3E7JU.=O"#6\W_\9@*&I?B]C=?DUK
MD!<,2$Q/;,?1?A"=.3S\XB)/_+5N_,.NJWG79?;<=<U]BJFYJ:S]?;_+S2E'
M4:UX7</+Z>!./\$U5;>)4*B978&QRK7,2P@56LBI'*E9TN,Y$7O9F+/\V7\-
MECIE& :RU$QI%_/!%;+84\YY%[&UTH5MCY@!%^2U%_WI'>#=%J-9GO+%T(^9
MV)<QU-F]5HYYTLVMH#[UT6.IGUDAX P9GP*IVPI=$6KM6@$.'6>ICL!M6TSM
M'?Y45G,9X33E$7)]T>[M'W&]4</(7BIID7156DFM'1 Z7#3)5-PX%F0)5 )F
M%Y;X3PO!&@91&O9I80,J&CR=3/^GN10 &M9;O4VW,5S?M54#EM92(19NK1M_
MN5HF61:6L9[M"!65"=9X2%R=<>!\.1>,E5J8(5W,V:#VU5(BLH_572*[?=UY
M)9=_F=P&XIW&S5Q225G<U90@.DJ*X1YWO6$83=?8E)C+/=L5WF'%.6*U/>$!
MBI-P01OJH6"+^=P1'A7(S9[B0:,KAM,!2B Q>AI -6$>SHW&3=0XW1W=$> I
MS=F3Q4F];&+_\2 )?E7AB=XLQ=IE45@1&IPD4M\0MA1-;=4.*M<^LN %6M-2
MZ9\9=1P8.9A 3=<7:6"1S5;*P9(BJED&.LT,G6!%X0S?10P739SYK5P:OI>U
M_5[[@1__:R6D#-87[+E8L 5@"(:B?'51RH&0><%B^OQB2ZZ6':8BOCUDPLT1
M24ZA.3[9N*F6"3;CH7F06%DD(FD;:D%@//Z<@HD6B9TD16H+3AY=\9T4GAEB
M D75V)F9M0T69N$6,ZJ@*44E&W4.V%0.,E:8M[6D>7G72VG=_4SCQ+F5!U4D
MXNUE8 'DI.G>Q^#A4"J;O(CC'S7;BE4 ,1!#)A##,&C",$"F9%*F94[F,&AF
M,E"F9GZF9X;F9HKF,(#":)XF:*(F::ZF:K9F:KXF:\*F:\:F:';F:":#;.8F
M;<XF;^IF;^ZF;_JF;7(F<&H";A;G;R9G<"+G<MYF<SYG<1ZG_W(RIW%"YW1>
MYV1*IW5"IW92)W:RYG"N9G=^)WENIW>:9WF>IWJF)WNBYW::IGM29GBVYWK&
MYW2.IW"2)GPRYWZB9G\VYWS:IX#6)X'2YV_B9X$.J('&)X)69F1J9F9BIC),
MJ#(0 RA4*(5J H56Z(42 X9JZ(9VZ(1:Z(8JPX5BJ(5Z:(9BZ(2"@HJVJ(IZ
M*(A^*(J::(FZZ(C::([B*(V&:(F"J(J>*(UZJ(<*J8Q2Z)&&:(R:Z)(*:8NR
MJ#+,*(="J8@^*9+B*)%6:8KZ*(M*:912*9%.J)=J:)B*:)$V:9B2Z)52Z89N
M*88ZJ8[V*(5J*9S6:9O2Z9TNZ8PFJ?^*2BF)QNB)9BF4>BF6BFF.VNB+\JB5
MKFB8 JFAHFB5?FF7'FJDVFFCLNF:;BB9RNF4)BJ22FJ0WNB+,BF7CBB>>FJ9
MYBF+*JJ.ANJ5-BFEQJJ/ NJH\FB1?FJA?FFJ BJNONB?<JJ:FNJA;NJM<JFK
M"NJE*NF.?NJF3BFDAJFDKNBJ0BNAXJJJSFF--FN<=BJV*FN0ZFF._NJB/NJW
M0JJHFFN.$FNT/BJVTBJZ2FN6IBFK:FNNFJFN,NJ;_NBP9JNLPBN'0JN1WNN9
MKBFO3JJFWBF_3JNQ&FK!NJJIPFJI<JO$KNNVNJFSMJNP$BR^7BS##FFW8FR2
M9FR^[JB\ABL"G-+_ZZB6J,JN+,NVK,N^+,S&K,S.+,W6K,W>+,[FK,[N+,_V
MK,_^+- &K= .+=$6K=$>+=(FK=(N+=,VK=,^+=1&K=1.+=56K=52Z#XHPS[0
M0]9V+=<J0SU 0SWH0]B&[=9F;=E^K=>BK=C20]F*+=F*+=R^[=C2K=IJ[=V>
MK=S6+=BV;=?B+=O6[=[&;3V +=GVK>"F;>#JP]^>+>(2[MR*+>!J[>1Z;=F"
M;=YF;N-F[N7JK=EJ+N76 ^BN+>4Z+NF>;N6FKNE.;ME"KN@6+NIN+>QB+MT2
M+M[6[N6*+MH:;N&V+NY*[NH&[^BJ[O ZKN*6+N?N[=WJ[N.:+?%N+O0B_V_T
MHNWA'B_J,J_O J_:1F[V'F_W^BWB+J_M\NWW)B[XDF[YVJ[L#N[L"N_FVNWN
MKF_Z_N[\0D/L%N_V)B[K<F_D6F[H)N_WKJ[Y\NW:LN_@1B_LXF_@NBW[2F_H
MNJ[K?FWY,G#O0C#]\N_K:N_TSFWX=BT'%_#G+F[G4C &5R__>FX)7_  6W #
MU^\$B_ !(^_OWN_T[J_^FFX*:Z\*1S ,^^[_]G .]RX%/R_8\JX!NS#W J[<
MHC#VWNX1V_#ATK #OW#9[@/91L,^+,,^[$,]8+$6,VXTF.T6:[$6;W$88W$]
M[,,9;W$7JS$;8S$:JW$;<[$7O[$;IW$=T[$<F__Q'+<Q%NMQ&?MQ&KMQ&//Q
M'W=Q&^-Q%F^Q'!>R&P=R'@NR(7/Q(]NQ(\,Q):]Q&FNQ(W/R('NR&2\R'2<R
M(6?R'B]R)XOR(I<Q*E,R&3,R)YLR*\>R(D.R*/MQ)O<Q)BMR(4MR*^OQ):OR
M&H_Q*8-R)1-S'.=Q*^,Q*6OR,;>Q+2=S,;LQ,,OR&S>S*ALS+3>R-2/S( \S
M+O-R-Z/R)]\Q-X^R-$=S-X<S(7_S'',S,Q_R+A_S.=/S-CMS+ .R*U,S-,,R
M/\-Q.4=S.5\R-MNR0=NQ0(?R00-S&K-S'6_R/_]S,T^T/.^Q+SNS,D=R1NNR
M.>-S1R-R* ?S0E\T1R?_]#F3=#)3M"7G<D7W\D:G,D'_<3UK\RD#-#'/<DUC
M,TR[LSRK=#77\C7'M"F[]#2GM%&S=% /]#Y7-$[O]"0#-4,_=2G',T(G=4@K
MM3Y+-4:7M#\[-3EG]5>WLT(S,C@K\SW?LMC&L1K3@TPS,N-N\5LS\B"S<5Q;
M\2#'-5XS,M?"-27G-5__]=D"ME];L5OK=6$+MF$CMF(3-A?G=1H/-F0?-F-/
M]EN/K61']F+O-66[]5U?MF<O-F9O-FA_MFB7=FB?-FFC]FBOMFFG=F+;M6!W
M]F.[-FNK=FO#=6<W-FW?-F\S[FPC]F];-F!K=F@3-V?S]6_W]FZ3+6CGMG+7
M__9RD[9Q0W=S(_=S7S=F"[=H:[=M1W9R=W=T4_=U3W=O.[=W8[=YAS=VN_9W
MJS=XB_=[KS=\IS=\'[=\WW=\&W=PQW== S8C_S> ![B #SB!%[B!'SB")[B"
M+SB#-[B#/SB$1[B$3SB%4_*"SW6!8_B%5SB'=[B'?SB(A_B':[B(LW&)GSB*
MI_B D[B*M[B+OSB"LSB,_[>,OWB-SSB.Y[B.[SB/][B/_SB0![F0#SF1%[F1
M'SF2)[F2+SF3-[F3/SF41[F43SF55[F57SF69[F6;SF7=[F7?SF8A[F8CSF9
ME[F9GSF:I[F:KSF;M[F;OSF<Q[F<SSF=U[F=WSF>YP*YGG/O.9_WN9__.: '
MNJ /.J$7NJ$?.J(GNJ(O.J,WNJ,_.J1'NJ1/.J57NJ5?.J9GNJ9O.J=WNJ=_
M.JB'NJB/.JF7NJF?.JJGNJJO.JNWNJN_.JS'NJS/.JW7NJW?.J[GNJ[O.J_W
MNJ__.K 'N[ /.[$7N[$?4#NR)[NR+SNS-[NS/SNT1[NT3SNU5[NU7SNV9[NV
M;SNW=[NW?SNXA[NXCSNYE[NYGSNZI[NZKSN[M[N[OSN\Q[N\SSN]U[N]WSN^
MY[N^[SN_0/>[O_\[P >\P \\P1>\P1\\PB>\PB\\PS>\PS\\Q$>\Q$\\Q5>\
MQ5\\QF>\QF\\QW>\QW\\R(>\R(\\R9>\R9__/,JGO,JO/,NWO,N_/,S'O,S/
M/,W7O,W?/,[GO,[O/,_WO,__/- 'O= //=$7/; C+O"&[MZ6+M*W;],S/=U"
M_=+_;=13_=0K?>=B?=('[M8_O=5G/=<[?=5KO=A??=A+/=A[/=FC?=>/_=E_
M?=N;O=J__=K#?=FGO=O/O=[G/=_+?=_CO=\'/N /?MP3_MT7/N(?ON*S_>+;
M/>,_ON-'?MU/_ML7^-X+?N)#/N5?ON%K/MU_/N=GON2#_M^+_N:7?N.?/N:G
M/NFOON>'/NO#_NNC_NR[_NC+_NW3?N[;ONIW_N[[?N^+_HYC./'3N/'+]?&;
M./(OO_(WOX4[?_$SH/_S3W_T0W_R4__U5S_V2[_V=W_V?S_W@[_UAS_YC[_Y
M;__Y>W_YHS_[JW_ZBW_[P[_[Q__ZS[_]RS_^UW_^O[_^]S] [-M73Z! @@4/
M&A2HK&!#APH1-DPX4&+%B!<A9J2(<:/&B1\M>@S9D21(CB9%GAR)LN1*ERIA
MII39,B;-F2QQOKRITV;/G#5_[@3*,ZA/HD>')A6ZU*A2F@P?1I7_.I7JPGT,
MH=7+"NUJUZU:NV+5"I:AV*UA]WWE6C;MV+5>W:)5*S<NV[EVZ\(]BW>O7K)^
MWYK]*SAPV[Z$Z1XV/'AQX;N $S-^C)BOY+R4(5=V?+EQY,V*)W?6[)GT:-.9
M46-6+3HUZ]6A87..#5IV;=J@248]_=JVY=N^@7\.7KKU[.&[72<W+IPY<=Z_
MFR-?[EQY[^C%K5.?+CT[=^C:NV/_[OVX^/*O<U=5O]XBV(W+]ND[&.T@O7WT
M$7(]6"]:_(/P!]+GOOW:0J@_^P;J+\!] #PH*X7H$S!!BN13\""HYJM'0(+P
M\Z^__;AZSS^!.K2OPX'T,Z@_^01J4, ._PEZ4,5]$.3/( $;%$A&#C6<D: *
M(<*0Q!YY% A($"&"C\4!!3(Q(;#V6_&_&YFD2,8):[001XAV'%!"&W^T<2,A
MO:2HPR,-"G'*)4NL$L6-;%S2Q2IC?/+ &1?,L4 S>YPP3 NMVBA"/HT$,\TD
M1ZS2R?S@E+)%*F'<$TL\>]2SRT']]#!(B 8M4E,DH9H*21'9K,]-*&>4$U("
MK[0Q2RHM)1!30X$<DU,BJT3S35(S;/+4%"=4=<%(6[USPCRYE+5/6L6\\-8-
M<S5TUS5[I?'71A.=DU@[K3VVTF0A7/9#36T5%-<SI76/VB%]/1'58*<<EE5N
M7T5VHTO%I;#90/\SA!;=<:=]M-1VGP0VSGA[W-; ;IO=\EYEOQRW5F?-]?<@
M7?]B3^/UQ&I1GVCLTP<^D&F,1N0F35YFPY0%I(<^DS4$^<./7691YI!'QOGC
M'U4FF3^16^Y/Y9)/+KEF#H_>&6::\0.:9 9ICB]GH@&L>>B?AW;YYYA=#E!F
MFUW&^3Z=F^[9/JR#AIIJE(\>>^F7Y6.:YZBA)OEDDJU&&>@$]];Z[:ZYAMEM
ML>WN>6Z?62Y9[;R-%OSKF+>66VJZS99Z[+6I7KEON /WNNV;+2]\Y\D1WWSQ
ME-EV/&G.)7<:P<KOMH]QJS7/FG69/5>]\,N=/OSLQ+NVO>BP=8_[=JW_2:^Q
MJH[K)EQVU#/GV_;(<0\<[-U%+SMJM!47ONK'W3:>>N1=]QC[YX=/G'N_C0><
MZ>N=)]UWZ=/V/O7KQ?];^Z=AGWIV]8%WO)F!#W2QDU_RZ->]H*7O<ZL;W_Y>
M%S4#_F]OZQ-@[N 7.K+-SX*G8V#Q(*>_^35/@YBC70+9USGK(>U\!RQ?!^W7
M./R%L'T0U,C&<"BJ[3F,1<#J6I98Q,,ZW:A3]PDB@WS5%0HIR4Q!!-.&@'4R
M?R%H43W<B!3_LR$AIF4C/U31$0'4P_WLS%]@3**0I-C$/RWH76E$&L%&%$4E
M9=%>5JR/L;86'R3&<8Q%%)S#$(1&)G+(B3-[_]/%!GDY:S4M1E><H\?JV,@[
M,NR/>Q0C$<]EQFX)4H^$7".1Y-A)1591DD9ZI-J^%<<NXK&281RBUS+YHST&
M4B%N-.(GH>A(43Z-E%Q,R([Z@Q7U<"V2OD09)35Y25B64995XY?EF/FI7")R
MEU1DDAU-F2TM6K*4B@-B,PNU)\A%$Y#/M.4?GWC(;$X1CMB$)AU3Z4XO\@V<
M?,0D.6=ISD2BTY!MW*<U&6G,=T(RGMV<9QZWN",RJE&/SE0BSW992#:&DIV+
M#)- L4C0A*X2F?54YC@96LZ'0C.DZ?1G-=O937$&DXLY=*E#&/(ADW&.IDI3
M'%3@DQ68U71DD-,/2_^'-C7<*2FG!"GJ3M5FN /1YZ==(1E/D7BR!S$UJ9=3
MZDT?I=,*;0UU$:*JC1@2U,L-U7(/.BJ0@FI3K34UID[:Z<F(6B"JBI5D5^T:
M3MNR4Z[>S:<3"NN6GAJ\LAHUKVC%D5J_RM*G[A4^<9TJ6.AJ'[NR%(E:Y0]C
MO938KD36;5$M:F6YFE3$0DFQ;JT07 <[(*YP=K)*/.MEW]K3G;&UJH$56FI?
M*[3#OJQDI'6J:=&F)+L1:"HQY1M-]\K;NV:5JYCUJF__BD3;>K9 N16M<C7;
MU@'%EKJ/72U@)8M8UQ86MJ>5;79K:R+!2I6PEM5MW5R%WL5RU[$\^JYTPXO_
MW?&ZU[E]!6MZ.UM?T"(UK=B%[E@Q*^"Y@A>^2]UO<[G[7-IREJSL';!A&]Q;
MVL[7O-VU+X!;BU?^1MB_0&5PA3]KW0+']\ <#FY\AGO#E[ZT;1!-&T'$9B5<
MJ>U%%%*<LY9DQ$7J:W1ODA#?+.JKHNFH6_1T6(\^IA"N*&^X"M)CUW0,+1[?
MQ\> LTJ033;D,!49+$?^69*MM60N(LC)>X0RH*8,H9")Z<IPWO'0>BQ++W<%
MS"WC\IAAQ!4SAWE1:080D]D<.3<+*,I68ACOZ)RV++^'T7^NLZWZ+&;_D%G0
M!O)SF]0<YR^F\LU2?G25"R+I.FD9SY:^\9<30FA7_T/N4(/^M*E"W6176>Z*
M!+&1X4)$E1J3U,LY7C6E]2BQ'\.Z(+*6&*V-[&DTYQC1GB8UH^%\ZCE;6=5M
M876EE;UGAF3:1$0.M!Z_.&U>5WO43\:VJ:F\[50K;M)TS/.E@1SK3YL;2;96
M=ZX3O;1%PQC><B;7I>L-R7N_FL_ZUK3X:BWM0E-[S=9V-\$='>^#=SLKWTYV
MEP$V;H>7&]#]EKBBUEWQ&1D[G+^>[8QACJ&9IF^237LH2V4$G^?E,T5490AA
M\^>KG*-E4C;MT<]!VW-#,\D^,O<*GX)V6?\HG7DZ[Y[0^?06H(=0Z%-B2]%Y
M>W2*%%7IA,/QS9_.HZ@SDO_J>[*Z8*W5\[]LW:9Q]SK:0Q9V 2&=[&9:.GZ:
M/B-AJKVW;/=[U:T%=_O(7>M1Y;K='_7U71M][V,WC-_-;BVG#[Y,?@M3VX>^
M<V<ROBMTYRWDD2CY.U&^]$E_N%(_%C<J447FL?]>S66Y>;<G_K9QSWKKYUCW
MQ=_=Z7E/)]\OSZ&_GUWW<E_[YP^_>]%C_</(#SKJX:/Z-.L=^,GG<N8#[U=C
M#LKS4X]^Z*_N^^I;_OK#CSS>87Q\RY]%^>!'.^?)_S+H*Q_QTU>_:KNO_79/
M^XS/D)"/_KXO=)A/\,:O1\I//D!O2OQO\7[/^A[/_5(/_ECO ,&"Y.1GYI;E
MR&#_;L9$;HD*0KN&[T,$K8_,KGZ(9L=$[KT"#S\Z;I7RQP%OJV^D3$-<SNY4
M\-$<:/7.2W9VD,$@$(DZL)9LQ_'X2H*0Q*WF;+68S7.N+NB2AB*2D'6<:M58
M4 %=\ KS30:WT-ML,(1PT+/\+,MZ, 7?1'F"</FB1GEJ<&J.$#Z2<(E<,&Z&
M,%&RD#^B<(]*D K7B^O L VW2_9BB@N)J 6OKA ;3@P3D0SOZ ;S,&O"!7-X
MD$_(:GE&!**L F_RRLBZL D;4>#"<''&L 8GT0PK,0VY4 QURA IX@U;$!0G
MC0XA2Q;GI@HU9 ^7I ^'2PH;;A%Y$;%DS]?B3 LCL>-&_U&V2O$880T2F405
M]885J] 2U1 6P434<.QM)F\/Y?!;@A$)N7%RBM$7GW"[_A!  I&8!M$8<048
M$7$:,Y$*25&P'#$&47$9=RP(SY"H7)'IH"<3>6031S"'(FN V*QKV@0_*@<_
M&"D'$Z8@:\423R^5>N9(#$FYR$6H/ FP+@9,$@<BUXC\F.2]  3/?FU5PD=,
MG(FW9"\E;TFF9"_L.C)J(!)9!D4CU08BY:TA"4FLN$DB7X0B7?+6M&2/,E(D
MY67U7!+!;@DD"X4FAX8D-<4D<U(H5;+W)K(E%>0E#\9A1D8C:Y)9OA(GE4\<
MH8PIJ_*-@ 0HC4@KIY()3S*T4+_Q(L4R]IAR(IWR*R^GXR2F9Q;CR$*&*A*2
M"H\)+A^R2-!JT^H2J>ZR8912+V6J*=/L*1<K*J4K)*FR**_)1K!2^;22T592
M7KSR42Q*2L1R)MO,)BL2+?\,)$FS,ML2TOH#+A-')C4E^![S-5,35LR')_GR
M,OTR,P6NI^:2>ZSR+1WP)*N*QTJS*Q_'+W\S)A\%J13--8_2.'5R+6G3,U$-
M-_=&-QNS+ _Q*'_37I:R,H=3WO#+VP(SRKZ",-'M(/\1,HDP4&4.+06/T&::
MT[+2QJNV+6X(48^T2Q6=DBN&"[$&%,J<D3_OT"0!E!"=;<[4ROQ(!D$3C[P8
M#1T%CB'_<VLTM#"URPH%;D$Y$D)7L/,X5'$$U$,(]$(K+T.))$$AC4%AU$%9
MU+)$34(CAT(_S4(Y\@AI=&4V%$"]L,ID#T3]C$=K-,U^:].PJR:%=-=4=$1\
M]$-ODYA.BP=E-$I'%$.K5 7/,"2%\6R:;2QZ;RH<*C^7[$K]LTD5C4F5U$N'
M%$R?] ]1-+X:M$-W5$2[)4MC=$H7:4PO4T&'STB)$$F;L$X#-$1A)DQGU%"O
M<$_O!$X)#T(?U0F7ID G51+_;=12C29'_510(Q12!S6^@E1*)P\LBG12-#5)
M^]1%474L%-5 ;W1*$X92?; _,[5%Z;1//15/;Y5(#=56E\W\G"G6U'2/['-C
MG&=<9 1HYH0I&[,[DT@FW]+'D#-0":];W4I?N"RJ-K-=!HXIP[4D?0Q=N6Q.
MP!4UY^@VN17EZE(J?_.B_-)>RZU:*S-=KW)=^[5=@;--E/)?P8E@25)?MTM<
M\[5<AXQ?)T4[Y566V)4K%;9@M_5@3:5>'=9?;49@.E9@V2A@)=;5_.1.+#9D
M,18TYQ5AOQ7EM+/1PNBJ=)1EB*3RA$V#I!61BN9)#R9EWW5E)[:AZ#5A0U8[
MQY6)_]XU92O6+$VV8@<N:+65934VB8QV:9DE:8FV(<^59)U6V:#67>EU:H?V
M8J\69K.V89>V:R/V:P$V8J-V; 6&:K=V8\\6*)]-:Q66:;WVV<KV9!]V8#>6
M;$TV:._65&*6.GO'D.X&:&Y6B9YU8SC2!*FUV=[1FY2UZ^Y+WNQ4:Q;H0=]I
M1J%O0@4D!@#@=%$7 &( #<8-]GH$#4YW#.1T9O["$H_D<Z7T<KTH;RR1(3(!
M!U#7 ,1@&&P.=@$ #7#P;H;A=-&@M_PL$H=O<Z6I*V[@=#-A;7C3B^I0<U'Q
M=@,G>4$7BT37_%#00P!->^V*56<W0&K7SVYW;6J(+G<WK_^@KT13:8-P-T)P
M$%(71"P^]#.9AO=0:TEM=/0@RWV?Z'OSMSG%=PR/$'JGSE12\(T^3$^D8G)M
M3#\MER@Q=WOM3GJ]5VX6V'UY,Q(?^'*V[7R%4$9!B@UY\"UL-YWR)GZS]U+I
MEWQO-)]Z9X3W=WW%#DE)*8#1I[$<4WMS\8.[-X%%>&U,LH%-^"] <:MR=X6'
MM(5#\84W"X$-:88[IX:/5.I.>$%UV'!X..I\N/* &(!Q9XCEMX"Y-X9I=XGS
MIHE+^#/? O BV%<F^'(J6,8BERH"M&8 AFT*Q:;8$>44E$#X*LPB\5#F1+!H
MD%F$<9)ZJGI3%W4#( :ZZ#KK01+_K)?[&AF6WJN1Z^39#/D30_(ZZ<%T+YEY
MD=!XTX!.-D033G<2N.QNL"Y2<'EHE"$3;%D@6)D8:DD!?W!.C*N/>C"4C_@?
MZ?'9)OF8QG*945G)>JJ8J429#7E\=<R4>>N0T>69KXY& 6:97=":^Y=.B-F#
MG05=3GD,?1!.LMF=W^21;RN2G=G-,I<J+0W&$$1]2 >0752022)L"KF;I]GW
M=+F:M7F>J0222UE?P!F2U?F@S<Z<Q<Y=XIF4KYA5>Z^1)SJ<7=B1&[J>&?J<
M$_H\P=FCN<Z;3246D7F4KX6>R]6E,Y>CHCFE46Z12_JBGR2CT9FF@XZE"R6B
MZSFD=[J<_X_:G2&*<W":G0W:G8UZI1>:G,/YH:$O1[97GP&&;OS9:?YX8ZI5
MQQ P%NM8K)$0C66X1%A&K>]1G.ZX?@%X'X W  " KNL:=9NWK4ZTH=<M>L=X
M$0<R@,MZZ<["/BS9KNG:KL6 BS*!KI%766-O2$(8/W[82A="#(Y7@PO";*H8
M6(3)@,^TK]=Z$D%W1]X:A[<X/JOG P_55F(1B9VI9]_'12I,[ [EB4\;XC*'
MK4>FM9W%I=$ZM?$0=W*'+H7D+$#[K_7&<);[3V^[\[K*5 (Q>J,DWA2$S:0B
MK.MDK%=R'LW:#H-[09!GMTG;N:D&#5@9 ,+@>H_YU5Q'M5O5L_^ON/*>N,B,
M%PUDN[9Q]DUPVX%I+1,P^W2%5Q/,CY8!X ;^\" RX73%P #G>]G>&[#W(0T8
M'&>WF^>.F-IHA[?-&XKA6KA]![YM]+?%Q*]CF[89IXL=,U0\'+5+;KF+;(Y]
MVRJ &RY /'FT1+]'"KG?F)H+8L/+VT>?.__XRE>F>S%4Q+J3Z*O5P\3U,B*N
MAJ/QL",P1IM[]IHAPF.?!C@W.1;IPY)#!1H"' =^?.6XS,M5",O5&DYP%2&*
M,C#I%8DHG'FA0AF ]W2%F1[F_'IKG)#>21AI6B>[8L]3+9'8UV*?QM>>K.O@
M')Y'ZE[Y62(\$Z(7+5)0[V")Z!<_1<W_)TF1(=<R=W&,\/F=?^1$%J1+KI68
M-EF7G8J(V/P(11U<!6=>W7RCK_R<5YU6MMPTQ1MZ#E%/V*)"VH;>IL+)9WWL
MH"7H0CW5TL7*]<2V$5?7#X(84C>QCY?182G+Q6EK,UV1I:6F(<>3 2"6S7%5
MXM/1]22DE<&26[EY \3 R9RMZ\' KW?/+MK5O9TK?#E "/W"8UW2;?W9+9Q@
M)&;7NY+2:9NX,!#3O4;3JQRJQ[G-S7W*_[W+I1W@43TZZ2;:A]FXO.;5WT4M
MJW&8#^W4:47@'UW+L?O@P3=-!](J8G#8L8S)UX-@[:O,_HN1;(]$*A<P4UQ
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MC C%1="",3"%TD@6DK1?104J8QX:E(%2D20)'2A&3#)F4M2!,2@3S>%,36(
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MGNPHN05_"VVRD@1\[+#5G$/3LAS%\ZU&,+<LB3,LS8H/O]]8:_/,)>V\2#K
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M?\:DJDX; 353=QDZBNUQ^7+&;6DFR495KL]*U-I=)RD*U<FA&OSB0Y.96.;
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M)O38ML5E).H"6@]TEL]R+,P63G"QNUBRR"J4I1PQ">AKO@GBJ_0,P(V19&J
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M,&VLC6V\DIZ$)T#A>2E+HD/55[9RIG:]C#.W<LEK?F>H5ME+<+KCV=ST]RP
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MX[$*0AR+MRQ:!RFIHNU4_]W%AGRPU$!HBXPZ@(@J$)EB'YC2&9@A!-8A1-$
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M\. 4X@AUM>/Q5SUTT"1070X$CT:Q;D.,E>T^BO9I@BSS1$&&+EQHQV,=A+9
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M@1"Q-R6050+N3J[>UB[*\O(8M1J,,]"OAQ$VYBT97PS'P"?3*)A0#TM%$N_
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M_2AK 3DE8D"1"*$"+-F,B , 80ELT+ "T^ANF7"&1/E]SA@-]O<8,2"#=Q@
M;.F"?3@E:3"%[8@X8A",4X(&[NAK]_AN.("*YCB$UQ>!.%"4Y&>.6*B":#"8
ML14&EQDE>8F/5AF"?"DE],"9N+@"Z)AOUZ>+D &7NYA]"[B3PNB,4I*"=4B
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MN_: )&JBK1LE'!@-R(RLRK#%1KF[_6>I ]O0TON Z(F2!(M]!S ,RT"?8*C
ME>B/$2W5]8J ,BV>T&BP;PN-,7#$*MK$\>;/+9VI#GQ];(*%T0"O$9I]^FJS
MI-K4/UK(WZHX[LF.EKA]&XJEUT>J?$B?&^K.#^N.,"F]\0S </N>-)C8_TN1
M.""SWL>MF1P96)G 1'B[8G""H)A]-CE^53W7Q"B$(9E*#^A]Z'< 0/V+3[N3
M30U_!_BU^\"9=,FA=EBH@UVFI)R-;2MP%0S"<PF".BK#_V\0M^*,RAJQSIH\
M%,5\J+ %L\8&K9'AJ\[LDV(  PM8@B?(@FY9JU)RD0<=)=B+G;Z(BALMQ9#1
MK%=ZECWIA--MB9/ZQ>R(BH2H#)&YIL2 BFB9"6><.$!<T[VVDU](U2YYGCYX
MT6X)@L(L!F1)R\RJA@%YI*DTT VN#TR]?IK0W?RG@VYIR[B-$# PR36\C_2[
MR?-V?2VQI=^7?>4)P;:)QW9YK.G*@2NLHLJ0LFA,LCK=JZZ9D/7-E@T.ALH
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M==6&:HBQ2K@FH8) C0TGXYM.):LC1S[*ACM))*0; 7?!M'WD_V_J0TT]#!(
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M$"FD.<J;):W_PQ0Q@#*B.X"] [&44HS$> L\F0RM$+[$0Y_O )&!. XQL3_
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M/-4\BFC"+\!\@/0*::1]+(,"R>/4V8*6M'U\ZJ )!0)%HA&J/Y*19ZZ*5?
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MN^(-+WG#.5[SEI>[Z05OZ,)Y5+1ZEZO8#*MZT6O?^N*7O?FEZG[IJ]__\A?
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M8##!9^$I'MK2V76&S77@+>0A)&#2HSHYK9M>YV=JG=,"S=1R*HA=1^QN@/9
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M8XN_@WH8   'NCH&4/P&:%RK8P  DD$G8F#)?^/(NWJ]8?S)!1P =+RJ)P$
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M[3N_WON_#F3!YLN]^X/!$]P.V:M!VBN^_$- ZL-! IP]CS.Z!?2_"FP^(EQ
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M6!K^.#!VQPGF4RC.2_:ETY;DS60<BG=E4MH"@ "(WK,0@^RM( #@7K8 @!6
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MF 0#D([$!67-_[UEA6CFF%E<7XZ5V*[FY'7LM;#M6$$#4Q[E<":)V6:+3 B
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M2P:8@=-1%=9_B+FX]7CTO86<U,MPY#5=:TU5DZ,J>^7781)&S2H]FL!@U==
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ML533!$R184V!"(CK:,W8B!@XV1B2S5;41,A:5-:+.07UL 03U0,./)#1F-!
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M"AJH2IU?&CFIDHE.6NFE'PHXL)5P#"[9;">M^+U^#Q38QDTA?!!3V9ZUCD7
M',6-OJP3,[%.5[_#^BFV<%7-+>^Z,M<W.Z-F-*[F\GR;-67Y1G72M6;%S=M.
M@QV,1!3S:^U$09$[:-?P%);MWW"C:_O8QMM2YE*$JS4POW3%.ZM2PP5WFN"'
M9=,[_\> S7/K-GU97#1BAA]455NO:>^T]]VO,FU#@(&]L;/]]CS>TD@#K+CN
M2.N.CKG6NDX;= '5)7QWS#5[G=[#T2OU.T,_^[9',YE.?Z(E)XEAI) &$@.
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MD'XDS4[B#^MHVA)"@W:MAQA19?C(@NI(!10+(R11!4++T%0*,BRQ\# BCU;
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M6( YF()'1/_2\@."-[0^,'CI\I> \Y>#%[B!]7<K0!B$83@A'!@A1#B#]]>
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M&JA FK.-*I@\"ZD[2Z@_V[.K^B[*(+)#I[--6K/!JJ%T89XZRIB)Z6JEHHJ
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M9>@(BH4XRYB0'6)45N<1#][)5OK*031P# =#G9\$ !F0!,( Z-IINLJXL.!
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M[98<2)MR]!+6Z3B &!CJ+#^(9.GE?X4U/WS+Z0B9Z?\("J)X4G"4F336#?5
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M]AU ?-Q  N;??A## B(?>F0?_YF'&$C@YF'5]'%@!](<5!#?>+A? N* ><2
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M'33.B,P9(F8T\I6OW*4B5NJ=+T65BBYW="XM:1N TPJ"QC( I;6$^VG<4#J
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MI4".3%,.)UOQA%>8Y+4%)VT6%^/P:K+3#!DE)5[5ZS]X%%5#!;2S@VEZ!0U
MN]SF8U<SHCD>,;<5.CKJ!("\6) Q(U[YVGJ(S:D/PG\*!'NJN[-GNRD.1;-)
M!:Y9^R(127.>A2<<V:W!=KC)=+EG12#F12P.V0U(8M6NQG)P<B!G6:QXQ23$
M@<Y:A[4IS*0LWK);UX\@]G-H_SDMLF18 H3N((.]?-H4ZZ%$YV5J=@5R !PE
MMKO\LGLD:%N_$WP@4!N,Y*O!P3%F2H1/'J.!H$0\-AN,B@PUOLJH=$>^5J^W
M<5%XD.-W\1MLL;PE!%Q'IMMCK <E5*4CQ+FJ_\OWBX"R*,=(0#3!APKGEF]@
M-*+.HJ!N1#Z(G[2(<#^*00*3F]7#N82SUU2)Q7F-*-1JJ:B;GW#&G\H9,Y10
M'1.R*PIGXBH%H4^1,Z##H@X0T\-FJ1S=#VND95 K?%*=0#,!!N1VI*!A!>ID
M(I[0U#VR(<*@RZ;*AAB(*H1">J#2:%R)FB[(2_PP#&92Q%*]+$ 42QEH^$A(
M*CS(FX.B)>H".'S.-0)VF9EM>GP0WU("#!V)B8)6PLJM=;)=0 Z)A>C5-S?)
MK>F=L&M]1* CU%R2?ERGRZ(A("=BC$C=2H4,+8"=*/"R[KXO&F$E"N7K61J"
MHI6J)3B91.GYU;\&.O_F!=IPRJAH8MZIBM?-T2.@)QI48#1&K-EKXMG+@WWB
M&3VLR-(&WB-TQMP):1_ D $M[9>TH^Y^9)>DW8]0PTU:I^ZP_9):AT"E:K)B
MX(G,IU)@GJTHI- B[J=JSC<!D$,A[+Y_2JI[U[\[B$G\U(\0:3XYO=\]"F2@
MP]&C#M&Y$#!V"FHNB5[+8BVQ](DLG0L?_B'&8N;OU<GNTR'$WN[(8H0(W5/H
M75K(XNP)I%C$CX[G/'5O9[CF9':P#JKJ0:Y*;<=D#R$/)\0./[]J;AC@###>
MSR":C%D]GQY W^8.[+F&$3*8ISE0Q*@$@JC2)=3]VYB,0R8<N3L<"Z'I,/7_
M165.XB/*END^^*J@FH?'AZ,5:0S'<G\^;(B[90Q#;*Q-E3+"!@)#]E/ .@/
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/.[9D6[9F>[9HJX8! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>advm-20211231_g3.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advm-20211231_g3.gif
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MS#.J_S/5 #/5,S/59C/5F3/5S#/5_S/_ #/_,S/_9C/_F3/_S#/__V8  &8
M,V8 9F8 F68 S&8 _V8K &8K,V8K9F8KF68KS&8K_V95 &95,V959F95F695
MS&95_V:  &: ,V: 9F: F6: S&: _V:J &:J,V:J9F:JF6:JS&:J_V;5 &;5
M,V;59F;5F6;5S&;5_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D
MS)D _YDK )DK,YDK9IDKF9DKS)DK_YE5 )E5,YE59IE5F9E5S)E5_YF  )F
M,YF 9IF F9F S)F _YFJ )FJ,YFJ9IFJF9FJS)FJ_YG5 )G5,YG59IG5F9G5
MS)G5_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P ,\P 9LP F<P S,P _\PK ,PK
M,\PK9LPKF<PKS,PK_\Q5 ,Q5,\Q59LQ5F<Q5S,Q5_\R  ,R ,\R 9LR F<R
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M#&7YI$I59N959EJF.&5/2L('I5:@C);=191%%\I\YF5DYIPBI7EEDGDRZ1^
M'1*IJ*)L>JC_WD&ME8B1,D4LYUY)N)6FVT#15&HA3C<N!ZA!RNRH(HP9O='G
M0Y1:FE*G*G;U7X>K"L4F96]\=6N,%\%XYT(8XJA1J[9=YBF/!F6Z68]  CGH
MHM#R%F>A%5PZT(U.DLD4AT'V6&M#MRYG!"C!@6*'DF%*VA.WTG&E907C4EGG
M9-K^-*VU6C'X:T6%\KJ0JJ#5*Q2[SP)5AWF@A +*P@GO&^W#COWVVT$H&FBH
M4Z!DF%.PXD+4[Y2=9H3BBCMA6[!5I8)W$"AO\M3H!J-6M:/#$WGIKT(A7EQ4
MQA5>2"/$0!-H(+P5;CI0H2,+G!2W6^($,'$/,8@O1V)6T')-'(*Y_U6H-R,5
M:<Q4];LG1K'1?)"8)!/%= 5%H6AUT'!+JR+3UC+-L<X#D2<Q'$8/Y"M"=E17
M7[R0DF;9N91EQY][I^[(9&Q(,GVU0?.:QW=!3+=9K' J3B[0R#F"3M",]5&9
M-,UE'P0-'*T5<7E"XTE,>(5+XAVX>83/Q[KE?0M4=C0H4@XZV 1EG9J,W^XC
M^D"B V]>[YD+A+AF-$^;:[+3E[:L0:DK<VL1=T+S_:BQU[=]\0'NDWWN O&G
M>4%Z\WX0M68;%"S4 _UFF?B&'_0W]JTS@C(44K[!9<=)CIO0O0 G.,VPCU"@
MV=_(IJ80M'GN=\'#W/ 68J6 U2]N(&1-H>L6%)W0->AI>,O<D@98$/I1#H$P
M8B&AN .'.L1'<15R3[]2U!P?':AO0_L@03J5(M+\BF=+HB%#=G@^P%5(6V@C
MT\$:9 KW)<X@/W*8VU)',=I5"#D[_%&-"-:Y#<&0-#+T6X185J@A;I$[X'/(
M@ACTAM[![V<$N1N9[E:$VIPJ04B$#Q$]5*]PN8AK7L)7%O^CHL/9##Y*0V2>
MZO:C?;PL/S,$4+OVH4*$89$T8V,(P$24R<J8XI&::N$:7^BLS17$AVU"CH>T
M5*/%O;"(H$EC^W)X2B;:$2$H5!I!LL@?-S(H3WT\"!$=E\H0_SH3*KO:QV\>
MY3O0U*E0VL*6S;C3MYF]DEJTNMG+K),=(ZBH#D=K7!GG:,T6QJHA/&,F=,*S
M-B^"[8W,T>7H"F5"8>4-1M/24H*X.)!+ LEAOUF2:KX$.8$L(Z#\-*,\N:G*
M@.V(4Y%"X 9^:1!/P:B."5D>\[XULM*<T5^9,V<XK;7 /-9.902)S18K9#QO
MWA%1KD&?X;P8G4WMREG7\F*;NGG#^:A(6R_+6;^L9=-_XA1F'=5H!*MYS-()
M1*6406<>P:G1?;WLDCE\2,XN2!J+76F9C0--WVK:)L\]\ZU!B1/;JD;/GED0
M<Q$DS\BJ5='E'#&,FGM60+.XRP.YY_\\ 44L<N1*)G8)<XCN:]85]R$9LY:F
M.F SSDOC:! ;6G4@GL6?\OJ5UC8.DZ8Z#5CV-ODYP"I1FM6Q&6*94%C#PH$^
MCT6?I># 6R=9:Y81&HBJ&KF[24J4JT:@)D$.5L*",/=(RVT3<%G+-5R"1KGZ
M(TC*&M1;+RG70QE")6GQMEUQ=3=/U*PN3MU3':QJ!K%!38U>?5M1^ AQI/[,
M'TX;UU=_E;<TYUU.&I7ZKL7&EI_MU:]A=7O2/'&@($:J*FN!)<^PJK%VFRPI
M;ZT'X1W==JEP#3%2HKD/5+5V3*/-;V2*$!QW?NK"DZUM3DTG-8*$:\:@T(U[
M <D@RIFXM=S_,07R&JF;S/63E \AX;MR\\T&-1G)*;;P(-MYM$+]2DONB2=4
M!0*-X6A"-]%X@WY,QCW47HN"E#-"[RJ4(S=E)SNAT%=!*Z3<"D[7E9\[ZBOU
MS+S&(4=\&;J3EE/#&>?%YU(J78Y6K\KFH'*'3 A$3DDI$YR'IF_.<'0TB@4R
MZ&+Y$,J^*RKFC-#BF&;ZM-RY[XE%*\T?L9A* ?U5H&W\Q/AN>A_;!<V7!1*-
M.ERJIH7CCGXRBAQ#@^9Z[7-U<*8<XX60;LD(BBFU./MF+=W)8J6^'VLG)N)N
M#T6NC.YI-?T:Y;0EI)C2SM.=HD'8?;YSEW,KW((9C"Q5<D>&K7.(_Y, F:%2
MJP\ZN56FD>*3QKMN]='1C?= V.DJ-5+YWY\=]\6&M@%_KZS'_44S1="=3M+T
MKJ4"*:_&,<<?@!JM2[:+:-[ZM:]]Q[>YM(YXI-S390W%G+49,A'%LZTE@M3\
MQ8SN%B>II9]=(<E)JI9Q?2N0].?"JR"[VNC"69YN^P[DY_4.=[V9H"6+LS)/
M!PF7>Y3<[!1S)^9JG;J5^<3,1IK:XP;9U:5^?B:J-AN67O>VWG-RK _-RC*]
M1-98$:*P.C3PW1+GE4@YY:1-1>I-T^(W=+J8)^3,L>$+8;C4.WR@7\'2K2NC
MN,U7C;?%;]$@GY=V=.[DT2T7]-2MQB0':?\7=X"^3B(+,[P5,RYORA!UQF)-
MZ+RE5T:71OQ^60?RK4VVUIYC&OB?AJ**-N5RI[+Z5)N*_DU]S^D=I=%X1S?S
MRLQU>*$G/NG/QIN4.&_U*J=ZI##'+_>E62BP12^JW%DT(Y&4I<W37\7T]WX-
M$5K2A2OIAGF95 &_MP'7HV039CS$LW<2Z!(O V.F$2*J\5SFECDP)&O0$4I5
M(S"SIG5X-F=Y@FS=US/)4GQHDW=?EWQ!=SR@A4T6L0PW)BK"%2':XED= W^W
MMG)Y FDJ$DHWABB;Q"#Z=$OF)SWRQ%G'I5'DYG!E%VJ!13N@-VK,)$.CE#9;
M2"9=:#\J-W3!A5?_H_=_<@*$594B=S*")P9J5,>$4J6&*;B$9%80IQ)*J66$
M'I@G>%A!-%A*+.5V4E@!(!A.190=,<00@<0V455Y/FAN);9*\":#"G:&R(,C
M#).)1L.&53=>?%9/X355$SB*-L%MEN1QQX(<R-=/X/0_YV=]KG> O-)W%!1Y
M!1$*IU(D$<(9ICA[R!1L\+%HRE-\%@$KM;)XY68BR#A:L+</<C:)2Z8Q5#AA
MA'=1J->*P.=LV-A4SBB)=C@<P'6%MX1'ZD.,I&<B!C<ZQ(B+99B"6@.-[O%I
M#<8KSR@0P?2-#R>/UA4C['AVQ9.+]C:%>P5M5R9^P&*.IRB*)HB#[A=C__H8
M6$PG<8RX$''6CB08C_U39@\G=U!G80R1-$L$':C32@AD'X%DB)9(BBH9$^#6
M?=$Q*_@%934%!PMSB@)(A3&VA5/25/PQ)S-'AOX(AE-5*)JP(3\&090(<:!&
M$=\1'362CDP8?__FE :!0B;BBA&61%<2&RZH4^](<N#8->.8&@GS?U$H$*ZH
M>FU7:Q61:YLS> <G6FY3+R@W1M3R@H-B2$"X38?8<<U6-6WFC0/)4%&X-D )
M@]PHAC14DR]S90HG2F$(CQWV6CC)*RCG.".X(UVI:=1HAG6W#TZW!/[CC2!7
M6 CHAU*)$)PHA=L(-61D*L.WDK+)$B1F=W'RE,I\!HV_PA\%V7FPB"30 )!7
M)8AQ]T5DN(1J.2Y%8T;QX74<(&K$%S :X5X38CQ(E9O)6)RQZ4)!9RF9^)UK
M&"'V=Y04$U C9TE#2&LWV8VK-S^-!)X*4Y,6(5"VEC9?Y6ZL%GN4R'Q/IC,<
MEF?U 9Z:.(B>AY!-A7+@(Z +4V3]<IS46(\DN)N/V8V^R278F9"*QGX,*(MW
M@GSCHJ Y1E4,J1!UV)'<@6RK2"J7AJ$;((SZV:(.D7YD]7!J^20@.C9Q-H29
M&)\+4V>S__FCR3&&P]DF=Z*3:#>1=D>(IZ5NC >=;>B?2*.+L3ET*N*"*.(Z
MTADU&5F?_K</1AHU- ,-_&&7<,=KZP=:G%A3CIF/T.%64:>(_<)1,8DW\C9A
M3H*'B6F:L8A[3<2ER,:?7#8MZ/B&<WB6!',I_7<IV>6.,(@08K-53L:AUT*>
M"*%->(5X:"F2[(>D%+H<>'@JZ!>9 9B4-IF4H,J9)U.<F'IQN]B(E'AY9?=I
M)O*3-U>""#%%/:@0[::AY]FI&Y"$0!JL*N%>>6A^BS<MU\:)A&J&D^4\QFF"
M654DYZ0@#/(FI<)02?>DE<&@.KA]="H<9#E I@ 'EQ0>[*:#C_^26/OTAB;S
M+/789<29-Y>"<B.Z#+Y&$&3W-DFR+TP3<+]Q;<L*H2LWH?NP.JK&(:X3HM=D
M;6KGE(_B7CJ3?H6Y0_^X(Y8G5_Z2:+%8K7U#'OAXEN48<9&XGM/6L;_6H!4+
M=@$Y?[KY?,VVK#B3/(NJ8"/*GB_[//!S*0,9'O:*J #54?$Q;,\X'L=12@EB
MBQ8JLO-C1&>SFL#S*^[% ?MR"N(HK%9;$1PWC3\8@D?*'"C$I 3*8.+5C*/*
M5V$7I2[64)Q'J0NA6;2R)'66,P&WI% ('483EK2R1[ 9EK\%2K6J&:S#'D<[
MCTP51O:A6L4E; QA5EA*6GO8?AI)(\7_)99X66':@K?@)$6 =4R?*89<-1S:
M\C7&AV -%)CK^:55=B!XJ$+G4;KT]BS UI%"%8/B\K4@>ZH#V*WJ2:JEB;L"
MH0GO@EALDB/3 EX#-4L3(G;T)EF@EE2;VJMF!XG?J">.>DSHT1J_ J^X\P:-
M<K7>&R7M&'4%&G'M6A\&";,S-4L6UR+2*GM=NY3(=YH-\5_JU#7+"*Z/U#C[
M0CJA**CKBIEM4F;MB5%/A6?&J)4NZEX(-[*:Y%8$8Q[G:Y#X6F$5ZHL[!$ZZ
M=#>R]2W:UF YHE[8"$05@H+1"R YDI8>FK;B!%P15Y$J.Q#L^,*3.EXN:<(1
MO)XX@Y ]*;M)_PFS43<<.<)LQT3"-W@QT^*B:(-3?=-W"6(Q+IH0*;H0!$6M
M6EG!<#A+0?F]6CR=0EK#$X:K> -6&Z )C?EVE-&'G@N; C,T/HFVD/4E K-#
MV4H0M5%5R=19$2*.0O5(>6<=?N4V)D* 1@!+6:K"^V)IDK6GL(9+G;O(IW*X
M120N<KJ[%4+&FCJ(:'PM&+LCF6P0.<I3 6-'?BP;VB=_S$'(D-1\I &\7W+'
M2%F"11RI#1F1<VJZD+N7/-58TOARC1IA"VEE9>R72LHE?UB)%>"BI<G)UYB_
M/VBFGXMG8MHAM31/8PDD1E /C;@<)&Q+#8&Z";&:Q;/)$KP/P!N'J?^ZQ>@<
M$;UH=])7R)K<(+PXH0++:Y9<'S39O@9XMOFG3+NSP$V&G--Q8)=5/^DWM\4S
MN0[T06PD(9P!2V0R>%8B(10TSYS40(!;/]2Q-[T#/--"6YS$.IV#'1'!1DR&
MK&I)N==R2>@!K,J4T2K" 0E+HG&R+*8741%]'1<7'P4;(D5@!Z)<?ZI#KKCC
M,-R(C&DY$,H@U ;DH+!K,PR4Q\5S*Z0VJOYRU%",D!;#4H4BC!2M#('3.0\4
MU1J=+$+-'1Y=JK:Z#!UTT0AA,4>K(A$(DE*\=B1Z23W=E2!M/N22SGR-%+X+
M%%G-%W^M=QIXA8;9UY$(MHB]V(RM$EHRR3@JP2 ^:A>//8H%_1#]V*A:7-F-
MW=F>'1+W%Q11Q!>A+8$(.B(8Q]>E_=FLQMW:N&<9N)&:.5$G-3R%<D';L0U=
MHQC%\&2-6HS;<E6UKCW<K,U6MGT3]:3;=V'<&]#)(O:%$O65WLO<SDW<UDW<
MKVG0,6'<?4H7\:0NNXV0),JVPOJ:PGW=Z-W7G:;=V^U%W>W=H+N2<HO:73S=
M2\+>Z9W??2TF3O@3Q>4Z?>%#_6W9R4.BOJW%8A+6^KW@#-[@#O[@$![A$C[A
M%%[A%G[A&)[A&K[A'#XDB$.9:/%L<_P1# L8QOC>+U$> [XMP;W8)[Z9'?\>
MXWKAEO)+%:M3!!CK.LKU-)V)$D@7$@2E)5>#99S$O-&(TJBJ$8]7$UMXSD:Q
M3 7.$,7KY%0Z7FQ]$-?JB)5:XI)T-3DSP!61N,U4J8(#1S'#.H(ZXLQZWA9Q
M+H(*!Y/M@\YR'OQJY)(5GF ../ULSVHNX_J=VW"=%3.EMC*&Y"0!SANQJR65
M$(.F'AQ8P(9>Y!9)$0%,$PK<YSM!<4L9DC![F*"LD*74,HO.:2^E$! 5Z8R>
MAANJA)PKEI/6.9#]=ED\$N6\M\SA@E\K5>?SZ 5\)U,,/P!,MGYNX2AT:&FV
MXEX3EN3(C #MXW1-XDSKQ90[3M)NY[>\Y?6-M67_M1(LL^)@3.5#\>A/-QW@
M]5A:AF$X"ZG-;K-FJY@EGBQGA.F=9.P0UDI5&KFP:36Q7EOC3A)65%I)6#6:
M T<M)DEVCN>V;6FJ#DG#KN%"_M,TFA1?WH1-IN H@>@:\>X4VLR56"S,_53W
M5:+%P1XH#KX1?V(6;Q3RB.D_!71CR<ALYF\G:38[(F2UO>U=-$N8WGHOI4L_
MW#CA5\7YW!"8(2YQWA$_;^7V^U+C99),CU.^?LF058 YU_ 9_NL=![)) ;HY
M5@^5@]_.KM@> :%#,R59OAPM5B7?V7H).J 6W.-!H?%6,;,1X;;ZF^I>DHG9
MXY%)*C"G9VM (J5R*!$E_S5 9)<VD^$Z U0E 65QXK+7RT"OX-X2)2=? VEN
MI\UI8%5HX,GVX+DIX!R6/7U;GP'V5G_=W/E))V\49V^K+),3&)\1:9J(P#[I
M^@7BJ.TE26'55"%7$6@0M0XSXLVE!O%0C:-<A R,KA1(_PKO.$*P^O;LL5M0
M#J-Y3>RC@[;O*9$R\2KI?.^EC?:_U][Q&B>P_#NEG,;FIS_<,-+)J;\T6,\3
M%)WQ4I]X+N+["J&7N(>R1T$M !%JWT""!0T>1)A0X4*&#1L6V1!Q QR'""%6
MV%!A7T2,&Q2"PA@28;2+$HT4!"41H[*#$C.:0NG22,:,)PW",0F1)JB*,3MZ
M+/](,R//AT(I.N0XM.=2I@AGJB1J,-I/C ;M)+5)$%K(B$</S@QI9^'/#5'W
M17,9T6Q3MFW=OH4;5^Y<NG7MWL6;5^_>I<OL%"G"M8A7@H&3=NPX4*=0E4 +
M^BVYP0C+@XC+0L-9U2%FG1V+K&68DBMAA3@E%O%)<R"<DI\58A9:)!I(FAJ#
M_@2]#S;-(F^B,>5:]B;6EC\I)XQ,NB)MU04S9T2]&V.190>3)P35>8/KA7]K
M;Q>[3SM9S?M,3\=N)/+@WP?/;]?]7/)QIG:>3B\2OJ =RV2%5T3KM'V>4@JA
ME%Q*:)G&'!LHJ0WT&^C Q H*)2G3)+(N+,9R8^B]K ;_ BLB"!6Z[\&*-JS(
ML*Z<JRTZ^2;K"2VN/AP.-^=^0LV@QD8L["?E@JK-K.<P^I$O(X]$,DDEEV2R
M22>?[.G"M"*2K:#%%LQ(,:&"RS(F!R52SL$#,2P*RXAH7$C!M.!H3Z$Z!/.2
M(_'2PHA'\USZ29.T= S2/3,KX#"AQ@3:KS&#QJP@1X46J\#.AL;LDJ W7)(M
M,HGHFY,FY;+[CJ,J#Q)MRD2U)$\E@MX4T"!E1'5)DX,F]90D/-5B*M0MJ30+
MUEE#"M3/CGCBSR3L@B-QRS;O]+3&%5.;*%B,S HP(C5I(G2IJ\"T2B5%%TJK
M5X*F+:],C-XH2-?M9/W26X*D&_P/(6@:(^Q:] RBJDCM'&W0QL+VA+)??_\%
M./]@@0<FN"%8N4)XVQ*IB@C$+QUDD;'@MMWH)R,0=NABB8WJJ:2??"M-)I2"
M>X^LZE)CN#';"$+1RDY;1DK?VR024BA\'>Z(W*9HFW!=K%3LU""-(ZK#( 7]
MP_&@8%4^$\12A?*9)AHK/&Q6$UGL2+V7X>MIZ3_;'9(Q6E-,BC*($:):SH3D
M'3M"QHZ]<BWF'H1T6SW1"T[=#'=2ENN%>(Z4H<C07/0G"#TTS#*_&9J4*X88
MV[;QIA]ST-&A-]!9T*3,@K=@SS\'/7311__\JD3AL ..);HM3.ND %-/,==#
M*D(]1=^-#?6T3FYPZX;+- )UUAP\]F^KJ2Q^(-.ABW/_RJHAG/9A_^C=O'G)
MX"B1P<?[%)HXEI/B'3F5;O[(T$*1%C5\[4B;5??:()10['EKMQ0PP A:?G%H
M+'WYV4(WKMH&JA6: !80?[6;E7J,H+=]K"I5%>-(;D(5KD,U9BV-<=5 9,2\
M"FH*@K_3THHLV)2X=; F!'1)D;)5O8J4*%YB8Y4 '7(EBEGG=?^;U[[*)CX/
M*H0JU0)<NT@W1"(6T8A'1*)5V'2H&55&*!R"&4$NEQ5EP(D@_N%.!AG"A"5&
M+"):;(BS J@<."2-(( CDO+($KGOV.%D(1()D&@&I+ 01$\]; A90&,KQQR-
M3 L)T438PL?AC'! P8%09 YW_[:S7&EF8#K9;&AT&-!(:5MEM%![^'A)AA&%
M0!')G.#(HL4+881&UZG/:/ 7&P.1I7PR6XW%\"?+"G:D:$,B2K0J (T/"K&%
MW#LC*Q5"-:XDST_"))M$%DE)I[DDE,62&D,"^2%,4NF,V:NA%%UR,S$%TR4,
M3&(XQ3E.<I;3+MIJB4H&*$?_%<2!S='F'R'8D?"YQ58J-)!V'/2I@=3!>VY+
M84'@N*TU&>1*VD-8M2S))VO&C&_II EEV(;/$"ZK5H<QB.3:&<(TQC,CA.FF
MST)"F?@!JB%I6><^Q/BA@GJ)GJ<*:;[PF"9#1JVA'A4D4U@'4)HDKZ2O?"A!
M3(%,[?]@:A^(HLA0A76G>3&3*25L'N&4]R6C2D6?_)QA;4*)JCE^KXY%\8S@
MT+G*6YDII?L*"3ZI$I4)^M*<;X5K7.7Z5E#8X2_83.>O$I*W;(7U?!EI4TL'
M"8<ZN(XF1:N//OVJQ@<>]3"\].9- Q02R'HSCM_KZH#>9U#>G.B;")%/>(!F
M3(-RA7P)J=!/"BG/?3#!C*0B&D'>"4*>7NURV2Q.4"5%J6\U)GGW$BEKI71:
ME2*3(),%K)6X@MB>^)&"0-L48\KW6<[J=2,( I5I80N4Q81'C]1#6. TMM$(
M6=&J8CLK2@Y*':9<;I&.NQ&VQ+4XIQAW:?UI3%5[I$QN/?'_C-^=:X %/& "
M#TQ7*:/M0"P#176N-F4 W@?"P*F53RZH E)]U"=?NII_.E:U(X-:>;$+8M;R
MM:+2,Y5#)(P0MN5HK-)4R3.78[Y5AH1&[]G6^H(9WEMU%+@G]6]?.>AAUC;3
MHM<ZX7[,NY"#208A$,[41^L3T(CE,+(4Q!I-ZJE9CHAE@G:"U%'> XH-5N!D
M3L7LE%P6P17>5+:1&14*54E""_UO<F2U,C2+S- [[Z/)=#J3MTHDXX*LU;(9
M(6Z!%;UH1C>Z)\=C6&[;QB?KUMC"LXK*3GOR3OPV=F=BRYS7MC6WE=5V98BJ
MX4_9V2XX0CK!"M$T]3!TSZQV)-%,_PSQ+#TMI0^Y-[)8(HMH8>E#%L;WSJBV
M2%*8*Q^*+32,/D((FC5K:YUR"8 1*5X0%\4O5;%22KDA9DZG<IH[@C"*\_R.
MRZ@=WXX>5VP4=>RY.V8X)7>VWFX.&5<"Y<"O,I9I@]';E;@99)GNV=$'1WC"
M&\UL.("")5N"*'D+#14' QHQ43%QQV)C!S+;"K>;=I!7FCQJ1KKMPT=M8BU+
M3/$3!R?2*A9*>CT&"BF1EK-='B2-!S)R@_ASL9EJ=UN_-&<7(H6Z./0;(6W(
M$:_XT]XPM;%#</SDHT>Y44N!%)<89M+FE1IE3HYV4F25YQU;%"O+T\^@^(PG
MI)-&X 5!5]>E@0J=+6N<)J$T%\6:C.&N8YA=-8LF6SRFU@9CEE<*1WSB%2]7
MW]+QU1FG]*2+FS505-[REP]LL1TR[C['[^,]L8Q^>$TAG<?[LI#:0/&DY/68
MNO#RE@]%Y3VKV^:54GO%Z@B\#21=+X(]:E:.#'-32S-0Q![VE8?LE?A^16#J
M^J:AH$KR8EI-W\?2TVOC;;>3TKW<+R5LKL9WN&]_EBEQ*)!>DRJDE@WH#1P'
M\A7QFO;RFV7))^236&W*)Y=I2JN\=GOT!I7#:+;LRS\ U!RYDX_Z6[P%9/_
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M$'&-N=G,RCPJK?&,AJ-"=CPF7&R(\3K%G,LUJ!S GPNNI"*QC]CX#-)2!M;
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M4@@5.   "  8"   B &!N0&Y&(9)& @Q*.2"H(< ..2#"( PV(< \&- %F0
MR(2"F(05,(!!5F2"B(%+#N1!/@A&7HA)  "V4 8Q& A5AA)4;@LQ &%.AF2#
M"(,_+N55'@@T  !B.(A,^&4Q^.6#4&7]2H-,/@YEV.6"R(1,;F0@F\"\,.,R
MUH0RIH=H4&,]YF8$IF&".(!0+A@Q<.6X"(!-5@@T6 %,R00# &8#0.>$ (!(
MW@=]N.6!B($T>)(80(-QRH0 X.*EB $Q@('PP8%R'HA_GF-^/HB!W@<<N $
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M$K*@%.X2%2)0%AX= %R.CE2A((%+_]V (BA< /9=U]3_31=V81H&@!JZX>7
MX1NRH1PJ#QRVX1O&@.3M@L+5 @P<1  ,3AS2(2$.XB#&0/W%7Q]V31K:X1PZ
M(B2N822ZX23JH?[M0M\ACAL"HD&LX0IX(BAN8BAVHB@Z3ZPE7OS1P@HTXBA^
M8BF2(BE:(BIBXD%\8D&X(BSBHBYVCBT:Q,/(8L5A8@P(CG\(HC$6(S)VX3'6
M32+RH2[X(2"VH33>(342(B(&XR)^HO+$P"(<8#DLPL7 H28"0.>(AAL61!<^
MS!K&X3:RXR"6C?,03M>@2QK"8SO.HR&2XQKNXSX&8CS2H_/D8S_JHQLJXS^Z
M(QZ28T$69#^&QCT&9$(.I$(J_Z1#RB-$RN%$\N-"5B1  J1$,N1&'B0^1N1"
M$B1%BN1%:F1&-B1*>B1(KF1(/J1+9N1+&J1,"J1$LN1-DB1,GN1.8F1.QJ1%
MSF10^N10"F1)TJ1)JB13UJ13+N53*J54%F530J553F524F54ZN11)F16?F5/
M5B56AN56@J58:J5!',!!U,488$WKK, !%(3-#5+=7$M,3(*H<>##<4A'J-SE
MV0 80D4FP( WPD!@<D5''" Y1 E;)"8%,F97..;\0:982.;,469E$F8 EH-A
M?L5@^N4WV "69((6+. N[*67]%_O?9JBC QKBN!K$E]LCM]LTN;M\9MKWJ9L
MZJ9M^O\);CY';5)%HO!F;ZK';PI$<$[%</KF;C)G'"5G5"RG<3Z3=/K%<89/
M=7K)#!'(0<0 7!ZF'\4A3[!:+6B:AVA:_?7=O&R%K=6?(FS!>IZ%K<7:(FR!
M>[B%9<1:+<3 ?5;>K=5G?Y+%?.I"?19>6%A&>C)+L(6!>VX!MX"*J.W">SY*
M[VC%&*@=1*0!ACZ$AK*=W/5$A[[=581HW&4%B2:=B6YH59QHVUD%BWXH3[QH
MBGKHC(JHBZHH5<@H5NCHB.*H5/"H,P&I 3D*1+B0NR$$C X20EC@)-S  4R9
MAS3ID\VE$<;  :"F6W3$E5+I6&@IE(*%EF*I680IEVZ%EY9?Z51(*1?=A)HR
M6=UPQ4R@09S>A&6HDH)FR5]81GQ*79[>:=CUZ9YB':!N19WJ*:$.JM8A:J+:
M:: RCJ)6W:..7:1**J,>:J5J1:'Z*:4:ZC5E:J,&T!C\Q4R4CO%<#GC_NA&X
MO,N1N1&&%$17*$/_@!NL*H7TQ>JKVNI6S.IU1@:NYFJO:H6N<D6P"NNO9L6P
M^BJM(NNNOD>Q8L6Q FNSQE&TFM^T&M"SZF#7D"HFU8T%KFH45=.;>JNXCFMM
MF.HLI2JYHA$ 66FZMJN[#F8 :*L-I4$8+&M,<*N[II%!Y"N_>NLDF&L3B0'$
M? 6Z]FL9'8!=&JS"ZE@F/ R:!I J;5%#R,L!P,"Y90()0@3A+*P4A2O'?BR+
M_6MGIE#[=:0:@@Y/8*9-J&7"*J<PJ048R>K+PNS, FO-,LC-&FO..NO.TDK,
MADC0G!NZ< 5>3FD)AH'1LBG2?BE6%"W36H73_SYL240MT2ZMU+:$U6X%U6IM
MUG)MTFK%UF9%V(IMUX)MV7;(V#;MV:KMUY)MVUY%VL+MVLKMV]+MTU9%W$+M
MW.IMW0)'MKY0<%S8,1V3E<[0#<AAV9P;OI;="H3!%C3,68A!XS[NU0FLXZI
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M0 <@T@JV6 ^V6=?U;6MB9A]B:7(@.2#_;3JNX65;J64?MVH7-UI#SSR^=M=
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M/SW"@OQS@0 T/NVS/@7T/@\T/PN4/!^T/^O'0",T0!NT/1>TX78D%NE%+&X
M **A0)PB5=[/?8@!!H9$0BA"$V+N0YWO*1/B!E1 *N1P[D@D1%2C,2^%(J*!
M"[,NQ?8!ARA2_SK"'R$$_OS1'W&NK2YM216" #EBX)QH2I'IC%;@#&#R$</
MH.3HB#2IE4;EC,* )[642V$JBJC4-M(4G+X.)YTA5'KH2X6(E,IHBI H + T
M);44DTSJD<Y(#/^*,S>?H<7,Z(@,-9LXXTJS=%#Y=!_G-(OJE)( ($]%LDSY
M2(HPE8HJBI+PU$WAM*;*::6"R8<&:2D;"9*D*"9"E:1DBBQ4=:/62 M_Z9Q<
MBJ3V2:)H=54URJ$N1%?K"%=CJ4^1"9^$-9F(M9X RE7/*)Q>%51M"9]L]9V
M%:.<-8BF-5IWM55[-:-^]5@WU5A=JEBM*5R1M8J*29JVM5II]5RI552?M59I
MZE:A-5Z):*.6M2'2U5VMU5O/%%S955QWB5R_]8F4%5V;55_7=9ZP]5<Y"0:L
M(B^##8<HBRG6R.+6$0;&0%:B#@!2Y2GE, L/X^"FPE%C3B+B<#'S[S#_=(,S
M'A.GQ! +(R769DE#]('L%$:H;$.D;N@020NT:F,V;0(:   [<],G16(98& 3
M+=%H5R,&+/$EF=8DH$$%E+9HCQ)NDO9I8_)J$2(:J/8WH]8CH&$%E!82P[8D
MQO9I1_)L6^, MNJJ-$,B3J5Y=C$7ES$8RW&O\E9O16L:\6Q?W.QN!^L;\?89
MT7$<-VMOJ[%O/^MO2PMC"'=P%9<<#1=R)Q<<TU$<'?>T-%<:/5<<_\7A3/,E
M%,YX.+-2)D%E5,9'(,)F]%#AR$(_-@)*:R)7!-494M$DT. &!!4?<M<F=O=V
M?S?'>-<2AW<D@E<EC_=8BA<2E_<KFM=W.504_X5W>H5%?72F[LIK!4C0!0=L
M"#D"?)'D"JTP"J7P"<MW"M,7?<.W",^W"MN7?#="?,?7?-<7?N?7?>/7?O=7
M?>\7" &%??-7?@>8?PO8?P]8@.L7@1.X"B=!8F?B@8]C'9F.V#3$,F0%#:#O
M'HD*:&]"0L+@#"!PN3:$ 8-B'<_@QK"KA$<8NO T5*R7NE@X,9&WA$.P)E!8
MA3WP &R,2#<BR@H-RQ"MX11-7XJX7XX8B8?X89*8L9H8>Y98B0WMT*9XT+SS
MR]JLS*HXT:)8L9X8BK?8B+O8B\=87K[8C,L8C<.8B=-X8<X88-YX89;CL!3.
M4"*X'BW/0&(+&C*!4V:<]+;:$ < X" N6 1YKC0T(?):PA\5N2=4LY&',I&Y
M5B,8>9)G39*'\C,LV5(R(=9>(Q.&H7:"SNA(N91-^92W[8'G,.16(+?0IX:<
MXH$M@RSXSN]0^9;]S8-Q>9=YN9=]&2]$ES7__4U%L053VBH15VY 8%3>#OF7
MG5G;R.^9I7F:J;F:7R(-(/CC"ADQF*VM<&!.9=*6K7F<<4V7R?F<T3F=GUET
MBR_;<$ %S$*H:@="WJTC>$N=\3ED1CF?^;F?_7GDL'D%AHTE]'!<;EA??*B=
M24(2EJ_=8L*24>R?)1HOW'&B+?JB,3K;V#DD9FO"2C<DO/9)H$^A^R[E=&(9
M<$F'8M@C/C(E&,_77IJ3(3GP9MJE#6\H;[HT<CHG8AKK;+JF38-GKZ(@A)JC
MB9JFN3:H7^VH:;JH9=JIGWJIXU&JH;I(=]JHI[JIJ1JIMUJKO1HE8CJJOQJL
MF9JLL_JGJ]JJS[HC_U29LD1TD?EP:5[6D=?Q(;:N)<09>5>@ G# AZ%M'7^@
MKU>Z7&+ QE9@L#U"#@T;L3M"5A8;NU;@L8'"L;>4L5."L@][0,>S).0P#6#L
MR61E#!@:M&- M/V:)$)[M%&BLS_[LDM;M7'DM4][)%)[MD.BMBV;TDP[MW';
MM7=[M5? LVW[MF6;MXO;MV%;=X.[M6/[MYL[N<'+N95;N(U;NJ,;NDWQN"G0
MNK-[#%*%MT5DCV+Q#2)%F&>-#QEBMD(,-AWC0]<[ZD8%4N3"4!0.1<A.,)[$
M,!C"K^4[)NC.1\+"^GI(+%Q.I=V"=FG; 5)@P5/  7+[,<1 P1G<P<%+:/^>
M]RM\:U<N7.E@P,(?O+$[?&@^'+5#7+M&_%@RW,2]DD!-D4M\Y")=?+J^! =H
M&%%B/%I<G+%GO,9A?+UX_#)NO,5]'$:"7,@3@L:)?,B-'"%>',>5?,D1X\?+
MI<AI.\>3_,BE/%VHO,J?G,N/7,>W_%C"_+;'7.G*W,R[G+9M@!:5S#!7&22@
M8OO4+?Y(I$&LPAUC8$@>>#) (\\;[KO6;P\_Q+^YKRE)4RH= O,DH]#;S0 ^
M!"I&BS1#HX;,NR3R&B2.BL$97"A_[5(T?<$Y'=-C@(G( 9Y/DM1-?2;?J%92
M/39B8!>^R%4V^1UA76HHI&I&'6E:/2/,F:--6BK_5>-2,H+EA+TBFE+4ASVN
M?ITJIVK9C_T=D[W9H_UKIIW:C5W6BAW*L-W9E9W7M[W:?Q+<?5W<H1TMH8;<
MRUW;I?W:S]W<K5W=VQW>W[VNNIW=XYW>F[W6=R;4.::\.7H%AJ0_&M(  EX%
MWH#^8/9LZ,='Z<XIFAG_/ V^C6='I=( G.\-'R4LMME'*0\R$T(B[GHE$+Q?
M<.#34\ 'O-,O,D'"-1WE$XUZ="$\I7,+=H=59![,8/[F2;=4P8<6=#[A:/Z4
MX"CEF3CGT<>G)8O[?N=>E%XAF+XZ+5<AH'YQ$V+JJ1X+ U=9K)YRJU[,GC[K
M,V+K$U?JP;XBQ+YPNS[I5<\>[;%>[;U>Z\N>[-U^[M&QZ:_1[NM^[257[O,^
M[M/>7G@>E"HX(P*:LC0A--4-IW8#OB<A&4(JQ9IY#P^COB/SX]-"Z]B[AFP#
M0IZR'Q'=BNPO4DC_S'JW.5VZF24N72$>&""=: 4HP.0I8$>X=?;5=6%I'V'M
MB.49O +N=:%68,UWX5FTP$Q/JEQ_GV>D!@PV@UZ97PO4ZJW,IY]\]?9C(,2;
MIARTH%$'ME\KZOAU85>PG\0 MOB[O\/+:F>T()_LB,0R58?:GY3HR:#B-/YW
M:/XU2?[5=8TD@F"7/S\ XH"* P!B "!H$.'!%0<2#F0X, ",  96&)!(T6+&
MBS$:'GPH\ #&BA<GDMP8H*/# Q!9ED1I4F/%AAL9MAPI,R='CR%OQGQY\J3*
MCRQ#X@2J,R5/D ^1.LW84&&,E!A#%CQX56'1E3YAHA2ZM&C$GT=1#NW9__,I
MV9D=KTZ=.M%JPJQ9&7(U2G:MQK-,1>;]NC=L2XU_@]J52C7N0+IS$]HEVO6D
MWIUWQWHU3!ERVK)Z:9*TB1?P1;"5_5Y.VG&@ZJ*$3[\\H$67-UW?9&^9M"^W
M[MV9+.+>#7PWL0-B]DTR@%M9C!C&D2L+@ 9X#!6[ZQDHOB]3C.@W NB^ 6!?
M=V7&#_S6K9SYOH[T<G<$CB8 ^>#T@=^(D4GZ@?GU^],O>(!_ BIS0 H&'A@#
M?P(NR&"##CZXFW(''@B#@@PJLX)LM.E22X(0UJ<<+>304@Z)![3W87#*S>;-
M+BWNE^*"(9)3RXCDP!CCAS/6**)\.4(XHX@UXO](7T4Y*A><A^BIMYN2N2$I
MG847,JF;DPU"V:24,E+IGI8#<KF>E_YA6:68(()IY95HFGEFDFS21V:70*ZI
M(YUSNEDGG@_&&6:>4?J9):!EWODGH8$:.BBB<NYI)Z-Z,BHB+;J,F"9PQP60
M'X/) %!<)ICNDUYVGRX'G*?Y99)? #?DUEMTQQ&3W0KY+4=>)@!DBEY#[BEI
M*ZSHP8 =A+;&X.L^:!CT(W >_3C&#1,Z$&RRTD[KH!@-3-C &"D>.ZF(P%)K
M; R1DO,MM6+<P*(N6D0+;F['CAL#N^W6]ZZ-V\TKX+DDBABO?Q;]>.YN.$0'
M7,"Z#1R<P;DAG*+"^S#_#*'#$$>\ZL$$?RCQQ10+K'&U%2_<L<<<QY@QR1\_
M'#*#)3=\\L0/KHQQRRDO"//&%IL\,LLYVPPRSC?K_'/,.[\LL\\];QO#AM[<
M(&^IOC5(3 PX-(<;/;H>]YM5V!T; ':9##3),-#E)@9!YKD'XR1G[T8/J>(!
ML(QN:;Q$GB9P?>H@#@?%2Q6NTA;DW8_Q4>##V/@>CF\:*Q!N>,,Q;!$&<?.*
M$4,86TC>;MF68X[X/I1OWG3GNGU^>>BB4PY&Z0*RE"P:*Z#A^LRQQT[OZ[3G
M./OKN-NN^^ZP]QYC[C,W*+SOMP?/^_ ,%F\\\!\RC_SORB\(_;;)-S^]@-4_
M_W\]]MY_'_WQUDL/?HJ*DY\CZJH+.+>LU*KMM^CRYQL## <8<"^X*1D@K3+$
M9/*F^0FP/\K0! "3I0Q4!5!'"CP</1HXOP0><( J@B %T6/!_L2 ?PC,A";,
ME, /CLF#"QR3 4L((A+V3X4=%"$"3]A"%*;0A3\*H0SA!,,:LE"'-#S2#H^4
M0Q_V,$8V7.$04U3 "0KQAA4\(@.="*0@$O&'1)3B%)7HG]X8( W40H,!BG7!
M,(**&,101CWF-1,QJG&-;&RC&]\(Q_X4)(YTK*,=[XC'/.IQCWSLHQ__2)_C
MN$]:8@B ) "IQV4A<I&,;*0CQ3B51TIRDI2LI"4OB3S)3&KR#1;AHB8?":!/
MBG*4I*3C'$N)RE2J<I6L;*4KQ2C(^+VRCHJ<I2UO.<L-XG*7O.RE+W\)3#AJ
M\3S_P51C*/WS/RQV3H),I!8S!?A,:&;PBLT<H3*1.$UL7I.!V]Q3-H,3@ #]
M:!+="0,Q+57.<^Z&G $P9[+8Z<X<P5.=$)KG.]-YSW;2TT'V'"<^_:G/?,8S
M1OV4YS_A6- 4)52A!R5H0QD:4(-&5*(#=>A$+5K1#RU4HP_EZ$7[T[XW%).-
MM:2/&&!0 1QP#G'Q^8%*32>ZEKY4?C)=*4L#X(,<V!1"KJ. 3F'Z/)S^5' K
M. /E@*J]HAZ5J$;M%\D>%X85 %4@/\*!&,BC##%,+3A6Q:I6Z=-54'TU1F'-
MZE8_5-:QIBBM9T7K5<7:5@BQE:QO-6N.YDI7K\;U07AU_ZM>[UI7M;:QKW(-
M[%[S9EC _C6O<&6L71TKV,(N=JV)I>QD_=I8R![6:<@9Z1J/:5('/ NIZ1/M
M@: 51C&8UD"H19QJ1WNZU::@M1B3+6V3]=K3DM:D-WB&,WS+-)/Y%KB[35AO
M?^N,X&(L!C:BA7+K<TJ%LDL,\9O$=*M[7>D63)8+LNYVM;L;ZH)W=-SM;G;K
M>5[T?E>CZ7V0=\-;7O^\E[SC)5M\!SA?^[)WO>J%;WT]=]_^Y!? ^_5O@>E[
M8/TFF,#]17"#%?Q@!@NX(@'V+.)*&J$"32@%1&J7A#;<8?E]>$(A=F8,-LSA
M:GX)Q266D89)K.(GG1C$-U3.;__Q\0P<5VI+-\[Q,W;\I1[K6(;*T1"+*J1!
M<:;H!A:*$Y.!X^0F@XE!3X[0E 54Y24M6<I;AO*5L<QE"&59QEVV<IFU_*$Q
M@^K+_5$SGZ@<9C:ZF<WUF?.9R9SF.#_(SF+6LX/XW&<OWWG->19TH<U\:#3W
MAY-;M+ 8 5>?3.  Q3ZH<(HR(5L#59J"F*:TI3_4Z0W[0!.("_6$-BVL28N:
MU,DR]8%&#6HQ.",?R'4&&C[-&UG3VK>VQK5N,J'K6M]:6%NP$8_"$-_H?BAP
MR@(.LW>CY-P\6S?1=M"T<U-M!EU[']G6-GVZO:!M@UM XE[VMU-4;G,'9]S^
M2?>#W/W_[G.W$=X-HG>]Y0TA>WM[W>IN=K^AC6Y\QYO?^1:XM0U^;X)/>)".
MIN#^ZJ,)"J"X A9A2%86LY*+:P7C"Y'XABM0%8[+A2@:+WG&'>/Q"5&@)28G
M^<E=WG$4.R DEIE)75Z#<;/$?,,SWPO,1\Z2E)\6Z#YW24H6PI&=JQPCA6G-
M3,* 7-_FXPQ'GXK-K6YQK!\ ZL.=-=4G\G*@#R0,O/;Q&2J^\;0##@S[LI$6
MC$Z6MH1=Y#FWGV)<DO6"" 5P,3G 1.Z.]I:+W>]'Q_O@32X1PJ>%Y7-'2.(M
M8Y"[2>8TA ?\U7].=[\;/?*<H?S?P]D4QF/>\?:#/-]=@Y/*_X/>\(+//-B1
M+OK#PR4TG)^\[??R&=(7/O.M5WOC-?YZP_/^Y(FW?.R'_WC3<+[I2%']XGT_
M^N"C??@N+_[JIP]]N20?(\M'?=\___S> W_SI[^]4R(/>YIGG^,;;$WWS7\4
M])]-&2>CCQ8]V? !II$^44.Q 6)\)BB&9 ,T8@@"@' R8Q,"9/V3@ :H(R_F
M@ C4@ :R@ 04 SDV:[\% /I0)SZ&8\X0 "C"*#WV6RL #7,2*2ZR"RL@)D82
M(\#&7ZS27MDQ@PT"@P;V(#?H8#E8@PRB@Q#&@S%H@SVX(#\H84&(@TBX@T,H
MA$R8A&IDA.(E+$0H(%'H:[]&A5F4A?^1MH5<V(0^V(7V%X:E,H9D^(5%.%W[
M)#<4EG\4A&'A=2T'DBV=8RW8HBT75(>Z18=QR%K9PRQ\.%M^2!_-\BR"N"!C
M (BW133(E0_/13&\UHB&6##'E6..Z"#UXBW*PQ!5%5A-DU:>V(F*)5;%!1R$
M)5F995FC*(I918H"4UFI^%BP* :MZ(I>18L+$XJ0=8OX\HF:M8J1Q5>Y*(N[
M:(K!>%FGR(J_2(ROB%FQV(RS6(1/TX8"!%KTH3@4L'*2F")C$ ,4H%+:2"W<
M2 $.D#^=(XXS)3^4XXT[]3('L(Z[6!_J^(U,)08& (Z[X3I&=1U,%3GW2#:5
MLS[]X8(YHAUD!W #\94)W7&0_9&0JG*%P=&0"TF0'8%LK59.#UDJ"HF1O-$1
M$OF"%VF1[;21OZ:1(>F1EU:2/Q*1(XDO*ZF2%,F2V0&2*IF2!%F3EP:3(5F1
M-.F0K=:1+-F0.VF3(FF2EG8I,>,YC0WRAE!&18B31 =(1/\#E0-B1<M4E3HB
ME?CRE"O43=[4E0Y21#KTE>[!04EIEF>)EFFIEFTT3&N)+]7HEG$IE_V1$G-I
MEW>)EWF)ENV#E'>YE'H)F-.(+(%)F(5IF(>I2?7@.HV&F P"EXT)F;RD;)%)
MF95IF9?I6@ P&E/1EW;YEY@)FJ+T'J%)FJ5IFJ<9%3$ $9TYEY!VFJ]Y29,)
MF[-)F[49E_6X C%P Y,PE7/Y<+8)G(!$$,%)G,5IG,?)2QM$9\C)G!2TB<T)
MG=$IG=/I1\#&FM2)G1I4EMG)G=WIG6G?"9[A"4>R*9[E:9[GB9[I>9Z1I)[M
MZ9[O"9_Q^9KD*9_U:9_WB9_YZ6BZI)_]Z9__": !FDGA)* %:J 'BJ )*D94
MI: -ZJ /"J$1"AST*:$5:J$7BJ'KN6T9RJ$=ZJ$?&ISX Z(C2J+_)6JBE#F8
M)ZJB*\JB+3J-!.JB,2JC$*H,DS"6HE.C-[I,-MJ;>\*C;)2C/0J6/[I&R22D
M4#--#"I1NRE@"JF&[,2D !6E%C6E5*J&#0*E5\H@62JE6MI=3II/50I18EI/
M8-JE8>JE L*E2YJF\F6F;(JF9RJG<#JG8XI_,QJ/!F YG*)&];BG\ @P!Z"/
M@$HR6Z<%7=.GAHJHJ;5U6\"G8J0YCDJH#:.H&B.B.<(TQY@;F8J*N\&ISBAF
MS+AGHCJJFOIGI'JJIDIEJ-H@GPJ,J=JIH:JJ"^*JF[6JLTJKK'JKL0JKH%JJ
MO-JKK]JJNHIEQ%JLN'JLP#JLR-IFPHBG_P43 ][@#>1 +I,:,=$ZK=6:6C>0
M@8UHK=4" ]Y "]-:+A1T4N)*KM_:(.>:K4Y%06@0KNVJKLL3KN/J#>7*GO\E
M!N<T8/MJ*6FHKVVZ3@"[8/Y:L ([L 6#L+G1KPO+L 0;808;L0[;L %KL0>+
ML1D[L1?K7A#;L0K+L1\;7A0[77?ZK*!B .3 (1M2@?.B#"F[LK71LAX6 QDX
M7 ,800? (K0@(BWFE#HK&SQ[(T<*)P>@LI(R&S,++L]QM!JBM-,R'.DRKCA"
MH;3:9/7G9EA[M8-&?XGV)/77JEOKM: "MG &964+9F?+M6B;MA'"MOZ1M6/;
MM7+[MFTFMH'FMO]TN[9[J[=XBQYU6V=WNV>"^V>$:[81$@8<B@:/>FEA4!O3
M*B):<)U5Z+BRX7:3FT5DQXB]-D"9$ ;B&BG>(+F<]KE".ZZC*T">VR+36B.H
MF[IA0"/DL+JN*S^JB[21FRDI^F^Z,6W;UKOTL:'D!KR[*VT!!T[&ZVS(NQO!
M2Y?#2[S[P+S->[S/&[W.F[S4J[R\F[W%6W#3V[W7^[W+N[W0B[WE&[[::[X'
MY[U^%!\7P31O59I*P2!I   4$0"+L0*Q,1O'=K\$D1%8@1%8H1$?8;]78;^+
M\;\"$0#ZRR$C$@;]6[\5 < 3(< 70< 6;! '[+\2'!)GX&/(]< 9?!'_",S!
M]4O!!#' "HS!$;P"!,S D1)5%1P %SS#(@S!"6S",XS"*YR_&@+#+;S#.JP"
M!6S#) S$.2S#@//"#GS#)1S 04S#!CS"&PS$0ZP%D:(A#VS$$ZS# )#"0[S"
M&IS#,W'%XAJT4142/($5&]S%1'P0P;<:/W$WZB?'(1<2)QS!;6S!VG=W X''
M!<S&60''=ZS'A5Q]?4QX +S'>7S(J^?'AAS(?.S(B1S)C)P0@_S(B@S)=3?)
M?[S(@,S)= S)C"S)HJS)IWS)NT?(IQS)H1S'HPS*NF?*E1S+IS?+I&S);ZS*
MF4S+>^S*J]S+0BS+K\S*I/S+O(S+;DQX*X',P(!LS,,,S,GLR]#<S)\\S;9,
MS,$LR%7G%J=<P-]LP> \P^+,R.3\S9@@( 71$NQHF?@3'D24-(\K&T\[+44F
MS]Y S_VS E$W9 0(M.,ZM41;M+,!T-[@L_@"#2O@(DJ3SQ*XT(_;T$?RSRSR
M?]A&'2\X@U9HAD_HA$L(AF=8A668:R"MA23MA1S]T2B-AB9]TAZ]TBH=TBPM
MAC(-D2(M@S2]T2[]TCH=TS#-D#9]TS[]TS@]TD(]TT9=1_%A/\KYSO^D^9M/
M96SE.$"4$]7^B#LW\(')-:_4$ZV1XJX#="QFC,];G2\P$+NT(-4"=%)G_=7S
M0SD[ZZYU^8N'58P/8ZS^4=<,DM=Z?=?]L=<+\M=XW=?U$=B"S:Q^/=A<E=B*
M?=B$O=BE^-@'$]F2W=A@-=FX6-F0G=F:K:Q\O=FUV-D"4MAZA"&Z4IJ$AUL'
M #GEBH>J'0:L;:Y;)SY3K:=:D-93#0-A\'96C3NJ#09M#=:^?=OS@P;"K3'\
M29 /?)*EHMP(V=RM]MS)W9,J&=W2O=R@5MV-.]W6'9.>N]TOF-W8_=W:?=W"
M$M[B7=X.XMWIK=[G;=[CC=Y Z=XY.-_M#=__[\W>/EC??W05INF:8BG0,O)-
M!#C@$=24%!1"(AA&T:1&#+[@TU2U)ROA$_YMN@N:3TWA@)FO&<[A'6[1[!:9
M^^?A>!GA(V[B+/J8E_F9)XZ6R,WB+^ZB*QZ9*0[C9RG7-8[C)TKCE2GC%U+@
M 'XX#DY-6OGC5U+D,6*DBR3DSG3DW/0FPUFG8^JPZ*0J4ZX;:TJG66ZE4>Y1
M9,I&6([D3>ZF51ZG7 XA26[F[O6F6Z[E4E[F;5ZF9)[F_*20)NL?/=Z8.[ZN
M*V YSC,ME ,Y4C4Y?+X%P/TRA&[HZ8/H@"H&BSXY *D"O)U:CIXYA.[GN$7I
M_3$0G/C9E!W:HGW90*/MV)V.V9]NV*8^ZJB>ZKZJ1J)N4@!YZ8A%ZG8]ZZZ>
M,+!NU;;.V:S>(+KNZ;SNV:INV;4>ZI=-Z\+.V*KHF!O_?N$6?JW=HJWFDC0L
M8@/JJB\V ML>,R[9;C+;OHO7[BWJBHGDD.AV!.[1_N<WX.WFHN[8#E.C>6D>
MJ][RWM%DX[!1..7X'N\@&VO\KH3VON\CZT;Z_CSBXNX!/SKY3N\IG?!(L^[]
M+O 0W_ 2#_!3Z.__[CD*?_'SOO$,7_$6'_$@/SIV_FW_4IKX4[T6."(LLH('
MN")&M@L1C8#ITB(1_?(L+_->1O,Q7V/1"O,Y#V4KH++IPH)\=/.RP?/U+/3C
MTB$ >/1)*R8EKD&&RR!I,K<08O6 ^RA?FR)9W_54OR!>C_5@+R!BST9F#Y9"
M#_-%/_9J^R%H[R!P?R%JS_)L__\@<E_U9.\?>%_V>C_U;M_V>?OV?D\??-_W
M@'_WA+\/>AZ9+I'<(J(T8-"7GJLACTN[!+D%E2\;E^^#F3\;EH^4F>#Y2L/Y
M13CZH#\MGCNN2.\-DL]'HJ_YHCOY81 I)4(.I4]LL;\%\>7LZ@N^ _?[#M)M
M*1_\W LAPY\BR/\AR@_\XKO\UKM&S-_>L>_ZQP_]PG_]2IG]11@&U/^0TH_]
MZQO^Q1]NV[\@X*_]XI_^Y"^\ZL\@Z+]O[*\LO>]9Q$!#RH #AS0MC)\;] L0
M,0 <4'$ P HMNK[I\L8P3  8 0RL, !1(D6+$RM&G&@P1@ MWG8U;/A0($&/
M PL"./^YLN4!BV!$DM1E4B5,CBM2'J"H4PNY6N1HD=.UA>?& "A97JSXTJ+
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M\D;]JW\8GI"_21L^WE@_-R(([O.^Y@B#)4F+<M""RW"^^TL_]JM D.@YDB!
MNIB^D\"("0R1@@"0ZDB/]@A!@_ )71@T78! "<0(_@@/XC,0LIB(@4@(%=2"
M_K"0@8"X",P,Q* ^%+Q!^\,_%X0.$>D)YIC!%:C!%,R+%<S!'\0*'IP-@P!
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M0I&,JH=I"A8QTXQE@-[P*Y),/6>.U:XH,8"44(8N)A%]:*'LHAP85 ;H!>#
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MKT8!F-=]'67@WDI]735+V<0CY0#PD3;R634[,UT"\P6#!K]:HXCPY^BE&S3
ME! BU6#1A,@TUAJ* =9VAB(RFBBQ8T".W5][]$@G2$1>Z4Q_J$W'Z$Y7(4??
M:$S^T5&/WU*O-8P.WU2OR#OVWU8?-^T8B5V@9!69")?6_S*7A*<9YM@9WG64
M'.%@?[%M^3&6+/8'5DEB/_9ER6&0ZW5@AQ8?YO5IIW9GGU5H__5LK_9:VO9K
MAY%H5W9C9W8J"HUE99!ET$F"\".0O:ZDX"2 >?.4D?,HN8A\X2I]8)6ZYMB!
MX:IJ6K-39.-I.H 'Z@_'T8<" EJY*4V]08."P,E3I9<;P(<[)N \Z5\^MO@
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M%4"#+#,KE0J0"A61=>JG!Z!'3316,IT&=6@^)156P;.QEVU5J$&)@=&*MHL
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MNY\;NWFIO@W<D@B\O17\D)C;*AU\OX5;P@&3L^N2AX28)0+WI@P@^7 @-6(
M!A@B!M[ ,TALH([)^F?HX9Z#6:7) AI6((6$9M%@P(ERF6J=XF9.F91#(L8G
MNL?_S,9A>91SO#U/F<8-XL<=.L@K)$=O% :)&K'L>$ -^9'W.)(AV8\C=,L5
M>9(9.<NQO,LEF9+-^,H#.<S1G+# ?,SO^,P1F8[A?+6T7++8?)&Y_,[)W,Z_
M',_Y/,\R-V,"8%XTQD4$0BD&_T4S2!><TF 2K*N7HU82TD#C@#B!.455JG@M
M-N5X,#U$;J"H.+W3/]V+G\6X+AV++?U5:@O5>6O40>]4.X)U;;B'Y92#_?2%
M9YV'47@C;#W79UC6=?TB>'W757C865A4B#W8D7WNE-V]F%U3G'WJ7/C6@7W9
MC;W:I;W7[Q37:2K<AD&&; 1KF8)%@&)S-4-$\J*78H!F$2)%Z$\G;L"LF>/%
MRT)=PV"!&:/>[WTJ\AV!FX+?*3C VD[?>P1:!UY:"SZ"Q8+$$I:_YET5)98A
M"M:$)/Y=Z]48(;X7,7Z */[B+1X7-=XC./[C/7[DA[@A'H.?Z37E1;Y=29ZU
M;@#EG?^G1&)@Y4'>@5A^XVT>D7$^YUW^M:B3Q-IC:YGCCS3#)\ )=DIW&00+
MB#:91819(3B<=S-!$W+<+7Y6.W8VZY-7/+3^T )+&8:!ZV$V ??V=<\>[?]6
M.DU7NUX"YS0!!MHZT2>A'C+X;:$F=[M';-->=?>>[_\>\,FVVMZ@<4FL(%;L
M9\P>,PR?(PKW6> :(>XV\",WZB;?\B__V%RNR4"G(E9 #+&6<UH]+M*@B"\$
MY6&5&%9,EK_'X3&_VY;7]6-?]F<M8S7!PV$#IVA^$A@]:?1!(, IADA"_2A]
M]H\MUHL?^9-_TJ3>(E*DJ5P#!X 3!DH?L>9+#- @WN5]=Y67O]M>B/N_'_Q%
M"-"/8RA*U_R??R:(GRN"=VFM/N#<?_W'7GCAGVCEOVGM__[I'V@;S5L/!" F
M[1M(D."D&P%N""Q8\&#"A0PC2C2(4.'$BPP=6L3(<9]&B!TG?@R)<21)B29/
M1DRILF%%D"T'LHPYD^;+F!EOXJ3X<*=,G3YKMA2JDBA)HT>![D3JLZG3IU 9
M HAQ(*K5J_]8G8H!H$QB@!@ LJ)9<4;, 3%9(XY%$R8&VK0<T01@ZQ8NP;%;
MPJQX:Q6O7KY1_>Z]*A@PU,)V58J)D7<P1K!-<8CIJDP,#HF2*5O&/'E?Y<L[
M,WO>C%/T9Y^F29?N?#HT:]4M4X->K7EV3-FH7]M6B=MU[=R_?8_>?;(W[>'
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M8PD2V=@L5K#$*<YE0\K93KYI(F@X@(XT 8"%?&4?@%N<YP:"!@ 0PW/#N@$
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M3V?)7QT+J("-MOQ;\L,1H5^\O_W<W_UD:>Q4B^'>/_XY^^#D?_[H?_[BO[/
MG_Z\_[GN'__RO_WM_ZOK/_\6/OGXO__\_[P $>. BGT%#1Y$F%#A0H8-'3Z$
M&%'B1(4 8@2@F%'C1HX=/7X$&5+D2)+_)4U"/!#CY$J6+5V^A!E3YDR:-6W>
MQ)E3Y\Z'%@_P!$HS0 P#)I5ERJ3,*%*E)8\F=<H4YM.F+JE&A1HT)S&I#F,
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M_YDBSV!V2F] \P$?[7%T8D] 8U_V9,?V!^SU!60<^Q/V%+3V8)= ;;= '![
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M@ONMM^*6VVVXZ)+_F^ZXYK)[;KOJNKLNO?/:*R^Z :R@J(H.C&A H0' $ #
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MVS[OD0WN!0?I/_(TH/Y"Y+Z6&O_IQ1XEU/[L"3S]I.KQ+<GIPYX9\?Y4\#Y
M+3^.W/YYD;XH.G_M 93S<1'T9:1.9O\CPI[M!4+R633X7<WK(X[W2Z7Q8Y;Y
MJ;[LN[?VOT;Z17_SVR+V_TT"]!4?\\$>ZOY>(+[?[.G>^@-_KXG+07)&8$]C
M&U? U5#?K$\_](]^&S6?\Z$!_?DQ*2RE8U8@C@!"V;Z!! L65 9 S+X8 /8A
M5"BFH<&)!#,!R+3PQCYB "9!2T@Q9$2''2L"D!AR(L-]%@6*B;%O$LJ4!E<
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MSX_^]*M__>QOO_O?#__XRW_^]*^__>^/__SK?__\[[___P^  2B  TB !6B
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M4+/:RR*;0A!*FY'H2:MQLM8/EI:32S7/'=IE#K4_^X.T4 M#^$0"<<HH8A"
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M@(D?MU+ ^W[R9S_.^IZAI8'S0,]US1*>%<2M#*Q-][=7O3-?&O3>\#[A#ME
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+6M3H4:1)408$ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>advmlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advmlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X /H# 2(  A$! Q$!_\0
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M,GFV=[ EQ$W^RP!&??FLWXA>,K;X?^"]7\076"EE 72,G'F2'A$_X$Q4?C7
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M)S@?[+97I]W%>*?$?XP:]IOC[PMKWB#P[+H'CG0I!%=%5VPWMOU[],YD7(+
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3, MCG'M4E%%>@M%8L****8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>advmlogoa.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advmlogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X /H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZQ_&'BB
MT\%^%]4UV^.+6P@:9AG!8@<*/=C@#W(K8KY^_:*O)OB!XR\*?"S3Y&4:A.M]
MJKQ_\L[=,D _@KM@]U3UK:C3]I-)[=?0\C-L;+ X256FKS=HQ7>4M(K[]_*Y
MG? ?XX>+=:\<0Z+XY\N)/$%E_:6BLL21C9EL(NT<AE5R-V3\H]:^DJ\(_:=\
M$RV?@S1?%7AZ);;4_!\T<\ B7A;<%05QW"E4;G^$-ZUZOX/\:6'C#P7IOB2"
M5(K*\MUG8NX B/1U8],JP*GZ5M749I58*R>EO/\ X8\G)JE?!U:N68RHYR@E
M*,GO*+W_ / 977HT=!7G'Q3L?B==7UD? >H:/9V8C(N%U%3O+YZ@[&&,8].]
M9OC#]J+X?>$)#!_:QUJ[S@P:2HGQSC[^0G_CV:T[SQ+XPO/&VA'2=-#^%KR&
M*:66:/:P5AEBV>58 _=XY ZYKS,7BGEL85JE*4E*2BK1OOI=KLNK/1J8G!YF
MIX6C7O*-K^SEJM>ZVVU.%_L?]HH<_P!M^%S[;?\ [35:]^+?Q:^%JFZ\;>$;
M36=#3F74-%;#1+W9N2,#W51[U]$TUT61&1U#*PP589!'I7I?6$])05O2QQ2R
M2I!<V'QE6,NEY<Z^<9+5?=ZG/^ _B!HGQ(T"/5]"O!=6K':ZD8DB?NCKV(_^
MN,CFO-_BG\6-=^&OQA\(6UTT*^"M73[/*QC&Y)MQ4L7[!=T1],;N.]</)IZ?
ML^?M*:5#IG^C>%?& $3V8.$CF+;0%';:[(1Z+(0*]1_:0^'G_"Q?A7J=M#%Y
MFI6 ^WV>!DET!RH]=REACU(K50ITZL;ZPE^%]/P9YM3&8[&Y=74/=Q.'EJH[
M2<;2T_NSCT?>W0]1HKS?]GSX@?\ "Q_A;I&H2R>9J%NOV*]R<GS8P!N/NR[6
M_P"!5Z.2%!).!7%.+IR<7NC[#"8JGC</3Q-)^[-)KYGC7[0/Q4USP??^%_#7
MA)H3XEUN["KYL8D"19"\@] S'KZ(W3J/8]S+'EL%@.<<#-?-_P 'H_\ A<'Q
MY\3_ !#F'FZ1HY_LW26/*DX*[E_X 68CUF%?2$O^K?Z&NBO%4^6FEJM_5_Y'
MAY-7JXZ5?'2D_9SE:"Z<L-.9?XG=^ECY5^'/C_XW_%[3M0U;0-3T"UL[>[:V
M,5U$%*L%5L#]VV1AQR3FNM_L?]HK_H.>%_\ OG_[35/]A_\ Y)UX@_[#4G_H
MF*OHRMZ]54ZLH1@K+R/$R3+IYAEU'%5L35YIJ[M4:6YXCX;TKX\1Z]I[ZQK'
MAJ32EG0W21J2[19&X+B(<XSCD<U[9(VV-F]!FG4R;_4R?[I_E7%.I[1[)>A]
MC@\$L%&454E._P#/)R^ZY\J_#?Q]\</B]I=]JV@ZIH%K9P7;6QCNH@A#!5;@
M>6W&''4YKK?[)_:*3YO[9\+R8_AQU_\ ((JI^P__ ,DWUW_L,R?^B8J^BZ[:
M]54ZLH1@K+R/CLDRV>89=1Q5;%5>::N[5&D?/&G_ !_\7?#KQ#9:1\5O#\.F
MV=X_EP:Y8',&>.6&Y@1SS@@C^[7T,K!U#*0RL,@CD&O%OVOFL!\$=2%YM^T&
MYM_L>[&[SO,&=OOY?F?AFO0/A3'=Q?#'PDE_N%XNE6HEW_>W>4N<^]8U5&5.
M-5*SO8]?+:F(PV85<MJU74C&,9QD[<RNVN635K[73M>QQ5S\3-;C_:6M/!BR
M1?V')IAG:+RQN\S:S;MW7/ &.F.V>:]?KYUO?^3UK#_L#G_T4]?1537BH\EE
MT1MDM>K6>+]I)OEJS2OT22LEY!7COA_XG:YJ7[2WB/P7-)"="L=-6XAC$0#A
M]L!R6ZG_ %C<=.GX^Q5\X^#_ /D]CQG_ -@=?_0+6BA%24[K9?JAYQ6J4:F#
M5.37-5BG;JN66C\CZ.KYV_9[_:&U/Q]X^\0>&?$,D!G5GET\QQA/E1B'CXZ\
M8(SSA6R37T37Y_\ AK1;G0= U'XDZ1&QU7PWXF_?X/#VSA00?;=\I]I&K?"T
MXU(34M]+>IX_$F88G+\5A*M!OE7.YKO%*-].MDVUZ'Z 45G^']<M/$VAV&K6
M,GFV=[ EQ$W^RP!&??FLWXA>,K;X?^"]7\076"EE 72,G'F2'A$_X$Q4?C7
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M)S@?[+97I]W%>*?$?XP:]IOC[PMKWB#P[+H'CG0I!%=%5VPWMOU[],YD7(+
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3, MCG'M4E%%>@M%8L****8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>advmlogob.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 advmlogob.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X /H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4ZQ_&'BB
MT\%^%]4UV^.+6P@:9AG!8@<*/=C@#W(K8KY^_:*O)OB!XR\*?"S3Y&4:A.M]
MJKQ_\L[=,D _@KM@]U3UK:C3]I-)[=?0\C-L;+ X256FKS=HQ7>4M(K[]_*Y
MG? ?XX>+=:\<0Z+XY\N)/$%E_:6BLL21C9EL(NT<AE5R-V3\H]:^DJ\(_:=\
M$RV?@S1?%7AZ);;4_!\T<\ B7A;<%05QW"E4;G^$-ZUZOX/\:6'C#P7IOB2"
M5(K*\MUG8NX B/1U8],JP*GZ5M749I58*R>EO/\ X8\G)JE?!U:N68RHYR@E
M*,GO*+W_ / 977HT=!7G'Q3L?B==7UD? >H:/9V8C(N%U%3O+YZ@[&&,8].]
M9OC#]J+X?>$)#!_:QUJ[S@P:2HGQSC[^0G_CV:T[SQ+XPO/&VA'2=-#^%KR&
M*:66:/:P5AEBV>58 _=XY ZYKS,7BGEL85JE*4E*2BK1OOI=KLNK/1J8G!YF
MIX6C7O*-K^SEJM>ZVVU.%_L?]HH<_P!M^%S[;?\ [35:]^+?Q:^%JFZ\;>$;
M36=#3F74-%;#1+W9N2,#W51[U]$TUT61&1U#*PP589!'I7I?6$])05O2QQ2R
M2I!<V'QE6,NEY<Z^<9+5?=ZG/^ _B!HGQ(T"/5]"O!=6K':ZD8DB?NCKV(_^
MN,CFO-_BG\6-=^&OQA\(6UTT*^"M73[/*QC&Y)MQ4L7[!=T1],;N.]</)IZ?
ML^?M*:5#IG^C>%?& $3V8.$CF+;0%';:[(1Z+(0*]1_:0^'G_"Q?A7J=M#%Y
MFI6 ^WV>!DET!RH]=REACU(K50ITZL;ZPE^%]/P9YM3&8[&Y=74/=Q.'EJH[
M2<;2T_NSCT?>W0]1HKS?]GSX@?\ "Q_A;I&H2R>9J%NOV*]R<GS8P!N/NR[6
M_P"!5Z.2%!).!7%.+IR<7NC[#"8JGC</3Q-)^[-)KYGC7[0/Q4USP??^%_#7
MA)H3XEUN["KYL8D"19"\@] S'KZ(W3J/8]S+'EL%@.<<#-?-_P 'H_\ A<'Q
MY\3_ !#F'FZ1HY_LW26/*DX*[E_X 68CUF%?2$O^K?Z&NBO%4^6FEJM_5_Y'
MAY-7JXZ5?'2D_9SE:"Z<L-.9?XG=^ECY5^'/C_XW_%[3M0U;0-3T"UL[>[:V
M,5U$%*L%5L#]VV1AQR3FNM_L?]HK_H.>%_\ OG_[35/]A_\ Y)UX@_[#4G_H
MF*OHRMZ]54ZLH1@K+R/$R3+IYAEU'%5L35YIJ[M4:6YXCX;TKX\1Z]I[ZQK'
MAJ32EG0W21J2[19&X+B(<XSCD<U[9(VV-F]!FG4R;_4R?[I_E7%.I[1[)>A]
MC@\$L%&454E._P#/)R^ZY\J_#?Q]\</B]I=]JV@ZIH%K9P7;6QCNH@A#!5;@
M>6W&''4YKK?[)_:*3YO[9\+R8_AQU_\ ((JI^P__ ,DWUW_L,R?^B8J^BZ[:
M]54ZLH1@K+R/CLDRV>89=1Q5;%5>::N[5&D?/&G_ !_\7?#KQ#9:1\5O#\.F
MV=X_EP:Y8',&>.6&Y@1SS@@C^[7T,K!U#*0RL,@CD&O%OVOFL!\$=2%YM^T&
MYM_L>[&[SO,&=OOY?F?AFO0/A3'=Q?#'PDE_N%XNE6HEW_>W>4N<^]8U5&5.
M-5*SO8]?+:F(PV85<MJU74C&,9QD[<RNVN635K[73M>QQ5S\3-;C_:6M/!BR
M1?V')IAG:+RQN\S:S;MW7/ &.F.V>:]?KYUO?^3UK#_L#G_T4]?1537BH\EE
MT1MDM>K6>+]I)OEJS2OT22LEY!7COA_XG:YJ7[2WB/P7-)"="L=-6XAC$0#A
M]L!R6ZG_ %C<=.GX^Q5\X^#_ /D]CQG_ -@=?_0+6BA%24[K9?JAYQ6J4:F#
M5.37-5BG;JN66C\CZ.KYV_9[_:&U/Q]X^\0>&?$,D!G5GET\QQA/E1B'CXZ\
M8(SSA6R37T37Y_\ AK1;G0= U'XDZ1&QU7PWXF_?X/#VSA00?;=\I]I&K?"T
MXU(34M]+>IX_$F88G+\5A*M!OE7.YKO%*-].MDVUZ'Z 45G^']<M/$VAV&K6
M,GFV=[ EQ$W^RP!&??FLWXA>,K;X?^"]7\076"EE 72,G'F2'A$_X$Q4?C7
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M)S@?[+97I]W%>*?$?XP:]IOC[PMKWB#P[+H'CG0I!%=%5VPWMOU[],YD7(+
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3, MCG'M4E%%>@M%8L****8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image.jpg
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MI9]^$O<_,#!M^Z-(W,G_^K%R+\<_XH<^_4 ]-&S%KY;>'W\4\?P/FN182^?
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MW:/7B^JO=*.5C:1!JV/]9J.:N/>%K96WK'X)7/_P\%OJ.TKV!;@YUACBT]+
ML.A>K21R*S&J%D![]42$M"&1E!4EV1?)N*<FS(:M FQ*SNEIT=W^3'*.4N%*
MG"H]6IIXAI*MI$_*YM%Z%NGG=3?]?4UOFWHX6AD_(E6N6CGWMQE=XD;SI_E]
M5'VFWPFCXCG"PT]L4RPL'G-?A<4QA.EAJ:H_V5-'8B?G5']G6NA>_/07CA2R
M45Z5'2.2.C9(&Q\,?5PDQU*6AG3J8Z!6OC]7/X3S^ GJR[.>/OK3I!UK;<R0
M-H-;Y9=V(@6NAGCTL5Z%J?RQGHSRJ6Y2&NJ8._PGY:+GO?]8V8E8=@/UD]Q
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MM4NZ>V0\D&-=8J>O9O<_ZJFY93Q4W[63PSX[D]KJDG1(/=QG7KYCGK[G>/Y
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M,P<8[D&&>Y#A'F)[95L]<91M^1C.GCR.,]R>.GX$)XX<QK&#!W'LP $<VW\
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M8,^ EZ\=8<Q)K5 'A]ES7"%PQS@@/L45&;D^R"\-1F%Y*+(+_9&0YHJP& )
MI"E"HV<@/-84$;'FA'-3!$?,0$CX#+892Z2FS")T>2(OUXO Y8TJ^F]O3L;<
MMG2TU+'L"QA>J@_2$[V0DQK(NHE">5$"*HH349(?CZS4,,1&>,/?9Q9<7:PQ
M<Z8%[.S-"*1FL+0RA;GE#%BHK:D"[/'C)V,X)^9OOCH"K[PP%*^_,@SCQTR!
M@SW!898KP=0,;[TYE./M2WCZSR_@3W]Z'G_\XPO42WCFZ;?PZJMC,&HTH</2
M$FZ>=HB,Y;B4Y8_L_%!DYH4@(R<(Z=D!:D4_(,0.3BZ38&HY#";F;\/:_EW,
M<IL,%X]I<'*=#-N98V@GT#T&<SRG(8*PF)+FA>043P*T(\=I2WC[F"MY>IMR
MC#:%EP!] ,N=8V,<P3,QT8=]QXM]SH/]<1;<YU@1LJ?!VFH\KQ.36":F'-\)
M_H&$X0!;UI\#RWT6XW+@V&K!NK9$8M(LCC$N'!=F\MIDRW&#UXU$&_@'383+
MG!%P<W^74&W*:]9LE;ZX^#F,:Z8"_;!0=_;G("0G1B$U*19)"=*N(Q >$HJP
MH#!$AT?3/H-]JQ25974H*ZU#44$E"@NJ4%)<@W(>U]>TH+MK(=:N7(UM&]9C
MTYIE6-390-C,0 'KMR@U )4Y@6@L"4%+13BO26$$\""4L)\69'LC/]L'&<F\
M9@39$CHMD1'GP>M/%O:LG8MSN];@]/95V+>\"ULZZ["EN9:@7(=M]0W87M^(
M[83I7FI'8S-V$IYW-;=B=VL[]K9U*.WA_AX"]3[N[^^8J[2GO1,[VMNQO;,=
MVT1=FK;.[>C3YKGMV$R[C5V$\7D=Z%TT#_M6+\4Q@O7I[9MP9L=FM3VV>1W!
M>PWV;%B)G>M78,.R>6BK+D)*I#]<;:?#;.)0F$T8 D>S,?">Q;[D;8L8UG-B
MN"N2(EP1'^9,X'9%:HP7[3SAYV;/:_=8#'O])3S_YS_BF3_]D>/%LP3.E_'T
MLZ_@S\^^1KVA@/3W?W@13W-,&?8VVZ&9/?P]@]B7XA%/A?F%P,MY#ISM'#&+
M #R'P.M'T WV(B03C'U<W.%B/Q,.EM:P-36'G9DE9MG8P7.V"P(]O1$9$(PD
M@G!V<BIRTS*0R:T:_Z)CU8W&Z-!P!/OZP\N5<1#&':UMU2JWCYN[@G$=R-7C
MX?13F)V#ZA)Y[::<^[D("0B%Z70KO/'Z"#S+_+SPXC"\\>9X#!TVC9J.MX9,
MQAMO3%1Z]96Q&/G.#(Z1H6BLGZO>,Q7@4J_Y??TUP?IS@C7A6M]^JF__DOH?
MC=9DL/^$_JE//OY<@?5''\K^%_C\,^T1\>^^_8'0_3D.'SI)\%F!\O(&%+,O
MU-2T8>&B5=BZ;:_Z9LJ%2[+21;"^<4_!M3%@WR9@W^D#;/F^ST=X_P/"),'6
M>!79>"79>!5Y("3+L0[# B4Z=,J^V.EPJ4.T'O9 L#;>EW#%KP")#E(Z1 OH
M&$L';1V !&PD;HE7X%8>0Y;50UFA$RBX8WBL5B3@K .V2*!:['2]QW+2[:Y=
MNZY 3N!8(%OBT^%*ES%L2QH& K;L"]S(RJK Y,$#1W#JY#E>6[550@$: 6<!
M(H&<"P3I,Z?/X\3QT^IFM[QS?_P8@?K8:8+F<>S:?8!UO@>]._9C[[YCV+O_
M&'IW'5#L(!RQAORP:NTFSO.W8-W&[5A/,);C[H7+4=_4@:*2*F1D%2 KNPAE
MY;4*L!?QG #UVC4;%$COW7.(\1%B#=_1D7W1R1/G"?V7<.[L)6XO\O@<3M!>
MTBBKT +)VO=;3BN8%NDKUP+:LDHM4'WPH#SF?52M7HN?PX<%T&557ZM/O<P%
MM.51<&D+>AWK[4V.92MM1LI8(%?V]?HP;H^Z'[$7?\;2ZTW<Z?[%7K^YHP.\
M<=QZ^'K<(CFG^Q/(-];Y\VRS%P34Y2;8^^R7'Q"8[Z@^*S=(SIZ_JFZ2'&=9
MR[>/U'>.#I]2-\Z$%<]=N(;S='OAX@V&)X#,_G:-^27DWKQQE^DAF!.^!8H%
MM#5HEA5I6:VF'?<%R@6@Y9UY)073_792IZ=/L3[9[HX?/\4MXY9O')V0NF0_
M/"?IOX';MS@FW/T0[]V3&XB?J4?$?^MWSOXB8(L1P)9'Q/75:P'LK[_Z1GU<
M0/NJ(_#9%]_BXN5;V+[S !8OZ\&"Q:NQFAUA,SO,ALV[L&+51L+U"E37M1%^
M"!RQJ02;#.075:)C[F*L6K^9@+T=2]?VH&O1,K1T+D1CVT)4UG9PDI8'6TZZ
M7^-%Y/>_?P8OOO@RS,U-D)$1BR5+F["]=P$V;6Y%9U<&"HN].#&21_QF(#'5
MG#!EQ<F2.2>R4^'C-QZ^ 9,0$L8+=)@5 @+,"=;F\"5<^_O;<&L+9V=.&DU'
M8>JDMV%E.A81?JYH+,M5%_S>GJ58OZ0+R[L:"-.U!.8ZM;^26DJ([JHN1'U^
M*LK28U">%HN&@G3,KROA^7JLGM>(I1TUZ&XL04-9)HJS8I"1$(3$*&_$1WH0
M-#P1%^U)('-'9*0;)Y8N3*.SFL@'!#G 5Q[_\^?$*70V)W$!J*G,QK)%'=BX
M=A56+U^!EOHV9*<7(B(T"?Z^,0CPCZ.T1Y0# RG"=DA8"N2Q;7E<NZBL#8VM
MRPG9&]'9O0%U3<M8%ZTLLPI.E@L0$4- )!3'&0 Y0>!:@74U4@G#:5FUK$<"
M+R7'*01@.9](&!:W"=P*D,<G$QJ3RA%#B)45Y&A9D278BK_<@E;D%[<CIZ!%
M'0OT"O JV)459OJ)H]MD0FUZ5CU!7%:]*4*T;#.R";R$[%2"MP!U!@%8 79N
MD^%<+=/+M%&ILDVO48 M:9,TQ<IJN$C%9P38W$\@V,MJ> ;#R&68.1(GXTBD
M?41D+@()U?X!*6H;0K@.#\]1J^71LN).L(ZBY%A6I",CB[@M(V03SF-J$4?
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M3L$;;PI@3\1;W+X]9 K&CI&/&7HA.3$7*PDM-V[<AOS$E\SG!*8__DC ^5'
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M:W%@TW+LV[@4>S<LP;8575C968T.^6)^5BR20WF]=IP!NZDC83'^;<PT&8-
M9]85RSHO(03%:=&HR$E"=F(DO)P=,/[=$7CS]5<QY*VA&#9\--X>-@ZOOC4&
MS[[\#O[$\>1/?WX3?_KC:_CS?[Z,%YYZ%6^^^#;&#AT+T_$FL)EN 7L3:H8%
MG,RM,,=N)OQ=/0Q@':@@.R$T"FG1\4@A[ ID!Q/  ^=X*?F[NL-[MAO<"<TN
M\IBYM1UF$=1=[!WAYC!+/5[N:&$-BZDF,)TX!=8<XV?;.A"ZG=2*N?B1U7/_
M.9Z(#@Q&<E044MF6TN+CD)J0@,BP"(Z=<S!IH@E>>_T=!=@OO#2<?7P<(7NR
M>D3\K;<F8PBWPX=-Q_AQC,O,&8'^'&/:YW.,O(H']^4)Q1\(OE]R/-3 66#Z
ML\_DO6P!8I$&VI\85K#EO6HE XP_(@-8RRLY(F.XUNR^5F#][3?R,UWW.9'_
M&+MW'V;[;T=B,@$[OX* M88PM1\[]AS&OD,G<>+,)5RX(N]QOH<;=PC6]SY2
MNBE?D;Y+Z#;HYKWW"-D$90%<703!#PBRLA7PU:#Z4;#6I,&M0(4 A[[:*))]
M 1HY+VZU,/O!W1C8=>GA:H MJVV7U.K?N?.<R!-DQ,V'!D"71]I5. ;WHMMW
M-+A6D&V0I$. 3B!.X$X>FU7P3,@>"-BRFBWV GKB3ON D\"VI.4RP]#>"3YT
MZ"#!Z90"KNO7Y9UON9$@'[(C:#!='W^LO7,O^O!#YIGIU,I25N9O$KSD0V>G
ML'_?806IZWHV84'W$EZ'V]3'PQ;,7ZI6DM>OVTIM4>?ER]X]:[6MO ^]8L5:
MK.1V=<]6],C"W.;=2ANV[,'F;?O0N^NP@NH#A\]@/[7OX&GL/7"2VU/82^W>
M=T)MCYZ\B+,7Y-'D*\S?>>U18(*_2 ';J;/J,759Y3S-K:3[T,&CZB>Z9"NK
MG>)65I[5^^'J@UK:1[4$FN7) >U=; VN]8]LR7G=C5XGZ@-:W HTZQ\%DQLU
M JS2'J0]Z9"MPZ](@:Z1Y+S(^%B';CG6_<K6^+SN1XNW/WQISU+7LM7=:VX?
M38,>A_B5Q\'EAHSV]7-Y7%Y6].4Q>/G@',OPR'G6Q3ELV7Z$S+<-7?-6H[5]
M&9I;EZ"I91'J&WF-JYVG?JVGK*)-_1)02]M2S.U>@WGSUZ)[P1HL7;9.M8F-
M&[9"?BYQ\R;MYLS^?8=4W5U@G<JK!J*+%Z[AW%F!:^TQ?WGR0&!: %V>2I"M
M/)$@X"SA+5VRDN/=/#34MZ"NM@GU=<WJR_%B)Q^_7=>S$?(3;<>.GE:O#V@_
M8_@U?NLSXG\U8,OV <'ZP4/"]9=?X?K-N^JY^O4;=V'IB@U8MDJ[TR0=0U:Q
MV[H6$]@:"%19\/0-@X<W)X%QZ2S@=G8F%B [SB9VH(4KUJ%E[F)4-G4BJ[@:
M05'),+6>C=>'C,$?GWX5+[Q"N+:PY20H$>V=S>A9MX!JQ^*EQ:R\2.06N' R
M9(WD5 )VJBVAQXI0/8.3-5F]-N$D;"8R,WV1D>ZG8#:<<!U%L(X,]42 KS.<
M[,Q@,GDLS*9-@O<<9Y3DI6/5PE;LV;0(>PCR&Y8V8?7\&JSHJL2BEA)T5F>C
M47YFAA/;&'GOT6(2;,8/A^/DT0B=;8?BN ATE1=@25,5EK14HKNY! WEZ<A+
M"T5T"">B<RS@Y6J* &]K7B2=U0I+;*P[H6PV? .M.7&="FN'=UD&PS##9BC,
M;$=RHCL)\E&?JHH<=+4WHK&N!CD$E^C() 0%RB/A\@5K67%+(7!1_@2XX P$
M$_+"Y4-ER<6(3R= IA$$4\H46,KCVK+ZFUO4BJJZQ6AL6X7ZYN4H*.T@N%8J
MN(Y2CXJ7J97J5,,CX0+; J)QR03K)"I!!VS9"LC*RK7(&+ %Q@5T:_KLX^@V
M,57@6$!;H)W03!B6\ 6,!9 5-.<1L M:D$W)OM@I>)9'TRG9%_]B+_ M6TFK
M FNF4V!=!VE9N1; 5JODM-.!7J2MF-<J2,\A8,LJ=K+AW?3(Z#Q$$J@%G@6L
M!:3C".GR?GJ2/$(OC\8S//F 6D14/B?CV0@.S2189W(BGLEZ22? ),+#,YXP
MDJH@77U$+C97P71,?"Z2TXJ1EBFKZ#GP\@TGU,S$NV.G81(G8+-<9R(HP@,A
M,:[P#W. =Y UO /D'5$'!(7.8EQL.WX.<'4QAX/-5-B:3X*+HR4B@WQ0G)6.
MELH*=-14HZ6B#/5%N:C*345E=B*51 A.1F5."O=349U+L"[(15-Q 1H+"U"7
MGX?:7(/R\@C9!.QLPG5&EEJQKDA-0R7ANB*58"UP+="M #N'X>8QS#Q.>C.1
M&9>H5F'"_ (0[.6'8!\_]1,VGFY><+!UALE46XP9-0-#WAB'5UX<@>>?>9M@
M/43!];-/:UL![M=>&871(TW4N^AA0<G(2B]'<4$C*DI;T41H6;:TAY.&8YPD
MW#/\!(K^<S%?JY^)D4F>K&H+;'_]U7T>RSO9MSC 'E9^.]H7HJMS,98L7HL5
M'/3E RG%Q16(8_H# OSA[NE"\+0G))K"SG$B;!Q'8Z;K.'CZ3T-(M!4!VAXQ
MR?;JL? H*C+!&A'Q-NR#A,!8CDLQ%-V%15'A5H@(MV8?MD=R@BL*<[1WYUMJ
M4M%2E8;&BA34E22BNB 69=E1*.3XD9T8J, ZC@ 7'^:.M!A_ G<HDF/D(TIN
MF.U@!5.329@X80S&CGT7(T>-P%""]5M#"==#6'YOO(&77GJ19?D47GC^CYQ\
MOX I4]Z!LXL9VZPSV[ WQU!?]D\OCM5S.'XXP]N?[<K#&C-G6\'6P1+FUF8<
MCPG(-A:8.=,&KFX.<"?8>WC-AJ>W0/8<MGDORAM^W'=QL8>-'=U;32-@FZFO
MFUMP?^K4L9@T^5U,FSX*IJ8C8&?[+CP\IB TE&5&J YG^41&V2(AP0G)R;.X
M=41\O /WG0C,SDA-FTTH=F2?XS@:9<XQGY =9,6QT!K!@0[J6Q:)\=Z$:F_$
MQ+BQG&=S['>$KX\IG&>/@Z/#*#@[CX&W]S0$!UNHQ\4C(FTX%ELC)<T.&=EV
M[(]6[.,S.,9-1W3<-/95;F--V?]9US$V3*N\8F3*L=>2X[,3HB)=$!8RBX#O
MI#Y4&1T=P.M/%,-(17IV ?)Y?2NM;.%XVZ7@NEXF( 3K^J:%:.*VO7T1YL]=
M@J4+.3%=MAQKEW%_;BLZJMD?"Q()U]%4)&IS"-890>Q; 6P702C*"%,W<,MS
MXM%<DHEEO/9LF=^)G0NZT=O1B:TM;>I#9?+1LAW-5$L+MA&FM[348W,SU51'
MR;8>6YH;L+65P-U&X*:VM#1@544I.M*3T) 0C05Y6=C>VH2#"^9CW[QY!.LN
M["5<*Q&P!;(5:,N*MKRKS?AW<G\'W2G(;FW#9L:_11XQI_V^Q0MQM&<%3F[O
MP<E=ZW",D'UPTS+LZEF(':N9_E7SL)6@W3._"5TU^<@G2/LYF<-R_%"8CQD"
M#YMI2 QT5S>[BU.CT5"<B:K\=$0&>F+&E/%XY^VW\,ZP=S!RY%@,'S$!K[\]
M%L\IP'X+?_C3:_C#?[Z"/_W^1?R9>NZ/+^/UY][ R#=&8M+(\3 9.QD6DZ;#
M;H8YG*T=X#7+%8'N7@CE&!9!P$X*CT9&;**"[-B@,&4?Y.ZM -O7>0[<'6?#
MR<H6MB9F,)\\#6:3IG [%5;33)2=G;R[S;!M9W!?;<UA/F4:9DR8##.Z=[2T
M@;<KYRS^@8@-#45<> ABPT,1$\ZX@D+@P;28F]MBV#OC"-=OX[D7AN+5UT<K
MP!XV?+IZ5%Q6L]]YQP03QMO 9!KAWL5??5E9'JT4P!;U 38E[TT_"M@$XS[
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MNED]-KZ=@^>6W@-8L78K6EF0M:W=**IN041B)BSL7?'RFR/P^Z=>P#,OO$;
MF,%)32PZ.ENP<=-R;-P\'PL7EZ*N,09Y1>Z$/EO"E"5AC9.>>$L$!$_E1$_[
MF%E8A*Q^N"$UQ1O)\OO7401K3GS" MW@[68/>T[TIDT8B:GC1\+%P0:92;&8
MWU:+#2LZL'YI/99V%J.C+@,MU:EHI1K+DU!3&(NJO&@4I@8CUG\F9IN/P]3A
M+V/JT)?A9CH)6:'^Z"C)(V!78DE;%1:VEZ.E+ALEN5%(C')'H+>-^BD5?V];
M3K!=$!_GQ8FC/%))> JR@XO[=/7Q'W.;83 C8%O9OPN7.9SDQ?ESX"I  ^&Z
M*+\0\IO!P8&Q" Y*1%A8!B=X\@A^+@*"LN 7F(G T&R$$O8BY>O9J03KM#("
MMJP.:^\@:Y!9JF!: +:\9B'JFI8KV"XH:5>0*F[CY2-G="./CZM'OPFCRC\5
MFRB/A0M4&R2 K2!;/R9@\SB>0)U L$X@9"O IIV >3S=)*7)N]T:),O*LZR2
MB^11;X'=K+QF9,MJ,K=R+(^,IV=KCX&K#Y\1T-/E$7%Y-UN=JU<K[-I-@')M
MA=J07[523<G'U.0&@WI?G.[4H^;T(^]OJSAR&U1^8Q-+U#OIX5&YB)!WJ^4]
MZSC]"^;R\3=YWUR3*I?X$D[4<PD7&? /3"/T)L/+)Y'M,9'@D<SVF(.TC"H4
ME;1R8&GGM@DY>=7(RBGG8%2+0D[ 8Q/2,=/9 Q.GFF+"Y.FPMK,E3,]!1)PW
M0<T% 6S3/K)Z%B1?;[9&4)@]0L)G(C#$$3Z^-G"9;:I6LLU-)L#*="K<9CIR
MLAF,G.0T5.05$MB*"-AYJ,B2CY%EH)2@+"I+RU KSXT\WU)<BJ;"$M3E%:"&
MH"P?,Q.XKL[-)33GH#PS$V4$ZG+Q0X"N2I='Q;-12? 6^-8^>):-4F[SDE*0
M'!&-2$X2@[U\$.CIBT!.1/T\?.#B- ?F,^P(U]/Q%N'ZY1='XL7GAN,Y!=AO
MX9FGWE1;6;V65>T1PZ? TFPV@@/B49!;PXEB)ZHK.U!7.Q=+%Z_#?@[X\AC1
M!YQ,R4=W]$<=E0R318'MK[Z4FX;W.:Y]CX\__HKCV3T.UB<YT&[F@+P<\[J6
M8N&"51Q\UV#!_.4<^.<2M.7K]%$$26<X.)D1-B?#RFX,^^=(0O98> 42U*()
M6@2^" 'K!$)TK"7M+! 8;LYQT)0R0R!!,(3P&$:XCF!=QD3+SZ*YH2 G$!7R
M]??2.%04QJ \G\J+06EV) H$KA,""-2^2 CS0'2@"V*#.?81L-/C0Q ?X0<O
M5T>839N(T2.'8^2(=PC8 MGC,.K=,1CY[CB,>'<LA@R3G^V1UVV>P="AA.NI
M0^'H- E^ 83+F%GLCZX<2SW8%[R4$M.\V'<\"=JN</=R)"";8\KT21@_<3RF
M3I\"6SM+N+K.A*>G*[Q]W-G>/>'G3[#V]R*X>F#.'!<X.3G0'>&<;F<ZV1'*
M;6%J-HUI&X%W1KR%4:/>Q/CQ;\+,=#C#FJS>O985Y43UU)$S8=I%@71,C$"M
M)>T<D97MBNP<-V1FSD9:^DQE%Q?OB*@H1X2&." D:*9Z2BDVVEVM+(>'.7&<
MM"5\6\+38SJA?P)FSQH+%^=Q<'61+Y./A[O[),(RKS71-H1W)_;)F<C(M&/8
M%DA(,F7?-N$8/14145,9EP7M'9A.>_9W2X2$6+ ^Y3L9=@@*M&%<]H@,=T5L
MC !V),>+%)9GOEJA*RRI)V3+3<TNCK?ST=BZ"$U4<\M"3C*ZT=S8B;;F#BR<
MI[T&U+-\,59UMV)):R46UA>@LR(-M;G1*$H.0G:<'_M7$,JS8U&3+S?)$E&=
ME8QY9458W]:*WKG=A-JYV-;<B>V-[03L=FQO;B,@MV!K6Q,VM]6KKXIO:*K%
M^J8:K&^L4?MBMYF0O;FUGG;5F%_(OAP>B&Q?=S0DQ6!3<QT.+5Z _=WSL)<0
MO:>MDUL!;5G-EE7M3NRB_<ZV=D)V1Q]H[^!6('L;X5I 6R3O<.]<2+^K%^'H
MEI4XN7,=CO>NP?Z-R[!SS0)L7]6-;2OG8M/2#JSI;L2\VD+DQ ;"W7H:;":\
M W?+*8CW<T%FI!_+)%)]8+2^. MQH;ZPG#X1[PX?@M$C1F#TJ#%X9_AHO,ZY
MQ0LOR>/AK^.IIU[%G_ZH ?8??O<<_O0?S^&%/[^,H:\-QX11$S!]_#0"L2G!
MUXJ@[*!6GKUFNZE5Y5 ??\2'1BBX3HV*0T)HI%K%CO(/081O,$(\_>%G>,S<
MV<:.89C";.(D3!\S%B;CQL%R\A3,LK2"SVQG^+FXPH5N3"=,PIAA[U C,'7<
M)#A8V<&+<05S[(P(#D94F*;(L!"V\Q#VMP XS'3&&*;SY=?>P3//O\WM*+P]
M;#)&CC)E_S(A9$_%B!$S,'&B+:9-M5??N9!7:8YSPOK]=P+8/W%<_$JM2@M@
M?RR K:!:H%@#9NT1<9'L&TF@^W$RG)>P1+(O@/T)Q]K//^,\\JO[U /:?Z72
MT=PVGV-/#N<!)>CJ7H$-F_=RTGX0._8<5:N6QTX1"L]=Q=F+UW'NT@V<X_;,
M^2O499P5,"(P798O#U^G#%\@OB8 )(]&$WQD95=]4?L#@5KM'66Q$QC5P$A[
M5UD>I5:KCPJ,-,G'Q01P^W]+]V[?OD"H]NBU]NBO!MH2GP;U&AA?)\#)>Z*G
MU2KV-0+K>PSC0WF4G>[>%R"G'X%LV=YE6+<(2;>8AML$['L&:)>TG#NK?81+
M;HZ<9_XORJJ>@D8=M.6GMNZH?,NQ0*8\2GOFC*Q"7B0HR]>]Y8-C%UCNI]77
MN\\+4,I[K_*59UX[U0?)&(^<W[?O$#815)8L6X4VCB,UM?+MB"H4%)0@-34+
M24GIR,\O1F-CF_H]\\[.;G1U<GZ^8"G!>BW6K=N,C6I%LA>;-_<2IGNQ=>M.
M;-NV"SMV[,$>>7R;D'3T^!D<E\=]SUQ23RR</$OX/<^T7[Z)2U?O*%VDY$F&
M\U=NX<+E6SA_B>5Q4=K"377SY>K-]_I?'2#HRA>LI2W(30CUU>BK4I]:^=R\
M*3<^M#(2>-97G74HUB!57X66\YJDG*]<$5 5H!68E?>D]9L2VL^\"6 _"KG:
M%[P5W!I)P%ITX\:C<'SSINQK]O)8N28M3;KZP^X':&-HEG./ VS=G9Q3X:IV
M+A\0DX_PG<?I,^>H\ZS_\P3K<SAZ["0.'#R,/7OW8??NO:PO@[B_<^=>;-LN
M7W<_@+4;]F'^HLV\IBW@?+P*D;&Y"(O*XER[@//H<J1FR >'Y?7, G4N,BZ/
M\XI",D(QY]\E2,\J1VY>)?(+1%4H+*Q6WR9I:9Z/)8MZL&'=#FS?MA^[=QW&
MWKW'"--'*4+UGD/J%8"]NPC56[=CTP:Y>;.>\SCY4OPZ]6AX9X?\5%LC2HJK
M4%HB@-V$IJ9.='3(U^67<+ZWE#"_S+"_#)LV[609W<8/#_\)7Q$7P)9W=.3+
MX7)'\_WW/U)WA>21D)ZU6[!L\5IVI$W8M'$/MFX_B)[U.]"]>#5J.$E(SRE&
M4'@<?(.C$)W(R7A="Y:NWH@M.PX0KO=CQ9HMF+MH->H[%J&BL0NI>>5P\@C
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M<SL6$);E'6\"?6]3([;+E\B;:$]8WMG:2J!N(U"W]4,VX7J7K&P3K#7 [E*
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MZP.&^X'A/7%Y)%T@\,:-NP2D>PSO+O-[&Q<N$*#EW726GSS:+2N^LII]3E:
MSU_2'O,^>5:M]._;?QQ[]APC^![##M:[?.UY_<:]VNKC\LUH;EV,K)Q*A(0E
MP\,K7,G7/X9 G:"V?@&QB.)\,Z^@EG/RA9B_L >KUFS#IBV[L'/7?NS9>X!A
MRR/#.["]=Z>":@'L0_)U[2/'<.+D:?6;R0+^ZND EI%L;[+,Y'%V@6DY)Y+5
M=[$7-W=8#J);A&6Q$^G^]7-R(^0NRTJ@^X[<U'B?Y<YRNW'W'JX3H*_=TB2_
MGRYUK=6WIOX5;'WUF9![6X"6 'I#5ICU%=^?/Z:MP:X1%'-?5IT%K#7_EW'U
M&D&:$"WO-\N3"]I7Q?O5OXHM(*U#M@;8>AC]NJ*@7L']$P"[#Z*?"-A7<)7I
MN7KE$JY>OLCYYT76RP7U:/CQ$P1L)?:U4Q=PY.0%[#]R&KWDM@V;=ZK5ZO7K
MMV%]SQ:L6[L9:U=OQ(H5&[%XV29T+EB'FN8ER"UI4;]2%!Z;RSEI!@+"TA10
M"UA')10H^(Z,SU?G!,!=O"(QQR>&[M+5TZ:IAL6RC,QZSLWKD)I:P^ME#?)R
MFE!9/@]MA.S_/V]_X9W7M:3[PG_"=\>X9]Q[NGLGV>'$B9G9EFU9LIB96:^8
MF9F9F9DLM"S),C,[=NPX#+:#>R?9T-V[G_O4?/4Z2K[=YYS;M_O8H\9:6FN]
M"^>J6;]5-:L&>J<Q,[F$);:]Z8E)-+/_24].0*C&#_[4C3Z>9"M_']K<(>QS
MXPG;V<C-+D)>;IE*A%M>VH*&^GYTM(\3L(^CK8V<P[^+BIO)'G5HZQA5];O_
M]K?_HA!QW3^![+\1LB4)AM0QE+IVDJB@MX=PW3N*B9$YS$^?P1+A>IIPW=L]
MCHK*%AI$Z7#Q#("KCP8)F7EHZQ_%_+G+.,T7?8Z*L6]D6GFO&UK[45[;CL2,
M8MBX^&'3[D-X8]UF[#Y$8TKCBQH"ZM+R)&[?629@2UV[*E16AM,H<B#<F2G
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M(WXB8(O(]N(5.,..97!H DW-6L]B<TLGCS>"H>%1+FMFVTDB5+G!VMZ8@'T
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MLR<N$-XD*[#4+OX =^]^A%NW'N+*Y=NX<('@=OF6ROHKM7.EO,X3@O$3@K'
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M1 ?8.AC6@;8.DG5 K5LN\SJ@UOU&)[KEOUVO VSEN?Z2SY[RZ6K(EN<A8$W
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M>]F6U^**V#@?1$51$1%*[&R.P>#P+NCMV0HS \*=NZO* BX9P\6PJZ915T?
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M%>VC0-O5U4S!MQO!V(.@+X#M(N'Q3A;*0^WI*:'B'@C2^!"$/;C>'L[.5NS
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M[-ES_YL ^T]_40]/PL/%:YV;4TAC( %!0>$TMF((,P5\ +U4AGQH"Q<P,K&
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M^ /)R$U0%*@F&'\B"<:4?*.\SP+*\D'B<TE$IDJ0"4C+^/(O5^2+E:G6@RV
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M[-4>[!]I?)X_>Y&-H(PWRU^%HH:'Q:@$#C-SBSASX1H!^Q+Z1F;0W,X'T3*
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M?NMUZ!L?X8.+1-]@,W\[AA,GN]#<G$%CQHW&FQD-&WO"3Q"J:E/Y4 M0WU2
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M:BL:45-6C]:Z-HSUC6%Q9@%7SU[&0^J8+QY_@J\_^1Q?O?\([U^ZB(N3QQ5
M"V"/--2IZ7&"MA:PVS#31<#L;,,D87:B50O8QSE_G--Q0O9H,_NQYA9**T9;
MVA1DCRM/]@ NL.U?(6"+%WNQIQ-3C77H*LA&260P$@BCH99&2'"V1DU<*([7
ME"C /D6@7R)4GZ(L4TYW$*Y7 /L<I^?4WQTJ^=E2J]3);E&EO^8(V +9<X3L
MY9%>7#DQ@7MG3^+]BZ<X7<#EN>-8XO(3_9TX.=B-4\-].#TZ@-,C_5CF_/)P
M/^%\2,GR\ !.]DEH? NOL19#]67HKRE";W41NBH*T9R?1=A-17UN)NKSLE"8
M%(,H'QIMIOJPTM\#1U,]:#PLD1CACO1X7P78J5(NSML>[E;ZL#RR'4:$ZV/[
MUU'6PD1O'2R/;H2#R79X6.^'O[,^0CS8[OQMD1WCK<9GU^3$HC*=<)T<3HE$
M>6HLER>B1O)B%!*PDU+A2=MLW^[#>.N-+7CY90+VRYNU@+U1 %N2G!EAS3I]
M!=B;MQIBZS9]'#A@3-LC3&6_EO''3Y_)D!CMAT0M#&D!6T#[/PS8*R*0K9/G
MX["IEP6R__C'/^'9-U(+^R.T=8XA-:,4)67-6%J^3K#B_@G9DOCSPH5;F)\_
MB\7%\X2AR\H;)^ @%6YF"1W34_/*,ST]L\B_3W%ZBK!\$OW]Q]'5-8S>OG&,
MC<WA^/$%@O8)-2\P/36UQ.U/<]^RKPM86+A ,#^'DSR.@+38N&<N$%0NW<2E
M:W=Q34HPO4>X?_@)/OA8LF_+&.;O\>6S/Q!"_T@8_8.:?_+MC[Q'/ZIZT2J,
M6L#QBR>$[*=X1MA^QOFGGWZ%IX3IKPG6(L]$N/SK+[D-8?,9H5/ 52#T*2'Y
MZ3,!9?'@:CW LOS9-R+<EI#]Y&L"N0)KRK.O>%PN>R8>;FV(N()K 6:*@+.(
M%J*UH"U0+9 M\MF7XKU>#==:L/Y*1/ZF"&1+?RQ>[&<*EG\-UW_O^<O?.LA^
M#MB\%I'5@/WW1+=>QN#??_"0]I/84%(CG?830?O2M5M8.D.X)I,,CLX1KJ<I
M,^@?G,/ ((%U@,MZIM'5>9PVU'$"[ Q!^R3MMU-8X/,_<_HJX5D+V3+.6<FM
MN[AS2[)RBU=X%6"?NZ$%[(5+!.SS"M;'">^]W3/4Q4.TQSI1F-_(OHPV:&HQ
M$N)RD!B?@TQ";%%!#4J+&[B^1OV=GEJ@/-EMK7ULE[.8G6&;I$R,SQ&JI51C
M+^&Y5WFP!; %E@6<Q9LMT<4QT8GL?Z-065&'Y5/G<.?V W4-%V3,/]^1I<4S
M2DXMG<6I4V=QAJ M"3$7YI=YC%E([?7\_"K:]=GDH73$IQ0@MZ@.M8U]:.\:
M1V?W<;2WCZ&QKA?E)2W(SZY"1FJ1NI[PL&0%V%[>,KPU%!X>(0JL!:I=*>+!
M5B'B!&U[.Q]"K N,C1R4F)HZP]K*'79V7G!V]H.W5S#MATB5S-??+^07P ZD
M?:'$#Z&T+\(YC>3?X7[^")+$9PYN<+=QA)N5 T';#A[V=O!V<H2OBRO\7#T(
MV9[P%,"6+.(VSG"R=51CLIUL'0C9#G"RLU-E2LU-C['/C^ ]6_BO ^S5'NQO
M^+*,#(TA*D+"P_UI'&:R$71C=FX)I]B0IT^<5M[KILXAE-=V*+CV"XF#OJDM
MWMF\ R^__38V;-L,,QLS)&7$H*NO'O.+ U2>O1@8*D%AD89@::8,(0\O?4*<
M.X$ZA0^U@LJV$G6-Q<@OHK$1%0A[1TL</KP/^W=OA]Z>[3#FO+^+'<HRDW"\
MNQEG9T8(V..X=EX >Q(7S@P1KFO04!M+\*#A$\+.+VB/\EP'A^VA,;27^]V+
M,('H2 D+)T"';H=_T#;X!1&R0W:J;.'!W$X+V+L46 ?'[$)8W!Y$Q!.N*1$Q
M!'5N$Q'&OT/W(RJ8P!YX 'Y>^^'DM!N6MGM@[W:,0.Z#PK(<-+>WH+ZIG0!<
M20,MG<:VA(1GTP@K1&14,:60YR4EL7)7 #N/QFTAC3P";@P!F1)#P(XF8,=$
M2R9:@K?4N.;V(>$9"K C.)^<5H&<PA8>LQOY)=W(R&E!4FHM054\SEJ/K4"K
M3G1@K9/5<"VB VS=]@*]X@D7,-5N7Z) 5;S. M1:P.ZB0?L+9(LG66!8"[=:
MSWF*\J"OS%,$J-.Y7@OBVN4Z !:/LRP3B-8"=N/SL/#LW&;D$*(S"=#)J=7J
M7,4#+^<FOT]+EQ!V\5X3\D7$.ZX\Y'7J'-3' FX7S]_%2*AX9(X*O??UBV/[
M#(6=?0"<G8)46:ZLK'*"4S=:FOO0W-2#_MY1+"V<5<KW)A6;?$W7R@U"]JV5
M$'$ISR5_RWAL+6 +4*OP\'O:<EXB]V1\UH/'2@2P99E\J94.166TY/+KU^Y1
MH2^CN;$?1?D-R,^I0V&>*/,Z0D@>O*GH9$RVOKX!#(\=A;6-*3P\[0D04K[+
ME9#MP'9N1< VAZ>?.3S\K.#I:PV? "Z7L:^!+MR''6PM#:&_?P?V;]L  [YS
M'I;&2")T5:8EH;VT")T5)6CEM#PC#;$!&C@86V#_)AIVKZW'ZR^LP2N_>QLO
MO_ N7GIA+5X@7+_XT@8:>0>@;T2H"DY 1GX%RJKK45%3C:JZ2G3WM5.O+.+1
MA^_30/N:</TCP54 5SIFZ917 [;49/UQ)5Q;!]C\^S\-L$56_A:X7@782@C6
M/_Q!()O+=.NYK9SG)Y]]@FLWKN'XU"1:"!_5U76HJR=H-S2@HJ*,;3&9[[X_
M =,6EI9\/M:&\/*R)UR%H:HR3R4RZ^]M0I]XKCL;T-W>B+;F>A4"7EY2K+*#
MBY07%Z.AIH;K.S Q,H*%N1,X?_JL*M=TCAUM7V<?$J.38&YH@<UK-^/5%U[%
M[W_W,G[_ N7%5_#:*V]BS5OKL&G#=NS<OI>R&UNW;,/NG=2O1OIP<;:!IY>=
MBGZ(2_1!7E$$RJOC4%(>S?<M' D)P81K?P3X>Q%HW>'IX<:.U9GP; \;*VMV
M6&8X9G!,><2/&? ZK<SY#MG!T<$&MK;FD))@DO3,C=#EZ^5$G1:(C+08PG(4
M(L-]$1KLP;Y':EJS4PUU5PG-I+9U>)@+.V%)=F9!P+:BSG3BN7@@,=&3NM %
M(<&6"K ]//3X_NISO3GON1//V8.ZPI5ZRT:%@L<G6E(_6%)WFA*$30G;%OS;
MBOO@E,MB"=HRC8DQHY@3LB4QE#V7VQ*P+0G+DBB-@!]M1S"W567P_ --E$<[
M*%2R]3LC,,B3.MZ'[Y\W7-T\X,(.W]/+E\\_DL\[ WEY)0JT2TIJ45!0B<S,
M8EY'#B%;0L63$1TED%V@DL@4%TL>D0XTU/=2[PRP30RBHVT(W9VCZ.X81FMC
M-^HD]+RT%G45#6BO;\=HWPB63RSCSI5;^.SAAWCV^&-\?N\]O'?V#,Z,C1*B
MVS'25(_AAEJ,<BH>ZDF"ZV2[ #6%<"TRQ7YKNKU5 ;B$E8^WM&",;5LG(TV$
M[<86_JX#"WW].,M]7Q@?Q?G102Q+/6Z^W_6I\<CT]T <VU6&KRL:4V,P55>.
MI2XIQ=6.DVWMA.9VPG,'EB@R+EO"Q 6T!;!E;+8.L&7<MH2*2]*SF=9Z3%%F
MNPAF*KOX..Z=F<?]\TNXO3R/2S/C.#TVB%.$ZE-#O2HD?+ZO$W.][3C1TZ&@
M>G& RRDGNB5C>AWZJXK1692-]H(,M'/:75:(OHI2]%65HY?2F)^#U)! N)H9
MXNB.#3BTC;"LOQL!KN9(BO1$9J(_T@C8B6%LMUXV\+(S@)/Y?CB8$L3-]\#)
M8@^<K?;"W78_?!P/(=#- "&>Q@AV-T:8IQD2- [(C?5#28HD/@M#16HDJC)B
M49.=B.J<%)430P [)SD-WJ[>.+#W*-:\N54!]N\)V#(&>_TF?6S=88HM.\P)
MV9)H5A_OKCN$M>OV8=>NHS1^_:F;FG'AXC7"K$0+_1D__?P7ZC*!;/$^$K"_
M_3N _>T?"(\4 M/_"+!U'LSG8<$$))T(6'VM8.Q[PMH?<>_!YQ@<GD=>81WM
MA7K:A[,X=T$R(;^/<^=N8F9F&2.T-25\=EI*7LT2I&=.8O+X+,9D'/3P)$8Y
M%4#1 O0);C]+L)I4D"T>:@'N$W.$C:5+.'/F*O=[ Y<N28295/QXA-NW'G'Z
M$->O2ZWK>[AZ\SW<N$.0>^\#W'WPH<KL+5#],4'T,Y4PC/ IX/G-'PG2/_':
M?^9]^!E/.2_+GK"O>L)K%._LE^*%_8+@2WGR.>6S+_#D$ZT\Y?Q3+E-P38#\
MEK#Y[=??X%LI)\;?/^/\,\*U9$27I&T"RSHXU0+V+Y#]].L547 M7M]GRHLM
M4"YAY@+77ZV \VK1P;: M7BS/_]_ =A?\[R^YCG*.>E*H/VO K9XX@6<U?2K
M?P>PGTA8O79>,H;+4 "QB227S>T[=U6(N-A0EZ_=5D-61_B<NR0[-L&PMW\6
MPZ-+&!D]Q78P3WTY@::&H97DD<,$XN-L.R>4/;6X(#6IKZCP;QF2)V'5%RY<
MX?Q5Y0U6H>%<+M[KLX3K!37V>@G'QQ:41WRH;P:MS2.H*&E'=@;MV43:GO'Y
M[$.RR <IE&3:[YGDD0(5,BX.DOC8+"01;/-S*ZC3NU4[G9I<8/M>9OL^Q?8]
MS_8M6<G9?L=G%& +6$].R+$ZV#>DP<W%2_%946&Y6B=UM@6PY4. )#83S[6
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M9[5X*ZM5&'Q]?35R<M,0%.3#3LB"'8PEVYHW\G+3T=G1A'&"P!BEE^#1WM1
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MT5=LA[ZDJ/7BW94?%E3XLWBO/\<7A,4O17A/E*?ZD\_PQ9P(7']%V/P=]]$
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MKMXB6)_"X,@6-#03M)IZ,$3C=\^^8SC#1N/Z;0+VO<>X<>M]7+YR4XUQ>.C
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M3G"RUU&W!"FX=G>1!&(!!.I@Z'V#"+><]_*'GZ= KAXA^F!$A(8A+E(@.X:
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MZ^5V26(FWFT!<YEVSL%U"\\OXTU+UO)6Y/T3@%U4K/7)IC)4GNP.[L=K2JN
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M#G+=(0*]R&$%VF8Y,B?'N%[D*,L=8?G#K*? ]4'* 14JWHW9.<C>0\@^,#:
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M>+ _ES&X55< L_=:^E\+8)O#Q*4?]BW:7U=P\L1[M'^.86;G =5N3HSMQ.#
M-G1U;41S\RCM+$EFUCWGQ2Y7=F-\0A&2DR6AET2#BN>ZC%"=3SV<"5-XAG)V
M& S)\/4-5TFZ?#P%5 ER(0++"4B-245:#&&/H!DI(=B$LPB":'1P"&TS$P$[
M@MNBD101BY2H>)9/1$IT(A(BXOC-$Y )E@:_(.@]=7"W=X'3.GM.71'@Y8_P
M0".YA>!H"%?#386PG(&0'!%D(J1'(X;P;B+\"DR*%U>\O#(-YG* SCP,E<"C
MA(J+)SN D"Y]G5UX?"=;)SB)1YR [>S@#C<7'WAYT)[S)H![Z<UMCGAV PB>
ME* Y"=0'<;UL(\@3VJ-X7=+%M:RX!HUU'6AOZ4-'VR!:FGK)0$W((:\DQF60
MWQ(0$FB"+\^A^ER[>,//4Z\ V\CU8<%A,/'^"61+>+C.RPS8>IT.H4$A"J:U
M)&>%N=)W/ 7QT3$*L"5,7+S9D@Q-EN4^6'JP!; US[7 M8C#>GN5]$R@6KL_
M&FAK/TAHXV,7Y1;B],DS^,__.< V'^CY@/TCSKQW%>V=HS3&BFCTA&/)<GL:
MU?/P__E_7\2KOYV/T(@H3&R>P/E+QW#LU!3ANA;-;8DHJPQ$<8DO#14/&BFV
M!"$K&E"+:%"LHH'EBZ+B. )X,K*SHVAL\ 6-]D.,]%FB1)F\$!K@!'='*ZR7
MT'"[)8@-\T9K32ZF)[MQ;/<DCLU,8,=(.WKK"E&:9D(\C9]0W6(8_1<@UK0,
M23$V!.R52)"AN>*7F?M0$["3LVR0F+D"<6G+?_)B2TAX1.P<9$N2LP0N)\ZG
M+%#;)>MX5.(*&HPK$1VW&N%1:Q >:8O(*!=D9)C0U5F'V5W3V+US#]J;^@A$
M17SX&;R63%Y7-N)B<A =F878Z%R^H)4TN%J03\F4X;8R)$E1$V%U %T]A.R1
M:?3T;Z41W(_\DGI"=HD"[(3D4B2EE"M(%@^V>*\E#%R@5T!8H%BFLBSAW5IR
M,TO %N^W>*T3DLH5:,M4UFE>[.[>'>CHVJ:2H$G&<>V8 O "UB(RKP%V58UY
MO&N!Z_I&&?-:AN,:8CE):B;]KJ4>S7\#UP+<3P&[C0;M'%P_%[#-(MG4$Q)+
M$!2<##=W(UQ<#;S_.30@:;SM/<?W]#[E'LZ<OX-39V_@X-%SV++S(#H'MZ"H
MO@\1V75PBR["ZI <V(3D84-L-7RR.N&?TPU=:A,,&<W(K1W%\)8C.''F%I7Y
M)_CDHV_P <'X[NT/</GB;9P]+8DUKBG(%L"^<?-]W+[S&'?N/<'MNT]P\^YC
M!=4W.+UY[P/<>_@I'GWP->X]^ QGW[NEACJ(B\]7]??7T]#.;T9WSQ0V\YR[
M=K]'R+Z$(T>O$[2O86;W2?0-;D-961O?IQ*DQF:C,"T'H]T-N'1F(SY\LAUW
M;O?AZ-$R3,_DHK>;@,7O2$*)H@PYR$ILI1%7AG4V_GCKC:58M'"Q\I)5EY=C
MY]9M.''P,$X>/(3#>W;AV-X9G#]^ .\=W8?9[1,8[FY">UTYJDKRD)F2B$B3
M$8'^TI?&$^O6V/%8UGCCS64$[&7XY0N+\;]^O1"_(FB_/7\=UMGJU \(6=E5
M:&X=1/_ 1@ST3V+SQATX<^H</OK@8WS'AEO@^G<"UQ+BQ\9792R5AI>-L$P%
ML#6O];.>ZV<!6X'U<\#7$HZ?!6Q+R'X6KK5E2]&.\ZQH^SQ/%&"+$*S_\.-?
M%%S_D=,__.$O^.%[\1+]!=]\_2,^_O!KW+KQ",>/GE>_QK<V]Z&YH1?MA.R:
M\F;$1R6QL?>&DZ,]'!S7P\%I+5S=";)Z%QH(02@L3D)E30;RBJ+-2<B,#@B@
M 2^ '1KN@LA8+R2FLEQI/&H;LE%5F\7O+QJ1T?Z$65=X>F^ FX<MX=B9,"E#
M9 53V, &^<#3RXE O0:K5A&PK9<3K%?#UM8.-C9KL' !@7_Q"MBNEPS?K@@,
M]D!PJ O/;X^H."=DY>M06A5,"4)!B1]R"WRHD[R1DN))J'6%,=0>>O_U\/&A
MZ!Q46'A@L!??'W>U[.JVFN"^@L=>!Z/)C3K7@S!J"U?7)=A@]P[L;-_D/7F7
M!H U05D\TCI"KR?!V9'+S@0'+V1E^A-$ Q5D%Q-F9#DFVHE@+/VM5[$.ZQ 9
M8:]@7" [+=6;;1(A.C^ ]\@?2<FNO"<K"=C+8&!9"7$O*HHDX I@TV@(8N/M
M84/ )FQY$+!=EV+=NM]BV;+?8-7*UZ#S87N7H"=41Z"T. %5%6FH*$_C_@DT
M_,(1%1V$L#!)Z"8AXO[\1L7@"83>+PQ&0R(!/0^YV0+1M83L6I255O$Z*MA^
ME/&Z2I";6\;ZU*"JLA4-]3V$; )VTQ#J&X8(V4-H:!RE/A_C\BAJ:H?8YG:K
M7!_Q"26\KA3H]-$PF)*015#O&YK$H6.G<?WV73R@0?O@P0/<NW,+UR^=QYFC
M!W!@YU8%V=N&>K"MMPL[>WNQF\ L"<WV$K!5!G&1(<Z+!YN ?6!BHYKN)7 +
M9._J'\)4=R^V=79C*T%;QLP^.KD1%W=.X^K,#,Y1-QT=&35[L3N[L)\0KKS8
M/,_/ 7MP3LR>[,.JC!FPCPSUJ^&[1 2R5:AX7Y>2O;V=F*4(;!\9&\3Y'5MQ
MZ]!>W#MV$-?W[U9>[ -<OW>,Y]LZC@-;)[!EH .UA9F("/2"_:HE6#;_55@M
M>@UKK=^A\;H8'DY6\'&U@=YK+>T/>T*X*^*-'H@W>2+.Z*5LEX1('R1%R=0#
M<?PFX\(<D1KGAI*\(-26A7,:B.189T2%KF=Y1R1'>R([.1 5A;'H:LK#Y$ M
M=HRW8MMH"\9[:C'448N1[F:,\%JZFVE/9.3"Q\T/\PG8O_GEF_CU+]ZFO(,7
M?K, K[^^ N_.DSP+]OQF[;%XD2.LK=Q@L\*-WY$9L*>G#^'CC[]16<1_^.$O
M"G8%TB2YEAFJ-$ 20-4\HC\'2PVN1+0^UC(O^PD@BI=8"[^VW/?WA.MOO_M1
MB0;7 H.:6 *V^5P";ZS+5SS.[[XB8+,^7VMU?'IL2\@3T2!01,I8@J.(+,MZ
M[7I$M/*:R#KM^F2J'<MRF[9=*V,ISSNNY3HYEAD^GP5LLXCW6H-K#:8M(5K[
M4>*_"MC:-5C64]NNW2>IDP;+4C=-+.^MMK_,RSK+LAID:R)CA(NW^G.Y%@D-
M_^QW:IBNCS[DNT([0;S7 M@BYC#Q]U68^,6+5W'ZE(2(G\;^O<=5%O'I'8>P
M=>M^3$SL07__%-K:)E5_Z\*B%@738CLJP$XI@V3/SLJ6KI82/EZH(B)#0E.5
MPR,H*)'@&09W5P*VQQQ@!T>3*>*1%)FD/-B)XI4F)$80SA1@!P43L(T$[/ Y
M+W;43Y"=$I6@O-D104:$$IJ-A&:9!GKY0>_ABQ""<%1(&.()YB(QA.P(0F 8
MH2^<$!I#X(XS11&^PPG8(010<T*P"*/I)^^M +; HX"B],,.T8>H!&+BM798
M[PA'BH"VA*![$':]W/W@ZQ4 /Y] 2@#!-I  3= DL(?P6H(#@WX2 6WQ:AM"
MC.29.&1GY*.FLA$=+;WH;).LZETH*ZE#6DH>P3H181)&;XR!(= (#V=/V*]S
M4'7P=&:[SG.%RKC7O'=AO!_R T*  EMS/VIC,.]C5+3J<UU55H[:RBJ5/5SZ
M7PM@RS:!:P%NF8HG6PL9UP#;S<E%>:\MX5K"PR7\6X!:[H^(!MHBLJP\VCYZ
M%.<5X<S_#<"6/YF3/MC:W_<__ FGSEPB;'4C."0>-JM=\1O"]?_S+R_C-R^_
M!0<7#]0U-N#DF:.X=O,D=NT=0$M[&DHK0@C0OB@L]$1:NCT;\L4TX'X+#X]W
M8#2N)UB&H+0LF2]_$HTM$^)B Q ?XX^$&+T";0%L@[\#/)U6P,5V"0PZ>Y3E
MQ6.TJQI;!ILQT5.'D?9*]#66H+LF#XW%B2B@X9,4L0ZQ!/GX\!5(C+9&8IPU
MCTV0CEVB #LI@]"=O5(!MGBPS<G.%B(\5@";8,UR3P&;<)VT<*Z_-LL2U"/C
M5B(B>C6,X6L0$>5(8S&4QDP)-F\:P^Z9/9@<VTZ :2?8%R$V,H_75("$V +$
M4^*B.1]7K+S6 M<%!0*-S2JI61HA-S>_B7#:AP[I,T<0Z^[?C#H:VGG%]4A.
M+T5<8C$ANTP!L<H87MBJ8%H\S *[(@+  MWBV7XV/%Q$]A5 5V'F<] M'FS9
M1V!:(%LRBVN +<?\6[CN4X MY<T>; VPQ8L]QGT&6;:7D"])S<Q]KF4JH"V2
MPVO/X[7+=C66=CY!.[>5D"W]9LP)S22YF0;6,B\AXO)#1*@Q'<XN!@6HHBQ[
M>FF,'9-Q+C\EY'Z):S<^Q,4K[^.]"W<(R5>QY] 9C$\=0'W_5B15=,$GN1+K
MP@NQ)KP$3DF-\,OO1V!^'_29;8@M[D?+Z'X</'T7M^Y]1N7^-3[[A(#]Y O<
MOOD0%\[?(&!?P;ESUY4'6\;!OG;] 6XIP/Z @/T! ?L)]_T =]__& ^>?(XG
M'_\>'U N7GX?$Y-[J-1K:*C'$!BBJ-B+:?2.8'ADEML.8M.FP]BZ[1AV[CR%
MJ9W'T3\XQ>?;B@0">7QT)O+2"M!15XN]4_VX=643 7LC'C\>(.!W\/J[</A0
M$Y5=%E+B$Y&34HW:TC$49'93V:;!V9'*ATHL(ST5@WTT6&?W$;"/X-#N60+U
M=AR<GL)Y&I@73AS"@>FM&.UI0TMU.4IR,OD=12LE[NU!P*.27KEB'>:]8T6C
MC8#]ZG+\ZZ\7X5]^N0 OOV&-5>M\$&),Y3.N0VU=C\IPW-=/ W7S#.'Q#(WU
M!_C\TR_PM32PGWZ&SS_YE'#]!;YBXRU +9YK@6N92FBX +06 FX)UK)-"QW7
M %N&][*$6X%BRY!O2RC^>X"M[?,\D6V6Q]#$\IS/BAFP_Z0 ^P<!ZS\2K G7
MWW]/(5Q_3\C^P_?_CF]__V=\\=EW?,\>*6.AMVL4':V#&.K;A('N,527U5%W
M)" @P ]>WBXJP9B"T1!/%<J=EAF!@N)XY!9&(RDU$&'1[@1=!P+V!H2$.7%9
MPL/Y_+-#62Z.H!O#<B$(H]$OX=_Z0!?X^,GXYX[P]>.\KRL\/)WA["Q9PM<1
M&%<3%FVPTL:&\^L(MO:<7T=#W1HRU)?]!@?X^7M"QL4.,;HBR&"'Z#AG%%<$
MH[DC%DWM42BI#* N<$=BLA.2D]T)JCY(3/!&1+@;X=*%8.VF/-=R7?X!+O#3
M.\';UXZ OX;SDC#-%<$&\6HO(^"_"3N[-^'L- _N[@L)IBL1'R_=C?3(S/!#
M0H([8F-=U#J93TKR1#KA.S-#C]04'T1'.=-H6 -_?VOH]38(-0AD.R@H3TIT
M)V#KJ'<"4%@<0+WCCK#PU0@(7$Y#3));ZE!<$H'BXDA^3[S7)B?X^MBP'LN4
M-]W+RXIU^RT6+/P7+)C__\+>[AT56IZ4X(_L+!/A.)Z@G(R2DF3J_UC5ASXV
M-@2147P>82$("@R$#XTO3W>]&C[-%)K .F4KF"XIYC=95(K\W")D9Q8@)[N0
M>K-< 79%>3-J:[O8'@VBN46&8Y3<&F-H;!;=+!Z=8537R-")_6R?13^WJ#9%
M'YP '_\(&,*3D%-8A:Z^4>S>>X@Z]#)N$;0?/GP?#^_=H<ZY@/>H(P[LW(+I
MB2%L'^C%#@*M /*NOD'LF8/L6<KN@2'EK1:HWC\^80X5E_[80Z.JW QA>4=W
M'[9U=&-'5R_V#0WCU.8MN#P]0\C>1<C>KB![7V\?]G;W4%BFIP_[>2X![<,\
M_E$9^HO['1D85 !^@-L/*!CO46'B1X<'?@)LE?"LKYO'(V032!5D]W00LGMP
M;&($%W9NP[6]//?L-,Y-;\/);1MQC*!]@O-[-X^AIZ&2AG((W#;8P&;QFX3K
MUV&[:CX\758BD.^H,= )$83JN'!OI,?ID9MLH#UB1'Y**+(3#4B/#T):7 !2
M8W5(C/(D9+L2MEV0SG>M($N'HAQ_9"2[TNY9 V/ "H2%K%60G1;O@[*"2'0V
MY6!RL 8[)ELQ-=&*38.-&.]KQ$1_&\;[N]'?T8[BW$+X>09@P=L$[%_\%K_Z
MU]_BE__Z%G[SFWEXXW4KS)^_'HL7.V#)8D<L7>*$%<O-@&UO[P\9$FCKMEF\
M__ZGU*?2A>7/"G;-<*L!JB5@"W ]A3,-$$4TP'H6L 42M3[. HT";-J^O_]6
M?O@TAX=; K86ABZ><CFG)+_\W>]YGM]SF4 M@/WEUP3J;PAHG/_\2Q%S^+F(
M)2"*R+(&CMHVK9RVS?(:+,M:BE9&VZX=0]M?V_[W1"NC'4^KAU9/#4 %2N5>
M/16!6]GV%)HMQ1*N-<"V% VPM7-KYQ/1KL&RCI;UT@#;LFZ:R++V X5V'[3C
M:T!N*=I^DN5=<K%\_#&O[>,OE7STX6?X\,-/%&"+!UL@6P/M]]\WCX-]Y8I$
M$E[!F=.7</KD)9PZ<0G'CLA8V&=H/QW%V-AN='9N4H M8>("TQ(>GI9>"1F>
M2H9XE>XR%97R8V,=HF/R5!Z?@,!$^.OCJ'_#X>41"IVWD5 6 5-@%*(,XL6.
M)RQ3"-AQA@A$"@3[!\Q!=@AA.!2Q!O*,,1R)X83!Z'BDQ5!_1\0@BD!I)%B'
M"90'&!!." X3#S4!3R Z?@[,XPC8T<$F1!'Z8@C>"81K\8K'&",01I@,)?0:
M@[G_7'BT+,M8SA+JK/6_-GNOO9376@#7T=8);H[N\';S@:_T@_:6L.T@R+!9
M>E\!=!Y#3Y 6F*:M%R2AYWH]YP,0PN.'AA!&"=B1K$=J8CJ*\DK).?6HJ6A
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M WMQCKI0QKI.Y/.P6?@6WGSI_XL5"U^#AY,UC4(W&IEZI"4&(IU@G9%$20Q
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MVYWW[DK8K' F8/LJP+9:YD)QIMVEYS>82OW=BIT[]^/.W<<$8]&??R5T_:"
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M!=Y$9%Y 40-)@3%+N-7*B:AUEG ]%Q)N!FM--._UYP3KS_'%5Y_-B82*_W.
MK<T_>V[S><W;_]XV2]&.HXFV7H-8R[*6(MLT*!61^>>MT_I)F_N^_V.(-O>+
M__MB_M%"YLV@+?60.EM&&@@TW[AYF^WW>1P^<@RS>_=CU^Y9)7OW'6![?A0G
M3IY6VP6^!;2U9Z[]B/(L5/]]P#8GO9,D9PJL/R&@?\KC?/8L8,]!MH24/_D(
M,E;__?N/<>_.8]RZ\1!7+MVE74:[[^ 9[-AQ&!,3,^@C8#>W#M$F[4!63C5U
M619U=9Q*,BNC)X33;I&(0GU $MP](I3W6F [*#A-11GJ_.+AY!0*^PV!\/8,
M@S$D$1&F)$08XBFQA&!"9(!1 ;8/H=:-@.WFX$2(=8>?\B[SNR)@AP829*6/
M-"%50#.($DSX%@"799D7#[$20K:! &XD))K!7"!50KH#N#^/)V4"S'VP)3Q<
MDI#)U S8/O!V-0.VA[, M>><R#HS7(OH//P)]3R>;S",?I*MW,3K,,&D)WBR
MCD$$ZD!"OWC7@P7\":BAA%"3OWC>">.T&X.] PG,>HI<AYZZ)QCQT5'(2$E"
M>E(BXB(C>8\,2L)#!,P#$20_*'C0/N TG/<C(S81M86EZ&IH1@>EOJJ&X%R%
M.NIQR1XN'FJ1F@J12B72'UL\UN*Y%K"6$/*VIF:UCP"V>+CE?DM2,_G!0?-.
M:R)]K\W]KT,)U08%V2("V);C8 M@_Z=E,K+_QM\_!=A??/TE>MGH&"*"$4M%
M/K2Q!T?.[,'^XULQMK4.M<TQR"OQ(31YT!AQH1&W'E'AJU0V3.ECE)-.8R$K
MF(:!'R+#76$(H=%#(\=@=*6QXJ&\V-X^&[!V[6*L6/X6G!VLD10=A-:: HSU
M-&"DK1IMY=FHI7'14I2&B;9*'-XZ@"N'=^#&B5TX/3N)':/-:*]*1T%*$-*C
MO9&7J$=-823:ZY+14A>/LN)@I"0[(2J&@!VWDH"]DH ]!]E)5@1M26)&R(XS
M0W9DW'*8HE8@(-0<%NX;N!QAT<XT6J+1T5.)R<W]F)K9S.DDC=Q.&F-EB(S-
MID&7RVDIX@G8J1DM-';:D)G5ANQLPK0 =FZG\F(K[[4,7Z7@NE%YKM,)GVD"
MV&I*6,ZI0Y*$C&?6(C6['KD$W?)J E++)-H)I"*2Z5L@5Z!9P#HYM4IE"!>@
M-B<5DS[03R%;UID3C+7_!-@B&EQKGFQ9I\&U!N//!VP!:<*;#.I/$<@6N):I
M!MB2Z3PG7ZZ3]<BN4R+ +2 NR7>&1F8Q/+H7W=T[4%LWHKS7EH!=QN-G\WY(
M&,_*55X$ZY5XY=7E>/6U97CIY24$[I58M=H# 8$):HSL5AJ1XM'>?^@R#A*T
M=QVYC.V4C<>N8_#P333NOH2\L6.(:-H.SYP>K(^NQ')=*I8XFF#G9J01G(JJ
M\D9,C&S"CNTSV+)I"N,$PBV;=V#WKOW8L^L IK;OPJ:-.[!YRPP;GV,X?>8:
MSE^X0["_A(F-NU1X9E):$<*C,PC8^7S.M;SGS02!"O5#@4AR2J7Z,:&E=9(-
MP0X,#NTB>.[F_GNQ?<<1[)X]10A]#SMF#J.>"B0BD@J.D%!9:L*NJ3J</3F.
M(P=H] W6H;1$^F,F(C<W&T5%Y;QW+:IOI20S*BKG^U'4@8*R'@*V),[;CIZ^
MS:BL;*'1GX( _Q"8"-C9&?S&*JM10\4F223\J?C7K%J'!?.7$:H7$[26\=XO
M)UBO(&"OPH*%#FQX@A >1H.SH!'MK</8.+X3L[L/X_1I\5K?QI5K-W'R]!EL
MFYI&-PWNUHXN] V-8?>^P[AZXP$^^>([?/O]7PF;TB=98%- F2 M,&T!UO__
M =CBQ99^C6:X_H[P_#WE._'<SUW;'_[P1_SIQS\3LO],P/X3_L*IB%R7#%MR
MX=(-S.X[CHU;=V-D?#L&1S:CJV<$-;7-A*L<& PF-8ZRIZ<;W%SMX>YNS^?K
MBBA";G("82 I%*G))B0G&0F@030X? EYU,D$7"-AUQAA]O(&A7!_=T>L6+&2
MSWT17GV%</W:4AKLR_#.6\NP:*$5K+EMW;JUL+>WA:.C'0T1PK8+(=O3!;Z^
M'@JT0T+\$&8*0'1T,$$S%&EI)F1FFI!.B(V/]T1XN+WRY!H,MOPF7%26\_CD
M )6 +3+61R5IDZ1L4;$>%#<N.\(8OAXF2FR<(X_EC?P"/7+S"*B9'OR^"->$
M[-@$1X*X P'='@;3!@2';N UF3W5XK'VUV^ SM\.GMYKX.:Q4JV+9YN1F6-2
M@!TG(?.$XM@X=X*T_!#@I,;L-ID<$2J><$JXC"T>SGL51$CW7L'[OH+7L0YA
M$1MHM)GK&!EMA\A(>WY?=@@.).@'K5>9RP,#;3AO3?BWX77:(85UE^',TK*]
MD9#JCN0,'7*+PE!2D4 ]*B-M)!*BHY&>%H;T5('K2!07)J*\-!UE)9EL5U*1
MFIJ ^(0XQ"<E(SD]BX"<S^,4L>TH1U9A'0HK"-(- VCJG$1'WQ:T=TVBH5$B
MA-I17-9*7=ZA +NN47)I#*"THHMM11/?JPK>AQS$QQ'P,XO1T=R%V:G=N'[N
M$@'[$7[_^ F^NG\?'URY@IO'C^/L[MTXN&FS"A57R<]Z^C#3.X!=O8,J%/PI
M8(\HL-Y/.2#AX\.CRE.\BR [(T)(GR9L[QD;QZ$M6PGOTSA+P#XWNY?GV(,#
MDYLPV=R&YMP"E"<FHY[7/%9;QV-)YO A,V#W$+ UJ.[IIO3@1$\O3G#Y>%^?
M&;+%NTVP/B1)T"@'AGI9KU[6LQ=[!P?5.-XGM^W Q;U[<7'?;AR=FL1D;ST:
MRE*10WLCUN2,B! [Q!"P,Q)U*"\(1VMM*OK;"S#>6X5MPTV8F>S$]&0'MHS4
M8[2O!(-=.>AM3T%G2S2:ZD)05>&%DA(G/F<[MA-VO.]VR,[?0'&DS>&!BII@
MM@&1J*H*0TZF/XU(@CS?T\*<".1G1B(Y5@Q'7]5G4A()2;_+%4L%L.?C90+V
MRR^(%_L=O,[O>,&\U5BYPD4!]BIK#ZQEF^KB%,AO-HS?:B*JJUMP]-@90NKO
M(4,*"F"+YU2@2 #Z_8>/\>!]D2=S\DC)^X\>*\C^QX!M]M8*Q/VT;0Y*O_G]
M4YA5H,KM/WFN?P)L+31<Q!P:_N77 M6?XO,O/Z'(]'-\KKS8_P7 IOX5$<C4
MMFEP_#R1[99B>4P1K9RY#D\3?CUOWZ_FRO]4SF+Y;T76_R/ ECK(O9:(@9\/
M<_8L8$N$@$0+R(_:4G<!8_%87[UV0\&S@/3.Z5W8L7,&4SMFU+S(],QN[!29
MVR;0?>3H<>79OG?_?07+<BQSE(,9MO\>8&MB]G1+6+AXKPG8GSP%[,\__YS'
MH1"T/_M,O-R?*L"^=_<!KER^B3.G+N+HX;/8O_<$9J8/8^O6?9B<W$5[:AO:
M.T904=5..[B*[5T>62,)OGZ2Q"R:;4&B\F1+MSWIKB>0[:N+@Y]_(OPY[Z-+
M@)-S&%:M\H6-M1<<-@3 UR<207I)WA5-Z(TF_$8I. WR"2!@>Q*N7=004=YN
M'@1L\2X3A EN G8A!&TU'!6A5<]M00190X!X3F7<:H(K1>:E+[6(E!?OMY21
M>>EGK98)VZ'!% *M)/4R!$G6;X([(=<2L 6LO=V\J1,(U)X"W_X$2"G#J2?+
M>_%XOI+%W(B(P'!$!H4C(L!(R);P;4+\_X^YOXS.(TOVO<'OL]9\FC7S?KCW
MGJ9B<IE1!C$S,\,C9F9F9B9+M@R298O,S.PJ<S%#%T/W@?_\8Z?24KG=?>X<
MN.](*U;2SLR=^63N';^,V!%N,B[<2\W+NE#O0+4]Q(L@[B'CSMGF"'!+1/#
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MSEW$W.$C_"WVHG=P" ,C8YB>.X)KW/;^IU0VOOL+OOWQ7PB;$E5;++H"QTO
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M6,,%M G3$JC,S]U/6=_56&I7+Q7DS$]@G'#MX^:IQH8'>K&OEH!KP01L2K@
MOGPXX#4$B_C)-2R*O^23%G=WN3Y?;O=5^QI"PA ?&85D2;&5G(J"S&R4Y!:@
M6 )RIF8@C="=&I>(](04I% 28\1R'8?8R!AE>9:/#&+U%S=X 6'YT*!;_2-#
MPE5Y ?.8" /$TB]P[61K#W=)"^;IK>YON$!VD"91K$\T(3V:X"_W5#Y6R'WV
M<G:%!W7A_/^Z,=B+?T_#]9/C_AO^^L_?X9//[^+"U0,8WU^-NK88Y!1[(B/'
M&=G9;LC.\$!LA U_P$WP]B"H1ME3>0LD)(8@/IDW.$HBPU)!"'5">)0'%0H?
MA(2Z42&37*H;86FZD3^Z/3NK)(QV-F)RI MC777HJ,Y#4TD:.FMR,-%3@R/[
M>G!F=@BG9]@I[^O$1%\UNNJRT5"2B/KB1+159:&/8#W<6HF1]DKTL%.K*8I&
M9A([C0C"=<@&GG<M 7L=E9WUB$G<B-B$S53,ME"V4FG;CK"PS?#V7,V7;C5\
M?'=040E'_W S#LWMQ:X].U%36T>%K@!)R3DJK4541"82"%/Y>2UHJ!M!6^L$
MZ@C:HIPD)!9322RFPE6AW*.U]%2$; )0MEAWQ;)+P%9PG2I3PG5Z/=<W4DD2
M]VK)"]U!T-6%L)W3Q'UJG[B"R]AK<1&7\=CMG?O4^.P*&7=+R!7+M8S+EN/K
M@<UT<!:+M,"7GFI+@%EW#5\.UAHX_RU<+Y?BTAY*-\M)+NXE2)= 9FF9\N&@
M$HD2K(V +8U<<]M.] U.$K 'N*T4@2')5.QS6.\^!==3TQ<Q-#*O@KG)QP,Y
M7G1L$9S=#-AN[('-1DX$;$]86/G!Q,Q;+:]>:XU5JRVQ;KT$9G+%#E,?F-F$
MP=8C&8[!!; +*X5=5 T"<X>06C^#A(K]\(EO@4- ,7RC*I%9W(?V_H/8<_ 4
M#AXY@YEC9S!W\@*F%\Y@>&(6G0/[T#UT +LF3V+N^$T</G&'P'T>5;6C\ W(
MI*+BB35K[6%A&40ENXB*;Y]R_6YK'^?];:'B6XBTM#PJMW7HZ1G!^/@4@6@6
M^_8N8&KR*&;GSN+$R6LX?_%M7+AT%^?.W\'18Y>P9]\\[]4$1L?W879V#@</
M[$-[4PWB#6%L/&U@MFT'A;#@[,-UZ2@I:$!U93<JRR7-F8R5EP\HW<JK0%+
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MG(I(@#$/!=EBR19+O.3$CN#UQQNBD9F<BMST3#7F.BDF5@%OE.3\EFN+3E#
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M9_MG8KYHQ;:"LZV]^I AYQ>8E]]!X%JF<D_EWDH=Q9- /@R4YA7@ G7N_R.
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MZ2'(S@PE%,>CKBX--=7)JDQ:NB]BXUSX6SGR?CBHR.R!P2X(#O5AO<,1'9U
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MK*U),?'(3$Y#>F*J"G*F4G,M6M+%:BV +8'/),)X:GRR$H%QW>JM!46+0GA
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M;W$9E['9Z>D"(^X\+Y]W K:WEZD";'\_:S6F.C,S"(6%883<(.3D!J*X.))
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M:Y'//]<LUUH$<K',2S^Q"+,4'99U8%X.K;).P%L'<+V,OH\J3]$!^A^!]F]
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MZEU1[+L,00348+;-02$(5\#L18@F!+NZ*9@.))P'BG54H)@@)\L"X6$2%$Q
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M5SYDEJ.\+)[OC1-<7(W@X+B)@&U+\(A$:T,QQ@8[,3D^C.G=8SBX>Q<.[IG
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M?_ (CSA>/'[\1,&U5!<7Z!5P5+I.UX\Z8(M\-4TX1KP5N*9(IXVO.(Y(WK6
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MJ[$4C=59J"M-0CF-D,(LPG6V/PIR SF(^R,EW0/AL;;P#3:!5Z 1_$+-$4#
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MVC4A\/8(@0>_0W?'0+C:$F2M/>!NZP9O0JFW@Q.\G9P0Z.M+^S>!-E0Q]]_
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M,13QEH8'<#_<3@!;JI&GQ\0A2RJ*QR4AG8"8&,K_"0Q#7)"$BA,*";WB51;
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MA(.$ZUVCO=BPN@F=*XI1P__/3PU!5I(O,I.]>)/<D9KHC/@8.T1'6B,ZFD+
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M2J2-:)A >7"$*M+JYNR)G*Q\'#TD1<[^F]MTR9\L_DT2L:?^WKYYCH&^#OZ
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M/*S=X&%%)4+(MEYJ#N/Y!E@Z>S'F<5"8_=%<#A"+8$K0CJ#R7UFW'.,;-^#
MKAW8MWT2DYNVH+VQA9^%$ZB7X--_F8%%LY>H@AX"UM;&'!R-J5P-'6!A8$]@
M=X3)4F<L6^*"!0N<,&>. V;.LL,,"0F?P2GE,P+VIY]:XY-/+/#QQR8$;$,L
M7&Q#* E':>4*C&W=@8M7KN/5VZ_QTZ]_QB]__JN"*05;RCOP$V%/\U3+5/=.
M_T> _6_!VF\!^C\6_?^__T'"QO^$7W[]&P'O7VF8_8";-QYBUZXC6+-F5+7B
MZNB05B$[<)1 ?/VZ]"C]$G?OOL"E2W<(TZ>Q8^=>&I8[59&N_0>.XO29SW'E
MRAW<X'ZN7KV/BQ=OX\2)2YB</*A!=L<Z&E^CV+)Y'XX?NZQ _8NG MD2!BY3
M@6SQ8&N@_<6S+RC<AM.GS[_@YT^YW3.\HJY\\^7+_Q)@3_=@ZU[LZ;G8[R'[
M]^_?_S\R_7O3OR^!ZNG?F\P+9$N$@X182AZD0+84Q9,02FGC-30DK;PVJIZK
M*QN:"8LY\/$.X*!KR=^J(2S-K3FH^?.Y2J8!ET.C+9_&61YR,[*0D2Q5/Q.4
M),8E("(B$H'!P03H$$3&12,I/8& '8^(V$!X^/*9L%\$"]MY<'8W0'"$(]((
MU(6EL:BL3:7^R$1992+2TOP0%6&+R# K K8C4I/<5$5P >R\_%#JC A"92BB
M.=;X^-O0,+6"KZ\3 FBL^KA+7U%[N-L[(,C#"TDTE/*2DU"0FLQI(@K2>0VI
M232&PSFH<_#W=B6\>2 T2/*SPSG69*"IKAIKNSC&K>W#1LJ&_M78-+@6NR:V
MX-2)P[A^C;!UZQ:N$(0.'SR!L0T3:&WI0V%!'0&X@(":36@M1$9.-0J*5Z*@
M9"4R:9@G98@G6P"[D( MU<&E<)E <C%!NW0*M"L5U$I>LWC!99J>(7VM)82\
M DE)&FP+9(O7.5'Z::>5\W[443\V*P_U2H)N:\<&!=2=/5O> ?9TR*XE9!>6
M-"O(3DPN4W#]>R*>;*D6KD.VP+2>D_TA:'=TC:D7K675JY%=V(KDS!6(2ZHF
M9)<C)DX\Y.*UKT!^_G+4UK2ALV, 6S;MQ G"U"6I<GS\.*&G5T4/.-HN@:7I
M)W!SFDMC:C'"0@P)UX;*>QT12;".7DQ9A+#(A0B)6(C@\(7P#UX(+[]Y</6<
M#0?7F;!U$)D+/S\;Y.<F86B@"V=.'L2#NU?Q_(N[A.R;>'A//-GB?1: UKW4
M>@BY+MIG.F!+@3---.^U"C6?^ES6Z?N1G&TII*:)5"T7R#Y/P.:4@"TYV->Y
MW75N+^'AUVY<X_Q-U5KI[+G+.'#H%"9W''H'V!LW[T=;YPAMDAJX>\41L/VQ
MS-!/>;%-*<N6^7!<<<'<N784:\R?9X7%BZP)V X(#8U5_9"/'S^%6[=NJS95
M-\7C3LA^\L4CY<76/=BO7[]6[;I>3?6HUCS9U&6BW]YJ8/WJQ5N\G"8"V2]?
M?*F\UM]]_1-^^NY7_/3]G_#]MS\KR)8P<2U4_'M5</(+ OG=!U_@TC7J\+,7
ML6/?80QM&D>/%&'L'T1?_S#6] T3<M>BN;$3U16TKS*+J0<*4%ZV'%T=4J]C
M T%X /5U+2@I)B03>DM*Z]2X,C&Y'\=.7.#8<H;CPQZL']J(M=1O0P.CV+!^
M,T8(['T] VA<T8K2HBIDI.8B*3Z=.BX#6>FY_+T4H;BH!&6EY:@JKT1E227M
MUG(4I9=0EQ2@("T/^83KW)1T9%._I"?$JY29U/AD0J#6KSDO(P]%N06$6>XO
M)Q79&;$$;*E3(84D[0D"5O#SL4% H"W\ [66M1X^5G!QMR)D6\':QARFYB8P
M,C:",<72PIR ;4>8\*1.#.)^PU%5&H;*TD"4%?JB)-\;A=D>A&LWVM]NR$IQ
MIW@@,T72;0()J +9*;P6ZD/:ZUFIH90PY*;'(#.5T!0:!!=[>T+U,BPB7"^D
M&"Q>"EL+:W@1, 6$1 28I("KY *KL&7"I+25<A:XLW(E9$NG"3LL6V".>3.6
M8";MJ!E_G(4YG\V'X4)# J"=\C8G1L8@*S$5N9)[*_<M*H'SF5A15H,^_E8'
M5Z_%VIXU6-W1@Y:5S>\\V"J_5T!.0I0)O +9 MCBR?81;S+/22!; %L\VI'<
M5@!;0%J*EDT7Z:DL4P%K"2$7$=".EI!CKI-0<A_"G:NM YPM;>',<W>U$K&'
MD[D-[4E^5Z:V<#270FT4<WN57^[NZ $O9]XC0K:$A(LWV)1P;;186EHNPX+9
M"Q5DBR=;BI@)5(OG6D2 6D0\VWK^M0"V7OQ,[KNKO1M%O-B>JCIYH+L_ MQX
M/W@\5P*QHQ5M7>F-+7 MM54$WJ?@6H]0T\6"Q[8@7%N;\9ILW'CNTB[,EV.I
M'P'9G\?S5D78O%Q]$.(O7FS)L8Y2,*R#LNZ-UG\?TNM;]?;F5"!;!VD1_7]T
MD67Y?UV"*/X^_O#E?CS=^1OC;T]$YJ62O9]L$Q"LH#HD* RA!.N(L&C$Q20B
M.3$=L5%)B R/0W5E/<Z<.H=_G<;!_Y6__\_4]._^_G4:N'_U]B7&1@:0FQ:'
MXLQXK.]MPL&)81R:7(^#DX3JB2$<GM3:<AT1R-X\@#V$ZYV#G=@]U*T@^]#8
M6A4ROJV_%:.=]0JP5S>6JXK?%7EQRH.=GN"-_(P@E-,(JBF-P?+R>-26Q: T
M+PSYZ0'(3PU$>4XD'Z)4M-7FHWM%.?J::K&QMQ-')K;B\R-'<?; (6REX==4
MLX**(H<**X/*J8@*M(J#<RU!>@6E$5D$VK1,:4-"R,V3WI^$:REPED<HRV\A
M8%,47+_WHNJ ]SY<6P-M:2TE[;1:VC8H"!7XDS Z:;>EYU2+_!YTZR+[U$%:
M1.;U8WT(V-,A6[S6.F#+O "VY%A/AVO=TZU+:;GNO7X/U2+:NFZ55R[S.FCK
M7FQ9+V M!=[T-EJU]7VHF@+LRKK5"K EWUH*F^F K;?B$N_U]/QK*6XFD+V\
M<0!5\K]2*&T*KN6Z-<_]>\"69;FW<K_TL'TY/PDIUSW?RNLOWY7\#P&[@( M
M</W^90'G2^4^M:."QZNN(5S3L%PN+P)JNU&87T_C/ ..=@$P(=0:"F0OL")D
M4W$1=@6PW:W<X&GK 6\[/KB$;&<)BY'^V(N,83!G*>9]- ^?_J\9^*?_XR/\
MR__O8Q@LH'''!UIRK?;OVHEC!P]B='"]*OQD347XV1]GXM,_S%15,ZV,I5"$
M(ZR,"-<4\V7VA&YYJVN+)0OLL9!P/7\^#:%Y+I@UVU&!]:<"UN+!GB$>;"M\
M])$Q_O"'9?CD4T,.LJZ(3\[!ZOX1G#E_&4]?O55P3;;&+W\2P-;RKL5#(%.!
MY]\+ Y?YZ:"M_F<*T$1T(!-(TT4'M^F0K<.;OJR)K)L.Y/R_'_Z,7W_E.?[R
MKWCV[$N<//$YUJ\?IZ&W!NWM_9S?BL.'S]'8DWS ;Y1<N_8(1XZ>HX&T5X4R
M[]BY!P<.'L')D^?P^>?7<.WZ70+V?6YWGY!]C^MNTX@ZCW$:H:M7CZ*U=2WZ
M5H]A^^117+AP"_?N/:4Q]X+@K!4S>T7C\?G+%USW%(^_>$)YC"=/'Q.PGQ"\
M-<A^\>H97K]]0;BFT2E@K42*G=$ 52V]-'B6MF<"T.*E%M$A6P?KZ9\)9&NB
M0?;T%QKZO?QPW7\D^KV7^0^_,_USF1>P_I6_$_%DR[*$B]^Z_4#E>6Z;V*F*
M'ZT;'%6YV8.<MK1T(BLK7WFNI2B*L:$IG!Q<"#GA-$(3D9*8A/@8,<BDJ(CD
M5$FQD1#U1MG'QQ<>GE[P#0A 1$P4$M,2D$#C+3C2%TYNYC"QG MC"X*/TR+X
M!%@B.L&#^CL8)14)!,-\K&C,I?ZF<1/I@(A0&R3%N2"=!F)6IA]R<X.I1R)0
MS/&DD&-+6B:/&^4&OP 'Y0%R=18CP1@VIF:J.FU&;!+'F2KT-*Y"7W,S5J]:
MA8&.=AIO+:BO*D-.NN1\Q2(G(P7E17E82;#NX6?KUQ"HA]9AZ_HACD-#V$:9
M'!W![FWC.'[H *Y\?A'W;M\EJ#TD--W&Z1,7,;EMKPI_+B]O)#!+^ZL\I&:4
M$6(;4%S1A&S"=W)F&>]',2&[$ G)!4H2E0AL:Y M(>,"V)(#G9M7C[Q\CH&Y
M'%]4N+E$:U4A*9F@+I[LJ?!NJ0XNQ<LRLNJH8YNHX[M5JDY[YQBZ>[>B9\TV
M]/1M58 M7NVVSHUH;!Y2+T,+BE=QOY)JI>5^BZB":ISJQ=9D63SJ$BXN%<8%
MK->/[%$5QJ6RM82-KUG#_?>.HX7'7-ZT'J4U:Y!3U('DC 8-LN/*E#<[/J$4
MR03ZC(Q*%3+>UKH&$UMWX_C14SC,<;^_KP>9Z?%P=S6C,3B'T_DTII8B+,P8
MX6&&" E93%A<A/!($<)U^#P$A6D2&+8 _B$+X!,X'VZ^<PC9,V!E^REL[>;#
MQ]L&A7G)&!M=P^_O!)X^OH''#Z_C\8-K>'2?D'V7D$QHEB)F2J:%@=\B.&O
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MLH:'5SBOKTGEY#U\\@+?$JA_)C!)FR8=I 3.=(C6 ?I#P/[P\^F +?L1^!)
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M; NV;=N)8\=/J:(_UZZ)=^<N;M\AT-RZ3]#6BMY<OGP+%R_>H#%Z!;MV'L/
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M$LE?%G$D@-M.>:\-%IIBT5P#+):7$8N,869HK@!;AVB!:P%KO9B9 +; MX@
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MAX8D7+P=.3GY"/0/XH LQ5&LX4C(]G1S5VTRXJ1?:4PL(FB@^/EP@/3A[S:
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M[)+\8DBOY-CP:(0*X$T!MK1'E?9<TJ8K-C@2<5*,2T*9N5YRL./"HWX3$BY
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MD5:$A+AL3DO1TS6$:Y=O_0,!>QID_^G'[_"  \71'5NP>[0?!PC8QR9&<$H
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M D+5&&S)@ZV-NY:IC,?6K-8:7 >(E=3- VX.3LH]7MS#9?RUG:4-'*VI)TH
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M@?7&=K"T]8,?P3HMIP)%^B:45+2@OJ4/N_8>PNW[3_'5KWY'"/HK_D2 _9:
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MLYUA&(!,95G6^Q&RM>!E MC1*E5:+.N<]X6P+8 N$>D%QI457,T;QF)+FJY
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M0]>(Y&R#!3N+$)U;U(&<@G;DZ-H)OU)F!Z%.7+5?6Y-_#+RO(5OF!9@%KK7
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M^0WK2 #Z'\MKP/YQ#G)#'7^KQM7_CLN_5T#\CV4Y0&OW1Q-9)_\OOW\_76>
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M..^)6+!E7LY-N8G+6&Q'0C*/Y>[JJ>(-2$R',-95=$0<8L,3$!D<B_! GG]
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MX$TLKV)1%FNLC.<5>!,03DVO(KS)F+-6@ILADK5 GBPOAVN9UV!8 VH-K@4
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MUK6;.+QT%!VMO<C)*B9<LX)92=+!9V35("N/<*IK0W:AI']Z#=CB@BS@)2(
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M2-3HL]'75J, N[HLC^\6 21(AE $(2DIFM<5"B=']D.K5^.__5__#?_VW]^
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MNVV#!Z'(WV\KPL,DR-E6Q,49(R9V,Z)B"-G1:PG5!.SPMQ$8]A:G*Q 2N9H
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MKL#ZQ7L?XB4!6.1]0K" Z_OOBTBN:\,X;(,5^TM\(2[9GWU!>/Z,,/TQM_E
MP;6(@/;''\OX;+%R$\!5Q/$O".F?*0A\29&I@FT![1<?XLE3@:D/<(_G>NO6
M$T*B0/893$TO8&AH%L,CNPC:"]B_<%SET#YYZB+.G;_,Z[^)^P\>\YQE++8
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M<D!I>AP*DJ*A2R)D1X4CW-L70>[>"/,)0KA_./P\ @AQ3BJ5Z<9U)C!A70D
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M>9;I1+ 6D/=T"X"WAWB@^/.87H1F%S7N788G.ME[JO\"?"6'="CG ^#JY$'
M=H"5A14L=IC#VM(*=COMX.@@V0.<U4</^YW./'=/^'F'())UFI&B4R[=S6Q3
MNUI'T=,^AM[.<702M,5%/#^G@N!;J$3@."4IG^VL3BT+=(NKM\"V!"H3^)9Y
MF4K0,A'YZ%F07XVR4K;OQ62'G$HUSCHQ3BS@,O9Z&6"S;TBC'OYCP*Y1TTSV
M'V*ASB1$%Q76L7UK1T5Y&PH+ZEBFI*WD]ED5"K(EDK@V#CN1,!\=E4W)(F!W
M_M<!]A\)V ]N7L7^J6&,=]1CI*4:O;4E!.I,Z-/C4)0<C?),-NAZ'?IKRS!0
M4X[^2CWZRTN5#%9POJR$+W4!6G6Y:,[-0GU6.BI3$U'#:5]M#?:R4SNZ_S 6
M=A_"4/\D&FK;T5#7J2+*38SOQ?#@/)H:!ZD(U$-2D$C'GBY!S@3DQ(I=)&[B
M\C7<X&Z\'( UJZE FLPO_U^F H*:15N 4$!-QA.+RWA/WU[E+B[KM.T$_+1R
M!>:TLC20U"!0Y.?@6K;3 %3VU<!.]I/M161>]I'_-)']BTNE++%H"V3+5+:3
M[>58$BQ,+-\R5EC&;@OTBENS6*_[U+8BI>54F B, LX"U)U]>Y0(: LX+P?K
MGUJOE\.U_%?;,*K*$FN[ *F<HUR3]@%#ZF4Y'&O7I-63@*L6%$W^D_J5\?$"
MV?)!0RM#MI?_I6XTP)9]92J +<>6\F0[0UT9[K>NB/='(H>7=2FKM4"V6++'
MIXXH$<5,UI>*"R2!O+"DC<?H1F6-88QWE<J/S?)Y7('KM/1*Q,87(BHZCY"=
M@VA.X^.DX2BF2/3"7)76Q,,U'(YV 6S$_-AX></,S V;-CL0G@UCK%>LM,([
M*SE58&V%M]XRQ]OO6&#]!GM8V00@A.">KVM$3>T VCHF,#5S !<(<!\0\'[W
MW7?XR]\(U93O"=H_",':,/\] 9OP\AVA^;>_P:]^_0U%K-@&$7?QY8#]'X%K
M$0VL160[V=ZPCV&_UP!EV,8 VM^S_.\(M.]C:>DX>GI&T-X^H,#SY,E+"J;%
M<BUP+99K<0V7-%W7KS]4@'WQXDU<O7J'VSTA7+]/*/Y P>W[!!FQ*@OXBF5<
MHE.+"!2+:[> ]'N2#YM3L5B+A5JLV@+5#Q\^5B+C:.4_ 6\!:@%KD5\2:@6T
M/V6Y/U>^6+8-D,WRGG_ <@2VY>/ $Y[O=079$Q,"V9,8&IK!S/0"UYW L>/G
M<$I!]E6\^^X=0O9S!=F??4:0_O+7/P"V6'5?C\_F])>_)&3+1Y)O6)<&R-8L
MV0++&E3_.,_U:]C^.?FU<@]?YK6@[MO?BW:_?TZT;5X_!W^_OZR78_QPG&7;
M21G:,R:!^ 2R[]\7R+Z$W?,'"-F[,38R@YY.OH?EU81L*FG!@52XG.#M9H>8
M<"JKA<GH;BU&?U<Q&JM2D)TJ:4=L8&=AA)T[3.#E8H_XJ!!D4?G+SHQCYQJ/
M_/PD%!6EH:(L!TWUI>CMJ,-P3XN*1C[=WXN%R0F<7EK$M7-G<.O*1;Q[Z1S.
MGSV)\UR^<N4*;MZ^@_N/GA"L#5!]G\_V71F#3<A^^O['>)_OZ'L??H*GS^7#
MRRO(WK^$F=$)C'3W8[1[ '.$[<7)73@TO0>'9#HY1R%L3Q*V)Z=QD/WATN@8
M]KVR8N\9&L0^RGX"]N+8$ Y.C.+(S!1.[=V#2T>.X/;%RWAZYP&>W'^"&^_>
MQ<+",32W#B ]NPQA,5E4XME6I10AD8I%.D$V4WGXR' <MK&$[%P"=[Z"[-97
MD"U6;+:W;!<%L@6N-4NV_/<#9!-Z!:PE=W72,LA.RZP@,->QW6U78[(%I@W6
MY>D?8%NF;9V3:**R)KFLQ;4\EVU>6F85RS%8LD5D7H-M@6SY/RNWC@ B90\K
MZW5/OP13D_YZGOTV(;MG!AUBR9:RQ5*N[U#7EY%93?V!91*RTZB$2=390BIA
MK2T#F)U9Q)'#9W'XT&E,\WXT-=0A,R,&H6'V" @P0T@HP3K.' G)YH0@,X*T
M,4%[$R%['2)B5Q.N5R,F<1WK80O2LLPH CVFB(PV4H#NZ;D9[NY&" RPH.+I
M@\;Z7.R9[\.5BP?Q^.$5O'AV"R_?NX>7+^[CQ9-[>/;HCI+W"-P?OO<8+Y\_
MQ(-;UW'ZZ$&,];&/*LY#>D(8$J*\D)K@I8"YNBP&76V9&!TLP?1X)29'*C'4
M5XJN%AV::W)14YJ)@JPHI"6X(R'&FG5@!7VI&[HZ8C [78#%?578MZ<"4V,%
M&.C)0G]/-B4/W1VY5*1ST-VNP\A )?;.=>+(PC".[1O%H=D!')X>P/&Y$9S:
M/8YCLZ.8'^Q0ULW)WC:<7-J-N^^>Q^,[U_#P#@'[[@W<NW,#=VY?PVU"]AU>
MTWT"M@#XC=/'L*N_ S4Y2=#%!J*&@#Q8DXU=':68;2]2UNN6G##4IP>A(2,$
MS3E1:AQVO^3'KRW"$.&ZER#=G!N+NHPP-&9'HJLDA>L)C;7Y:"M-1T5F- H3
M0U"<(NEE8]%<G$JPSL% 73[U5UYG>1H:"Q)0GA6'C/@(!/GY$E1V8MW:S7CC
MC94$[)5X\YWU>&LE@9OR"P%M0O:*#:;8;&:#[3:NL+9SQPY+1QB;FA.PM\+5
M:SMB4QR17^J+RH8P!=BEU0$$9GL$1VV%=_!F^(>8(BC" E%Q]DC)\$1>41#A
M.10ZO;B2>R(MUY&0;<=WVIZZBBOT%5XHJ_2 KL0.J9DL/]$8H1$;X>>W%CY>
MZQ'H8X+X<#OE E^='X=&UE-301(:.=^<%XMV78(*;"9@/5R9H])XC4JZ+HK4
M9S?!ND-/P*X@;-<5*VDJRT-%7@J*,Q-0FIV$ZH(,-!"Z:PK2H,^,9YTEHJ$P
M&ZUE12HG>WUQ*2KRBW@.68@A\+K9N\%,K/RK-V,]9?,&$QAOV0930J7%=BO8
M6]O!A9#GY>9&N/9#9$@@_+W="=R6L+'83ABU0X"7!R';&][.+K#;04 TV@Z;
MK59PW^F*8/= Q!%<)?IW9EPR4J)BD1 6H5)K2>[J_+0T%*1+Q/-,E&3EHC ]
M$YFQ203I2(1Y$T)=?.#GY$W EJCBD0JND\*3D1@NKN*)B"1@>SGZP$J"CJW:
M@M4"V&^NQP;>_PT2Y([/PHHWUF(E9>,:8Q5%W='6#2[V<@W.L+-R@ ?+CPF+
M1UIB)F+#$^#M+L883^J+[MA)R-YN9@T3R;/.>I)\ZUM-+&!F:J5$ 'L3GS,9
MD^UDYPE?KQ "<"C!.0PA@=&4&/ARV87GJ-*C<1N![@#?"(2'Q"."UR/;>7L&
M*(C>L4W<S\TXW0%;&WNXNWKRV?&'CZ<_H=V7^_HJ*(^.8'VF%J HOPIZMI=E
M13)^N@&5^F94E;6@F.NR,TH51!L@VP#4,A5PEH^9&F0+>"LA?,M4<E,GBBMY
MD@ZYV>6HJFACV]B',I8MP<QB";V)<6+%9AD_6*Y%7@-V5KI8K\D,G&:DEG._
M4AY/#UU^#<N1(&?4[0G8>;G5/T"V6+,%LL7:;8@F+H#-YS0Z2XW;5H#]U_\B
MP+YW_3+V3@QBI,TP!KNGNHB G:$B"E9D):&N@"]B9;%*NS5<7X7!ZC+TEI>@
MAR]:?T4)A8U\:1&:\K)1D9J,DL1XE'':7E:&O:/C.'/H.$X</(7QD5VHKB2
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M=O <MQ/(MR$Z9CN"@TSA[;49;JX;5!"UV&@GE.L3,#G>A OG]K.=O(*//WJ
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M_3H!^^:]QPJR;W-YD]LW9 HY0K9,(7>;R\N79W'TT''F92>&^D;0U]%/T![
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MM"/15!"%>MZW/"L,F8D^A!IGQ(3:PQ#M0ICR175A!)KDHUM5/&I+(E"4X4L
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M(;&,>:]&5K8,(^AA^S-*!76*]64[6MNVH9G]M(#VEJ8Q]BELGQJ'4%K9J?J
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M,6HE(IR '4? -B1E*4-7_!Q@BVMW$@%;K- B20D2[$P#["2RA'RPR&5?5$+
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MWF)Y337F.[:0"J'$A2E%47$3NGO&^=O=1T5S-T:&>E!5+E/&^,#;8R-<G5;
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MM,0Z*NERK#R+'/_*2JO)?+ 6T!9%X?=PK;DP$PSG+-@*JG^%Q@XU[[18D27
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MSF!FUVY,C8^B=0N?(2T&88'V\')="T_7I?#W6H:0@!4(#UZ%L)#5"!$)6TW
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M$P79+UY(-/6/%6"+Z[B,S_Y0I@V3R.:??DC _A"?_9F0_<5G!&QYC_)._SW
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MP\HG%0[!V03W8KB&9&&32R0L7,(0$)5!T&M :\\(]A\YCN<$;(%J[4]X0+A
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M.P6RIW?AXHD3N$68OW?])J'^&DX?/8N9'?O0VSF,BE(9LY:/\/!4 J$$H<E
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M4>5Q'/9)/)[U8W/L03ZKO'_>F^4D8LORUM-M6%YV+%\125<BVRPGFSC>(^8
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M#M<Z//]'@*U],)'G^9B0_0$^_(2 _;%8X&5<^0=X]DQS>Y? 93*=UX<??J%
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M\-Q42@KOQ6<0,4L]3J@D&!EYO52Y[JM\R+TV\7J;"#KF E4"XK\*88@ MHD
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MA&*!8YD$W9C&AQ<790'H[&8-JC-U::80\C()4(3:7 6UXHK6K#I7Z? EH)D
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M<_&YQ89]/8'C)G6#NLI&OBQZ A@!X$GJQ%.-$EAP^QA;A(XQ! 5)H& DB!!
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MRD>$HL?H[+B+SK;;Z.:R72[C%V[@U.'CJ"VMPM'B0SB^OQRG>(^G2LMPLN0
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MQ^]^-PP#!DQEPV8= O@#3=]1P'LM9R/^$*IKC^-64XL)#O+-=XH8_F<3V$S
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MYD=\1GW*OS_X]&OTWGN"NH9VG#AU">7E-2@N+L.^0DVAMP?IVU.0&!^%F,@
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M?.ZG,,FG K,#]F%E&.$W-ALQ9JCJ7B0G[$9\%+^[FNI*L.J? '^'H2R8;*#
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M;EYKQ-&*8]B[,P>I\2E(H_9N)V!GY>"0YKG.HW+WHG)O-JKV[C'3<57NS7"
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M"($Y= ?+?1?+-Q,1D1H;K7(17*M30=-Y67.'.Y>/7/5E=9:;?G3L#J1LRW=
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MU2>/(SQE'Z:LWH,ABRHP:ET]X;&+C? 6PH(B(PN&K*!.1@;R!,T"/@$(84'
M80!;<K:B";QTC /X_JYL,'I6LD0*SD80U@1LDM:E?K"V90.V#1\"EWX9ZZ,
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MK[%J6_(S(/TB)9CKZSLNN Z6=[*&H/+[ZZ]IA%G/&- F9&LHD#I1 \F/_\.
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MV<<XP[1D[W_^[^>W/PO7^DT]"]0ODC-<VW$*[.WZ[>J=;&WNQ+&CIU&TKY2
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MX;7&!][K?!'D'8JPH&CX^X9A]2I/S)JU#&/&S"1<C\>;;XS$'S45U\L*:*;
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M@;0='=Q9SG M>):UV09L0;!<M 7(&B]MOG<.V7!M ;:V*9B9SMMJP#Q,G.8
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M%#PT;[5W GR]"<4^B3\+V,ZNX8)K219LVPHMR!8P:UV +7:S7<PERZ*M=;F
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M+34S,S,S,S,S,ZB9N5O,+)F?[\FJWNZVQC,OS3FG([*K=NW:!:L@\[<R5Z;
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M2::R'?EN+53_O*QT=CWA\_+DM2)/GTIGF, TH7F-B,=:Y FA6A'-^LIR?D_
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M=26B@,"=%Q.%? )V05P4 3N:@!U#P(XE8,>A.CV1DD"PC41*J >\''2@?_T
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MU.*1)H=(66 %IE> 6H'JR!_%61$5KL6+O1:PK2R#5CW8 MGF O0JS$L6\57
M3B1@_V\-$:>L_+VDH=_:W(/0$$F*%48E0>@D]$E\N]09,S!V@X&D-Z?B,R;4
MJF-G>0)6!#$)%5\1"QL1M>ZCJ4"P-*HCP<^1"M""D'W-&B=/7,?!S\]@W[Y#
MV+5G'[;OW(GMNPC5>PC7^W9@WV<2.KX?1X\?YTO_.DQ-;-EX7KP(5$"V 4KC
M*SW&5(:B""5T7;S7(J)D-0 I(O,B&O"4]44IBI+4*%01 5V-LM5D _T1LM>
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MK>Q^J7--")@BL,J8Z\4E-31<$H!I1(5L\63?Q=*2)-*:Q0SA34#[7<@62!;
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M-%9#QA7 EE!=@J-2:UG&2/\8'D[Y$;"[5V0M8 M _!0BU%#PE:1F!&PEU)G
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M3,I#))^-B,@TI*86*?6-AX86T7]C#C75G<C-D8SAE4JI+AF'W=#013 ?PL#
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M:'C[$79]J)@(:')<KAZ$43:^-2%< 6S)3$>8UHB=@X1]B?"S "L5H3.5I:N
M-<69(.S BV8G^^7^WQ5';M^=T.P50(5)L!7QH:+W#4F'7VC&CR++9!U95V!:
MH%Q$F:?(?D1<!.8ISH1\1RIU!]XL]G)#_ C8TI,N(I\%AL7;+( MG04ABF'@
MY!JA>/ CHG,1'9>/D/ ,*G1NDVUDZ\ ;7@%M@6Q_WO02,BZ95.6FE5X@@?95
MD)=]BM@["ERKHGJWJ>P)])K( (WW7, ^/;L!V?G-2,FL15A,OM)9(76N+=C^
M5FQ_6SXH4OO:E-=0,KS*^ T;PKJ'6P2-BW@$^?+!L/>%.8TJPZN&,+UN"FM#
M&T7TKQCC].&+V+/M"VSX>!<^^M-6_.']37C_O4T*8 M8_^I7&PG:&_''/VS#
MCNV'<>V:.7Q\(A$;FX&8F!1$QR0C(S,/]0TMA)$I0LQ]&M8$&HH*2#2@Q1,F
MGJX58UWU6J_"M8@:1B[AY*J((:*"]D\!6PTC_WG %B!7O=9KO7$R5E4-BY7Q
MMR_X_2ON[Y48^(]?86'^+@%Z",6E=8J7+"8^B]<Y"VE99:BLZ50\DOTT(CJ[
M1M#0T(WJJA945C0KGNRFQAN$J1'T]DT0K&8(U_.8G%Q0O(V2O5E)6+4"T'=$
M"+RJ"%@3N!51OQ<O\\V;2PI<"S _6/%,"T +(,E8;('$1X1N 6N-J)YJV8;
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M ]?]^A%5,H>^F6=8>/ *O>-W$)\["'./%NC:M\ JL ]1Q=.H&;F%%H)#4LD
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M%K!-2G'8.@=Z7EGP3RA$444]1H?'\8HVC(*&\O>3=\ />/;J"8;&!Y%;4H#
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MB)<QRZD9J,\K0%-A >H+LE%72&#/C$14J!ULK<_A^O5]N'AY"TY?6(<3%S[
MN6L?X;K1!AC;[("YW6Z86FZ'ON$&:.M\##WMCZ&ONX[3/T.?G\T(S#96V_D>
MW4E8W@$;VYW4 [NI)_<J@.WJ3=CVW$-=N8LZ<1L,33="B[^[</DCG+OP,<Z>
M6X_39S;BW+F=T-8^ D=[/06TRTLST-M5C['A;DR/#V!FM!]SA.R)]G8T9^<A
M*S ,Z;XA*(I-10DA,2F"^L79&P8&%KA(R#Y_S0A:!M8P,'6BOO.!JVL8?*CC
M?'QI\(E>)<"*7A-;1&#8VU\J=U W42>I7FQ?&H1B+P0IG@P7=S746P!<O-4"
MV%;4FS*5=629/8T]C9=:X\760+9XHV6Y +0&[ 6N@ZCW V@#2&>SDGN%OU,[
M "3<6SH!)$NYU,KF]D0$LJ7,ID^B M?! 6D("DA% "'=/R )_H$4ZFPI1>H;
MF Y/OU3:$8G4Q;$\QG EH9"%A,!;>;&M?1'H%XE,ME]=>8TRUK\J-Q?1?EXP
MUSZ/8P<VX;,]'^+,V9VP=;J*R#@7I.>$HKZIB+IF[D>#FF8AOO_Z>_SPO40W
M_J#8B4_>/,/0] R*:SL1G%@!$X\\G+3(QUX"SE8!;/%@FZP"MH2(*^'A!$D)
M?=UM3* S[,$NPSYE+/9?!6R3+@6L=YL1L*7^-7^WS:"9@-U$^""@$A*V&\G8
MU4H<=ZB%;4(?LKJ6,/CH!9:_^0J+?);'EY]A^MXKS%*/-TS=@T_>@%([>:]^
M,[3])Y#1_0*S4HV#I]<\^ASNL2/XPJ@9ZZ^T$9 [L>Y*%4[85""R= 3#]][B
MM@#VX@N4MO"WE5TH[QY#^]Q39'<^AF[0B!*ZODZ'O]-NP4:M2FBY-2&G:0FW
M7JT ]ORW",B<Q5'+5FS2(H!R?4D"M]VH"1MU:R$A]+I!DTAI?(6IN[3#7_^
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MF)K8P)"&L(V5,\)#XU!:7(/NKD$EF=J$),8BU-^]3<"^\X2 ?9_[5J%/X%E
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MBMV&E2N +5Y",>A5P-YIVJ+"]1K WFE$PU_&5$L8^%\%;)GG,JZ_0QFC+27
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MS,_,*TG+[A-H'A!H'A"N[TLY*\FL3;B^*R'=;+_[=Y_C+N%Z>>F1,I:[M64
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MXK//SQ*0O\1''^_";W^W$;_XU<?XQW_^$_[G/_P!_^U__!;__7^^C__UCW_
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M2APPK<!.PQIL(PAO,Y/ZUVL!NXUP+5YL@6M)3"8>Z78" [^7T.]_$[";^;V
M=2OV6,JT 9L,*K%>MP0G/9H1T[",\2? PZ^ _M&O$)$PB;.Z5=AT.!OKC^=@
MX[EL'+,H053Y$-=[CN'EYXA+GX"C9P\BTR;1,O8,LZ^^0_?M5P@L'L)1ZQ)L
MO)"+;1=+\(5N-:R"NU%&R)IX]!7:)NXC-*T;YA[E< ZM1V$KW[$/WJ!YZ@6<
M8D8(5Q78>JF H%: ,]:E\$OM0??4 SQX\SUF'[Y!9O,2#"-ZL=.Z$7\V;,9Z
MI909V\JH!9MU*K'/M!J&88/(:'V!N<>TP]\ 7;WWX>#1CCTGB["9LH, OYD
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M>/]WZ_#!!^OQT4>?4M;ADW6?8@OA>N^^'?CRT%X</_$Y3IZFG/F<\'Z L'V
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M^=D:-&@6[2<"=B !G6(>U 4SL:@&MO)8/6 ?PI*X%B3O.8?6<U_CRGW@RJ?
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MQ+,03ED'%[<@S+&TPJNOSU"6Z9_\]%G\].?/X]>_E;G6K^-W3PM@OT; ?IF
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MQOZ>@!TV#YX^IO#S7XC,S% </ER-T>%>MJTQG#TS@7-GQG#A] C.C/:AO>8
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M)OBOK<)<ETV8;E<)0Z\F9?4RU0U2,1^ ,>')D+ ZFV!H0*5=K-@2Z$S2<&F
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M$,MB>#TA;)?^#9BCX[WKFC%'ZI[/@P0,E*CN1LH"_9\$;'DN>7T2*\&8L"V
M;:P;9ON:8)V<5,_#'+]^ GX3E@7LAWUX%;QC*Q#$=UHH^2PB5J:5D-TH<;&2
M 8E@G5B@C*4R_5;B,B6I^=:;%62+%5MB5V3E\)V6+QF:MBN/X<#@)-@Z^L'"
M<B5UFEGXU6]?PK_\ZV_P__[SK_%/7/[KOSV%G_ST&079/_VY-L?Z%[]\$;_^
MC>8R+J#]]+-OX+G?OXU7W_@0TSXT(5^9JP!G,][[$$8S9F"N*2%[CA$6S#7
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M)J@0&$T(0V(MTP!;YF&+)5L3@6NQ5)L07$P(UL8"U[+^$*[_!& K%W&!:K$
M:R)PK>79EM\BN/FWP<R/YR,0&1.JC000_0EW DV!!"-^1T!%K,VF!&*Q@IOI
MAK@<4-=M2) 1P#8D["FK]"2$B/5:HJ)+SFXCWIO*\2T@)8 M(,SC# 7$9-"
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ML7]W'0[MK<&A/0>Q?R<!>\L6E!?FH2@S"5DI$4B-U2$FV 5!7FO@Z[H2?I1
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M_PBL-9$4H"KH6(;,-Q1+MP#X(\"6P?JI\O!<\GVQ9$]&UY746UG9VEQ%D8>
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MBYN7S!%6(].3[@SLX"3W8U(R.TX)M"8INPBF&9FER)81X$Q)ZU$(23'FZ9T
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MRG6Q7&O6:PVPK^&Z0/;UZ[QG/6@_ FR13WA?-PG8G][Z7,VWG@K8&E0+7&N
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M3YP\K:S>&EA3+EQ@N[ND0%G:Z,CH*9ZC%]4[CZ @OY**.]]/8=G0\;WFYY/
M]TO*)& ?48!]Z;)X(FC6ZZGP_#A43Y6I8/UH&^M[$K+UEFL-K#6XUH.Q7O10
MK0]2]CB$/WP'3!%YWF6I_[XL%6 +6/,=\!7;R.?\[?-\7KO:CV%W]7Z4E6['
MYDT[4+E]/_;LJ</! _6HK6G _KV'L'7+%N1FIB,M(1*I<<%8EQ!$L*8D!6+=
M6G^DQ/EA;90W(@*<H7.S5G.QO1V7(LAC-:+]'1$?[(IX GB4GRW"O*T1ZK&"
MH+T<D;XKE25;X#O ;17<;!;#SGH>;%=9PL[&0EFPU]@88(W=3-@Z&<#)PQ#N
M?J;P"C"'E[\I7+UFP<GU [BZ3X>OSH@Z@!DB8RWX_K=$8MH"Q"7/15BL(71A
MT^ =_ Z\*-[![\,G=#JAF^#M;P!O7V-X>IK!TV,.?#SF(]";UQ7H@*2H !3S
MGNOV[E& ??',"4+V&$Y.#.+T>#\N<_W&Z1,XV]>/COV'4%.^ X?*=Z%Z(X&3
M"EQHP%H5ZT0LV%,!^X=PK<5PD77QM),!=+W(9TV/R5. +3J,'JSU<*T'X\<A
M6_0<O3P.V7*,'*O_GLA4P)ZZ3XZ5[X@+>%9.)2&:T"O+R?4<9<G>B;Q""52V
M4T&S@+: M "UP/6Z# VX-="6/-E:KNS,G.T*S&7^M<3,V+*5H%TA+N.[4+RQ
M&@6%5=C YS(OIQPYF1L)VAN0GIR%=2DY/-]&1*=5P#ZL#*8>9?C0?0]FZEJI
MD/?"6*R%/P!L0I6RI@I8Z>'JSP!V@(@&$4^T7/^'1<!!;YT3D7/JY4\=-W6_
M?OO4_7^M_+7?>70MRLHY*<KR/.7SWT.4A7[*9^W\!-G 1W4C%F=E=1;7?0%
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M:WD/;B:S;6!?$8M%2YSPYEM&^/G/7L __H]?*+@6*_9/?_H,?O&+Y_'+7[^
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M,V5M;J8T31&9/]]&D7J5.I_:!OY4_4^V@?\+ZE] 6%F> WL)QWTPX/ILEK\
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MLKCQD7A-W&%9?LYR_8P0_RG.G;N*OOY1%>U?HOYG914IP([CNR,CHPC;MQ]
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MRKD+-RC7",A: "F!YZF K1<]7.M%CONA$,PG@7HJ6(L\/D=9+V+%%L 6ZZT
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M2'"NK,U8E[A! ;;TZ3KVX_H@JGIH%J!^'*KU\*T';#V0"X!/!6R]GC(5>O6
MK!<]:.M%/LLQ>LA^7*:>0XX7'4A^0W2FJ4"O_[WT]5NI Q&TL[=!4G-E2TJM
M D(P@5K NJ1TOY*ID"V6[*GNXJ);):6(3B8##!)?)95]/<LI0J;C49=(WHJT
M=3N0L7XGLK*KD)TC:<*JL"Z[&N$IU; /W@X+M^V8Y7H LWW:J.P3K@D IF+%
M)"28""1,NK@^&; TD'JR_#=<_]>(I&?2+,_&8H&F*$"6[>*5P*5*)T784G!'
MH#,@@,^BS%1"P/;OQZR  4)?/X^5 1:>@W#]E^O_S[6!__/J7V!6 UHI2PV2
MQ1HM<"ME+%9JY0' ,M&+5C>R_7\58$LD<H(^13NO6,@ED)K\IJ3G&H:9[P0L
MO,<PWZ<?*P-;X!I3@\#4'8A8MPF1J>2WY%P"M8!T =^3Y(Z$$GXN030Y+U+X
M3MZ=XI6<)FQ2P/XB&L:F*PC*[^ G/WD6/_FWI_&SGSZKK-?//"-YK=_"2R^]
MCY=?^@ O_OY]//?LV]S^!I[EOJ>??IG?>Q&___V+>/.MUV%L,H.L,H]LMQ0N
MKHOA[#*/8@%')^F_9F#UZNGLRTS@[+@ [CS&S7D)07NAF@+EY&#)[0+3<^%@
M9Z'!M9TEG C7CG;SL&JEI.DR0WRL#L>ZZ@G8?^<HXG\.L!-9J#K_>!5,2W*@
MJ31:T>(B4*@Z 9DK)!V'= S2.8E,!6O]-OVZ=%K2D>@!6ZS8LI2 9=(YJ3#O
M&5,!6ZS8,LI:JJ!Z?4XI.Q!V0!E%K-CU\!<KDGL([.S]":0Z.#B&J/G4P2%I
MB(W+(Y"64(%AYT>0CV?#$'=Q/6"+A=O;)X'WEXR   *VSUJ5_UH >]KT>7CM
MS=EX_<U9>&^:,3Z<;HI9!N:8,V<1EBU=14BUQQH1*ULUK]IJB366+5@!JT6K
MX&3MK #;WT6' #>*JY\&V/9N<+5SAJN]$SR<70G9GO!P]80=%>>EBZUA8;X8
M)D8+8&0T'^;F2[%TJ0,<G8/@'YC,LL]A&8H;OI29P+9TSNP<^3E>7#58YI+V
M3(*:^>@25'VE992@M'PO=NXZBJJ=1[&Q9#=26=9A(>GP\8HC)$3"5<0M"EXL
MAX"@5(3(G.Y@*BNZ./S_V?OKZ#R2+-T;_?_>>\[YSIF9[IZFZN)RN5Q5AC*S
MQ<S,S,S,3+8L2[)E9D;)DFR!9<D6VI*9N0QE%T-W=7?U<Y\=J;15GNJ>GIDS
ML[[[W?.N]:SDS,B(?#/BEWO'CNC(-#:0LE%>4H/-Z[>BF8V;U@,M.+A])[8T
MU!.JR[&VJASKEU=C3745RK*S$<W[LC4VQ[QI<_#!6Q]@TFOOX9W7/L3;:BR[
M69CT[@*\_X$!9LXR8UZZ(3@X05FX5JY<JR06KY4KF[!G3S/&SEUA(_<;?$NP
M_G;<]7LB".N _6)>VZ;#];]JJ:;T8W0X%U"7<WVIH/H%B.MP+18M79]S^6LV
MN+_[3AK8?U+;;]Z\CU-](]B]JQGU#5M4A-9]![HP,'@%EZ\^PH5+,M;U>32W
MRK!J1['G0"OAN@,=W?T8'+F(BU?N$*X?X^:=3RB![$>$ZX>$CX\)' \5+/\U
MP-:WZ9)UNK1E@@J!Y2<!>]P"*&"MK(.$%K'XBHOXU\QC"?#T].DS# ^/8GE-
M([P](N#F%(;<K!78L[L3?:>N$ P?8(3J'107\4MH.W&.8'U.#;_5VJE9J-L)
MT<<E")J M( W(?SH<0)VQQD"-K<3J(_)?EPO@<+:!:X[AM%VK!_-+2=P\. Q
M0G:+BL+<<_(4SA,";]^]RSS0+-8*L,>'Z9)YL6!_\LDG_R; _O13WO?GSY2+
M^%=??\UC/L6EB]=X[384%%3!SS<2=K;>\&0>I*:5$:YWX=#A7G0PO9W=<G^\
M!Z:[LWM$?4CI.C'(>0(VYWOZSJCH\*+>TZ/*8T'VD6&Z^K@\3/B\<.DVSE^\
M31 ?P\Z]S<@IJ( 'WQUF5HZPXGO&CY"=E)K']V 3MFT_Q/\VG[7Z302W>FS8
ML N]/->U:W=P]\X#PO''N'/W!5R+1?KJU1NX<?TVU]W!Y<O7,#1XAI#>C9;F
M-K0>/8:NKAX,#HS@_+E+/,]-W+FM6:[%&OZ0SYJXAS]Y\CF?%;%:?\9K/.6Y
M/\;8F$0-'\;>O:W,DZT*^ 6PZ^K6$_KW*&^4T=$KO.X#_A=N*4OO,$'^_(7+
M*H*X#MABR99YF>JNXG\+L"=:KW5X?MDRK<.U+EGW8O[%NG\-L-5[8_Q](5#]
M_1^!W__A!Y[_<YP=O8B#AUK0M'8CUC1M5'#=TMJAUFW>O!6KZNNQ@N_*NMHJ
M-*RJQ,H5A.W2-!3D12$CW1>QL;8(#3- 8/!\ O8"OO<-"8(VK+?<D)_GA9QL
M+\*D&Y(37) 0XX*P0'NX.1C"TG N3!9_!!OC^?!T,$&$OP.2(]V1'N^)K$1/
M9"2X(RG2 9%!YJQ[C.#O:0!_[V5L;"R%M_<B-E#F$K!GP=-O-KP#Q6H]CX ]
M#_[A<Q5<^X?,AG\003MH-NN*.4SC?(2'+V(]NP0A3&]8A!GK#QLV>&Q4(\C:
MR@+V=@X(#XTB7%=C0],FK&]L0FUE!2J+\U%9E(W*@@Q4Y*6A-"L5*TJ*L'_;
M5IP=D"CBXQ;LBV=P30?LBP+89W"^NP>]!UO1MOT@]J[;H_I@5Q0W*,"6."I1
M,86LPTK_A9OX1+#6+=83YR<"]D0#@0[8NF7Z94C^*=A6;9CQ91VT==C6+=KZ
M\;*O;L5^&;"?@WHY]Z_2Q[0F9-=JXUH+3(M[N [8.F2+95N/+B[6;/$&E""Q
MZ9DUS)<RMI?8/H@M0%1<*6(3Y:.\C/:R#CFY&]E6VL+K;25HRW0C<@K7(SIU
M#9S#ZF'HVX3%_KNQ+.*X!D9LG!NJ?K@RI- )30JT7H8J72^ ZL?Z:2#X/_K?
M+(+44D*UN B+U7*Q1)-F^2U5$J\$S1U\:<*X:SC+:G%,'Q9%]V%A5*^:+HXF
M^!&T!=:T\PH<:N4O0V[][?+7GX'_YY>_#L("V!ID:U(?,!1@CT,V[U^#:EW:
M-FV_B<<)7/]' 5L@?8@:X3E%0\I+03OG  QC1F 2-0JSB#.PCC@%E]AV!*3N
M073N>B05U"&E@._'?#*(Q,:2(7ZSZI&9(Q9L0C;?6UFY]<C*XSN3\\)R MAA
MD5DP-';!FV_-Q,]__A9^_K,W\,M_?DL!]FNOO:\LV)/>^4C!]=MO?80W7IN*
M5W\WA9I,R)Y,N)Z"]]]_GZPP'8:&\^'H9 I?7VL$!EJ36RP1$FJ!T% S!(<8
M<UGB?$C0,EN$!3L@+,0!H<$$;2X'<W]1D+\5 GPUJ-;EZZ4!MJN3(7*RHMEV
M_R\";.F#W=K>PY<_H2TNCV!=P4RL92:N5*Y%$L5:@%F'99G7K=0BW25+!VNI
MN/0*2P-K37KEDJ_<Q64(#,+SN(NX]"<NJY1^U^+;WXC2RM4J,$=Q.:^55X&H
M^$SX!$3!Q3T8+FZA:HB<T+!,R)C6^06K4%JV%N7B)B707K8.!84R+,IR-525
MN(2KR*/C+N)QK'#"P_/@X16O 'OA$CO,6VB)I8:V,+-TAJ6U"ZP(T/9LX+H2
MJCW=?>'IZOT<L%T)W<Z$9#=[#_@Z^R'4*Q11A.P8IB\F(!(1ON(B'H@@+S\$
M>ODBV#< (?Y!"/0+A)>[#P';!6:FMC RM(*!@25,3.Q@8^L)=Z\(!(>E$YP+
MU<<-R4?))PEV5E@L0Z@U,5]7<WTC\[V.%6;5\\CA2:DE*"YK1-.ZO=B]YSCV
M[>W"YHTMJ%V^C8TZ CGWC1?+/>$Z+"('X5&YB(SF-#*3@)V%[,P2K*I=@[T[
M#Z"=0'/T8 MV;=J&#?4-;-S48F-=+3:MJL,&SJ\H+D%R5#2<+&TQ=^IL3'[C
M/;S].X'K]S%)X/J-&<IZ/>7])9@SUQJF9I[\L\0B.[L<M3(D2$T#BHHJ"0DK
ML6/'?@P,C+)1_90-6;$0_4DU:'48?@'6NG3 UJ!9 ^(7<*T#]D2@UO4"K%\"
M[ D!C>1X':ZET:U)K+KBGOYG_/[W?R&4?8O+A./V]I/8M'$/5M5M0N/J'=BS
MKP.]IR[ATN6'N'+U,0'J*H'Q-/8?:L<^ MO1]A,$K 'E2BQ#>5VZ*I&G'U*/
M%&C?NO.8T/&$H*%9I?\:7,OZ%]9J33IHZ]L$5$2Z^ZV^+/"B6P!%"ERX3N;%
MC5;R6*S8$EG["N%LUZZ#R,^I1'9&!9I6[\+Q8X,8&"2HC=Q$W\!5=/==0!?5
MR?ON[+VH+-=BI6YN'29P#*/U&.&9$'V<@-U.J&XCC+9VCE "V6?4V-=M'2-H
M.\Y]CP^J(<PD&%QKZTFT'SM)B#NE+.GG+U["S5NW\.#A P778L$6J[5FQ99A
MNC17<6W\:\U%7!-AZR< 6_IC/R-L/7LFEOMGZG[%<G_[]@.6ZPF4E=7"UR<"
MMC9><'$.1#S?B_4-.PG^IPG'EY2Z3IQEVH=QE&F6CP+'.JC. 0(VX;IWE/N<
M4]T$>D^-J3[X72=&T,%MG013B1PO_>]/#URD+G"9L'JP'17\;X1%)<*1[QL'
MOF\DTGA1R7(VL#<3VMCXYCNQG._$IJ9M!.53A.=[S(]G"J[%O?OFS5N0X&3B
M"G[U"@'[RDU<)X!?OWX'Y\8NJ4!H!_8?P8[M>[!WSP&T$0H'^D=PX?P5POA-
MGN\.;MV\2]!^0,@6CP "[+.OE6?)@P>?\KP/<.;,%71W#^'  7$-WX,5*]8K
MP%ZQ8JT*=";>*",C%Y@>E@N?5QG*ZP8!7\;3%NNU]*,7H-;A6@+RZ<#]MP#[
M;\&U#M@_ME#_V&U<LVR_L'S_&*[YS"MOE1> K7NSR+M"/JK)NTGV/\>\$K=P
ML5P+7&_?L1='N-S<<HSOLSU8V[0.ZYJ:L&Y- U;6E*(D7^)9Q*(@.QH%.>'(
MS?)':I(3HJ--60\MYGMX"8'(C.]U!Y:U!^&'@)U+:$YS1F*"(^*B'1')1D2@
MMQ5\W2S@[VZM I[%A;DC.=H3J3$>2(EU16J<,^6$I&A;Q(19("+8A&!NQ(8(
M0=Y_,7S]YL'39R8\?&; T_\C^!"D_4()U(3KH*CY"(Z<C\"P.? +G D?OQGP
M\Y^%P*!YK&<%L)>QD6.$\ B>-\J.@&T+9V=S6%J:P<[6#I'AT5A>68NM&UEG
MK%ZK +NZI! KRJB2/-049J,B-Q-U9:5J'.S1H7[<N:'UP7X.V!?/*A?Q6\,C
M&.L\@;Y#K>C8W8S#6PYA<\,.5)6N9IY4J%@JD1+4]"7 ?AFL)T*U+ED6")=V
MB]Y&F2AIIPCP"AB_#,DZ2.OS.F3KD"R2]?JQ^O$3 5MO!XED63]6G;M,K- 2
M$9S'5TO ,FU<ZXE6;'$37[/NH-)$T);]Q'HM06,3D\L0'5>@ZGCI#A8678J(
MV&I$Q]<A+JF>^<!&<C;;%45L>TFZ"AO8WJA!8&0I;'V+8>2Y @8!FV$2V:(B
M'QOJDFC0E ;8)[ L1D3H>NXVKH/U1,#6HTYK>AD&_H_^$R301H 6U^!%+*^%
ME$R7Q$L LW%Q>6E<-_>5H%L2U;I+DXS/3)E0IES6HUX_'\O\_Y3_3TK@56D<
MG/]=&C_'3YW_WR(%V+'#U%F6L6A$K1,O!.DV8"Q]\:,&8!EQ&K:1G7"-/@B_
MI(T(3U^)N.P*).>6(2.WDCQ'ILNL0T;&*O)=@P)LB2">5\AWF!C\Y%U6U*A&
M-O(+2,+"Q;9X];5I^-G/WE36:P%L"7#VB@0S>W4*7G]-+-;3.)V*UW[W/E[E
M^M<(V.^\]3X^_$"ZY<[$_'FS8& X#S8VR^#F9@(?;S,$!!"F0RP0%F9)F1.T
MJ6!M7.MPUHOAH8Z40+:=4EB(/4*#[! 4(%'#K>'O8TG MB1@6RKKM:N3T7/
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M[&W8L E&25$QUJY>@Z;Z5:BM*L>*BF*LK*3*"K"\.!=5^=EHK*S$D=V[,$;
MOGW](JY?EBCB6A]L&:9+BR(^I(*<]>P_H@#[R-;#"K KBQN1FDIXC)&A*#7
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MMW#^TDVNNT'@OHG+U^X30I[AT9//"0"$/4*AN.>*7H9K<1__6U)]L,>!^J<
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M+,MXU^:4!8("Q)IM^QRPPT,<"=[2-UM32*# MH,*AB;6:V=[ V2F1;#]TTK
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M"E1F!E\O$WA+P$XO(_CZR-C6)DH"VP+9P8$V;+=1_C8JZ%F0OYT"Z] @QW'
MMH6;DS%<' R1E1Z)OM[_(L 6V! 7<1FF*RPR [$$[.34"@5L^A=?O?)ZN0(3
MZ6[A^M=?J6CTRF9BA:-#=C'!3RHE[:OL5DY928D5NTH;CJNXK!Z9N1(E.Y,5
M?@SAFN 9EXR,7.EGO)+'-J*2(%Y9O99@O>%'@"UP+6-DBP2R2UF!E?.A*"G9
M@-R<!L3%E<//+Y7P%P4[AU#8.X7"T244SH1--\]0-B;"X1\8A9"0:(2%Q2(T
M)(J%%@I?;W^X.K@2L.U@;\F&DY,7@KR"$.(5C%#/((1Q&NX=HES$H_S' 9O'
MA?L'(=C'#WZ>7O!T=8>3O1-LK1WX\#C!R=$-+DZ><';TA(NS#SP] Q$8$HO8
MI&RDY90CNV Y<@KK5. 2"2B@6?_E*_M:]44I,[MA'*['AR;APYZ648T4&;XD
MH12I2>7(Y;8J5N1K&O81HIL)AP=16;$.22SCD) D1$>E(B^GC #=B'6-Z[!F
M50-JJZI4'[J&Y<O15-^(AMH&Y#/O@P+"86IB@YDS%^*]]\12/1/OO#L+;\F8
MUV]S^LYL]15KUFQSV-@&J,CNXE50LUQ<]QNQLJX)>_8>5)9KL<I*%&YMN"V!
M8='? ]8B#:"?!R)Z#M83+=0OI&T7=T_-PJU)^EQ^3I FG%&??OZ,T@%;7,6_
M5L>(]?JSSWZ/V[<_00<!2L8.+2GFO:S8AKV[NW#RQ$7"QT,%V*/GV!#OOTK0
M&L+AYAX<:N["T?:3!+%AC$H?UYMW<9L@)-(@^R[&+MQ0P:[.C%[%I2MW"" "
M&0(#3Y4^?OAO!VSI\WJ7L'*7@'WGP<=*,B^Z]_ 1[C]Z3%#5(/O1)X0/ZF/"
MMK[N,>'EZ6>?X_.OOL)WO_\]?O_==P2O)P3>\SC>T8%]!PYAW\%F!=G=O4,X
M0=#LZ!E!RS&"]=%3.-32CY:V$;2VC:&U=10M1T=PA.L.M?3B<&L/CK3U$+1[
MT=HY0, >(IR>)EB?P.&C79P_B<X3IPB=O0334Q@Y,XPKUR[@SKWK3-\=/'Q"
MN'Y\GWDC_:TE.)L.V-I8WKJ4^[?<ATR5!7NB--!^-@[:3QY_AL>//B-D?X&K
ME^[AT('C*"]K0%IJ*4&R$=NWMZ*O[Q+.G;^O+-BG")(G3XVJ@&7'NDZCK>.T
MLL)WG1A5("U!X'H%JGLO*<E\;Y] MBP3LGLN$*S/CUNT-8F%^^2I,?7!HK=_
MA/DJENP3V+7W")H(<!LW[U%]_B]=NH4'#YX1J)\1@OD<W;BG0%A<Q 6P[R@+
M\6W-2BQ#=1&^10+*,A57<.F7?>W*+77L_7N/E1NX]M'A2R6![$</GRGK]0W"
M]>C8-71T]&/;MD,$0<)!,=]).=5J'/NZNBTX<* +0T-7"=8/"??R7[B%L7/,
MKPL76'97"-G7^5S?8ADR;?>TOM:Z9X4.U +7$ZW8$P'[7\#U!.D>%R]OFPC=
MLDW.H9UG_,/+.&#K?:^?NX=_(?_Y[Q5@2ZP%&9-_<. <[[$5&S;L4!+0;FGI
M5('PUC9M147Y2I0451 L"Y 0'0\?-S=8&QG :.Y,:AJ<S18C-L 9%=E16+<\
M$UM7YV+7AGSLVIB+K>O3L;8Q#K7+@UE/>;*.=.0[WHZ@Y(BR"@\4EW@A/<,9
MD9%6"/0W0["_%6+"G)$4XXGX*!=$!%LC+-"$<&V*1,)U5KHCX=8%Q?E.R,^Q
M1GJ:$>%\(:)CYB LZB,$AD^%?]@'\ O]@% MH/TAO(,_@%?0A_ 2RW8 @=IO
M!KR\I\'#<RK</3^$IS?WX_J X%D(#E](L%Z*T"ACA$2RT1-H#%?/I7#U,&"]
M:</ZQ!WQ<=Y(C/-!2KPOTA+\D9$8@,+,:#14%>/@]JTXU=6)\R-#N'+A+"Z=
M&\8% O;ET4'<(FS?.3>*<]TGT+Y])PZNWX+CNXZ@=7>K NS,E#)$160C(BI7
M>9^)55H^[NOM#UW2!A%)>T3:*P+5 M=Z6V;B,=(F$;"5]HFT662=ODV6!8#%
M$BWM%0GR*I*15'3)LD"V[*>W=WZJ[:.#M4"U;MW6+=PZ:&LB9!-P=<@6R;*X
MBPM ZY9LW65<0%NFLDXLV+)_7J$$(:I%>LYR)&42LE/+$1%?C)#H @)V+B+B
M\I"<7LP\*F-;H RK5E:R75"'K=LW8,ONW6C:?@"5ZPXC<V4SHBO:$5#< ]?<
M/MBD]< D@6 M[L6Q'6RTGR"X$:P(!1*=6H/&%W!E)"((RIC++\9=_BDHF @,
M^O++ZR?JY7W^H_JI:_PU_?2QSS\F/-<X4/ZD>,Q$_>C\XX#\(^FP.?&:$Y<G
MBMMXC64Q$LQJF% U#)/8(1C'G()Q5!=,(@G7,4?AEMR*X-Q6Q)>U(J>V#55K
MCZ-^:P?6[CB&IJV'T+!N&VI6;4!^]68DE.V#7WX[[-+'/[(0TE7YQW8_+W]M
M""]")I^!OY87?Q=@__^<),\GP'6LN&&+-&A6^2+Y,Q&P97E\?^V8<8U'9Y=S
MO;!BCY?IORI]7Y$\8U+^0]0@S]W+Y^ XGX-#L(S?"^>4O?#//8+8\J/(7-&,
MLJ8#6+US+[;LWX$M>]9C[:8&U#?4847U*E25-;(-).\QOM_$-;R"G#7^#JRH
MDH#7JY&87,KW?R3FS+? [UZ=-AY%7"#[=_C%+][ ;W[S+MYX_4-,>F<F)D^:
M3;B>C2F3YV#&M(68/V<9%LY?QND"S)LSAY ]!P9+Y\+4:!YLK); S=680&T.
M'T]3>+D;*\DP7+X^)O C9/MYZY*AN,RXC?(TX[(%@OQL$3INO0[VMT> CRW<
MG4W@YFB(G,PHG.IKPU_^XX ]$:G_\J,E_2> W=;>PTJE&A'1F8A++%)#=&E?
M?<4%7*N4,K(TR;SVU;B>E9& M>;V+16+IG]9N6B5F*Q?HZS,9:Q4JFHVLV+8
MHE2]0K[02I^C=<@O6H'XI#P$A280KF,0%IV,U,P"%)75LI)9PX)=JXF 747
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M!=@U->NP:]=1IGN,UWK -'RB^BE?O"0?B\ZSS,9P_N(%_M^O\WF\RV?O@8H
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M8V8"J.':U)K+-KP?J[!FV(;N@7OL+H2E[4):\4Z6ZV$<;NW#Q<LW5?OH1U#
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M>5]QA[F>Z6*Y&,N]QK7PN98T\UF0#S_R7#R?\EC"L]K.9UP=%WV((,_C$@[
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M>@47+TIDZ <*H 6N[]W_SP=L9;VF9%[VE^/E?#)LF)23#&TD5O5SYZXIRZM
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MV0AYZ9$X?5*"G/T'Q\'^>P&[H^.4@M[$U')D$% %Y+()<F(M%9"3BDHJ)BT
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M/F$N&\%960A*3T5(2A(2<K-0W; 2[9UM?/??82F/6ZQ_XO>G/_T%$MQT<&0
MF[9O1&8ASQ4?#9_H*/@G)"$X(QO^:=EPC(B#@;L?C+T"F>Y,Q!77("JO##YQ
MJ7 )C8(;Y16=!+_X3'A&I\$Y- D>G 8F%R HI9#;,F$?& <KWRC8!D83X)/@
MDY .G\14>/#>7*,CX9T0B_"<=,06Y2(L)PV^27'P38[GN@S$%^<CJ:P8B51\
M"=O]Q46(S,N%:U04#)Q=L-3)"0ZA883,3$1DYR$\B^?(RD%(9@Z"TC+A%9<$
MN\!PF'L%P=HO'"[A"7"/2E93^X!(V 5$P#,F&>'9A8C,+4! <BH\XV*8OGB$
M9F8@IJ"(*D-H>@'+(0/ND2EP"DV C7\T++TC8.X9!@?>7V!*/A**EB.NL HA
M&?D(2<]%5&XAHO,+F)9,>,?'P85I]DI,0GA>$:(**Q"0EL\\2(=70@;\4K+A
MEYH!WY04^*6E("0G"[&EI4BJ7,%\6<&T5",@907+I0D1N=NY;B]B\G<B,FL#
MHK-7([MB'=9N.X@3IX=P[^-[^/T?ON1?7OHA"UP3MM6\]C[XTP\$;-;A;9TG
MT;AQ%\J6\_U3P?<A.4XLUT54/M]%J5G+63>D8:FA*]Y\9P[^\6=OXG_^K]?P
MLU\0J'\[&;]^91)^]9NW\,M?O89?_?(U0O;K>(W /7GRAY@Q8PX!6X-K8R,#
MV-@0KIVMX>9F#7<W C:!V,O3'/Y^5@@-L1\';!L5)=S;Q9!PO0R^;L8(]K%
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MUKKEFOLKJ_4$EW!*P?77GRO7F*^^D7[@!&N)&OS-']D0_XJ <!?'"3Z;-A_
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M ELS2U@9F\/!TAZN]JYP)5R[V+O!F?-.=BY*#K:$8\J9ZSU=?=1Y GR">*Y
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M_,,7(BS6"#'R[DJVY[/C@#!"OJ>/"<QMYV*IT8<P,)T.&\=%\"!X^@99<TH
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M'[V%^8NFPL1\/JQLE\*.Z7)P,<+_E[>_CJ\C2?.\T3_O>^_=?7=V=V:VH;K
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M#YUBQ3"?#ZF+A?$,-$PD8+</ #;5+NIBA41U3!+0UB20+7VB-: 6%VX95D+
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MHSUA2I:^XV$\+N&MS$3@-1&232BOCT=U<Q+!-YG G(C<LD@D9P<@+M6']V)
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M1XR&TX0)Y"D#X=H?04%>Y"<O<DT0TB7_$:9-T5Z(#'<C$WG '&M 1J($,R.
MFXV<:K"=3=C.20U50W,59D4J%_'\]"@%V/EIL4B+#4=R=!@FUE7C]/$C_WF
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MMPW;W]^.=8N78F'/9,SMZL#\R=U8-&T:ELR<A?G3IJ.SJ949,!?A05'P= V
M@ZTW+,:X8\1P@6N1*RM/-XP:[0,GYPA$Q^2P(=#)Y[=<6:X7+=F K1_NQ]4;
M#U1_ZQ=??X]G;+P__NA3@O7'>"@-; FR)/U /R=(OR"XL*&OHA</@/7K^H\!
MMN8NKL.U6*V_^58;U_H[@O7+E_]"N/Z9#?$_JND//_PK?OSQS]SG1UR]_D#=
MP\RYRPC7\[%@R7IL%;@F3%^[]0S7;S_'I6N/T7?V%N'Z$@Y)5.B3_>@]>Y5P
M?0N7"8S7"!;7[Q*H[Q$P[Q,XJ=L$;1VP]3[9KX.TS+]RY]9!>S!@OP*4-TG
M]TWNW(.ENW[_1_1KR-;ZC^O7J5NQQ3JO0[9,]7D-L.^J,9$ENK1,)0"< +9
MV@U"MNCF+;%DWU9 K4F'[)O*C?S)LX\44'WQQ7>JK_"9,U>Q;=L^+%^Y&6LV
M?(B#Q\[@S,4;V'OX%!:O6(\9<Q>KZ)C+5JX;T'JL7+,1&S=_@!V[]N'0X>,*
M;*]=OXTGCYF&SSXE@(G+\QU>-\_'])9T&PS8XOZ\_\ 1;-FZG="Y$T>.G%*
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M/R6P??89/OG\<Z7_9P%;X%KZ=$OPLY?X6N#ZNQ^4I?I;7M.WWXGE^F=\\[4
M]L_X_OL_XZ>?)-[ G_#PX6<$G=.8OXB-F"GS,'/>2FP1N#Y[$]<(UK<??(XK
M-Y^A]]PM'#AR 7L.GL&!H^=QK/<2>L5Z+> HENK[!,K[#W"+TSN$M;N$# D2
MH5MS10*> MFBU_MF_WN /5@ZI.C6Z]>!^G4-!N8WZ=5V?[G/ZX"M]?_6(%O
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M+&9%VZ/@NK5U,N;-7Z:B9XMKO)[O'CQ\I)[3E:M7F4Y7</G*5076\@PE&)+
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MR=.G? [,NX2A&[=NXMJ-:[AZ_;IR[]<BADM>EL!F&EQ+W^M? [9 M>0C+7Z
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M0_MG?/?R7SC]DX+J;[_Y$^?_3+ &M_E70LK7.-UW'>O7[2)0+&=^68KE:S[
MOB-G<?[J UR]_1P7KC["2;%<'[M(L.[#AWM.8O>A,SC:>QE]_3=Q[@K!3%S
M'SS&;4+%K8>$9XF.33!Z\/B9"LXE\/PJ()A ]H,!X!3W:&V\8%FGNXOKTGX+
MF CH_<?A6J3Z]*IYV?YO[*.&=-*D [;6[UJN0X-LS7HM_94_X7UI@"W7+Q'$
M!;0' [;V04$@6P*^23]TF6IP+7"I3Q5D#P#VS0' %KA^\$C<PQ\3L#^&1/@6
M]_]OOOE>?4QY^O137+HB7@6]V$RP7KUI.Y:OVXH5Z[=BW?L[\,&N@QI<G[V,
M?CZG*P+"-^[CXI6;.'3T%#9NWH;U&S9CW_Y#JD^V!.BZ<?.6@D1)9[E7L<[+
M/<BP:^(B+D&]M.%KF!Y,AP>\=X%IM9SW\1'SO>1%@6P9LFK7G@-8MGPU9LR:
MCSGS%BG WG_@*$']JDJ7ISR'I+58Z!\38B6Z]\=\5T1R#7(M][C=74HB8#_B
M]<@XW@+2(@75S[7Y3_B,/_U$ZSO^*^NU NSO6:Y+-PF^ ]_^"S[[]#M<O7H?
M.W8<P;RYK! GSB!P3D%'QTS,F[\"[V_9J88WDS[5XJ)_]_Y=Y5%PX_9U/B?Q
M+KB%6W=O$[COJFM4'P)$CQ\SSS,OJ^'57N57@6OY,"/]OC6O +[K$GA-P36A
M>F!<^K\$;'VD '%O?Z7!</TE?PM@ZV[A8KG6X5I 6]+B[MW[Z.WM4Z[ABQ<O
MQ90IT]#1WH49TV?Q_=^( P<.XYARWS^,-6O>1T_/+%14UB$C,QNQ\6Q<188C
M.,R(@"!?& *\X.'M@O'V5@JT@\,""7K-V/;A-O0)1/?WXU+_><TMO/<4^OL$
ML@G69PB79\[A$N?[>2T73A'&^TYRW0G"]G%N?P1]Q_?@P.X-6+]Z.J9/*4)U
M12 RTJUA3AB*)/-0I*>-0E:F!?+S;5!>YHBZ6G=EO6ZH]T!]O3M_NRG(KJQT
M0EF9 TJ*[5!28H^R<@)OI2.**QR07R: +7!MH^ YLT! FG!-R32SP$J!=1:G
MV52. #9!/;>8(%TX5@W%E9XW@MN,YC&L5+3QS%Q;F%/&(3+&"I'1/'Y>&&;-
M:L3! YMQ_6H?[MV^A-LW+N+*Q3,*L&]<[5=P_9"ZP;0Z=> @=K+>VK1\+=Y?
ML0G;UFS#JOEK,:EI*N&Z'B6Y-2@K;$)%23MJJB>K8#W-XOJH _9$#;!UN-;A
M5^9UJ!5P%2NVP/;?"]>#@?GUY0+4KUNO-<@>L&)W:Y"MK$"=2]0UZJ O%FN!
MZX+BB6HJ@"W0+>M$5353U/+<_%9D9#4B,:F&Z5JD -K9E?#L$$80#N4T' Y.
MD7!TB8;3@"8X1G)=",9:^F'X2$_6X1X8/MH;8ZP"8$WHMN<VSA[Q\#2DP&!,
MAY=?"B:XQ*CU0[GML!$2R-07$YQ"X>5M@I]_ MLW283X.#@XAV"DC0_>L?#&
MNS9!&&H?AQ$N.03-6M@$]\#>M C.*6OAEK,5'H4[X%6ZAP!\ #Z5A^%;>12^
M%2=@J"342E"RBCZN(SR7GZ#$S9L07"G!Q\YQ'55^3HTM+6-,2S]I@5]#^2GJ
M!/P(Z7[EXK8MT^-<1L F,"O)-ISZB3CO1\A6XOZ_S%>(^N!/^0F EYU44.U3
MM \^O&Y#X5;X%VZ&7_Y:>*3.ATM"#UP3.N&=U 'OQ$:X1)9@G)\$; O&>[9N
M>-?:'N]9C\=(>WO8>WK $!J$\+@H1,9'(3@Z&'ZA!A@C#3"E1B"S.(G0E(:,
MX@2"'-N'<;[P"7.!1Y 38=R5\UX*Y'Q"O> 9X H70K:]HS7+FS%P]>([QNUS
MBDPHK3&CA# M ;7RRF1LY CDEXN[L!GEC6DH)$"GY$4A)B4 D6:>.R, :<61
M*&I(0G5'%H$W!Y6$48'3G*HH F<XX3",D!C$[;T1&.6&P'!Q#P] ?&(4TC(2
MD)67Q'*!X)<3C+AT+T0G.R$VU8709T!)710:.U,PD4#=-2,7DV;EH8/3%L)U
M]42";)V)YP]&#/<+,[LB/-F=,&M0UN7XS$!"M"M<C=9P#;"&D2 =FRZ6YDBN
M"T%8HC>7.2,DP4U9OPMJXU'9EDJX-A-B>>UEP<J*7]1@(EPGH5+.Q_G,BA "
M/<O0TA!EW<\LX_WE^2,IW\CMHU#<D(C"NGA>5SABT@P(2_ DU/O E!9$V([@
MN2,0G1*L+-2^H:[P,#H2KB? )\0%03'BVFWD/001V@-YW!""=33RJV,I/H]J
M E\-Q6D6KRVS/!RY5;'(+F=;/L,(8[0K J)<$6'V5^<2T,XJ341.N1GI17&\
M=RXC8!=4QZ"FC8#=F87JY@SDE)!)T@B7!/L8<R"BXOT1QNL+BO12 >&2^9Q*
M*LK0T$S ;IV.%C&0M@E SR+S2!P&EC--XL$RA?/3".(ST= JZ^:@2:S=[8LP
MD656IY1=5!?9KU.@NDL >R'7<4KNZ_@%L%<3L-<, +9FO1; [NC2 %WV[YXL
M6HR)'3*$\"26:14("3'#R<$?8T9.P)!WK/'6[T;AM_\\%/_KG]XA8+^+(>_*
ML%TVY"A7A 0%D'W""=7,A\G12$^-YC0"20DA2(@-1%*L6*8CD)T4@]P40GA2
M)!F-^8?ID1+KC[2$0&0*8)L%L U(B"*4\WV,"?&"*=0'+;4EZ#MQD(#]\P %
M_\?^_C[ ?OD#CAX]3?A=C)J&J6@A4$M_G;:NQ6CF?#,?5LO$N0JP]:!FNEOX
MK+GKWFBYEO72-UNVE8ATHBG3EA'B-5=OZ4\MOZ=S&S4^-B56[AD#(*[Z6PM0
MR[9B,1^8[Y;]^:#U(&<:9&OJH71+MDB6B3M[0_-,5(F;1-T4-+;,4AEG&M?-
MGKT:/9,7HK:Z UGII4@T92(I+@LYJ44HR:M">4$-BG,JD)M1@O2D L1&I2$H
M@!60(0K^_K&LB&)9(442LD/@Y<%"U9>-LD"Q/"<C*3&;F2(?&90Y,8.P;%;]
ML,/#HA$9(0 =1YAF@9L@%NL$I=C8>,)U+*)C8M0T/CX1R>94I*5D\/IRD)]3
M@*JR*G2V=&#!C'G8N&(]=K[_ ?9OWX$]V[9BV]JU6+=XD;)>KULP$UN6S<76
M%0NP9OXL3&MK11&/$>8;!N=Q7A@_Q@/68[PP=J0'1@UWQ<@1+A@SUAWC[ SP
M\3,A/;N2SWZ&<J&>U#,7"Y>LQ;Z#I]C(?JK ^BL"K?2]_N3SK_"<#?R//A7(
M%L#^Y)4%FV#]RH*MN\)JC>TW ;;6P!: _O<T&+!_($QH?:R_^TZL5W^B_DS]
MF]+WWX. \6]X]O1KG#US$YLV[L.LF<R_TY=BZ8HMV+6_%WWG;^'\Y?LXTW\'
MAT]>5B[A._;V$K![L9=P?>3D1?2>OTX(OX<KMQ[BQGV!:X(8 ?L. 4/@^O[C
MIW@D5NA?+-%:U&V16'FUX8UN*0F8R3(!50'K7[N*OW*IU:7#M8#9Z^GW[TOV
M^5O[#09LL<;J@*U9<C7)M6E#-4E$:6U,:PVRM8\(&FC+QP31O?L"VV+A)*A1
MXD8L@;!T*[YFY1;0%H@3"[: FS9,UZ,GCPBAA,KGSWD]XE(LPTTQ?T@$Z4^_
MY+5]CAMW'N/$F<O8NO,@EJ[>C/E+UV+YVO>QC;\/'3NMNB_T7V9:W[R/Z[<>
M$;+OH?=,/W;O/80//MQ%P#Z,L^<N*>"5=/WBA>8](1\7Y-H%O 7 Q>(L("W
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MC09$A4MPLV#$R[L4%XJD>.9O3LVF8"3%A"(U-@SI"1'(2(P@5(<@)=Z(E+@
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M4I M@;#NZ5;MN_>8#H1'ZMZ]>]R.$/GXL>IO_(RPIH)X":@1[I_SNCX66!/
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MEW"1S,N'"=&7/*]FP99U&DCKZ:Q+!VL=N@4V=?@6N-:W$:D^WNH#@DB 6]*
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MAY-QD@G9HJ^^_!Y??/[=+W"MZ4N"GO3]UF#J31+8&NPRK$N6:>(]2. R0K8
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MS,IIFH+BZ3/%:KV.<"V O1YSYF\D5&]6@#UOX6;"]09EX=;< EA!=6M?/S3
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MR :Q2"N(/@JWRL,#.@J/JE-<UDO)E*H4]1*P>P>&X!J0#MC*)7S >DT92B_
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M4S6WU\0>2\PQ[[-8J F\XH8]'; E_EK])D)P5O*Y9BDP+1#X2@!;/D^M?TE
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MPRI[@-L,P#J[GW#=R[_IX=\2SJ=<ONVD/!<!6BS4SA0G0K?*!"[GP-]<,B_
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MP9;LT-=N]&'5ZNV<0+I45O"W@,W)9@6%H-W*[P+7<C.E/EIIN;PY7L&)3LK
MK.'$M4ZY;LDV4A=-9?M<)F6^MJ.-^Y&EP+9,9/+&6"8KF02G@[6(=@+40K56
M9"*4OZLC8)=7L/%*EZ*BLAW+EF_&KMTG<>ER/V'H(97&I\HJ(S&%4D9EA K
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M@V^T)3S"C"EF< TV4TG.S)ST8&BC"ST+?1A9F\".L!T8XXSD/&]DE04@O8C
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MK>+:"%0TQ5!B%5P7U80BJ]07"=F.;&-C]JV%2@)C#!&3;L,V=V9[>_ >BF=
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M%" [M4A]#PN*AX.--W066F'61P;X@&#]P1]T,>,]/4Y(AE@PVQPF!L[P]>+
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MXS<O:M3+&@77G^%329['>S,=L+7/Y'2P_D>NX>\^X]-%"],B8K'6BL"U7)O
M]<\<AZ1TG#P+_?WCN'SI%DZ<N(!]^T]@Z[8#G*.VJT2&+<O78'GG)FS>?D E
M-3M\["QV[#J CL[5:&ALP=*ER[!QXWKLV;T#FS<0C(JRX.YLC<7S/\3B>3-@
M8C@?5A9ZL+<S@ZN++<)# PC7A=BS<PN&^KOQV8LG^/*S%WCQ^!X>W1VA#./I
MY#!>/AK&Y\_&\?+Q$/ING<2.S:VH*H]#ABAQZ?94(IRHJ/AP'@M&8TLHEX$H
MJ_*D(N.$K#Q'BC.5#2_"9B JJV+0UI:#31N;<.S(%ERY?(+CRU5"]DW"]6WT
M]=WF/;B%@0&V)V5XZ";GLA[<'>,<UGL9YT_MPI8-]6BN3T1QOC?24RVHG.@A
MC9"=DZN#HF(#E)0:\ECZ//X2PB!ANV@A%;#%5,9$=)!;I(NT;!W$Q,]'9/1B
M*CW6J*N/P:Y=+;AV=3]&1JX2K&_SV+<X?][$",_G[F OGHP.*^OU_9O=N'7T
M!(ZLVX(M;2NQL;43VU9NQ.956["L825*I41E3A5!LP%2MJ6$\W<1I4#"IBC%
MG!LK&]82KC>AB;I&J[R(%["E+*4L7[$;R]MW*>MUD^@@U#4J?@.NWP5LT2.T
M\/RN:/4*[>__GO5:X%OV)\<4EW"!ZMQ\*JE<YE,*Q7I=W*H!ZQ*"-6&[N'@I
M[_]2!>$I&?4(C2J&DT<*],U#\,D22=CECAD+O?"QCC_F&(9AH7D<%MND8[%C
M 1:Y56*)3PL,@CMA%KT15@D[8)NR'P[I1PC5!-N<"W#(O0S[7$)UKB:#MW7.
M+<*Q!IXEEEJ3>&PZ8,MG+6!W:[8C3%MF$;;%HBU9O[G>COL1EW*'K*N$]RMP
MIKAE7X9'U@6XI9V%4](QV,7OA6W,5MC%;H!#_!HX)W;");$=#K&-, TLQ@*G
M9,PP#</O]?SQ^R5^^-T27_QAL0]F+)+,YT[X<(X%WIMI@#_,7(@9A.I/%L[#
M?-T%!.N%,#!?0OBR1&2<#_ND#SR]K&!J,@]ZNA_#W%Q'>9L$A@0B(#0,CA[>
MO)]6^&2Q#F;,FT=PGX]92Q9AMNX2S%RR .\OF(T_$+#?7S0;,_468)Z9'HSY
MK#N%^,(K)@2>$7YP#W&'=[@[PI+\D90;H0 [,2\,P0D>< FT@+6[/JS<=&'C
M:4@8-X"1_1(L,9M'D)?LXQP_O*P1FNB#[/((%-='<NE/V'9"<)PE?,)-X!%L
MJ+)&!Q$THPBIDE4\,MD'4KHK(M&;\$5X*XY!3ED\TO+#"7RN</22^M"+X.!A
M@,!(1^7JG5' <\L+14R*K\HF+N[< M]A<6Z$,LUW_PA[> 99PMG'! [NQK!V
M-H"-LR$\_&T0G>1'N(Y&7EFLBL\6B[-85P64!?*\0S1EL\P(V&8VNC EV)H3
M@*T<C>'J(]9C3^241J"L(1$%E;'*K=DW1%S;32@$^@ ;@K8C(=J)(&S'W^P1
M&N.FXL?E//T(U\'1+HA*].6Y!"$DR@<N7G8P,M=3&=UGS'H?<Q;.AHDE]^?N
MI #;QM$"^J8+V2\^@8G-0KCZFO,Z79"0X:<L\=F%@=2]@U%0&DI].QR%9:'(
MS/-%0JH+XI*=D93AH>*MTW-]%(3G%LGV0<J"G9#NRO.S0D"D&4+CK15@%U:'
MJ=CT@BKNIUAJ74LRN$C4+(U#17,D,HJ]E%MX2+RILEZ+^[: ;U5K-.J7)Z*Q
M(PW-G1FH6Y:"PJH(0K"W*A,6E>S&^^S%>^ZGW, %J,7C("!2DJS9*,^#X%A[
M!=>1R>*N[H;,(E\4U8:AHB5*';ND(525YQ*+MM0OEQ)HF45AJ@9V?FDF"DKR
M*66$Y5KR2A.*2UL)S1H7<'$)GVZUEN^RU,*V%K*UL=@"V&^%,"U 32FO7$7>
MTW@-B8CGLK)ROXG;UI1-%O=R@>N*:DFFIDETEE_4@NS\1F1(''96G;)DIXJ[
M>#I!.[T*R6F5RFT\.;E"B;)BI_X]8.<HJ49>1BERT_*1E92![*0T G<Z:O/S
MT%%9@6W-C3C<O@RG.U?@8E<GKJSNHJS"A=6=.-:Q% =6MN+"@1UX>F\$^-L?
MIRCX/_?O/PC8NSCIK.:DH@%LL5Z+)5HF(9FTY"9/AVOY+!.<3#XR0<FDM'S%
M+B7:"4H[8<E2MI%)3<!Z^EMF62=++6"+O%VOJ8\MM=?DC8F*,:Q>AI;6+FS:
MO!=G"0*#0U*[]2F5VT<8'[^OK(Y2Z_KNQ#T*X7E, ]B#?7WH[R%8]'1CH+</
MP_W#&!NDPCDX@=&!<0SUC6* 2NA _RB5Z3$,\K?K-WJQ<\]A=I8VA$:FP=4S
M$FY>L0@*S^&#7(WTG"9V'.E TI&H,)1+)G%"MEIV4+EB1Y.W0-()Z[K4FYXZ
MR;37N(:_M5/AJD=L4I&"Z^BX/(1%9L#+)PHN+D%P=PM!D%\,HL-3D!B;B>2X
M+"1(?'9H$OP(X#86[E08+3#S0WW,>%\/[Q.L/WC? !_/-('.(EO"-P?CX"3D
M9E>AH6Z%BB]OD-C;U5MQ\NPUW!>X%HN=N)S^]"<JOI))FM [%8_Z+3]_^\U;
M!5H+T-/A^ETE6T0+U=/E7P5L@1^M:!5ZV>9'$N//O_R)?_L+[MY_AH.'S[$_
M2?]9A?4;"16G;J"G[R[AX1FA^2FZ>^\JF#YZ_ JWO: R+ ML7[LQC)Y^PC4!
M1)(]B35:P@G>PK76@BSRDC#[#.,3#PCNX[C=/8C;MP=5XK.QL4E"F[A-2]*Q
MSREOLX+_EOQK@"U9KI\I@!8 DAP"_T@T5N7GW+<F'ENLQ5K _N[[/_.>_@F/
MGGR#VSV3V+[S))\W44B7*]"^<*D?@\./>:^>JWLEEGYQJ>\;O(?KMX9Q[N)M
M!=B7KO80R"84B(DE6K*F/W[RE-_E?@G@/U?K?P73OR7_#F!K2EMI,FIK(?OU
MYUQ^_K4"7XW(9XU\QN_:1'.:#.<:N!;1U,&6]A W_!<\5SE?\38@+/%</I?:
MX%]^0V#\4@&VQ!U+UG!):"9)O@0T!>@EX9GV.=#"MB0_D\SA4B=[_;K-:%_>
MB56=:[%CQQY"X&G<O'F;_6("CWA_Q HL("V@+7'8VGAL6<HZ<0T7Z_4C.;^'
M4A;K*>_)2YZ;0/848"O8_AJ:A(.2&X%P_>FW*@SF).%Z]1IY(2KA.2LXQF["
M]EW'<>Y2+X8GV#[/OL"CYZ\Q<?^)@NO;?=+O1]C6=W#GKKQP>*KZC\"U>E'#
M/BHUP5]]^EJ=VW31/HO3+=;39?IS_UN _7;;7P.V-N9:8JT%L'_\\<]<]T?>
ME]<J]\'ITY=QZ. IY4VTC7"]5N"Z?2U!: TZUVS%MIV'L/_0*>S9=Q0;-G*N
M:FTG?%6CJJJ:[;(2!_?OQI&#>["FLPU9:3%P<S2#D<[',%HR$]9FB^!B;X(
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MBGC$IP7".] >CN[FL',QAZV3-:SL;6%L:8U%!J:8.7\)WB>DSYBW '-T=+'
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MY;V1>U3*CB=+>0%12LB6SB=@+2GL16KJ)#G+4F3GU;%3E2$NL0!1L3D(B\B
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M6_E[<=E]_04!B/):Z@(3_L72^)HB\"1 >8D0LV'C-M[+!O;!&O:S-<KUNV^
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MP@"4UL41;I,(PZ%L(_9A[R6P]5@ 5S\]>(?ROD9:L!]9*LB.37=!5DD@^Y$
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MU1VNMG;P=W%":E0HFLORL+6S!8>WKL+)W6MQ[>0NW.T]AT_O]^"S1X-X\6
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M<+P?4@KCD%&:C-BL2'B$NO,W<P73<_5$##%'SP"+30G6;DX$55\$Q@4@B,]
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MD[ATM9=@?0F'CU_ $4+2J;/7U#J!Z]Z!.^@=O*O<H 6T;Q.P>[AN9/P1[A)
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M2 /8!.W,0B\D9[MPW^[\3' N"58O;'*YG\KF1#2NR$1#>SHJFN(AV<4S^9L
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MI3T*LMU06Q5&X,_!OCU-.'=Z/:Y?V8/>[A.X,W8-CU0,^3!A>U"!]CA!>V1
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MG@3N0.04AR&W. 1IN3Y(E-K5DKF<D)V0[L)^=&*?$YQSW)%=[(NBJA!EO1;
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M1K1WC!"J):OSF +M%LZK:UB+2BXK4%WZ&J[E:\0*-5\K5JX!MOI*S1=G3<,
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M^0JTX^-3"<RI*"HH1'=7*T9'UF#;MO7LFQYT=I2AM"0>&1G^A&PW K8CM^.
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MJPFH_$@LSYPOB<$$KL5E^S5@2X;P"1' _E3@^B.1-X#]*9>5=<0*K3)IO_P
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MN9]%^H06!W%O=8!WN#-< \1"948H78JY^@LP?>X\3)DYC\>Z -/T%F,68=O
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MT6R\-TN/,*O';<_A,2V$WNS%6+AD*<QM3.%%*(\EY$FMX=K65#1TYO*:I6N
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M>D[0T;*'*^NU FP-6I].E/!Z]DRS("K(ULE+<=<6D)7M_;Y,=O]6H/S19_B
M "16:0%L >]'8HWF/I\(* O R_'Q>'6 +3"N]O>K_?_>OF6^P+7$8$O\[1O
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M_M[>\/=T1T2 +])BPU%7G(6A_F8<(ER?/;@9%T_NQNVK)_'HWF4\>W2=8$W
MEJ1F*@;[&A[<.8^+I_=BY^95Z&LK1T5^/'*3@I"7&(C2]##4Y,:@C0K%\MHX
M##1$845]"*>#T%<3C!XJ\AV5X6@ND_U&H+8TCL"?@K;Z0JP9:,..K<,X>?P
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M1A@3""T0&N] T'%7%C^Q6*;F2EFF(/@3]$UM"8E+IV*A@1Z!>CZ,K?1A8FW
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M%]4%H(#@G5;HICQ0(I*E7C7GUTC2M$0>9R2?>[Z\/LX<C_+\D,2",B8]E?=
M2HZ<7R DJWY)O7B5^"&SU!7)!?8*L"-2S1"::,YGA"V?H3S^U%"DYZ0@O[@$
M)17U**MH0VE9!]_UA.N)#. EI0+9!._*+@)T#Z67 "V)SV09L7)W*M@6B[;$
M98OKN+B&5RCW<+%@:^6W=-9K 6H-JD5Z4538HQ*C28*T_/PVOH/E/5Q'P-[P
MWPO84@>[4^I@EW6AK&H%7Z*K4"+EN.2KM?JM ;9D$!7(%KBN)(B+>YC =0V!
MLK9E+>I:UZ&NC=+*%VN[N)H/H:5S&-5</BFI$OY^R03L-'9L,S8.[\#1X^=Q
M[-1YC(YO0T5-+:+CXPAB65BY>@WV[S^$T9%Q*J;5A.P0+%ML@3EZ2[!PWC(8
MZ)O"WL89P?[A*,XOP^C&S;AZ\2J5KULX<_PX#N_9B6/[=N+T@1TXL7<<1[8-
MXL#8 (Z.K\*E_2.X<W8O[EX]A9O7+N'&]6NX>?,&E>C;N"LQUW<?$K(%L)_@
MUMTGN$[ OG#]/HZ=N8;M^T]@W>@.=*_<2+BF$M&Y"DW=:SF]'FW+A]'>/X*Z
M]G6\(3L0&E,"9\]D6-A&P<@\#$9FA&SS<&W:-!B&Q@$P,/*'I4TX@D)S450B
M]:U%X1S \KXUA.M=RG7_Q8M/%50+8 M(2_SU%U]\]RO10;9FU9YLQ?XU2/^>
MO W8DT64]=\2#;1%81>(^8'P+[&7O^"''_Z=8/:52N8T,+"1@[N:@[H$E=6M
M6#^T1<53G[MX2X'UV0LW</3$>8+U2>P[<!R'CI["R3.7E+7Z^JU[N$'8^ >Y
M?0\W*==OBFOY367-%KEV[9:*E17W:5W")W&C%8NV!ME:/+6TXFHMUFH=4/^>
MO'C!=2DO7W[ZVS)1AUBY=E,$EG4NVW(,TNKV_1KN.:VY>+]2[LHZ:_1+J=DM
M4*V$L$[0$WD;L&6;(O+Q0',7%L 6 -.@6$2F)__60%L3W?]U):9TZ[XMO[6N
MS)=]JOT2ZL4E6>H\3PY1$,OM%U^\&:.?<_IS O9O6;)U(O#\3\%ZDFBN[MK'
M IT(9$LV>QFO,IXGAS%(JQOCLMQ'G\IY?<KM2/9S[>.!Q)<KR_BG7Q%V/\2U
MJW=QXOA%G#AV 9<OW<;3)Q^H#PE?\;[Z1L$I]_'55[S7OE3RU5<$=#7_>W7^
M[[__.2Y?OLM[>#_:6OD<+6Y">5DK6II78 /A^OCQRWS.O%#7^=GS5[A/N)9,
MYY+Q7+*?RUB1\:%+7B;C^.T8Z\EPK1/=AS =6&O'](^B?8"0CP'_"-8Z$< 6
M]_"O"=A?_\1YDP#[)\K/_-\O/_R OU'^_N./JOV*??KHWGV<.7E*)3$3L-[%
M=O_^@]B_;S]V;-V&#>O6J\23(@*,-7SNQ\;%PLW=!;:VEC VTL?"^3.Q>+X>
M;"T-D)X8AJ%5;;AZ=A^>/[RL8JR?/KZ%1P]OJN1=CPC9+Y_=P8?/[^+YHVNX
M?N$P]F];C]5=-:C.BT=VC"\RPMR0%^6-JI00M.3&H*<D'OV5L5A1$8$^*D1=
MQ;YHI[+15A" SM((M%*AJL@*07YJ,"H*DM'=5H/5 ]U8O;H?&X;68=/X)@R-
MC*"C=SF*2JN1E):'V/@LQ"?DJ@2.V;E5R"NH1U%Q,PJ+I'9GXVO %I&7O ;8
ME P1^9] =AFEF%*$K.P2]=Q,3=?J9F=D%**TI!J=[;T86K<!6T?',+Y^/=9W
M=Z*WI@(=I?EH+\I"0V82*A*B41$;C:;T=/175&"TJQ.[!M?BT);-.+U_/RZ?
M.HWS)T]C[\Z]6-F_%I7ES<C*$DMZ#7)RVU!02 6%(%Q:MI**#-_]DG=%7//$
M>E#5B\H:PK6X^]5+\K,5E '4-*SBO-6H(EA7$JPK*H=043',=HR /DJ%?@.B
M\U8C@'#KF;("+DFKX)@X"(<4J5>]"PX9AV"7<12VF2<H9V"7=0[V!&H' K5#
M]B78$;!M.,\Z>R*&.N\4;')%3L(F^P27/PK[]$/<UCY5H]HQ:1.<$S; -7$-
MO))7(B!]!4)R^A&1OQR1^;T\EFY$Y70@)JN5"F(+%>\6)&<V(R6]"2DI#4A-
MKD-R?"7BHXH1$9R- .]DN#E'PMK"#\OT73!_GC5FSC*;L%(OPXS92]DN)>10
M9BY35NOIA&N1:7J&!&Q#S25\VE(-KJ<3KJ<OHBRD+"!<SZ<L($C/QY^GS%,R
M9<8BS"0XSUMLAH7Z%IC/=NY"(\[C]F<OYCX78^XB@6HS+%IF0F!>AD4&A@1(
M2SBX.1!XG%569VMG:T*F >;JS^<R"PAV1C"WL>1R$A]M0/A:HI(:+35=#%,;
MJ4DLI9$DJ5<XX3J!4!.-N$P?PIFM<M$6(),XSO+F&%2V2,FI"&59"XF5!&9B
M*3;C=HRY;2,>%X_/T)BZC\1GV\+9PPDNGDYPE.1GMN:$;P%]B=&=J1)JV;H:
MJWAC@:'2^E@T]Z6C?64&:CMCD%WFJ0#;/Y)P%45E/EZ@PY7'20#@_L5R%IWB
MK5R.]4UF8NKL_XEIL_^ N8NG0=]X/L_7"#9.[!MW&Q5G'!CIR/7\5(FC_*I
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M+Q/ [^ 6X?G>(X+TXZ=LG^+^XV=X\.3Y1!RSYNHM(") <OG*#077(E+62"R
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MZ U+,P?J'A:8,\<(TV<LFXBCEOAIS1(M%N<I,PC9,_0I2RGB&B[6:QU@&RK
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MOPS8 S\#]B_+>(F05[F4#.+E%9+D3-S2>:\O::.T8& 9 ?OZ/QFP6PG8A6R
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MWOW;8H!P*37VE^7E_J>* :JGRB^V$<!F?P2NI?ZU'JH_T\N' M<2Q_U+^37
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MM[B15_#:$O"7;/D"E2Z^"SD.\SB/S-D^#P7-1=51"G"K6N-1W4XH;XE$054
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M!8J4TPM4H"]6^YR2$.6:+U9Y@6[E>I_AR'EOSW/@J*S4F<4^D')>DC4]HR!
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M\IB2G$_.F1ZJIXJ,M2'^^M?@6F0J8!L@^]=D*F!/%8'KW__P$WY/N!; _HZ
M_>U/?\37E*\(VE__^._X]L?_@2^__0.>/O\*EZ\]4-?QQLV[L7G+'NS=>P@'
M#A[%Q,1&/M3JD9J:3A L4#6<MV\<P8'MX]B]?A4F!GNPJK\5RWJ:"=DUJ"DO
MADY;0 "DXM_5QK%;B5T[MN+$\<.X>.$,KE\]CUO7+^'!G:MX?/\&GCR0DEQ<
M/I(D=+QO7+N"R?W[L63)  IXO,C("(0$!R$ZDHI78C0R4ZFD)8<B+<X/*5&>
MB MV1#B5X AO&Z2$>T&7DX".&BU6];5C\^@0MDZ,8GCY"K34-1/(=,A*+T9Z
MJA:9Z67(R:Y!;JXD*&M&7EX+LG,;D9TC5N4F55ZDM6T0G5W#:&E=H3*C"E"+
MF[A =C9A3^*O):NXO*G7N\1U0$O8+J;("^[\*2*074#X%BF4;03(N7VQ9"4O
ME/AM:8MD'J]&?GZ-7O*J49!=2W!L@"ZO#66:3F@UX@(M-;B;"/&$]+(NE%*9
MT5;V4.'MI)+5@8+*3BI&W2BI[:/2VH_2QJ7(JQE$HFX5PHN&$*09AG_.&OAD
MCL [8QV\,K?",W,O/++$XGP4+GDGX*(Y"1=)1J8E6 M@EU'*3W%Y@L!]#*Y%
MA[B-)"G;H\IH.:5OAG/:1GADK(=/UGH$Y1+<"]8C3BNQU.MY_/4HJE^'TJ9Q
ME#>/$:S&J7],H*5]/=H["-2=LIS@F*^EXD6EJG& RE8/K\$6:+5U*,RO0@''
MIS"W!H5Y]91&?FY"01:7&?70I%8A*Z$8J5&9B V)0V10*,("?1$N,<H17HB)
M\49,G"\BHKSA3VAQ<K7&(@MC3)\[EP Y![][FY!-0'[M;<G^O1!OB$7Z;0%E
MB<V6&&W"]3L6>'N:)86 _8XEWGA+RFV9ZBW8;QE1]+^3W[SQEEBW"<<S[;#(
MW!VN7OX(BPE'2@XAJY1"!3V]V N)>00_0G:RA@JN+I1*?PKJ.HM0TZ)%AB:9
M(.=&L)Y'\)]&T)D'>W<[^'.>A\3Y4*D/Y3G.0'-O,5H6%Z*L,0$I^=Z(2G,@
M9+LBIRQ863<+JZ*I=(O5U)UP;0=G;UN*U$FV)TQR'*P)4F;&A&=3+# UQ:P%
M"S!ME@#V'(+]7+P]<PYFS)48:\EJ;@\'-UNX^M@@--:34!O%>9>*@K(40FL\
M,O)YC1*J\TH2*0GJ_U*R*CC:#=[!MCR^!9<V*H&8@&Y9?1*J6E)1SK8+^$@)
M(TG8)  @L"29GHLJ);XW0FTOL=Q2%UE<?2.3" D)K@B.D5AI2:86RC;$<3OV
ME]"2G$L8)*"GYP=0!- E%ERLX($\#X3YS&#$) <@A'/"AU#DS7D1&.Z!H B!
M)$>X^5I3;)1%,CC*"^&Q<@[]N;TL@Q :'02O '=8VIESS&9@^NQW,-=H+G5&
M*_AQWD4G!;.?/O"2;,Y!U@B-EQ)-_NR?.\':7L7!AR6X$W*\$)'DJ9*?!46[
M(C3.BWT+('CS]PD!_.S'/G+>LEU>P?:P]S"&B?UTV+K/5=G@Y:5*94L:2AN2
M.$[1!%I";*(G0=H1=AZFRGH]S_P=&-O,@*7S'+@'FJDX_'P"<F%E*L<CG/OW
M(!!*?6]KSC%S6#LM@IG=PA<NZY(M?;:R: =$^')>)J"H(@WYI0G*0NL3(G7*
MY\+&=3H<O&:QKPMY;#.**?MN3%"V41 JB<KRRR()N9((S);]M>,Y"8"N-I'W
MJ:07UF)Q(?=$3+H3^R:)Z6P(ZX[*:IU?&4#Q0U:)Q)T3"K4NR-6Y4[PI_@I,
MQ6HN<TKJ;V=K)1N^*[Q#S C9Q@B(M%3S*DL;R/MD".$\7,50ES=%0!*6:6L)
MSH3U+*UD^99ZZ>'(UT4AKY203;C,T49QGP*Q4B)+8%C<J(,4V,M+H)@4'\X3
M3\X)9Y6'P-9U$1QXKCP#+7@>G9'&N:?1$=HK.0[EDG$\1KT4DNLC/)[WIV0_
MI.9RGT42^TV0+^98%XI[O5C, Q4\Z[.RBP5:YHZXT>O=[ 6XY?H1X,_528UL
M<3>7, RII<W[1%THURF5[!/[)5X%4CL](4OO)BXO%1)X'Y+,_BD:5_;+5[G)
M%TE2M_)P7N-1!'U"?E,NJAO+R)9U*"UOI#01MEM06=W!9R3ANKK[11;QQ5SV
MHZIJ,;^3.MA]"J[%*TQR5#6W+E,B];(%LO6ENRCU*]"@P%HOC8VKR".KN8V
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M)T 3; G3DO&TNV<M!I:NQ^+^<30V+5- +9"=GE&N(%NLVP+7XA8G\6CBMJ;
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MJHS7N>5>A&MG7D-.R"YUA:9<ZE+K2[25-22BHC$%)352KDK&S97'D3 #,Y4
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MQ%.?@F/>"3CD'H5S[F&XY!V FV8?92=<\[;")6<CG+,FX)PQ#.>T?KAG=""
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ME>MW<??!DY]A6L0 V#];L2F/*.+^+7"B7_ZZ*_AOR4NX_6WYVP%;RG[ICV>
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M\71"67BBLTI(Y>9OA* 86Q6?*PF6<DNDA!C!)-6%_;7E^-DJ=UF!<H&YE)P
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MM<1<"US??_ NY\0'A&N.E<#U1]]SG'[/<?I>C96^U)F^CWJP9IL(UW]/P#8
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M]B^C@D9%*B4+.=D%:&GI)$!NP.$CQW#QXF4JQ]=PZ<IU'#E^!L-C6U!:U8;
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MZT5E2%=NX7K7=^G3J_);]P?#]6\ [.^^^XE@_4=\QWY\_RW!^GN!Z_]!R"9
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M?2",C?UA9.Q+^/:A>'.?GEP2PDW$2NU'G2&$0!H)5X\HPG8(H=N7^H4;Q9F
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MG.^*:#X3PI.L$)I@16AV5)X,69*0KU02HVD 6Y*$Q:5YJ/N?FA?,_L3KC?>
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MO8<>S%32MZ5PXYB*2B(\%X>CJ%JN.Y)C1#+R2S(^=_Y6XJI%Q/5;+/22["P
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MQ>9J4ERXQ(83BRTG%<IR.^B9NL(O-!F5]3T8'%F#GMY1U%2WH+JJ"0,#JW"
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MI)8]*.)Z,=NNN%!>7#0@.[4<:?$%2(K*1&QH(B("(A#HZ4/ =H*OJPV"O*D
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M>'LKGEZ:Q"<G!_'QR7X%V,\N#../-Z;P\ZUU>'QD!#M["U&?0$7.A9.D-2=
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M"*"(>^T+%_'W^9EDA'Y )7PN5&M%"]=SX?EE.-6"\MQM_U+Y<X"MM5#_.1'
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M7Y>7)P*-$8D>[)>!2,P(14QB,/Q#/.#@:J.RBJ\PTL$RO25*5ACIPMS&3+U
MB4H,))1&$>()[81BR7@M(M9AB3>6_B7K!55A?"Z*U51*1$F(@B;[NX"E)/.J
M;4]"8W<:ZKM24,YSS*\*55 N+V.DGPJDOK!Z2RWI8&79S2LG5Q2$$+ E6[H5
M'+TU;O?RTL+1QQ+._M;P"K5'4*P+(93W),D%H0F2C=Z6?=F>_< =^>7!A,AH
M%%>S/Q'>XZ1T5K(#^Y0F;EKJ>XO%6^*B-2[I[AP/;IQ'I3R=-:3TF[F=#LSM
MET-*PTEF]N@47^X[4,&_Y!B0&.E82=26XZ3<QK-*?9%7J;%BYQ&()8F9@'%&
MD7AEB)<%(3O"2MT7\=*0:TS.\>.ZN)G[H+0A A7-D<J57DITQ64Z$^HU[2G[
MD21JDE5?,IY')?/:.7[%@BTOLN(SQ*(>Q&-Q#!6&<)L 1*7R6<W^&IGDRS$I
MV=C%U3T5I?59**GE,ZLXC>V1S.=,%O6/*C7'U-2-<RZ:0&V=0+98L7\;L+60
M_6*]C[^5%\"=G+?:L7)L%E??O8U_^_?_%L#^"<>I,+9V#%(IJ$1"8A&"0U/A
MY1L-WZ!8)&<6HKUG)39L.8 =NT]3Z=R'MO8I@E@?"G);49C3B-+\!E04UJ(D
MMQA92<E(BPE#3E((.FK2L7]=&SXXOQ8_W=V*'V^LQ;,+H_CT5#\^.=F'+\X.
MX[NKD_CQ^BR^.#>!:UO:,=N0AK)PWD G*\0ZL\/YA"+9-P8QGE$(<0N%EX,/
M["P=X>KH@;2D#/3U#&'+QNW8M'8S.EN[D)Z4AJA@/MSBXE&>EXOZLE(T5Y:C
MK;H2?<WUF!SLP=;9,>S:OAK;=HYB[88!=/34(26=@.W@@G<6&>"55W7PAU>D
M/(<Q7GW-!*^^;HP%BZQA;NV+\)@,E-8TH[6G'VV] ^@9&&&;;%!NX5>OW*+B
M^H2*M"C0 @62@$D+!UIE6I1H@6%1CK5P_=<$;+%2"VA\RN5G:EVS_(S'U<"'
MIFZPP,DWN'OW0^S=>Y(*]@1*2YI16-!(A:L/HRLW$W[/XO2Y.SA[Z1X.G;B*
M33N.8&IVAY+-VP^K+.*'CI['P2-G%5SOV7<<>_8>8UM(+?'+N'KU#J'CL0)L
M 0T!#HFA%K@^=?H<MSV ]1LV$>37<KE9 ?:ERU>YS4-N*P#\Y#E4BR7[N0A<
MBSR'ZKF@*___*7B^D+F0/!>PM<"M%>WG+XM\]_(Q15X&ZI?E9<!^V9*MV?]?
M#[ %AD7^!+ %EI^#ML#SRQG"?P%L0O<3?J?9QPO %M&ZBL\%ZI?EKP'8FN1E
M+T0^^XQ]5E.B2P/8&G?O+W\YGKPXDA=( M<2%B&@^;64XN*XD3&G8J^_^!9?
M??D3Q\J_\O]_83L^P\5+][%]YW&,CFU"1]<X>ONFE.5:@/ORM?=P_1;[[,WW
MN7X;9R]>PYD+E[F\@HM7W\75&[<(WAKKM;PXDOZ@[4-R/U3L-\>^O&C3ELR3
M<_FUR+C5UKO60/;+<"TB8_SEYX'(;P'VU]]^C6^^^YIP_2V?\=_CIS_^C'_Y
MUW_'CS_^*S[YY"N</W\-L[-;5%+&AGK"9-\H-F[<@8,'I=S>,4Q-KT5C<Q/R
M"C.1G9^(HO(TPELJL@HBD9#JAZ@X-T10N=-*2(0#) ;;PX_*'P';,]"12K [
ME1 /*A].,+.S)%!0R4Z*Q>1P-ZX<WXDGMT[CL_<OX</[[^+>>W=Q_=XCG+AR
M%QOWGT3WR"0GQSJT5I9BYU SWM\YC&<'*?NZ\71/&[[8U8Q/M]?AXTV5^&A3
M.3[=7(7/M]7B\QWU^&1[ QYOKL/===6X0:"^-B52C>MK:G"3L'UO;2T>K*O'
MH[4U>#!5COOCA;@_5H@'JTL)V'6XOZ85E\;;L:NG!2OK&E!?5$. KD9&>@T2
M4ZH1FU2%6"X3TVN1EDV@SJU#-D66:3D-5'2:J.2T("J]#>'IG0A-[T5P^B "
M,U;"-W4,[H1IAY@16$<,P2IB&+;1HW!*7 W7M FX9<B2_Z<0IC-7(KAH"I$5
MLX@HG4!(X1#"\OL05S2 C(J5**P=1V73!&HHM0VK"+8C;+,!E)?W421631.O
M)O]75(@R,J!*7]75#A.>161=9!!U5%CJ*0W57'([*2%6RVW%S4ZLU[\ ,T4@
M>FX,MLA<N/ZU2!DO@CVEHIZ_:^ Z8;N"4L;CEO 8(F4\]W("MD!V!:%;7@A4
M$K3KJ4RU-D^A4\IY-:WB?-Z.@M0B)(4G(":0BGE0,.)#@Y$8$:!JKR=$N2$^
MQA'Q<;8J4WA,HL0KFE#I,Z)29XBH- -$)!M0R:?$&",L1@#<&;&)/HB,]H6O
MGSN<J7>XN7+=FSJ05SQ<G*)@91D$8V-?!==Z>H1L/8%MB@'7#3RP0M\5.BLD
M6[B#LEP+7+_]CKF*N7[M37V\^;8!(=E<P;6YE3LL;3UA;>\%&P<O+CVH6SC#
MV-R6<&U!J#!6[N'S%YJH_2Q<8HM%2VRX+B%K^H1A?57S6L970F8X<DKCJ>3&
M4H$E_.:%4 148PA\"83>5()/&N+28@A#!'@',^B;:<HQZ1A*2:85T!>(-C/!
M"A-#@IX^=(T,^)D1#,V-8&PII;9,X.)IC]CD"!17Y:*D.H=@% ;/ %NE[(L5
M.#K9D\ 0B_J.3 IUI+HXGH<OH=8:DB%<$BE)#*PHY.(6[A])T LV),1:$KH\
M%/3FEH6K&%T!;$T<MI-2^*7^M7N *9=6A&$^8P+-8><N&;B7\?R6P<A2%R96
M^KRNY9 :R@*PZ83=RJ84E-53A\WU0$"4&6'43$%3<4VTBEU-R0TB6 A@$U2C
MG-A/O'AL<?&6>M%6!$^I06V*@ A[Q"03O')"V9Y1ZF5&9*(W?$/LV:8:RW="
MAKCHAB*K* *YI>+Z&\W[$D60%^#66-Z3"/T1"5[J^6AH(2[7K^&-!?^,-^;_
M ?,6$EK?>1NOSY^/5^>]C5?FO:4 ^^W%;\/ ? 7;V 'A\;Z$$FE3-U5236J7
M!T0YP#?<ANUI1XAS(5B)^Z\?EY+5VIUM90U;-P/"]0KE'NX9)"\37!$4[0')
M1N\=XJS$-U3<Q3W8I]S@[&5#>#."@86.2JCGX&$-[V!Q;7<F;!NK!&@+EBU@
M?Y'O),[<!X&1/LK=/#C&$^$)DFC,FVWMC]S*4!03KB7^6$J;2;UI5S]]0ND*
MGHLYV\,#*=EAR&!_C4\)@T^0&ZSL3=D'EV$QCR/9X9<;+%?QV#:.G%?\G=@.
M4C]= Z%29UE*<VFLLF*Q%I=E?P71.662P5I>0%CQ?!Q4/Q!8%/"6!&F5S?%<
M:DI8"2!J05&2@HFE6V,)]B!H>JO^J>*=J^)X+T-XWN[P#9,7%?;L.[P7,5[P
MCW*'I[P 89_P"+:&;P3;.MJ62TD 9L+MC=G?K)"8Z<9^XH\LGGMBICNBDYPH
M?&9Q7(B'1V:)+[++ A6PIN7Y*VA.R!2O"'DAQ/M B)=R<";6RSB>]=B?)&N^
MNRICIKPE4J7>M1.D=GM"CJ-*WB89TR5&6RS\\J)#RG^)U3F[-)C7Y\-[YLCS
ML^!\;4[0ED2#4L/<D9_;LPW<D/=+0CC">;G4\_95+S1D'^*N+TD!95^2]3PM
M7ZS\OI 8]? $9R4Q:5Y\)LGWFF=43+JO>BFD>4'D@FANFY0;B*S2"-Z#.(Z;
M!"1E4C*RD$NVK*P1*_0DZNJG4%O+N>XW %OF-RU85\@+8#4']O+_7LY#G <K
M.PCJK1A>N097J<O]U0'[%\2>8QK7U,$^C;K&3L3$9<$_D!.*>R@\?2*0FE6,
MWN'5V+[W"/8?.4<@/8%5$SO0W#*.LI(>E!5WH9XGWU#9CJ+,(DYVH?!W<4",
MOPN:2Q.QCW!]_\P4OKRV%C_<F,$/UR;P]865^.K<,)Y>D&SA4X3K]7AV:0;O
M;NO$VL9TU,1Z(<W; 4D>KDCV]D>*7Q3BO6,0[!0"%TL/6)LZP,:2#]_@"$Z\
M[=BZ:3LV;]B"]N8VI">G(C8\ DG1T2C,R$!C>1DZZFK0T]2 @=9F#+538>IL
MQ<10)V:G^S"SM@\CJ]I055M,)3$*EI9.>.<=$V6Y?O558[S^FCE>>]4<;\ZS
M@H$1!U PE<SR9O0,CF/EQ!J,3DYC_>9M.'/^L@(<K<OJ%\\59P4%SRU5 @FB
M7(M56Q3M7V?Z%I'/_C+ ?EGQ?J&0B_5+8E _)6Q\S.4G7+X0B;W^XBN!G6?X
MZ*,O<>_>$YPX<1F3DUO0V-!/P&ZA0C. D>$-V+KE.(X>>Q<G3M_DO;^(C03J
M"8+UQ)IMF%F_&UL(VP+81T]>P@G"M"0ZVWO@!+;O.(BM6_=A]^XC.'GR J[?
MN*= 4L!/X%K*;FGA>L/&S5@SLQ9KUVW$SEU[U>>2.?S1XP\5S*GZW%P7T'ZD
MUC6 .U<T@"L JX&;N>"I!5$1+3QK?Z>%H+F?S?U.^_U_M \1@>6Y$#U7M( ]
M]WOM_W-!6[-?S3&TYSX7JK6BO2;MN?VY[;0PK*S8OR':[[6P_+)56M8_%.OU
M7_";EW\KL/MK>0'9VK&@%2U,_];G<\'ZE^WF +98KP44/_KX"XKFN"IIX-.O
M?LD[(-9KC6C@]MG7/^";;_Y($;C^&7?O?8%CQV^P#^Y%6_NX<B-JZQC#])J=
M.,0^+S6N)>;ZVO7[N'#Y!LY=?!<7KES'M9MW<.O>?=R^_S[N4.ZI? $:J_7+
M]T4 6Z[CZV]X[&]_5$OMF-<"M[QLTYS?B_&M<BC\\N+LSXO\1OMR3B-\3GSS
M->4I(?LIG^_?/ ?L?\'/__+O_,UWN'/G 7;N/("NKB%458FW2@^F)C=@SYXC
M2B8GUW,B:T9.7C:R\A)14)*(DHHDY!7'(#'-A\]*1X1R$@X+MT4$E8CP2'L$
MA]G )\ 2;M[F<!871#\'*L6N</!R(%R;8;FQ'LPLJ(B'AV"@K1ZG]V["X^NG
M\=6CF_CT\7NXSW8\?_4VUFX_1 5]B,>J0G5Y)=;TM.+B^@%\MG<(/^SOQ0][
M6O#MKD8\HWRYHX%07:?DBVV-E"9\NJ41'VZHP_LSE;@S68Y;$Q6X.5&)FY,2
M?UV+VS-UN#U;AYNSM;B^EM"]MA+79[G-FC+<FB[#7<+XO:EZW)ENP65"]M'!
M=JQO;D97005*$O*1$96/]/@JI*>U(B6CBTI )Q605B3D-B(AKPFQN2T((UP'
M)#?#.Z$%'O%M<$OHA&M\+UP2ABBC<(D?AW/\!!QB)V$?/0F'Z%5P(G"[Q/9P
MNU:XQ3? ([$1(;D]2&^81DG/%I1T;T!>RP1R&D:07S^,TD:";M,(:J7\2".5
MC[I>U%9WH;JJ U45':BLZ$1E91>%"H:XUU7U42D9H')"H"8DUU,:ZD?00'BN
MH]02A&L)N74B!-Q:PFT-10!9 %L2E_TJKIK[4<G+GLMOP;5\5D5XEF4%8;J\
MEO!?RWFFII]03:%R5,SO2G@, 6P%V3QVA?Q&7@#4CZ*M935Z.V8HDVCCW%2>
M6XGTJ$1$^P4BPM<+L2$^2(XBW,3Y(9V*?4J""Q(3"->)EHA-,E/QUM$IQHA,
M,4)XLB'%@."A1R!902C@Y_$.O(\!R,DGH&;%(2(R%%Y>OO#R#$: 7QS\?!(4
M8%M*EG C#6 +6!OHR[J/RAJNNT+J74M",P%K:\PG6(OE^LVWC>=8KXT(WP0K
M4R?"M!O,K-Q@9.8(J7VMHV>.)<L)+CKZFC);2U;@K7<D3EM>[%L1S.T(V(3L
MI998K&-"^#6#@YL]E6H?9?U)*PA#NEB'J-Q*!NR<\DC"A:;<EM2Y3LZ)1%1R
M$,%*@,L!+CZVRAW8Q(8@37@SMA8KM!5LG#4QV YNCG!T=X2MBQ7%'!Y^=FS'
M0)369J*QJY3W+HT*N"L</<5-E6T:[ZPLP@*TU2VIA! I\^7/;1P)468$.#-(
M[=[D7''?#4!"EB?_M^?Y6!!.K FVSDHAU[C?^BK #HZ1[\62;$D@(^CZFZAX
MUR "I2<!V]J%4&V]F*"Z6&7C7FZXF$ VG\MWX.ICB;3<4)372Z*F4$2EV!%P
M]'G/37@.GBBNI7Y8S6=9EB_AT(;[-N6^[0@$ODC/#U?6YB "MR1!LW+2(40:
M<#M[925,S)329KX$47LX>9K @=MX!5M"LI+'$FX%AL3%-KM$2HI%\?A1:EU@
M/C[=CX#EIL[/V$H\!5XC1/\38?IW!.L_X,T%DI%] 8'['7XNL#T/;R\1P-95
M@"W9N6/3Y 6$QL4V/-$=4F?:+< 4'H15R<X<(B\E8IU4<C.)O_8.L5-6:XWE
MVI;PY,PV)]@0R*2&NB0["XWS);P%\_S">&U!'!>></6U91N;$,[-U,M2R2H?
M'.W+^^W ?F,(7>/EJHR8B;4Q8=P4INQ+)C8K8.$H\,Q['FK-\R,PYONQ/XJU
M-%C!JE^XO!Q9"@NGA7#RUB<P.B,U-XQME83LH@1$)03"Q=L>DAE>UT@'*XQX
M'",]&)H9J1)QU@YF;'<SY6$003"5,FRY9:&$NQ"5C"XBT5ZY/0MT2[RU"@V(
M,H?$X8NKLU8D%EG.2;*+BX4ZO=!?_49@6P/GP01!3:RR6'$%&L6"G5D4IMS_
M)7-\$,%:++!)67)_HPFT(0B,]8![L V<_<S@QG[J&2(B]\>0(OW(!.%Q-LIJ
MG9#NBM@4PB7[?VP*C\/_)7Y<K-B:\Y,R8)*]7%[LA+.=P@G0 0@(=X&CA\3C
M2^(S/=B[FL'=SQ[^86[<MQ?/SPOQ!'>)Y4[*DZSB?";F4++%[5U3\UJN5?8O
M$"_C45R[Q:W;R5N/]T^/8TXR^YNR[2P1E6JO8KESRB4CNF059SM5AQ*VI:Q7
MC"KM)1X%*NLXSS>[A/>C)(SC.5!9L .C.&YC'-EWQ=5>7,G#>#_\N&]'N :(
M6[T^V\H _E$6B&%[9W(?>>4)R"E.4W6RRZI:R*<CJ&^<Y!PUP7E,8\&NYARB
MC<$6L-:ZA M@R\OETK)NM100KZX5CZMVE)2U8&AD&E>NWOKO >RGA+H]^P[S
MP'4(#(Z%7T TPJ.E_%0=(7*6<'42)\]>QNX#)S&Y9@>Z^]:HVF(U51*S-83V
M1DZ&A;6(#@B#LSD'HY41"N+]L7&D"N^=FL*S6QOQ]*K4NA[%-Y=6XELNO[VR
M&C_=6(L_WMS$S]?BSIX!;.TL0$.B'U(];9' !WR*KQ^2_4(13=CWL_6'DXDK
MK P<X&#CAK#0:)2756%\;#76SJQ#;V</LE+3$1G,0185A:(L3@2$Z^[&>BIS
M+1CN;,=83Q<&N=Y:58[ZL@(T-Y2@I:T"-?7%2,M,@9>/U+&TQX(%%@1J<[S^
MN@7>>,T:;\V3NI?>\/!*079N$]J[QS$^M0&S&[=A^^Y].'WN(CYX\BF^5V5O
M?E8*L\82]:T&"IX#@_RO4:Q%P?XMT4+VKX'Z91&E6NM&*I9HC35:8Y7^0DH5
M??$Y/OW\8WSRV1-\^L5'7/\('W/]DT\_XKE(@C6)0?U29?F6NM4S,]O0V2DN
M> /H:!O%ZO&M5+Y/\[MW"<WO8M?>,YC9L!=C4ULP.KD9TVMW*F\&272VY\!I
M'#EQ$2?/7%59Q \=.8O=>XYBV[;]V+[]  X=.HE+!!-QG;US]SXN7KJ*(T>/
M$Z;W**B>F%R#J>D9;-J\G3!_DO!]B]#Y^%>0J8U7%7G"=I:ZXK\&W!> +<O?
M F.1E^%8N]W<S^9^I_W^/]J'R'\78,MG<\]#N^W+VXEH87@N(,\5[??:Q&B2
M95L#R>+*_+E:G_M[6?]S8*V5_PRPY[I%SP5I[1CY<Y_/=:G6U,&6%U??_EG
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M>,+ P!>&!O[0T_/!,AU7@K4#WEDD8&U!D#;#O+=-"-:2T(QP/0>PQ3U<SXB
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MFL#G18"*1&%5M )L 7@'3\E\+-9% F%.B()LB9GVXOG;N>FI>M:NOF;*%5?
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M[4(Y ;6FF7-=^VHT=7(.[EB-YO9QSL6CJOQ(34T?JJNZ"=<]J*944<0MKH(
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M6/^.BO]G.''R$GK[QI&0D(OPL!0J.\U4'G;AV+'+RG)]@@KW/H+RKMV'L?_
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MB/Q6:]F6[<02*QG%M1"M!>FYHOU<\\+GS\.U%IPE&[PDJ1-Y : O(%LK\ID
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M?2NZL;2B#3F+:Q 970'OJ$;8QW7#:O$V6.>=A$/A)3@77B9@7X13W@4X%ER
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M<(W4\'QGO=:Y@*_\&:XUUW"1Z8"MN89K<*TLWI3I@*W%7@M@:W MH*U9K@6
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MEF>4N"&MT)& ;:\@6[+T9Y1X\OL ]8R1YT9!A;BAAR"58RU^L0_'MX<";<\
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M7'?G[F/>%UTI+HFY_B7 UF!Z.F#+WV*Y?O.USBK]H=5: V4-NC7PGB[3M]6
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MZB^3FVEPK64+G^X:+DL1;9WVMV8)5]9P@779WSNXE@1H8L&6V.N4U IEO1;
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M_?<!6X-K@=3IUNM? FS93@?7.BNY_"WK!'AOWQ:0?JBLU"K.FC M<NV:?'Y
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M;N_"V*9M.'?E&IZ^?*E ^H>??L#W/TJLIQ;OJ8-G 6T-N*=#M1*5.5Q$P%,
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M;&F@ZAF;6ND1A$P)($[*[30YQX.0X*[<5"N;8U&Q-%:5"Y,83_D^/-Z5VSK
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MQ51?-[8-K\.6#:LQM:8#XRN68JRCCE*#\64UF%Q3CRT#G=@YWHOMX_V8&-R
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MZ__F3?/O>\+>CCW[4=_4A<+B>OZ(S\*2I9NP=0M_S'8>P+[->[!Y\4HL[AW
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M6(_%2S=CX>*-EI#B>:NP9.E&;-^A4F8W#6PI#%CUL!\\>D1[3&!6R+?"QBW
M;05L:RBXQ=X ID*:Y;%^1%!]\N@YGO'OK_GWO3MLZQMW</6*PL(MBM\6C_1=
MJ$24O-42I#MU]CI.G+EF[/AIVJDK.$$[??8J/U?X]PT#VA<(YT:\2Z!-P+Y
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M)%R/'3T9$\=.A8NM$^$Z"&5IZ>BMJL*"]C8LZ^W!TKX^6C\6]O00KMLPV-R
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M@#& @.UO<B#E-2NJ3D9)=0X*RHJ0GIV/B*@TN+J'LUT\,7RDO,\VQH:I-K;
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M*Y&74HJ\K&:4E\]&5=T25-8O167C,E2V+$55VR)4$Y:KV^:@EI#=T$*X;EV
MUM9%:*=UMA.BNQ80K!>@EZ9E-_M^%ZVG9S'Z^J48_@G:NQ:AIGX(Q65=*"CI
M-*K<Y2K)Q?>J59ZK;@8JJX;,;[G NJRTC\?#W_77?Q<5=2$GIP5)254(#\^'
MMW<R7%UB#0P+L 7:TZ>'PV9:,*9.#?P-M 795L"VFB!;GQO ]DTS<!T75V9
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M ._AX*RG#XN&9F#%_ 582=!>3.B>P?>Z6SK05-.$LL)RY&<6H#B[" T5#4;
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M1H@KJ%%I)L))GA,2<J:;B8B\2F_C.:UI2T$!KUDDK[LF6/R#0Q$6%4? CC*
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MA9TFG%NYTO)@"Y"M2T'SVQYL>:K?]F"_#=@RO=;Z"B^WBIT)M%-3:HR7/-3
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MDJ@6MK5\F&KZ2UQ.WOWBFCC,7-2$LY<.X%__S\^O*?B_]^__&K!+2CN,!UN
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MB$H(-GF=:;FA)D<YMS2:QTI@(:#*"ZU\S_ X'P2$JY26ZD7;$2(]C=>JL:L
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M22_5A#:UL_FWE,>OW23XO@9L?4\AY=J6);1< FJW#&0+L+6.[.T<[+\6(B[
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M*!V'H-V/\.,5/)$@-)D .LU88.1TJ)Q3<K;J"_L2?)P)/3;&0F(=V"8>!*0
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M6V NL!:LRXXK1_[T!?.>/A-@"ZS_7L#6==%K ;35<VUINS?YV=9( +W6^A;
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MQ"VLW+ ?';V+4=TP0,B>CY5K=^/0T<L\QP>XQ+Y_YNQU?/75&1PX<!R'#I[
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M9,5U8<8;+<^U!MD%U4'(*N5YE?NCI$YUJK7=&*X3AI+Z( ["@_EW)%2KNXZ
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M:%[GY/-WNDBE#'M0537X6YBX\J\S,QN-]UJUKQ4:+HBV>IFU%&2_7:YKVK3
M/Q$ODPD"K9 M;[85L-_V: NT90+S<6.]:#Z8-#X =M/"X.$:C]#@+*,2'A.5
MB:" &/@0EOU\.-#WXT#3+Q"!_D$("0I">$@((L/"$!X<C"!?/\*U)\T+@03N
M$+\00G4D(@(%UW%<)B R.!E1H2D$[11$AB8B+"0&P4&A\//G=WT]X./G"O]
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M(UOS*B'U84BX8-H:-FY5$]>\U;MMM2&#/3"8<#VH/^%RJ#M<[(,0%D"XC4A
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M<D1JWUY!SO +DU=1VR#\YT7SG/,ZS CA]PG5A$T)A"5D!?/8E?-M$0^3 )<
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MXP,_)ZN"#Z)*/I3*^" J(VPWFKJ>,R;/P_2)L]'-=9HXD*LO)W17M:*MIM,
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MI@37%SN^QA<[]V/M^IT&MJIK.Y&<4H"(B"1$1B0@+2D=Q?F%J"DO12WANJI
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M<ZWKZ/:]I[CWD/OPE(/)Y]_\#-86>\=S]DN(N!6R/PP5_[57^S\"ZP_A^D/
MMIH5J#\$;.NZ^M\"UW\V+[*>L)TO7KB,O7OV8=O6G=BQ8Z\1PUO_^79,)6P5
M%]<A.BJ5 _<HA$C5.#H)&2GIR,O,0E%V%DISLU"5GXO&XF)T5%6AIZZ>D-V
MIK(*E&3E$"B2C5IR!B&B@+!=7E*#2H)U=443&@G7[<V3T=$T&4VUW03O=A07
M-2,SNP[)A,5D G9.1@%:JRJP:EH'#J^>ANN;I^'^EAX\(5@_V]B(%QL;\'I3
M$]YL;<>;+R;@[9<S\&+G'-S9/!MG5D['P063L&_V!!R8/1''YT_%N26]N+RL
M%S=7]>+^^NEX]/EDPFPW[JTGW*YK,2'BUU9WXBK!^NKJ2;BV:A(A6T)D$B7[
M^T MLX:%"Z8-+',JLRZ[9<+,"=GK"=F;"-E;5"=[ B&[$_=,WG<K[G"=.ZLY
MSWVXM^X]9&^=BF=?].+I]EX\)%S?W#0;YS<N-"\0MBR<CSE=D]!85(?"M'(4
M936@ID(YU;-14S\3M4VS4$^P;FR?@X8VSA.PZYMHC;/00 !OY%1>YY:V7G3U
MS"$PS</$R7--:M#\A2NQ:NT6;-SR)6TG5J[9A#GSEW.=681F 34!NWX"IY-H
M4[G-Z6C@M@79@FIYK34ON*ZMGX[RRHG(*V@U0"V0CB(DQQ*2Y;66&;B.RD=(
MJ. ZE7!-4'0,)3C[8<Q8']C9!W-9K 'JF)@"I*16(BV]&HE)I?R.19!4ZPT9
MZF(@NQ\ALF\_@;.3"1M7&+GJ9*MVMD![]&A_\XRW>JXU;Q4WLRJ(RX8-\\10
M?4:X'CW2$_;C_>#C&8[(4.5-"ZX)R(3FW.04Y"0E(STNU@!V7%@$8FBQ$3%(
M)%"G<9TLB?S)$@G<B9PFIR,_+1N%6?G&<M)SD!J?8I3)(X(C$17" 7<$83LR
M@5!-V"9DIR1F(CTE&ZE)&69Y6' TPD/B$!W)[T6E&4T83X](V-CJ)8(+VX
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MA7_X^/^'?^SS?QC('C%N(&R<"* >%I&L@ A/@JL$O/S_QHR 6(Q%0"P@TLV
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M+?B5TJK*=MV^?8= ]H*@I7)O!$H"]LO7_-[+Y\9>*-?XS6L#V9;ZXH)K@9L
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M.[>^W\#UI<V#EB=[@Q4N;GFPG^5D_\> K6E]N,!I%]=UXQ)!^^)J&K=[<>T
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MXA[DYW>BJ*B'$-F'@H(NI*<W(BFIVEAJ:BT2$BJ-L)FIA>T>_U3 3' M3[4
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MEK!=V1Q#2$A']_0<$W;>.3T#S?U)1N2LI"$$F:7RX+H10*4 [F)*7#E[C25
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MK(@$12K<8P?3"D^T -D*>Q1,JVVV66'? F-U#.U.YK#97I9[RJ^V /GOV8L
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M?4[A-AQF6\K3%F2GYLH+FDA+0DH.S[4C@*:27T'&,ZM0=$%V3@7?RX1?1T&
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M@;(3_Y OO<>/\-# ]1,\^4&*P?=QFI"SYXL#V+#I;2Q<O,YXKA<OV8SU&S_
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M;#4YV*^;<EV=71(TDW+WLUK3_Q%@:YH=&OX+P!Z&:P&T;?\18.LW"BF7!UN
M;9L@6Z;:W/)>JP27 -LV@79%5;\)$U>(>(JCRN1@)R:7/\W!EC=::N!2")>7
M.C(JQ\"U0#LNOA!IZ=7&4RTOM:RPJ VY>4I'J#*67]!B %L>Z-*R;A04MG)^
M(U()VP)W>:WE(1><U]8-F8\%*E.F_=+^-#6K_O9TM+3.YKS7T4]K;!A$9GH9
M0MF7\/8,@Z]7&,)XS<=&)!O(3HDC8"?G(-M!P')PW4D92(E--I"MT/#D:,(X
M(3LF- *1P:&(DCA@="PR4E*?PO1(R-8TV[,MLZ9EHU#3"==%6I:6I^5S<E!:
M6(":<H6#EQG05A[V2,"6%[NYL1%3AX:P<L4J[-SU+C[XZ#/LX_-0ST#I;]A>
M:]MC;<'U,^^T!='__P?8-ES;.=E/;3A]YY'IL_W(\<=\5]WDN_0<WQW'\.%'
M![%EVR>\)Y8B/JD4XR8&X0\O>^"U,7X8,SX(H\8'XN71OGAUG"=</%4*2KF^
MA()JJ8 GHV-:!@;FYV+:HD+,?+T44Q>4$FPSN$PH0J*5;^V*@' O=M #$!(5
M0+A3Z2=G@@PA)<'="";5$GAMP"ZK3V3'/<ITXJU2782_8G;N4\?#/_+W!)S?
M<WR< 5^%APNP!^<5F?!NE;]2!U^>7PDBF=K1K8)K"[ %UTW=!6CHS",$J:9T
M&J=EHW.H&/VSRPC:)6@;D')X COX$F721X10XV&6R>-<0C,YX%4AR"SV-]Y!
M>>]"8L<A,LD9*3G^YN."ZOHF9"@/U]D 3ERZ<G45/OLL-%SAN@(>>1:5CRW0
M5AZWU)<UK[0^@D 2@(1,3Z[;'<'14P@^+ICB,\F$-#NYC8:[[P2$QWDALX
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M)8GGDC#8INLM'>4-R2920F)>J;D!/"<JG^5EH#(E1VD+@;Q/>"U5)*&XRD'
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MR0\J8Y9?D6#"UBOJD_B;4$[SYK4K8(Y 24TJ:EIR4-.<AX**5"2EA_,Z\T9
MF#O\0MR,H)X\VJ&QTAD0^ JR!=@2NR-DERF/7 "<0$"/,_><0N#3"T,(U8F\
M1JW]K6Y1;GX2+1G5K1HF$+"MJ!.IG"M:)*?,'VF%NHY4HLN-U\_PQZG" .YG
M%(]9%*_O:/3/;,#7ASXB!_]IF(+_:__^)@?[5P%[\4KX^L?@GW\S$:^\YH5)
MSF'P#TQ!5FXUVKL(U[,6<IEEV+[C;>,%O'__B0'K'W^4JO?/>,0.]:-AL'Y,
MH) ]L>U7 'ND/0/J9Z'A]M\29?J!XUK. FQ"LX'L9_;@\<]/ ?L. 5O#^P:P
MK7F:=O7&/0+R67SP\1=8MW$[%K^Q&F\LWX"-6Y5+M1^?[SV*/9\?X?@WV+'K
M4ZS?^![M7>QX\U-\\ME!'#IRAE!]F5!- "$ GB 4GCI[GH!] >>>@^<7 [8%
M=)HNT+3SEY]Y=CDD>%V_(2^G2CU9*M2V!ULP]C3$6&!&T[3+@NKA&M)V7O*+
M/,9V>UX$B9JN^5I6O[/;9[?Q'V4C 5O;M;W7\BH+K"7ZIJ&\U)<NW3 B9Y]]
MMA\K5FS$M&GS,'O.(FS=]J;QI@J,!:^/3 WT/^/>O1]-R2EY70\<.&D ^\LO
M#YL0\<.'57/<KE4N#ZSE";8A>R1,RVS MFWDO.?GVUYG@;+.@2!:@/V$UZDI
MA:4HBN&\;!NT5<K%.L_R9NN<ZMQ89IT'FCEG%MC;YT?;LQ7-9?)H:Q]T/"6X
M9G7 ANV))>KWY'LKO$^>:]5.?^>=3[%XT=IAN%Z.C1O>Q9Y/#QNP/G_^#LZ>
MO4D(O\AC>(+'^5M3?N;@X>],B+V$XA0>J*B"*U?N\G@K-UZA^ZI[+>^U.F*V
M]T;>:4$UCX>Q7P=L:_I_#K!5 >#A<,?OU\SN:-H?\&[?N6L^2'SU]3?X\*-/
M\=9;[V'KYET$ZVU8M6P3EBQ8@QE3%Z&K8SJ:F_I16].)HL(ZI*84($9P'99(
M$ B#EYLO KT#D1C%#DIN"5JJZ]%>WXCZR@KD9Q$,HN(1&< 7L5\TXH,237AX
M%H%!WNS"M%P4T'+2<Y&9KCS8,B2E5B,FL8F=AQZ$9\Q#:.%:!%>\A8":3^!;
MNP_>M0?@57,8/E7?(+#\4T05;88C=S8:RWNP8=H0CFQ:@,N[YAJ/[U&"];>K
MVG&4,'N2X'QF0Q_.K+-RH)^:\1QW$;P%WY:I]O1Y+GMI\R"N$;(%V+*K6PF]
MF_MQE3!]G8!]@X!]0X!-L+ZZJ<>80/O&UG[<WCZ$VSNFXB9!_ZH-V2NE2-Z.
ML\,YV:=I)PG6IU;W$JX'<&D]X7KC-%S?R-]L&#!":Y>W#> "8?WT]FDXOGT6
M#F^?CZ\VOX$/URS'FMGST57;C:+L.N3FMJ"\>@CU+?/0U+Z0 +W(LJZ%:"6$
MMG:-L.[%:.LF7/>\@8[>I>CJ7XX>PG4?H;=_J@79@F3;&_V?L5^ ]3! _QI,
MCX3JD6"M_.NG9;HZK9K7"@,79 NJ!=<2-;,AN[YQIEFFI^\-4XM;'D/!MI:1
MV)GRKZ-C"Q$:GH7 X#2$A"O?N@".- F:U1JX%D07EZ@,5[,![L0DB:#EFV%.
M;CVJJGO1VC8+;>VS#63+2UU8W(2JFF[N[T*L6*7J&I\8+9)%B]>S+0I9'R+\
M3S/C,V8M,^E6,HVW=<Q 7D$=PG@?N+F'P7ER(*:XA,#;@QU@[SAC_M[Q"/)-
M0GA@*F+"TA#'96,C4JW<[)AD@G4BP3K&@'5,>!BB0D,(XT&(# Y&;'@X4N/E
MP2;@$)P%T/):VX!=D)5)N"8TYRL_6X"MT'$!MKS;V03J I07E:*TJ,0*%^?O
M\C+349*7;3Z859<5H+J\"#45Q:@J+T9S8RW>6+( ^_9]@9NW;YJTLX<R/G-L
M !:(VL\?&TSM>?;\OV?V<L\#M@W96N>+GGF_,"WSC["G@&T_4RV/O(1Q]:X]
M?>:Z\6)_MO<8WMF]'VLW?(C9<S?RFIV)^*0JN+@GX]4QH1@U3K6QP_BL(_36
ME*"SOPF=@W6H;LHAF,0:+UQ(M#L\_"?"Q6L<A\X(BB"8)8<@MR0935W%F+&P
M&4O6]F+!B@[TS2HCA"09+Y?$CA02KO!2>;IJVU,-I&@HT%9N9JS#Q>1YIN:I
MG(\WTHL(LZ6^A*I E#5%$&P2"*<.J)ZU.O'*XU9)'W7THU,\$!0]">X!K\+5
M]R7XAHTS8"RX;N@4I.:AJ-+!M@;!,T#M?XT0-M$(A4FD2K!NB3J%$RHDP&2%
MPA96QR*[.(+0$4CX]3$ G)P=PM_$HJ8U ZW]$H_*)? G$Y()EC4$CH8PV#6T
M+>\UH:LIW "V\K%;!QQHG^I ZU "F@=BT-@7S7D1!M144SD@W!WAL3Q>Q>EH
M["A#QV 9&GO2"6X*R?5G&P--^W++>-RR@PV$!D2Z&L5L_P@70JH;S9/CG@1N
M=P+F9$QP&XO7)KR,/X[^+?XX]K<8XR11,8)GHF!9RNQ2#@_A<0\E@(;Q/$A\
MB^<V3:'7 9P7#$<AH3]?ZNO^A",?@JEJF7L8H33598YQ2 PNF.U3WB^/>5<6
M]SL!N97A2"M2W6.M/]( HR,WSGAN/0)<,6'*&$RD"81]0MW8;D)?^!3CO9;P
M6&Y%#.HZLM#<EX>:=M[[E3%L4Q!AF)"?*7#G^@NB>2PB")[^)JQ>'O$_C/X-
M7IOXDME&7)H@D>>HQJXC;8&TPLWCT@-X;<9S>@*O/3Z[N-^A\5(1=S> G5W^
M#+#+FF)1K@\Q3<J?CS/7KF!4X<^J@ZYQA42K3KO*8PE$8U.]$9GHS6$@P9K/
MQ'A_GE]+K\ WV N3/9PPVFDT7AG_,EX>^P>\/.[W&.7TDLE+]PV;8CX8)&>K
M7%D"K\,X0G<D0F*"X!?JRVO8VP"Z(A=2N/_9Q5Q.(?MQ;CR&"C=WY7;]D):G
M](($Y/,89.3'F@]BD03]B#A_A$;[LAVN/$X3N#VE0;AR?W2-*?I#'R7"S7ZH
MIG=>62S7$XLT7B.)/(:*&,FO4/UJ!^\'WI?-\F0+KE-X#<A4-UZ K6L\QJ1(
MJ,:\%/93\MQYS3CQ6(_C=3B>^^9I %NA]:5U*9@QOQT'CNSY1P"V#=;/C'C-
M%3\C[#M\<,]?N Q>/A'X[>\GP=DU#-'Q^2@H;D93ZR [('.P<-$ROE1WFAQ,
M>:[__.=_PU]H/Q B)&8FS[4 ^XEL&*R_MXT/Y*=AXL,=WI%0/1*LE2,ILZ=K
M_*>?.>W'D8!-^X&0+>/V'SSY&?<?_X1[CPC8;,>=!P1L#N\^_(GV(V[=?8(+
MEV_A\'=G"-=?$JYW8<FR=83K]=BXY2V\]\$7^.R+P_ADST&HOO7&S>]AS;I=
M6+UV%_?Y?<[?AWW[C^&[$^<)U9=P4D!(R#EUCH!][AQ.GSV'L^<MCZC@RX99
MF0VT-HQI7# D<)5'S:[->]. K(;WC=VX=8_+65Y.RR,M*!6<*I?7FFZ,TV2:
M?OWF7?YN>#TO %K+GK5MI-GSK]^P\HKUVW\T8(]LB[:IXR&/HKS))T^=-:K4
M*EOV[7<G^.*6!_N&$3F3.OCFS6]A\>*5>&/9:KSYUFYS'>K#@U(4!-B/'OYL
M%*LO7+A%.+Q J#YN %NYV!(Y._*=E-Y/$=Y/$1(5)JYR:N?-]B]>LB!;I;'L
M\V2;Y>%^!N!7KHX$;7L9#:V<=WWPT+D03$OHQ@9L0:<=,OY+T+['Y2W0UG%Y
M!MD"ZF<?/63V\=.V]7' #A?_!6#S7G[T2(*#O.]^E)Z!%2ERBT!_^/!);-OZ
M+F;/9B>_=RYFS5QN\JT_VW,$QX_S7)R[P^-W!Z=.7<4A+KMOWV&:/-='S;%3
MF3/56S]W_CHN79+G^@&N7U=N_"-+.5SAX3P?ZB1:D"^@5HFPN^R 6BKF#QX3
MI G)IA[]"+-5_E\,U"--:K96I\]^EHPTNX.I<3TO]#%/G=(+%R]AWU?[\=[N
M#_#6VU(+?Q?;MKR)-2LW8>$<0E'/'+0U#:"^I@LU51TH*VU&;DX5DA)S36FN
MD,!80@'AP,D#OFX^IG105E(:\AWLS*=E(CLUG1W]%,2&Q2,J(!:Q ?%(#$XQ
M@)T9P\Y^(COUJ30NFY/!3F56$3*RJI"8VH"(^':$)DY#>.8RA)=L1VCE^PBJ
MW@/_FGWPK3X [^HC\*D^"K_J0P@J?1\1V6^@J* /2[IZL7_E3%S:,A7G-W;B
MY%K"];IN'%G7SV$_CJ_KPZFU!&P!]6H+K 6YLC.<+KBV_Y:=72=O]B"N;A-D
MS\)-0O;-'=,(U0.XN;6/\$Q3F#@!VWBP!=C&>CE=D#T5=[C\+4&VPL7EQ5[1
M1FO'F57<QJI>6C]A>XAP/9UPS>ULG(KK&PCQ&WIQF>N\R&V<VSF$DSNGX^BN
M>3BX:RD^7+<4*V;.0U=]/TH+.I"?UX'"T@%4-<Q"?=M\-+;/-V#=WO,Z 5JV
MF./\NWO8>A:AO8_3^Y?0EJ)S8!FZ"=B]!.&^(8*UX-< \/!PV 32MD?[>3.0
M+9 64(\( [?-0+76-PS5+P)KB8&--"-N)M#NF&]"Q6U/=@VMFA MD-8TE>[2
M-N?.WV1,;2FO[#?AX>&1N0@.RS!JWRF."N.I+BQJ04%!$_)I&A=D%Q0V&>B6
M]SHQJ0BICC*S;&55MPD+;VZ5$KB$U)J0GED.1WH)0;L!73VS^>Z45LENK-_X
MCA$'[>E3:/L@X7\:VS*?8+T4TV:^P7;.,+^)Y/7OZ14)%]=@N+F%P]TM AY3
M(N'I%@U?KW@$^B4C-#"-T)R.B! 'PH.33<AX9$@"XB(3"=@)B(^*0E18*")#
M@[A,(.<%$<;#D!03C?0D@I8C%3EI#N2DIQ&2+<O/S$!1;C:OF7R4%Q:@3)"M
MDEP*&Y?W.CN'@)V/TL)B%.47(CL]$VE<5UI2 M>3PGE9J"S))UP7H;92@%V$
MIL8:+%^ZF,_2;_@<NX_O?_Z1_0\^\_C,M<'8>O[][P/L7WOVC33[.?A":/Y?
M,"LUQP)K:YUZETE-_+&)6CK']^W1XY?PY=<G\=Z'![!Y^V=8L>H=3)NQ%A75
MTQ"34 E7SU1,=(XB8(<C-"H6Z=D\-R79IO138EH$0F/^?\3]A;L69Y;V#?\7
MW_'*\\P\,ZTQ @1GN[N[N[N[*^[N;B$!DA 2$B $)[ALW-WBG>Z>GO,[SZMV
MA3N$]/1(]PO'.JIVW:57V?6KM=:Y/(VGRYFP-LYU%,:ZC(:SAY,1-DM@I[^X
M.@/-W87HF5:&B7,JT3N]Q @7E1*P!!U&49@ (J^8<BX[)N43P(L(J#R_5>$$
M&P]VUMU,J*U MUSU>PDQ*I.E'.5<E<VJ"R-HQ?WHP<ZK4"UBJTQ62*R@<B3<
M R26]:8)YT[.\3=ANEV3R]'65V:4MCT)G+][X__@7W[_?Q/J7B5D>" EE_!5
MQ$Y_:0C-*B&D$-NJEF3N:[K)Y\XI53AO$('<UT"?!1:$Z&:IE&>:'%+EOTK(
M3-[K\B;+2AN#"=P!**CA<=4%HJ(EDJ 8CY;^!+1.BD'GM%ATS4@@<,<3H,,-
MM/@2, /"O)"2%8_JICPT]^2CL2>%P$I :0XDJ 014B((<JJ%'4E8#49,JNIQ
M*X];N;MA;)<H V7!,7X$3B?"VEL8/G:H9>-D;V*T&X$JV EA!+_XS& "<"C;
M+(3+!2 RR0OAB9Z$( E>1;/M$PF8L<BO(E161B"C.)"_J>ZT*V(RI-XMZ/:%
M1,;R*^-X["G<UT0>=SAA*A!I15)C#^ \@6P_ :"7J4D];-P0O#GZ-8QR'LZ_
MQ\"5<.SJ*R_\2 +B&,*DAP'JVHYTME$NZMG6A36Q!M8%V"K')3&SA*Q0SNMO
MA9P[#<5O7O\7_._?_+_XS1N_QABWT0B-4QWI2$B4+;<\AN/!1MU<X><";-68
MSBA2)(654ZYU1Z7(P^^)%%Z3F65!R*U2";E!X[@5UAQN/LA(:3XAB]=OH:\!
M;'U8*F);I? :#)<Z>)2+N=:"HSSA&^P*#U\GC'<;BQ%C1^"-X4/PVS=>P:]?
M^RU^]>JO.?X;O/K6[]@VKV.<QPA>S^/A%^;)=?C1 A$8&<!KQ)?WHS?<?3WA
MZJV<?6=X!RF:Q!F>@:,PSOT-MJG"[M_D^5>TR5CXAVL?>%[C? Q<RR+C Q >
MZV>N.0&V6\!0MLEHMH</SV,X"BM5 BX4J8,Y_TI)4#YY?'H@PI4;GZ"(!7]D
M%4N03?7!PTWZ0$Z9//E11B2QIDV"?C&H;G^N/5!8*[5Q3\2DC^?V%"U@ ;;*
M=$F=73H*T^:VX^B)/?\@P'[T!#-G+X2G=QB&#G=#6 1?+)4=Z.R9A0F3YV+*
MM+E8M7H#]NT_S [_/7S]]1_P_?=_PG??_F#!M4+#C5GYUE\3)F3?#-K7FJZ7
M@L.+P09L&ZQMN+:%B.QI^MM,X[@%V-\2JAU-X=_?$;"_)6!_8\R":T+%HZ]Q
MX\YCG+]X"P>.G,8'._9BS?IM[""LPV)VK-=O?!\??KS7*(GOW'4([V[]A%#]
M+A8L6H<ERS:Q _$>@7N/@>^C*O5T[@K.#%S!68*-X'K@L@78YPG8%P9A3<!E
M>QM_R01)CH!ME7JRRCU98<2"+@&,8%2>: &J50;*,9?W97:;\&T\X8-0IFW]
M9TT@)R#^6P%;\_^2.:Y7^V.W@2!1X"I E#=98=OR,!O /G&.\&@)G"D'6U!W
M\.!)[-SY.79^\CG'C^',N4M<CVJ.JB/ :^#)MP;R5"O[U*G+!K#W$[!5IDMB
M7J=.#XJGG9&@W( !>@&J(V#;4.UH/P?LYQYE^^.)'=9MH@EHVB^=)\>0< T%
MUR9LV@&T?QHVKB@$"[(=0_G57C9@W[EGM:O^UF_V?NIOG2N5P%*'2/>*[B/I
M%BAL72KJFS=_B,F35 -X OIZYV#UJFV$Z^,X?4JUU)7G?I-M=\7D9Q\XJ/#Z
M(X32HSP?9]A>O,8O$*XOW6(;<]O7'^+6K:>$ZR_9[JIYK8\& FP=(T%8=><-
M7#LJF:M<WB D?_53^SE(_Y)9@/W7]!SL9XM,'5*=IV/'5>OZ$VS=]C[>>_]#
MO/?>#FQ<_R[FSUZ*;H) #:&ZM+ !I03KXL)ZY.94(36E"#%1&0@-3H#_(& [
MC>8+;+P[@KT#$1T8CJC 4$0&A" J) +1A('(X'A$!20@-C 9B<$I2 Y-06I$
M(M*BXI$1%X_,Q 33D4]/SR.X5" FL9Z W8' N.D(SEB)D*)M""C="=^R/? N
MWP^O\J,$[)-PJSA+.P7/XMWPRUB.C.Q^S&SJP.?S>TTHM\I:&<A>WXN3:_MQ
M8E4/3J[HQ%E3@YI [0#2YF\#V);I[_.FE%:[@>PKZWH'(7N*41J7F-G]S3T$
M9PNP[R@TG'9[$+(M3[9^ZS. +;NSL0_7"/N7EA&NES1C8$D;!I9RN\MZ<'65
MX'H*X7HRX9I OZ83-]:VX]H&U?7NQOEW)N#TN]-QY)UYV+U^(5;/FH6.VB["
MDI2L.U!</AGE=3-1U3B3G<09J)4HF""5$-U!B.[H(;QV$58[9UNF<4YK[25D
M]RZDV9"]&)U]A&C!KX'@EP.VPK%M>QE@"Z@E9&:;#=@V5-OV,J^U3'"MO_6;
M"1GGL*5UMO%FVSG8MC=;IG!QP;B\V--FK.4[>KD!\LSL!I-_'1FMCS?5*"QN
MLW*J2]N1E]=@/-2":)F\U\FI4@PO-<.,3-6P5OUKE>?J1G5M'[?5S76HUG8Y
MHF.S$!Z9;D"[LKJ#?8+%6+;B'6,S9BWG\<TR\-W1-=T =W/K))15M"(EM1A!
M(8GP](J NT<XO#RCX>86 :=QP7 :&P)WUR@"=@*"_%((UBD<)B+ )Y861>".
M)EC'(2XJCL,(A!.HPX+8J0QF)S4T&/&1A*"X6 /7LO2$>*0E\CY+3C1>Z+S,
M=!/N72+1P?P\8\6$[:)LE?0B:!.VI1Z>3=!.2TY%0DPL8B(BD! =R>6345E2
M@&8"=6MCM;&6QAI,G-"-S6^OXSOK#+[\YAF^^NYK]CD(OT9C@O!L<JS_>X!M
MF^,RCLL*=%_VW',T"X;_!P![<%]T'-8Z'0";?:NKU^[CW,!-[#]T#MNV[\>*
MU1]@]MP-Z)NP#+4-,Y"5UX'0J%)X>"?#R2T4;E[^\ L*1'"$!)G\X>GG2K >
M1Z"6.<'5T\V8"\T_E$!'$"ROSS$JQ?6=Z>Q4RXL5;4)#!<O*XY1W3RK'RNT4
MC$Z<78[I"^L,B N6+0CWXC#0>+CK.U+1T,5UM248L,XI]S=67!MF1-&4\ZE\
M4.68*A1<'NS@F/$&M%636.K-"@^O:DE'VX02U+<7(C$C&B/'C\#_\W_^+]K_
M#\/'O&;*7T4E^9AR2E)^5OYI7D6X 225 #/*YRU9W%:B@8N8%#]NRY,PY\9M
M>//8PCBO<L(3#4RH))>\UZ4-!.NZ ,*8ZEY[(:N4H%CN1> D9#='H*XS&LW]
MT>B>$8\)<]/1,R.#()) B DD)+G .] %$83"G!+"23/;HB<)37ULEVYYQD,)
M\9$H;TPPH>HEM1)T2V!;J]U3V)Z9'/*>*4TB>(?"-]0#SCX\=U[CX>XGA7=W
MN'@[$;Y&P\E;M9N=$1CE@; $;T0F^B LWI/08]5GED>WH$IAOZG<9A(MD?N?
M1,B-1GJ1(-O+>+23<_V,ESLE3S6J0Y&E4%^>ZRS"=58IIQ4'$8H#V6[>\ EU
MP7C/$29D_;=#?F4\MF\1M.7!=O$A7/N,,N'NWB%CN$^N!#%>$TWQJ.M*(Z2E
MH* ZFMLAJ*>H_)-RQ17.[DT(=8.3UR@,'?TZ096 _>O_A7]]]5\Q=(P^NNC:
M(#!G^!&"%=:M^N-!!'0):GF9=<2D^?-X]:$AQ!QW8K;EL4_)YS)% 3R6()Y+
M@G9%L+'\2I6RBC" +;A6J'-JOK<!;'V@$60FFN@*5X3%NB$BWLL KF^(*UR]
MQF*4TT@,&ST<0]X:AE>'#<'OWWR-]@I>'_X:WAS]AO'LCW$;CO$\)C>_\01G
MI0)X&(5X3\*U5X /P=H3X]S&X:VQ0S&,U_-()YKS:^;CD<;'N [!:)<WS/@H
MY]=Y#1"V \:9T'"E=@BRPV)].>[*:V.D\6"'Q(YE&W@;;W)!!8^C),*4&DO*
M8IMD!O,^"D9,LC]"V9Y!T2X\/@](T5Z@K?M.:0:Q@V'FY8W11M= M>>5XF$K
MZI<VAO,^4UZ^!]M>YWDD)("67Q[.ZSD>977)!.RVOP]@"ZY_!M@/GV#>_*4(
MCTB"7T T"DOJ^9*<CDE3%A"\EV#YBO7XY-//"",WV'G]WL#U-]_\@4!-P"4P
M/"5$?\D'KSJ]!K )N19D<ZAQFLIUZ<&OSJ]C!U@0X&@V4-O _?T?_C@(V((%
MY=OR ?_5UP1JOH#8T7[,;<H><;L/:19D?XL'W/:-NT]P^OQU?$;0VKQU)Y:N
M5%CX6MHZK%[_'G9\O!^?'SB)/9]_@2W;/F5GX6W,F;>2+X@56+9\DRG7L_/3
M@SA\Y"Q.G;W,%\DUDW=]5CFP@U!MV15<)"C:@"V%<@N*+)@VH'E7D&EYD#6\
M>U\UE 79RMFUAH\>$;@)UW<(6=>N7,=E0N:UJS<)S??,.7K$%ZSRGRROMX";
M4"XC<-^59YMP=Y7GZ-+%J[A(:-7^",*T_9<!L;UO+YH]W]_JO;8!VG$=%E [
M>O MT[BF61[?&S^&APMZY<$69"L,6>)9=^]98<>W;S_AW_<,:)\_SV.[J$@!
M >43=CJ^YO7WK0'L!P^^,CG!Y\Y=,R)G@O+#AT]#-;)5PLM6*#]K2H!=,MNV
MP_9_]$(/[J=MFF[_9N^[]9% 'PL4FF]%%]AF11FH#1X:4)9B^>DS$F:[RN-Y
MR/VU(-0(?YES^=2<6[N6]AU]6.$Z%/:OD'/MCZZG&]JF/IBP;>\]X+FG:5S[
MHGVZQ?:^>_^!$=MYS'M2>>E??_,#M_$U5%+EW2T?8<I4=MR;^]'-3O"2Q1OQ
MZ2='<-K4N;YKO-;'3US D2.G<>@0X7K?87RV]Z IRZ6P>DO4C.UQ57#-[=[4
MOC[C,1&N[W]ESI,-V):8F<+D'W!?;,!^S'U2R+J 6J';/S4+LBW0-J'B+X21
MFS)[,N-1&81L/@>^TC/E*SY3!NWK;_C<X+/B&YHZA6J;DZ?.8/?NO7C_@P_Q
M/N%ZQXY/\-ZV'5B^= UZ.@EKQ03JS#)VMLN1GUM%N*Y$>EH)$A/R"=B9" ]-
M0A [^U[N07!WXLO'V1M!7GRA!X19]7E#(TV>:$QD(B*"$Q'FGX1(_V3$"[##
MD@G7<4B/9J<A-A*9"3'(3$Y&:E(VXN.+$1Y=@^"H#@0GSD)(]EH$%V^'7^DN
M>)7N,]YK#\*U*^':J>(<[0Q<BC^#5_IRI&;V8GIC!_82L"5(=G5-,P&['1<V
M]N/T^HD&L$\L[W@.V +I09BV3.// =N";&OX'+(G&'7Q!ULFXN&6/@/9/P%L
M8X1LPO5-VNV-$CWK-Y[LNYLL+_85Y5\O;L*Y1<TXO[@5%Y=UX?JJB0:P;Z^9
MA!NK>W!]30>NK^_ %:YK@.LXO7D:CKTS'[O6+,2Z63/0W]Q#2&HB!+8@IZ@?
M%?6SV#&=2YMEX+J^92::.PBIW?/0V4. [9Z+]B[!]2P#V :V!=T$[+;>!3]"
M=@>MD^-=@V8\S01N1\ 65-MUJ3L(\)W*T^:\W9IO$+!5GFK2Y!7&)A)V#6#W
M:QT"=,XO,!=<:WE'P#9*VW/,W_I=VY?7N[MGD?F]N766@6Q;3;RN8<I@Z+@\
MV9/0V#*#4"OE\[F<9]J/I;OR"EH(M]T$X3X3\EU0T(0LPK6@VH!U2ID1/%-]
M[-BX0@)V!=NVUHB=256\A$ NP*YOF(B:VEX4%#4@(3$?P:')\ ^,)\1GHJBD
MD1 U%PL6;<#299LQ?^%Z3)^YC,<[$W7UO2@M:R&L-Q+:JWF=YR(H*!&^OK'P
M]8F#NWLD 3L$XPG8KDX1\'"+AH]''/R,)SN>D!U'V([CO11/B$Y"8FRBR<&.
M"@VEA7 \#"FQ"@M/0&Y:*G+3%0Z>;  [/2&.XTG(S4A#87:F$2TK-?G4!:@H
M+C3#DOP<%/"WK/0TI'&YI/A$WKO1!/<01(2$(I607EU>BLG]/5@X=R;FS9Z&
M&5,F8/Z<&7CWG8TX?OP(G]=W\/6W? ;1C,;$WQ&P7YS^#P?L02^VO=VG[,OI
M(_%=OG]OW'S _L]-'&0?:>L'G[%OM9'WRAQ>>_WL1W8CK[ +Z=FMB(DK@Y=O
M',;RV3G>E1UY/X6A^L+-VQWNWF[P]B?$!/O#-] ?[CY><')WA7>0#Y(R8PG8
MV:CK4 AO O*K)(KD1P@3#*N<4_2/.<H*P6[L3L?4^=68O[*5D%V+YKXLXPU4
M9SLIQ\, 2T6CA,!23,YU>5,T\BH#D5DB96(_=LR#";P1[/R'LQ-/(,KV15R:
M)\V+G7SE5:LT4!A-7C4N6Q''?0R'AY\K?OO:*_C__:__"__[5_^;@#,< 6%2
MUW:!5Y#R?T<0,)4+2C"ND#!:,COZJ2BL5/UHOC_2 B"5[Y 8E=1R,2'HRM$6
MD.MC@D325)JKI#Z(Q\[I5=[(*G<GG*G>MA/-V82\YU5:(FC5[1'&<]TY-0VM
M$^4ICS?UK7U#G(SXE/+;589+RLI24&_N%V2&LSWDP5;;QJ.^(Q.-7;EHZ,I!
M4W<.FGLUGLO?,I!=QGLS(Y3[ZV<@VS?$"X'A_L:\ MWAY#G6B*$I7WN<QW""
MK957[Q<^WIA_Y'B"C^I2!Q*:!9)1/$^Q**Y3'7.):(7P^ ,, *<7JCQ3 *%4
MWG )G"EBP8]@K6LAW !M+ %6"M[CO482>E\W</TOO_\GPO _X[7AO\4(YR%P
M]AY!R)-JNY.I"QV3QC8NX#FO#.%V%:(=S>M+-=0%R,HS5KXVP9/[+9&TM\:]
M@3=&*!3^U_C75_X/?OW:O^"UMWYO\K&=?89"=:ZC4MS-LJF\3N2M#R'\JC26
M7[C*=WDA+IW@1\C.X/6C\/2LTE!>>T&T &27!YI]D0=;@*U0?7FM8S-4QLJ)
MX*^/+E8D1$H>IW/_M;TX FARMLJCA2(Z.8#GP(/GV,F44'-R'X_QM#$N8S!R
MO"(-AF'8V"$$["$F+]W5=QR\@WG_!;L3K 7"\EB[\GKV@*NW"Y<9CE>'_IIP
M_L]X<]2O,=I5(#V<\XWF_./@RFMIG/LP O80 K?*MKT%9\^17,<8DX[@%ZK[
M6&*%H^ 3HGK7JNGNR?L@$%EL T5)I!=$F##S^/1@DTL>F:AT!ND>>!@Q.H6A
MVU$4JAP0&N\$"1GJ7E5HN,J'*4Q<'\CL4/'":ET_^K@QAMM\RPR5AYW-:Z:H
M*H: W8(O3@JP_]LB9P+IY_;\__-_CQX]PZI5&Y";5XK,K"*T=4S Y"ES,77:
M BQ9NA8??;R''>PKIO/\W?>6J)D\UT_YD'UL/%9Z^/+!+A-,_VCL]'(^8^H
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M')>,A&@)G44A(2H*:?%QR$E-1F%F!HJSLSC,-*"=E92(K&2)G1%<.+TX)]L
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M\M8AH.QC>%?LAD?E;KA7[8%'Q0[X%&] 9.$"%)5/P92V"=@R<Q*.K)A"D)Z
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M]VXILC)S$!D1#0]W+S@[L],6',8V*,/<N?.Q<^>G.'WZ+)]_-XSWVA[J/?Z
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M99@$_M;Q>AK8$K3Z2DC+?3A&C'N#-@3CW4?")\C-A+3+]+M$V<:Z#R&<OX7
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M%.,\?XNQ[K_A-M]$2)R3 :P$GA=Y^N/2O3BO+Z%.;19FPL73\Z*1DAV%J,1
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M1J7[^AH"M@3%UO?C"@'[TIIN#*SJ)&@K3/R_"MB=N$! ODB(O["FG^,<KK)
M^R)!^S+MF@":V[HM(WC?XC*W./T6YY'=I%U?02!?WHU+R_IP<07A>OTTG-\T
M#8?73<;6^3V8WMZ$JOP:Y*0U(8]P75HY%Q7U\]EIGL,7_0QV6*9S?#IJFF<1
MK@F2A.M&8Q(Y>P[8@FI'L\/#;<C^&6";TEO/@5DFJ!8XVV9#MN91GK1,(=WZ
MN[N/\#G1RL567>PF[FMQ:1=2TJH0'5N$"$)R9'0!H;D4:1FUR,II1$96/=(-
M<+>CJF8"*JLG(#>_Q<!X>$0N@D(R$!B4!O^ %'C[),##,Q:>7G'P]4M"4'"Z
M 6]YM14^+LBV/=D";86-R[NMWY()Z_$)14A*+N/?#01BE>^:C>[N16AMG6OR
MKU-3:PG9Q8B*XC7,?52)KOJ&203LA9@^<SEM&:9,X_'QNF]IFX+:^A["M;;9
MC:JJ#A05-B UA<M'IIL/44GQ><A,+^.]5$HPSB181\+=)1C!A._,U!)4EK>B
MKJ8+%>5MR,VM)M@7\S[,0UAH.OQ]$PG5L?#VBH&O=RS\_>()PDG\/0/)B;E(
M399E(24IG9:*M.04;B>-L)V&G*P,Y.5D\Y[+,_==7DZ^\7BGIV9QF4S>@YD$
MZS2"?#+W-1F)"=G(SZM <U,W%BY<CD\^V3.8'G/90/6.'1_CW7>WFI#QLWPV
MZ]TMP);WVO9@"ZHMP44+LE^$Z+]F+X/JGY@!UN=F]X'4_['Z0,_[47:?R;'?
M]")DV\]4QW6]S/3[3Y_'7(8P_>67^I#Y1]H/9MP";3WS]:'A^8=0*W2<ZZ$]
M':SL\?#A5WQ??,5WWU>X=N,13I^[COV'3V';AQ]A[N(%:.EN1FE-$8JK\U%:
M6T K) 3G$@)2"&<1A#@?0H,;HM)<D5'B;R! @"T/H3QO$@3++2,$M&2BH3./
MRR>SPT[PS@PP(<&EM5))YC52$F/R3Z.3O E[!)1*>>62"9O):"5@=T[)A(!:
M@"W8[IAL>; 5+BVE<95SRBD+(KA$<+D$XRW7MJSU!A&L/4V.;G2B/]>O4EPQ
MR"J,,I["R$0"4+0'_,/<"<#N)O=:N=FJ YQ?'F$ K:&'8-,11:A1+G@8:CMC
MT=S/?9N4RJ'$QQ(X3.10 "2EY# "1 !RR@D-E83#BDA"BNHN.QG MLV38!D4
MY62 JK@Z ?6=63S>7%HVVB9DH6M:KLFSEM>ZJ3?)'/N$V068.*?(?&1H[$DR
MPF_ZP*!R7F4-L0;&!*FJQVP@._1- M 0 LXX E: B28HJ(HV'R(2LY3WZL]S
M%(&BJ@0#?MG%\9#JN')S/?W'8[3S4 P=]1J&C'@5;XY\PP#ST!%#,&3XZWAM
MZ"MX9<AO\;LW?HW7A_T>(\8.Y?P"\C?Q^O#?\_??&P^VD_MX>/E[PMW'#>-<
MQQC 'D-P'^<V#./<WS2 +6&WM(( XZV69U964JLZVR&$WB"")L&7UXY4W!6V
M'Q Y%@$18XTW7F6X0N,4<>#"W]UX[-ZF[94?7]W*:[)=2O92FN<U0Y,.0%Y%
M*(&48!CX"CQHH?&CV18^QH,N;V]<ACO7.9K .A+AB>-Y_KQ-F+92&PIKH@C0
MW#>"?TYY*$&;\V=Z(CI-X>*$RR*"<G$D@3T,L>E*HU ^\SAC"J%.R0U'5G&4
M"?^69D!R3A#_CF#[)R"O7.6NK#!UX]$O#1X,#=>]%<_K*Q;5;9&H:HLP>@45
M38+5<)Y+'P/8$4ECN0_.R"KS1F&M/PIJ_)!7Q>.J$/S[&*^V/JPHYUZI$ &A
M;,]H@G6,%-1]V*X*!Y=(GE3#P]DF5OFMZ)0@3G>'J]](C'9[@_8ZG'W>(G"K
M_7G/Q'G1/$PM\WB)FN4&$J[=X!8T$LY<QB?,E?L6P/5%L0TET,9[OSX)^17Z
M<.+'<^N#M%Q?%/)Y,6M^!P%['RGXAT$>_J_]^YL ^\]__@M^^.'/^/Z[/^(/
MW_\)WW_[1WS%!ZC@^N&#YQWI%SO0CIWK%\V":GWY_#L"ME$4UW0K?.G6G4<X
M<NP,MKZW$VLVL+/][D>F#O;VC_?3#N+]CPY@ZX<'\.X'^[#M@_W8\;&\H_)&
M7^"+]!HN7;(!V\JOM8:"*@&50JOOF=!B0=[A(R>Q_X#J!I_ R1/G#% +KJ\2
MWBY?(L31KG)>Y1C?X7)Z2>M+N(869%LYV0\)V0\)U\^>/,'73Y[BF;9#*#RY
M<R_VK'T7V^>OL"![UG+LFK,*GQ&P]\@6K,5G2S9@W]JM.+3U8QS?O1\#QT_A
MQN4KN$N8U;8>/GXNHF7#M2- "PI_": UW;:7_?ZBV?-JG39D/S?!-=O1 /9+
M[#8!EX"GO&1Y4B]>NF*@3UYF$T' <7W<L%7'E6^MO&O58A9@"Y[M\' !MH8*
M$7<4.!.$:SF9:E[;'FD+L&D$7\&O;0+.YU M+^[SX[./R['][(\3=AO;9D.V
MAO8TS:]UZS@5FBW0/GO^/*[>N(Z[#WE=/"'@/N&\C[DN+OO@L4+#V6%1B3+"
M]5??_#L-QG-][0;A^O.36+;B7?3T$2K:IZ!_XEPL7;$)'Q*NCYX<P"4>[]6;
M]W&1U^:I,Y<,8*M=%)FACPSZ2'"'UYVE?B^XMCX&/7@@T[%9JN$OPO6+SP#'
M9\2+9I7S^VG'\65F=_1D=D?/!FQUZ"S/M3IZO-]YCPJN/]S^B0D#W[#^':,6
M_L'['YFA:EUW=4Y 80%A(S;->*XCC?<ZR82)9Q&X"_-*45I4R6$9@3L/<=%I
MB Q+1'1X"A)B%&I:CKJJ3O1T3,>DOED$[:D&KCM:^U!7W83<C +$1R0@)C :
M2:$)R(I7;F@A<M*+D9U6C,+T$C05U6).:R^VSI;G>1Z.K9YA5+_/+:O%P.)2
M7%E"6UI!T*[!^:7-.+.L"Z=63,2)U5-Q?.U,'%DS&X=6S<*!%=-Q8-E$'%[<
MC6.+6G!Z<9.I+WUY13.N&K7O3N-9OKJNCZ#=1]#NM6I,$Y8%U>>6MQK[SP#V
M  %Z@' ]L&8B(7O"(&3WX +W_Y)RJPG3-V@W"=<W.?_-E1TT#;MQ@W9M13>N
MTBZMZ,'%E?TXOWH*SF^8C2_6SL$'\R=A3GL+ZMC^N1G*"6Y'4<4,=N06LU.[
MB)V7>>S<S25@ST%5TRS4T.J;] %I%FTF&IIF$+)G_!@2;H.U/->R%_.O;7L.
MW3\%;-M[+;!6^+?L1< 67,LTWM'-O[M4@YO[U3@-I>4]A.=ZPG4Q0L)R$!B<
M2<M <&@VPB/S$1%58,8U+2JF<!"ZFPCD->9O*7Q[>B7 W2/&F)M[-%S=HHP)
MM 79\F@K!%R>;(&T<JZ5>VT+H<DJJ_H(WYVFGG5>/J_1P3SN\HH^-#;.-(#=
MW#P;E943D9_?1M"N05Q\"5)2*U%2UL%VF46P7F( >^KTQ01N>;"G\!A[N?XN
M;JO3 '9%>0OR<JMX+^4A-CH3*8D%R")<9Q"ZXPC8P?X$9>](A <E(C4Q'P5Y
M-2@I:B  5YN:V+'1.;P?LQ <E$:H3B!@Q\''.QY^O@D("$@RGO'X>()U*MLJ
MM<"D<B0D:%J**:F5EIJ&K,Q,Y.3D\#BX_OQ"6C'WJ0@9Z;E(C.>]S/L]-"0&
MH<&QB"1<IW%=516MF#1A#E;Q&2FMCZ-'3^#4J3,&KC\D^"U>O!33I\_$DB7+
M?H1L.TS<AF"!L@W9_]. _;S/\U/[)<!^L=]DFPW9=C_*?K[:XXY_V].>P[6,
M\QC UO/V3X-#FB(;V:<S@&WFX_%_:=7(MD7/U%_3\G)\/'RH"*XO\>#1UT8G
MY/+U>SAT[ 0V;MF,J7.FH+VOE:#=R'N\G%":CKC4:$0G1R V-8(0&D8+,.K(
M27F>)E>VLB6!$!=-B) '+,!X1E4O6>&P)352<8XGS%D*R34MN03X- )WD*E%
M[>0YQ(10&Y$J D>YU,?[T@U@"ZH%L J]KN^*(UQ*1$PU=2,).Q)*"B-L)*"I
MFT#:5XC:UFSDEL8B)MD/P5'*09:850CRRN((\ D$EQAVZN59#H#*62GG6"&S
M"A67JK7@1]MOG9")GAG9:)]"0.LFZ+2%H[8KFG!M>:T;>N(,\"@/6R7'RINU
M/PKKM4**+4&T!!,*K#!F'9]/Z!CXAX]#:(PSDK+\.4\\FGORT#VE!%U3"DT>
MNHY;I;BL,EP6N,MKWC917OP<SI>#IIX4@JCREA4RK+QP"[#S*^4!)I#F$Z8R
M)'SE-NC1C2%@*E\]A>T;3-!R)3QY<_Y(GI\DGK<D(SBF,/&@" ^X^J@$UA""
M]2MX@\#\^G -7S-EMH:.?!-OC1F&D>,4^CV,T/P605JYY6,P8MQ0 ]BO#U-)
MM+?@YNT*OV!?0K:'R8$?.6X81CD-)60/-76_Y8$6/)?4*3P^B><UV83^2\@K
ME\"K-(/$3#_N*\&-PZAD#X3$.A'XQA* E??KS//HR6O.EV"K#QN!/ =L^WI>
MCP1UA577=:0:JVE33C;//]LG*H70&_Z:L8BDT01E'Q,"+JA/(6Q'I[@0&)U,
MU$4\H30EU]^D->24AW$^B>W%$+9C>*[#C7!7..<+3W)#=*HWV]W?Y!Z')7AR
M_>/AYC?"Y*E[AXPCO%H?<)3OG98?8CS9*CU64IML 79N ']7RH _ 52UOU4?
M/,; M:Z#FO8H5+9R>J-"WK6O?MQ7-Q,BGI#EQOWS15E3B%&T+Z[W0VZE)P';
M U+KUW4I?82P.#>H/)>[CS/<?5WAZNT$9^_1</(> 3=_7I\12K-0K?9H[@_O
M>0*VPL''>0[%2)?7.'P3GD%CS >#^,Q@MHW*M(5Q^\$$_$!$IGG#.V(,QGH/
MP1B/H7 /&(< 7E.1A.R,PFA>;SP7K1E\#B3Q/@WA^?5$=)(+TKCLY!G-^.*$
MZF#_G0!;H>&V_>4O,)#]QQ_^C8#]9Q,>_M67[,RS4__TL=5A?EGGV>Y</X=H
M0;$>[ KOMNSY-.NA;[\,[#K7CO6N'5\2>CF\^(*0_9B#;>!:IOFL;=Q7B:X+
MU[#[\Z/8MGT7WMGV">U3O+/U4[R]Y5-L>/<3O+WM,[Q/L-[UV2E\OO\L@>P\
MCA^_9 #;4JL6?%E"5E:NK>VQ%%C=-S FR+8%M?;M.X)]GQ_&$4*=RII=(L@I
M5/S&=2[+=4B!^?9M1W AD)I0<7D*:7<E>'8/CQX]PI=/G^'K9WQ1$=+N7+R*
MLWL/8>_&;>R(KL"VJ8OP/NWCF03MV2NQ>^YJ[)Z_!KL6K</.)>OQR>K-./C^
MQQ@@8-Z^= T/N+U'*N4T"-:.$.P(B_:X#<HOF\_QMY>9YK'!^L5EK>EL QZG
M"0<?-(U;X*WVM:($5,Y+T&<KC%M>9OUF"8X)CI5/K;QJ ;/.D:8+L.6MUOF0
M]UI#>; %V)I7@&UYKI\#MBUH9D.V8[BWS)JF?=8Q69 IT[BF62)N FBKSO.#
MAU;XO>.QZV^UO>/'#<>( LUSF<>KDC G3IW"V8%SN'SC"F[<O8D[ FT"MNI;
M/Y0WX.EW>/ST!T+U7WA_@!V:?\/UFT\(UZ>P=/D[Z.HA=#1/0!\[CH+K[1_O
MQ9$3YW!.'WMXK+(!MNMI7K>GSUY@FUWA\2N20!\*N*\Z1NZO3!]G!-8/%>[.
MX[+J6?,8:99HF8#WI\^ %R'[15-G3.;8H?MK9G< [<[>CX#]+9\KNM?O/3;W
MFP09Y;5>O6JC 6S5N19<+U^V%MW=$TTI+GFL?7W"X.\;CO!0>:_33&<]*R,?
M^3G%*,HO-9[LK'1VXA.SD!";B<38;*00'++22E!24$?([D!K8Q_:6VB$Z[;F
M;M14UB.;ZY!J>"RA/2DNFY!>BNST*F0DER$_M02M)358U-6)]V=/Q(&E4W!J
MU62<7]F'@66MN+"D#A<75^*R/-C+R@C8I;BXE'\OJR<TM^*2P)> >VYU+\ZL
MZL5)@NJ)91TXL;@9IQ;5XQSMPI(&+M.(2\N:<7%YFP6]:WMQ?4._L2OK"=FK
M.W\&V+:]"-F.)@_XP.H>HU)^GH ]L'H0L+D_JE]]6:'?\E /0O8-SG^#TVYP
MV@U"^+65O;BRHI=P+:\W(7WM))Q>-PU?K)N+3Q;S.NWI0TMQ'?+3RWF>ZE%0
MVLL.T"R4-2]$:=-BOMP7&]BN;%J$ZJ9YJ&V>A08"M4I>-39+W7HZ_];X3R'[
M1;BVO=;ZVX;O=OXNP+8\U\\A^V6 K>DV8#MZL9M:9Z"Z;@(*2SJ0F=V ^,0*
MA$7D(R H [[^:?#Q2X6W;PH\O9-HB83F>(QWBL28L6%P<8LQ\T7%$#3C2Q$9
M780@ KDG0=/%-=+ M3S8\F3[^2>;84AH)F)B"9OIU29/6Y M*%9IKL*B-@/6
M"AM7"2_+)AG@EO>ZJ+B#H-WRH["90+NK:Y&QNKJIA/4FI*95(C>_P93B4ECX
MQ,D+,'G* DR8.)?WTG2TM K@.U%6)@7R9E17M:.LM D9:<6(B4Q#1$@2(L-2
M$!N1ANCP5(0&Q"'0.PK!?C&(YO3D^#RD$;X%U_%Q^28T/#(\&R%!Z03L1'BZ
MQ\"#YJF/"83LL+!T)"06\CC+>(QEW+]\)/+^C"=D)R1R?2EIG)[-?>=]7%",
M EI^?@F/L0C)R5F(C$B$OU\$UQV&,'W\RBQ%<V,_9DY?BO5KW\>G.P_PO7W2
ME"H\=.@H/OED%]:L68O>WGZC*M[2TH;Y\Q<:C[8 7-$]-F0+E 76MOTMX/RB
MR1/^4GOA66CW@6RS^T:.,/TB7+^L'V6OS_&Y:C]G7VZ:5RF"?.\\$V#_D<NK
MFHSZ=>KSZ9G/^;[BL4OT;%!5W')Z6-LSZS#O +X;V*?4>^SV_2<X<^$2=GRZ
M$\M6+\6\)7.,]4[N1EY)#J(3(Q&3I+(_B03N1(*1PF!=$)$\AA#G1> @>%3*
M.\=.LSQ9F?YFJ/J]4C4NJDI$14,FJIMSS#"W) XJ337*Y?=X8^0_8ZS[:PB.
MEK!4$,$B#LT$34%FRX04@H5*=X49$VS(@UO3'F\\N!)+J^_@O!.+T#ZA!-4M
M69#:M/)S!=A2MU8(=!$ALKB:G?JR&*07AG$[8=S72,X;8\I9)6='("4[%-DE
M$5!I+>4W]\_.0^_,++1,3$!M)V&:H-T^F8 ].175A)W2AF"H;K?$UP1U$B53
M[6OE_);5Q1.<$@U@1R9YFWQC"8K%IOD88%3)K[JV#%/:K'L*]WU2/EK[N2T>
M=TN?\K 3C4=<T"0/I!35!8QM_9G&R]W8E8:Z=NY'JW*P"7L$1Y7KRBX+,E[:
MO IYTT,)WCR>ED2T]&<;+Z[*?X4GCB$$NAC/K#S;R@\V2MK) 0B,<"-@C\1(
MIS<P=)34UWE^"-A#%/8]BM#D-(IPY@)OY;;[N\([T W!$7X(CO2#AY\S(7HH
MAHU^ V.<1\+#UWT0L#T-8 _C\D-'OX;1+D,(>:HM[FL4UFO;TTS>O937=?PJ
M0Y51&&C@6>'2:B^5 U,*@'+C(Q(M4:]H(Z07:'+=%2:O-M)'CJ*Z$/,!II*@
MKH\O$CK3!PC5+]?'C_@L+I\PW)CRO;-*_7C]AIF/-0JUET<]-8_7<)8?8E*\
M>-[<>*TKY]J',*YZ[!*DBV/[19EY0N*<X1\YEC:>X.^,@"B%4PM:AV*LQQ .
MA\$C<#0"(IVX[U+8]S''DEL6Q?97C>Y89!814C-]#6 K[%O>:>VO2K55*B2<
MUUA5JP0"0PC._B;L6^'L$8G.B.$PK<"7UZ!5*JZZ/93COL@N9_L4.QM%=@%V
M6D&@T2CP#7$V'T5&C!N.(2->PVMO_1:OC_P-WG)Z'>Y^8WE?^O)^B.)^Q+&-
M@^$5/![CO88;+W9 I$K)\?<<B9[%\ACB>3]%LAVX;E[;\EY[A8^!D]];</;E
M-1 X'EY!SO +<^%]X,OCC.3Y3>6UGX[2FAC><SX(CQF'N"0O=/?7X-#177^_
M$'$;KO5/@/VG/_Z;\6!_^_4/)O=:@/WE,RO_^F4=9MMLP'8$:Y7TLNTY;/_W
M 5L/<R.L,0C8@FV3%Z5.-[?QZ,DWIJS1T1,#^.C3_83JC[%NTW:LW_0AUKV]
M ZLW?F@@^X.=1_ 9X?K0$>7M7C" ??KT%:,>?OFRI2XM\+( :Q ":<9S26!4
MR2+-(R^@:B[ODA 7[<#^+W#JY'GCO;Y]B]!REU!%$+BK\DI<YC;7IWK9,BF+
MFQQ7,QST9A.HGO)%)0_]LR=/<4?PM?<@=J]_%]OF+,,[4Q<8T/Z0'82=LU?@
MT[FKL'/N2KP_8RFVSER"CY:LQ>%M'^/2D9.X0WA2:9'[-(&<]MN&8$=S!,)?
M,D>8?IEI'L?UO?B;:F(;R&;[.;:EO8S&]3%#P&=YK17"+:BVPO6O<ZB_!U2W
MF="HZ %YK&W/M(;ZX"&8/GGJO(%MF:/(F>:S(=LNT65'*MP<C%;0;X)[6V7<
M]G*;(6%<$"ZHMO*0GQI32H6@4_#]_'B?F^VUMDVP;<&B /5+<_S2/SAS[AS.
MG#]+(#Z/"U<OX?KM6R9$_#'OL<>\%Y]\*;A6:/B_\Q[X"Z_!K[#_X#FL7/V>
M$2-J:IG$3O$<+%OQ#G;N.H@O3@[@/(_C H]#8'WNPE4"_&6</7\) Q>O\O@D
M,C?X <$!L 76%F +KA^;CS3Z@& \$7\#8/^R:;Z?=AS_(U,;V1U!VZ06KH]6
M@NO/]NPG4'^ ]>LVF_K6LC6K-PZJA4] +N$Z."@&[JX!<'/QAX]7* $[@9W[
M3!-RJA#QC+0<9*9F(U-#E>U*R45J4BY2XG,(!!Q/S$=F2A%RV<$O+:Q!=443
MZFM:"-R-*"VJX#*Y2(A/14Q\.A_<!4A,J2) U"(UO@JEF568V=R&[?,GXXLU
M4W":8#JPLHU W()+A.1+BYMPD8 \L*P&YPG8YY<5\[=B7%E<1JO"E275_+L6
M TOK<7YI \XN:<29Q0TX0[ ^NZ@6YQ=;@#W :>?YF[S?)F1\M83(+,B^MD&>
M;.50$Y8)T_]9P#Y/P#Z[II\VD>,3"-D68%\B^%\A5%\;-!NRKQ.LK_/W:ZL)
M]RO[<7$EH7P5EUT[!6<W3<>1]3.Q8\D,+.^?A.[R#I1E-B(OHY$ 2'"KG80R
M0G-ITQS:0K[@E[*#O!S5#4M1R[_KFQ4>3K!NGD((E$?5@FQ'P/XE[[4-US:$
MMW7,^1E@.WJP;;.]US9@V^/*GZZJG8"<_$:>^V(#RQY>B03G.+BZQQFH]O))
M-N9&L'9RB<:8<>%X:V00A@[W-T--\PM(1T2DPLC+">CEB(@BH >F&K/#P071
M&@JLY;66FKARK078<=RV/-H";BF-RY,MN&Y@VRB?6B)H36R?JBKN:VZ+40]7
M_G5)22\Z.A9@TJ15Z.]?9N8IK^A&:7F[*;W5TC8973TST3]A#G^?C9YNKJN%
ML$ZP5AWXG)P* ]?EA.VLC%)$AB;#WRO">*PC"=H)T9F()62'&<B.1*!/%$)-
MJ;LTQ$1E(R8ZE\,\1$7D(B0P'=Y>"7!UC8*S2Z09RF,?$)2"J)@\)*64L U*
M."Q  N_-N$2N.R&5;9;*^RT#J1DYR,@J(&SGLXT(X4G9B(I*1E!@#'Q]POD,
MB$-F>@DZVZ=@^9)-V+9E%W9_>@1'#IW!L2\$UU]@Y\Y=V+SY7<R;-Q\-#4I5
M*""L%Z*]O1.K5JW!@0.'<./&+3X/GQ@XECE"]O\$8"NWV]A@G^>7S.X;.9H-
MUK:I'^4(W?9\+SY7-?[+IGEMP%:(^,\!6_TQ>:XM[[5,PF=6W\PR[B_G5?_P
M&?N52G.Z^_ I+E^[@0-'#N.]#]_#EO??P;;M6[%ZPVKT3^Y#96T%"DL+452>
M3\LB-,<2"+S9N7="<JZ'\?[)@YU7KAK)$<9#IUQLP40B83NC(-QXD,OJ4E%2
MDTS X'49/A;#QOX+7GWK?V&<QZN$8C<#4JJ?W=B3BK:)&80N@F0G8;5>\!1@
MZF%7M4A$C%"K>M3U%J"U]1>BM;<8Y?669SP@P@7^H>S4)_B9>L<%%4D&LN4I
M5'ZX]C&_(I;034"M3B7D\+<RP4Z,@;+FWG3T3,M&[XPLM$U*0EU7-!I[8]$]
M+0-=TS)-Z'A1K?8GV +A"D)9@2<AQH<P$\RVB.+Z":YY\I;[FE!XY=I*+3RG
M5&'!42AO2#" 7-V2Q&$2 5BEQ])I:>8#@F Q*4<?,481B,<19'Q0QN.51[:A
M*Q--W83FCDR"O,2N CBO%X=^!O#E_91W6\KG\@ZW3\Q&4T\Z]RV0ZQO+]3EQ
M7G\"CY2U@P95IOT0&J.<]+$8[S$,(\:_3BA^%4-'TI2+[30,;CY.!J8CXT(0
M'AN B'CN8T8402F6;1UD2G!)R&P\ <[3WP/^(7[P)F"/<1YEPLE?'?IKO#7N
M5?@$CS4?8(H(JCJ6KBEYZ)Z:A^:^-$BT3?G0$LM36'-&80AA4]$0\<@ID]>8
M<)GBPNO/@VT<:L+Y:]L3>,R$Y.H@<ZU8(?0Q;(L('F<@SXN_\5[G5800.GV0
ME.>"E'PW9)?Y$JY#N4P$H5FUFA5Y$8WBF@3SX2$VQ<]XV@.B5/?:%3&\GE,+
M%"D0@\SB*..Q#HQV@E<(83)H!(%R!-P"WL(XKR$8[?8J ?L-N/F/A'<H 3QB
MK,D7UW&EY++MBT-Y/L(-7.LC0DRJE_DM,<O7[+-@/Z]<H>)6^+Q$SDKJ0I!5
MZLMS[6X 6_GKR3E2.P_B>UKAXQ$H;PY&?K4WP=H%:84$[&(!=@"W%\(V"S1I
M$ZY>8S%\]!#\?LBO\*O7_@F_>OV?\,;(W\+9:R1"8GR0DA/+>X3OC,P(!$9Y
M&"^VA,[DK<XLBN%^J?Q9BKEO4O/#>3WY("S)@X#M"O\89_A$$*HCW+BL%^]%
M3YH;E_?D\HKNB$=-2RHJZN.1712$V"17Q!'\.WNK<.#P)_\ P![T8,M[_>TW
M?'C:8/U41KA^2I"6.4#UBZ8.],L ^UL"^W/8_FF^T,O VA&N[9?)BYUM?2DU
M#W.5Z_J)BB4AY-FWN'/O*<Y=O&F\V!LV[\"*-5NP9OW[!.T=6+5A.]9L^@CO
MOK\/.W<?Q[X#9PG8 SAQXA+.G!%@6Q!FB6=9):SNW!-4$PSE@15 &G"48)55
M=UF>TL_V',0G._=B]Z[].'C@"YPE>,N#_> ^X>3A,T+T(USG.I63;8F?72?4
M*3?[+B'\OH'K^P\(8X\)-E\^P^-OO\*3K[_DL@]Q_?Q%')>*-B'[_06KL&W6
M4KQ/F-XQ9SEVSEMEA,\^F+X$6Z<L--/WK'H;IW<=P$U"FR#I'LU\&!@T1Q#^
M6\T1F%]F?VW^Y],'87K0+ ^PYGG$H?;Q(<%).<H/"(\:9YO=N$_HO8T+ S>,
M*NF9,PH%'S "778(N !:.=9V"+C.GX!;4*T/(/K=SL-VA&QYKQ5>KE!SY=LK
MC_[DR?,FO]X*+5<.N.4M%] ?/'C,A%9KN8>/)'#S-0'T2[:Q<JMU#-:QZI@%
MTH[';K>%/5W>;-N3+>!6NUR[2?"_=A4#ER_R^AW I6O7C,#9$XG*?/U'//OZ
MS_CZ6PF:_87K_([[>!4;-NW$I"F+"0Y3C1C1RM5;\.F>(SA][BHN\GJ[=/T6
M!GBMR5MP^OP%G!FX2+CF]7?-RBFWO-?6M6![KBVO]6,S+L&V?S1@V_>\?;\[
M=@+E3=>]<^3(<7:(]QAO]>;!O.MU:]\V2N%3)L]$?5T;TM/R$1P8;<#:>;R/
M@6P_GPA$A/%!'I^-%$%T8A828Y,1'Y6 A)ADI"5E$K9SD9Z4@Z28#"02$I+C
M"-K&".')^<C/+D%17AD*<HJ1DYZ+M.1,0DLZ8KAL)&$\/*X,T3%52(ZM1G5N
M Q9U]6#WTJF$RRFXL*&;P-E,J&[$I47-N+RXG?#<AC/+ZG%J607.+B_!!4+V
ME24EN+:HC%9.T*[D?%6$\6I<6$007UB#<PL)U[0!@O9YPO4YVMG%C3BWI-EX
MQB\2FJ7V+;"^MIZP2\B^RJ'4P 74CH!M0[9M%V2$:P'Y!:[CG!3)"=5G",SG
MY(56#C:A6^N_3 "_*EO9B6NTZZNZ"=:]!/P^_CZ1ZYA,()]"N)Z.,QMFXMCF
MV?AT]0PLF]*'CLH6E&4THR2K!V7%DU"N>LP-'!*>!=GEC7/Y]Q)4U2]'3?TR
MU#4N)%C+@ST5]4VJ ST)=0VJ\VP!]HO>:]L$UC9<Z_>? #9!68#=U?OS_&O'
MT/#G(>$VD,\WWNNBL@["7@F\_9((SV$&FH>/"#(@+:@67,N#;8%W+,8[1V'T
MV#",'!UB;)Q3)']+0D@8K\6T6A06=Z*@L.U'!7'5MA8PJRR7/10\-S9-,^,*
M_4Y,*C.0+=B6@KC"Q?5;;=UD \T2/Y.X65/3+)25]2,SLQG)R35(3V\PGNSZ
M^NDF+WORE)6TY48UO*%I MNYGVU$R.Z>ALZNJ01-;K>A!P5YU8B/S4)<3"9R
M,LM0F,]UI10B(C0) 03I$'_"4#2A*+48&4D%B(M(0[!O%'P]PN#C$6[*WH6%
MI"$J4I"=1^#.09!_*CS<X^#$]G!B&[FX*#0^FFT3!W]"=FA$)B*B<Q#%^S F
M@6"N>O6Q:0B+2D*X\JIC4Q$=GX%HI8%$I2 X)!Y^_E'P]XM">%@B,C-*T-XV
M"2N6;\8G'Q_$(;[WOS@R0+@^3\@^@;V?[<<''^S VK7K,7,FKS$"=D%!D3$;
ML"5Z)@%(P;1@V(9KQQ#QET'TR^QG0#UH=HZW#<-V'^BOF3VO;2\"MF._2J9E
M[.?K?VR#S_9G?Z I/%R ;4<EVGTS]<=X[(.UL2W85K_,-NVGYK=RMQ^S3_F
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M5&Y7 F<J,17.W]T1%#L<ON%O$.3>,CG"625LIYI8(R)7TRK 5GL&&_!,RI%
MF 2RK!!C 79=1S+;4:74,KG.""3G$71R/9!1).BWPJ]5*BHA7:6O_! <[0:O
MP#'/(7O,JX3B-S#.XRWXA;H:I?'$C C.'\:A!+KB3"WQU-Q8A!&ZY<EV]AQK
M%-R#P@/@$^!E0L9__\:O\-LW_@]A_;?P('3&I'J;#S+UG1GHF5Z 7IH^+F@?
M52\Y(4MMHX@ *6FGHKXCPWQ\4<FWI&R%AG/Y2D41*#]9'Q,BH))F\OCJ TQ!
ME3[TJ#ZX1+Y4ODI":N$P-=9K]6%$("[A,"N?736O<\O#N?T$5#5EH+ R&7&I
M00B,(#1&."$HQA7AB9Z(SP@T4)ELHCA\C>?:(V@DW ?AVM5_.)Q\WC2F:5I6
M@F=&C"U!@.W&_;'RX,UUD*MSX .IX,L[+V]Y;+IRL16>[L/K)8C[JS)Q FSE
M]@?QVK*N'97I4KZV//#2)2AME#@?X;W4 ZF%KKQ?>+WP^M3UE5$4BJ2L8/:'
M?. 3Y()Q;B/PYJA7\<K07^%W0_\5;XY^A??,6(3%2=4\#MG%*=R_.*B,EU3%
M4_.B>9\G</M6WKX .[<\'HG9P8@@7.L#1!CO\U #VMXF]SHF)93'R^79C@F9
MP;P/N/\\YT75JOD=Q6=(.#+R>*_D!J-G0@T.'OGT'P38__;O^.$/?S;"9A9<
M$ZR??&-$SIX\T<ODY6!MFQ["CEYL1\!^;OK;@FE'>_$%8+\H[!?(SSK;@X"M
M!_NS+_6W0%L/>JDK?VN\V-<)9P>.G,'&=W9@R8JW+<@F7*]8^QZ6KWD?:S9^
MC"V$[$]V?8$#!\_@^/&+!K O7+#R>^6UE)B5@8\'A,'[ NV[!)'[!ECEP114
M:;YSYZ\0RL[@<P+];H+M[EW[<(@P=F'@*NX0%.6]5F[V60+;"8+;R1.JHWW!
M*(SKA7V?<&.\AH\(-(\?X][3)[CW[ GN?_D$CSA^G_MQ]>P 3GUV /NW[,"G
M:S;CHZ7K\-&B-?AHX6KLF$O GKD4[RF$?,82[%JV 2<_WHL;%ZX84)('^T>P
M_?\4L%4+VC8!J3R^@Y[@^Y;=NR=[QM^?XN;-1T;5_>#!D]BS^PCV[3N.X\<N
M$GROTB[QG%DAX?K (>^USIN 61YI>:A?]&P[0K8%V'=YCA\9DPJ\UO?99X?Q
MZ2?[.#R$_0>.X;.]A_'>^SNQ?/EZ+%BP'&O7O8-]^X]R_3QO]RW(?OQ8(BY/
MS?'9QVY[J_6WXX<-_>W8_@)MA8H+M 7<]QX\,* ]</D2SE^Z@JLWN9U'O.Z_
M^B-X2_!^ 1X^_B./Z2[W:S^F35])6)AJPL.7K=B,79\=Q=F!ZUS' USFM7G^
M\E7"-8___'D"]GF"^R5<OGK=Y)O_N$^#^_(<L!\_!VSS-Z_#0:C^1P*V3/>]
M/:Y[7WH&1XX>Q_;M'V/3IBT&K!4.+E&SE2O68=+$Z:@HE[)Q%@+](^#JK)(_
M/H3L !,F&A00BZB(5"0G*E0UWP!V'.$Z*C2*%H-$0G9J0@9A.IU@P!=>>"HA
MVP+MA*@T0G<Z?\\D@&<B+3&#0UI*)E)3LQ"?DH7PA!P$1N83F(JY?#G*,FLQ
MHZD%[\WNQ1=K)^+"IGY32NN"PL,)UY>6=N/\LDZ<6-J(8TLK"=GE.+^\#)>6
ME.$JX?K:HDI<)6!?)6!?)F!?(F!?(& +KL\OK,.Y183JQ4V$:]J2)IQ;VLSU
MM1C(/K^\S8#RY;6$7@+V]8V6-UM_&^_T+X#V3P";0&X!=J^!['.K^@C8/01L
MJRS89<YW1;92)MCNQF7.>Y$P/B"X)EB?7S\;YS?-PW':KG4SL79>/WJ:&U&<
M78W<U%:4%4Q#;<U\U#3,1G7C%%0V3T1ETV1V0&>BJF$!IR]&;?UB@O1\@A_A
MIU%0+;A^#MB.WFM'N+;-]ES;9N;K? [, FS!M,!:8>&.GFO!M;S5&MH0KM\$
MV'E%+0B+S,$XYPB\.<P7;[SI@R%#_3!J3*@!:D]O 7:J 6V-NWL^!^VQXR,Y
MC#8@'A"4A=3T>M3434$KX5_'*)!N[YB#WC[N2_=\,RZU\$[EC7,HR);(679.
M@X%K#078\F(+LE73NJY^"E3&K*-S(3H[%Z&Y>2XJ*R<C.[L5B8E5B(\O1TIJ
M#:?U8\K4E5BV?!L6+MZ$"9/F\W@)Z"U]J&_H0EU=)^&Z%PUU7<C-+D=X2"+O
M)=XO<=G(2B]!:E(>HL*2"=<QB A*0%)L-G((V)G)A8B/3$>(7S1\W$/A[18*
M?Y\8A!":(\(S$1F13=C.A)]/DH'J<6P3)[:)LTN, 6TG>;,]8N#E&P_?P"0$
MAA.J"?<1W&Y(9"K\0Q*,!8<G(91_:^CC3SCW""&@!R& ^YB144Q(GH3ERS;A
MHQW[<?3P>9P]=0VG3U[!%T?/X@"?YY]_?@"??KH;6[9LQ>+%2TR(>!/O6X6(
MSYX]%^^]]P%4PDO/2!ND-11<_T\ MJ#Z&YD >;#_X]@'^FMFSVN;W8]RA.L7
M^U=:SO$9^\LV^&Q_]CU-0F=6_O5SP-;SF<?]U3-C7WXMLR%;?;3G?3,ID3]5
M!0QIB?"=IO?C]1LW<6[@'(X=/\K.[B%\<?PXWVUG.3R!'1_QO;MB&29/[4-[
M3PV:.@I0VY)*J)6 F$)>PPG6B83=+,)0-I\9J>S\1["#+O$D)P,65FALA '"
MJ&2!RPB$QHTUGE0I:3=V$W;;4PQL*NQ7GLF:M@3D$BKB,IT)F,XF'%:ASAH*
M9 6L\CB6U*0BHR :(5$>!#Q+L5JYIL&1/@2E$!,&+=!56+$$K11&+2]R0V<.
MFGL*N/ULXUV3=UEYS2J%) 5GA>>6-T48J);8F-2\%:8NE>:4/#<D9+N8_8K+
ML  [.=>+X./+_2.HY"NO6YY(KK,NT0"VVB FS8VP-@XA<:.,T)9RIB78)L5K
M ;%4HHMK)9CE;<HO>02]2G#[/;Q#AQ+4QG%^'S):+&P  /_T241!5!-Z+P^\
MPN^SBI0+ZV=$N=0N6I>6KVBRUJ>:V2W]Z7R6QR*_*L3D\"IG6T)B2=G^2,XF
MM.6'$NA"H;)= 81"5Y_A&.7\&N'Z%8QQ'0+/P+&(2/#AO&S'_"BDL3VEV)Y3
M&LLVD[A<$MLYW(2-CW,?94I[^8?XPM/7'<-&O8G?O?ZO^/V;_XKA8W\'=[^W
M3+AT=G&H"77OG5%(*T!3+Z^GVG!S?C*X;P+>\L9$7A=9:.W+04.7(%OYSX)<
M;Z07^9B\:X&RT@?JN^T<_6AS; HSUP<>M4U>N?+U+=$P144H=[ZV(Q85+6Q'
M@>N@,)V4OLMJTY!=%(_(>'_XAZENMCO;78)>NI8%C[X\?U(*]R!@.YE\:S^V
MF5_$>(Z/A5?(*)ZKT0B,=D9DLI6;;4+ "=:*-! <2Y ND><K+MV#;>&*X)CQ
M"(Z6(!J727(U%LU[)"G;:_"C"O>M5F'E;/.R$+9!,,^A0LDC#(#+$R_AO\P2
M>=D]S$>?M$)O\R$JO4"B:H&(3P]$1+P/ GA,$K-S]AJ%L6YO893+,(SAT-W?
MB?N@T/@P)&9&(24GALOJHY!T%!3ID<Q]B>$UILB 2!Y#**28'A*GL'M71*5[
M(2;3#]$9"AGG=4ZXCDL/(]CKHU(DSTFDB4A(R_?G-1M@GAWY?&[D%(6C=U(M
M#OT] =OQW[\1L"5N]K4>@D^>P_5C/@@%V +NGW>8+?LEP!94?\=U/C?]_7*/
MM:/9+PK[)6 _[%\$;.7]V.(:EG@2]T7[\?4/>,AC.'7V*B%Z%Y:NW(QE*]_!
M\M5\>2Y_!PN7;<:2E=NP;M-.O/?!/NS><\R4Z#I]FO!%P+YZU1)]$H#<NT_P
M>$@X)&3??6 I*EOP)&A]2#A3#>:[9KF3)R_P97W,>+(__>1SOKQ/X^(%0MZY
MRQP_B?W[CM .FU)H)PC9%RY<-L @#[:\AH\(UP^?$#@%V$\)QL\>XQ%!^_$C
MCM_B/IV_B(M'3N#DKOTXM.UC[%Z_Q8#V!_-68.N,Q=@V;1%VS%F!?6NVX/R>
M0[AS^09?_D\([I9Z]9U!N',$/AOT'('XOV):AVWZVP9,U81^/I_EJ;YS5VU'
MN+['8[W_C!!'<)/2Z .^=.]+;?1+MHL%U[MV'<8:'L^2)1NP>?-'.'C@#*??
MP,# #9ZOBP:N98)G&[#ED;;SM15A(,C6[S*['O:ERS=Q_;I4P/F2O_[ G/N]
M>X_BPP_WX/WW/^7+_3,SOF'#-DR=-H\=4(4,EK.SV6E@6[ O0;R'#Z4L^T=V
MDO[ \Z</ Q90JUUUS!I*)$VJY!K:;6^IJNMZ>F@Z:.:ZYC4NT+[+:^ZJ.AX7
MKN ,]UW*W\I;XRT#WAY<UU?8M?LT%BYZ!ZWLY#<V36(G9!$V;_D87YP8P.5K
M=PGF]W#^RC6</'<>)]AA.77^',Y>N("+5Z\:,3D3B6&?K\%S]ARNG^#A UXW
M]PG9M(</K3#X_RY@6^&$+^\DVJ;[W1ZW.XMZ1FBZ]O'LV0%\NNLSO/WV%JQ?
MO]EXK]_;M@-O;]J&V;,6HJ:ZR2@&AX7&PMLSB'#M;;S7GN[!1AD\A)W_6 )S
M6DHALC-+D)66AZ2X9,2$QQ"PHQ$=%HNXR$3$AB<B.C0!,6%)!(14PG6Z >R$
MJ!3$1R4C(3J9$,X.5G(F<E0Z*"L?R>FYB$S,1G!4#H)"<A$>G(>,V$(TYI5@
M87L==B[HP:GU4W%AXQ2<7]F+\TL)JLMZ<'99!XXM:<#1)94X2<@^NZP2%SA^
M>5$5KA"JKRZN,:9Q"[ )UXOJ<'91 \X0K,\L:::U$+!;"-@M)DS\/(?G"-KG
MEQ/D!<#K>@Q@W]@TP0QMR'X98!O(_AE@6Y"M7'#E9%]T .S+J]IQF<M<)F0K
M)_OB*A[;J@F<=RK.K9M%N%Z <^\LP<$-"[!QP41,[&Q >6D%<K+JD)O5@]*B
M603LA:AKFH^ZYAFH;9Z,&M6])D#6-O*WQKD$Z;EHD*G^=8/*14VA33: +:$S
MVRO](F#K;QNN'7.T]5N[PL,)KK9'^D7 UC1!M03,FMMF&LBV 5NFZ?E%K0@E
M)(X9'X8A!.PA0WTQ=%@  3N,<!A#>$Z AY?"Q%,&03L%KNX)&.<D3W8XQHR+
M,)"MWQ*2*E%9/0G=O8LP:?)R3)N^&K-FK\>,F6L-9%N>Z#D&M@784@Y7?K5@
M6B'CM@FP9:5EW:CF^J2TWD&X[NE91LA>0G"<8\+#4U/K$!55A+"P7*2GUYKU
MJVSE^HT[L(0P.G'*/+9O)PJ+:U!86,U[JQW-C3THS*]&6' "_+S#$<-[(B.U
MT*142!0PE$ KF(XD]";POHF+2$%D4#R"?"+@YQ$&?\\(!/O'(30XQ7BQ0VB!
M_BGP4@B]4R3&CHO$>*=HPG4,AU$8Z\3V<25D>\; PS<./D%)"(K,X#V6"?_0
M5':N$^ ;G(3@"()W=":"N ]NWA$8/=Z/;>R/T'#" _=[X<(U?)[OQ?[])W#B
MV 4,G+N)\V>OX]@7YXQVRHD3ITV.]?[]!PQD+UJT!#-GSC;YU^^\LP6'#Q_E
M>^*F 6D!LF!:IK__LW ML^':]E@+JK^5Z7DWV ]ZL2_T'YD]K^-ST]%^:9T6
M /]U,V'BBFPTY;H$UUJ>ORF*4-YK ]A/.?XB8&MY;<,";*WG"?N2^C MS1*E
MWUV\I/?X%_CL\[W8NV\_CITX!97KO,#WW^$C1_#NUDV8LV R>B96HZXUW939
M2<OS,YUXY19+);BR*<6 44%5%#O4JH-+L"!,R#.93O!,XU >2'E[Y3EL[,Y$
MWXQ26AF:>N1I94=<'M8"@8@G@6:,\>1&ISH9;YQRBP5,V26A)N1;'7>5X(I*
M]#,B3N,("V-=1L'%TYG7I >O3Q_^)B5E'[/-K%*%=RM_.@F-75FH[\PV7G?5
M[,XJEHA4%%0&22'H1<K/K9:G-,KDA7=-S3;0G5'L17 :;\*W!=<":^VS]D\A
M\P+XW+(PPI#*DL6:=E'X<7*.2C2Y\)C&$]+&#N9$.[-M%.JK<.@(DP^<72+%
M;T]"W1@#UJ[^A&R_U^ >.-2$&\<0A#,(NGFE\035:+:I1*?8OBI_Q/5(!*VJ
M12KEEGA875>B 6R3U]L<1Y,PG04\"E/.*U<)I2A3'ULJYZX^PPC8O\=(FL9#
M8]VY?AX3@5JY[%F$HLQ":[FBZD1.)V"GA1/<7#!R/('-923<?5SAY#X.;XYX
MW82'#QWU>Z,@[A,\AFW@R?T.0VU;BN7!GI%GA,[4WLJ5EG*W/-:U!/"6OFRT
M3\QE^^>94'<!L0 R+M.)$.EI/->JC]XQ)<N"])IPXP$.BU?.L.I9JST4CIYF
M/C2T]*=R6PFFY%5172AR*Q0^KCQL?2Q(0&8!GYD) ? *<(:[GQ/\PZ68[4L(
M]F;;NYFR52I3Y<UA8)0K0N.]3&ZR/-KR<JO^M4+'(Y(\>>T'$7(C>%V$0S6S
M!<<*_U:(?GRF]?')/V(4US<<?N&C31UV>?<CY16.$VR[\-[A-5NB:XI 6LEK
MG_MJ:GL3N%66K)#'JS#QC&*5$!/ /X?XI!R59E,=;.632P_  WZAO"^"G. ;
MXHZ "&_XAGK"(\"%Y@RO(%?XA+AQ7]RY;ZK)'<OK)!VEM9G<1L*@Q]K+'&<8
M]]6J]^UDA-YBLWQ-F:[XG!!$I@28]@J*YG:3_'@M!YDH%7GO8U)=.'1''MLB
MKY3W<'X(NOHJ<>#0Q_BWOW<=;/T38']/"/Y*X:B$ZQ^]US2-*P_[99UFVZP'
MZ-\.V(X/_!?-\05@/=Q_&;"?$+"?/!-@ZS?N-_?EJV_^B*=?_4#0N(_=GW^!
MC>]^A%7KMF')BG<P9^%ZS)R_#G,7;3)UL#=L^A@?;/\<GW]^#,>/#QA05JZM
M)6(E2+( ^]Y#>:XMP-8T@90EBB584CCS0UR[=@]G3EW"9[L/8OL'G^*C';NQ
M9_=^X]&6$)-RM/=]?@A'"<GR9)\_?XDP?P-W"%OW"9^/",./GCS%PZ<$&D*V
M[#'M":<_(:@^)I ]O'8+M[G<Q<,G<&3'+NQ<^PZVS%N.C5/GXYWI"_')DO4X
M\=ZGN'GL+!X1LO3REV?4>%,%?/>> [;L'P?8&I<(F,*A99:G6EY@@?7#A]\:
MNW__&]R\^9B=G:MLLX-8LG@#.CJF$"0G8][<U6S3 SAV3-$&5TT-<@/8@^'<
M"OVV<ZH%V/)B:]J%0<B6]UJF<0&VU.*O\1JY>.$VCAX]C]V[#^.CCS[']NU[
M\![;</7J=S%IDCJC=8B-34=,3!H*"JHQ>?(\@MT."[(OWF8;R^OP1P.;.GZK
MC)<5_:"A2GQ=)NQ*(=T&:\>V%]0*K.WK_"'/UVU.'^!^'S]U$6<';O#Z^PK?
M?/_O/)=_XO'>P-IU.]'7OYAP/86=[WE8SFO[D]V'</K<95R\PL[CY:LX0;C^
MXO0I O89G+TX0+B^@FNW"/KLU.ACBY7JP',U:#\%[*>$:T$VQ_\' =ONU/TU
MTS- SP='?09Y^=6&^P\<PGOO?XB-&]\A5&\Q(>+;:"M7K$='>[^I<1T8$ %?
MGQ!"=0!<"-=NSG[P9:<[A!W]2"F#*]0[7:6Y*E"86XJ<]!RD)Q*>HP75,8@(
MYLLN.'80L),-)"1&IR,Y-@.)O ;B(@G=48E(B4]#3EH."G,*D)];B,S,7,0K
M3#PF Z%A&0@)SN Z,I#)Y9KR"[&HHPD?S9^,HZMGX>2JJ3BS@A"ZO NGES7C
M^)):'%M<A1-+JG%Z:2UAN=[D52L_^S+'KRRIX[ 6EQ;7X@+A^ASA^O2B9IQ<
MW(I32]IP9FD[SM+.+R,D$ZYE\F0;R%YA0;9"Q 78-]^>..C)?AXN;H/USP!;
M(>*$:0NP)7;60^CN,27 +J\A8*\>!.Q5$E=K)UQWFASMLZLGX8P)"Y^#TP3L
M8QL78L?2&9C5VX**LA)DLMUS"UH)@E-05CJ;$+2 X+R U[/"D^65GFC"P!N:
M)M,&<ZT;9M((V/4S45<_G? WS4Q_,3S\1;/#PAV]W'9N]G\&L#5L[WZ>IZV_
M"XK;?O1@#QL1@&%O!>*M$<$$['",'1\%9]<XN'LJ%SL5OOX99JAI(T:%X(TW
M_?#F4'\34CZ>0!D<HCSB1O/1H*]_"6;/V8!%B[=@WORW,7'2,@/ JOEMY51/
M9[OPV&D:-W\W3C6AX0)N"9X5%K7SV=6-RBJV(]NMI66>L<;&.:BLG(2\O'8D
M)54A,B(?"0EEIKS7U.DKL&;=!UB[_GW,FJNP_$[DY)8A)[L4U56M:&^=P//7
M2+!.-1^L8J,%V 5&SR VT@+L0()WH%<X@@G5LA"?2 3Q_@OVB4)8 ._!D!2$
M$XZ# Y/A[Y=HQ,T\W&+A[!QEX-K9A>-L(WV@&.\: V>/6$)S'#S\X@DOB?!7
MS>WP='::4^'%=?@)U*.R$1J=3>A.P5C78 P=Z<ES$LC[,0_=O3.P<=-VON./
MXXLOSN/4R4L8.'^#D'T#IT_R77)Z@.^!FT; [/+E*R84_(,//C1ENK9OWV'@
M^C*?IWHVVH!L@[;,AFW[[[_%' ';P/6W?\!W?.Y]Q^>>S(;L%V'XKYD]K\Q^
MACK:R_I7,D>0_B6SGN%6'\_JYVE9_O:?!NSOV5;?$;"_(6 _@U+O+EZZ1) ^
MBD\^W84/=WR"/9\=,!_"[]Y]S/?E/1P^>A!K-BQ!_Y1Z5! :,_+]D90E,2H?
MXYF6AUKAXE*'+F^,)_S$<SS:0*/ 21":4>0+J3X+]B1LU3^K&%/G5V+2W I3
MKJJ$X"!/GQ2?@V-'P"OD-6,JL21Q+GF8E7M<7*.\:7F%(P@/OKS^QA*NAV(4
M 6^LRUBX>KKS.E5>L2NO4^61LF.?[0$ID*NVL')^&[K3#,@I=%SP*X^N:B]+
M\"R' "^%ZLP2/Y/?6]4:@]J..)-WK9#UQ&Q7X[6VX5C (RA7_K/$QPJK!$,1
M!- 8E-8EF+:1\G1TJIN!*QUC4HXUE.*WP$LAWO* )_!W*41+T"LP:@Q\PT;
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MZJ9.Z)^']>NVX]-/CF#_?N5$'\>!@\=P])CJ2%LAXC9@*X?^,@%;]:YM3_;
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M/R*@S3:9C">,GX85R]<2#+_&P0-'<8H0?T9NRF<N0"6:Y'JF&ILW.(E+;A/
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M%FD;L+5NB_X63 NJ!=<"ZE:*+-?:UC)D"BH'CD!*>A5"PK/@Y9-D7+[[.\?
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M A$=R<C"*!'&@IV:0\GE>J[J7ZL^L9*8*6XWG) O-_BTCK:76W2V]0* YR?
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MZDG[AO1"/_<WT:47P?KM%S@OO(KN?;JCIU-O]*(X>3K!/TRNUE$=;M4QA,L
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M0X:V\QBMIEZ\(S85CI@4),6EF42 2O27X<BB9",],9M S;Z?58K2_ $HR1N
MPNQRY!*VLPC=F83M#$)V2F(NXF(S$1Z>@L" !/CYQA&N$^#EF0!W]WA"=A+\
M_#,0%)QC(#N$D!T:D4_)0U!8-@()U$&4X+ L/O/I\/)-A+-K!'H3KGOV\8>[
M5Q22TTK0,F0\YBU<C0T??H:=NP^9\?&ZJ5HAT7QWSWAW&2CF6&,\B#HLU!*M
M"[0%UA+;:OT4IFV+->61O9TB6+>%^_V-:%\!-L%5</W=#P3F'RD_?8\?_O@C
M?OKSSQ3J0(1MP;6Q9G,IH)8[MJS&W_U(\/U!0,WS,)#-\5;"8SZDOO2(NM,C
MZEZ/J7L]?C*V6G#=&;!_J5/I^!WP_*SH-SH#M@W91BS(MK.(/X5K6YZ%;+O<
M%\_ML961_"&W:ZZ0[G97NINI**($J*KP<0W'3Q[&)Y]MP(RYH]'<5HKJAAQ4
MUF8BMT30$8'T_%B4U\J:.Q#MDQL)LC7&C;NL3A9<!RH:"(K-<I<E:+0Y,&A8
M(AI'2AP&LEO:,S!\8B':IY9CS/0*C)I2BJ$3"M X(I/?EX5069G]":_A!.-T
M- TM(V"7([\D'6'107!R[X]NO7J@6\]>!K+[.CO!Q=,9G@&RYGG#D1%BLFXK
M$5OSB (T#%6IJW04#U3FZ3@#,'(3CTGV)&A[$1XL=^5*E7=JC$9E4R2!/Q:#
MAB8:%W>Y7C<27!73_+0V=2J/%47XM!*YR05=;N.J=RV@5@(OQ> *H@7!#<,R
MC.NR7*%'3"PR\<1-(Y4-.Q$#FN),6S6.2#<ER_1YV[@"8Y46+,LM/Y$0)W=N
MN>&JYK:222ES>74SVX=0;"SKH_*,]5J_*?!7@K7PQ+XFQCTESP=*CB;78UGX
M8U)=^9F5X5VP;M7M%BRE$NX4:ZQ8WV#"5K"!:T<F 3\Y&!&Q0? +\8&;MPOZ
MN?8A9/= 'Y?N</'J#?]05V-!S2I2:3>!91SRRI4-7N[W00:N"ZN5&3Z0QU9<
M>Q#OK]S2TPAH\;SO 3PW;I?[^, P ].E=7I)8672EI> KB&!T"; 5JQO>F&(
ML<Q7-"01PN6FK8SC<6R[5 P9FV/:73'-87'N/,\W\4J7W^)W+_\?O/CZ[]&]
M=U<3Q^_AYP5G3S?T=W?AW.#!N8$PG.= 3DD2KSN,<$U8352R.WD-R,U?6<YC
M39*U.(*[(%N6965%5S]0%G=E_%:B-F5,5RRU548K@FT2RWZ62OC.XC*=[1Q)
M".;O!G0C-'='>(('KRD<Q=4)_&XB@3W&@+;BKQ5Z$)[HPOVZHI_G&W#VZ0+?
ML'[\CC?!/  1";X(BG*#;VA_PCHEI+\IO>;LU1=]W7NCOT<_> 5ZP"_,&VY^
MSNC>_RV\U>M5]';KQN.X\Q@A?+YCD9H;9UXN)&9&$I"C>/]C^<QP.R$[,9N@
MGN2)2(<7/POE<Y;$/I.+JL8<WO,D[AO,Y\H=D8G./)XS$C,\^=T@D[-AUL*1
M.'SBF_]]P+9BL&WY@0,@!^-G(+LS6/]]N+8 ^^D@__2-Z=\#;(D-V,].!-9Q
M+(5<8F>GU" N9?\NE7_%PRJ)QBV*+-KW'OQH7,?E=GOD^%E\_M5.K-_P,18N
M7<^!>R4FS5B,R3,78^;\%5A&0/YP\Q?X>N<!DS3J(H'U.@?[&W<$E(34FX)L
MN75?-LLKUZ[@Y)FSW'\/P?T#3)D^#T.'CZ,". IM;6,P<N0D3)X\!XL)]!]_
M_#GV[SMF /L& ?H:)Y"+ERX0)DX3^D[B_+G3N'SQ JY?(8P1P&]QGYN$X5LW
M;QG@52*T!YK43=RY8(<P) @6,&F_:W(Q)S3K;Y44DZ52T@'7-F#;UNO.@&V.
MHZ6Q:%IBX)H*AD0O&A0;?,. MB7Z^Y:LU%0V[G(RO2]O O410M1]3IS7;MS'
MZ7-7<?CH61PZ<AK'3EPP@'WIXBW"KT#XKI&+%V_CY,G+V+W[*#[Y9#O>85N-
M'S<#DR;.QJJ5[V/[]GW8M^\$]NPYAEV[#A&V]^*KK[[%UX3K??L.X-2I,P9H
MKYLVO6G6Y>:G^':)UHVG =M5P'WJU%D</G(2>P^<(%SOQ]H-GV+2]$6HKA^&
MW**!R"X<0,5_)!8L68NO=A[$B;-7<?+\=9R^<(-R'8?8+[[:N0_O;MJ"):O6
M8_F:#?ADRY>\M\=-7-_Y\U<IEZ"D.1=X/Z]>O\R^<XWM> .W[_$^W;_%-KM#
MJ+Z'NRK']I! 2R7NYIW'N'G[1UR_\2-.G[K#:SR"I4LWHGWT+#342]D=C7%C
MYV+%\HW\[(#)J'[N_ U"]14<YSD=5P(\ O9%7:N2\+$ME!'_\K4;9OVJVH?]
MX\:-.[SWSP*VY?[]!+ I6MI6Z^>!M2W/PK5$2I/UK/,Y)EP;J/[^+Y2_XH<?
M*#]R_0?%6%OCA#6._)'?^Y[G?\4D-/N 0+UJS1H#U^]]L(& K9KV:S%EQEP,
M:AI&J"E#2$0RO/PBX>H1 B>W0/1S\D//WI[HTM49K[S>&[_[P]OXU]^\CM_^
M[BV\\G)/ G9_='G3"=V[NL"YCQ<"O$(0&Q:/U/@T9"9E(3LEF^!,P,XO1D5Q
M.2J+RE!64$*H)DSGRAV\'.4$[Y+<4A03KDMSR@C8Y03L<@(VH3LM ^F.%)C:
MVDJ,1H4_/:T<J2GE2$HL0'Q4&I*BDU&0FH&6RC),&S88*Z:.PY8%4[%KV50<
M648P7J*LX$TXLJ@9!Q8-P7["]7["]0'*H46R9K?B^((FG# UL2G<[_AB;E_6
MCB,KQN/(R@DXMG(<3JPD\*Y0QO 1'9!MR6E"MS*!"ZC/KU:-;$'V.+,\MZK=
M?"[(-M9O?N^4 'LUC[.6R[6C<(IB@'LUH9J ?98P?YY0?W[U)!Q?-07?+)Z$
M%2JOTS04A26#D9P[!&E%[2BHFLS);QH&$0+K"<$-@Z>@D9"M\EN#6V<1_@C-
M!J*5P&N2L5JWM(ZWX)I0.U@6:P*B]AT\Q+),/PO7_RQ@RWHKN!XS=@G&C%GR
M"] 6?&N?$=Q7];+E>MTB"S8!NZEE(I<3N!R/QI9QA.PQJ*H=086[&7')Y50H
M,JA()%/QRT)X7 FB$RL0%%E(A<F!5]\.ID+E@]^_&LCU2/1R3D-@5 T5B)%(
MRQF!F(2!""4\A@0[$.@7#2_W8'BZ*TE?(E*2V/\*!V'@@#94#QR.BO(VE!2W
MH*" L)W7A.+B(:BMTPNX.1@Y:J')'*[27*/;WT$[K[%]S&)N7V LU[+,CQXS
M#^,G+<*D*8LQ;J*L^#-X/>THJVQ$?G$U2BOY6S7-!/N!R$C.1GQ$ N+#XY$8
MZ4!*;(KQ],@49"=F<6D!=GYF"8IS*U"84V'@6F"=0OAVQ&4B/CH-D1%)" F)
MAW] #'Q\>7W>T83J&,)U+#P(V%X$;%_?-,M-/# ;04%6YO7 ( *U2IX%$ZY#
M]7<:O+WCX.04@IX]O=&[CR^\"-=)R02.YM&8MV 5-GWT.;9SGCC&^?X:QSL3
M?J.*'+=O<TR[RW%+0&W)/8H-T;8(H.T27,_[[&\!6_H2E[;NU&$5U^<VH#X!
M[.\%UM_C^Y\IA.OO?N;?E.__^ -!F_K0'SD6$JY_(%Q__R/'SQ^I*Q&J!>./
M?N#Q"-H/C/"8WQ->*?<YUCZ@;O2 ^M8#CJ</*8^>Z%Y/(=O2X6RW;QZ/RZ>
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MZ '-D6Q7O1Q1S?-D4Z),)<BZ]GD=OW_E7_$OO_\_>.GU%]''N3=\@GSA'QS
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MW/:8P'&+D^YI?/GU;KS[X58L7,[!VT#V$DP@9$V=LQ3S%Z_%VO<^P=8O=^$
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MV<$$;!_$I?OP&8GB&-&*_4>_Q%_P0P<%_^?^_8<!^Z$!; YVMOP7 -N"[,Z
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MN'4?%Z_>PO%3%[%SSQ%L_/A+$Z,\>^X*K%[W,;83/O<=.(Z]^X[BX$$E,KF
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MYFWN77Y%A %]N6@W$BJ5&5P> B6U$03K4(*A'V'9QXAJALO=6_7 ]?(CMYR
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M^R#[QW'>WU.$ZF/&;7W/GCTX<& _H?<$ ?LR%;I;N/>0RMP3E_ 'N,ESD0?
M3?;'BU=O8__!,]CTT==8,'\=%?ZY&#9TBI'1A.M9,Y=AW=I/C&NXZH2K/-C)
M$Q>Y?H9R"B=4 YL*I:S7RJ1N)WRSQ89L@75GN'X*V+]T![>AVGZFGBI%4A1M
M1<T2^]FSQ=[GV3'#BKN6:[@E/_XD5_$_4X']'A<N7<>>O8<)UY]C_?J-1C[X
MX!-\^.$6PO5Z3)P\G?VI"1G9A51<DM#'Q1^O=W7"*V_UPYM=7?!6-U>\T:4_
M7B%0O_QZ;[S\6F^\1K!^F]O[]/6!!X':WS\6P4$)" R(A9]/) ()V]$$@/3$
M3.1G%!C SG#(Q9L#<DHZ(9O;,V7-SD5Q;CZE$*5Y<A,O,_'9E455!K(%V.5R
M&<_(1U9BAH'K9 /8!&O"2$),,N())@E<3R1P.R2$%L5^)T=SLHI/15E6'H8.
MK,:"]N'8/&\R=A-6#ZV:@D-+VW%XX6 <(5P?FUN+8_,&X3@!^RB!6F6^#JG4
MUY)A.+:T#2>7#L:9I<TX1SF[C.O+AN*,,H,;H'X^8)_@=^4VKG5!ML#Z\KH)
M!K3/KQF#DZN&X]C*-AQ7K6M^Y_+RL;BVDK)B-"[QV.=6\1CKQF+GRDEX;_8D
M3!PZ%M7EPY&?.Q0%Q:-153L!=8T3,:AY/!I4WYI0K?K5M@BP;2OV\\2&9ULZ
M@[4M]F?/^[X 6Z[AQFH]AN!,&:4L_ :B!=/O=!(+KML)UH)1U9I_*MHVWY3&
M:VZ9B %50Y%#V'4X"A&?6(CD]$IDYC<@I[ 921D#J1#E4%%*- G/7"F]^D52
M"0]&E^ZA<'9/0E1<);+SAR*[8#CBDNK@'Y(/']]D$YL<$YF$#"7:RU'YMTH4
MY)0C,ZT020G9[$<9B(O.0'QL-AR)!<A(KT!!?KU)?J8,X\W-DS"4UZSKF#AQ
MF8'K*5-78.*D91@[;A&O6?'GLWG]A.S1:ANU/^\9Q^JRBD84E]8AIZ 2B03G
M\,A$1(4GF!=0>A&4'I>.U-@TI++_IO-OQ5]G$JXS**GQ64B,(5A')",ZC-<7
MEHB(X 2$$:Y# ^,1'!@'/]\H>'J%P9W/H@!;%FQWCRAX>,9R>X*Y?C__-+9!
MIA'!MK*+R[KM[9W(93R<G$+1IX\_EX$(#:%REE>%$<,G8>&"U=A@X'HWQ]ZC
M9@Y1"4WI 4JVJ5 85;6PX)ISW7W.>;8%^[\!L!\+5#GN66!-2)0QH9,\,3 0
MBB6/"-H/"9+&S5LQU81NN7K?)H!>4Q6)VX]Q\Q[!^?&?"-)_)HQ3/_OY3US^
MD0!N0?5#'N\1Y2%_[S['77GJW=8+TKL<KQ_PLT<_&_W-'K=_*1JG+7C^[P+L
M?RQLLR=B;]/W+;$-,'HIH1*L=Q_<IG!^OWT)YR\=P^'CN[![_W;L/;@3Q\\<
MQ]5;UW#WD>;2>]1'KN/DV5/8>V@OMGR^&;,73$-U?2GB4D*@9&."#]7UE5OU
MJ$D5&#=C(-JG56#H>)7.RC$EI6I:4PA?J6A2?//H0@SBOHHMSBZ),+'&,<G^
MIEQ54@9AJ30/F7G*"Q#"9[L?NO;LA1Y]^AK77A</3_@'AR R-AK1";$(CPE#
M8)@O L(\$97@CXP"*V:YLB&)X)), )8U,=FX@+>TIYND6,VCTC!H6 *WRXHM
MR,["Z&EY&#FEP#KG4?EH&$HX;<Y!68T%V045"2BM)9P36&4=UG4UC<R$RF;5
M#>&UF;K4R<9=6>7"VL;E8-@$E:.293*.@$TPK \U;LT#!T<3NF.XKR [!>/G
M%&+"G!+^G6+<H3T#N\/=KR<"PCT,9"NC=VIN!Q@3N *B>A"^NA-HG$WY,UE]
M!=ARLQ[4QM\?I7)811@VOH2@74SPS4-UBRSRR02N6+9W"&'4'Y&)/@0O+P1'
M>R PPIWB ?\P-W@%6A;K@'!!?A@R"Q)04)["[SH(:X1.@GYBIJ^Q[N:5*\.Y
M _4$1,&]VENQYK)>JRZXW+Q#8OLB/$&QU)[F!8'<]E.4<*X\BM"8W)'L+9E0
MJQATE31S14A<7_.]Z&07[NM+P&;[U489ZW@YV[*\/H2 '4J85U;T! )G'.+3
M@GG>3NC>MQOG@[?P1M<WT:5'5_1VZ@-74TO=%]X!?NQ#'NC9MP_UFK>YWYOH
MWOMM]'7I"2]_%T3$!2(Q(Q+)V5$F+CL^/8A_!_$<E%4_&@4$W8(!"3R?.()P
M)-L@&$J"EIH?B.RR< /(C2/8-T;EL1V2C/4Z.8]ME>_/_7F,,GTG!/$* \B3
MY5L>%2FH;E5&_F24U,4BO3@0,6GNB$AR06RZDL3) \2!LCKE%TCE;RO'0#+!
M-M%8L55^*S!22<]\$!3M@] X GU&%/ML!B&XD#"<:^*M@_F9)^^M5["+*4WF
M%>1LP+R7\UOH[?HV//A9=%(PCYM@K--R!\\N5F9R9;H/-@GXM%1=;UFQ2P:F
M&%'2,_6)*(>'\8X8.:$.NP]LP[_]3\5@=_[W"\!^R,%64&V$RO$S<&TKRY;"
M_,\!MB5/H?D? 7;G_6SY=<!^JN1+](;4E#PB*&ARM=S$-;E:$&%9YQ[A%B>B
M2]?N$YRN$K*/8L-'7V'IJDV8]\Y:3)^S#%-FO(/)A.U9<Y=AU6I"-D'YX,&3
M.'M62<ENXA)!^^SYRSAQ\AP.'#Z!'7L.8NM7._'AQ]OP+L'@O0\_Q<:/OL!F
M0O;GG^\T *E)_X*R61.NY:JL[.%*F';YBI2!BP3%JP1!"[ %O )#P: -BS9,
M=I;.\&ROV[#969X%;"D5MMC@V5ELZ+9*;?$8*E5&$6A+Y")^BT!VD^UXY?H]
M3G[GL'G+=LR:LY10/1J%Q77(S*Y$5?403)W^CJE%NOWK??B68+IO_Q$3,ZS$
M7%H*3 791X^=,6VD6M5J5QL:+UTF0-_2N4KQ^=XL[YH7* 3_ZT\A6TO;8FU#
MMM:UGZY3BI+*8JEDUH>;/D%]XS X4HI06-J L1/G8>["M;S_ZS"?\L[R#5CS
M[B?XZ--OL7WG84[JIXTU>P_[P/:=NM>[C7RS^Q .'3V-TV<O0K6N3Y\YBZ-'
MC^'0H8,$7UFP3Q&PK_!W;Q-<V>Z*G6?_O$V(O<&VNT5EZ.K-ASAZXA+;[UO,
MF;/*0'5#_6@T-XW!F/99F#5K.=:N^1C;MNTAO)_"\>.7*!=QE.!_^/!I8\%6
MN^D%D+*F*XNZ7@1=41PVY5G MJ'Z/PK8-CP_3^S/[7V>!]B6Z(6;Q@.-#\H6
M_B/OTRWCM: ZJ!LV;,:Z=9M,B("6BQ>OQO@),U!?/P39!(Z(Z&2X>X7@K1ZN
M>.&UGOC=R]WPTJL]\>J;??$Z8?O5-_J:V&M9KM]ZVPE]^_G!FS M93PL+-D
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MB42DPQW!,?T(V&XFIE<QS[)TRS5?"=MDJ59[RX*M$FL";,74-X_,YGW/1^E
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M>[@ .RR8D!VDYT//2CH<T>F()VQ'A228$(LP2CB?RXA@@G40)9B0'99B(#O
MC^#L'@%W K:67IYR"2=DJ_ZU5PS%!NP$>/LX"-3)!JSE$BZXUN<N_&Z??OX$
M;!\$!%%!+Z_'E*GS.4YLP <?;L'GGVM^.<;Q3_.GW, U5EDBT+;&JTX@*>F
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M+[^./_SA9?SV=YR0?DOYW2L$F-?QXLMOXXVW>J-'+Q?"-94=0D<0X2,D.,9
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M4V^C.SX3; I,%;>LN&2)@-Y.%';QDI)F7<+EJS=PY=I-'#MQ#IL__1JSYZW
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M<UN%9&MREX MX>*/5 $N\;3:@5FFHB#$6RI0+1"L )O+[$6[9/Y7,.XE[WK
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M@*\ ]POQC%)>O7Y-A:B]H7U#1?*&^_JF)PQ*UA41>%1OJ0ED+WD,$A;V^K7
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MI=!3:+"18&!6_8-3$M*1D92.U'A"B34>4@4\QD@0(9!$15@)PD;5)BF2AI.
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MU+0L1%G#;!H)<FT:8$FJ@HG_BZ)8$Z4 6@G"=&F$<AL"@Z0]6QHLYG1$AL?
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MH/2&?X0#?$()F)Q*CK+TIG;Q&4,[9C &C1R$(:.&8N#P(?AB8'_\J<\7^*,
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MPGT.ITCN<Y#*.7;V'J&UR_(8H@!TF&-_U2Y+>E/[!,M^>\/5VY50/!)]!P_
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MQE+BD5\5C\SB&%Z#*%@2)<\Y  &1WO -]8(O[P'/0#<5&BUYR,.=!F(HP7K
MB$\Q<,3G!-'1T%G%V\TQ.L7&>R4"[GX>&.8P@H \F#IE"#[O.PR?]9'I  P8
M\@5&N?3CMD?"%.>KO/N5#7FH'%N(%$)B0&@0AHT>C;X#!Z#OH+X*L*7@F:O?
M$+@%#()[X$#X1X[@,4KA/#V/)1;YE7%(S3?!%._'_SG U7\(G'P&$LJY?L P
M> 811D/&P#=,/._.B(QVAYFP&YWF"UNJG"]/0K$KC]D907IWA)O]U#D(C/2"
MFX2JNP[EM1C.[TO(ME3RUO-Z1T+RHFW2YSK)D[:=*V%^C )L*:XFN=\2$9!7
M&<UK)97-@_A[?DC.UZ('8C*\8$IRA"7%&7'9WKQ.4M6^IT4: 3LYA^<T(X2_
M%:B>NU"C.WQ"'##&;1!UM.2R?XY1SMPOMY'P\'-#04D>#AP^0#+^:P\%_]?^
M_BG EO84&S=N05UM$QH;QA$VUF'KYMU4=@*+"S!UVARL6+D.)T^=4P.5#&JB
MD.R@_9T*G;)#MD"UW7,MH>+?$*S_<X#](Y66B,S+<EGO@W$ORO&W1K]=?@7L
MW_G?[XE=&<O +(.Q@(<&M1\@6P-L 3W-D_IK#G%/$2X-$)_B^HV[.';\+#9O
MVH4%"U9AVM0%Z.Z>BZ[QLSF_&,N7;<;^_:=4R)<,\,KCR.\+)(GG6N!:\GL5
M8"L0E.K/$K(N.=9O"'!4>F]>:J'(G!?O]5LJ0RT76 /LER_?$0B?\S=NJ/!G
M >S+EV\KK_DC@K!XL*7XU6L"H%TI2IY3[Q<+=M'.@RS_EOOT'??U*P+A<URX
M?!=GSE]7H=^W[SW% RJM._>?$JYI%!#L)?=:<L2DY=3NO:=5.'G=V"[DY5>C
MHK(!TZ;/P8:-6W'PT#%<OG(#4L1+SI^\I#AW_C).G#R+L^<N00J+J;QCWF\"
MF0+8$DF@6HST!FP[5/^.](9K$?F.';*5A_?M#WC^]!M<O_H$APZ<Q?JUN[!R
M^2:L6[L-!P\<5RWKY+>DA^:K5P+9CZF@'W#Z%-**2RJ3JCQG@>VOY#ZGLN>S
M<?O>,U5X9NKT%:KB<4/#3'1T+,;\!=NP8^<Y'N<C'M\;W+[[2H72G[UX37FO
MSU^^BFLWY/Z05((>:.X-V,^?XZG ]=,GO!Y<YY%4&)<4  DCUT+#I477ZS>]
MX?KW ;NWY^?WGJG>SY+]_Q^>+<V8M7NOQ;,C!NB[=]_B[MTG.'KT##9OWJ/@
M>LN6_7PF#O#^WXHIDQ:AGO="17DCRLHKD963"DM,",*,3@@UC>2 .X)&PBCH
MHIV@CY9")5Y4/BX8[C *_8>-Y-0# <$F&OR)JAV1KP=!Q,D3GFZ^JA>P+^'8
MU<4/#J,]X4; EJ).,;9DQ,>F$"22D9:8@HPD2F(2P9&03<!.(6PD6%-AUL40
M7G0($,]W#V ;PJ,(V2)41H1K$8M!P-J*.%NT$@%L?00!*"@$OC[^\/;RA9>G
M'WR\ Q$62L5B2T1N;BG'U4Y,D!=N702_QFX4YM<B):F0H%. K![ 3DNK0$H:
MSXL4/2MM1ZFTN*J>@)+*\2IT,2:Q!)&F3(3ITV&TYB.6H)V268_T["8DI]?#
M%E_%Y<4P&O.03$AL*VW%IAES<'[=8MS<. NWUG3@_LIF/%S>B(=+&@C9+7BT
M<AP>KAF/VY2+*R?@Z/(I6#M],EK+FY >6XID;K.XJ).@/$W!LO2M%J 6J21$
MBXAG6P!<];?FO"RS][>VYUEKA<QF\+-(3W_K7P';'B+^CP&[M7T66L=)>/AL
MY946H&[N6*@)YR6\LY%0W=!*P*8T2AAX*^&ZA;_7(-O6/.^U==QGGM>2DG9"
M73,RT\?R.E01*,L08RU08!T>%(< [RC5@BK(C^#KH<.PH=[XP[\.Q__[_^R+
M_Q<A^W_\ZPA\VM<%?6ETCW8U(-R4AX+R29@X;2.-TMT*LDO'SD9.R41DY(]#
M0EH]HF)*$6;(0I@N'=;H?%[O2F2D5R N.@OAP18%V,ZC?92X$+3=Q)OM(I =
M G^?< 3[Z7A?\A[4Q2+!DO(!L&/2D$P CC?%(=80TP/9,;#JHB$MY 2LY7OB
MP1; CN?ZB7&\[V,)TC$B65R6I?8CAK ODB@%^)(*5.$SFRU%P75B8@YLUC0$
M!YGA[B:MN,((VCJ*7E4+=_,P:D+ %G'Q,,#9@Q#MJ8>[MQ'>OGQF?:/A[6F!
MAQLAW%D'?U\;0;X4;:TSL621C+U[U'BQF^/GV;,W")1O5)]C"=L6F-/"D068
M/[QP_WC\ZJW7[6.<?;W>8H^^^P#8FMC',PVN[>'A8IO\\FOG%!4B+K;*3USV
M,X'\EU_P]2]_H?P-;[[[!?>??X6C9VY@R:J=:.V<S^>XFW ]!0W-\S"A>R6F
MSUQ/W2C>Z_W8L^\L3IRZH0#[PB4I;'8?-PG,#Q]2A[UXC]>OOU8Z^\4K\<9*
M_0U[:I  XPN"]G-"-G7PM4>X3# 7R#YRY (V;-J+N0M68MK,Q9A'R%ZU9@>7
M[5>R=OU>@OU1G#U_F_J$MH:$BE,OO"),O_J2-L@[ C;E%>T,50!-Z1%-KWP,
MV+WK>OP>'-NA^3\C'V_C[^4? +:\..X!;$D/?$<])Y%Z8O>(_2/GZ^[=9[37
M'N/\I?LX>NH6=AVXC-6;CF/Z_*UJ/"FMFHR,W!:.IV4(B4SCO6O!:(<PPK4_
MA@Z34'%OC!GM"U?70([WH?#BN._AXX[ ,$)(DI[/>PQ2LDU(S(SD\V]&_;A,
MPG4EYG+<G;^R"=,65*-C:B%JVZ1E%6&MB- H1:,LG@B(T$)[I2IX7GD,RNM3
M.+6H\&]]C!-UHP,AQ1,916'*6YQ3IH,UV1T!NL&4H9SW0E&UE;^9AIJ6>&07
M2S$L-\*'!MDYI4&H;#1AW.043)R9K0!;/-BE=1)6'DG1$^!L:!Z?ADDSBS%[
M<<VO@"UYV#5M IG2(UG:40G@ZU6H>DE=C +7L>VI:!J?@::N-%5!O*+9K,+#
MM9[0X4@O," I2T<0"E&YQ)(C:TD(Y/$3U//,R"B(AB':'\,=O\ ?^_Q?Z#?T
M7^'J/9(@[06#+026N$A8XW4<2R.A,X=Q/ V$7Z@'W'Q'$EZ'(L3@JLY[=K&T
M,-,A*5O:-X4@MSQ* ;:T19.66^*]-A$4I6IVH&$,0J)X;F,\>G*!)===\V0K
M;W:9 +>98!U- (SE<40C,8OC,.%:9PU4+:@D]'N,^W""Y4@X>FG>W)&N@S"*
M@#?252"[#T:Z$'8C)._<AOSR+-X;&8A-B49@1 "AV($@.(R0/)1P/11_^G00
M_O197WX6P![(^\()MN10Y)8FHJJA "55>8A)BN9]YXV!0X?BB_[]".=],&14
M?^6Q]9&B9A$$Y;"A\(L<CG";BPH'3RTT(JW Q/LI#!%63_B&CU: [>@]4%49
M'^/1'Z/=!_ 8!-()V\$C">&C5=$Q4X('P=B-Y\H1_CHM[-T4%\QS8>%YML&<
M$*D@V]W?@8#N0KB6<Q_-ZQ"+U#RK@GH)_T[*"^&^^!'4W7C.73CU@%0/E_SK
MO,H89/:T#HO-"-!"]PL)YFG\[?@QL*2Z(#'/C]='PO@%KB.X;0%L25F0-(T@
MZ&W>?(9<X!DX6IV[@<,_09]!_XK^0S_G^1D -Q\7%%<4XO"Q0_^=@/WA3P"[
M=YLN*0RQ9,DRI*9F(CDY@U X"6O7;,2633NP:M4&S)N_E+($ZS=LQ>DS%]0@
M+XKHIY__II2-'8*5M^M[+3Q<Y)OO-+C^YEM.5>BX += ^&\A6^0_ NS>X&PW
M_O]71;;56Q';(5M$H$3S8HO'5 I+">QID"V%P>RMHP2P1>[=E["CZX3H8UB]
M>@OFS)%0\?DTJF=C\B3QBJY2H;*'#Y^C I508X+E _$^2JBO>">U/&,-##4X
M5)[1-Z\(U*+D-*"VBRQ[^5IR<K60<J6 7WRIO..7+MW"R9,7<?KT%5PGP(E2
MD9[)XKT61:-!F,"S73Z\4+"+!MH"V=_RMW_D;WV/Q\^^5&'@UV\]Q$U"X+U'
M+_"08'>7QW']UGU<OB9P3;ER%T>/7\+RE=O1T#0)B334HJ083V(FJJKK,67J
M+%6E6X/LFY"0>3E_ MS'3YS!L6.G5*$O@6\!;#MD:_G(<IX$F+47'Q^+/5];
MI#=<:^?SMX#]U9>$PC=_QJ,'7^(B#8U#!TYC[YZC.'3P)"Y=O(['CYXIN/Z:
MROK=N[=X3L!](I[C1T_PA-=-HAH$^M^\E;Z>?Z9"_S.-E;<X?O(JEJ[8AG&=
M<PD/D]#4+'G7:[!QTS&<.GT/-V^_QMW[[]0+BTM7[Q*PKU.N\KS=A/2^OG/G
ML;J.$M(F1<[D'I%[3?IM"UQ+KGYOP):";4^?R<L&S7LM^V-O<Z(91+^%:[O8
MC4_-V/S]9\N^_%=1ZXJ!*O^3YU(+G92",W*/2<3$'IY#B8+9N'$/MFX]@/7K
M=F/APK68/'D>6EH)8^6UR,RF(1]O@M[L1SAQ0;AY#*':$<989PZ0K@C1.Q.N
M1V.DTU ,'CX$0T>-@:NG/R)U-DCK(0M!(BP@'('>00CRIZ(-UB,LQ @_WW :
M[P&JO["!@!$?FXJD^#2D$*;3$D0(VG&)A)-$PG6RRE]-I-B,\8@(,BK #O0)
M102WUQNPC1%&!=@2%AYCL2&^!["M4188(O4(#0KE;]+0<O>&IX<O @)"$66B
MH96<34"M5H ]OG,&NB?,Q?AQ,U%7W8&"7)Z'M'(%V)GI50JP4SF?D5.+[()&
MY!8U(Z>@B<9>/>*2RZ"+RD) : +\@N,5I%EBBY&47HLL 44:A,GI#8A.(&1'
M%<%B+$)V8BVZJKNP8?I,G%PY$S<V=./A^C9"=3T>+:G!@R6UA&V"]IHVW-LP
M'A=6=V'KG Y,:6I&478CP:<9:>F=*"V7/.GI"IH%HDO+QZNI';+M@%U>*<LF
M:'!=*T#[ :ZE]59]HWBO9ZAM_1:PIT+Z30M<UQ&NQS9.ZPD3_WO 5A[L7H#=
M-&Z!@FL-L.<JR&X4+W:+>*X)]=Q>#:&ZJG8"JFNX;SP?Y14=!.PV%!:T\+S7
M(MJ2AXB01 01]@2L_=QU\'&-@ \ATMN=(.D4C*%#//&G/XW __7_[8__X__3
M'__C#R/PR1?.-&J\,'!$$!P]S# 1H&N;YF'VHCU8M/(0IL[=CN;.92@HZZ8Q
M5(-P8RX"PE(0$I$"LS4'R4FE2$LI(=AF0A<6#3_/<+@Y^FN0/<:W![+]X4E#
MWH_WLWBQ]:'22BY6]<1.LJ4B)29= 7:*+1F)YG@-LL63;8CM!=AF?L_,>UCJ
M!<0CUIK">S<%,=94SJ=1TA%KH[%GS>2SE4[ )GS'Y1"PI0A:+N&:GPG7R2GY
MB(G.0%BHC?=X) &#Y\:U![#M<*T VP1W+Q/<1+Q-\/ UP=,W"CY^%GAYF>'B
M% DG HLWU[-9<E!5.1ZS9J[$FC6[-+C>=9SZZS+'P:=*_WS/\44 5\8K&;>T
MG.O?CET?CUFRW*[7_S%@:]_[3J6L"5QKH"V_)5"M>6&Y3;%1E'TB=HD6(BYV
MB8C ]9__\E=\1_GZY[_BW0]_P:-7W^#LE0=8M^4PQD]:HJ)/2BLG\EZ4-(?%
MZ)JXHB<\?!MUPF&5.WV2,'[ZW V5=G69^O,.(?#I,]'%W^#-FZ\AQ4;EY;+H
M&]%_:BJU89Z^H0YXA?OW7N(V]<G-&T]PG:!]_OPM[-I[#$N6K\?T68LP:^XR
MK%BU5;7UVK[S*&VY?2K=:__!,[AZ_0&>OJ2^_XJ_]=57>/&6^O/U<[QX0\@6
MVT,5415;0#S"OP_8,NT-V!]#LAV<_UGI_=W?EW\.L.6%C+P<D(X:<I[D9<1=
MWE>W;C_#M9O/<>K"0^S8=PD+5^Q#Q^15?'YGH[1Z*HK*NSG^=G)\K8/!G,=[
M5ZJ+!V/P$"]"MA><' -4JI*OZ!M//JL>3@B.\"%<QZ*FN0!5C=DHJDHD(">C
M96(>ILZOQKP5303L9DQ?6$O +D)=6Z;R4$NK+8%" 0,I9.43,EIYX;)+; 3>
M!,)#!"(LC@2FP0@V#B=$>T):2DG?9JGJ+57#?<*D!=,0Y?63EE]C"9+531I@
MQZ:Z$LX<";8>R*\((WS'H&MZI@)L"1,7X"ZJCB"P1W!_3*AKC>>YR.'X58XY
MU!&SEU1CRKP2C)N:A;&=B9#V6]+B2P!?^D(7UT:CHB%> ]@VZ05.N&Y/1C6W
M4UIO1DYY&.%)JJ5+E>UHI.28"-8!A&97@J.S@J%(LS=A,Q+)V1RK; $8Z=PA
M#KB*  #_]$E$050?G_3[O]%OR!\QQG4(W'W'J.)=@>'>"-'Y(507R&D0PO3!
M"-7[PS?$%3[!CI JVRDY1A02A O$&UIB4M[JPFH;]R\%5<U)/'=ZY=D.C7+@
M.1L!SY A\ HEB')>X%$?ZZ[R?R4/6"IK2[BRUE8J' GR<B E H9H_K[!!_YA
M'G#UI9WB,H@0W4_!M",!U]EGN*JL[>JG39V\A\#-7Z+T? G8TI(L#5G%''M3
M;3S^0(*Y P:-'(S/^P_$'S\9B#_\ZP#\43JE#.Q+&V@P_$*=55_PM%Q>\[)T
MI.<F(S)*!P<79ZXS2!5%^[S_YQ@\HA]A?P2WZ:HJA@?H1L(W8AB"3=*>RXM@
M*SG6M$WB_?E_-\*S(WS#QL"+]YQ[P CNYV "ML#V$+7?$FKN%C!8M<V*(*3K
M8@2PG2FN!&A_)&2:>(\E\E@2".TFVG'^\(_@.D9OGB<=,HOBD%O.>[PL0>79
MYU5:>3^8D%88@=C, )YC"4'WZXD>,/ ^B5+%SN2<VU)]D2AAZ7E!L*00QF/'
MP)3LA/@<'ZX;#*G<K@&V]+_6$; C8$L*1$24!Y\C)P+V&#AY#,/P,?UX'_T)
MG_7_(S[M]Z\8-GH(,O/2L>_0OO\.P!:2[D73O_,G\+!@X0+8:#"&A(0B+S<?
M4R9/Q>I5:[%ITS:L)FPO7+2<ZRS#ILW;"3]7"2KOE&*RATII$$P#_#L-K+\6
M^;;'<ZW@^K=*L#=<B]@5EAVR[?*_&[!%T=H5L S0O3W9=N@4(!,PLP-<;V^V
M!CX:_$G_XC-G+F'GSH-8L6(C(7L9IDY=@*E3%F+FC&58NF2C"A67T+=SYV\H
M^)6B&UIA*MF^Y'IKOZ% \245W&NI6JUYK-])P1&*M":199*'JX6J/U4>3_&,
M7R6P7;@@Q5%NJOE;M\3K2@"C(A; EK!C+51<H%/ 7([S[P%;$PDE_Y;R@PHC
M>RH 3ZB^2_"]*[])L).*I#*]<Y^*_=8#U9[K),%^ZW8:F-.7H*2LF<99/N(3
MLI&>48"*RK'HZ.S&[#D+L6;M)NS><Q!GSEY2$0#2^UE:BDCOZ5.GSZM657)L
M6N]G*>2EA4/+.=*,C ]0W5O^&<"6XW[[YGN\>O$='C]\AQN2,TX#Y_RYJ[AZ
MY18>/GBJJK>_?R\MR[Y2S\AK:<GU0CP'3ZBHI8#<0Q6N)X7@WKS]GC#\)??[
M)M:LVX/)4Y>@J45Z]D[!A.Y%6+%R%PX=OL)C?(;;=U_CYIV7/>W,;N/\I5LJ
M(N#JM;LJW_ V 5O"_^YS'^28'SZ2X]:B'02N/TA/I?6G<MSBT9>JX1\ 6S.
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M-6CH*"!H9J-Y0BXFSBHC6-<HF3"S#(WC<PBVJ2BN241!13S2\\VP)@8K#ZP
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MMZ85UU=UX,2B#JR9V(R6TBIDIE30T.%V2F<AOV8^2JJGH51RK G5 MBEY1\
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MMV#*W :T3RY%;9L4U4I$G>0F=V4IJ6D5SW4L<DJEBKB5TQAD%T43@ T*#J5
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M!1=O9_B&>B(LRA?2KDO:6:47:WG;$@8=E\G?2O14K:E,\=Z$6P'#*(H MIZ
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MLJ4'Z*,GFA=;"Y'[$$WP,6#;@=H.U[U% VUY42+"Z\EKIAD./!\"GE])"*(
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MK[_C,R%M]6B(2FCX6S[3]WC_G3QW!3OV'L6&+7N5;.1]MF;]=LQ9L!P3ILQ
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MQ9?TE4Z57M#E<<@J,"$E.PSI>1$HJ;:AH3T-K1.R57ZUA(J7UT>A;*R)^V.
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M+158VE*#E9TM6-[5CHY:PF<*%3)A.<#="WXNGO C)/L3B@,H M?BP0XF,&N
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M['""MS$@BG ="F\/&L$\5H-OI H+]_.)X&\;X>S@KP#;R5&\V"%P=0F#FXN
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M]56AX>&!5(21R4B-ST1*7":A)4T!=E1$%F)B"I&@ %OS7J>EUR!#"I'E-(P
M=AW2,JJ13*A.4E!=CD01R<E6.=MEB$\H0 3W%Q*<@,B(5)4S7%G1BI;F!10Q
MYKOY6O*B6U%*H"PMEKQK@C6-:N71IA02L"5T7+Q9^;F-E!84Y+83NB4W6[8G
MH!,H"XJJD)U?@:S<*I7N4%@XB_/$7(+J/-[?\PC$;\.[E7!=7O\Y<*V+"A.O
MU/*O-;B6 FA:=7$=L.MF+E* 755+(*^:K4+%I6IX3L%HT"Y0H!T9DX,(PK8
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M)L"$G[OYNB,L-AC126$(DRKD$5[P"G)6QRXYY0X\?AL7$YC:3829_21(J]7
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M<U-,FF:B"LA]/(XRWH1P/1WC)IE@PI1IF&)J AMG&^6QCDS@6!.8P^-]5-T
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MXWMM*"YN0TEI.TK+.E0U;Y5O+6'A!& !Z-%@_5. +2'D[XH&V*,\VGPM4*W
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M GF\'C#&<IS")6=:Q!:>05;*JRTAX'ZA4NC/![[!K@1U,YC:C(>9[3@XN)O
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MEP;<]:&;&+IXC>]=59!]XMA9'#YX @<)VX,#1Y41<9S +ZW.I&KHO?O/5<3
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M%,EE*/*J@I!5[HO,,E\4UH:@LB6>D)V(PNH8!;1IA1%(R14O= 3!E?H_G+8
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M)EN!VA^"[H^)#K^ZZ.^/!FP1>3WZ>W^)Z+_Q5C'\N/P49.O>[!<*OK108O&
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M@VVI')Z<6HZ"PD9"YCRTMJ] !T&[N749I!A9;GZC"O]6Q<NX%."6OMAZ+K:
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MO6_5_?@=[M$&V#/0@[E+./<WY:*T*@5YI5&$;"WG.;/8GZ!$8"KP)FA)!>X
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M]T1W".P*8,NZS/<"=MIX::+L(HZUB$0C??8YQ_-SCNN(%_O)DT]H ]Q";^\
M%BQ8P6NV ,N6KZ5.'<")D]2#U^^H""XIZB7Z1X!7?DMYS>6!,76:Y& _(1 _
M>O9* ;9$?MTCD _?>TH=2)OA_$T,#)[!EFT#'+M=6+FZ%VO%P[_E '7P4>S9
M>XZ_=8LVB+06>X-GM&>>TZYYQC&0!P7RVU)83&J/: ]C1GN,WP+VV[1 L>'$
M9M/NC=& K=T??SYDRUB.AFM==.>')EKM''E/EEJ4F>9QE^.1@J'/7SW%Y:LG
MT;-[)69U5V)&52J*RF)16AV/&;629RR]CKV5=S NTQE9,_P(UF$H)X26-4:I
M?M(9);Z$5'=$I#A#\EH%J')F1&)&O810QZB*XZ4U 10_E-7YH[HI"/5M86CH
M((2WA:.T@:!.8,TJ-W IZQ*6'*#"EKV#I\'9=SR<_<;!RSB%(&J#I!POPA/W
M*87+"(02"BZA[%)A7+9Q\AE+P":(A4TGM#IP7]X$*3]")2$VQ48!MN2+I^2[
M<NF(:()V3+H=/]<\V<6U(<BKD-!M\<3Z\+L\+L)Y7H4_@8U@5NI)&.4Q5/H2
M0GVX+CG<WH1L?^7AKVB,517,BZKBD)8?CL@$/W@'.,+&T033+,:IED_3K,;1
M!IFF^DT+> K$28$MR?/U";'G^P1+UZFP<IZJ' *>@2XPA'@1LKTA?:^E796Y
MG2G,[4U@Z62BMA.XMO.8IKS7 GC2FBHRQ9W@Z:"\MD$QUJJX5WIQ( $N4$%G
M1(J3"O7.*/'GM91JYE&$[$A"<SC/)X)+68]2'NW<\C"":PAR*\*X;82J@EZL
MBK2%<5LCL@G9F:4<#]XC>>5!O'?""-GAB$OWA7>0-5Q]+15@)Z1%(C2:<S?/
M8=SD\62L#_'1N/&J4KBII17,;:SXF:VJ-.X3Z J?(!>>LWCII\">@.T5.!WA
MB0Y(S/&DN/,\;7ENTQ$2;\Y[U(G@S.LB?==+_9&<ZXW8#%[W5!>$)#@0LNTX
M)E(Q/I#G$\GMHI!1%(I8'J/TK;;WF Q+Y_%<3H.;P4J)JY\Y[RL+A'(<4_/\
M>%X1O/=B>-])A7;QH/-O)->?0"Q1!])SW8WKWHA(\"%D>\$8Y:[:B(5$2QLO
M7]YK!D1G^B \C=<FR1DA2=*NRQLQF?Z(SY%(@2BD%\8B,LD()R];C)W\,?[V
M%W^'?_\?_Q/^S;__C[197;!AT]8?1'+_)?]^$K!'_WO]R2L"]ARXN-D3A#_B
MDG] D?Y(B ]"7+0'X=H&"3$.*,@VH*0@!#D9!L3'NB(DV([&BAD-F4F8-.4C
M?/#QK_'>A^_Q0H^C,6+""V].R#;%;P2R/YB(,1]/@K6%#4*#0U%>5D:H68K=
MNWIQ8'  ^_;U8^M6Z2>Y%CT[>G#Z]%E54$)[^DV%0K#^['.9& 48-,^V-N&^
M!5P=DO60;%EJVVCR+D3+:PU$WD*V+OHV.D"+R/Y&B_Z[?ZZ\NP_=DRT3MT"6
M:M\EH5E*I +G&\KG5')?$N0^QZT[KW#VPCV"ZWDJM$.\00:5K%K=C_D+MV)6
MYQITSEZMO,P[=Q[$L6.7<9&0?>V:>+ ?$@X?J'PM"2^37"X-M 6R'^.A>,HO
MWU8%4&IKVU%1T8397<NX;_%:;Z$1W878^&P:M2'P\8L@')30$%E!"#Z.<Q>&
M5;NNBY>E79<&V4>/#V'O_I,J-USRIWMZ#V'7WN.$:D(V%?+> Y3!T^CG-@+@
M&PC8ZS;N@E:=="\V;>FC@MZ' P=.XO*EV[A_G\J>!H,*T>:Q7QFZRO<OX=K5
M:[A_]QZ5-HT[CI\8"%)P;.# 02Q93H4W>RX6+5N!GEW].'+R#"Y=NX7KTMJ+
ML'R+P'[ZU%5LWM2O\M3*!:ZKVM#:N@"K5VW'P8,$.(Z=_/8PM[]^@V-YXR8-
M"PD-IT'YB ;*TWL$[$?\73%4WN9=RW&(Z("MO_\N8+_^1 \-UP#ZK==:#![Q
M4FCR%K2U[7\(V)]\#]A2E54\,U+01^YI[4&4W-/:4W\Q/"14[^JU.SR_4]BZ
MK1\;.>X]/?*@Z[@2\4HM6;P9+1R'TLHZ3K#I\ WW@86+*:9:CX>YPV38N9K
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MB<U&0F0&(HR)\/>.XF^'P-$^ ':V_K"S\2=4^\'"PIO [*W&5!Y R!C;.X;
MF7 M+;G<Q'/M'J,@VY[0+0\UIDQUPO3ISBJL/#.C#%V=RQ1<]W)N'Q@XJ7*O
MI5WA\Q<:! KXO87KMWI2TZLR)[V%Z]$R&JYUH'Y7-+@F3$E[SV__B&]'RRC
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M_R7:<W>IM[G/YW)^GQ'^7ZKP]J<$;?'$OP5LWC^\9S3 UCW&!-_O*XO+.&F
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MF)"'YJ9Y6+MV!^>. YPC#ZJ'=%>OWB4X"5QKWFCQILH\H\&US$/: VQ-M^J
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MAS^, N&_X-]/ O8_CBJ?]MFGK[!A_5(J42IS-Q,$&6T(V"Y(X(5-2N ? 2_
MC")?@G44VEOB4%<3AC+>.*4E1A07A2 [QXC(*#<XN4RC,?,>/AKS*WPT]@/*
M6'SX\7B\]]['>/_]#S%QW#C86IC#X.V&J/!  GPH4I*C4%*<A<[.1FS<N(+
MV,-)>CLV;5F/C83L?0,'J-1N<:+_5'FPOZ8BE0E30:H"; F=TB!8!V U\8T
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MBK9 MJ0T"5S+@^*KU#%2W%4 6]X7&T;LA?<VB,B? [:(P+7(4^Y?HM$DXNK
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M9Q-0[SV&Y#Q+'VO1)[<)IQ(:+OI"/-<"UPJP;\AG=_D=+3=;[(/W=H@&CWK
M5O*28RCI<SQ'J2#^@)![Z=)-'#]^!D>.G<29<P+6UPE]$F6E;5-ONPC :Y#]
M7N1S!;6T,\3.>DQYR'.XSW.\^^"I\F)+T3.16Y*?3=B^H2!;/-F$<,+RS=O/
M<.["717%MG;]?MX[6LCXHD6;L'K5#FQ8OXN@O0_[]IW"V;/4H[>I)Q]RK)3W
MG^/U0$N5$LA6^I* *S5JM#!Q0BUM(RV?_L?>:#TX_Q1@#Q9]D3VQ(27%4+SB
MHD-%EPX6>4\O^O?T73LTD?>>\A@?\SK?Q].G]WD<#[F/)]S^(WY^CV-V U=N
MG,?)<[1Y#M#.V; *DV9.0T5#/1(RL@E0B0B,2D1P3 HA+PNQZ<5(S*DFD)7
MCW.!LX\/'#P)+]$>!/(8ZKL"3)E33M N1,^D3+3T)*&F)4:%4V<42RZK]#,.
M0DI>J'H=37B*2G8CI/H0A,4KG(#"RD1D%$2JW%8I?"6]E44\"9^>@3:$;3N"
M+*$Q*QCYY;$\UF34M(H7/%F%JI?41G-;$CHN0$J@SO9!:I[ M52<)M@3HJ05
M6%J!#E)Y7,+#!;#S*J4=E[1]\N=Z4JC*&J'Q9@0C<\*:+<'6F3"NXSJ!*&N*
M4E!?7!V+]/Q0U:8I.%J'L#A?)*2'\_@3*(F((S-(B+>;KZW*O_8.<4(D02LM
M/X;GFH:Z]B(T]Y01UM/YOA=AST3E!]NXC>:X&BH/:V TP9G;CTKQXM*#@":Y
M\@+!6AAX<@'/D; <F^F"\&1[!=?^T>9<6JD67=+_.B'''8FYA%1"=@K/.ZU0
MX%G:LTG[,U]$IQ$0N=V(),EI]T!DLKOZ6T!;JG%+Q7<M/UM:F@430(,(N![P
M";6!D\Y$10X:6HCG>CA&&8V @:DA;3,+V#K9P\G=!:Z>U">^7#_0BV#M@]#H
M $@AM,2,2,)U#&V1*$0E!B @W)V0ZL)QE-!K7T*KC*D;HI.UGM1I!8&\EGX$
M< ^$$JA]P\WA'6:&@&@;'J\KST.KJBZ@'9FBG4-H@A/'4*JL2YZ_)>P)QU+H
MS-IU!!R]C> >**'B]FI,);\_LT@B(/QXC^AXOTO:@3>!7J ^&/$9D@K@ '=_
M4]@3T&T(V<Y>$BY.@([3(23&'9Y!]K#3F<'$<0S&V R#,6';WLL2/CRWD'A_
M^$=YP\'+%B--A^&CWQ.N?_V_\$\__U\*L/_O__3?\?_\QW^B[M.1AU;^XU7$
M_R[ ?G87BQ9,1%*BC@;H:,3$F",EU1H)B:8$WQ$(#AJ*^#@3E!*J&QN"4%_G
M3\@F7%=XHJ;:GW =CI;F.'X6S_=C4%1 R$[T0R -<!<',SC:F,#=D0/@:H-
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MI!URY!PN7*1>OZ4?6ZTOM_:PFO+X$6&?XT'(5L>JCE\>$FCR(60/?HBCE_>
MK3VHD#!S;3S^.F#+:[W76L9RL,A[S\46$[N,X_F">OTY1=EK4B/HQ6MUGURD
MS;+_T&FLV[0'TV>O1E5='Z(3*N#AFP%7KW3X!!8@/*X.R5D]!.!)**J93CCL
M)R@V$AIC8.-JHWHZ^X?;(J<D&+4MB2BOBT1ZON32$E[R E2XMX112]7HC()8
M@G D(A,]5 ZO?[@]P<Z/NH?OY\4@F! BE;@-S4=0OQOR.)P0&.%%T'?F^\8P
MM1FA6G'ZTQY/S@Y2H"OAVN*M#B68^H1:P2M8$]]0&P1'.W&_W'>*!P'(4?58
M3B!$9Y?ZJ79/V67^ SFWOLIC&9_A@=@T5P7BT6E.!"YGPINK\GIG$&8S2R3\
M7& L "DY03R&4(Y-.(&?T)@2A(@$7^71]N7QZ0)MX>IK!8] &P1%DRD(XRFY
M4M0M!/&9_H1E3T*B/73!IO"-L$1LIH['$X:<"FG!)<7= O@='X*=CNMZ(#Y+
M>G?[JPK@>54A**B5/.E09/$<$G,]$)/A0A&H=N>VW-3?T3Q^"0M/*?!2^=BI
MA3X\'RT77L*H%5BG^?!\*2F:MSR:[R5D^Q,\0RC!2,CQXW<X1H3->#)44(R+
MBBQP(#/9.)G#TL&2<[@UYW([SNW.<//R@L['!ZXZ=]@ZV1*ZS;B>)=R\'>$?
MZHF@"!^"J0XZ/V>"M1T_,X.IM>8)-[(4&0X#\Z]@2OO.V=.,]X@CP=I5Y6@'
M1CH@@& <1- .)^C'\APDY2!9KD=^@'H=R6L=FN"L #L\R9WGYLEK[Z85.O,T
M@)W'*+@'F'$=5W5^TLXKB_=N8A99,-Z.,&X.[Q!32.AX5+([X9[@GBH%YSS5
M^<=RO,(3/'A/.R,HTIF_#QWB> \G9$K/[3 $Q%#'^3C W,4<=K1)I95L2'P0
M_'C>]AZV&&$\'!]__A%^_IN?XV>_^CG^UR]^@?_WO_P/ O;_@+V3!WEA!?[X
M+_\' /O5BSO8L'8FRDO"$1=MAL0$4\*U"9(2C1 ;:T@Q14:&(RKY0VEIB41+
M:P0:&D-06^.'BC(OE!1YH) W7DZF.S)3W9#."Y(2[X[D6!U2XWR1F\H;-)V3
M0:P?(OT=$.QE@3 _0C:!.B+8%I&AMC08[!$::H_@4 =$\H>3GAF-ZKI2]$H5
MX5DS,'W./$R;14-ZWD(L7;X*F[9LQ:'#1PA!UQ1(_ "K"E@UT5>)E->#@59R
M>!04\S/Y6REK]<3][P=LO;S?Q]\6_;9^2N2X7X@,P/6'@"UP_8T2F<@%KI\2
MKF5RI\)YJBD@:?%UB\KN^)F+V+!Y'Q8OD]976RE;""5K,&'2/'1T349']R1,
M[)^#)2O68\N.?831DP3M"SAV\K("ZQ.GKU*N\;V+V+G["):MW$@P[T=-?1L:
MFKO1.V$:6MO'$S[RE??:VR<289&I2$PJH"'=C-YQL[& RG3YBJ\)=-NQ>/%F
M2 [X8@+PZG5;L'//09PX=0%GSDOU\8LX<^ZRJFQZZY8&UC=OW%%P?97&S24)
MT[YX!=>O7,<MPNXM&G<2-BXMNZY<O4=X/(U5!*AY"U9A 2%[];J=V/:UA(>?
MPE8N5ZSY&K/GKR98ST,;H;J9$-72.07C)L[AF*Q0U;0/'CR.TZ<OJ@KE%[@_
M@6L)J98^[%)M52J3*^\"EW=H2-P5PV6@+=C=>P^5_.. _=Y@TP/U>\#6R\"V
M>;]K@*TW!'A/?/.-\EQ_^[T8HN_4]B]>OHJ]^PYB_8;-A.JU"K!%)$Q\U>H-
M6+9B%6;/G8N><=T$M1(DI$1SPG;B1&T 8XLA,+4B7!.J!:PM"-IVMJ/@YV6+
MC(1@-)5G8U)[+>:,:]6J@%,6]W5BZ>0>K)PV'BNGC\?2J03E"6V8,;814[IJ
M,9%0W4>9W%&%:=VUF,7WYQ*PYXUMP5P"]EP"]MRN#LSN[L*,KDZ,;VI$$^&Z
M)"L3.:E)R,_)1%55%=K:>]#9,XG0/!FM ]=RZ<JM.'#D/,Y=OJNJ_%Z\^@!7
M;CS"I>L/<8SW\]H-.S%V?#]R"RH0'9N&T/ DA$4D(S8N"\G)!0JTJZO:T=PT
M#@V$[;)R C,A6](>Q),M@)TN'NQ!@"WAW$KT@"W>:\)U1EX+TG(D[+N!X"S>
M[6;D%+4BI[B5!DXSTG/K*75<CY)/^"98IW-?&0+8^0V$FV84$JZEU98"9L*R
M'I[U?_\ V%4"V&-_[,46".?K,JY364U(IC%7UR!]KK6\:X%F/5B75TKQ,:UJ
MN,"X +" L+R6=>0[ M*M[3.4Z/.L&YK$ Z[OA4U@YWJROH"T'+<\'!# +BC6
M>G*KORDY>4W*<YV06*9Z7DN^M8MK!.P="('BN5:>:.E5[8SA([5B9%H?:SM\
M-<067WYEBR%#'0C<XLWV@K&QCX)L<W,)']?"QBVM?%7^\2C"K7B=3<V<X>SJ
M!_^@:$008".CDQ$1D83P\!2$AZ0@.# 1P0&)B A)I?[+0D)L#A+CLY&4D(.L
MC&)45C1APKCI6+YL$_;N/H;S9V[@RJ4'.'WR)K9L/(2>SAF(C<J&C:6'@FOQ
M7IL:._Y0X$Q5#[?UA)N3]+\.AK]W& ()^%J;+CU@)R&!]Z.$B:LB9T&1"JZ#
M?4/A1[CV=I,0\8#W@!TF@)V P(!H^'![[NY!<'+R)6 3K@G8#BX!<-%%T-B*
MH7$5 T>W"-@1M.U="=9N881KD5#^'0Q+6V\8&#O!F,?JX16!S)PJ=(^;B06<
ML]>LWX%-FW9@S]Y#*J]70IW%(ZN'&=7^B@ H4"9+T7-ZP-;K4:7??M"#HE??
M@\Z_%K U[[5\1_9!W?E&BCI2N'S]AG#_=D#XV6O9_YL_\%B_YSS^' <.7,$2
MPG7OV"5H:9Y).V:F NR>OGD8.VDNQD^;A^GSEV/Y^FW8>? 83O)\+UV_K7*-
MM2K:#W&'\^]]SL4R7VN%P60>EQ!F0NGS-YR+Y:$#X6T L%\(8/.])P+93UX2
M.A]S7KJ#T^<NX?CI<SA'W29AUD]D_#@^$K4F\"BZ0:\79"Z7<=;LFH$'%+)]
M;OL%0?(YMZ^O(BYP+^]I#S[DV.1Z/5%>6@%L%0XM'N !^1"P9=_RP$3.2<+^
M[XG'6GFN]7#]$@_%L\UM/R3L2DO1NP\?:I!]1R!;>F3?Q8W;U(OWI?C9,YR_
M=!?[]I_!NG6[.?Z;L7C1)JQ8OE5YL:4MY)K5.[!ERUZN<T*E9UV[+GI60%NB
M!$1$MTK%<X'L <#F,4K.O]8[6^Z]#P%;[#Q-7OZ02BCW(V%;/:@86$< ^R]Y
ML =RK.7UWP1L@6O1]Z*?><Q/^?J%7-.GKW'O[A.<NW"3MM0Q+%R\B?;77.06
M=B(\NARNGAFP=TZ&FV<.0B(EI:@+*5D3"+334=<^'U4M$Y&<DT^ =(.)#?6Q
M_9?P#C9!?+H;H5-'$'%7(;T9A9*K'$+PE/#><,)P$@HJ$PEKA-%$-X3$$@I3
M?0GDT2H?US_4'68V8S!TU.\QVG@8YP(;!(;[$+)]X$9HL7$RI1C#W<<:87$>
MW%<@MT58)0AYAUC!R<L CH0H%Q\3> 59$\Q<5.$L"?&-32,(\;C2"GR15R'5
MLB6GV8_'2: D<*K/TSWX6O)O*5*1.\=#A55+[G%VF;2 $I#R)(QRW31"9TXX
M]6DDHI,""?0N</6Q(D3Q&%T-E=BZ&\+%UQP!A+&H%!\%LPI0"7AVNE&P<1L&
M)Y_1A#T'@G,HRIL34:):DPF(^_-XY;@EO-U'>5ISR\,A_:M+&V-1T1R/LJ88
MGD<HCTL\V9XJ)SN5(M7$8PG;T>E27=R% *[C9]Y<>D%"S*6ZML![7+J?>L 1
MGNB)X!@W'IL;PN+%"RS>;2D41N@6S[8*4R<HQKC#)\0)+EXVL'6Q@+6C)6R=
M!:P=*4Z<WYT)UCIXB/?:PP4VCE:PL#6!E8,IKZ4UKYNC FU[%VM8V)G2EC.$
M@=E(C#(:@A&&7U(^QS"#SS!T].\PTN0SPOM(Y<D.C'1"6*R[\A3'IODB25UW
M+?4@-H/O<9SBLZ1JN'B2I3>XDP)H>8"0F.VOSC68[WD$2G$T8WB'6?/</)%5
M*BVY8K@,5=<].-:.(&X&SR#IE6U)F)?*[_8(C+)'2)P+KSO'+]V7T.ZE0MB#
MHIS4/1;%L8G/"$)\)G5G4C!T(3K8>SO P<L>;@'2)DP'%V\7F-N98\CHH?CH
MTX_Q\X]^1<#^)0'[5\J#_?_\Q_\&6T=7+%RR[-\#L ="Q&4[@V60:_S-Z[O8
MM6,1VEM2D)7F@-0D,QH7!DB('T.X-D)<@B72>1,5%_NCIB8<M=+SK2J8?WLC
M5TK1ISDA,\49683KK%0=,I(]D)K 'TR\)W)2 E&9'X?&TE34%2:B,#D(*>%N
MB/:W(6B;(<C3E$8$@3O8#N%AS@B/X&>QO(E3PI&5FXRBLCS4--6@<]Q83)DQ
MG; T#_,7+L2"18L("JNP9]\^7+YZ32DA"?EY1:6MA4YI52,UI200^U[12ZL'
MO7=;/_'J#0+-*- F8/TDK$W$[V%=V]X &'_P]U\7;9L?BC)"*"\'Y(5>^!TY
MWE<\SM<"V52.$H;TZH5,Z#*!/U/A2<^>:R%+TM[K+I7054+AR3/7E!=7*G2O
MW[B;,+5%A6CWCI^.MLX):.^>B$G]<WF3K54MLB2D^L@Q\6)?4R*MMPX>/D_#
MZCBWL1\;:&2M7+.)VUE/F%V.MH[Q2$K.@:]?!(*"XY!&0[2JI@-CQ\W K-DK
ML'B) /9VU;9CY\[C.$+X.7'R@JID>N[\)5R3T&L%L(3JV_=Q5Q6!T>#ZZI6;
M*AS\,F'WBH1I\_752U=QG<!]\[J +HV=VX]Q_N)-E7>^<,DZ]$]?A.FSEO+U
M1JQ:NY.@O1L+EV["Y/[%/-=^U#;VHKJ^!PVM$] SGL<X?P76$:[W[3^*4Z?.
M$:XOXQ+W<^6*Y,)IGFN!ZUNW[ZEP/LEADZ4&UQI,2YJ"A.??H_$U.#1<[WF0
M>W*P\2)_?RAZR-9 6RK,"F!3:-3(DWP-LC6P?L!K*T;&XR>:8A<1Y2]I!'+?
MOOM6/#Q2(?<Y+G,,]^P[K$!:0F&D3<OJM1L55"]<O(SCM 0SY\ZF@2D5MW,0
M%.$+.Q=S&%D,AR'AVL1J"!4P%3J7EA9#86]-N-99(Y-PW5:=CQF]3<HSO6!"
MNZH$/K>G68D4+5LRN4O!]4(NI?#9M+$-"K"G=%9C*F5:5PUF]$B+KD;,Z6W!
M[)X6S.ALP?0.KMO>ALFM+>AM;$!S13G*\W)1D)&._,QT%.7GHK2XE!!8C9+2
M.H)F T&PE??S)"Q:NA&'CE[ U9N/:>@]Q_5;3]7K*S<>XQ)A6Z(RMGU]$%.G
MSR?TU1*RTE2KN?B$7,)>+A(3\Y"67H+\_!I4<)M5U9W<1PNRLB5DOEQYKS.R
M",'9A.N<6H*UUAI+JGYG#10YDY9=2J1]UT !-"EXEBMP2>@5R2-LYA1*.Z_&
M ="N52+0+B+ +N'A$D(MGFB!:8%G)66#A']+"+@6!BZ>9\*U*GK62L!MXSJ=
M!.@>U-2-)_P*8$L/;*D63K 6F%80+070I/C9>)ZO5D5<\K;UU<?%P]W8/ 4M
M;0+8XL$6C_54!=W5W%9UK>1G2PBY%$Z;P.](F/G <13QO/.;D9W;@*R<>HY=
M+5+2JZA+2E1!,[^ 5%7$3'*L3<V\E,=:P%H\UN*M'C8 U4J&VQ&J"=<$[*^&
MVA.\I1>V)XQ-?6%J[@\+"W]86TO!,PGM#E&0;68N8>6.W!YAU\P)3LX^" B,
M0C3A.BXV%;$Q*8CA/1!)R X)B$>P?QRBPE*1&)=-P,Y&>DH!:BM;,8OSRG;.
MCZ=/7,)MWD]/'W^#;U[] <^>O,/10Q<PI6\^DN+SX6CG"Q-#.Y@8V1.TI1V7
M)YSLO.'JZ L=8=?;/42UT_+W$B$TZPC:GB$(]HG\(0=;0#LJ6/-:2XNN(!]9
M1^#:#YZNOC\ =DA0#$(XYP8%QL+7)P*>W(Z;6R <N2\[*7)F[P-'UT :[Y'0
M^<9!YY, =Z\X_AU#B:9$*<^UG4L0C2]O&)F[8+21'>P<:2 GYZ*M>Q)F+UB!
M9:LW8LN./=0+IW#EZDW.082)%Z*3--VJP;46O37X8;1>IPV&:[WN%#C4/-#_
M6K#61*L2+M\3/<UMOWY)B"+<O*9>'(#L5TI$E[[#4T*GS <'#U_F/+@+/83K
MNOH9J*>TM,U!][CY&#MQ'OJFSL<,@>MU6[%=(KM.G<=YSJ'71#_)0U3.P??4
M'"SSM ;7 J$_5+NF/?&48_&4Y_E<QD>\RP3LYZ^^Q1,"\./G;PFB+W#^\FWL
M/W(:FW?L57+H^!D"_$,\>4E(YM@\X[BJ[5!?*-WP9_L2YX",J=@HXBG_EO/_
M6^H! C7EF504Y^?*7GG!L2$@/J>\>#'@P5:0+<>KU7=Y\J%PO[(_[0$OX?D^
MA3I(>:\?O<"#)Z\(UZ]X/ER/8/F NN@^==(]0K9XS&]+N#AUIO3*OGZ3RYL/
M<.W& ^K\FSAPX S6TQX0R%ZT<+WR9*]<L0VK5VW'ZM7;5!V4G3L/X<2)\[S?
M;@\\N)8B: +KT@;S 8^-NN^IZ%(>ZX#HB^OI(5L37@<%SQPOWG\_MM'X-T7>
M%V>+/'300[96R&R0R-\4>9BM1!^J/B"JV!GEA2S%PR[Z^?$C[3T98UZW.W<>
MX0(!>_?NXY@S?RT:.*=FYK0@*JX"GCZ9_-W%P8&0[1=8C*C8)OX&NY!5,!%E
M==-1T3 >.27E!.0@%;9M8O=[F#M\"C>_T00T>Z00KJ4B>'Y%/#(*)&PZ$EG%
MB2AOR$)U:Q:*:VB;#81TBU<P-3<,R5EA!"D/PI@1AHSZ#%^-^%0!F*>?&X(C
M_!$4[@N?0 _E^?0*<$)0I.3H"O!(RR@I0B6MDJ0(U2@X>QEKWG%";5J^A*K3
M;B>TYI2%H+ Z B5UD5R&(*-88$U"D,5S[:X 7, Z13SP^5Y<>BFOM:I4+M7#
MB^28==R?&Z'>"TE9!+/T4/B'N1$TC6%D-1P&ED,QAK:*$>T4"\<1*K\Z*,99
MP75$$N$ST!+FCD-A8/4IC&T_)X2-42'- GD%U5%(+PKDNCK"G(2W$Y8SQ8,L
M^>&2(QRL//92A;V\,0%EC?&JK9:$MZ?D2\BXORKJEIQ'X,N6?&TW2-7P^&P/
MBHZO*9G\+-.7VPU 8E8PSSN $.FN"JVY^EK#(\ 6GN0>KQ [^(0[J-[. 1QK
MWU!7>/H[*4!V=+.!]+2VM+. O;/D6SL1FN4!B"U!6D+"7>'A(SG8#G#6V2@@
M=_6V4QYK.\*UN8TIYW=)]1N-,292;9QC9C($!N8B7_+]SSF67\#*:03<_2V4
M!UO"\;,*HY!?GH"BZF3DE<=S3$((TAX\1F?UX"(PVDGUMI;P[U!>HUC>6PK"
M"<7BQ?:+L"5<$]BE]W6F-[(YEOE5T5Q**S2)%G A9-OS?&U4Y7"?4.E?;L&Q
M,>?2$OX1]APKWGLQ3@B(<N#V[)1'74+'PQ-Y7TC;-G*B;X0GW -=8>=AR]^%
M!4QLS6C#FF"$P6A\^N67^.7'O\4__^HW^-DO/\+/?O$;_+__^7_@__Z/_Q4V
M]LY8L'CIOV,.MAZL]?(GO1O[7_#VS1T<V+<,?;TT8 MUR,VT04:J"9*3"-=Q
M)@1>J2KN@.1D5V1F$IIS?)&=S9LLU0/)TLHKU@DI<2Y(3] A,\D+Z8F>2(_W
M0G:2'TJR(M!<EHJQ=;D81VDM3D9E>CAR8GR0&.R"*'\'A/G:(H3+4/X=(8W1
MH_TH@0B/"D183!#B4V-16%Y Q=]**)R(Z3-G8.;L69@W?SXA>S5V[MZ+L^<N
MJ; H*3"BGN(J(6A+A4W]$TV9<#GIR60J.:L*7I4QH(?JP:+!KWQ/^^Y[(T&V
MIWVN?>_/O_M3HO^.]KW![^F?YJLGJS1*]*"M>>,UP-;D%>4EA<I2SH%*\[D\
M91UXPOJ0$_R]1_)$67I3$C!NW,?ILP+*)_'UKD-8NVX[YLQ;A@D39R@/8/?8
M*9@P:3;?6X4UA-*O=QW' 1J-AXY<4A7 ]^T[@SU[CF/O_N,X?/04CI\\IY9;
MMNW"M!GS:)03(+*+D%]0B9;6L>B?MH!@O0XK5FXFV&W%QDU2P?04E<LM*ADJ
M8BK+.^(-OGD3MV[RO5MWU-^W!60)M-<E_/NR!M87!7C/7U%P?>WR=5P5V*9<
MNWQ+5:Z]=O,^3IZ]C(W;=F/:[,4$Q:GHZ)Z*L>-GJPKJ?9,7HKMW%F%@/"&E
MA49_ P&B UUC^ZGD5F+#EEW8?_ X3@I<7[BL0JDEW_KZS=L$?ZU5BLJ3H\$@
M8>#ZI182_O[IN@)L]?=[P-;#M<C?#]CBL1# IA$C\A. K87)48$//#E_2M&\
MUV_QAL:JW.MW[C[&Z3.7L&OW(:Q:LYDPO9+PN9*OQ1LE@"U]76E,SIF![@F=
M*"C+IM+2P=1F%(89?*+$P/(KF-D.TP";"LS.<@3\7*V0$1.(]JH\S.MKQ^K9
M?5@]<SQANI-03< >VX397?68T].H"I<MF-B)>9,Z,8L /F,<X;FG@6!=B_Z.
M*O2W5U*J,;VS'C,)U]/YNY[2T8+Q+8WHKJ]#2V4E:DM*4%54A.K2$C355*.]
MJ1'M+<VHKZU'04$IYZ(<SDE92$HN("BV8/+4!=BT=3_.G.?]<5L\)R]XCSSF
M;^#QP-_/<>'R7:Q>MP,5U6T("4M&4&@B$I+RD9)6C$1N)Y9P%1N7@_2,4@)N
M(T&^C<MFY(J7.J<.F=EUO-_K%3!FY300'ALI_ T(5&<W:97%LQIH/$F1LA;D
M%8G'N0M%!.)BBK;L1B'!.:^PC3 M($[XE)QN$=DV@53 5 %VB81Y2_ZR>)7?
MRX] 6X3;$Z^U@&TA ;NXM)WK=?!^[R90]Q"$>U#)97FE;$L>''"I\J(%IL>A
MLHJP7#/0KJM:6GI):/@$Y9EN;IU*$)$V7%/1W#*%OR?I:RU@+FW NA3$5]6,
MY?>D,)H<AX2V<\SR&PG5-4A*+2-4B^&8CY#P+'C[)\/5(T:UAS*S\(&!H3M&
M2/CW""E IGFKAPVWQQ#Q6 _5 'O8"'L-N$=RO5$N&&5 &#?U@:E% "P(UC9V
MP7!P"H>S5!QWBX2CDWC#?56A+W/Q(EN[P\W5#X$"V)&)B(E*0@R7T1%)B. ]
M$!P0BT"_:(0%)R"*P!T1FD3(SD1U>3,6S%V!HP=/X_[MI_CVS;_@^V^!UX2V
MRYS3%BU8C>ST4M@3IL>,L(2)@2WLK6A $6Y]/$(HP?#5T2A48!VAX%K>DTK@
M.F<_>'&] .EA[1^M6G1%$)Q#"=<"UH'>05P_ +X>_H1K'W@X>\/3S1^^7B'P
M]XV GT0.\;ON;D%P(< [.TN(N!_L[7W5TLDU&&ZZ*!KP\?#R3:(D\G4B83L>
MKGS?SBD(9M:>,#!U@;&Y,VP</!'&<:FN;\6,N0NP;.U:K-V\&?L.'28@W>)<
M([G FMX2_:>%YLJ#:NTAM3[R2UYK^E8O@W6GINOT</UO NP!D?UI@$W ?TUP
M)&B__(:OWW!?2@BUA,UKMQ_CP)&+6+)R)WK&+T%MPPQ4U4Y'8\M<M'<MP-@)
M"]$W92%FS5V.581K:><HM4G.4-=<D@>M MAW.>_+/*_F8"TR2>;S9P1>.7_-
M"TK(HVY^*DOJ[.<<IQ=OOL>+;[XGC+[#G0>O<.;2'6S;?0R+EF_"E)F+T3][
M"9:MV8H]ATZKOO[7[PC$4R<(,'*[,K[RL%2+;M*\Y7IOK8)H\5339GC.,7[*
M]Y[P.R)/"?MBYXB-H![(#]@*+WA\XES0'^]3;E\\YT_T#P<HCPFO#ZC#Y"'R
M725R3-R_%+(CS#[F=7_*[\M^'A/('U&'25C[@\?BV><840]*"S")^KI"?2H/
M9JZ+1YOZ6NR _?O/8MW:/2H76R![^;(MRI.]8L56K%RY!6O7;B=D2Z'3"[AV
M7=J5:?I5CD=$(KED3%34P""XU@.V_J&/.% T<-8>*JA(0-XK(G*_J'M&/7#@
MN@,/'?2A\YJ^_A"P!^0#_2WK"$P_>_:$KZ5=W0,N'W)[3SG._)P0+@\*I&;!
ML6/G:8/M5.EZ[9TS5#11=FX+(J.*$!2<RV49DE-:.&_V(K=P(G7S>.254D?D
MYR,N+9)P0>@--H>#YS X^XR$5*46#VQA53QA,$X!=F91+(IKTU#?E8_6\05H
MZ$Y'68. C121"N(ZH4C+"R4P^\*==K?46/EB^.\()%_!QM$27GX>A.P 1,2&
M(2J>DA"B\K6E(%9TBJ<"'.]@:SAY&OX V!)2G)H;C()*[KLF@?N/I\2BM%XD
MFM <RN/T(UCI")ONA$XI;"55QJ7*MA3VDH)@7@1??X(OX;<R#.D%6G7KT#A7
M1) G$C*"><R!T/G;P\1J!.V4SS'<^"L"]G#"]1C"M1F!ST%Y4)-S@PA@'G#T
M,L(8R\\PROQ3@M<0..@,%; E$:#%2RW5L(.B[53(N^1%2_7T.(J\CDGU5NW+
M,@I#D5\1PW.0GN#2NLI7*]15(F'O001NZ0,NQ^^#%+Y6GFN!ZRSI#4YHS_)'
M4G8PQR>"YQ[*_>E4M7-+)T-8.AK QM6(UU/:6=GR^%W@$^(&-Q]G.+K:P\'%
M7K7<LK 5P#8G8-L2L.T)SC8J%%SZ7'L'2;5P@F\X)<(=@12_4#?U<$36M780
MR+: J94QP7,T#,V'<_R&*X^UG=L8.$BE;\\Q</$Q5)$)X?'N/-80%%4FH;P^
M0TE.:3QBT@+@$^:DJJZ[^EE2S%7[+5V0%(ES5@]!8M+$X^RMQE[RVX-B'53N
MMN1M2TA^?E4D<LIY;0L#."Z2]^Z."'X>2G8,C')4!=UT@9;P"+" 9Y"E"C7W
M"2. 1]C /]*6VQ.8%X^YP+DKWZ-$>!#(76'M;($11B/PY8@A^&K$" P9/@J?
M?3D,O_GD2_SJX]_CEQ]]IN2__/>?X3_\Y_]&?>?T[P78&D:_!VM-_N6/?_SA
MC[??W,:!/4O0-S8;5:7>*"MR17&^';(R+9&49(&H* L$A9C30#%'2(@E(B/M
M$2-/BJ(H$4Z(BW!! D\VD1<W.=(#:3%>R$D,0$EF!.J*DM!=DX.^A@),J,U#
M5TD:FO,249,5AY*42&3%!B$F6(= +PZPIST-!V?X^O(&\72&B[L#7+V<X!/D
MR1]\*#)R4U%96XZNGDX"WG3,6[! %6A:N&@I-FS<IIY\WKXC(=,"UG^@?$?%
M(N%2$LHF(5,R<8K'[SFA1$++M*?M[PT'S7@0&6Q,B.B?C [^3#,6--&#]E\2
M_7>T[_U8],:&6D\)]S$ V'H/@"B(#T7SQ&LA7_)T5<*G1#EJ0CBC,KI-92>5
M2R6\3T*A-V[Z&@L6KN D/Q=C":7M'1/1W3,-_9STERW;BDV;#V+'UR>P>_=I
M[-US1E7Z/" AY 3K8\>EU^,9'#I\@NM]C?D+EF+*U%F83MA>O&25JN2]:?-.
M7HNO5>&QO?N.XNRY:RJ<^_Z])[A+I7O]*D'V\F5<NW*9\$R(OG 1%\Y=P/FS
MYW%!>EN?NXA+Y^3]*PJH%6!?ND$A9%\D?$OE\\LW<)&*^]B9"UBW[6M,YOX;
MVP@&M5+X2=H4M='8EQ#9#A04$GBR*I"75X/&QE[,G+44F[;LQJ$CIU0^X5G9
M'Z%>JK<JL.8QBM?ZQT!-0V-@J1<-L#6P'@S7 LOOE>][N/XIT=8;*.1"HT$,
MJ$>/I,@+Y<%S951IX>*:5_S1D\<T@*1@C0;8\L1=#$P)F93[2MJS'#UZ%NLW
M2$_K=5BP: V6+%^/%=*6:_5Z+%NUBG]++8/9F#"5D%17A-!8/TZV8S#4\'<8
M:O Q1IE^!F.;(3"U(V!;#X4U)V-/1U,DA_J@J2@3L\<V8\VL/FR</P7KY_1A
MU?0>+)O2B8436C"[NP$S.NLPD\M9A.J9$SHT&4_()H!/[ZS%E-8*3&HL15]C
M&2:WUF!*I^1FMZ"WM0G-594H+RA 7D8F<M(YN1>5H+.M#3.F]F/^G#F8-6T&
M>GO&H:RL!K&QZ:IH67!((M((Q'7U/>B?OAA;MAU4D'WS]G/<NO.<]_]+_A;>
MT%!\K=Z75(6<_&KHO,*5Q,;G$ :K";3UO$_*$<>_HV(RD9A42+"N1SFA46"R
M0$*\"=0Y.4W(SFXD:&N2G=-,:2%\TQ B7(ODY#43-.5[6ENL"@+K#R'8%,E)
M+B! YQ"D,PGJ M8BF01T ?;<_%84%G:@N%C@N9OGVZ-YG =$PK@%JL5;7"SA
MX"HD7).2 ;B6>[^<OX7RRC;^W4+0;^(^*85-*"*("V1+L3'Q9DN(>&75> 79
MU37C45,KH>$3T42@%K!N(60W-4]&0V,?/Q>X%K"7?7';7):KWQJ/AW"=SWWD
M%<@#"<)U2@DBHW.H.U+AXY] L(Z"5+(VL_:'H9D71AFZ$:Z=%3P/D_QJ@6@N
MAPRS5W MD"WOC1CM3*AVY?KN&&7D@=%&G@1L7YA:!L#2-IBP& 97]VA5!=S+
M-QX>GM&J6)F=G0_L[;SA0OCT]=9"JZ/#"=%A<8@43S'_#@WB/100@R#_* 3Y
M11&T(^'O$Z[>2R1DUU0T8^ZL)=B_YRAN7><<0& [33VSE+^MDJ):>!&8I?V6
MX4A+V%FXP).P&^0;B3!^/X3;"R((^Q&R?=R#U6?NCCYPM?=2O:P]G/P(T)H7
M6_IAA_I'\KL$<H*UGZ>_!M@ZPC@!V\W)"V[.!&U"MLX]$.ZN 7#A]QWM?> @
M'FM'?S@Y!L#)*9"P'0Q7MW U#EX$:F\%V$D*L-T]8^'@% I3<T^,-G3D>#K"
MCL<4%I6,LJIZ3)@\%0LY1ZS;NA&[#NS&V8OGE3[1ZSL-F,5[K<&,_*W78;(<
MK"L_%-G&OP6J?RSZ$'%NBSI2"Q6GOGQ#/2EI57PMT5]/>!PW[S_#P1.$ZU4[
MT#MI,>I;9Z*Z<2;J6Z2"_Q)TC5N"\7Q_^LRE6+Z"Y[OG,,Z<O8S+5V\KN7+M
M-O6"%""3%*'[N$,=(/.\S-LJ')Z@J>EF 37"W"O.ZP+9?$^\T2_?T 9Y^R\$
MTW<X=_D^MNP\AAGSUZ"]=R9JFL:AKF4"CV$F9LZG[MR\!_L.GU4>[CO4E8^?
M4K<_)S03XB7'6_2 +!54"N1R[,7;_8SCK^0E[1L>CP)\!=+2:>4EON$Q"62_
M%,>"$K$9-("7;3P1NTAMYZW:GH"KZ#-]&I32/0*T!%G]NL]I,XG(/@70!<I_
ML#TX/E(=7?2EZ--KUPG8U*TW.892,^7<V=O8M_<,(7LW%B^6RN+42TLW$:ZW
M*2^V%!S=0/VU9Z_T6+^DX%R\V/*@65O*PV9Y(*V-A1ZL)<]=7@MPBVX54);S
M50\4. X*L@? ^N5KCH<\D%&B0;;F?!D8FY\*G=<#]Y^]+R(AY8\I#RD$;,JS
MEX\59#][SF,5QP>/_=J->SA]Y@KV'SB-G;P7-FXZ@ 4+-F!LSVS4<LZMY%Q<
M4ST%=76SJ3=FHJ"D&RF9)03<1 )V.-(*(@ARA.,T#P4;DN^<5A!"& U7'E+I
MXYQ>&$&H34%S;RXZ)^>CK2\3]=V)J!RH-)Y?$4Y@XG;R.!_&>1*R3##2Z L,
M&_T%C,S'P-K>0A7*"HD,05)Z/+(*4I%5F*ARH",2=<JSZ$6H$K"6-DH:8+NH
M2M_%-8DHJT]&474<<LLC*-+JBH!:*7VTI>^Q-^%41W'G>>B0J2J,^Q&L!;*]
MD%'LK4+),U01-"FBYJI"VZ4'=EP:@3B1<Y^_ TRM1V.XP5<8;3H"5HX29NQ$
MJ",0YP01X**XS2CEP;;3&<# ZG/"]3"5O^[D948H<R1$^R(AVP]AB4X\'VM"
MKX/*'Y<'")+SJ^4@2TBR*V)3Q3,?BNR2*(YS"!*S!>!YW*5!R*T(X?M2N"T
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M*+ NK(GE]J)4P3)';V-8.!$F/4U56+9OJ*."P,3L0%6D2T*4/8,E!]B"<.O
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MS)FS G.IK-:OV\7)^SH>/:+R>_T'O'GS1RKD/VC@*F%DKSG9<=+3()N3["#
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ML?75M>4S\5SKX5I$JFK+,B]?@+6=GW<0F+M16BJ>:X)UQ7@5OBW>9;UH4"R
MW8[BXC8%V$4$7O$F%Y>V<9UN-+5,1'?O=/1.F(&6]@G</R%^ + EA%P 6WG#
M5<BY>*6["-@]J*L?S_&;1+ 6N.[G.$OOZVEH;)K,WY( MNQ7CI''6BC'W42H
M%N^[C$.=6HJDI5<A-JX0@4$"=M%P< PAW/ES+O?!&&-/C#3PH$BE;W>,IHP:
M,_!:\JN-O;B>%##3Q$3$P@_&7!JJ[WNI,'$1 Q,OF%GZP=XI#&X"E))S[$.X
M)CAZ>T7"WR\:H2$)*M=:0L1# @F_!.S(D!A$A1&\!_I)2XAX6$@<HB*2$!V1
MK(&W5.CV#(&3O2<L3!U@3K&W]8 KP=J=4"VAVA).'L+UP@C3H?[1RAOM[RD%
MRB+4WQ(F[DOXEM!PO0?;P=)->;#E;_%B>[KX4[@]%U]X.'O"W8G&H8LG?'0:
M8/M2=&Y^"N:ES9>CO7BQQ6OM2Q&X#H*[>Y@":V\OCH%G-.$Z2HV[]!;W]4N&
M+R%;>HQ+(;DOO[+$T&$V<'0.1DIJ*>^5"9@P:1:FSYZ/9:M78_>!O;A\XQ(>
MOWA$^"* $"#U7NO!<*W7@X-UVE_2F?KU?AJ:_Q7RCMN0!XO?$;*_Y;X(E?J<
MYU>BY]\!CY__ 6<NWL?:30<Q<=IRM';/0F,'[^.>V>CJ6X2QDY>A;_HJS)R_
M :MH+^RE[CA[]BHN7[ZE>DB+]_KV'7FP*H#XB*\EW%D#;<V+K7EW1>\J'2VZ
M>@#T-2_O.Q[3]P3@=[A)T#]\[)(JOMG0W(?,G&IDY=:@OG$<9L]=I5I*'CQ\
M#CNX7+IB$V;/6X8%2U81R'?BT/'3N$2==X<@^4!"MPF3TH-::JS<ET)D Y M
M7F3E8980>8J,B4#_-X3';PB84B!5VD5)2+^$4FL%T;C^*WD@\2>N_P?J,((>
M 5@Z:8B^EKHHSPFK;]]^JXIGOGE'7</7\B!#A9-SS%4N-O79XQ]TTX]UG.C#
M!]+&B[KTACRDN':7@/T0-Z4VQM7[M!\N8^?.PUB[=IMZ,+QX\5HL6;+V!\A>
M3_MDURXI>G:!Z]_%W;M/":3/.?Y2FT12IV3[6NV2]R'CFH=>CN$O [9>_OT
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M*".,,3"'I;4+7*6@DU\D @D_OGX1!(9 ^/E'(#6M@/=HIPKIKF\8B]R"VA\
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M3S^&FZ>GJB+^QW^TR-E?!&QY/?#OY<N'6+MN/HJ*8Q$688.(:"O$Q%O20+5
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M>B\:9.N+@NA!6X6,WWFL(%L,C L7;N#8\?.$T2,JG'KZ],5H:R7 TAAO;)B
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M8M'RM>@9/PVU#;TH+F]#>G8MHF(+X!^4 B_.27[!D9POXU!4G876<<7HGE*
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M4OS.F&!MQ*6)R@>W<C*!H>4(?#GJ$WPV[#<8:?(5'#PLX!/F@N 8@7EOGGL
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MJG7TBE:[7J*(Y9[04@:^50:#7)=#ATX2IK=@T>*56+%B'=9OV**,Y&G3Y_P
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M5SA":<2*=SLRD-\/HA%!F%9P'9ZBEK$"V*&)B E/4G ='\E[C@ M(>(2_BV
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M&Q<OXS7UX$\$Y>]>OL"KP?NX1[B^?/8D3AT]B)-'#N+"F1.X??T*!@?Z\(S
M_)*@_>K52_[.&UX[U(]#8"U *_#_] 7M#.Z7 /;3YT\H#Q5@/WPB_:T)W$.
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MG@1: FY(0!3" @BUTO_:-Y3Z*)C+($3XA2+2/P(14MV; !WL'4&8CB!XAR.
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MN2^:!UOGQ2;D"V"/"!?_$J1'BDZ/BVAMR8;?UXJ7_9Y\"=@:3 ^+Y/)3WOZ
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M=1OU2@&" Q+@YTFH]8I"H&\T? FH[@19-X*IMUL@ KQ"";UA"/,/IX0AW$\
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MA:Y)>)EX-71Y4]+R1$3[7Z<LQ<,C"G<HPH *^MU',6I$41.P/PUYL'G>=0]
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ME;I#$3HD8;XAGP$[)C :<<%QB*5$!403JB/YN50)CT"H@+6/%#3C]RE!!.H
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M)Y](U?50[G<8T@F/ I"R[^$$[=!H;T3&!R Q(Q)IN7%(2"=81DN>M3./UY,
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M?<8*!=62EUU=VZ5"PUM:YRK 7KEF%Y:MW([V[L4HJQB+X#0  /_T241!5.I
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M8@6PG[]\P>M$\M0%L#61XU"5SX>.921@:XX+[?[XQP#[KT6=)PE1YWZ\?"&
M_9S'_)+"_7S\&'=Y#=WD]7/G3J^*%)!SU==[#Z=/G<.!?4=H0YSB__U\_R'.
M73R,V0NFHKHA'4V=>6B?5H2:QF3DE0KH>2,]WY-+#X*V-V$Q$-53H]#4G4+
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MHJ+ B]<_X-K-A]0%)] Q<PW*ZN>AA-=L7>=:=,S9C@5+]V/=AA,$BLNX?'$
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MJL#9'14JJ!5,&7Q P)9\:RELIBMN]OBY4NI:I7 =6 ][Z_^K@*WE\HTT4C7
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M'[N@ +OO-N^/QR_QYB6![#7AFG"G=/HGZB?Q7@\!ME9$CN>/^R+>:9WG6@?
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M!@G74ISFD<K;DDJD(E)!?#B'2RMLIN0W<*V%@XOQ) \2Y!@U^1*N95QD7,5
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M)?7SNLU8O7XS-FW;@:.G3G*>[,<S@J662RI0*'.Z0 UUT$?)J1Z&[+\E_Y.
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M( 8&'U.>XOZ#9^@?>(HKU^_B\+&+V+!Y/Y;0IIB_:!V6+M^"+=L.X]B)R[C
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M$;(OH_^6Y-I<QI7SQW#D ">CC8NP:N4T+%[4@AG3*U!?EX*<;!]$1UL@-,0
MD1&&2(HW1WJ*-;(R[ C6C@JN<S,="=CV2$VR0VRT+8*"+! 89$N(#D9M?0Z:
MVXIH*"4AG3=!?*(]8N/,D)AL@IQ\"Y17VZ.ZW@GE578T7BV1EVM)P+9!:HH4
M7+,GV#LJT \+-T5@\"0"MAZ2TBR16^2$PG(WY)6X(*O B9#MA8JZ4%0W1G-2
M"4823TYPI!4<72=#WV@TQD\< T-C0]C8VM PM^72&O8.]C1R>'/&QZ.LK)2
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MXCT6%"FY '@OVAE@LND8#!W]=[P_\F\(C@C IFT;\=//6IZ7/_KY?< >^/Q
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M)Q8N6:E!=DNO*MF6FEF)X+!,0D<$#(W<,(H@+9YJ&6\]:K2UFA?OM8"VE76
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M:H?)QM:<6L'<REX-O;2RLU6EHU3Y)-/1,'.8"#=_:\*1FQJ_'9OAHR2>D"2
M+>.O)7MW.F&SL#()A5-3D9P3"8] 1\+\V%\ >]3$,=0!9JH,F*N/LPH-5][:
M &>5 $W&;5LX3H:=APD\@VT(9&[(+ E%>6T\)1J9I=Z$-CM$IQ/0LEU4N+=
MM@"VE.V*2')4H=YJ['51$,JFQZ-Z;BJFS4E%!?<QI3865;,)W'5Q**H*(YSR
M/-*=">:VA#YK!=D91>2.:3$$\T2">!QRR\(AV<D%:L7SFI IX=$2XBP)XOSX
M7UX(BW.%;X@#G*5N,QG$W-H*!B86&#/>""/'3,+H\0;\;LIVM8(38=7-QQX>
M_@[P#78E6'NKDE0RUC@DR@]^(9+1W15NWA*V;Z>B"@Q,)V.2R3C"[CC8NQNJ
MI&O1J03;_ #D$O2EYG=@I"-!6+*3F\$WU$EEZ_8*MH47&2XP6H?L8.15Q*!\
M9@HJYV2@<G8&VT*F62B=GH;4_ @%V.8.$S#>9!@!>R1,;64\OBT\>(W\PMT1
M$.D*[S [> 3S?R+,$9%BK\+"Y=JD%7L@/MM171^)-$C.=U/K$G)<$97JB. X
M*_B*@S?*@NWFQC8,XCD$<=Z;<.V)R$0O!$>YP<U7ZF1/Q-C)P_#G(?\'__G>
M_X%OD!<V;%G_OP/8/Q(./_GP&0'[.LX3 ,Z=/(,SQT_BU%'"]-'#.'OJ$"Y?
M/(IKUT[B]LW3N'E=Q@/MQ/:M'6AJ+$-VEI]*@.;N,IH&]3A"M@$AVXJ0+5YL
M-T(V&RO%$^%AC@1LWGRA;*C4<!JJ"52H,8A/].8R*QIU9LC-=41EM2>J9KBB
MJL8)TV>X8-HT9Y24V-#PM>!O[&BXNJ*LW)U&GQ/!S HIZ<9(3"5<ITU"0MI$
M)*1KDIQMB((I=I@^VP\SYP6C8J8/BJ:Z(G^**V)2+'F##L6H,?])(WT$/-RM
M$2 7W=<)ODJ<:9B+N,#/GP\<(;MF1A7A>@76KEO)CGXQ6EJ:L&[].IR_<($=
M[L=*X6J0K7FS15D/5LB_4LZB% =WM)P?#-A_6 CB;X_!?K,3_R. _3H$ZFW
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MY[E0#TEB,P78XJGD_A4@B^?Z%^\UCVTP8/.8?T_$DRV +;"F>[%%9%Z%B0\
MMH)LU9X\3K;IYZ\T.T%TI;(+: M(>+A*:D9=*:"GP_777U$/4N2891RVM)_8
M/O);>5$L<"S>8?'P"U0+8'_S[4_JGOWXX\]4I9 C1\[0UMI&/2GE 1=C8=,B
MVA(KL&'C9APZ?!Q7K]U2-H &V9J^%LA^])AV[?5[N'3I%JY>N:W@^=3)B]BP
M?CL:%RS![+I&='2LQ/[])PG7W.;J/8J4_KRGJI)(4K5GW*?8#&([:':%O, 7
M.^,CE:U>E?=29=S^38"MY&VX%M$ ^Q>X%E'WD7Y/#<"UG#]M%[%%I#SHN0MG
MT-320#LY'E&QA)"L:)1-34=M?0$ANP"SYN<0J+-0MR 3LQ:D*YG=F$[XSL'<
MYB+,;JK K*:9J%DP%U-GST5.>17!)H[ 9(>_#IV,H>S3)A@XP=#$C6#M@LE&
M#@1 .P*V$^P<72G.A$0+53)*0KS'FXR M8LA?,(<"+%>B,OTH_A2O"D$SW3Q
M( OL!A&N$U%:G8'LD@3"F">A<"+>'_UW!=@2#F[O9H^@J$#$ID8B(2,:*3EQ
MM/MC$!KG!T<O:QA9CX>Q#;<C9 ?&.".U( 3%U3$HGAZ![#)?).6Y(#'7!<EY
MDES- U)V2R0^TYT0Z:Q"PZ4V=DYIJ*I_73TW#=/KTPC92:B:D\COB01*K:15
MAB0+(V"'QELC*,9"A5JG%P:@2,J238M#7KEXJ(.0E"VEOWB.!&SQ%B>I%PK>
MRJL=&N?(\Y3P:1NX\/CM76S5"PHC,RL%V,-'3<3H<9,QT<"(;6T$8TLC6-I+
M0B]K^(6Z(S(^$'$IX8A-#D=83" !6W).N<+9PP&V3C8PLS+%9!/Q]H_%1)-1
M,+(<1<B>J$+6I4YW886, 8]%:(P';)R,8&8["79N%G#QM8&;OPT\@^W4&.NP
M!'=(&37)(B[)R;++>&[%H<@J%:]V@GHQDI03"N\0>[;_6(PQ?)_WRPB8V4D9
M,@LX>%C"P=,"]IXFL':;"!OW<81L(P78R83HE$*"=*XS8C+L"==.2"V4Z ,_
M@K<?KYD[(I+MX1]E1N WXKUHRNODA.0<7[:C#R(271 6[X*(! ^59=POE/>A
MBPG/>3C^]-[_0_D_\ _QP<:M&_[G 'M0&6S\],./>,Y.X^;5F[APZCS.GCB#
M$^RTCAT\A..'#N+,R4.X>/X8.ZA3N'7S'.[=/H\[-T[A_-G=V+:E$RU\ (L*
M(Q 3Y8! /V/X>$Y"$($[)M(2:<DNR,[T04::+Z*CW.#O[P ?'SX4P6Z(BN)-
M%>N-T' G! 2:T["S4(G,BDH(Y@5FR,HSX+PY#4@[E)79<MZ&!J03#4M/5$[S
MI%'JRF7VR"VP1$:."5*S#)&4,4F3S$E(RS5&<:4#X3J0'48HIM5)MD0W%%?Q
M8<JVX4TW"B9F[\/%Q8C'YH5X/I1AO$F#@UTH;CPF5_@0MMTD*8"O*S*SDMFY
MST4/(:9K^5(L6MR,Q4L6T8A<A6/'3[ S?ZJ4[=N0K1L9(H,5LRB97R";\N\"
M[$\EE)P=\=L=O=[9B[R]3._L!W?XVGK"I@"V@FQ17@3K 84JBE5"Q37%0^C[
M1)*@?0%)2B0A>R]>ROZ^HZ+^'H\>?893IVYA[=K]:&E9B5FS)$Q5$BG5$2CF
MTFA?@MZ^S3AZ[ )NWWF"AX\_41!]AW!]^^Y]-;W_\#$>/'JBY.$C&6\M8*V)
ME&>1[+&BK$6T^M9:Z)DNHAPEO$L?>RW'_QJHWY9_$; E1%P9IS1\OI'0-YD*
M:-. ^5:&"GS/__Q<E0_9N>L@VI>N4' MAL+&C=NQ;?L>]/6O5= ]LW8VI\U8
MLWXC3IV]J#SU#YY\C/LT'*2<R+5;]W'CS@/UHN'IAS1*/OI()9PYL'L'>I:U
MHH-*='5G*[;U=V#[RG;*(FSO:\'6;@)S5R.VKVC&/BX_M&89]O>W*6_V-L+T
M5LHV0O2V%8NQ=?DB;.'R[5+&2Y*A];5A0V<S5K<U8F7;0O0N:4)OVV)L[._#
M_AT[<6C/?FQ9OQF+F]I07EJ-Y,0<1$6D(- _!O92DLC:$X$!L<C)GD*PGH6R
MTIF\WK-06C(3B8GY<'<+@8D)E;.1(PR-G6$LH;,V/@2/<%4'.R:Q"+G%M9A>
MMT1YL)N6K,*\AA6HF;D$N?DS$1R2#EO[0!B;2+(S+]C8!BA(<78)5R*9IH."
M-<!.2Q? %FB>0?CCL1!(=1B5>0D3EW#QUW MV]6AN&0N[U-"<TF] FV!:^75
MU@&[4)*=_39@ZU"MRQO>:WXOJ] \VZ5E<APBC;\ ML!U]?3%2@24132XYN^G
M$MP)U"(Z8.LBRP2\5<@X(5O"XF?,U)*;39VZ2(V[EM#PI*1I2$B8BKBX<N7!
MCHHJ4%[LF-A")"67(C6]')G9%<@OG,[SJ.<^)%-YJQJK[>F5B$F3W F/#I@P
MP05&1IX#9=&DSXS ]!D-V'O@%.X^^)CW[6,"X5DL[UN'F?4+D5<Z#=&)F0@*
M3T1<4BY**^I4Y8 Y]6V8-7LQZF8MPER"<\."I6A:V(7FYBY"]C+"]V+D%LVD
MX9 &=_]X9!;6H'?M;ER\06/X!?O4[W\&;7-\Q_[W6^JUGPC8HO)>??$*UZ]>
MP^Z=N["J9R46TTB?7EF#@NPB9!+RTQ*RD1*71<A.AI]G&&PLW3!IO 5&#3?"
ML \F$Z -,6JD*4:-MB HF^.#829JK/DP@>N1%AA!J!89-8*_&6F)D2,L">):
M),4(KA\V7!+SF>!]_F8$]S%^LAV,"=E6]GZP(VC;.@;"QEZRX0? WB$(YKR7
MQT^PA;FE.Z+C,E%=,P_S&UO1O'@INGKZL'/O7ER_?9O]_2M\\X,DT/H"SS]C
MWT:XEG!Q"9&6,EUJ3*OT6X3K?P6P=:@>++KN^BW1H5/F!X.UKO?4>GGQ2+#^
M^GOQ\/Z()Q]_@9-G;V/EF@.8,W\ERBN7\1Y8AJKIO9A=OQX+FK:@==DN]*XZ
MA.U[SN/DN3NX?/T1Y1[.7[I!P+Z*RU=N$+#OX-X#;<RLA!A+GZWI,XJ$R"NX
M%M&'[[Q]ON\^I]\2_5S?T..4+WX!:L(U]RTB^51^D5\ 6X!(1*[+ $R)IU@)
MKQ=USPOJIX_EI? 3ZC#V_\\^>H&7A#PIR259P\7CK4*"]6,1L*9\H;S7/$:!
M:SG>?P&P10:/QY;_5\)YY2TE5'_VBH"MA-\%KBF?$; E,9DVE$K G#KS);?]
M5,Z-[?**QS8 U]]\13N((B',VCTG.O1+I8.U.N,"IY\IW2J +4.J).I+]*T
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MB&0G)9%LI[ $WC.QM@B*L>+41GFR):P_1EZBI'HB3KW4\&5[.L'6U0CC##_
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M\"Q=?@W1OR?_!<!F>W])X^?;[[_%CP1L*8]Q@_"[=Q]A>LTF]*_<A(T;]RC
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M2WDKJ=%>5#('>06SE.07UG&_!&R";3&A6\\L_G;=Z[?!^O< 6]]>UE=4-BO
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MQ-G+#[%N\W$T+=J F;-68&;="LR>UX,%+2NQI',=NM=LQY:]QW#LW%5<NO4
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M\;:<VB&&8!V;9D_PEJD=X=L)6<6^*)T6A2G38Y'/ZY:0SN-+]4#MW *</".
M_8UBX#_Z>0=@__KSXX\_XODG\F 1L"]>Q(7S%W'V[#F<.G4:)PC7)XX?(V0?
MQ:F3QW'^W!E<(C"_#=57U+SV_?*E"TID_OK5RRJAQ$V"P?5+5*#<]TWQ>%\Z
MB8/[UJ%C:2TJI\8C,\L#B4G62$PV15:.%4JEWG6U.Z94N:*PU(Y&O#G2L\QH
MV%DAG8V7DF2'Y 1[K<YVNA<RDSV1%NN*S!A/E"0'869./!I+,M%6D8^.B@)T
ME.6AHS@;'869Z"K*Q(KB'*PHST.GK)M:B(ZJ$G3/K$1O734Z:J9B7E$.2F+"
M$<.;RMO:#"Z6QG"V-86KLS4\O G7_LY\,-SA[N?)&]*3AJL'#53>H!Z^B$](
M1&U=#5;T+"-<]V/5FGZL6[\!>_<=P96K=_')LR_Q]5?_4*( FXI+?[.KP;0H
MGP%E- #9RGA0G;,8$;I2^NV.5N],!W>J(GJG_7NBP[5NH W>[[OD7;_3 /9=
M@*V+#M:O/=CO%@'L-Y?I0*V++/O%J_&[GNHWY=> K1EG[Y9?KQ=#0@RO;ZGT
MOZ#!<N_1$QP^=A)KUVU"=_<JK.S?B$T;=Q%.=Z*]K8?W^0PD)68@(2X9I<7E
M:%W<JN!ZQ[;-V+5](_9L7HN=:[JQI;L-:]J;T+>X$3V+%Z*[=3'6]?9BW\Z=
M.$_(OG&=BEV%BM_#S>MW.'\'=V[<5L_8U0L7"=7GU8NRRQ)M<N$\SAX_@D,[
M-JM];^MIP[85B["M<R&V="S YJ7SL7UY$PZL[L"1#3W8LYK W[4$JY<MPKH5
M'=BT1N!Z$WIZUZ)QX5)":ST!<P;RBFJ07T+H+"$ %LY !@$[,Z<:!02LZ37-
M6+BP&QW+UBE/0-/"Y:BLFJ]*-X5$I,/)+93@YX%QD^TQWL"!';@_O C*7KX)
ML+8/QF2II6SJ2240  >7*(2$YQ-LYQ.BE]- 7\[_K^>R+!5*[N0:BM"(3&3G
M3T?5]"8%V N:NI74-RQ'7?U2!=]U<Y=B 8])X+JAJ0?SN&[N_.68H\!ZF0+K
MJ03KLHH%"J %J"5D622'\[F%OP;LPE)M*H!=4C[_#;BNE,S?%)G_5P!;7R>>
M< %K@>JLG!G(S*Y1(O,YDER-Z\23+=]C$TKA%Y!&N(ZFX@PE! =K8AM$N Z"
MF:4?C"U\86KEI]K5R26"D$RH]HZ#CZ^,L4Y6XN$I<"V>:U>,)E .>6\2_OKG
M<7CO[Q,Q:I0I#(WL86[I!BL;+T*Z/]S<PQ$8E*1*HDEX>I9XM MFJF@!@>O0
ML#0$!"4@):T8\QN68L?N([A^^Q&>\QEZ]9T&UY*0[)L??L+#CS_%VLV[D9I3
M1F/! Z,F6%%IV\'<E@HZ-@LS9DM2L[58TKD2<QI;J1@7HG9.(Z]I VIG-:"F
MAO=%[4(L7MR-52NW8O,&*1NW$0OF+$913@42HE(1%YZ U-A4Y*9EH2@K&[FI
M:8B+C(:/9P"L>%[C)]JJESW#"-C#1UE0),)""PL?)C6M"=BCQ]EB['A[C*%(
MXK*1HVVXG93ATF0$@5MJ7H^4J4#W!X3O]RWP_ON62H8,L<![[YGA;W\WQM_>
M,\+?WYO,?9C!QM8;L?&9F%8S1Y4=ZNCJ0>?R;O2O7(V]>_?C^HU;JJ^2\<P"
M5_)"4^N7?]TW2Q^E1=Z\V7]+__]?!VP1@40![']0>,U^@>PW ?M;*4LHL*BB
MK[['B\]_Q)-/OL.5>Y]B[\D[Z%IW1'F^JN=T8\;<%9C;T(N%B]=@<<<Z=/5N
MQ:8=AW#\S&5<DR1F]YX06A[R?KE+8;]V_P$>/?U0]?&J?R?T2=\KNE&&Z'RN
MY#L%@)I>E)>>A#_J4^G31<=H44X?*ATA[2'MH)VW!L*# 5M/4*8!(N'U:PVP
M-2_^KP%;VT9KJW<!MHB"^<'M+E[^@;87.)9$5(-%2CR*!UIMQV/]FO-O@_(_
MD]\#;#D6/31<]X2^!FSJ<KEW%%S+O21M+=O)RX<?"+<_4C@5P%;VBKQ8T:!:
M37G,*E1=AVO*+P ^&*QU4?;.:Y'_TR+'Y/[5[EUI)VE7R8@M>6RD3>4>>/9,
MA@1\AD>/GJL$: </GL+JU=O0VMJ+N7,78Q;[A7GS%E,/]6/KMOTX>?(2+ER\
M24"^K(![S]X#.'3X",Y31]Z^=0=W[TB>DT?4J1_BTOF'V+_W(OJZ=Z%Q?@_F
MU'52I_6COW\7]NP[@]/G;JB707*_BJ?]H90&N_\4'SW\",\>/<-S O;SIP3L
MCU[B)8_SLQ=LVT]Y?[X#L&5XAR0I?"F1@"H:4'MN==&?[W?9<[\E@W__6Z)#
MN#;5?_>E"F=_\N0C51KUVHV;N'3C!B[>O(FSUZ[CX.E+Z-NP%V75S?#T2X>)
M93@<W%*1D%J'RIIN/MOK,9//>5)F):R<_##*P!2F]G:$IE DTB:/20LEB#G!
MULT0EDX38>=N##L/8U@[3U8EG5S\S!$8+>66I&25+X)IT_N&2]@Q82K9AT <
M2DB/(("'JCK'@9$.A&8K> 98P3]<:F+[(C4W NGYT02]0!6*;>,Z$0:6'Q#H
M/X"[OXFJ.UU<%8N\\C"DYOL@)4\3"0$/C7-08.WJ9\Q]6G#_$L(M]:H#D%44
M@8**V(',X))I7$J)A:G2715U22BO34)>123ASQVN 28P<QP-8]L1/#])DN:*
M^ P9+QS)\PHD/#O!V<<4CM[&RN,>$B=)TCP0ET$(SPCF<7CS6.WAZ&D%5U]"
ML[<#3&V,J1O'8H+Q1,*U*<SMK*@GK:DWK6%D;H7))H1M<UO8.'KRVH0A("0&
M?@1K+]\0N+C[P=[9'3;V#@1L*X*X&>TN"SBYV\&;'!,0YH/ <#\$4?R"??E[
M#SAY.,/62;S7U@1N>^7M=N3VU@Z$>ZM)!/MQE#$PLQT/)T\S!$>Y("DK&-G%
M4<@L"E/UOL/BI7:VO$"P(#S;$)3M$4$)3;0E4-L@3  Y6<[=#9$I4E/;34&V
M>+%#$WD]TYS5N/?X'+9?MC/BLIT0ETDA/,=*.#@A/3S.FE,;Q!"\XPG8B9F.
M/ XGW@,>**P(065M'"IGQ*. USLITY/BQ?NTF,^P /97 Q3\QS[_,F!_\NP3
MW.1#)(!]\>(E)>=II)\_=P[GSI[!V=,G![S8IW#QPKE? /JR NK!HL&UDLL7
M%(3?$,"^=@,W+@L 7.94/-RG"?+[L6]O/R%[.BJF1A*P)3&9$9+3S&C,.J"D
MP@T%I4XTW*V0DF&.I%0S)"1:((F-FI+(Y6F>R,\)1$E^&(VI,!3R!B[+BL3,
MPF0T3,G!8H)S>V4AEE44HK,\'\O+\M%=FH?>TEST$KA["-<K*HO0J:08RZ>7
MHV?6-/3/G8F>.3/16CT%,W+2D1KD"Q_>C X6!G"T-8&KFPU</>W@[&D/.Q?)
MS&<#8U-+C)]@B)&CQL#$U @1T4&HFS,-*]<LQ^:MZ[&:H-+3NPK;MN_#E2MW
M\>QC=FB?4ZG+."516$JY"T@+4'->C>_5(%N@6E,\FOQW %L7O9-]VQA[E[S]
MV[=%WT[?SVN U<8^"V2_+6(L_6N _<]%?B_[DOW^5P!;"PT792Z&J9S'FP M
M\OH-N[S8D/8?,&*IB+[B-?O^!ZGM^AT>4"$=/7D&:]9OQO(5_>CK7X>-&W9B
MP_J=6-;>BZD5,Y&1EH?2DJEH7;04ZU9OX/J-V+IE,W;OW(;]N[?AP+:-V+6N
M#YN[V[&JK0DKFA>@?<%<-,V9C;;F9FQ8LP8GCIW M:LWU#CL&Y3K5V_C^K7;
M?,9N<?X&KEZ\3+B6Y"Z$;,J%,Z=QZL@A'-R^!3M7]V#SBE:MWG770@76VSC=
MV;,(!]9TXC !>^^Z;NQ8V84=:WJP>^-:[-BX$:MY+HN7=&%FK4#@+$(E88I@
M75!:ASQ"54X183"?,)@[78%H><5\S"'0+FU?@_[>;2J\3A+(+&SN)D@L1"I!
MVS<P 9:V/C R([C9^<'5(XJ@& ES*U\8&$FB,U\NBT581!YALA;39[2C8>$J
M-"]:A]GURQ78QB84(B XF9*"J+@\PO!T5%8O)#1W*)!N7KQ2>:PUF.Y44_%R
M"VS7S%J"ZAF+N'TSIE0VHG3*? 7/.EAGY=9H<)T_$WF%LY!71+@= &P=LG41
MP"Z=(IF\WX1K';#U\' =KL5#/3@\7%^N>Z:S<F<@(VLZTK.JD9Y9K>:S<V<J
M;[; M8A =TQ<,0$Y%<ZN403?4-@0KG6QM"%@6_G3 /*C,O6G,@V&(P';W2L.
M_D&I*JP\E"* ;>\0 D-#%XP>98D/AAIAZ! #_.VO$_#^D,DP,' @F ?R=V%P
M</(GN'O"TLH+UC8^_%T@O'QB$1&52]"NX'%6(2FY!.&1F03_.'C[1B$J1A)V
MS<+RWG6$J(MX^-%S?/'=C_C\VY\(89_A\*E+!.<V> 7%8,0X<PP9881Q!K;L
M5P.1GEN!I83K/8?.8.^1L^A=LP7SFMHP@V ]OZ$5;6T$M84R'*%1&=--"Y>B
M;<D*-#<NQ8QI<U&068+4^ RD)V0@/R,?I7G%*,K.1VI<(@)] F!K[8Q)DPC'
M!-T/1IIQ:H%18ZT(U);*<SUL(#Q\Q&@KC")@CQEG1\AVX%2';/%ZV[#/M\$H
MPO9("2.G#!?/]E +0K49WON[J0+K]]XS)VB;8^@'%@K$1X^QHLYP06!P J_]
M3-ZO2PG7?>PWUE!?;,>QXR=Q^\Y=U4_IY78$-/1^]EU]\^ ^6!=9)OW_?P^P
MQ8.M _:O/=C?$*XE7%S Z[-7/^+#YX3KVR^P^^@-+%MY #4-*U$V8QFFUG9B
M=D,_&@G7B]K7HXO]PJ9M1W#DQ&5<NB:AX(\)+(]Q\\X#!=@W),?$PT=X\I$D
M+!/OM0P_DG,ES%$W:CKR!S45/?GI+R^?!?8$WL0C^KEZ"2L)J 2T14=(6\GY
MO0Z!?^V]%AVLBP;0 M^:CM8A?+#H</[KMM-$0?1OB*P7<)3K.U@4I,LV Q#\
M+E#^5T42T*DD=)P?O,^W/=<Z:.O+U/VE=*+ M;2%G*_>#J_M%5TWOFZOP3+0
MI@1NM>V ;?-:W@1LW0.N[4ON3VDC_?Y\_?)"UHG>EIPN+PBN4IWD)L%82GBU
MM'2AN'@Z4E(*D9,S!=75]6AN[L"JU5NQ>_<1[#]P KOW'B9<'\;Q$Z?56&HI
M _KP(2'YP8>4C_'@_@O<O?T)+E]\A$,'+V/#N@/H[-C$OJ:7^^I#+^_; X?/
MX_+U![QG/\3MNT]PG_*8L/WA P+VXT_PR0!@/_^(-LDS0O-SMN=+VA2?4MX)
MV!IDBQ=;RK'IS[>(_GS_GCWWM@S^_6^);*?W#?H^]?U_1AM';*EG+U[B\;./
M<>/! QPG$VS;?Q1+>S8BKW0. 2Q! ;:G?QYRBUI0.W<-YBQ8AXKJ=D0EE,#<
MW@=CC"Q@8F\/[[  @E,P8<N#P&@%>T*U>X U0=*3P!E $/,B:-K#U=\";@&2
ME=H1X8GN!"\OY=5-S Y$!@$W;TH<\BOBD5E,D$TA2 ::PY8 [>!N +\P E9Z
M #(+HI%9&(V$C$ U'MC9QPCF#J-@:C>,X&Q( /,F8,=0HE4Y+O%<)V9[JLS3
M@5$V/"YC.'D;P,W/# $1]@B/]T!LJ@^2>0R25"NS.!19)3(-4K6NBZ=%HW).
M&JKF9*"P,@XQZ5YP#S*'E>L$6#J/@[.O&0)C)&NZC!>6DEUA/%]/GJ\MQ4:5
MM8I)\R(T>A/R_1&;'HB@*$\X>5G#TE%>/A"&G<Q@:#D9XXW'8;+99((U]^]H
M"RL'>1EM!V,+J3-N21%X=B00>Q&J?>'DY@5;!V>86]O1WK)3X[2=W!P)SM:P
M=;:"F[<C_$.]$1+%:Q 3A/"8$(1&!R,PS%]!MJ.;@P)L$4F(9N<BL&U),8>#
M&YG(S1R.'A;P"B0XQWNSW:-0.BV%;9N(M/Q R%AT*9T5E>RH2F])_7'Q1H>2
MX4(3N#S5E<#LA80L7YZ_9!?W5B\:HE+9YH3AQ%QO2.WKE *IC^V)Y )/?I<$
M9^Y(E/VE."$ZR8%3!\*U$Q+2G0C7SDC)<4-&H1?RRX-14AFAX#H]SP]Q,O:>
MUW_>PE*<.;\7/_W\Y0 %_['/OPS8SYX]H\$N]?X(R9<EB<-57!U(;G;M*K\3
MF"^</ZODXH6SRHNM>Z\%IN6[R-N +>NO2A;R2]S/1?%@7\)E^?V%$X3O8]S7
M7FS?M@P+&O)I1'HC+MX2\4GF2,NP07J.'1)3+1 3;XS81#.DIMLCC]N4E82A
MNC(!-;R0U94IJ"A-0%E^#,KS8C&].!7SIN:AI;J$@%R"]JHB+"5D=Q*VNPG:
MO5,*T%=.N"[/Q?(IN>BHR,/2J?E8QO5+Q9-=78K>V=58TS ;ZYKG8?G<&9B9
MGX&$0-ZP5D:P-!H+2_.)*O.YG:.,>S#&Q,F3:'2-H_$T#/_YI_^+]][_"ZQL
M#9&9$X>VC@9LV;86FS:O1W=/KQJCO7OW89[[?7SRR9=4?C\3TGZFXJ"A0,6A
M#(3_GP"V+N^"['\78.MP+?N3_?YQP-;:=; ,;FO=F! #3WXCR]6XNV]I4!(:
MCI\ZAU7K-J*]8X4"[(V;=F#;UGU8WK4:TRIG(SXN77FOY]4OQ/X]AW'N] 7L
MWWN VVS#WMT[<>3 'AS=NQ.'Q).]KA\;EB]%]^)FM#?,QY+&!G1W=F"GU, ]
M/>#!OGD/UPG8UZ[>4J%M,KUZY0:?K<LX?_8"MSNKLJ>>/7$"IPX?PM'=.[!G
M_2H"=AO6+VW$IF6-V$K WM[=@IV]2[!W50?V$Z[W;^S'@<VK<7C[!AS8L05;
MUJU#1SL!=8[489Y+4*RCS$%913T*RPBD)77(%<@FA&83L@5("XOKE!>[I;E'
M ?;FC0>Q=<MAMLD!+._93,CM($A.)X3%P]S24X&&E8VO2JQE;N&MQ)DP&!&5
MI\8>SY@I(><$YI8U!/UUA.S5F-_8H\+ <_-K$)=8A.BX?*2D3R$$UZJ0< D3
M%X^U +9,!;!GUR\CG"U!U?2%//YY!..Y"I %G.6X!:HS<Z8K$;@6V!:X%J"6
M;7X/L,LJ&E2(MT!UE937>@=@"T0/KI,MWW7OM0"W@+. M,"S@+4.U_)=/-JR
M7B!<1+:+2RA%0% Z7-UCX.@<H<+#]1!Q:[L0%0$@@"T>;',; J5C*%P\8N ?
MF(KPB!R54,S=,Q:F9EX8,\8:PSXPP=#W#?$!9<A[DPG<YG!Q"4%B<H'R1OL'
MQL':U@O&9BXP-':&D;$KK*Q]X>H6A9!0]I&))4A)E5)>A0@*25)@+ML[N03P
M&F6COG$Q=ATX@KM2?N[CSW#JXDVT=JZBTLN'D:4+_O+^!/QER$15KBHD,@VS
MY[=C]\$SN'G_&>X\>HX#Q\ZAK;,?M;.;T$BP[EZQ <N6K4+]W,6HF]7(9ZL%
M#0L68>[L!E1/G8'BO%+D9Q:@.+<84XJF*,E-RT%D4 2<;5UA--F*YTV('FFJ
MO-8C";U2&FXD(5L\V3I@J_'7HZTQ:HR- FM=1HW1('N4$D(VMQDI'NT1%@1L
M@6H3_/UOQGAOB*GR:(\<J6TW?H(#+*V\$1"8P.M:B;JY+6A=VHWNOC78LG4G
M3I\]KX!00H.EQ)6( )DR? ?URR)O]\.#^W,162:_^^. 3>!3@"V>:]U[31#D
M>@78W\J0IV_PG<#A]S\3L'_"G8>?8?_QF^A<M1\S"==%T]I05-6&JKKEF-^\
M!BUMZ[&T:S/6;CJ(P\>O$*X?XOJM1P3K1P063N\^H-S'[?M2EE'&X!)8/M&B
MDWX3L#_[EOVREH%:^FW91N!./'*B&_1H)YF7-I'STV#V]P%;@\;7("WS@^6/
M +:^3HUE?P=@OPW$_R[ 'NRUUCW5[P+LU\+[ANV@$J?)N<K+AD'GKMI'VDF)
MS ]XJA4HZ_*Z/34/]N\#]NOVUD1O*[E7Y3Z6E]ORHD6RC$LR-'FI\LDG7]!.
MO8<-&W:AJFH.(B-3X>]/P$K(025U;TM+)_KZ-G#]3FS:M(O/V&["^!&<.W=9
ME7V3DJ /'S[%XT<?XRFA^.F3SSC_*>[?>X[KUY[@]*D;V+GC./N:M:B?MQ0+
MFU=@S?H].';R&JY<?\)]?(1[=Y[BX9TG>$+ _O@)P?I#VB,"UX3_ESP^ >Q/
M7[#-U= & =AW 3:W$9%K,TCTYUNWY40&/_?ODL&__RW1MY7]Z<MD7NY1N5_4
M_?OM=WCVV6>X>/,6MM!>Z5JY$8U+^@@L\^ 7D@LWKTQ$QE6C9$H[:F:M1.7T
M3MKML^%-'6-HZ8:Q!&PC&QLX^;K#*]@#'H$.</&QA)N_)8()G4G9H035&%6&
M*R3.G7!-:/,RY-1,)2\3\$S.#4!Z80AA6,9)QU!BU7Q,JB?W9T; '@]G+R.$
MQKH2@D.041")M+QPQ*;Y$9@="<RFL'6; !O7,9PW0C2A+J<T&/E3PC3 +B1X
M9;@3]NUXC*:$ZTFP]Y@(9V^IVVQ)V"7LQ[LA.EE>!@@(>R$I1[S>OBK,O'!J
MI(+KZ?6Y**M)X?)@5=_9+= "3CZ2O,T:_I'.A$P_I.1&$.@%LH-5&'AXDCN!
MVD>-O8Y.<T=DLHS_]H1?F L</2T)V$:P<"!W.)K U-8(IC;\;F]..+:!O8L#
MI]0E=@+8UC!0@"U>;!EV9S<PCMH69E867&\&&T<[^ 1X(2#$%QZ^SG#RL(6G
MOS."(GP0'.G/J>;!#@CU@V^0-[=Q)V [\G>2:=R*4VO8N]K"U<L!7@&N" CS
M0F"X)_S#W! 4Z<[V\5<O-DK(947DLY2< (0G.%$(USPWJ0TNV=Y#$R4L7/->
M2SA]4JX_K[%D3P_@=KZ\/I))W!N)V5)?W$_5QD[E-4HK8GN7^".C6!+"^2(E
MVXN0S?VFN5)<"-<BSESFH@ \G5">5>2'S (_)&=Y$L()]_&.!&P?-#17X-S%
M_?\['NP??OA! ?;UZ]<' /L*.ZSK"KAOW;J)V[<XO7F=G<T5Y9'6 5H/$Y=Y
M\6J+_ JR*5<NRCCLR[@FXUPN4:$2TL^=.<IM#W,]E>RAM83/.:B=E8K"H@!D
M9;O1N'1"<IH=HF/-$15CAN041Y25AV'!_#QT=<S$JOX&]"RO1\O"2LR8EHTI
MA8F86I",&259!.P"-!.4EU#:"=D=E.64WFDEZ*LL0I]XKLMRT%Z2@24BY=D*
MLMM%!,9KRM W=SHVM-1CW:+Y6$;@KLQ*0JB' RPFCX+!N*&P,!D'2XO)F#1I
M#(8-'XHA0X?@;^_]%7_ZZ__%D _^ F/S<8B(]L&,NE+T]+5A\]9UV+!Q(WK[
M5J.O?P/V[3N.^_<_HO(4 TH 6WLSJX".BD<9#P-*2+S:.O1IP*<K+>W-XQ^1
M/](1_Y:\O;UNW G$ZM/?@^S!H/W/Y)_!]7\-L-^$:TW1:T M\[)<7R=O\*7-
M]67Z=A\_^Q3G+U[#NHU;L*2]$XO;.K%RU0;LV+$?Z]=O1SW!-"4I%V$A<<C.
M*D3KX@X<VG^,\'L!!_8=PJX=NSG=AQ-'#N'LT4,X<V@_CN_>CAUK5J*OO0U=
M2Q9A57<W]N[<R=^<45YJ27)VZ]9]#;"O$:XI5Z_<PN6+UW'AW$6</GD&)X^?
MQ"G"M0#V^>/'<.8PG[/MF["]OQ/KEBW$NO8%V-2Q$%M7M&![3RMV]B_#GK4K
M<&C+&AS?M1G']VS%GBT;T+^\&PWS6U S?1Z-EWK"XWP*8;)J 4HJYJ*@C( J
M0M#,)8 *E*JQV%/G$WC:T;EL'=:OW8OM6X]B^XYC6+]Q/T%",JDO0TI*,6QM
M?0@<UC T<H2%I1=L;/S@(J6X"&PY.36HK6U#<],J+%F\%LW-JPA6,GZZ'ZWM
MZ]G>:Q4T%Y7.1GI6I9+,G&F$Y1J43JG7QETOZ"*,KU" /;-.PL )L^5S%8CG
M2+;Q@3#P7^ Z=[J:5^<Q -0"T3I8#P9L%2;.J8S7+I>ZU(1I@6L=L.6[/@9;
M#_\N+.9O* +)LDS@6T1@>S!@ZV"M0L,)UQ(:KD.YB'Q/2JE <&@6/+SB59BX
M>+)%'%TB8>,0J@#;R-P',I[=B&)&T+9Q"($K(=O'/QF>WO&PL0W"Q(F.A#\+
MC!A.$!QJ1- VQL@19NS?/)%(6*ZM:U'UIP6R/;TC8.O@1W#VA36OE96U'V'1
M3V4KCX[.9]]=Q6.?RCX["UX^D<KC/7:\&2896E.Q1Z.VOA$[]Q_%\;-7L&K]
M#N045M) \,2PT<;X\WOC,72$$9S=0U$V=0XV;#F ZS1>/_GL>QJ?/^#RC0=8
MNW$7&IHZT-#8@67MJRDKT=+<@86-K90EU ]-F%4[!U4552@M*D5I80FF%$]!
M1?%4%!&T$Z.3X>7B"S,C@NY8,XPF8(\8+2)CK2V5!WO$:/%@"URS33@O@*U$
MPK]'6?\B"JX)V:,5:(LG6\+$K:@/Q%-MBB%#"-B$[*$?F*MM)DYTQ@2VM;&)
M&_S\$U!4/(/W[Q(T-BU%V[(>]B';</SD63Q\)'#]#7[\Z6?\\.,_E*&K][.J
MSZ51KO>U;_?#>M^KBRR3_OZ/ ;:(%B+]S;?BN1[P7DO.B6^_U>0[@6RI=?T/
M"O#LQ3<X<_$!5FXXC+F$Z2FU'2BI7HK*62M0.W\E&EK68LFR3>A9N0N[]I[!
M^<OW"=8?*L"^?I/S=Q_BSOU'*I?%?2FW]:%XKPDLS]F_JTS,<M[L>W4=*7!-
M/2FY35Y^^A7[?ZU/E_Y; V3ITS5OG.@(:1-I#P41/&[1NSHX:]N_!864U]"G
M;?LN>7?;O5OD?P?+VX"M7E;(.ME>KL\? &P=K ?O1_=<ZW#]*77@8,C605NV
MT>1K K7\OW[N KI:&^EMHHNF'S5@UNT43:>*C3( V[^\%-%%^\V;(FVN73?Y
M+VDON59RS>0:RIAZK126Y%SYC/O_EK;KYSA[]AJ6+U^-O+RI" J*0T! #-+8
M7]75-1&,^PG8DG!T(U:MVH0M6W;CX,$3!&RQ<^_0MKV/NW<>$ZH_P3,"\2?/
M7N'#IX3LQR\)V1_CYLW'A.RK6+]A#YI;5F#VW%8T+^[%V@T'</3$#5PAA%^_
M_@BWKMW' T+V4]G/4]HX'_%^%;@F6(N\?"%M+FTOSZK M0;3?P2P_YD,[A/^
M59'MI8^0-I?[4*:2E._!TX]PX-A)+.M=C8;%76A8U(N:NF5(SYV-F,3I2,F@
M/BU>C**R5F1DUR,XO(@P%H;Q1O88,YE]O[D%K%SLX>+G!,\@1W@'V\,WS%%Y
M<>,R I&8(S6G_1$832@-,">4&L(UP%AED9:LTO%9!*D!H,TH#D)VF203"T5\
MAC?\(VQ4V+=?J UB4WT56*?EA:D$:3$$M:!H1_ZG.:&>T.YOQ.TM$9'D2'CS
M4.'A,HY:/*0QA#0_KG/RGD@8'PL[]_%P\)RD0L4E.9?44@Y/<%42D20A[*X*
MRB6T/*\\'!6UJ9@V)X?33.26Q_*8 U5XNU<H(39(2E=)V2AW0F0P,HNBD5%$
MR.8Q)F3[*<",R_1 2(*,/;96(?&>0?8\%D*MJRFLG4R4%]O6U0(.[K9P]G*$
MJX\+7+Q<";S.L+0G8%M:P<#4 I/56&Q)?F8.4RMS C8AW<Y2P;&GOSNO5P3B
M4B(5'+OY2'BX +8WOWO#.\"-\.P$)W<'.+C:$>!%[ >F=FJ\MI19\PYT)Y#[
M(2HAA, :B!!R3G"T%R(3",39H<@JYOD5A*L7$H%1]@B)D;K44O_:!2'Q4G;+
M4HF,NY:,XDD$\:2<0%Y/?V[CK1+;1:;(O4'(SB$<YTE".H%LPG5I$+(H&9Q/
MR>%Z GI"FIN"[(1T 6UG)>+=3LYRI\AZ5T0E.BJXCHIW0DJ6/Q8NJL*%2X=
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M9=TJ+%W<BMDSYZ&Z:@ZFU\S'S-HFU,QL(D0VHKQR/DH(TJ65#2B=VH B@J;
M9W[1+)26S264-V%A0Y>"[%7].[!^_5X:*9HL[UJ/\K)9\/ (PX3Q5IA R#8W
M]X";6QBB(K.01]"=,6,1FA?VHG71:K0T]:N23;-G+U-9OUO;UZ%C^6;EH9["
M_\_B]@+8J1D5:JI[L@7 YS5H@"T>;P%O69>=)T!=K6 Z6P\''P@)%[C6/=<%
MQ9J7>C!<RS+)+JXG.%/AX95:>/A@P%9)RPC/ M+BH1:P%H@6.-8!6WXC(A N
MZP>/O1;8EN]:<K.YOWB\9;\"VZGI50B+R"7T)B@OMHB;1RR<"-DV]B$PM?!3
MB>(F&+IA@H$+)AFY*="VM)%D)R&$Y !,-G E7!,HAYEBN-1[?M]0@;8I(3 B
M/(,&ZF)5"F=%SR9>]X7\SU)$1F<A,#@%GEZQL+,/AIFY%^SY?^(5SRN8R7Y[
M+G+SJQ&?F,?C"25@FV/(!^/X_U8(BT[$K/IFM"[K0V7U7%7W^6_OC\?__<LH
M#!EF #-+=Z1GEZ-WU59<O?D(+SZC$4X=2'L>]Q\_QYX#)U59GOGSE_+>ZL22
M1=UH:UV!Q8N7*;BNFS4;U=.FH6)*.<I*2U!64HJRXC(4YA8A-2$#0;YAL+5@
M6XRSP.A1IA@E<#U&0%H;>RTB<"TB<"U>[1&CK3%L%-MHQ&L1V!:H'CU6PL7M
ME6=:C<.6]<,M\,$P,PQYWX3"=N6R\1,<863L#B,3=[89#8KD(NHYJ7.]$DO:
MNK&\9PWV'3B*VP1,B4P2L);ZT0)@8O3J?>G;?>[;_?#@?E=$EDE?_\<!6R!0
M\_1JGFL=W#3 _NY[@6MY20Q\]<T_</?!<^S8>Q9-K>LQ=>8RE$U?1KCN1EW#
M6LQK6H>%B]>CLWL[-FT]AF.G;O :/U5AMC+^^NK-NPJP[SY\K.#ZT1-MW+3J
MWPG7"K!?\ISD!2?UHP9I@SW8DMSL=7^N0:"(0+*F*_4VD//6O:0:.&J +=/7
M^E63_[\#]MN>;!VP97LM4[SL4\Y3P%?:46];:1,MR_Q7%!DB\$H2H WH24UW
MBK[4=*?8-?\,L'7]*F ND"W_*==+[F^Q%P2NY064)$"3ERDRWEZ\SH<.GU&A
MX!D9Q0@/3T9B8BZF39N']O8^='=OP(H5:]#1T<?I:FS:M!.'#Y\BE%_!I4L2
M 7:7=JT MF3]_@(OGK\B:'^*#S]\@2>/G^'1(TFF]D#]1T_?)LRI;T-U31,6
M-/9@];I#7'Z%MMQ5G"&$7[UT!W=O/<'C^\_PD7BR)3S\)>])>?'S_W' EM_I
MSX=,I;UEB,:)L^?1MW:CRH%1-[\-S6UK""AK52AX9LX"ZMQZZMSY2$F?BXCH
M"CBY)2J],VJ")49/,L4$4S.8.]G"/<"5P.5%X")X1;HB*,8-80D>"(UW)UP[
MP2O$6GFN)?NV9) .)H!%I;H@-M.- "J@[8K$7 ]5[SJC*!#).;Z$="D)9<5]
M.B(A(P#I^>%(S0U1@"WUEL/B70CS5H1D EVLO:I/'2G)L5(<"/4N!%YW%1X>
MD>2D$G'9NHV!M<MH.'I-A+./@0)L[Q!+'I\#(A():LGNB$YQ(V!+R+>'@GZ!
M_<+*>)1.3T/YC$S.)_,8([FMK_)<2P9QCP I8>6 Z%1?@KUD*P]74)F2'\!M
M PG:'@B*(P0'FZB7#*Y^5CP&"P*VB?)B2ZBX +:,Q?8DX/J&^, GV!=NOIZP
M<W6"F8TU#,T%L,TPR=@$!B:&,+$T@K6C!1R5IUJ\MR'(*DQ!9GX20J/Y6Q]9
M[H" < _XAWG"PU?J8DOB-",8F1L0T-D>3C9P\716WFQ//W>5",TGB-N'>BG/
M=T"8!SP#V'8!]O /=T%4DA^2LD+4M0B)<8%/B T"(^P1D2#7VHE@;0VO,#-X
MAYFK[. RYEI"PR5S?'2J#[=Q1TB<;,MV3I6LZO("0JN7G5H0B,P2GD.IC,,/
M1&*F%^)2W1&;*F#M1JAV4Y =QWLF)EG&9]LA+-:&QV'-J1UBD@CA:5[(X/W1
MN&@:SE\\C)__MY*<Z8!]X<(%=CJ7?P%LS8-]4\'U@_MW<?\>C?L;U]X)USI@
MZ^'BNDB]P<L7+^'R^4NX>/8"+A*P+YX_A?-GC^#TJ;WLG';@V-$M.')D/0X<
MZ,?V'<L(H WL$&NP:%$%VMJGHW]E(W;NZL:1P^MQXOA6@L,>G#FQ&T?V;\&6
M]3U8MG@^Z@G!TTMR45.<C3I.YY7FH;$L#\V4)>5Y:BQVS[1B]%>7H*>R .VE
MF6@I2<>2*=GHG%Z,GEH9@SU%2>_L"JR>/QUK%]9AW:*YZ)D_$_7<1U9T$ *<
MK>!@.@&&8X9A^'M_QE_^]!_X3\J?__J?"K#'3QX!-R\;Q"<'(R,G&@4E::B;
M6X/.KD[T]ZU&-XVIGAX)6=JE$G-<OG);96\49:3J:'[Y@S(@/AL [%^4#I6]
M3$6Y::)UA.^2MSM<7=Y>KW?$>F<L1ME@"-6-M,';O2V#.^FW13?T9%^#(?AM
MP/Y793!LRW?9QW\-JG61XY+C$X^T!M'2MK]6]*]%ELN;>MGVR8>?:'"]92>6
M=?0HN.[J[L?&S3NP;?L>]/:M)0PV(#>G%.FI>2@JK$#]W$8L:U^.ONXUV+1^
M&_;LVH^CAT_P/C[#9^,B;LK0#,+PL;U[L7W=.JSKZ\/JWEZL[E^%C>LW8=?.
MO3AZY"0N7KRFO-<W;]U7@'WUVFT^BS?Y_%WA\W0>QX\. /:QXSAW^A2N$-RO
MGCV)"T</XOCNS=B[OA?;^I9BRXHE2K9R?OO*3NS=L!(G]VS#F<-[<7C7-JSM
MZT9+8Q-FU=1C.F%HQDQ)+-6LRB8)8$^9MA!3JILPM:8%E36+4%ZU4 %G8<EL
M%!- ITJ9I9IFS)_;CL7-/03M->CMV8RU:W:BMWL3:@GJ49'IL++T@*&A/:RL
M/.'O%X?LS K,H &SL'$Y%K?TH:FA&_6SEW+[Q90EJ)_7@9;%J]!,F5'7ICS1
M"<FE2$PI0UIF)0%Y)LH)_C+&>LZ\3I4E7*;3>"Q%I7/4]@+D(OHX:QVJI117
MWH!H8>&OH5J'[<*!,EU2+JNT0H/KBBHM/%P7W7NM>Z=U[[7 M0[8 LOZ]K*=
M+)-QU@+6NN=:ONO;RWYDN\& +5G$Q8.M>Z_%DRWAXI8V@3 T\<)X O28B4X8
M,\$!8PEYXR<[8S)!V]#$ Y-EW#7!\/VA!,$AAH1K(^7!GCR)2M<_$=.J&MCO
M[L#.W2>P>>LA@NT:U,UIY;DMX/%5$^ZS5,UL:P*[DW,X@D,R55WN&7*=9B]!
MZ939B(S)@*V#-R8:6%-D[)87H@FZ67GE"(].A:&I/?[CSR/PY[^-Y;PSHN-S
ML&1I'\[1\/V,SQK9!>SV%& _^?@S'#Y^ <M7;,"\^J68RV-I:NB@CN@@<#?Q
M>*>CM*08Q<4%*"G1I*BP +E9.4B.3T%H0"1<[;UA8F"/<:,LE)=^Q$@SE=SL
M@Q&F&#K"1$V'<9EXKP6N1TEI+LJ(,=;*BZW@FB(>[%%C9%RVC,EV4/.:!UO6
M:X M[?K^4/D/ 6P'F)IYPI9P'1"4R'NAAO=O-U;TKD=WWWILV;87%Z_<Q'/V
M90)9 JV2,5GWWNG]\-OR=C^L][>ZR++!_;X8SX/EGP,VX4H@[0V19>(!_@[?
M_? CC_5G[N='?/3L%4Z=O86>E;M1.W<Y2JM:45'3A9GUJS"_>1.:EFQ&6^=6
MK-YP" >.7.'Y/L*-VQ_AYIVGG#[$C3M:6+AD#7\@8Z8__%CU[ZJ_EH244NI(
MLC'+"T_"V:M74H'C[3'8KU^6"AQ_2<#6SU&F@T4 4=9KT]>BZ]??@VSQ[.M)
MSS1Y<_]OM^'OR=OMJT!;YF6][(LR>%[__L]D\#X&C[T>#-BZZ)"M@[6(_.:7
M_?!:?RDUM[G\<_5B7]J$;25. 24"US]J4\DV+AG#J2^UY'/:=/ UTT1>'DE[
MOQ9-_\KU$_OD]?TJ][?H>0'KI]2]$B:N /ZS;W#OWE,U_EH .S]_*E)3"S%E
MRBRTMO;1CMR.WMZ-G.]F/[%,O?1>MW8K]DL4V5D"\95[M&<?X]Z=C_#T\4L-
ML*6._"<#MLF K2%EPRY>NHGM.P^A>5$/^V MY\:"QI7HZ]N#C1L/8I>4\3I\
M#A?.WL!U[O?>[2?X\,ES KO8/U^J$H)B=^C/K@[8KT6@^]?VE/Y\ZS:;_BS_
ME@RVZ][>UV 9O%]]*K^7^6?/7Z@D9R=.G<'Z+=O0U-J)F7-;4+^PD\_P)K2T
M;E2 G9(Q![$)-8B)KT%4;!5\ _-@81.&T>SOAH\U5QYL 6S)).Y#*(NB31Q)
M"/./<"9P.BHOKWBNM=):IG C7/M&6"&<P!LOB8]S/9&0ZTX )41E.R,^QX6P
MY4G EIK3OBK\V#=,DI'9(9Y +=[KM+Q00FPH4G+%B^V)X!@'A,8Y0LIXI>3Y
M*:B.27,B8'-_ N\$LU#"O'N@$>P]QBFX]@PR55 NXA<NM90=U;ZD]K*4^!*X
M%TG-]R<LT\XO$J]Z#/*F)"*G-)[KPGAL7BJ9F5<0 3N0D!]&X",XRCCK^$P_
M50LZF>>061*,U$(?A"?;LQW,X.*GE2*S=1.X-H")[4086T^$N;T1'#QL5 WQ
MP,@ A,:$$HX#X4[(MG82+S8!V\P4$XT-,=ED(DRM#6#O9DX@=R!D>B,Y.QI%
M%1G(*2%@Q_K Q=N*8DU0=R%@$Y3]):F9!4%]$O<Q'L86AK C8'OXNL$_Q$^-
MR_8-]H:'GQ9>;N]J28 W)MQ/AJ6#@=I?<+0'KT,P)9#SKJH&>$"XC&,7:.;_
M1!'J>8Z>(6:\SE*VRTEYJP6FQ7,=(N6]8EUX/=P0F2SA^#(^7NI<$[)S Y%6
M*/71Y=I*.+DG@=X5T93X= \D9[$]L[T(V>X$>GNVD3G_WYB0;\JVLB> \WKE
M2&Z74-0W3L7I<P?^][*(OPG8EW#U*HUX?K]Y0Q(J7<>=VS?>\&(/#A<7J/X]
MP+XL];,O7&3'<YX&/[<Y*V.PS^#".2G_=0"G3NW#>9[LE2N'"0R'^?_[</+D
M%NS;MQH[=_9BS][5.':,4'UV+\Z>WHM3)_;@[,G]N'#F,,Z?.HRC!W=AR[H^
M="U9B(6S9V!>]13,*2_"K,(<S,I-P^SL5#049*!M2@%Z:\JPJG8*^FI*"-RY
M6%R>A;:IN5@^HP3]LZ=B=7T55L^;1I%IM8+LU8TST;]@!I;556)N62Z*DZ(0
M[><&9PLC3!PY#$/^^A?\Z4]_(F#_&7]__Z\T7L<C*,P3F;EQ2.=-'9O(&R(]
M'I55E>SDVU6HTKIU.RF["-E[L&O74;;!%=QFA_S))Z+DJ+B__%&!MBBE7R!/
M*7L=KM\-V**,9*IWQF_+V]O+,KVCE4Y7C++!(*H;:?HV[Y+!G?;;HAMZ^O[>
M!FQ=!D/T[\G_#&#+VW:VKWK;+B* K<&T%E6@*7Y]7L+"+],8WKYC+SJ[>M':
MUHFN%?U8OVD;MA*N5Z_92&7?AJIIM2@KG8;J:;,PEW#=W-1*8&Q'V^(.0O9J
M*N2].'F"S\.YRRJZX\KY"SAYZ+"J-[V5@+UC\V9LW;B9V_:A8VD7X70E=G#_
MIT]?4& M@"UP+<=RZ?)UG#]_%6>X[L0Q0OJ1$P3L$SA[ZA0N$MHOG3Z."\</
MX]SA/3BQ>PL.;N;_KUE!T.[ UOY.[%C=C?V;U^+8[FTXLGL[MJU?@\[V5LR;
M0TB>/@?3I]>C9D8#92&F$:ZG$KZF$*BG$JRK9D@9I<4$;JV\E81.2_FF<L)V
M)2%[6N5\[F,A(7D)FA=V\5Q6*UDPKQT%^=,0%! /!WM?V-EZP\<[$NFIQ:BI
M7H"%A*>FQB[4SVE#[8P6)7/GM*-Q83>:6OI1-W>9@N*(F'R$A&<JR,X;*!4V
M8Y9D#E^&>JEQ/7\Y@:]=>;H+BF6\M4"U!M8Y^>(A?EWC6D2@6H=L#;0' [;
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M*6[B!+<$)PY="<6^R)X1@IR9P<B<%H!)4_Q4DK($0FYLJH?*+BXEO)*S Q1
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MQND3IU%;O0=[Z_;CS.GS*M:ZEX MV<,O$JHE&VI'QR6T2PPV 5O<Q!LO-"O
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M1FF K;79.JS]+< 6:!/ UL]3/V=-_F\(V 9P+9#[$73[Y!\!;!VN#:':4'3
M-@3MGP&VVH9V3.]Y/._Y(GZ@?,-W\=VW/^'5NQ_QX,D[7+QT%T?KF[&K^AAV
M\AT63Y=CQUO0U'H5UV[R_CWG\TN0?BW>>%+FZP.?&W$EY_IZ#/;? FP1PV=8
M[MEK_O?XR0OEP=72VH6FID[JI'=44K+>WOLX=JP!Y>5[L&'#=@7;XB)>4W,(
M>_<>PX$#QW'DR"GVHTWL,Z_BYG6)E29</V/?_Y(B\=&O"=AO"-AOGN+EVZ=X
M]58@6RS9+W'W_C.T7;R%??M;L&[M02R8OXWZ7!GFSV-?ME3ZI]T$^7V\'D=P
MY!CUU,ZKN/N @,[VZX72203>=<B6]U7>6SE/':Y_';!%_M[[+/*Y+F<HANV#
MH>CZDHR+CG3__D-5PJRAJ07'3Y['H?JSV'/@%#9NV8/9\]=B8LI<A(3FPL,K
M!78.,3 Q"V*_X\ZVTA;]V+<,'&J&X6/,,7J\&4',"*,FC(6YO8G*(BX)SGS#
M'1 _*9"P&T_0C4)HO N!:SS< HT1F>R$O+D1F+\L&;.*XY":[X$@ K9?]%A$
M3[)!]NP !=ZI!%/_2$LX>(XD9(]1;N!B91;7\$3)2LWQR"170J@3HI)="&%>
MR)@:2,@.1M9TR4KNAZ0L+\2E>W!Y'TPB/.?.C,+DV3$*H@6H(Q*=$!KGH+)@
M)V?[(VM:.+*G1R U5ZSC[@15!_@3$J5.MV^8(V'03L5/"R!;.(Z&E;/4]AY/
M,+1!6*(K]Z4E[9I(L)^8ZX-DD3R9YG%DN"(XWDZYRSMX3H"=NPF<?2P(EO:$
M=E?NQUV5.?,.=H9/")>-]B5@!BMKMHN/(P';0H-K1S,X>ED22B7NVT(=?SS/
M13X^)&4&J&1P05'."GHM[$?#R'P(91C7'0L[5W.X^SH@(,P3P9&^\!/CH#\A
MV<=>)41S][57L=M6CE*'>S0L[,;"T<,2;KYV</7AO0UT5("=-"F<D!V"X"AW
M'IL%87\\S\-:6:N#8Z6V.8$YV!Q2_ULL^O&3_"D\MF1O9;WVX++R84)JB,MU
M-'<8!4NG<;PNINH:^T>X\/S=U(>"T%@WPKRX[/LKB4N3\($ /A_RH248T=QF
M (%=7/7-[$9BK/E@1"4&X>#1.OSYKU0V_@N_?]A%_-FS9RIKN+B(&P*V5J;K
M$B[WP;,.V8;6;$,QM&J+='=I,=KMA.NVEF;",N%: )MPW='10L!NYW*:='>U
M$;!;"=BZA;M%6;O;N$Y+<Y-*VM34< $MA.JV9H)W<S-:&YO0S/DM#81P2M/9
MLSAW]!A.[=^'^II=V+ME RJ6%:%TP4R4SIV*3?.G$::GHZ)P.H?3L)707*%B
MKF=@^^*9"K!W$ZIUV5$LRQ.N">'KY^1A ]??O&@>-BR<ASE9&0CV\,;8X>/P
M]9=#,63(6%A:V<,_*!"QB9&4,(1&^L##QP&VCE:PMJ.BY>@&?[]()"=/IG*X
M%&O75"K7HMV[#A.VCZBX[,.'Q6U>$J ]9J<G2@"5"'9$,M1J4(H2]NGKO"YZ
M _M+#:LNGW=6ANO)?,/&V7 [GS?((H;;_'OR^7;T!ET70Q#6(?O7H%J#9&WY
MS[?SN1AN4TG?NLI%_!7!F8 M+N*BK+VCHO;^/14)*@"BK#U\1"50:EQ*?<Q[
M3_A.7,.1HZ>Q;5LM.^T:=MH'5;;PH_6GL/? (51LVXYU&S9@XZ9-J*ZIQKX#
M^]G95A*L%V/&C)E*YLV=C^7+EF/']ITXR?4:SS?C],ESJ-Y1B]*U&U%6NAD'
M]Q]&]\5+N'='OJ[?P^7NRRHS>&MS&[H[Q:WM&JY2+A&^.]HZT=9*:>OBNW4)
MK50XF@GM MCB(MYTX0(:SYU'P]DSE--HN7 6'8V$]&9V_ARVGB=HGSO#=^<\
M+IPYA7U[:@FR!,>9LY&3E8?LS"F8DC^7D%V(_'Q"\N1"PB"!62S54Y<@EY(S
M90FR)B\F7$O\M5AXERC GBXQP_F+"=5<GG";ESV?PP7*FCUGED#V6H+S1BQ=
MO$%9LO-RYB$V)A/>7A%P=/"#NVLPHB)2"/D%"L8WK-_.8ZM$0<%:Y.85(6'B
M=()U%L*BLI&:/A>SYZW!XB7E!+NM!.U-F%<@<+V*QU-"4"6\*NMU05^\M0:Q
MAC"=F?U)LG(D7EJ2DO&<\L3R+'"]#%.F"ERO)"!+.2X-KN?,6T_YCY"MNXGK
M0P%M?=H0K@6Z=8 6P)9QL70;NI2+"'A+W'5$5*ZR&DN\M;B%B_5:!VR!ZY&C
M'3%\E".&C2)DZU9LL; JJZLFF@7;3%E=AQ B1XRP@:V-GP+L144;L(6P5%G%
M9[KR(,JVUF$5X;IXV6;,X;6?/G<EA^M15+*5D+U)W?=0'I.S1RQLG<+@Z!:)
MH/!TI&;.P8QYR[%P<2F*EJSG<"WF%Z[@-9(/,.+V/A]3.%Q.4#Y\I $W;STC
M8/1U2OS]]%?@QY] !?=;7+E^"\=.G.4Q55.QW4JXWHR2XK68G#L#8:%1\/#P
M@*>G&_S\/1$2YH?HV%#$Q(8A(- /MO;V&#O6E.WS! P:8(H!7Q.$"=G]Q8(M
M5F>"M6$6<1VP-=%<Q)48@+4NJA;V0 LM^5E_0OH RJ )O*[C">6F&&ML"R?7
M ,0F9/"Y6$3PW$#H9)N_O1:'V)9T=%W%HZ=OE)7O P%;2C4:MI>&;::,_UJ[
M^FO+_KVV7I^6_W3 TR!0A/,$L@G7&F#S?[%F?O<CWHGE^M5WZ.E]B,/U+0JN
M2Y95HFAQ.18OW8:5:VI0NG$_RJN.8X]8KD_W$C8>X.J-Y[A]]S5NW7U)N'Z&
M._>>*;A^_$3:9K;+TEZSG9:/JH\(V(\>$M(>$[*?$;+U^&MQ/S;X(*JD+ZQ'
MP%H7K<_4Q!!@%32J:Z')/P+8GT.VONPGD7F?(/J?%CE&.5:Y7W)O>(]DJ(.V
M#K^_!MF&\V0]':9_272P-HS#_@C8W(8\ ^\I[WB^ M7B2<))@O)?\?B9W/M'
M.%+?AC+>^\5+MJ"X9#-6K-[&^UZ#G=7U'VM%W[K_' ^?<?N\/ZK4VW=_5?VL
MGE]&@VRYUAIP:_=/])B?ZR+Z\RQ0*H!]\]9]=%^Z1IWQ&F[??D(=]@.?F;><
M9EMQK%&%X.W:=0AU=?6$ZC,X?OP\3IUJQ/D+HG_VX-JU^WCT@'H"X?KU2P+_
M:^I9!-PW;SX!ML#UF_<O\/H=]8Z7K_CL/D5;QTT</-2.367U;(-J45BP XL7
M[\#JU;M16EJ#LDU[V&[NIT[ _KWE$FY2?W@J>@?!^J4236_1WE5YA_O ^G6?
M]'U8T !<>Y\-WVO#]_;71'^_]>OV>?N@BZ&>I.M3HB\]?/@(UV_<0M>E*VAJ
MZ>2];$'MOA.\OY7LGQ:R#\J#?T Z7-WB86XI<.V&(</LV)9:X*O^XS%@R'B,
M,M+*14VP,,=XB_$J$[:CE[B*6Q&P[1&;YD^XCE;QTGX1=G#V-897J"GB)KDC
M?T$4"E:D$+*3D#,[$-'IM@A)-$5LIAURYP9A3DD"ILZ/5N KF;]-[?H32$?!
M)]1*N0['2$WE)'$O%E=O1[5<_"0/).<0-*7,4XY G2N7D?\="&'N2,L+1MZL
M:.3-C"9 !_ _L7Y:J_CLZ!17 GD0X3L:^7-BD3DEC #OB8!(&U4&S,Y-K-7C
M"-3C8.MF3! T436]G7Q-X!ZH@61TJ@?B,[QY?IZ$:7=(]G*![-3)ODH$LJ5L
M54 48582H_E9$40EV[H'S\D/X0F^_$_BN@FHP>("+3'H_O -]8"CIPT!6:#7
M"):$7P%SGU!K%:,N%OJLZ6'JXX#$D ?'."F7;8\ :P+U>)C:C(2QQ7"N.TJ!
ML[.7-7R"7!$8[HE @K8D01-P]@IP@&>@/3P#[ G3UG#R,.?0"GZAS@@D_/N%
M\MC#W1&90-!-"T5<2C""(MVY/7/8NAHK*W1(G"M"$^0<[93KO7Q8D21G$F,M
M5NS()$_X\=@<O,;#S&$$C&T(_Y:#,<9T$(?#8.5D1&"W5A\=O((D=M].N>)[
M!NJ6;OD@8<E]N"O/",EH'I/BSVTZJ@\?8\P&8="H+Y0'P)X#U?CQ+_]W >P^
ML/Y<=&OVC>M7E1A"MB::15M!=ALAFZ#=*I;G-L(V ;JC0X!:ZFH+8$N)+[%\
M:S'="L0)UZTMK6AJ:D*C #0!N[F1D-U$J&[J<X%M:N:P6;/6$; ;3IU&&X&B
M^\(YM)T\BA/5VU!3NA(52PNQ==%LE"^<B0HELU#)X;9%L[!C\6SL+)E#J)[=
M)P3LDAD*L+<NF(P-<W*P=G8NULZ9@@T%L[%NP5S,S<E!I%\P3(VHB T<@U&C
M^$(Y>R \DC<U(0(A$=[P\K.#HRL?,$<S K85S,PM86IF WM[#X2&Q&/*E'E8
MLWH+=N[8A]J:P^P0#JA2$@</GN!UNH3[]]G(L]&5K[LJ6Z<!8!M:L'7E21I5
MO3'])3'LJ/1U/Q>]<1;1&^?/&V81P^W]/3$\AE_:GF%#;PC$.E#K8M@1_"/R
M^?9^$;"I*(H51/NZ_I/J^._)EVH":WV]UBDW-EY4';2 =5E9U<=[I,IQU1W
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M:Z7*\)W#_2M7<+%8]XD.UX8P_4EX+KDE2@2L1?+RQ?HLUF@-KF?,$NNU0+7
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MB_ROG@FY#KS7SUY^1ZA^B=:.VSAQ^A+V'VK!MIVGV$?4$;@VL[U<CO0,J<[
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M+9OVH)"*>';6/$+V?.6=L&I5.7;N/(B#!T_CT,%3J*X^@ T;RE&R9 7FSBO
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M*[!R!2%]T0;,GL5K0_B>G#<7D_/G8L:, LR;OPASYQ7RFDQ':GH:GSUQ X]
M<DH,LK-3D)>7@:RL24A-345L3 )\?8)@9>V$T6,)U\,G$(JUA#L#ADS @*$F
MA&V"]3#",\?[#Y;27..55=M0M')= MCF!&LMD_B08=88,<H>8XU<5=9V"^L
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M,KFO6[\9*U>58O.6;>Q<"!7'3BF87KEJO<KX7B;9@.L.X-"1(SA<?P![#^_
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MQAAK-@*#1@U&OR%#"=8C*6R3!X_ P.'#,'K"*#CY6"$V32ME)8 =GFQ+R'9
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M;4T-#N[=CS,G3J.M2>*?.]%)9:#UQ%F<J=V+PQLWH[9D&7;.*\3N.?-1-Z\
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M7T/OK?NXQ6W<OO<0=PC7]^\_Q*-'3U0\MNC4AG"M6Z__NP%;EM$LV!1Q%5>
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M#1V(T-C!'!^%I$DF2,VV0G*F-9+2;0C85@B-,H9OX CX!X]$=+P)MV%/P'9
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M:.%FK%ZSA\;];M[KS03FY2J9EY3IFI;+:=YBY!"H<_*78CHEEY)'N-:@642
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M,QR>X*D\S(G3_"F^/ ?Q#'L3L-T)U8[PBY1,URZ06MD1R6X$6C>>OR\!-Y@
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M3? XBGT'+^'2%=&7DO_D*>[<>4:X>$&8>8UGSR7AE)3E$D^P +:,BQ5P^V>
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M8.NJC2C/*T%!4AJ*XI-0D96-+3-GX^"BQ3BS<A4NK5J#*RM6XYI ]J)EN"J
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M8PC88R%9H7U#/!&5'(:H)((G0<G%UP;6SB8PMS=4GDI+!PL"L#U<O-W@ZD/
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M7$(V$I/SD)I>POYFMBI9E9$U3X5.J['8^<N15[A224&1P+(&S)^(@#1%(%K
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M,8M075*V$3/GR;CK'5BP?!=6;-B/;;M/X4A-+:XU]J!K\ %N/WJ!A\]?X:E
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M[%C\>?0X]O7C,682P5I_*L;K3<&XR1,QQ5B\V 1V@I?4K/:+L(6CMP%LW"?
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M;0V2+$7&:351&?-];Z-2[FQ%JR0]E"2'G'9++H-^*FX9!L+^089@7+QXF<;
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M'H=PPGI$1"*"@^-X/D$P4W M8> "UP;XT^<:8)NJC.%?C17 MJ;")H"/,5-
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M,Z&UO:U3?4%KK&]"?6T]&FXVH+69@$TPOC4PA#M#MQ5H2^BWC+L6$8 6;_9
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M047VU4#[4\#6Y./U_STT_WL!6]LFQ]&.JYVK3D17ZN!:[H7N@X7\5O?,_[6
M+1\X?E#_3X/J7^6-;OK^O=QK_L_O_X;OOOLK0?$[%>)=6]M&R#ZK/D8)9%^[
MUHJ.CCML=\\(V&\49-\A5,NRB,P_N/\2CQ^]QA/*O3O/%&!?5("]$]E9LQ#+
MOBXCM1CSRE9A_=I=V+/K! X=.(-=54>P=LTV+%NRAN"]&?MW[\7)0T=PFG+R
MP&$<WW\8IPZ?Q,6:RVBH;45S?3?MNIO8ONT0EB[9A$5+-F(-0;MRYU%4'ZA!
M]:$:5.T]@9W5QW'LY&7JI7Z^ZVR[+[]1']2>2.X!VG<"V,\E-)QP+9%YNEPS
MW$^UD_\:P/Z:[>&;#Q_4T+=OO]')=VSWW[//D42 WTM;4Z+[F";#.U\\?TW
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M\M@)='9THB"G$*Z.[I@[D[#PP21,F3@#"^;JP<+,&J[.'O!T]X:+HS/?F\%
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MPL[1'[X2%DYP]B<X!P?%(20HE@ =!G=G7SC;N[,-$Y[=_-D>"<;> M:A!.M
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MWOY,QAIY+?LDWY/Q20M26OT]>-=NX^WK*M+^AJ;M: !;._9II1T#->=#^Q!
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M6@)V.P%[%P9.'L;Y8S18MG8JP"[*3$$TH3W,UQWQX4$\AECDI,0K%66FHES
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M_UV K?9%[9/&FRW70'N=Y+IH 5L>J&BB%;@=7O>O"=S/GGY!.^@!8?DZ89G
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M%Z(XLQCYJ7G(B,] 0F0BHD)C$1.1B*3X3"3&92$D* $.]@'0UW>DG.'@&(:
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M;R[=$!3EBI 8=_B%.\([Q Z%%:DX<_'(?W62L_\ L F]]<M:D%>Z7(6$UW+
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M(YPZVX?VSBU8U[P!6[I[<.CH<1RG/;MK[T$TK6]%7GX)_/U#8&5E#R,"M<A
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M^O\0L"F"M$I:]CIQV=]* ]P"V5]\\1FW(Y#]!K0U@,UVP&W+;PI@__C#S[]
MM20QE.73)Z]X'U^A[;0+:]8W8UWK1FS=LP='>6\<.'H:JYLV(2HN \9FSIBW
MP!P&1O:PL'13@&UH:(&%"_5@;&0$5U='A(<'(('C=&Q"""*B/1$9ZX;$='=D
MYE.%C@0H4\+3/,1G32'<3$%6R1P45NFCJ-(,.846'",-X><_!ZYN,^#AM0"A
M$59(XO>S"CW)!T[(SK= ?KX5:LJ]L7Y%.GJ:Z]&QHAZ+<C.0&1: C% OY,9X
M(S_>&_4%<=C6L@Q#IP_C[JC8[(1GVK1CMT9QB[HS/HX[MV[A]LU1W*;-+(#]
M8/P.'MR^BSMCXZI"T(GCQ[%%('OI,N3DYB,H. (FIC:8-&DN?O?;R?CM;Z;@
MO=]-Q_OOS<3[[\_"[[G\[>_Y_J-9F#7/"%9V[O +CD)83!(!*Q0FMC:8.F\N
M/II&")\Q2R7/TC,F:+HY(2B"=A'ME+CT" 1'>Q,.[>'N[T3 %F^S&^S=K%3M
M;!<?2_A%VB,TWI%CN#V"XZT1$&N!( )I9)HCP5J\LP&$2"F?17M+:F#G!!&0
MPY&2%X'HU #".>UQ5V/NCP[,[ U@[6(.<WM3S-.?CPG3)^.#21]CRJPIT#59
MR/UP1&(F;:G*#%ZK-%Z_8/A'VA'R#>$59HR(5'ND\OKD5/HBO\8?>55^*E&9
MS*5.SG=%&O\FM;-3"@2*/1">X*3FB4LY,1=?(^7!]@VS5&'D:?G^7#<0"5PO
M.,8*7B'\6X0)(E,=D,CC2LXC?.?X(99@'9WJC8@D3YX?!]AY$';M%L#"41?V
M?.WB2YLWP!I>P;8JB5E M)WRZHO'73S@2;D^W!;/-R$].H7[E1Z$]+P8I.3$
M$K2#X1'@#CL7>U6>2\_$"//UQ9.MI[*)2WDN4TM3!==FA'!K!ZF%;:N69K2S
M32P)V)29M3$_,X>+EQU\@EU5G6Q7'RNVY02</'OPOR+)&?]_6^J_?P_8QP2P
M&YJ17;!490:O6-1!;5$JK]V,TJI-JN9U85D+ ;M9 ]C*@\V!OV*M NR"HL4H
M+%Z,JIK56+EZ$UK;MZ%[ZU[T;C^ ]BV[L6)U.]>54+$&%1J>DR?S'\5C)%"]
M%@6%A.J"-=P.#=<2V:9XLKE^;@.2TRNH4N2]#@/<O?L(^OLE&_=MG#I]$6L(
MTW%Q:;"W=X>3DQ<[F RNUT1(.Z)"Q,^='R1@#^'\.?%B]],PE\S$5PG6O-D)
MU#<ES/0:(5J@^G7]:M'(#;X?N:7F9TOR,TEN)F"MU2T"M@#WG?N/<.?N0XR.
MW2%<<SLCHS1VQC J<[>O7N5O]1.P"75G^_CZ/#N. ?[>90*UU @D5 M<7Y>E
ME"RZCO&;-W!G= 3W"=E/V"%]>N\V7CVXC6?C-W#[\@7T']Z+_9M;T+&\#HWE
M^5B:GX;%.2E4,AKRTE"5E8*\Q%@%@YX.[(P-#*$[=P'FSUJ(N;/T,7,ZC=4I
M"_'QQ'GXX..9>.\/DPG6'^)__^8]ZG?X[>]^C_?>?Q\??O0!)D_^D) ]";JZ
M MDZL+5E9^1HIF3G(%YM2WAY.R,J.I2078S63:W8L_\ ]AXX@FT[]Q.6#Q"(
MSA""QO#)\U<<<+1/DW]2@/WIRV\P.OX8)_H&V58.HK-GC\HR+]>XH[T'ZQHW
MH*FQ&1N;-J)E[7H"]EH"=C,.=+?CZ/8.'-O9CI-[VG%Z7SN.[=J _3VKL+-C
M*7:V+\6NCA78W[46QW9LPH6#.W"U[SA&"6R#1PYA5^L&;%R\".W+EW&06(\.
M;K>NI!3A_H&P,#953X3M[-G!>G@HP/;V<H>/NRN\G?F9C04<30UA8Z@#2T-=
M0HD)I(ZXK9T5'!QLX.DF\[4]""8>"/1T1;"7*X+<'>%E1V W90=D-!_./)>>
M5H;PL6%G9*8+"YY?,[VYL+<RAKLSM^%B"Q\JE-]+]/-" 4%W27(*VO.+L+NB
M!H>J%N% 12UVEE9@9U45#C>N0O_V7HR<.H:1"^=P;> BSI\Z26.FF7"3C  O
M=IB$_L3(<*3%QR(S*0'9R8E*68GQR$B(0UJLU#R.0EI,##+BN$Y\'!5+L(Y%
M3G(,UXU"9G(X<M(B4)@;C;*2!%24):(P/PKI27Y(BO5 1J(OBK,B4)D7AYJ\
M!%3G)* F-P&+"E.QHC(/3?5EV-!0B=45Q0JP\_F;F6'<IY PY,4EHK&N'L?V
M[,78E6'UH$GNE].GCQ&L#Q"R#Q"<CQ*X3Z/O]#F5O%"\V%>NC*CY>I*Q^.[=
MY[Q7'^/RT#CV'SQ#T.U2T2])J<6(B2?D)10B.;4"&5D:P)8LXL4RU[I4 ]:_
MB-!<* \ M6!=_$8E$B[./JJT=)UZ7<IUJRK78>F2303LG>CJIE'0=0RKUFY#
M9MY2> 6DP\HQ G:N,1S(<CDH52(BN1JAB57PB2R$A5L<9AEY8\(<!TQ=X Q=
MRT#8>2; .S2; V$>/ -3.8"$0=?(!=-FF6#:# /,7V &%[= Y.:68V-+)P[L
M.T[@.HG=.P^BG<;KDOH5*,@M05(\83HJ$?'1R>JUE-.*BTY%6'"<2DKFY18$
M5R<_PK47+$R<8$;CS9*&G).]-_\6"#_/-X =&O :L@G4$81L\5;+4C[3 KB\
MCPU/1')L.MM*+G+3"Y4RDG,0'Y.,D"!)@.8/8V-[S)IMC(F3=0G1>OAXLB$^
MG"P)S8P5:$^88JHD@/WAQ_KXZ&/)'FN"N81K0YF/[AR"E.0BGO-FM+1T8U-;
M#SH[MV/?_B.J+..G-(A_^M//2@(X6H^C&-D:.) ^Z-=!^N])"W!O@YR"(2U@
M*\E[?BXAX3*?6DGF5A.N?_P.W_](^/M1DAJ)!^MO 9N[AB^_^RL>//L69P9N
MH:WS *KJFI!?M$P!=OWB302--BQ?L07=W4<XCMW@&*6!Z_%;SSCF/.+8<X_C
ME92:?/ W@/UVB+A(,Q=;(WFOO-DOO]1X(!_)G.SG"G!?\'/Q6@M@O^)2 /O5
MUW_D^S\3O$'(_BL>/O\!PS>>8=?^BZA?NAFI60V(3ZY!5MY*E%>W8<F*'H)#
M+[;T[,9I0O6=!X_Q_.7GN$^8EX2C9R\.HO_R%=Q]^ 2??47PYXD03[:$B\MZ
M3PG6$C;^-F K[[! -J_KV]?F79B5UR+-M?J/]8\@6/XNOR&_^2Y<BP2LWX9K
M64_6_T?;?5O_&<#^-<A^>[W_K.3[6I#^>WH;L*4M::,A!*YE>9=VT?5KH^I!
M:-^I"]B_YRAZNW8JP-[<WHVM/;L(UT<4@)\^);DVAM$_< ,G3@VBN^<@;<D.
M99NN6M.%K=M/\/X^C_;VO5B^M!5K&K?0QNO#M2L/"-5?$[!_(&!_I;S7KUX)
M2,N\_A\@F<)E_S2>ZS=1!Z)_!-@"T@+8OR[>6]2K5Z_XW5=O0?8;P)8P\<\E
M$S[/C1:P_RB9]@G9$KWRXM,O,$A;M*=[)QK7$*Z;-Z!WYPX</G%"A8=OVK(5
M.045<'#VQ=SYIIB_T +FEJZPLG:#H9$U9L_6H>;"Q,08OKZ>B"=<)Z=&(3XI
M&-%QGHA)<./]Z(6\$A\45GH@M]2&$*6#^(PIA*2/D90]F> ]AW\W(&";("7=
M!#%Q!HB.,4)2BCWR"GU17A."\CI_%)0Y(BO?A(!M@475OMC8F(/>#8O1L7()
MEA3FHR@AF@I#$7\[)Y8V2U( Q_QL[.ELP<"YX[@Y.DQ;F6!]=Q1W[XWA_KUQ
MW*-]*[;NG9LCN#<VBH>W;^/^^&W:P3=Q>? 2CAP^@BU;NK!L^4J.P[3/(F)A
M:<EQ<NH"O/?[J?C][Z;A#^_/Q(<?S,$'U'N$; 'L]SZ<A9ESC6!A0YO-/YSP
M' ?/@& "K2VFS9^/#Z9,Q?L3)=G9=,Q9J ,;1UN$Q 0AIS@-Q=4YR"Q*(H@&
MP#?4'=Z$,S<_1SAYV7!IB\!(%\2D>1,2-=":E.>)V$Q71*<[(3Y;,G$'(*-8
M0I]I_\5(W6<I;27SEPFN62&(H(WD'F@+<P<]Z%O,@X'E NZ7 4QI6ZOLV;IS
M-27%9D_&S 73"*W&B.(Y+:[)1D5#KO*$!T83%@,,X1UNBN@,I_\?<7\9G5>:
MY/N"W^;CS*R9<[JZJY(SS2S+8F9F9F9F9D9;LF20)3/+MLR2+<D"RQ;8DFS)
MS$Y#,E1251;\YQ_[]9NISJDZW:?OO7VU5JP-VO3NA^*W(YX(I+)\,TJ]%,C.
M*%'GL99GD8C@'H1L#\3RV22=5T"D-?40F2-M0@@V4L0[Q +A"<Y(R/1!8I8O
MHI(%L"WA'6J"P!A+GLOK%?@I>;]C,[QX'5<$Q[H@,-H)GL'6L'$S@)F]%JQ=
M] GNEO +=X1_A!.O:P.W %.X!9KP75@B+%$ VY7BCL@4-X0GNO->$ET]E'4S
M 1E\_S$ID? .HD[B;*]8L-?K2D1Q+:S5TJ8.9 !]8V,"M@D,3:FG&W.;^K?,
M7S<TE;S8NM Q% NW%O?KP(3OU,;)#"[>MBP_<]BY&",U)QH#(V?_[P/LLIJ]
ME/TH(6 75^XA8.\D3'<J5FP%L*E8YA:U(8>*:6X!(;FPF4#<C(JJ-C1OVDG(
M.D:XZB-H#>!8SP7"]G'4-?+<@B9E[K58KV6>M;B(2U1?@6J![+S\+3RF'?D%
M5%I+VI7HO:7EW%?43#"O0EIZ*8J*Z[!UZQZ<ID(IUFA)^[5UZVZDI^>S@PF&
MMW>P8L'>L6,O^OHN86!P% ,2Z&Q8YF)?40*>71Z=P/4I O;-V[A+B+Y-^+O%
M06!>4G?-<5W<P2EBN;XEJ;QNW\<]L5X_(% _?(0[#V3N]4,5<+^Q7M]_\(3'
M$+KOB?7@(>[S__?NRCSO6[@Y/8WKA.S)L<N8O#**:^.7,7/M*N9G)GEO0K98
MK@G7=^8D9Z!Z;HIT.+?P[-YMO'QX#Y\^OH]/']W%JWOSN#]U%1-]IW%Z]W9T
MU)2B+BL))0F2RYC@$QV&M @)3.0##UL[&&OI8/7BY5C\[F(L?G\YEGZD@24?
MK<>''VH0H%?C[7>6$:@_P+_\[FW*[_'[W[_%_>]CR9(E6+%R&3OO)51JEV#]
M^N70U5D#8[&P6NH2M/5A96.@N([;VIG"V=66G7((ZT Y]AS8CS/G^W"V]Z+B
MKGG\Q!D,L@SNWGZ SS_[1IEO]&=QA?SN9W:X,F]O$H>.GL'N?=W8?[ 'W<?.
MXJA8XSKWHG53&UJ:6M#>LAG;-V_&[JU;T$TX/G=@%P8(V)=Z]F#D]%X,G]Y%
MX-Z*GKU-.+*C&H=WU.#XKB:<.[@%PZ?VXWK_&=R6E%#B<MQ]!%LJRE! J"Q.
MB,>FTE)T-#6AN:*"D!D-)[XW"S,S.#@XP-W=G8#M"A<G0H>U)6Q,#6&IKPT+
M74V84Y2YU6S@%FSP9FSDEN8F<+*SAB_A.C30A[#AC]A0=K;^GO!WMH:+F3X<
M##3AQHXTS-$:J7X>2/%U1[B3+?QLS.%GSP[<P1J>UF9PMS"&+Y<QA/3\T&!L
M2DO#_L)B])17XRP!^V1)!8X6EJ"[K +G6UMQY>@AW!B\B!M7QS![?0KC5Z_B
MR)'#*"\O0S(A.SLC'=45Y6ANJ$=K<Q/:-VW"UM86;&UIP19*&_>U-#1@4UT]
M-M;586-]+3;65J&IIASUE86H*,I$04X"\C)CN(Q!<4$\2HOBD9]-(.=@FA#A
M1CCW0&Y"$,K2HE&7DX2F@C2T$JRWU1:A:V,E]K36H+.Q IN*<U&:'(\, K\
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MR3OZ_"N"ZN<O\>RE!(65NO:0]?@1]:]'[*_OXMRY61P^?)EZTT7L8-^W;]\
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MQO'61ISL;"?([L;0V6Z,7SJ+F^-#N#=]%8]O7,/CF6MX<&T"M\8N8TKF6'.
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M LN?8!V.],(P95YT4(P[8=&9<.R& (IGD .LG7E-DW58J;D(BU:]BZ5K/R3
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M9\7?*Z[M)K!Q-5+ VLW/AN<Y\!K.\ MWX?E._,W6</0R4P!;+,-A"1Y(R Y
M:D$@Q8]P[X&D/-GG3LAVA'^4'<5><24/CA5/ $="NCE,[;2AH;\<B]>\AW<6
M_QM^_\&_$+(I[_XK?O_>[PG6;U'>Q=L?OH=W%WU(H%Z&Y:M78?F:583M)?AH
MV7M8O/)=:.@N@[F=#EQ\^#Q!_+VAM@B(L$>@I!.+<(2KKQE_BQ'2<J/8_YS%
M7_X[TW15U:G3=&U'>=U>RGXEFGAY[1Z45'=R/Z&WM!5%%9L)WMNH].W!KH/'
MT7VJ#Z?/7<+),X/8?^@T-K?O94.5X$"J.8FY^6+5$2 6P-[!!KR3_]^%JIK=
ME%VHK-ZI +;*FKT0L%4YL06P\PNV$;+? '8IKU,F(J[C[2@L::42*_FU:Y"2
M3N4XLQ(Y!77L"%H)V1UH:NU"7?-V5-:VHKQZ$_=M1>?NPX3LBQCAH"T!T*;8
M<"<(W.,3DXK%6"*'2]3P>_?N*T M8#U+ )@E -P6ZS8!^]&#!YB=GL.10R>1
MD5I,9=4%'WVHB??>7X?E*_5A0"76WCT83EXA,+%UA:Z)#1S<?*AD%V%'YS["
MPB"FKLY@;OH6YBFSUV_BVA0[U0F![#%<)O!?N7J9VS+_=(* ,*6(@(<BA&N1
M68KDV)X8NXP1 K:D5CIY]"AV;&EGQY4-'P\7Z.EJ0%]_/3R][!##!AL6Y08W
M;R/8N6K V7,=_$-T$1%GC,@X0RKG6@@)6X^PR V((60G)I@3JNT)V&X$;$^D
MI[/1)+HB,I(5-] 2WMXF<''1>V/-7@\K@K:MO1;L''5@[Z@+&T*WM01"LS'D
M<38("?%!6FH\B@JS45J2CY+B/';4.:@H+4!]31D::DI049B!/'8Z&=$!R(ST
M17Y< &JR8["M)I<P)^FWVM![1"S:71@^O0]3 R=P;V( SX-&$Z\  /_T241!
M5.<G\.+6-=R?',5XWQD,GCB,/H+\B9V=Z&IL1#W!NB0I#?F$A?RH>%0DI6,3
M 7M'=1VZZNJQC:"YE=)25HKBU"1$^'C P=P()CJ:,-B@ 6/=#3#6TX&ACA8,
MN;0@9#M86\#=SA:>=C;PM+6&MZT5_!UL$>'N@M1 7Y3$1* I/1D=!3DX7%F&
MD_4U.%-7@U,$[%.E)3A=4HS3Q44X)5)>AK,-]1C8L1U7CQ_&C4N]N#,U@H<W
M)_#D]G4\GI_"O>DKF!\;PNS !5P[=P973APCB!_ J4Z";,LF'.'Y)VMK<%X
MNJ(<%\O+T5]1@7Y"]47"NXBL#_)W#A&HAPC>LCY8685+LH_;(W5UN$30/BMP
M75B&@T65Z*YHQ(FZ5AQO;,/QC5MQ8G,'CK5UX%#K-AQHW8K];5QN[<#![3MP
M<,<.'.K<@:.[.G%BWTZ</[P7PR</X^KY8[AZ[AA&SW3CZH53F+T\B-O7Q@G7
MUW'G!MN=!!>42/JSTTHLA/E;-W#KS@W<N'F="LDY;&IN1$1H*"Q,3&%F: P_
M#V^4%A1A9T<G3AX_0=#NI\+.=G.9[><REU=D_K8$#YQ5IEE,3ZNF7-R<DRP
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M&Q=MN/L;PR_<DK_1&N$)COQM'HJ$Q#KSV?G<CMHJP+YT^K_'15PZ0@6PZU6
MG5/4CKRR#N26;$>^Y*4NIQ!J\\O:45JS!?4M5 KW',6AGO,XU3>(TQ<&<?3$
M&<+U 30T2_"R1N13P9/ /T5%+<K<Z\*B+2BB$E%:M@L5E03KFOVHK=M'R!;
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M.U%>0:"NVJ< MF+!KB%P*W.P^7\%KK<1T"60&4%9 6P57"N 72@NXCM04B%
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M8.2&^R(EP!49$3ZH*T[%L7U;<'VL#T_O3N/3IW?Q<.XZ^D^=0'-E!<)\? C
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M.#2):S?NX>%3WI?G/7\I%FR6/Y<2F/ SUC%)LR?Q!N19%HK\AH6_XU>1=[E
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M_ *  B0"UP+#OWH<9=@=9<@=@00! !K!7ZFRA\NP/#),SV^>2C&H55(!M$B
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MN" RU1$1*0Z<.B JS5&![*@TE><^)MV-(.[%W_4DB+OR&CC *]A6"3=W#W1
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M4,));$  RI)3L;JH%)M+*[&CI!)[2ZNPOYS S,K^($%8ALOJKU*![Q U6-6
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MPO*5QEBX6 ]SYVMCUAP-?#A; Q\0LN?,TR9T&T%'UP;F%AYP</"'JTLPC9
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M71& M&)?@C=MH%@;I9^S6Y A@=I$\6*')5HKWFG?< -"OC'B:.-GE?H@MS*
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MZK!JS59,3%UGV_@6]Q^_P8/'KPG:G^'-)U_CH\^^H63Z-=Y\*A[N+_&:\">
MK1X7^RD!^LD,S[5: M?OAHG/!.MWP\(%IF?.J\N5VGO]SQ#]1Y+KKKKV,R%7
M+;E'<L_D_JGOH2S[%5RGMU/KW64RK_9LJ[][5^IU_PBP13/7$4"5,J4&:_%<
MR[%)F9I9EKYG&9(LX=_R/+]E6?B.T^]E.?7U=S_3SOD1+UY_@?.7[F+7WI.H
MD_P0M TE:6Q-@]B0?3@Q> VGSS[&Y.D'&!F^BK$1EO\+=Y672M+O6C* 2]]I
M53]J\5H+7/\&V-_(\\KR))GKU9F_59$J_PC,ZF=?[M_,>D"]WF_K3V\C<,WS
M_8K7Z.MOY9JIKYO\%O<A+[&XOOKEG@S)]1V/Y>LO629?OL+52Y?1WW<"AP\<
MQ$#_25RX<(90?![G+O3CX.'5Z%B=A:J&$)35^J*DRI.0[8:$-%OX!1O#SE$3
MUC;:</>PI5T9B_;V1APXL ?C8X3T\V<)V)>G ?O6-&3?Y+-R!X^>W:5NX^J-
M,S@YL!=KUC:@J# .\;$>B RU133A)R:,D!'NA(1H'V2F1:.VL@AKNMNP8>UJ
M=+&-K2RN(E@7$<*+.*U" 0$X)Z,)&2GU2$^J1V9*$V&[#7G9G2C([53"O26<
M.SX^'\DI12@L;F3[TXN>-;O8?NY%9]<VU-2L9OO62,"N0$I*&3(RJI"7V\@V
MB^U<?C.RL[EOPG5*9C62TZN1F,K])9<A+JE$47QB,6)B\Q 5E8FDA#Q4%-=C
MR]IMF#@QC/L7K^+Y]9MX<.X\+DE4V<XMV+.Z%6OKBM%0D(:"A$C$^OK @^V;
M,:%W^:SE6/+!"FBR33-C.^1@X@Q/6T\$./LBVC<(*:'A5"C"?;SA[N $.RL'
M6!*PC0SMH*5IJ41NS9ZGQ[9-EX"MB_?GZN'/M(/^8[86 5L3\Q;KL7TS5=K2
M92NUL4QS)?1H5]K0AG4/L"?LRA!2(03L8 6LW0/MX1_AAHC$0 1'^\+!PP;:
M1AJ8MW0N/I@K'NQY6+!LN3(\EX6=-3P#70G$GDJB-/'&2E_CI#P/Y%4'H[@A
M$ODUX4@K]$=LIC?"D]P)O8Y*]FXG'T,X^QDB/-%)Z>=<UA"+G#+:49DNB$BR
MX[HVB$YU0'*N&S*+?2D90]J#<.V.#.XONS2$T.W+8[8ABV@I<+U<[WVLT'^?
M #P7QK9+8>E,^]B#(!_@@( (+YZ//_S#?>#NYP([5QN8VYD2M U@:*D-7;/E
M,+77@D^X/7_#'\GYOHC-<N)Q.R(QUUU)S!:9[,+K0SO=7I,0S/4E3Y.K&:^1
M)6S=3 G8NC!WU"+@Z\$CF&P1ZT#0YOF&6BI9RIU]#>$6:**<MS,_2TBX9!J/
MR_"%;SAM?A=M&%HO@Z'5,B69FI63$9R\;)!?EHWQLZ/XR]__ET+$9_"UTL]E
M_\%C2,]B(8_/(H2UHW?3?AH#0P3K25:0$]A_>( &PE[4-_>@H*0)61(^DM.@
M\EP+7!<)7/\7@"U@K(1VJ_I("R@+,*MA6PW9:KB>"=GRG:RC!FQU/VMUF+A(
M'1:N_JR6&K!_E8 V(5K NJB\E[ M@+U6D8RS7<+E915J$<*YOIQC=DX3*Y!:
M&M"52$ZJ1%Y>,UJ:-V#7SJ,8/C6)*Y>OX>Y=21CR&*_>O,!'G[S&QY^]P=,7
MCW'E^A4<.'*,UZ$%(1$I<'21 ?&CX4&@]O;-AJ=O+EQ\LN$4D O7B!(XA97"
MPCL?^HZ9T+%.AY9E,I8916*NAA?^O, *B[7L6,BC>;W:<;3O""8FAW#BQ#[L
MV+86>W=NQ>3(*&[+N*/7;^#JQ2F"0A]V[>[F_4A&4KH3(A.,$)FHC^A$71J\
M^JSLC!"O>*^-E&&X@B5KN)\F_/Q6PC]0@V"MB9!P;41$$YP)X2GIEM,AXHZ4
M$S)SG/C9@16E)0%;'Q&19B@L"L3F+548&]N%&]>'\>#^!3RX=Y&ZA'MW+N#F
M]3-L;(^B9U4#XOB@B@=;PL)MS7000WCJ;*S T-$]N'WY-)[<O8R[ET[CXL Q
MC._8@A'"]0C![%13*TXVM. (X7-'53VZ"(N%!*EP/S\XV=L2L$U@8F%,8]^$
M\X8P4P!;$V;Z*V!FN +FQBMA9:H%&P*VE3[!6V<%++17PM9 #ZY6%O!W8^44
MX(?XL! D$JY30X)0%A>+=06%!.P&#!"PQ:,\0< ^3<">K*S'<'4]^@C7!PFO
M>R43."%.^EK?FIK$2S:6']V_C2>7+^(*&^7AS5MPI*4-^RMJ<)!P?:RH B<)
MV(-E-1@6:&=YF210GV[NP)F63IRF%+CN(#BOZL&4 M9K,;:Z!Z.K"=<]/9A8
MLQ:G103N,UQV>I4:LKD?0K8 ]DA+$X^]4<E2OI'7K#HZ$;&.'K#7,(+N[.58
M^MX2+)VM@:7S=+!D/@%[L0E6+#/'\N466,KI0GZ>O]!0 ;.%A.VE!#+IFVVL
M90XW"Q<D^$:@)C4/&RH:<*BQ R<)V,,"UM(?O+Z.TP:,$K9'FEN4?MI#'5WH
MXW1/?2-6%['AS,I&1UD9]O2NP['=N[%U[1HT5I:CHB 719G)2(\)5CS51<D1
MJ"M(17DFC8P@=S:DK$#-M#DU1J2O"[+C(PG8J:C(RT%)=C9RDE.1'!U/(R02
MT1%1R,W-10_W/3 TB$LT:JY>NTI#Z3Q.GY[$Z8EQG#MS&A<H >HK4U.X>O8L
M+DY.8&*@'T=X7-O6KL,&7OO-O9NPKF<#ZFJD[UDQTE+RD9E>0N"N1'Y>'0IH
M=!84TN H:H8,82C>G0*!:X)VCF039SV:G<>ZM* =145=A/_5!/:UJ"5@UU2O
M05EIF^(]2$\K(;17$K+;"-<;:)BM)WS7(RPL"<[. 7!P\(&CDP^<7;WAZN&C
M0+:]LQO,K.R@K6^&)31 YLS7(" OPWL?+,>'A.>Y-";FSS? PD5&6+Q4E1U5
MC(QY!.Y9<\7(T,/[<_05?3"7R^89$*8-,7N!B/,+]#![(??+]><O,<2B%28T
M%FQA9.X&<UL?_K8WY4G(#T!H9!+/NQK=/1NQ9_]1# Y/L&Z\@Y>O/Z%!+- A
ML$ CGK F'NQW(?LW(_E? [9(#.W? ^Q?EPM0_PK7%(WK7\>XG@;IF?J.@/V=
M+"=<__B+P,<O^(Q0<N?^:YSHOXFN[@'DYFU$4FH',G*Z456_%=UK#V'CUA/8
MLD,UY%I?_Q2FSM_$M1L/5;K^$#=N/,:=VX3%AP+8K_'\^1L%K-7>10G=%<^^
M&H;4(/0N1/TC9(MD7@!;OG_GW#G__PK8:H^V:@@OE:=6$=?]1B";@"(>; 'L
M[W[^"S[YXAN<OW(#J]9M1GYQ-5H[UV%DXB+N/7R%6_>>4SSW9SSGCSY7H/HM
M8>]C;B/3CWB^"F#S&@A<"ZP_%KA^(LG@GN+QM-=:P%KZ8HMF9DK_5WVM9TKM
MN99KH[XN_PS2?R2YSJKK/A-RU9+[HP9L5=(NU?V3==70K-Y.O6PF3,N\#,>E
M'I)+O7RF9#OU/F;^OORV_)8 M4QEF7PO\^KC47F#!4:E7,@]Y[FH]S<-UU__
MP/U0,B]C7?_XRW\2N/^*-V^_QM7KCW#HZ @Z5VVE[20O"AMI9ZS#IJU].#EX
M!>,$Z_')>Q@;OX6)\6LX<_HZ 5+LI->\/U_Q&,63+,<A_;^_(NQR^JT MLS_
M!MARS'*,O_:/?D<SGWEU'2#+U77&;W7'-&#+?F2?<HU^#["GP\252!I* %L2
MG+UY]8JVRPV,T\8Z>:P/ R=.8')B%)=HGYR_<(K@NQT;:?<TM,:BG'!=7N>%
MB@9/%%:Z(2G#FH"M#P=G3;BX&B,Z.@!U=>78NV>' M>7+I['M:M7<?WZ==R^
M+7!]"[=NW\"UFU=P]>8E7+EU 9=O3&%X_!BO;R>*2U,0%>V!H$ ;A 99(XIP
M'<9I2( MDN.#4%]3@FV;>[%WUW;T]JQ&65$IDN/2D1S+MC"]$H4YC2ABNR-)
MR3)2&K@-[=OX.LZW<!GA.KM#Z4>=D5&K='U*8?LC(PWEYM>AKKZ';>=N;-I\
M&&M[]Z*A:1UYH![)J25(2BDA5->BB&U=D23SS&]2NDVE"F1G5-,&K4*"0'9*
MN0+:\<FEB$TH1%1,#J)CLI"2G(^:\B9L7[\#IP?'</_2-3RD?7UM; RG]NW"
MWK5MZ&TL0EMI&FJRXI 7&XI8'R]X65K#5L<(MKJF!&XGA+D'("$@'.GAT<B*
MBD%A8CPJ,Y)0GI&(+-H&$0$!\'"1_MDN,#2P@Z8&;9M%!M/MGBX^9'OW =N[
M]_CY3[,T"=D:;-^,8&AJ1YO2'CH&QLJ8U5J&!$H3+6@;+X>1M39<?6T1&N>'
MZ)1@@G4 ;>T 1"0$$$@)H_Y.,*.=LEQG">8NF:L,V35W\4(L7KD,)E8FBD<X
M+EV&P0I0^AO+,%S9%8$H:XI&56L"BNMCE;[(OA&VL/<TA+6K'NP\#&#CI@L[
M3UT$1-DH8T/G5803FH.15N!+D/920#LJ1<*SG9%1Y*MXN'/+@[E.$'++0I%>
M$("06'N"+6'7?!XT#6=AI?Z'6*'W 99HOX?%VN]#TV@AS.STE7&^O8,\X!=*
MD WQY;PW/ ,\X>SE#&LG2QA9ZO%:+..UT("KOP5_UU,![)1"3Z05>R&CQ!=I
MA1+F[0'_*%LX\#Q,[31A;*-)*->%M;.1TE_:WM.$YV9(Z1.H#>$58@'O, LX
M^AC TEF#YZX%1V]#Y>6"2!*NQ:;[("$K &$);G +,"=DT^8GZ%L[&\+&A3#.
M8R\HS\'DN7'\[3__.DW!_V]_?P#8\O_;GP#VGOV'"4A%2JAA>]<FPO4@CIV<
MQ,#P64+V!+;M.H*FMEX:1Y(MO!;9N?5\:)H)GH1J2J9Y!0+877SH)7/X.E03
MAFNF ;M:0KQI+);. & !9/%""S2+=_I=3_9,R7+Y_ETOMAJTU1[MF<O44GFY
M9X*V_/ZT][IB/0&;D%TJ(F@3KHLI%63S-ZB2<H)WR2H:OZQL<IJ1FEJ'Q 05
M9.?F-J"A?A76]V['T<,G<'KR+&[>O(6GSY\0L%_A\Z_>\OI^C$\^_PBW[]U1
M(+N\JAFAX6GP\(R%IU<B_ .RX1>8QX<R&PY^N7 ,*8%=<#E,/8JAYU  ??MB
M&#N7P,2Y"#I6*5B@Y8?%.NXL@)$\_D8<Z>O#Q4MG,3AX!+VL>#;T=&'XQ$F"
MZ77<N7I-&3_[ZJ4Q'#^VB95@*BLV.T3$&R(FU0BQJ0:(2S%D!6>,N 031$3I
M(RA("WZ^&O#SH7Q7(C!($^%1>@1P4Z1F6$&5T,Q: >ST;'MD$*S3,AU8^=HA
M/L$*D='F2,]PI\&9BZ%36W#KEL#U%.[?NX"[M\]1%_#P_F4\>W)# >V3Q_>@
MIC(7WF[6!-_E\':Q0DUI-@8)UW>OG,'#FX3Q2Q,X/7 $ SLWXT1/-_I;6S%"
MN)X0X.Q8A;%5ZW"B8S4V$VPKTM(10<!VM+6"L:D^#(QU8<2IJ;D!+,ST"/+:
MA&L-F!HN5Y*LF1MKPM)($Q9Z*V&JM0QF6BMA8Z@/=UMK!'M[*IFHDR+#D4"X
M3B)LET1%8FU>ON+]'6P@K%8W8))P?::\%J<E^1B/X4A5#?;6UF%_1P<&=FS'
MA5.#>'3U,MX^NH^/[]_%P[-3.+-_/XYV=F-/)=<M*L<1@>N2*O0756* T^$*
MPB@!^TQ3!Z9:NS#5WHW3;5T8:^W :#N!F6 ]M:X7@QV=.%!7JZB_LP.3O>MQ
M;M,FG-VP$6<(VI,"V*NX_2INT]E&P&[!:$LS3G#]7<6E:$M,09:7/_R-+6&V
M4 .:'RS"LO>78/D\+2PC."TE2"];8HJ5*ZRP<J4UEG&Z>*D9%BPRGH9L RR2
M,')"MA8AVW"%,9R-'9#@'8Z&M )LKVS$L896##5(0K9J7J\JC/"W1PC9XM4>
M;6W#",]G@#I,X-Y678.U9>786-^  SR7OIV[L7_+%FSH[L*JYD8T5Y:@)",!
M.?&A*$N/16-))NH*TPC3P0CSLH.GG1$\V( %N=D@@0U ;G(TRK+34)Z;C>+,
M3&0G)B,R,!BN#DY\_CQ9E^5BZ_;MF)B<Q.7+5VCD7,34Z=,X2\B^=.XLKIP[
MA\N\7Y>G!+)/X_+I"4SQ?A[=O0N]'>WH:FHB9*_%UHW;T--%(*YH0'Y.";+2
M"Y&568R\W"KDY]<2LNMI;#2AI*P-167MA T!ZV9EN,#,/()Y/J&[H!,E1=VH
M*.M!7=4ZU-?VHK:&=2;!/(U&2W)2/M>I1G-S#]:LV88. G9A835"0Q/@ZAH(
M%T*VJUL W-S\E?&N[9T(N5;VT#4PP](5XJ76HO&P4NEK_<$L#<R:K4/ YG("
M\X*%!.PE)EBRS$0!;/%HS^9WL_C=A_.-:&@8<MZ80&V*N8NHQ::8PS(PFV5
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M"$-.12"2\[P0F>($WPA+Q?MLY2))R'1@[V$,ST 9C]N-L.R%X%A7^(39*-G
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M44>[L5;95O8C0%U(P"ZJ6(62:K9Y];VH;A0ND&Z:'4C/K$!T=":B(E*0D5*
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MMFV+V*8M6&"&>=3L>2;X8+81WIMEB/^8)8"M2<!>CO=HWRQ:K@<= S,8F]O
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M>8<2TE%8(HD*5A.RN*QTC0*9A85K"%\]A.S? +NLG&!;N0'5-0+8A.M&0K'
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M[ UAX6P"&W<+'/"T@:V[-:R<+'' U0[^88&TB=.0GIE+&URBG 2P";R!!-.
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M&F.7ZW"GKQ./Q2"9'$)KXT54EF4C(3Z0SYP; D(.PB_0%IZ^YG!QYXO:U8!
MJ@\+L\W8N>T=;%K]!G:L7XJ]VU;!</MZ[-F\%CO7KL+^73H((6#7EA:AD\_.
M1'\W;HX.87J4$+W0!UN@>JBO&P.]71C@=%C"Q@G8?9UMN'[A#,[4\%XKRT=M
M22ZJ"S-1692%([P7SI^LQ8VK%ZEZG#E]!D7%94A.R:)!D<5W2 '?DV5*3HO
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MJG'D9!VN-=-8'Y/AO.[CB31&A.S'CQ\3?.<P/#+.QFH$@T/C;,1F<4L2O]"
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MV[)5V+5V$XRVZ<+*8!\\[9T1Y1^**+]0>-HYPWR/$0RWZ,!BIQX\3*P1;.T
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M<GH> T.3Z!L<P\S-VTJ(_\>?2C]O3:2!_#;*<ZW457WF-?,::4!;^1-&ZJ#
M-*_7[P*VYKG^5=Q?U:^ +7\\*8#-Z9<+4H&;@"U_VLEUD0@8R7]PDS946V<W
M+M5?1_VU!G1U]V%L?(IVS@RF)B8(V(-*HLO)@1Z"7!MZ;ES&Q:-5J,A)17Y*
M',ISTW'N:#7:KE_$Y& W'MVYB>>/[^%#&>?Z[AT\I*WVZ.Y=/+BC 6P)$7_
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M&4Q;.!!Z>UVQ<8L%5JXQQ,I5^EBUAEJ]&\M7[B!H2]<IMJ5L+U]_:RW>>H_
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MZP$S.%GLA\G.;=B[>0,.&.LC(=@?IZK*^*S48[RO&Q/]O1@E3 ]U$ZP5P%Z
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M@#T@L*T%V,-#W>CIOH$ZWL>YV>$$3@L<.+"##?86V!_<!C<//1H:^Q 88HZ
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M3""[B=O>R.8Q"<OG,S-Q*#86V;Z^"#]@"W]+,\2ZNZ"2\'Z^K!CG2PMQKJ@
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MR;H?>9P__O(7Y8^W%R\^QM3,#-J[NG&CN17-[;17!H8Q.#R.P:%1# X.87B
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MH *VZL56X5D;I$4J:*N0K4X%RK4!.X3E5,%:G=<^EQ)6SH=;TV>[2@%G52I
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M7< 7C@L\W*V1GA*"^HM',#/1C<?W9W#W]B3A6D+"-7 M6<.G"2'3G-X<EZ'
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M1?!A$$7R 8DBR,82;M,S#Q.PS^/0D:M\.5PA))Y$2H9DW2Y J +7?#CY( D
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MLA>\V.V)+!.ES!.PVY+3T2:)T,2+K7C;\Y4P]VN9F3C+XY_(S<'QXD(<+BQ
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MA(I#-2@JKT J[=R8^&3$)J0B/2.?8"VY8D[@\.%SN'&C$P\?/,-?_FL.;&W
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M37CE Q!*")?!Z>5?KJ34<I24GUT("V]1O-@9?/CB>?/&2E(!Z?? &SV>-[Z
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MJ8)K@6Q16(1XJ[4)SL8"MO)@CX:(Z^ Z,CI7 ;82(5LI(EMYJ 6R!:)EG+6
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M'4<.8__6+=C:6(/-M6785E>"K56Y:,J+1W&<+U((-QI/(T2XKT>X^QJ$N*Y
MB-LR:'S7((L-JC+#'<V%!)K"2#1D1Z*"@%U,P*F(BT!K5B)V%&=2:=B2GX!-
M7.?VXA0<J,DC8)?CU*9J'&DB<)6FHS(E ED1WDCP=T2PLRG<S=?!1<9&66Z
MG=$JK%LR$XMF3,#2.5.@OY2=Q_HU"+*S0U9X.)H*\K"WN1Z'-K=@;VL=FLIR
MD4>XU@2ZP-?1B.M8#4_KU0AU-4!RH#7R-:[<GA\:<OBW1?%HKLK"SFV$T.Y#
MN'"V!Q?[3V)PYU9T%I?A5"+A.3830RGY&,HD-.84$92+<#Q/ #L?[3+6.$/&
M(7,Y JL";!F#74  )61V$:Y/\6].9!7@* ']:'8)3A14H9.0W575@I.5C3A:
MRFM90O@D4'?(6&Q"]G 5)4G0"-H]5!>AN[NA!8-;MN/LO@,*H'=5UZ"(8*WQ
M\D*(LPLB/3V1%QN+[36UZ-M_ !>.'L7973O1SP=$)T'\. '[<%X^#N7DX! !
M]U 6(3<S&X<)UD=X#$<I >SC2CF$[%QT9.:C*UOKN=<F.2-H"USKRG2E:DMT
MZ0!;Y\$6N%9@+E!>7(K^LG(5KGZ,^[ U(P.MF9G85U.'CEU[<'SG+K16\\&<
MGH3XV%!$TH@)C_2@4>&*P&![^-#H\7"W@+V5(<PVL%,WV(! %WLDA_DA-=(?
M,0'N"'$GB+O00'*S11+!NZFJ %W']N#R2 ^NG.LC8/?2$"-@G^Y1D'V.P'V6
M\-W5=0B;-U?P01T(#P]]6%HNA(W-0GAXKH%_L#Z-J@U:R/9> 6>/I7!R7TZM
MY(-V#1S9)AS<]&#'!Z"EG8&JT[AXZ2),E0??A"_PZ:=3"-=?X/-/OL*X3V=A
MPF?S,9FP/&7B,DR9M%1YH\=/)BP3CC^;/!.?3I[!AR2G$^?@,\D&_MEB:@DA
M>RG&C5^"\>,%M/DW$\2#S;\9-TLE01O/Y;^:L01+E^O#VM8=,?%L3S7-:&K;
MAM;-V['GX!$,G[N Q\]?XKL??R:X_A.GO^#==P)XXE44V!.H_ [?4%('6XSN
M#Y)E/@"43CJHT!G8_Z847--()V#_2/WT/:%: 'LT1/P7&8--N/Z1WR4LG!\Y
M!0'A9YP>>83-6WJ1GKD90:$E\/++1E@T#;^\5M0T'<*F':>PZT ?VKLN8.CL
M;9R_\D#!]>7K]Z@[N'CM%N==)V1?X_0:KDF9HB=/\>+U6[QY]\%C+1H+OSJX
MUH'0F9$+Z*>!+]/;=^XK@-(!F #4DR<O5(BOU#B69%5RW#+&7'Z7=<NZM)#]
M 3IE&?E=UJ.3#DKDM]\[S_+;WQ)$QX*O#D;EN^R+'(.<)YWDN,8"MNZ%@BPK
MQZ9;Q^]![=CM_*WT[P'LC_7QM=&= SEVN;X"U^*9%M#6P;6<"]U])>=$[I&+
MEZZAKW\8'9V]Z.D=Q!#!45ZTW[GS!,^>?:/@^OKUQWPVG<?N72=16[.=$-&(
MO()&5%1MP\8M1[%G7Q<.'.[#_B,].-S>CY[A2[ARZQ'O[]=X].QK@OH[O'CQ
M+5Z]DD@+N2YROTM;'P5KVI _LJ']*/>@0*_ +@'[1P+VC]_P^S<\9FFW_P9@
MZ_3Q[^\E,"WKYSITGNN/X5I*<<G\ER_>*K@>'CJKO->B_K[3"K:'Y47$\ A&
MSIS#Q?,7</4B;9H+8L]TXNCN+:@MRD!<L#L\;?5A:[@$-H:$&,M5\'*4,' #
MN-JM@P/M 4>;=?!T,4:(ORVB0IT0$>R(T& [A(<ZJ,@I;U]3.+K1_B <.7L8
MP3O !D'A;K2=?6@S1J&EM1[#I_MQ]\XM7+E\67G5CQ_K1$/]5L3%9L'+,YR*
M0"CMO.CH+()@!<HKMZ&Z;C>R\QJ5/>CF&<-G2QR?->FTH8MI&Q,L"8A)!$H)
M"P\)DTC(/-J0 M0?LH@+9(LM+Q&KNN&>43'BS<[]C02V(\2;39M?!]@R%2^U
MC+-.'TUZ)M[LK.QZY0T6R/8/2(:;>S3</#0JM#R6Z\\D,(L'6P"[N+"-TS:"
M= MR!5II!PM<"VP+?.=R70EQ!0@FK'IYA2L/MJMK +Q](FCSIB,IN8Q]N;8<
MEPZPDY*UD"U>9TEF)J'@.J70[M:J3BF5MKP"['1"=%83X7HCBHNWHJAH"_+R
MVI!+WLCCO@EPBT=;O-O*JYU!L!9V22A%3$PA8C7Y2.+Q)D7G(3:,YR4P :'^
M,8B-3D9A7BEJ:*.45I0@/HG7R<<)E@[&L'(TAJ.G%>QHDQC9K,<*@\58N'8.
MYJ^:@86K9V#QZNE8NFZF\F*+]]HSV%J%BDMR,_= ,[@'F<*2$+O!<BY,":?N
MA-" : L$RACI>%N$QMO#-]Q2C=66D.JUQHNQ?-T"E<%\P?+%6+!L&>8N7H;I
M<Q9@_)2I^(?//L,_CO\44V=_@94;EA!\#>$1:(>0& ]$)7E3/OSL"J\@:T+W
M.NB92;*T*5A#P+9T6JP\ST'<MM3(]H\R(1@;*2]TD,:"LN3^FW"YU5ACL !+
M5L_$BO5S8&"YE"#.=N1)>4F",SU$I=@@O<@+V>7^2,WW1&22E.HR0T"D+DS<
M%'8$=GTK0K[^ BQ=OQ#+N;_+]99@V;JE*GF<GHDD47- 9&PD69%LE)V.E(P4
M\E4:<O)R"=@U.';L&)^QDD7\0R3W?^;??Q"P*]EP,MF0"=CQU:-P3;@4$10%
MN#5LL.&1>31<L]58C:R\>E35[D!-_0[D%M1S7C[""7_28"5#=DJZUD,K(=EQ
M21\\U_$$:(%H'13KP%>F.@#7_9[$&UJ@6L9P"V2GL_'I0'LL; MDCP5VD7:=
M%!N>=KW<OLZ3KJN#+>.H?P/3O_5<B]Y[M3\";/%B)Z40M G9$AHN(>("UO$)
M.HT"-I64/*KW@,W&+HV?Y^<#8+?PG+5P&TW<QWH:NE7L $L59(='Y*ES'\5.
M,9J=8J1$$83(V)AX! 8D("XF!V6ES=B]YSCZ!L[AV@W)+OX$CZB'=Q_@R9U[
M>''W+NZ>.X>> _NPIZF14-F$COW[<+ZW1P'VK:M7<.WJ95R1Z;4KN'[U$G4.
MUR6C^)6SU 6*X,UESY\>1D][.P[NV(Y-=36H*\Y'35X&:O-2T92?C&;"<$U:
M&/*CW)$<8*G"PQ,"C1''SB AV  9T68H37=&8U$@-I9%H(6 7946@B)-  JB
M E$1'XF6S"2"=2HVYL2C(2T2=2EA:,G28%=I!@[7%>%P?3%VE&:B-BT*>9&^
MW(XS8KW9,1"P/2S6P=Y@&<S7+,#J^5]@YJ2_PU?C_D]"]CAL6#H'9JN6PM%0
M'R$NSLB.X;J+LM%26<CCR$0.X3HZR 4![N;P<=2'O_,&A+H;(L;'"&E!%CPF
M>Y0GNO/X?%&3'<:_2<36MG)TG-K+\]*!2[W',;Q]LS:\.S$; WQ8GD[6 G8W
M8;F=\'B,@'V,P-F>E4_ )E 33OL(K'VY5'X>^@H*5:*ROL(R0F8I3F85XDA:
M'@ZF4AG\^WP"=7$-]N>782M!M2TYD^"9BX,%I>@LK\50=1-.$Y(&:YK05]V,
M[MH6]#1OQNE=>W'Q:#OZ"=D;R\J0&!0$+UM;N%JP([2UX_4)1E-I&3KW\KXX
M<0(C^_:@KZT5I]@Q27CV(8+_P;P\0K;4N\XC\.?B:%8NCA&0CXNX#TJ$:P'L
M4Q\!MBK3)26Z,D<SB!.P!;0E7%P!=FZ1\G"+Q_MCP.XE8)\H*<&N[&QL)N#O
MK:K!B2W;<6CS5C16E",S)0'1D8$T)KS89KS8=KSXV9EMQ ;.3B:P,%X+@U7+
M8;%^+?R<;) 8ZD/ #D!LD"?"O!P(US2 "-J)!.R&"N[[X9VX,,SK2<B^<*:'
M@$VX/MVM(/O<2!\!NQ=]?4>Q;U\CBHMH2/B;P<9Z$6QM%](H6$.XUT=@B#[\
M M?#TV<UC:&5</5<18-(/!J&\/0SY6=3V#L;P<2"#UK>DS-G20CXE_CLTR_P
MV2><"EQ_0@C^9!XF?KH0DPG+4R8LQ^2)2Y4W>MS$>03JV?ADXG3\X\2OU/33
M";,)SPL56'_^V7*,^YP:OXR O42%C&NSA"_"S-FKL&"1'K6.VS:"G8.7@NO2
MBCHTM6[%YAU[L>_0,?32(+W-?N2M@+-XK0G7W]#(_YK&OAC\XI66&M@B,;I5
MHB,"M5;:SSJ(&"L=7'QL8/^^Q)@6XUW@FO#"Z<_O ?O7WP#V3X2='W_Y,WXB
M8(OW^MJ-UX2(,S20MB,HI *^ <4(BZI 5OXFU#4?PO:]W=A_=!#'.LYB:.0F
MKMY\C!MWGN+JC0>X=O,>KA.$15<EE\7U6[AP[08N\_.M1X_QY.4;O!+85<<_
M"M;?:H]+)% D<'W]QAWE83QYJ@OM)[L(0B.X=^\1WA&H!*!E*MG)+UZZ2O@^
M3TBZK+[+.?WUCW_&'__IGPD9/[\',)%\EFU^.WHN?_^\_;\#L#^6#CQEO^08
MQNICP);O<EYEOW7[_/\FP/[7I-N?CR7'+L<CQ_7Q,<M+E^<OW[X?1B#SY#>1
M+">_2R3$N?.7T=G5AZ/'3N+8\5/HZNY_#]AW[SS#\V??XOZ]UQ@8N(+MVXZC
MHFP3LC*JD9)<CORB%FS<? R'CPWC,._]?0>[<>@X073H LY?NXO;#Y\KP'[P
MY"V>//F&P/H]WKS^$6_?_HBOO^;^?LUVSOT6C_5/[ ]^XO'\Q'MJ+&#_1,#^
MZ5O"\+<\YN__9P!;LI7KX/J/O_Y935^_>J="K8<&1]#9T3OJM98:U^?5O(&!
MTPJRSY\3)\(59<^<'>C%B0.[L;F>YR8Y"L%N5K U6 K3U;-@H3</]J;+X$:P
M]G8QA+^G&4(#[1$;Y8F4I !DI@8C-<$7T1'.!&P;A(79T4:V0X"4+O(U@HOG
M!K@0CCS]+>!#</'PL4-0J!>-_5)>KU[<N'D5_?U]V+__$+9NW8/*\A8DQ.?R
M>1*KLFA'AJ?3ABPBZ#4I[[5$B@I@!X6FPT4@UEM#P$Y!=$(A;>0&52E'HCX3
MDJIHCQ=IQV)'"E1KX?JO 7:DYH/G6L&UA(V+1WLT]%O@6I?03"!;YDMI*PG/
M%F^V0'9AD81/-ZH0<6_?!#@XA<'9)0+^_HF$['R"=!7AN8%@W:P NY@JRF]#
MGN1(HBTO7FV![FRN3\/]D#)=SLX!<'#PAKV]EPH1#P]/(R2S_R:$RW8%ZJ6^
MM0"V2 !8QDU_@&KQ-M/F5M)!M@ VF2*CD8#=@KS<C2@HV*R4G[]1J4!> !"\
M!;!S57E=&>8I<%VBQIE'"NM$9B&6T@2G(<PO#B&^,8@,3D!J4C9M@@H4%DO5
M)0V<W.QA8JD/<SM#.'E:PS/ @7!I08A>A>4&B[#":#'6FBW#.FJMT4*L,I@'
M/7,)$]<G5%LH+[:$B_N$V< [S!+6[JMA8#T/9A\!=B"!UB?"3-6O-K!:C,5K
MIF'&@HF8-F<29BZ80;A>@B4KUV#ALC68-7\I)DV=B4_&3U3AXI+AW,3&$+XA
M+H1J?\2F!B(\W@M^X4YP\[."HX<))+NYJ=TR O(\&''[-JY+"=@&[[.,:]+L
M$94L]:QM^-D6T:FV"(FS@GN "<%]/8RM5ZOZU_;N/*X 4_XM%6K(_3=!-)=/
MR7=#6I$GDG/%$^^H:FY+%O.@:&N54=PSV!R6+NNQENUQ^89%U&(LTUN,)6L7
M8N'*N03X!0JR[5WMV-:\$!3FSV=],.V:**1GIJI(@J/'#^/!H_OX\Y__1H!]
MXF0?-U[!!I2!J*ABQ,41/N-KJ3HE+6A_ &PI3"]CKXM*VU!1O575XXM++$!P
M&&^RB$S$)A03/F7\M=93FZCS8H\"]GMX)A3+9YWG6:>/05OGS=9YLF4JD*V3
M_";+R+)C 7OL>D2):5)S6[O=I+116!9(UGFC/Y(.K'_O-Y'ZVU'(3DKF.D;#
MQ=^_F$C@\2G EO 9$3^SD8MTWFP%VFEL\.FCV<K3FKG-1NUXFKA*GNMR]292
M-WY&$U/,SJM8E?>*BLY'8& *O#PU\/'2(#HJ$\4EC=BUYQ@&3U_ S5OW\4"\
MV'<$L._C]8.'>'[S)JZ(YWGW+AP@.!W9MA7]QX_AZMD1W+E^#;>D3N/-&]IZ
MC9+L[-H%W+@J<"TZK[S8DN!LJ+<7QP\>P+;F9E05Y"$[/A8IX<%("?-#?FP0
M:C.BT903@\KD0&1%."(US!J9T;;(C.&4#28_R0Z5V1YH+@E6@-V0&XKB>#]D
MAWDB)]07I3'AA.H$Y<5N2(M&15P02C2^J(P/0EMV'':49&!'<0::,F)1%.V/
ME  7Q'G9(8:*8@<6[$3(MEP':[U%6+]H&I;.&J] VTI_"=RM#>%F90P7"Q-X
M.5@CPM\3:7'AR$Z-1DI<",*X+D\7$[@[$8X(UA'LW.)#K)$4:H&,<$OD1=N@
M,,8>A;&.R$]P1TE6&-H:"]#1OAN7SG3B2G\[1G9L46.'^Y)S,1B;C=-)^1@D
M&'=G$[ )C@+7QPB= MA=A- ^\> 26 <(U_T%_$[ EO''?47EZ"DHYW)%.,!.
M>YLF%1NC4[ U(0M;4W/1&)>*DI HY >$HCQ"@TW)&3A,(.^M:,!P30N&:B64
MO T]]1O1T[H%0[L(S@3L@0-\F%?7($.C08B')_R=71'HSHXM,@H-!.SC.W9B
MZ- A#.[:B9ZV%IRLJ\6Q\C(<+BK&8>[;$0+PT='C.,[C.$&(;A?Q6$[P6-HS
MM#HEQZ>#ZU' [A;OM=2Y)F#K$IR]AVNJ3\+)*1567E!,P"Y3=;M[)4R]K S[
M"?D["PMQH+8>QPG7^]L(2J4E2(G7(#C("_Z\?F$1'M#$^A"TW>#G;P,'>P,8
MZZW NJ6+8+)F%7P<K) 0XHV4"#_$!'@@U-.!<&V+4&_>JS'!:*K,Q\E#.VAX
MG21<=^$\P?K<&8%KK<Z-]%*2A?8XCAW=C(:Z#,3%NL++0P\>[FL1$&" X% C
M! 4;P#]0#SZ^Z^#ELQ9>?GH$;A,$AEK30+)7\&]/^-<W7(V%B^9CZM3I&#].
M /M+?/[I-,+U3(S_9 XF?K( DSY9C,F?+</D<<LP27FD)9'9/'Q&P/YTT@R*
M<,WI9Q/GXG/Q5H];3JW$A/&K,)Y0+EYLJ7']V>=S,77:<JQ:8P$S"U>8F#G!
MQLZ3YRL--76M:&[;BH:63=C&>Z5G\ QNWW^"5V^_PS<T?M]]3[ 6CS7!2$D!
MPJCG]AWG?T/8HW1C(G42Z)1EQ^IC\/M=HWJLE$%-XUJ\UP+8/U"DZ ^ S>^_
M$+YH:/_TZ[^H<=>/GOR(SNZ;J*PZ1".SAO=&&?O1!F3G[T!]\S%LV].%_4<&
M"-<CZ!FZ@O.7[^'&[2=J[.GU6P\X?8 [#Y_@_N-GN/.(\^\]Q%7VI5?N/L -
M O#]9R_Q]-5;O!Z%;#D>V4\Y'@$G@20I939R]B).=?00A$XJ;Z.,E960<1U@
M"C")9_O P:/8R?,N4X$EF2_G2HY+H$P^"W )8&N!2PM=.OA2UX'[(<OISNOO
M2<ZGK._WH/!_0CH@%OT>8(Z5[GATDGGJO'*?Y6_'KG<LM([5V&7^I_4?V:9N
M63D6W;678]2]3-!=6P%KG?=:SH>\Q)+E).'9V/OI"/MRT8GV3G3W#&A#Q*_<
MPOW[+_#HX=>X=/$!#AWJ157E5L)UC8+KM-0J&IH[<>C(,/H&;Z"]XRP.'.[!
MJ9X17+A^#S<?/,7-^T_9[I_3$'V+IT^_(V#_2'#]"6_?L/T3LM]]K6WC6KB5
M%UU:P/Z1][X2P?>G;W_!S^I%&(^=;54+U[^-KO@]Z7[_"W&]J@^0^MI<CTXZ
MN!;OM?0]#]A?C9RYH)*:G3K9C=Z>0>7)/CU\#OU]/.:^014B?O'"995D[,Q
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M/WZ"@)U>B:"@S%' KF)C(60GB*IH#!+R9"QS;#&GQ<C(KF<CWX[JNIW(R6]
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M8=\3&@ /5VLX.9K W<,,?@$V?,!;P]W-&.;L=%<MFXO%LZ=C_9)%<+<R16R
M!Y)#O1'CZX(0-SL$N]HAVM\#^2FQV-I0A:XC^W"NOY-PW:LD6<3/#FDSB8\0
MND>&NZA.G!EH1^?Q732XJE!1DHS<S @:#0%(3/!$+&%:HW%2WFWYGI+B1V,I
ME/UM&&)B_.#E:0=#P]681_"?-$GJ7$NV\&D8/YZP/6$6)HXG7(^C",83/UO
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M_ U!Z#7NWG^.V_>>XL%CR?3\;@QDR_[HSK'V/,KT!PGM_0T0_IX^P.&_1SH
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MCN8;"%P+L7C6=,S[:AKFS9B.I0OF8,W*!3 T6 QKZZ5P=EX&#X\E\/%>@I#
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M=TW&GA,Y%S)?)]WY>2\Y9R(Y]E' ?L>V_^YCN*:^^PBPWX/UJ-1PD-'S*!+
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M\PO7]P/N$:BO7KV+\^>O8^3L58R<X_3\+0R/W$!7GP#V '8IP#Z!]C& _8H
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M(3L$)=&4)N(]8!<3L'/X,,P((S@3DM,(T&G!_D@/$:^VS ]$6F@ 4C@_)80
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M3MF'QQ ;CDVUW)?CAW!U9% ;N7%N&)?.? S8[1CJ[2!D=Z/GY FVF>UHJ*I
M478F<C-249"=0<#.12&!.R,U&1&AH01]9^BO-\"">4LP[8O9F#)Q)B9/G$W-
MP>1)<S&!T_'\_L%C_>\#;*TDZ=D"C)M(P)XX'Y_PGOED N=-68Q)4Y=CQISU
MT#=V0SC[]/+J+31:#F#CUH/8OOL8@6P 5V[<Q6L"CXR5_.;[[_'FG60S?J>D
MA>S_"F"/]6[)Y[$: ]BC1O980_L]8/_,>=3/!.M??OVC2F[T\R]_QH\__#->
MO?P1ER\]QH&#@R@JV<)GB(S]RU;/B/RB3:AIW*]*<IV0<.MS]W#IVE-<O?X,
MUV[(]#&N7"-LW+BO2G/=NO<(=PC7$AZN$I@I[[7 ]3=X_8Y0*)#XO9RC7_$U
M(41*F EDOWC]M4HN]N+E.P(QS]L;&8O]DTK ]M./?\+KUS_@_(4[V++U")+3
MRVG09K"?YC-67F3SV9>05HJ<PCK"]3[T#UT@W!.,N8UOO_^C&@,K2:XDA/?B
MQ>OHZ1G&T6/=.'BX$X>/]N#0T5[L/]*#?8?X_3COQ_[3N'KM)IX\>:8\IKIK
M)M=(!]G:<ZN#Z=_3?PVP=9)K+W:&#JX%J'\/L'5PK5N/3&6]O[>]OX4^ /1_
M#;#EWI;S+NWHQ4M)9O9:79/7;WA?$;9?4)+L[-4KJ3?]#L^>O,7]NT\P/'0.
MNW;N1555+<&Z'/7LO[=L)5P?/(P3'=T8&#Z':[?$<RUP_0Z7KS_"H6,#J*S?
MA2R"47'U#FS9TX-3 ]=QFF ]=.$!>D_?0N\POU^XB^MWG^/1TZ_QF/?9HT>O
M\/S96P(K[P\)!>>UD.LQML:Z'*ONW,CQZZZMTNBU_FOGZ%\#[+_P7'-9=0YU
M$L#F]!>!>SFO_"Q)$^7%T;U[#W#APD7T]?6CDV#=3<#N[>I&?[<DHQQ6'FM5
M?O2:%JZ/'3R ANIRI"=&(]3?&5XNYO!P,(>[C15<S:WA8& &^PT;X&*\'N%N
M)BA,<,;6JF"<V!:-CIU1.+XQ'/OXO34]$!51?B@,"T!!="!R8VE_1'DA.L 1
M@1Z6\'8QA:>49/*R14B@.^+BPI&7G\7K6$90+D5B?):"ZZCP=,1$Y=".*$0J
M 2Z=\);,J7AV10)W4H>YI'03<G(;"*GYRH,MBHS*HDV22WNW& 7%C:BLWDSH
MJX<F6CS8$?#V"$=P4")MWD(U%+.\:AN*RS<C-;L.,4EET(@-2GLSDK9T<&0>
M @CT 2$9" S-4%G%$U/*N=Y6Y;'>P;YS][Y>[-C5B1V[N[#_T" .'SNCIN+%
M+BAN4T,_5<FO&-KPG ILQR4(3XCW5ZK>E!*N2Q K4;)DC'3:T*K\50;M\;A"
M! 6GPM<O'L&T5Q-E3'-I$YI:]F#;CJ/4$;1LW(OR2IZ'O'K:_!+!JO5@"UC_
M'ERK[7X$V+\G26 F *V#;/%<CX5K\5@KN!:IY:J1(Y$A11M15-B,[ P>2WP.
M;8DDI-(N2G T1:K=:E3YZV-[D@/VY'BA)=T;N3'NB AT@KN'/9S<'>#L2<#U
M=H>+NQ/L["U@:V, 1WM]V-NOAY7U2MJ>RV'KL H.SFM@Z[(2-L[\+J'@7NO@
M2CAU#S:&6[ )7(),X!IB#L]P:_A$$YQC'1&6Y(I(VM6AB8[P#C>#G=<:F#DM
MA04AW=G?$#Z$?=\([H>/!8QLUF.=Z6H861O!PMX:&TR-,7_94H+U3$R=/0W3
MYWY)X)X. XNE*LS:/](*_E'F!&MC!,4*5)L@(EDRAALA,$8/?E&TO0C=(7'&
MJNQ65(H-@FDG>X<9P#-8$IX9J[K=P3$V"(VS)T#;PS_"!F[^)C"S7XZ5^M.P
M8.4X+%TW&>8.2Q 0:8G8=#=H4EW4&&T__KUXL#T"]>'J)S+B9[:U,"M(&:]0
MPG5$HH2G2TUN6Z[?C%"O!TOG9;!T6O6_"[!K5%B(C'^6FRXZIDB-Q1# SN1O
MM0V[%&#GY#>J,17A!&Q50X]P+=YK28@F@"UP+1 LH=SBS58AW)1 >P)OSJQ<
M=@0UN]1;KTU;3ZCQW'E%S6JLAH28R!L[2:HF(26R7JGC%QLO7FO=N@7^!;QU
M@"V-3-Y>2:,C *>,@KA*C"8)T@3VQ:-.6);QURI$O!8Q!.S(6,(HCU.2/L2Q
M$4E(>';A1AHY&Q5@Z^IT"QS+9ZFU+7KOT1;X_G= MFXY69<.LL?"=32/1:11
M6</E]QHDI$@2-8%K'@>/1R2?$WA\DNE<,J&G9[<@(Z=594&7<F/)/'Y)DA;)
MCBTXDIUE6!K\0U-5^33?P&1X^,3#W2L6/GX)B&#GG)%1CIKJ3=A+ [N[<Q!G
MAB_@]-!9]/;TX]2Q=IS8?P#MNW?CQ/;M:-^V SW\?JZC$S=.G\'M<Q=P9>@T
M8?JD O'C>W;A^-Z=.+%G!SH/[L;0J<,8Z3J,OL/;<7!3&;:4): VPX]0;8UD
M?SW$>Z_D= T*HLQ0F^**UIP@M&9'H"XE J6:4!2H\==1*$V(1D%,.#(C @C6
MOD@-]D5*D ^2 V4JL$VX$\@.#U9*EVED"%((W,&N#K S('2M70$7,T.$NCM"
MX^^) !<[F*Y;ACF$ZXF?_!W&_^'O,.X/_X#QG_PC)H[[%%],^@S3IGZ"A8LF
MP,)J/H+9,<0FF")2LYX/MB7P]R=T!RY#1-A:1(;K(2)$']FI[MB[K0A73A_#
MP\M#N-Y]"KU;M^$0 ?&@C+'.DA)5!>@E9/?+>&."9$<!?\LJQO;T C3$9R+9
M(P0.JTVPXLL%F$N0FCM^+F9/G(M9D^83K!=B]A>+,9=@/6\:-74Q-1\+IL[%
MXFFSL63J3"R>PHYI_"0L_'PRUO*[_<JUB')RY?F,Q3:"[;&&>G2UM:!G8RMZ
M6IO13] >)%P/M+:BKZD9G;7U:*^JP7'"]?&22K03>$_2&.CD,;03L'>FI*$J
M)!3Y/CXH"/!'660XRJ,CD.GOC5!+,_@8\%Q86R##TP-YA.P"?W]4<OE6PO">
M] P<SLO'">Z'K$L@NX.29&9R+A1@<ULJ(5I>L9*$B_<5EV.@M%(!=GM9!786
M%*(R)17YB8FJ%$9#13F!-ET9,;;6ZV%NMA36-LO@YK&.UXT=/Q\$(:'&\/1<
M!RN+)3#:, ^61DOAYT+ #G-%FI21"W$A6-LBU-,&$=X.!.Q0 G89^DX<QO5S
M0[AY<037S@M@]^/L4(]*<#;8=Q+]/2>H=@SP6I\\>@@[-FU$35D)"G.RD$_(
M+LK+02'W,2,UG<94!%P<7;%!SXAPO1Q?39V'*9/F4)SRVDZ9M "3)L_'1(%L
MSA?(UH*V3CJP_BU<_U8? /M3PO4?N-P?9/DI"S%CWCJL,W" 3T \\FF,;=S*
M_=U]''OVG\2I+A[;U3MX^D* CL;T3S^KT/"W,HYX%*QU^FM@K=,'P-9!MACG
M(AK@A$6MY+/6(-<!]@\Z#Q:W+>'@2@JJ/^@'-95QEU*.Z\\T]/]%>:T?/7Z'
MLV?O8,^>;A05;U*AAZ%A M>E*.3WIK;#RD \<O(T^D_?P(6KCW"%8'WE^A,%
MV#=N/<7-VT]PBU!S^]X3W'WX%%*:2^!:QE?KX%J\UZ\)@P+5[W@<WPCX?B>0
M+9[L'_%&RF<14%Z]H5[S_+TE1'PCQTBX?O,#+EVYB]U[VY&=6ZTR_P:&IJED
ME8EI%509"LN:L'O_<9R[=!U/GKWF>@DBE,#7PX?<K]OW"-CW<>WJ3?1T#:AD
M5W7UFU!;OQE-K;NP=>=1'#C2A0["]]F+UW#OP6."O@[FOE: )Z MUTG.^5@0
M_'W]VW#[ 3*U /H>N,;HWX)KF:^#.+DG=.N2Z<?;T,W[6^CC[7ZL#Q"I/5_O
MP9"?=6'A HQRON7</W_Q2GFL!;"U[4G*JG'>\Y><Q_M,,L(_>X='#U[BQK7[
M&!H\BZ-'3V#GKEW8L7,[V^H>'#QR&.U\!LNXZPN7;^+N@Q=X\/@-V^\C'&L_
MB_KF R@HW8+2VIV$ZRZ<Z+F,'D)US_!-= U>Y?2Z2H!V]<X+W'WT!H\(\T\(
MV,\(UZ]?R<LSMEM>"^V8:BUDC[TN.LEWW?75MN/?PO789=7RA&3Q5/]%6+B\
M6/L+L.;Y%&_U1Q+ %KC^GOW**[;+NW<?X/SY4;@^U8$.JEO@NJ<7P_T#.#]R
MAH!]'I?/C6"HAU"X:R=JRDN0'!>%T  W!'I:(<C# D%N5O C6'B:6\'#Q!+^
MEA:(=+9"9H@#ZK.\L*\^!-V[HC!X0(.^7=$XWAB.+=E!J")@ET8&HR9%@_H\
M/H^R8@A9?@CWMH.?FP5"?!V1$A^*DH),U%25H:JB GEYA4A*RH8FBL\$PG5T
M!&WNR'S$T8Y.C"]#*NW#9''"Q)<HZ,O-;T%YQ7957SH[IT&!:$@HGW?L.S02
MPIU:QOZD5HU++BB2Z,TR1$2DP<<[$MY>D8B*S""8UZ&B<BM*"-<9.0+7I83J
M(F@$,+F]&-JBX;2#@R)R"-E:P):QV-'<EHS;EN1FC:V'L&7;26S?V8F]^_L)
MUR.\%T]CZXY3J*C>B32"J=CO$=%Y2@+HD9I\%>F:F%S.8Q%'&6UYPK5(/-BI
MM(UU,)LD'G4RA7] $GQ\8WE\*3RV$O728,LV]M^[CF/CY@.HJ-I,AI!H6.$-
MKI=VNX"U+BQ<!]5C 5LWE>?!QQ*'HI2[E?!O.=\"U&-+?LD\D4"X2G#&Y>2W
MO#RY+MM05;4=)<6M?,Y7H9!V7)XF!FF>3DBQWX!\YW6H#3!%6XP3FA*]41+K
MBZ10+X0'>"&8]FM(2!#"PD,01OLU.,@;@;[."/2Q@:\G@=#5$,Y.Z^'HN!H.
MCH1LEU5P=.-G]]5P]%X']R C@K,%/$+-X$A@MO'1AQU!TR7$ M[1M@B*<T0P
MX=4WPEPE/[/Q(*!3XO7V"9=R7K8$7FO8>QG#V'8MUINMP@;S== SU<,RVLLS
M%\S%M#G3,6/^#,Q>.!T+E\_ !K,E</(V)+#:(3+9$=$$V,AD*X0GF5.F"(DW
M0H"&ZX]82ZU'4(R1@NNX3-K=:0X$7RGO):';LGUS!$194M8(C"* :QP10."W
M<UN/Y7I?8>8BVM^K)L+4;BG!V1(QM*]CTST0GN"HRH-)V+>KWWK8N?/<T+;S
M"#0A>,OZ)"R<VR!42UBYU-0.CC$ED//\\/AMW=8B)3N<=L#?&+#EH1].H-8"
MKF2GEC=0^4CF@[^HM%6-E2YE Y6LX0+7431B)$1;8%H!M0H/%Z^U2#S96HF'
M61MR7@ZIC5W"CJ)UTS%L9F-M:.+#@#=GLB0VBY>QWD6\X8NU-SV!4P!;2H1I
MQ4Y'0L,)H1)N(HHGH I@:\=BR_@+:7A:P!:PCHFK5-*.XQ;H%M"NX]_5? !L
M#3L%=BX2HIV:U8#L@C8EJ:TM];HEL[<VB9D6M!4P*VFA^3\"V/)9-Q[[8\".
MBA/(%D\V?TOD,MS'#V#-_98D<1()D-8P"MC-!.Q6JDU-T[):D)(AM;MKU;CL
M<%Y'&5,3$":@G4G0SH1O4#J\_ 2T)=MX/'S]"=H$\8S,,M37;\'^_>WHZA[&
MX-!Y#/0-H^=$!T[NW8]#&S=C7V,SU8*C6[:A]^ 1G._LQ>6^(5SH[L-I0O;
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M^CO0OVL'#I=7X(#4O*9D['&G9,T6D"RJP)'L(G:^:2@-BD$JX=K;V 'KYZS
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M@TP: DVMN[&+H'?P:#<ZN\_@\M6[>/;B'6&.!C"?!^\(!"I+^#=:;_58_><
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M:^VV %:N\^#HO1Q^$4:$70N5O=O*>0DLG!?"V7<U_"--58AX>((=@J*MN)P
MN 4!VAR.G@8PM%S&_9B..4LF8.[2B5BY81;,[7F\/L9PX[$Y^QBHD' GG[5P
MU\%U@L"ULTILYA]%F]]O.2Q=9\/6:RZ\PE8B($;@7E_5[O8,$L!.XK.YCX#]
M3Z,4_)_[]^\&[),=?<C*(8"%)?&FS4-^4:-*:-:V^3 :6_:I,=B)*9)5/(_&
M 6\^@JJ4XM*5X$HF9"M/MB0T8T-*XLTG8R0D57]4;!X_EZ"8-U]SFWC#)92I
M585X2"B) FQV)%IO]0>@EA#S#Y\%4N^N_0  __1)1$%4FG6 S75JM*6\I+%(
MXY'?M)#-1L(.0 O$HU LI;X2"+"2/(Q3 >QHPJ8F5G[3@KE(/FN]YEH/M4@^
MZ^!:MYQN6;6<["\[(X'FWX/LL8 M4X%JF:>#[ _2SI/P[D2>1P'JL5YL^:Q
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MR;8L,\@@BR5+9I>Y#&5F=I5=T-W5_;___:2RK')7S_3,])RS7GEM1V1$9&3
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M?Q\?'ZRV68<%\RTP8?Q,0O4X_/Z=+_'>NQ,)P83E#V?@0P+V1P3LCP6P/U]
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MXO"XM;S'SHA.<B4PK\.J=?,Q<=K'>/>C_X$//_T]IL^>C*56B[%RC156K+'
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ML GNZW.RT$BHEMCKQN1$M*0D8U-J&K9G9&)O=JYR-^^A]!+D^S+UZ,\T8(B
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M51*TA*1"!=A2WC69^F@B)9KZ9PSU2 %LT4\EOY+HZ:(_&_,2&?,8F>:-.KP
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M9E37;U:@'1V?@U!-&K114@9,8CD,"E#%;5M9KY-%496W1P+6-01G@>QJ_KX
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MF,K!)5F#W.A@I(4: 3N2X!3CXXC4, _D\4%6DA:.DG0-2C(XV'"J3PJ!+BZ
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MV,XQ O;)(T<PT-6)III*Q&B"86]CJ<*^5BR9A=7+S>&\;BF\G%=0K.!B*SJ
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M#33>*Q#J*;'2EGQ0<DH)\EP&/[?%\'%9R,%F/GPY'QG"!V**+W+2 Y$0X8)
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MN/7P1WQ]XP4N4VX_>(U'SW["(^Y++(M??74:70<ZL&-3&W9MW(3.[;MPJ/T
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M87]+-CI;L]'>F(*F @).BB?RT_S9-U.QJ;$*&QJ;4&C@N!26#!>7<%6J3_(
M%9=L)&#O4Z4#\PLW*D.'@+,8<6*IG\433 4D8\4@(K!& %: +0:AM^#Z%\@F
M8*N8YP1)+D;]-DY MQ 1 KL"B01V29BK,S3#4"2QUV*]WJ@LQQKJYG[4UWS]
MI2I,*L+"LY0.JS<THJIZ.QJ;]U.WWD?=>@?RBC?Q>X3>DJT$]*T<Z]J0K6]6
MX"RZMA&N\Y5A2CZ+KBJ_81*Q)@M09^H$LNO55+YKU/N+N'TIP;A>@74E?[N\
M<JL"[$R=N)\;7SI(:2^!=6,&<DF^+#6SFWF\ M8;V0\V_@JP)4_3&YU90-JH
M0_\:L$UZ]1O=6CQ8)3.[0+3)]=L$TB8K]>C/(K\ -D76)?'[&=39=3P&'<\_
MC?N7_4KI7LF7)(:QN$2".'DE*[4$>>E\5J>7HX37H80,51QI0&%8#@J#LE <
MF(*2@%@4^VE0Z!N"/+]@Y >&HB T'(7:<$*V!L4QE#A^C@V&+MP3<5ZK$>Y
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MP2V)O;XO%G1YD2;W2UZ(F #;]/)%[J6Q;8R6?PNHWQ9U+7BMWKY^QFO&,8)
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M1 F9E'PZA$G1%7^IGB->B%(1AY]EN8#H:# 56)48Y\+B-B5Z0JQ8AT77-1K
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MLYT=N/'5$=RZ> )?'>G"MLU\:*:%P\'%DG ]#58VT^#D/H]@/9^ /4=!MG?
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M*5J+T" _^'JYPL-Y'9S7KH#CJJ5PLEX&'X<UB GR07YZ"C;5-6#/YIUHK-J
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M7Z^F)L VKFO\Y86 24SG9$Q\9GRY8()K.?>W 5NF<F]&BPFX_Q9@R_H4><E
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MV-%C"JX/5==BW[ZCV+WW*!J;.G'[[D/\^+_&@RU_AH!]%_L.%,/5<R566DZ
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M+V=)J5*A!<0%DOD[!>;B*=:D'UL#6$WR%<\O(%WUT9:I0+8&V +%>03LG)\
MVS#L6\!9!VT]8[@ MMY'6X=N6:_VX?&"):Q]X&.!H0=;(%N7OBS7K4.V+(<+
M8$?Q814)9!.BHPC4 M:&D*UG"]?[7>NAX?K07MJ4Y2#G$<V72EPI(A.V(3*^
MC*"]50%W:'0)0;L0 01M7P%MZ3_OEZ[Z3#JYQO+ABN;#%<M[E\3R2N>]ST%L
M=!Z2X@J1GEB$@LQMV+7U(!JJ6]![_ 3Z&WO0O*\6>PNW8'-< @K#@@G8_@3L
M0%3&!Z BQ@O;HSQ0&>.-G0F!A.Y ;"5\;X[V1EZX,^)\K.#CL CVUE-ALWH"
MUJP>QY>E:"RLUA!Z;2?!WFF&DHW=%)[; H*_/0KSPY"3&8*H,%=XNTLF4FMX
MNMK S]L._CXV\'0WPT:'N5B_7I*EC86#XS@X;*0<"=LND^#M.P?^ ?/@Z3V=
MUSP6ZS>,P)IUP_D_1\)J[3BL64^@=YS#%[(1&R4+EH$CXF-=>/S5L+:8A66+
M1A, )ZBLI?'N=BB/BL"1E P<B$]%OH\_W,6#/6X,)@SZ&)-&#,*"F1-@LG@F
M5AG/PSK3)01S8[B9+T? ZE5(MM^ +3Z^V!\1B2,$Y%J10'-4-.JH>H*S>*P;
M.55030E@UT=R>V04:D7<[U@TEP6X:90T$K!_\F +7%,"U1U49U*Z4H<N&=.:
MH-VII@/S"6GH'E!/?#IZD[)P.GL3>K,V84](-**MUL-VWF)8+UP"E[5K$1'L
MC[346#ZG$? -V@@KFZ68OW@LVYS!A.PA,%H^&JNL)F/U^NFPWB" /1OV+@OA
M[LUVR-L<ZVV-L&3Q)$P<]SG&COP<<Z=/P9I5*^%F;PLOZ6=/P(X-<4-V<C V
MY\1A9TD.:G9O1T?-(?0W'\>)]C:<Z.I!=UL/&NO;4%&QG^U2.BRMG#!UQC*,
M&#4+@X?*&-8REC4E\$R(UOI:$ZH)UWJ(N"8=L"=Q?J)*<B: /7S$'(P9NPAC
MQRW!R)$+,&C0#'STIRGX[-/IA.J%/'\C3."V:5-,8+S,!JXNH4A)*4+%]FH<
M.=RDX/K\^2MX\.")!M<$*_'"_EP:.(L7TA"P/X0BF>KS.B09 O:'$*1+MLE^
MO_0[M<_ 5,'6=]]3/^#K[W_$MWSUT.['S3MOT-!T 06%AQ$:6D)#EVVM/XVR
MV.W(S-Q+Z*Y&T>:#*-]QA"_89K1U]:/O%('CS'F<.7L1Y\X3KB_?P/7K=PG1
M MA/\>C1<SQ^3$#E]#[+1K(WW[I]E]/[>/3X*6'H%:]? /LU 9L@0AAY]]5K
M3K6PW_/G;V%GY3%"?A:LK0)A:1D >X<XUH$M*"MOQ/'FRSA_Z2ENWI?,WV\5
M7-\F:-UY+-[J5[A-D-8]V"*!9_%0ZUYKO?^U@+:6Y&P@E)QP?O<)?_OH*:[=
MOX\K=^\0OF_C\HT;.'O^(LZ>.X^K5V^HS*?/E#?^I9JJ<98%LL5[3<!^0; 6
M?0C8.F3I(>,Z2(GT>9F*9+L&UYJG5@#R[WFO#>%:O_<Z8!M"MN%Z53\&UAM*
MKT-_6_\<8'_]C0RU]H.:-P1F'0+U[1_NIP.E7A:Z]/*3<I%AKQX]><[ZQ+K&
M>R_E)&'A*I.X)/.2WU.OI2S?$LS??8LW7WQ/Z/V!^C-!^WO<8]TY<^$V:OG>
M*]U^$(EI\B$^&]'QA2I9[.ZJ)M0WG$9GYQ7T]5_'J3.W<.'275RY)H!]G^+\
MC=O*<WWS[CW<?_P83UX^PXNW+_'Z"]9G K9T,= !VQ"L1?J]_Z5KE75_#[ -
MM^GZI7*5Y9_6\:'_BG#]BN5SY_$SG+UT#5V]I]007&UL:Z7?=4=;M\IW<:*W
M#Y?.G<&%T_WH;*K%P5U;L6U3&K*20A#F[P"[]<98O'@B)DP:A)&C_X0Q8S[!
MA/%#,7/Z!"Q;O!#K+%:SO7="@)LWPKT#$!L00M .0UIX!%+#0I'@[XMP3U?X
MN]C#VXWRV4B[Q0$;'*RQ9NTJV-FMA;\,@900AYSL;.3GYB,C+1N1X;1EO2,(
MRN%P]XRAO9,"'_\,VH69!&H9?295>:%%.F0;PK9 MD@@6\!-$I])J+AXLPLW
M[5/>; $\"4669&D!$N)->S:$ *>-G4WXYC1(P746P3H-WN+UYGP< 753Z2%L
MW].$K97UR) 1?&C'>7@GTM:)41&& LMB'XKG5[R\,MZUH;=7H%/L3;$GM6A.
M39(H6+S1AHG-Q-,L$N^T(5 +?,LZV4< 7. ZB]"?5U"E %ML<$ET)H"=DKY5
M3=.RMFNBO9^:(6'> M5:V+> LHQYG9I>R64Y5SU,7(-O.7\!:H'KW/R]:OHA
M8(ODFI6'7B!;]V+'2-CX)G7.AH"M0[9(O-D"VKI'.X)EJL.V +9XGX/)!R$L
MVW"R0HPX"0GPR?Q?B8D2ID[.X6]EQ(D03B-9+O%IVY"4P>O@M2:DR.A#M,?Y
M&^&5Z-@"OO]R:"=G(YW*CLI$3K!D%D] IDLT<IRCL(GW<[-G+$H\(E'@$H1T
M1T\D;W1!JJ<[TOP\$>?M"K>UJS%_ZA3\Z3>_Q?_Y__H_\*M__;\P;.A'F#5[
M-$Q63L:JM9-@L7XT5A.N+=8/IDWU&=:N&P5?KR7(2G;'GBWIJ-^S#2T']Z'Y
M8!4:#NQ ]9XB;-^2@)Q4+X*R%0()UX%^BQ 588+<S'4HW^J"\E)G9&=8(BQH
M#NWHB?!RGXS0P'E(CN,^:<N1G[X4>2E+D)FP!(D1BQ$5N 3!/LL1'FB#C)00
M[-A>A".']J/VR&$</7P(M;6'T-Q2@YZ^1G3WUN)8G21T348D;3@_UPV(Y/5N
MSLY W8&].-'6BK-]?3A)^ZVOHQN]';WH9-O2?+P#QV@_5!]JP.X]1U&Y^RCJ
M&[MPZ^[_1L NWY&I!O">/O?W6&3R&99;#H&)Q><P,OT$"Y=]A/E&?\*\)1\3
ML#_!K/F?*,B>.FLPYBX<!U/S182J#03",*1F9B([OX@/T296:.G?(%_A9#!]
M2># !Y4/L/1K$PG0BH=8H%4>Y$0"X&:"=5EYK?KB)15?OII))D(92DN-92U0
M3 @5+[, MI:43"!3&@-M$'R10+2$H4A"!9&,O2?9"B,)>9+14&28@5P?-DP'
M6OEB)[ NC9*<GT@\V)K'6$!7LC**!SM/A<!+IEM##[8 MAX";@C< M,"UCID
MBY176SXX2#_N< D3U\[!4#IPZY)E';)UP [C?FH[&]&P*.Y#< X7R)90\0]
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M$?R?T2PCW1Z/%WM<[@'A6_IG1\7D(":&/!2;A0P9G2DJ%WGDFUS?5.1X)*"
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M]KFAN=H5#55VV%]JBK+,V2A)G8KR[%G8M]D(1[8OQY&*%3A4;H;=Q2N0G[@
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MB_A_='@5<!7 )K2S893P&.D;+OT!Y6N9?$$+"R]4<"]9QD,DU)W0+&'>NG3
MUCW8.F3+_(>@K3S:2@1]"<F.+%0-G#2*FL=</.XL0S:.JAP& %O6*: >V%>D
M&D@![P@MW#N(TP]!6X!:'FS]"YH.V7I?; D1_PFT^3^59)N:%A.T^0*@T1D2
MM0D!_'^^;$1\@[/@1] .DC![N4]4$,]1UGL0LEV]D^#JD0 WCSBXNDD?[4AL
M6!](R/6#FU,$$J)RL7/K0;37=N)T2Q_Z:IM0OWTG]F7G8FM4%/+]?)#A[HP4
M)SND$)8RW#<BS]<-FT)\4!3IA^*8 !3$^B(CT@T)07:(\%N+,)_5"/-=C<@
M*\2$K$-<V#H$^Y@I#[>5V3A8FHTG3!LA(<85!;G1R$Z/0F2H%WP]''A.Z[!Q
M@SG/SPC6JV?#W'P23$U'$)"'P-)B%.SMIA$,YO-Z%L*1L+?.;BJLUD\F8,^
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MO 3,8^,WJ3[<NZJ:J184%!WD0[Q5>=']U/^74'5)=O8>KO\68'_HQ9;MLJ]
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M:*C<AD-%^=A/T-Z7D8:]R<FH2HC'WK@8["40[R4D[XN(P('(2!R*UC*&UP]
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M!&SM0K'>QA_VZ_T1S)?'YJPRM!YHQI7VT[C>R@?M4",:ME3B8%8^*N,3L2G
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MZ .1A&L"]D%.JPG;1P2:"<L"S,<)TN*Q;HH7$:XY;228BQIB!<2C%&B+-UO
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MEG!Q\5XGL-%)3"M7H"W0+>MEN"_IDRX-OI1? .%:^@'Y<RI#G45+8RL-8YH
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MRDP#1X'LER^_Y'&^( R\)<QJ8/@5K^N['[XG,+W!O<?W<.WV==P@8-]]](B
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M=?#9[NN[@),G+^ L#?-SYR[A_/G+N'2)D'WM%N[<N3\ U\_P_.DKO"+$O2-
M?DDH^$(^)+ LGA%\'\EP70\?*SA]J;RIFL2C+E$ DB1.IEK8N'BNW^#Q$^F;
MK27KDA#SK[\E6/":7KPA*#]^@)MW[^"6)%5[\E2%BC]X^D*%BS]X\I+@+5G%
MGQ*N'RG=N/\,=Y^\)E03F@GP&F"_4U[J6P]?X!KW%1B7+.1W'K]2VQ^_^A)/
M>"Y/9&@Q NHS_@\-L#4)M+XBL+[E]7[!Z_V2$"/Z0D&SIB\'/H+(6,P"1CI$
MOQ4/M +;]_OJ'U\4'+/<-+B6#Q&2(?NU^E_R<4)^*^ N'U:^57WK?U#S<KQ7
M\KL!D);0>ID^?_Z:Y\[CL$Q%/\$ZKTVZ+ AD:["G20-L[;S?]ZW^9_0A[/TU
M6.O2U__U_C\H??'5CP.2>?[^I_WE? 3ZY?QXKJP7\OP]??J,</T8#QX\PF/I
MCRW7+U#[Q0^$[#]3?U'3!X^_P,FSM[#O4 LR\RH0G5"(N)3-*-EV&,>:3J/W
MS&UTGKB&H\=/X%!]+XW%2[AP]2%NWV?]>B1CN#_'O0=/.?\,CU6P2)$  /_T
M241!5 FL4B^>2WV6#T1O!.KYS+,,E5BN\OR_DO[7$LU"L/[O],'^2;PW7[ <
MOE11*MI'A_?E-U!.++=OOODSZ\6/+*-OU?V7#V+GSEY&;_=)M+70$&YN0P?5
M1P/X3$\/3O=VHZN5,%BU&YDIR?!P<8*YZ7(8+9J'Q?-G4M.Q?.EL6*R<#[,5
ML[@\!K.G?(8%DS_"NB6C$.FX&*61ZPG8SCB8Z8KCF_W071F"EJW>.)1CAWV9
MMCBZR0/-E=%H)0 <VIJ$3<D!B/!V@*_3>L2&!F+[EE(<K:[!GIT'D)&:CT"_
M*+@X$9@W!A&N"<S>"?#W34$0[<^(L#SNLQTE10=0O&D? 6<+0H)2X>$> 5>7
M,+BY1:F$988AXK\$V+KG6B3S MR&7FV1S.N0+5&#$HZ<7U"EAJ^5\:*CXPI5
M/B%7CQ@X\_^ZN$?#RR\1$;$%2.?V MK">87["+\[%!SK4/W>*RQ.$\W[:PC7
M N("X89P+?V5)=.V%K;]\X1FXM02N,[-WX,\GI],U7C7A&E][&N![ER5Z7LW
MLO-V*<A.)URG90I<ERL[.RF5_X>PJK*-R_\EI,9&ER!*0%KL6MK*86$R7Z3L
M_W NA]-&C@CC^1*R(WD=4;0W11()()Y^Z>(ID9<"V3&T;>-X30D\ML"U>(E3
M"+2:.*^\V01J2< F<#T V#I(&^KG@*V'B@NX\YW&\HI+W(H8@KPXQL*E3W8(
M;?9 Z8/-^^I/R)9^V3YD$<)V4  AF_:P7&M28AE2>2Z2O"V92B#T1_-\0WG^
MPA.^P81T0G8H@5MX)X&V=AJ9))O*8UW,3RA&7DP^<B*RD!.2C(*@.&P.C4-I
M: S!-@S)+A[P-+/ RNG3,&7PIQA&&W74D-]@QHQ!6&I";B-D&RT?3DG7X&%D
MMU$PLQS'Z1@L6T&V6SX6)J83:&^-5B/BF*V<S&?6%*GQ;MA:&(F]Y<FHKLS
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M:WZBZ?ESZJ7*(BZAO_(A0Z!6LG-_0:#ZYCL!BZ\)-2]QY[YD<;Z-6W?OX:X
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MF_>?X-8#@>MG:ML#[O.0OY.III<_ ;;FN99[24@2^!D H@\A2 <E73^#HP'
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M\\*F$#_D4RD$UE#G#?!:OQI.EBM@M]((ZU<L47(F=$?XN" G,0*%Z7%(B@J
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M<>%L'_J[FW!@;SGBHX-@N6H9)D\8B?&CAV'^G!FPL;: IZL3?#S=X._MA=#
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M2?BVUN=:ASY#[[-(#^.6Z8=0K>^C2P=K!0DTCK6^I0(@ YXX ; !X#:4MK^
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M6#ZW&)M7+,?6->NPG'JE,*\4H:'Q</<(@;M7. )"DFE[Y=,N42(R"0&%=H8
M.SZ>8$W[+#:&\$.)CJ;M1KB.E >;$ATCT"80118BG#:)QEP+H#7#C*9M$EQK
M[FHM<PAF&A\M>-8Y%F!;VQ98VV]_Z-2QQ@@+]F0KR2,KP+8B_BS UCDZUV:C
MOA]S;0_7%J3)]I)8]J'E[=:VSM%XW[**583KU2:AF6QD>;#_,\#^T*MM[3.
M+:!EV6AZ*0/7M!LS":Z9A.",O/E(HPBLDWD\B7";F$D0I6@]F4N)0L!E:RH)
M6%+Z B31MD]*U7!0V[.G*<Q;"<[2;))!NSPWMP[Y9BPV[4R%=!.J<S3_=BMP
M&^@F+,O65/E:Y2CY(\BVH%JBWTCLRU5VK>Q;E:5]^0O =8YUW++)[6UO#<F,
MI)W_+M*5RQC61[U+DSF\]3WJ7C0,(44\0BY)%IN(45AWXN(4*4%)*J04L/[D
M(X7+=-;US.@<Y-!^+@C-1D5D'N:3;9:DE&%):C'F)62@)"(6:3Y^")_N H_Q
M8S!Y:#^,Z=\50_NTQ^!^[3!B6$>,']<-CDX$[,G=,&YB!XP<]S5&41R=N\#7
M?S2R,WU1OS 'F]<NPI[-33BX=3T.;%J'_2W-V-^\'/L)UX=6+<>QU:MPM'D5
M]BQ9C$U55=A278O#RU?AXK8=N+[O(*[L/X0S>_?A\(Z=V+]]!_;OVH4#^[E-
MX#YZ] 3M1 NPCQ.P#YJ0< 'VEE:XWKAQ)]:NW4I;:QWJYC>R/M<@/"J--DH8
M4C.*J)-/_/>-P?X0L!M75&.6^TC"\A<? '9_+I5-7 G-E!&\BTGA/M:Q+0'[
MRU; _L0 MHX)PFV>[KYF.=/#EHE\RJRN!.SVF##E:XR=] 7!^C.,G/ 91CE\
MCG%.[<P8;F4;GS"Y*T:,;8^!P[[$@,%?8?BH3I@R?2B5H0M2,\/98+.IN!0B
M7DK%E4N%EL8*E4HA:"?FT9#5>!?;N!>%BVOZ)XW]S<E3;]\R@O5BX[U.RYQO
M>N>J:FQ*0XI* *V$9Q*!M6#;/N&$E)TE5JBX)GY/3*4R4[AX3AWRBNM16KD2
M99H_NW09E4&-@4N%?402E&T9Q 7:%F#;))HBR#8A(:T *GA6X[/@6N/+Y5TV
M@,WGL@\#5R-.YS-);+!M\UK;]O]'P+8@VQ*KD4NTGDC1?LV/+85FE!KE0\ V
M(3VM(M"V(-N,QVX=DRUO=@1%TW#%$;X3>=QX_WE_2L@A!?4A8*O7M+1\I7E'
M"N/1_.1F&J_(? 0:R,Z!;W F/'P2"6U1A,U0!!"T\]++L&9I"T[L.(*+^T[B
MW(Z#.-R\$9MK%V%%7A$52A+*@\-0Z!^('']_9 <%(3LT!'F1X2B.CT59<@+*
M*05QT4@)\D>,CR>20P)0DI:,Q14E!K++<S,0$^0+URD3,67\2#@[C,(TIW&8
M[3()[@3OV2Y.F#QA%$8,[(.^W3JB5Z>VZ--%/8&],=MY',)]"=3AOD@(]T%"
MF!<2([R0$N.)M'@W),=/1VR4IN@:"2_/082S/ICJW -3I_3D^@!X>HQ$@+\#
M(=N!P#@24Z;V@^.D'G">VH>&PTB$A#NSWL^F(3";0#P-OEY.A/$IB QW1T9:
M",$S 17EJ9A;GF:6U969J*G.0F5E.O+S8A 3X\7_X8A)DP9B]*@>&$J%.F1X
M![;)+ACKT-TD)QPUKA.&CFR+P2.^PM!17V.$YD5TZ@PGEQXFPL7#=PB\ X?!
MPV\P9JMCSK4OC?,^MNGY1O7&+%<G&B%)V+R5RO3R,=R^<Q%7KYPFK!W&"4+V
M\6,$[",'*%H>Q.GCQW'I[#E</D=C_N1I[-ZV'4L6+$!:2C("?'WA-ML-LV>Y
MPL?+'U$1<?R %V$QX;IE[78T-6U&:>E\^/I&8\0(9W3J/ AMVO9#NPY#T+[3
M2)NWNH<C 7O2[P"[?>?1YGC;CL/1QH2%]S>>Z\\^)UQ_9H/KOWS<R28?=?H=
M8'_Q>7>T^;HG>O<>@2G.<VB@96#NW$6HKU^-9<O6H*%1&<-W$*[/$Q8)@_>?
M&."P>=;> [8%2!_"M+7^(5Q;@"PXMO=42RS8ML3:;P&V/5B;8S_K.(UM O;W
M/[W&VY_?$+!_ ;F%^X!O7OP#EZZ^POJ-%_GA6H? H$JXSLE#8,A<9.4W8?Z2
M/5BVZB"6&[@^BET$L:.GK^/D^9L$T6N$CC,F^4AS$P&:8+VR<166+5Z&>97S
M4#MW'I8N7(:FQM58V< R6[(2]8M6HF7-5IPZ>8G&O<*V?R"T*NOR:[P@Y&HN
MZX>/GAJ/LA*/W2-L"XY51H+HUZ]9EBI' S&"3ML^^S*66%$# FH+L"W(EB=;
MU]/Y]J#]G+^Y=NLNSA*R+UZ[B1MW'N!F*V#?>_S, +3@^EO^/PNP'VMLLI*:
M:<PU[TG'7PJ*_Q,8^B-8LM_6N@VL!&>V9](S_V> ;<&UO-<*??_;W_YAE@\>
M/#3CV?,+JP@CT9@PR0?.TX/A&Y2*U.Q:+%FQ#?N.7,:EF\]PZ\%+W'[X'6X_
M^@XW[G^#*[<?XNS5FSAQ\:H![,-GSN'PJ3,X>O(L3I^[A.LW[_(=/H?F]A9<
M?RB"86N\M 6+'SZGM6T!HKU8@&T/V;J.KOT.LI^I$T49SU_SF*[5"I3?$Z8%
ML>\ 6YYL&UR__.$WO%+6;-;_%]\KJ=D+[-AWW@P!RRE>@<P"PD3U1BQ?<PR[
M#M[&D5./<9!PO7O?9>P]< G'3]W$U>N/\9!E]?S9&WS[#=_+<[Z?%WP'WU((
MUX+L5_\"L"56V?PSL<ZS+ZL_$JO\+*A^5YX_M(Y=9[V0Y]J:#UO)]IZ_>&TZ
M!077)JG0MCW8O>L ]N\[C".'CA&PCQO/]>'#A[!C^Q:V[WH4Y*8CR-<-4R8.
MPYBAW3!Z:!>,&=89D\?UA,_,$4@-GXGJG! LJXQ'4UTRFN<E8$5%.)84^*$F
M;19*8AQ1$#$>)5$.J"!H5\:[8&[<= /6A1%3D1M"2 ^:AJS@62B,#L"\G#2L
MJ*G&FOH&K%BR@@;_<LRK74;0JB:T9,(G,,%$843&:FHK0DFB;!,;U!H/-@$[
M5C89X5IB 79$)&T:>;)C%=8K:*9=%EUH$IJ%T&Y4!G%YH.6Y5IBX/-D";8W+
MMB#;>*AI3]I[K076$MFM-@?1>YOSPP1<LI<L6TF0+3BTP%!VE6PEFP/(!MCV
M'E1[$+0';-F1L@]UOHX)KF5_558K6WC+NXSA@FO)AU-S_9%\"-@%\OC2EM-8
M864.?P?8>0O> 78*;6A!=3SMZ3A-?TM)2*>]2EC6=+C)<FC1QDP2F":W#JE,
MXO/*IJ0]GII<CM2D4J0D%",IOAAIR64$OFJ"_7S:F+0U->]V(<&8<)W;"M@*
M&U>'A<I1X*IRM@!;92JQ!VU[R/YG@&W9VU:9:M^'96^5NV63&UN?D!T56X:P
M*-FZ10BC:%RVX%N.)NM=FOO4O<G)Q^=6>'ARJQ=;@!T=5TC;.P\1<3FTPW/Y
M>T)V?"$R8@N03?LY-R0'Q:&YJ(PLP'S6LT7)I5B87("ZI&S,C4E&?G X$N9X
MPM_9"=-&#L&(/EW0I_,7Z-[I(_3N_C$&#?B<]A3!>O37&#WF:S@X=J)=UQ\A
M(1-9_NZ86QR'IOH*[%RW H>W;L#A+90-:W%X[2H3&GZT>24.K6S KL6+L)%P
MO:ZB KL7+<&%S=MPY]!1W#QX!&=W[L5A;N]:MQ';6M9CVX:-V+%U*V%Z+PX>
M.((CAT_BZ > O76+O-A[L6G3'JQ9LP5+EJQ"2:FF+\Z!?T ,G)S=,7+,% 2%
MQF,'?_/?!]AV%W[Y#K!'8<C(+TU(MP![I@>!@' ]RZ.O27PV<8HRA6O,=3N,
M<VR'T0Y?8_C8SXT(N.6QUOAL-^]!-*P56C[0B#*13YTMP&YG 'O\9'G)OR)8
M?TWY"N.=!=B=38BY@S,5[\2.O&9;#!K^%?H/_@*#AK7%Z G=,<-U-$(CYK!R
M$H(JBB@EK&C95$8)5'Y)!.QL)"5I_D%6K*A<0D:!J;39.>J-4W* I:SL=81(
M*9]:*JA&HSBD+-1P!-,:<ZW$9Y:2TS[+>RUE9Q^R8X/M"M/P%2(N[[6@6J)U
MP;42?442#",TIID*^9\!MD1)SY+3:MD(%QNPE*A!J@':QD3K Z#_J3!Q&R#;
M [8:GQJNEMJV(%NB<RPE:OO][\7J0=-2C5V)'_0;DWRBU4,MP!98_Q%D*_&9
MLHMK^X_"Q2/X$8K01X3EJ?)3YX04ALI=BDH*KJADZ3O 5F1!2=D*\X[4\Y?*
M>U?O7AC?J0#;/RP7?B'9\/)/A;MG'&;,#(7;K#!$!*>@(G\>-J[8C!,[C^'Z
MX?.XMO\DCJW9C'4TW!<F9Z(Z,A[EH9'(]0]"JH\/DGV\D>+OBXS@(.02M$OB
MXU"2&(^L\%#$$K!C?#R0$1F&FKQL--3,17UE.0K3DA#J[8Y93A,PQ6$T9C@[
MP,=]!D+\/6E(N,-]QA0XC!J* 3T[HW?GMAC2NPNF3AB!@#DNB _U06HT_W=T
M()(C_9 4Z8WD: \DQ\Q&4NQ4Q$5/1'C8*/CY#<&<.?WA2D!U=QL #X\A!,51
M" J>8,3;=R1FSNY/N.X.9\*MJ\=  LXXUGMGA(9,AJ?[6+A,'H0IA&6W6:,1
M'#@5L='N2(SW1D*\%V)C/0A_'FP[;@@)=B%83\#4J8,QGD;/B.&=,&Q8!Y,A
M<NCH=ACIT(EMM2O%UCY'.;#].[9G.]:PCZXF4D4=::X^_>$=-!2^(<,(V8/-
M=']S"-S370=CQ)ANZ-.O T:/'4A#Q1?+5\[#Z;,'</?^9=RZ=0$7+AS'J5,:
M@RVX/D"PUCCL$[AX]BP!^SS.GCB-HP<TS_%F0A<-C(("Q,7$(L O")YS?.#O
M%X*4E&S,KUN&39OW8,>.(UBZ;!V-F5Q,<'!%CYZC"-8#T;;]($+T*!,"WJG[
M1(*U$SKWL ![O D9;]=9<#T,7[<?C"\(UY]]WIM@W1T??]K5>*T%UG_^J*--
M_M(1?_E+)P/8G_'X5U_V0(=V?3%TR$2^KTCDY\]%;6T]ZGA? G\E-=N]YR#.
MG5>BMX<V;Y[Q7MM@^3U@V[RK%E +_BRPML0Z_T//]8> _:%8YTGLP=KZG<9:
M*WNV0L2___$UWOST!F]_X6]_!8UNX.Z#G['_T%W4U.U$>.0\N+KGP<.G& DI
M2U%1LQ6-34>P=N-);-I^DK!Q'D=.7\.I"[=P^OP-G#A]R?0>*Y2K:=4:-"Q=
MCJ6+EJ*JK!+9:9G(3LU"=7DU&A8WHH'&<>/2)JSCQ_+@@9.X>?T^--^RX.&E
MP%CE\TK@],(D'KMYZXX1K3\E& LB!9!F'+*@4W#]G=8IK8!M#]E6.5NAXA\"
MM@G9Y_O0^2HWE9'"L3467"'0]PG4#Y\^-TMM*SQ<\QJ_X/^6%UOCK.5YU_E:
M/E/2+^[_5F#$Z_QG,/2A? B:6MK@2W.?VSIE++#^4%0N6JI<E-1,WFLEK_OK
M7Y49^D?6R[M\/]OY#2C M)F!<'#RH:Y-0GIN'18NVVS \L*UIX3J[W'W\6O<
M>O@2=QY_1_D6MQY]@VOW'^/*G0<X?_T60?LR#IXXA=TTF@X0OBY>OFX@5R H
MD!;D6HG/K''2]I#]1\]HP:.UWQX.[0';@FR=IVM9D*U0<4&^&99!N+6N9Z[-
MY[< ^SON^XYP_9V!Z[]3_D&X_AON/'J#0R=NH*%Y#PHK5B*KH 'E-9O0M.XD
M]AV]AY/GO\&QTP^Q^\ U[-AS 4>/7\>U&T_Q@.7T^-%W>/:$;?D9Z]$+MEW^
M_[>LEV_YSK[G<ZMN:KYQ>=>M9[7N[]T]_@NQSM5S_RNQRNU#,>6ML?S2$:SG
M NSO6(_5(7CF["7LW7O8C'G<L7TO]FG<-77SH8.20\;3M&?W#JQK:49--6V6
MV#"XS72"X]@!!.MN&#>\*\8.ZX2)(SMCSI2!2 J>@JKL0#14Q&!E52R6E85A
M?HX7*E-FH"36"?D18Y$7,0[%!.VY"=-0F3B3R]DHCYN-PJA9R B<@E1_%Q3$
M^&-!?@:65I1A06D%J@HK:.S78/'\E6ANWDX[=S/R2Q8@+"8+_B$I" I/IUV2
M:R [/M$VYCG.1.\)A@G6@NM6B8HJY[>UC':8AM$IK%>0+6]VL7'(R(MM3<^E
M*;D$U0+LQ4LVH[IFM?%DR\-M>;#M(5M@K=\9:77NQ/#X?P;85IBX!=@ZQ_)>
M:RG[2K:?!646X-E#WH> K7/?>ZX%U^N,6/-=:YRUEH)L:\RU_=AKP;3EU;9
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M_6>$RSLXRW=\^>9=7"=(:WF<[WK7OD/8OFLO#AP\BO,7KN#.75OTAI5X[(\
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MV46QI8B.DYUD VLEG-(X6>62L88+:I:3F#C:C+(;93^V0K:6"F56J+B9J8:
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M>L'"#6:>[!+:B KQ582EY<4V<&T'V/)@R]X4X GF) )!;5MVJ66;RO$CL8=
M.5MD]UF0_<]$]J$<&H)KC;V6*$Q<V]:0/4&VPL1M\V#;DIQ9X=^6:)B?M;1$
M-JOQLNN^4ZML@$T[-YEPEZ2H2-ZO-=XZ)H7EG$);E#9B5)S"Y7,1Q7<1'92.
M2+]D1'DG(L8["8G^J<@*SZ!=EH/2^%Q"(6VXR'3DAB0ATS\6J=X1!+M01+N'
M(M(CG+\C;/LG(#HDE;">13LW'S&)?#\$[42"IPFW9GFJ7'\/SNI\L-G55GEK
M^2%D*PFO!=BRN57>]EYL"[(MT-9^>\BV 78K9'.9DEY'FUE#,Q>0632M%^U=
M7D>_MT5.D$.,D %8SQ*Y-!YLWEL6GR%;LQEESZ,-O1#Y9IPY[>9<7E,=!>8Y
M^*QZ7D4ZL*XJ"B I+!-I!.P<EFM)=#8J6:Z:*[LF/AM5T:F8&Y6 \JA8E$5&
MHX0V<9$D*AK%,=P7'X_RA 24Q,<B)RP8R3X>B'&=@3CW&4B<,Q-QLZ8B8;8+
M\OQ]4)<0A\;L;*SE=WX7[;G3:UMP<^\^W#]Z'+>/',.%W7MPF'"]>_4Z;&M>
MBRU-:[&9LI&@O7[Y:K0T-&$-10E0FU:TH+EY UK6;L&&=3L(V[N,DV7#AMU8
MOWXWUJS9CF7+6E!6MI LF$Q;<SJ^_+HG_OTO[3#1:1;6KM_\/P/8KU\]P0HS
M3=<8#!WU)4'8!MB.T]H1G+\RF;Y'C%?6[\\QUNEK ]>VL=,=C6=:P"W GN#<
MSGB[!=2"[%F>?5O'7W<S\V"/=VIGPL"GS.QNDJ&Y^PR!J]=@3'<C8+M0Z4[2
MU%]M,7S,UQ@Z^BLS'GSX& &WYEGK@#$.G3!F0F>,&ML)PT9V,-F-AX[H"L?)
MP^ ?Z,Y&G$1%5D 0RZ5BRZ224X@XE654!BMH,8I*%V/1DO58OF(;%BW>0 5!
M)4?PTWA@]10*KDW/H90=U]4[J09E-2XEP8BETM4X;8D:9%7M&BPG7"]OWFM"
MQ/-+EA)"*P@;>48T!CM.X1RF5^H]8)LYKP75*?(0UQ$^!=ELD(1@]:BIYT_3
M(@BR%RE)!M>EO!1.+86J^Y5( 6O;=H]6)X"2(;P/'_\0L-58M6V%"FF_Y<W6
ME& V1="J&'CO^J HS-M -AMG/*\M22#<2^S#QA.H?$PX.=<%VL:C;40]A51D
M:?P0\%W$)B@$BN48+6^V/-FV4"CUNFHL>5:.>A!M@)V=6X^<W*649<C-(7QG
M+4*VE!,51"+?AZ;*" Y3F*JRB_-#&5G LB^$$J*9I'6A&03,?%04S"<0K\.>
M-7MPJ&4W]C:N0\O<.BQ,ST%A:!02W+P0/F4F@B:[((*PG>(7B,+H6%2DI*&<
M4A"?@,QPPKAZ\L(C4)*6AB45<[&VOAYK&^JQN*8">>D)" _P@.=,9[B[.,)S
MAA,"W*<AU'L6/Q)NB Z8@U@>CP_R0AS!.\9O#D+FS("[\U@XC>D/IW%]X#YK
M..%Z*C*2O9";&8"L-%\DQ,Q":* C_'W&(LA_/,*#)R D<#3\? 93!M" D/2C
M]$%8\ #$18Q 2NQXI"5,1%:J,[(RIB(^7HG1^F+:3(+US/:8ZD:XGMT13C/:
ML2U_#<<I7QF9XM(.K@1I;_^^\"&PS_'K2<@F>'MWQQR?WO .& C_X.$(),0'
MA1+R0WE/8;R?""<NG0CF$S';;22A>@#&CNN%82.Z8^"@;NC5NS,Z=VF/-FV_
MQ%=??XJOVGR*;MTU'=\PA(7[H+JZ@,IQ.8X<V8FS9P[CU/&#.+!W!]:O:4;]
MPH6H*BM':4$1*DK*L7#>(JQ>U8(=V_9@[^[#V+WS,%8W;R74+N [3X;#)'?T
MZ>] >!Z)]MTLL'9&M[Y3*=,(V-.X;ZH![ X$[/9=' GAX_%5^U'XHNU0?-9F
M .&Z-S[^HCL^(ES_Y5.%@G? 1Y_*:VV#ZW_[T]=<ML/'GW1"V[9],62P(^;P
MHZZYK@L+JU%9M0#+&E9BZS9E##^-2Y<OT_@^3>/[$,Z<.XO'3Y_2H+7!L<;-
MRG-G2ZSUQV-^!7R6M],>EB462%L>:TL^!&Q[D-12QY2HR_)<&[@F;/_ZV]\(
MU[_AQ<L?<>GJ(VS8<A0E<QL1'E<(SX TN/FFP).0'98P%QE%C2B?3\.Q83L:
MUN[#QITGL// &>S81\#>?1![]Q_!B=,7<.W&/=Q]\)SR#:'J'BY?OH'SYR[A
MZ*&CV+YI"U8W-F+%XL58MW(%#N[<B6L7SN'QO;MXP7+Z]IOG>/'L&WS'LGE-
M4'G]X#%>$*;OG[^$RT=.X,3N_3BR<R^.T_B_=/(<'A#@OWOZ'=Z\XG,+HA3^
M*] FO+PB7!NQ0(8 896+??D86&:Y6X!L(+D5K.U%^ZW.CP_/T3M\]RX%UWJ7
M@JI6N+;>PWO MB#)YF6W(.F/ %O'!-66R-,K$/T0L#7EUGNX_H$@_7N/]4^L
M)P)NP;7.$Y!_Q]]I+/!;WH.R63]\^-QXLT^=OD10OH2+EV[BYLV'N,]W>>_^
M-ZS;MW#@P'%LVK03Z]9O->%W.PC9^P1AQT[CU*D+N'#QJI%CQT]C#]^3/-E:
MEQ=;\*E[UKU;]R^PEF=;HFT]XQ^!Y._A\)\#MB4ZQYQ'X):\)4@+<)]_H_!M
M6W;QY_)FLWZ\>/TSGG[W$VX]?(43Y^^Q;I_&O*5;D5O>A+R*-5S?B\V[KK(]
M/\'5JT]Q[OQM'#UZ$8>/G,/I,U?-E'(:ZVW5@^<O7A"L6;ZO^&XD+&]%')CQ
MYNH\X#,9L>M$L']62SX\]J%8Y]F7S7\FYER*57X";'FPY<V__^@ISERXC#U*
M,+ESC^D<48CX8;6[$V=Q[-@I;-NZ$POF+Z3!'X?9,Z=C_+B1&#UZ",:/'T[0
M'@['"</@.'80'$?UQV1"]DR'0?"9/A*1GA,(UTY(#W.F.-'(=T!:V'AD1$]
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M__#_2?2.WBIK\SLPLH4UOP-".SC4<4&8P.QWPG=F0JL)J0I!_NZEPL+?P[5
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M_&S:*>&9"":4A09E(2J<-E)$(2(B\F@#9,#/-Q'>A*W H"0"2@$*2^M06=>
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M^V/BQ+'H/T!12IW1MV]G#!S8#0/[=\:0?ETP;E ON$T<C21^$RO2HE";%T/
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M$M12%K+M+B-\KUJY$:M7;T%+RW:LHYVX;N,NK.9Z[8+ER*2M5EE;;Q)P_H\
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M)'H;R!XYKBL&#ON*\CF&:#RT9.27&#[Z*XQQ:(^)!-_)T[O#R:6K26 VP9E
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MP/J]Q&O<-4537FD\L410'14C#[,2DU6P<2PRXZYKZS:@JJ;%-!PUIO<-Q=8
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M]V^^?XWGA/GGKPCS9GSL>\ 6T JH32(PBK8%R!I?_9CO2TM!LP6[$AV7_"O
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MN0 +E;<E6+2@62^:7CY!L"!;\U18":[U\FA]+=?+)>^L7DH3KDUIN076&O:
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M[<,*0D!F<A[\/ +@L< =H9[^R(Y-1'5V'NIS\U&9G(S\T%!D>'LAD7 =[>2
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MT\'X_.NA&,;"V$T5<VXQC:L&5"Y=QO*@$K7+Z[&!1J<@XM&CIP3E'I@6+%M
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M=:*SI1VKFU9B;5,;(;L=ZPG6ZPG64E=+)\%Y-4%[C2$#L&F+OX%K@K2TB=I
MR#8 NZ4+G2R[VQM8%BSO0-W2%J/]=3$!.S^'<)U3AISL4J2F*!=# NSFNN#;
M$9/@NLC7"!'_+_]54/P___<_!-B__?P+SITZCJ[5K5C7V8!]N];BB.!Z_WIJ
M PO:S88.[N_"KAT=6+>V#C7+LI&6&HC ( <L]I@*QP6C,7W60$R<VAN3I_7&
MC#G],7O>0,R>/X!0W1N39GZ)\=,^Y?!SHTLO]9_MO'AX=YOJH09H"Y8%SO)H
MSS8@6I[M+S#=_E,C&=IT^\_?R&R?_;6QOCS><Q?VQGP7[M>M+]6'L*XNP#XQ
MVG=+RE ^>[X\WWV-XT^9^0W&3O@:XR<2NNTFP-U]OM&?8V"0#\(B0UF )?#A
M*J Q7<6"F\"6I:^3^EJ99WP5C5/H#V5TEV6$A,@K3-!36QP"J\ W+D$>5[UL
MA<9\?6D44+=W[L.J-0=0W[0%!2S,5% *:I7A6I[QF%C">0(+TV3U-5U#F";(
M&IF[K?!LRVML'B>!QU/A6UBR@OM?C[K&35A:O88O7(-QW# 64H)LP;6&FM9Y
M66U[WH9KC0MB)3-$W/KJI@)!!:@)SWK!]27. FP-K7!VP;="7+2.UGT;L#7?
M7/9'R+:&5@&C@D/S>HZEL'@69JQ E<%14A<)ZK=;L)V07&942()IP;4\V1G9
M*@34A07AG4-]5-#Z8;P>@8&I\"-D!P>G$<Y+45C:B,J:-M34KT)+>Q<V;=U#
MX^H$+IPYCTLG3^,4#9 #Z]9C:T,3.HM+49>:AH*P,,1[>"!XX0+X.\R#M_UL
MN,V<!.?IX[!X[F3X.<^"C\M,>#I/AY_[' 1[SX>?YUQXN,Z$N]M,!!"ZT]/#
M4%.5@^;:(BPM3$-V@D*OU;[9&]%!2Q#FNPC^A&TOE_E&VVQE[9X^?C2&$*Y[
M??X9^GWU-8;TZX^10X9B[/!A&#-\($8.ZX-O!WV-P?V^P( ^GQ.LO\+@/KTP
MC.L-'S 0HP</P?@1(S%US%C,F# >,R=.P"Q"^\Q)XS!CXAC,FC0&#@3=Q?/G
MP-]U 2';!8&+%L+'V1&^5, B9P1R7L"B!0A:[(0(7U<DAGDB/=:7\D9BA"M"
M?>W@2;!V<1H)EX6CL-A] GR\I\'/9SI\/:=AB=M$N#HIB=MH'G,P1@_]AK^A
M#\&?T#]Y(B:.GXBA@X;CR\\)U^\2KO_E,[SSKU_CW;_TQ8<?#,%77XY'_X&S
M,&28 ^%Y@='.VH3L148_V -'F-[L0=1@@?8P9P+V O0;.!^]^MKAJUXS\=E7
M4_'QY^,)VJ/P_D?#\-Y' _'9E\,P9/@DS%^PF,]4%I8M;T)C<RN-J^6HK:M'
MUX8-.'WFK.$Q^U%&/ ''\$+3P+8 6Y[J%P(J#FT]UM;06D^ _0:Z-:];%EA;
M$BA(?S;O[P!;'NS?N5S>:\+(3X2+U[_^.UZ\^ANNW7R!W7LO87G#-J1F-B(H
MM B+EJ3!;7$:O'R5$97&=/X:_N9=:&L_B-4LJ]:NV8,UJW<1GO=@^]9#U$%L
MVK@;FS?MPLX=^U@O[.7T5J,M^L8-V[!E\TYL7+\5K<TTW(JK: @5TC N1^N*
M53AX\!AN$:Y?",Q>RC/ZO0&F NP[=^\;B;$N7;F)LQ>NXM#1LUB]?CO+R1H$
MAB:RS@B 9T XDK/ST-#>@<V[]^#0B9.X=.T&[C]6HJL7!!^"W+TG>*3$5X^>
MX>D3PA:!5_= ]^(Q(?PFP?K2974E==5(1*?C"UBMCQJZ_IJG]M<*!3]U^JPA
MC<NK+6^[E4W<@F?K-SPDO&O< FD+B"W _F>>;%NXMCZV_"/ UKAUOM9S8.SC
M%XFP); 6P+V!:TGSN.QMP.:R?P38:H-M>68UM #;DJ#:&M=R:UUYI:UMM(Z\
MUA9PJ]VOYFF9(-/V7"3+,_OW@,WQ7_E;?^%S_0O!]N<?#,A^]2/?,X+V\Y?/
M#=A^1O!]IH\N2F"GZVCD'N ^M%_JY0^_X,;MQ]AS\ P:VS:AL'(%\DJ;L;QE
M(W;N.X<+5Q[CZO5G?,=OXL#!\S06S^#X\4NX_-TMW+[] /<(IX\?/^;S]$?
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M-V$*$2=<"ZRC%4V04(D8*CI>33"M'E]X/6FO*IMX;%2.<?_#@E,0X,OGT9]
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M" N()6@G$+13J'3S8TFH,HTK7Y'.T01J\WQ[9$&V!=IO [:M1UOVKZZIP-4
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M?0%[]Q\VVD3NW+&;]MI^VFV'<?KX<<-S?8IPO7/3!C0M6XK,A%C6-8MH#\[
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MT8$+$$M#)B[4C4-71 >Y(,)_(9<YP'_Q7'B[S>&ZL[!HWE0XVTV$Z[QI6++
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M2X"_5SA" @@NW8 =1:@64$=&J2M-UN=45(P^=-.&(5SW]%<MKW:)82>%<=O
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M(J#[N]O#S\V.QL\L>"V<P:$=_ GQ@>ZN"%CD!C]7%_BX+(27BQ.\7!WAY>8
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M9N;6&; :883KE!)4Y:%FY9; XQ"8]8' _$A@#F/Y>R*Y3H3"VM5?-]<SP-L
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M_!N7;<3!#7MP>.UN[&I<BY4%-83L3.2&1"+5+P")/CZ(]_8PD!WAN@ !\V?
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M9=[^GE"M#.<:\U?AM;<)U%>N:ASC.[AZ\SZ/_1BWN=V]I]_B_K/O<)^@?8L
M=>7J#9PX?A([MFS#ZM9E6-:X!*L;6[!NZ0IL:.;OM*S&UA7K<6#3+IP[>-(
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MU_[R7&O85?7[CM30K!%MYZ@I%:%II"(/+;B6)]*&Z]^#:EOV>FUG0:N JMR
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MQ?QIHS%K\DA,G3 ,4SF=-6LBYB^8BOD+IV(.VYP9L\=C]IRIF#=O+F;.F&O
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MPOF8-W42IHT;A8FCAF'LL,$8-60 AG[9#_UZ]$"7#AWQZ8>?XD_O?("WW_P
M;RE+N(;(>K,3U9G+'?'FZ^T)VNJ;_1E>?YU _<K[E(;O^LAD&'^5T]?>^-3T
MI7[O@Z[XY/,^^+1=/WSP:2^\]5YGO,+U?WCC,],G6]YM>:\5'OXZE]\@M/_I
MO4[HV)GG-'P*YBWPYC.2S>>I 24T^-+86.;DEV'UNLTX?_D&GG[S [[74#<T
M9 4DCH!MP[4-*XZ [0@W-EC;7LK?@Y3_G"SOM1*9_?J+H/JO!JPU;RUS^N=_
M)^S]B$N7;F+=NFU(32N@D1E)(S0>&9G5J*Y;9_(V+%NQ&ZO6[\.V/<>,]_K"
M]5NX?$NAX7=PXY[EO;ZE_M?W[^/^(X6(/R$4/<,S@M$W7_%_*M'3XQ_P\/93
MUF&$FI,7</S8:9PZ>1Z7+E['S9O<]^XCXYF4]UI#8%V[<<>,*7R3ZVX2KF[=
M>X0[!-A[CY]1&A.;RW?OX\:UZSAW\A0.[-J#;>LV8M/*-=A(J%)X^,962^LY
M+VU9N1%[-NW":4+V;8*]/-CW"-I7>$Y*9';V_#6<OW2#<'_K^7E<YOT]?_Z*
MT17.W^8Y/>"Y&,#F5&-MFRDA^Z$=&G[_P6^\UP)L>; %V/)BOPS9OR<#:@[E
MPU%:_S)$_YX<@>V?D;:URZAC.=5W=ME\&: U;Y?9?Z[<_F/ MB7 E'?Z@:(:
M"-<:F_G2Y>LL%W?,.@W5)0#5,345P K&U4=^W_XCV+1YIXE V+Y]'W;N/( ]
M>XY@__X3.'KDK/%@'S]^D4!Y'*TKMJ&0!EEZ=BVR"2\UBS=BV>K]6+GA,):N
MVHO%RW9@]98C.'+Z%J[>_9IE_BL35:&7/ \>/N+]?(;OO_\./_P@N.:]^990
MW0;8WWTG_4>XMF0!L*Z;(V1;U]MZ82 Y K..8>NWQWI9;<?^66#]"W[^55/6
M,3_]:,8*O\MG]L*EBSATY#!V[-J);3NVF^F^ _L-7!\Z<LC =7W#8MH+X1@_
M<2+Z]>V'(8.&8,[TZ0CT=$>DGQ?\G>?">=I8S*<MLF#24#A-&0Z7&6PG9HV&
M$Z>SN3R-ZZ=-)6#/GD# GH+Y3@3L>9,P?>9XS)PY!7-FS\;TJ;,Q<?P,S)WM
M3%LQ'@6L7\O+>#\R:2N$QL+#/1!>'N$(]D]&D'\&_+PSX$OY^5($; V7Y2_
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MY?K#V+G_(K;M/8O5F_=CQ:8]V+K_&(ZSC-YX]!0/>*_N/_L&]Q\KB_DW)G_
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M=+'IBZV^V9&QA6T>Z6R$JD$SPWBQ85#C0\4FJS^U0KY901C/N 799@QN_D8
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MI,TH(%8.&GF9!6&Z+B8)6=MXX?)V*HNZ%=JM[16NSWTD[B>(MCW7\I!K3//
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M -H9?LX+$.#NA(A 'Z33_JDJ*\7*9<NQ;LUZ+&EJ14XV[<#0!-KI$?#TC$
MH3<T. 6A02D()@0'>L4BV#L.<:&IR$LI1FW)8C37ME!+4%58CBS:9'$$^MC
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M6'<TVHVQ3H/_^Q\LSZ"1 6TNMX7>6D!'PY^0(V_@M]_\F2#Y V[>?$+HO4$
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M45750(6]V@S2;MXR1 #?C<KJ3NHMI=1W"/X$[-CX?$)(&>&NA@I\*Q7]7@*
MYHXJ,CC[[GQK7JI NV0$L&5A%IS8("VQ 5OKEF70@ED;8'2.8%EZE:,UVH9V
M.["9;;U^##Z\+P'<=BG7NH[3?AN6;/FQ9]$SZ'KV->UU^_EUG.TB;J44^S'
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MD!+E@H;R= QM[<#) WMP>,\>;.GN1165_=3$3$1')!$B$A :FDS 3C>0'$Y
M#@[+HJZ3B: 0S<<6:&M^=C+U$.I\A.S2DC:3K[B\HLNX72<F%1/"\@Q@1XZ
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M4?#Q'X?@T,G&DNT?--Z M0!;H.WF\3)E%-P\7X&G%X';9R+\_:8A,&"6@>S
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M&K\8 >Q_8"/VWW[^$G[VJ]%XZIE)^/WS4_"[9]30O81_^J<7\?O?CR9(3R%
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MH$01QA6)DG#=4A>-KI9D--7&$+*]$!FR'&&! G5?=#87X>#N?AS:LQD]K6P
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M %L6:4&VY$F8=A1MLUW&[7G9UIQHRVIMNX4_:<$69*M>":P5E,P&[$>NXB.
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M_7W[T=?+]\!M@P.R:N\T@S."\MS<$K;?W3A,2'S_@T\,@%KU0,\BH.>S*%[
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MU'4?N8@3LN55FIZI<J8!'>JW!=1O"^0)8<VUUK?_,<#6]%!+'ENP;2NVH]B
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M,D4C_GQW&C558!))@BS^5&I2V6$4LV/JX'?>VSV 8P,[L+^3D,VR4!Z?B(S
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M&K"Q!F\4+,UXGBB.@LHL1677<LT69+,\LUS<UF^*;4W67&@SZ*4ZR3IJBSW
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MAN2X+-;S E1E5:(IMQXM>8UHIDY91SVT@GIW,:^;3\GF?=)T/]:!>(K@.I[
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MW5CE:Y;%.4[(2%R&E-A%!.EE)G>VE4-;J;XH7,]-7</"L9;PO F-!?[84I^
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MZ@IN$[*_^^?O\<=_(9C\=RK<?Z(B;JS:%EC?^XZ*,\4 -L'WGI''H"VH_GL
M6Z+M?P]@2Z3H"Y0< 5NBWQ8\_;U6;,NJ)_BPK7V.@&U;^^QC!.%R(Q:(R;IY
MYMQ%MF%[V#9M09-R(7<-FW15>_9=P/&3[YD459<_N$[0OD70EE7[ELFKK'1*
M5Z]>)V1_0\C^!G=NW\!=B@#[UDUK;K8E?QNP[=_V-AVK]7N$J"\^NX9#^T^C
MM+@)?CYQ6+/&'ZM6!;"]E 4[ P$!>0@(*D!H1!E264\U5WK[W@LX?$:NX1_B
M]*6/N/P )U[[$,<O?(RCYS[Z 6 ?/'D9!PC7%DR_@5T'7C<6;%FRM5VRF[^W
M[#Z#SLV'"9!#Z.K?2;@\2GC]V,#7MYJ&8"S5=UDV!-069-N K;GSIDP0KJW<
MZ5:@+4L>P[+*A 7BCZVJMNCWWP)L+>T!%'U[>1@(L-]Y]P,3/5SNX8+K\P0_
M ?>;;[U'H#Z-S5L4U*D-K80PN8^_]?9[^/*KZSS_EHD>_MY[5W#LZ!OH[=EG
ME&YYVS2U[,;P_C=QXM3'V#ET#@TL,U4-?:AOV\KW0[#NVX6.[AV\YB#:VK81
ML(<)GV<-7'_TX34#[8+KK[Z\YP#8=UF61B#[^@-\\XU 6_.A+;BVQ91KBG$E
M'RG7CN((VG\;L*WWK>]B#VIH(,,>S) \!NO'><H5+?ZK:]?QWH<?X=R%UW#T
MV$D</'@,!P\<Q<']1W'LR E<9'UZY]+;>.>-2SA[[ B&!OK06%F I$A?N#LM
MP(KYX[!XSJM80LA>NF@25BR?B75KEL#;S16QX5%4L#-0D):-DO0,5&>EHK4@
M!7UER1BH2,)@>2RV%8=C1V$(=A6&8C=E,#<$'6D!J"-<-V9'HZ^F $,]+1C:
MW(.^MC:4%RG0:38A.1T1\C0+EZML#B+"<Q 9QNV4:$JD<E83OF,BLWA\(?)S
M:U%)R"XEO*:G5_)\#6AE&K!2.J-@GA]"W4&NXK)@1[$/-8"=3 C[-P!;@\#J
MI^0B+L#6W.SDE'+":+-1M@724KXM2)9KM])[]4'SHYM;MIO]4M(%U[EY#69I
M*_"V4J]S)?HMZ+9<4JUYGI85W$HK)-&Z/0]42P&"K-YR$[<AV[)B5YMU0:C
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M4^#\)-0Y6JYMN+;G7TN,%3M=QH]*,YB@YU9 *UFPJZL''KF):_J@TJ@&!6?
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MP,I69=7=8,;1KERY$4U-:]'6NA&;-^_!$4+7Q8LW<.O670/9#QX(D!_C:TJ
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M2=N"<7F Y:U^X[$6_%!E A["C_4J"HX$R )>2>M6%H M8 MLY%V5EU62-UN
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MFTF8-V,A KT"3$1'7G(ZFBJKL6G5&NS:N 6=J]>CL;81^9G%M.4S:?-G(H:
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MH&U47(VL]$*J!'FYM>00O0A9;E[X1$3F(R@D"X&A.0B-4K1&$<*H<-5S ;#
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MT+$=>[?OQX&=N[%EW2HTUA8A-RT4@=Z3,6/21Y@X^N>8,ZTW KTF(RPNQQD
M /_T241!5#;< _$1 0@/\(/[HD68.G4JQD\@8,^8#C</-];#(&CJ+1\_MCL+
M9V#&[$F.UYI+S84]9OQP3)P\%G/GS^(Q7FP@H]G!9_&W%]-PJF1=+&>C6TSC
M0&%@(?#S\T924B):6UMQ[-@Q7*)!?)U@(%VY= .7+UW'M:N?X=;-NSAW]C(V
M;MS*YVXI?UL5#<&5V$S(UMC3PX>/XRB-:'U?H<O*7OU;P8Q 1O->?T\P>B4
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M8C$[<LE -HT<0G8>X3J_>"U%R"9L9^EM7UX+H9J_C1VGY@C/T/1E!.S<8C:
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M=EP,(9L0DYU1B4I"=OVRM5BV=!VO62_':]AW:T:2*K;?#32>VPC.'5C>L,Z
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M29PZ>0-W[VC^[E\1LC6UTTL\??YVB'A/P'[;D^UZ+[L!VVZ_#=@"Y6Y9R+:
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MPOEK/.;O?O#T6SQ^_BV>\G<^(V _(V _(V#;,=C&:TVPUA #1[QFC?4W,"U
M?EO=4.P28?%G].< ^P=^;LYC )O/R*^=NJ_[\/#14_,2[N3),V:8R'["]8$#
M!W#XT"&3./'4R9,X=_8LSI\[AY,GCF//KIWH6-6&NNIRI"?'P]_+#;.G3\(D
M)6@<-Q03QPZA!F'LJ/[<IATU>P+\?!8A+-37M#'^BNKQ\38*"/!'9%@P$J+"
MV#Z&(2XT!&%^@0CP#.!Y@Q 2&$G@R$-C8QNVL:W=M?L0UJ[=BMI:]BDYE6P'
MV7\FE[)=*Z7]4DBXSB-\Y"$I49";0_LE"]%1&69?;G8URLM6H*J2!G<9^S0"
MISR/FJXK(KJ0D%ULIC!*I/&OG"3*;IR8)KAVH-H -F%;H>0)[%,3"%C*N:*D
M9P)MC;..CRNB"FA3Y1*^"MGG5]$ 7D&X5+BTYJI6$K.U!) .+N5Y7D.@UAAK
MA8>W<KV=@$!HKE/R(T&A/+#+C/>YL+B1UZTD8!I_JN\XJA9@"ZP%U=1R,Q^V
MYM%=;SXOYM_/*Q X"M(%ZPH5)QCHY36->YM!W(2,:URQC'P:]!J;K<_UF?7:
M"C"SL@FLA %YV.2!%C@K3%=CK*U76EYL_1W'^RNP;S#0K<_DO98W6\^1 6VN
M-Q"T%5HLN!% N(*U %<0+'AVA36MVW!PS:9BI3F]Y5W/SF&?;<9-Z^5"HP&8
MXA*->54HKO*XL.\G  E\LI3T+5O>:@$UO\=R<D!;XW^UK9#R>G-NS16>3MLN
MF: 83[ATIF++@TEVEUB(Y"360]:WX. $<H0GA@\9AP_?_03_] _OFO'5?_^W
MCO[Q[QV]\XOW,63P""Q9Y(GLS'RTK%B-3O8=:]HWH;:*OS^3(!R?A[@XU>L2
MLD8ETN2U9QU,2JQDW>-U)%01=%E'$PCCO#8!GZ:/;6C>0ENO$V6L6VF$[$C6
MR]"(+-9WGD\OI%B.%J0M-%OU!&QM]]RG<\@K;;W9NA\"2P.G!%Q=AQWGKGMH
M95Z"<"DHU^>YO,^.Y]J!Z$)"=1%M.<%T<3GMOJYE,0&SE)!;KO,+AO521U!-
M":Y= =O6(PN[KAYFK5MI6]"MZ[5@K?-+I5TJH7U<S+];Q+]?*-N2YRMP@6OS
M,HG2TH2 TX[4F&MYK@U<&^^UMKF?]FPQGRVI,(]UG,]=KH9D\+G*[1JVH1EQ
ME+37.)MD"U/%?-[DN>\&; V;X+5U169:[W5R2CWK0RUBX]AV$;"C%*$36\JR
M68?+5[_X+PP1_Z-_W3M?OWZ)K5LW(2DI%A$1083C)/[0%%;D$ 0%+H2'^V16
M^+%P6SR&@#T*"^</AX?;:(0%3T5\S&PDQLUB8SX=2?'3D9XR$SE9<Y"?-Q<%
M^;-8N#-143X?2VL]4;_4%W4UWJ@J=T=Q_GQ"[Q0D1H]VPKKC",+Q4Y 6-QGI
M<5.1FS0+16ES49P^%R49\U&1LP3+2OS0LC0":U<FHG-U*C:M3L/&5<E8LR(6
MC294?!%R4GD-"9,(U1.1GL0EI:FX4A,(VTGC^3<G$.PG$>PG\O>-0PS_?F2D
MPKQ'$FH)S,%#C"?7\>;V@[M[+[A1_OX*A9_(AF<N;]P<WK )" D=3L >09 >
M05C5\8,1$#0<X>%C>2,G$ES'(9#;GE[]#6![>"H#^6">:P0[US$("QMOO-C^
M?B.P>'%_S)[S$6;,_ !SYO4V8>/1T;/9H >P ^5O7%V!O7M6X_3)';AP]@#.
M$[3/GCQ(Z#Y$'29D'\:Q@P>P<TLGFALJD)D1!%^?\9@]NP^F3_\(<^;VQI(E
M ^#N.=!XTKU\^A%F!-B#$1$U I$Q(Q >-10!P?W@[?<Q0>9C^ 7V-7-I^_@-
M@)MG/\Q=V O39KZ/"9-^@3'CWL'H,>]CQ,@/,6SXQY@\>01\?=W9P2<A/[<0
M.1E%2$G(17QT#I+CBVD8U"(C;1G24O7&DPV_Z0 <N$Y**:$*V<"4HZRR$?4K
MUJ*Y?3.6-JTG[*TP;\J5"3(D/!\1?$#BD]G9=X%O$L^I9&,:9YVDI&;R)"N[
MMS*)$P"3S%()SOB0$;"3,I>AL'PUZMB)-;3L0&U])QN*5A.6HP02>F.HMX?I
M;.P4WIU@# @:&/P[2FPFKW56GL9D*VD8&TV":FXA'V:"M\+%G:1G_)U9#6:L
M=CH;"L?#74_(%JPVF?W6$R[8%J0KB9J .T]CN\Q8:85S.R';SOAI)2IK(X +
MM G0!KS9*0J6RSK8V*XE9*\SRR+"MH%DA8JS$Q5<"[JE(B5"$X03M@O84%D5
M&L\WS]D%U\;#+J W1D6S >MT_H8TEFT:?U]Z&N]A>AT[O%H4Y2]'X_)5K'M[
M<.K0,9RA07IHTT;L))QV+JU"1T4QV@KSL)R079D8@Y+X2)1P69Z>B/*L9.2E
MQ;']H#$9[H<@&IY!$0%4$/S" ^$5Y ^/0#]XT_ ,C(I 6$PT(J-C$!L=S?J5
M@(+L;"ROJ\6&=1TX=& O+IP_C>O7+E&7"=):7B54W\(]S;5\[VO<NOD%CAX\
MB>4UR^'O[8410_NCS\?_C$$#/L28$?TP:>(03)TZ''/G3N"SZ\;?GXSV]@;L
MVK,5!P_MI\&M!$>G#$3>N2?XTWA1P?5OS'S,W_U(4"!,O^R:[UA3>KTR<V53
M!#]7?4_P,"*\&A&XOO\/0%JRX/7GU0UE%LRL5].!:RU=Y0"W ]T"#B>IELXE
M\%>2MU=*-M4%VB\INS0R8V9_)#R]-DF]KES]%+OW'D+[ZO5H;&XG:*_!BC9"
MZ*JM6-6Q ^LW[L-.@NB)4S=Q_?H#W+G[#;[\\B5!^P4ET'Z*AP^>0'-=/WGR
M",^>/2)84\\U]_5C MHS0NHWA+3G^(9P_?S%$Z-O!-W?O6#Y?X=OOGN%A\^^
MP8W/[V'OH9-H;NO$LL:UZ.#?/G#TFID?^\3Y+PG8]PG0=PG5=ZA[V,_U?=H^
MS?WR<I]5*/E=,X_VKD-7">L':-BTFV$LR:GE9AQH<5$3^[@U:&_;SG;Z-&Y<
MO^\ ]G<.8#_[YI7))/Y,GO@7"A>W\SE_WW5/Y5F5',#N^4)%^_720V#M1"#8
M: 2!M2(H]'=^,.'HCY^\P!,"[G/^385="U %TS\0H+__X;?<_@U>__ [O/Z1
MV[_\/?4'?/^K/^#;U[_#PZ>O<>W3KUA>Y]#.^R3PJ27T+">TM+9LP[8MQW!P
M_T7LW'&*@+W#S(5]\.!Y?'I+H?[ZVZ_Y&Y4M_!6>\S<J9/\YX5K+;UA/=#W?
M$J8E"]5&79YKYUJ[7NX8F';T]CX'H/]2]81L#>G0"X?ONUXX_/BKW_$9_17A
M^CENLGTX<_H\CAPYCD.'#N/(X<,X2AVC3A.H+YPYA?.G3^ HVYI-:UDN!.N"
M['3:%K&(C0J!OX\;%LR=AJD31V+<Z$$8/:PO1@WM8S1QS% LGC<=H4$^B(X,
M12@!VL?7CWVR-_MC?]H"X032.+9K<4B,B4)$<!"\W3VQ>+X;EWZ(B4I&>>ER
M=*S9AJU;#F#]^MU85K>:AF@-048PFT_(*32*4[+1.$60Y1,^"I"47$!#,Y>&
M?S:50SA0<LAJ0I8\Q32LRP792Q&?5&* 0V.R%3J;F%*.Y#3VT51BUQ2:9OQU
MDCS8-03L.O:/>K',93+[2X)V/,%<7FWKT4Z0AY%_+R6MC-!69R"[NEKCJ>4I
M4TBU,FVO-9YF3;^U;+F2>JTE*'1E"Z^0@;Z<;?%2&MO+" A-77#MO-QR554M
M07TYS]/8Z:A!<T8+,O3RF09\8:-YF:#A9GD%SA1'-NS4 H#"Q@4 QHO&_?I<
M$"YO=Z:F^$RK02HEP)2W37 M;[7 6L L+[0K8,MC+="P@*VE388F^#;CL[M
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MQXXD $]B0S&/#UX0&^\L;-RX#/OVKF6GOPTGCNW!R6,'J$,X=4PAXR=QG(;
MCJTT:AL*>/]\X.LW ?/F#R)@:\JN_EBTA+#OWH_ W)=_PP'HD/ A""-<AT4-
M07#X  2&]:7Z4/T,< O$O?UT38+S@>8<L^;TQL1)[V/HL']"O_[_@!$C/L+"
M^0JK#T=Y23'JJNI05E#%^U"(%';XJ8GEA&]V .R(,PF]V6S\,XR!J@:MB U1
M*1N")AK?6["V<Q>6KUC'AU>@S(>"WXU6@YG(SEN-:!=<)Z1)"E^3"-:4]BF9
M61R!.E[K7,81DJ5D-L;YA,BE33L(\'NQK'DK8;0-J320XVE()-" T%1=R93>
MW.L-O7D[WP78@F0'D)7P3, KP%9&[@YV.NT&OI7X3-(8;1M&;J?UTDL +07J
MSGGD(78\X@Y@VVS?CDSB,<KQE+>91D;;^DS)R@K,F.D.0O%:%%>LI]&_'B5<
M"K(+R]88B'; N5M%1H)LO8'DYQ+W"<+M>' [=9@\V J)*V #EY>U@L],@WDY
MDLJR3V79IK'S2,NL9B=;C?**1JQ9O0D']QS"F4-'<7K/'AS;W(E][2NQ=6DU
MUI44H2T[ \UIR6A(34)#1BJ:"W+05)R'BIPTI!&ZHR*#V#&%\5[%\MXE(#HU
M'F$),0B,B41 3 1"XF-X/Y.1F9/-=J4 M145:&]NQHXMFW'BZ"%<OGB68',9
M-V]H>JY+!K _O7D3]^[<PY-'3_'DX7-<N7@#'6T;$!^5@!F3)V'HP-X8W/]]
MC!G9%U,F*(QS,*9,'H@I4P9C[CS-#K"(G48R6MOKL6W')NS>LYO@> ![]Q_#
MX6,7<.'B%[A]]RF!@A J(/TU0?O'7QK ?DEXUM1"WQ'V'*C6LEO?\[,?"!\_
M$@2E[S7MUW\98#OZ@=<B_=AC3F4KA<4ZX<96 CCGLS\"["X93[OUOG-=V=2U
MM+"M9'#R/E^]>MUD7=ZP<3-6K=F(E03LIA8:DJW;T+YF#S9N.HH]^R[B])G;
MN''S,6[?>8%[]Z1G^/+^8WSUY4-"F[*+/\"SIP\(UP_P_)G6'W))F/Z&<$T]
M?Z'R?X*GSQ]SJ?#QIW@A;_9WW^+E]Z\-Z%V[=1M;=^Y'XXH.-*XD9!-.MNP\
MA3V'KQ.N;^/PF?LX3) ^2*C>3\C>1QTX3;@^]Q G+SW!J4N/</("P?/(=:QH
MWV6&N00%I['-3T)D1#;2"=JEQ4UHH &W=<MA7+E\VP#V]V8ZLU_AQ0N!I^9_
M?L'K<[S8 FP+TC9<62]%3)ESGVOT@N!;'FIYK97Y6X"M?7JA\>BQDI-I/NO'
MN'/W(:4D90J[?T;@UM_1^062_\*E8%(OA+C\05YKP?6_<?EO>/KBU[AUYRD.
MG[B&U>OWHJZ!!EI=!S2/<LO*K83I7?QM1W%@_P7S$F'3IOT$[:.X>/$S_BV-
MDW_-O^=,N>5D N<Z?Z?T@H#]PN5%C%7W&&L'?@7/KC#=4ZX>ZK]4]MQVJ?/\
M4F'QO_F]*9-7KW]M$M'=_/0.SIZYB&-'"- $[!/'CN/TR1,X(Z\UEY?/G<&5
M\Z=QXM ^K%_5@M+<#,2$!,#/8Q%\/1::J;-\/1=@\8(9F#5U#"80L 76HX?T
MP;CA S![RG@$>;LA.2Z:=@C;M\@H^/H&P-W#A_UK$,*C8I&<DLHV-AEQT6SS
M?'VP:/Y"S)N]@.<.1G9&$9H:.@@=N[!*4V[5KD%>SE(DR6,LC[6 F/ A;W%L
M7![BX@G8!.NTC&*VT33V"3DI&80@@D\<@3<QI109V37L2QK89]"8)[AJ.Y[G
MB(G14*P\ H/"9WG.Y!)S?$(R#=3D<HH00YB)4_(@ ]C+N(_K@FX#WPX RBN>
ME**IC#0VMH+0YB0E*R,@*[3;AG?+P]S8M E-S9M9WPBHRP7%&GLI*-&\RX1K
M@G&A0L(K6HW76CE:I#*"MET78-?R7$J(*M42M@7>A:5Z@4 @S"80=N6 R2M4
MTB]!IL)0Y7US/&Z20ED="43E;6LV(=(*Y;5#W@3*^JX\P )JC:U6F+<RAIM0
M[QZ ;;.%VZ6D\RNT7%,LZ3OR7@NTFU?21E$B-)Y3'DA!D0TQMF!G(<^&&0N^
M!;PZS@"VQDH3DG-,$C*!M<+AG1<(3HBNU(SBXC9>YSK4+>WD=="&('3K6'U7
MGNQ,7J]RTJ13!K#U6WC=FBI*"6=3TZL(V)6$W4ID9?(>4SE9E<C/J489;;AE
M&D=?1;!,+T"(=Q#F39F%R:/&8>S0$1@Q<# &].Z-7N^_C[Z]/L;$L>,0&AR*
MJHH:@O4ZK&1;757)\L_G?>/?2$IB'4PH,R'IZ;0CLPAEV;*U"&,IK(=)K).)
MM!,3E:@OOA01D7GLPS,0&I;%LBHE1*Y@&:N>;3+U*"U=X.6$=DO6D]WS!8:V
M7?=9V6W!M+YKI6WMU_T29 N@!<X&0']"%J9=Y0K!!JY[P*_ 675#$&UEX+I+
MVM;G-CQ<Y]%Y7<'=GE>R?\O^/7U'7F+CL>8Y"BL%U[0Y:2\:6]%$72HBD[8B
M)7 VSPPA.I_U1"J@BKA=S/V%]O?:OT\5\_N%"A67QSJ#=36-]S25=5>BO9U)
M.]G8R 6MR*%]G"/(5B0FKZ.,U_5'@%U&6[BT@^?6\,=VUH^5O,?U;%?)#&J;
M"-?)J36\_UMH<]S]+P#LO^#?+W_Y(RY?OH2.#MZTRG("=C[A)Y65.)85-P%E
MI5DT'$K1W%2.VJI<9&70& YW,Y#MY3X!'DM&P=M])(+\%'8]&2E),WG,;#YD
M5.8,:CH*<N>@NMP3C<N"J1"N>R$_:RY2$R8A+G(,8L-&$;+'(96 G95$J'91
M;C(!.\7Q:)=D+41E@0>6502@OBH(-24^*,E=A)*<12;9F<9B%V3.(61/0S8!
M.CM].C4-&6F3D99,@$\>;[S7 NRLS)G\G;-8^-,0'C&:0*V,V3_']!D_(Y2^
MAR5N"I4FB'KW(R#WYT,Z$HE)4Y&2.H,=F /8"J'V(UC[!PY$4 A!-6(XX7L<
MRVXJSSO='"_(-E[N@*$(#-*8;38BE#S9'H+KQ?*4.Z'C@2&CC'P)Y5Z$;'=/
MA9@/(VQ/(+@O9*6-,/"\J;,9!_9MIC&P%R>/*DS\,$[+(#A^#$<.[L:VK2V\
M7WD\/A11T?-Y_>.P<-$0S)W?UV0&GS>?0+R$OT^AXH3LP)"!A.M!A.S!B(CE
M[X@=C)#( 0@(Z4\(YV\+'8[0B#&(B)J T/#Q\/$=@;F$]C%CW\&@0?^ @0-_
MAM$C>\-]R0QD$8Z6U]6@H:Z>D,T&-[4(R>STD]B0I;/!R5:#H]!P=KC)J:7L
M&,KY4-2CI7T3MN\\BHV;]Z.BII4=>#&OI9"=>!6AE)UCCL8[-Q"$EQJ/M.1
M-A^>+LAV -L!:H%V3'(UHOE0R8N=7RK/M>!Z/P%^)TK82)GLDH1K"]A);' U
MUZ<RI2J12P(!VWK*->^U %FAYYFY#F1K;FF!MKS8@F +U9*3",V9TLO* 6TE
M1G- 6\=D$6 =@';@V4*U/.7ZS$H@[GJ<(+M0C4G9.@/6 FRC"FVOI>397F-
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M?Q8\/18AP,^+<.V'D"!?! 7X(BXF&N4EY6A=L1IM+>NQK([&=2&-4D)KDB"
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MEPM,N\IXK;NDJ<=<O=D"; >\'8!Z*3!\\BUA[G/LWG<<JSNV$K(WH*5E(]N
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M7E-V?OJ;+.61<01G3F7]#B-H"[+?@;;=7=P290^/C+4LV>]<N"4]05LP+;%
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M!-2Q6+=N'(\[GC*1YS")^TWA><V G]=2-G)_/I<L[-K>1&5A&P&[@T"]PXA
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M)AA9.'\LUSOP77'$S)GCL&3I'(2%^J&ZBI"]>Q<.4#G8L6,/-FWJ0,>.?;A
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M'6C;>!"%>8WP6!]&\ K#AN;M)GOXO_RKO3;US[^7U520+5=QQ2$KJ[<=LBW
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MN'B:2OXY0OSYT[A,X#[9Q4%[<RNJB@N1EYZ!C.04^'EZ8\PH1_SN-[\A8'\
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MKF6=UGW7]N;C#45M2\]#ST>0K67![OM6:TOT; 7Y$@NP=1P=UWJN.K[:1T_
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M#TB!>S2O6^&@QEU<SXTZ>ZS>:>JJIH8][X7>Y]1T)054?Z#,_0+K9KZWJD;
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M9>A7,D'EX8F-E]>IVC#U^(A,<EHZP@C3(:'*TR!=G,)U0=3U TW)7&X3DT]
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MUC4HRRM!;DH64F+B80N+0G1 *,':'V%>/@CW]D-2>#1U\$)L:MJ(CJT=:-O
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M\.+Y&[PB3+\B5+\F*+[BN;Y\J6S>;PB6@FX"]AO!M6*N[2+W_^]Y3W[@_3&
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M/H&<"K0)U&Y>'"A]E DU&0$!B7Q_HN'I%@(_CS"^BTDHSB[#%D+4_HX#.$#
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M!K )X^7EF_YG ;;DO_# _\89^[\??OP.!P[MY8-*0G"H/V+CHY"=GT' SC>
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MM8O7</+(28P,CJ&]M0_-S3UH:2&,-2A4GC8/ 3LZ*@<1X9F(BL@RH"TO=JJ
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M$7S\Y\";8+W#5_.S'X27]P.4^Z%D:)X[[X?73LW9GH5M.^>9VMDN;K-A[_
MUJR]BX#]%VRP5W;R]83?($)V 3LP9:G7"'<%DJB$4I+JD)9&^"5DIV=T4+14
MYT@H5NW#['IVTE16,7DFJ9D4>6?W 8SO/8N1T5-&>6K^EL*3E/TZ)KZ,<,W.
M/HT&A,D>K@1E$BO1F5YV&U3;Q+8N<(Y/ED*H)SCWH+YY$IV]Q]#>?015=6-F
ME,T&X 1V[J_:?IJ[+,!5\H9TPJJ6@EYYARUHEO?:@FPM+8^V!<O:3R+OM.7U
MMD!<GW\-W=I7,"UON:!>Y]2ZMMD 6F#=ASR5#*/D4PH(Y$:XC[S=>;R'632$
M;.%6FCME@^MDU7(MK$=KQQ"FCYS"C<>?,G-H7WSY=3Q# __&C6<).-=PZ-!)
M&AMCJ*)"SLZB$<(.5G56\W-HD!8U45I07*!E$_L8=N"=8S@\?A27#IW%)8+V
MT<YA#!<1F)-RT1&?B:Z$3/0D9J,O-0]]6>S<"\LP* \/P5HAX@+L+@)W9T45
M6HM+T%)4A+:28O1456)(@$TCU814]K8; _5 7RLFNQNQIYE]4FD&"I)#$1W@
M!A^WM7#?L@3.#@OA(D_VKP%;H>(>*[B^&CMV;"!@;S:0O7V' SP\-\/5;3.W
MN]%PBD %KV5D=!^.G[A@RG>=.$$X.'P&1PG<ERX_CE=>?0>??"I8_2N^DD?[
M9U&69@&J0JT)I0(:)3B[#;?_;\0&QK\-UM8^@FI;V29"$9<69,_<5[__]CO+
M<_VWVZ!]1RS(MCS<,T5P]J4&#@A:YCQ?$FH__P0??'@3K[_Q)IY][D5<O_$4
M[]%CN'#Q,9P]>P-'CES"V.A1=';L14OS'G2TCV'/T#2!]BSOZQ6<.W\#5WA/
ME2SM<;;)IY]Z!L\\\RQ>>/Y%O/;JZWCWG??P\4<?X_///B< ?D48M('U%Y]_
MP>67^.HK)>"2AU79PC^QE>7Z2-G#[R0YFRF65ULBP)8'6P!X^>(U/'[C:9[W
M%;SQYMOXX.:'^.2S3_GLOL)W/WR'[W_\ 3\0KK^_#=A???^C263WUGN?X-KC
M+V+RX&FT\ETHK^VE?N[D^TQHZY_&U/15G#K_ LY>>HG+YW#B[%-<?P;7G]1<
MZS?QS(M\_UY\%<^_\@9>>^L]O'OS(]Q4R:]/OB#@?\%V]C4^)61_1L#^-4C_
MKV0F3/^F<)^O;\LW_&SJ@!/4+5&V]2\^)V1+N/XEMVG?[]@&?F"[T?K[[]_"
MTT\_BU.G3F/__@,XL/^@J7=]Z>*CU$F/X_''GN+]?(J _12N7+J.PS3>NCH'
M4%1 @ST^'5&1"4;B8E*0$)N&K+0"5)<VH+6N W7E#<@D,(3N#L(.+W>^RP[P
M\MA"/>V&\-"=B(GV0U24+W6]-X*#O.#K0PCG.^RI:1_;N;[=#6Z>+MB^<QLB
MHZ)07%2*MK8N=!.N&VI::<.4(R.Y$+D9M'T$V$K(5T\#FL9M5F(I@GP3X+S%
MGY#CCH6+'3![WGH#U@\]LM)X'!<L6(N-&UQI*T2@,*<$72U=&!\8QM3P&/8-
M#&*XHQT#30W8TUJ/?0+K0?9;_:WLPUHQU=/!92_V]P]BHGN ^W71(*Y"8E@*
M?+V"X>'D!T?['5A!H)X]9Y4!["7+':B#(Z@[*PDGW32ZE6Q,P&LK>61 ^7;R
M,7D!!=@VJ3/SA0V<$E25%5LEL8QG5@.W!HX)$33FY=464,MS*YVK[?I>X>::
MOZUC:UV)S*2G]7N)0%U (!BP %OP(%@06,@C*1BRO) "!PLP)((' 79E%2'%
M2FQ6-H"R4H*QR=S=BQ+J;%O"L5X"\Q A:8P011W>M9_0-F4 6V'B5D9TB3)7
M*R.ZS:NO)*JV*B6";%NU$@*CRE 1$E776YYZ':=_X B&1TZ8J6E-U-4ZISS7
M^?F$!$UKH^UA\U[G("0TTS@&!-A1T?D&L-W<0V"WS GWWF=GX/KW?YR-/_YE
M'L%Z/OY\SWS\Y9YY!.SYN.^AQ6Q+RS!G_@JVK^6$[*68.W\95J[:!/O-+MA$
M<%Z]:H.!ZV7+5K$MKL.&#9OYW5;8\[OU:^VQEM^O7[T1'LX>2$],QQ !^\SQ
MLSAU[ Q&]DS09B>L%=?P^57P650COZ@!I14=O#>\YY7=U.^U?)=R:6NFTX[/
M0X;F\Q.,U:XT)SHQ65&)%-H/@FP;8-<B62'<M"]4)48)T#2(K\S@*N&F&MBZ
MG[K/NK>:8ZVVJ:@ #8CT#QPVI=(T\*'G8$JDT?93.3 ES1.(6IY>M2NU)P&L
M/,1J.VI3&JR9Z;D6W%IP+6^U)3/A6@G-M(_ 6,?4L74>P;J65AO6.71,M57K
M_!9<6S!MB;;/A&OK]_J=?J]CZWK5]O5W"9ZUCP%F'E?KVM<ZGT3K/\/U[?=#
M^PJPR]BN2]G&BWG>$GVF:$"LEFVWH;H7#54]J"MK(TPWHK:T$:VU[>AK[\=@
MUZ 9_,M.RR1[1)-M4M':U(0#$Q,X3]"^=N8L;IP\@QN'R1-3AW!M; H7!_;B
M:',_1DJ:T$3[KR26@!U+T$XL0$%&.?O0*N2J1K;F71.@TW*ZC*ATET [.:L=
MR9FV\K@"[<S<3N05:C!!D-UMO-?9F?7H;!O#,T^]C+__PP#;?+#]^^KK+W#V
M_&D^M JD92830%*1EIW""TU">D$Z"BKYQU44(KLPFW]4&A]@)CN  @)8%;K;
MFS'0S1M*8[2KK0G-]36HKZ8"J2AAIU6,QL8:&HW].')T$@>G1S$PI/K%-6AJ
M5J>M;)2)" [VQ\Z=7GSA=J.HD 9R6Z.1UJ9J0GP5FAI*4%66A:*\!!K<4<C)
M"J4![HO8:$\"IBO!U0N%N<$$^SA4%D=2B6TG7&]"<, *!/G9<;D$(83AX(#Y
MA,\%?-A+"+T"ZQ54M,MY'#O$4Y()U^F)*PG4JY&7L@;%F1M1EKT9)92<% (=
MX3PD8"X"?&93R<TGS"[A^97TS,[ =0)_GY)$2$Y=-P.RU_"[E=S'!LF"ZX38
M];R&U81S.QYK(17X @3Z+>+Q;%[LU*3-2$NVYS6M,1 =$6H#:4NT3?/,Y9V/
M(*@;X7IXR%+;-86I9C>!GN>)CUIGP%H2QW7-78^)W,!SK^!YY4570C3-RUY-
MX%Y%HX'@K;#QT"U(3_,QWNP]@PTX?G2,QN 1&C&$; +VHY>.$KJ5$.TP+E\Z
MB+-G]N+0P6ZTMN8B,7$[@6(I'+<^0N-C/@("ER,B:BVB8GG<R.78';((_KOG
M$;1M2=!V$+)5SLMSQ[UPWW8WY5Y^?@@[?>9BA[>2IZEDETJ"S8:#XP,$['NQ
MT>$A;-^UEAU>*.H;RGC>5G;>5,8YM;SW-4A.8H><U("4%-6N5"(1PA^5?IHZ
M9W;H202_%$)V(0T& ;7 >FC/<3."K%%SA2C%)VD45:.E&CUEY\X7T^:YUOR/
M)G;VMF1G&;D$8H&V@6MNR^1WQC-=CV3"M>:$5->/H:OO& :&SZ*SYR@J:T:0
MF=/*X]<:R):W.XW'5((V@;5$=;8%NX)>*U1<GF8!L<!8@"RPML+&9WJS!==:
M"J:UCQ52;GFMK:7VDW?<\E[K7-;Y##SS? +JW.(NOO^=R*&1I'5=2SX-HGQV
MS"J3ELO[F*UD+EG5YKXF)BL,JX0=80WJ&GHP/C&-BS1XGWO^);SZVNMX\:77
M\,RS+^':M2=Q\. )M+3T(C>W LG)^4A(S$524B%4:S4WIP[%/'8YSU6ND,32
M=B[;:;#VL ,?QXG)4[AVY"(>W7<<Q]J&,%'2B)&<2@RF%Z$O)=\&V!F%Z,\K
M07])!?HJ:LS<:P%VCR"[DGU,22E:"@L-9'>6EV&@KM8&V-T$[![!=1NE'8>'
M.G!X3P>-UA8,-9>A*B<>\32T=[JL-B'C3IL7P-EQ(=Q=5'/>CF"]C$L* 7O;
MMM78N6,==GEOA/=.>WA[.V#'SBUP=]\$%Y>-\-KFBHC(</:)U6R+^W'BY"53
MPNLP 7O__F,$QC.\5T_CS;=N&O 14 M4;6)Y@FT9N@4S*HLT$X)_2V8"\&]]
M+['@^'\'V!9D_QJPK=^:K./?VVHB_Q9@_^_D&_Z]FE-NJY/].;[XZG,N/\.'
MMV[AM=??PE-//X^KUYX@,#^#)YY\F=#\"BZ<?Q)3DZ?1VS-I(+NU91A]O9,8
M'S^*HT?EK7X,3S[Q+)Y__F6\2J@6X,J#_.&'M_ QH?G33S_]6032EGSQ!:&;
MY_^2U_$98?CCCS_&1[<DGYKP;\F'-S\V2<S>?>>FF6^MI3X+KF]^\#'>>O,]
MO/+R&T;>?NM]?O<AX?H6;GWT$:'V,WSSW5>$ZF_QPT^$RQ]YWW[D,U9H.*'S
MK?<_P6,T#@X</H^.GG'V!P27\G94U VBL_<0]AV\0J!^!J<O/,_ETSA)N#Y_
MY7D\]O3K!.KW\/(;[^.EU]_A\AV\\>X'^."C3W#K4X+U9U^:FN,&L#]1'6I;
M:/AOP?1OR?\$U+\2#9+<F8_.;4:T;A/+PV^;MRX(_P'??_=7_/C#OQ&P_V8&
M*5YXX16<.W>1NN8PIJ>5#^0"H?II,Y_]Z:=>,,_S.ON4BQ>N$JY/HJ=[$ 7Y
MY33DDZG38A$9D<#U5,)V)I+BLY"2D(.<]!(4L<\HT,!>8B9A.A*^WC[81LC>
MSO?2>Z<K?'S=X1_@!3^*ECY^'M1-+G#WV@)G=WML=7. D[LSW'9X(B@\C'UI
M(1J:VVGK]**FIIG]&&&!YTI.R$-N5@4JB@E7I32P<^N0')T#WVVA<-C@1;!Q
MQ(*%FP@_&PE":_'@(RL,[,X77*]W05! ),H**XW'_?B!PSAYX!"F1\<PUMV%
M_L9Z##2R[^ILPO2>+AP=[3&0O:^G!7N[VC'6T8G!Y@ZT44^69Y<B.2(- =O#
MX;[5'XZ;=V'C.B\L7F3+3KYPZ28X>P10/Q4;,)*W51"C,E4*Y<TDZ BR)8)(
M:]ZUO-;9!$+-&<[/[S!>6$&J(+M "3SS">74,\74'RJ3)2FCCBE2[A&! ?6=
MYFUG9C48D<=:<[BUOX!<7G E,#)"2+# V8(& 84\D )L08;@0M\+1BP@L2"[
M0@/6E02&\@$SU[E0ACBO5X"MNMBUU-%U=:.HKY>7>A1-+2K3-&'@6C:#<K7(
M7A!8R_NN*6:6YUT# [I'-KC67'2%M]M@6UY30;;->ZJY[.WF.'W]A[%G^ 1Z
M>P^;.MS*8JX(@$SE,DFI--YK@;4D4G6C8PO-^BZ?.&QV\#'MYNY[%QNX_OT?
M9Q&PYQBPONO>^3:X?G A'B)0SYJ[S ;7<Y;@X4<68L[<Q5B^8ATAV@E;MKA@
M(X%Z^;*56+1P"2%[Y6W =L+Z#5NP8N4Z?K<&JU>LA3/WC8N*1TM]*\:')S T
M,(K&AG:4EM0@)Z><0%I*&.8[E5G!]Z&!]Y\PUD@X))!)KRO965IJN:WF<0[M
M)(H 6QYLE5Q-T)SL5 (VH=; M;S':FNZCQ0-P,A6T_VSYNFKA%JR<KXDEIK[
MJVUZ-GIF&L304@,ZMC9;<QNN;?/RU2:LD&RK1K7:BT#8\ERK70E(!9]6V2Y!
M=5?/(5.&2^O6O&MYKG4<'5/M4Q"K8UDP;\&T!<?ZWKH. ?1,N-8QK#9LK>O:
M]%OK]_JMCFO!M078^E[[SOR-]M7YM?_,:]&YM8_^/BU+*464/-ZS7/Y.4B@(
MK^HS@T/UM;P/*M-7W4W^HIU;UH+:BA:T-G2COWL8/9T#*"NI0D)\"MMO')]O
M!KFP'-T=[9@<'L&)??MQ:3_AFH!]8^(@KHT0LOO&<;QE "/E+6AF^RE+RD,A
M;<+"E +DIQ4AEW9A-I]#IO%2=]'V%F03L G7283KI PE%VYE>U'(N"V!<%ZA
M/-FT7VE?9V74D2]'_U& +>%_,SS87])8.$? KJFK9 -*Y46G\:)3D9)-V"[(
M0&XYE4)I+L$B#4EI"6QH!-V"+-37E*.3(-Q#R.[I:.$-;><-;44+H;JZLA15
ME<4$GWI,[-M#@_$@IH_LQ> >*9U:=BB5["1S^")$P<]O)[9O=T<(03LO-P-M
MK0T8Z.M$3U<+CU6)&@)^-:^AMC(/==4YJ"Q/0T%N%$'4C[#H147I30!/X/E+
MT==1A-*"<,2$;X7_KN6F5)7"H\,)K[O]"'N^L[F^P$!U0NQRQ,4N(P O(VPO
M(]2N0D[:.A1D;D!QUB94YCNBKM@5=25NJ,AW0@ZA.3%Z!:+#; G4XJ)746&N
M0T;J1F2E;T!FVGH>0_.P5_/:"'])"D-?2]B5UYE03#"6MSDAAK!.$?1&A:U&
ME+)J!Z_@=2XUUQD3L8H=UQI$A\O[3) .66ZV)1":$PC@^BXJ3-YI?L?]PX((
MUD;L"-[+S3[IR0[(3'%$:H*] >OH\#6(C5Q'Z-[,Z['GOJMX+S3XP'.$KD=4
MQ":$AJQ'@/\J^.Q:9D2)Y1(2ME-!QM,PK<6Q(Z.X<NF(\6!K>?GB85RZ,,WE
M-#\3H"[LQ\$#W>QDLQ ?MXW/=#E<7.>9D''_ #N$1?!<42L1'KD,(6&+$1C,
M[8H*")B-7;=K9GMLNX=&R]V$ZOOA[3.+V^>:K.2^?@NI2.;#<]ML;'5Y@(!]
M#QR<'N$^&]@AAZ"JJH20UH:ZV@Z^1+5\H4OY7$NY%+15$]:D[.39EF>UF&VX
MG!U-&Q7E!(9'3F)@\*@9C99B5'9.4QM1X6[IM03F!L(NX5'@2[BV 78S7VAY
ML.5M;N4[P^V"8Y7P(E@GI2A!1QUR"-=5M2/L>*?1TW\,'=W3?,]&^<)WFJ0-
M22J[D4;AOLE\\5,RZI%*PT)P;7FP+1'XRKLM&+82E2DLW/)J"["UM.!Y)DA;
M8LV[E@C4K;G7"D,75 NR)?JL[?GZCD"=5=!ADDAD*HD$]U,2MGPJM7P:$WF%
MK<@MH+&5WT#%5\6_O0@)21H\*V>GWL%W?@K'3UXD #V))Y\BT+SPDBF5].13
MSQ$B+Z*G9YCO?3EB8M+9"6>8I'5)?$9I!'7-F\KE,RFD$BCF.>494&AB&:6^
MN@?]["@/#A[$A8D3N#9Q')<'>*[&/NPMJL-@9@GZT@K0EUED +NOL P]I97H
M(53W$K+[:FK14U&%#@)V:V$16F@4MY=RO^HJC+8T&@_V@5Z%B'=B>I &ZW /
M3HSWX?2^01P?[3;>[+*T:(3O<H*[PS)LV3 /6S;-@\M6A8HOA;N;'3PHGN[+
M"=BK"-AKL7/G>BXW$+ %V9O-O&Q7U_5P<MH #T\7A(:&T0 MHY$U@NG#IW#R
MU 4</W$>1X^I-O)E,V_X30*9:A,KU%K ^L./?^-2D&UY@>\ ]K\G%OQ*9H+R
MK]=_Z[<S1?O,_,U,R+X#UQH0L #[3HCX_ZD8R)8W6^?[YBO"]I>4+PB 7Y@Y
MRV^\^0Z>5<CSDX2LIU[!L\^JG-<;N'+E64P?NH#^OBE"]A#:6O9@8& _#APX
M;6I-WU!"N>=>PFNOO85WWOF \/L1/I8W^A-EN18\?V+DDT\$W)\8H/[\\T\)
MV1(!-[_[^"/<4@FM#S\Q<'WKPT]-Z:TW"+$61+_\TNMX[=6W#$Q_\/Y'!K+-
M\OV/#73KM[<^^AB?\'@://CV^Z\)U]_AQ[_^2/FK><9?\_FJ-O6-)U\B7)\C
M7$^@ID&>ZS:4U?2@O?<@IJ8?-7!]_,Q3.';J":X_@0L&KM_ "Z^\CU??_!"O
MOWW39!]_AT#__L<?$ZX_)UQ_@8\)UY9\JKGE!&QE0/]?A8;_#,XS(/O?DR\,
M0//W@G8"M,0<WVS[Y;KFK'_W[1VX%HR__=8'N'[]29PX?@9'CYPD:%\RGNKG
M^=P5$?#<LR_CB<>?Q87S5W%@_S%T=@R@L*#" '5(< S"0N*H]U.IFS()V-G4
M^03>^#RD)Q4A,[6$^K*(^CP+,5&)A/%(ZK]@! 4%P,]_)W;N(E!3=OEO@_]N
M;P0$>\,G<#NV[7*'LZ<C-KMNALMV#P1&A2.SL! US2UH:.M$18U"3TL0GY"-
MN+ALJ%11?FX5"O-HK*<640_'P\/9&^M7.6#YT@U8NF03%BVVQZQYZPE$RPE,
MB_#0PW98M]8)P8&1J""\[-TSCC.'C^'2R=,XM?\ )GIZT%-?@Z[J"HRT-N+
M8">.C??CZ%@?^\9.[.UIPY[V5G36$G)R2Y#*>Q#J$P$?KV!X>X3"PR4(&]9M
MP\(%]GAD%N%ZB3UUJP]"(M.HO^K,G%8!C.!0H)>1*>^D+4.XK<REP%' TVR
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M?/0IY1.*YI";\/#_&&#_>K__27BLGX]Y6S[CWR2QM@NDO_F:;85P_</W_V8
M6T"N>Z8R9N?/7<'I4Q>,A_K&]:=Q[=H3N,Q^Y-%''S.#)9<OWS#333H(U_)<
MQQ"N0PG68:$)!.=4),1G4;*IZ[*1$)N+)-5T3B9<L[_)8+^3DI1+^,X@#-,N
M24A"7$(\PB-#X1?H Q]_@;4?@B-V$SYW(S#4#]X!.^"ZW16.GENQ8[<ODO.R
M4=/:BJ:N'I37J?\N1C2/%QZ=QF/E(".=Y\H@<,=EP7=7*!PVN6#YDC58O& 9
M[!8K+'<3EBRU-Z'A=]VST-0E7KIT/?Q\0E!17(5]PWMQ_OA)7#Q^ F>GIW%H
M>!A#S4WH)%SW-]1@JD]P/6CD,/NKJ8$>#!&NFZNJ4)">C9C@:()U #R<O.'N
MY M/UR X.?KQO,Z8-7LMYBW8B$T.^CN3D))>QKY=<U+KV!<3>HS7M9J?;9YE
M"ZXS;\.UPID%SB7%-B]P>3FAH((ZJ&R VVV)PQ0V+N^V +RL3( ]8#RU^BS/
M=WHZ]1MU8P;UJ!5B;@O3UO%L0%QR&[(%"18@2"Q@L&!!(") L>0.J-CFU983
M[I7\*"]/"; 47DSX(6#KVFMK1VB'3J&[^S!Z>X\0?)6(S ;4$H&V-0=;'E(!
MLN7-GPG7LBFLN>.V<'?"/\4&V[I_=_85,"K!6R=!;6!0<[(/&1#4L94\3B'A
M2LAJ>:_CXHL0%)P"ARV[^.S6X ]_G(-_^=>'C/SN]P_A]W]\&'_ZRRS\Y>ZY
M!K ?>F0IYB]2UO UF#MO&1YZF-#]X!S,F4O 7KX*&S?8PWZ3 ]:L6H,%\Q?@
MD8<>QBQ"]H(%BS&?4#V+(/[(['G\[2(L7;(,Z]:LIWYS1U!@,.)CDY"6FLGV
MG<OV4&@ 6S9 >G8E[:4:9.8UT%Z@OB[O1 ,ANZUU#.VJ%=ZXAS!&^X/?FR1G
M<FH(JC4 8;*(4VX#MFT>=BU!JHZ,HGNI^?&V:0JZI[J'ND^6!UN K?LE+[_6
M=<^5F5Y>;(7Y-_#9"1(%JFH;FB<MN%98M[S&:D^":WFO9T9#Z#MYIK6?H/K_
MQ',ML-8QU$[UV0)BJPT;>X;;U&8M[[7:K-8MN#9MEF( F&)YKBVQCC43Y&<>
M4TMK/YW/>E]FOC\69!NXYGZR\V2#)O,>),LNU: :MRERL>1V!8!:4ZYN&(W*
MG$_(+BMKX_O<P';;B-JZ;O02F(=&#J"E<X#V9B52,[)IS^6@I* (K35UV-?3
MC[-[I_#HOH.X-+(/Y_I&<+9W&*>Z]^ (^_'QNC9T%%:@(C4'^7%IR(DC:*N\
M84H-\C)X3[/9KRC)648KVP[A.MWFO4XC? NP4[/X-_#]SF9_DJF,Y.FUZ)0'
M^[\*L+_^Y@M<N'B6-Z.2%YC(BTGAC<A%:6T)*@3"M:4HJ2Y!:74Q*FI*^> K
M##@/LC,?'>['Z% OQKB<VCN,Z0,3.')H$I,35/J$[J:F&C0WU[*S:$%/K\)Q
M&]#47,V.HX(/I8J=51U:%0Y.:6FN0S.AO9WKO=UMZ&I7K6T5'$]!6DHL4A,C
MD9P0BH2XW81C7\+U3H0$*;F(!R'1CS<ZADHH!<5YL4B,]8;_KO78[KX(N[8O
M(5S;40AU_@L11EB+BEB"F.BE5'3+D:2P[I0UA..UR$E;8R2/L%V2O0F5A.S:
M$E>*&ZJ+75%1X(J2/!<4YCBC*,^5T.^%VHJ=J*_RYKD]D)NQF4"]DL"\ LFQ
MJTT-;M7?3DO80/!=AZ08BL*WHPC>7$^+%PQO,>"<J/G1(:L0'K@<(2JSM6LA
M@GP6(2Q@&>(CM*\#,A*W("76WGR.$S!';3220(B6)$9MX/$W(CEFDQ%]UG[1
M(03R,/XFDG >L9'0OA:ANP7=W#?!">FI;DA)=D%<[&8:(ZL)V7:$XR78L7,1
MO'<M)V2[4'%&8Z"_"D>.#-+0F<2%<P=P[LQ^G#U]@.OR8BML_"B-GX,X=*"?
MQFP)&WXHPD*V$B:6$R[F8Z>WK827C]\"^ 4(K)<@)-3.0'<0@=O/?YX!ZQW>
M#QFOMG_@/ 2%+.0^BQ$<LIB@3<@.6 !OW_GPW#X7CDX/$;+G\+B;V*F&4)'G
M4A&7\R6O0A%?RISL4BIM0G92 >+C\PC817SY:]GN!K%G^(A),*+,H%)^ZI0E
MME%E&@TR(BB9A%D!M@UV;6( FR^M1"'AZ9DJ!Z)ZFS)&",O)U<:0:&@<1U^?
ME.41*L\]QLC0'#5]G\P.(I4P;D20S1=?7FSCR;X-TQ98:YOF@"?0P)%(T0BT
M+8^V"=FFF'G3-$ LD-9GZ_M?0_2OQ=K/!M:V;3GR+-#(R:+Q).^U\:3S7NC>
MY- @R,W74D:8,CR6\^\OX;H\UZWH9\<Z??@LSIQ1(JEKN'CQ!@WA)_#88\]R
M^20.39]":TN?F7,M[TYT#(W>Q"+"M4IU*(R_@J)1?I774"0![S'ONSSIFJLN
MI9!+@Z:8!F!;51<.#>S'58+4DT<NX,E#9W!E[) 9!=U34H,>A8@756"XHA;#
MU7784U6+H<IJ#)17H:^L$KVE%>@IJT!O926&ZC0'N\5DW#TRU(?CHX,XN7>(
ML@>G)H9P9M\>G-TWA!.C?=C7V8C&P@PDA?K VWT#7!R6P67+4K@X+H6;LQW<
M79;!TVT%O#Q6$K)789N79#5V;%\/[YU*>F9O0L8]/=9CZ]:U<'!8#R="]JY=
MO@2!1!J!O*Y>GF=R"D>/'L.)$Z=P\N097+APV23X>N^]FU#IH^^_^Q'?RL/[
M%8&9L&/J4QN@E5?[MP';6I\)Q188_]_(S./J\\SC:-LO(?NWP?G_5+ZE?/.=
M$KS9YF(K&9@2N=GJ9'^.#VY^@G??_P3OO/,17G_C)EYXX2W<N$'H/'45DY,G
M,# PA2[":7?W&-?W8=^^(SA^_#PA_'$\]=2+!M!??^-=X\U^_P."ML#9B&I1
M*X3;)A]];).//[$M/[PEK_1'QBLM[[5"P 73\EQ+Y&&5"+KUG<+%!=9*A*9L
MXQHDT/W2X(%M[K7D>T*VPL/_AL\__PZOO?X!SIR_@;Z!2>IAA1:VH:EM&'OW
MG\6Y*\_AVI-OXM+U5W#\[!,X=.Q1G#K[.!Y[BN=][>9MS_6'>/?FQ[CYT6?X
M\&.* /O33PG8GQ+>Y:W_#)]\\KF9)R[H-1 LK_.O0/D_"MCZ.V?"M):??J+:
MX9J;KOGM;"]?*2S\;_CIQ[\;N%:8^'OOWL*33SR'LV<OX>2)<\9#_=ACS^ Z
M ?O(X=,8&AS'V-@4CAT]@\/\W-<W!LT!C2?8AH;$(RR,<!V=;J V(8%P3<".
M8U\3%Y-#F!9@ER.;QGUV>B4RTJ0K-,V)[W1*.OLA@3&/$1F&X+!@A$2$(#0J
ME( =#/\0/^STWP[WG1YPV^6)W=%AR"TO17UG)VI:VI%=7('8Y&R$1:<B+"H-
M,8+Z! )29 JV;PO$VC4.6$2P7CA?Y9"45&H5X5KPLPKW/; $]]PSG]^MAJ>[
M#_*SBS Z,(RS1X[C\LF3.'U@/Z:']V"BIQLC[2T8[6@A3'<3K/?@.&VO:?99
M4T,#&.OI10N-V.R4# 3Y!<'+=0?[I)W8YN'//BD0#IMW8/F*K9B_<!.6VFTU
MH<:^_HE0Z:.,K&H:I9K+K+!;0@_[8@T\9[+/U8!G.G62O,VF%!?U@\+ +;!6
MB'55U;"1TM(!ZEQE\"4 <#]!L[S2%CAKOK.VR6,MN+8 .S>'1O\,P!:,5U:I
M=-<=3YQT@,!%,A,0!"("' NN+5"Q08H-4.05+^(UYQ*PLY1D-$=@(,_Z@ D-
MMP"[K^\H>ON.&"AK)H1I,%ZBN=>":ULR,X6V*ZS=%@HNL>!:7FU+%-)L0:'$
M%A9O>;P5=M_,/K^7]O ^GE/SA@_Q7"-F>UQ\B9F#;0L1SR4T%M F2L46QUUX
M>-8J_.L?'L$__^[!V_( /S^(/_Q)D#T;=]T[SP#VPD5KL&S9!LIZ+%J\ O/F
M+<%\MK]E=BO9'M<;6;E\!=OC8K:]!5BX8 'W6T)9B@6+EF#!PL5F?9G=,JQ9
M22A?OP%;[+<0M#WAYQ.(R(@XVC;9;#/%R%#.@1R^5P6$ZR("'T6)R$J*6U!9
MT6424'9W3:*S8X+L,<![09 C',<GEAG -EF]!=<*$3=P3?N'-E 2)4V#.K1!
M=-]U;W3O-1!O&PBJ,%&(<I1H($*>?X77)R:5F7T%V;+Y:NJ&V YL<_@%M )C
MB=J+X%(.%BLL7)_5=M2.K(SA\E8+K&?"M:!;W^L8%M"J7:J="F9U' M@+=BU
MMEO>:YW#:K-JPQ9<6V"M_:S?2RQ0_ZWSZ+?6P))^:^VG?;2TUF?^SCJFMFD@
M0P,<RN NNU-VJ&SA/.ZK_318)<]_0],(&IM'4:?(A!J]FWHOZ_C,&U'7V(^N
MOGWHH;YM:=??U\QWI@K%A63)TDKTMW3@B 8.]^['F>%Q'.\=Q/'N?LJ D>GV
M7D)V"[H)Y_69^2A+RB9HYR(W0;7[:U&4R7<_F^?+I'U*R$[+H(VM*D+9G0:P
M4S);C(V>J?Z%MGDZ_X[VUA$\\]1+_SC _A\SZV!_^Q4N7CKW"\ N*,U#:4T)
M2BCYY?G&@UU*R*YOKF&#:L'04 \FV)GOWS>"J8EA3!*NI]BQ'YV>PH6S)W">
M<F#_7G90;0:P6]L:V$$UHZM;R; (V03I+GXWL6\4)TX>H1%^ D>/',#HR""Z
M.UO0)MANK$$CKZFJO,A =D),",*#O1$4Z(G@W>X4#_C[.F/G=@?L\-H,OUW.
MB K;11 /)F#[(LA_"[:Y+86[\UR"]CSX>1/F=B\S<YHCP^T0I;G3MP$[-860
MG4Q)6D'878ZLI)7(35V-PJP-*,O=C/)\1\*V,ZJ*W%!>X$:(=T%QKBM*"]Q1
M7;H==17>J"1LYV<Z&J]U<LQJ O$Z4V\[)]4!N6E;J.0$R)N0&K>>WZ\A*!.^
M^3DGU9&R%1DJ,498C@U=BS#_90C8,1_^V^<AV&>)V98:ZX"TN"W<9Q,_$Y8)
MS,G1F[G-T6Q/C=W"SYNX?0TB=Z] !"4J:)7YK?:/#=^ ^,A-E,V(BZ!$.B I
M=BM2DUP,8*>EN-#@V(SHR'4(#UN%H*!E!-<%\/#D_=NQ!!$1CE2BD31,*VGL
M#^+<63[K<P=Q\?QA ]B22Q<T+_N8"1T_?FR40%Z+LI(X&CAN\/%9#J]MFDO]
M,.41;-L^AQ"_&"%*QA:QFLIC)17&4@0$SB=HSX%_P%SL#EZ T+!%" U?A.#0
MA0C8S>\"YG.YA,NEYGA;'!^&_>;9/":/$>[-3C2%,%O&]ES-CIR@751.0R"/
MAE46LC)+T-C8@^'A0Q@9/<:VN-<H/77&$LW+R3+S@1I-!Y[-#CF38GF2?PW8
MILR6YD_3(##@G*(LYC6FK(;"WQ1:UM%Q$ T-8V:47B%PVD\U+2468)O/[+PT
M.JM.3 #]:U$'%Z]2'4E40EP*O@78"NW6T@HAEUBAWM9VB15J;HDUUWHF7%N
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MMBU,_)MOO\3%*^?0U%+/SB>?1BL54%J<2>#AZ+D%3MMIZ/E[("C2'[%)$32
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M]KX9_KZ;X2?ANI_O%OCY.])XW\+WS!Z>.S;!:X>]D6T[';!MAR-V[')!6'@
MVVHVVU<'X7 21XX<,4G/+EZX8NH!O_K*6R:T5LG.E.1,8"O/J%6V:R;PFN^X
M;D&TO-<S0=F2F1#][XFUO\XS\UQWSOF?,0=;<$TH^UH)W>X MN7%E@?[D\^^
M,DO-R=; P:V//L.KK[^-QY]XUG@_E6CO^HUG<?7:<SAW_@D</GR)8'T2HV-'
M,#9^Q'BR)R:/X>BQ"[AR]0GC 7_QY==YC+?PQEOOXJUW"=:$[7<$VK?EO=N
MK4SB FF!M>HY"[(%U#,!^S->G[[79ZLNMFIH*W/W9Y]_C8^YSTU"\1MO?H ;
MO,[)R>-H;B:XE+?1<.I!>]<^[-M_'A<N/X_K3[R&2]>?QXGS-RC7<>D&(?1%
M7NN;-PU<O\OC?'"+Y^&Y#%Q_RNOX[#,*(9MB\U[_UP"V+0$?G]MMP-;2!M<_
MF?7//OV6]^-SO/+RV[AV]2F<)E0?/W;.>+$?O?*$"0V_>.$Z^OO'"1@IV.S@
M@:U.VQ$2&H^X^$SJB42^0Y%\A\(1')+ /C>7QG<AX3G?!M@*#X_/X[Z4.$F!
M,?IB8XNX+*+^+Z%17D)P+") W@;LF 2^<Y'8O3N(Q]U%2-Z)P$!__B::,)B-
MB@K"?6D982 7T7%IB(A.I7W$<VG:B^:2TM"/CZ^@'BN&MW<*UJWSQ9S9F_'P
M0P3K^9NP>+$]%BW>B,5+-F#E*@<X\^\)#XZA_5%!(W20AN9^')[8A[WL6_H:
MZM!35XFQCA8<']^#\X<F<>'P%.%Z$B>FQKG?,,;Z>U!77HG8B"1XN 1BXWIO
MWB=_N'F&PM5K-]9O<<?2-1NQ;/U&.&W;@8C$1*3G\^_-S$=$3!K_UC3$1N8;
MP$Z)JT9J0@U2DZIY7VP :4!&H:(IU=!T)\V=MLV15M@W#7F!,*6P4-FY!=$*
M 5<)+!M@"ZSEG59",7FL4U.IARA:MY7)NN.Y%ECKF!*M"Z[S"PC7^;<]UP)5
MZND20JX@PH**GP&;<%/);?I.X""8$-PJ*BV'^BTO7[J^&^45!.@:32]02/C>
MVX ]03M!<\@5\CYH!LTK"4*J=:URGDIX)LA6 C+9"QHP5S).B9*_*0=+KCQ]
M2NI&G:HR9!(!GL!.)<NT7<G>!-D2JQ:X2=@EL,Q2^:XVX[GN[CF GMX#7!\V
MH*HRH\I9$I=0@(#=\=BT>1MFS5EAYES_MW^Z&__]G^_%[Q0J_B\/X ^_?PA_
M^?,LW'?O?#STD$IL\=D[;H.[ZTY"M2/LEJSBMM78M-Z!;<8+WMM\X$/9YK;-
M>*:W;+:'_<:UL-^T!DY;J9?<G6A+NV*GARMUFPN7;MCAX0$O5S>X.[F98^S:
M&8#0T#C:"'G\6RH(E#7\V^7$:"1@\SXEEQHO=G14+N)B"V@#59K!!-U;*[NW
M(-!4*N$S5M;J?-I29OJ:;!0^/TVY,X!-^\B M8%KFZ00M#1HKV=A:K,+:/D;
MZYZ7"! )@"K[9MEZMKPR2MC::."R^+8GV()KS;,65%NBS]:<:PNB_U?R:]"5
MJ#U: T,VN+;E")CIL?XU7%L ; &V:=,\EJ[7>A]F'M,:5)JYWZ\!6]_KO!+]
M5MNUC^Z#DAEF$; STVFC47*SFE#(-FW=/TW94$Z$ZMIA ]:5&I2BE%8.HJ"D
MAS:<X-96MC91D4*$V^R4,I2R';0V#F!T^("I^G#TV"D<.7H,!P\=Q/[)O9BD
M334YV(_)KBX<:._$D8X>G.H>P#GVB6<T9::Q$^-E]>C.*4<=^^L2]K>Y,03X
MN#)D)M40Y!MI5])FS:1=R&6J^AKV5_%)FM)8S/>\'T\2L/\!=;#_AP'L_S%C
M#O;7WWR)*X]>9*-I02D!MZBT@(9]''8%[(0G(=LOQ >1">%(3(^C@1Z'^$25
MU0JCX@A'"D$\,R,!1869J*TI)< T8&BHBP;+$ X1B$^?.4)CYC*>?^$9O/KJ
M:WCQQ9=QX_KC.';L. 8&^MFIU1G KJ^K1E5E&3O9#*2G):&P(!N]/6TX=^88
MGGGR.AXG8!^=WH>^GF945^4A+S>>^T4B.2F,#S^6@%V$/B51:R-@E^0@/RL1
MA3D)R$P)142P.P)]-B'(?Q-"=]LC.& =#5P[[%)&:Y]9A,C95( +J!"7L3&M
M07&!/<J+MQ!\MQC(+L[>1-"V1UG.5D*O.^I+=Z"IP@<-Y;M05;0=97F>*,WS
MXM(+)3D>W-<-!9FNR#6)R^P-9&<E:;ZU$[<[&="6)[N<D%Y5[(F*0NVO!&@;
MD9FXF5#MB>KB0!X_E" ?0(AV1]3N==B]PXZR#&%^:Q!'4$Z/=4-FG <2PYT0
M&; 1X03FF*#-A&]')$4Z(C%R"Q(BMA"T79 :ZTY0=R*HKX+SIME8O_Q>K%UV
M#S:MO@]>+O.IU-<C/<65+Y$;DGC-"J$/"ES >S,'@<%SL5L>Y% !]Q+X^MH1
M<-?RGKDB(ST8E>7IZ.ZHP=1$'R%[TLS%EC?;R%E!]A'*09P[M1?'#O5B?+@>
M'2UY*"N.05KR+H+V9GCS;_/RG(<=V^;!UV<AC9C%!.DEV!VTT$!^0, <<RU!
M00L0HE)?(2L0'+R"A@^AG/OZ!RXT);QV^<[']IWSX.$Y!ZYN<PG9"[%SYSJ"
MH"_*R[+1W%3'=LK./K^42IV2666\UU)D2E@B4;A6@:G+V6(\J0J/SB)09^=S
M&R4CMPVI!-,4=CZIZI39>4L)2*'+:ZTZEBVM^TSG)9"6 C#)%;C4G&O-O5;'
M_S-@WX9M*>=DR6W 5N;&N.1RQ-!0DV@]C8J\@!UL><T *C4/C!VH:A6:I&2W
MO<Z"XC1=FR!:GFIYG'4=@F.*.AI3VUL>:?X=630$-$AP1PBX_)L4$F[S*,M[
M3>%O-%B02.48GTC#-:F(RK.<]ZL!S:W]!).#.'E*]:Z?H#S&]7,8'Y]"5^<0
M&NM[H=K5^81V==09J77(3%-2(2H_'EOS\+()U=F\MSDTVK+SI$1UOSLI7="<
M:P&V@>R\'G[79T [EX"=RXX\DW]_&A5X:AX5:VX%4K*+^3<6(#^G&'5EM1CI
MZ,.9L0.XO/<03O>,8**B$7U91>A.ST5?3B'&RBHQ55-O /M@<S/VMS1C7TL3
M)MJ:V<FWX\! #Z;W*#1\  ?4\??W8F]/%X8[V]#?TH)VPGEM<3GRT[+XSD4@
M:-<.['#="O>MZREK:72LPW;WC01L>P*V P)\'1'@OQ6! 1(GMG=GMG57!.YV
MA5^@"WSXV3? V:S[<YN/OPL!VPD^?NX(CPR@,LV@@<?K.G  )TUF\=.4<[AT
M\1J>?>9EO/_^Q_CR2X&N %L@K?)67'XGT/T.WW[_ [[[@9#]/:'G6X'QUU!&
M[B^Y_.H;PK+D:]ORMV#ZM^3? VS;9T&]K9S8;XDMZ[E5RFOFYSNB_<S?\HU
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ME@)9';^R^I=AX7<\UG? 6LG$;.NV[?J]!=F"82N:0SD%='SKV#JG]M<V?2<
MGPG8^KV.I?WT_EB# #JF[H<\^?+^9]V6;+;I/$T)83L68)?JO>?[4UZIN>*$
M^1H-: FP1U%6.<3[*L!N16IZ(_L.ONOL1S*2*I!.6S:#MFQNEI(0MZ&K9Q03
M4T<P3<@^=.08)B<G,3:\!Z.]M+$$V%T])DS\9.\@;3<N.WMPK*43T_5MF*QJ
MP5!) UJSJU">6(*\F&)DQ98B.Z&2(%^'')X[6WT0[<QT_@WQ/&\L]ZMM[,=C
M3SZ/O_TC /MGN?WOFV^^)F!?9@-JY0,I9B,NHG&=CHC8"(1$A2 Z*0K)F4D$
MBS2DYZ320$^BD1V#N(1(OACA5&"1['05JI7*&Y[/#J<2W;TM&!WOQ_3123,'
M^ZEG'L-++[^(EU]^"<\]]QRN7+F"0X<.H)^&:EM;"]I:FU!76\V7()LO3"+!
M+1DU-148'QO"J1,*,9[&^"@[FM9Z5/ <A?EIR,U)-G"?E9&(DL)LU%67HKZZ
M#&5*T)8:@\28W50V.Q&^VP,QX=NH,'R0FN"#F @W[/9;BUT[EQ#L"'2[YB"8
MX!8;8\>7?S4*\S:AM-"!RLH1Y86.!.<M*"5<EV6[H#+/ PVEN]!>LQM=#2%H
MKPM"4Z4?C?A=A.(=!K:+LUV1G^Z,O#0GY*1LI3CQLPL*"=TY*5MN>ZK7<WTS
MBE1'.\^9P*TLXYM,8C0!>E6A#VI+ E!=Y(^RW%W(2?9 2M16Q(5L)D3;(S;(
M 7'!CH@*V P_CY7PL%\ ]TT+X.VR'+NWKT7PKG4(\I&L1UB  R*#G+#;FYWD
MQH58.O=/>/CN_P</WO7_Q9P'_@GK5MR#7=OMD!"SA>"C3.+V" ]=1L-_'@%V
M'I7N8D3'K4!,W&I$1*[BO5I)8V,EOUN/<,)]8L(N%!?&HK.]%%/[NG'R.)7_
M:97PDA=[FNM:'L;%,P1M;CM_Z@".'1[A2]2"IOILOGB^A.HU<'69#3?7A[%M
MVQSL\E$IK_D4K6O>]2PHLW@ KRDX> G"PE;2@%J+\(C5" ZU0U"(K::VRG@%
M[%:Y+S[;78L)V'.P9<LC\/):P>?KC9*B5%15Y%-A%U"I%[,#*:/BK:72LY5\
ML)5]D$% 6%7]O PEO)!'5:'@@KM.O@.M)ME&(J%8H=:J%5C.SK&M8Q)#>TX8
MR*Y@IR-#)#Z>A@H5[IWR(U:"LWHS^OI+P+YMQ/!WRIZMSB"&2B@R-A]15$0)
M*64$S 84EW>BJFZ G00[<DIE[2!*V$GF%PM$%:ZN08$&"L^119BG*".G2ELH
M&9M*BF70J!$\9UI>8RHAA<(+K+-R&[F-QH@\S69?=DXF2WHME5@Y#4]E_<[G
MMA)VSDU\UT=PX-!QG#M_A<#R%)Y^YGE<O_XX#A\^@<Y.&4@T:-@!9O!OU&AH
M-L^;S?-KF</S"ZY5)D6 +;C.I?&18[P4-,AH=.45=IMEEN;LR:.=HT&.;F07
M$+()V#DTQ#)IG*31($G-I^&65XN4G'(D9]!83LGC.YV/ZI(ZC'3NP<F]AW%A
M\AA.#.[#OL9.=LY5Z"\HQ7 )^YJ*:DS5"K(;<:BI$?L;Z[E/'?8U-V"JO<5X
MM,?;V[&'!F]?8Q,ZZ^O06%')OJ$ *=')"/$-@[>'+[:Y;(.7LSO<';=BR\9U
MV+AF.39O6 $7QW7P=+/'=D\']CM;X+-K*XT0)_C[.\,_P 4!@6YLN^X("/)
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MO1Z)!,/4F'4FJWA!QA:* W)2[?EY$V%<\[S=45FPG8!M ^V:XD#4% :A/"<
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M*M'VN6#[]OH79BE(%A@K!/Q.*+A-!-B\_J\)U%]]86J2?_XE_T[5)C>0_5N
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MO,U*WO<_@_5,$=#J>#9PIGUT>T!&2PNPK6/8(%SOIIP5LJML^]FN1?OROAC
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MZQV^6['=QQ';O+GT=L7N$'_>SS0:E4VFMN38V %3UUERX #?N4N/X^67WS:
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M0>>_<Z]^*;\&;$OT6=YK32G0WR6P_NRVV+*3?VGJDUNAXQ+]YB>VJ[_C^Q^
M'W\$OO_^W_#IIU_BN>=?PHF3IS$^/H'QO1.8GCZ,,V?.\6^[CJM7'L/9DY?X
MOAY$94D#@ORCL7FC&U:OV(S5*^VQ9/%J+%JP$AO6.R' +P(9:86T#VI1D%=-
M796/J(A4A L>(],1)\A6B2Y"=FPT(3LJDWHLB_T]/VM>]L^ 76H,=IO17D8C
MOISZ0$9\J?%T"\@3>&S5_"_@N:JJ.VCX#Z*9$%17I^1>\N3*0ZO?*WLN@2*E
MV'B'=P<GPL,K".LVN&/M>A?LW!5&0[4.O?T3F-@[C</[C^#L(8KR*PP/XM!@
MGRE;<VQB'(?&1C Q-("1_G[T=?6BN:$-!?EE)F.S:EH[;MU%W>D/!T<_K-^T
M'2M6.F/5*F>XNP48[WUQ<2,!0WU_!?5<)@*"$@EE20B+XCU(**">*6$_J4%=
MPG=L(47E%XM-8B#I,R6VE,$M$)&7SPI1U6=M5_^N?27:5QY!*PQ5X=B:7RRO
MHW21E>A3GS4O6N'7Y16]OQ"5L)*W6M^;3,\$"96JJJKN15V#/)Q#QIO;W*(,
MWV/41S;/=16-_+*R >,15ZDO6T2:LC8KI)WO56D;C\_CU,A+.6 &Q&L)%P)L
M>:HE@FZ!<[,R(Q.$E(1,<WZ5-$M)M!(3;8FT-%B@\/"VCOW8,W(&H^-\?_N.
M\OK&# 1IKK=$7G2!G-9M\\>IVP0]NC:CZVQ>19. C<L\VA8%_%M+*GI06=N/
MNL8A-&DPH4W>>D)U0P\_#Z"K=PQ]0Q-HZ>A'5EXQ=OKNQJJU]I@S?QD>FK48
M#SZR! \\M!CWWK< ]]Y+??3 8@+V2BR<OP[SYZZB?EJ(N_[P$.[YPX.8<_\\
MVHW+L''E.CBN)RAOW SG35O@3,!VWN(,#Q=W^'G[(#HLG/9S(O(RDI&1&(W(
M(!_L]'#B/M19]M17CHK0\N;[%4\;OHA_'^\3VUPR 5OO5 +;APV*E>E;]]$&
MQBJAI&V"9ME$>O:"6.6T41URY;51J;2&QC'3#F0SZ5U5(L&9[ZU^K\$;"[ 5
M#5%ALMP/0MGN2TOZ:*?25E >'6-[L!VRK:HM"Z[EE;; 6F(E-A-8&]#G9]O<
M:PNN-7=:R<DD"O6V>:0%S#:XM@VF"'KEZ55I*S-GN49P/6C@5) JX)TI-E"V
MB3[K6+*%K./9X/J.:)OVL7YO[:_O9MI2-D"_XWVV0KQU;=JF]BA;S #V[;!Y
MA<\K+X!$L*WW26U9;=8Z3DF9PM+UMP^CHG*4Z\-\3AH,&:0HFD057VS)"@MH
MRRE*--7,S[9%Q2@!7CW?Z_Z^?9@@9.\?/X#)H5&,=O=@I+T-HVTM&&]OQK[V
M)DRU-N((MUT<',+CX_OPQ-@D+O4,XVA]%\:*&M"95HYZ]M55<86HI.U9GEYI
M(#N9-G5X;#Z*:[MPZ?'_*L"F 77RU"D^R!(DIB0C.R\7!27%?,GY<A3D\<7-
M)E"D(S$MF4 =;0#;)] '._QVPI<O5UAT*!)2XY"221BF)*;%4_0Y@09P!BIJ
M2]#27L^.IPU#>WJP;W(4AZ:G<.#@/@R/#*"%8%Q>4<K&7\I.LMYD%Z^MK>%+
MH.0'Z0:R)1D9&83L0A05%!,"TZ@PXY">FH[:JFKT]W1CJ+\7W7P U66%R.3U
M),=%H"@W%=UMM=@[W(6AGB;45N0B.R42B5$!2(D+1$92((%Z&R*#-R'83QG&
M%R(R=#$28Y8CE;"6$KL:25&KD!C.]<@-R(G;BI+T;:C/]T%730B&"=@3_0D8
MZX]#;VLHZBMV$HQ=D)_F2'%&H;S7!.OBS&U<>B*/@)Z=Z(BTV$W&DRW SDMU
M1'&6,TKYN^+LK2C,W$+C78#M@K)<3Y3G[41U@1\:2D/14AF+MLI$E&:$8+?7
M!JR>=P_F_/F?,/_NWV/Q?7=AR8/W$K#OQ=*Y]\!N_KU8MO !K%SR"-8LFX>U
MRQ82LA=A'0W\32N78]/J983KA7#<N B^.]8B(=85.9E>R,Y436Q[Q,:L1$38
M4B/1$2MXOU<C,7X=93WB"+"J61T8N 3>WO,IFC>]FML<$!/#WZ?ZHK(R&4.#
M]3AQ=((P?0K7+E_"9<+UQ;-G"=NGS;8+YX[@Z.$1]/56(2<GE,"^CI#Q(-9O
M_#.V.M]/B)A+F+9#2/AR!(<M0V#((AH&"XP$A2Q$2)A 6W!MAYBX%82H52:4
M/8K7'AZYG/LL@9^_YF'/,Z'G7IYS"=J\UMU*?A;,3J&(G6D[#21U/,KVG8>(
M2(43$K)3Y<&5(NPQHKIZ:812U80N*NM!8]M>].TYBL'1D^CJ.< .LY\&0X-1
M%/)>)R;(XUM#J25D:_ZRX%KSA@2>[-@%F@H5-X"M4EU51M'(0(EFQQ =5X"D
M5$63M*"U@QW-WF.8F#I)P#Y(V*8!4:91;UMR"]/IFI%!C3[*X)'BD ?;$@'W
M3+ANO2TM[-R:V-')>*@W([^I@GT#V'5\)@+L!B0GE"(R(@M1D1G&2U17V\IW
M>=SF:;IP$=>N7\?C3SY)H+N"O1/[^?[2J,@D5"?2&%7"'RD^>>=U_/0ZGE,=
M]B]%UZQ1?W7P6DID@&B47\:*3=FPDZ;Q5*#144G9((6?R_HI5&@:,2ZG856F
M>>EMR"S@WY93AU@:CZ$T)$-I4">EE:*VIA-[AZ9PGI!]]>!IG!W9CT-MO1BM
MJ,40^Y>QPF(<**^\#=GUV%=>@>Z</%0EIZ$@+@FY"2G(3\U&3G(.P@-CL7&-
M.^Z_UPZ__Y?9^/WO9N&/__H(_O2'1_#G/SZ$O_SI(=Q[MVJ0SL9##U$>GH5'
M'IF-.7/G8-[\N9B_8!X64+2<OY#KB^9CP>(%6+AD'A8MG8LER^=AQ9J%6&]O
MA\U.J[#5=2V<W3;"Q6TSO+:[(R@XB.];%HV(!N-1&QB8,&7H]NT[BL.'S^#B
MQ1MXX?G73 CR=S_\B+_]_6_XZ[_]2+#^UH"U@%IP+0_VUS][L"D*#]=<[/\#
M[_5_AE@>\)E><&5 GPG8WY'.[@"V37X-V-:QK'G!@D4!K=8MZ+.^$VB_\<8[
M>.JI%TP"-)7G.G7J4<+K%4P?NH"I?:>P=^P8]A&V#QT\2_B^9K)Z/_GD2WCA
MQ3?P)B'[O?<_-%[L#XWWVB9:_W &9"NQF$+&);:YS[<]R+RN#VY^A.=?> 6G
MSUS"$(WE^CK-<:LC(&C0N== _O%C5W'YTO.X=%& _3A.GKB.RQ>?P;//O(%7
M7GX7K[[ZK@DO%V!_\,''A.I/*9\3LG\-V+8LZ_\QP-928KNW_[> _=77*K$&
M_/17&V!KWO6KK[Z)"Q>O8/^!0P:N#QPX:.#ZZJ/7<>WJXSA[^B)&A_:ALK2>
M.CH!3@[;L(9PO7:5 S9M="98;\6Z-0ZPW^B"[5[^B(M.HWU0@]KJ=E26JP\J
M0TQ4!L)"$HTG6Y"=2,A.H,BK'1U-R.8R1I^-%UN&N@# 9OB;W!FI*K%H"S%6
M^23-UXY6J#DE,;F0_54M#=0N WH='?L(VB.T9P1DM3R.;6!/ "^)5@A[4!R<
M77VPT=X#VW>&(#.G@L;[,$;5!TU-X_3!(SBS?S^.C8WAZ-@H3G']S/0A')F<
MPNC H D'+RO1M64B)"06NW:%PI/0[NP:B,U;?+%ZK1>6K73!JC6N<''V99^=
M9J(@ZFI["!<M_+N*^+M4!.Q.1FA$)N)H=":G\7B4^&3J'MZ#"/Z-D908PHL&
M? 66BH(2B%CS-[54I0T!BOIVZ:TXZHD$0I(,<>DEP;7FCPI>-+?5>,(,T,@3
MIGG&W$<Y10C42B*F >J*RC[S62'<)LNS@>L6LY]*8]4W#%%?4PC8DJ9FPG"S
MDI0-\_>#W,^6I5QBO)?4"SIF974??]^':H&U@6NN$U[E*:U16*_">^6!)#!I
MF[SAC4UCW%<>Z0Y>MRT'B95,R_+L"[SEB>SM/X+QB0M&!H:.F[!FA>H*1.01
MM #;@FP-3-C6I<-M2:<T7SR/YU).E;QBZCW^S:65/:A6.#S_SH867F=]#VV-
M3L(G[=W><8Q/'L78Q#1M@@X^RW3X^ 6S7?G#:YL?G)VW8\,&9RQ?M@'+[3;R
M77'BN^*.]6N<8;=H/68]N 3W_ND1W//[!_#(/;-H,RZ!_9KU<-OB""\G%WA2
MW+8ZP\61@.WJ;CS8,>'AM)OCD9T:C^38,.J_G?#V<H*'\V9;AG$7)^S:N0L1
MX3'42[F\;V74]P3GGP&;2X$U1>U&3@7=UYDB+[95D:65D"LOMB!;HL^J$:YH
MA+CX8KZ_2K2JJ1XVR-9QT]A>%::O.?"V.=<*"2?0$@"5,$]EG!1)J(@Z@:2>
M@=JI/-+R3EM0K:6U;GVVO->:)VXE)I.#PWAQ;XML%4&L[#*;@\ &UP)9FVA>
MM@W"BTI^&ZYMT&ISG,BY8,'U3*B>*=:Y; #]2R"WOK>.;9U'Q[==+]\9[GL'
MKAOXS.3!YOMJX)JVH:ETPV=#^]!XMMF>U6[E_+".4UJN^[&'SV<$9>6*(AGB
ML2DE@[R>?HK^'LVE5\1E'W]/FYJVH'FGV+?FT%9K:NC'WM%#.#E]"B</'<6A
MD5&,=7>:2)ZAIEJ,-M=A7TL]#G>TXMQ /ZZSGWQB; +7!\=PJ6L/3C7V87]%
M&_;DU:$KLPJM&56HRZA$*?NW5/;Q,03L*KY#5Q]_#C_]([*(&YGQ3PENCAP]
MRIO&#CL\#/%)B4CC>EI6%D5>:1K5N9G(S,LB-*<9R/8)](7;-C<X>VR%QPXW
M^!&T0Z."$9,8A?C46./%SLA-06YQ)HK*Y17/YP/,9D>9Q9M?C);6!KXT;7Q9
M&MGP2]G99A-.LO@R%-,XKZ;4LK.K1A7AN;24W^<J;#P;A?F%*"^M0&EQF0'M
MTI(R--0UH*^[AX#=CXZ6)A3S.N,(_='ANY&7F8S.EEH,]W>@O:D".>FQ"-^]
M X'>;EQN)X0'(CW)GTM/Q$;8(R*$8!:\E)!-J RU0Q3A+LQ_"4)54SI@%5(C
M-B,OT16EZ9YH*/%#?TLD)@:2,;DG%4-=T29,O(BPG)NR!07I+BC)]$!I]C:4
M9&U#888'8=H%.4E;D1%O3\C>@*Q$>VYW)D2[H[)0"<_<49[/X^?RMSEN*,GV
ML'F_"?6%:3M1EA6 ^N(HE&>Q8]M%P\+N$:R:<R\VV\V#,X'9<>52;%J^D! ]
M!ZN6/(R5BQ_&6KNYA.DEV+I!"<[6PWG#.FQ9LPH;N>_&E0O@XK 407Z\GB0O
M%.9Y(X_G3$O93 -$Y<P(L(3:B)#%B Q?:KS:T:H?'J4YT"M-K>R @,4$8T*Z
MKQV5O1U!=BF7JPFIVP@R:310VW'FU'Y<O2RHIL%_[B0NG#F&"R8!VE%"]K2!
M[/:V4D*I#]S<[;!AXWUPV/( /+<+L)?1$."Y"/DA$<L0'+J8@#T?_H%SL3MX
M/@%[,0V7931D5A!*ER,BRHZR%!&$[M"(I69>MH_O?.Q4IO%ML^#J]C \/!;"
MU\^!'3R?67,]^@<&V!8)9?EE-+*4!3:/G6\55%I#'8=&W;)R6MG1-)J,E@TM
MXQ@:.8&QR7,$WF.HJ]]#N&V"ZCDG),ISK1%9A9/54&X#=JK@6@E>"+D2$RHN
MR"9P&N\UE3854"P51105AD+ULO/JT=PVBO%])W'P\ 4#V<UMFM]"XS&OP21#
MD9*VC9"W4MFK@R1 LY/,R-8(I"7Z+/ F5&<IG$^A<[8R!AHT4);%E/0&4\I
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M%3N4#N[;1B OYSGRLC)07E*(OLXV3$].8&)D"([*,B3'Q2(V(@IIB4G(S\Z
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MRG,F)*]$3*S*=\TE9,\E+,]!;,(<Q"?-17+: F3GK4!1V5HC67G+N&T>CR&
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ML"V/=G'6!A0JNWC.)N/];G=$$K 3,=R9B<G^ @)V/KKJ4E"4QN?DN0RN*YZ
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M@!-]/3A&?CS1VX/3 _TX.SQDDJ"=XF=G1T=PF\#^Z4_? ?[RSS,4_!_[^X<
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MHM7(S%K&ZUMDPMH3$A8A(7X)KV<IPL*7((3W*RIJ(PVM2-37%;-=48$-]1)
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MO*QJVK=U4"(]E133,Y,'N$MSF+NW4W=O-FU"[<..7%#$GPW7>E]F [6=15Q
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M5G3T;N/_.PG<!(.I(YB</H5=^R[BV*D7<.7JFWCMU5_BW7<^PL]_IHSAO[$
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M[-][$=NF3F! MIE"W6G7EI<J"J(6!7FEA.X*M#4V8JBK'>,][=C:IRSAG3A
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M24%Q:AX:"VO14]?%B7L,/1U3:--DQDE,R5YJJ0#64J%4'>PZ G8]!U$[H[@
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MRP5:&9QUCSI.0&Y<PS=@93-8VTKZ9L5=(A!0$B8M;8N;8$?@H[E*UFLE-A-
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M:D')%#DFC:V@K8<@VSJ"ND:5W=*X:%FR-UNQC1"<94&U$YP)LFW EA5;D&T
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M$R/SJ"IO169&)>&ZPE1YR<IMOB4Y>4T<[QO(#TVHK^D@"TW@ZKFK^/%?_HB
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M6!K-Q$Q_$J$[V20^D[OX+)=3@TD8[XO'1'\\IH82,4.X%F2/]L42KB,,2!O
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M=JUK0;8-VL,;5FR!]005.8D-V5I.4NF0:/_0^+HI85%+A;2PO >IV4V(BJ]
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M6N#\\:=_SWT?\Q@^#\IG7VS(KWG\%_:Q5OSUOP?8LH3K__F/ %LO,@Q@4RS
MEO5:];$)VA]_AE_^W=_C;W_V<_STK_\&/_G13_#C'_X$/_GQ3_&#'_P$;[W]
M$:Y=?QJJ1M#00J@L;4596;>QOG:RCRMF5: M !-(QB<4(R P">X>D3C@%@)7
M]Y -JS77/8*Y'626GH1F7R5J"K!BL;V]">$$[/W[?>'HZ T'!Z];LH\PLGNW
M*W;M<J&2Y69B53UXO<" &+;)1$1%6B[C$1'QQKT\,(#P[AU,L/8W$N@5C,B@
M*"1$)B*%()U$B>6Z #N02EX )41NZ83NI!1!=K4![!)"L;)MEQ&N9<4NJ[0
MNXJ*; 5!I%0))0G9!>6=**GI(62/H7]R!9.+5)[G%(NX0E@>H\[412!K-Y M
M@-&+B':"FL*!3"9Q95TV<#UMY#9@6_6$E9VYKF&,(K=S>0C-<1Y8YGQ Y9V
MW=O/\8J /3Q\@B!XDLKR,<+'*J\S1[#F/%%#F.?UFE5O6] J2S3AR 9K;0NN
ME?Q+KN&RT HBM2[KM=S#]?L:*-]0]J6$2Z3L2V&7Y5!B6Z]MUU59TW2\8$9@
MHVS%LHY)>5>-7P'%*,?R,8[!6@X07F3]M(!LVKRH%?@(Q'6\1'/B.&5B4B)
M/V$RA,_P^C,<AY5Y>I1CM^*N97U53*]=5UE0K><OZ[42GO7V+9K]?5+^>VW
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MWH!Q2V[O,TG.%(=M8%BNXG+S%C#_/9<"[%]1/C;R&:':$@O&+2"_#=:V_!O
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M!.RG"=9/X/57G\);KS^%EU^\1A!8Q<A(+0KR@JFP;4=@P'V(BMI&R-['MG*
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M<>G\%3Q\]08N7;R.BY3K-Y[&\R^]@0^_\U?XZ<_E+OT%0= "U/]J8/[/R)V
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M!&XE&A,<MG!91QBNK!WE."WKB&#%2F@V-'S0N+ * &1EDQNL($U>/J;Z Y5
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MF^S#R:$NG)L8P+7%"3QR< :/K,W@VJ%I'!KI0&UN*H(]#L!A^S8X[]U#@#F
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M^,"7]Q+L%XZHL%@DQE+W2,I$IH'L/!3P.A5E!/NZ9L[Y!/F*:N1DYR$E.8W
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M<=D^7F"R&:YM$+&AQ0!V$\\G'-<KZ1IA2#&X2FHU,7W< /4\84D>.P)K0;+
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M2:.-6T";L[H'S?I=S=SH(52:9S[&WW*&4+=(H#U(._4(5/)*<\Q53L[R7EN
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M_>Q7^/7O_H3?_/Y?\<O?_-%DR3;ASX36Y3!\)RS?N>VOB?:WSV>?\]\E_P[
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M=30509"M_5)2*\B?]1@9W8/7W_AO FQYL$^<.8V\(@)VN W8B;< ._$.P!9
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MRRNIB+F4!]RJG4VCDTK9GK\MP):B,XE"C-*R1$ MP%:(^?CD<1I8ATVHN.9
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MB"=@1PJP(Y#%?E&2HXHTK;3G!-AL4YH+S:4@6# LKW-9F07(RAE05Z<LWTI
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M1$SW9V&Z+YOKZ1CFN<8ZTS#9PV/ZLS$[E(.YH5S,#&02MI/0VQ2)5L)U:V6
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M#4!O--0&T[@(1WM;!)=A%/:1MCB..6GHZ<A!>V,.(3^=_3@>60D12(KP0UC
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M9]?T+<#N[:I#+0&[LBP-!7FQMP"[MLH"[*&^7$JV 6QYL3M:X@G7<;< >X2
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M$C+9OLM16MYD +OD;P3L^L89]KG;@-W>-8/910NP%_?^-<"6DK\3L&E0_D7
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MP]D&:H91PWXJ:2"@-M7SV1(("G*KD9*8A8281/:-1$)%*O+9ORJ*:U%7U4%
M[T5U)>&_M(]V<S\!FV!;-VFB5FH:]#M-LBTI/)SMH'F.[5KSSO5_";)W\?]4
MF+B2A\T:P-9\:CLD7"_RIJ:/$GA/$(8MP+8A6S6K5;9,7FPK$9E51DM)XI1D
MSB288_NHYV]GS;U69G$+L&?G3IKC!=@ZET*@!=82E>E25(X 6Q"J^Q)@6V'B
M E$E&[/F8"OIE]JIF<; WTDODE3:3FU=HO9\)V";=25EZ]_#MJFR5I;(*RU1
MZ+<5'CYOPL/EO>[D>?19<#T^>@@38X>HE]EFN@C2;5.6"*XE.F8)KC\'V,O
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M;$\2PKNZVM'2+)BO9R=O-LG-YF;'L&O7#!87.* /]:&AMA+E)05HJJ_"^,@
M]BS.X.#>11S>K[)?A)\>#MHT9G,S8VG(Q!!84]'7482)H6J"M:0"LV/EF!XI
MPEA?%OK;$M'=2$AK#*<!'$T0)JS5!:.^V!.UA->6"E\,$^!VC>7BR&(%3NRI
MP:E]=3BUMQ['%FMP:+:<D%V,?5,69.\:*\#,0);)*CY(X!MLC36 /= :A<[&
M4+35!Z&U/A ME-:&(+332.]JB:(H\9KF68;RGGG]JF!"9 B::I0%W8^0[6[
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MYB2.[II"7UL54F("X>JP&MLV/@!/]_4&HB,B7*B8*5&NB(QR0U2T.\*X+3#
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M+*E$4VDMAMKZ<7#N(,X=O8!C^PBA?3.T3=HX=E4C*Z,*!?G-M%&5>;Z7]N(
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MUWBMSY]UQ[DS;G"YX,GS'8C@@".X%J@2KA4BK6EL>*RIX)V5FDE0+C0>:X6
MMS400!0"7J'V7+7H:&I!3V>W\5[+D]W5TF:6R],ML,[+X)A&L0#;>+"CX@Q<
M2RP/M@!:\&V!]F<!V_)B&[A67K;:>A&:Y9&6!SLJ.,K L>6UM@#;@FS!MR \
MU#<$@5X\;M]@XZV/YG$F$+)5]"R)P)YX[#?:?F92IH'KW/0\GHL\ ]AIR?DT
M_DI16-A(&\%N %8AVTZOLA-\+:#^K.@[P;*@NDZ@11%D_S\!;'FPG<4?5<R)
M,,LQ2B\W_UO>:WG\!-,"-LM[K7!Q"Z[5(DPPWM X;$20)Y 1V,C3:0I$&>^U
M7F!2" FCA.MQM>JB"+*5^M)F6T9]ZRP:VV9,^.OT[!Z6%0VUN,_Q>(50J'#Y
M >JD$0.4\D8*MJP*TOK<S'-31QU26=F'4AK?"G,-C4S'.1=YL G4SYZBG,87
M7[B +[UPR<#UYY^Y@"]R^N*KGGCCC" [%.==PW!!WFOW4)QS"R&@!^+TA4"<
M=PF#I[<J+Z=QW*.=5T4;RC:,F>%9S Y-8KBK#]VUS>BHK"-@-Z&_6;G7G6:J
M\/#1[EZLSZ[@VN5#7+U\ _.3Z^ALZ4,9[X_BO'I"=I<I1M:HEZ*-SOQ[ 78M
M=9X@6R'B]=2!31V\APC8.O?2E?)&6R\XK.L@D-;Y5U[SZMH= ]L"1Q-2SFNJ
MZS,@'3@HN%;U[BN8GKZ.&>H/@?:(]!)UD0J<";"5&ZR<9H&LH-<"64&M/,WJ
M3;VW[_1>.^4MDX<M8)Z<I&XC4'=U3]'&G2;8+A[!]3430JZ":,K5UKS@>FWM
MELG#M@J9":X%U"8GGV.<1#GY*FXFP-8^' \C%_SK.P&Y[HU/ ;9>+/#>U?$+
MJ$VE[J.I!=>Z9Z>F]\TYT_F;YW[,3/$<C:T;P.Y5]!WAN9D *L!VT/Z1QWJ!
M(*=I4X.#-F E*LI:,#ZZA-W+M["S?1,KR_N$[%W"WQ9&1_@_>1[Z>Q=-P;2!
M_F4#V"/4Z7J)H=#TB:D]3$Y?H:AFC%Y&7>:SLFXB 0M*.A$:GD6(#L#SSU\B
M6)_"O_Q7KYIJWU_\TCGCP3ZE@F4$[+-GPW#J5 @AVP_//NM.P';F8;_XH@_.
M7XA&2'@^4J@+L@BK&=F<$MR+2ULYYMC1T3% W3F%U<4-[&[LXO*JBO?-87I@
M%*/V?HQT]:*SI@G)$;$X\?+K^-QO_!9A_SF\^NKK.'GJ#"Z<OT3=X@E_?W^$
MAH8@.C(<\7%12$J,X3,42XE"<E(H/P<B)240&9DAR,X-1T9..!)3 Q$=[T\)
M(4\F("<W%\7%562^#M37]9+[^E%:W,USW41[NP:)\46(",M ;$PV"O/K>.].
MT[8A9%]YR.MYF7S61<C/,8"=D%ANG \S,]=HES\RTZ:F<63G-"$EM0IQ\26$
M\%*.EQ/X^*N__;\!L%7D+"X&L83J.$IL:C+BDA,1EQ2/>$I""A5>:B*!F\HP
MDY"=G8JLO'3D%E*)$K(_D6RS+*<@ SF%^IY"N,XG7!<(KDNS"=?9*"9<EQ"N
MRP37%.5QEU$J"+75E81L0G6-VFA5E*"*D%U+\*UOK#+ ++ 6,%LBL-94(&W!
MM1-FU1=;E<>56UUIUA-D"\A_'6!;8@&VQ%I'U<M;6AOX0#N!6B* %B@K=/RS
MHN\$Y/)\*WQ<8*W\;(&Z?BNXGIH>,Y[MZ>EQ;&VNT1"^C:L'5%"$Y_P\*O><
M+%1751B0'ASHPSJ-215'FQCGP-M0B_*R$AK8M0:RY<$>Z+%CI+\'<^/#V%B8
MPLK,,(8=3830?$)V*B41C55Q:*Z*0E,%X;4^$N,]Z5@G6,L[O4.(7I^BD4S(
M7AXOP,9T*8&ZTL@ZYU<F"K VJ7#Q*ARL->#Z1A,.5NO-9Q5$FQ_*Q;@CU<"U
MO3'2],6VMT;2$(LU@"TO=%N3VDT)L@,)U_[&DUQ5ZHOZJB!"=NB15SOLJ0?;
MZ<4.XV^=1=+:&H()H;X$;'>4YZM/MCN/R\^$A\N#W:O_U<'_1>CN;"*LJVJX
MPL;YOTPN=@5AH4S>:V]."0BU(52*L83W1"-MC=&H+@\B8'O3F/=T0G:N'^=]
MD)WIA2Q*84$0SWL*AH?KJ$S&<?_!'L'ZH0'L+W_Y"3[XX!%!YC'>?_\)WGGG
M(1X^5%NA*X3L'0+V5;SY^ 9NW]FETJ%QT5;*_Q&*S%3U&O9$4TTPC=4('DL$
MNIJ#"=A^:*OS04NM%X_3C<?@SG,3"$=7-'KLB>CNBD<KSW=C4S3O+TD$[^$@
M I,W"@K<45#HC>(2 ;? .YF&5!D'>#MA=XD#U396UM<(NZ.HI]%06=N"IO9>
MC$RN8G/W+O:OO66*;W43[FKJQE%;+P-,D$I854]- JB#BL_62^"UCQ,8"7X=
M(X3P8:X[2"@;- 9H/Q7=XLH-[.R_B:W=!X3Z74+X!"IK>DU8E-91E5D!MFG?
M0OAT@K:*J"BT6Z'C\X1W9R5:DP](I21@5G$?M:;1O(S%X=%M K8JQ#H5FJ9Z
M>^R$;*>'IX7&2B,-F>8.&JK\+'BV/-,*^]9;90/: P)L_H;_HXL@WRVA@2+(
M5NZU<K %V0-4E%*6@NI^_M:9I^W<CC-/>]W\1J!MX_\RL*XIMR>X[J"1U$FC
MP=:WS&NQ28.5BI@*8GI6K4L.N.\[/,XUG@NG9Z=%WJB6$8*VC#<'IPXJSGX:
M(&,<5]3O=9G'O<ZQ90?+*U>QLG* Q84MK*YN8&]O$QM;DS3**PC,X2@J\4,E
M(;F:L%Q:XL9[_!32TUY'?N%9&H->:.WT1U.;#Z^3*RJJ+M#8O4BX=N/8[(Z*
M8G=4%7.=JC ,MF5B<: :F^/MV![KQL90%U;[N[ QZ,#>^ CN<>SZVMU;^-:;
M]W%[@^>SIA21OFXX]\9S.'?R6?AZG49,C!<5I2^5H;=I<Q<5[48%ZD(#^!S\
M_$XA*. "E6XH]S,'+4VU<-C;:? ,8GEY'E?V]W#GE@J>W2%DWS!YV>^\\R&^
M^[O_!G_Y5S\DW/XG_.H?_T_*?\$O?OF?\+.?RXLMP'9"M@J>"7Z=D'TL7/R?
M ?8G\A2P?^R$;&?E<*WW:< VGW_^4X(]M__CG^/[/_B1$[#_X,_QK6__6WSP
M\?=P_YVO8_?66YC>N(;NT154MHX@IZP;:06=R"KJ16'%&,IJIE'7S.>M;X_W
M'-?KW29TCU$7MU%/5R.61D9<8A$BHS+@YQ\)#_< N+GYP?62MX'KLZ=="=M>
M\/4.0FA@I %LM:\2<(8%A".<(@]O'(TK%2!3SK4\UP)L>:WK*ZM-?K5"Q5OJ
M&@Q4V]NIZUK;GWZO\/"BG#P49.48T-9\?F:."0,74,MS'1>AW.DX ]!:9HD%
MVIH>!VP+NI6[;<+$"<'R8,LC+;$@6X LP-;W$GT6B.O[$)]@^'OXP\_=#_Z>
M ::O=F1HM*E$KF)H213!N,+/%88N+[8%V/)@IR7E&@]V9@:/KZB)8VFO,RRW
M_2AL^PA\?QU<2RS %E0K3-@2DX_]&:#^K!P';&M;QR';67U;XZ"B?U3QVPG)
M FM-C\.U\E05#JZQ4J)06GFT-9X:K[?@FE"NRN@J7"70>QH:+KB6)X[CJPEY
MU<M,A;M.$9P(<I.SAP:V5?#1 FRE-ZCX5N_ ,A:6#K!]^1ZAZP9!:LU =CW'
M?ZO-F3RQ B_!DOHTMU(OU-4-<<SI17FY#7D%C33.<^'J%8:73[CBF1?.$JS/
MX_F772GN>/8%5P/7DN=>=,7+KQ&R3_OAS(4@7'155?%PN'B&XZ);*,$["&<O
M!,/5/1+!(2G4Z^4<4^P8[AW'>-\X^MM[T%U/.X^PX6AHY?C69:2OB7#=U(;!
M#AMMI%E<V[Z*P[U;6)W?@JUM$.5%#<C/JD(1 ;NFPH9&GL=F7F.]+)!'ODZY
MU_5#J)9^Y/FM:R9\*]]:8=[22;Q6 FNKG9O.B\Z/KH5>.LCK+%@59 L6G>W&
MU@Q\CRH*BM=D@M=DBM=D>OH:8?C 62E=^HKZQ]GVZI.P:7EU!;X*W1;4*D=Z
M;?TV=G:5:O26\5SO7WEB/CO;::DNB,*[M8T5;D,>[ST3$J[OG;VM[YNI(%N5
MR%4EW/)>:W\%RP)J148TMZBBOKSTDP:@!=@":VM_!-CRK.N^D*?;A(,?O500
MH.O%@^8=!%MYN)U@K?/A]-#KGA7<SLP>F'U84'V3V7V"\P9&AI8PV#]'*)XF
M5',?6@<HU*,$[+&11<Q.JT?V(NIKNY&548;BPGK"\[0)&3=P30"?G]NA[&)V
MAO]G?(-VND+&9]'7RV=FT&J!MHUQ OVDO/(\!V/<GR%>*P?MD:Z>15Y_C>%U
MIMO#<\]?)#"?,MYK ?;_^U^_[FRE];*'@>S77_<E: ?AS-E0G#@9A)=>\L87
MOW")OSF/+W[Q$EY[+0">/JE\3LK);%6(CBM"5&P>TC+(-34JVCR*J8EYS,TL
M8&%*%?+GL3&_B*W%9:S/SF&>MF!G73WB0L+PV@LOX?._^5MX\847<?K465RX
M< ENKA[P\I .\4& GR]" @,0%1Z"A+@(I*7$(#,]!NFIX9P/(203KK/#D9L7
M1<8D>*>'44^%(2$YBN"?AB+5Z:ALIBWM0%/C$!KDD*GHYWGN0DY6(W5]"4)#
MTA$<F(SHJ&SR81O&Q]>QN_^ ]^,#<P\6E[0C)K:(-D,I;=YN=-)&ZNE9,7"=
MD]N">).C[2R@EIQ21KMR'%_^RK?_%P+VL1SLT-@H1*4D(BHY 5&$ZJ@$2GPL
MHA-B$9L4AWA"=B(!.X6 G4; 3L])0R8A.RN?RJ@@TXCFM2PC-Q49>2G(S.?@
M)4]V<08A.PL%I?)XYQ"P<PG8^2BM*#1B"J65%G @+4*E@6K";06!N+S8?#9M
MO C0EM?:A'@3JBU/M@#:\EX+K(_#M375^OJ=X%HBF#;5RH^%B1\':WT^#N"6
M)UO0;'FM!=.:6MYJ"[JM9=:\E9_MZ.DR7NNEY3D.9$L<T*8Y(([P@5V@<7B(
MP^M7,3HRQ.,F>!&R+8CN)3POS,]B=67)?-_86,]S1*70TF0\W,K/'AL>Q #A
M?*C'ANG1?LR.]6.DC_O06D% RR:@)1,PXU!?'HF:XB T58:BOR,)B^.%V)JO
M,-YJP?8:(5M>[2V"]=8\X7E:^=7YF!G(Q-Q0-E:GBK"[5&WRL967+>^VO-WR
MA@]U)L#1'$WE%(X.PFL'P;=;D-U%B.V*05>;0KT%T:&$["!3;$R@6UNA7&C"
M,'\CP%8.=I<@LXW;:9$GF\N:52D\Q'BE:\N\4%[@@I+<"RC+OX2:4D\>H_*4
MHXPG6R+(;JL/Y7'[HXY075=.D"=@UW(JR%:;KWK"M\#>&:H>R7T*Y7<!*"WP
M06$>83K/A[#MA^("?Q,R7L#YPH( E)5&$&[2J;1J"#"CN'=W#Q]^^! ??_P6
MIV\2LM_$>^\]PMMOWR=@W\3MVU<(V;MX\. JY8 *2.U.JI&7%XW4%&^"C0?*
M2PC2#01LA<6WAJ*C*0"M==X\+AV;)^':C4:L&UH(W3H?:JO4WA;->R#F*6#7
MU4?P>5$/;V\..#Z\;WG\_*Y>5<;K)/&$VSP.^.U86AW!]/P004]P78'RZBIT
MVGHQN[B!C6TJQ>5K!DH;E4==+:-+[3\(A5U2>,KYHU"IV?L4)CZ&MB[>ERU]
MW):=\,Q!DXI3!4;4WDO]KI5W/3&]:RJXUJK?9Y7# +8*M,AP=+;S4LL-Y0):
M7FR%B<N[HMQ &9:JG#ME%*JVK?V3@2C#49X8+5,K#U4+G21@*^=*(L-0K<'L
MO<I_I@&J2JVJ:$OE;."V?YDPK%#M38K"OYV@K#?,\BX[X5BP+5#F\?>M0_VO
MM<Z C!Q*_XBJBW,YE7P?#1[G<GFYM2T!.<^7$>?O-&^G@:O_WT[CH9W&0S>/
MH8?+!>S&.Z0<1[4?&[[,8U4^^1+OFQF.)3QG;<-H;>FG]-$8[>.UZ>>Y&>1Y
M&J*,<#V"=.\L%<X,NKN'^=M^*OQ^;K,+W8XRWA/)O#?B:.#$T0#DF%"M>]P%
MN3GG4%QZ"?7-WFCM\D-+AS>-=0^.H>X<BSS0P'NQIIR 7>B&.@)Z3V,"YGI+
ML3G6C,OCG;@\:L/V$(5P?7FP%UL#O=CCF'5_=0GO'NSAX>5UPK@-Y9E)"'0_
MB_,GGH7;^9<)T.<0&>&&Z!@/1,=Z()* '1ZE%B 7$!AX%@'^YQ$:[$YE'F(\
MV=55131>JWEL+30L![&^MHQK5Z_BSNT[IOC9_?N/\>Z[7\9O_PXA^R__GL#\
M3_CEK_X/RG_&SW_Q3T>0[?1D__<!]C\750O_!P*VQ%DYW"F":R=@<TKYZ2]^
MSO_)__.37^!OO_\C_!D!^_=^_\_P]6_]&SQY_SO8N_4N1E>NHJEO'H4-@\@L
M[T9*00=2"VW(+.E'4?4$:@C7;3:]_#DP<%U)N$Y(J4= 2"X"@C-YO@J0E%*"
MI*1\A(<GPL\WE)"M_&LO K8KSI]U@X>;K^D''4[H# ^*1%A@.$(%JH1K9TYS
MM*D>KIQHY5 +FIV>:_6Q=A8OJRFK,,L$U?)L"[;EZ19XZWLK1%QP[9S/,_G5
M@F6!M0!;8N5B*S=;,&UYL2W(MN!:(@#7?B5&<TH05NZUX#K$-^0I9 NF!=:"
M;'FA+<"6!UOK!'D'&<#V=O6!#Z<!A&Z= [7SD@?;5!P_!M@Y:9\ =FIB#E(2
MU=JKC.-J"\&0SQW'(HU)_S7 MD!8HG4$RQ9@UQ <)?\]7NS/ K;FK64:%ZTV
M5YHJNL=9"$W@_DE8N#S45ONBXW"M90)O'8N 7.DZ$M-ZC%-YEP6\SM!=A>PJ
M?_:R>9$IP%8NJ0#[N =;(>*=/6NF:T)CVRS'$8Y5'+/'"&8"+Q7+4C_DX1%!
M]J2!QP8:V/)DRHMMM6EJ;Y\R>=A5U7V47I26=R"%Y]\O* XGSG@1HL\3JB_@
MQ5?<"-->>)$0\OR+;GB.H/W<"RZ<=\%+K[GCQ&D?7' )AJ=W%'P"XHRX<_Z2
MFSS8,8B-RT5Y:3.Z._K1USV([F8;6BH;T5)1#WM#&X8Z[!CM[L% 6S?ANITV
MC@-+HS.XMKF/.P=WL;]U'1/#\[1=NE&<7X?"W#J4%C:CIM+N!&Q%'5F ?73M
M+<"N;1I&@[S8!&O!M>6YM@!;4UT+B3X++J7+5#!L>>66@6Q!LG2=PO8GIZCO
MII7G?$ 8(=#JI2_U=(]>P*@5FF/1A%(+_+0=A4P;\#1RC7:IO-<\IBN/36BX
M1-7#5]9N$%+W"(N;O!?6#63/SNUC9?6&65\O3@363KF'S6UG6R\G7#M[9PMV
MY5W6-=9U=^;W_W/ %H@+^O4;>7\MC[?TGB!;O^_JEO=:W46F8..R7MD#M$6&
MAN4UEG=>J0R7,36U^W1[.L99[0?WOU]ZT3YAI-<QSND8[:DA(_HLP)Z;(>Q/
MK''9L+D_JBK:S/K*Q1X?73;PK6KB,]/;6%R0-YOG?T*0O6 @N[]_P;R$&"',
MCTT*LB]C=$)5PZGW>8^W\7B:>,^7U_0@)J$8I\\&XG.?)US_Y@E.3^,W.!5H
M"["??>Z2D>>>=\$KKWH1K@-P\E00@=H/+[S@3KB6%_L"GG_! V<O1,(W(!W^
MP1F$[7C>X]$(CTQ'?F$UGS$''+8^-#<VT^:NI$W=B,G!?JS-S6!];AJS0_UH
MKBQ#3'  3K_V"EYYX7F<.WN:4.UIH-J(EQ=\/#WAY^F!0%]O1(3X(R$V#)FI
MT<C-C$5.1B2RTD.1G1%*6X* 3;C.S(E!6F8,4M+CD9&5RGTAZU74HE;MY^K[
M3-I;8]T(;8L15);WT>YN(ZA74]<7(R8JEX"=@_3T"C0T]&)\DO;IEEK&W>#]
MM(RR<NK(K 8#U,7%M"O*>U @W9E:@X0D52BO-I"=E%Q&VW4,'WWY?V8.MEGH
M_!-@[Q&PT[.SX!7HCZ"H"(0EQB(L(<;D8T<0KB,I49R/>@K9B4C*H!++HA(C
M9*=E4P'F<$I)Y7Q*EOIH)R A+0X)Z51XF?'\+HF0G8Z\8@$V%6^9,YR\6+G;
MRH^VQ+3[*C*0;:2T"&4EA81,9WZV!=;R0%N +>BVX-H2*Y3\LY^UKGZG_R$1
M-,LS+<^RI@)I@;7EM;;@6Y^M<'$5/9,GVPH7EWP2 N[,QQ9(FTKC1YYNS<N+
MK:D,W,6E60Y*JP:P9^<F.? ,<R"8(*@MF1#Q$8*RP+FF1A7.:TU/[F$NFR=@
M+_'[Z>E)#/*AZ._O-; ]-SN-Q<5YS' ;0WV]Z+=W8[C/@=%^.P;L;;"UU:"]
MH<A =DMM&AHKXU%5%(SJXB!T-<1BHC^'D%V$Y<EB G89MA:JL+-<BYVE.@)V
M-98G2C#9GX7A[B2,V),Q-Y*-C;DR[*W6&-E>K,#"6*YI^>5HB41W8X213L*M
M0K6[6L+A4"5Q G9W>Q0!,I*B*0&Q*8K &$ZP#3%>;(6-M_ W FR;^F=WJ^]S
M-'\?93S@ME9Y=@GH=8$$9F\:^:XHS;M(V%;A,R_CL19D.]H)]&TQ/.XPX[EV
M K8?&BHX+\"6!YNBGMJUIK>VL[*XI@H=KRCV0VF1+Q6E4TJ*_%%63/"F%!?Z
M(3^7DA?$^S,>W5U5-.XG\.:CZ_CX*X\IRL5^@O??>XBWG]S%PP>'N'/G"@W_
M7;.. 'MEE<9,?1X'@4 "-D$^G_M0&8"VYE#S4J&+@-W>2+@AS#37N'/JCJ9J
M>;#=J,@)W8V!:.6ZS4WA:&I4RZ5(#E:1A(XP/C>!*.'^"[2;>'[;.@A0;5&H
MYKDIK? C2(>@L3690)>/YG8.=#69*"A)0UEE 3IXOXY-3'$06Z3"FS8*7JU
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MQOI2L#15@,W%<EQ>KL#&0BGF1K,Q:(LSA;FZ"'WV%N40$Z1-2ZZ(3P%V=[N
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MW8=?Q2H!8V#Z"IK[MU!E7T=U[S::!O?1/GH-'2.2J^@:OHJ._CTT=:ZBJ&(
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MRPG;ZE5=2."F%!3EHJA$;;=46;S(0+8)&Z\H)MPZP\0E"@\_GH-M>;,MF+:
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M468%42D%HY+W3GUC !H: E%3Z4NX]D!9+I^GH@#T-R9C?;#*>*[O+@S@]LP
M;DT.X.;X &Z,#U*&<'MB#+<Y+MV:',.-R5&N,X&'R_/XZ,H.OO/@-G[O[8?X
M^H,;N+%*8ZFE$MEQP?!W?0.73CYK(-O'_74$!YU'9*0[HJ(\$!'NBE!"=E#
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M73!YUP)L"ZIU?RL\W)+CH>-?>N8<7GS)%:^^YDF(5I]L+P*WIY$W7O>@?O#
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M-DY-A?#6: /8@FL5.:LGO*O064>SP#N&ZSM[9@NN)4V$R<8:'[0V^,/>'FX
M>Y+_:WHT"Y-#&0:PY<7N: Q#4W4@:@G$545>!&A?-!(0!-AM=5%HK@I#76D
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MS*.ER8'"_"K$1*4BP"^*US;9?&YMME/O]1*NVU!948VRL@K:2(VTC>W&BRW
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M'U&^-O\?#<\1 OSX]"$F9@^-E[N/AI)M< 7MO3P_A.P6&\^?3?,T9/E_6VF
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MXD!V#CGYEY"3XTDCWX_WLQ]B8WV1G!)! ,BA$=B$GOX^WI^#!-\>5%3;4"G
M;E'_SC4J:X*W?8/&W"HZ%-8L,*1!H>^ML,JZ!A6CH&*C0E5!LVLWW\.M>Q_A
M\NY]$R;8WJD\PT'^9MC M8H+M='8[.Q:,(9-9Q>-/6[?@+9M@X;J*I^I>1JB
M4ZCG_VCKFH%Z4T_.[F%BA@8%#9OV=AJ'[31N; +G#2-]O33\AO1&7;U>;U%N
M8DIAW,J7IE$HR.ZVR:"A$46#6% [/$9C8O$65C8>$:Z?8./R6X3MQUA<NV]R
MLI5W/3R^CWX:E,I/5*ZBC499GXS,"4(VX5HP/#RID$I^/\ACH6'4X2!8$Y[;
M:<2V$:1;]6*BFP:S;1D=1C3/?:%T<KUN50BG8=:O]B<TL$V1-<*_('M\DA!/
MT!X;(V";$'$5N=G%U.0.)L:56TX#SK& +AJ&+0T3O+>'45?1A_IR.YK*N]!%
M139AFR4L7\-[US_$=][\#KYU[^MX^_(#W)BYC.N3J[@QNX);<XN<3N-@:@B[
MXSW8G7#@0"V\YL=P<VD*-Q>G<6-^"M<)X5<G1W&%8]P^(?J*A-"]-SZ RR.]
MV!KLP29E9VP 5Z9&L#IHA[VJ!-DQH0AT.POW<Z_"X]*K"/0^A=# <P@-/FNJ
MB <%G71*R!F$A)U':+@+PL,]*%X(]'>#F^M9G#]["I<NN" TA 9$?@7'R6E<
MNW8?;[WU94+VNS@XN&T@^]UWOXS?^_U_B[_^FQ^8/.R?F8KBO\0/_^$G^*N_
M_@'^Z$_^#-_\YG?QYJ,/L+=SAV,JP:*7!C8!NYGW:&?W-$8G=GA//,*UVQ_C
MUH-O<_I-[%S]&&L['Q"TWR5HOXN%M?>PS/G9A8<$E'WJEWGJ!!D$?10']5PG
M,C-K$!>71V 07"?R6&,0$AB%,!Y#'.$R-RN?QDXURDLJ"8-Y!&OJ5X511\LC
MG&Y"PR6% NO<(E03Q&MH6-:4E*&JF.!<7(:&\DJTU-1RO&S@6%G'\;#F*5S+
M<RVP5A5Q314J+L!6[K4\U()KS1_/P<Y.33/ +<"."8M$&"$ZT-N?D.V/Z+!H
M_IX GIR.. *TPL:US K-S4G+-ON=Q..PPL+CU <[6E"=C%3"<EH<MT_1?%)4
M N(5]AT:;<2TU^)Y28U7>[(LX\57OK5"PT/\PA#@'8(@_PA$A-(PCDI#?$PF
MDA,(UAD\UJ(ZU%:T4O](VCCF-M.@KD=>=A724TIHH)<8 U %<P38)L=/1MR1
M1]F":PNP-;7"PRVPML0*#;< NY. +3$>ZPZGUUICC0!::34"<AF2=?6$:TJ]
M6CW1D-28I#H,ZHT_,<7GF\^V %OAX0H#%U2KW>%QN+;Z75NAX1+-6X7.QCD>
MS9B07D$0QRA!NXHI$OKD)1\:5H<"CIT< \W80^#NXS[T<[E NW?P*!^;\P,<
M^YQ=#SA5F+B9:IDS-UO%SWJXC6[;O*F7(?#O[)Y#4^L8BLLZ$1V;3R .P3//
M.$/$_^7_ZR5G+O9OG<(7"-1?_,(%?.E+3OG"%\YR>HYPXP,_/]J;4>D("TN"
M+Z^WF[L_+EST(.2XX)*;.WS\_;CM:.3D9M,>*R:<E:"\N !EA7G4WP6H*BGF
M/<_GI+22]@;MO]I6CI$$;L<$=>PL[:MY\S+ 7#..G3+J)6WMZMFL;@V3U%-C
MM!<Y'G1.&""?&-_&W(QLL .,C_*<*G?=H?!P9XBX6ID)G,UYYG4P+Q]X;:PP
M<<N+K:GRM-4C6]7L!=@2>;)5=5N0*D#52PM%!XR,JKC89>/17EY1SVP![E4N
M7^,VQGGO<KQO[.5^CYFH@:F9;4+M 8&9<+U+D+Y"N";H[%]Y@+V]^P3N>T;T
M^>#J(Y.+O<EUE<LMC_CDU ;OG\O\7P=8W3C$VN9-K&_=,I"\OD' 7G,"]C0!
M6R]M=+P]/8H0FZ,-.T.]/$=]NX31T4W,<9_7".C;VP+L6Y0;A.Q#PK5"P[EM
MY<>/4T^V.)"=6<SQ,=9 M0I\N;DJ%S\<$>%)2$KD.)":CY043M/R4%1486J/
M]-!V&1K4-1V'K7L(JDW2T=Y'.W:0UV2<=BQM,IX3=4ZIKNSDF)L'EPLA>/4E
M-[SZL@<NGN>8XD]H#LF&OU\*7%VB</Y"*"Y<",/%2Q&X0#EW,1QG+Q#(7:/A
MY9>&B)@2)*36(B*N'!X^:?PNFO=X%->-Q)FS(01L'P/87_BB"IXY*XH_^]P%
M+CMO /O9YT[AN1=.XY77",YG/>#*>UO]W/W\PN'I$4A@5@_L<P3J4WCUE3?P
MRLNO$*R?Q[//?)[/T6_B^><^CY=??@:OO_X"UWL1ITZ\A-,G7L;94Z_"[>(9
M! ?X((%\EY')<3HSBW9?.F+C4A$?GX6,]#*";@,AN9723ND@0'=Q:D-1@9WB
M.)K:45QH,RWL2HK;D9=3QW-?1ON1UR"YC)S4@TG>D[N[CW"9ML0(;;3*RFYD
M9]<2X-MAMTUA9F8'L[.[O!?F37M$I>?D$\[+:)>HWD"SBDQR[&VDG>?L*<^Q
M]:GPN6ATOG@J+NE ?F$S[^UY O;O_/\'8"L/6X!M ;6S/=<GGT.4@TW #I;G
MFH =RL%*%<.=(L^UX#K"B+8=%A^%</XF,BD6403/Z!0J7X)G;&J\D?BT!"1E
M)1O(3N$TF9(JX"9LYQ1FH4!@3< N+"%<%V<COSB+DFWFB\MR45I.R*XD9%<Y
M(5LP75=?3KB66(#M]' +L"TOMY6?;0'V9XNF6;"M4',+LMO:&@Q0=[2W</"D
M=+126M JP":X6X"=G!)O/-BI:8F?\F!+2KA.%?^'O,X]_38,C_9CE,;F$*?R
M:/?T=M/P[^1@HU[:=HR-#F-Z>@*3$V,<G$<Q.S.#U:45S,_.8WA [01Z,$S8
M&1L>(*3U\W,W;)T=Z._OQ>+"' >H3:RNKG [(^A2?VW"=6=;*W_32P <P^7U
M93RX=1WO/[Z/)_>N8V]C&N.$;%M;$<$N$ZWU:03D6!H<?BC,57]H'S34".["
MT4H0;JCSI_CQ'(08;^G@0"*&*'T.PEL'P:[1CU#O@_H:;P*V-Y1C+="3)U5>
M;6=1,[7D4DLL7QHX*O(52( 4^*E0F@J'!1-F"?B5!,=R#_Y_7W2UA*&W.]9X
ML0<(VOW=\830&-A;"?R-\F2'&%%^=AM!N:[<'R5Y[LC/<J&QZ,IY><3E&5<;
MK!ATMR:@NR7>>+];%+9>P^]JG7VXFWE\334*4_>B>'-Y((&5VVV,<DI##,]3
M+"6>()[([Y,(YVGH:BW :%\#5F?[<&UG'F_>W<>';]W%Q^\1LM]_@J]]^#:^
M_I6W\?Y;MW!U?PZC@S4\ODADIEY$2L+K5!RG4%9\@<?NR7,1P.L:;"((;!TJ
M&J=*ZP&\#H'H%GSW1O/<QU!9A**1Z]=4NJ"^U@/-*FA&<-:Y;ZCUY;D,,N=6
M40+6N=6TG>>SB=>DHM(3ZI&=7^2"[%P7I&>Z<J!U07RB*Y+3_)!7&(OJNGP:
M0K64%AJ3;7SV.OG<]*.% -W5N0H; =OFV$*W8QV=MC4"X0J-Q04:>U-<WVF0
MROC3&_?QR6UL;M\U8>%;E^_26.3OJ-0:FQ6*.4 #<]0,J'HKV=8F#X&*PBCG
M;<F >[=]E?^'@$ICI84&3T/S!%II2*KO]-3B >97%9*]3V-PA4://$)4YOH=
M(5UBYV_[!U2,Y0J-RD/,SM\TTXG) X(IC58:@_(4V6@(*=^QAT;EX,@V(?HJ
MYI=I-&P\P!J!:F7S(9;6[V%VZ18F57%W<A^#8ZKHK9[9:^BF$657<3*%<](H
M'IO>Q^B4\J:=D-U#0]9&6.ZDT2D/=7LW#>6N>2-MG'="-8^9^R#I.A)M5Y M
M3_;@Z&6.)=PV]WU\ZBK/)6%[@H:R"JYQN0H5";(G:-R,\G\.*:14_T_A^XT3
M?.Y&T5HWC);J/C17]*"]NA^#;=/8(+@_VG\77[G[-7QT\P,\YG6ZL[2'FW/K
MN#V[C#L<BVYQC#H<'\+5T5Y<(R0?3HWR^VG<XAAT<WX.UV>G<# YCGU"MD+*
M]PG1^U/#V"%@;Q&P-_KM6.NS87NX#U<G1K W-H39SE8TY6<C*80&TZ53<#WS
M,CPOO@9?SY,(\#N#P("S" CD-.@< ?LB@D-=*&X(#?.D@>U#P/: VZ5S./7Z
MZS2,7J-1<1[N;H%(32WD<8]3R=_"O7OOXLZ=)S@\?(";-Q_@R5L?X#O?^1[^
M],_^DJ#]=_B[O_\Q_OZ'/S'S?_PG?VX ^\F;'^(:C<_UU>NF:,O@(.\C&K9=
MA!<'P4&5Y-<N/\'!K:_AYOWOX/#NM[%S[6.L;+V#F>6'F%ZXQ_OG)N%FBWIC
M!+EY;<C(:J#N:*8QT8;<W$8:AD4("TU&4& L)9K'&TX)0VA0).)CDY"?2YU7
M[@3LW,Q<),<E$:[CC4<X.RT31=EJET5(+BI#?44-FFOJ.8;5<;X*5:74=P3M
M.L)S4W4-VNKJ"=IU)C1<RZV>UH)L?19P*P];.=8":(E"PS458%NBSX)NP;?"
MNZ-"HPBW(83L0$0$1Q">D[B?R2876M]IJL_*&\^@I,A;$A5/\(XQ$A^98+S0
MZ?%IR(A/1V8\UR-@&P\V 3O!>+;EY8XU8>>I_'T6X5H%=R09*=E(Y+HQX>H1
MGLCSEHFTE&)D9E308*PPX8O%--[J:,2U<JQIY9C3PFD3P:.VVF:JV>;20-3+
MCIR<!NIWA8@/?@JPCWN6+;'@^O\*L-5%P43&'$&V(F6Z**HLW4&X;N6S)X.Q
M3O!>.\RI@&K<@)TB<@2NXQQG)C66$(8%S H/E_=:XZM$\P)N%3H37!_W7A\'
M;'FQE8<].KYKQ@IYFQ5^;K,K=%LP+R_W#D8Y=@US7.L?)DSS=SW\?8^94CCM
M%1AR6_I>X^00QR1+!@77W&=U0M"+2AVO7B#4\SQI[%;J2Q//3T9.$[Q\U,+(
M!\\^>P&?^]Q)@O4)@O5I ]+.8E 738[K%PG8IOHR0?S55SUPZ5(P_/QIPX;$
M(R H"A[>0;CHZDEQX[P70FCS)J<D&"=-9641X:D0%;0O*TJR"=A9*,I-1UY&
M,G+34SF?2[U9!WM7+V%K&F-C"X0R]:>>HCTXRFLS9'*NFYJ&>1PCA.PQ7L]Q
M'M>$4PC8W=U3M,66,$[(GN9UFISD.,SS.#*\17VM4'-!M+/]EL*_52'<"@.W
M@%KAX!(5-5.U\>-PK7F!O54<3/ OR)8G>W!(W3.<@*W(&N4SCXU3-ZMSA5Y<
M-RF";)Q ODA=L8W%Q6N$\)L$'T+T_B,<[#\VT]W=!X3;!]C9N6_$?*9L;MW&
M$H%]BK\=&R/,3PB,=[&RPNUL$N@)W^O;-[&QK?SL6P1LP?@A(9S[,;'#8]S@
M?>P$;$EOSR+/RSK/TYXI$+?%W^SL$+!W;E)HF^X)L ^QN7D%4Y-+:&MU\/DL
M13B?;Q_O4+B[!\+#(PA>7B'P(6 '!9([(E.0F)!-R"Y ?AYM_>I6ZKM>@MPP
M903=74.F)DE[6S^WIW9K*H;6@X9ZAQD#B@AVB?&%\'*/QANO>N+%YUQ,2[B+
MY\/A[9G(,3D5?K[)\/2,@QO7<76+@HM[)"ZYA>.\2QC.7B)DNT3 U2L10>%Y
MB$VN1EQ*+<)BRA 8F@__X&QX>B<9+_9+KWA"%<6=@.VL*"[ 5L_KYUXXBQ=>
M/(O7W[B("Q>]X>T3Q/N;.B$PG,<;B(L7/''BQ 63#O'"\Z_AN6=?Q#-?>I9@
M_24\__PS?#9>P)DSK\/%Y2SW]2+W_9+Q7+M=.@N7"Z<)V%SN=HG'XXW(B' D
MQ"<@.2F5YRX=20DYA.,BI*=RW$RKX;C9B)RL5N3E=A&Z[81L!Z471464XEZ4
ME/2BO*(7%15V0G,G\O*;D)961="N($C7<RSKPXBJ[:_?Y76^P?M\P2RKKG;P
MGASB<R1;CV-K?;^![_+R3MJ8=HZ]?>0Q.5N<8-W0,,YUQE!7QS&8>K2V5J*Q
M<L"D3A04<A]Y_?KYS'[MZ_\_ .Q_!M;'Y>COQS_]":Y<OX;LH@+XAH<8CW,$
M!YQP0G;849BX@>@C4?NN3TNL@6F%EDO".1_!91&$\@A!ML+##6"'$[ CN$X$
MUX]$6 )!.S&:H$W%FRS8UI2*-#4.L>GQB*/$$+ZC4Z@P.9^2DXIL G:^X)H@
M75":@WP.@ODE7,9I :6(RTKX75E%@7.PK"DQ,%U;1^-!WFQ*K;S7!&_!LS-$
MW G.3KA6>+A"QYV ;15-<Z[KA&TG9%<Y(;NEG@]B(P&UF?#80OD$L.L(V/)2
MY^=GF=QKP;5"Q=7?.S,[#9F<9G":4Y"%"OZ/ULYFV)4[W:,>V2W&,][5U8J!
M?@<-X&$.6F-&IFF43HR-8*"7\-W=C:&^?LR,3V%V8@83P_R.,CL^01G'V.
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MW;_%=[_^*WSV^GM\^LFO\.#P<QJ:SXW1.$P(T4.07HZGJ85#;.U_CGM/?FL
M^^ZC[[%]ZW,LK'_"\7-@(A"J:@>1EE[%\\U#7$(ATC,K"?\UR,JJ,(6:8J+2
M$1Z6A+#0>(0$12$L)-IXL#/3<U!JKT!-51UU<;7)(\VE,:1"8?(DEQ7:45-:
M03BN,=#<T=1"O=1F^ELWU]4;C[3RJK5TUCFHTYK->VK/I3!9 ;:KU5:IV4^B
M=14]DQ?;@FQ++*]V=JH 7TOUD4Y':H)RK1,01<B.I2$H#[NV:2G/<AHA.3,E
MRT"V0MOEL198)\8DN;SQB1G(2>&\>037^5SF\G5V4J8!;.5J&V_ZD>1EV0C6
M=NIXSL.%92BPV9&;5430MKN*\J@@3WD[I1/%]E84%S<;+TL3#3=!D@&E-@F-
MN!8";=,HC42"=K7:P?33'ABF+4 P>5=%W 79Q^4X6!]?E^Z16(!MB6!9]YZI
M\T!=)#'W(G6I"O:H@(\*^5C%?!0"*0@?&=DQ8==*_=#]+#@6+ NDY;&VO-?R
M7!^':ROW6D ML6!;ZZY":3=XG%W:)=M&/TI?=O(<]7!1>F5QF3IO]2'FE^Z;
MOSDTMDD]+_VS1LC>('03V*7CY(6=ILXDC*N[@61<WEOJV9'Q/>Z_1:A>1F/+
M#!PTCELZ%DU?[8Z>5<XYW0@-S\>5:S$F1_7"A0!<OAP,-[=07+X2:HI"J?KR
MB5-^4'5F ?=''WOBS%E?N%T-@8\? 2N4 ,3[Q=LO!.Z>OO B8(>$A2 I)0[Y
M^1DH+\M#-6W)FBK:8U7YG!\+45]=P+&?@V);"O(RDU"8FX6ZZBKT=?5Q7IXG
MU*UC>EK]QOD;=E)'M@RCB3#6Y!SB7#7*:SUI +NW3][D>1=D][IZ.0NR!15S
MG!,$VI)9X\65M]K5?DM%YJR0?'FT55E<H> 2S9<J:B:H5N27J6;/=6V3YUI@
M;57AEEB>;!41LPJ*34YQ3N9^'807A90K)'^$OY_>5\[VUM93W-A]AEO[+W'W
MSALC=VZ],J]O'\FM_1?8O_G<[+>YX:J2/L=Y?';F)A87[F"=Q]GFG"[O]?8>
MEZKR3<#>YNO-'<Z5JJR^>HA9SGGCDS=YGIS/..:'.;ZF. :7#%P_(EPK+/Q3
M O4SPOP3W#EXB+OWU(;L$&MKNP3C,0/745&$6A]5SPXQ_<X%V3X^X?#T#"%T
M!IOU\/ DI*46P&YWP.'H@+.I#TV-O6BH[^:RC_?Z,.%Z'.UMHW#4]:"PH!YI
M::6(B\TC/*?#USL.;I=#<?Y, "Z<#<(UMRCX^:0@.#"+>CD'04$9\%?K+?\D
M^/H+L 77T7#SC,05#RX)V5X!:0B.S$=,<B4ANQ'IMA9DY;4A,]>)F/@20G,\
M3I[V,P^*WOO W54DS0"V)TZ=]L*I,YZ\%[P,7(>&Q2(^(04)B:F(C(R%MT\@
MX=H=9TY?(4R?QT<?G258G\0'[W^$DR=/\KT+O#:<(SF')B5$FU#P3/)8>DH\
M$N.B$!,9BK#@ /C[>,+/VP.A00%()&3G4-?GYQ93RF'+KD161B4_5X/LS ;D
MVEIYG0C/]@&"K,!Z!!758[0=QU"M=+.&"=IZ8X3F$9,+74:=6U3<@KR\1A06
M-1N'C!XBK=%64B$\K;=WS)A]RQ5^7M$-M=ERU _1OE2^]1CO,XW[*>I!P;?
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M@?N16<X3N&:7Y*6^0R.3$$O#LT^&*"%[D,;3& T?>:\%V+,T5B73-#J,1]N
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M7*HI.&9+L2$_/0^%&04H3,\WD&U+41ZV"KIEF/.Q9? \TC,(T@)LV@IJ&U/
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M'(^<"[74^P:N.5^I"-GV]B?8V7F&O1O/"=.OC.S??&%>:RFY*:_CQA.35[[
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M1QA/:#L!VH0O=RM\.1D3(VG</Q5#?03M'E6_CJ<H##S6P+:\V0H35T&T9@.
M+L"6. F8+<V1A$6%ID>;4&:%IK<T$2"YWL-C6#G;PUP.=B<2L.,)UVK?%4UH
M)O"WN(JIJ2U8;44P*NS^*"OR)0C[TI ,A*.2QW-$$Y!CN7\<P3H.PP39J9%4
M+$YG86$J Q-#//>N6 QTQ!.NTS Y8,/T<)X![.&>#$)(DO&&.ZK"45T6QLD[
M#!4EX03Z$!I]$7 Z,C$[[L2]6XMX^^(N(?LE(?M+_.[;K_#[WWR)'[XEO'SU
M""\_V<:MFZ/\?1SH;L\B(/.\Z_G]6V/1V\7K1NEJ5_5OA=\'<AE(F XAY$9@
M:"":$F.6 [U1W%]>;EU#?P*['Z^G/\':#_4UZB\>8*ZUN>Z4>E[K\@HO*B5W
MV,L\4,IU079QF1=R"Z\C+>LRDM.N(+> T-[,[SW9A?6U!:RMKF-V>IF )AB6
M!XC&1Y? =9L&FW*D!=CS''\R^F8(@%L$UOLTTE18[!Y&:)0IO$Y ;4+7"-<N
M[[7RR^8,M NPVPGN6LJ[TV5:?\DK/0<G#8]6&0P3VUCA!+U[^R76;SS%!.&Z
M<V 1C>U4RBT\IJF^*\!V%2P3E"JO6DM5Y)4G=VSBIH%2P?3:AL+:GF/GQDNS
M7-_\A,;!(\SSG.6!'IW:-> \,$J#<G+';!-8+ZT_,+*P>FA>3R]HWQO<;P.]
M-(0$VOK<" V3"85K$ZSGEK4O#0^*H%L&J4#:\E3W<"(28 NL!> 2P78?WQ.
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M^*O??(;?_?H%?OG9(1[>6R+<MZ"[U8:FN@1.]/'\KG'H;(TQ#R7:6Q1R'VP
MNZ,UD+]%$'J[PPC:D1CL5TZ\"[)[.@79P;R.A.LZ']15>:*VTM,4C6MN"#(/
M-Y2G75--F+9?17[A%1257"-D>U*\4&!WY]B]BO3LRTC+=(,MWY_W6S(G]#HL
MK8QS8EXC9"L_37EG$S0.*.VS5)J$/1I/O?*&T*"4L:E\/A70V>9DO<REBK<H
MG\W9/&84<5>7PKCUU%X>FUEC;,IK[0)L>;&7#&!WR+O"XYF<1RKSGH%5PND]
MW#QX0WF-V>6#=W!=WTK#Q!B;<S0<%]]Y>[7L[.'Q*!:8RDLC(!5@"ZAW;[["
M_FWEA[_%C;W7V*2AL;KYQ'BLY846+'?)L)%!0\/)@NQ%&D[R9&NI?2?G5&%W
MQWBP]1F7-WN+P"Q/SSX_1P"F@;*@\$L:&[-++LBVO-G:]SA@ZS,"<.5?&P#G
MN9M";$>B[R;/_, 0X9^&L\+;+= V@$T#1]]1WOF%)9ZC6GQ-T_BEP6X@F]>]
MG1-E&Z]OBXHV$;";"=J=SC',TXA^O$_(?O$K_/;%5_CE_:=X<^,V/EW=Q).%
M13R>=X'UI\L+>+8\AT=SD[@UUH_MH4[LCG7CGEK8[2P2KM?QV<$&WA*R7]]<
MP\OM53Q34;3%6=R;TF=<@+T],H[5@6%,='2@N:(,>:KS$>0+W^N7X.%V'A[7
M+]+8N0(?G^L4#X+K=1K9;KAP_@).G3Q#XX. _=$Y&BR7C/?ZPP\OTH!1*-TE
MG#_O84(('02Q]?5]/'WZAO*:AMU3W-R[B]T;=XSGY.DG+PUH?__]7^%O_IJ@
M_??_%_PW__B_XN___O^&W_[PW^/%ZS_@YOY;3,_?YUC807OO)CKZM]$WLH_1
MZ?L8FSGD;W4;C2V+R,QI1D!0%HV?2!I-40@-349<7#;2TXMI.%:AJ+ 6104U
M4+_1]%0:@_%IB"%X*CP\*8%@2\#.5<$P0FP^1=[K4@*P0%@YTRK2)$^TTU'/
MWXQS4UV]>2VQBI8)GK6OM@FL)8)O*^=:^UC[J2>V0L\%M )JP;6JB*M5U_%J
MX@)K5S5QSM<Y^83>'..9E@?; FS+DRV@%F +B)6#+6^W!=D2"[!STWC,;,[Y
MN24HHU%=PF6QC9"=E<O/\3H0L+-Y7IF$_/24#"ZY3?L75<%1T\(YHA>=;<.<
M.T8YC@G4!&L9<H(4>5>.0\QQF+$\A1;,F/TH\G(W*E2Q1;#M FS!YW' EIZS
M /PX6!\';NUGHFFD(PG8 F>%A^NU*[^0QZ=HW8)PM0T47.L>%6"/CKA:"0K*
ME<^M7&NK>KC.U0H1/P[8 ND)@J_$!=7;[T11/,<!6T76NA2NSJ4>WDEGZJ&=
MHGQ6UAX2HI[A%O7M/O7M-M<7J'--QP9"Y* >.BK\6;G&1[G8 FPCU$/:IEQL
M4R1M0OL0PK7/S!U,S]TU2[VG\^ZG;AT8I@RITK@BH48Y3[4BF9 =&II)T(C!
M5;<07+KH0_'$]6L^\/,-0C#A.B@@B,"@JM)>" [P0T)L)&Q9*9R/,U!>E,7Y
MWX;&JGPT5A*NR_BZ-!-U9=F4'$H>'!7%G"<K4*\HP*HJZL$64Q1K<FJ=@*BH
MIPU>QS6,CJGUF:ZSH%MPK993+L_R(,];D"NQ<J3'QK=,V/8JKZ-:HJERNSQY
MRKMV <DH;4_76+7&H<:EQJ?&H@!<4*(P<AU38H6'Z^_(8RVXUG850'-%7[C@
M6J]U#FJ%)< 75%MB/-D\EYTCV20P"YJW.>=MK#\R7F:%<H_P=QGBG#O*\]7K
M/_9@"["?8>?F,VSO$<HIFRJPMOG8P/6"\=0K3>FV>:BPSGGR)O>_<_N%"Z[5
M8_O!*Q--='"@G/#[M%E5_(WW$.&ZH*@,R<G9A&3R1TH.$A.S$!863\A6U?@C
MP#[GCC-GKAFY<,$+UZ\'PT^I T$)A/)DA(>1=V)MR$@OA2VG"EF9%8B)MIE6
M;Z=/>A.NKYB">A^\=QTG/_;"V=-^.'?6'^?/!?%XH1QG$7"[$LWCQL'3*\$
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MK@3BXCD/N%WRA)>[+_R\_>#GI301#[A?=8.[VV7X>KIS#(8@.RT)I079J"5
M-U85H(F W5!.H"[)0*T]S2SK!-ME-CC*"WA?E/"^H6U97D8=V A5G!X;7S6
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M//>Z$!IX0:BJ(, 7^Z HWPL%N3XHM8>CK24/2_/=>/)P!]]\]2E^^.X+_(Z
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MUL!V09'3M.229UKC7P]P[A]^A0</?VD\V+HO!-<2@;8EI@@EEX)D@;6\X0;
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MW#&!!JB=NJ03G>W]J*MI08E=@-UN/-=]O?,8Z"<XFH@9 G7S!$&;^L' \H^
M+;@Y'@XN.0[>+KA6431Y$_\\8%MP;4&UM6Y%CNA^M.Y)\^"+^J^]S=7S6G!M
M%393 ;/CWNL_#]B".'Y6YT>1)UK0+ ^V(%N +:^U0K;7>$\OKSXP7D1MUSZ"
M<0&VPLIUGJ[P<!=8]PUL$JY=4"U=(ODQG]KE@9Z8%DQQ'U4.ITS.W#3%SVX?
MO,6]^U]A>^=3$T8L<+3RCM6F:EH/'0G8\@*/3ZC0FN!3>GB*YT3I5J2!"B7U
MTECNXF\W8N#Z_NUG^$0MG/8>86]U#QLSJY@?FL10*^_-TDKD<QRF1$8B*2(<
M:?&QR$Y)0CKMG*BP8/AYNL/KZE6$^OHB(R$.U<5Y:'>4H:NQ'+U-9>AN+#&0
MW51A0WU9#AHJ"-B5KE#R_O9FS(Z-8F5AA?/9%L][EW(3$Y/;!%S^CKR&G5V\
M]CT+[^#:&C-Z**S(*SW8U>^FR 1+]/!8WCWMJX@*C3L!M/*R%;ZML'&]KW&I
MI1XT6V!MP;;RH4?T^QSEY6M<:"PIW4!+C3&!MZK/*X]?XT@I!QI76NJU 'MJ
MBJ#,]V?TON!;<Q/G!?WN>LBB>4+SBN9#/9"U1*\U[VA?I2AIC*B[Q;L'Q>,<
M,Y,W.$_?XMAX@-V]9P:N[SUX3<!^A4/*PT>2E]C??\#S6>6XEE>R#K9<.S*S
M"I">84-2<@;"(V+AZ26PO8;3IR[C+,'TXD4/@K:WD8L7/0G?>NU#X"0O1%!W
MQ&<C(3$7J>F*%FV&HX'S5L,@ ; !H03L<P+L#ZX1KMVXO&YZ47]\PIMP[(M3
M9P((QJZ"9=?<XXRH_[K"P\^<"S"@?>%B* $[DG ?S644_SXA_%PP3O.S\GB?
M.*F0<1_.0RI.IE9?X;A&N+YZ)8A0[4/0IOYS]T%P(.>:J!@#U@5Y.2@ES]14
MV:G32E&O"%PY#3EF;>KF%!&&0&\O>+I=I?Z\"F]W3_AY^Q*P_1$4Z(^0(']$
MA@4B,2Z<8!V+G*QX9*4+L(,1$^%C)"4N&+D9L2BVI<">F\IE(@IRHI"?$\:_
M'T:HCZ:=FH22H@S8"VTH+BSDLI1S7PW/J14CPPNX<_LY'C_ZDK;>/8[?4>07
M-IB'&)G9U<C-;S"YU1J[JI+__,7O\.CQ-T8?"*;EV18X6WG7Q^%:@'P<L%W[
MRHOM@FA7W^LA@O6@$<&VJP?V,< N)V"7M5&_K/U+ FQ"=1:!.IN0S:4 .XZ2
M0.!.LE%YY7+B)-1*7.OI2.-Z>EX&,O(R";S92,_-0:J- )W#FR([QT!T(H$[
M*2N;VW*0PNVIMERSU+;X='FY"=B<G".3U-9+0L!.(F G1E.B$)80:4 [G,NH
MI&C$I<8C,3T)R9DIA/HT_MU,V IR4"#(-I6ZY1563^HR ]OR9E<0O&ODQ7:H
M3[8+H"V8EECAX"8D_.A]P;4)(Z>T$)9-:RZ"M8J<J567<J\E%F W$:#K&S@
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M7;&\V:[679<O1Q*^H_CWPPC^@01L?\X]OCQ'POH)3\Y%7CA_Q@>7+OCCZN5
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M,)O&YL8R[MRZ@</[M[#+\QGB<6LJJ0CS4@G9<2@OCJ+1%H-.9PJ&>G(P-E"
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M>:V=!.5C@&W!M;R-$JW+^#,PS?VL(CL20<\[T":X"*Z/IY=8<"U=8HD%V'J
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M\:9("?TVFM_T>^FAB*#:\EZ;AR1Z&'PTYDPK(H*!O&\:<U9(N$1 +;@6:%N
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M[1@=&\3"X@S6UA<)&@3HJ1%"\1A6EA>Q=W,7]^X=X/;!+6QN<8(C#$_,3&*
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M; ED# Q1!#;' 5NO!4<67 MX++$@VP VQ[O ^D_!M:4G=#])M&Z%AK^[]_0
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MZ8-5_.JS!_CAFY<$[#>$ZS?XX>O7^-U7K_#KMT_P@I!]8[T7XP-VGD,B09M
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MKF\@J#=CW-F*"0+G9'L7(;L+'01P>U8^H@(C<)T&S9F/S^/C#\[BXP^Y_(\
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M>*Z+BVM18G<0RAJHCYVTJ5N0;W<B+:L:$3%Y\/)+P@6W<)PZ%X /",6_^)"
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M^B_>NV8 6[!]XFP )1 ?GP[$!R?]C0BL3YT+)9!'4B*X'HP/3Q+ /_(B; ?
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M6A>I*^<Y]B=14S7$,=2']N81CLTU/+KS&+]\^3F^??TYOGOU!K]^_@IO[C[
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M:8;@XKKBFXY7&WH!NH9WK"=@6S\Z;^?S#S"?&>2U1TTO\@/#![%C\ABF=Y_
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MK_MR0@Q@<\[E^D:U6YXD5.]%=\]A]/8=0U__,2X?,:#=W++'0'9MW02=1G5
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M\(XS5<D%J+[NS/L<7."P3M4#-\)A+1TT0K9*?7W<"9^$VXC@4,1&1"(^*MK
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M>KW.<UZC7GWC#;QL1&>9\U=>?Y-ZPVR77N%SO<QG?.6U5\W]==Z;?.=WWA&
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MW/_FF\\;O?4VU]_1^2^9^^C<-[GM+1W';6_QVF^]]R)M$V&)X?_&.R\PSKY
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$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131165127656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 18, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 Saginaw Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,750,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the definitive proxy statement (the Proxy Statement) for the 2022 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K. If the Proxy Statement is not filed by May 2, 2022, then the registrant will file an amendment to this Form 10-K on Form 10-K/A to include the Part III information in this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131171345784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young, LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose , California, USA<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131168606792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,195<span></span>
</td>
<td class="nump">$ 62,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">270,993<span></span>
</td>
<td class="nump">367,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Add: Lease incentive receivable</a></td>
<td class="nump">5,709<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,248<span></span>
</td>
<td class="nump">4,709<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">317,145<span></span>
</td>
<td class="nump">434,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">86,000<span></span>
</td>
<td class="nump">19,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,060<span></span>
</td>
<td class="nump">27,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentReceivablesNet', window );">Deferred rent receivable</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other non-current assets</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">439,727<span></span>
</td>
<td class="nump">482,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">2,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">18,047<span></span>
</td>
<td class="nump">13,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">4,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,320<span></span>
</td>
<td class="nump">20,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">101,108<span></span>
</td>
<td class="nump">26,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">123,542<span></span>
</td>
<td class="nump">48,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2021: 98,381 and 97,549 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">964,965<span></span>
</td>
<td class="nump">937,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(714)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(648,076)<span></span>
</td>
<td class="num">(502,536)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">316,185<span></span>
</td>
<td class="nump">434,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 439,727<span></span>
</td>
<td class="nump">$ 482,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentReceivablesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental income recognized over rental payment required by lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123394697&amp;loc=d3e40879-112712<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentReceivablesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167729192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">98,381,000<span></span>
</td>
<td class="nump">97,549,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">98,381,000<span></span>
</td>
<td class="nump">97,549,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167608616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">89,181<span></span>
</td>
<td class="nump">73,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">64,441<span></span>
</td>
<td class="nump">44,641<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">153,622<span></span>
</td>
<td class="nump">117,950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(146,122)<span></span>
</td>
<td class="num">(117,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(145,540)<span></span>
</td>
<td class="num">(116,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,114)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(145,540)<span></span>
</td>
<td class="num">(117,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="num">(428)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (145,993)<span></span>
</td>
<td class="num">$ (117,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.48)<span></span>
</td>
<td class="num">$ (1.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">98,039<span></span>
</td>
<td class="nump">85,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">98,039<span></span>
</td>
<td class="nump">85,146<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e709-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170477656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 174,957<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 560,704<span></span>
</td>
<td class="num">$ (725)<span></span>
</td>
<td class="num">$ (385,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock net of issuance costs</a></td>
<td class="nump">344,298<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">344,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 20,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares (in shares)</a></td>
<td class="nump">2,043<span></span>
</td>
<td class="nump">2,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 12,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_WarrantsIssuedDuringPeriodShares', window );">Common stock issued upon net exercise of warrants (in shares)</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes</a></td>
<td class="num">(2,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries</a></td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(117,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,507)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">434,347<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">937,134<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock net of issuance costs</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 25,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options, shares (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued under employee stock purchase plan</a></td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized gain (loss) on marketable securities</a></td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(145,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 316,185<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 964,965<span></span>
</td>
<td class="num">$ (714)<span></span>
</td>
<td class="num">$ (648,076)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_WarrantsIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_WarrantsIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e709-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116633155&amp;loc=d3e31531-110899<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131172326904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 676<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170916760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (145,540,000)<span></span>
</td>
<td class="num">$ (117,507,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,645,000<span></span>
</td>
<td class="nump">4,158,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">25,194,000<span></span>
</td>
<td class="nump">20,391,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium and discounts on marketable securities, net</a></td>
<td class="nump">2,770,000<span></span>
</td>
<td class="nump">521,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Accreted interest on BPI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">1,063,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">342,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(25,000)<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,257,000)<span></span>
</td>
<td class="nump">5,854,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable', window );">Deposit and other long-term assets and deferred rent receivable</a></td>
<td class="num">(990,000)<span></span>
</td>
<td class="num">(18,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,719,000<span></span>
</td>
<td class="nump">1,587,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,612,000)<span></span>
</td>
<td class="nump">1,585,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses, other current and non-current liabilities</a></td>
<td class="nump">3,274,000<span></span>
</td>
<td class="nump">4,147,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,114,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">2,928,000<span></span>
</td>
<td class="num">(1,540,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(107,831,000)<span></span>
</td>
<td class="num">(79,291,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(407,514,000)<span></span>
</td>
<td class="num">(570,386,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">492,356,000<span></span>
</td>
<td class="nump">295,315,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales of marketable securities</a></td>
<td class="nump">8,990,000<span></span>
</td>
<td class="nump">6,748,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(15,123,000)<span></span>
</td>
<td class="num">(11,844,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) by provided by investing activities</a></td>
<td class="nump">78,709,000<span></span>
</td>
<td class="num">(280,167,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering of common stock, net of issuance costs</a></td>
<td class="nump">1,685,000<span></span>
</td>
<td class="nump">344,302,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="nump">12,687,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,043,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="nump">901,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of BPI loan</a></td>
<td class="num">(240,000)<span></span>
</td>
<td class="num">(61,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,397,000<span></span>
</td>
<td class="nump">355,985,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="num">(26,725,000)<span></span>
</td>
<td class="num">(3,473,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">63,423,000<span></span>
</td>
<td class="nump">66,896,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">36,698,000<span></span>
</td>
<td class="nump">63,423,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">34,195,000<span></span>
</td>
<td class="nump">62,424,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">2,503,000<span></span>
</td>
<td class="nump">999,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">36,698,000<span></span>
</td>
<td class="nump">63,423,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liability</a></td>
<td class="nump">84,005,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination', window );">Decrease in right-of-use asset and lease liability due to termination</a></td>
<td class="nump">15,768,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_RemeasurementOfRightOfUseAssetOnLeaseModification', window );">Remeasurement of right-of-use asset on lease modification</a></td>
<td class="nump">2,052,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable and current liabilities</a></td>
<td class="nump">$ 1,402,000<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in deposits and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_RemeasurementOfRightOfUseAssetOnLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement Of Right-Of-Use Asset On Lease Modification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_RemeasurementOfRightOfUseAssetOnLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131171006648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of the business</a></td>
<td class="text">Description of the business <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or &#8220;Adverum&#8221;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $648.1 million as of December&#160;31, 2021. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2021, the Company had cash, cash equivalents and short-term investments of $305.2 million, which the Company believes will be sufficient to fund its operations into 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131172239352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text">Summary of significant accounting policies<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#8217;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support the growth.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb">three</span> to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets and Purchased Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates the carrying value of amortizable long&#8209;lived assets, whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#8217;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within general and administrative expense in the consolidated statements of operations and comprehensive loss an impairment charge of $1.1&#160;million, which includes $0.8&#160;million associated with the write down of right-of-use assets and $0.3&#160;million associated with write down of leasehold improvements, net of accumulated depreciation, for the year ended December&#160;31, 2021. There were no impairment indicators noted for the Company&#8217;s long-lived assets, fixed assets, for the year ended December&#160;31, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, management estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The Company bases the right-of-use asset on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. There have been no significant changes from the Company&#8217;s original estimates in any of the periods presented.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and using intrinsic value, which is the closing price of its common stock on the date of the grant, for the restricted stock units (&#8220;RSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2021 and 2020, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Comprehensive loss comprises net loss and other comprehensive income. Other comprehensive income consists of foreign currency translation adjustments and unrealized gain on marketable securities. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, restricted stock units (&#8220;RSUs&#8221;), employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326, but does not expect the effect of adoption to be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170974232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bond and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,894)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#8217;s consolidated balance sheet. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of December&#160;31, 2021 were temporary in nature and none were in continuous loss position for 12 months or more. Management concluded that none of the Company&#8217;s marketable securities were other-than-temporarily impaired as of December&#160;31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, $47.0 million of marketable securities had remaining maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MjY_6080290b-1a2f-4c6f-9319-23bad6204282">one</span> and two years. The remainder of the marketable securities have a remaining maturity of one year or less.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers within the hierarchy during the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company performed an impairment test to measure certain right-of-use assets and leasehold improvements at fair value. The assets are measured at fair value on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable, by comparing the sum of the estimated future undiscounted cash flows to the carrying amount of the assets. Refer to Note 5, Leases for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131171009144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lexeo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#8220;Lexeo&#8221;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $7.5&#160;million. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the initial transaction price is the $7.5&#160;million the Company received for the license granted. As described above, the arrangement provides for additional payments to the Company when certain development and commercial milestones are achieved. Because these milestone payments are not within the control of the Company and are not considered probable of being achieved until the events occur, the Company did not include them in the transaction price. The transaction price of $7.5&#160;million was allocated to a combined performance obligation that was fulfilled during the three months ended March 31, 2021. The Company recognized $7.5&#160;million of license revenue during year ended December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170676760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Redwood City</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company has a lease for facilities in Redwood City, which provides a total of tenant improvement allowances of up to $10.2&#160;million. Related to the Redwood City lease, the Company provided the landlord with a letter of credit in the amount of $2.5&#160;million, which is classified as restricted cash under long term assets on the Company's consolidated balance sheets.  The Redwood City lease expires in December 2031, with an option to extend for a period of eight years. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2021, the Company entered into an amendment to terminate the lease of one of its Redwood City premises under the existing lease and paid a termination fee of $0.4&#160;million. Concurrently, the Company entered into an agreement to sublease a portion of such premises at $0.1&#160;million monthly base rent. The sublease will expire on March&#160;31, 2022 and may be extended on a month to month basis until June 30, 2022. For short-term leases the Company does not recognize the right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease termination resulted in the requirement to test the recoverability of the carrying amount of the asset group. The carrying amount of the asset group, consisting of right-of-use assets and leasehold improvements, relating to the lease termination exceeds the Company's anticipated undiscounted cash flows. Accordingly, the Company reviewed the related right-of-use assets and leasehold improvements for impairment. As a result of the evaluation, the Company recorded an impairment charge of $1.1&#160;million, which includes $0.8&#160;million associated with the right-of-use assets and $0.3&#160;million associated with leasehold improvements, for the year ended December&#160;31, 2021. The assets indicated as impaired were written down to the estimated fair value, which was determined using the terms of the termination and sublease agreements. In connection with the termination of this lease, the Company derecognized the corresponding operating lease right-of-use asset and liability balances from the consolidated balance sheet</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">North Carolina</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#8220;NC Premises&#8221;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the North Carolina property through October 2037, the remainder of the lease term. The remainder of the tenant improvement allowance under the original lease of approximately $22.7&#160;million was transferred to the subtenant. This change in the Company&#8217;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability on the modification date. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the weighted-average remaining lease term was 11.7 years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#8220;IBR&#8221;) was 9.4%. IBR is an estimated rate of interest used to determine present value of future lease payments in order to measure lease liability, which rate is what the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the IBR, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,672)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Lease incentive receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the years ended December&#160;31, 2021, and 2020 was $12.8&#160;million and $5.8&#160;million, respectively, which includes variable lease costs for utilities, parking, maintenance, and real estate taxes. Variable lease expenses for the years ended December&#160;31, 2021 and 2020 were $1.8 million and $1.5 million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2021 and 2020 was $5.2&#160;million and $4.2&#160;million, respectively. Sublease income was $1.2&#160;million for the year ended December&#160;31, 2021, which was classified as a reduction in rent expense.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131172297176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,797&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,072)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,725&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170994088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. Through December&#160;31, 2021, none of the goals had been achieved under the license agreements and no milestones were accrued or payable. Because the achievement of these milestones is not fixed and determinable, such commitments have not been included on the Company&#8217;s consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170971464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stock Plans</a></td>
<td class="text">Stock Plans<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#8220;2006 Plan&#8221;). The 2006 Plan allowed for the granting of incentive stock options (&#8220;ISOs&#8221;) and non-qualified stock options (&#8220;NSOs&#8221;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs were granted to the employees and consultants. In July 2014, the Company&#8217;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#8220;2014 Plan&#8221;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (4%) of the number of shares of the Company&#8217;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company adopted the 2017 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Company reserved 600,000 shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2021, a total of 33,965,569 shares of common stock were reserved for issuance and 5,717,148 shares were available for future grants under the Plans.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% stockholder may not be less than 110% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over four years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,579&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $0.1&#160;million and $20.8 million, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of options granted during the years ended December&#160;31, 2021 and 2020 were $5.18 and $13.39, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, there was $43.1 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of 2.9 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#8217;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#8217;s common stock on the grant date. RSUs granted to employees generally vest over a 2&#8211;4 year period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted during the year ended December&#160;31, 2021 include 1.3&#160;million shares of performance units with both performance and service vesting conditions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020 total fair value of RSUs vested was $1.6&#160;million and $2.7&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2021, there was $4.5&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ESPP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The Company reserved 208,833&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (1%)&#160;of the number of the Company&#8217;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#8217;s board of directors. During the year ended December&#160;31, 2021, 397,763 shares were issued under the ESPP. As of December&#160;31, 2021, a total of 2,130,542 shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2021, there was $1.9&#160;million of unrecognized compensation cost related to the ESPP.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Recognized in the Consolidated Statement of Operations and Comprehensive Loss</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,194&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,391&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, the Company recorded approximately $1.6&#160;million and $0.3&#160;million,  respectively of stock&#8209;based compensation expense as a result of the modification of the vesting and exercisability of stock awards associated with the departure of its executives and directors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170708424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text">401(k) Savings PlanThe Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2021 and 2020 was $1.0 million and $0.7 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170983368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,375)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,327)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,393)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax provision (benefit) were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for the years ended December&#160;31, 2021 and 2020 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,607)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,318)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#8217;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased approximately $60.0&#160;million and $28.4&#160;million during the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had U.S. federal net operating losses (&#8220;NOLs&#8221;) carryforwards of approximately $393.4&#160;million to offset any future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2021, the Company also had U.S. state NOL carryforwards of approximately $227.1&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2021, the Company also had approximately $50.1&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had federal research and development tax credit carryforwards of approximately $13.6&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2021, the Company had state credit carryforwards of approximately $12.3&#160;million available to reduce future tax liabilities which do not expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has total unrecognized tax benefits as of December&#160;31, 2021 and 2020 of approximately $21.9&#160;million and $8.7&#160;million, respectively. As of December 31, 2021, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate, if recognized, is $1.1&#160;million. The Company does not anticipate a significant change to its unrecognized tax benefits over the next twelve months. A&#160;reconciliation of the unrecognized tax benefits is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,558&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) related to prior year tax provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to current year tax provisions</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, the Company accrued interest and penalties related to uncertain tax positions of $257,000. There are no ongoing examinations by taxing authorities at this time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170675800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,998&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131168538328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212; The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#8220;U.S.&#160;GAAP&#8221;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Short-Term Investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;All short-term investments in debt securities have been classified as &#8220;available for sale&#8221; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#8217; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#8217;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#8217;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#8217;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#8217;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Uncertainties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#8217;s investment policy, which limits the Company&#8217;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#8217;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#8217;s ability to attract and retain employees necessary to support the growth.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb">three</span> to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Valuation of Long-Lived Assets and Purchased Intangible Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation of Long-Lived Assets and Purchased Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company evaluates the carrying value of amortizable long&#8209;lived assets, whenever events, or changes in business circumstances or the planned use of long&#8209;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#8209;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#8209;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#8217;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within general and administrative expense in the consolidated statements of operations and comprehensive loss an impairment charge of $1.1&#160;million, which includes $0.8&#160;million associated with the write down of right-of-use assets and $0.3&#160;million associated with write down of leasehold improvements, net of accumulated depreciation, for the year ended December&#160;31, 2021. There were no impairment indicators noted for the Company&#8217;s long-lived assets, fixed assets, for the year ended December&#160;31, 2020.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, management estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The Company bases the right-of-use asset on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Research and development expenses are charged to expense as incurred. Research and development expenses include</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#8217;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#8217;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. There have been no significant changes from the Company&#8217;s original estimates in any of the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and using intrinsic value, which is the closing price of its common stock on the date of the grant, for the restricted stock units (&#8220;RSUs&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model requires the use of following assumptions:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The expected term assumption represents the period that the Company&#8217;s stock-based awards are expected to be outstanding and is determined using the simplified method.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;Expected volatility is based on the Company&#8217;s historical stock price volatility. </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2021 and 2020, the Company has recorded a full valuation allowance on its deferred tax assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">Comprehensive Loss&#8212;Comprehensive loss comprises net loss and other comprehensive income. Other comprehensive income consists of foreign currency translation adjustments and unrealized gain on marketable securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, restricted stock units (&#8220;RSUs&#8221;), employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#8220;Topic 326&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326, but does not expect the effect of adoption to be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131171007208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s cash equivalents and short-term investments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,323&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(317)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,993&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost Basis</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Loses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,894)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,891)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,191&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,305&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131172305384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Undiscounted Future Lease Payments under Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sublease Payment Receivable</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,690&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Present value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,672)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Tenant improvement allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Lease incentive receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131173228696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,259&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,701&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,954&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,234&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,797&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,174)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,072)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,060&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,725&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued nonclinical costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and process development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,047&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167570920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.579%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except exercise prices and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining Contract<br/>Life (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic Value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,995&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,073&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,366)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest as of December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,579&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#8217;s common stock as quoted on a national exchange.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Option Issued Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the RSU activity under the Company&#8217;s stock plans and related information:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">(In thousands, except grant date fair value and years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Units<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant Date<br/>Fair Value<br/>(in dollars)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual Term<br/>(in years)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(590)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(305)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,875&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,120&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,194&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,391&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131171336136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents domestic and foreign components of loss before provision for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,375)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,327)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,066)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,540)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,393)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Provision (Benefit)</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the Company&#8217;s income tax provision (benefit) were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current tax provision</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax provision</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax provision for the years ended December&#160;31, 2021 and 2020 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax expense at statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,442)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,787)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of internal reorganization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text">The following table presents significant components of the Company&#8217;s deferred tax assets and liabilities:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,741&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals, reserve and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,838&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,613&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,279&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,963&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154,672)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,227)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,183)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,380)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,607)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,318)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">A&#160;reconciliation of the unrecognized tax benefits is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the beginning of the year</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,558&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) related to prior year tax provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase related to current year tax provisions</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,119&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized tax benefits as of the end of the year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,677&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131172332472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,562&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,998&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131172292600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of the Business - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (648,076)<span></span>
</td>
<td class="num">$ (502,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 305,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170814408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of significant accounting policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 1,063,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of leasehold</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of assets</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131165568728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 271,309<span></span>
</td>
<td class="nump">$ 367,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loses</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">270,993<span></span>
</td>
<td class="nump">367,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: Cash equivalents, amortized cost basis</a></td>
<td class="num">(25,808)<span></span>
</td>
<td class="num">(58,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: Cash equivalents, unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: Cash equivalents, estimated fair value</a></td>
<td class="num">(25,807)<span></span>
</td>
<td class="num">(58,891)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total cash equivalents and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">297,117<span></span>
</td>
<td class="nump">426,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loses</a></td>
<td class="num">(318)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">296,800<span></span>
</td>
<td class="nump">426,196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">10,311<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">10,311<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">62,268<span></span>
</td>
<td class="nump">328,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loses</a></td>
<td class="num">(218)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">62,050<span></span>
</td>
<td class="nump">328,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">177,215<span></span>
</td>
<td class="nump">97,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loses</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">177,155<span></span>
</td>
<td class="nump">$ 97,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">47,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loses</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 47,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalent Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131173142264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities', window );">Marketable securities other-than-temporarily impaired</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears', window );">Marketable securities with remaining maturities between one and two years</a></td>
<td class="nump">$ 47,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities, term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities, term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than temporary impaired investments available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170412120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember', window );">Lexeo Therapeutics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration and license revenue</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=advm_LexeoTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131165160552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 08, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 26, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,503,000<span></span>
</td>
<td class="nump">$ 999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLeasehold', window );">Impairment of leasehold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=advm_TerminatedLeaseMember', window );">Terminated Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseTerminationFee', window );">Lease termination fees</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_OperatingLeaseMonthlyCost', window );">Operating lease, monthly cost</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance', window );">Leasehold improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance', window );">Leasehold improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts', window );">Number of renewal contracts | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average IBR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseLeaseTerminationFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Termination Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseLeaseTerminationFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseLeaseholdImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Leasehold Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseLeaseholdImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_LesseeOperatingLeaseNumberOfRenewalContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Contracts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_LesseeOperatingLeaseNumberOfRenewalContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLeaseMonthlyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLeaseMonthlyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLeasehold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLeasehold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=advm_TerminatedLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=advm_TerminatedLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167665048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 6,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">13,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">14,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">14,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">15,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">133,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">198,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Present value adjustments</a></td>
<td class="num">(91,672)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Less: Tenant improvement allowance</a></td>
<td class="num">(9,577)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveToLessee', window );">Add: Lease incentive receivable</a></td>
<td class="nump">5,709<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">102,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract', window );"><strong>Sublease Payment Receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2022</a></td>
<td class="nump">491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2023</a></td>
<td class="nump">5,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2024</a></td>
<td class="nump">6,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2025</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2026</a></td>
<td class="nump">6,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="nump">82,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Total undiscounted lease payments</a></td>
<td class="nump">$ 107,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveToLessee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of incentive granted by lessor to lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40010-112707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e40019-112707<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 30<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123388062&amp;loc=SL77916639-209961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveToLessee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131165498792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 46,234<span></span>
</td>
<td class="nump">$ 37,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(13,174)<span></span>
</td>
<td class="num">(10,072)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33,060<span></span>
</td>
<td class="nump">27,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">12,778<span></span>
</td>
<td class="nump">9,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">26,701<span></span>
</td>
<td class="nump">24,631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 4,395<span></span>
</td>
<td class="nump">$ 1,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131169114024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Compensation expense</a></td>
<td class="nump">$ 9,209<span></span>
</td>
<td class="nump">$ 8,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">550<span></span>
</td>
<td class="nump">1,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedNonclinicalCostsCurrent', window );">Accrued nonclinical costs</a></td>
<td class="nump">2,895<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent', window );">Accrued clinical and process development costs</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">State taxes payable</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">1,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 18,047<span></span>
</td>
<td class="nump">$ 13,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedClinicalAndDevelopmentProcessCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and development process costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedClinicalAndDevelopmentProcessCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedNonclinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedNonclinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170680216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131169316904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair values of options granted (in USD per share)</a></td>
<td class="nump">$ 5.18<span></span>
</td>
<td class="nump">$ 13.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to awards</a></td>
<td class="nump">$ 43.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, weighted-average period</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">One time share based payment charge related to cancellation of unvested stock option of CEO and directors</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares authorized for issuance (in shares)</a></td>
<td class="nump">33,965,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">5,717,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum', window );">Award price as a percentage of grant date fair value, minimum</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember', window );">Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum', window );">Award price as a percentage of grant date fair value, minimum</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold', window );">Significant stockholder threshold ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of performance units both performance and service vesting conditions (in shares)</a></td>
<td class="nump">2,585,000<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation, weighted-average period</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">$ 3.90<span></span>
</td>
<td class="nump">$ 15.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair values of RSUs vested</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares of performance units both performance and service vesting conditions (in shares)</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan', window );">Percentage of annual increase in number of shares available for future issuance</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember', window );">2017 Inducement Plan | Stock Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for future grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Awards granted to employees and non-employees vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember', window );">2014 Plan And Inducement Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options granted period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock shares available for future grant (in shares)</a></td>
<td class="nump">208,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants (in shares)</a></td>
<td class="nump">2,130,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage', window );">Percentage increase in shares issued</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued (in shares)</a></td>
<td class="nump">397,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandSeventeenInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=advm_StockOptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=advm_StockOptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandFourteenPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131169283384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Summary of Stock Options Activity (Detail) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">10,432<span></span>
</td>
<td class="nump">8,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">8,231<span></span>
</td>
<td class="nump">4,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(5,366)<span></span>
</td>
<td class="num">(646)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">10,432<span></span>
</td>
<td class="nump">8,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">13,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">5,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance (in USD per share)</a></td>
<td class="nump">$ 11.65<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="nump">7.04<span></span>
</td>
<td class="nump">18.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="nump">5.86<span></span>
</td>
<td class="nump">6.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in USD per share)</a></td>
<td class="nump">10.32<span></span>
</td>
<td class="nump">10.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance (in USD per share)</a></td>
<td class="nump">9.34<span></span>
</td>
<td class="nump">$ 11.65<span></span>
</td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and expected to vest (in USD per share)</a></td>
<td class="nump">9.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share)</a></td>
<td class="nump">$ 10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contract Life (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">$ 31,626<span></span>
</td>
<td class="nump">$ 48,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, Aggregate Intrinsic Value</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131165095256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Schedule of Stock Purchase Plan Valuation Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">122.00%<span></span>
</td>
<td class="nump">89.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">1 year 2 months 15 days<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167540504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Summary of Restricted Stock Units Activity (Detail) - Restricted stock units - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,585<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares)</a></td>
<td class="num">(305)<span></span>
</td>
<td class="num">(590)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(694)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value (in dollars)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in USD per share)</a></td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">3.90<span></span>
</td>
<td class="nump">15.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share)</a></td>
<td class="nump">5.26<span></span>
</td>
<td class="nump">4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">5.68<span></span>
</td>
<td class="nump">7.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in USD per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-Average Remaining Contractual Term (In years)</a></td>
<td class="text">1 year 5 months 8 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167629400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Plans - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 25,194<span></span>
</td>
<td class="nump">$ 20,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">8,875<span></span>
</td>
<td class="nump">7,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 16,319<span></span>
</td>
<td class="nump">$ 13,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131173224008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Savings Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution by company</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131167728232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (145,375)<span></span>
</td>
<td class="num">$ (110,327)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(165)<span></span>
</td>
<td class="num">(6,066)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">$ (145,540)<span></span>
</td>
<td class="num">$ (116,393)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131169076344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes- Schedule of Components of Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131165237512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal income tax expense at statutory rate</a></td>
<td class="num">$ (30,563)<span></span>
</td>
<td class="num">$ (24,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="num">(2,787)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(2,672)<span></span>
</td>
<td class="num">(3,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">41,324<span></span>
</td>
<td class="nump">24,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(9)<span></span>
</td>
<td class="nump">595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges', window );">Impact of internal reorganization</a></td>
<td class="num">(9,763)<span></span>
</td>
<td class="nump">2,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition', window );">Uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(7)<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation change in state uncertain tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170935272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 111,741<span></span>
</td>
<td class="nump">$ 74,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals, reserve and other</a></td>
<td class="nump">2,255<span></span>
</td>
<td class="nump">1,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">16,838<span></span>
</td>
<td class="nump">11,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">9,741<span></span>
</td>
<td class="nump">5,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">1,613<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_DeferredTaxAssetsLeaseObligation', window );">Lease obligation</a></td>
<td class="nump">24,224<span></span>
</td>
<td class="nump">6,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital losses</a></td>
<td class="nump">9,850<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">176,279<span></span>
</td>
<td class="nump">99,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(154,672)<span></span>
</td>
<td class="num">(94,645)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">21,607<span></span>
</td>
<td class="nump">5,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(20,227)<span></span>
</td>
<td class="num">(4,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(1,380)<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(21,607)<span></span>
</td>
<td class="num">(5,318)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DeferredTaxAssetsLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DeferredTaxAssetsLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131169127384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance due to net operating loss</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">21,944<span></span>
</td>
<td class="nump">8,677<span></span>
</td>
<td class="nump">$ 3,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits, if recognized would effective annual tax rate</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">393,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_OperatingLossCarryforwardsSubjectToExpiration', window );">NOL carryforwards subject to expiration</a></td>
<td class="nump">57,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic tax authority | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">227,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State credit carryforwards | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">12,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 50,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131171363432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits as of the beginning of the year</a></td>
<td class="nump">$ 8,677<span></span>
</td>
<td class="nump">$ 3,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase (decrease) related to prior year tax provisions</a></td>
<td class="nump">10,656<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax provisions</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">5,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits as of the end of the year</a></td>
<td class="nump">$ 21,944<span></span>
</td>
<td class="nump">$ 8,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140131170816008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">15,562<span></span>
</td>
<td class="nump">10,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">13,288<span></span>
</td>
<td class="nump">10,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>advm-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="advm-20211231.xsd" xlink:type="simple"/>
    <context id="i9df7f768c6944081aa26e835855e993b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cfd24eb4d89453dbcb821bb7fb4079c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i10ee18cbd41f41fb8035ae70d3ac055b_I20220318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2022-03-18</instant>
        </period>
    </context>
    <context id="i2c917411737449d0a88f9f35170ed838_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53f24fd80d7847a4a109b4930dfa58dd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i61bf30013d1447db830bbcf1c0f8e693_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8bf0483faf9c4578af16fb35b2fa264f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5d6e133ae95f4549b3dced0eb367c851_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3feb10512c544b2be5df43808067ffd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1545d1dd80f34ac3aef307e7cbbb2e71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac60871d0b6541e7b3972cd6bb0b694b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a914f1d116d433589863bd5a9a0f6a0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1e120d0535d8453791e0f2c600950d30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib98193b039da41878e8829babfad3291_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ca06aba1d444f9692c01566cac96dbe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i795d1398d0ed477da363e54fb41ee0b7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ebd7da8b96a4cedad752dba138eb1b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie798bce7c7694970a7f83c3c90201b15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c53c953f5be42b2a5877734d774a767_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c7935b84f04449fac206a423055e6aa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9fac97c217604a89ac8040860830763c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib014e00f9b8e44bb9cec4471e9b7458e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1d8be49b7bbf4251910929fc132243a6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i198713b3bc694250846e3c8d7a262676_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9e36a17528e246b0ab9dcbede5458fb4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9878b1af9a524eeeaa9c8427214abf99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifc2e87b6775540219d86de876645d890_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i11aa3c6438434617967b1b14ac83e990_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03259c961d784a7f9273e4d83977e07b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4f9e3e52f534877a4e117ef7bb0f6f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd8584c0ea5b463ca366376a46eac4d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9538a71ff1d424989f80b9467a6a448_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">advm:LexeoTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i3388e01ba0cd4c2bb002f33d9f0729df_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i15c6315f35b6402d86b1167231385890_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6311b039ae14140ac682b123ba2e20b_D20211101-20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="i6c50a8ce1839401ebdedd41b23664dc7_I20211101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">advm:TerminatedLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="i6fe35d41e331443d948be3c7be2e9ec8_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="icd7de60f78ff4ca4b73e44e0bed3fb91_I20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-08</instant>
        </period>
    </context>
    <context id="ie64eef970c89427db31b4a0fad29b6a3_I20211026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-26</instant>
        </period>
    </context>
    <context id="i00fd997b49304a6fb48d58e552aeb8ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bfec030c89344d68297b3d5723d72af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ebc23bbab6a4b809a58be9b27bc6683_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2b342bb0ce1b4ddfbb1fc42da05b8954_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9d7cb21878274c689e6a89f1c23e59d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd25a4e655954753968ec44adaaed1c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76e6ddf942cd490c98176b6a38c05c9c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc3a06d6569a4f0eb845ce032f5207f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if01fe6f2e1c640889f794f6d0cb75b01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i299d93d81b8442fea229100cbe836c75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4372ddfd6eaf4ebdab2698da6339e4ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i966d761db5484ddc9c6cc7e401bba8fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i151723aa80f341a8952a483bb904ee20_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:StockOptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandSeventeenInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="if01574c0aec8441ebcd6ced712437994_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0712c015900b4ee29ae1903994ae8913_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a91a547f88e4a6a81c47e8971ea1f72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">advm:IncentiveStockOptionsAndNonQualifiedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic18936e5d4e5454ab245e22276a0fb26_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandFourteenPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1974c638bb5e4a5990d928e7aecd0c6d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1c8c42cfe214c2e915d20a2db5f37ae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i675005a96bf84236b0181223cfe2bf55_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i55d4e6f877b540b484ca25983cbe7bad_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id078bd5264c44f8d85cbc656e1a30010_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1aa1a08442284607a20e7c4f8d0e72b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8988b116ae244c71b22a0159529f37af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i637b2d0774af4daf84893a36dbbffb39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iab1fca633f724372ab4c9e5aea494549_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31af55d22bfb48c4b7cc961ba70d0f12_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">advm:TwoThousandAndFourteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibdf93b275abc44ef8fb8c54d925edaa0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09580173048e4c7ca33b47016c7728b2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4828bf008756429682ad64a18e6f626a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98df46a84d42486094eb52256840d178_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if6f92a2c752147398b0b7cb89424a66d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec59229ab7074b74bd212f356c86ea60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i92372011da0b4b8d9b3ff9c9bc63cda2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a4cbf761c8a4a17a861b8bf1844e0a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78c00f24526d4abea5fca0722e1248a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f8ae5b4a0644993bf5b58e572c9d713_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic2ca53fed51a445cbea0844f267402e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib61d35f9c1b7487797a8b6521663d206_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19e8bd338962449c9e2411b96b08c1be_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i44fcf3a223a1481794c8de42a0377a7a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfb6a75db0aa4095bfd093ce5e08bfd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>advm:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8wLTEtMS0xLTEyODIy_561d6547-6c3f-4eef-bf28-e4026f8f18c4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8xLTEtMS0xLTEyODIy_893cb665-b51d-4322-80ba-418d21b97896">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8yLTEtMS0xLTEyODIy_b42a1d16-5d48-44b4-9db3-4b9a66d80a7a">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV80L2ZyYWc6YWNhMzRkMjI3MmJhNDAyYzg3NDA0ZTc5MjYxODYzNTgvdGFibGU6MzJhZWU3YzMxMmMyNDgyNThhYmI3NmQ2MzIwYTNjYmYvdGFibGVyYW5nZTozMmFlZTdjMzEyYzI0ODI1OGFiYjc2ZDYzMjBhM2NiZl8zLTEtMS0xLTEyODIy_febceb44-b147-4d94-a6d2-5d644a168014">0001501756</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9fac97c217604a89ac8040860830763c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ie4f9e3e52f534877a4e117ef7bb0f6f1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MjY_6080290b-1a2f-4c6f-9319-23bad6204282">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <dei:DocumentType
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzQ3_b02b7c06-a27d-454d-8d7d-a38545fc1197">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6YThmYTkyMmE0NmQ0NGI1NWIyYzBmNDFlYmQxYjdlZTgvdGFibGVyYW5nZTphOGZhOTIyYTQ2ZDQ0YjU1YjJjMGY0MWViZDFiN2VlOF8wLTAtMS0xLTEyODIy_5c623336-a701-4b76-8185-9252c7888288">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8yNzc_f11b686d-26b1-495a-90b0-d06c3dba7e6e">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8yNzc_a3f7e91a-ecee-4c71-9a72-3c4125ac7d27">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6NWYzNjliYWFhMDRhNDg1NGE5ZTMzYzY0YzRiODhjZWQvdGFibGVyYW5nZTo1ZjM2OWJhYWEwNGE0ODU0YTllMzNjNjRjNGI4OGNlZF8wLTAtMS0xLTEyODIy_fe8f4d3f-9941-49b0-ba93-1d6c6e342584">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYw_2ddf4a96-ab21-4931-8309-62ef17f6569e">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzQ4_337e9429-23cd-4101-81c8-ee36933f8695">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZGIzOTg3NjA2YWYwNDRlYmEwZDIzNjA1MzAzYTMxN2QvdGFibGVyYW5nZTpkYjM5ODc2MDZhZjA0NGViYTBkMjM2MDUzMDNhMzE3ZF8wLTAtMS0xLTEyODIy_e385d4c6-155c-4b30-bea5-cd794f8645da">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZGIzOTg3NjA2YWYwNDRlYmEwZDIzNjA1MzAzYTMxN2QvdGFibGVyYW5nZTpkYjM5ODc2MDZhZjA0NGViYTBkMjM2MDUzMDNhMzE3ZF8wLTEtMS0xLTEyODIy_aa7e217d-ff6c-4372-9622-07139ce287cb">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYx_4103d87d-8bf3-4375-a725-478565d3a0e0">800 Saginaw Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYy_965c48e9-2de0-410d-88c2-53b912223d73">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzU1_e791a271-0966-4c60-9864-4ab6c20fe50c">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzQ5_80142aa4-69c5-4daf-b3a9-f1461ee12e1a">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzUw_36c0a931-d191-4046-ac2d-a007ba2b5735">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzUz_739b7902-e6b8-4de6-8791-61c5279b4e52">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6Mjg2YzgxYjNmNWMwNDkzN2FmYTUwZWNiNTlhODYxZmYvdGFibGVyYW5nZToyODZjODFiM2Y1YzA0OTM3YWZhNTBlY2I1OWE4NjFmZl8xLTAtMS0xLTEyODIy_867a0d8f-bbff-41b1-a329-1f6acb065a40">Common Stock, par value $0.0001&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6Mjg2YzgxYjNmNWMwNDkzN2FmYTUwZWNiNTlhODYxZmYvdGFibGVyYW5nZToyODZjODFiM2Y1YzA0OTM3YWZhNTBlY2I1OWE4NjFmZl8xLTItMS0xLTEyODIy_be5a93a1-9c8d-426c-8161-7cde46644adb">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6Mjg2YzgxYjNmNWMwNDkzN2FmYTUwZWNiNTlhODYxZmYvdGFibGVyYW5nZToyODZjODFiM2Y1YzA0OTM3YWZhNTBlY2I1OWE4NjFmZl8xLTQtMS0xLTEyODIy_69a9e5dd-651c-4857-91c2-55942ad0ec6d">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzE5_504b74b0-e525-4cc8-a849-ab1902b30fb5">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzU2_651b5ecc-4ab6-4915-8d01-f6706aba08ce">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzU3_0f4cb005-1d3b-46b0-8e88-fa2a6c842c46">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF80MzYz_b1ec8047-0df2-4078-9b48-4ffa9400b45a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6MzZmMzIyZjkwZjI1NGFkYzgxYzNjMzRhMjVjYTg3NDgvdGFibGVyYW5nZTozNmYzMjJmOTBmMjU0YWRjODFjM2MzNGEyNWNhODc0OF8xLTAtMS0xLTE1Njc2_5d5c9648-cd05-4258-80e3-1ae9464a915f">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6MzZmMzIyZjkwZjI1NGFkYzgxYzNjMzRhMjVjYTg3NDgvdGFibGVyYW5nZTozNmYzMjJmOTBmMjU0YWRjODFjM2MzNGEyNWNhODc0OF8xLTMtMS0xLTEyODIy_78313d01-0675-418f-aad7-9cea17993cac">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6MzZmMzIyZjkwZjI1NGFkYzgxYzNjMzRhMjVjYTg3NDgvdGFibGVyYW5nZTozNmYzMjJmOTBmMjU0YWRjODFjM2MzNGEyNWNhODc0OF8yLTMtMS0xLTEyODIy_9109db3e-4bad-449f-b7fb-80a8b35e7283">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzIx_8f73ee7f-20cf-402b-bf3d-8fae2caa1759">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzIz_6f4163f9-5744-4669-a21d-d83f24b6316b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i6cfd24eb4d89453dbcb821bb7fb4079c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8zMzgy_b975ec8a-ec54-46f6-aff8-c82423ed942f"
      unitRef="usd">320300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i10ee18cbd41f41fb8035ae70d3ac055b_I20220318"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF8zODQ4_4442360a-b4bc-40cf-b552-6cfca7179f5e"
      unitRef="shares">98750717</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGV4dHJlZ2lvbjpkNDBjMDEzMmUyZTI0ZGIzYWUzY2E2NmQ4OGZlNTE1MF85ODk1NjA0NjU1MzI0_3102a100-0670-488a-b633-897018fd74b5">&lt;div style="margin-top:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Portions of the definitive proxy statement (the Proxy Statement) for the 2022 Annual Meeting of Stockholders of the registrant are incorporated by reference into Part&#160;III of this Annual Report on Form 10-K. If the Proxy Statement is not filed by May 2, 2022, then the registrant will file an amendment to this Form 10-K on Form 10-K/A to include the Part III information in this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZjM2MDAyZmUzNjk3NDlkM2I1ZjNiYzU5MjQwYjQ1NmUvdGFibGVyYW5nZTpmMzYwMDJmZTM2OTc0OWQzYjVmM2JjNTkyNDBiNDU2ZV8wLTEtMS0xLTE5MjAz_cc8c786c-81e0-423f-b9cc-5a25105aaa04">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZjM2MDAyZmUzNjk3NDlkM2I1ZjNiYzU5MjQwYjQ1NmUvdGFibGVyYW5nZTpmMzYwMDJmZTM2OTc0OWQzYjVmM2JjNTkyNDBiNDU2ZV8wLTMtMS0xLTE5MjA1_24877110-0839-4f4c-a8de-042fb99ed384">Ernst &amp; Young, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xL2ZyYWc6ZDQwYzAxMzJlMmUyNGRiM2FlM2NhNjZkODhmZTUxNTAvdGFibGU6ZjM2MDAyZmUzNjk3NDlkM2I1ZjNiYzU5MjQwYjQ1NmUvdGFibGVyYW5nZTpmMzYwMDJmZTM2OTc0OWQzYjVmM2JjNTkyNDBiNDU2ZV8wLTUtMS0xLTE5MjA3_77b14bed-58be-44e1-abb9-45890d8cb817">San Jose , California, USA</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzQtMS0xLTEtMTI4MjI_dc1d563c-b432-4009-bac2-aec4e745e93e"
      unitRef="usd">34195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzQtMy0xLTEtMTI4MjI_04ea039a-0010-42e5-8e0d-56d0daa6c3e9"
      unitRef="usd">62424000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzUtMS0xLTEtMTI4MjI_0a1cf308-3589-42a9-829f-55b7c06949cd"
      unitRef="usd">270993000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzUtMy0xLTEtMTI4MjI_7893e2f2-4c09-4f75-a11f-76149fa8baa4"
      unitRef="usd">367305000</us-gaap:ShortTermInvestments>
    <us-gaap:IncentiveToLessee
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMS0xLTEtMTU3NTA_6de6d34d-69cf-4053-8603-f8fcbebeb590"
      unitRef="usd">5709000</us-gaap:IncentiveToLessee>
    <us-gaap:IncentiveToLessee
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMy0xLTEtMTU3NTA_dd4a15b5-0ec9-43aa-9f91-75eba36c8885"
      unitRef="usd">0</us-gaap:IncentiveToLessee>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMS0xLTEtMTI4MjI_46a349a7-ee65-45c6-b4e8-aa90969fac3b"
      unitRef="usd">6248000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzYtMy0xLTEtMTI4MjI_14bc9c7d-ef8d-42c6-b762-7583437ca340"
      unitRef="usd">4709000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzctMS0xLTEtMTI4MjI_94476017-42af-444a-85d6-7bbee528c1df"
      unitRef="usd">317145000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzctMy0xLTEtMTI4MjI_cd6d4f9c-7fff-47a8-a31a-40fc40e2fd44"
      unitRef="usd">434438000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzgtMS0xLTEtMTI4MjI_4144bb98-094d-4863-bdae-a694b570b4dc"
      unitRef="usd">86000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzgtMy0xLTEtMTI4MjI_4543a681-7ce5-4214-857f-d034610f2310"
      unitRef="usd">19376000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzktMS0xLTEtMTI4MjI_561d3ad7-4fce-4951-9e8d-0a495f55eed1"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzktMy0xLTEtMTI4MjI_8567f168-6b7d-4123-b9a0-eb605d955623"
      unitRef="usd">27725000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEwLTEtMS0xLTEyODIy_bd03081a-d4e8-4708-829c-90f7459acb56"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEwLTMtMS0xLTEyODIy_03cff55e-7fba-42a9-a867-89fe6ccff82c"
      unitRef="usd">999000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTEtMS0xLTE1NzYz_1ad7a18e-3ca4-4efd-b185-1ea31129b8e5"
      unitRef="usd">769000</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:DeferredRentReceivablesNet
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTMtMS0xLTE1NzYz_da5a7799-5f43-4bba-91d3-4df058e31968"
      unitRef="usd">0</us-gaap:DeferredRentReceivablesNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzExLTEtMS0xLTEyODIy_3b6ce8b6-c6fd-4005-ba9c-fc772e785d9d"
      unitRef="usd">250000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzExLTMtMS0xLTEyODIy_2621589e-97b3-4d28-aad0-227352d4864b"
      unitRef="usd">29000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTEtMS0xLTEyODIy_f71f09b7-60aa-4eef-a27b-66207b823592"
      unitRef="usd">439727000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzEyLTMtMS0xLTEyODIy_8bbfbe52-8302-4a01-b7a5-ed58552acfa9"
      unitRef="usd">482567000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE1LTEtMS0xLTEyODIy_63ec4d9b-7a91-4796-8e49-fa021b474aa4"
      unitRef="usd">1387000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE1LTMtMS0xLTEyODIy_4db83509-5a30-4b80-9ebf-6bfc6e1b4d36"
      unitRef="usd">2810000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE2LTEtMS0xLTEyODIy_321b5940-7732-49fb-9cbb-45f5404984e4"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE2LTMtMS0xLTEyODIy_05cdfa5d-8d08-49ec-a047-56b7987d4797"
      unitRef="usd">13588000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE3LTEtMS0xLTEyODIy_73a078c4-7af8-4ce2-9e76-9faa08ac3a05"
      unitRef="usd">1886000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE3LTMtMS0xLTEyODIy_08fe20f5-e255-4fb7-b877-f3207a105de5"
      unitRef="usd">4473000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE5LTEtMS0xLTEyODIy_748b4f88-7518-432c-aa64-ac7280916229"
      unitRef="usd">21320000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzE5LTMtMS0xLTEyODIy_21f9468c-6de4-478c-af43-fee6cb27b41c"
      unitRef="usd">20871000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzIzLTEtMS0xLTEyODIy_b3c02568-50fe-44ee-b58f-12634db825b9"
      unitRef="usd">101108000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzIzLTMtMS0xLTEyODIy_9c82d54b-7506-47d3-9bbc-dd2a9728e8a5"
      unitRef="usd">26235000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI0LTEtMS0xLTEyODIy_2bcb9b2e-e05d-4524-9c53-47400fc74601"
      unitRef="usd">1114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI0LTMtMS0xLTEyODIy_e18b1e00-9df4-4eff-9eee-6496092129c0"
      unitRef="usd">1114000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI1LTEtMS0xLTEyODIy_29993085-17bd-4328-9d2b-7afe0dd138e3"
      unitRef="usd">123542000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI1LTMtMS0xLTEyODIy_a27fa64c-cde7-46d7-9f20-7e1448c7a145"
      unitRef="usd">48220000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI2LTEtMS0xLTEyODIy_09f8991d-5c7b-4a8c-b520-5e69db4e1b72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI2LTMtMS0xLTEyODIy_79300e15-5fd8-45d7-ae2f-b22b9a036653"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMjE_92589c27-0cf8-4b9c-9d1a-6a05d11e54f7"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMjE_cde2385e-a233-4a82-8156-b179acb7b9d4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMzU_6c2d51a1-f222-4193-a616-59c1d05825ce"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfMzU_c204284c-5e11-4962-9e38-85ba7a4bdca5"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_8a279201-a6b1-4e58-9d4b-e667f375d829"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_a97ae0c5-b1ce-43d4-b48f-7b350f6a5579"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_d42c1e6a-f7ef-4bf1-84c1-e219320cf4ab"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTAtMS0xLTEyODIyL3RleHRyZWdpb246ZmI1NmM5NTI5ZGUyNGUzNGEzOTk5MjhjYjVkNzMzNzRfNTc_e22c7b95-4980-4f74-80c6-471425d7859c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTEtMS0xLTEyODIy_182245b3-8707-4d15-9ba5-79c3fb976308"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI4LTMtMS0xLTEyODIy_7baa4e38-62e6-47e9-8a64-d981c05b0725"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMTg_63c24965-ecc1-4a43-b937-f82e4e34eb67"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMTg_7a391002-04ab-4ba4-a6b2-ab289b27d92e"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMzI_6b512d5c-8671-4ef2-a18e-de6ff135085a"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfMzI_c97aa4a0-967d-4ac5-9eb6-11cb795d59e3"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfNzU_1537102d-1de0-4027-b286-49e4de6a2977"
      unitRef="shares">98381000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfNzU_d5db6653-cebd-4eb8-a479-e960ea5ca4a7"
      unitRef="shares">98381000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfODI_16a25e9c-103a-4c3a-b4e6-9114e5a3629a"
      unitRef="shares">97549000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTAtMS0xLTEyODIyL3RleHRyZWdpb246OTIxZTRkZGQ4MjlkNDQ3MmI4Nzg1OTFmNzRmMzNmZmFfODI_6ba69aa0-409d-4d48-bcca-63c1e345dcc7"
      unitRef="shares">97549000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTEtMS0xLTEyODIy_2ac0ea1c-0521-4919-b25e-f37f7d287be6"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzI5LTMtMS0xLTEyODIy_b7636ef8-2cfc-4a17-8b45-f20066fad274"
      unitRef="usd">10000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMwLTEtMS0xLTEyODIy_e248d8a9-8faf-40d0-a668-30376bc4a47a"
      unitRef="usd">964965000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMwLTMtMS0xLTEyODIy_30055abe-f07b-4558-beb7-2a0479754981"
      unitRef="usd">937134000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMxLTEtMS0xLTEyODIy_caf863d3-66c4-48d8-a8b7-0cbace3585da"
      unitRef="usd">-714000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMxLTMtMS0xLTEyODIy_a8003503-0e8f-4933-9ce1-a7ff31b0ceb7"
      unitRef="usd">-261000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMyLTEtMS0xLTEyODIy_5eef177b-f434-4a74-93b0-6c9f70b36d5e"
      unitRef="usd">-648076000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMyLTMtMS0xLTEyODIy_5c881b65-5db8-4370-80d0-57773c94a75a"
      unitRef="usd">-502536000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMzLTEtMS0xLTEyODIy_36b385f9-51e7-42e8-aa3b-a03c884d5f80"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzMzLTMtMS0xLTEyODIy_0f109174-919c-4755-8185-026d19bcd5e0"
      unitRef="usd">434347000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzM0LTEtMS0xLTEyODIy_ab42e534-330a-45ac-9771-8e0a637a06e0"
      unitRef="usd">439727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjEvZnJhZzo3N2I2YTdhYjJhMDI0YjIyODYzMjQ2M2NhNjRiOGE0ZC90YWJsZTo5ZjYzMzUzMDI1ZWU0MTc3ODI5ZGNkODJjMmRkYTM5NS90YWJsZXJhbmdlOjlmNjMzNTMwMjVlZTQxNzc4MjlkY2Q4MmMyZGRhMzk1XzM0LTMtMS0xLTEyODIy_13a57686-fd40-425c-8ce7-3ac1303580ca"
      unitRef="usd">482567000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzItMS0xLTEtMTI4MjI_092fc672-5157-4805-bce0-c22320a29e8e"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzItMy0xLTEtMTI4MjI_f30ceaba-4449-4e4b-8fa3-c96833dff21c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzQtMS0xLTEtMTI4MjI_9623b860-7c6d-4320-a433-61850f911194"
      unitRef="usd">89181000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzQtMy0xLTEtMTI4MjI_5883c185-452e-45e9-802b-47a2ca907be9"
      unitRef="usd">73309000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzUtMS0xLTEtMTI4MjI_b75c0ad8-bece-4f37-8c23-1ca704e3515f"
      unitRef="usd">64441000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzUtMy0xLTEtMTI4MjI_515f8d7d-aa41-4362-825e-b16789af9b16"
      unitRef="usd">44641000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzctMS0xLTEtMTI4MjI_69604615-4adc-4f65-8a93-7ec43222dd99"
      unitRef="usd">153622000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzctMy0xLTEtMTI4MjI_e698b85e-23ce-4032-9bd8-e8b70d729bd0"
      unitRef="usd">117950000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzgtMS0xLTEtMTI4MjI_4516e530-e8d8-4c72-b499-e1c2a39dd0fe"
      unitRef="usd">-146122000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzgtMy0xLTEtMTI4MjI_d1bb9253-2faa-4137-be39-34b06baaf835"
      unitRef="usd">-117950000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEwLTEtMS0xLTEyODIy_db7289d0-5020-402f-b17f-d6273851fb39"
      unitRef="usd">582000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEwLTMtMS0xLTEyODIy_49c670b1-ae51-427f-a22e-3e00729d7e7d"
      unitRef="usd">1557000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzExLTEtMS0xLTEyODIy_ba361672-a7b3-42b9-8a98-1b1284462286"
      unitRef="usd">-145540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzExLTMtMS0xLTEyODIy_1e391b7c-fd2c-46ed-97de-d95f27dbc29a"
      unitRef="usd">-116393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEyLTEtMS0xLTEyODIy_894a5d4a-5e8f-46c6-9294-01cbba7a61af"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEyLTMtMS0xLTEyODIy_31d6accd-9b49-4cbc-bb01-cdd633aab999"
      unitRef="usd">1114000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEzLTEtMS0xLTEyODIy_24450372-5775-46aa-a8a6-b29e59b8e4ab"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzEzLTMtMS0xLTEyODIy_ff848af2-0936-4c63-8ff5-ade06698418e"
      unitRef="usd">-117507000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE1LTEtMS0xLTEyODIy_ced8ddc4-76d4-4e23-b542-7388ffb2e0a1"
      unitRef="usd">-428000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE1LTMtMS0xLTEyODIy_bf843ecd-9b6a-4437-9cf7-137587f02b48"
      unitRef="usd">93000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE2LTEtMS0xLTEyODIy_a2802a2f-8a65-47e7-bcc8-d42e84e677d6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE2LTMtMS0xLTEyODIy_752add41-248c-401a-9c8b-c5f23afd2e3b"
      unitRef="usd">-342000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE3LTEtMS0xLTEyODIy_29bbeaea-0d67-4479-8954-cbd8edff7256"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE3LTMtMS0xLTEyODIy_9ad082c1-1ae1-46d7-976a-5b30e9a2317a"
      unitRef="usd">29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE4LTEtMS0xLTEyODIy_3b8d3223-c563-461b-8a97-6926b58042dc"
      unitRef="usd">-145993000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE4LTMtMS0xLTEyODIy_1a58edbd-4e6c-4fe6-9dfe-4901e04e32c9"
      unitRef="usd">-117043000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTEtMS0xLTEyODIy_ab008883-6d57-4e33-93f5-cc71baed5234"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTEtMS0xLTEyODIy_be9b58ef-5844-4a29-a3ec-bb8d2d0bd9c8"
      unitRef="usdPerShare">-1.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTMtMS0xLTEyODIy_1d95a106-0e87-4817-b25d-5c145c0b6cf0"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzE5LTMtMS0xLTEyODIy_acc0c24b-a84c-4b53-b8b0-faab544ff66e"
      unitRef="usdPerShare">-1.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTEtMS0xLTEyODIy_63193338-0002-4aa5-b92f-283b8a675105"
      unitRef="shares">98039000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTEtMS0xLTEyODIy_92d9f286-30fb-4cfc-bcb6-1aa2ea311dc7"
      unitRef="shares">98039000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTMtMS0xLTEyODIy_74ddbb7c-43d8-4c45-86bd-e2be81b4cd6a"
      unitRef="shares">85146000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjQvZnJhZzplY2JmMTRlZjUxYWE0MzFlOWUxYjAwMDliNTBkNjIxYy90YWJsZTpjN2I1MDVhY2Q2Yzg0NmU0ODdmZDhjYTJhZDk4NzYwYi90YWJsZXJhbmdlOmM3YjUwNWFjZDZjODQ2ZTQ4N2ZkOGNhMmFkOTg3NjBiXzIwLTMtMS0xLTEyODIy_7d5270ad-e5c2-471e-9865-7014df7aa238"
      unitRef="shares">85146000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i53f24fd80d7847a4a109b4930dfa58dd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTEtMS0xLTEyODIy_d46cc972-74ce-4732-a132-f7c7555dbd2d"
      unitRef="shares">67329000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i53f24fd80d7847a4a109b4930dfa58dd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTMtMS0xLTEyODIy_f420393c-6242-46cf-8f6c-5f35858ea125"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i61bf30013d1447db830bbcf1c0f8e693_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTUtMS0xLTEyODIy_63f1e994-e8ca-4094-8930-f5c894df3bed"
      unitRef="usd">560704000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8bf0483faf9c4578af16fb35b2fa264f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTctMS0xLTEyODIy_5c4bc5ba-1933-43a6-a1d5-0e567ef64f77"
      unitRef="usd">-725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d6e133ae95f4549b3dced0eb367c851_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTktMS0xLTEyODIy_3eece75d-24bf-4d64-961e-e4c386b9bf06"
      unitRef="usd">-385029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI0LTExLTEtMS0xMjgyMg_8b60d829-c461-4ebf-95e8-89970c766fd0"
      unitRef="usd">174957000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTAtMS0xLTEyODIyL3RleHRyZWdpb246MDA1NDE3MTk4MTAyNGRhZWIxZGFmMDA5NjQyZDIzOTdfMTA5OTUxMTYyNzgzNA_d874fbba-4298-4e86-800e-cd6911fdb08f"
      unitRef="usd">676000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTEtMS0xLTEyODIy_118340de-69e7-4aa6-9ce2-bf4a8010b590"
      unitRef="shares">27600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTMtMS0xLTEyODIy_95506d4a-8545-4540-a700-05c7a1dda5ea"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTUtMS0xLTEyODIy_c7d1cae6-4fa0-4c8f-908f-a7544f08d016"
      unitRef="usd">344295000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI1LTExLTEtMS0xMjgyMg_1bb14df3-2deb-4bbd-9c69-db26aeb7aee8"
      unitRef="usd">344298000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI3LTUtMS0xLTEyODIy_1bfa470d-5586-4813-b7e0-5396741fd27b"
      unitRef="usd">20391000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI3LTExLTEtMS0xMjgyMg_aba30313-b5a2-4c1a-98d8-8da9bef60e04"
      unitRef="usd">20391000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI4LTEtMS0xLTEyODIy_b8b89bca-53df-4367-ae8d-57213b180e95"
      unitRef="shares">2043000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI4LTUtMS0xLTEyODIy_c3eac6a7-e485-4ac9-87fb-dda74d3c7932"
      unitRef="usd">12687000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI4LTExLTEtMS0xMjgyMg_5ffe4ae0-b032-47ae-ae10-32edbaa4e12f"
      unitRef="usd">12687000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <advm:WarrantsIssuedDuringPeriodShares
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzI5LTEtMS0xLTEyODIy_2157f8cb-ccf9-4f6c-8eec-57e510310f90"
      unitRef="shares">36000</advm:WarrantsIssuedDuringPeriodShares>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMwLTEtMS0xLTEyODIy_b42893cb-6dc3-4bea-bd9c-86d4ddc6755b"
      unitRef="shares">114000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMwLTUtMS0xLTEyODIy_0cc4b119-f25a-4528-abbe-da0319ac49de"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMwLTExLTEtMS0xMjgyMg_79ee72e0-6c25-4845-803e-0ec7c79b1e58"
      unitRef="usd">1100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMxLTEtMS0xLTEyODIy_fa635a3d-3353-4db0-aa65-9f256ae7c051"
      unitRef="shares">591000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="iae8ba2024c2544b6941631eb71512ca7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMyLTEtMS0xLTEyODIy_9809fa86-aa78-4153-bb53-d5150c32160d"
      unitRef="shares">164000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i89da5f04fe2340da83ca6de1664a80e4_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMyLTUtMS0xLTEyODIy_36847f8d-9cb7-4fcf-b458-9143c44e3eb8"
      unitRef="usd">2043000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMyLTExLTEtMS0xMjgyMg_dd9eafc5-dcab-4156-b167-97b3a10376bf"
      unitRef="usd">2043000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMzLTctMS0xLTEyODIy_8819f26d-f5bf-48d5-b90b-162cb952dfeb"
      unitRef="usd">93000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzMzLTExLTEtMS0xMjgyMg_453a5c58-f8ee-4792-91b8-c6a410f0a2a8"
      unitRef="usd">93000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM0LTctMS0xLTEyODIy_a96a6aee-b3c9-402d-a700-9df70f61649d"
      unitRef="usd">-342000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM0LTExLTEtMS0xMjgyMg_5c2ceddc-1486-4c0b-8d7f-5f7bd66ec721"
      unitRef="usd">-342000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ia5ed6285a9f64dd0a4f97604d71c82a3_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM1LTctMS0xLTEyODIy_dfe00ad0-5d48-4970-85f3-ecdfd97a7963"
      unitRef="usd">29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM1LTExLTEtMS0xMjgyMg_5b52781b-3aca-4676-b138-57e8800de9b8"
      unitRef="usd">29000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib3feb10512c544b2be5df43808067ffd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM2LTktMS0xLTEyODIy_cf6ac7e2-8c5c-46d3-8499-9523de54732c"
      unitRef="usd">-117507000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM2LTExLTEtMS0xMjgyMg_44e36ed3-361b-44be-94f4-ffd8c427d0df"
      unitRef="usd">-117507000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i1545d1dd80f34ac3aef307e7cbbb2e71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTEtMS0xLTEyODIy_486fda6d-f59d-44a7-8d08-eaa66b7d364d"
      unitRef="shares">97549000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i1545d1dd80f34ac3aef307e7cbbb2e71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTMtMS0xLTEyODIy_3ea5d65b-fc97-4098-ac11-1436d3830def"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iac60871d0b6541e7b3972cd6bb0b694b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTUtMS0xLTEyODIy_c8f86a5f-9c83-4491-859a-c98117d1ed41"
      unitRef="usd">937134000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a914f1d116d433589863bd5a9a0f6a0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTctMS0xLTEyODIy_607f7a20-8d2c-49e8-9058-0b00bb30e7ab"
      unitRef="usd">-261000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1e120d0535d8453791e0f2c600950d30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTktMS0xLTEyODIy_fca42634-7999-4911-92e5-5bd37c16c14b"
      unitRef="usd">-502536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM3LTExLTEtMS0xMjgyMg_a193d648-ae51-4f71-8f93-1ccca550dae2"
      unitRef="usd">434347000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTAtMS0xLTEzOTU2L3RleHRyZWdpb246ZDgwYjRmOTc4YzVhNGM4ZDk0ODEwMDM2OGI4NzUwZTBfMTA5OTUxMTYyNzgzNQ_aa639da8-28a1-4813-9fef-8eac43410bde"
      unitRef="usd">9000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTEtMS0xLTEzOTc4_4ecdb3c7-2f47-4bf5-a528-de12b476788b"
      unitRef="shares">121000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTMtMS0xLTEzOTc4_177dddad-10bd-4b1b-b2f7-2bdc4ad804bc"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTUtMS0xLTEzOTc4_eb22619d-052e-4ac8-82f7-35f4c1739fdd"
      unitRef="usd">1685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM4LTExLTEtMS0xNTI1OQ_b3c56a73-b513-457c-a848-897321cc723b"
      unitRef="usd">1685000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM5LTUtMS0xLTEzOTc4_7372c512-90f8-466c-b345-f570844b434a"
      unitRef="usd">25194000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzM5LTExLTEtMS0xNTI1NA_59627a40-c848-4891-9eba-9dd572ef3afe"
      unitRef="usd">25194000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQwLTEtMS0xLTEzOTg4_a25d8fa6-6e3c-4fa0-abd3-77843aeb6819"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQwLTUtMS0xLTEzOTg4_ba37ce53-c575-4d85-8209-edc37b6520cf"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQwLTExLTEtMS0xNTI1Ng_1fab05ae-0355-4df0-9308-2046dd7a5230"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQxLTEtMS0xLTEzOTg4_8fc8d01f-2979-448c-8826-a7f35d3dcd0a"
      unitRef="shares">397000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib98193b039da41878e8829babfad3291_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQxLTUtMS0xLTEzOTg4_9c6369c9-6a65-41a6-a224-d6a43403cd91"
      unitRef="usd">901000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQxLTExLTEtMS0xNTI2Mw_0252c555-e149-4672-9e99-d8cf87c034fd"
      unitRef="usd">901000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ia0e7a2fa6d2d4e858ffb9fa247799ab6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQyLTEtMS0xLTEzOTg4_2088d83b-21f7-4cca-8bb3-6d3afca5b605"
      unitRef="shares">305000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i6ca06aba1d444f9692c01566cac96dbe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ0LTctMS0xLTEzOTk1_b2575ced-5323-4f25-86c3-8e863aea24fa"
      unitRef="usd">-428000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQzLTExLTEtMS0xNTI2Ng_65076af4-bfe9-423f-9161-934396caed14"
      unitRef="usd">-428000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i6ca06aba1d444f9692c01566cac96dbe_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ1LTctMS0xLTEzOTk1_faaab420-8795-4b30-9df6-b42427da6f9b"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ0LTExLTEtMS0xNTI3MA_072494d7-8155-4e99-909a-69713ad847b6"
      unitRef="usd">-25000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i795d1398d0ed477da363e54fb41ee0b7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTktMS0xLTEzOTk1_2606c809-0427-4d63-966b-400011e93ab8"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ1LTExLTEtMS0xNTI1Mg_7df8b94f-1ed0-454a-8296-bc0353eb9d08"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3ebd7da8b96a4cedad752dba138eb1b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTEtMS0xLTE1MjUw_09bcadf8-1e99-4be0-b00c-71f448ee246e"
      unitRef="shares">98381000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ebd7da8b96a4cedad752dba138eb1b7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTMtMS0xLTE1MjUw_f72ddd07-a2be-4cdb-aae8-0ba46a5dbe74"
      unitRef="usd">10000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie798bce7c7694970a7f83c3c90201b15_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTUtMS0xLTE1MjUw_8aa9c25b-2062-4190-b99e-5ede21d8340a"
      unitRef="usd">964965000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c53c953f5be42b2a5877734d774a767_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTctMS0xLTE1MjUw_21f19f40-900e-47f5-a2e4-41c98faeaa6e"
      unitRef="usd">-714000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c7935b84f04449fac206a423055e6aa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTktMS0xLTE1MjUw_6db1e1d3-f06e-4abe-a093-776f5b3db10e"
      unitRef="usd">-648076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMjcvZnJhZzo5YmJkYzA2MmNhZjc0MDRjODU3ZWVmNmFhMTRlYzBhYi90YWJsZTo2Mzk3OTAxZTQwMTI0NDFjOTFhM2E1ZjFiMmQwMDllMC90YWJsZXJhbmdlOjYzOTc5MDFlNDAxMjQ0MWM5MWEzYTVmMWIyZDAwOWUwXzQ2LTExLTEtMS0xNTI1MA_fcf02893-69bf-4177-8e35-afd0355d895f"
      unitRef="usd">316185000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMtMS0xLTEtMTI4MjI_ee00e988-a8eb-4885-a1d6-8024796fbce2"
      unitRef="usd">-145540000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMtMy0xLTEtMTI4MjI_b274bdb5-f58e-4fe4-839c-d4707c7e57b5"
      unitRef="usd">-117507000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUtMS0xLTEtMTI4MjI_ae5f197f-a6a1-4d9e-88a9-73d23161a046"
      unitRef="usd">4645000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUtMy0xLTEtMTI4MjI_67e75c0a-ae77-4892-9a70-097992662e7b"
      unitRef="usd">4158000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzYtMS0xLTEtMTI4MjI_20740af1-5fb6-427c-bedf-c1cb94f7f481"
      unitRef="usd">25194000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzYtMy0xLTEtMTI4MjI_ce7de134-b0ba-45c0-b8cb-9590074cd170"
      unitRef="usd">20391000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzctMS0xLTEtMTI4MjI_426e051a-a448-4c97-8f84-a15bda6adf06"
      unitRef="usd">-2770000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzctMy0xLTEtMTI4MjI_a289547e-c4e1-4efa-8de8-e6b4bec96191"
      unitRef="usd">-521000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzgtMS0xLTEtMTI4MjI_6af34d34-fc8c-4300-83fc-dc750a762581"
      unitRef="usd">0</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzgtMy0xLTEtMTI4MjI_9a4f714b-5eb4-4e5d-a8e7-ecd4d5001d43"
      unitRef="usd">17000</us-gaap:AccretionExpense>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzktMS0xLTEtMTI4MjI_2bbae4e4-738e-4cfb-a59e-8616619322b9"
      unitRef="usd">1063000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzktMy0xLTEtMTI4MjI_aecf8050-623c-43df-b997-8387f74ffafb"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEwLTEtMS0xLTEyODIy_245fb61d-392b-4201-a860-552d7a13cd11"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEwLTMtMS0xLTEyODIy_c18ad148-f786-43e1-8cd7-7fa0b84c0506"
      unitRef="usd">-342000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzExLTEtMS0xLTEyODIy_e0fa5cf7-6e9d-4bc4-a2df-1a361d95c79e"
      unitRef="usd">25000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzExLTMtMS0xLTEyODIy_8fc0881b-5db0-4664-8650-d7a51c150756"
      unitRef="usd">-58000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEzLTEtMS0xLTEyODIy_d1b13314-64a9-4e25-8313-92280d23ba44"
      unitRef="usd">2257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzEzLTMtMS0xLTEyODIy_8780ed40-2939-4bb3-8c75-c69e6ca2798a"
      unitRef="usd">-5854000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE0LTEtMS0xLTEyODIy_dd23321e-234d-407a-8c3c-5709f03f0ec3"
      unitRef="usd">990000</advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable>
    <advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE0LTMtMS0xLTEyODIy_90b2ad98-2b8b-418b-876d-4a75a569475c"
      unitRef="usd">18000</advm:IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable>
    <advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE1LTEtMS0xLTEyODIy_42b677c4-a348-498f-81a8-4d749a409890"
      unitRef="usd">2719000</advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE1LTMtMS0xLTEyODIy_17fd03b5-231d-4083-adb1-9857f9910d47"
      unitRef="usd">1587000</advm:IncreaseDecreaseInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE2LTEtMS0xLTEyODIy_3c06e0bf-14dc-4c4d-8072-a6c3ca09012c"
      unitRef="usd">-1612000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE2LTMtMS0xLTEyODIy_34e0f133-ca62-4081-abe2-b7a973d70083"
      unitRef="usd">1585000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE3LTEtMS0xLTEyODIy_6dced81b-ea40-4644-a5ef-f7a319d24e55"
      unitRef="usd">3274000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzE3LTMtMS0xLTEyODIy_be734f7b-e1bc-40ee-b05f-ce94cb8c08c6"
      unitRef="usd">4147000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIwLTEtMS0xLTEyODIy_fdcb0480-758d-4d6f-933a-e68a948569fa"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIwLTMtMS0xLTEyODIy_0717073d-58d4-450b-a5d4-b055b48fb8be"
      unitRef="usd">1114000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIxLTEtMS0xLTEyODIy_ac3dda6e-6bb7-4010-bec0-477b5bb36c77"
      unitRef="usd">2928000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIxLTMtMS0xLTEyODIy_3840dca7-b467-4f6d-9d46-d5dc96dda60e"
      unitRef="usd">-1540000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIzLTEtMS0xLTEyODIy_dfe92e85-2ac8-4859-abcd-0e0497d1c8dd"
      unitRef="usd">-107831000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzIzLTMtMS0xLTEyODIy_8bbb9ac1-0cdb-4985-b0dc-861770e0e5ef"
      unitRef="usd">-79291000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI2LTEtMS0xLTEyODIy_bf1705e8-912d-4709-ba3c-e79f88be2c86"
      unitRef="usd">407514000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI2LTMtMS0xLTEyODIy_40054ff9-ef39-4cfa-a3c4-0b329eacef06"
      unitRef="usd">570386000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI3LTEtMS0xLTEyODIy_4aac2c28-26f5-4230-a58c-90163eda0d8c"
      unitRef="usd">492356000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI3LTMtMS0xLTEyODIy_6e6cdc43-65a3-4598-b6c0-a48dd6e808e0"
      unitRef="usd">295315000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI4LTEtMS0xLTEyODIy_421938ef-e2ff-466e-9d7a-3fecf3c7fc9d"
      unitRef="usd">8990000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI4LTMtMS0xLTEyODIy_63a02b91-32ee-4ea2-b0de-d6bfdaa8373f"
      unitRef="usd">6748000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI5LTEtMS0xLTEyODIy_491b08a2-d5b0-4464-b365-18738248c40c"
      unitRef="usd">15123000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzI5LTMtMS0xLTEyODIy_4edffdec-6898-4a25-a48a-7cb726d7fd2f"
      unitRef="usd">11844000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMwLTEtMS0xLTEyODIy_20ec0fa7-3391-4cd0-b799-5e873545e91c"
      unitRef="usd">78709000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMwLTMtMS0xLTEyODIy_2a78c25e-edbd-4784-81f1-8595e1a587d3"
      unitRef="usd">-280167000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMzLTEtMS0xLTEyODIy_57204ce5-e0cf-4416-b5ad-c755f7c5ed2e"
      unitRef="usd">1685000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzMzLTMtMS0xLTEyODIy_3679905d-bcbe-496b-8265-a69b291c8800"
      unitRef="usd">344302000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM1LTEtMS0xLTEyODIy_33ad23a3-063b-4aa9-b41f-e4ffbc8d9ee3"
      unitRef="usd">51000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM1LTMtMS0xLTEyODIy_804a3809-d318-4be8-a570-232f2c8481e4"
      unitRef="usd">12687000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM2LTEtMS0xLTEyODIy_8009ab9a-05cf-4570-81de-0eedf5a55d9f"
      unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM2LTMtMS0xLTEyODIy_0a9693b7-54ce-472c-820a-315408d8ad4a"
      unitRef="usd">2043000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM3LTEtMS0xLTEyODIy_ee072b38-d06a-4daf-9c43-36d9b9aa24ab"
      unitRef="usd">901000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM3LTMtMS0xLTEyODIy_23f2a20e-64ad-4fae-80ea-c5c1b07c0a13"
      unitRef="usd">1100000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:RepaymentsOfDebt
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM4LTEtMS0xLTEyODIy_2bfebd58-f959-4072-af47-1e1bb7781d81"
      unitRef="usd">240000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzM4LTMtMS0xLTEyODIy_af68ffa2-d915-4e6d-8314-36e007d61f86"
      unitRef="usd">61000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQwLTEtMS0xLTEyODIy_c49c827f-2a1d-40ac-90b8-9522322897d1"
      unitRef="usd">2397000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQwLTMtMS0xLTEyODIy_6f15be49-17ee-47ce-bc7e-3ecc7bf17844"
      unitRef="usd">355985000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQxLTEtMS0xLTEyODIy_65e12912-19cf-4f88-ac16-2b83ab8b26e5"
      unitRef="usd">-26725000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQxLTMtMS0xLTEyODIy_28012148-be01-4bae-b878-b02313949cc7"
      unitRef="usd">-3473000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQyLTEtMS0xLTEyODIy_d1909de5-329b-429f-92f6-9aa26358b9a8"
      unitRef="usd">63423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQyLTMtMS0xLTEyODIy_c90d63d5-2d4c-4e0b-921e-c9627391796a"
      unitRef="usd">66896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQzLTEtMS0xLTEyODIy_b3c8a5b9-e3f1-4c4d-bed5-d8a6c49076ec"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQzLTMtMS0xLTEyODIy_0ec076a6-bb96-4655-b735-f44b167a66f4"
      unitRef="usd">63423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ1LTEtMS0xLTIxMDAw_dc1d563c-b432-4009-bac2-aec4e745e93e"
      unitRef="usd">34195000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ1LTMtMS0xLTIxMDAw_04ea039a-0010-42e5-8e0d-56d0daa6c3e9"
      unitRef="usd">62424000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTEtMS0xLTIxMDA2_bd03081a-d4e8-4708-829c-90f7459acb56"
      unitRef="usd">2503000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTMtMS0xLTIxMDA2_03cff55e-7fba-42a9-a867-89fe6ccff82c"
      unitRef="usd">999000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTEtMS0xLTIxNzQ4_af7bf2a1-8b76-43d6-aa15-4b607192e993"
      unitRef="usd">36698000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTMtMS0xLTIxNzQ4_1e5f91b2-de81-4a09-921a-2c82d9021478"
      unitRef="usd">63423000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTEtMS0xLTE1Njcy_59976b3f-bff1-4cd4-a6e9-a5336280f221"
      unitRef="usd">84005000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTMtMS0xLTE1Njcy_c1472db4-a00e-432b-b93c-9a624db7df2a"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUwLTEtMS0xLTIyMzM5_d80a608c-adfc-478b-a103-7e9cff267f91"
      unitRef="usd">15768000</advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination>
    <advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzUwLTMtMS0xLTIyMzQx_18efa9ee-d3ec-48c3-9063-82fdf225ad27"
      unitRef="usd">0</advm:DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination>
    <advm:RemeasurementOfRightOfUseAssetOnLeaseModification
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTEtMS0xLTE1OTEw_df8d2e3c-834b-4424-9551-071ed346e4a9"
      unitRef="usd">2052000</advm:RemeasurementOfRightOfUseAssetOnLeaseModification>
    <advm:RemeasurementOfRightOfUseAssetOnLeaseModification
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ3LTMtMS0xLTE2Mjcy_1f4d1e18-a24d-4893-bce1-de9ce303bf97"
      unitRef="usd">0</advm:RemeasurementOfRightOfUseAssetOnLeaseModification>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTEtMS0xLTEyODIy_e35094ed-2695-4993-8d28-6d193c6d37bf"
      unitRef="usd">1402000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzAvZnJhZzo1MmM4MzA4M2JlNjk0NTkxOGY5OGFiNWQ5MjNlNzA1Yi90YWJsZTo1MTM2OTM1N2YxZTY0MWMzODJmNzQ2OWNhYTUxMjA4ZC90YWJsZXJhbmdlOjUxMzY5MzU3ZjFlNjQxYzM4MmY3NDY5Y2FhNTEyMDhkXzQ2LTMtMS0xLTEyODIy_8c70ab09-2f91-43b5-948d-eefa09f4ce6c"
      unitRef="usd">403000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzYvZnJhZzo5NTUzOGM4NTA4YTE0OTU2OTBjYmM1ZDI2ZjQ4NjJlNS90ZXh0cmVnaW9uOjk1NTM4Yzg1MDhhMTQ5NTY5MGNiYzVkMjZmNDg2MmU1XzE1Mzk_71a23d22-9fbd-4b0a-a285-a8a6767b727b">Description of the business &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or &#x201c;Adverum&#x201d;) was incorporated in Delaware on July 17, 2006 and is headquartered in Redwood City, California. The Company is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $648.1 million as of December&#160;31, 2021. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. As of December&#160;31, 2021, the Company had cash, cash equivalents and short-term investments of $305.2 million, which the Company believes will be sufficient to fund its operations into 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzYvZnJhZzo5NTUzOGM4NTA4YTE0OTU2OTBjYmM1ZDI2ZjQ4NjJlNS90ZXh0cmVnaW9uOjk1NTM4Yzg1MDhhMTQ5NTY5MGNiYzVkMjZmNDg2MmU1XzEyODc_76d8f869-7ac4-499d-88ad-bdd7e81ddffa"
      unitRef="usd">-648100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzYvZnJhZzo5NTUzOGM4NTA4YTE0OTU2OTBjYmM1ZDI2ZjQ4NjJlNS90ZXh0cmVnaW9uOjk1NTM4Yzg1MDhhMTQ5NTY5MGNiYzVkMjZmNDg2MmU1XzEwOTk1MTE2MzE1MDE_6e37af3c-80ee-4484-95e4-caa820fb2777"
      unitRef="usd">305200000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU3_390a3a38-096c-49ba-b818-0a73fb08fdc9">Summary of significant accounting policies&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#x2019;s original estimates in any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;All short-term investments in debt securities have been classified as &#x201c;available for sale&#x201d; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#x2019; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#x2019;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#x2019;s investment policy, which limits the Company&#x2019;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#x2019;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support the growth.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb"&gt;three&lt;/span&gt; to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets and Purchased Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company evaluates the carrying value of amortizable long&#x2011;lived assets, whenever events, or changes in business circumstances or the planned use of long&#x2011;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#x2011;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#x2011;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#x2019;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within general and administrative expense in the consolidated statements of operations and comprehensive loss an impairment charge of $1.1&#160;million, which includes $0.8&#160;million associated with the write down of right-of-use assets and $0.3&#160;million associated with write down of leasehold improvements, net of accumulated depreciation, for the year ended December&#160;31, 2021. There were no impairment indicators noted for the Company&#x2019;s long-lived assets, fixed assets, for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, management estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The Company bases the right-of-use asset on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. There have been no significant changes from the Company&#x2019;s original estimates in any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and using intrinsic value, which is the closing price of its common stock on the date of the grant, for the restricted stock units (&#x201c;RSUs&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model requires the use of following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term assumption represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Expected volatility is based on the Company&#x2019;s historical stock price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2021 and 2020, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Comprehensive loss comprises net loss and other comprehensive income. Other comprehensive income consists of foreign currency translation adjustments and unrealized gain on marketable securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, restricted stock units (&#x201c;RSUs&#x201d;), employee stock purchase plan (&#x201c;ESPP&#x201d;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#x201c;Topic 326&#x201d;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326, but does not expect the effect of adoption to be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ2_8b22a139-6433-4842-99d4-f79f483836f1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014; The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United&#160;States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:UseOfEstimates
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQz_fe81363c-7afe-42d5-89c7-0a768bdb2d57">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, fair values of financial instruments, and incremental borrowing rate. The Company&#x2019;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#x2019;s original estimates in any periods presented.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUw_73c12836-e8de-4968-9617-a7b6ee962ecc">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Assets and liabilities of non-U.S. subsidiaries that operate in a local currency environment, where the local currency is the functional currency, are translated to U.S. dollars at exchange rates in effect at the balance sheet date, with the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Upon sale or upon complete or substantially complete liquidation of an investment in a foreign entity, the amount attributable to that entity and accumulated in the translation adjustment component of equity is removed from the separate component of equity and reported as part of the gain or loss on sale or liquidation of the investment for the period during which the sale or liquidation occurs. Income and expense accounts are translated at average exchange rates for the period. Transactions which are not in the functional currency of the entity are remeasured into the functional currency and gains or losses resulting from the remeasurement recorded in other income (expense).&lt;/span&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU4_3b2d6a56-00ad-47ff-8266-91aed176bc19">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents include cash held in banks, money market accounts and highly liquid debt securities. Cash equivalents are stated at fair value.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ0_7463ab4d-cf33-4249-93b5-2d4d7400cca4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Restricted cash primarily consists of cash collateral to letter of credit provided to the landlord in relation to a lease agreement (see Note 5).&lt;/span&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUx_7580f705-d7b5-47db-83f9-aa052b328d4e">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Short-Term Investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;All short-term investments in debt securities have been classified as &#x201c;available for sale&#x201d; and are carried at fair value. Unrealized gains and losses, net of any related tax effects, are excluded from earnings and are included in other comprehensive loss and reported as a separate component of stockholders&#x2019; equity until realized. Realized gains and losses and declines in value judged to be other than temporary, if any, on available-for-sale securities are included in other income (expense), net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. The cost of securities sold is based on the specific-identification method. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Interest on short-term investments is included in other income, net in the Company&#x2019;s consolidated statements of operations and comprehensive loss. In accordance with the Company&#x2019;s investment policy, management invests to diversify credit risk and only invests in securities with high credit quality, including U.S. government securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether declines in the fair value of its investments below their cost are other than temporary. The evaluation includes consideration of the cause of the impairment, including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses, whether the Company has the intent to sell the securities, and whether it is more likely than not that the Company will be required to sell the securities before the recovery of their amortized cost basis. If the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other than temporary, the Company would reduce the carrying value of the security it holds and records a loss for the amount of such decline. The Company has not recorded any realized losses or declines in value judged to be other than temporary on its investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODM4_fd6537a6-d525-42f5-8262-2fcd49490e59">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing gene therapeutics. The Company&#x2019;s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzUyODI_3c8c5bea-abd1-43ad-b55e-e38a72997431"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzUyODI_4cd3aa99-95d8-4a5f-b72c-0cc4fb6c4325"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODM5_055e81c9-6aa4-41ef-9b08-bb04b0f4cbb8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Financial instruments that potentially subject the Company to significant concentrations of credit risk consists primarily of cash, cash equivalents and short-term investments. Risks associated with cash, cash equivalents, short-term investments are mitigated by the Company&#x2019;s investment policy, which limits the Company&#x2019;s investing to only those marketable securities rated at least A-1/P-1 Short Term Rating and A/A2 Long Term Rating, as determined by independent credit rating agencies. Management believes that the Company is not exposed to significant credit risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to certain risks and uncertainties, including, but not limited to changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: ability to obtain future financing; regulatory approval and market acceptance of, and reimbursement for, the Company&#x2019;s product candidates; performance of third-party clinical research organizations and manufacturers; development of sales channels; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; and the Company&#x2019;s ability to attract and retain employees necessary to support the growth.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUy_a58edd33-4ac9-432a-9dbd-6b61559df9b2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Property and equipment are recorded at cost, net of accumulated depreciation and amortization. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDE_2414cb6e-3f19-45e8-a656-7f77fd3284eb"&gt;three&lt;/span&gt; to five years. Leasehold improvements are capitalized and amortized over the shorter period of their expected lives or the lease term. Major replacements and improvements are capitalized, while general repairs and maintenance are expensed as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib014e00f9b8e44bb9cec4471e9b7458e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzcyMDc_7007e1e7-8bf6-4b59-89fa-3250fd294ef2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODUz_ab22bd1c-e9a7-4b56-aae5-eac49c7af628">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets and Purchased Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company evaluates the carrying value of amortizable long&#x2011;lived assets, whenever events, or changes in business circumstances or the planned use of long&#x2011;lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, the Company assesses for recovery by comparing the carrying values of long&#x2011;lived assets with their future undiscounted net cash flows. If the comparison indicates that impairment exists, long&#x2011;lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecasting of future operating results that is used in the preparation of expected undiscounted cash flows. If management&#x2019;s assumptions about future operating results were to change as a result of events or circumstances, the Company may be required to record an impairment loss on these assets. The Company recorded within general and administrative expense in the consolidated statements of operations and comprehensive loss an impairment charge of $1.1&#160;million, which includes $0.8&#160;million associated with the write down of right-of-use assets and $0.3&#160;million associated with write down of leasehold improvements, net of accumulated depreciation, for the year ended December&#160;31, 2021. There were no impairment indicators noted for the Company&#x2019;s long-lived assets, fixed assets, for the year ended December&#160;31, 2020.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzQ5NDc4MDIzNDc2Mjg_de772fe9-6751-49f5-93fb-4461dbaceb1a"
      unitRef="usd">1100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzQ5NDc4MDIzNDc2Mjk_a299ca19-ffcd-4621-b4fe-3a2914356e2e"
      unitRef="usd">800000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzQ5NDc4MDIzNDc2Mjc_2c7df3c3-2804-4ed7-883a-507dbce1b23a"
      unitRef="usd">300000</us-gaap:ImpairmentOfLeasehold>
    <us-gaap:AssetImpairmentCharges
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzg0ODU_b8544f4f-13a7-405a-98bc-0f4277314528"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU0_1f957101-0eb9-4c93-ae52-b4d73b967eb7">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognizes a right-of-use asset and a lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the incremental borrowing rate, management estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. The Company bases the right-of-use asset on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the operating lease is recognized on a straight-line basis over the lease term and is included in operating expenses on the statements of operations and comprehensive loss. Variable lease payments include lease operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQw_321d953e-df42-4d29-8df9-aaee599c5d3d">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQx_058bfb92-c60d-49c6-b5ef-0ca34cc427b2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Research and development expenses are charged to expense as incurred. Research and development expenses include&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;primarily personnel-related costs, stock-based compensation expense, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical trial materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advance payments for goods or services for future research and development activities are deferred and expensed as the goods are delivered or the related services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates research and clinical trial expenses based on the services performed pursuant to contracts with research institutions and clinical research organizations that conduct and manage nonclinical studies and clinical trials on the Company&#x2019;s behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. These estimates are based on communications with the third-party service providers and the Company&#x2019;s estimates of accrued expenses and on information available at each balance sheet date. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. There have been no significant changes from the Company&#x2019;s original estimates in any of the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQy_95867d4e-6fc0-4411-b057-73ac8622c6c1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid and other current assets, accounts payable, accrued expenses and other current liabilities approximate their fair values due to their short-term maturities. Refer to Note 3 for the methodologies and assumptions used in valuing financial instruments.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ3_c6b86799-728c-4296-b805-9e5c4fde0631">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Stock-based compensation expense related to stock awards to employees is measured at fair value of the award on the date of the grant.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes valuation model for stock options and using intrinsic value, which is the closing price of its common stock on the date of the grant, for the restricted stock units (&#x201c;RSUs&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model requires the use of following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The expected term assumption represents the period that the Company&#x2019;s stock-based awards are expected to be outstanding and is determined using the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;Expected volatility is based on the Company&#x2019;s historical stock price volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Black-Scholes valuation model calls for a single expected dividend yield as an input. The Company has never paid dividends and has no plans to pay dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The risk-free interest rate is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of option.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ4_0ed4a209-ece3-4d9b-af65-7f52cf26ce4e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;The Company accounts for income taxes using the asset and liability method. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period when such determination is made. As of December&#160;31, 2021 and 2020, the Company has recorded a full valuation allowance on its deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax benefits related to uncertain tax positions are recognized when it is more likely than not that a tax position will be sustained upon examination. Interest and penalties related to unrecognized tax liabilities are included within the provision for income tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU1_4e885a66-ef28-4958-a870-3c9e466e6f68">Comprehensive Loss&#x2014;Comprehensive loss comprises net loss and other comprehensive income. Other comprehensive income consists of foreign currency translation adjustments and unrealized gain on marketable securities.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODQ5_83e1fa27-d48d-4781-8e5f-e28635d3e5ce">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, restricted stock units (&#x201c;RSUs&#x201d;), employee stock purchase plan (&#x201c;ESPP&#x201d;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xMzkvZnJhZzphNWRiNzFiYWQ5YzA0ZjgxOGIwZTUzMzkyYWI4OGI0Yi90ZXh0cmVnaW9uOmE1ZGI3MWJhZDljMDRmODE4YjBlNTMzOTJhYjg4YjRiXzIwODU2_f5dade94-b57b-4b62-aaaa-f839f35c9e86">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board issued ASU 2016-13, Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments (&#x201c;Topic 326&#x201d;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326, but does not expect the effect of adoption to be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzMwOTg_6afcbe4f-8c20-495c-a889-79c2ce01085d">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bond and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company&#x2019;s consolidated balance sheet. Management regularly reviews all of the Company&#x2019;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#x2019;s marketable securities as of December&#160;31, 2021 were temporary in nature and none were in continuous loss position for 12 months or more. Management concluded that none of the Company&#x2019;s marketable securities were other-than-temporarily impaired as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, $47.0 million of marketable securities had remaining maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MjY_6080290b-1a2f-4c6f-9319-23bad6204282"&gt;one&lt;/span&gt; and two years. The remainder of the marketable securities have a remaining maturity of one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers within the hierarchy during the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company performed an impairment test to measure certain right-of-use assets and leasehold improvements at fair value. The assets are measured at fair value on a non-recurring basis as a result of the occurrence of certain triggering events indicating the carrying value of the assets may not be recoverable, by comparing the sum of the estimated future undiscounted cash flows to the carrying amount of the assets. Refer to Note 5, Leases for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzMxMDA_7ba81c79-26ff-4d3f-95bf-6168463cbccd">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Loses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtMS0xLTEtMTI4MjI_0a7b770a-6ee7-481c-ae4e-93e8b19ba265"
      unitRef="usd">10311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtMy0xLTEtMTI4MjI_ad863967-088a-456d-a630-76b8e7d6bc3e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtNS0xLTEtMTI4MjI_6809f781-8056-4984-960e-be37b8f9afaa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d8be49b7bbf4251910929fc132243a6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzMtNy0xLTEtMTI4MjI_6acc22e0-aee6-4642-95eb-8918cd6dca7b"
      unitRef="usd">10311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtMS0xLTEtMTI4MjI_04063e8b-bb61-4cfd-88c3-a89b8063b20b"
      unitRef="usd">62268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtMy0xLTEtMTI4MjI_6cb608b9-f271-4b7d-9105-f5440df0ae9a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtNS0xLTEtMTI4MjI_78740e38-754c-4475-855f-f2fcee8cf910"
      unitRef="usd">218000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5fd8f0ec4c140eba3d181d3b7fa312b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzUtNy0xLTEtMTI4MjI_63f8cbb2-ad8c-4b15-be42-77a411038b0a"
      unitRef="usd">62050000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i198713b3bc694250846e3c8d7a262676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtMS0xLTEtMTI4MjI_731b0d94-528d-41ee-beb8-a27924f93721"
      unitRef="usd">177215000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i198713b3bc694250846e3c8d7a262676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtMy0xLTEtMTI4MjI_73d684c8-19a0-46aa-8773-db5e95916e84"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i198713b3bc694250846e3c8d7a262676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtNS0xLTEtMTI4MjI_baf316b7-c8c7-4078-85ce-1f571e501636"
      unitRef="usd">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i198713b3bc694250846e3c8d7a262676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzYtNy0xLTEtMTI4MjI_cd143f1f-c984-49cc-aeb0-23a9285ab604"
      unitRef="usd">177155000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctMS0xLTEtMTI4MjI_3995775a-ae4c-46fd-ab01-5a614c8ac842"
      unitRef="usd">47323000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctMy0xLTEtMTI4MjI_d93c12a0-0363-41a1-9dd2-cc4f6bb0206a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctNS0xLTEtMTI4MjI_e88f1609-af6e-4bf6-8b35-aa31c8788bd8"
      unitRef="usd">39000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e36a17528e246b0ab9dcbede5458fb4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzctNy0xLTEtMTI4MjI_f7f328fd-06e7-48d3-b0bf-d27de2b51ecc"
      unitRef="usd">47284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtMS0xLTEtMTI4MjI_45e017fd-cc92-4ebc-9ec6-6223f7bba271"
      unitRef="usd">297117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtMy0xLTEtMTI4MjI_ff7c4a20-bd1d-4528-a359-385854b1d482"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtNS0xLTEtMTI4MjI_f5e452c1-e3fe-436e-acc6-96b115ef59ef"
      unitRef="usd">318000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9878b1af9a524eeeaa9c8427214abf99_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzgtNy0xLTEtMTI4MjI_7232aca0-139d-4f08-8c10-aceafe8f8ec9"
      unitRef="usd">296800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktMS0xLTEtMTI4MjI_4f2b3693-e5c7-45f4-8d2e-e5a9dee29a5f"
      unitRef="usd">25808000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktMy0xLTEtMTI4MjI_dfc9c62a-b420-47fb-9c69-a7c53655d11b"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktNS0xLTEtMTI4MjI_1b580407-c7fe-4ba4-a15a-c44cb5507fe4"
      unitRef="usd">1000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzktNy0xLTEtMTI4MjI_852e03a6-7a2a-4b8c-aef7-8e90518bbb0b"
      unitRef="usd">25807000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTEtMS0xLTEyODIy_f5e2ca06-d7bd-4279-8c93-c215cf5b2c03"
      unitRef="usd">271309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTMtMS0xLTEyODIy_de4af58f-33f9-48e9-839f-fe8011f5c196"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTUtMS0xLTEyODIy_0abafecf-e5ec-4017-8a99-03085156c19e"
      unitRef="usd">317000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTo1ZjkwMWZkMjE4M2M0MTE0OWQ2MmVjYzM3ZWY4MjFmMy90YWJsZXJhbmdlOjVmOTAxZmQyMTgzYzQxMTQ5ZDYyZWNjMzdlZjgyMWYzXzEwLTctMS0xLTEyODIy_7165b43c-a6b0-474b-b2a3-f19618bebe1f"
      unitRef="usd">270993000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc2e87b6775540219d86de876645d890_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtMS0xLTEtMTI4MjI_5669547d-923a-4c49-9e35-5bf9b3935925"
      unitRef="usd">178000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc2e87b6775540219d86de876645d890_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtMy0xLTEtMTI4MjI_1ac4fbea-5ab1-46f0-8aa2-defc6fbf27fb"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc2e87b6775540219d86de876645d890_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtNS0xLTEtMTI4MjI_a0bb3ca6-6053-4ecf-86de-e604838de894"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc2e87b6775540219d86de876645d890_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzMtNy0xLTEtMTI4MjI_cfdc882b-e301-489e-9528-5b8a7f33fcf5"
      unitRef="usd">178000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtMS0xLTEtMTI4MjI_8092fbef-1812-4210-aebd-8e7b4eef4cba"
      unitRef="usd">328583000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtMy0xLTEtMTI4MjI_8ae03b02-20ed-4881-b259-2ecd176c14e3"
      unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtNS0xLTEtMTI4MjI_63f33522-221f-4dca-b188-4e4fc83a05c2"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i11aa3c6438434617967b1b14ac83e990_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzUtNy0xLTEtMTI4MjI_f9f66de1-e03e-4db5-92d8-d1ef67ef1bd5"
      unitRef="usd">328699000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtMS0xLTEtMTI4MjI_21e57aa8-b94f-4b08-95e8-cc471fd8a1fc"
      unitRef="usd">97324000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtMy0xLTEtMTI4MjI_0ce0f6f9-3f4a-4dc5-9036-d08644ee0b3f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtNS0xLTEtMTI4MjI_c202a757-8872-4947-8462-5aeee92611b0"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i17c70c9ce0be428fbba3d718ce6bdb10_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzYtNy0xLTEtMTI4MjI_82596efd-cdee-4b9f-9a4c-5747bd8a436d"
      unitRef="usd">97319000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtMS0xLTEtMTI4MjI_5704e878-c512-4a42-b1b2-3eb18b0f7221"
      unitRef="usd">426085000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtMy0xLTEtMTI4MjI_b1fb639e-1c30-461e-9a2f-85b15620fa20"
      unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtNS0xLTEtMTI4MjI_9423c7eb-4b30-4654-a17f-e72893164ce6"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i03259c961d784a7f9273e4d83977e07b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzgtNy0xLTEtMTI4MjI_f2143245-080a-44b9-964a-d057aeba84f1"
      unitRef="usd">426196000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktMS0xLTEtMTI4MjI_be7c14f4-31e3-4cb4-9094-713de0a02370"
      unitRef="usd">58894000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktMy0xLTEtMTI4MjI_c46b4ff4-5702-4852-9a84-d6e4f65d41bb"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktNS0xLTEtMTI4MjI_7f4605b3-a33d-4f53-8c6b-42ce28b7c548"
      unitRef="usd">3000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzktNy0xLTEtMTI4MjI_d8476a19-1cfa-4832-8801-3e95c558a80e"
      unitRef="usd">58891000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTEtMS0xLTEyODIy_e91db49a-e56e-4971-905b-391b14063501"
      unitRef="usd">367191000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTMtMS0xLTEyODIy_6d34efef-bee0-4626-a075-35ce14b2ed69"
      unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTUtMS0xLTEyODIy_413d2bf2-c948-45a8-b1c6-5e0bb1e191bd"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90YWJsZTpkYTEyZmI3NmVhZTI0YzM0ODA0OWVkOWQ1YmFkMTEzYy90YWJsZXJhbmdlOmRhMTJmYjc2ZWFlMjRjMzQ4MDQ5ZWQ5ZDViYWQxMTNjXzEwLTctMS0xLTEyODIy_06d49733-a1e3-46f9-a4b2-fb3e56b96f30"
      unitRef="usd">367305000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI3NjY_e8cc5fb6-ccfc-41af-9c9d-cfddcbb661b1"
      unitRef="usd">0</advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities>
    <advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI4NjU_daee709c-1d84-432d-9d71-4a7a6898b71c"
      unitRef="usd">47000000</advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="ibd8584c0ea5b463ca366376a46eac4d1_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDIvZnJhZzoxZDIyNDMyNTI4NzY0OGQ5YTJhZDBlZjc0ODRhYTJlMS90ZXh0cmVnaW9uOjFkMjI0MzI1Mjg3NjQ4ZDlhMmFkMGVmNzQ4NGFhMmUxXzI5MzM_33db667e-f8e6-4dc5-b5fb-d0f7c1b17821">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3OTQ_241e5d74-e1f3-42f3-9d35-32cbd047cda6">Revenue&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lexeo &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company and Lexeo Therapeutics, Inc (&#x201c;Lexeo&#x201d;) entered into a License Agreement pursuant to which the Company granted Lexeo an exclusive, worldwide, royalty-bearing license to certain of the Company's intellectual property to develop, manufacture, and commercialize a gene therapy product to treat cardiomyopathy due to Friedreich's Ataxia. Upon execution of the agreement, Lexeo paid the Company a one-time, non-creditable and non-refundable upfront payment of $7.5&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company is eligible to receive additional payments upon the achievement of certain milestones. Additionally, the Company will receive royalty payments on net sales subject to a cap and reductions based on patent expiry, anti-stacking, and a defined royalty floor percentage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the initial transaction price is the $7.5&#160;million the Company received for the license granted. As described above, the arrangement provides for additional payments to the Company when certain development and commercial milestones are achieved. Because these milestone payments are not within the control of the Company and are not considered probable of being achieved until the events occur, the Company did not include them in the transaction price. The transaction price of $7.5&#160;million was allocated to a combined performance obligation that was fulfilled during the three months ended March 31, 2021. The Company recognized $7.5&#160;million of license revenue during year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9538a71ff1d424989f80b9467a6a448_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3ODI_9c33559c-4177-4b76-ba3e-d1eddd18e54b"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3388e01ba0cd4c2bb002f33d9f0729df_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3Njg_54cf4e93-55e1-431f-a7cd-6b69149ccffb"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i15c6315f35b6402d86b1167231385890_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3NDA_a7745e88-43dc-4358-862c-7079fbabd95c"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDUvZnJhZzphZmRhOWJkNzI3NDE0NDM5YmQyMzBiZTNlMDUyMGY4Ni90ZXh0cmVnaW9uOmFmZGE5YmQ3Mjc0MTQ0MzliZDIzMGJlM2UwNTIwZjg2XzQ5NDc4MDIzMzQ3NTQ_c60573fa-a027-42a1-8f27-a0f1e6c288bc"
      unitRef="usd">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwODg_e83cbc9b-12b1-4a7d-badc-60456951a3ad">Leases&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Redwood City&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company has a lease for facilities in Redwood City, which provides a total of tenant improvement allowances of up to $10.2&#160;million. Related to the Redwood City lease, the Company provided the landlord with a letter of credit in the amount of $2.5&#160;million, which is classified as restricted cash under long term assets on the Company's consolidated balance sheets.  The Redwood City lease expires in December 2031, with an option to extend for a period of eight years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2021, the Company entered into an amendment to terminate the lease of one of its Redwood City premises under the existing lease and paid a termination fee of $0.4&#160;million. Concurrently, the Company entered into an agreement to sublease a portion of such premises at $0.1&#160;million monthly base rent. The sublease will expire on March&#160;31, 2022 and may be extended on a month to month basis until June 30, 2022. For short-term leases the Company does not recognize the right-of-use asset and lease liability and recognizes the lease expense over the term of the lease on a straight-line basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease termination resulted in the requirement to test the recoverability of the carrying amount of the asset group. The carrying amount of the asset group, consisting of right-of-use assets and leasehold improvements, relating to the lease termination exceeds the Company's anticipated undiscounted cash flows. Accordingly, the Company reviewed the related right-of-use assets and leasehold improvements for impairment. As a result of the evaluation, the Company recorded an impairment charge of $1.1&#160;million, which includes $0.8&#160;million associated with the right-of-use assets and $0.3&#160;million associated with leasehold improvements, for the year ended December&#160;31, 2021. The assets indicated as impaired were written down to the estimated fair value, which was determined using the terms of the termination and sublease agreements. In connection with the termination of this lease, the Company derecognized the corresponding operating lease right-of-use asset and liability balances from the consolidated balance sheet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;North Carolina&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company entered into an operating lease agreement for a building in North Carolina (&#x201c;NC Premises&#x201d;). The lease commenced in April 2021 when the Company obtained control of the NC Premises, and the lease term expires in October 2037 with two options to extend the lease term for a period of five years each. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2021, the Company entered into a sublease agreement with a subtenant for the North Carolina property through October 2037, the remainder of the lease term. The remainder of the tenant improvement allowance under the original lease of approximately $22.7&#160;million was transferred to the subtenant. This change in the Company&#x2019;s payment terms with the landlord at the time of the sublease was considered to be a lease modification and the Company remeasured the lease liability on the modification date. The base annual rental rates, payment schedules and amounts under the sublease agreement are substantially the same as the original payment terms by Adverum to the landlord. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the weighted-average remaining lease term was 11.7 years for the Company's leases and the weighted-average Incremental Borrowing Rate (&#x201c;IBR&#x201d;) was 9.4%. IBR is an estimated rate of interest used to determine present value of future lease payments in order to measure lease liability, which rate is what the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. In order to determine the IBR, the Company estimates its credit rating, adjusts the credit rating for the nature of the collateral, and benchmarks the borrowing rate against observable yields on comparable securities with a similar term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payment Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Lease incentive receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense for the years ended December&#160;31, 2021, and 2020 was $12.8&#160;million and $5.8&#160;million, respectively, which includes variable lease costs for utilities, parking, maintenance, and real estate taxes. Variable lease expenses for the years ended December&#160;31, 2021 and 2020 were $1.8 million and $1.5 million, respectively. Cash paid for amounts included in the measurement of lease liabilities for the twelve months ended December&#160;31, 2021 and 2020 was $5.2&#160;million and $4.2&#160;million, respectively. Sublease income was $1.2&#160;million for the year ended December&#160;31, 2021, which was classified as a reduction in rent expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <advm:LesseeOperatingLeaseLeaseholdImprovementAllowance
      contextRef="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzIxOTkwMjMyNjczNTk_65c6ba37-1434-4870-9497-47113802e550"
      unitRef="usd">10200000</advm:LesseeOperatingLeaseLeaseholdImprovementAllowance>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2NDA2MDA_b130124e-09c3-4c01-8ba2-36e229fa82a5"
      unitRef="usd">2500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6bf46b1f1896441c8e9093d9105aaf3a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzk4OTU2MDQ2Njc0ODc_314ed2cf-a5e9-4cd4-938e-bfcd3adff41e">P8Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <advm:LesseeOperatingLeaseLeaseTerminationFee
      contextRef="ib6311b039ae14140ac682b123ba2e20b_D20211101-20211101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzQ5NDc4MDIzMzQzNDA_741334a3-ad7e-494d-8fe2-a08fd197bc1a"
      unitRef="usd">400000</advm:LesseeOperatingLeaseLeaseTerminationFee>
    <advm:OperatingLeaseMonthlyCost
      contextRef="i6c50a8ce1839401ebdedd41b23664dc7_I20211101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzY1OTcwNjk3NzYxODA_54f52684-c8f6-40d2-b3f3-a0c0d10945ef"
      unitRef="usd">100000</advm:OperatingLeaseMonthlyCost>
    <us-gaap:AssetImpairmentCharges
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzY1OTcwNjk3NzYxOTU_f0442595-ab2b-44da-9f7e-c3196198ca64"
      unitRef="usd">1100000</us-gaap:AssetImpairmentCharges>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzQ5NDc4MDIzMzQzNjg_735864e6-0c62-47ac-9d66-62107b82e864"
      unitRef="usd">800000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:ImpairmentOfLeasehold
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzY1OTcwNjk3NzYyMTA_e5feb753-908b-4812-bd31-bec074abf1f9"
      unitRef="usd">300000</us-gaap:ImpairmentOfLeasehold>
    <advm:LesseeOperatingLeaseNumberOfRenewalContracts
      contextRef="i6fe35d41e331443d948be3c7be2e9ec8_D20210108-20210108"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzk4OTU2MDQ2NTk1OTA_435613af-eda7-4188-9f46-bf50fe3acc4d"
      unitRef="segment">2</advm:LesseeOperatingLeaseNumberOfRenewalContracts>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="icd7de60f78ff4ca4b73e44e0bed3fb91_I20210108"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzk4OTU2MDQ2NTk2MDc_5a05de05-69b4-4dac-9584-a9bddb4724bc">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <advm:LesseeOperatingLeaseLeaseholdImprovementAllowance
      contextRef="ie64eef970c89427db31b4a0fad29b6a3_I20211026"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzE2NDkyNjc0NTkyNDg_39eff524-3814-44d4-80c0-372a8ede6a8a"
      unitRef="usd">22700000</advm:LesseeOperatingLeaseLeaseholdImprovementAllowance>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i00fd997b49304a6fb48d58e552aeb8ba_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2Mzc0MDY_9d317bb0-8850-4d7d-8cdc-1710deff86d1">P11Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i00fd997b49304a6fb48d58e552aeb8ba_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2Mzc0MTM_9085f9c7-dab3-48c2-8095-60c4337cba9d"
      unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwODk_64d91d1f-66e2-48c5-b408-f623485de4cc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the undiscounted future non-cancellable lease payments under the lease agreements are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sublease Payment Receivable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Present value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,577)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Add: Lease incentive receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzItMi0xLTEtMTI4MjI_519019d4-6196-4e8d-9cac-cb2fefeb9b30"
      unitRef="usd">6049000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzItNC0xLTEtMTUyMDc_e6e62827-2055-4631-8393-56588b8177ad"
      unitRef="usd">491000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzMtMi0xLTEtMTI4MjI_ba93b982-cd61-4e24-8b8f-dd286633ffd1"
      unitRef="usd">13947000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzMtNC0xLTEtMTUyMDc_8ce16eb0-e791-4e17-9ae6-d444319fe5b8"
      unitRef="usd">5844000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzQtMi0xLTEtMTI4MjI_f3281d2d-4266-45a3-8e4e-f239da913ae5"
      unitRef="usd">14406000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzQtNC0xLTEtMTUyMDc_de396c05-8632-4b36-879d-547fc16d3e96"
      unitRef="usd">6019000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzUtMi0xLTEtMTI4MjI_7449ed17-b646-4018-9c3a-7bfc5e21580a"
      unitRef="usd">14880000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzUtNC0xLTEtMTUyMDc_8a82e604-a19d-4fcb-a99e-1df8c58faba6"
      unitRef="usd">6200000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzYtMi0xLTEtMTI4MjI_6fb2a9ec-b3b2-4843-840d-a8478679fb49"
      unitRef="usd">15369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzYtNC0xLTEtMTUyMDc_cd461aed-1727-42a3-9096-b7a9dfd40630"
      unitRef="usd">6385000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzctMi0xLTEtMTI4MjI_be911a92-2772-48d8-8452-fda82363f45d"
      unitRef="usd">133883000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzctNC0xLTEtMTUyMDc_55312ce4-eb10-4eed-83ca-9754603ceec8"
      unitRef="usd">82751000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzgtMi0xLTEtMTI4MjI_0f6134e9-1031-4d81-b129-4ef75209714a"
      unitRef="usd">198534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzgtNC0xLTEtMTUyMDc_59af616a-4180-4775-8773-9f6e109db387"
      unitRef="usd">107690000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzktMi0xLTEtMTI4MjI_48bd3598-92ff-4513-81ed-7f362cf9bd12"
      unitRef="usd">91672000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:TenantImprovements
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzEwLTItMS0xLTE2MTI2_c6dc1a22-437b-42ab-9b8c-b6bd7a9ee23c"
      unitRef="usd">9577000</us-gaap:TenantImprovements>
    <us-gaap:IncentiveToLessee
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzExLTItMS0xLTE2MDgy_6de6d34d-69cf-4053-8603-f8fcbebeb590"
      unitRef="usd">5709000</us-gaap:IncentiveToLessee>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90YWJsZTozODhjMjU3ZWYwNjE0OTQxYmJhOTMzNGQzNTQzM2QzNC90YWJsZXJhbmdlOjM4OGMyNTdlZjA2MTQ5NDFiYmE5MzM0ZDM1NDMzZDM0XzEwLTItMS0xLTEyODIy_5c224545-a7ae-44a2-8ced-fcbd33191d1a"
      unitRef="usd">102994000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY2MTQ_171c5132-c52c-4c21-809f-2f348dd786af"
      unitRef="usd">12800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY2MTk_36050570-7a7e-4678-8915-754618bc1216"
      unitRef="usd">5800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:VariableLeaseCost
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY4MDM_1087d0bb-7e25-4805-971c-351ba12ba8e1"
      unitRef="usd">1800000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2MzY4MTE_9f4169ff-d5e0-4bbc-8f73-0349ca3fd661"
      unitRef="usd">1500000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzE2NDkyNjc0NjA3MTY_2baa85c8-8f47-4780-8543-1f5600a8ac43"
      unitRef="usd">5200000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzE2NDkyNjc0NjA4Nzk_4ecceccd-fe24-4d2d-9a26-fde0031650e3"
      unitRef="usd">4200000</us-gaap:OperatingLeasePayments>
    <us-gaap:SubleaseIncome
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNDgvZnJhZzphZTY1ZTFkZjI1YmY0ODg1OTVmMzIxOGNhOWNjYzg0My90ZXh0cmVnaW9uOmFlNjVlMWRmMjViZjQ4ODU5NWYzMjE4Y2E5Y2NjODQzXzEwOTk1MTE2Mzc0MzY_c8f0cc5f-9e71-4f30-8d30-38a050abf81f"
      unitRef="usd">1200000</us-gaap:SubleaseIncome>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90ZXh0cmVnaW9uOjFkZjA3MjdjMjE0YjQ2NjBhNDczNjM1YzljOTFhZjFhXzM0Mw_c26f8237-59cc-42a6-b4c0-077034f4ed95">Balance Sheet Components&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90ZXh0cmVnaW9uOjFkZjA3MjdjMjE0YjQ2NjBhNDczNjM1YzljOTFhZjFhXzM0NA_bf751dd4-d89d-4cf1-b340-c702221b715c">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,072)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4bfec030c89344d68297b3d5723d72af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzMtMS0xLTEtMTI4MjI_6016ba11-02f0-44c2-9493-1a93c9c3b4d4"
      unitRef="usd">1224000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2ebc23bbab6a4b809a58be9b27bc6683_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzMtMy0xLTEtMTI4MjI_13dde35c-40ad-42b5-a113-2151f758d0c4"
      unitRef="usd">599000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2b342bb0ce1b4ddfbb1fc42da05b8954_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzQtMS0xLTEtMTI4MjI_1c218455-30bc-4488-8e3d-c6251c0e77d2"
      unitRef="usd">12778000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d7cb21878274c689e6a89f1c23e59d1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzQtMy0xLTEtMTI4MjI_5c192ef5-8b50-4e23-8b1a-44e41c98b311"
      unitRef="usd">9354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd25a4e655954753968ec44adaaed1c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzUtMS0xLTEtMTI4MjI_dc4c0884-32bb-4fe4-9027-e2cf2206ebd3"
      unitRef="usd">1136000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i76e6ddf942cd490c98176b6a38c05c9c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzUtMy0xLTEtMTI4MjI_b3c27c60-7df7-47db-8f86-82a547b4cd43"
      unitRef="usd">1259000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifc3a06d6569a4f0eb845ce032f5207f1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzYtMS0xLTEtMTI4MjI_99a09057-88af-4d7b-81f5-3e59cf399c44"
      unitRef="usd">26701000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if01fe6f2e1c640889f794f6d0cb75b01_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzYtMy0xLTEtMTI4MjI_74b2056c-67ea-4aa0-86f6-c4c509b30a76"
      unitRef="usd">24631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i299d93d81b8442fea229100cbe836c75_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzctMS0xLTEtMTI4MjI_8f9bfcaf-30af-4b25-80e6-097f75e1c269"
      unitRef="usd">4395000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4372ddfd6eaf4ebdab2698da6339e4ba_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzctMy0xLTEtMTI4MjI_1228eae8-6ce7-461e-a0bb-0d99059184da"
      unitRef="usd">1954000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzgtMS0xLTEtMTI4MjI_8e9f1073-aa5f-428a-8559-6a454aaf642b"
      unitRef="usd">46234000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzgtMy0xLTEtMTI4MjI_b2962500-3de7-473e-8c29-ff7603770c63"
      unitRef="usd">37797000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzktMS0xLTEtMTI4MjI_86c8bb7e-ae68-4cca-8c04-f982a086277c"
      unitRef="usd">13174000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzktMy0xLTEtMTI4MjI_8ba7519a-313a-48a6-8e86-7762464cfdce"
      unitRef="usd">10072000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzEwLTEtMS0xLTEyODIy_b110ead3-ecbd-4fae-b2dc-1200ff138759"
      unitRef="usd">33060000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo1MmYzZWMwZmI3NzQ0MWNjYWQ4ZDFiYWQ3M2YxNjExMy90YWJsZXJhbmdlOjUyZjNlYzBmYjc3NDQxY2NhZDhkMWJhZDczZjE2MTEzXzEwLTMtMS0xLTEyODIy_a1b20c94-b4d1-47f8-9b0b-c54df79a652e"
      unitRef="usd">27725000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90ZXh0cmVnaW9uOjFkZjA3MjdjMjE0YjQ2NjBhNDczNjM1YzljOTFhZjFhXzM0NQ_e6f9fa8a-604a-462f-8bdc-559865abfad6">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued nonclinical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzMtMS0xLTEtMTI4MjI_444448bf-27f4-4f46-82d3-483b73b4af42"
      unitRef="usd">9209000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzMtMy0xLTEtMTI4MjI_b4250f69-a979-436b-9c4c-720486f0b25d"
      unitRef="usd">8344000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzQtMS0xLTEtMTI4MjI_4844fc33-8f2a-4c66-aa4c-e491bbbd5257"
      unitRef="usd">550000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzQtMy0xLTEtMTI4MjI_4878c86f-411e-49e2-8759-7af321b2fedd"
      unitRef="usd">1075000</us-gaap:AccruedProfessionalFeesCurrent>
    <advm:AccruedNonclinicalCostsCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzUtMS0xLTEtMTI4MjI_d63deb1a-09b2-41dc-84ff-33d51898763b"
      unitRef="usd">2895000</advm:AccruedNonclinicalCostsCurrent>
    <advm:AccruedNonclinicalCostsCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzUtMy0xLTEtMTI4MjI_91364fce-b403-4db1-9258-0c5865b86d42"
      unitRef="usd">1824000</advm:AccruedNonclinicalCostsCurrent>
    <advm:AccruedClinicalAndDevelopmentProcessCostsCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzYtMS0xLTEtMTI4MjI_39281d43-f68d-4a8f-8080-df284d6db6af"
      unitRef="usd">2058000</advm:AccruedClinicalAndDevelopmentProcessCostsCurrent>
    <advm:AccruedClinicalAndDevelopmentProcessCostsCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzYtMy0xLTEtMTI4MjI_350bd534-0b95-4848-a455-592d87bc46a3"
      unitRef="usd">1020000</advm:AccruedClinicalAndDevelopmentProcessCostsCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMS0xLTEtMTY5ODE_53172c38-ffdc-41ad-963a-f06cbc704acb"
      unitRef="usd">1318000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMy0xLTEtMTY5ODE_a5fc4085-968e-4dad-8ebb-e8f73290638a"
      unitRef="usd">40000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMS0xLTEtMTI4MjI_c09a737e-a21a-4719-8326-99d4135d0594"
      unitRef="usd">2017000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzctMy0xLTEtMTI4MjI_370c2fef-8559-4dd6-8b94-917a3ed126a0"
      unitRef="usd">1285000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzgtMS0xLTEtMTI4MjI_db9b8c9a-6e99-4b92-80b0-9cfe1d72864c"
      unitRef="usd">18047000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTEvZnJhZzoxZGYwNzI3YzIxNGI0NjYwYTQ3MzYzNWM5YzkxYWYxYS90YWJsZTo4Y2ZiZDlkODg1NjQ0NGQyOGI3ZmJlNDE4NWI3N2E1NS90YWJsZXJhbmdlOjhjZmJkOWQ4ODU2NDQ0ZDI4YjdmYmU0MTg1Yjc3YTU1XzgtMy0xLTEtMTI4MjI_4fdb2296-25a0-46f4-a57a-ad31fc0689d4"
      unitRef="usd">13588000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTcvZnJhZzozNGRjMGZlMjRjZTk0ZTE0OWFmODM5MTIxOWZlOGUwMC90ZXh0cmVnaW9uOjM0ZGMwZmUyNGNlOTRlMTQ5YWY4MzkxMjE5ZmU4ZTAwXzE3Nzc_6bc93552-1626-4bb1-aaa0-10d44a10c1c2">Commitments and Contingencies&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is a party to various agreements, principally relating to licensed technology that requires future payments relating to milestones or royalties on future sales of specified products. Through December&#160;31, 2021, none of the goals had been achieved under the license agreements and no milestones were accrued or payable. Because the achievement of these milestones is not fixed and determinable, such commitments have not been included on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNTcvZnJhZzozNGRjMGZlMjRjZTk0ZTE0OWFmODM5MTIxOWZlOGUwMC90ZXh0cmVnaW9uOjM0ZGMwZmUyNGNlOTRlMTQ5YWY4MzkxMjE5ZmU4ZTAwXzM1Mg_bc03a38c-3939-4095-968f-c1f5b322f99c"
      unitRef="usd">0</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODQ_12ea0ab9-2621-45d9-b512-19e071fa5ac1">Stock Plans&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2006, the Company adopted the 2006 Equity Incentive Plan, which was amended by the board of directors on November&#160;15, 2012 (the &#x201c;2006 Plan&#x201d;). The 2006 Plan allowed for the granting of incentive stock options (&#x201c;ISOs&#x201d;) and non-qualified stock options (&#x201c;NSOs&#x201d;) to the employees, members of the board of directors and consultants of the Company. ISOs were granted only to the Company&#x2019;s employees, including officers and directors who are also employees. NSOs were granted to the employees and consultants. In July 2014, the Company&#x2019;s board of directors and its stockholders approved the establishment of the 2014 Equity Incentive Award Plan (the &#x201c;2014 Plan&#x201d;). Options may no longer be issued under the 2006 Plan after July&#160;30, 2014. In addition, the 2014 Plan provides for annual increases in the number of shares available for issuance thereunder on the first business day of each fiscal year, beginning with the year ended December 31, 2015, equal to four percent (4%) of the number of shares of the Company&#x2019;s common stock outstanding as of such date or a lesser number of shares as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company adopted the 2017 Inducement Plan (the &#x201c;Inducement Plan&#x201d;). The Company reserved 600,000 shares for issuance pursuant to stock options and RSUs under the Inducement Plan. The only persons eligible to receive grants of stock options and RSUs under Inducement Plan are individuals who satisfy the standards for inducement grants under Nasdaq guidance that is, generally, a person not previously an employee or director of Adverum, or following a bona fide period of non-employment, as an inducement material to the individual's entering into employment with Adverum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2006 Plan, 2014 Plan and Inducement Plan are referred to collectively as the Plans. As of December&#160;31, 2021, a total of 33,965,569 shares of common stock were reserved for issuance and 5,717,148 shares were available for future grants under the Plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options under the 2014 Plan and the Inducement Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% stockholder may not be less than 110% of the estimated fair value of the shares on the date of grant. Stock options granted to employees and non-employees generally vest ratably over four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except exercise prices and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Contract&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#x2019;s common stock as quoted on a national exchange.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of stock options exercised during the years ended December&#160;31, 2021 and 2020 was $0.1&#160;million and $20.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of options granted during the years ended December&#160;31, 2021 and 2020 were $5.18 and $13.39, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, there was $43.1 million of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of 2.9 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs are share awards that entitle the holder to receive freely tradable shares of the Company&#x2019;s common stock upon vesting. The fair value of RSUs is based upon the closing sales price of the Company&#x2019;s common stock on the grant date. RSUs granted to employees generally vest over a 2&#x2013;4 year period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except grant date fair value and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs granted during the year ended December&#160;31, 2021 include 1.3&#160;million shares of performance units with both performance and service vesting conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020 total fair value of RSUs vested was $1.6&#160;million and $2.7&#160;million, respectively. The number of RSUs vested includes shares of common stock that the Company withheld on behalf of employees or sold to cover to satisfy the minimum statutory tax withholding requirements. As of December&#160;31, 2021, there was $4.5&#160;million of unrecognized compensation cost related to unvested RSUs that is expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, the Company approved the establishment of the 2014 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The Company reserved 208,833&#160;shares of its common stock for issuance and provided for annual increases in the number of shares available for issuance on the first business day of each fiscal year, beginning in 2015, equal to the lesser of one percent (1%)&#160;of the number of the Company&#x2019;s common stock shares outstanding as of such date or a number of shares as determined by the Company&#x2019;s board of directors. During the year ended December&#160;31, 2021, 397,763 shares were issued under the ESPP. As of December&#160;31, 2021, a total of 2,130,542 shares of common stock were available for future issuance under the ESPP. As of December&#160;31, 2021, there was $1.9&#160;million of unrecognized compensation cost related to the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Recognized in the Consolidated Statement of Operations and Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, the Company recorded approximately $1.6&#160;million and $0.3&#160;million,  respectively of stock&#x2011;based compensation expense as a result of the modification of the vesting and exercisability of stock awards associated with the departure of its executives and directors.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan
      contextRef="i966d761db5484ddc9c6cc7e401bba8fb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2Xzk5MA_1eca8da3-811d-4252-be57-50c9d6ce0843"
      unitRef="number">0.04</advm:ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i151723aa80f341a8952a483bb904ee20_I20171031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzEyNjQ_c40b2688-e5ff-4abb-a71f-3e92a347f678"
      unitRef="shares">600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="if01574c0aec8441ebcd6ced712437994_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzE4NTI_d3d78a3a-843d-471c-b306-e675efe79623"
      unitRef="shares">33965569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="if01574c0aec8441ebcd6ced712437994_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzE5MDk_de4e04f9-164f-415b-bb0c-2be251d86d9d"
      unitRef="shares">5717148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i0712c015900b4ee29ae1903994ae8913_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIwNzc_3a9011b2-81db-4362-8f78-13007f7b0512">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum
      contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIxMDc_e093561d-05cc-4f2a-a138-133713069e81"
      unitRef="number">1</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold
      contextRef="i9a91a547f88e4a6a81c47e8971ea1f72_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIyODg_5ea80912-4454-431d-b49e-8f610efebaeb"
      unitRef="number">0.10</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum
      contextRef="i9a91a547f88e4a6a81c47e8971ea1f72_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzIzMjQ_f83e4969-980c-4475-a738-c5e6dd8fe25a"
      unitRef="number">1.10</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ic18936e5d4e5454ab245e22276a0fb26_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzI0NzI_3b95e5ec-fbea-4fa3-a2c9-52338b8054b6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODU_588eedb6-b15e-45d3-8085-cc87e93b564b">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.988%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except exercise prices and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Contract&lt;br/&gt;Life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic Value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(646)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;The aggregate intrinsic value is calculated as the difference between the stock option exercise price and the closing price of the Company&#x2019;s common stock as quoted on a national exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtMS0xLTEtMTI4MjI_3ed3b925-946b-4bde-8fbc-1b29a94fe30a"
      unitRef="shares">8995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtMy0xLTEtMTI4MjI_aaa968ce-b951-476f-81d1-e558b63803a6"
      unitRef="usdPerShare">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i1974c638bb5e4a5990d928e7aecd0c6d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtNS0xLTEtMTI4MjI_a9ed3f30-b172-4b39-aff7-6a743e88a076">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzUtNy0xLTEtMTI4MjI_1370e4e6-01c1-4cc4-9fb6-bd2b3d42d750"
      unitRef="usd">48073000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzYtMS0xLTEtMTI4MjI_75b0655e-a2ec-4232-a5bc-8c153428f098"
      unitRef="shares">4126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzYtMy0xLTEtMTI4MjI_e51898fa-0e3c-4d2e-ad63-6e7fbe527026"
      unitRef="usdPerShare">18.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzctMS0xLTEtMTI4MjI_7bb0cf34-cd6f-402e-89ee-eca810591efb"
      unitRef="shares">2043000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzctMy0xLTEtMTI4MjI_d9796a6e-3b6e-41f2-a04d-0365fa6ed0ec"
      unitRef="usdPerShare">6.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzgtMS0xLTEtMTI4MjI_0be314a3-41a2-4d75-b58d-2a716517504e"
      unitRef="shares">646000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzgtMy0xLTEtMTI4MjI_f1e4107e-d1bb-4273-83e7-290e58cb95a0"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktMS0xLTEtMTI4MjI_ea5b8023-eeb8-4b55-84ad-6ed5ce937122"
      unitRef="shares">10432000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktMy0xLTEtMTI4MjI_1b4e4573-2857-4d31-ba03-48152b8e2738"
      unitRef="usdPerShare">11.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktNS0xLTEtMTI4MjI_d125d389-13ee-4b96-a6a6-decd41c5a96a">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzktNy0xLTEtMTI4MjI_0b347400-875e-4e6d-8bc4-a7e7eec5364b"
      unitRef="usd">31626000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEwLTEtMS0xLTEyODIy_86530402-61ce-4ed0-ad57-63ec33c40871"
      unitRef="shares">8231000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEwLTMtMS0xLTEyODIy_98e78974-41b1-45cd-805c-be5ed97d275e"
      unitRef="usdPerShare">7.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzExLTEtMS0xLTEyODIy_d19030ce-9b5b-49dd-aed0-c36787677f62"
      unitRef="shares">9000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzExLTMtMS0xLTEyODIy_a06bc957-69b6-4186-9ae3-18884b38dfdb"
      unitRef="usdPerShare">5.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEyLTEtMS0xLTEyODIy_aaf401b8-7566-4358-bb33-13c500a3ba14"
      unitRef="shares">5366000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEyLTMtMS0xLTEyODIy_7721c2b0-94e5-4239-b1b4-44e71be6aee7"
      unitRef="usdPerShare">10.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTEtMS0xLTEyODIy_e7d7c412-d9b1-4261-9f21-3b326b3152ed"
      unitRef="shares">13288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTMtMS0xLTEyODIy_6d6774c8-82e7-4028-8679-c0f5ab94f653"
      unitRef="usdPerShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTUtMS0xLTEyODIy_eb1c2d5b-24e8-49ab-a743-e4254ea0bc83">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzEzLTctMS0xLTEyODIy_b806153d-a689-4638-97ff-7f8a5a6d4d7a"
      unitRef="usd">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTEtMS0xLTEyODIy_4d7c9e5c-f55d-4a38-8d9f-4a3d24a359c8"
      unitRef="shares">13288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTMtMS0xLTEyODIy_4525b700-f2cf-4e20-88a4-db6793b8ae22"
      unitRef="usdPerShare">9.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTUtMS0xLTEyODIy_84130ad7-5d15-4677-b3a9-fee84ef0cffc">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE0LTctMS0xLTEyODIy_f1312b9a-b2ef-417d-b24d-cca65aba9c4f"
      unitRef="usd">145000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTEtMS0xLTEyODIy_a69ea41d-3775-4d1e-a6ff-27a37c0fd9ca"
      unitRef="shares">5579000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTMtMS0xLTEyODIy_89d9722d-b521-4280-9ea6-313f8e226ee0"
      unitRef="usdPerShare">10.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTUtMS0xLTEyODIy_ec5899de-6379-49db-8bf3-bc77093b4356">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowYjkzNTAzNjhkNjc0Njg5OGNlNWNiNGQ3NGZkZTFjZi90YWJsZXJhbmdlOjBiOTM1MDM2OGQ2NzQ2ODk4Y2U1Y2I0ZDc0ZmRlMWNmXzE1LTctMS0xLTEyODIy_09ceeb00-9d68-4158-929e-d9d0917b7e58"
      unitRef="usd">145000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzI4NzE_470ac090-5a58-4a8c-903b-d9459801d73d"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzI4Nzg_0227244b-7ce7-46ae-beaf-3da5c487f621"
      unitRef="usd">20800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODY_d149a787-2988-40ee-8fa3-8d2030770813">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes valuation model with the following weighted-average assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtMS0xLTEtMTI4MjI_7984be1f-89aa-41d6-9c68-528d68bde137"
      unitRef="number">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtMy0xLTEtMTI4MjI_d1aeed21-32a8-4b60-b631-03d87930b03e"
      unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtNy0xLTEtMTI4MjI_811cb7fe-f40b-4b23-a136-07f399c4145b"
      unitRef="number">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzMtOS0xLTEtMTI4MjI_d22bceeb-9ffc-4507-a5f1-6227262bf1c8"
      unitRef="number">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtMS0xLTEtMTI4MjI_085e89cf-16b7-44de-8223-f452e6ed3ef8">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtMy0xLTEtMTI4MjI_3177bb9f-b832-476d-bd28-495b2c611ed3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtNy0xLTEtMTI4MjI_959c7f56-3f7c-445a-abfe-0630d1c98857">P1Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzQtOS0xLTEtMTI4MjI_55a1a675-e37d-4d65-9529-0c7020d94205">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtMS0xLTEtMTI4MjI_47c56ada-94a6-42e6-9cc5-a6500cf0a364"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtMy0xLTEtMTI4MjI_3305987d-2201-4bd8-b95c-b498020827e6"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtNy0xLTEtMTI4MjI_490d40d1-37bb-4895-aa83-51319adff70a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzUtOS0xLTEtMTI4MjI_35fbcded-990b-4f57-8c65-ad58c1483231"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtMS0xLTEtMTI4MjI_23c30c42-2ed7-4d76-a622-53ef2e9d07d3"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1472edca9eb0496baa3829ffebad4ea2_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtMy0xLTEtMTI4MjI_18f053f8-67f6-455c-bcb5-bcc432f09b68"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1aa70f992e8d4a0eb08888166fc39f0d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtNy0xLTEtMTI4MjI_b9ee4023-9a4a-4793-9a39-afadebe23d1b"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia501eedf89104d61a7dc80aa99b5d78f_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTo2N2MzN2U2NTczMGI0ZDEyYTMxM2MzMDQwMzAzZDA2OC90YWJsZXJhbmdlOjY3YzM3ZTY1NzMwYjRkMTJhMzEzYzMwNDAzMDNkMDY4XzYtOS0xLTEtMTI4MjI_b4b2faff-c6ae-4214-a8dd-21c61b087a47"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMxNjY_8dc3807e-aa2a-413b-8ab7-09319832b9a0"
      unitRef="usdPerShare">5.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMxNjk_deb5cb3c-5698-4c73-a74a-c62b5e5879be"
      unitRef="usdPerShare">13.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMyMTQ_9de713fb-7339-403e-b8d1-b2a79019710b"
      unitRef="usd">43100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzMzNTk_0c528a72-0a46-4a66-aa4e-aae4e0a16e68">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="id1c8c42cfe214c2e915d20a2db5f37ae_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzM2NTA_57e861b8-7c64-4c6e-9c06-8f4a939ea6c9">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i675005a96bf84236b0181223cfe2bf55_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODc_615d8921-bee9-4b2e-8329-02680c98abe4">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODg_18d20e1f-5450-49b0-85b2-4a305369a0fb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the RSU activity under the Company&#x2019;s stock plans and related information:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;(In thousands, except grant date fair value and years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date&lt;br/&gt;Fair Value&lt;br/&gt;(in dollars)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(590)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.44&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i55d4e6f877b540b484ca25983cbe7bad_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzUtMS0xLTEtMTI4MjI_73367f06-d3bd-4b22-9397-3e0a7fb68981"
      unitRef="shares">1121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i55d4e6f877b540b484ca25983cbe7bad_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzUtMy0xLTEtMTI4MjI_f2b2e6ad-c50c-433e-af12-ae544ca4510d"
      unitRef="usdPerShare">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="id078bd5264c44f8d85cbc656e1a30010_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzUtNS0xLTEtMTI4MjI_ef0ea141-a816-42ff-97b8-16144dd1d641">P0Y10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzYtMS0xLTEtMTI4MjI_4f00eb4f-47c8-4936-ab60-a880abc7c88f"
      unitRef="shares">105000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzYtMy0xLTEtMTI4MjI_7aff34f9-2d5f-4c2d-9e0b-09335c7296f6"
      unitRef="usdPerShare">15.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzctMS0xLTEtMTI4MjI_257b5a07-da2c-427b-90e2-3765317f1733"
      unitRef="shares">590000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzctMy0xLTEtMTI4MjI_5ebbaf8a-a805-4b67-bbce-55525655ff6e"
      unitRef="usdPerShare">4.49</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzgtMS0xLTEtMTI4MjI_b85802dd-1ebd-4de6-825c-b1391a4b0a8c"
      unitRef="shares">96000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzgtMy0xLTEtMTI4MjI_d08a7463-9ef4-4f96-aa6c-42d14ed87459"
      unitRef="usdPerShare">7.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1aa1a08442284607a20e7c4f8d0e72b5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzktMS0xLTEtMTI4MjI_2f20e749-5a11-4e11-bf85-77bfef348682"
      unitRef="shares">540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1aa1a08442284607a20e7c4f8d0e72b5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzktMy0xLTEtMTI4MjI_7286e8b3-2f8e-4401-9b02-c45dbac1952b"
      unitRef="usdPerShare">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzktNS0xLTEtMTI4MjI_516fe4b9-b812-435f-8f80-42d2cfd003f6">P0Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEwLTEtMS0xLTEyODIy_7a7237c6-cc61-4463-98e7-c22caedd82ca"
      unitRef="shares">2585000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEwLTMtMS0xLTEyODIy_7e7614bf-f924-43b8-b877-3c0f2c6d7ef7"
      unitRef="usdPerShare">3.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzExLTEtMS0xLTEyODIy_eb471b97-3be1-4dd3-80d9-2be15fb927bd"
      unitRef="shares">305000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzExLTMtMS0xLTEyODIy_03ddac94-2bc6-4500-805d-0b572ab467fd"
      unitRef="usdPerShare">5.26</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEyLTEtMS0xLTEyODIy_55ab413b-198b-4a27-90df-ff090693ead3"
      unitRef="shares">694000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEyLTMtMS0xLTEyODIy_c1975c6a-f06b-4957-b6c8-62c107ac1710"
      unitRef="usdPerShare">5.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8988b116ae244c71b22a0159529f37af_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEzLTEtMS0xLTEyODIy_ab15e0ea-f3e6-486e-941f-8a1c002a163c"
      unitRef="shares">2126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8988b116ae244c71b22a0159529f37af_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEzLTMtMS0xLTEyODIy_8ac32c51-387a-4fd9-924c-9a6be71fdee9"
      unitRef="usdPerShare">3.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZToxMjI4NTU0ZTdhMDg0ZDhkODIzYTQ2YjNjMjEyYTY2ZS90YWJsZXJhbmdlOjEyMjg1NTRlN2EwODRkOGQ4MjNhNDZiM2MyMTJhNjZlXzEzLTUtMS0xLTEyODIy_6f0081a4-f434-451a-ad15-6feaf6524d6c">P1Y5M8D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i637b2d0774af4daf84893a36dbbffb39_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzE1OTQyOTE4NjA4OTAx_60176a0e-44c9-4e7a-b925-fe3a92a452dd"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzM5Nzk_379734e8-5cb7-4c6a-8ccf-2b51cc3c8fdc"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ida3bbbabab2f4fa791c17bf597a3de12_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzM5ODM_2adb86e3-b0b0-44ef-b582-c2f942e79f28"
      unitRef="usd">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i8988b116ae244c71b22a0159529f37af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQyMTU_f76e3b92-1920-4ece-858c-5591547afada"
      unitRef="usd">4500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQzNDU_8133b190-5eab-4730-b622-b241cbc8903d">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ0ODM_fedc5e65-4002-402f-94e0-8b89f0c4fe6c"
      unitRef="shares">208833</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage
      contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ3MDA_17fc6ba2-07be-4a0f-9eab-25d9d8f54720"
      unitRef="number">0.01</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i31af55d22bfb48c4b7cc961ba70d0f12_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ4ODI_16b462db-990c-401e-beb1-8d9e570aa63c"
      unitRef="shares">397763</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzQ5NDE_ae5e3875-8f26-4e3d-866b-73795729d186"
      unitRef="shares">2130542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="iab1fca633f724372ab4c9e5aea494549_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzUwMzg_d2a9ac75-71ce-4a51-b0b3-90d5e5836fb0"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzU1ODk_6b08e46a-55b1-4fec-aa7a-cd92b9a231e3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibdf93b275abc44ef8fb8c54d925edaa0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzMtMS0xLTEtMTI4MjI_7f55aac1-1caa-4af9-b68b-2b6de766a0b8"
      unitRef="usd">8875000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i09580173048e4c7ca33b47016c7728b2_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzMtMy0xLTEtMTI4MjI_0660d043-d574-4f97-9177-e8b7300c9e08"
      unitRef="usd">7120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4828bf008756429682ad64a18e6f626a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzQtMS0xLTEtMTI4MjI_61652bf5-f175-4d5f-aa45-40f32c7596cd"
      unitRef="usd">16319000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i98df46a84d42486094eb52256840d178_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzQtMy0xLTEtMTI4MjI_90e4a0fe-8f6d-48ff-bdd9-1ceabb5695f2"
      unitRef="usd">13271000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzUtMS0xLTEtMTI4MjI_f6a0a73a-62ef-4308-a34b-484e1ca58487"
      unitRef="usd">25194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90YWJsZTowY2I5MjAwYjhmMWI0ODJkYjhjMzUyMGI1YTJjZWYzYy90YWJsZXJhbmdlOjBjYjkyMDBiOGYxYjQ4MmRiOGMzNTIwYjVhMmNlZjNjXzUtMy0xLTEtMTI4MjI_30f1cf18-d35d-4879-9928-97a448371b5f"
      unitRef="usd">20391000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzUzNzQ_dd57e8c8-b128-441f-bb5a-976d9966748f"
      unitRef="usd">1600000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjYvZnJhZzoxZWE0YzIyMTg0NWQ0MzNhYWQxMjc2ZWNiMjdlZDg3Ni90ZXh0cmVnaW9uOjFlYTRjMjIxODQ1ZDQzM2FhZDEyNzZlY2IyN2VkODc2XzUzNzg_e5b9d07c-f6fe-4d45-8685-c9f58900bfe2"
      unitRef="usd">300000</us-gaap:StockOptionPlanExpense>
    <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjkvZnJhZzpmNzAyYjc2YWY1N2M0YTVmYmNhYWMyMzg5NmM5OTVhMi90ZXh0cmVnaW9uOmY3MDJiNzZhZjU3YzRhNWZiY2FhYzIzODk2Yzk5NWEyXzQ0Mg_6738de86-ba56-4d2e-b146-8658b06c7e05">401(k) Savings PlanThe Company established a defined-contribution savings plan under Section 401(k) of the Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements, and allows participants to defer a portion of their annual compensation on a pretax basis. The amount of contributions that the Company made to the 401(k) Plan during the years ended December&#160;31, 2021 and 2020 was $1.0 million and $0.7 million, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjkvZnJhZzpmNzAyYjc2YWY1N2M0YTVmYmNhYWMyMzg5NmM5OTVhMi90ZXh0cmVnaW9uOmY3MDJiNzZhZjU3YzRhNWZiY2FhYzIzODk2Yzk5NWEyXzQxNg_55e28170-3897-4d7f-a000-c3124c6aea96"
      unitRef="usd">1000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNjkvZnJhZzpmNzAyYjc2YWY1N2M0YTVmYmNhYWMyMzg5NmM5OTVhMi90ZXh0cmVnaW9uOmY3MDJiNzZhZjU3YzRhNWZiY2FhYzIzODk2Yzk5NWEyXzQyMA_bbea4a6a-f579-41fd-9cd3-920c2c694ed5"
      unitRef="usd">700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTM_475f9725-e93b-439e-bd64-e8df8b2c72c7">Income Taxes&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents domestic and foreign components of loss before provision for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income tax provision (benefit) were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision for the years ended December&#160;31, 2021 and 2020 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of internal reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company&#x2019;s deferred tax assets and liabilities:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals, reserve and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. Based on the Company&#x2019;s history of operating losses, the Company has concluded that it is more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company has provided a full valuation allowance for deferred tax assets as of December&#160;31, 2021 and 2020. The valuation allowance increased approximately $60.0&#160;million and $28.4&#160;million during the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had U.S. federal net operating losses (&#x201c;NOLs&#x201d;) carryforwards of approximately $393.4&#160;million to offset any future federal income. Approximately $57.3&#160;million of NOLs expire at various years beginning with 2036. As of December&#160;31, 2021, the Company also had U.S. state NOL carryforwards of approximately $227.1&#160;million to offset any future state income. U.S. state NOLs expire at various years beginning with 2037. At December&#160;31, 2021, the Company also had approximately $50.1&#160;million of foreign net operating loss carryforwards which may be available to offset future foreign income; these carryforwards do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had federal research and development tax credit carryforwards of approximately $13.6&#160;million available to reduce future tax liabilities which expire at various years beginning with 2036. As of December&#160;31, 2021, the Company had state credit carryforwards of approximately $12.3&#160;million available to reduce future tax liabilities which do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Section 382 and 383 of the Code, our ability to utilize NOL carryforwards or other tax attributes such as research tax credits, in any taxable year may be limited if we have experienced an &#x201c;ownership change.&#x201d; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who own at least 5% of a corporation&#x2019;s stock within a specified testing period. Similar rules may apply under state tax laws. Due to a June 30, 2020 ownership change, we determined that certain NOLs and research and development tax credits for both federal and state purposes are subject to the 382 limitation; however, it was determined that there should be no material impact to the ability of the utilization before expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal, state, and foreign jurisdictions. The federal, state and foreign income tax returns are open under the statute of limitations subject to tax examinations for the tax years ended December&#160;31, 2016 through December&#160;31, 2020. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service, state or foreign tax authorities to the extent utilized in a future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has total unrecognized tax benefits as of December&#160;31, 2021 and 2020 of approximately $21.9&#160;million and $8.7&#160;million, respectively. As of December 31, 2021, the total amount of unrecognized tax benefits that would affect the Company's effective tax rate, if recognized, is $1.1&#160;million. The Company does not anticipate a significant change to its unrecognized tax benefits over the next twelve months. A&#160;reconciliation of the unrecognized tax benefits is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) related to prior year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2021 and 2020, the Company accrued interest and penalties related to uncertain tax positions of $257,000. There are no ongoing examinations by taxing authorities at this time.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzY1OTcwNjk3NzIwNDk_1fb50a50-841f-4f69-8438-34a609f616e0">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents domestic and foreign components of loss before provision for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,066)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzMtMS0xLTEtMjE4NzM_a6f713f1-0c6a-4512-a25b-4c3cdac16b25"
      unitRef="usd">-145375000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzMtMy0xLTEtMjE4NzM_4cf83cff-71a4-4646-aaf1-b09db14d8145"
      unitRef="usd">-110327000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzQtMS0xLTEtMjE4NzM_6d119bce-8a01-42ae-8667-53a1287f7b9b"
      unitRef="usd">-165000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzQtMy0xLTEtMjE4NzM_d350216d-12c4-4da9-bdbf-f5773d92b288"
      unitRef="usd">-6066000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzUtMS0xLTEtMjE4NzM_0faa1123-9714-4ce2-9b6d-fa53d04b8001"
      unitRef="usd">-145540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTphN2UyY2YxNWQ4OGQ0ZGE3YmYzNGJhMDdiMmQ3ZjNmYi90YWJsZXJhbmdlOmE3ZTJjZjE1ZDg4ZDRkYTdiZjM0YmEwN2IyZDdmM2ZiXzUtMy0xLTEtMjE4NzM_a1f7c7e3-b20f-4620-82ee-f5e7ac1a10ac"
      unitRef="usd">-116393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTY_836cc436-d0f1-4e31-8c56-004d63fbcba2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the Company&#x2019;s income tax provision (benefit) were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzYtMS0xLTEtMTI4MjI_c166bc9e-91b1-4f6a-ae68-cb1d5e3fe9df"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzYtMy0xLTEtMTI4MjI_daa030a9-2808-4e57-b390-0e77d8e66443"
      unitRef="usd">1114000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzctMS0xLTEtMTI4MjI_b775dab5-ae21-4f04-b742-daaa15b0b256"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzctMy0xLTEtMTI4MjI_2f5bc4be-a383-4b69-9796-5e9c562e7104"
      unitRef="usd">1114000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzExLTEtMS0xLTEyODIy_e474ba4e-1d55-42cb-a411-b4e70d29449c"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzExLTMtMS0xLTEyODIy_9a0e56fa-a5ae-4f05-9d68-911acba58868"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEyLTEtMS0xLTEyODIy_dafac520-7fed-444f-b03c-4f641b6a8201"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEyLTMtMS0xLTEyODIy_df647580-3b6d-47dc-b8a2-39f68be9ecaa"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEzLTEtMS0xLTEyODIy_b1dd5d31-e011-4137-8ef9-307b4ec4acd1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpkMjBiMWZlZTE3ZmI0ODEwOTJmY2U5NTE3OTFlZjM5MC90YWJsZXJhbmdlOmQyMGIxZmVlMTdmYjQ4MTA5MmZjZTk1MTc5MWVmMzkwXzEzLTMtMS0xLTEyODIy_0aa5b422-d87c-4df9-b866-3886e254c20a"
      unitRef="usd">1114000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTg_bc90aebe-ef06-46df-a14f-a451770b3f75">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax provision for the years ended December&#160;31, 2021 and 2020 differed from the amounts computed by applying the statutory federal income tax rate of 21% to pretax loss as a result of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,442)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,787)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of internal reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzMtMS0xLTEtMTI4MjI_983d3bf5-c08f-4488-912e-de4a93db16a4"
      unitRef="usd">-30563000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzMtMy0xLTEtMTI4MjI_060d9f4b-7d1d-46c3-8269-6fea00153008"
      unitRef="usd">-24442000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzQtMS0xLTEtMTI4MjI_653b4672-836d-4956-86a8-7206edb0c14e"
      unitRef="usd">1662000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzQtMy0xLTEtMTI4MjI_84aa00d5-e68d-495b-9b47-13a9d4a8f06f"
      unitRef="usd">-2787000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzUtMS0xLTEtMTI4MjI_0bd59723-81eb-491a-9403-e2d0105d57fa"
      unitRef="usd">28000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzUtMy0xLTEtMTI4MjI_4e6b8a4c-6a11-475c-8f5b-9455c5b56bd8"
      unitRef="usd">941000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzctMS0xLTEtMTI4MjI_277538e9-0924-403c-b394-130a5c9b22fd"
      unitRef="usd">2672000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzctMy0xLTEtMTI4MjI_d09eb55b-5770-41d4-91fe-bf60caa64622"
      unitRef="usd">3150000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzgtMS0xLTEtMTI4MjI_b359db48-fd95-4b88-8d33-c770b22fb966"
      unitRef="usd">41324000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzgtMy0xLTEtMTI4MjI_e4a449f6-dcd4-41c3-a724-f2d67d9216fe"
      unitRef="usd">24817000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzktMS0xLTEtMTI4MjI_93802d69-a21c-49e7-b35f-29ef056293a4"
      unitRef="usd">-9000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzktMy0xLTEtMTI4MjI_4e6db391-f082-49c0-b8e7-de4fb9a6371e"
      unitRef="usd">595000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEwLTEtMS0xLTEyODIy_f081f3eb-2df5-4eae-ad15-a348439a2e64"
      unitRef="usd">-9763000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEwLTMtMS0xLTEyODIy_8c0e111a-c5a5-46e9-8bac-889d102f6c41"
      unitRef="usd">2669000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges>
    <advm:IncomeTaxReconciliationChangeInStateUncertainTaxPosition
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzExLTEtMS0xLTEyODIy_599b0b7e-5d26-41ce-a5eb-fe1d22c85f3a"
      unitRef="usd">0</advm:IncomeTaxReconciliationChangeInStateUncertainTaxPosition>
    <advm:IncomeTaxReconciliationChangeInStateUncertainTaxPosition
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzExLTMtMS0xLTEyODIy_5c500eaa-dd42-456d-a770-480763036fd4"
      unitRef="usd">2305000</advm:IncomeTaxReconciliationChangeInStateUncertainTaxPosition>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEyLTEtMS0xLTIxODQ1_d6a2f24a-1af4-4227-a7ce-31dcaf854e2f"
      unitRef="usd">-7000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEyLTMtMS0xLTIxODQ1_9e64391a-8fa5-4ff8-9a07-2268a3c1d8f7"
      unitRef="usd">166000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEzLTEtMS0xLTEyODIy_989263a5-9d68-4156-8f2e-d800e6a1ab70"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTplNDA5ZTFlMDE3YzY0OTkzOTUxODdhMTVkN2IwM2QzYy90YWJsZXJhbmdlOmU0MDllMWUwMTdjNjQ5OTM5NTE4N2ExNWQ3YjAzZDNjXzEzLTMtMS0xLTEyODIy_4967f440-1d1a-4f9d-9dcb-dd0742c8a6e1"
      unitRef="usd">1114000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTk_4af7f49d-90e2-4cff-9f2f-2273e954978a">The following table presents significant components of the Company&#x2019;s deferred tax assets and liabilities:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals, reserve and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154,672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,380)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,318)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzQtMS0xLTEtMTI4MjI_a9a75f0b-350c-4c15-95d5-3478c8d1b666"
      unitRef="usd">111741000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzQtMy0xLTEtMTI4MjI_6b8e8261-b167-4817-b660-c943484b0801"
      unitRef="usd">74023000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzUtMS0xLTEtMTI4MjI_3454fe82-6568-4805-a9e0-dfc036904916"
      unitRef="usd">2255000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzUtMy0xLTEtMTI4MjI_8cfbbd9c-ea12-4c28-9f85-1e896f9a10bf"
      unitRef="usd">1588000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzYtMS0xLTEtMTI4MjI_17c498c5-e45a-48a8-ab31-c2965bef4106"
      unitRef="usd">16838000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzYtMy0xLTEtMTI4MjI_88bd5699-08fe-41e0-8cc1-89b75cfd5d1a"
      unitRef="usd">11727000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzctMS0xLTEtMTI4MjI_e5f5ffaa-5dc9-4560-9805-215c713dd89b"
      unitRef="usd">9741000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzctMy0xLTEtMTI4MjI_9531b2e3-991f-412d-b8fd-886f643700c5"
      unitRef="usd">5975000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEwLTEtMS0xLTEyODIy_48944cb6-c4a0-4e5a-923c-11d96d90bf46"
      unitRef="usd">1613000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEwLTMtMS0xLTEyODIy_11e690dc-61b4-4d4a-8b98-4b7b3f6180a2"
      unitRef="usd">18000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <advm:DeferredTaxAssetsLeaseObligation
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzExLTEtMS0xLTEyODIy_4f95fe00-ebc1-494e-9834-eef291fa1360"
      unitRef="usd">24224000</advm:DeferredTaxAssetsLeaseObligation>
    <advm:DeferredTaxAssetsLeaseObligation
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzExLTMtMS0xLTEyODIy_bac8b7f2-0efd-4927-bee3-0629128c3788"
      unitRef="usd">6630000</advm:DeferredTaxAssetsLeaseObligation>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTEtMS0xLTE5Mzc3_29040ecb-4db1-4a67-a20a-085a749f4b58"
      unitRef="usd">9850000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTMtMS0xLTE5Mzc3_12fa8a62-7e65-41a9-9591-4ed74abf1197"
      unitRef="usd">1000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTEtMS0xLTEyODIy_92b6a485-4987-4ab0-a6b7-7b40babdc88b"
      unitRef="usd">17000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEyLTMtMS0xLTEyODIy_6d739621-81d5-4c48-98bf-608dbf529bd6"
      unitRef="usd">1000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEzLTEtMS0xLTEyODIy_60536c58-cd86-4fd5-8a60-6a9228d455b6"
      unitRef="usd">176279000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzEzLTMtMS0xLTEyODIy_145b93d8-29c4-4eec-a9c5-f307943491ff"
      unitRef="usd">99963000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE0LTEtMS0xLTEyODIy_5878bb64-b1eb-4ffa-b588-cfb2a255022a"
      unitRef="usd">154672000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE0LTMtMS0xLTEyODIy_7468a712-102c-494e-ac9b-ed99255ddd3e"
      unitRef="usd">94645000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE1LTEtMS0xLTEyODIy_b9a4371d-e6fb-4ef3-8bed-8123eb7f0a2c"
      unitRef="usd">21607000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE1LTMtMS0xLTEyODIy_2fc8f638-2581-417b-8796-8f1adda6ddc0"
      unitRef="usd">5318000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE4LTEtMS0xLTEyODIy_5b8f53db-5c92-403c-8848-53d5ae25b329"
      unitRef="usd">20227000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE4LTMtMS0xLTEyODIy_afb6b3f6-3057-423e-885f-dfc53083fb44"
      unitRef="usd">4183000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE5LTEtMS0xLTEyODIy_227684dd-c587-409e-a206-2f07ff9cc660"
      unitRef="usd">1380000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzE5LTMtMS0xLTEyODIy_2b6d2aa4-85f9-4372-89b7-e78e175ef1df"
      unitRef="usd">1135000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIxLTEtMS0xLTEyODIy_f640b66c-874c-45c9-9ed4-7cd43ec699e3"
      unitRef="usd">21607000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIxLTMtMS0xLTEyODIy_1b9b1599-a006-471b-82c9-dd4d470b1e65"
      unitRef="usd">5318000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIzLTEtMS0xLTEyODIy_7de26d33-eb39-4e5f-93eb-0985e71981fc"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTpmMGViYjE4ZDNkNDc0OWQ3OWVmNWQxZjQ5YWIxMjdjZC90YWJsZXJhbmdlOmYwZWJiMThkM2Q0NzQ5ZDc5ZWY1ZDFmNDlhYjEyN2NkXzIzLTMtMS0xLTEyODIy_ddf15534-5938-456a-bfbb-92ade903cdc5"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzExODY_d6b36e58-eb18-49da-8a1e-e1fc888454b1"
      unitRef="usd">60000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzExOTM_54fd242c-228e-4419-8d75-19cc5be74dbb"
      unitRef="usd">28400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="if6f92a2c752147398b0b7cb89424a66d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzEzNDQ_9f0b080e-830a-4db6-825a-3be79ebc48d6"
      unitRef="usd">393400000</us-gaap:OperatingLossCarryforwards>
    <advm:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="if6f92a2c752147398b0b7cb89424a66d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzEzOTg_aba4e4ea-4073-4674-8acf-88178a1f40c4"
      unitRef="usd">57300000</advm:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="iec59229ab7074b74bd212f356c86ea60_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE0OTA_2f3a256e-9da7-4b0b-895e-de95dccb5495"
      unitRef="usd">227100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i92372011da0b4b8d9b3ff9c9bc63cda2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE1OTA_cb60c49b-26c6-4321-b9b6-fa1ac401ec48"
      unitRef="usd">50100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7a4cbf761c8a4a17a861b8bf1844e0a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE4Mjk_dbef6fe0-d8a9-4568-8357-105df7f3ff74"
      unitRef="usd">13600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i78c00f24526d4abea5fca0722e1248a5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzE5NTU_692700da-d33e-481c-9243-87144204a772"
      unitRef="usd">12300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzM0NTQ_70deb7e5-bac6-49a6-945f-4b07825d2fb9"
      unitRef="usd">21900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzM0NjE_ee0bcf5a-6a5a-460c-b193-2b85c8112a7f"
      unitRef="usd">8700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQ5NDc4MDIzMzAxMjU_735e949a-4216-4c31-8d20-1a54369d7789"
      unitRef="usd">1100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQxOTI_35fff19a-5925-474c-bb84-5af04f3a29f5">A&#160;reconciliation of the unrecognized tax benefits is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase (decrease) related to prior year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase related to current year tax provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits as of the end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzMtMS0xLTEtMTI4MjI_1dacee05-a4f4-4255-ba0d-2eade3b74be8"
      unitRef="usd">8677000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5f5ba15416f84c1da3d8dda2c05448a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzMtMy0xLTEtMTI4MjI_deb5d370-c3d5-45f7-8368-2d53577c8983"
      unitRef="usd">3558000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzQtMS0xLTEtMTI4MjI_a0c3f3f8-a7c6-432a-8f05-8ab50ce70482"
      unitRef="usd">10656000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzQtMy0xLTEtMTI4MjI_eb6c0c0d-497d-41a0-b0b9-a856f1569422"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzUtMS0xLTEtMTI4MjI_5a8a47f8-27f6-402c-93d1-a1c80cba21de"
      unitRef="usd">2611000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzUtMy0xLTEtMTI4MjI_cb5c3e16-0c98-4a50-94e2-e4c7677a3ab9"
      unitRef="usd">5119000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzYtMS0xLTEtMTI4MjI_bec9b60c-1819-4452-9732-bd61bf1623d1"
      unitRef="usd">21944000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90YWJsZTo1ZGYwMWMwNTNlNDE0NTI1OGY0ZTNkMzIyZWI4YWI3Mi90YWJsZXJhbmdlOjVkZjAxYzA1M2U0MTQ1MjU4ZjRlM2QzMjJlYjhhYjcyXzYtMy0xLTEtMTI4MjI_c223f8a1-8898-4325-962c-6a0318fd144d"
      unitRef="usd">8677000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i2c917411737449d0a88f9f35170ed838_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQ5NDc4MDIzMjkzMDE_37cad620-3943-4e2c-b5e6-21a1ca39a687"
      unitRef="usd">257000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzIvZnJhZzoxY2Q5ODg5ZDJhMmM0OGNkODk0ODAxNzI1NGJiNTQ4Ni90ZXh0cmVnaW9uOjFjZDk4ODlkMmEyYzQ4Y2Q4OTQ4MDE3MjU0YmI1NDg2XzQ5NDc4MDIzMjkzMDE_afc7700b-7a59-42d5-b82b-43af74fa33c3"
      unitRef="usd">257000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90ZXh0cmVnaW9uOmUzZmU5ZjNhNmYxNjQyNGVhMjE0MGUxM2Q1NDNlZDE2XzI3MA_73c6f2d1-7025-4df5-ba09-73ad4ed0bc50">Net Loss per Share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90ZXh0cmVnaW9uOmUzZmU5ZjNhNmYxNjQyNGVhMjE0MGUxM2Q1NDNlZDE2XzI3MQ_00889fb5-c684-4c5a-be11-282bc0a125b3">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2f8ae5b4a0644993bf5b58e572c9d713_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzMtMS0xLTEtMTI4MjI_3a087768-a1f3-4004-bc32-26158fcac40d"
      unitRef="shares">13288000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic2ca53fed51a445cbea0844f267402e5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzMtMy0xLTEtMTI4MjI_cb4fb63d-32cb-4d34-aea8-ae846654f2af"
      unitRef="shares">10432000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib61d35f9c1b7487797a8b6521663d206_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzQtMS0xLTEtMTI4MjI_163ed9bd-c3b8-43f7-a2e0-c80e49d87827"
      unitRef="shares">2126000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i19e8bd338962449c9e2411b96b08c1be_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzQtMy0xLTEtMTI4MjI_aea5212a-9c99-41f2-8b56-5ee536caf5ef"
      unitRef="shares">540000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i44fcf3a223a1481794c8de42a0377a7a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzUtMS0xLTEtMTI4MjI_7b6c1f11-326c-4d33-b678-13d1b774e463"
      unitRef="shares">148000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icfb6a75db0aa4095bfd093ce5e08bfd1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzUtMy0xLTEtMTI4MjI_284aa7e6-76df-459b-9725-d5c43ad11de3"
      unitRef="shares">26000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9df7f768c6944081aa26e835855e993b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzctMS0xLTEtMTI4MjI_4a2d9bbe-67b7-468f-8895-8beb69d88cd2"
      unitRef="shares">15562000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia63877dd99df45f9a3d588dad816b894_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjQ5Njc4ODBjYjE2ZjRhNmM5MzllMDRiYjFkZmIwNDBhL3NlYzo0OTY3ODgwY2IxNmY0YTZjOTM5ZTA0YmIxZGZiMDQwYV8xNzUvZnJhZzplM2ZlOWYzYTZmMTY0MjRlYTIxNDBlMTNkNTQzZWQxNi90YWJsZTo3N2RkZGRkZTIwOTQ0N2YwOWM3NjgxOTcyMDljMDc3Yy90YWJsZXJhbmdlOjc3ZGRkZGRlMjA5NDQ3ZjA5Yzc2ODE5NzIwOWMwNzdjXzctMy0xLTEtMTI4MjI_e8537633-8a73-4355-9da7-b4d1c42c763c"
      unitRef="shares">10998000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>79
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *V!?50'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "M@7U48/,!1>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TU%,'1[43PI""XHWD(RNQML_I",M/OVIG6WB^@#>,S,+]]\
M ]/I*'5(^)Q"Q$06\]7D!I^ECAMV((H2(.L#.I7KDO"EN0O)*2K/M(>H](?:
M(PC.;\ A*:-(P0RLXDID?6>TU D5A73"&[WBXV<:%IC1@ ,Z])2AJ1M@_3PQ
M'J>A@PM@AA$FE[\+:%;B4OT3NW2 G9)3MFMJ',=Z;)=<V:&!MZ?'EV7=ROI,
MRFLLO[*5=(RX8>?)K^W=_?:!]8(+4?&V$K=;P673RN;Z?7;]X7<1=L'8G?W'
MQF?!OH-?=]%_ 5!+ P04    " "M@7U4F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M *V!?53O!C!YM 8  '@:   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5E=<^(V%'UN?X6&[G1V9P+8,A_)-LD, =+270B%[.YL.WT0M@!-;(E*<DC^
M?:]L8Q-J9,_T)<$?]^CH2CI'NK[>"_FDMI1J]!*%7-TTMEKO/K;;RM_2B*B6
MV%$.3]9"1D3#I=RTU4Y2$B1!4=C&CM-K1X3QQNUU<F\N;Z]%K$/&Z5PB%4<1
MD:]W-!3[FX;;.-Q8L,U6FQOMV^L=V= EU5]V<PE7[1PE8!'EB@F.)%W?- ;N
MQY'7-P')&U\9W:NCW\AT927$D[F8!#<-QS"B(?6U@2#P[YD.:1@:).#Q3P;:
MR-LT@<>_#^CW2>>A,RNBZ%"$WUB@MS>-RP8*Z)K$H5Z(_6\TZU#7X/DB5,E?
MM$_?[70:R(^5%E$6# PBQM/_Y"5+Q%' I7,F &<!^"3 /=>"EP5X=0,Z64 G
MR4S:E20/(Z+)[;44>R3-VX!F?B3)3**A^XR;<5]J"4\9Q.G;H7BF$LUAB%$3
M?5F.T/MW'] [Q#B:LC"$D5'7;0WMF+?;?H9YEV+B,Y@N1E/!]5:A,0]H\!:@
M#01SEOC \@Y;$4?4;R'/O4#8P6X)H:$]?$ID"[F723@N"1_9PW^/.;3NE+7^
MIC=>GG,OP?.L.?]KL%):PKS_VP+9R2$["63G7(*$'\-JU.CQ=4?+1LP>[CK-
M3Q86W9Q%MQZ+ ><Q"=&"[H34973L.%K&U$*GE]/IU:,SIY*)P,Q&!(ND-#\5
M2-G\^_&''RKF0#_GUK<B#F,I#;5[IGS(U'=*I)6?':W9=''3L_&ZS'E=UIQ(
MDH"X)]I\?ACM6&L2*MLX7N6<KJPX8ZZ9?H54A13-XFA%91D7.X;CN$VOU^U?
M6?BX3B&:3AU&"[IA9@U#NF8D*AVW"J!! %(01^B."4W]+1>AV#"J+M"$^RT;
MU2-]=^M0!3PA81B)&=$+M-0PSY"0:"ABKN4K_ _*^=O11V,;25R0Q'5(/I(7
M- E@]K$U\Q.FEO&N@,1.LXN[EQ[NVQ@6DNUZ=1@.@D!2!>.3_4"?X3WTP,MS
M9X>\=!RT)!O&R1Z-).Q^;$0+(W#M4GY*=&BN8* ?Q9Z7DK3#+6BP%Z"=!L;&
MK[ (UZ[MI_SRF3B7XIEQOSR3=LSAP$:ML O7KO*GU.9":=#F/]GN_/*P(UYU
MG)YGXU;8A5OA%PDSV-F?IV('Z'4=&Y'"'UR[J'\6QJ_F6\%M8EP!TNOVFE<>
MMJ:F< ?7+NV/3(,QB#5R\?O5![2D?BS_,ULS6G:DH8@BT)RE%O[3!=J!)3^3
M,*;HG=-RP$!^_LGM.;_L8.^FMD3:EBLNG 3;#0!L-F!\@Y:OT4J$99PK  :C
MKU,;D\(HL%W*#WE#XQ=_2S@<",YY6@70;+ <#?ZP<2I\ =?RA6]P+&P^<5 P
M&%VB8.H%:*)47#[W*C!GPD:M, 1<RQ"^BA ,%$[,R?9$EIZ6*I#LA KAQ[6$
M_["Q3#=MR=0"A8W+B=D1OU-E8U9(/JXE^1.NJ4S/^6:;2PY42YG9$2N8%8J/
M:RE^,G1H"$:T$;)4."IP9H(WB>]3@ &0( 6T,2QT']ME.V.XC$@8HKM8P6-5
M/I9VG(HC%2[T']NE.R,TCJC<F-GU*R#H+;A2M".\/'?_[Y2 "R/ =OF>#.\7
M:! '3,-V8J U!?M.-I'W(=F4,K/C53'S"I7W:IT7EEL0,ENJ*F J"15B[]4Z
M%<SC5<A\R(\@9<MPE*%T$Q130GR^];#3 M]^+FN^T'6OEJZ_]=NE,56%'F(-
MX\:-*Y95>C+DWA&EJ\M^U^F[_3.LCLHR=B$^G'W5T6D)%O/*'/36%*2J?'-:
MA?HP_#(=SQZ7:#(;/BSF#XO!XWB$[KZCQ?A^O!C/AF/8:4HS4979Q>@M-85+
MQEFBE#LI7EZ1F<DT.9>_-\_GR<WEX>8'M(89;QZ8 M>A^C*E--%_P$PRO!5A
M  YU:$,6AU?(.V(G79:'+L,3+="<2(TFDTD:S=3;$@\RBTS(")E"4@M-TA9.
M6"*(XD*C-8ACTL24O"*<%N4N3  _Y;5GL%S,ZXAP!)L1'B0X0">AD+?XIOGV
MP+P W0GC@*8\#MP93POE1A,8/P&Q';>]PH4]NV<.<I;G1*<"H'*-%[;KU:S&
M'=>8[N%FJ7]4@%65/@O+]6H6Y3)666WN/"\[W/UW&ZO"9KU:-CL$8A)(37A
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ME\;6J>\6]F%$Y0+L^D%*<QJX#=JG-OD+4$L#!!0    ( *V!?53<IW,]\04
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M82ZSAT@V 2=I%/G=1,P@Z/9Y?0>)_3PP.$=Y-J<9[CW.T_DJSL.A\%KIA>P
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M(^O^<<L9@+<"\/M& @_N7^P4]C!U7_\+4$L#!!0    ( *V!?52_O96"S0(
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M%U-H$ZH\\Y<W1FZ*8_-2&CB$%Y<9)2E55@">KZ0T;S?V!?67E_E_4$L#!!0
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MP@^<T/'Z8N>ZV#3$?E_HPB!$YKXS%B%O&R&O5B0C$8)L CH1L%X0EOKH2&U
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M!:I0 G!_Q;E\.E$?(K??PD__ 5!+ P04    " "M@7U4&EO0*$4"   P!0
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M?&F(!R9L*W[2T/H _K\RAG:&3] _DOEO4$L#!!0    ( *V!?52#[R2[^0<
M (<B   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULK9IM;Z0X$L>_"FK=
MBUUI>AH_ ,THB31);G0C[>Q&R>W=:P+NM&\ ]QIW'N[37]G0#1T73B+=O)@
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MSE<@44Q$/D'7D6D?^0A%1FB<YR.EA^O>DW4'K23H=G72[!$;B2303EX?POQ
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MK >+JK-BG;N'C$#,!_4309P,Z3.D04T809..%">D9558"E4YMNQ'=NV<FV!
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M3?,#@KIA+-#))_*IK.CH%!W5[@B:1D=F&AH&DB\;3A"?$-(\&EO;G6DWL1?
MCU(IXRU5&SN/FC*CV!JY?>JT8^@FCCUQ)!9N,V=B"K7%>3..W&PX"\HVFQFL
M&(_M;-$9/>FGQ5&F0P#J'3MM\\AYI4FR.NY(.Z%\[MR>\R,O(L&R'VW1OZWM
MU&4QKNBU'H3JXT;3E+[2ON$![??;:-1G2?;$OMZ?Y-6=]-RF5KY(\:QV#-Y+
MH*$K<Q>U-GS0ZNW#7]ELG+=VU'.,O-IO'/+^G%L0<_4PU]C9K6^F$7-R>1+@
M<D*)\6+N"C!=C+M\Q5$5'"+\)MJS31F4,V;E.+:=W)N@:8=[\$-K*I A5SO:
M^I!"X[)]4H[X)K 1+=O.V3'K+.IVRG&\D;"+.RF+;E&XCVY!G"))>#%*G@L\
MTH1!8D/:L[92S9/,TVLGZ7C/-,QG/W9<'8V1+"L*QYK2F3JD[$YJHB17 ;59
MG-&RR>#)W0SDLC^PN,7\<9&J;4:;T[E%K39WE )3;"1UP9V-3U+4*A6-ONVW
MT8B6[(\96"PTK9T7W%E5MP7&>%5B#,5'4=!O/X%%RCL2C%LJ<V_0T &DE&I*
M:**)?<&33LA4=\&@:/S+^RQ;DO?AG!M,+RQY2)XV7ZG)3<6?1E6YA/2R-?3N
M;;WK4?O++5/[GARX]'KR7LO,A(QVY$>)T130*B&3-@[<[M'+8W7JYH)G0,^=
MS'B&!3G?Z'/#K0PAKT*SQ#M>;V_?A>DEKW/<3CG[5OC9/N0</9T>ZOFSC(@)
MZ=@_G1SA%'I SC>Y-3:S!4O**INM8@-!>='HXP>1KFEAN):QBA)YUHJG+-:\
M,^XA*#(@><N<QDECT* C[B 4/N(H*$]6J!0O50'IT\T<1;/1.*#LT$0X/(T)
MBQJF(]V1;N/8$9IV\%N/7FCV#;J/].@N/YHWG,[I+>YEB1B)3.89BA6_=X C
M1&[!MX^?#'H;!4<C'TENO.!$$V?C?"97:8!5#N-PHK^+JYMLJ^,P[6OGYB^N
M8;*M.?#=)GU#FF66/Z!RF]I:WT*EB@V@,6.YP2LI/RT7@V:,XZ[.7SV;KX?J
M3^O[);F& T><83QUA8<!)XDB*ZXT/"G (%"#@+<7 4@8<"J#G!*4W(+>]?@5
M%\5.I>V2E\(BY:VR0I1RH2!CBK++^$2^+04S:#L_<_<PFJ-$NP9,&()(E%33
M2K4Y5=Y8=S*,*W.EG)DZ=741J]",WM+DR$E\_QFD2:!UC%+8L.KMMMHF^'1F
M;7$AM,HZ7D<^LYRPVG:FCIWZ\ZM=DU*1*S.+F9QC<X'\B@]2QBB:X?A,<R^'
M5KG9DZ1SRZ*0 $V)NJ?W7G)H(+T_=Q(V=^C:X^HD:U5M2TB%U8[JKTAZ;7NF
MD1;F]H)HYV(=.10%)'J)5U5BV:/\3N@G-([Q[7+]L"P_IVY8.3(6JG/YT7AS
M-.'O>)5,^T,_P:Y\Z8DIE21O[FXF?XHZ9>YG88"ZR OR16$SN8FF^:YL*)$*
MNS?=-%(HNF@Y" PQ,UPJ-W<^LFRTW'\^80>2>G2H'%7D:VH@]Z163U6%&YOC
M'=M6NT\FO%A\_K82[\OD6;RH$GL$Q*MRCD\[?<L*#W"C:21JH9T<%7I9ME!H
MG<KWSA2-088[4DY2J'72$XQ9P>:B0D>1W1!*D)NZ^$3(M5LNI 8GA4I:JOAX
M^[B9S)$2$8&8:P00'!B?FLB0XI8&_TX &9U6&BI+ @LR,/_<-":[6R2?SPG;
MBGF:RU$_H<5 '=&KHT*5U*Y<X"ZR(5\R.G4#2=98:8ONJ6>3"V3QMFBZ07CN
M JQT6DYN5U5]=[H/=<4_-5%+CMBU(SCX#R*<=_F&R+K=@6&Q>"\OIYV1[%+H
MQAP- #RU]BNL%8E$8YT&:+OM/?_VBFV6\6YF<2L"TTD+\20H*%#C_.9FI/L,
M6<3748G:$E%P5/H#!3W;B=3K3#2WT@D^6;KL3CY/1@$WAHB49'Q$&K\48R>Q
MT^*?"6@6*::,H#7>IX2W24->W[Z9_J#&/1?6U-Y%[Y= ^=D-Q]MT>B]H"E?B
MB:=;56?/@6V!N UE/F"_LAMQ/MK'J_+777S?]:.6R ,<WG^,%&!=7UYI52@W
MKQ>C;L%?#CQ>]HCO&)XVU<WM.QZYO'JR* ;^6'2]LX!?/8OM\S_QU8FG9>*K
M:*[_22]6=&<FBX<@9=TGUU]/3L*TH8^4X>HXPT2R9C2VT;*G>!2'LBA-O<4%
M:&+%T[B1;Y97WR[BAV^7EU^6'[Z2R#]]<26]0%50WI0A(Q(1:0?J#\LLQ?PN
MCLWYP8CT<=A:^IH%>BB)\V=9?S]E97I9^T;TLDH9>IS\W8Q%2C7E'V.(W=/I
M-S'X$H'T[<:KJ8J]RA\H40)SQBT>EQQ1^NV55!E'91.TZ_&R35_"GRW3M9EX
M^;7HMV+9+]#KB2N<\SNW\DL784#E9]/7HTI;1 9EAPBWW1?-7=.&/U.R]ZA3
MFD!%_/$!\;RY+FQ*D !+-SVFTS=1Y]L@;)PN%IUB5DFXMB( ^T5^Q]M?Q[\>
M4)Z50@9VEV);N"ETVM-&+VR=8O$-[EPG''7U%>.H:^4YJF_[%*PF>(!J\<8%
MB"(B&.+<:X-<M&G$AH/O!YS-,,Q+5G!!(K'YJF/T%-A_+0?%$^&"1]R8W(EH
M>INN8L1+./'JPB8O+QH7BX>K4S^$=5'\YMC>$AK%+ZOQ+8END)\?2]^F'V^[
MD=\LRZ_++[_]3& 6+2>MW=#0R]7?OWHD[53QP] ?^!?,UOTP]'O^$U5,Z_$"
M/=_TY'/U Q9(/VGWXG\ 4$L#!!0    ( *V!?52X]N.[6P@  $D6   9
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MZ(HVX/G&&%__(07-B_JK_P-02P,$%     @ K8%]5((_&E&F P  &@@  !D
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M@:853RZ(E,59OO!4)9( GLB]E@T176_T(W2A!7015RDF6<2+/,.\%*HZC->
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M#<8#T-YJ[8X3'V#^.[#Y&U!+ P04    " "N@7U429<TT/ "  "0!@  &0
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ML#JTVW7797[#NU[]6;A2&0\:"Z9.QN=G";BN_W43LDWL.3M+W,'BL.)/!KH
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M;/@.%VZ\V?&W+]1J;[9\N5$25886X/W*&-_<T ;MQ]"7_P502P,$%     @
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MC'&G?UR</8L/#T ZM@0^U,*%-)=CFV!7\R&=G;=#TSP^.LUX"DYA;#@>NP7
MTJ'TXC-F;);B$O>$ARK@Y88,6:TYFA5K#&/-!/,#J9>"($$<4?%"^BI$;*<
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M?X^!^)":!Q+9:-44F^,4,<L$(KXY9#EVX<A2#8[YEA,+?2CD)AW2W/+/"6+
M&!Q*.7X-?L!1@G$+8:Y&2I"Q**--3H:L(*_!XV/\YH)<RM6GM0M-H?<:-#)>
M'Z.",1'3K8V+D)(&BW./FJ,B@X0;3?,#I)M^*/#;9Q(&K(#07# $?2C^!@KH
MTU#?$W]I/['YA"'WG>6EWJAV%0N$W"!I:SY2M=+[?F4F%&M)LTV%T0QN!7 D
MBL1JCDR9F"-H<=^,M%<K#O.S+6$"!Q3,^K]HIAFU8. JTR7 +QBZ4/N5PWZC
M;$P\42C4=+G99Y\>>1&)9;A!%RT_H0.GS(P7[3F][/JP+R!%%T.K28^NL74T
M-GM9I$0^ZR9I=2LM$JGR.NYXKZ $M!=7+*S,C3>A"HQ6;^__SOZ4?+0O;U-9
MY+KOQ>EJ[1\1.OV5 PL_YZKS:6OVIV9*R?I<!L3@9S6.<"1@( $)CCXRJLZ%
M2ZJ+?K*KV L&; "Z0'^1*H,HC.PY[M".F@]IVOX.MQ-2F.!H4QNZB#Z%,LK:
M>V&X*\\JO>R;8O@29@E&L!S'!_&;>)(RQQU%[:"-;VI+0HM!@J*@40CP)#*D
M,X=JS_V,Q+AW,S';D8ZO;%4/BQ%BY('%EF,#TM;0IU!@*GHGPP4AGAV1^='@
M47,A$A^?F/ECLJ&(ZS>#SK'_HC0B=P  X:PDU,1EX(]3E$%R=K:UZZC22_+'
M<#T6&I?5%-0Y*6VY_'YQNGS^ID!-;TK4%!#?I-C]M2FC_-U\!K"5O8<,[BIU
MIU *!SB9,LLH/XR]+J,:\I3PQ*!H(<L^T36)87\,*Z07YCPD3YM;57.CS.>A
M9\[=OFX5O7M3;RPJ '*QZ=82RI$J>3YK&>"2T8; !MV_J>-&1H5GZ)H-C>%U
MJH.%^42ULLQXA 0Y9NYRTX0,(=-+L\3^[>N;#W[<P'V,VBGOU H]V_N<9Z+;
M0U7/7F!-^73MGX^Q<1K((V^1;#_;HH(D97I;5[&,J&S@/7T1J?T9PT,JMBB4
MR<+ZG-F:3\:51$7X*A^9HX%I#$H*Q6;ZPI >1%22<BS9*XB =#ADBJ),<^B1
M.FNBSS!VZ(OB 4.R(WT:L98^G>!7BWX6-EGA'.G1;7ZT7ZJ_O]^BWUG82'@R
MSU"L^(,!9J/M%G0[?3.H"A=G V%MPCH%)9HX&X?%.=,(0+<;^HG*6,[0LPF)
MPT)[%)?-<AZ>=<V.>X;#&U(R-_\1;5VI(> :(E4< .59\Q5>26D.:7;=(QS7
MP__B6'W=5W]H9^=DL78<+O##5%LJHW)B119<*=$,*(R0'Z(55A@@ >4Q#W)D
M^7,?,%CD?J3%Z4:BT /Y"YJX)PW%EP^?"OLF^XUSE@WC!3?GE%=&6V6+R$2\
M-CF=Z!DZ\EF!J!$3^8)CBR&(&)!VT%*TD1+8++X9;I=1?XYL3GV5 *O0C$[3
MY(AI_? %6Q.'^!"_L6X/C>NU3L#RR-IBQ6B59?S:R9'EA-2Z4W5LL]KOF!YE
M7$T9F<[;.=18B,\Y+PFYHH*8[S07E85B$39FZ=XR*R2H5WI'XP[.[,))$>*M
MA#<ZE#ISDI\%N]8EV,1J!V4,")JN+>^1%N8JG:AJ8SF&+U*A]!*O&C;+1NTW
MPH6^,8S\Y\O[>?EW:F60*V.F.A9?CQ^%2)Y)[- .Q?V?(5?N)>:=2I(@MZ:0
M24>Z/]>R,72?Y07Y&R!JU. =XJ595R.4>J>ZL0]5M$"PL^YC9J$4[C-\6(=Y
MH^7FH1$Y$!2F2V5_*W=_8[N34CT6%>Y*B9_/:$,1UX@6LR\_5J)]&>2,78:Q
MU$8,.\>(0YM&F:L$=%6-^'-TDH-Z">8MU"N,^7NCBJ) Q85=DSL,&?\)PIQ!
MYR+73#YO[TN<G<J)A<E#V:Y/Q8T!K854U^G>'S6:(P6,/!%7"2;9,416D2!%
MBQU_AHB43BN5W>4&BVU@_GW5F/1ND;PXQFRGK.!E;EFY/-UN\F:4G'UG_:0M
M_.I)@D%\<Y#ZE6RP\5Q6V^=.U:DV5CGK6>A9F'HVZH>.'X-('P@X]GT+*3T?
MM>A6MILNS#])Y=S_<7FZ+P-?Y:HE+V': =SP3SH\"%6]IZ/=D!1..JO_#].F
M2AUY.1&=Q)O\?F8Z#UA:A\JH9<"+T9ZE :$UXHX_=*>;>?PJ1-'UA^FDW6/D
MNA78?O^;$7'?1[9%5SZ$3:UI4[#EX?-,EE5IZDNA/;?2831:NNPD.;Z- I'U
M$<_*^ C&_E6,'7FXLZ]Q.V?)\X^N1?QX @QR&O+VYOWXDV9WG+L.)B$"A.0Z
M'3UP[!8/?:]C1!=O/'4-'[T'5I=B60/QX9P%<I\4CUS[?GFZ9/U:HUVH*K_!
MYVQGAU!3,ZV2_MJ4@"K_-9!W?GFQ"/G@W/]4C+K!M;/7^MHB.,"^35-=W7S@
MD?/%XUDQ\*>B<8KE;O$B=F"]XX[%YV4PM^C/>A?Z&;LCDT7>D(*.QY=/1PRB
M6F_CSO M'0;X9(=H;!,*'@0+&!1$T-1K?!&&2/$\'N39?/'=+/[QW?SBF_*/
M)Q(V2C\LI!BR\H$V9;P!4:QT@H!DRA#7?@NLSA'XZ":"!T/2>R]*@&(8_EO6
MWXY)F5X.M6NA1[3T6R<_9C9+X=/\A:S8@),^5,9]:-+Z$;\($5!S^=6XL,$<
M18[7)5>4/LJ7:F)0TX"]A^ME*S@'$IFG;M7XS8FBX)1%LO [)KZ<L/^I"_G\
MF.^16UW9>@C<%C%=6:7&G5M%=>NXXEF5Y#UHMB$X&+_&))@I5X2H$MY! 8^O
M:?H#$/O'(*\F]?-.$:O<>"A" FJ/](Y-UX>?4RKO*H ]!ABB\K@J?ES42R^L
M3?"B5OCH2D+ BR>,@"\#S9'?WJ9(1P)VJ!-9&0]6A.])E'NKD%]1C9@6T'V'
MN^G[_:0P+*-P;/["0#1@.'\M%\43H4<P'DS:ZAJK4S=?[..,W6^KO+Q(7$S/
M3^KY\^*[LUM-?@2^KLN-=ETOGZ!-OZ8O^%[)=VOSZ_+YWY_)#4&Q6:M7-/3B
M[-LG#Z2D,_[1VQU_Q79I^]YN^9^H$] .+]#SE24H$/[  NF[QJ_^#U!+ P04
M    " "N@7U40"G?I:8#  ";"   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6RM5FV/VC@0_BM6KCJ!E)+8(9!L 6E?=95NI579;3^<[H,) UB;V*GM
M0/=^_8T="/2%K7JZ#Q![//,\S\S8<28[I9_-!L"2+U4IS3386%M?1)$I-E!Q
M,U U2%Q9*5UQBU.]CDRM@2]]4%5&+(Y'4<6%#&83;WO0LXEJ;"DD/&ABFJKB
M^N4*2K6;!C0X&#Z(]<8Z0S2;U'P-<[!/]8/&6=2A+$4%T@@EB8;5-+BD%U=#
MY^\=/@K8F9,Q<9DLE'IVD_?+:1 [05!"81T"Q\<6KJ$L'1#*^+S'##I*%W@Z
M/J#?^=PQEP4W<*W*3V)I-],@"\@25KPI[0>U^P/V^:0.KU"E\?]DU_J.DX 4
MC;&JV@>C@DK(]LF_[.MP$I#%9P+8/H!YW2V15WG#+9]-M-H1[;P1S0U\JCX:
MQ0GIFC*W&E<%QMG9'1>:?.1E ^0>N&DT8,6M(5PNR<F:6I$[(;DL!"_)>VFL
M;EJ_WB-?E&#ZD\BB&H<9%7OFJY:9G6&FC-PK:3>&W,HE++\&B#"-+A=VR.6*
MO8IX \6 )#0D+&;T%;RDJTWB\9*?U^9&F*)4KCR&_'6YP/QQ._W]"L>PXQAZ
MCN$9CGE[&%R!K[G9D-O/C=CRLNO!?*.T?6M!5UCV+1CKR_ZC:K_*X\[VA:EY
M =, #Z\!O85@]K@!LE(E'DPAUT0@X^%P.CT65Z]557/Y\OMO&:/C=X843B-\
MH]$<-8JC1M(3$C%48]#']"\(M@>J!>BN1>2RPD#Q#RS)D\0W2OGM\-98@0</
M1W_"%DI"W8Z!%]S_^AG?5ZL&@<D;0N,PH10'7B9[]]5HO]@",/(TF _(6FU!
M2Z?2Z\>7CRQ>B(&BT<(*;/&(A6R4=2@]1K.^,\9I[$I2@?8'H>8UID/'XY#1
M%-7U1K3OIS1-T4_72J-ZLE!.YW <)BPY8B9YW]E8-B2/RB+:K]26Y4A"QXXS
M<=I8/@JS.,8TC;EH=](I4H^EN(Q^!W:Z-XW[>_(S/&\(&],PB7-72?PA&X8X
M:QSF>?)=3^/_K:?C[%Q#<>77NIFP+$RSA%#<<KVT[^>C//^^D[EKT?#8(O1U
M)IK_APX-V2B,L[0EI7'?&V@^.MNB- NS?'AL4;(WT9^V*!GA9LA=>QP9-LFW
MR%F3."4_>DE%)Q<&EF#MKT4\W:J1MKT[.FMW\UZV%\[1O;VV[[E>"VE("2L,
MC0?C-""ZO0K;B56UOWX6RN)EYH<;_'H [1QP?:64/4P<0?<],OL74$L#!!0
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M\T -,V[8&-FYN;*7AJ:46];T6T!E \A?26G.&UM@^M%L?@!02P,$%     @
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MF%]NZ4\#:F= [UNE[&'C"*:_(:M_ 5!+ P04    " "N@7U40/+5TL(%  "
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M^#GF<",92KGLJ1S7],)I[&7R'5T&DIF]LM#)>_ 1:P)9VG4BIUM\P7=-?HZ
M'SM3YB'5Y)D/GZ6A97KOKGH(*^D-(L=/0VYXSC3UX9!#)WNO@@K5TKY]N"RV
MM>D>"/UH_[RZ[%X5+\N[M]DGH994SZ'$!8EZ%!8C4-U[I^L8V=@WQEP:>K'8
MYHJ>B*AX <TO)-7>;8<-](_.B_\ 4$L#!!0    ( *Z!?525RF@S/08  .00
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*58;6_;-A#^*P>O&V1
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ML)FT]0ZHFP?\_>X!K>VC*7 V*]BB(%!W$/@^+01:>DCDAUY3Y"QV:I5AY+<
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MJJ1Y^<]">2/9ICB<GS,I65I<KBE94IX;J.<KQN3+37[>7_^_,_D?4$L#!!0
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M?@'-+XS!5<??)?U?@>E/4$L#!!0    ( *Z!?51[*()(90(  /D&   9
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M@M^XQ<C1XI#\SRUV6R"^$)D,/2J3RK;(.;9U0N6;$R"#TRI7)D;\)O9YFRY
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M*@/$5V@A=.,(]8!HD:(WORI6ZK]27:"/VNGY-2C*LA?:Y<OR&CU_]@(]0ZQ
MGS>\DMI>3ERED9I\;M*@NJI1D3.HKB&Y1#Z^0,0CN,=]_O?NWJ&[J_EI22(M
M2<3&\\_$VU5_@1::+75( OI^H\W1>P6Y_#&0S&^3^3;9Z$RRSUS1#)7[A,,N
M5Q^3=;3(1C.7]FXV"HD_FKAW^X2=6OE1%$>MU0'440MU- CU!J34%S&I\BJC
M"E)]?[26)(S6-U0CISD7BOVV!WW@Z_CA'JR7V,?1,?H^,\^+2#_\H(4?#,)?
M]')\@0KH)3HX >'[7N@=03VU(E%$@GZD88LT'$1J[F6E0'0H+6;)5VI+!0QT
M7=1FB)Z^Q<=MLO&CMOCXA%-,R'&/G!H%<=Q/>]SBC(?[F]YR0147#^?P'83%
M7B>ZWM.SC?<T'C\JWTVX0\*C:'S$>(]9[ >C?LYQ)[:8#*)]6XF"J4J !;IB
M]V8MAXCHI!7[_X'W3A[QL#[^,^^G.H>Q'Q[3WF-%@C.MCCLQQ,-J> -Z&MKP
M+$4LUY#OP* <I+U3+QS^!]H[*</1X](>G6IV&'GXF/<>LU'HXS/$=V*(A]5P
MS@NI1%6/M7INTL#7NN$'J>\4#,=/3SWIA(UXCTI]$^Y@>O'CX(CY'BL<GPB-
MNS<%FT^0#U2L62%1!BOMYEU&NO]%/=77&\5+.QC?<J7';+O<Z"\A$,9 OU]Q
MKG8;,VNWWU:S/U!+ P04    " "N@7U4MVM0"@P#  "M"   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6R-EM]OVC 0Q_\5*^I#*VW-+P*A J06-FW2
MIE6EW1ZF/9CD *M.G-D.T/]^9R=DE 3$2V+']SU_[GRV,]H*^:K6 )KL,IZK
ML;/6NKAS796L(:/J5A20X\A2R(QJ[,J5JPH)-+6BC+N!Y_7=C++<F8SLMT<Y
M&8E2<Y;#HR2JS#(JWQZ B^W8\9W]AR>V6FOSP9V,"KJ".>B7XE%BSVV\I"R#
M7#&1$PG+L7/OWTV'QMX:_&2P50=M8B)9"/%J.E_3L>,9(."0:..!XFL#4^#<
M.$*,O[5/IYG2" _;>^^?;>P8RX(JF K^BZ5Z/79BAZ2PI"773V+[!>IX(N,O
M$5S9)]G6MIY#DE)ID=5B),A87KWIKL[#@<#OG1 $M2"X5!#6@M &6I'9L&94
MT\E(BBV1QAJ]F8;-C55C-"PWJSC7$D<9ZO3D@7*:)T#FMF2F(BM$#KE6Y".9
M8\6D)0<BEN0^260)*?FTP_)1H C-4_)#KT&2:2DE*L@W1A>,,\UP]'H&FC)^
M@UY>YC-R?75#K@C+R?-:E JE:N1JA#<(;E*#/E2@P0G0&22W)/0_D, +_ [Y
M]'*Y]U[N8LJ:O 5-W@+K+[PH;T_ J<;TS)A*N%"EQ!S\OE\H+;%,_YR9+FRF
M"^UTO1/3F87!Q%-;^E M0E<.*R\#Z\5LX,UD&'C#D;LYS%3;* Y[O<;H'6"O
M >R=!=P72"'%$I39XY23)4#G2E>N^@< 4>0=0;9M?&\0=4-&#61T$60N\@3'
M6(*,B5"Z$S)J 03Q,#JB;!OY<7 BE?V&LG\198-H]AKF-<&\X@FUP9.WR,R.
M.XG>;Z-[47R$WC;R[=;H0A\TZ(.SZ'.-VX!HNL/Z+^@;7?#.*AVTIP[]8[ZV
M4>\$7=S0Q6?I['G5Q1-WY,L?'/&TC?P@/E&0PX9H>);H66BSOO6"P^'A*NSA
MFM2'*_]_N'8%,&SM:#_V>L<1=%B%41P?A> >7";F(O].Y8KEBG!8HLZ['6#-
MR^IRK#I:%/9^60B-MY5MKO%_ J0QP/&E$'K?,5=6\X<R^0=02P,$%     @
MKH%]5 G\N)SH 0  XP,  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
MG5-+C],P$/XKEL5AD:!.4LJN5FFDMA&" ZC::N& .+C)M+'6CV!/FMU_C^VD
M487H'K@D'GN^QXS'>6_LDVL D#PKJ=V2-HCM/6.N:D!Q-S,M:']R,%9Q]*$]
M,M=:X'4$*<FR)/G(%!>:%GG<V]HB-QU*H6%KB>N4XO9E#=+T2YK2\\:#.#88
M-EB1M_P(.\#'=FM]Q":66BC03AA-+!R6=)7>K^<A/R9\%]"[BS4)E>R->0K!
MEWI)DV ()%08&+C_G6 #4@8B;^/WR$DGR0"\7)_9/\7:?2U[[F!CY ]18[.D
M=Y34<."=Q ?3?X:QGD7@JXQT\4OZ(7>145)U#HT:P=Z!$GKX\^>Q#Q> ++T"
MR$9 %GT/0M%ER9$7N34]L2';LX5%+#6BO3FAPZ7LT/I3X7%8;(Q2 GV7T1&N
M:[(Q&H4^@JX$./*>?./6\M X<E,"<B'=VYRA%PYP5HTBZT$DNR)20C4C\_0=
MR9(L?=R5Y.;-7RS,VYZ\9Y/W+-+._\M[*5PEC>LLD)^KO4/K!^#7*ZKS274>
M53]<45U5E>V@)M:\<(E>Z5_]&"AN(T5X%Z<BR=GI4I5=W%D8_Z_<'H5V1,+!
M8Y+9[8(2.XS4$*!IXS7N#?JAB,O&OT*P(<&?'XS!<Q F8WK7Q1]02P,$%
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MX@6Z+;A6K^$A7+_G60:3U,E @WYFE4%2ZW)1Z4(.Z(()>B\*O5#H79&R=%O
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M /A])H1>WY@%-I_OG/T'4$L#!!0    ( *Z!?50'X2&FNP0  -X3   9
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MFPV$=L8'FK4TF&.J%;_$@\DMD9H4',>;]3!HB!/4-K3?N6R3\!K<O1$FOT/
MZ1<$[ED4$$UW@ZA>!'VAOV7JMB>L"%H=<P$[:Z8=3EVG55$*,V\*^U)3MWIH
MC6YU([@68-DV-5B8=INKP@SZ4P?UL*TE!.HUY+SQC>!K=XDX4[_=551F[A3!
M'KJUC$"]CO2UP1'$'44&S6E'_7KL7*^'>JTP<$!BNDUQ!&NWRV8VM3KEX8ZI
M^+7"3%/QM31!O38--<@187H#89XSJW4(#@A1JU&.8.)W,WE6)>=,:@V!LT\V
MS >2G?ZRDEC)3V<FSUG@WVA3\/P@F+7[^?EG=*T52*\5U<+]ZQYPG"^MRL<
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M:W-H965T<R]S:&5E=#0R+GAM;(U4R6[;,!#]%4+((0%::[&3%($MP$N+YF#
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MN?T,;3XCRY=+KMV3;%O?P"-YK8VL6C JJ)AHWO2MK<,>($Q. *(6$!T#AB<
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M?XH3M1F ?VF:<7Q/U9H)33BLD#(8C+&0JAEQC6'DQDV)I30X<]RRQ+\"*.N
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M?(N$V:W1S(O-C8W6:@@S-JZ4T*M$QZG)=UTI]UQ*5(! JPP+0%_02A=+6E)
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M!WM*HBA)_ A@?@51A"'P-.((I@ T8$@4->?@SGD4KL^I</,;T>0W4$L#!!0
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MZ[(YY+/N?^OT$U!+ 0(4 Q0    ( *V!?50'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ K8%]5&#S
M 47N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ K8%]5)E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "M@7U4[P8P>;0&  !X
M&@  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ K8%]5+O)WUTE @  =@4  !@              ("!]PX
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *V!?53<IW,]
M\04  ($7   8              " @5(1  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "M@7U4O[V5@LT"  "W"0  &
M@(%Y%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ K8%]
M5)$Q.0CL!   A1$  !@              ("!?!H  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( *V!?52L!MZGD08  !<?   8
M      " @9X?  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "M@7U4&EO0*$4"   P!0  &               @(%E)@  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ K8%]5(/O)+OY!P  AR(  !@
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M970Q,BYX;6Q02P$"% ,4    " "M@7U4V7"(["P)  "T%P  &0
M    @('\7   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M *V!?52"/QI1I@,  !H(   9              " @5]F  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ KH%]5$F7--#P @  D 8  !D
M             ("!/&H  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "N@7U4J$OA%W,+  !:(0  &0              @(%C;0  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *Z!?51#SR#:T0(
M !H&   9              " @0UY  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ KH%]5-W\7@U]"@  &!T  !D              ("!
M%7P  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "N@7U4
MQ)EBM,L"  #?!0  &0              @(')A@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( *Z!?53'W4_K-1L  .-8   9
M      " @<N)  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ KH%]5$ IWZ6F P  FP@  !D              ("!-Z4  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "N@7U4"#NX:!P#  !T!@
M&0              @($4J0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( *Z!?53J+3!WQP,  )((   9              " @6>L  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ KH%]5$#RU=+"
M!0  @ X  !D              ("!9;   'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "N@7U4E<IH,ST&  #D$   &0
M@(%>M@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *Z!
M?51U?++C\P(  "P&   9              " @=*\  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ KH%]5!8H/4=I @  5P4  !D
M         ("!_+\  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "N@7U4-O2+5B,#  !("@  &0              @(&<P@  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( *Z!?51=+R<G6P4  .L9
M   9              " @?;%  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ KH%]5"A\).VN @  %@@  !D              ("!B,L
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "N@7U4>RB"
M2&4"  #Y!@  &0              @(%MS@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( *Z!?53#":NH7 0  -@1   9
M  " @0G1  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MKH%]5)X]15V= P  V0P  !D              ("!G-4  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "N@7U4-1C]QH4#  !G#0  &0
M            @(%PV0  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( *Z!?52W:U *# ,  *T(   9              " @2S=  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ KH%]5 G\N)SH 0
MXP,  !D              ("!;^   'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "N@7U4<)>*(4$'  #*(P  &0              @(&.
MX@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *Z!?50'
MX2&FNP0  -X3   9              " @0;J  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ KH%]5!K7>G0[ P  5 P  !D
M     ("!^.X  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *Z!?52C$\Z-H@(  -P'   9              "
M@>[^  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ KH%]
M5"A5H/?- P  :0L  !D              ("!QP$! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "N@7U4!AKDD^$#  #T#0  &0
M        @('+!0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( *Z!?53+&-QT" 0  .\.   9              " @>,) 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ KH%]5-?,TH76 @  JP<
M !D              ("!(@X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " "N@7U4GSV7FB0#  "G"P  &0              @($O$0$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( *Z!?52W%LKC
M'0,  # 2   -              "  8H4 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ KH%]5)>*NQS     $P(   L              ( !TA<! %]R96QS
M+RYR96QS4$L! A0#%     @ KH%]5*\96W,.!   KB    \
M ( !NQ@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *Z!?52.83CZO0$
M 'H=   :              "  ?8< 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( *Z!?52<*],/O0$  '<=   3              "
M >L> 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Y #D A@\  -D@ 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>97</ContextCount>
  <ElementCount>319</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/DescriptionoftheBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of significant accounting policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Summaryofsignificantaccountingpolicies</Role>
      <ShortName>Summary of significant accounting policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2110104 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2116106 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2120107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2122108 - Disclosure - Stock Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlans</Role>
      <ShortName>Stock Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2129109 - Disclosure - 401(k) Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/A401kSavingsPlan</Role>
      <ShortName>401(k) Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2131110 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2139111 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies</Role>
      <ShortName>Summary of significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/Leases</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2323304 - Disclosure - Stock Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansTables</Role>
      <ShortName>Stock Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/StockPlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2332305 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2340306 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of the Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of the Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of significant accounting policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of significant accounting policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RevenueAdditionalInformationDetail</Role>
      <ShortName>Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail</Role>
      <ShortName>Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2424411 - Disclosure - Stock Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansAdditionalInformationDetail</Role>
      <ShortName>Stock Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Stock Plans - Summary of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail</Role>
      <ShortName>Stock Plans - Summary of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Stock Plans - Schedule of Stock Purchase Plan Valuation Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail</Role>
      <ShortName>Stock Plans - Schedule of Stock Purchase Plan Valuation Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Stock Plans - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Stock Plans - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Stock Plans - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock Plans - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2430416 - Disclosure - 401(k) Savings Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetail</Role>
      <ShortName>401(k) Savings Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2434418 - Disclosure - Income Taxes- Schedule of Components of Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes- Schedule of Components of Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2435419 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2436420 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="advm-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="advm-20211231.htm">advm-20211231.htm</File>
    <File>advm-20211231.xsd</File>
    <File>advm-20211231_cal.xml</File>
    <File>advm-20211231_def.xml</File>
    <File>advm-20211231_lab.xml</File>
    <File>advm-20211231_pre.xml</File>
    <File>advm-20211231xex104c.htm</File>
    <File>advm-20211231xexx1019.htm</File>
    <File>advm-20211231xexx1020.htm</File>
    <File>advm-20211231xexx1021.htm</File>
    <File>advm-20211231xexx1022.htm</File>
    <File>advm-20211231xexx104d.htm</File>
    <File>advm-20211231xexx105b.htm</File>
    <File>advm-20211231xexx108e.htm</File>
    <File>advm-20211231xexx109.htm</File>
    <File>advm-20211231xexx211.htm</File>
    <File>advm-20211231xexx231.htm</File>
    <File>advm-20211231xexx311.htm</File>
    <File>advm-20211231xexx312.htm</File>
    <File>advm-20211231xexx321.htm</File>
    <File>advm-20211231xexx322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>advm-20211231_g1.gif</File>
    <File>advm-20211231_g2.gif</File>
    <File>advm-20211231_g3.gif</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="584">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "advm-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 13,
   "contextCount": 97,
   "dts": {
    "calculationLink": {
     "local": [
      "advm-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "advm-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "advm-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 453,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 2,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 6
   },
   "keyCustom": 24,
   "keyStandard": 295,
   "memberCustom": 9,
   "memberStandard": 30,
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.adverum.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of significant accounting policies",
     "role": "http://www.adverum.com/role/Summaryofsignificantaccountingpolicies",
     "shortName": "Summary of significant accounting policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110104 - Disclosure - Revenue",
     "role": "http://www.adverum.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112105 - Disclosure - Leases",
     "role": "http://www.adverum.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116106 - Disclosure - Balance Sheet Components",
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.adverum.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122108 - Disclosure - Stock Plans",
     "role": "http://www.adverum.com/role/StockPlans",
     "shortName": "Stock Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129109 - Disclosure - 401(k) Savings Plan",
     "role": "http://www.adverum.com/role/A401kSavingsPlan",
     "shortName": "401(k) Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131110 - Disclosure - Income Taxes",
     "role": "http://www.adverum.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139111 - Disclosure - Net Loss per Share",
     "role": "http://www.adverum.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.adverum.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of significant accounting policies (Policies)",
     "role": "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies",
     "shortName": "Summary of significant accounting policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Leases (Tables)",
     "role": "http://www.adverum.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2323304 - Disclosure - Stock Plans (Tables)",
     "role": "http://www.adverum.com/role/StockPlansTables",
     "shortName": "Stock Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332305 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.adverum.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340306 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of the Business - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail",
     "shortName": "Description of the Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of significant accounting policies - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail",
     "shortName": "Summary of significant accounting policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "span",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://www.adverum.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i3388e01ba0cd4c2bb002f33d9f0729df_D20210125-20210125",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenue - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/RevenueAdditionalInformationDetail",
     "shortName": "Revenue - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i3388e01ba0cd4c2bb002f33d9f0729df_D20210125-20210125",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Detail)",
     "role": "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail",
     "shortName": "Leases - Schedule of Future Non-cancellable Lease Payments under Operating Lease (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.adverum.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424411 - Disclosure - Stock Plans - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
     "shortName": "Stock Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Stock Plans - Summary of Stock Options Activity (Detail)",
     "role": "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail",
     "shortName": "Stock Plans - Summary of Stock Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Stock Plans - Schedule of Stock Purchase Plan Valuation Assumptions (Detail)",
     "role": "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail",
     "shortName": "Stock Plans - Schedule of Stock Purchase Plan Valuation Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i0f70cdb760c642cdb8de1dac011c66b8_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i1aa1a08442284607a20e7c4f8d0e72b5_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Stock Plans - Summary of Restricted Stock Units Activity (Detail)",
     "role": "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail",
     "shortName": "Stock Plans - Summary of Restricted Stock Units Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i6e8c356d701f4f35be9187ce2a163f85_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Stock Plans - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail",
     "shortName": "Stock Plans - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430416 - Disclosure - 401(k) Savings Plan - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetail",
     "shortName": "401(k) Savings Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes (Detail)",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Components of Loss Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434418 - Disclosure - Income Taxes- Schedule of Components of Income Tax Provision (Benefit) (Details)",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails",
     "shortName": "Income Taxes- Schedule of Components of Income Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435419 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Detail)",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436420 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Detail)",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i2c917411737449d0a88f9f35170ed838_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i41c2ee94a0c54d108cea4f3db8e6d49b_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)",
     "role": "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)",
     "role": "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail",
     "shortName": "Net Loss per Share - Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i53f24fd80d7847a4a109b4930dfa58dd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i53f24fd80d7847a4a109b4930dfa58dd_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of the Business",
     "role": "http://www.adverum.com/role/DescriptionoftheBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20211231.htm",
      "contextRef": "i9df7f768c6944081aa26e835855e993b_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 42,
   "tag": {
    "advm_AccruedClinicalAndDevelopmentProcessCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical and development process costs current.",
        "label": "Accrued Clinical And Development Process Costs Current",
        "terseLabel": "Accrued clinical and process development costs"
       }
      }
     },
     "localname": "AccruedClinicalAndDevelopmentProcessCostsCurrent",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedNonclinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical costs current.",
        "label": "Accrued Nonclinical Costs, Current",
        "terseLabel": "Accrued nonclinical costs"
       }
      }
     },
     "localname": "AccruedNonclinicalCostsCurrent",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.adverum.com/20211231",
     "xbrltype": "stringItemType"
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Amortized Cost",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "negatedLabel": "Less: Cash equivalents, amortized cost basis"
       }
      }
     },
     "localname": "CashAndCashEquivalentAmortizedCost",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Gross Unrealized Gain",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "negatedLabel": "Less: Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalent Gross Unrealized Loss",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "terseLabel": "Less: Cash equivalents, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "terseLabel": "Total cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "terseLabel": "Marketable securities with remaining maturities between one and two years"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination",
        "label": "Decrease In Right-of-Use Asset And Lease Liability Due To Lease Termination",
        "terseLabel": "Decrease in right-of-use asset and lease liability due to termination"
       }
      }
     },
     "localname": "DecreaseInRightOfUseAssetAndLeaseLiabilityDueToLeaseTermination",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_DeferredTaxAssetsLeaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease obligation.",
        "label": "Deferred Tax Assets Lease Obligation",
        "terseLabel": "Lease obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseObligation",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncentiveStockOptionsAndNonQualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options And Non-Qualified Stock Options",
        "label": "Incentive Stock Options And Non-Qualified Stock Options [Member]",
        "terseLabel": "Incentive Stock Options (ISOs) and Non-Qualified Stock Options (NSOs)"
       }
      }
     },
     "localname": "IncentiveStockOptionsAndNonQualifiedStockOptionsMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_IncomeTaxReconciliationChangeInStateUncertainTaxPosition": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation change in state uncertain tax position.",
        "label": "Income Tax Reconciliation Change In State Uncertain Tax Position",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInStateUncertainTaxPosition",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in deposits and other noncurrent assets.",
        "label": "Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable",
        "negatedLabel": "Deposit and other long-term assets and deferred rent receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInDepositAndOtherNoncurrentAssetsAndDeferredRentReceivable",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease right-of-use assets.",
        "label": "Increase Decrease In Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseLeaseTerminationFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Termination Fee",
        "label": "Lessee, Operating Lease, Lease Termination Fee",
        "terseLabel": "Lease termination fees"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseTerminationFee",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseLeaseholdImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Leasehold Improvement Allowance",
        "label": "Lessee, Operating Lease, Leasehold Improvement Allowance",
        "terseLabel": "Leasehold improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseholdImprovementAllowance",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_LesseeOperatingLeaseNumberOfRenewalContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "label": "Lessee, Operating Lease, Number Of Renewal Contracts",
        "terseLabel": "Number of renewal contracts"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalContracts",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "advm_LexeoTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexeo Therapeutics, Inc",
        "label": "Lexeo Therapeutics, Inc [Member]",
        "terseLabel": "Lexeo Therapeutics, Inc"
       }
      }
     },
     "localname": "LexeoTherapeuticsIncMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_OperatingLeaseMonthlyCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Cost",
        "label": "Operating Lease, Monthly Cost",
        "terseLabel": "Operating lease, monthly cost"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyCost",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards subject to expiration.",
        "label": "Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "NOL carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than temporary impaired investments available for sale securities.",
        "label": "Other Than Temporary Impaired Investments Available For Sale Securities",
        "terseLabel": "Marketable securities other-than-temporarily impaired"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_RemeasurementOfRightOfUseAssetOnLeaseModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement Of Right-Of-Use Asset On Lease Modification",
        "label": "Remeasurement Of Right-Of-Use Asset On Lease Modification",
        "terseLabel": "Remeasurement of right-of-use asset on lease modification"
       }
      }
     },
     "localname": "RemeasurementOfRightOfUseAssetOnLeaseModification",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Exercise Price As A Percentage Of Grant Date Fair Value, Minimum",
        "terseLabel": "Award price as a percentage of grant date fair value, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePriceAsAPercentageOfGrantDateFairValueMinimum",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award increase decrease in number of shares issued percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Increase Decrease In Number Of Shares Issued Percentage",
        "terseLabel": "Percentage increase in shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseDecreaseInNumberOfSharesIssuedPercentage",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Significant Stockholder Threshold",
        "terseLabel": "Significant stockholder threshold ownership percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSignificantStockholderThreshold",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement increase in number of shares reserved for issuance percentage under plan.",
        "label": "Share Based Compensation Arrangement Increase In Number Of Shares Reserved For Issuance Percentage Under Plan",
        "terseLabel": "Percentage of annual increase in number of shares available for future issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementIncreaseInNumberOfSharesReservedForIssuancePercentageUnderPlan",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "advm_StockOptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options and restricted stock units.",
        "label": "Stock Options And Restricted Stock Units [Member]",
        "terseLabel": "Stock Options and Restricted Stock Units"
       }
      }
     },
     "localname": "StockOptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "advm_TerminatedLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terminated Lease",
        "label": "Terminated Lease [Member]",
        "terseLabel": "Terminated Lease"
       }
      }
     },
     "localname": "TerminatedLeaseMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandAndFourteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen employee stock purchase plan.",
        "label": "Two Thousand And Fourteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandAndFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and fourteen equity incentive plan.",
        "label": "Two Thousand And Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Award Plan"
       }
      }
     },
     "localname": "TwoThousandAndFourteenEquityIncentivePlanMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandFourteenPlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen plan and inducement plan.",
        "label": "Two Thousand Fourteen Plan And Inducement Plan [Member]",
        "terseLabel": "2014 Plan And Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenPlanAndInducementPlanMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_TwoThousandSeventeenInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen inducement plan.",
        "label": "Two Thousand Seventeen Inducement Plan [Member]",
        "terseLabel": "2017 Inducement Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenInducementPlanMember",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_WarrantsIssuedDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants Issued During Period, Shares",
        "label": "Warrants Issued During Period, Shares",
        "terseLabel": "Common stock issued upon net exercise of warrants (in shares)"
       }
      }
     },
     "localname": "WarrantsIssuedDuringPeriodShares",
     "nsuri": "http://www.adverum.com/20211231",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "verboseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r45",
      "r98",
      "r99",
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r220",
      "r227",
      "r263",
      "r264",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r447",
      "r484",
      "r485",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r220",
      "r227",
      "r263",
      "r264",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r447",
      "r484",
      "r485",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r220",
      "r227",
      "r254",
      "r263",
      "r264",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r447",
      "r484",
      "r485",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r220",
      "r227",
      "r254",
      "r263",
      "r264",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r447",
      "r484",
      "r485",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r44",
      "r45",
      "r98",
      "r99",
      "r221",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32",
      "r416"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium and discounts on marketable securities, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r199",
      "r200",
      "r201"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Accretion Expense",
        "terseLabel": "Accreted interest on BPI"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r35"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Compensation expense"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r35"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r196"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r49",
      "r50",
      "r51",
      "r472",
      "r490",
      "r491"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r51",
      "r61",
      "r62",
      "r63",
      "r101",
      "r102",
      "r103",
      "r356",
      "r486",
      "r487",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r301",
      "r302",
      "r303",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Restricted stock surrendered for taxes"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r266",
      "r268",
      "r307",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r230",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r268",
      "r297",
      "r306"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive common stock equivalents excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r82",
      "r193"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r93",
      "r142",
      "r151",
      "r157",
      "r181",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r353",
      "r357",
      "r372",
      "r414",
      "r416",
      "r452",
      "r471"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r42",
      "r93",
      "r181",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r353",
      "r357",
      "r372",
      "r414",
      "r416"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r167"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Loses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r165",
      "r188"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r163",
      "r166",
      "r188",
      "r457"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r269",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets in accounts payable and current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r27",
      "r84"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets",
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "negatedLabel": "Less: Cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r85",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r79",
      "r84",
      "r89"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash and cash equivalents and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r379"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r38",
      "r206",
      "r458",
      "r476"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r207",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock shares available for future grant (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r416"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value, 300,000 shares authorized at December 31, 2021: 98,381 and 97,549 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": {
     "auth_ref": [
      "r252",
      "r253",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]",
        "terseLabel": "401(k) Savings Plan"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/A401kSavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r66",
      "r461",
      "r479"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r161",
      "r370",
      "r371",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r130",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r161",
      "r370",
      "r371",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r336"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r336",
      "r344",
      "r346"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current tax provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Marketable securities, term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r337",
      "r344"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r94",
      "r337",
      "r344",
      "r345",
      "r346"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r15",
      "r16",
      "r326",
      "r453",
      "r469"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentReceivablesNet": {
     "auth_ref": [
      "r41",
      "r389",
      "r390",
      "r393",
      "r412"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental income recognized over rental payment required by lease.",
        "label": "Deferred Rent Receivables, Net",
        "terseLabel": "Deferred rent receivable"
       }
      }
     },
     "localname": "DeferredRentReceivablesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Capital losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r332",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals, reserve and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Contribution by company"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/A401kSavingsPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r82",
      "r194"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r242",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic tax authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r67",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r362",
      "r363",
      "r462",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net loss per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r67",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r362",
      "r363",
      "r462",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized stock-based compensation, weighted-average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail",
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r61",
      "r62",
      "r63",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r127",
      "r182",
      "r230",
      "r231",
      "r301",
      "r302",
      "r303",
      "r340",
      "r341",
      "r361",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r486",
      "r487",
      "r488",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r365",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r222",
      "r255",
      "r256",
      "r261",
      "r262",
      "r365",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r255",
      "r256",
      "r261",
      "r262",
      "r365",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r222",
      "r224",
      "r225",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r177",
      "r178",
      "r179",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r223",
      "r229",
      "r360",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r373",
      "r375",
      "r377",
      "r378"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLeasehold": {
     "auth_ref": [
      "r82",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The adjustment to reduce the value of existing agreements that specify the lessee's rights to use the leased property. This expense is charged when the estimates of future profits generated by the leased property are reduced.",
        "label": "Impairment of Leasehold",
        "terseLabel": "Impairment of leasehold"
       }
      }
     },
     "localname": "ImpairmentOfLeasehold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets and Purchased Intangible Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncentiveToLessee": {
     "auth_ref": [
      "r391",
      "r392",
      "r394"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of incentive granted by lessor to lessee.",
        "label": "Incentive to Lessee",
        "terseLabel": "Add: Lease incentive receivable"
       }
      }
     },
     "localname": "IncentiveToLessee",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets",
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r95",
      "r347"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r142",
      "r150",
      "r153",
      "r156",
      "r158",
      "r450",
      "r459",
      "r463",
      "r482"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r95",
      "r347"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r198",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r316",
      "r324",
      "r331",
      "r342",
      "r348",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r112",
      "r113",
      "r141",
      "r314",
      "r343",
      "r349",
      "r483"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "totalLabel": "Total income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxProvisionBenefitDetails",
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r312",
      "r313",
      "r324",
      "r325",
      "r330",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal income tax expense at statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Non-deductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible restructuring charges.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Restructuring Charges, Amount",
        "terseLabel": "Impact of internal reorganization"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofReconciliationofIncomeTaxExpenseComputedStatutoryFederalIncomeTaxandFinancialStatementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses, other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r81",
      "r405"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r180",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Undiscounted Future Lease Payments under Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Present value adjustments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessor, Operating Lease, Payments, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Sublease Payment Receivable"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r34",
      "r93",
      "r152",
      "r181",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r354",
      "r357",
      "r358",
      "r372",
      "r414",
      "r415"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r93",
      "r181",
      "r372",
      "r416",
      "r454",
      "r474"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r93",
      "r181",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r354",
      "r357",
      "r358",
      "r372",
      "r414",
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long-term liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]",
        "terseLabel": "Manufacturing Facility"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) by provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r55",
      "r57",
      "r63",
      "r65",
      "r83",
      "r93",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r117",
      "r142",
      "r150",
      "r153",
      "r156",
      "r158",
      "r181",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r363",
      "r372",
      "r460",
      "r478"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r142",
      "r150",
      "r153",
      "r156",
      "r158"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating lease, impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail",
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r399",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r408",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average IBR"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r407",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of the business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/DescriptionoftheBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r35"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Deposit and other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r374",
      "r376",
      "r381"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": {
     "auth_ref": [
      "r49",
      "r52",
      "r53",
      "r54",
      "r380"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax",
        "negatedTerseLabel": "Transfer of currency translation adjustments balance to other income related to the liquidation of foreign subsidiaries"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r72",
      "r74",
      "r164"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r269",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r416"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value, 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r76",
      "r300"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r72",
      "r73",
      "r164"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r76",
      "r300"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r195"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r197",
      "r416",
      "r467",
      "r475"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r197",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of BPI loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r310",
      "r448",
      "r500"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r89",
      "r493"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets",
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r231",
      "r304",
      "r416",
      "r473",
      "r489",
      "r491"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets",
      "http://www.adverum.com/role/DescriptionoftheBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r182",
      "r301",
      "r302",
      "r303",
      "r340",
      "r341",
      "r361",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r139",
      "r140",
      "r149",
      "r154",
      "r155",
      "r159",
      "r160",
      "r161",
      "r241",
      "r242",
      "r449"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaboration and license revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/RevenueAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r243",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r406",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareScheduleofAntidilutiveCommonStockEquivalentsExcludedfromCalculationofDilutedNetLossPerShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r175",
      "r176",
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Provision (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Income Tax Expense Computed Statutory Federal Income Tax and Financial Statements"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r268",
      "r296",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r268",
      "r296",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r269",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r275",
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Option Issued Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r323",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Awards granted to employees and non-employees vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Term (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Shares of performance units both performance and service vesting conditions (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)",
        "verboseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in USD per share)",
        "periodStartLabel": "Beginning Balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant Date Fair Value (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-Average Remaining Contractual Term (In years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair values of RSUs vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contract Life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair values of options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r277",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending Balance (in USD per share)",
        "periodStartLabel": "Beginning Balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Vested and expected to vest (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r267",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail",
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail",
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r269",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "verboseLabel": "Stock options granted period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r291",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansScheduleofStockPurchasePlanValuationAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r232",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stock Plans"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Restricted stock surrendered for taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r455",
      "r456",
      "r470"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r90",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/Summaryofsignificantaccountingpolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State credit carryforwards"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r40",
      "r61",
      "r62",
      "r63",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r127",
      "r182",
      "r230",
      "r231",
      "r301",
      "r302",
      "r303",
      "r340",
      "r341",
      "r361",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r486",
      "r487",
      "r488",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r127",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Common stock issued under employee stock purchase plan (in shares)",
        "verboseLabel": "Common stock issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Common stock issued upon exercise of stock options, shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/StockPlansSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Common stock issued under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r40",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "One time share based payment charge related to cancellation of unvested stock option of CEO and directors"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/StockPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r93",
      "r162",
      "r181",
      "r372",
      "r416"
     ],
     "calculation": {
      "http://www.adverum.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets",
      "http://www.adverum.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r404",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "State taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "negatedTerseLabel": "Less: Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesScheduleofFutureNoncancellableLeasePaymentsunderOperatingLeaseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r171",
      "r172",
      "r177",
      "r178",
      "r179",
      "r223",
      "r229",
      "r360",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r311",
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized tax benefits as of the end of the year",
        "periodStartLabel": "Unrecognized tax benefits as of the beginning of the year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase related to current year tax provisions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase (decrease) related to prior year tax provisions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits, if recognized would effective annual tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r135",
      "r136",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofsignificantaccountingpoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance due to net operating loss"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r403",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adverum.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=116633155&loc=d3e31531-110899"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39896-112707"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40010-112707"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e40019-112707"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123394697&loc=d3e40879-112712"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123388062&loc=SL77916639-209961"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r501": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r502": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r505": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r506": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r507": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r508": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r509": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r510": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r511": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r513": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r515": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r516": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r517": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e709-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001628280-22-007698-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-007698-xbrl.zip
M4$L#!!0    ( *Z!?52:]T"(AV4# /\J'  1    861V;2TR,#(Q,3(S,2YH
M=&WLO6M7VTBZ*/Q]_PJ]S#YSNM>RB.Z7I#MG$2X9>F*3!B<9^))54I6P0)8\
MD@R87_\^3U5)EHQ)(#'8)IZ]5P?;4JE4S_W^Q_^[&2;*%<N+.$O_W-*WM2WE
M_[W]X_]3U?^\._Z@[&7A>,C24MG-&2D95:[C<J!\H:RX5*(\&RI?LOPROB*J
MRN_9S4:3/#X?E(JA&<;,C_EKG7C,#MQ0#4)BJI;NV&I@A9JJ&Z%MA(YA6=3O
MG+^.#.H;9FBHE&F&:E&BJ<1V/=6E6DAMBX3$HAWZVO(=U_.T,-"=R").Z)L^
MTZP@T&D4:);&'SLHX>W@#=/BSZU!68Y>OWIU?7V]?6UN9_GY*]WW_5<W>,V6
MN.@U97%]X4V0)]L%"[?/LZM7\,,K>"?]OU9U:7Q3MM;DE^.J<9K$*</C>U7F
M)"VB+!^2$HX7%]!4>"7=J!;!F^C,(W$-0].<5^+'ZE)"KX:M!\(7+!\/M\-L
MR+>F&Z;>7#>>OSU8VH0]%B5)0]9X&15>M75']>K?>A_=5C5/;3P7+KV\_ZCQ
MU^K2.U>V=X@_!Z2H=WA3Q//6A6OU5__I?C@)!VQ(U#OO5626H;O?.@EQQ?0@
M[KM6-QLG45T^+M1S0D;U/1$I GZ]_($#1M7TQA$5>7GW<OAR]M+7"4G/_]QB
MJ?KI9 LPF1'Z]H\A*XF"-ZOLO^/XZL^MW2PM@3[5_F0$+QV*3W]NE>RF?,41
M^]7;__F?__FCC,N$O4444BM4^>.5^/*/5V+I(*.3MW_0^$HIRDG"_MRB<3%*
MR.1UFJ4,-A#?O,8+62[^C"EE*?\3?N\!D\CC4#S_ICQFT9];L4\C-W(=+W1\
MR](\G1##89YI>[;-?-\,ON[A5C3X/W6*OBD9XJ-9_'H'^ Y%WG.0D/,M16 =
M+'M3OH[B&T;5B"2('C&%+ZGY>1+L95<?C..K4[,[IA?[5V?O_8NCB[_MWD5H
M'>V]NSB]V#?.+HX'O6'7[MXF27?O.#Z].+@\&QY>]_;>#3Z8O>3T-M..^J?F
MT=[Y]:EQ>-,;GFJG_;.+HW[7/NOO:*?#PYNS]V=Q=^_OZ]//GO;!.)N<?@F=
MTR^]0??V^+)[<6AVAW\->GL[D]/;<Q/^U<[ZH=V].+TYVCN][?7/K^C[@SAX
M_\GIWOXU./ORR3R][=YTA]U);^]\TNL/!O ,LS?\V^C>'EZ?]GL7I\-3><]G
M>):=GO6SV^[P(#GKTXON[3X\YU [VCO4C^":TXO0.(/G="_>#;I&+SY+O.L/
M_?VR>Z+=P+\3N&[RU79TZMB6JSJA&:D68Y$:1(:G,DLSG,B+="^TMMX>['PX
MV?_C50O 3PGO2M0<Q$5(DE-&\@/XIM@ ^'L OKD#8,\WP\!!Z6KK5+5,PU ]
M+2 @<3UJZ('O>KZS]1:!L#3X?H3U,[J!\(,@/+D#X< RB$YU1[6IY:F6%5BJ
M3P/0J0*?. [U-.(2(.'39X3O?@KR9+(+$,Y)<IA2=O-O-MG ]GNPO;T#VX@%
M(0LL2PUTX-&@$ELJ<:@!H'8LB^B.I^G GC50?&Q-=VWG43".2.B[(2@\CF81
MSR>A!ZJRYVB>J;F.&7X#QE*C>?TQST8L+R<?03\I=U*Z#XK(" G[4\&B<?(A
MCI8LE&^ZMY=79RE [W8TZ'TYCGNW</)?_K9/;P':%^<W1^\/K\_ZGV[A.H#8
MH06?M=/8U\[^,]#"X>>4?/''1\-]_>P]8,L76&<ON8!]#8_V]JW3BW=)K]^]
M/>K_-3B].(?/Q_%_;L-)=V__JV'I%O!=IIJ1[JN6S3P G.VH0%5N1$W#LUBP
M]?:C^2BJ9%;D,Y/91F2;EN>ZQ&*Z[K+(#0(M<B+]Z^%]@-IC07G"PG$>ES$K
M=JY(G) @80=9?D(2UF?Y<,EPZNT=2CAE-V> ^;T]H++^H=6[/=6.W@.\^GCV
M[Y*SBQ HZ'@ GY/NR0R<8 ] U1I0H]Z] (J^^-L"> V  B^[[S\/>[=_6[WW
M!_#YT\U_;@^1TK\"MFN&KP6J3@S0?T(G4GT3(&:8 :&.H5F&9P"<]+MP>M76
M?',6L9R!N5',4=C1@'E=<+,$(*EPV^=U"6KZGUM%/!PE:*/P[P8Y KJEFV_?
M%!26>-5>0SQ_^E"YAR(;Y_P3-_I>2^P1H/T1GEXMQ#A#KS[%%#]',<L5OB$V
MUU;</?QWFS7-WORV^JJ]^HBK ]4GL.'R<H^4[&UE$VEZ==_TMWJ;='JI;JBF
M/GV$^*7Z7#WD5>N@YIZ;$T;4 '*UJ.=;MDF#,/! <PK<*+ TUP\%U6F.J:W
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MB#;+CGQB4MOS**&>[@3 K+E$TRJ)MBH(T))HVL,EFK8PB6:;D6%%8!E2U[-
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M(5@!$3-T*S28K]O4T(A! SLR01BM 17^<!G?SR+'/&?.\<FGETCICFMKFDU
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M=8%6%X2RT1 _Z1WU%W0B42*%V;.P!N7K<)T!%JN?V'K\JQWN<N:](T44 E]
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M'SP2$UTGC>6VE?YW;D9$(W$*5B<5+73A.KY5)25#!,MTWR)L>V?GXO5"CCP
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M]-M(@0V568[*OQ*1$+Z36P"-[H$2_/ZM;H-JI!39$#0BG)S442;9&/Y,@;W
MSW$T^=9K!B (6 Y\ O6LB9 2I*CT-E T9E6Y,!LG](X.&"?)G>_F75@,YGW+
M;E"(S'X+0C:=_0Z[5&/Z0WE'Z0Q8$K.K.U^SHHR'<RX78OW.(W.&O1SN[)JQ
MR[OG "N Z)ZS]BA#%A"3I/H>!'?CKC@=L\8O*%A3=BY:;0O!"G(<@<(UP89
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M4;5IVVDY&Z8:01-'X"XXPY1'7AO>ADY;1E06JG"Q"ORKCI[FXW.N#J!BB>L
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MM.PSR\]!Y%?S_>JRH..C"K=_;]S5MH1;MS9SH:=B*Y.AH.D(MUQX14KA.+R
ME0I:=52XYH(5S&&T;3#IKC.M.X2G84)^IW:F*P4(-U#-54"@44+"Z15B$[*(
M=0#V'Y_R*'X['\=H1Z:LM>'*CRBNJL9,3%L]--,K*E\!+WL9H=)088!,/1.
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MQTW:5FLQC-VT@,!B6W<"\L3KS0I(\)EUC6\L7$#BDO1%$8G*R-DWG'#= "*
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MJ \W"V<5/3M<Z,((_SFB=.?:AQR60,W (82E%2KG(22.7!O)R&G<1DJDZ.V
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MP@@\_D:(HG"ED!E#6+TV37Z5E2HL\MM5PSBKLT<Q+/BO?;&O+U4P[+!WRYC
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M=%1*W7;&^69]H!1*<,?QOG4TX)E\ULA?\,J$D!G++*-P@T150YET@\M 46=
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ME.^YB;R/-[:S? H6_<D]43N%/$W]S_UV_O1KL?.GWP_RNH5\P%[]=[\)[E
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M)/]KGL-U3&J$>,UJH5 S_;SM6)$3[9!L!'@ ,=/T-D&HSR3,=$"Y+:R>M?W
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M;RXXS*/J)W+.5#.6>-QNR[S7]3P2Y(=5&3^,HJ]!+2RB]%F6^3(/>\=#25W
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MP1*6VQ1;,]PX *3L7<K +F,M*_&IMO7(\P ?PDR*18+-])ZE(=(+*=1R]=S
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MLH8 ;(J5=W)(5%(G-L#Y%:57%X4'9/<AH"D9DHZOH^'AM^]OORU8O/>8WTB
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MB)&'@-@)<;=*=\E*1&-5M"HJP[1A'"71"<I>.N6$_V,7O2:0K9"F9]D3?I=
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MPF!4)6W!R.TSD"W_RUT6^6.*6FE7-I<GR^IB\Y?'5EJK&U(V^\O)PR]^LXV
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M984]B?\;O9$DC3.(I]4:Z,@L5U"7(>)!6N!T2$K_QU161PMM7%^T6,TJC4
M]Y7"0;$X=Y7V6J"5(^;)XV$Q#B[P[2)8;C7MQV4<WWC,=V1<4:S?!)/+().P
M7MKU57CD)553^M$CF20R-V5'L6)8!OJWRV6Y#8]2!AM=KG"*M+(.Z2Z\J;JF
M*ME0!U-9B7^C+QPVSR1<@C\H/*X[A^'FX BZZEY8A&SRC*KK=Y'FCD2O=)J;
M$NV>+H""_+!%16 ?:<(BQ!,$46E!]62_JH5N4FT[:\(?VDLV>&:<G<668U^
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MAU:S"@/2JK2Q/)X,P<"5NE$A<JLZ#]B@9+XBJ\'=<"?AL9[F+$'&0%QPX&8
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M_I?U+<YT/0W',1:']U\$^O8FJ+Z5U]'A=&I1P?+<.) 4/[!K:AUP+!^X.6"
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M*\_5KH_E;ONJ8]&@<\5P-=HI-N%D2!L>,?49H%49 9<[IY7Y3R3#I+DR32S
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M^(,YRL11<#=+RF][K0QP!9:,2T&=&E<1P,KCH;C649V@\=HJB61A;S&WB/<
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M"R8-^TZA9JJAFW:C*LO$L5,-ZY0 O+VG^HPJH%;=*7=E#X+</=6M?,)DEH)
MBHT<$#M\Z[(76B:O2R7U%*E?#W3,[B77]G5Z-ZAQ)-9E&XQ;,4B7J697!F-B
M1ET@]"P&CAK,<BN-.IQ8=?0).I1T4M6<*:UNZ^TMX^%=7#Q7EO\ZMIG*"R39
MU4&;5C?(;$YLI]FMI%F/C4#=(K^G@=[X<B.MLGU^ /RPKGC*!;IGP1FZNJDO
M6^BNYXLNF:3QVH4+Z-U>QPJP$Q2HB>/7O5R\$2+&NN_ %_'3LA\OA:1::E4I
M+LJ-E,Q#,EJN4W@HS^Y8KH"Y9P.&2OT:$+F5CG%L/7+3:SOOP[/^;R/9Q,#=
MX3$RE?A(#C \5'G/;/.*FG"'P(DVWRK.:7A&1P< (?_IGPDH.VNG<#I8DY@M
MCQX6[86NZ=F!9*X[S0_G4F0\TC^<(DQN<E*Y..(?,X1358^2[+%@;G+!?>T8
M+R=<!7KV3+X0B:[)>Q-@.KS *)ML*&FVMF/_":9#_:>PO9K^FL?)B=6VSOM.
MM1W(?I?;(O'.BQTX4%A+8E6X%+CFOD4Z8FZEFSK$\?5,":1K J+5#;7Z%CFX
M=J)   R>4?IG'JHM$V12BKHKCD=8LT33H-303**RSPZ6"/WZSWFWNKGX/O^1
M-!"*'ZE"(A38+. 9YA=8E\AP)0(_K2P;5@.@,UTLHBBW,'.?@J4ZKE$(8D;A
M$JQ,W,:L85H^- SK%R^N.+:X)5SR!BMB>+=([T>> V'UZPKV)XI\<"^<L FW
MO"_Z]E@RH%2VKO $!L]W89-I.=CFB 2SLOX'\)E$SY.,Q6"W,+*+^EYIB+6R
M%7L A"8SOHD5U*;O*K^%#D1\[KYRXZP=!'Z4LU$Q&$7V;0CE*>@^OCBC/3M2
M*S&P>]C4?2,%A#TCTS;^G)YLE&_[DA_IOIZ$#2M2E50O,]W2:!ILG.* ?G@'
M]/>3L:ID?.Z#V^SOE2,T-": T37[_$Q(>.('\A?(>V0QZ8&SY3@UOCJ4T]:
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M56H68ZKUQ?= 8BZI$EG#>Y+W&<),K\M;@<%N20J=6*=[Z4JF\;.>#]6]5[Z
M+"TSAW>T3)TK.3?%;1DV,*4XR$Q/&!<=0)?M8P2, T;"1H]E^6["NK&*ZO!+
M#+;UFGQ'E^7\FAPV=NK2])(75G5XC[5VSPH[;7/Z,AXET6W"(:,H5O7##)0'
M?GX"!ESW.1JH(\G87<15Z7(HMN4U.$49/B=WRXPSS;X%MY\A<=Y5/CC'/GX?
MU=5/GM&$)P]B*#7[I%R=H'JQ7(\7_'=9G,AV8%P'Q8H.%2J3QXRMP1( :ZB.
M5<75=X?M8FA%;B3[+D[-A*" !T$F.)D@-=-^G @=*OD69<,(YN,%86=>-]2<
M^MP9-)H1.:+?TI>_=5^^6L$</?WC'SY;? 1*UH^?)2B1\ '\^NFS)]ZG%74G
MG(,HM)+BM-U-.9^P@&>&<!(#-@%3H2=4$$H>@Z7X"A@0ZAW<<R]A6.A\N"Z+
M0RU.-'=(#,[F>$9HEC\"X]7-Y\<M8N,S+5#]78A')>$<'8<*WW[3>0,\\!"5
M#A"_$(HK8):X)Y3?QEY5WN+I9]YEX#1RER#I=&2?,1:&EN=@5>%^Q?H91[OV
M.,0+99$=KVRKCBA054_@9$P(F9,16A,MRE(+0?:^8T9;_Y>T];7L+A=O9$L6
ML_8.&]('G2][RBVXDL^@#.7@-MX155()H)[TM55*@M"K*8XX+XUW:;_?'I21
M1@H,]"CK(E^3X6XG/FW DW2U&=? L(")<JR[2AN^TA)#6+R=. K20!^50[HH
M: *S1292+69S;S1/:<IUH540Q1:H@"OT=-INFD;G6  $*+#;G_(DMK#'QT'9
M3MXZ2P(&+:9K#M39D8DJ6G O1%;158@\(NQ!3# :;4^UB8YCM9_!_O+O%5NR
MZAI/F*0HG*>9]V$;-](\Q(;NY=\QF7'QA5],IR5(4$6:@D#XJ@ARRC2@(WFW
MSR4XI'.YVW+EE! .\]_D#!AYP*UR;]%3U<V>UA! I#Z3%A]:TRKTN/VV\ _Z
MI@]O@YM3G?5UW"G/BT8T;3RU2J1UX9+ENFQ7?:O:YN@5F7\U9*&2]SE7\'P%
M[[?G"MXI/,JOMM$X]B7YOJ!8W'=)K68"<:%X^_CC)NU'37$ER\(C!M/"0B:,
M5[&UQ5'HH*Z8"G?9%8^W7E%^1=N/R#-*R)^W!P9=<"[ZQ$\P]D\FFU83)HD0
MLJ+RP 0V=63"P%0A[5])N6CO$#6FM)4T#+A,N'GJZ^"B<4MI=SPXY'ZY^ EY
MVKEP*%^%<Z6(G-^-9OC)-U]$H39+-.J<A^O\9CSOQ&)5;X4&%Z^#Z,6R9=84
M54Z&- P5X\(S4&8*C]G2@1NA.R6S;@T>@ L,FC^JJ_TV1\N$Y)3X4HI1#R8I
MQ ?L@OS0KZ\5417O<+GXLN%N!,X<V)UM:4O.CHE*Z1$IW19YS'=%T>G"T:(9
MP5=[R;!%O]MG_\)#"[0HK"\J=-;+V[+N6R3Q:^%_@K/\ 7"?)B-834P64%"Q
M2VXXH*Y62>AB6M<KDN9:&=6/;T-/91[IS^@LLNC(MZ5:J(L:&(/GZ,9A K=,
M%+0+'EX(Q9B).%R29:J,?D[O2M[B4,D:#EJ34_"EN2%9?I(%=<4WJ@\FH&)B
M&@B')C,7ZH9AGU3[&6,$(@H/.HQMNH3%O \&'55?5[:[7'P_783D:R!>0ER3
M1+*)]("66Z5C*.8,#6O'HT;1:\YB4%&$5+QF"Z3"0JP@Q=!$N<RI<8=<=309
M:GL5- =1H\'XC(=GRH8X%6JTL1+Q4D%%"YIC/C-#K':3[UOF(TK7G0N#J5J.
MCIJA]=465;I^.QU"WQWM657O?]"S>MK6X"LRZ:*:F9R#@I*<Z&JD$@A:(Z!A
MWHOZ.)GN2 ?(.WBZ4YK)Y*1F0\M/V#$<_'ZJ N@\K2D$*$[U.C9\.2J0JRJ!
M5*0=R*FFR8H4;IV0N752.0([[N.*A(-CBNZRB[9,ECZ7S=$)_<J7@,U]X\JO
M2HH/OQ6;T9BVN&\=@_)]/%TGO@1?0<UZH]UASB.)4UU3A2!=H$9+@.Z'0FJ(
MT6W.!O+:<R!G;N]6/M-CS=WC-IN(&@&<-Y(Q2L%UT'#^L&YW!\O@\XIQ%'1F
M)SO)M':0-DN;,;/TKT9,SN#_*;XU74SN%L<H9S,.A$PN+:&6'3'#BB]^4^X3
M+$IP!?;H>SQ6[473/>6#3GP9:Q6;I 4T@(2W3X8G&RQK(7S%27ATE0_YF.[M
M?N$D=R\J*-1]Z<&CTH7IX?#)#HB*JWFBL^H$6-6RE8V66<A0DX+#C!R"-#-;
MYQQ)<*\6Y*?0]MEIO"P%<4V]WH0%2R,0MG%M%C[V?33E+AFGE'&_5<9.E/5*
MT77)MX>6#Q 6*J 4LXDS,&6'/D!7\\%UC?AX3-?IC<EX%\O)MK+#B(,?ZAE9
MO1,_8V#FW*N8.I?> 6J>++[.E7;.2I.K61M3;SA\>P%"F+C%H,XS0WTJH;1$
MI=3]2X,>VU8:7B+E<D@LE?1%8&!<)3>FUUW?@SX76R_L]/;X8"A&B!I?WCAR
MMV&9P,&/VKXU!B\V]-I%/7\;%D%QXC1:F^ V3*T<R;I7N9#XCO9JER%^]F?"
MA(2")"*T>"J&V@I'X\ \]M2/5@D-0[AN*2O#'1W:9"<#P?.)\/O$[:@DNW9
M[*9#GVX[ ]=0)IZR^A; KSF7A: 4?CN=QM.6,PYS%H.DG)N)+,:-BZ[:,)H
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MS_4=I6H\]0X)7B0Y*/PBG+<L=8F$FV%%(K:<%L34,Q^A!: #-%QF5>XY;>7
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M2(EAJI-^FA0@@8ZC0?I,ZIW;G$IHY$(S&\,A/"^;?Z/HU1#"C4T:-^4(0[0
MC**?E#?H+(IKN^-W#\\@13MO%EU82HUU3!+,THB47>>R(@EB!N_3?59YVVXH
MAO$%0I6+!V?63A")"LI2F2*.PH0)G9XZ,FU<-_4==:-NW,W"Q);KI : 5><A
M7\I+@68TH(Y2P$FR$3,'T'!-EE#Q%@I / "!:"@19&RY5.TC37K4[EQUGVG<
M3MO6?GY8W.4XS");0;7X!BQRGWS\]&->?:]%?.HUJZYKP?6*J)?7V S/:?RO
MZ(2CU;UCG0YQLO[,4_1<N>Q?@J:9+O(M62AJ4^$?P_<7'Q&E5%2+I^^+?S5Q
M-_6W@DU$[3=?F3P395:XLPU!JIX'6&_AEX[$.F?I695JY\,EGBPT/.[35#P'
MG0:_7XC;;A)B2<?,I[4CWE_3@X5D@V5]@N=" )@U.6R$_&*PHO/\E@>I+37%
MDJF8[O@YTA93,RK177U!+:??XELTC;3'F%8FWZYZ5HTVZL&(*RFK<,X25J>L
M"*^'?Z#[&?_<D<&26FU9_8!:7:;GM$C1TEF\ZW?Q01[CR3-F7%P7*G:Y%%51
MO!; @6&CE>N>]%$95,4@%[LH4Q"NV6ZD1(5#MK*\0M_MIM#J8?YC >LQ:NLU
MR-F'9@6>VX/7M_!'C1YV8M6Z<,K%'\6/Q:JG79M9R $( UO5'X(]9@(:#5,2
MDE/'X=X4^X*^%?Z[S:E56[.B=R7);M?K<G-@J@$ 0CH[/''$A)'OHLZ:G332
ME)V0LM#;O<U_7#SOQ=/[2[UL\7[AU8/I^[V<(]B'-C"\-?@A:;%'5^$O8360
M*_(THV__D6\0UHHP-[8W\".X[;DMQ;O7TYR!DF8QIT:]C@ (O[H)=Z@->A8=
MH.N:62GU?%3_4W TS-FO0,X#Q2F*#:*D&=)L3;$I&G%^!!\JIC@^ &T"<M8N
M5;#ORN26D42K%G_I0_3X]/<T*I\\C2'VFWY/IVQ8+'T#)M)=*38O1K*,D(,T
M%0&)&@(MF7&Z[F7W3PT6AU]U)._-@:HLF1XMG.\=T%TY,,C'WDM?ZPYP.9YU
MFJ485K^]Z858;.I!$->)<@%QD++LNSR*,/#0G.Q<OM68YF8&J^D9*4F#*XON
MDS_P^&;!0A8M6$D7G]-_%N@))",6=ZC& )AO05'3P ON50RF$J^2%#7()OJ&
MUBC[_U8!\3 )I.EMH2E%Y-S(,(H'FYP/R.'S 7U%QTW3XUC7U1]/6_*EE<@9
MIL.8$8A#0#Q\M@X&'S&Y;GR,6(EX(-C7S%=<1ZG=D>\<RN3 !H>&7(PA"71V
MA?,.)U&G? P8NZ(.-H<=DSU)J>K31/6S;)&HN/+SW>4@_953T0XOY9N;&E;7
MT8O<O*\.Q >4Z$0\;4JVX&_>=[ZKFW?#AEYR;I)75D@5*+,BKHH,!H^DK ]3
MU]!58>\BM8*)5[ETMB0*LU-0QN+KF0\F[7=SIPTR\*(=-S-T*C B4J7A_M5!
MB$M$[IU+:YS+P65B+C*QR33/ \,; E*8)1-"Q?C-/ J\Z,C/I8XMF>X6PRWX
M*/&S);'%J*C,@9J=WSK 1R7PY'Q=[[OA=>1EYVCGQ)))MDJX1@].=SJ?U",Y
M(G,RFTU[2.'E)-RH5QCTB:4JH\A\-P5.-3[O.7N7C#ZCS,M*ZFJ3ATH,=@9.
M#051_768BL4G<$.>\LGT>;\FON_G' @[)^?I8B5M"+8P$/-J.R&,B/'*Q$/O
M*GA+P==8O"DH5B/2UV ]NP)']HN"LA%=<-GEN^$9\O:=!F9DFG<[;5>, L=K
M^9K=$JX)(>+R\#K_^?3R$^HCW6Y!\RU6@_R6EM[C4S,L? K2"/65E@'#*R)D
MDFP4!89\9(? X4!7O;YF&FW.M,CTU57$P?==3<P^*_=TR*K<#B'.:E3I2"M;
MYT)>AY&[YARM#6EX0:LNB"?HJ_4(*C"G.=N0,*7_14=RB$!;2M71ZRO$]8[!
MQ>2)V\Z\"I[$5AS23YE/IR]X%RH5Y>1J%1M)>9^>D/MP8L)/!^?"Q/'^]&D8
M:J#X\VBO5SX& +:=^(##I<.!43G6W>>OOOOJQ<73/Y)]+HN- A3\+ CWC 9[
M80ALT%K!9C><Z_XF%_?[$^0MY*1!+N-3_OTGEXN_XRQ5U\O=1]AA6<(HSK-%
MC7Z2,"*W:-VG&S_]+_H879_&KM_3___TO\R>"K#=YDSDQ]KX_,[[TTW&KC@[
M,=@J<7#E:!E"7L]5:5^5_N1<E3Z%1_EU5*7?@G@6R45O.1!;E;?F.:(_))>8
M\TA)2)G M<U*2T16#$I*5'QM$:U'N3M8!4\&S/$5QX-*8"M$Y<6/>TDVEITP
MLW/#2GB6/D)FI/;JWPCG*D(,8;,K5V/B6PK_PQ/QH=S-/42P0YPP'$>IF8;F
MK[DK)AC" <,\G*0=I>3#MU^BXG7(+&P'P6H(2<K]MO#IK3S,_GJ1=U.Y.JK?
M29X&IR6>V7R!T0.&[[TA5EE$ G_4.%R2WC0_?^[#^AKC!?[\YX@7B". UVN*
M&RGEO::F6YK^*\X*TP#\.2P\SHJ^QJ O1#B[VZ)W*LQ$"(GW6_'E;';8G\.1
MP87-#EUH*3UPI%;VCD$:]-D)Q0M/E@K(D4$R3U/2%NXY+A=_JY,3'4BUN 1N
M"_$06I=;Q*G)/;AUS.2-KWW:(<'WS+2J@?GH$)^,S0RN-Q6798H^\*U-L5*F
M\#S<3GKPM(0W5[1+NE.\O.=T(=S?F"G$%ZCL"IVY 0$?$M$QSBZ.BBY46*7C
M7LU)S._;&R/VIL?61+9DSWT5U:?(3+GLGC*$@#<49NKG1J=#R4$!;&QBUJ?M
MW#?X^M![X?"=XG/X\>=.F5]2HMCMA4G^/;;0&L!A@N9Q$N<.CU]*W[TM& Q1
MKJ((BVK14+TW)VK>67MVGI=?:EZ&?"6<+E,%DR;6NQ2WC6^>Y^-1;9@AC[CN
MK?N#_9:([PJ'U+DGZM$'?]AZO<JAPG[B3M%4I</Y>&D!CV-E$TM @I#]R1B!
MT5!8IG!/4*L=M2UQ'2SO!$WKKR0UFC0*_N#8$K@ Y9BW11IYFQ\,SLS9=&$8
M4?KVHM//#T@8CYQC(X\^ GG8G:34)NJ4VQR(2PXZ'F2S!U[G4'W9M(I.?&%_
M3H$:%+Y6N>5WBM$8#V6Y9LDI"@/QMOU2(SBGRD3B>D,)6=D.7[RX"AN ]'1$
MJ .A@M,@<*5<_UME(1IVZZUNPIZB$MY -E<R3(R@Y*"$WX8+6 ,=52I\URLB
M_O=$8=7BJ[^]L!; IN 6+OYSY5]RT(FHX@'H#M2%Q?"+;U_Y""G5>MW4"9T3
MAK9MK1A_I!FMFU".%<2P=BI2$^;V$#LBC_0 "+$&=DLOZ%[[3AB1Y,GR:CB8
M^DCUW".A^(XZ I[&(9-YHZJ4X+9\5V@7#(#?K.E.**"(H/9++7D67%L*N?5=
M9?4F7+G(UT,N(+%.>90L3(4R+33U"&D;N8%R1N=45]*.5D6]NW-E:K?,4Y\O
M>2^7'2.FVR&MX.A2#,*@BX6YL_Y LM#05:73>4K8B^%?.)B"E6XJ S 1GDU@
M5?9%A3#BOY275<4>/\+I_N2BW8(#_'5LN]5^G=XJFWL%3T:"/IU -XI3\Q<A
M_0+^]T/M7I:$1?%MAN!6A\4D]1@-752[2#EGW %AK^!&$]LOV&6[TT-.03S)
MT$BK([O7#.O14_&]'A)#!7OG%47O;@KN(+CO823]=TT9G0IO+(12\E*\G-I@
ML=>]R,MQ%Q;G^9.A8.OMQV)X:SK)()(7AI,Q)LJU(I!@3]Q"RV% JRKKQ7T/
M]BSB;<XIIE\R0B#K:,0!#Y;Y"2>%^!+!(C#.3TXBP1^L"EX+A,\S['QZUH?/
M$K7Q.=Q^M/F,DO-Q?H02%"Z-HDC)[O <"(0,#O>=EAK.,_+X,Q*EHRM&G5=<
MMXIDL(I)$H4WA2E9<I<.:*=$>D30EHE 27M*B I%Y?1,J?\+SG2P<^\2<KM-
MSQ"U*+Y63%C!\PP\_EXS:4K0U!!.3-#+;-Z$ ?I"/8P4D7K>$X])]F:2<L.<
MP#$&Q]@@S]A[,E]UA:E=%K!]#7?R.JE"<V%2/J2'.C04]!3$'A_"JNV!>=2%
M<37\V-[T1%QP5RG^\;:LE4PW/"4)'-K]$V$K#WY'C]M&4?W0]*G;]@*UU^CV
M.L9Z3WO-04HZB$+:)%>>^(!3\ I_YX-DCC13HK_SXG^\Q5\=/""6!GYR_A(D
M?=*1OBY:JHZ<Y^01 Y[8T&_G<%G=4H;F.@>EZ+96C?)%V,=%)2D45IEHW00Q
M*S. -\A&IYY5MB"'0*]D%1AH%H2/"_#",04BP5:MM_-]#,@B\AW5 1S&XMHO
MX;5')<SGI,:8\'PV ?ME7:\7S_6OKQLJC["Z[ZQ@7TI 9^G&P8,C(:A=V@+F
MJO+MH2V%J%U2I%RL7?4(3IB\?7XK_"HARI^>(<JG\"B_.$3Y;.??T\Y[/>M1
MRG(1]GG13CJ/#W07C:%P4W*,A\RF?=5YAS_W)E3Z^O9S;1KW]0LL/RIVLQCV
MRJ%@,U>#]=7?),,*_[MB& S5,6R,>'0T&;%3L\B-WO8IRMPIOSN5HFKI!U9M
M"7I*M+;T.$[;FI/0Z!SGT@V. 3SA7K6:V$=RBB"F-7?V@7X9'XCJLL*E#K$2
M3L@O<[3MFVSWFG^(- H0F0*V^O%",$IVI7'5K)]AT<R*BDL#.BO:D]2,KK0[
MA7M+AGQ,<WU2*__<,F5WC%^7&WK=P#UX#9^EX1X3ZN=L5S"1+2O"2<)-T.&9
MKE].&D3SIX(!F@//4_-'% J%UJ<<FP'2>Q%J+OFFS,O$(N/:M9&L2Y81;G7B
MZ)37<Z5(KBA:-;>$)A+@  Y*)%7NNDG>_1ZF0RY..QR+AE285\((47OO.- )
M9TV%8F=%+<PI9X@&W2D*>J3N93TI0$U3G)%:!WD@],C/14G2Q005+ %_R-TO
MJ:>H6O/MQN@#.J"7BGXZ=G$L;0:D&#G%C%)>+IP"PF+6E3N9C]@S/RQK#VZM
M<E>60/43G'YU,N35V<Q^AM,#A^+;SS/['KTV[\,.W\E<?G!B]-A]<1J?5HV>
M_Y+PKTP!RN8K^YJRH6XYZ<2?@[+I=Q72)M^4DOD LK*+N4_3.6&>;F*;P=L+
MZB)+_;EF NJ7"W[H)V'],N[X(-8!ZH#;<99"(1_<GU"52I(VZC>8D5?110;T
M49H1JP&3WXE0V3![-H. FZ*R=%9:J2N)GK$IU]><7P$/5!D;(7TNE(JF>8CL
MPNJCP@#+DEE[=3GC-HMAXBK=!!0B4\PB>@]I4I4\0_R/I28%N64*=$R08UH:
M:)#(')6[Q2W6V](A?(^B4(CL,0&B2-/5AZ<#QF [':+933KH%9-M$(NNU 87
MOG_US0NS*H*#M"+L'?5*%>^PY.E[!$UN=\0+T_ QY)L]Z*]J!Z>MAE.PY"2<
MY_*7.,](\56I+ P5KQ^A5AD8DB$\EEY5[9&BEQDJU8>_-R?NAGS/M6YN!E57
MS?LD8=*N7GSWS071)6C5?&I*209S'<(5"1)TDIBH%</+Y*%$5\;6E;XL/&W;
MNN5TY)K!M,K)*E"]WWY,?Y2G L*Y#Q%!&7&@F#2UXVZ9/L9RB_G=Q4<>I8L)
M;V""Y+653N3)G,*!=L,D'3#,B0[*5./6_<'E4U+F(B6GNA$U2'W#"*^-K]=F
MGK8/PT14(IV_CF:F;>KTPL @6G\QII$Y<%DLSE8 KF KQ%P0V3M3QP@-F>$L
MR9'=,:27V_+M%ZZ[F$@UP*K,*BRN UK2^Q[BAO<TN92PXSOR"]"+V_;-;7%P
M62IB!1.V5(ALNFY.647!=RS 2:)*=[ FLJQ)U13I('=D$0FH'H/T>4%\TE/I
MJP&K26WJG.$/X4\XP%5?FAU;F0XA W#3KV5WNG1XJ0I-X?PTV_I.EZW6WD_<
M^(!(#DVX /.N,6<')]-,:TN'8G*S$L5-3E*H@/4*3:5Y)C3HKUZ__>JY@N >
M;LLX-A$%%RV,0+R'Z&6&?&(1"P804;)!C!S<6FSPF4)J-P]SW>$;\DGF-SB3
M#>@K&1$LG"4575$[)IWM4E17_G-XLDR+KI#G 2T$TC3V@MB45=%W#>6D&%[0
ME<L:ZYT ;K3=1.@E%EOW#4NF=T0%BETLU@25<_I97T*IP%O;F/MZKSYJ^*V$
MJ/92LJ6RH>6W05$MW%FK'D_OAY[W@Q@BCBW5%V\.6Q3O%L045)?KQ%0R4X#O
MQ..><@(K;/.==GVT;;UBGD>VS]/&EA_<2#\,_&:J0RI:+DR&XV=KW6A3CTBC
M >>_:NR'V83DT*$19QX-UJP:/]-8A-8?NF'$]. =C.",V[YQNU"0TS3"9-$3
MNRM*TXG$04*G:)8L7-"4L<!4:0T9W/<VU6GE.HI(-MD3#/C^N-.V['8<JF!'
MF'9IED^;(]CEOF'-[R35,.E:90D1K/-/0$PW6*]A< ^\^%SL2J[EM!^V+MI]
M6$>.+Q79Y[GG/?$92#>6'S4=J_%^>L@,T,!JG7]KP\L=*\P&,F9(,K?F7GZ1
M';$APN@*L!/==ISO=T%X,)=-SERSP6)[X?C((ZA"+'HE.9/J@8I9=I3T4B:<
M*56@7W0L[N>1M963C%^DB1D?)V]O%'.!.W$3-_68"'O\0'1-NMM$942I11+.
MU+*=B(8_*BZO+S.>Y933B3QI)V+$+>)L\9X@B :[+T'VB'>?SK\Y%1O.@-[$
MQ_*-2^$ :HGK%?W"91M5KR<-H9L3F0:\[KST]Y'A/]/M)5B6S\Y8EE-XE'\E
MW=ZI)13OK-_..$)B[@/,5#$'!0Y8RR=2BUTP_SL."<G;[2N3D]H7JL'F^8IS
M7TFY_Q!**@8Q"4RA7YK[9>^=>QV+?#<?,M!%6&U%_#L^=MJN7KT3+AN68%^A
M7_*T78LOD &B::"S)OPW\^& 3I) =9BF%;6/LKU1=X!2.*0L-Z5KFU"%.V*M
MB8*ID -;VP[%JAU>%7((HH40AB \7%W%)%/\#=?SF/CW(54;R1H,J3ZXPSR,
M2^9S3YH'FF@7MU45V\H'E9T-NLHH&I\<;H35_3+L-Z W91,@S:2-%W$2&&JA
M7I@?CRL#7Z3#HNZ*)>J2M%N(4/L=6!@E0R5$O,FTIQ>DSE5P\*[#UB5VYEQ(
MQ:-D5]@0EOU#^0"/O4+RAZNRB,K"8QUJ"8>$ZT ]0.VU+XIN_ 1$<C <L/7#
M;$7[@=B$DS+R+WKK;Z]J\F@KI&%UG+IB=5.Q4)*.9HSGCK1XTTK9;#AWUN3[
MHJ>$AB:G 6E&2%X,?%QLFDV^HA!!<B;=P3O-\^&+I HGXY<3-]4S6GU<.*7(
M5M^=^3)<0#TQN**,-SV^O)KI:ZB@/B D?-A9?.(!X<PB_5=&>S./<#3:\]_Y
M((.]#\\<?I^4!!U,J*RB@IEN%B7+8XBHJ\9JAI*U0*_#[J3FCGPIP<6 \/6^
MH39V&2:></H>4T:#I7K <6W'*OWV-W0VUX=\&S6R3MTN?B^0.D3A*,C%T7C8
M0',F>5G6@W-,Y%QA.?-MI(_5\&5/ AE:3 S^2MAK^;50!73&&WRY^-8*CX0V
MYRH0D]JPW^.>)5R@*11LUQ1>Z&W7DU]&\T\?65^ OULNS!1']"A+*(Y(NIN3
MM9IOCJ]/(.9*Y7VC5<6%%9R>7%L:L/@7?(NDY6B3A_4N+4E@1,D4D)A++;29
M& .UK--X+G5T9QX=5=,$HN:&KB,)5RP(7@Z8X+X5B')])\1U[@LDI+<GG"$#
MLTN&(+5Z_(R4WC!SHF516[WIR%:.)B/XOMB7R<8;[3I?1T01RVLTSJV9#\^4
M?NGHL 6/6;<J*QT%9"-@<](.1HA"+ *<OMD"ZS_S>%$QW/!_[N"<]@?"^H/^
MJ?4 ,&F4<8S_T#=ENQ:]75W"ZC/I7<!R% %YR7<BA]DRL4&LV\:GQW6O+0<P
M=S1KR36DM,# \EGN-XT,%0;DX1_?,+6_*"-+ N)EW]3[PB0'PE:["AO*R/U?
MOKR*XK3>;T6#N),<2(T[:B'N11.J3(M,G2Z:/; LRGI/<+.P3G+!<>>KF\(4
M?>8>(NH>" @Z#H-^I2JNZZ[T!U5*X^F0!1272V<3R]>P8:=T _O[;-?#L;^'
MUYZT6_"B8-ZI">SI6XH&E+,JN;XRQI/E].3V,=W3TD-1XQ/8U"N1K)B()-B-
M]TO L1F.%*M-?V?QNJ9V?>2;3'K=+5)*P3B'@*=LPV5-3@H1"*.8'/),E87'
MDP%(D#*4\  ?D1:)$"C>B'3>?4N9+:"%] :]B)%J4BTN,SQ&3A)O(<184P10
M+GL^*6G.FF79X<[+HKNCNX13[@(#S1F.FV!Z]&>WRFA"=20$/ZF"(J^18+$P
M(]QRQ0H'."%' N_T$ .4BX8/>@-;*>)BR#J ;S%>!ECLAK^F)V:A#/=8<8FE
M,,+)^#2%L;4L51JY&Y57E64?PKONN:,)L@X*3=5I@H14MX#V9!N>I67 ^<%6
M\)UA3IQ[%0FTVQ *C_BSSX6MI+#UVW-AZQ0>Y5=;V)(@'UU5T:\/]K>DF*9-
M@[Q1@Z0Z^?01$V'5VKQ=Y/1]U&-#D(F(Y>(':%(2+! R.G4S"G\(A1C#,28(
MP?G>-(2I53D<^+2> F.H"@&?E.LX&MOG_37_LW=JPXJM\KZ$PD3US%X/LP3O
M46;4ZA-;X/"*-^5>FK_)$2;F7T9(CEO8P@,QD>M%<,5"!*EY(CG(;@CYP,_-
M78.@?0VQ\P4RC'5U?4&1*4I#I&%,(YZQVG0XD\(%RSAPZY),?3HRJ$F(,\:L
MYF7;]/MN6/#@9((RN ]1DLB^>SC5*A4'HX#&'$LF:IG,/TBUP/E51N]#HI5A
M,1/14]OO(B,VS?V/EXMO0M!20\KR[D@V#J\>1>XM.4>I[]'CA#ET?%2.;#!9
MI4?J&1&:Y=<P/1QZ$.%^ERWH[BBA0.X(16TB^SNL*M(3)Q3/5K)TV?(:^?.^
MHBS@?,N=7$L<'##D1FRIPDYIR5"2F1(DK!$;ARC\(S@ZQCLC##\Q3%3?AB,,
M!MW6#2N;4_FT0L((6$NLS!^" T2-9"T;1'?YR\7+B#/D%-B#)M3O93>ATJ*(
M9(Y9$TYT]7O!G<HX;/+;NO$\WO,][Y8&PM//W3J\!"?M#8 ],#CW=/S1%G ]
M<6V^Y3 XKT:"A'ZN&2H5/D%6.4PDZVE;/R/L,/>]#!*E?A^XW-C]]0D56:0[
M#)N.AOGH>PRK1$[:R57&UK^P$=&/56XXO<?BPA&O_.'EOC1S7=4\MYF+R-DP
M6Y!' B0<)I1%7)EW42D<!POQ<256.2'-T@J!I!K<!4_?#=%QHI19@_;4P8!E
M1T<,4>%QP*?KU-7*R$1O[EP[&'-@,H[6U17M@03D/,ZK?/^ 651I03HVRHJ:
M^T0KP!W7DS,]'*UD?&)G% AND_6EN7<G.< TZ% ;1SZD9DA.A1S(IE29"VY<
M.3K25E"-[:612/W[R>&](?<)CL"6"IGPM$+$(B_')4NMKC;,$-=2H9)<+K+2
MP]V5S W@TGVE;7H,\=]WN'<<;SY!K,"1'%/K@BL1A6=B>*^;4K)B>RN=V6Q.
MX6)Y#GC7G*TFF;P)[^.>*=]_*=J4F2[0#FPVXBR76U;255O@YGY=T.&JYSZ?
MY&&5K,[$H8_+RH\D<=@K:17^(1.!Z2U^9/Y]*JU;9C#:@&AD-7!17S<1R9F1
MG%3ODY%@L-"T=2_$F89M62%2/ NZ/;JZX;JDYEZ9\/3HTW!B,H@<NT;\7O_]
MOY?-;_Y[/$?E^O_\Q_VILL\^_8]_IY]ZU"O]ELZ4Q;?1Z2?@V>?*AO#*^M@^
M.'?[;\6UJ&JCA+ @/0!UA*+DFA>P6C7AH&9?AC:X(.FDS3_\@A!U!FS MLYW
M5(.1&X2A(D?B>+P#3-=Q:(_V0">T%!3K<T5W7,8[JK=UVK[^Z]'021V%VFI[
MJI7!Q*ZV>:D!?3(UJ.I0%W1FLV1_TPU^G4ON5AR]V*YO2X/S+#MJ$&?DSPXI
M%B3"6"8B+))&4+YL+%1V#/Q)R"T8;*[E1(BV64^QJ7#>T!KD15G^2&^4%I*7
MJ+#KI>2;(8BHMY*.$7J.>2C!MBQZ!<27,<^'%M>8-CSL]ET-M'=ZMQ")@W5D
M&WZY)B106!1EWJ@2U=J)<5PC6]P,),X45*WG[8DO4,H[TJ8/;CP[>8ZUT8,B
M:LK:3AL<%_#E\4.%[/UJM,^C T*6H'31FZ9U:.9V>Y)+_KGI%]"G3XEGMP/7
MY7+QEO.43![(U W*^\2(KXX"LH:(E@K0<2F,A\+2:Q!\40K*J)F:@GPG2KMR
MSNX&!?]BNR6WXNGOG[6+%W^[RGC<MJ+>2#W X09$C'+!HPQV39.FN 4J:G&U
M#?NKO[ZAM+OM!H5O324#NA+5&WV'OA6OP94BKJZ^:[E>+VG)B>OPL]9W%_K*
MH*HR9#8@M$UA4F40@>(4LO::AFO?]&$^VFSN'FNFX,P7?JQI793<-'UHNV+'
M4&5-/M/2)W1!.DR9%*>87V8=[-$%$L8,X?DQ#"TQW#!?QN]>/GV*CX"_,([!
M5W_[XJN_??7V?SB)G8EV$O5%""4%EM7H,'7\'(P08"LF/ OT>Q -PCPY,KH1
M_FXLY#@0-6R05$T;%'14K"$D&167$"]^W-?\='7Z"K9%A)%C3]N ^>*7)>%)
M6=V1D8]&4J<>!&6=F-.D,32#"7=$70M9;%@A37.8O,090I! "'YWAA"<PJ/\
M*R$$_TZ6AL1LD),GXA*-=0^*)\\^;.\POE(KS%2?E_U+\>.,"BMGEF7%&883
MB$QYW1WV$6K(+7_2,-,B,Z[$'61'79J;DE>4BK2FFEF/ (G>Y':6S"AV^VU]
MR*1L0_E9''%\%'?$*CLK;IW@&*/KE 4'/I;B1J%4YBVWQ_=Y5=(94MVY-B5V
MYHCL**?3/7PQ8;W=6%U_+JL##UA+<CC5J=>OT1-\X%$E_ P>4_"&)Y98/NA1
M@9^;H&8D4A[RB3[^XS.BY@G'DDC6(J;9;,LECQ88<8O2I(.U(8A#'SB==M+0
M8[[\GZ]?7J%4(C12=1/)I8 P:.4<]M!>?.O!B\P]7L;D%LSE<JTL)$+(.SE5
M5L9A1R7=<.0#NV?,?JX;S#R*!B&$*VPK;R3FJC2A-^3 KMF-ACN1T@2)TV]'
M?JJA-G+^@0NQC,L'6>'D_D20X5>=(C^MRTQFX!VU:_Q8K'I:!(,F:_3G^4;L
M?+-)VEO$@=85%GQVB>^I9Q@0<KN/*Y@!=;IJ^C)AO8T?R&:?@+R[NJJ*;99.
M%GS5#XDI=#0M^X;8#/<T#G/C-C\LF!B.,\ !RG$&*G,IGWDZ"78Y.M@&5Y-M
M14C]E#%KA$<:O8YVE#/0RR73I&23Z3I!(%V'=4?Q**&D@PWZ1Q_6-VB.?^K2
M\&VK$XMS.*8YMX'8LZ5%2)0>,_\L\0'MCDYAZQZ@VR89R[F*MD*4(3\?R<LH
M>FOJ.Q=2*Z4][]]P,W8)V.Q&% GR08!L\-H:!G&V_8==]YELY4%GG/1^T=/F
M$B<R(1RGGHA+,[Q1R8VJ23?S]/M&LU&ZWMR\_5 (.*<+YUJ@A+7#"\:EXQ>@
M6\.)\8W+*X&[:J#;W4@74ULD"$!:@5-K--_5!,[TG9;9L,TR8B%UB:(=QISB
MK;&ROPFC_$5#J;%V52\^#V]/K4#,O%L&1[NEEH&;W F;TH[&)F?E9@K$^Z8"
M1S'Z81+TX]2^9G$$BFH7AR)OVKE]?M3*Q)T:KXO^ *56&60 T954WCK>=B<T
M0*B(<*_2<K]\#"5LY<&G*H0318!ZWA(DQL'=:U"%"/>@7>A:H/)]V>F$I9\M
M(T#7OXG@"4^]-2_EVXM<)&*J /$1_)]TG9'_PG,IS6>+L/1I:[1]P^4%7K%;
MN#<R[L[A2<GZV( 6C#(&62=+),?+[8J\2@O*]'SL7&J#/_8CNE-D0W;N9!XZ
M86QBB8[VMESWE#K[$'U-;(T*O4!%$WD\I64;VUL5()FE6YFF<I&Z2<\ZSQ9Q
MXDOV>\'AJJ #O1Z_3G.=5Q+OH,*C:-\(/I(^J_&G(065*X&KU^,>AE;[OFG[
M(9'G>[%V.79S?3+FTY$$ #??'X+?D;!'2Y#V4)T+GFIN!].B2A(H>L*J+%79
M&$*Y&$K@<7,B%<HG[E0S0V1G&6,PL47[%B\X6(?\U)Z=6'=^,N?"/SR$B5EW
M I[(V+I&Z/<,9"PDW^%[-Y,W(&YT'/^R>UC>B#NV$\#B>HU*>KNG1M$X/)6/
M*P:G[5#GAYU/+YXV?C_#-Z98SU>QVR^6SCP?P<2)E5)F',$F\V>#IU,DH$]7
M_+4D7F:ZLIX1A5^B.N@CREBZBP6S7_,4%S+M1IUC^'-<97AZ*Y(E<>$D0^$?
MEAM"P>S3J'<2BW+@4GA W.-WBMM-GJ'FMG!;)47=N%!IQG6-[A#OEBX'V-$V
ML'10C#ZZD[!1F<I543$A_Z%1-S5@L2T?W)'W%D%>$Z8)-4IK@G_^ZKNO7EP\
M_:-VPB_(?A34%4W>,&?8BH',R5Z$BB.VC5<,]BHUK\5H4E-TU2"0G*2[Y@F;
M*F%[O$1M;3"^4=L8<*Q713C[3SX:HYG164A''^7=M9@YR"D=YB;":93DZQMN
MVC!"@>(6=EQFO+TIJ'!^$5Y\']S%0MW0NEFG]ER.TYLBWR)8YC8PJ_.JZTF&
MX98R7# E9#2WR(LSI 4B?HTPOTO'%Q'U$<EAIOE83KE6TN%.2BJNGP8T!=H7
MGJ^<BH_ 08Q8/V$52#70&CL'(P [YYXJ;KML.SXBBK9K1\YUL&;!JM8[#(#O
M=K,3$9:)*7)\CQ1GGY5]P-%DD+L)'FZ:V1+*Z(4U?;4D&A&%/WG#PO"&9Z-3
M.?>D+SCPZ**^N3SAI4B& @8]>'S4'NBI.[P\@3EOFAD5]H33WDB"-R1J!&._
M>=3%CTVY"U$3P0U8FNR&2!:J:W7T!EV([*=Y7)XN#EEA+F&/;*BSH_7/>)M[
M7B-AHP@/-RZIB$,##$*6M'T.Q FFJS%)46+"GJMV1' #.V)@3=M'IEPC!*1A
MH"4. YC'X2,,9&6B"7A[K_LU]J\FL9)B$,)(A<=N:)RHW^)R\8; X*A3D05(
M0*#<XBQE6CT1(P,8?&GCJEW7+EM#UX&GR2"Z2"G&2!RCJ>7JX.I N5!IW#W
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MX)3+=B[.^N+L'\[%V5-XE%^L.'L"L,NGOV7):TX9'H5Y4"B9=WD66>$Y8^$
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M9>3\T=_$YE-$*0:?^1[HC^A8N^]X%C-#]#+1J0"H%1>.=V2SE[$\^/B>$$.
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M%=&BZ[;6:Q'G")<F!6E0+-RR#O%DN^+R,. 7T!;[$K4/:B"+Z5-DH:VB/UY
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M&AX<E5UQ5S?O)F * ZC*.'W'!5W@IITT;L0ID]26R3L:WA+9"41G;2<=0I1
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MC73*UAJ1"5JR<W"_0-6!F1AEZ'42_S09;G3\YZ1\P/J&_[P(OX=% C>/^IK
MZIXH)!&]'D:I-B"O)D L40TC&I.X3T. H&1)5B]7U/1HVU )FZ+P*_DNM_Q^
MV^;NW+0!FO]QP<:PB[1YVJZ*UC#I40( O8@3J(4F[/:<_/N+.1^3K#+"$84I
MFRT,(<EL<ID5N6 >/&ZD(479@/8G(=3KIEPVYDQ)=M%J5<WX*BQG"DJ^:EI5
MG:JJWWFEH27ZTF%D6)4E$ U$F:<:C%:N)<\L^;37G%4LU8?!K2@4U*(<VJ*M
M&Z1D'\<$729[DP5NDE;_MN&C(+Z0U>&C]<.HVG]KX9\JVPX]2QCH8".\_V>"
M@$AP.'#K"EMYT/N1_ 9P:8?X93W]45LNZ-P7J_674M]Q6$ ]M&P]TXXNZO#Z
M&5C&VNDI::LP'.*PG//S2Q$E44NT$D=) ?/(UX=$KDTD"0K81BM5)9.$C*$B
MHQYQF.KUPU:E!LUU E;1F/KHP#;,])R_,(2J-47K!99;ZQU=<>'*D<KPV 3]
M2-%30D.O@201E(],KBM'LEK8IA61KS8"JA&5\W**#=E=UTHM:>1U2:,V#.7Y
M=*W<S7 4Q6-(UT2WRBI#12L%J/++%,1L5DQ5#0)8[%$]7O+55I4A@OZ6U&"1
M17,"T)-!*=F+08'%RL+4\*@PI*\8,933*J,OHE1*5._2S0.X@U"A7@/@:+<5
M2<5OM]@MOJ00"1%A+L4@0ET7*IPHM;S<#_+7W^_MUD)@:_:VSD(B2])N,49Q
M>F3HK5;@B-W-JX\!'"I*>JECI #M-+XE=:"T+)F*05]2HS24X\ZRL1[7K!&!
MBQ%>*1^DR,[/)7 =+!6V=%;$;0">IXIJ:R]K@&$8_ Z?5U_%KY#?O_GRZ5DG
M,=#Z_%8-#&Y]Q<6$')@1H]X43,S>90QHI<N!@(@SA!51)T)@)]3'$8HAHSJM
M#9O[]&A^$3A%*LJ6J-Q&,)$B\R "O4P:JPPVD?S)TH<2F&(^H< *'92"C5$G
MB0A*5:DC6M#7P5O>6B1790CQR!4*I44AQ^BI,BF26,ITC4PNA,4U(_RU9L:D
MHE L<LC)565IV-A&#7!@9*ZEH"U9]ET[M#KW><+M-$(!$>8?BB 4FA%Z9EIU
MN9#3]N2B+,=ULDZ )D:C=C*KQY"G!5_R;(J^D$POYE7250L^X\()TD\4)!&W
M ]:UK)0EL56,3(90JEB5OKUU" QUN.*<:N^UQVE'1VL[G2A53IRH[;X/10('
M'2F%(Z(ULN6/M%N:N#46ODK(]"B&/1^)T32VN1X*7>P8A]7CZ=:!FT]$=56M
M/WJHV%U(@7"$</PZ$ER<OQ*$*_+LJ7?JF$!"K.<3#;"G'FF>"U-*D,^6KXV7
M]BO42]?"OS4:(7"7=("L63%G/4/239,Z%534S?+TU69(SWCIO*K3%.I8AB_=
M5VM)7 T$S**$ KXXFI=KLG-\I5YZK^@S7(8Z$;,VH2IOW<@$8S%$1;.]8YQJ
M088>T35K- %D[%9H74![>%[5:<)[]5FH3O(F<NPWV7"Z<EYX8A)9.T;7)"Y(
MS_B:Q5^C,/Z*BG^4<M\I5$$P 8D*H[MD54F2+-A8&X=234/4X$V)O9!K*WYX
M"RHD2A'$G,@FX>#/)Y+R4O(GB(Y<(E 0"X=6+6&Q]53^'PXCR,-E1=6KC7[E
MTD( 9@F0D[2+FA>8.[(@72EE82S4]CP2L%D*0TABKBY!".EE0943HRMJY<^(
M6GK,^J(7L\15QDV3"G\+@P50,818K!B*)[ROA;BW@19U7-,P5:9+2US7L==D
M:!=LO7 N<F:,+ \L."#4\4D%)(ZH?5*GZ0#L-507D3W'<S:?0)H&16<^(0*E
M!#4\$6OD6,@L,+M%W1%U4Z !5R.P7D8?%@<X5G]0A+Y0:C=6<;P:N6DDQEB_
M96L,VC4PKP-R?E6"2=)R2Z ZT+$:93!&CRNDN;K71C4<PE\3M)IY(0A%5; .
MT;5ZTMD1KZR5X^BU5K+JK%X(4]?A3>NP5JL%EF*O,BRI\5ZG\%Y)UZU,2UEO
M)0_G363<A^@&0FB>_BM+]$2DU/(K";KEI3_'-CPQD!6)XR3#X5]0C"+-Q+TO
MH^UA,2$\'Q&-K[C&EZG%MTVEO1*>X.G9T>]$U2LHQ?#;*L&IH!LQ9\+T=2-#
M1!0T5MU#RO^_L=ZL.N5Q6%X8Z2B_6@,'D=]GR1_/,OZ@(5/)=GC^GWLL9@A&
MXSC0ZF('/8/4JXA'G/&]>#?G<_T_X7CZQO@CCTJX"E7K\=F[/W85=(M\[AC5
MFZX1JI)F;'"!@@6YRSO&>Y(B"3Y=>=H'$F/Z1."TGXJN/.T"@O(0/?C40,W#
M.? QZ@"[4JG* %-((![2?\6OJR0%5P9<<5!(8)PG?$9T<U?%ZW)9&VDRO*C+
M*=29*'"YXS\/]DQ[:"#.WCB+!6S:[LG^*:[J54B%XO@*0%T)KU#!88>B0F[4
M?B!&5 $I2F9TL>!CJ*P1,2F8UXZAR5F<%U/JB815+ BIB S7&I$'5\MXSQ08
MW17U.+-Z(A]D"+>UKNK('."&)+<A,J'0^!-%@Z$.X *C:X+TUA:GIZ4W<;P,
M86EUQ+75!:;5=0;/H](HH9=7S*JW9&[I!YE?4285'/![0:JK"[8B \N?B#$L
M;"J3$/6U!FPM+J0$0G5>PC9#3(> 33)1YU_%"O$6H?M-()XLZ\_>F@5Y, U8
MQW< "Q@RXJ6&YHSGD0_Q73XY+^ 6>TGWH* CF?'EFM$WA2YY50_4?ZW84!HZ
M15[ST-$Q9M4=HN77,<9&1UX4J-8%5O9!RKAS*ELIKHC*!)M$Y.L%.J. F$?S
M7M<W-Q]EV,$)N](0$.44<.R:7GER=_EQW7P!'PATB#@IB'L 1!F0T>?K=J4"
M39I*GXD@O2IYD+70<BWSA+6]SU=6%2+!5%''596.2B*JI_F*<4^(@AC@?ZF:
M-7&/B3@Y&9]XFH7FF4#3KM !PE.@AB*DO8HO,G99_0RWA"L7T8E%)[HB3JB0
MU26=AU)C-%RH5,1$BA@]G7ZLS! ;B7=!F@)Z24,1DF#V1.H/GC3+1N0$U1_*
M)YV!,0\%!U-,D"0J(1$QKI:Z<H%:N8#?E0NT82@_1X_IIX;!)N^LH^,/9:7H
MR BI[!^ 2,\F$XS2P>E#3T.T9TH]05\4VAYT"AC:4JM H)[;(MD,FR"@R6>E
M78G:I#8D+"V^82B.!1>_N& :5CP9J*<"3\$=.-+"A@NHUW34YURE05DQ?W7C
M>E.QI?KMMH*N +[ +4398$;MF]H,FA<B%3G#3<%7#%G_)K)+A/MQW-"[R*;"
M6-H1GIKQNP3.XF9*?7*-7Q@Y!*9%:ET! \;S\5P0KU36;$KH9TATX%O4=#B9
M02IDFF=:=)H8*:L7@0DYH1I6^#U^#/2/HEKAO,CG4S0T:Y]<7>3P#(0N <RL
MF>'_;\H?:R:>0M6@=XH<=RC+^,#N9X1^1D@0.\8I]>\9Q7PD3 _"7:5C0$F"
MRG$]6(8RQ ,1_W>>5:&QW<DDG,ZY'TNNW (.?Q]K\S#*.L98,)7:"LL33ZYH
MUZ)#$5:(T!3JUTX)GG'$R%Y.:/#W(K\)?QOR9P$YPVA1-99-!+$-N!K4MDI)
M[WI 4%0 \KG<.++ZP,"17^-G+1>5JF!-=981-63I3(8(3DG^F9#&]RPJ$*&>
MK^V =NNJ $J)B6ITD1WBDM(M'X_S"9V,GNK#%F=4QO4JH6H.0DQ.?%$^7(>M
MT_RQ"]8X[Y*8M>T6[&ZUTA09J$X"_&OY--#.-W0?%)2 A93(WLK*J\13.M:Z
M0S7%)O>$[$$P$DF[-E4TG70J)BUE.?FL3AX +@B,MK=JN!7 7(7AKU0'X<#
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MWQ4[2$C(HDE4%=JJE10@E+43A%=\UZ#RD*D5B1RK3'T$#]32O*)9/1J%DZ]
M4!1_E6WJI-(0.87,B)IM61-7.#/1B!#Z,-:F#.<ZWS/8,<1Q D#RFE2JYH@N
M3;#5[=>;8V7M]9B0P%/!MP>Y?P'KT^63'R9? XW#DJ$@!T -??&[A=[JB9<
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M*53?JQY_X:S=^H\&+BJL7C(U<*B[JO0>J+(BH]@+M*Z4JBA+]4VM2 OIN2#
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M_W.)[@]TY\5H 62_R%HQYE\ /@JHN0;.W9*>5SU"VA"*3(3V:8/]J19$<8M
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M=/@DXZ-APA8)9Z^-E_8KX9B1DB'Q0)H\7?;PY7"]*(TCGKSZBN6/?^F\ MR
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M1GLGT#]8H!LV_# >.(GO1=QQM_K<AD]<<QA%L9DD3CCDOCL;A#ZWX?L]Q^W
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MVQ*Q_CE9%LJU*)<=Z<*C)EUT^-%]W)!.96U192WS2+K]R!WXZ=#T;8!A=]C
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MJ%Y?K *@SP>IG"2P-%RGBV>J4XVII0EI*P7B*BKDO-<H<!HUCQ*,M2SE &L
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MAZSFX"\[P9#3#@.V6"<X3TG*O!OR!5MK\U<R35/[\%?](@9D853V..9]DJ>
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M,I\;-CL=L__FX=9(QHU46F/OB$S<2F^8B9@[1T)RF&-[1*C:F'SKI)H\PQD
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M+!'R/BUFF9RSD4>.%,O5ISXY9$6NF)%$@NO%*'4&(*^-)5MY!ZQ$55:'FMQ
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M@Q<_OFU$==@'\?W5&9Z<]+MY%O.FMRRUWRS )'C"^?A!FP=93O98#EHNMOP
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M.MD[A#$? MWZ?;_SX=N?G_8^_GVZOWU,]T[?DW]_VR%[WSX=*6(I"Y0BDUQ
MW&&++-4"66VEDLHIJES#G^OMIELY)A!Q FEQX:V0G KCM-944$:-\3X1X+D1
MB.Y9MGS5*.;*SX&O.F<U+P=(&I[$EAL-8,T,!JT)41LODSF,@L_&/UW+LA'1
M#W_^.SCP6%IOLU>0'_ZW\8-/GO,Q>, XF+T5@'Z.3EN_=0"3_$D/?OVX$P>
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MJ [5G_2[V7L8QZ8G<9"<LLZA\^997K3>7O=4XXQ +LYN0ESU1+0^CL)QPPK
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MU70ZIPUDIUW%;@[K3&L7_-[5\-V/]J0?"ZI,*Q6?]<&3+NJ_IS6NIT045W?
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M &SU,8'I/G&*!E@;8'V9P+H&N-KD@ST.KMI97,V)R QG%FEAXF8L-\A0S5
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M,:(0948[03&GDFZ\3M"6D"49S'_/L+Q9S31.9I);['5FN&!6,R%8+C070('
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MOIR^A_%^RO8^'UZU3]_R0PK:0_=.]W?>7\5\6KCO$<RA-5891*A)F2 .W$X
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M\@Y?+BQR?+/I6_]?F-%8(CC>O-,;52PN795L?3F.-4>]&0J_62-04026K?O
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M:"E(ZC_OK,/TH'%9O):TPPV$'**^>QU-](C7?$ /Y*4:D6_%'S&@8DPVX,F
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M C;F$1=8(2L203+'.TCJ$LFUX/1X@N[\%^FW4 ?SRA$ T'%:^ZW1*D/<QGJ
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M' &G603+6.?>8)PDI"WQ&!>KN,\[D61FIO'L%+2*&JVB1N?);9^&E574Z.L
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MIA*N!1>NW<V=0VJ#TS(RY+##L C$A)S0%'F:#*=1F43URCI=NZL(Q$"X5FN
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MEV+I_*O?\4>@4+6_FO RO^7#<E-YBM_GL2A^)>__62[.PSO!$@SJ"'=ZG&O
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M"XI1SE=GL]'U,%CPJ>U<W#QHHQBP9:$@SXYD/^O?#V%*J"8*(Z:- B13"5F
M!>09H;G(7[1&9OHY'BM36QCF68G'7,3C8F?CT+EH@4%9E(0R"(R3@(P/#!F*
M/<WZ'8/(!'6\,%]M<DV^"9SNKD5LL)APNJ;R)MU9NUO4U'I7)+7"U:[3R/)B
M<^/$@;F/KT^QKMMN]GMWGS*64?!":V;VL=]BP#=^/H+>*GI%;X\ZU]D8WX&F
M=*(]03;!*[ZSS7-[T5WY_39U -XP,O*C@W;GT*0TMZ$I74\A.ST*L7E7K/3Y
M*'@FNS#/4COJ9(S[QZ_G2 '1*=(M83G/H)09Q+]^M^N3YG_A3!2"YVZC;+>
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M+RVQ3N$Y]1J<5HU>V,5706D%I4MA<[S!KE'/B*<CGE!NI$JP%B(2P KAR01
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M_0[ 3RQ/N-E@K-_-;<?@K)L-H0<'K]6>K3G>6)[@1BO\Y_J]JKYX>R>'W,*
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M\%6I:-4+]76J\]P81Z7.\U;G$?JAN-16$8H(IKZ,LK+>.!2#,:#-(006@7Z
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MQR>7\/TA4]X&23%BAC/$(P"6$U$B2BSQEADKM5JD-:R:_5G.ODU>*8P=4E:
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M/ -HL<#/A=@A./V4C0X+5JFA)SNR!WSOSEQMC$3%QJ?;9IU9,/[X.+<:+K5
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M/?&9>.MX]'$9=Q<\G,CG7*52.3,,K=FJYBN>^'!6W/7]LTHC/.NI[ZF P D
MT6H=;J/#>4@'#HOU2,K@EBVJ&N5&#5H]\0*;:TZ?.:!"7]BG5]L*1[+%Z0?%
MT:T76O(('028]E[]R!PS!-%X3/WIVP$Z_&@8@M[U!66;^N_(3R!^8F<#G]'G
M,SJ$UEY0YY5.@U_.YWHZMMVS!62W 64U!/LB3R/K(<OU#93L_JM=;=4;S:9F
M#O3ZL$KK9JO28EIU,-"MX4"K:O1;XY?/CS@5Q$G7(&]N&"PAVL5I J/R!&,*
MR@*:LDRM $9\BB73PX?&G0$R#IT$["+^QR?+#B8.G5[8+N\??^B3?+V<4R@N
MBUH*OR<N2TD"[5'EKFIL7<L/2SDK<SF+=<7<M4:YV5A]52OK[[Q6J]3>]>2Z
MME;JY:IV*HUME>M[>&NUW#):)X* 7BG7M?>]]O"-;93U=[[U&**EU39KSX8.
M]]$3"BMOU9OO-^;V<YY\<X&<&DO-N=YM^ZY_?]>_?.QVR-6_2+][W>UW;]O=
MXT=9)!E)>H'G"%AJMD5B3$X*Y^[?7WI7O<=_#OSSS[=_?+WJ]G<+<![!(IWN
M0[O?NW_LW=T>%BUYG1M.IPWE=>^F2S86N +A<M?_NCD@ZSNL!"X%; >81 &K
M&.2X8-WW[_[L=;H=CM87L&C^ZCU^R?$RB[9*\60V"'2,%$]E/L739T'HVR8N
M6Q/9GLM7ZEMODSTK[E/)'Y7\4<D?E?S!Y$_E^(&!$P(,N+FAJ+EXU+SJ] J]
M_JT%,C%7'WCYEES0,U72'4\<;\J89./["#Z+*]C7KI)4+)SG'5V'.^$B:YU?
M?HA%T5# ^E7JS,8M$6NJ;0@%).%5VQ":R*W,GFQ.P_^.\ !N^ %$&[XHW6+%
MPH5E8;430>U$*.\I())C&E8[$0I(P[-#';1JK9XZU$&O?@,N;FRS&6'NZHJH
M]%JZ5JPL(M1ZJZ%7M@GEG4"_E',LG>/B!NK1.=XF[Z)8&5E9)8\5*Z<CU,#*
MK1_DC_]P[7#C)'+JYLTY6Q%UCMUGQ=.*IU40>UN>[BB>+AY/RT5>5:.IU:O5
M<ZMAM"J5FL6INGF(55[*GRZH/_UPII\?KI9QUGK_>^1,B<%/2]J72WD"*"!1
MJS#WMD3=+2Y1Y[:*:)/-D^T]\X?P3PJDN(%/O/;N3!*ONE75&3T=E=M2&C=W
M&G<A!MD>4?>)$=OE%5!\SSGE0]Z2[M'3/G\OZ<@#@RG!"2[A,^ \PKXS,^+L
MY0V'P(=^0#Q@.*0YF"?(=>  L^';^Q3%9>E617'']L,TQ7&GS7$_M895:]8J
MU=G10AH>+<2/V-3G6;(''QV[-BA0NK!(!G6Q9?O,##U0P4@[;S6S"N?E.>M6
MW$6K>!B0T50K5M7)YQRP5KFV,6)Z@;>.%)YV5Y[H5W<]]SL;3QS!OK>>>S;;
MJ]F1),M/YV-N((CXWG-L<UHB;#B$JTBZ8BE 15?G\"GJS>^8JG/X1(6>3#/O
MJ9QRD[!R#.=1[(*KO7Q]P^ZGS9$,G(&DC)+,&"6-G1@E4U)3%HFR2/([ILHB
M$76),FV19#(68*A80'%I]TT9B8K#/)=-:!ABY%S4DD@5@NC+0A"RB!./P:\^
M>7AY]0E\SPU^A=R+SWCN_/'#OT=P392E,S1%V(JP\SBFJN3$C()4]<7M2;O
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M>1TQ>,8'T;!PKL%48O@>OD>3OPUK1L^F[ R6$K%]L HGN$+@A5_';CTQE_F
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M+[>I"@L#XV>M-\7:ZY2KO+;/9B^Y3RDQ(T"W@T0D#3;WUU]+,\.\0,R G9!
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M=#H])>)IC$75:S1%*GO%?.:4=^OT82Z3QP,/9)CLK]%KU<[+::WUL]ONED_
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M=/6\7)_1KI:_R7Q HAECS5+<\L:[X.V/\'GQ=D_(?_, W+-(8>Z;LM(ZJV[
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MG0S:VSINK\N?"UQ!&\7B=+ @60Q(7JNQM.9&%UE&5V01WEG;1^LWPAK2VM>
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M,E2>A-=@:Z9<D=\OE/&^<-'I:O.['J.[WZO]'CY)]R7!,)RP[X/V8KSX-%O
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M10&A!DV!&G"RH<HGBUZKW*E'XM80=ZR\ZWONZ8!,VE-9O;GT?'6?X,OI24*
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M99_?9^*! C%>>YNU2%'4\5@?R>GL)4D1!YL4BAFBR]%%28\KY_.:,"HSY=X
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MQB%,KF?#M^/<M&?==NGK(N(*?4;NY^YN_]+M>R+T+/B=5@DR>\&D3@)I(G&
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M$=$4CT)%XGDPA"E)DX&LF:I3V?<0JJ.C4F\FJ!#?7[H2[_/R;:]N<R,Y:GQ
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MQA52.0),2YTXS536.=7>A:D?:RQ7R=+KZ+3W:S#^;#Z=-K.)'Z?2H:B9M5.
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M(D8I]- \<!(2 Q*]Y=91)B2M%&4\PV+YK1:LO9C\,(OEF>;4@0_$B-*[W^#
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M(!@:A$"#4&@0&FT$0!M!T$8PM!$";81"&Z'1<  :#D'#86@X @U'H>%H-!*
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M*\=F-,<(5+4"\BG(/A/GLH6DM+9 *4^VIX?@ YOTFO6Y^AB9+0+O>Q+O$OD
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MQ&8-%R3=FR8X>MQ;O@"5I3S:5F$]'AU?8Z0\NTXJT3V>/;_&I=[TW1_WO!E
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MK;TG)CSM>97T.V$@]*>"JHM+\52<4/:!,05O#P8_=PC>IR5V-?9IFV]%=_9
M.J,LH7I[E][/";IQ4PYR*PC\T<ZX-,=1<$WG6X FE"4C94VQ_;>@(2VIG^%V
MO7>?N/S'X!\G2ILLG:Y2'Z:TN>9I;UD^N@E-X>>/^Z"?"=>[Z 2H%VH=QU6A
MG^38P7O/6YEB2C'8'47)WT7&>@':5__:<(YL?[";#E$]J@SOJK3\A XN($>V
MDKV32#M1V%BM%E*MA?,4J64'GVWG^B^IRT)4A;43<+\>4V(D+!W(C^X"!COK
M$MN:%A3K[(5 3PU]2D&?WD;9.[@\TG2G@Y?\/_[^<(D4R)?>^L"UR&1/K.\H
M1"YT8&A^'\,IM?I9)<8G3 &:].TI:/J!]:>\JQ03F:];+V%\ \8B0._[T^ "
M_BES%![F,:Z#R[LQ2["*K91[FJU.Y9L;EV77*9WW9RD\.+*'#M7@G21</Z&E
M&DI,9<H/O&XW3,""L_8Y_39G].%)0>[BG2V5E,G)/O:B;BMQ!WXDEKN.PV8U
M_5$+]SX(<>%9_^+M1RPF4:>=/6KF R/Z:-ZRC_$VRIRY?P^=>2,1FN]>?IV;
MUK5M 'L[T ;X8R&2^XS"]*F(_C Y!Q[]L"!B2CK'HE7;</"9<:<)2PQ1 ;ZO
MU<DZJ\]2\)'_R:$JO/37XT$/Y_66NC8;Z\U!F1SQT0E*RXB<Z28E9FG 2$]
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M0SMB5*6+-;%:--*9/:L\P7FN,G<J+3LR^;I%IN7@%>")!S!%Q\'"OE'+>T/
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M('PN2T4,7QM2TR57^6T6L+M8$%>K_E'BD>\8E2?F^_/'(^1TKDPE@]_#AQN
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M%#\51@A3QD"1RY]$OR_FZMHQQ6@RU>AN-+_XKL\URIRN\Q:HMQA:Z0A\J45
MP@E":'MV<D2.5KY3[&5Y'G!2&R<72;URH$8[&<U3HD5N*Z6H6AH:F\\$:TKV
M=*?O"V:/^1M&%/_RNW%1E'VK=[A.4D@P*R,3UC>)Q*$Z9<GR+^&D=KEE0 6M
M"R)CJDM')=I@S;3LJ][#PXN(R)@?/+C:AC'T*K=\Q2A!>=^D:8^'2641N^:L
M!N$"\D=']I$HO82"LP-YL&(NE \<0A'"+AA)T&D-&\Z8FU$?8CM6!:U?J&<
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M+\=7/RW[*^VOPCKH&YW?K=H'K;IX;[6Q;G7OA?4$VO3%;O5>W.J^;#/0N#6
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M0,42J96RE858-/IW _IX)2L@0DM]YDE T5YJFP[TW*D:9%H'I6&JJ9U$.L.
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M:9=;<[=HQ]5"K7%;8U=/+9A/K]4+)6%2',-]P,<_P?: O19:H4PW3TUGLT]
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M]H)"!FU!#1=7%C?<I-C"R*T\,0B/.,0@4R0RHL&9Z%.X[7/W,%-L,=-86]J
M*>XR&76%[PV9*9N&  :GRV*<OS6/N=F:@5J;>7JIR[4U7_.HS_EVO9F;=]<G
MP^  YBZ'F+E%;U/3)M-_G2@ +;,XCUG6QE1MR0.]1?PHPMH00^NL"V@?Z7;
M,*4Z ^@&QC=B0<-3\VPQ?$:C:=EB-]J[-0Q*1YI30,,Q@J671[P^(\FE(]-K
MQF5LD5!L5!BQ<SMO0"I0>:[V#0#@#"#8O[_U-?U;D /5:-/9@Q5<:(7ZP,-\
MP+]<@YDQ$MCY:EV-1<%.()SP:[2Z7QR5A1.UE3*.(?[_N<C]_"><B632S.5
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M%'/8QQWO3V7V59YF^89>%FI19?!<,3 S>,^,0:^G3"FD(CNY:;@NAD[R/9H
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M?;Y<?(K-^I&3D:69]IFMQ";! 0T.0+@H,B$U<KH,FH"X<  *?,%_PN&WFH
M$U$,(KP,ZB78:1"5G*2=3?LFC?\+U)%]%'\JO,*XA!A+J#4AF=D!?[Z<L9-
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MQW52DX-2K6-<.EIQ1K5&95K7Z(:DU!S.)4E?ZA=2@40R;?ZRMKZMDIFR0C
MV"!U\GAF& 0FS#,X;)D+&P8 GGD#KTQ3'CB<80]MY%-8<LPLH_-*&,2@IBAB
MSJ\DK6?BX#2]]=J$G(6BC5ZQM==Z<NBUVHI4^$#[7P#[ID$$^9O? (I9ZPC(
MCH+]5:G<F*O\:/\GHAZ5\$ 1_$8&,63  >:P&B,HDPEZS[T75)Q*:U(NE4XQ
ME"--L4J4X=6E -=@:.E7663I7:F =Z@D6Z53:IP6'\8XN,7%)2R+V$OC9I5'
M7EFF5+H*8[LH62Q23<86 ,"DI/X%RV;!K<2R8B3N+AD3 , @B\6UUW2^)+TU
M@4,:<.  !/@@#6J%J8@W^-IH!+;#>^8S1#8\X ,&:U@'O:. )@Q:7N%Q&?10
MQJ(E;*H%?Y2 ?8M?8A?99TR?L;]]%6<[/5E2E[2)G8L1E&E#^"9/ RH:).P2
MCWA<9"#O+JQ#!NZ2;PLZ+$ULJ.,U+I!DV13P-OF77(T!DV/ U1O8<A[_ -#"
M++,JCS%'PK>V[BU7>MM*L3(%RU"24LJ&5Y044;"UBEG9B&OR!@149AG*N P"
MYORB%]G79SXYW@5G<L],YUO?'-U;9NT6C6,Q=L_+&6B"'&RJ#ONG/XI>7_S\
M:9W.;GC?$U?6A\T,6W=Z+\5=O%9,O#7&;BEMXX4*Q0T8L=M>$K%TU<XRO'3*
ML+*<T-6EPY%22=9+\>(\O%VF2[Z4?$*J!,^ZRDS*#88>%0#<@$>1 ( QJYNN
M@Y',UKJ>^G&I;J:IA.$&X3212M\J3P^)FV4FP4$. KIN'/S@G)Q.J9T!.Q**
MQUVP UX.IZBC:$4>--+[WM6A.6Q'BZY[:@.1_[C<#:\IT;;VKJ%F+6R[WMJU
MGG:UH(Z\B&CCU<_-A7,)F[$NK0VZH=J\2P)SI<FF'M1>V_+(.K4ETH<YS$68
MJ<E<!0 RL J#C<V#RNS(AU2%H4ND]LN6/E7V5[?\EY)5R2M<#<7U.-GI,Y>Y
M)&_  0(1&ZP\?49[8O>X!ROW$GP?7OSX/*S?$ 0-1\_1T'*_K-\S?9 Y!AZ/
MOYHC91<X?OP[**0D5NTD5?234\L0GVD[D>N)$K.SE3 %I' *@OFJ&KDY;9L+
M,!NRY0L+W-JRM=@VE..I5XO "'28JFJJ13@#%0" ,!"+>U&R>6"Z,, *)9L*
MKFI!IHC!&N$YK*/ :C';MEYKIBIS@Y>!(I4 (R@:ET?1('IBJ<;0! 20GD1:
M!L%#/V5  ,^(*S<AK93:.#W+_S\M%)RZ0XZ'HQKKJ ZK@;3UV<+#6S_D:,*,
M8JR!J+_[,T,X_ A):KPB%*-OV:1/&PW&>ZU/XS0]I"*7,(T8R:W0VZT<&RL?
MJAB(442JH[:H<$!J YC,T['>\HJ,D8>D PNCB[UUF:ZHB(&A:[*H>*;7FRIJ
MDHJ;RCT=LT#0,:[>8@I)$)Z5T"(B; DA)(V5813X6K%O*8(T0)!%6P9HT(]&
MTX\T0 -02)X7.8W5(K5O"J/^BD-I=!;.(@B%J(>$P(^](0CWF\9]:S"!NJ.N
MP3"$XS>(\T9TG(@(ZL/$Z<,ZVZ"_.L)VLL+4NL,WD0U0 ( NV:9Y:;V: [-'
ME$!;VO^F).&8'-H7[2*,?/&I77(+GZK "?2A@$R&GUL*VC,FSGG!9* ]9) R
M=E@F,8B$D!0#J9*16&L2SWG(;=.==[D7ET1)K*@N=(H&(SB"FC2".X"#.["#
M.P@A](L&32B"-T, '*@,O/K#$L$!38"&1D._Z.";1LN$''@-T%A&D+/"_ J*
M+$Q'KHP0.ZJ:_FBP!!)#!>E*\?N5?;";Z!B6!BD_:VPDLS3+34LMUV(OHL##
MH4 UGL!*GP2W#3*I4""A:,H\NQB^T6E%B)0+';2M"F0]+7,+;4.]:>HR@/F+
MK#+(>1@S%;#,&  ZYC+!9]M($QP=KH(!X#.8(@*N#M0YGE+_N93SMMO8R2:P
M@R8P@MIL M"HMS>8#$WH#DU(@\D8&NV!K\9P %Q9M$:;&^4D!@=X S\)#;["
M0^][E/"+2^LDCO-)EOAA-$2:K(6HK.N<. <3$&'1#O@+Q[(\Q_#TQG6\KXS[
MRVV9G,1 K?A",>B#&2FZP^D9#ZZXEX8TDZ_JQX*T$O!:R%("/EPZH2\3KK#8
MERZ#0(:AM>"CR&(#4*,3@[<PP24#Q9^3JF&P':.CJ@W$)0=$S9?;F,HLF55,
M!O,RA>:[@YJ$@R:043B@*Z(HNP."-% H.Z.@%L6!!@1(3B%=-R%5!@?(!-C
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M7K5::<&>92MOH8C!)1)S.1::*TR4*4QCYJ5$=(UP-#%ZF)6$D:;2 4R' ZN
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M)289*:SHI4 :,+TXAI61>*FY1%O'2;MB^4!->])=:GXT9B7RR,'7?0W 4P.
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MA#-]"CD\.]P &E"B32!AS?K1S/;3Y\&LS\.JHO*B'V66 S2  T!H6C(#@;+
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M0,&3,1\^&)AX0PQWLQLFP"$3)8W1105[U[T\]+TH@AM[NP*C?1*IDN*JMM[
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MK])R+-<2+=U2+M\R+NER+N'R+NL2+^V2+_?2+_42,/-2,$T$% 0" "E"'Q
M!A43 1C3,0^@,2'S,2.3,B?3,B43,RLS,R]3,SN3,S]S,T/3,T43-$?3-$L3
M-4E3-4]S-5.3-5_3-6,S,R$S,_?,,6V3-F$S-W?31V@3. [S*PF"G""NM;H(
M82S0>C+GBT*L/Y:!)3@C-#;LX K$.:/!#N[ #E:G\"(A$^[@"%QLC1)O-^"
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MH"RS8AQVA'B0BC<F!,J/.^JXX>>B%RXCQQ8:3E%#J).DT$6U1G20)@!P2:I
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M/F=R7W "8&X 7PFW"^T#)@\E);NP/@@E<YFB)1/%<-N$@U>R/J&R@\*@!3?
M(P948P\Q8Q\!8RF!0"M64B'5*THW$B?5A1*"8]<2_V?@-X86M$'Z4E159G92
M]5-I@2]N1D)DP61?1U6&=R]6-55TB"]W&#!Y."]Z>#!:!8A\&(A5I511=61?
M166'MP_TX#<.0'HLPTD=<UB4Z#5(@TD!LEF$U3&M-6PHHU@>\XFA=3.B%S.>
M)WO0,HF>A31JHU8F(XJ:.'NF:%B;V#*5:">\L3-O97I7PXNA:(JAE3*YV#&0
ME8JVR#.#I1EM\XMK95F\B(S'B(N6&'PFPXJOMVQ81X8,<EO=4E.I$12)QQEW
M4'YP$!- X5Q&0'7U8 <P@B+U$!KH=@1EI")&8 0.@"&TLB.>$PWSAA!)$BVF
M,%XH@B&KDT!+XA"P(R$L1?]C#*F%3[=T+241!P$' + (& @JI!)1//B#H&(I
MX/,F?U)@VC-0+Z%..G$3)8@#^01@W\-/B+(F]D0HQ$-@XC1/+D@!DG )I&(I
M/$@E22@0*]<E/HDID9!S0%B4 D%S\^,I / &FE X#5F0-.9B#1E>3.(KYE6%
MQ#*5 <>%2P=3V1*.VCB6#J(/0'.'345F[ )V@IA5?1A5=!>7=R>':(9D9Z:6
M7N9W5*9V9;93?JE"<N=E?[>615673::':&F(;T96^C!GDW6+R[=\VG=\QS:*
M:R59H"@WRFB9FDEYG DWH"A7QW:+C]4R@]69FG6:H&F9HLEYI)F:RJ<SM-A[
MD:3_B;39>Z4)F;T7>:,Y5XVG6;NYB[J)5G 3F9#8>LN -V39-]<F$W: ..N7
M&<N ;N9'&NY7+? 7.>/VCIS$$S_R$XOG3BY!2_N7$+1RGO5&2_R8$D)B8E H
MA1*1="05A;SR8EF8$CD""CA@ U<R/P@%4;W#@ZCB ],#DRP)<0.E)YF@"9KP
M SAP "8X@P+6)]_3<=V#3C )<HHB3QL7/FB@85_281+%)?^94%]BA#V84+>#
M@PGE82'J.PF'@2N !B2F/U<)A0@9GQ3RA$=78EZI=$2W$/0)$3W:@/VV)]F2
MC<NYI$Q!#_6@F(8HAP1#5(,8EQR$9GZ(F$>%AUJE5',H_U5=6HA=.J5>6J9E
M2HA79:9JZJ5D"I?W$H>%B(=0P41B*1/B@1FN*1V 9IRQJ'JAJ)G,B$FTJ'D;
M@XO/J#6&.IS2.)RS69RIE8N,A:CMI*B6QZ>-"JF1V$[!N%>+>HJA*)K0N(NO
MV(G0MXJ8FHLWLU?21XK'J6>ENHN0!6F2^%J6!38&,B!,2AO45D&@H:O <37?
MUTI&< 03LP^AT 33 C%51RUQ8 2@\8X=0B*AH ^9 0J8\SG(D1,79QON]!*P
M=$Q0&0T8@X^J8S@5,D#+8A([ZA%)1V,+M&+*\C_MFC\[L@)A<**K<I$Z.2H\
M.271<Y.),DZ'DE\. *'^E2<#Q?^!$Q<I#50\"=9@!KJ"!P:36N(EI*(^&0F4
M/MF1W^2B&PE?,J>B(#LE)(HEBV  F@ D!!F?"_BC#/A,##FO*S65/^=B6.D0
M2;<L+^4LN=JS.$4:?VA59%I58<JF6Q45#0  2KNT3'L #5 !1EN(5+8O:)AV
M1@MX9XIF4%8P6SJE<NBE4QLN7*M$>PAF8EJV6P5G-+$Q#M!Y<)6GG"0>DKFI
MF <MP F:@OJ;1.-YO+>W=-6WROBWI@DMM*.TQ-!.U,@RFG #2RL&A9L)6<2X
M %"W2HL&:W2+?#NXDDAYKYBXD$I8J0>;TGBJOKEYJ/BYAAIZU BZAPJWGYBX
MM"J)G,?_&: 7B8'J5[X9N,%&,CD1?)]$AN(G%,WF?^&X$_>'>$#1.$VP&8RH
MG3PA-SR!K*O!(0=Q,3FAK3>1?;%ACJ"!8ZX3.\RD(3EZ@"T;$AY%E2=1$DC'
M@.L*+,!B+":E(V@   *1@24*A#W8GQA97P]77PPK/6F2/ B;)]P#*0FF/?*T
M/=43*"$9L&<2*0]FDV+B S-G@_I["5_RGT*I)3^X)2&[KRCZ)4?9/A8[*DWY
M.4&ZE3I[OESI/U)X+#EK@/798NY9OBP!ACZ;PZ($%$_AM7':+G)Z+R*DF%]Q
M $Q[Q$W[AUJK5$E%,$UL5&;J=H2(I4Q<IB[!+OX2ME>ZIE(Z_V9;/*94=696
M!J6'IZ3*< !Q^S.&FHMVBXR<AZA[.S*89[NIVHMS/'F]*7N<FKNFN<=Z##3'
MQAMBT+C#R+G*4+B-FPE*.PQ7$P-**UF5BTFIA<>\"\AO7*A]#,B<:[O*2(Q^
M7,E^B[ANVWF:@8R3, FC;(J/ZIDCZ#*&?#*2#(V89WJO2&JFJ8N\6[=QF\N5
M&,@J T4&<A,]%KS@6%V[)1.,8P3$1:V(1US3THB@$:U&4!F=<6[,ZGBS\TA
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M:NY/\5JM/"+AC)#=ZQ-=#Z^0DE.B?KU!XS>JK6M5T94\V-(-OBBJ7#V1:V#
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M1,>Y@>^A.\?93L?AJDF8,%&+/V5 &[9)C:B*@4S@*O]10\7R^1Z]>XV^XZH
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MFG&%1(A8FM_L5E4=3(EXQ+UL&J/1A!C8@CN4N.75F5W KI/#F*U8+N=""JN
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M4Z2DBC)<X$%H@JJ\3\JA7 GNX)-I8 ^2H ON( 9&6)&=H$4)W=.QCA6:W#Y
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M6^U]1;7<615)IG'*(K-81QLBUF%6YT=)#1E.R#T69,/9XVY=W(E$5SVRUU2
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M+_[QE:<\P.4;7WG&;W[PC9>\XS//><DCX/!^#SWH0<]YRZ]>]9YGO>$UC_K
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M^1FC@\9G2>BQ>!8:19.F=SNW*UWAQ7S#X4#=<>,'\MSI_P$_\ 5_\-4:%'Q
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M-:K4J52K6KV*-:O6K5R[>OT*-JS8L63+FCV+-JW:M6S;F@7UYJ=0H$'G]G2
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MW- R8==8>WU%XZYT)[L! 'QKH[8_3*]5>.&*+!5SH^)*S40A8K]=:.!_RP4
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M;E_[U9'-7?8PT*N_GIIO0+\AW3TD@+*2'?VL5\#SU6]FKJ-?NIY%LUY- AH
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MF&!)< &H8$D;G-6@@Q,6!)5!T$P2VVC[0!?62LOIE) !!67RFQBX[2.9,L1
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M   ' )  (   ! & 8  0"@#" 4 D0!L T 8!M,$ ;2A &P[01@(" (  $"
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M-ABJ#85JPZ':2&@  !H @@: H0%0:  <&H"$P@!0& @* T-A4"@,#H4AH0@
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M'Z@5?.%F#"V9FI@I_:[L0'AP;:T5Q-6N%D)%#AZ(IRGUXU6^V_XM\%DLA\^
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M!20& .!T41< 8@ -Q@WV>@0-3G<,Y'1F_L(2C^1SI?1RO2AO+)$A,@$'4-<
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MZUBLD1"-9;A$6$:M[U&<[KA^ 7@?@#<  ("NZQIUF[>M3K2AURUZQW@1!S*
MRWKISL(^+-FNZ=JNQ8"+,H&ND5=98V](0A@_?MA*%T(,CE>#"\)LJAA8A,F
MS[2OUWH207='WAJ'MS@^J^<##]568A&)G:EGW\=%*DSL#N6)3QOB,H>M1Z:U
MG<6ET3JU\1!W<H<NA>0L0/NO]<9PEOM/;[OSNLI4 C%ZHR3>%(3-I"*LZV2L
M5W(>S=H.@WM!D&>W2=NYJ08-6!D PN!ZC_G57$>U6]6S_Z^X\IZXR(P7#62[
MMG'V37#;@6DM$S#[=(57$\R/E@'@!O[P(#+A=,7  .=[V=X;L/<A#1@<9[>;
MYXZ8VFB'M\T;BN%:N'T'OFWTM\7$KV.;MAFGBQTS5#P<M4MNN8MLCGW;*H ;
M+D \>;1$OT<*N=^8F@MBP\O;1Y\[__C*5Z9[,53$NI/HJ]7#Q/4R(JZ&H_&P
M(S!&FWOVFB'"8Y\&.#<Y%NG#DD,%&@(<!WY\Y;C,RU4(R]4:3G 5(8HR,.D5
MB2B<>:%"&8#W=(69'N;\>FN<D-Y)&&E:)[MBSU,MD=C78I_&UYZLZ^ <GD?J
M7OE9(CP3HA<M4E#O8(GH%S]%S?\G29$AUS)W<8SP^9U_Y$06I$NNE9@V69>=
MBHC8_ A%'5P%9U[=?*.O_)Q7G5:VW#3%&WH.44_8HD+:AMZFPLEG?>R@)>A"
M/=72Q<KUQ+815]</@AA2-[&/E]%A*<O%:6LS79&EI:8AQY,!();-<57BT]'U
M)*25P9);N7D#Q,#)G*WKP<"O=\\NVM6]G2M\.4 (_<)C7=)M_=DMG& D9M>[
MDM)IF[@P$-.]1M.K'*K'N<W-?<K_O<NE'>!1/3KI)MJ'V;B\YM7?12VK<9@/
M[=1I1> ?7<NQ^^#!-TT'TBIB<-BQC,G7@V#MJ\S^BY%LCT0J%S!37$!XU,;Y
M&]*XPKO_#E@ON$E [EP3E$89ZAK!]P%UB<$ ZGH?[AN83U<9 CP&,J&765D,
ME(%IM#YXP1Y 4'<8#D!U41=Z4#<1:Y"5KU?(K)ZN;^ ^)N%TTR 3OEZK#'RQ
MD4CO3_< ,N$_ 5]U65<@VKT>+)G J1X E&%%J/W 3X88[OP T& 9IFRT&?V$
M7?J.A11Y;H:E(ORJT5H8_=="F?MKBFJVU=ROPPKF<Q5P1COS>X?1J=OT@15Z
M.)O/.%NZ_[+%D9N$1T?U>;_V>_4O.C]*C:=H]%-I_'J0&6+.+B]4=F6;@^R"
M-_;F5U"Q *UH6&;UB=_D(U7HH?CS:7 ?#EO I?[UEPGI#UEZ__,&;?K#YU=[
MAR>\KB5A+-X/166_=P "VCYZT?0MTQ>MWKZ!^P3&   1X@$  2#B(+A/&<0;
M"J'5$UBOX,)](4DB)&AP9#V#"%=&0[ELWTL< - T'+DOIL>%"EDF%,CR8,*%
M]!J&U/<QH]%H) 4JDUD4Z<FA+ZLJ]8FQ9]*#2CT*C-DU9-250A563>EQ:DJ3
M2E\:=9ISX=.G;J5:/5I6(,R61)<6];I5[E*I PN"%8KQ*=:A#.G^34JWXU9]
M#'V:A7GU8-F^'@M"7MJT[5B$:S6W=.M5)LF13\>^5:I2(,_!"G':OHT[MV[6
M^U(R5;Q2IEG"+N.N+ER;X4*P)N_V-O];NV?AU4B9@NW)E;KQZ)0)EJ1W ^+3
MWL3" \"Q,.)$ #?VI8$X*2--BA$M1JR(7F&F^A';$U0/40QH0)0)4?O5Q)9P
M&@%P $E#';1@ +V]!\!#]%4XU# 0I=';/F+P!X 83"7T(7\QD 11115Q:"$Q
M[A%8V(  :++0@?7%<%ELVU%6$G?3:67=;)2-I]5R0FZFW'5]K15<0DS5]AA/
M/ HGI7-(4:E=5L\%25U24/+T)%&&26GD<5%=1UE,C 5'Y'-E]F0E=$*Z]*63
M9AI%IH-FCLE6CV1J6=UVS\DFW9M(P36>G5<>-Q=/J=7&7&Z*J7E5D\,%5YR2
MR(U45)G- 2K_9Y9A!JKDD/L00Y$!!69DH4V];<;7G4RFJ5IME.UD4FV,%3;K
MDS*^P=NB&)7J95]Z0LEG/10&@,9XRLP'0&N:6*3<40[>6AQW9VG[)5(4QJ>0
M8JNEQEBG?O**YK%_CEI2J; 5*:AEQFIZ)IEV?HDKIEBZ!.J^'8+*I58@&7LN
M9@G2^RJ9:OK8YJ*EQNFO7746C&>"!2?+8YAL 1QO4MH9^EFB)2U:6Z--%6O<
M;BJOO!M8176Z\$EZJCD67'6555=@X[;;74'W)IQ0STS^9-QC MFI' X5\;=T
M)DS1=V(T+DX"D:LEWO 4&DN+J,QZRE!&4P!TS4?C/E#/I4Q%8F"D__6,",5%
MT((Q,(722!:2M%]%!2IC'AJ4@5*1) D=*$9,,F92U($Q*!/-X4Q-8@"""RD-
MP-X6U?90 $C)_=2!:)AK551CWGP:=3'S^G-G.74'6LG">3;5CD':-:RC<>7\
MU6RJ<X72S[X%AQECD<'>5G1''\5OP*6?6;IDUK&>^\[/HXME[;0'?#SQD=E.
M\ZO- PW\Z I-QGOK.)6O4U*X$GTM:BJ[G*1P,K<+U:"B>>]DS8+N+K3OI_MD
M'+DMY#<3D<%:E%&B$#&N=PB," X*Q#MEM*U"X!+(M-A3GHUH COZ2$-%##")
M3%3$)G.!U@'$H(S@1(08$UD/ )Q$F8@PSI5X^[#0JD3B(8K<("8+N@$QYN/#
MHZ!*<HFS4 S !95H9,)" $@#X\S&'YM0* WZ6,\RHC)$'"@F@PR:Q%,"0SK_
MR0]U?N(?0U3G.A@F3W9QN=YV<H>[_?&,C*,Z7?#2B#Q3K2E[;D23G9B7NCG^
M18[3NZ.8VKC&Z_"13?N"(R#]]#NA+2PTICGCN9;#NO0)9'T>.XK[6/\&RE#V
M3#7 H56E,M:Q?5%&C1UZRDX( []#X8DRL[J*FU+3I9YA!#P@BHA-5A*1 OV%
M:@&8Q$O"$X!57;!!O6D14RBSCV%DPCP ( 9"(&* LBG$0D&KR(G8,IZ\A4$E
M2EF&>1I"H?;(A2(G6H:&FKB0];!&;3+)W!<%N(\!)9,AYAE//_=Q( Y%HT3C
MJ2%%9$*:U3C)5M#AD:ED([KO/(<T6BD=]& S%J9,]#7A&R/S%F(71#YT246S
MWROI],S*N*4RE"+,HUCW).AY+*0Q(4S=5"I169[4E!<=3[V>&1R6;&Q$P'O-
M1H="&%<NZ8\3]<QL*"4PI<#L)M$)C;G>-9O_W8SR-QL%2REG-B=5ONY*#ZUH
M275:4:;6BT$ATD2@<$*/"QI@:='BR1#I.J/E+.@^1+P@$V5HMUX"(#X [65[
M$@(@"L((*9X#J546U*"#* 1" >K-M +P5P9],6_&#$D"?;G2ST;NFRF*2'QD
M=%H8,:5$JZ*:B2#JIJ"!\R8XI5M3R8K2?]W$IUL":7!>.AW9?K2I(NT*26.I
MOK2.3*6=^NE&@5N4F%I2-C3=Z$TC:ENT=A6D9\0HT#8JU(X*UZB$02HC8;N\
MVU85JO9KC9$&MIJD7+5-QPFE?576HY72CSAC/6]))M62M$B/4:\#G\:><ICO
M=6\U.$M926@RD0#,__4\!:J-A*NIFA=)CFSK9,^5<#"13(1+#'1=6MDBHHE!
M'B@3^KA@9]&8$8C((#4%O=L^7"NXDD2DPU0T&U[5DQZ(9'@D"'%M&C R'V(\
MY8(<*I$U]W&#'\OP2GB1J6%HI;K58,2\0:)*[=PT24JJQCM$K5*/:(4TS5#I
M2D@+EVIJNC"-?;DZ]%L=THI2DCW>+K?,(<N:Z?<DJYBWP'A\9DS"G%N&4"K!
M]T*EDH:7VS"A%$BWNY906(>6Z%S9=DJU]-N,!IO<Y!=TQ86.]D #X)_H"\;%
M,S2A#\GE-R_D#29J%D$P\I #N*AK%4K* 2*WMXFL("W!E(EY1!1CB"![/O]'
MCH9KL5;8B:!!(6$;&T3<"D7V%$49T-A(7&3DUI!(9X@Q@*;'# H 'D9$# *A
M4+FCL: >$TXF,AH&4Q3WE#' YW&1$^B-JY83:A7E !/I\.(*"X Q#$^HZ=.H
M0K9,Z4E:!2Q70C0<D5/FYIQYSQI5\Z#;W)8VQGE/QJ$SEQK,D#S3,&9VZO/O
M>@M501?I9ZU.&*)+IVA9VWGC=7;S0DLGZ=-$O%97%DF]\K7IT'2ZRK:E\7V?
MGAM95@<E?);9GMWD,&,1K:8N$=:6;%JQ[A95+WI2:OBDODWQW.;*.TY+/5#;
M&QF(QR :"@!Z!O)/@QH@!FG(!$%1)&0J:20 8H#_,D2 PIEZ0#:K3QEB@^@Q
M13?M6!E#%'&V^1KX'1?ET*N!.][5/I")M$>'@;U0JJI)-XVERW6S55V]"".Q
MQ&\Z2ANK7Q__E=V.1A4Q]NM6'O&74ZYC.EV..766;)_(IA8U]I;<M"Q]3[P[
MCG(T/VIE$I.J$EJNCB&]6VY*P*XE!\U1,E-RRYHJ92\?:34I4X==RZT^2=R6
MJ5-;5^^2?B]].K'.-6A8#UTO4B/P810RTCG*AE E0B/OP2PFL0R1\WC3LG=$
M02&KTB(C,1\%@BO$,$TK)!,I4B!#$0,5X1+L-$#1%1)UAQZ;$1/GA'#,M!)6
MA'#QL0QW\Q++0"WU@$QT_]%#)'$X#*%/\:$/\U& "/)V%)$H#V$ QF([K1=\
MX$4GLB=4M%=4.1,[-34=U <J7R$SSW=_Q&,9V25\+$4FQ8=]QT>%$Z=\F/:$
MS2=47%@9^"<^TV==HR(:QL<6:;)_/N-]8?@R&B-NTT-^"F6"LP$<Z9<G4(>(
M(R%I(@$I]X=);R@^9 >('9)?.^=45U<56>%H>D)V;(%H1#,?]H81;K<02P,F
M #5",7&!'78#&!%E &!O$3(2YD$, A$Y ) G!'B#Q:,:%C(&IC(YWJ9$56,6
MV287(_0TD8,;3Q-X[E=D&_(VKYAB3#&!,/(4.! YH( ;N^0]8<%5S2$H#!$T
M+?_W9[E#,E1R%JQT=9 X'2/'2+*5'(PV+.4'2<$!9P4&/^9855XV.J26+B8(
M=!L7&5-R+$6'/$92+AURC^38?-52)F=Q:/3(+G16.I3"/.43*#NA1NY7-SSS
M<VBH&XM(D,CUB!GU.Y*X?=)1B3B3=0FY2I,6)+CB=S$P817R%!322P4R"2NR
M*-Q5(L.080BX#\G@3:2T$3$1$2/R;R'2%&)PBZ6U*B@6&BMV*OO6*82A":-E
M;MIW !7A%-YD%:]H.4T40[U4$4'V0L%A.R)4$R5!(6@0$P<2'TX6C"!2$2["
M507U91-3D>6(2+/!CZ?1DM#7CH2F1_I2)H@QB;YCCP;_5E+Z")B7T8^G^(_R
M8R>-5CP$F5]?.)C'Y9CY*%'' 180F9*O)A7BUI=@&(6]I9'(PY&,^#P?^66)
MB(B]PV9MN#"(MVC05!G7@BFY QR=V)@"1G4ZDCZTY!;%.)"69&Z&)S92DF<&
ML6.P,X'-9(0?<4'Y@6XIM!\&@!X#IW8V>):YLPSD=I=\P2\+(2/GX2+ZL$0
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M/HN\\KJXH"M,*0!UI!,OB'8[3+_%0NPHN]M"XC$\P+X#[<JN6BKL/,VJLD[
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MTG;I1T2ZSN*K*B :<' 4WM^?0Q5NSK3. 9HXR&W3,![=;L5MX8"DZ,-M^<!
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M&?_ >NHQ?NC60@ 7<B1NDSK TPIN&LQQN>';&Q!RVH(L'F<>*&^%/H#"7"'
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MAC*^F;$^,/9B?/]L-+P;;M$VX.(]08 HQ$MVKZ ;<\O$B/I6)O H;<UQ;>&
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M46I<)7+,PR;_\\_EYD>"M B;4(7GMLKN?.0?!4AVEE07CRM7%G)"0S$"Q6R
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MZ'Z?N2UUHB61<S8Z=D"B)"AN&+4Q&Y68Q[2V&J/(]2BRZ"CG4Z,DZ$YJ.S!
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M% 1PH&D@J309R,.';M(/J?T&LHRF@QS<Q\'45M3GIDPRW'"@D;Q:T2N!-''
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MQ8\BL(1@@)QH)-:$C(YR!)EI(L9).)744$JKY7__/!DBS*%'+,;LRQ^)U='
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MI,_'C@B(_!EW3*'&V!O=.!/"I(_!] H=L54Z]280\DZHWM:DB=A'I($!_"<
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MP ?$&(B8'/(#'UQ'$^S*@1:UY8 -]:@TUW( &G"R$338Y =O;!:Y?) )F^!
M$[C9EAUMPA>9W"4B:=B9#Q(I%>4())$R08Q#B#%&9?] Y U)\=M>-*(NL B$
MD6]$@$9\$)(US85C-MDD3I9RLJPL$0YXP8AK]B')2=Y,+ S!9$."0RZ/A$^!
M_C/0XQ:%0S))SHR)*X^!5#0]ZAP*G.0L3 "58ZLMFJ= [52(8#Q8N_+,R7/2
MD\YX%E2WPNUSG\<A3SJKF9H*D:TU/>35E&!E3<' CWVKPE*<0'5 4;FN),OY
ME'G8)"C<709L*O*0#0G%&@1M#TX*T<\$@U2V_YF/=:7S7P5?F!P842@FK!/0
M-EF#P*5P\'#AT=1".0>DQ\$).-![J&"< S#AI!!PR['(XB:D'+PA2'\<A:%R
MJG?!0"F/09]1J3\=5T]<!='_@.;KS'7^$YKZ.(I_07005C0'+E:E37R4L\R,
M3K<V<7I.;5B!8&WZ-T/I 2>H4!*I;4:'NQ<BCV_=68WG=&2F(+TPGVMR*8@
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M/MV/22\%E8<:;9S:N"G:JT+<^G['J2+QST/2\S5B7Q5LV4%.ZHUF[HYL"W<
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MIE#ZSK-[+9/+5"TTWFX/1P6J-#&UU,S>T&80/<\ 1Q4WI=;F_N-6-BU,Q>1
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MQ;WO.<VN^Z/.1YTWTE#3G$&FL"BI530-F%P!ZG8XN4D=M,=I$4R/;W8OZSI
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MH7U1,@G91X (^'^0X7\ $(%/<GS5AH=LQ!!^4,*!\P<9U[=]CW$# +!^CP$
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M39F.U$L,D1F?-OD& 5BNUQ>W^NJ96^BP_6B$+CF'V\BP1>F60^BK,)D)81
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M@ST&%$4CLVA#_DM]&Y$*D!?":/"@148\Z>-4[%P64"/[,[Y$ZEC4@[NC5N0
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M4 U9"0:=42[ZT-#D3QO5CO_,T<S 41Z%E)BD266(!N-$3E!X ^54ADRPS7K
M32S!' AETK*DAQ7=RQ_E3.Z\TLN 42TUBBSMTD8I4B,UT,G,A!E:T?J<N\O<
M@'PAD7J0T155!F)04><43S#%2RZ]4Z'P43T]BCSMTSGA2TZD2=4L3]8DAD^(
MTVC /R>=S0<5$2*=T;($0<ML4$"=RAV]5*+X4DU%E$?MU#HATC%-RM8T4S-E
M3Q>L!9,_;8K<@,T(A4TY/5,FK5!0Q53XK-6>6%5<W0==W=4HR8TB7<K4?!7U
M;,ZRE#LUX=3,.,N#F% YM4T07-+JE$]?G4IEK=82^51L+0DHW=8R@4P[, 5.
M- 7*3% Z589Z0*Q&S1(^S8XI?4I)E=,E?4W9]%:B;%=[Y=5;]=9>S=<;<:68
M!(6Q%-90,%#^.U7!M$\OZ=>BN,W8G%1H3=!GA0;$\M=[W==MO59[S?]4BXT2
M_GL#D'V#4>5$UI13:'#*.>%8IJ!6Y)C2IH16YEQ/]JRGCM5)E=W8>NE8AJU9
M%EF):,@$U0Q94*#)TS1/D34%F477.MG9H(B[EY50>56&I'U.GNU)IKW4JP54
MC:W:&XG)3.!$."A1OV3-5Z%,.7U*PH23;M4.ZG16Y(#-1%U098!-W/DOA>5:
M>L/7C=76?-5;O*41(GT#U51-O\P$)%7.I$59.LE:GD L29U/B*U.6OU; -S:
M;65</<5<RJ40H U9.RC8(X4#\TQ04WW6V&19.+E9I9C43%A0R%U1$)1-.]U<
MN]-<,%U;G>5;VE41IU12D(4#D-U$H#7/5TF\4OHDS,G]$I?Q$%9%CF@UTT@U
MW>/=W994W<O%6&RU7>IE"DW  1RX 23EQ#>P Y&5S!1]S2&=73/Q6Z.@3CHE
M!O0MRT,%P;-$W>V].^W54NO%5MR]WQ216C>(HAO  9$-64U 4@6US6585(.H
MV'7U$LLE"B(E!O4L2VAX5@HVTT\03/\=Q?[UU_R]TA#N8*% 2I#%@0:( 1](
M@]]] [*=USJEVCVQ7658T%>!W3E53Q@.*Q(&P!'F4?;-7MW_[>'L&*0#!MFX
M6F'O1=(Z,-4X=25D!93]_0GYC 9BD 0Q,%X-EM4JA2HBKK<I]E4*P-YJ_>$O
M+@D3?@,6_@$6]H$!1M+S7$\01%N4DN*<10I]R 0TD($;F-<M+ET+;E$S/&,K
MTXDVK5DSMM$@)N35/6#R5>,WJ(,TH!X?.%QBT 1CM=] B6"?()9G)1@QX TG
M1MC;9&2[XV1?#>-='6/F-67,V+_Q[5SSA ,W8&%B3=#8;<^!.I2KE4_6S6*(
M&64&10YB=N4K6^14)N-D;F5C5HIE@(8C%MPZ^%@6!MY2C=,H?N"E'>*?@%<E
M?=9,".97,5U7TN9FMJA$_M /[EMNT#YGH= 'TP3>X)5GP256,UW1LWS31F%8
M=;5-UY17/=[BLB3F07;GWUIGG&5F$%9F@]9+(AU<P!391Z[G:[9-!GX4A/X)
M2;U@2G7BZFSH8V;H3AU297@9BBUH;\UHD.X):*X#X$W.T_S=Y&Q=4N8B-=UG
M-BT*7Y9:RV1.V)56L]Q+35[I+R+IF2'I?(6#R-F (LC7V(2&HR92HO8)&=4$
MEP99TZP# WZ50QWF1WD#(WB#F0EK._B)%J5/TUW1&Y[5J?XMI8X<(UAHHW%/
M7WUKR&G_ZK;&B;T<7],TW.2T9O,=!E)>5&8U9SH!!<G1"=8)BAGEZ$E%U"K%
M)?7-Z]:9G*/V5Z7>&1Z3Z\FAZ[P&!:L>W.24Z5)-6G2]VT(I@IK!Z]&L)\&L
M4M,MV14M9LJ^*+&FG+CV5WVH&<_VU=N>F<VN[:O@/Y>.Z."]Y>6\S4],WD)!
M;)DI:Y[XO[F-W!4M5GSN;>%VG9I!Z6W-;*9&9)UA[K9&RIB6Y['D:J!&5^YV
M%)EA;9[P9ML,,VA-5 6F6L/.;GVQZ\7669W [KJ>&??&;X$]TI#]VE)=T!5U
M8$IQ[@V ;J! 5X@%015%6+3%/_'&;WV9F?7N[N_FV9BY\)6^F&"0%5_!G6DS
MG5K4=A35#O"2J%\&C=,9DMO3QG#@$NO<]G 0]]4ZV(#]SFY7R@06%MD#+E?K
MGMM/I%E+0>P>[XEEN&1)'6RGO&\:1YH-V'!O!06\K?(ISP0<\('6E-/53. 5
MO>A-N?'H_L2 AE\$)V5]GG+@PG(WUT\XQV\BI9ZD!4$$'V:43?%/(;HLGJ%#
MI6\>]N\X+W1#WS_T95T&2<@$7)K1.65K?9$[>D #WJCA])S3.&UQ1-]T3N_T
MU:U)W/E$!H55%Y40*=\4ZIP$:)5>%J5M3W]U6(_U9N5@^13UP51<E,KQ3?'F
MEI544Y=U8 ]V3S_+0;9)&:U;I^3S4"DFAII14"06*Q=V:9]VHAYHW*G?:Q='
M91<5Y29F]6Y1:@]W<:]M#BX)7"?S?=E+9G&E9/<_N=/G4Q]W>9]WVHW-+6-@
M&FOSUKE@KV)@**9W@ _X,[9@G!CJI'G9.J9:TA1XAF]XVHW0FTQ5@/DB?7@+
M7'(E77=XC=__>%P=T=S S7@W%4+G>)(O>6S%S4&.=J1QT9 W>9=_>2NS@ VP
M )FG^9FO>9R_>9VW>9[/^9[?>9\/>J#G  O@ *(_^@HH>J6O^:-7>J)W>@NH
M@*<'>JK_>:L7^JNO>JS?>JWO^I[G *DO^K '^Z-O^J<_>W%4[<_ID#%F>Q/1
M +?'E[B'^PUH>[JW^[G/^[I_>[W'^[V7^[^_>[X/_+X??+\_?,-/?,!'_,57
M?,%O?,A_?,DO_,BG_,DG?,QG_,O7?,OO_,QW?,_G_,^O_-'??- O?<S1@"57
M>[H'?-=O?=A/?=D?_->?_=JG_=C'?=O/_=OO?=[__=T/?MT??M\7__[B)W[@
M1_X.>0O5;ON_?W[GC_Z8D?ZXA_[IO_[JIW[KSW[LWW[OUW[P[_[PYW[R_W[Q
M/__R'W_S+_\*,(P?>  '@'_YCW_ZGW_[KW_\OW_]SW_^WW^ >.! (,&!!@LB
M/*@P(<.%#AM"-/AC'\6*%B]BS*AQXSX+'#YZY!!R),B2(DV2/*DR)4N4)EU^
M5 DSY,N5,V_:S-E2)\Z=/G'&_"F30X671BQN2*IT*=.F3I]"C2IU*M6J5J]B
MS:IU*]>N7K^"#2NVJ[*+8\^B3:MV+=NE1<RVC2MW+MVX;R\ZJ%#A 86]??GZ
M#0QX\-_"T38J$UQ8,+0?BA\3AKP8<-E]%?_R7M:+>;/FSID_<P;M^4&%RAQ/
MH^;8<S7/UD)3GFQ)<N2&DQL\6JB-.^;0WC1K^N8=G/?OX4&%%T]^_'5)V+<Y
M+*NH+&D%ZANJ8[^N/3OW[=Z[@_\N/CSY\>;+HS^O/CW[]>[;PW\O/S[]^?;K
MX[^OO_V&BZ#R [B?@ $2.*"!!=:GG8*@6 2*=0="B&"$$TI8(87F;<"@17;P
M15I>I'FXEX@?CBABB ^8AE$H'U( HE\@4E1$AR6Z2.*)--+XP&'[W-AC9C6:
M^"../;9806I'(ED1;+_1Q.1Q3P[5)'%0VA32<ZVY]M)NL5797)=<SN9EF&!Z
M22:79FZ9YI/,G<G_@45&U!6GG'/26:>==^*IE"87%9&GGW\"BE5U.\:H5'6!
M(IIHH(->] .0-K989(>21@HB!=%IE)BE,WJXHV,WY@4IIY6^2.EEH H9:HDD
MJAHBJZG^2,&>2=*JVIA;?IGKF+J6Z61.6?(DI4P[#0L3EL(N:2RR6AH++&U9
MPF&1!@\>JJ"UU6)KJ+8/7KMMM]QF"ZZWX7Y;+KGGCINNN.N:JVZ[[*(+K[OQ
MOELOO??.FZ^\^]JK;[_K'DKH/M$P=:C!U"*LX,$*)[RPPPU#S+#$#T\<,<47
M6YQQQ1MCS#' WB7UAD4$5_MMQR=KC++'*ZO<<LHOLPRSRS%;NX'(#9*Z_ZFD
M+YJX\X?04%0DBP\\ /0^_^E(T<T65=!B@YG=#(IIH(1XT1M[.;#CBW<I#>)=
MH&BXCZ9#"NDC:2G6FC9%146Y'+/)POTVLT3II)MM;'ID-][.\KWWF3\!SL%S
M>5OI-P>$.ECROXOCRV_CC/O[N.214^YXY9!;GCGFFT^N>>><NZOM17#4K*CI
MIZ.E^%.A6$1Z4ZJC'KOL7U4;-D5PD!:IB('E5:3NN9,F(J8G^CX110YHJ,P#
M&#W =47+[!5M1G#L-?U>1G=H],AY&8\1*+T'#WYG168FJ?1JHU_2X':S3;=(
M5UY95-YWOP\2^S&QG1O?*-F=9>$?Y:\V]9L?X<( B+^8Q,]^MJ&?^_0W0,$Q
ML'T25*!'VB<LU]CM2KNQ2)^\-;L/@C"$(@3APC($%X8=+#L@Z\X*6YA"%%I'
MA3)T80QA*!X:OO"&,]QA#7/(0A[ZD(8ZM.&V<GA"%1:QAD-\81!YN,0>*O&'
M,&RB#:7(Q"@*T8I0Q"$6G:A%D"F(>92:E(M\-+06H<TB(-+0K"RSE\HX)FO'
MJ\"LX$"!\SEF5M! $44^11%H7&9X%3 >]!R *:IQ#7?2BT89Q[BS474HC?_H
M0](%G12W8EU22GX32@/[ITG6+.MO^PLEL62C++=]"3;%LHGM:A:>"UDHEK"<
MI2QK2<M;VC*7N)384@Z%*8I,QX-.@5TOI4),8;[.F,J,RC&Y]91FEBZ9S%PF
M5*!Y3"0^TW;!+":YBEDP:CX3G,,4IS2K2<YO3C.=YE1G.-E93=OM@WJ<ZEG9
M<D8I@5WD1Q?11*@\U3R*:,(OP'R ] III'TL@P+)X]39@I:T?7SJH D% D6B
M$:H_DI%GKHI5\  S2;6Y9%<B+1.OVL0<#0J.E"^Q()1NU:N:J#18(9WIKTP)
MT[DY4$T,% GBD.G,$0(UJ$(=:NIJYKQ]P$EU,_S_9@FUU50L,O6G+8QJ-)?*
M3:E:U:E8Y:56J\I5J%[5JUZUJL",\%1T*C699\TJ6+N:UK5^=:IA?>M6X6K7
MNN)UK'E%(CY_X,AZ?@9XG>&C1BQUOCWJA;!%H*-&HE&!J'VHH@]H8T4S(T?+
M.* BEJW, PCY(:U9*K!_2>SN;D39CQY)E:5LZ91NZMI5&A"4.'VI*.<FT]IR
MLI*LK2EKPX32DH;R?/OH4S>3Z+G+?2ZYR%WN<9L+.N<J%[K,?2YUHXLYBGD+
MGET=YS6CN5VUFK.[X@TO><,Y7O.6E[OI!6_HPGE4M'J7J]@,JWK1:]_ZXI>]
M^:7J?NFKW__R%\"NW,!1_ZG6M(Z6ZE$XNNR,5$6BB@3TLWU\ #RE0U" "G0?
MB*TP] A+&HHL@T1:^UJ&Z]$J&E4JQ0W6"VIIE4J:NM2F:C+EX&3[XK;!UJ7
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MPPQ2TDC;0#"[#HUI4 C;;&TNQ2SM;*E3%#+TK;XH^M"XX'H[:H.Z"EK*+JU
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M.*B2MQ9R #F'ZQ-L[2I!Z9IQ*FFMM =[/;JM+HD +H=L/;B@W[H^)">0!(D
M_ J35)BO^V!XM_="D^B Y^>9^_"7&P"%80IW84IJ5KJ)=WJ*-KN5QGB6_*>
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M+#O*W(Q][!>F!B'0JIBV7A>Y&(S07OO!$:J57)?-3-RH:^I^Y8=R!A'.!U'
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MA,5894C;TU(IQM&F &(P'E@:_C@P=L<)YE,HSDOVI=.6Y,UD'(IW95+: H
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M6<HQI4(3W$Z##O5DN.1.HRW86@TA"HG+= @'>*\C*M$P=\LH4O//Q)%+E.$
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M!N3?%HW+]JB:2 4Q]!]/Q@6UWV+9 7#=1&I=-""#&BW$4(,4KG:;?L8=M%<
M#&;"5$,()1<90M911&)HPIDH80P",=14#"H< %%K).XT3  [9>?B:QT:5%"
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M!W0_ICJR-BJ84*N*.BJT(YRT).RS)0RD, L-SQ' C;NCU.JA4YNPYLFT4;O
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MP[3+=I6QGGV8* U!*8RZ@&.P8%KDO@ P:GLTAQ? >'2W=BG4BJ9HR;WP1EP
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MT6@(5I..N<RBI5 3C^ _-OR_<ON*D62( +"C;8G;O^HM@H@XR3PMV1*+&P@
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M+N)=\GTA>,! &I*'-3;$"6Z=7V3"&R2?$C:$&%A@&H1!.H8'#FP!#OQ%!@*
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M0$>-:@D'-&*W!B(,4*L;8Y(AT=(V"*P+$66=>"?*&$P@)&$',8ZM;),DF7
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M?5=1;)@ZC-58(N^#\5[PW2OO;6J:U&>WF:1!4*E!*JI5_XUHBK=KQ?10I.>
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M74HF84+UU>)2/<P]R"V1YC*IRDP0NB Z308UVLVHS4M.$H32>TG+4#0AZ7W
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M*)B"*KB"+-B"+OB",!B#,CB#-%B#-GB#.)B#.KB#/-B#/OB#0.A^S*<B0]B
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M*K%8UH1-"8=0R/422(B0359F"_9,WS:(:* SKY&&!GJE6)JE6KJE_[>G5P
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M^[10&[4F4CNU5%NU5GNU6)NU6KNU7-NU7ONU8!NV8CNV9%NV9GNV:*N& 0$
M.U!+ P04    " "N@7U4<SFK3R<7 0 O%P$ %    &%D=FTM,C R,3$R,S%?
M9S,N9VEF1'=E4-OM$^T/#^X4+V[!@T,I[@[!BQ.LN+= @P<M#J&4XA*@Q:V&
M:Z"XNSN% J54<M__O1_N?MO9F=VSYYQG9A]-;0T96<<KW"+LG\#_"P@ P
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MZ9NG)_ --Z.-HJ,WH$S#,#A,+S8@/H*P=LJ0B/];I&AO:@4'H_(&H4JQW7G
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MIOG"(S6O8:S]")\(^$MW[7I_WIP.TZ?W9VZ\PE[T%=HD $#^S!E>Y(]B541
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M[-(]UD/B!6Y\-WZ4:!RGH*.7D[^B4PUG/)=L3CIM:!_K/U&$ZMD0O6N?A/W
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MQ6:AKP3"PY-"SH."Q /"U+Q"OP-$[ =%^L7%3IO%'K5 F0-%B2&B@0@(;XN
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M^B>F7LEH-,'6C,":'A\A6Z1QG6M=[YK7O?;UKRNBNC< .T4*0@BCJSPW,0#
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MJ;$8K;&SPM$<L;$CT #%=L1]+(4S,F'MJ._]/";\ D ?&$4L#D F)$(9"B0
MK,@>T^X L@+ZQN!2#&!4*@/$K*(>R 926&2-&D(98&X",P(L/B]1=.[<I"(C
M0.WO8N 9\&$3\8&IEB8D1_(12]+Q_TSB4D3R)9V!KEX-)6%2)J$&)D72)&?R
M)5/2)K6&)E52)VG")4>R)UER*0* '*1&%UBN(JKO)$0'(:(RZQR'<ZK2(Z;R
M<:X2*[>R([(R=+JR?<*R6L;2X,HR;2KG<-)R=#ZG=-I2+4T'+M]2+E'G=/#&
M+G-**]<R<^:2+>O2+^\2+T&'*_=2.*)),"S2\@Y@&!CRZ<;0Z;*.(I8.(6"
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M +;XN[_#RVIGM""?[(C$,E6'VI^4Z,F@XC3^=VC^-4G^U76-)()@ES\_ .*
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MIF<JIW ZIV.*?S,:CP9@.9RB1O6XI_ (, >@CX!*,ENG!5W3IX:*J*FU=5O
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MU*N\O)N]Q5MPT]N]U_N]R[N]T(N]Y1N^VFN^!^>]?A0?%\$T;U6:2L$@:0
M%!$ B[$"L3$;QW:_!)$16($16*$1'V&_5V&_B_&_ A$ ^LLA(Q(&_5N_%0'
M$R' %T' %FP0!^R_$AP29^!CR/7 &7P1_PC,P?5+P00QP J,P1&\ @3,P)$2
M514< !<\PR(,P0ELPC.,PBN<OQH"PRV\PSJL @5LPR0,Q#DLPX#SP@Y\PR4<
MP$%,PP8\PAL,Q$.L!9&B(0]LQ!.LPP"0PD.\PAJ<PS-QQ>(:M%$5$CR!%1O<
MQ41\$,&W&C]Q-^HGQR$7$B<<P6ULP=IW=P.!QP7,QED!QW>LQX5<?7U,> "\
MQWE\R*OGQX8<R'SLR(D<R8R<$(/\R(H,R74WR7^\R(#,R70,R8PLR:*LR:=\
MR;M'R*<<R:$<QZ,,RKIGRI4<RZ<WRZ1LR6^LRIE,RWOLRJO<RT(LRZ_,RJ3\
MR[R,RVY,>"N!S," ;,S##,S)[,O0W,R?/,VV3,S!+,A5YQ:G7,#?;,'@/,/B
MS,CD_,V8(" %T1+L:)GX$QY$E#2/*QM/.RU%)L_>0,_]LP)1-V0$"+3C.K5$
M6[2S =#>X+/X @TKX")*D\\2N-"/V]!'\L\L\G_81ATO.(-6:(9/Z(1+"(9G
M6(5EF&L@K84D[84<_=$HC88F?=(>O=(J'=(L+88R#9$B+8,TO=$N_=(Z'=,P
MS9 V?=,^_=,X/=)"/=-&74?Q83_*^<[_I/F;3V5LY3A E!/5_H@[-_"!R36O
MU!.MD>*N W0L9HS/6YTO,!"[M"#5 G129_W5\T,Y.^NN=?F+AU6,#V.L_E'7
M#)+7>GW7_;'7"_+7>-W7]1'8@LVL?CW87)78BGW8A+W8I?C8!Q/9DMW88#79
MN%C9D)W9FJVL?+W9M=C9 E+8>H0ANE*:A(=;!P YY8J'JAT&K&VN6R<^4ZVG
M6I#64PT#8?!V5HT[J@T&;0W6OGW;\X,&PJTQ_$F0#WR2I:+<"-G<K?;<R=V3
M*AG=TKW<H%;=C3O=UAV3GKO=+YC=V/W=VGW=PA+>XEW>#N+=Z:W>YVW>XXW>
M0.G>.3C?[0W?_^_-WCY8WW]T%:;IFF(IT#+R300XX!'4E!040B(81M&D1@R^
MX--4M2<KX1/^;;H+FD]-X8"9KQG.X1UNT>P6F?OGX7@9X2-NXBSZF)?YF2>.
MELC-XB_NHBL>F2D.XV<IUS6.XR=*XY4IXQ=2X !^. Y.35KYXU=2Y#%BI(LD
MY,YTY-ST)L-9IV/JL.BD*E.N&VM*IUENI5'N463*1EB.Y$WNIE4>IUP.(4EN
MYN[UIENNY5)>YFU>IF2>YORDD";K'SW>F#N^KBM@.<XS+90#.5(U.7R^!<#]
M,H1NZ.F#Z( J!HL^.0"I KR=6HZ>.83NY[A%Z?TQ$)SXV90=VJ)]V4"C[=B=
MCMF?;MBF/NJHGNJ^JD:B;E( >>F(1>IV/>NNGC"P;M6VSMFLWB"Z[NF\[MFJ
M;MFU'NJ73>O"SMBJZ)@;_W[A%GZMW:*MYI(T+&(#ZJHO-@+;'C,NV6XRV[Z+
MU^XMZHJ)Y)#H=@3NT?[G-^#MYJ+NV Y3HWEI'JO>\M[19..P43CE^![O(!MK
M_*Z$]K[O(^M&^OX\XN+N 3\Z^4[O*9WP2+/N_2[P$-_P$@_P4^CO_^XY"G_Q
M\[[Q#%_Q%A_Q(#\Z=OYM_U*:^%.]%C@B++*"![@B1K8+$8V Z=(B$?WR+"_S
M7D;S,5]CT0KS.0]E*Z"RZ<*"?'3SLL'S]2STX](A 'CT22LF):Y!ALL@:3*W
M$&+U@/LH7YLB6=_U5+\@7H_U8"\@8L]&9@^60@_S13_V:OLA:.\@<'\A:L_R
M;/__(')?]63O'WA?]GH_]6[?]GG[]GY/'WS?]X!_]X2_#WH>F2Z1W"*B-&#0
MEYZK(8]+NP2Y!94O&Y?O@YD_&Y:/E)G@^4K#^44X^J _+9X[KDCO#9+/1Z*O
M^:([^6$0*25"#J5/;+&_!?'E[.H+O@/W^P[2;2D?_-P+(<.?(LC_(<H/_.*[
M_-:[1LS?WK'O^L</_<)__4J9_448!M3_D-*/_>L;_L4?;MN_(."O_>*?_N0O
MO.K/(.B_;^RO++WO6<1 0\J  X<T+8R?&_0+$#$ '%!Q , *+;J^Z?+&,$P
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MLH6T4$GX.GF0\2\2,<((GR>=\<]<#F(#MN=E^!()@&,J(J #GH0MBNE*\,'
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MT1^M48424ABZT1(UJ",E* WJ(2 EHPKZ(!PE2")-)W&A+G"RKD!DHD!+@S!
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M,IHHL6- CMU?>_1()TA$7NE,?ZA-Q^A.5R%'WVA,_M%1C]]2KS6,#M]4 !1
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MJ'$CQXX>/X(,*7*DPA@D3Z),J7(ERY8N7\*,*7,FS9HV;^)DN?! SIX:HZG
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M/,CSXDEX?,JO?/*0/,N8_$O$O,OC*&?_[+/1K,\C[7)B3<U"6\_C1-'S;-(
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MB)3J"9S_9#*4A.A73FMZ9G(HH4F:P$D?V\F5KDDJ11*+Z B9_$H70/*%6NH
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MCC]R%&2./O;(HI(XWC<DD$4:&65)4UIHY713577EECXI8\ !Y &0QD5B&!"
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MC_X*ZN\BZ19@E8?\_KKCOCPYM7">-\+P.O*=[X#7DQ\"S7<]^JUO8^[KG_+
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MHY8=:0!3KA8 TP45%/NS5&MR6%JU6)NU6KNU%N*B%[$X)/@J<-V'2\18'?J
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MK=K*R%>$K[JKO&K+LRS+L2R%JNJKOMS+0!BKPAS,OPS,9CQMI<MK"FQP<D>
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M69=C693U!I5=NIAU6880SHV(&7'=AY^%NX, 6K!#B*)%DYCM$(^=NSU9NX)
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MP\^CS^C\YV^?>](/4/>U_WWPCW_8YH=*L07B>.W$0,9_H^*AE%$XP1 C$S#
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MPP0]5#5.)O4T>6)3@\570TOU54<T60\15R@-#+3?E%+)5F1"$'>$-6;TC*U
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M#,>PZ-#03N^T#O?4#..4Y\CH"_54#>=04/&T3P.5#0N527E/0-FH*^%F"\#
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M&,+N<X]M6))O>)(+.9(OV9(-F9(Y.9,K^9,[.<(>K=74"B6,_TOIH'787/=
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M%::+4(U($'SSK3 A02*FZ%.2$Z%959<F:0@:FX%6_[A4;1'66=6 #8W(WYD
M (K@HU41IJ9$O/ET%)P_^5?84*GI*1E#!^ZSPHT7E8KDI37=))%I&0K5IGZR
MSDIK0<08@)5% =AIID\WX<>>JA&-NM1#HF76ZUH)/6>17UF]Q.1"1Q):5(P(
MV81G=SPB]5RB  0'UU%=-4N96W@5-2R1AG:W4'!",=2M<C<0>="W/2I$;5<R
M102-EV_%FM6RB-Z+5*!+Q: ,OP8-*UN[%K(:[YOV*LS%N<IB!:W%-$6$$9/.
M!KPMC2J*%M&,[DYJ;EC3&IR2?[>YO"U-QBJ);%5-G630M:<MJ)0!V,8<THHG
M8:2NJBE9!"]5,T\*P(PXA40+<$HR/540N;T]_>W0 1<'TW01IP1UKLO62%-J
M7BM375$H_K<N9=D>[>E>2(OLDQB9-,J5L?\"O8^)FKF:6$0#UTIXX?_W'8 3
M&D8>J$P @].$.'ZHILT8V2FY99J#32LX"7<=O2HQ,=%JYV"R/O&W>73SN>?5
MKUTQ-&%3?*>$XE (B:YQ2)4S1]+C>1U);K0@&P2[E_F.G EZ5',($^_VH7=8
M?B>Q+-GRL%K^^\/AO<XI>@()#U7M1#\*?J?/L5<?ZW&ZKB!$DA[?'^YAN<M^
M45*Y?K_I(6'.VTE0.BH0GQ6D>)))E4*$E#FUI>Y]"J%748(G$2[,BU.2B8M2
M9,<AT(AO9#E:(+'8A#//".6#3#E)<SXGJ9VE:#Q*@HI>ZL08Z]$$1:Z1#DC*
M![=1Y<UES8M:3B3"$;9=! TK<)[ACHC$K,3_ &$+"4 ,,"*) PQC:[*BX</>
M!K=ZF&8PN?,*3-!S(#&8J%%L^D^T#( 3'P:M(YDRFOV>\Y5^708GAMF0Q(+"
M*1SZA#$8L6("NT/'N&%OC2TJ"WT,M:;5<6$?'^.00M9F'\@X\)"5>EZW^,B\
MAV&$C$LQ)"/!HID[(L:,730()DG5M13B!HXGD2.0&N*]M,B&E!%*X^SJ94&2
MY+)36BP)%^FC,%+5+RMH[%L:J9>S.TVBC3G:HR!;\D>?*$^6=42F5O $E%ON
MYSG,E)A"H/>J6#KJ,XS\XM=2PB\<?1(:ZB013V)SRCOZYFQ+$2=(:'A/"EZN
M526Q2&K$E<2 "I0B_V@(0&F>& "-I $ RP@+ !(:)P,$ "5+W =ZTL 2Q_DJ
M00/A7>V:&9*;?65!G>.2*J-BPADM:"_P6A )#<(>]*RT(5R8UBU=2A!#W<EW
M [E9053'F)=NDRM?69^3<A?3A71HIAO="U Z*,064L2G8<':)D\Z5*PU1Z8
M:AI_&BF99<UTD#1!5317N5)M2FTX8'W6<SY*GXKJ4CA"%4D(A?,]_5&$(5)B
MZAUCP[M)0D=204U?0[Y:RE0QM:8.4BNL%F2WF>JU=2LM*49 EY5I%K4^I /3
M9 NR4Z1$%2H<N6K"9@K2M;JD(1$YZBHCP]?5)2>TA1)D:?%:/5FVE*-%$?]@
MP?I&/VM2!$4">6I].+*1N-75(*I;2 \G\9VS+HR?=FG63!T[T.SJ)Q,QZ)Q!
MPP"3#>$ )OK0Z"0.<"#U)503=+)0=XDSE;1@-YEV^:6^XL5)ZS3&*:2!KTSZ
M-1+6%*LD3]*<5&L+ %?FAE3")8A,DJ5'JSP(/M#KBF\9?):3A8^"32&KLNRB
M/OPD,K/I.6=7 $H??Y[EL^ALCQI;9A94A5A,"1Y-8E*;$O1 .+$_;-&OM!12
M D\+BV5C($GL\N*)1,L\_8V209),7Y*X;V<',FLK7TD2-TSEM@5D#85Y3)0?
M'=E;2%;(@E$%(0</$TNM$XZWIKR0G31X(&?N3'[_:<(3=A(XP>U<B@ 5U^,3
MWQ KWQ%SD:D"S@27Q\1N.HM&Y+0/>NA3NY0^8GG14)X 9"( "J'' 3"V*_6=
M]T ^PY5]@'*LRG8EB%=D]%H_V%RWKL^-8,/I#XD<DO'P<Z7+-:5?1]J;E29G
MQ#1!;83HIL3_+<B54'$>8Z9T7V3?1YST8<^!*31?E$J[*_94=;)!N^TBK_2*
M<[[UF-I,(I(ZA]:YGA*J>5NMZ=EXS4LAT%=P'!HSP2\EK'ZLAV'J/SK[M3LF
M5#.4(]5"E?[[R5?.Z:1I;!9@*S$YP=KW1,)D[:X^YR-W#6M/8MU)>0\$6^5>
MMYV\+1Z1:Z[&CB)6QM."R&N"A));W8K&P2N-\_DD]#@;P=43'7( & 0@Z =8
MR %4</0#",2)1X]&SI\.]:A+?>I4K[K5KX[UK&M]ZUSONM>_#O:PBWWL2'R)
M:&)P $E!H[T%F?% A%[>,)!][G2ON]WOCO>\ZWWO?.^[W_\.^,!O/0UH'!4.
MD!ZG .AC&2 Y[Q31/A"(%E0@F[ZVX"^/^<QK?O.<[[SG/P_ZT(O>[\J(P:XL
M].FV?\LR8CC T.E1U8%$;A@!D,3H;X_[W.M^][SOO>]_#_S@;0M_^,0OOO&/
MC_SD*W_YS&^^\Y\/_>A+?_K4K[[UKX_][&M_^]SOOO>_#_[PBW_\Y"^_^<^/
M_O2K?_WL;[_[WP__^,M__O2OO_WOC__\ZW___.^___\/@ $H@ -(@ 5H@ >(
M@ FH@ O(@ WH@ __"($1*($32($5:($7B($9J($;R($=Z(%:)P8\@1:7AP8W
MD%#9AGDE>(*\%X(KF!_<975I8((CF'4_!W5A@%$?J(,[B'_$$ -A0 O?H C@
MU6L7%P!A (-MAV\YYX,_P 13P 04P$1[AQ -M6HQ( G", _"H#@+1Q]I('?:
ME83S(3HX( :2( ;C13;(51'Z,X91YX-HP#A=:(1_@54!98-'](83@0/-!!EK
M9'G[HR1 ]H5@QH.'B(AU=P-AX VZ0 ODX U@8#J-TQF9@!6: !.WPT@Y*%",
M1U8W0 %3D )30(H5T"L%)5&N!DPE=V)3V!MG, _Y$(OY &BF% "I&(@M_V,7
MDX #%\>)A+.'5>$6DX!IF.9V0%<U^H.)5'<# Y,&O>(6)^2%LY*'AA.,!1$&
M2Y@?U9B(W>B-OX<&6]"(C5@+NN -8? XQ+@"?R$&$[*'?9A=I3=(:8 #I&B/
MI.@ ('6&[B5VC:,/70&&LBB+\R /^9"-IO0T 5"$N1:&V76-18$&?5B,Q A=
M($5[R>@0FO90N8(3,="+-[!I *!TFW*+B#$J,9"#8+@0NO(_4O-(BZ</3R$&
M( 4 FO <Z.4V:5<C')%V!_(<*HF)NH(QDV""!J D,: ) X$##X43/KA0![!,
M#]60)N@Z3BF29C9TKO-0!A ;."!5C=,O7KF55/]A4$K)E"9QB_O@1+=(#+<B
M<UO94RAYE4HV44>'-N'50I*R4+=87!<Q42CXC8$IF+,B!HI CI!HCHJ0+ @#
MCY]T "N0"<L(#66)A&B70K<R44IB-Q,E$&&0=E@Q":G8E\20=C#A@S=1EDIF
M!*0H!:+8FDR  \R6!A/2.&\)46S($CB1BIQH>@" 46@ $:G8B\"Y*2Z1":EH
M41,U*IF0=F59>B')8HPD# ,ID%LH!LSF@_&AF0^E%)88!ID9%ACQ!F+0>G+Q
M<PR1=AAE@TGHEP#0B[U)$ 7E.IIP ^=U<.0YD<68ALRF#/^SC/5@:DB!$<O8
MCI2A>(RD$,L  TD99XS_] 8.\8.4 6*G1YY%@0/#$ WTX'3U$ WZ0)\UH0RU
MR%9*07N1 9(%80"CPHM AQ5<:5$',*#KN)((.A#$J0P'(""(IY:Z@14VBJ,.
M(A##8!DQ\(^-TYF_N':K11DM&D8]*D064B5*4IL+,2& 1IK_ :"PAA.0N0_+
M2)PLH1&9  -QB22I)Z"#B:9I>D0" 0"Z4 OD0 N.6 ZTL N]XI:98!EHD(/#
M !.>!GN'YW06 70'4EX" :B4T8N,A#:GEYT*JA1H<:.P9Q0Q((KW2(I,8"8%
M2J/[@ ,3,I/[ *-*625/H0PJ$)83\AZ_6)^;.!#+P$0XL *PUWK599H]VD K
M_T!H/#40&KH"R1"+!3D/L8@,,+$\29@)1<1(2L*E:1"JFJ "89&4H9F4_864
M!.%I?#&('=F1;/4?DQ ;/W>L-,.@-)&A!R ):7"NZ8JNQ)I3I\>/\EBCEW4<
M=6(W/[$:B0JF+*$0F<">3A<#4Z2O/J$/,6"%D78BI6<0*0JJ4X23.!F> _2+
MJ3D)<H>;*XH&C! ?21D#!S*2&;D/%RE[HX(&&-&QM0FRR9J;%&$ +M%,_LA(
ML8&P:AE 5$$,NZ*GQ#,J;DF:!+$,*A -PP E]1J?.>B5*5NS &87C8D4I8$2
MF*:F3PNULA(#XZ@+WP"G</JLD8$&$Z*0E#$ADEF6G_\:><HP"<WQJ4(KLUZ1
M<,107E:XC->:$@<P!:TY!2A@CR@0 QD:GRN0=!A17I(*@Q4:#2I0(^A%#P$@
MJ0,QFPZ6.!-2J YJ(6&X#"VYC.4E1\LHL#$P#_@0BP0YD >@H02A"3X3.7RX
MB\TQDN#:'/"8AQ6Z$ R*N:DIM)F KXJ[KV:QM6I#I10YD:U7#Z[4GP6!N0QE
MN[D)E?$!LX=5)U,*2\20!ID0LS:(N9"CH9+:H1#J= 11EA<Y',@JH<03% K+
M$KT8LP$[!O3:,1@1 $)7:@X!)3^I$#XCDBM@(L$KJEUJ%J2)FF'TBX\K!@^Z
M$477-QS+MR5B42!UHAY;O@,:/*6<VDS0-1 J,* =.0Q&6DZE:5!PNP_G&[7_
M'>S!5;$,^H #AFF.CEBUBE"[D3<J(5BC\$2L!O 419L3Q. &ZWN+Q[NJ;U>P
MG,HJCUD:!B"I".NR6G$6JWF/HV@$-V ]FOJ<C&>9T758B8H025<: AR?& MT
M5"$&.:@,R"JV:8 570Q@I9:)H-M3UM10-Z"%U2F+PI#"2:AIVBMT,+!)EB&C
MU4J4\=D6RVG%ZZF;AN?"89%T_S&&95L4BZ<3O$N1+'P0WAL3#63&C$3("!/'
M+]M316>);0BM76,WW\J@#]FJ^Q &XUHU"O&/$3(J]8F3XCNC*M$65)'';DEG
MPUDGYYF4K'S)!.&P!9J:[1HG\OH3#KNR9_&5R(H#_[9'$F'!IC6BJ3+'H,-0
M=+(,H4Q+$$A8-?/KCMV) YJ %<><,]Z;NQ\LSN-L$/\(7>10CMZP"XVX!0)2
M$3" ."+)1%]:N67IS0XB'=NBM+B,M@/1MN_JB@51#_HP"0Y BJ,XMU.  VD0
MNHI;)^<+K\1CB1CAB?B<I 7!P9L:L)$VDO>\HAQ-MA=$7JD)ROZ\#P'IN<%J
MD)+ 3J><G1\K$3:XQ1L]P,3\R'$"8LK:0D+[TJF9P]FIJ6B(O_&IJS\5 _E)
MC/7)3@.$%0"*$1<=$VS3-4PTT\D,)^^EKX2& ZFL)--+$>8<,S,9#<N3FL0@
M=,EPTG1DQ08!CQ7*.Z1):/]0U+4@^W-?.AK/"J1T]A]V_1-CFA-VL;/[H*!!
MBI-BNZLC*;:!+2E\W:4R>C>6[+YA4:6]^-*L^LL&\=(]:X/07,ZI"<;D#-KC
MO STH PWL 57^XA;< /TL,-F6!!Q7-5XFI'_* 8!T"]Y;,%J&R>)*@:+FC-'
M^+!I.Q%C7=H^D-"D2 $WT*'+T\P*V\QM*,!^FIM\@:H61<AK?:Q*Z;,H&Q-A
MZ(\?C0,:T;-Q[1.CO0PZ,9"<&P8XL S6,X92-*,W:A<J.;8S:A%)>2L-5:U\
M_:7%5-/<+=N-J5'<55\R2JX:6MKMR+LO$<(J<8L! +"1ZK4IFYR<B@FYG)%"
MUT+_7&9'&VLA:*P/-,BAC Q:?X$&D2Q&?/O;0A?&CPGAY.N7$E*C*MBQ'LY(
M$N61 2QS*^RI(JD"E&W%0KM$&G%>G/:JR/P3!]J8""%[6CR_B8HT="11RE"S
MVLLBFT(02IN1Z$FK<;+6#Y:6DTLUSQW:90ZU/_N#M% +0_A$ G'**&(0@!;.
MRPBO%VK#2F/#"HN#;7>+\%1JN^)I8LII!"$)$S41^M"AF$@!JRD"/B #F<#:
M!:$X-IPC1L*W8<QS=.9ZXS4JCQFJGRT&<WQZAP>C,KKGXWO8?.$S@.9IH[L"
M*0PV0BH&TRD,(5C!^^!*TPN#7?R8:&![M&LGV!K58H!T_T>)$4+WF9'G,[%+
M%:>^C JZOHMKB3KVBSY!#YAHAF@X7M!;#SM,=\H@ W+X&"7(. )5V?$Y!GEW
MATF4P!ILYN\.[T;A$,N0,#=P %O0V[\K0U8WQ$M!JJ61ADG1VU1QRIY77/5^
MA&B@#*.-))^G[P _@_F.Z 5/=B'<4/HP!M=QS_&H%F0^=Z7'; *5FDP>[R5O
M\M9:&BF?\AS*=<2;%0^O\LJ0H=[N>:,=\ZR-Z#[1#OX,#KO:\_N@#S\?]#Q/
M]$ O]$=?]$-O]#Y?]/2 ]$L?:3N?$HM'VBI/VC3_[0;!H=5K[FNMUW=WXH")
M'[=2P/M^\F<_SOJ>H:6!\T#/=<T2GA7$K0RL3?>W5[TS7QKTWO ^X0[90 _9
MT [9L ^ GPWU0/B&'_B(7_B'S_B)W_B+[_B!/_B!__>2__B*/_@SE*'1H Q:
MU/DAGW<"T2\4C_:E;_KV!Y/MS4YC_7?_V% RKZ&+EWO%-= <2OHA00_3,!!]
M#WM_W_M^'VG [_O!__O%3_S'/_ST( W_F/N[+_S/W_O2D+@SQ$[%)=@QF7>)
M^Q0-A?6G[_W??WX<^A2(/OY_1S4QB?U[/WKZ'FG9FWO_^!1+W7=.%_LF#?[W
M8(__Z6?V@)>][@\0^P0.)%C0X$&$"14N9-AP83U]#B5.I%C18C2+&35N+%B/
MXT>0(46.)%G2Y$F4*56N9-G2Y4N8,67.I%G3)L&(-W7NY-GSID>?084.)5K4
MZ%&D25$&!  [4$L#!!0    ( *Z!?5321^0K6-0  %D&"0 5    861V;2TR
M,#(Q,3(S,5]L86(N>&ULY+UY<^0XEB?X_WP*;/;86I:9D,D#/%#3W6.*JR9L
M(R-B0\JJ*0M;<\,98I?+J2;IBE!_^@5XN%-^ G208M:892HD=Q)X[P?RAP?@
M'?_Z/W_<+\&C*,HL7_W;3_XOWD] K%C.L]6W?_OI]]MW,/WI?_[[?_MO__I_
M0?B_7WWY -[D;'TO5A5X70A2"0Z^9]4=^!L7Y3^ +/)[\+>\^$?V2"#\]_JF
MU_G#4Y%]NZM X 7![K?%GWV2BH@F#%)&0HC\.((4,0_Z 8L"%@<(<7SU[<\R
MX#@(60"Y\ *(./$@B9(4)MQC/$*$$<3K1I?9ZA]_UC\H*050RJW*^L]_^^FN
MJA[^_.NOW[]__^4'+9:_Y,6W7P//"W_MKOZIO?S'WO7?P_IJ'V/\:_WMYM(R
M.W2A:M;_]7__]N&&W8E[ K-569$5TQV4V9_+^L,/.2-5C?E9N<#1*_1?L+L,
MZH\4;C#T?_E1\I_^_;\!T,!1Y$OQ14B@__W]R_NC7>)?]16_KL0W/;*?19'E
M_*8B1?6!4+%4TM>M54\/XM]^*K/[AZ7H/KLKA#S<[+(HGK6JI<1:2C_64O[+
ML<Y^O4!\1_)6^[(Z$*Y6]Z,K&4]A^M&9N+>*'\3X O>ZN5CDYH%ZN^)3/;N;
MKBX6?7R)73T6>466$SP6VVYZ(B_U!Q_4;VTWNJ$39%KWTU)W3U3QHQ(K+AJV
M?-8TR/B__:1^6ZQ+^(V0A\5;4JS4K%BJX;ZY(X7XG"\S]G2K6GBUS-D_%DRD
M-*0^@8E/(HAB]8/@6,"0QE'*L(>Q'R^JS2.^$"OX^TTG3=VE57\_6>A='7E_
M"U'FZX)M9[[[Y:'I3,UD>NY+?UV1>U$^D/8&);0V$AH]_OT5*3,&R(J#-]ER
MK2T#Q3_@0UZ60&D :A7^]=>MLI<#OIP:QN6X"':2;O&Z HVTX&O[KQ8;U'+_
M?T>QS-DS"9?:T,B+781R9HO0]CTNE7(U/)*4M-:O;4IA%?B_BF55=I] _0GT
M_-8H^1?3/G_=>SRNBTXO4K SH]5>\2O+E=7U4,%G Z>MU$$ 5/F@)ZL9!B72
M3R ON"B4E7U O;VG_X-0-MU=ON3O[Q^*_%%HH[O\3=Q342Q8Q)3URWR81C&!
MB-( T@1AB%@:,\$3Z>'4AFI.]#4WFMF("K*>K';$<@I:,U)Q!-C(A++%JB\F
M^-H(ZI!!#.!PRAZG^IN4.0P4WV4-DUN&,<8[DA5_)<NU^$UUL2Z:EC<?_J],
M%*K)NZ<W^3W)5@ONH0BE"8(\4D2"!&,P]5(,<:"MF"A(O3!</(J"YJ8L8M6_
MS6O2EV*\MT5+"FI1P4;6VI[Y>/U7.WZQ&P@SQAD-W)$YZ!2JX&LCKD,F&@23
M4VZRDV!2MAH$SBY_#6MD&*.I%<3[%<OOA5Y&+%)., \C3]DZ0:(66#R%E"<A
M]$+/2]*44<'%HMHL%L^^4L]:M[)SCJQ[7;XW>O&T5'+9,<]SP'P?IS21"$:2
M(H@DP3#U!862<>$A'.*(,QLS<3A@$QB&+@ SH^+!,(Q,M1J!1C#PLQ;M3^"Z
MJHJ,KBM"EP)4.?BL5BFKRAW;'D3"*9L^[V%2MCRHW"X;'KYH&-M]>E#<6:D5
M96TB?M&')I_D[Z6X+DM1+5A ]-NLUGR(<HA(&, T3"@D:@WH>:F?JC6AG;UV
MLK_YV6<;<<%2RPOJ4R682[A6?Q ML^6[?QIO,RYPAN'(W+ %KQ;T"GSIT%/"
M@EI:=[1@!(I3FCC=XZ2T8:3\+HV8W32,5MX(*8I"\%ORHVZNW':F..LU*8HG
MF1??2<'+12A2'RDN@0&- K4H3"*82DEA(F5"9( B%A(;B\&B[SG:$_F6<O0^
M-NO+:\<U-H-@QCPC03LR#W52 R5V0SOE%>B1DX;YM1',UJPT #"G'&73_Z2,
M-0"87?X:TL0P-OM<M%W=5#G[1[WO7GY:5]K!0ONL+# C L5)HA8YJ5HD>EX
M,:,IQ+Y:\G _(7$H;1CL3']S8ZV-N*#4\EZ!LI88Y%N1P<_9JOWX3W8D=@Y[
M,^)RB.C(9+4%\Z8!LQ$6]*1U1T^&L#BEI'-]3DI#A@#L4H_I;</HIEG<W52D
MJC>Z.J^MZQ^9,I9\WT]BWX/$QQ%$"1$08R]1./M2RC0@PJ<V5'.BK[G13+O-
ML)$5=,+:$<HI=,W(Q!%F(Q/)4;C 5RVIP_UO SR<,LBI_B9E#P/%=YG#Y!8[
MUBB+:O%%#;SHSNG],*94K9_B" G-$ CB2"BSA/MQZA&?^F;G]#OMSHT--(19
M666,+$'O5,","W8Q._W>7X#$R._X$1 <GG$=T?W4^ZQNZ;W+ZJ_=]WBWS4G>
MV2.*=._GL:^'S> WXIL>AR_B(2_T@J3QTMGU)0O2U/,BDD#J)>I-]1.J5@QJ
M5H^)1Z( R12EV&8N-^IU=N]Q(S382&TWFYLA;3:O.\=O[+=_%[II7/>L8'(Z
M\9OU/*D)8 7&KC%@=[,=%7&1J?;9NLBJI[<_V)WFMH_J85I(/V0\]CF4'#&(
M:!!#BO5F!>&*D*2?8A&9L,ZQ#N9',(V,H!,2:"G-6.8HB*<)Q04THW.'%2K&
M)'%.]0-\4 KVR[?\\5=U:TT%_XGTK[#YM7[_CS8ZR:M^3J7NK3Y[G?T+_'95
MJ<;TFJ%0%%&O%.JEP^M\O:J*I]<Y%PO/)TG" @)IR)65CP6&).4(AB1@J6"1
M1&E@^CX;]#>WU[L1&3R3^:I9]2J802LYT**;O_,FN)^G ,=HCLP(+H"TH@D+
M> :SADD?DY&(A<)]3K&YS8YB"'^\7[P1M&II*Q/E]2/)EMIUYUU>W)"E^(U4
M-:%=+^O!%/QZQ6^4J;+]YHWZ]%JJ5_W32MS>%?GZV]WM]_SO@A3E0L0Q0G'J
M08_$*42)]A^1200CB@7SO)A[S&@O8FQ!YT9JOY'B'Z+QH"HW&C=1SVJ%KU;V
M^DCEOM%+?T-%]5V(%<A7HO9SK;[GX$DK9D9YHS\'I[ER3J,[,LEJ+<%6S2NP
M410J3:%6]0IT*JEO.W7K46T4WGP-M,KJ&JTT4%J#5FV@] 9_G]'H\S9\OZ:N
M/\13\$SB?_JGP7C6GFJ(FNE>]U;/YW[0[@.,WO\DIL!4*'8VQ&3]#=PKU:>G
MKT@I^.O\_D&LRN9 I"CT^DF_A*^>MI=\)D_ZHVOMU?'V/]>U75161?VREI^J
M.U'<JG77IP?=1*F4DR)3\HOR;T*[MRF]'D5!OHF_J,8KK=(FAF"1A+%' A+#
MA&"UC$)40L(1@D02&J64H9!:>:'-0ZVY&3:M[(K"M$/([S=OP(.BJ]HQQ-(O
M9![XFNXLST+8&=E!M;909Y#AH \)Z&$"Z!/H7]?B FI@KD ##>AA VIP0*70
M 2T\5Z 'T!7H( (M1J &J9XZP39HS.%6^:S&W>U>_#Q4FW:S?QXZ'SM-F)=T
MPZR!+^)1K-;BG<+^=;ZJ"L*JOZEE[^MU6>7WHKBF9?W9@G./)$QP&$JB(U,$
M@2D6/DS5G!VH.1MQ+[&9K@W[G=M\VHK=9$'K!&\V"CK1P==.^.-G@!<-A=D4
M. + (\]1CK"UGC0LD7+*ZJ9]3TJ[EH#L\J+M[<.(ZYKS3),E67XF&7^_>DT>
MLHHL%17?Z_U:[860*&KR_=2'V L\G4]0+3%0[$,NPS!DH? X#FTXZWR7<Z.K
MK<3@08D,U1J -4+;49,!V&:LY!;"D0FIAYZ6%BCT6GFO0"-QXS/NCHK,X7'*
M0@;=3DI YC#L<H_%G1/OGNR;=N]735+!!9,<2<8$E )I'W.)="2+@"D+PY01
MG].0+OI9_<9;_QZ7TNB]/)OCT.7K^5JG6UTN!?]5/MOE&!3V,L:XCKQ7<>%8
M_6$V'@YM+6@N;G2=P>;!^8&8QT[ "3G_&,OZ\T [6Z,;=.4B <3.\OY+=]A<
M?WDKBGM_$:NI@;.4P3!*8F7%!A3B1"W$8QE%(<&1Q)YO8\7:"C WF[:3&))V
M3W%[0M_DC%!"W%^2),)@3,R8?4RD1Z;MO502>SNY&_F;*\#M*=0OS"YA#MV(
M"2<,A'C!'!3F$)U.2V'1SL $AGFANEB]7A>%6+&G6\7$)6$UV5ZO>/WGLB;I
M<C>H@$=1%,LXA#3&""*/I)"B((*I+_T$Q1BC2-@0X6!)YL:(K2*@T\0RD>'@
M 3%CP4E@'ID.=Q$&?2UJ[Y"^'I-$A5P,J]N$B(.EF38YXJ6@[25*O+C!@5:D
M/C%JLG!\5*K7W5<+' 82\<B#**(11$+$D.CT/LQ7MJ*?TM!'W,I4/-3+W-CO
MC7C(RZRJW\*\/I!>Y2O8"CLL9]A!< UMODLA&]NPJQ'JDO)L171HNIU"P*U]
M=K"G:8VP4\KN65HG+QZX'\GN!%\OQ2=Y=JE;'EOKWFK/M$6$22I#GT%)D6(0
MRB7$-,4ZPH7XRL9"B32*4W,NV=P(IU,,Y!*8;&^5)_>WP-=:2<NS8G?#;KA)
M^1*#.?;6Y+3C:+\?Z1ISM[N0SJ2;=N_1-:A[.X[..YCXH&KC6:1FJO5]LPWZ
M]L>#8)7@;[+'C(L5_T(JL1"8\R#Q4BC"NER?SR'F?@P3+GW/IURPP,HE:'2)
MYS:1=#("W@H)GC*Q/'ZB\4+C//(QUABC-_]#K5[)A)[>5V#S3'2J ZW[# ZY
M;(=I'D=>QE+_,0[ ; ?!V7&8=<<33UH?USJ+4#OG/@NWJ3UF%S$7 :.<0AGS
MNA".!TF0<$A($@H?1T%,K/:.QQ)T;E-4FPR3='("F1= KO6!*/BF!2Y?P.7B
MW&"//&$Y',+YSU.-LILE4KD-F:P?A5KC&<Q.AF,RCTGIG+!_C+G($')G4Y!I
M?\-FGF?"J+E,5%F3V^]-5K)EKC/];1SPHS@)&$8A3((TALA+!21IB&#*&26Q
MX)S$5@L?B[[G-C]L906OQ$K(3)<>'!C_8#,$9A0_$K CL_9 3*W)=@ Z3OG3
MIO])*7$ ,+LL-Z2)@<1%RCO]OPXJ>R1+O:WT1:B6,VV:ZR_J[OL?]*YL/-K>
MKUBAW3O>B.9?]?=RK?-J=UFUM&7_5DIE[2\2+\"1SV-E+4@.D3XJ(&&:0LRQ
MQ]. $Y8F-O79IA7?BCXG*@#'6[%!'9Q1WM4'F?4O8JMI_6&QP:'^WI)=IWU.
M# EZMJ,_,L=K5:Z _@EZ&EV!K;+-EWK8=S][=D,# NA0 #]W./SI"FR@V"8=
MU&" !@V'$\F+C*+;N6A:%::=SEYD>/9FQ)>18F@.R'?94C0KCD7@QYXO(JHC
M<[!VK8DA\6D"L8<8(3A )#+*5'*H\;G9\XU\0 O8+OUMDSCV@#L]!UP*Q\@,
M;8'$@"R,^RI?F'*QU^#$^17W5=E/IGC@FAF=:OXUUSYZ2R5G?=Z%:1I3&:I7
MW8L)1+&0$,<>@TP9MTGD1XAYT^P5F\L\.QKI3K$>-V+.X%1S9YQ?\%QS^.C-
M?\?X[,GF5OD_PMGFX:&:QT:RA=Q_C#UE^X&8Y(3S2-=#$U?\Q[JL:O^?V_Q(
MO'HM(MW5XHO>$"BS2MR(XC%CHK&*OPB6?UO5K30ITD(4$D:1@'ZL"Q+A-(5I
MFH;*<@UC@CU)?('LTEZ,*_#<)J\Z34#+;:S/@>*'_MTPK?EDPVTVC<UI$$>>
MPZX_OW]]=7B&VM+ U7;+1-;9UDM=UV6CD\N4'M, [S@AR,A"3YQ.9)HAV$]&
M,E&_+Y/*Y.T/4;"LW$;&W^H=\_>KJLA69<8:=I(X)1&-$NC[+(&() *F ?8A
M0B*F#*><!E;1ZU,(/;<)J1819)V,X+$VKG/9E/\%>:.9FIX:U:9R(+5Y#$9>
M:XTTN/-?;'W:KJY:U;>94?04USTR<\FS.F"@YK'4LA'\C['6&C 4KK.K6/4]
MH-3*%R7$IDCG)_E%IS;X)'\O11V$]VE5)S7X+>>9S)JRL O.4L_'$D,B$($H
M8#Y4*ZD8TC1F*$Q229#1WM^P[N<V\3Q30$\XA58!YA*NE=U<A]8"15=-VI7[
MGB(6A3#LQ^CT7#(^\J.[__1!_R1!+3W\)*&2OXG<!9]6;=:5WZ8"W:*FR*C@
M3U0IQ/T@V!7]&(SAR5(>]JU.5Z!CL,;/RFX,;V7 ]'+[/;^]R]<E6?$;G?.V
M$F+U?L77K.[]LWJ@VG+7H?"([X<^Q%'$(0KC1.=E\"!.8A]Q]2P&Q+PLEVFO
M<YM, L]/P%90H"6UH"QCL VFAS$@''E6T%6%.IG!1NA=/,'71G!#SUL[8"VF
M@#$ GHCY-=!5!W2Y 3K; OV@KO_%$<_; G62WHT;FX[5;?5[1N;6-P_;!_L@
MU-P@/C2>124KLGIQ\B%;B?>5N"\7-!8B]7@$/<^/(:(L@3CE"8PX#CSN>\+C
MS&8+ZTQ_<^/M1MRK+A%@3V3P50L-:JDM??W/86ZV7^00R9'I^U(0K7=H#*%Q
MNKERKL])]T4, =C=TC"];1C5O+]_(%G1V*9U'W?YDB]"E(2)#!+(!?$@BD,.
M*<$44LYDXL<^$P3;$,S!7N9&*ULA]<;"LA/3CD8.XVE&'A>C-#)E/ ?HPUF
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MX2-7.=IMU]N_E$2,^%$*0Q0IXT"B&%(_5?:_E%Z<AK$(=,3$!5OL,]Q7;[(
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MA\GBH3YW>KOBT\Q2>U+:T-AS6<?CLYZ0PS/]N!_/:2:=BT;H#S31]/2\<K;
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M:>WY9#4&9BPY%K(C$^,V9?F;?LKR!NNM\."# =3V%20'8.:VL*2- -/6FQP
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M,+TD6"XW6;+7[4S9<GC^T'WQ^NVGVO^;9X5@ZH&W33!Y>(P,#?V+D1_;*F_
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MZB"?(2]%#(8)1A"1,($TI8I/8Q12A#'RL%4EGK,]SHTP._'T9I26SSKA[AF
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M/G?K!_6)Z$(,M4M>_6U^)@S=T1"9F26C C\R$S51_:U7;"/])M2S+8K^/#'
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M!,1)3,="*M,S842ARM, (HH5H 1SF/(D"!-)N!\%BX=Z'U.9S$4U&;:[?;X
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MF/LLI"&E1H4@SW4T-\IOU[*ML%>-%[*"%'0"VVX$','7= O@<M2F6?P/ &S
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MW$ILF2+R!*R&RT<G8(UM;VV%W)#%V!6*CJ Q5DVBW>Y>J@K1$;5/U!TZ=L?
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M?&=J1?AXZJU5(3Z5&TWGVQ<S]M:4.OKOY^63.31L2A HFLLT%07(&)8 QD0
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M]VX70_-R%W5*!(VEN0%&OT'!(^28-GAX/% G0<8W/&KD_NBD>?>"B!02E$-
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MB"0YQR06>;Q8UR&>5VI?>9;,B@)(0P%]^4(R0:U)[<S:U,ZLU6;] $QJ9QL
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M)_9KG5?IU+%UX;H108&C#8XORX?U4BVYEJ%W5/Q5PU^9'Q<B%S!F"08R-BQ
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M;\2E >9&.8U\VK+8G5EI-OGETWLW'CF!T8XV;@$G,$OL1.O*M_ECA$M:>R6
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MQ5Z>U75TT.7ATR:+MCRK1#_,\OP%-U;E:LKH&*-LLS9FV/V/9;5(28YSCE.
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M$(CE+,89*'": J@H U0* 5)(1%Y 6G#3,L,^VN?@Z?.,\>&-<!&M176TPP[
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M=S_H$!!^W9QG1YK6BSFD[(F3<O#B$4Z'II.AGE!9?:5L)1=8:).7)1D@6"0
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M<LPAI$C"3"0NP32N LS-V;Z3L.FK6LMX6];%U2FP,Q9" AO<<KB:A5$[5'K
MA\O*L,4M:';&52%>-4O#%J)KV1K6SQG'=7]4\J/JLJ2J149XD0G%00(SK&T/
M6@!:H!P42/)<)0Q2R%W\*X>/GYOYH:4S/>1V\KEQU!%T=@PT'I# _'*,Q5WT
M:;-:\I?HS_;/K_*'IG+]RO_3HV?D/!Q>:>-HB$E)X;QZQY_\A:OFT._R'^6F
MJA9*LMCTI@ 29PF 19P#G!(%<J9$RBDK:&P5RQ%0QKE1RS]Z_2CK/I35JS:B
M;.;1CJ)>>78"\US8AI*UMO.IO#0P%;,JK71.SK]4[:0!H,/V=CP<RMWY]+8-
M6KE?KY_IZK-\TO;E J94$I;'0"4" AAG%-!,,(!@G')59#BG5H6/+@TP-[+N
M9(P:(:-&2GMGU%D0KWND;H4F]([3#14GY]20ZJ,]5&<?.IF;:DBEOJ]J\+J1
M-A__)L7SREB172]U67Y?<GF!:U:KUE'V49DS_8>UV5$V?&+VE94Q]6M+?R&T
M;4=Y(DRCH@R8D%Y 49(!E@HJH(0\ILC)\@LEZ=PHI6YF#WXY-3/:"#%'8S#8
M!%N:A'.8M@D-PYW!MU^5[[J9$W7$Q1OZM-S2E=&KBV-JZR&%V2@'GP&_]F P
M::>U"D.#?F(;!A_0W4)LG8\O2<J^+K<KN>!)K@J$<Y!)E ,H3 R$4 10B(C$
M,6(<6GD#SCU\;C1>"V7\8DGZ$_NY\[];EL,\B]YUL_ 63 )SI"L<3C;A);U'
MVX,G#YS,%KRD2M\.O'C-V.BE@W."HU.$K[)\7%"*<XY4!B1)];8.%JG^<+4Q
MEW!"11KGB72L9WMUR+E]SK_1\I]R6Z_25>\H30_]Z!J_=!5M.\O*+X9S.(/\
M.@3FB/ E6WP\1R]='7;BX"5;&$YCEZSO'!VVS:44=3[[^ZIZ-M%0'Y4V4QXW
MZWH7M*!$J(((")1*M<$@-0-1T\@G3V.9%H3 HG -VAX><6ZTTPG<E)[8**4M
MM/6#64=Y+714&:GOHK7<FG]<MCK5/7X<#R6OSX8=+WG%.# M'<+;26N0;.2-
M:H&]AG/;8>,[F/O*J%.'<MN!<":0V_+&D=%;=83FHN",4Z%BP).L # 5,: %
M(T!R2FDB<E@DPBDFJW[LW"*MVK3F6C;'"*L&)CLV<%<^\"=_/ZRQ>X#3@8)^
MPY::1T\;C'2@SDF(T>%O1R[[>CYZU49AR@5E60XPPR9H62J $TP!QR2-*402
MIKG3&G_P^-DMZ/IO#H5;+V!FN1*/1B+TLMN!X+$$Z[#2?M?3PR&F73S/JG>R
M4IZ_:MSWVEM@:V=BU?8N^;<4"Z54PAG+]"=+,@ Q9(!2I  51.!$Q8J[=1X?
M&&MN7_*; P.\B=3IVM[\^Y;XG2&\[3Y\3R@&9H&^B7W71,U4T5Y2?Y1@ 8=7
M?A@:;U*RL%#\F#EL;AD?*V+R+1>,)3F"D((X)M3$B C-&1D'J52QE!E)>6*U
MX!\_>&X$L8N"L$^L/L'JNL]_+ *A'7Y6RH^*_.AK>G/$1_VPR2,]^BJ<B_ X
M^/VX5;LKK7"_%F_W54O:D^A%(B 4QNB.S6H-198!)F,%1)[DF*4IPQ2ZK-N#
MH\WMP[Q4TL5MF1X&V&ZA]@9;X*_Y +&>I%=C4IS7:BM$O*[6PR-.NEY;*7^\
M8MO=-#(\[/GI:54'L=#5+W1E'&Y?ODFY?;NL^&I3/>MW;!\0Q'*D\EPQD A3
M847JQ1TG+ 9)FJ><%ED*"Z<,()?!YT8QK;Q1+7 =QK59FQ+OCL%;+O#;,4XH
M4 ,34%_LZ!#<GN31GV$BJ$9@YC<HRD6 :>.<1D!S$KHTYAGC.[]LRL,V#%WW
MA:^;7^1GR:4IZ_/U7QO3B:%:0)(Q21)-8H+E "+"C6LC!K)(,A8S"%.1NG9^
M<1%@;KRF7]#,O?.+$^1V/!82R,!<UHA^IO-+%SO:M'WI-&A;OVA%_'9^&8.>
M]\XO3D),WOEE#$3G.K^,>L[88*ZG4O*FSIZV"-NL[Z;22<SC."_T?B_-<Y.<
M$Q- "<I!4F18Q"E-D%M(_L!8<^.MOJCU)H;VA'4-X+J,L!UW><(MM >G)^6=
MWO3I-7J'7E_DNLW)4[D1S]Q/"1H'F#Q';ET>;^*0K:N*G\9J7;\EL,GT39:2
M*OTQ+U**X@PE!*0JHP J)0'A4H <Q93%$.4*.9WHNHLP-_K92Q;(>-J#[]E\
M&@7IW RH6H&V@Y[^EU>PHTY@?!U+:B_&/&VI$YA&6U.G3_+7*_2S7,M_T54=
MJRVI5)@S"20J] 81$@:P*O0&,<DUS:D<%=C)D7YEO+D16RU?5#8"CHB&OP:O
M/9MY FT"ZCK;];,5UW,,O"4PP1MZ]L=\]?Z=9P"P:==Y[K:)"^U\6*YEW<9M
MD>1%!AF#@,5Z!B#-$6 J3P I$LJ2(HXM*WWZ$VENS'1SM9;H3Z-;5"MWV9D<
M:H(MO?F33EMH'_\T,S9=*9T3D.=1.6<OUE^C4,X)C-[JXIP^>41CNS>T,F>O
MY@]36?X[79G']ZLM+G*LTDRH L!"FBJO"0-,(@BR(DE$09%0A-O5?K<<T>JK
MGK3NNUE1_QX9D2.YD[FZZ_QP^E,V*4L1LR_X:@O^,)/Z!'2BL$F#X7U=2$+_
ML)?7MH3K*! =.J3Y!7.BUFBW@NK6$LT>HL%>:!:/F:X)FKU.!]W/'&X;:6PO
M']9+M>2F]P?GIMJ*-NCKPJ3+?O1$(9'4+$T 0@4#$.,<,$YCP!F52<JI8-#I
MH-=NV-D9S<^/C[1\,0F0U5X!T_RRU2!Z:E5P-(CM)L'2Z/4.;6C#M@?E7N*H
M$SE4U(H33'Y-4[NAIS4_G> X,3'=[AY'5;_+K>'!3^7F^U)(\<O+']I>?;_>
MN2'N3<>\IF.IPDAF'&.0$H2U6:D8P%@6FJXR%,.8:P)3+CFJ]D,[4=8$>:Q:
M\HB;1?O9[ >7ZVBS<ZW1G=!N;.4P#W:,%0;=P*QE@*VMH4YLL_?^Z8\&Y9][
M'LS[ZS [DY<[8EX)S&'X24G,'99C(AOQA'%DMFOR^(:6Y8O:E&;#W92[6ZB,
M9Y0K#')(4P")P("9+K.<"500C&C*,Q=C:V"LN5E87W==8S5K[85U9*@A<.TH
MR1-D@3EHW_PUZLOIO_^K!1Q>"69HO$D9Q4+Q8PJQN64<9[Q[+M?+[7,I]8[P
MW?*'^:GZ33XR62Z08!0JE@!.)020PAC06'%3AHR+'"'(I%.B\>6AYL88.TGK
MR"O5RNK&%P/ VM&%'[@"L\4A4IV8T9^-H!ZW5M?1\$H6 \--RA77U3ZF"HL[
M1C(%79:FE:)L*I+HQW]84K9<U9;+;Y*:K 'Q<?W9E"\S%;/T!;]OUF7WU[K_
M45US=R%$HCA4*<B54@#&" %&E 280"*%2E"<.]DBWB2;'0]IQ>J&HW6T0BMN
M_:7UY6]+&3L>F/J;3DLZ>XU)"LU^?N;'G0Q]8^F7.[U)-RW5^@;UA)F]#S"V
MN$SYM-%;3_G+9BWVU29;XR0ML$I%$@.>)@+ '!/ "AX#(FC!$%(R9T[1=8.C
MS8UP=\)&3$OK:/$-XVK'DM[0"GTBN@/*"-HK,QO ]+/"Q',UF:$1)ZXG8Z'\
M:449FYM&!%ZTAU4?U;!SOC8+$DE2J;(,))HW )0B!0Q*#F2JM &8B5S_SX9(
M7 >>&Z=T!WP?573]5,K!D'.>D&$&"@ESZ,.^N2#L$+(1".F)8C?L#ZW_YBE^
M8P1>@X$<+L^;+J)CA)8'H1UC[O=YUO!C62U4RD1!\A1(F"0 PA@"++,4I%)P
MI7!&L%L!\8LCS8WH+WC.?1PS_+!NFNX%K=<Y8HC^-')Z-!RO8C'!^<*/J5N;
M7U7:[FSAQ\W-RNL,CC>;];:D?/O<9'&TM71C*N.$<*@I@DD J=YHXB250-"8
M0@55EK#8+8/KTE!SXX@F>:LG:IU]=+TFKRO"=F3A![? ;#$6LA&96]?0\)RT
M=7&XB?.UKJE]FJIU]8YQE/%?<OGP;2O%_7=9T@?Y^[/9KVICIJZ*^O%Y6VWI
M6K2N,+X@F(LD%4)O,"$$,&.):6V& *%(8)8712&2A7X2V]CRB-/X+I](7XIP
M7THG/J"-_+N&)4V=W\U>@0C48?]\?,5DMZFRHZ-@\ =FJ$[NJ!4\:B0WNZ.V
MQ')/^+NH%M\?;8U"S2N3N4DP*;F- N>8[\8]9!P%_DK+M7Y4]4F6]?/?+E?/
M>NA%SI"@.,E!G$D.(-$_8<H50%SFLI!Z>YLYG9E>&&=N]I*)B%QMJBIZTM]3
M352:ND0C:TU>8K-:T;+W>T<>NX2W'6-Y0#$P-W421EK$AHWNHE9*?Q1T!0:O
M9'-IK$EIY8K"QP1R[?*1:39;NC51'A_T_*S^W^=R68EE70^J/7'*"=:4D1&0
M9*;U:UH@P)*X *FVC_*XX @KJ]:OEN/-C3IJ<3T$?EZ#V8XI/((7VIM>XV:"
M&&I9H[ZP 4[W+('QFRQS9<QILV3L #A)C[&\;<0IW_NUWCC(K_2'K#[LJB-0
M%<>"PP0(HBB 2<X!(2D#!<6:4&1*A5W5G8LCS(T_&AFC6L@1A2DN(VEQ#G<K
M/H$I(A@T#@=HMT(TT4E9"]76R.GK+&Q(]<%#K[,W3G>Z-23WP3'6X(7CC*7=
M(S]+(^IRU11N_'VS%K(NH\E6LFLD(1,NTAPRD N(3 @4!S2E,9!"\9@*E%/J
M5%7?8>RYD:"6$>R%C&0CI:,%Y8*]G345"-'0>S&EI,GUTFRY(]#HL[&V#M6H
MR[OV4&\U\9^",P)&KW:8R_B3VF0C@#FVS\8\PBNUO=N4<OFPWO]6OVAOEZ:=
MM5[UEG2U*"!BA# $TB(3>G\H*2!2;Q(QQ22&&<X3)3W0W#4YYD9YK;Q1'=TH
M>H)Z(;VKLW(3 ?K$>C9DV$W(\75]Q2;C1EN$I^#)J[+,@3-M ;/D3^O'C6Z\
M^E3*;YJ5]9O9#/*[W'Y4>J0%BM,4P8P"Q:!I3))D@%"]#48QRB72MB$V?&E?
M &)@+"=.G*#BPX&HM4/>N;_J15CM",\36(%)[1"GEK!^^J#Q^ED;=7)KC@2U
MQ)JMMMMRR9ZW)A+/U,[^1,NA;GAC^J]>@\MW_]6+XTW=?_6:XF?ZKUZ]9:QE
M]EU66^-EJ$,O7_9EE[#DBJ8< XR* D!89]D4 DB$I&*B8 0Y9=E<'&ENUM67
M;YMR"^H(GKW,SOO)2[#:&D\>P KN8NMDO&NBUU^B/]L_@Y2NNHJ)9X/FTF@3
MFRQ7E#XU2J[=X+4,U;OEFFK3YZ#\$5))(K,4 9DS J#B$N"$*L P4A"B0J0X
M]E"&ZLS0<S-*=F6HGGK5DE0GM^]25.?FPHYNPB <F'^NE*+:"3]E*:H!Q*8H
M175N^#F4HAJ Q;(4U= 3)JZW;RJ2;E_>KZMM61_/5!^WWV3Y]1M=?WPRC^C'
M6QW%97V6)@15__M1:&JU@"K-S/^!C/,$0*%2@'$& 8(YR0J.$*%TDM+](;2;
MFX6WBT+MHB%WDI\&<?_T?AV]F!9\CE%;LYJ T(T#7ONE";S2W-R#X"YJ$(IZ
M$$4U1M%6@Q2U*-T=1N&>!.U>?DT]KFRS? GFT2,AB(9_C78+(2?76^>&H$).
M;&74__E/O94S6;&R7&Y$LJ!4,!9G#&0X-1LKG .2DAQ@P4B28YIQY'0<YE.X
MN:WQM8A5]*!U,12ZW43R\6FU>9&RJB,'UYLUV/_+]T87$Z.ME9EHI3\WQ8$7
MZALG;O[K;-/RI]4P^C0\G=.MC0.XSV-I.R?@7V-E&H#6V\(R-,;(=8%_D^)Y
M)3^JW2GSP8'AX9%B70YA[T.FB"":R@3D&.G-8HH3_3$D!.!$<L8HD9 JIW7@
M!F'FQON=+N8<ZU!N\R^] _HVLJ4FFCI7QX0K/^OO_R5Z)_5$:LNZ=W53.[3V
M0>A?U)'-(XX%;IIURZ5AHKD,O13TIM$V#J,MG1/F],$'KGZI_A:!IJ5V#]"=
M4+F/9]Y89?;MLN*KC:F)V&\9I'B1T1P"P4T20IP+@.,B!BD2!>00\R1UZL$Y
M.-K<R'=?;31JJT4VKHZ:/?>_T]_TGDM[V[61Y6'/SH,=6WI#-S =]L#K21JH
M1Y 5*&'JL9X=\75JK XI?[%NZN!-X^BF+8Y5:7O4L-B;Y]+$X2Q$+F-!$TTL
MPK0F0\;\DQD$1"4XHRD73#JE3IX?9FX$TTD9/35BNC'&!2CMJ.)V@ )SQ Z;
M5L*[J)71'S,,8^"5$BX,-2D7#*M[3 )7KAX;[:DE-1Y)8\9\7E;__.7EJWY2
M76XMSA7),\E 7&0<P,QTOT@T(T"(8IYE.&;"J4;5P%ASXX$#42,C:V1$O5:?
MS1EB.VKP!%Q@?AB)V8C SJMH> [LO#S>Q(&=5Q4_#>R\?LO(74H3A?[&4%+Y
MTA8"D##/86)*+62*:)[(4X!%E@$B9([3G"N(G?J9GAMD;E31Y688I\']\_;;
MIEQN7QQW&N>PM-Q@W(A0Z'W%.7!"],89@,'O3N+<0--N( 94/=DW#%T[[KM_
M*Y74AH?0,]KKW7#/JOI4<Y%IW&(J)* %-JYCB #A* :*X((D!$K]@PL## \W
M-R[HI#7)[M%J+^_?W?C@"L9VS. /N< <L0/-D$1/U+OH'Z6I>_5G)[-'OK #
MQRMS7!ER4@ZQ4_^832SO&NV&>'Y\7M&M%'54Q9F4E'9A%#E27*4,$)1* &7,
M 3;1X#E."&4)3>+$*4K!>N2YL4U/\#;8:R#YRMF383D;ULX-_QB']G=\?//^
M0I9:  O&&2'?WA#+T:=VD+B!<L9GXOB T>Q5/DOQ>?-"5X84.]=?##-"BOKH
M7*4 )BS77 4YH$(5,<\*S!1RY*ISX\R0F8R84=G)Z<P^9]&TYII;,0KO2:WA
MV8D8QI4ZA()O]C@[UM1<,:3P&688O'QT\OSC9OUEN^'_/*F-N\@82G.1:<,%
MY]*X2%) 8*H9 7,6)UB11%FU@[(9;&Z,\*:MPVV$O3M7CGMT&>Y!R&W]JWZ
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M:Y@_;P(A,.=9ZN^48'=6U]&)=8=/FRRA[JP2_42Z\Q>,L^N.<S%V00)IH;>
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MY&)[VUCKY/%QL_ZRU7;.)UI^+$VDE!3U$6;7?G%!!%%)PKFV2C*].XPQ!4Q
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MXL.DP3>41Q,IQ6OY-VD@7?%V$AOJ9A\#Y^%F/XWG$%+,$0:RS W 1EK B81
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M'PT>BH:9@W;ARU;F:/B[,UO2?)HOEWY79F6S2LZT^6;4QZ9P*PJ<2PBXEB7
M$ K H,0 (2ZHQ:I0.4JM<SSMAV;X6L?)CXQQ7_\1'I:<:5I(X^8EB@S B'#
MD=9 2VES4[B/+$^AZ9GJ@S(& =!_[$,2M\"=ZM /O/[UBCQ4W. M?1ZR@ZK9
M_L$X_>[HACT$68-!%D (=[9AR XX]+=.?HW1ZW49/:H"HZZR7V-H3A?AKR+#
MR RH1[E152WOGVRX=#.C4@I&*0*P]-1,!;% 0HV!4E3E.4$Z5RJ-F64(,:/,
MXJBL+:W<R[59F)"GZ?E/ V?+: 2HUT8V;G)[M='ZHZ;;/F25LGZ!4ZD[ <+3
MB,&8!M7I-4'_&"2G$5#W1F\:TU=/@95UP5 ?L?Z=6*^_VM7:2^ F"&QRHX0"
MI8$28)5[<FPW2]#"8D*U)K:$=\5:7NIY:KOV38E<GP23FNP2#W?:66*O((YU
MM-B.UFQ ]8)G1Y(/&,)Y"ZQAHSHO]OZZ@9ZW0+D9^WFS@8X4S&:S6:V/0Y8:
M8JZ/JV]-=2CJY'"C9GR.KS-9UHB2*0*8A )@A"@04E! K'LRN17$XJB\^^XB
M3,UVN6<3)[(UI\,>9[J&!7-@&U8)?R:<L5DS;E>9-%FCPT.5VQ]4Z9$4NC."
M_9)&IXLQ+JET9YA>D$YW;ZGC:5S-6[!:F_FGY8NCP!FGREA&2H",M "SO 0<
ME0P85)""<VL1QRD&[D9_4[-FM9R)&\LW,(W<"^X/J:&W;QN2D4K4L.IJ"I]]
M4XO;8V9Q)##][HS>Z'/<S<PX %[L/T;>ULV0/.K_W6VVM:%JP@S,CV9;Q0[X
MM=K'56I5U++ 1A(C08&1+]%H!)!&Y4!KAG*"9%Z@)'K\(82<FLEJZ>C7".M&
MR\#S[#W*AO,Y'*'MJO*K?52]'>0)B+.5KSVN QO8DR'=*^@#99OPKXJ_P?]Y
M"C5VAQR07@W[((*..AL,"?7I%#)H7QT7L*NGYYVSJ_ZL[-E+5M,N%S87BA<8
M(,S=PI48Y*8.]\FBPE*)(60HB2KK0C]3L_Z-F"%V(L@9#HXV*[O]IU@GQOA>
MPC9R 7L_8D,O7!NP]B(.P&E] X9^EZD7^AIW>7I=X1?+TAN7=V7@6NZLLRZ[
MM:?/%S[D=?NU?GPYQ92*D@)5: 4PE25@TOWJ"^\:P\J\Q$D9!%?ZFIIY.!(U
M:V1-I=.Z#&V<9>@)L(&MPWFLAF"]OPU'S_Q8E_L;F13KIN(OF;!NW]*!#.(F
M&;!;X*S]9MS[Y?'AZ,]F8]9?C'9>]?O-9B><WA_,VO- B4_FUZ7KWM<UFV%>
M&NTWSZ@0#&"MG<DA)08%@[@(B> PCR:1&%C8J=FL@X@^$$(LE[LJH2FHZ'W7
MY3Y*H@J)R<07,5\$QCN[6F=VYYX6=V&M<0*_PM!/Q75K.;6Q'B-^)OOV>OQ,
MHZW[T 3'_-0$QV2-RGXC,FN4SEJ/3U [H=#@* ]! CG'A!Z&D4@]JH>B"I92
M[8="M!Z*J[9@W3P4WA0T-L#'BS</Q2X\%,^NV[_T1 HRTC!=)1,96H;Q2$A&
M0O.(O&2L/CNL5.I X>/PX._7J\T)(>@,<:D0$Q84)8< ,X, IPP"B'(J),2T
M%"(NW#:IW^G%S_HSU;]6NZ*MA)*$&2 :\HCYO%<8Q\O.R)S,I_D661#[E$AX
M"%P3IL@A\!UIKNL)Y[2Y*A6OJY-.=&/CS1ZI^AU- \DWWQ<A>R$=>V8I9<QR
M"J@ID(_!X$!"XHN$&^<*6Z3S/"G!\$9_2?[?"#F!'WT?F6YB.CV'Q;,_7MBX
MM[%;;.PEH.-VKWJ$;V#+O8^#;5%$#!B8$0G,(#&OE_I\E4C7&P!<BF^]==MK
MYG)=JW/U#S/_]-E?\\6LW3+W9_/D;*+[_KO5,ISP[<3"D_[E,Y%+0Z"0@!A?
M5]:4&(A2,2!S10DM"(8ZO>3C)%2;VI[9E1J0KY$OULO3$V>=IR/PA":"URD%
MV0"5U4AE>ZBR%E:!F75JB6U]CO\$T^%Z4>\/F$37Y[ .DWK7JX27%@SMM^T'
M]^EO?VJ^<?]Y^?[VIW\#4$L#!!0    ( *Z!?53#(2,<N70  $1O!0 5
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M6*F-] >K_O:JNZF_XSO/@\0X,@0^8#I;$GRYB!^GZUF]P;=:.LS@49+5<K*
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MIU]#G.&J;@)TDJF8!9A,$8%BA']O9  6DG<VRJ3%8Q47^X/G89IZ<(0&@<]
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M%!UCX IWX)E) 8.3.LF=T/GDI<?-,QH/CVUUU,'I?]YH8M,],4_7Q&GUV&M
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M$T$*;1W7LH3=JF3WP-TC9(T[8*LC_ VENK%K,W=[N+]T340P-3W8^.J6YUR
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M$(JG(DM6/+2Q,7V'KB?+99A_VK8%^.7[_6[>MGH7E8HR4P"3 ]8\=%? J1C
MNCH!@NR#;E0%.!@+SSJ0?0I^G^JXM %!!RY+-52_A]-M_S$>LN<Z6B*6D02-
M)W>KY Q.TX^%TC+;1@7\UZCHI3G@48%PNU!P7ZUTA*CS_AE&,%5BG=>$ D$I
MD< K[0&Y428+5IAJTP7U)ATC5^7OK<\'@+&'<,?.J_SXY^+CY\59S9VH'9P6
M9\LUXGS[J'(Y3;[R=]X?A4N?$=%#D-F#$M9"[;@#)C,2DO<27?B1U[?/PGT@
M91\%+XXD[8Z0] &_$BO$V>MY/DL;LWR-J1B)$1<+<"L9A6G(P'NL1?M2,H_&
M)L&>"J%'5QRYC<+PV!E.OAV!YF(W5$YH<]S+FA$Y:&T*1?BU[1.Q0J>W,B"<
M34KF**1S3X7.#NN.W/Y@>  -+>N.8'3=KE[<Y&QB_[-E^EQ'KUUQZ#BSIF;#
M<RX#J,0*!.L9%(V9.'5>"GG(6?;X\B/W[VM[H@TH^0Z<YVW\<-$/VHMBM9$>
MBD\9E"T6G#,1I+*6G$>N#6LS%OP&&;WT3ALS(-M?+QV :G_!7;$]S[?VL24A
M2",H=DEU=DTD$$5+_F,LW@7-6%:^T72+!MR,Z_,? *[[TM7&U/38Q_.-A)-Y
MON^]\:)]N?#DN;($%-C4V4M.@O."I&Z)06Y0ZMMOS0\<R3LO.?+%UNC06#37
M4P^VMM)_7<+7?!%/.S?I&.G8\0K("THURRE!G9*9;209!MO&9#Y,U,B'>R^@
M'%I]'2#QAF?\_[;W94UN';F:[_-?$)'[\C(1U5HZ-.&6/;+<-^:)D0M2YNT2
MJ4NR=.W[ZP?)8I5J+RXG>9)L/[1:+DED OB Q); M:IM""G"&BM]!!M5 B7)
M&W(Y%TA1,!LKAF0;'#Y[I''#WNY0.(SHQKZ+;].,#XS]Q_GL_UZ%RVF9XKW^
MN V)Y-^PJ,E-+RR2FTY*!\$[!B%F:[6..9GMDG;[??^XP7(W4#R6!#LPE$\Y
M'Y]^_>TF@> 4UUH'**'V)X?BP>D2H7#'$E$I3&P3Y[QXK'%'U72#TN%%V $>
M?\'%NEMHMFD)NU4K+T5(IH[4]@Y4#L0J9AW$4 ++VFCG&U7GGS[0N$-MNL/@
M$&(;$7W+Q6KRJ?)NG8105F14Y-P*8<C/\#5+*^GXT5KC%2(CGW<;K-&GWL$9
M_==#C-W[VI'=P%$SC?OSOP?0W%1RT ;'I =5M4;E6%L;0@#D(@JEDO-IJP;^
M[6$S9FKE )$]%/H>_!M9[/^8SJ9?K[[>Q,;1&QLJ\<H3\48*"*).*\G*6,5]
M8&:K9X];"?[>5X\L^GT$-Q^"BV.+/_QQY^"!(=(-F<&*NH -N8=0%T*2KR_K
M;%P6Y5;/V+83_]VO'B=_-9CX]^9B!W[JJ[?D<Y?D3[?+%%B, 7U=%1/K4.62
M!#CC)&3M-?W&E%;;[@X_^\AY@BZJHD=&P-@)K5?)_3!+B[I-\,/LXU75Z(UT
MEA2>XN([YO?SQ8?E\JJ&"!0MU-Q*^(*_S0@J-0Z9<(D2T2C0%(6 TMI"L(:#
M9LA93BX6NV5)JNU!.R]D#0RZ>:<(Z. &J'.E-H_\WX1OTU6X?$3M^ZNZJ/6&
MYHDDO@OKB<"\MC:<45B<&?"@ N-&HI#-5G?O=M3."V-M0'X<P7: W+WY>U^M
M+ZY6O\\7]4'F1' E"@5\Q%\B6^7:T&\5 VLPHTNDO+I-K];@I'1>C&N+_'&!
M<4::\3U,+ZN#2:;B[_1O5Q-MLQ'9TXTF.8DF6P5.YPB)*9-0,(]LI(:Q/2GJ
MO%)X&GIR$$QZ49?X.A_B0SZ\^^/;=''=8K)^RS])2>64)87[AL4Z"*GN_LT>
MN)2J9)65:+3W:3 2.B]*'D$AC@Z$O37@.R[B_"A!\7-L?_<'!4#3)?ZRF":\
M6%[\B(=^+FM3\#:L\'V8+NK<)-PD2B?&1\V]25"8%20BYL!78>DBR=%,4=LD
MAHF1!SUWY[72,4/F\?#1?3[I.=;\.OTRFY9I(B:L8[3K :6?">_+^MN)EE%F
MJQ7(0&:$[M ,P24&)C+C7>;)\-)625XYX;A[3$Y2'8:4>2]^TSY\6/_R3US6
M$>;7%R:?*%2Y1#3K#C.2AA#@753 K;4Z.XY&-9H;-R 56^F$.S.=&!T.IZP*
M-Z_YEZO%U;K2LUZ7]/GW,-OT8ZZOR>6'&\=2HXY)5T:8[&IYV8*K0_A1*R$X
M9B9$F]G$QZ)P*Q7R?ZG0\6!TRNJUH?[&#[UEP.>Z%^S#;+68SI;3M/8^)R4J
MC8'<3O1UQGR2"*XV/S.A$Y/1(]NN7^YXJK4#==O5^]A?>G4<_)R!3MVW*/^!
MTR^_KS!??,<%A7>/@[N)L4Z$RAX?380:R$$4RH#W9'AB24[$1N-/CTOH=IIV
M;J7U4T!5!TJWU;C8C_/9=_*&\=HQ7JYMS=T_KT,4/\Y7_Z]N\+P9)GOW"0\Q
M!4,I9'HPV%"W=SKPQ7"P@A6E<O3FX?.KH1\'MB1O.P4[U[)^?P@Z9[6Z-D/O
MYXO-C^K?XQ/C"S.A6"CK%A_!Z*9/FL+4F#.ZD-&:-GOYCDOG=HIVKET$'6.J
M XT[5J3ZN@> 5B@?#((F#I*,G0;O$GD I=3% [;PU%G3SM LV$Y/_^IBZ F)
MHQ9]V[/NGVNC>"]:_L$G%65BQ!XR<)R#DL0L7[2!DJ5 PPQ3LLU2ZW'HW4X]
MS[JGHF^,=7"=MO/J;S_I^A\]9.)$^BB-(QXY7FN.-B.%TIA!NNAC2%XGWF9[
MV6@D;Z>/Y];(,3K;=T+:R;9UW#P>>8M//R*IS?;K$&#3!S/Q*1M3ZFKN6&>I
M1JD@V.S)6B&WRCD5U'9#BH]VY.WTYZ_.CZ/!HH/[:YT\NB;B[=7BMHY_3=RS
M\WVK3;"H!0^ ZV$=GL3ALF=@DM1"2:\]-G(%]SOP=M@_VPZ/(TBYC\#H1RZT
M4O#NC\IKG-ALDJK;V"RN;S#B8DC! 9,<&2>^:M7HJ?.3Y]D.C&?;*W&XC+I?
MH/?KU=>O8?'GO#RUA'F(17K;?,&P"_5V)JF3Q7H^)1&\KX/NR82)D,$GKR!9
M28BSF8#:YF7'R(OU#BSG_GRU6J["+--=\6E^>?E^OJA_.+&)9\M-ANBYJIMJ
M>'TC'4!(18Z/5<(]W LT=@;H17I.>^7>#L@>NMH_ #QZ<'Z'X\)U5#!1NC#R
M^25@#J5FD@LX'0T4[41*=$-&WME,E>=(.=$Y$P/BLYW*[ &6O;7EV[6GOPJ+
M51<Z<[\V\_?%?+F<1(G61Y4A$?TD%ED@F+K1.:AB)2=_<KL!9B-WF*V).='1
M%?WJS:& Z>&>>2G\ONM.W[2KYDG0INC$!$A/L97*)5. 1:8B,R^C,8%G;!BQ
M[G36$QU9T1#Q;<6].Z#]-:!G^*7ZE5U< \3G@M,ZQ>;'VP;O11(FUUNP#NM@
M/D),FD%"DQ5CP;-.@XLGB#G1^13]7@.' N8LM.:Q#UDTET9Z"<9I \HK!M%&
M"0PU*RBM$S9WJ3/[!1S]-5OTJS&'@>7 @./=K ^-N>XUN9C521]8=Q1\GM<?
M;6[>.OQFPQMG8Y+H+23IZN"/Z,FE9!84KZ*+=15JGX_(MJ5PW,#DA'-=32!T
M)NKUF E&""7I_@5O$I&N@H"0B"=.JBC0RDS!69=ZM)_"-(MK3EAA#@/%F6C&
MG=OW00/RO=DZU5DH&V?!D%-0A(J0'-K:^EBYQ KPE ,%ARQ'U><5M#NMXX9'
M)ZQ;C6'50[+L.!R:9.&#SQ0WRNH1JQ(X>"$3F)30,K3!\NXCIY<(/)L"3A.<
MCZ.6.X'N=$H^SVXYV.8]SGT&A8+(C5%0@D=0Y!= ("<:BC-.4.SJHAW)?1R.
MR+,I$76AF2.![Q1NRM=8\V@ZRHO<L887G0*#2,P E44 YTH SX7/9,"X9IVJ
MYDYTGDTYZR2TLQT$ST%!GRAZO,B?.H:2:Y0@1-:@D.)L'RP#YUE63CK'_4BS
M& >F]&S*:R>AI"UA> IJ.I#SKY5W7G*$8'@$E8J!Z',!ZR1GZ"+/L9Q]Q'D*
M%;PNE'($T)U)ZO7U@LV+'#.>@@ 4#M!Q!\J3"0M2,6#)U$=\SJE.T["'T3VN
M]IYP2O:(<#L3!=V6-9S.[S(R0.UKOP(7X-!)")H;%ND7V]N$H-T(''<QQ0FK
M7 L G8EN7>2\'DP6+G_(]X?0>$)IA,;Z)CV!<EI M"&!B1AYS/3?KL^BQXMD
MC;O1XH3U:#BP]!+&Q=>9$7?VJ#_AUS"=T<_?S&=KUER%R\^X^"HFB5FMN!"@
MR92 LB3!*&*!G)+4=6Z1;WE#'9?8TRXH#@CUH9:/'0EW?0QF.)!)SSC9N_..
M3Z1P*A0E0;/J%&0OP>620"9N75!<LM3PF4$7/#CM"F2_JCP22L_@\GW>HW^>
M1<'5=5LZ4[SL"BCC!00O'6AI2A!*6))UEXJ\![&G797L5V-;XZZ?RW>87/.#
MU2D^*>>X-L""D:"XT^"\82"CU!AR$D*X+N/)9TD:=Q/<"<>2PX"DEZML^'SP
M'?Y<?/FR6+\J?, H;E16QE7+Y_SU<J]84  3,C/#2(+8YZ:=O4D>=VG<"6O;
M<4#6BS8.<\'?9P2?"'*B8\8"MG;D*N4L>)8$2,,=BY:7ID_^FM T\K:XL15J
M?)ST/YDP_8[YZA(W<_SNSONLY%YS;;F\^GK-ED%F%>[UE0-/+SR<[#[F&7KC
M-3<Z 9>2@B49/#@C$+(EJVY#L:71^\J1YQENY+>9N[Q7-]OGJMP39JP.21H0
M)M?%<Q1W1A4U>!Z+LR723]L,A!R,A).>6K@+?A_9^%% T($3='UR^LL7?TR7
MDR"9SG6I6V&A)O^=@LB#!5<X'9YNJY3;A GWCC%R.6@<*,R'DDL'H-J?<3_(
MGN5Z@WX,7_'MO*;+)BHITF2C@*&(=<2(A&"RAZ2EM&B%P#)2@\$>U(P+\0/
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M,>)$8\J32:8V ^6_1[;U5?9-LDO&UCUK/-81 <$BQ0Y,@-&\%!F38[&SHN"
MU)]]CK:=^G1H"G;"\K]=?O=U]HEBK;'DO%GE2/X6(P0;+2FN-EXD6\S)Q<<[
MLN!$;_-_*WO0$M6]. 4'IP5?9TMD(L5"%I([JZMPZR1UH4$S@\JS*%UNV.S0
MGL"SST,?5Y4[0V0OBMHR@5C7';S.M2"$BMYF<%[6C$N5+&H&11NR>LXY&1L6
MCT:G_^SSW6=P8S?#\UE;@1WB'FZ2\J(H8$$;4(G\',\RAV255C[Y4/B_>0Q_
MROGU,[  C;!\]KGYEU<@Q>(]$U$#QI1!">$A<)Z@N(RA)%3*M7G:.Q+!)^K2
M]YYK'PYD9WT?[[Z/;SGQ(@O$$H K3=:86$+&C"R:M(I5)T?[1G/WNV+#N6;9
M!U2<HRE[:Q3W/[&D_NX1:^O,H]D2!YE4LL47##RA9%>2^IA,XIA.U@D$92B^
M4ZD8\(I[0&X"8DY:V3912R^326Y'!>/B^S3A,TI_N?Y(^MW/Y1.F^9?9]'_H
M4&L'=GW2ZX>%W(B$WB>P0I#;+&("B@,\1,\P!5]B#HW>T[0@YZ0GENR"Z^<G
MEHP%C@Y\N \S,G+X*PE\?=?]M"%Q/=; B" +8P4$C[)R6($W6D JQ9:H@S.L
MS;R(%P[5RV23T2 S;R._?J&X&4Y04A9&,4?\L;Z.%V7@6"CT"UIF,I<AM1FL
M\^*QQH7C8,+?#E1[2*(#6'TBF= !?K^8Y;?X'2_GWRI-&X]M,Y^BA@U!A@"^
MU#'/G*X1QRR"CL2X8H7FLLV.ART.UR7$]H'"XXDA@\JE ZC]'6<4WET211?Y
M*\5WU4E93;_C?:)<)#]%HR,L*")*Y0)>)TYQGN"629U9:#.:?JOCC=N6TPYN
MP\NF \ -XX7\2)HB:B\",W6%A:V_9(C<9"#G)+M@LTR-)H0-3$@O(VQZ\1+'
MQ$D':K*A#//3A&],P,03*X5E$6Q2&91.Y#)E\IMD+)GB266Y8$W0O]WYQG4$
M1H70P]&.P\NSTUSJA6+\7[^&[]/9EV7-/^Z3+GWT&4-D1%\^V$!)SWO0FN5/
MN)HNUG[!CZS1;2:(LR2E3V0/I2 '@94 (=41<[9(PS0+TK91WAT.>:@=>_!5
M-RKY-W)MRG2USD_?UB">5HW/))F_T4?^:U*$8IAK_WZQ'!1Q#8(F76&"I6(Q
MBE3:9(0')&)<B]@*G0^MW5A2/Q&3^*,R^&%6YHNOUP'#WL6E73Z^A2'=FIP1
M;*R5Y&HFSP"-J&76C! P:9 >8PV-D)LV.;@CVMBWI%2SJCZSU6(:K^HW5K%L
MM&Y1OW"!:P$M_KS[ERZ^SJ]FJXEVROO,-'@3Z^X6'L$G4K"2L/@LG7:VS5O=
MP\Y].I9T%PP^M*1'E&VGQO,ZO_(Y_('+?8SCW7\^A/%[]C@#&;?;SW\"2#&;
M(@1=Q(D@!2K)"%'40;&.9*GI+F16-]'4%PXU3 GEWD?_N/MSU#8S(K/V=A+!
MWH%+LH!G5;X8A$MM&J1>.E4/V>W#\?%T 64 .?1O1M;)J4.-R>9#!C8I3QWM
M"(;%<NV,UH5\;!= :4->?TP1+ N9J<*35VU<@(:&Y4=*\_I+_H;DF^*/+Z3_
M6ZZFB2[O]_3SZ9?9FO<_,!\XY\87!E)E29BW 7P=7:.M40XQ&Q,;K>,][.#]
MFJ==4/9\YTM[:7:0_OU!;G4TY[-UKV:Y)7>3+MS$TP](C3S8Q!0'Q[D"9<GQ
M](Y\3DWV/Z!W!4L;+^& 0_=0PFL)VK92[ JP[TK!NO;NAW+6O88UM3Y+T\OI
M=7;G/JTIJR@]142\]@TK@1:\RJ2A(8D@=5+(VP3IAYQZW.<F[2';6(Y=8?;M
MY@!$Y,5RB:LEW2,_34.L^]6G&Z_LCFI&EI6*%G1&<K.=Y1"B(&^8$W=%,+*8
M1N\I]SOPN(^@VR.UG?2Z NEOL\5M?9)(W5P;RSO/.Q]0RH)*/%$DB(D8JS![
M4D='\9OC6I!RYU@:#>';^\SCOM9M#]6F,NP_\KYAQ/R.0S0O/\V7RP?^/"[W
M+X<<]'T#Q_,'$GR$T#]+%4R=!HY,$:RL)C\S"PG&:!Z<9L;'-B]#FN<4*Y??
MDX[7M/AT=C6=??GY&R[6XGR"^YL <L)%4L;J^AJO/L(USH'32H*,*LCHBW*L
MS:OI P[=;\B_"[J>SDBVEV('E_P>I&[2'!/NN1&%!\BJ3A 7*,G=9@EBR0&U
M26AX-WC=G+G?8/_(<-U'AJ>)UG=_$(-)LM-:IUQWTWVD,++6*\GSH7_Z84;'
M(]6=Q$RA(Y)WCKG4/%UQQ JC0,N89'%"1=&RQ-6$J'XS!4?&>Q,4[*\0\U6X
M',_KO?T+ORSFWZ=+^K9--'#M"!Y:G]KS2X_B_^Y&^A&<8%.23%PF<(6M=V!K
M"#%Y2#R&C(G^IT[."7YSM:CFX9EL\U/Z>LL.9))+7K,COBXDT2(0.YB$H+2.
M(3J74Z-&R[W/W*\+O NV'O51'D>&'?@4&TIOBW</2)W422+!1@3O60:E)'%1
M>@?6YZ*X33R)-AKZRL%&[D([$CZ>AN4@PNH'>\]P<9)%;3J61(T*A118<?"6
MJ74#,C'*,U/R"-9PW"AJ7.0-(:K!_,:#&G?77[L/%W4NE@<;(":MJHL<(=HH
M0&65T3DN3&[6M;OOH?L-_ ^YI(\EQ0XLY0VI&\O_G!J:B!2I,02.QM2]K1:<
M).;JY%C)497<:*[==N<;>7S0L>#R#$P'E%U'B'R.'!;(ZM?\ =>U;(=&UZP:
M@F:6,XQ<,]%F@> K!QO7%(Z-P2&DU<']_1P95OL<!#F\G*.M;@X#ITL&45A0
MV2IG=,N<_'Y@&R4!><B].P3W3REY>+_U:OZHC[!FV*[J"W/Z^BL"[I_O,=?Y
M(;=_+\SR^^DLT&>$R]MY)4,7VMN>LEEZ\HC,/4(^TWGG,TL(AFE. ;AR$#62
M;@G-%#>L-#= #1\*W1?5,U;@8K41T*W [K4Q3IQ++AG'H4A-02A/"7SP$5*R
M4D;' _HV>U$&):/?K.<N"'S6L!]=TATXM,\0_W%>3<956DWCY<T J*=?SM>A
M)9/@C2])%V R%7+2# ,OO8%4Z&8U+%0O_YCPWNWX_>8)&L"ZH61/"\X3D1/]
MD!? ^L!0>8X0<A%@K)+:"N$HNA@;M/VZTD>"YDY2ZA> ](,W=)C:>[L9ZCA1
MF?.<B!S!3'WD*BQX+258ADX2U8FQ<$SX/3YBOXW\#<!WH(1VAYZ_AMX,O]0Y
M72W!]^;WNJCAP^S1PX6ZX^AV*ME_4S"!$\F\=M9G0%(Z4"%;BI"]!%V7+F"0
MPO@V<UX//WN_S?P-X-I*IOV:T(>)Y.IMOYT6.B))AZ+@28HA8<E$IJYS3TAW
MP?EUNE"3)FN55*-Y77L>>"N\FC/!ZZ#2ZQ>D3[DP=)^L%O2CJT5=9T.N]A=<
M3HJUQ.7B02*O$S,,49IC &:-T(D1Z;E-H># @V\%6GLFH&TBS1'!6W.JKUTH
MZV3B;W1M+%9A6KVB7^;+];BUB171"I7J5)9 1/I(#/9)0.&:>_K/9,L#A_5Q
M#O>@$VR%/7<JV#N>,/HUE^NIC!?Y/Z^6JW7^>J+)T[:,96"Q4+27DX*HD@43
M-1,L*YN:/B]Y]8!;0="?"@1;2J<GT#VHV"DZ*>/&02G2D^Y80;I#K@:WR=NB
MC BN\?BA?1I$V,FBZ@#VGU+!]%$H-G"I\[G/;U:DW(J@8SR7\(:+5 'CZRII
MX<CL!,XA*?326.,9MMRRU:2\^(BW'W%U2[ J-J+0GK2N+NO4CI/"Y3I+4^I2
M/ NZT>#%ET[5;_%O%WP\UR)TL!PZN.\>T;)IIYI]J<_FWH3%XL]R/?5A.8FI
MH!0B@/=&U,WL#IQA#(HC&Y0EX]*U&0:_PR'[:)P\'!FO06X@,?6(P*JPFY_]
MB)]Q\1WKT)R+E!97X7(YX:X$9GV!C&+M5Y*#00$.:%]4EL)+UB@9LM]Y^VBF
M;(_+X877*42O"S_W-:\D8E=T 4K@ 93-!5RV1*7,+C&>C&]4'=[R@.-6AH\*
MPD/%TRGJ'NC6F_LCWF]F-;W0FT$1F&"&1[ 4I-'E$#4X6=8/D43T$I4RHYG-
MG:D9M]@\IE%M*_@>P?_W^3S_]_2RKAK\0$*>?:GY]>L_FIA2)%>%=%I(HHB9
M#($A C$Z([.&!6Q3@-[EE..6FH\'UJ$$-7;-XQ%A/R$IUL_Q<OIE+;4)*FE)
MC3S$$LB)"<: 9^1G"_1:Y,"*<@\B[F=J&Z]]T[A%W\&1,SQW>[17;\*W:4TG
M/@K/:AM%9K$0RVQ]3^(%^$B*H)@O)G">>6@S)F#K(XY;KSV>I1I$1#UB;UV$
MF7!KLD(I(7(DBZL<@\@T R1;*U7(D5AXI'1-/<^XE=@C9F9V9GZ/$/K[@K1B
MHBS=R=%&.CNOW8S602A& I>*FQ(\RD:KR9X^S[B5U".Z4#LSOX.7IMMT%<;Z
M6)OE##%J!(46(<22@ <95&$&93H2GO9L!6U743T>N@Z42Q==RT]Q:^)LSB4E
M!MGE^C0[D_55!D$+F[B5GK/8ICO^J=-L!Z<SJ$3LROF^3-6=(?RW[$E>>&:D
M!2R:J)'6@&/<0M2D"$:8)'SS'-D3Y^KWR=E Q=1#9=&7'W6'FAK;3F=?+A:+
MVJ)WW1<5L3X3P0S:14TJXP.I'[$P)QM5$,:[U+Q>__(1NRFE'HR+K2!WJ)!Z
MNQ?OD/;+8OX-%ZL_ZUK655UV_5]7TV^5PHGD4@J?$C!7MR9ZI$O .@=,*OH)
M<R4UVN^^XT&[*9\>!XO#"*PK1-[>'W?(G&0LLH0@H2A1%]T(8EI(%I(+G&6K
M*/!I,^+@I5-U4R5MA;6#17$HL#ZW"SKOD'3MF J#(4E@2=5)4(:##T&#2T22
MT2B4.5)EZ/[!^GVC/6ACW '2Z+^+]R+G];N*.F&GS!=?UQ\]2/_N2Y\\<.?N
MUD0<9<2Y<EK5B6V*^1J64A29*9ZD4))"2IM3\4=;I7UHS^[]ESJ;#6\3;X6(
MN6@P*D0RLLR %R5!L=*@,:;(8%[#R9.?W'&C[0Y"??J9TS[,ZR 4O#W_Q=7J
M]_EBNOKSXH_I<A)81),3 X/HZ (/%KSD"(6KD$S6.:O&$T3NG6<<X P@X.<>
MCNS/[2XQ\W;^-4QG$^>S2+;45;N*6*.B@Z"L!Q^#CKG>TK'Q._4')^K$X!P@
M[5<!M ?K.X#0S7ZQ-_.KV6KQYS_P:\3%1+N86)"Y/OBL=>RZ14<X!F2 52E6
M!,L:!5I/':<W\.PCZ8>N[\%L[P [ZZ?#=3,M_<W+_W.UF"[S-%6Q;,CAT1J=
M8X' T8#*+($CN4/VPJ@8C=*-'E6]<K!.,N-#XFE(472 K,THC_O:X5E!YET$
MX5)=%^LL1.DC%+28D\M%-*H&/W6:3B+R(3%T,-,[ ,Z3K?SKRUX[7:PW"5+%
MO7*20;1<@]=%<^%ED=BF2O?LD<8Q0\/[TL/PO%?P? Q?<:-<*+E+6GC@W$I0
M154C:A30:2W34AM1VE0_7CG8N/[10.+?!E1[RJ(#:-T,_+NQJJHDPX*HNWQJ
M PTG==,I '<^&NT]9[)-Z\G]<W0(G'U%/!^,WV,_)+ACFW^:SG"]5'1BR7E+
M3@IPWM90U1F(R5K@T@E)00,%".X^8%[/!-Y^^CB^S' 7T3!LZ\!*/&ZU>U@B
MN9G:=/&U>FF32/HAC A0E*P!HPL0N<[@;)(8E;6AM!DSL^M)^\@;[@F,^1&E
MU $*7Y@54)B*@?X'KLBJG3Q"T)@A4[BAM0S*F39O! Z<X-#<BQX&60-Q?NP;
M['DR?KV*_XEI]7G^[H]OT\7FY9:S 9WSP'2U^ P9A, +L&1LL5$P+U\MAN[^
MM7W<>8?!IC&S.S!%3\<6UU85$Q-2V@1&1K*J)JZ7(D4*-H1QP;LC!_3;7W.#
MOS!O8XR&XGT',/IMML T_S*;_L_ZCKYY_CXI*9H2)8)4=:8J"XS"@N#!*ZV$
M5(YNZ39AV#,'&N?-=QOX#,'S?J'S^?>P^H_YU67^\/5;2*MWI9"EG7Z_7=%3
M%(\HLX4L4=87,AZ"UPXL>A-+\$*5-D-&]SOO.$_&CPJ\(276+RYON?D+SL+E
MNA5T/5<!2:2K]3PES!-$[FT@G3/*U5'22*1*(8"[Q#QW3&K7ILOQ@$./\\C\
MJ @=7':#P?0(DTV?X<G \TU?_I9F4TYW(.X8JQ0=3]RF LDP7?.J''Q]&,"3
MR$Q&BZ+1 N&&LTX?3)5^CN/O_DB75[D^VUG[L<M?KJ>>TP]JE!2^DGK7O_X)
M5U>+V?+3_/+R_;7?._'<%F2DY4D4 \H:08$3TFW!,43) RK7*F/?EK).FFL.
MQ.GC_']'>.C77:CMMLC066"B[I^RPI C;APX%D,.(2N5^HN FJ&Q+]1L&5#M
M(L*]D?@-%]-Y716\6#5V7Q=UL%-=D'9U6;-:[TE(O]!W+WY9G^#SC_T4RTG,
MBCGM-1C-,ZB</3AC$Z2"7&,IWCS,'#;W8[<__;A-:*>(]';@Z-= /TWSFZM%
M%?(35&M'I"GC0?$Z*3=0;.*<8F"L+%X;QI&W:;D<YOSC=M6=CU(, Y!^U6+"
M+<LV9 =12KKT4-1M6*X 9AD\8TI%WZ87]!"_I=EHV5,$[DXB/-!O>3?+S;(9
M'W%5*V_T1>MINOND*AY^Q!!YB!>/-5"2X5U85/!4'*V_Y#9R8\E):8T$GVMY
M*%I%0HZ*;(YTS!IKM&PSL_*Y$QUJAAY^[F?BX-_H+_QK4CC/QG@&2GH$95*N
M(_PR""_(E%JNO6UCB)X]TK@AU""8>&A"AF%_I^G0!YJZ;H-;#F!&-A_4P)@\
M=<36)J4V2<4Z^YF+C'60"8<8&=U 3A8;M62LT>./5B;E)CO\<[F8K:9Y>GE5
MJU&_8KI:K <@7%_6F-?NW/SKMZO5YG)_7AFLTCG4A04ZU)D<MN[.JZ4"C]Z4
MPC)7V&9&U/"T=&K$=D'AHR=:XPK\-*S?CYK)7281.[[.9[^NB.8ZVNA[N*SC
MMFX85N7W)ERFJ\OU8>;E;?UGF#<??<.V_4M)1S]C YM]9,:VO@Y4R(9[NNA#
MJETD,=9N6HI/0I88 M<F-YK]T?]UL&ZCMUY9Y3('ZR3QAY/?%:141$TJV4:!
MWK9YP#TL'9U> [N@K]TUL+.@.\CG'$CSW_Y\^@.NGYNIA#'6IZJ,45QAB0O.
M9P/.T76H=;!%MG%_&A(UK@*,B=5YG\#I5H?N/)RSVF(PY!8B\Q94P0@!:V^2
MH&";R$NFM.GO>NUDXZ*Y&PAM!>T]Y=D!/M^13SW_$W'M5O[\[<X4"J>R,CP4
MX"K7%0720#1*0> VQ\)$,HV\DF>/U",B]Y7\PZ39(&+8&T\4CL3Y<*^G5XMI
MHM!C3<QOL^EJ^>G7WV[(B:8DK17D4NK3*$]^F5<.N"/2O+ N8YMG^2\>:]SZ
M?E-D#2>.WJS5S1PFPQC6#(^6C!3$!$_^?;1@F;&\6&-<(T_RB<.,6Q(_GH7:
M@_5=V*8#O8J?;CO*91"!=*2 #-%73@J(K-0=&<H[Z[5SL<OPY:>=Q@@TLWCG
M$ZOL!XD.3.F!=&_>%DK-A8U&D]X'6S=_D@5P1I%!T*B\-NA$F^+Q(,?OT:%L
MC;QAX;\'#-K7-C9_4'^)88G_^W_]?U!+ P04    " "N@7U4VN=0BHH5   ^
MF@  &    &%D=FTM,C R,3$R,S%X97@Q,#1C+FAT;>U=;7/:2+;^?G]%KW/O
MK%TE8\#8&#N3*H)QPBT'NPPSV?VTU4@-]$9(&KU N+_^GG.Z6Q(@C)-)C.R=
M5,4V(+5.GSXOSWGIYNW?KN\ZPW_>=]DTGKGL_K?WM[T..S@^.?E\VCDYN1Y>
MLX_#3[>L4:G6V##D7B1CZ7O</3GI]@_8P32.@\N3D\5B45F<5OQP<C)\.,&A
M&B>N[T>BXL3.P;NW^ [\%-QY]U]O_W9\S*Y].YD)+V9V*'@L')9$TINPSXZ(
MOK#C8WU5QP^6H9Q,8U:OUNOLLQ]^D7.N/H]E[(IW9IRW)^KUVQ-ZR-N1[RS?
MO77DG$GGUP-YRL^;O'5^7JW;C49C7!^)UL5YLSFN\;-SIS4^^]?I*5!Y M>K
MFZ)XZ8I?#V;2.YX*).#RK!'$5POIQ-/+6K7Z/P=TW;NW8]^+X6DAW*S^5&-L
MCL3#"0P6^\%EK0XCQ>)K?,Q=.?$N:8(':BASN>V[?GCYIDK_KO"3XS&?27=Y
M^?>AG(F(]<6"/?@S[OW=BF!1CB,1RK&Z,)+_)RYK-7@(O5PH^ILPCBL]8>93
MJ^,DNO_XV'O?&[):M=+HK$[A:<3;P'L1[H5Z188C;#_D*).7B>>($*\Z>#?H
M=N[ZUZS]J=N_AO]#-KQCM]WVH+MUCB684[7YZ)P.[]L/PU[[5DV$#;L/GWK]
M]K!WUS_ZGI7[=Q+%<KQ4;TEXC!=?GIX'/U\2&X62.)S*B U@XI[#VJ#1#EF'
MV&>W@D>"'=[S,);<U2^'(@3=)!8=L<,8[_WES46]7KTRK-B'-JV3_SRT%/.3
MV%&[.F+ &I)GL+'2 W[RB/EC%D\%JT4Q<_@27_;]N9B-1&BAH:U9;+1D'&8R
M$O%""(_MDZD?._?L=L >NM>?[^ZN6:<W_*?%;F\[UC-15<Q>SJZ%RQ<\%,R5
M,XD>S)5\)%T9+YGMSP+N+=EA"63R%M81GN24018M$JI]<J-]_7OWX;=/['WO
M;MCM?.S?W=Y]Z'4'%NOU.Y5]L@A8DTD46/] .X!2R-!0>+P<UJQ28HQ23/D#
MZ[(.Z[$A:[-;-@ W=79Q]:/\=:-:.7L&C[U%E_:H,%<!=QP(&(Y=,8XOZ]7*
M10WY8(P=V1DEM0P5*D#P ,\&]Q=/.00=(HRY]#28<"@ ^=_$$ZQ^@1ZP=H&8
M0I0!4MQ!= ! 1^.>,JB@A0B"(\0!I@%.6&'HC0P!5!3@-\7C=A!*E]5:"F:4
MALEK5)> RR3 L3\1P*&0+60\)<2V*@T6*PG_2B2;"^"7 *G4RN\B92"N01#Z
M7^4,A-!=LMIYS:I>-%D(:\U'KF#1'PE:B;$0,8+A*."V*(7C?1C<E(.M$-=$
M$OR/-T$&'<HCQEW7Q!$I'X&)G!W"M6@+\-I&S6HTSAA,XZ@TRGY1K;+[4,PD
M"$89F M1&7%QE$@771IS?9N,)9A5I'7 4>47[#J4<U#Y!^$L?-]A'0@T+-8!
M;##V0T_R4O'WO9Y+&?AK@;@^55Y/6U;KO%DN>6V]('EMO4!Y;95.7M'W@\P^
M56B;+>N\24:V7();>T&"B[1V>.@0N/K,ER] ;FLEDUN42=<5=@QJ[RY+@TW+
M)('?E;TH7=S_OCQQ?ZW2J",?3*@/AC-- 3@BD@#J(0*E](]*?L>%508P#' '
M7(-7Z,J"( %6P2O%7Z&( I!NE4,0+ \CF>^Y2QVRP744=,![8*L]GP*X<>C/
M\"X9FF% 29@_@@6F+%^$'X:"BCT6$U]M$<24J,>W%_ (!O'+7&+$C==)[^7E
MP=KL \-<6)=]@O]]-ORQF; ]5J[Z=Y\M-OS8?>C>W#UT+90F"I=@+54*5WMP
M\!]BXJ/C"84M8^Y&2F2FF/#U'*D$(7MK3D(=Z17G8Q1B[?:%HU "#*ED9.V)
M^5LB"&KANGAJ:1QA"QDH78F2\5C:4G@V%8$64VE/*5^F@VAN?_'\A2N<"3ZP
M*+EF+IR$0J# CL$%^(OHAQFZ/2YK[9G,7&%I>]7,-2O-,\.KXMIPAP<H4?
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MI3I1!9\I?_,@M--=@[0C DZX,K!BH]#W9PQ,/O>R&2I$,/5=A'D\MJ="8=F
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ME"% ]1*@9(*E9*K$% K?9DX+P-]<AG$BS*H &VE<^%R!6"^MK&?Z:Y$8 V]
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M&,*D-'-$/]G !@/#WOM33VT)9T_^]:W7?_.O%[#.?3X3/W.EGT+%HQL8RBF
M)92YER9Y/2K>@>"5=(F%APUFOV-@=Q\*/ ,'.]5^TFKOMAX&GKP6Y#'L]MO]
MX<O!'8]^J;NU/^-Y\&YS%\/>D4_NN^5+M;0O'>O<\@2_HI'=R,B>BG"/YJB4
M"YF!F9*NY5_K]S1(4,[5ZW3OGG7%?L+#"C#%$],:5806!S\%AQ2E 2^^(^M[
ML8^T8.V,CFZ>2[%0O4X %#ZQ6ZS1[PL4G.WP)[EO1'QN!=M%VG[A-:G""24W
MO\E./M]GN^H)WS_B?UXII/%(*03IE<ZO!_*4GS=YZ_R\6K<;C<:X/A*MB_-F
M<USC9^=.:WSVK].+@S]?/VG6_U3]Y-NDX?D68F=D56T^OKW_'Q][[WM#UMZ^
M4;O\DS";=^_;G>[@!RGTR[Y+SO"0QABT:P9Z4OEW, $($=JKK]>L4B/X^CWU
MIO,ZW'A00A[\=5?9C-6ZURC2\YQ)*A&E&_Z-*-WX3JQ-9T]N9R_.?JM7TS]'
MOK.$7]-XYK[[?U!+ P04    " "N@7U4*T.RQ^P<  "R@@  &0   &%D=FTM
M,C R,3$R,S%X97AX,3 Q.2YH=&WM76U3&SFV_GY_A3;9R4)58S"!D$ V50XX
M";,)9(%L*I^VY&[95FBWO*UN'.^OO^=%4JO]DF3NW F0FJF: .Z6="2=U^<<
MR<__<G)^?/7I?5^,JTDNWG]X^?;T6#S8VM[^^/AX>_ODZD2\N7KW5NQU=KKB
MJI2%U94VA<RWM_MG#\2#<55-#[>W9[-99_:X8\K1]M7%-G:UMYT;8U4GJ[('
M+Y[C)_"ODMF+_WG^EZTM<6+2>J**2J2EDI7*1&UU,1(?,V6OQ=:6>^O83.>E
M'HTKL;NSNRL^FO):WTA^7NDJ5R]\/\^W^>_GVS3(\X')YB^>9_I&Z.SO#_3^
M[N/L0#Y3!]EP=V^_JYZE.\/TZ=[._K-LY^G>,_7OQX^!RFUXGQO9:IZKOS^8
MZ&)KK)" PR<'G?UI=333634^[.[L_/*@]6:EOE1;,M>CXC %<E0)C_5D)&1>
M_?V!S&XFN1F9SN?IZ(&P9;KT$7?BAMI_,OUR-)'E"$8?F*HRDT,<^D:5E4YE
M[H:A$?FQHVIW?V?Z)4QC:3(1B;2F\.;0P ZXQZG)37GX<(?^.\(G6T,YT?G\
M\&]7>J*L.%,S<6$FLOA;8H$/MJPJ]9!?M/J_ZK"["T32GS.>QP'TD^M"^27L
M=G=AU?I?QGJ@*]'=Z72?/=_&!E\G]G-M*SV<_^'D[BV2NXN;_$[.Q6XW00;L
M_G9J@1'+%S^LV8]>FY? 1["3%SI7\[M/[:.'S[I'O2PKE;7P^^.C)9*_MOCW
M:F,NU*.'^T^/1'\RS<V<].SY<*C*1!R/M1J*RU3#9WJH4_Q<IZI<.R>GARHS
MY<'OS!Q/E"P%<V B[A_YIT).Q#17TH+QJXPPN#]B;FHAQ=2PE14S78U%+P/-
M7T_$E4K'!5 WTLHFXK1(.V*C&BOQZ.'3W=V=HV,SF<IB3G]UCS:%M&LW.Q&E
MFAJP)F!Q86CLA%_M?U%I7>D;U;SY5M8E\L\K;=,Q?O"N<](1XA,0.M-Y+F9@
MDX6LA*E+G ,T$KE)R:3K0ERH;&9,)HYU-0?FZW6@8Y'"NU8E/"Y3+2:@9M.Q
M+$8*UZ ,2Y"(# C""<LBX\&H>UR=86DFHH)-H4G@3QA15U9D0&NI\)W./62,
M(7%!IE*=T<P^&YA6;7&]M!6YJL"[$')4*D6"'?- SW\:N&"B)J;4,*__ H6T
MLBFLN"HL+R$NJH$.2J$:50']3VQ'7(V55?P';_5 05LE%'!J2DP"'>#@&>PV
MT4R4QKL:T_9&ETJ<P*N>-N"B.RVW2^X+;4\WL-2/'_UH*K,,A'8K5\/J</=@
M"C[<\>)VOE2%&H(4W$/6?PG*4,03(BMV_^;Q">5L@).Q,I?EW(N/^.O>_DX"
M8\-&%;7,<Y"0OW:?)@?[.YMB"D(X!2T(/[7)-A-AZ\%G$#14 ?!Y::"+3&5U
MB@MC::NA!]#D_ZE!LC*R%6.3(W]85/##'*44-#Q)_;#.\RW2D9&@DWF)Y+4C
MB/(%HJ=2DRZ7:6K*3!:@X1<;HDAW#XXL+#30)<LL4(Q&(ZMS)3;2ND1# G/&
MAMW]/T2,#CI/OV.'CKQU.2Q5+E&5'2$3;>UU=I?C+-Q'[.#!BVK\8T1_-5/1
MCN?20L@L<X6K#(IW#C97*)F.Q00Z&*-.[2%O"/4%]KGBK=3 ';SK"JSNW%MN
MV%KU90I,P@X(V=95>UJ8<B+A=8S0P7468S3?Z%[,%/0"/U$I,2C0/ ML.>#]
M+F0%?@122^S(7H.UL,#(B<Z\!](*4Q%YL %Z ,PS-.!<T+X  \<&[!XJN1Z)
MOGAIBMK>4_UV6H0]3VAOB ,#6\[1,P=-P XFZ0J,GMN<Y[<6. ]>1]/EE"(J
MP"&R'"J: :X2=R$%]#A2E?M,3DP-,P<V@R;0R=[.+X&[8M6[ <P(G_\JH6_X
MLWO_U(ZM;E7MP.*A /.JX]9N.C/AMHL?(!?@:VTF *LQ&VO@#=IZ!0I@[&Q5
M(^33TI04+@PH% (OAO8PN(OL^#NV:;\3[_-2.PY2%LCT_0"9:9VWAY55)36I
M(YRS+D 2=89-1T;F5FSH(LUK-*^@@<HI$4VT ;]:4GZ&[#5LJ]U$CH1A,H7N
M,ZQIT(.+RA7V1X[8D2<APF5+8N5J:_B47?2TU-"=EM MM,A Q^;J1D++=M\=
MUBUH@DFWADD[YQR%"V>82CMN+>ZHA,[05D"T"'W/,:PC_SZ$4YX9%F=QW#]G
MW].@[8>73J"#M#)@"X O,"1KN:GPQT1#& -[U(,H@0@9K*8Y1XOS6]T?BEU<
MC]H2HZ&.0909II:S1P.Q"<Q/6[:($U"HI)?83B[N5RO4J>+.O7<$KA%L$6\[
M+F"5LUF%=5 8*X5&FT1[89#QMYCSG2YK.UQ.ERW$91H,J6)Q0[)*)8'WH"MM
M2A_*NS4D6COK(RPGY7O/"-=>5DWKD&Z'2.\T3>3 FKRNEINLQ<P6$>KOP^B?
M' 1P>UQZ<J8@/EL#6(?K+3F$%3J4^4S.[8-U./[^TY4X_C=(O0]6V3D6?1"(
M:BYZ,Q#%>^I?O/H>EP)9G3ZF;2<A'LL;=@]S59%.=V^ 0@)*;G3JW%\$FQ;=
M2QFI.;0GSFPH7DU2C0F*+-@$%&S4'036@;61I/1!7P;EL1@?P>^EJ4>L;AL[
M$C0*$HAZ?L6@8,8^CA7I?^SHFT2B3G**G)UJ'(1!'!@%NZ"1VO."-K]=Z?]V
M97^GX9XUD(1#4^X?Y1@'@GT8@9L#'@7&_R**_Y<BP<@?GZ*8I7J*G-D&],+>
M^TZ@*:\/B@8P$W#9&J2 6# !Z2PX<& 3GFO@#<E_>T>3>Q33'":?1-(R5C*O
MQ@EX 44%3(_-;[1%%G.O(KN6Y$LE;$-IOF8X3"*<TQ.<>',)^X76DJ2".F(U
M,E *HFA0.8-<V_&20] 1Y\$XQ\N ^B!3(#IZP @XMO%,!")CKD$W?<4JWUUV
M CY!SY'VJ84AEVJHRI*]'9HP:), 1-."1$@6^FQR.LTATB%NDU\0VX^<-_;L
MT..B[8I<OAA2B+K(Y>P>H@!7JW,?2^!\8*S[GNQ8C:;O=AX][#[9.5K^%P>@
M6,[Y,Z_)&-[E&7X'5L)._5*>!!XTWG^)6180'70SG"T>ZA*BDXE2Y/W\/YEC
MD.8\-[. $(? .6'O)G9?V+- TLV4A1'-1%T"UT($[D%M.P9AM^OHPUG!^+8R
MZ;5#= BF+%-M$07 S"%BX-1+@^L0J) ;J@[BEUS_K?[B\ R>,[UQ]NE\ROD$
MGWI"^>//EL)?F)>ML;U/C2Y,9'>G>R!."]!+K.'>YXA=$>JJFT^=\X;CF&B<
M&S I3K YF<8+0)I,6K<GC O&:A.7'DPG['^-"_$5##^XFN1 XW#8(*-]%;O[
MO_CE:S:KM9#1F/B6G#FFJIKU@I9^(F[9F3_!&04WN+2$QG +/SQSM%L9VJ2-
M-L]M"EJ4[J.'>P='>T_O'TAWR[D!M]Z50<_(;:WGYVB_UC >Y0[ ]6\T@H]&
MPH;2!T$O<+#@N(/['_!NH]*"0>+>/9/ AE?CW\0E+3$-PRRP*/L)'.'@T)&'
M:56%/@N,NL:-72W*+FA:F]OR -H9C '.:PVZ=BXN27P<K<']<942=FSJG$BS
M=>YDE@3 S KT@<!$@"MK,#D/\R\+'QR6VEYC.L6:5!-2Q'HS3=6T\N_PD+\A
MN/JN&K,[8$]7>PR/UWH,QZ88:@P.L-RAFM,^OB\-& U5(;>=%I16H TZ!Z]^
MQ''']_L4K>S[P>I5X8_ #@ =AUN/GTS_^#++U2IA0V[>GD9:*%38[812!;10
M[PWX[EK9K^Y0)$(4R0:QIHQGL'_M*#:$"* ;,+?(RLH':>N&0C).BQOD'!PX
M9"6C*"9V)=Z?GO9Z39E554G,<4-X"EZX02/N*UQ[B<M^.+(PRPFJ=N14%H%)
M&+]:+H5JTJ$X18R^X3>JU"5W"U=.!RHG,@-WIRZ#^Q:Y!&WG+7%X<[&%D0)X
M4BX/ZW=C&JV*;E:E(RXA-L]EF<]YC:GBB+!T!+E+#M70W=!EMO4ME-FAKK>'
M,M\AP/A[U,@M*0U$?N8H:D&1QBRQX! G+2135B']B@U"11F6#+)%Q6Q+X;.[
M@6^YO"_D#SU7!JF&)H41L$,"7L0RM@;#;'$KV5GF42!S; K$='-,R@5-CP\6
M:+/K9&BY-.8G-1.#NV0F=L@]H8)7B EA!\_KRF(9Y$M??-)#K%TCRZ!S2)&.
MJ:MO;E^#^ZMB! H V2J%CE)@SA14Z42GX$*"(O<(%!9/U:6O.P6MMP6<LP6Z
M$J%)&8@0UH@<5;K/U$:/,D/:4N-ID"'FO@-1<86#%QHG!VA%Z@)3B08MA+*D
MT$DDP6BZS#1TB-[\RO(MFB1E/,-$EPH\H6L:HY+7*L+:R/\&MSTN]HGF4Q>4
MC"448("I<IX+I1YG)6(*!7FXSH"MR1.S3Q]#7S"75&->I+*A/8>\I4_;4'@M
M,@=L4"(#1=M1S<EXQI#+"+U&E16F'V:$K]2@%-)H;H3,+*@VH@=,3IP*29J,
MOF6-MKCI"."59J*9?2$6Q]--I#FC)ZN6IE33FI%PK"2(Z/7;390'/FA"",<X
M;=W<$2W<J6HDQ6/Q@?&^*36QX4_<)D"PB.!2X?]B"-?W_ST\D6#LD[CZ!_@#
M9((P"L3&*$U0E29/Q% 7+";EJK0$= &:8JRG251(X3NCF;N.L#UWQ0A:0DN,
M(%)1< 4< SC&E[U[7DLPE.6:^(0H*/!IDT.!J19($Y *P^/@L)$LMI(;N:"/
M\FRP=:JPV"O_IFABQ* S9 Q<Q(0D,F97.D\& UGEA)K+,>.WV,_4S'_ JE2>
M3=N)&^$?<K4 !.48'/FUS%S1PE++55SJ!WST</_944B')F!O9^H&5R8D1E&R
M T+8FJ1,R1L6]11'WA@ TR!S34R)DB&+3=']Q><JTUQ:R_G;% PU<;I[%*T*
M]>$9,))_V&K'*)&$^EQKTWX3I9\^BT9!$#+7MG*U03!@$4EGJ4;\>]1"?6$0
MG]4P*O+!O.$&KK21)2&3894HU>3\<H0>2W6C36VQ2+8ESY&^:^OQ[]+<3;8Z
M!Q;(YHWV3UB,04R)#1JKL-'.CC7%N]<%8A8#\M VDY;[Q)7+[?ALV4C=/\AA
M;WV2PHACIY'O9;W]G*)D=N!;6;OY*@Y>8$GD*E2/"$:A^HR8M^'H10P=<>T-
MN?E-T^/KMD#%4#!-M5N9*X*(8]U <B0,H/*!^S&!0/(V<D=B4&6A%(+/RT=L
MV$%#C@[ZQN^F4YHSPNW0_)9H=;\=):P4_77BOBCC3  1W[R..^0K3IR[%!$3
M*S802S66^7#)TH;XRU>L.,+R.?G!6#"CFVP]:4)/![M&]U-N]]?*[85"QU)E
M=SL1OWI63SIBW;1ZE?B(,7-S[/-.[]JW,^.:K"I)OQR$. ]=1,TQEVP*6Y*F
MV,4=?@C 'P5TQEP3S$ Y"\337&Z=K";5\9:&:@UN$$?,.:  U[(C8&:8]QDK
MC'^2)240O[RLQSPT"<ZEPP\E+ !\Z!#$6$5Q>1B#(841=JI2.K;)AA4C)W@X
M45BC0N+\)^IV#\LTE28K16%T&_-"[1YJ?%>ANF1UB=6#:^^<WE36>**6J[G;
MCV1V0[H=3!W$'(Z)5K/B.J9.9>&*]=G#S;S5QS DQ'F-*993C R6BZB1/&?.
MV('DA.0<8_L:@Y(:2"YA+3,?B"V8LH[XR" _PA_L?S@'7]VX$!,L&XS@HC\<
M8N2KKP,5E<!CU]#!S(B94M<VK$V4JX./U'(A!&[1Q&3 /:"%!H+*O$$EN&-6
M]ELE.Z"Q=$7E^S"F2D&=R/(^6M:#]3;H'7@W*L]EH< 5_#U3:T&D/P0A73?7
M[M=2CC[7W(IZHFSL[9A0;=V% @0)8-T(@A,0<F,L*[ 4R YE2HEK*M_#M#L(
MMTJO64CC%T"6S3# 17P=CS\OZ*3O0T$V^K+"PPDP^=-AVY<ON'(0Q;'EA\;Y
M.E^WC899IM>CTM28S4>:W-'WM3-JD9N"<)<>6B5?=K&[3CM7@'DW2Q%,H53F
M"AA:!&'=M;MGR&4,*[$*'0F:R5"Q%KYC5520\+O<S;LC#[OKI?]$VREX"P(<
M;'0;VH4)MR(*1JB"4IY43R&GVA6HP*Z8"9;RH,5PM"+'9#P#VP1<DC F"I0(
M+ P7<WPG?-HN)_%\-W;VW!]D\N,FB'EI+)5&N!?-.B->J:L@++#@E5!!JHN,
MDW >2:.B:I<$#_4IOE><#;Y,QHF0K%S&%X$HE-74 :GHL*7C)$Y8!,2HA"#2
MB0,9Z1@_6':2E]?&.3_>X7']++1+FK(?VJ:;%?5YKT!H2]C'7CG05>FJ!U)H
M^DQ\Z%QVCIE;#XY$=ZO[))1]8]R LNH KBF2457LF< *)_@3$>,<?D.<V^6%
M6KE1&8V(4EZGKH-?>^\N??4EJ" T] CZ,H*!#YW*0$J*N)BYK'/G18#6356&
M*2@^8=LL9>#0@1HB9@KZ'*C#^D%'#KR^(6^DSJE+TI!>,S&W61,!>LV;442Q
M1E2'PS\N%TCJ+0.YY 4]I,7BXCJ\9(Z@(RH/I'_PPKG/<F)E5G9 4=-GM'A;
MS4IM1?M#+]RF(MKL_" ]N%IKD\5+$>K*539R^F?@M%$0?VU;/!UX$&3 L,);
M4F<SZ?WKX!DX26T2]8YCFU-0HBH)JP8ONBXIE?2Y1JHP9Y^!.@![7%*DRB0H
M%+\?=._*F@++=CX-59)7J(WB7J&PG<C3REKE=/C,G>=R,5 ["DS"4=0!+18'
M645\'CF54YF2[B=?C12DB\]\&X)&ID A7OPT%!M(&M(+:G-3\!\6H83)0)4^
MF01Z%2^% @WFLB[E0BXKVHP$;X4@( 9C-<)<8<]UUA0I<MTV+I''5EW5$YV6
M=FDMF 3X!XCX1+K+)["C/A=Z"ZDB.N*WV",OB^\%)X 5!'A]!)'AJS<7YA86
M)>(X(*V5!0GAX!1/]9)-P [0>4;G;R1+/AY._7ARRZA'3BL-R14%0;G1)J=3
MY*W3+"0%I8HR9MR@+IQMQA<3GQ[3DPT\4@S&;,1;X5F@!0=+1Q0SBR.(PW>\
MC8LB9QP:=H"J:7%M43LTRH#VB<X[EZ SY'0<,1[2/_<U:H[Q/<?QHC4(0E2]
M.\%Z6G).8J5#K#N1=,L54Q7Y.$V>N3DYYCVF,/.E G[PHV'A"BW%^U+?X(KW
M*ABW4',K7D.T3MX#%U?L[NSLT?E[R4<P5AX3<^/A)A&+Q;[#PEYR;A4F[=Y8
M.^T-4&6Y<B=)N2#0@33]+SAY:'M,PT;79YW&V >JDB:3QP5ZDSJO- 0Q05DU
MSB)*C@-7%@;P:4\Y,#?NEK;%-]P!6JZCP,)QG8?B9&8H*GW,6]4EW)3PT%)-
ML'[D6[P0WS-'N9"6F2&?T,FP\]M !',<O[ J]X#9DD%SLOU/=(A\Z.Y5LG1,
MB^HZ.K06=1$I] ;P"DXJW]H6@*]&J\%4WNIKA>*<!+L*Q/XG4,$))XA300'4
MH5K"FTX&EO LLS]R@=EG?.KO"J23R.C:L>PT)74M(A9T+1'>9.7"(CLDKIK[
M0!C7,\-#.14GL%"=SL,0[1!JD6Y<03XI4%,Q;(Y7#>(5%P2T-6INH);<\';2
M3EM;JPAQQ.B&-^!/)/P>(N$-%-QFT\B4>E;R3.YONV(I];XHLY3/5";,;5S3
M0]<+^0:)>QNK8"+YP+>;L_(-'<UI9VM=Q#?D4#"<- &U:%F'^)MNFE-3H"'H
M;IG.2J&CG%"#=P<9X4M-2$0"5+:0)V"Y6;AGQ"IUO6S0V]5VSOI++B>A(#56
M;4.EZ/@V@OLVG.-;<,CII4!9("5&\G  W58#=/>/5XXKJ#P#+1#*=5;=<JFM
M,VYNB)*-WOID"N,;5*?('7^NBY#<P]4E0 =IB+K3$!2C@X/6>RS!3YRJ(O!A
ML]VMFQ3:]@KOLZ&-),^/+H6A-5U\-=A0*D/RIZ;8OR/&Q8"(K\+QU_8XF(-\
M?E1\3+YM2A>P?@MG 3&5MIE.?^^9X+N#.#Y>CSA>,KSBSW$TARAN&WAL%]2@
MY^SOB7+G.9>"-Z8]),?X<J0F*HO.A[C(,2B2 I/@="&"T9G+.XT1L]2DM?RQ
M6 I=5O2W7)/+SQ:K@IR''Q MBE3XS0WO07'A9%P=2E":+P6$\%:5(ZP4;,([
M%RX$1V#37Q2 NK(>X+D[G$;NJN#<-1%1@230H*K%@\<NT]E;<-)T06 P._7^
MKHEV2W^KE_-$PG1MQ&$_"Y:_OK:M[X--G7.8?IO2=,HZ+AR96H:<4<*BZ]8X
M/M#%#:Q[Q@7OK>B9;J;#XFYB5"H:=5DFWXF,3IU2D$O7'L=(QE>(\<Y$\PX,
MXGW]1FXIE8S7<UKCG!4RI1ABJ& .R!J1S81E++C #3-6+5B=C&-@9*J!)6-N
MS1"O2+)XH;:E"UY<&5W[ HV?@YG7%WR]QGB%' $,RG%W6D;R3IF*P!VXSU59
M+SH':R[8@8D%%4B)6#KDUT ?'CAAYYKC.E_LZ- ?5\R>JY]%NSU9RQ!OE(P<
M>3E=R,_>"L:,1MB3$JYI4&GT]]+-.D/&7L%YU<JEO)M\OBGRN;MQS)^AR\#<
M%2IA](Q,)VLU&BHU4Q797.Z.#+[+>B[1\).PR<'7"KR=%/(*R!'$$[8264FQ
M^RTK#@HV)@,]HAMREN]>:GF7D39QDW#!$Q_Z1/.# 9N?V$^QL4_7;NQ'3%O=
MA?VC_!D?:7/I]E7I=%/ZD^#A@&"4&D=G!@^AN!QU:]O=7;'L6LAXN,:3QZC8
MC[T\T$_""\^^4L554ST#R,'MFX &_'  0:9RW++F8I6TQJCD!DSZ4*86#^F#
M0E>8.RA-H5-HI_/XMN)I-A3NNMCH+:Z2Q%B(ZISFK7LUL6XB  []R]/79U%^
M9"?!>B]*H_6;_NB[X:0S5KTT.H_1=C4WFP<5-IEH#MXG$#Z:+.+?%N\V5_)Q
MH2B&NNC9XUF3U>O#@#F_Q4_"UY8,W=%P"H7M3^/L='?6AW)\74]T*\W=\7<Q
MPS9B[*"IJJ([-L1&N$ECLZD[X(ORZ (+/MJ)3RZQ0I]<ENC.#M_ZY::[N9!1
MO%#51V7,B.CA*9N02EAQ+K:!(9</_%R-U>(=S7:5*:X1_@&)B@+(T*W/$N/A
M8,M7>SB,:$"G@C!7%]T,M.I>:-M*DBY7@B7NNN@FY\T8Y,(M(J5*2W F>%^H
MRNM&JYFCKS710HU,I;F?IJ3!9V8(&Y+Y>O3QS[S,7<C+K%8EZ[VF7E-!Y&7E
M%4*/']!/H/NQN&SB-K7+I_,/HG?\C[/SCV_[)Z_[HG=V(GJO+_I]<?6F=R7P
M\9O>O_KBU8>W;S^)BW[O!.S9V4G_XO**7H7__W7^]L/95>_B%%[HGUWU+\3I
MV=4YM#^]Y*[>P:<=\;TCO>EAM^+\_?OSBZL/9Z=7GP3TUKO\A_CGA_[EU>GY
MV26U/89?/KR]$A]/K]Y@@][5U?G%6?^3.'^%G5V(XS?GI\=]\;+_ZORB+] L
MGYZ]7B+K+A\G6+UE[^EK\/C&)E3+KN0GN$)1<L[?MK1L!I;!M__[?4\\8*G
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M_S/('&H#^+PTT$^FLCK%E;+$!] 'J/Y_UR!D&9F7D<F1>2Q:A$&. @LF@13
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M>UK0YNLMU5=;J+6*8JV(KK@@T<,6'W1G0?$- 98! L(HAHBB& L.;>0^3%#
M4CU!GFQ'*,.V^TZ@*:\5"@7P$3#8BG@'<5\"<EFPG\/&*=? %I+_]KB8>Q23
M'":?1'(R4C*O1@F@M:("?L?F-]HB=[E7D5-+PGX)&P>:KQD,DBAPZPE.O!V
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M6:GT$I<&<^R$:7 P=$-G,"A AY$!R\5U3;X<61/C&O ;U5X3U$6.UX'4L<P
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M8M4LDN?,"J,XSN7-T,&NT3.H@>02N"[SWM"<2>F(CQQ9QQ@$XP"'LM6-\_/
MPL (S@7#(8:^W#9040D\A@T=3(V8*G5MP]I$>2[X2"U6$. 6C4T&<@;\W!=4
MUPO<Y0Y1V=L*78#W=455^#"F2H$S9?D@+-S!2DWV,Z *E>>R4 #!_EM*K!6D
M_$UBE*NF_7U._7S+.=\NYZU"7KCEZW3$?6;N2:7PA084!\ "#XQ(@)^-#JS
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M?I(-A+LO.GJ+R^8Q-$.5J+/6S<-80A;BLB>7IV_.HG3Q3H(%N513<-+T1]\
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MJS6/J&_W33:#'Z-JG/_T'U!+ P04    " "N@7U4TA DGLP>  ! E   &0
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MV->O "&=; 8GKDK'1XB':F "*U3#+6#^L>N*FY%RBO_@J^XK>%8)!:B:$9+
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M28\!U:R&'/WI!20"7F1N0>U;1V'0 SQ!]P'=4RLL;=5 6<L\C38,K"?&MNE
M$I:!O$%.)@6(#\(V^0'3!1(FP1P$[3&ZKH2UI'&19(I"3M>0K]PL3Z=8B/='
MQ%KW_(GE(?J]E2%Z7("<V=Y*_!D-@'64(!<30M_U [RE_NG!TJ01^*+Q:EA,
M.0&B1[O3&V>LKHR5(FOX?V2? 1\J"C.- ?HDYD'F;JJ,LJF)H!N^!Q)PM<U(
M@3O8H\P"X4; IMPJ^'!7L+ZK3';K VH4);:9=JA;81H5IB#0+$U8C155UM!X
MD)^_-5_J=H+O&=[4N&#\:>P(Y!S\V8+W%O;E:GP^Y(G-;61O9_<0-'#@J,R;
M'[B+\YNW<I$H+PN,]E*>@FXNTCM@$#5,@AIWH+]X*<+)8(RS)#:E\V3$WH)4
M1K.#"BVD&G'W(UDOT4PA'Q@N1^8(D:+8>_Q]P/B&OEJXGZR)H^34\X&J07%X
M,FRD9:?)L@14M Z=2_Z)L#PS(7\R1%<;;3:Q*>A0=LE>/WBZ?A&Y>\ZF\>==
M&53#_=4&%I3<UPK$HVR;8I8P\>!1C!=*'T16S@X_CQT\?Y]OVUNDZ>P!2>#"
MJ]%OPI(69XW+S*$H*Z7LI<2E$W/&J0H59%AUA<TTSWV9E,M\Z>"8#19"=N>P
M!EA*-8C'F;@F\O&P1EW;9_JZD:D+ LW5A:=9(@ S+5'A1K^9=@:32V'_M@P.
M7JO=+28@.9-I"EJPJ,LR-:G"&%X2%EH_=>8RR8WA\WM3KJ5A_U7H94S-"#J(
M9]+!6O<3KT=L>#7H\OI-=*:*NJ10W'(B.P@F0^-KI! 3$1PY&A=(-1 9+.(A
M:U*VT?F%F9@"*%^A!>O$G\-]/UZP]>(^10#SRN:T5K'+W\TH/WJ'*YDF L3#
M_DR>&(_A@;/%Y?BTWQ6KL^3+@49O&Y8D5#,Z]DMKP);!2AZ\&R)88@(7?=@+
M._(^WT:?(!\KAUN%&@!XRX^%/P)=%^!XMK7_9/+'5THNQ_D-N7E_)-<^JKV]
M[B&>0V"FEZ;0F5;NHS>4D 2YAB-%4AYTU/';;N'H<P."QI@<*V3!Z[EJ*03C
MK+SS<;!>S%5.W(*IA7MY=M;K-;50#Y+?>HJXWTPX3@CU=X(QLS'F=[).2A%_
M](8[KM5J,L3Q?M&7#[]1I3&Y0!!M=+RBL<Q5B/ M!$RKMF+!N2WE%OH="^-\
M:GJ34MJ@A&Y0HBNN-1R)M,6,$8SD*Z5G84*-9<<OVI/:YEL8@)@A@D;VD\XU
MY]WHM/(49!6#OOA K)7"8C@6&YCY589,Z;AA+EQ;'<N$1THCIG(F8" 6:#49
M"JUMDK3AS0&8(U-BQD:!"8*1/^(7<["Y58>_6&;RE3+7_D-BKCM[>! 4BG4*
M==Z+NG)8X/<B%'+T,)-&(\J@*D0^$%-7G[R^)JM'E4,Y)!]^!A-E@)P9T.!8
M9Z S ?L+@1 L1*IMJ*@$<MD"S-D"(L,(F8Q I+G>;$TW7^6&R$QC8X0!YI%'
MH-)J@4 TG@Z0][*2;9"U*$><@$@21(W/DH4)T<Y?6@I%FZ3LR[C1A=)%F)K6
MJ.2M2D(^9*R 09\6SB3[J4M*#"67;A_CTKP7RH^;6C1$2M+S/.=;D;/*&FP:
M@8&]9!JSGBH7GV=GF U)6>1X$[FWABA-"4G;0\V)P1S*M$D0%5E6W'[<$0ZI
M@2EDR=[(G)MC;02/,T6:Z-1ILHL=<[3Y2\<XDC5CS>A;C:C1!W'.Y)ME1V/5
MI.: +&8U)_"&ZR;((QXTBK1'G#9O[HJ6L5HUE!*L@V4I.LNI)I48'7\)Q8PL
MTC+\Q9'$,/_GX$0'+8".S\6&/X FR&!%@YJBU94U10?LY9+)Y"/5]]^<YK]#
M MV3O%F2X@!X .Q^I">=)#,_8 2AK\<&1 +&!_:==(A.,*Q3EEP2R/YY$ZKR
M \/HH*>22_8[Q!]*_+;)QP!\+1$FP#<YI,6!&IGW2G[(VZ^4"@GTITJ'L_)O
MBK"3N,P4J1LIH4-L->4YU!\'%G+*<V:N3TU'L9:IF8D OR'KFV@2J2E\R7G)
MLH^)F&4XR]RG1R\\N8S5A 5_^.[QCT<Q8[4#2M-4W>')Q-Q59,\Q9M?:I,Q(
M%Q;U!%?>Z /E(X<8&XOL39:;8O?[D$Z:%=(Y3K'-:LM\TG^5G K-$;A(PL3A
MJCVB)&PVI,,VSV\B"Z?/DE4P+%AH\E<;/NPR8;%6#?GWY GU@1,"6):B-.[/
M&FS@)$9I*5883XG25KQ6CL% J^ZTJ1U6#;>8<B*TVL+XL\1ODU!<  KDLT:$
M=Y@7 Z\E-&A$^T8[TZ:I9KXMT?W2)S5[L]/2@;F4NVV:+FH:Z^=N.5CM;CDW
MXMC+U77,<W@QBUF[<RE LV4H/(>3B%;(']&QAOPSP=X&I>?#VABWW)";GU0@
M0B40\!@RYJD:*/>)ZJFI&T%.J %X/J _QO2)X(:^90?R+"1#L%RX!0BKV8C2
MD>&$V_1<<TH^2%2B+.I.G[;UEM+^*GJ?)W(&@(!OAN,-A:H K_0FP*2<#>A2
MC60Q6-"7HA4=J@H\8 7EP5)A@VY2_X@5!CA8P5U/PGV\,E/I2J%YH/*'G=6W
M?%=/5K.C7B7>HN>CZ4SUH&_MTVEVFL0J4;_L1VL=%7W-EK-LLF0[3>:L;P<1
MG9YDEAMS2\XB"C:@.\TGZI'8I,I0:RAQ\0Y]J 6;A:!;=@7L#./Z(X56;&>!
M":2#%_E8K'PH@^]4P@' A]Y[FK(H+N%AEU9IA)NH3 . 7K)V.45\K##AE<A9
M:6)X9%>WG6#(*&)EVC+_(#%P.K6H)GH%*I,U-H_BHHOV5[YZ [DFZ*\>GN6[
M6G4^F2Q]33!K2WD0()2C'PR_))0W02US(9>7T]J9,[(RPKD+,S3V:U1P:P#9
M MKE0:F?XXI=\99]Y>@/85'FE45UYVU.8)*P@K<D<(EAJ!F,4%0"6XS!!%,C
MIDK=NG@V20@+/E*+X52\HK')@=  H?N"BA,!NWP/$_>I5%) ?EU1;3&LJ3+
M3&G7D4D?KF9GOX"@5$4A2P5:Q9=LK>4S_5-<IJOV^K'^5C':VM*@DPCE_7!C
M[7SS/#(OVT4X4F!"@1O(C')<**T<,W2 N%5VRT2:#@!:-H/H/^)6M:$9CZ<^
M3"$ HKVNL*06-G\V:*N%)6>T(SFV5)HT[!5+-8''R^QV:$V-\6R$R7=Y6[FC
M%K@9$+<-OE92B^:GZ[:#!QC!<:0,8\60SW5J 81EEKX'KP^\56*9I1TYDZ&4
M#QSC5!*2_R+-Y>'0P]YJZC_1;E+#D8&NAKZU=@[3O9""$:JDX!FE&<B)]KEL
M<"MF3,5U-L**&)/S#ERCNTOR5Y#.38ZGV(3R,_VI[22*@'<C+\]#(5=8MX/^
M$XTE/.C_1;'.WI/,YR&56(A!'B9*W$BC<L$K\\USNG;IQE2?Y</_,?LP( (B
M(-XOZ1/DR"IDVJ94(7O-O!\5CS,;==*@4W0863 A/0<CO2KU'BRJR(OH[/75
MH*/Z>>:>ZS192D19=TL2YE\"G[5 >CW;UY7U>1,9//JC>-.][AXS@SD\$KM;
MNT]B!1E:#<A>O7]K@F!4%2N30!0=_(D.XP)^PUB%C^VUXMLR61$9<YWY"?[1
M^^4ZI-V!U$#=#'V^[+_ +SV71TC*M"[*UH57_$!09BK',")W'&N.,C*5OAJ@
MRQ1$,$"'V>$>'!B^(>^D+FA*$FI!F#"#<";QYS4C9?4I[CH8_''Q7"*?'%@I
M'^@S.BQ.G<:>^>0XHN1O^@?[Y[^78R=SVP792I_1X6TU)[65W \-N$_9D123
MWX>@)24E0T=7H?*A%QE]+T B^6O7PNF(@T #AF74@@2:RF 2167.4VJ3;.$Q
M-A8>2%%9<E6#X5-;"@>^KQ$JS+O(@1V "F5E*(+.0)$""+OWFC[?CHDB2PH,
MM9&U2V1L3'K5F$+IQ>[4=]SP9FO;<._$UD9].BRVB\NTOU4F)S(C<4WJ-3%(
M;U*'9\@Q,@$(@5$-!F(#04-X@6UN"O[#H2.!^NG[6!+P56Q9#1S,!UWL7"@K
MN8P.=LF,+=/(XPIWKO,FW9(+J?"(@F?5ISQ1]RT?U8)-4-U[BW>%)(1DSKG9
M8J2(.K',S\C'$F;!#6 6"+;3)#!"VO#<WN*A)!@GL#= $@2)%OP$&P:03, )
MT-Y!?7TH+;<;HWD"N#:9D:-* [(>@%#NM"FH*UFK,):HP*HD8,8/U*67S3BP
M$Z)C>KR!O8M F WY*@(*M)S!T@/%R.(!8H\+]@HG9P<N#3= M1)XML@=&F80
M^A-,P!X:@NH[2A /X9^%!#6/^ 'C^- :IT^2;#S&:@E23E*F0Z@[EM2#FZ%*
MU-(F5Z I0@]*;MSY0D4=*&5P<*66XM+J.SSQ'FBAME0S)WY6)6L/G""SM[-S
M0.GFDG/OEU:<^_7PD@C%4MUA[BXYM J;]B-6;GL#6%FA?*\?S@;T?K73#]0;
M(Q?'M&Q35(@\J7%7(2MI GF<G3>NBTJ#W1F95:/?(^5X?]C< B'J26TI.DM'
M^!9'G N#94&ZB&G6C%"4]UBT,H3X4?*&^BX:G\*%M L^14):8H9T0D_#7F\#
M$BQP_=*I(O@X%P2:I^U_H4(4O"V!)4N/M,BND_KW9(J$H3<^RJBD<D_YZ*ML
MN!ILY;6^54C.G2A7 =C_1B@XW#2T&(JJ8\9+$)WL"\1N4Z&@#H//^&UXE0'U
MBD+5CFFG28ML 3'':PGP)B87#]D[3ZM9\%W@>>98)5MQ^ K9Z2PNT;9ZY^'&
M$^2*@YHR80M\$0*VCB'?:,/F^FI!#6^'[+1SM4J<Q&C=^ N(CN#VCA.N'* *
MYQ4:2?.%![6&H0LAKPX#SMDAU+DW/-#QHS&?(CEJ'-TTQFK@:'IP..>-AP%;
M%;'2 BC,,3J&)K)->24@&[6]["Z]/PHN--[N>-S<TH5..SK*YJ($? 5SO?&<
M4K>+LJ&=?.<%B>3$!+)W4BH9*$5-1="U[V*-]IQN1X,B9!&4U(^'"^@V1E%;
MW4!G2Z \-]4H)GXL>YV#=IY/^B4L\\_5H10VE2EMD2=^7Y<Q2H2G2^X<A"&9
M3H-]A;(2!<%(@LHQ467$P^:Z6VW3VJRO%RJN2(F@1H9TIO-#(SNFA)907LFJ
M B$NZM;<I3-43GF+F=1'I"$&WS4Q<,P$PEV >JY=KK,O[53Q</R-'RF=N69+
M/11#-,GX]^UV;&=FH!(66MCZPN\%.X!ACZ$Q[MO:*/A)G8$W0B(C*3&:2FUZ
MC,Y]U&F$'DM-7"MM:[5LOL447?YN/KW$*XO1.4)*+X_<",*84_#29%'RRH2D
M,K"4E!UBSEEC*7C-,\J4S="^!GEEW<<"7=Q&X?.I?/.B)-4.8%#5?%,)'^?L
MS<E[79(KF/7#T &I_61H..R%6MRN2S#L8Y[\;T[6-6(M!RM#>Z?!<-,%F[SW
MR4[.F,G'VJ-%]RVRF*05-NO:NKR#<\^Y *!EB5+7>TQV)TJE_$L?9 N3R*0^
MGPQ&>L%1ZA7X"#!!FVK&P")!;VX8%T72\=4?SGAMC70)5-=5E(<DCDEI@&,L
M.54, W8M%S5I!Y&2*9V4M!EG!M@/UN&KLQSU7?,):>V^5E]'7&YUZM3/J/N3
M)H0&+MY.2TMX4+(R8@?><V7K>>UH1=\[V%B4 12'IFJYQHT0G!!L7;"-%-(&
MO2?%YX47ZFL)U'XDZ^R5DHDI(R=S\>E[<=BB&A) B1UM5);\O=#Q;L".3%#?
MM?(A_R:?P93%S#=8#D6%.0C\4G78%<5OC2"V1DME9J(2K8.G(Y7'1WT78/A*
M\.1P=7<X$\B03T .P:)RE<@MZ1+WS#G(W!KW]9!:&"SV1&SIUPD[\9OPYB-7
MP:+\09,U;.RKN-BGJQG 6PP"/80+I&@4%_GYX/6RX+2QH:@ZEDPF@6949["B
MPT=\6_?NW^3!RH5,EVN,&70,A+47%_I*D.''^V7OJQ#Q/D.LQ_BV"&61 ]R_
M\&L<7]XYE*L"<;7IOI75:)'>@38SD)G#0G\090I#$-9@G^ZQU$7Z$IU)/A#^
M]1;)*,Z/13N8,MQFK?<G8/I%=#:=7I_]?)Z$678ZF.E'T;C39KX;"_N67DSW
MLJ2HHZUE;S9?5/C(6+/C9JQ ,\L3PFT1;=,DF%.$T<V!1@T6K"P_'_:[\RC^
M)KZ;=>"[!) ;Q'TU>M[NSFHKEGNZ)6UZ'HZJCX&Z(?N-FEPC[L]+G2ZX"A1O
M\!IS^4DC2SJ;A Y-/7X/#*4A48N3YJOCS8YOILPNW)C021GLZ,[%6IT8DECV
M&H.XWF+9T,VH]:I2;L*T1 NIT?<'))48SW':$&W&0G''_4&\@[!/M448\TMZ
M)2U[D8UK!5M#$F"34=;Q[[=I8N?L@)YK16)59D&/XHNA;+$[K:8>OM9&2S4T
ME>9YFM2($.$AQZ LUC"K_2/:4J_)PPF8\A*]KF]0/Z >@IQ\<)_$]>[BC>@=
M__/\XNWKTY.?3T7O_$3T?KXZ/14WKWHW K]^U?OWJ7CYYO7K=^+JM'<"[/S\
MY/3J^H:&PO__OGC]YORF=W4& T[/;TZOQ-GYS04\?W;-4_T"GW;%YZ[TJH?3
MBHO+RXNKFS?G9S?O!,S6N_ZG^->;T^N;LXOS:WKV&'YY\_I&O#V[>84/]&YN
M+J[.3]^)BY<XV94X?G5Q=GPJ7IR^O+@Z%2B5SLY_7@#K(6/<JBZSBMX#BCYT
M9$H^<29J DE<,G1K6F20BVZW+^@7A4.L NV PDYC3F4/05JJ@,2E&_=[*4Y4
MQCE)^QU\.\=NZQ5>E'L)ZH(O>\2BH6!84U<XRN@GOWH:9N"\^64O7X]5 /,%
MRUA/%DNG] #+;'PQ*J^*:2$^OM)LL0D_^ZHME?L6I?X%D_QL ZI/DN6NCN'5
MQG-@8$#&"$P2\DDYX;VN3^A\]M8/2]\J*L1KU^$-Y)WA4"E(%J^8R;0<CYUV
M[XU_]PE6BRP6W6&@Z\L/9$E4XEM 9@T0ZQK?G&,I>6KE[3T8[2"\,>B%-I7*
M1B4L.Z1>0F=EUEW^)K#/P<X'<QF4;NWH7_%:UIAJ+EYJ!T('V-XOW9/5=/I@
MMO"?5?\]?-#7],2/1YA,<QK:[8@++MO]393P0*ED.1?P"K_Q#HN>5RZ^,OJ_
M1MU1C>#G3.6W\E<UU@]_ VM,_>=RK#BE\W-._GY@Q ;C#"-J^5N[>UL[^P(-
MYKV#(P&?T7<'A_QC1UQ>W_PN>G@8VMIVW^0S^#&JQL5/_P]02P,$%     @
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MG&8DM9(0&#SQ,#4"Z^=E:8R&24OKXXYQ[EIAT#F>[&2-I1/QU+700')[XA'
MK^#2UY7@&#@8P\:+Q]1A]VN.A1F 79&]61GMD9DS!&Y<&Y9DEF##M6KV"X%>
M1B2ZJ6-,@:U@1\)%J6=9O"4Y88>M+;2@ZJY&MB-Y[I7@FXHU&E]Q@J@IFZI"
M5-2G34;CRKW@\$XU(GC=ZI2XEHOCBO.&;QX&<RJED3-]J1_[T9)2#4@J&=3\
MX/W;2_PX3V'^&3Z5[M9-B=G,6MG^EY[O]%4VU(4C$D_!%BG^I",I[T6$$PDK
M@?M3[1O=E$Z^ ,VA[)$G1<A(CQF3S;>( L5B1? =$CAXOA'9M6:K[#(Q#;K=
MA8^*>HI<+@UL(@FQQVIDUS1P3+S@J^"D-^6,HS('.NVC#(3POT7Y6970K>[M
M[0=IDB^RAN52H+/V HL;HF)MD+I;8D:W)QIW!S-:'X86&=)Z3 VF]!PL,H(6
M5S2DX:?#/L"^(/5I52-$(]'3C1BUTA/,/B,F_M#@V(G\<GPE3DP30$9FR-PN
M\.IU58\F@+PN_#$49$Q4#'OT'M"^6'-YC9"D+'":YA4$O6U1EYO1%@N%U8\D
MA&/G)@YS6*<D0(@- 93J<GQU9!#>JEC,CHQ.U50GUQ)6J )ZLWE-:0@&%SUF
MLG(O9, 2:GQP"7@W8,%)IGI '/!;4C:)NSN3EZ1;V:&EQP76VC2J6P%[:Y%_
M13M\D8@;A7M'>9UB\M2C H5[)S]7VC6UI0()#6=U/0.5&S=^4S;*K2EZ<!_S
M@05IVF,^\.Z3E2+]AXCTWJVZ$9@N49LW4UQ5NO9$UXZD)L-!:L?BT2"L*=39
M#KND/7'>.]@EG$<S:JMH)3;>P\DB>DJU;TR@0SWH,BW1J>:%DG!.N"2ERJ'J
MEU*S]:**=,G00Q' D?5"]OZOZXY6*#W$!$_1A.*&::3>,<W)>F GY_Z/ANXO
M*>5=Y22SIT3J*9*-U4R+(((QE_6Y 6DEW@ 5^C)#4C8+G)UJHD<:EIE;9*A*
M!5P:5"ICA=9=U726;Z>C/=4,5\6<L(.;5:Q-=3"HG:G:,)D$M"9&+$],$7=<
MRM>59\\((%$95DU581U82<$<5(1$64@%N0O>S1@!)^!D7[RB0I.C0/RD",89
M)!,0HAE9$_P,\YUAZ@O<K88NAX(S>?32!@2*BM::HDI% ,VEU**:!!F/MD4W
M07S!XA99[>YMG"G,/*8YA<LI59B)N5$NZ=9$<ESZ(L4-V$J4<8D5)FMIH/2\
MX'[CE%E-]8X\@W'RV2$X.%B@@E '*MA5EQBU CH-C(C_^91R8(=C,;R7U#J2
M96LL/ISAO-9Z-,N#ZQCV,-(/WET6FMW/E D^EAR1JH9U2Y1W>QJ7K5/>LCGX
MIN,( \Z!J-9\IJ57;=.G58.G\12UX<VFTTG:F#:[>IY61/JIE"*Z4PD##H;)
MYW@TM;7C/>/EN-B8ZR3P>2+-U /+];\53[!J06 6$'U6O]!4',>8B=!'(Z(\
M?E5#FY)&J1G4EIS!]I!<KS>@L1;3VRBSI.QY^N!J:;N'FYRU;U-,NPVPI/9H
MO+5U&*/!Z6 TZ%^Q[8,D6(/C_M4&QP_[J,83(0<,*RFT!T&^A>R'W6R^ZH"R
MSL#!/F0#&(L]S1)0&1TG:UD^081B,9.H$K13DT@4N;S=M=4)=DJ0'+[BT6:N
MLB%4+$=6#(/=6!['+E%8$@A&+#QTDT#5S<'@3>J9E$&Q@C8,TAD1:8 NS:5;
M2>JZ&%==L<C=^/B+0/M*6D_.VZ>%=VPL1WDL)9).KH1M+36G,3][EZI4[:-Z
MFU:D*6LVA@;VKG=XN7)9^D3J3&!*F0(;*T(^<MG5T7&--<;B:F^B?N.*(8^=
M4R[N&1-Z)$\*F@SMA*XI3&Z'%P<ORP$J:RS!^GC-=8*4/Y&X!I$GHHGD? E#
M(CT-4LSPY!,F$;I_N(?*GSAMPP&Q*B C0>2<3R2\*AM8$]]1]#OT=GI#('K"
M$BEJZ>MI0DMLL7# AY9 X9E%R!L9&/.T@1JG#%#G6Y='K6)I,O@AM4A20DY1
MH"YEIR"?TQZW\XJ$&)0^B_W)U*@S1\8@%;G02FA'=*X["OY'H<MX$E#<E!46
M9DOV8/LGJ?/AM]ZQDZ?(^42@(3A/>Z1PL/^$P(H'Y+<-U;UJM-*=05.ER$J%
M+EWA#>LCEU*./.;(-#OX8X[L[I-55U=B  UUEMXMTM(I@Q*-Q&[5OZ\7?H[D
MFD[CJ9>0);/N273T[$>5L0124"6B'(DL@!(-HZD&*-U:B6X8OSK<(0%S=X[2
MUTCPM)CQ'8P9KS 1BO>:!HCG=4)QC:QJ$V61P[U$!+>:2(4P]S)XW'I36>KZ
MNK=6"C#CR'FM$C1AW50U8]HE*,6U#^H':98G8S/@;+$/:FE78\&M\#.DW<(8
MQY!JH)#3I 'Q<.?B(D[WV(P]0:HP%BI0EJ<TAP2C5EB_%154BM'0)IMC^VW.
M3'H>_AEKJ'<.=SDJAMS;X((A2YI;PT YC1&A[NP<93/F!"^8U"9FOR]E\]]M
MA5P)%8(+%<EZ<=(LC2L3B&A[*205SQWV]BY3'L4,-DU53B.^XX0VPG29%*@\
MG\7V*CZ2K:Q4"RHA=&UDF6:Q88]]Q3YP[3Y8W*&D9@351S86!Y:&8DD):1F3
ME#",8<2=^T7-WU"R-UH.LI#R HW7=)($8Z.]&@9FR0KVQC$F8Q/,TDE+38/:
M536#O ]^GF* H+$CD!:4JJ;:&5EC*K]C\_LI#GG!<I8(!217)P&.C(I'W"T9
MU_B9K6M:'5ODWL@'KS8:&!J+,+[5  (+" ;2',2,'W <A(F8]):Q\?Q;U;VR
MVY[(_KI8XUEO<$XTB<?]S<<72Q1(TN!4"%V9D>8R>-;DC=EIY@LS8+TF?)%P
M"E] H^%A-^CL*MYK&<XE1[0J4=U.>:&TQ68)7BU-Y3:U9HFE_8&A+).*%8,T
M!0\<&1*:I*X4<I P"R&H@,.M7J$V$;9V(5^BGH^GU(1,#Q$CI:E1((B7RS!%
M.4FJK\$^7>&- =U=.1[F"!\+*OX!RUJ"M[!>9JW97HM?,B.)BC6I_E0I!G4T
M$0G+)+Q4 8#P(&C(1[J$S0^BWE27%070C&:JFW C05P C? $)[#Q,.2L;4B+
MQ1#= #7Q1>#/BHP;$)QJ4L&U'X"&N#DW*NZ65NYJ]!Y5B&]\Z4HWW6J K69)
MC&Z&YCS54B-8@7L8&E$3PTOMQ=.]13SY+#*Y237;PM@N0T5@5B$B^:W5#E"O
M<=<=H'C\^8EUAZ@F+[&BY5V064WN9(<[=4BT=8@19[3/D;@\GN1SS9^I$R@\
MH/*1W H+HT5=[M98&+VKJ\'[<VITUSL_85K>T6AP_G[SA4$53\E+L:67BQYW
M=DW%X+/E O&'$RH;A3.=S\?HPB0&*E')CFK<-LW'>ZGZ7;91)JQY&1A#U>(H
MH#@^<$V\M^C(3U'XH"=. 2X\ )*^)-65EF'P6>S23[>SF/-$E=X(-5$,H[AT
M*:M>I1<8>K?.CA%\,U2+%[4SR=>C=9NWHPO?;J%B0,#))G:IZK16T-)P',(D
MI]50IU()F"R &F/BJP9#A1:!4TR!UJ5A .:6F1N9EN#2M4 PB;=3J3,2I)6;
MXXB4?B:4,S$])VK+1(+VK*07GI3O.$XQ00-_*>[;P:;UY?HKFCN5S.%,IG')
MVJ:Q]2$%3G(3@4*::GO"O&UQ-![S)KIMW6/>Y.Z354NI4;1*Q=^X'# U6J4V
MI83)$Y"=64H9CATI&# IRJ3DTA;D;<[91[]L4-9 KREE?!/ VV>2O!1.')BW
M88Z>"'[\ET,7YDQ1*]2<,+J:WFB7P:2L2X52A'9,F,I"%"7-ZLK NEP_S@5(
MPS] *V6R4C]%UY+"_!(E4:I/, I.<72&1"NBU\3K6J9R+2?H5_L1<$$AX:7
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MV:.]<W^SNBX%2QL(HHK0>70$())TZ)I"%T\VAG*D45LNUR$Q17:N</K%V[$
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M72;SWW'L+^%_LVP>_OI_4$L#!!0    ( *Z!?51YF-E[>R\  &\9 0 9
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M5]\S[5=BVMMD62;/A>7.PIS33%5 ?!,8 3E!+A9Y]E'/@3:3I1CN[T2/1]M
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MT\_=(W@[F!8G67FERQFH(D8:PTBP@NHBHYF$G%#S)GP=_>+O&3&G3)? H+K
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M:Z9?&Q70,XOZM<.H.Q][)>P#@G^!M4[U7')L,T-!;DVGA2I)SL35Q(E2%BW
MN!-6:HO54!/-DN6P"!?TKC%S>HHI;3D!I5CL6[QPZL,!NF)0\Z(Z(X<4*P.J
MZ2H8"DS9K!(5@)YQ/0NE9Q<$"YCHHNQ$[@-I=]1130(W6@3"T8XK9QFK)+MJ
M?V /&A57*2(PHUQ2CI4/!-=0#*S+  2=SF*7.E?7(:\DB"8BF4L*<X]8*ZQ
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M/#",<RL 0C4P+8Z3/#</X1 4CB-^*7JXQBCD8H.CLK9E4&I,!F<9MP%@@LP
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MVU2]_:Y=+TZ7K6!'>F%&@@^/8>G3NJSO)JVS5W=5_0[%X[J%R9UBTE?0ZE&
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MY<MFR.BM-0!$AT"+@^!!(&89!B6&,D;,[> )!%&N, Q-JP*6%M%*0A'8A:0
M'SBS&0"&EPZK'P(+E"I+>08OY;,$X;M@?^2H >![/)64947;+)UO%21)6O6'
M7<!@H<:.#F(.(AR.M0S=(I6XK4YXYB,M1770JZN22+!0J@"V0N-..0P,FU*C
M!2T=XST8),:)DB&0I=EP0U3H5@3XC.UUCS:'6PXD[FQ@R9MRJS0B>>Y5S75?
MN'.E4CDY\DR\VM\@@??.Z%:66D#1[\ T,(^,X1SR@)YR-DR3SV@+Q-5A'/T.
MQ81'(YP(T#;Z-DLCE%+Y<"KU<0!V!T*$-(W*@PF OAC0G16@ NP(MJ0S]/!8
M:!EL*K))$F+$&0:D /[BT5-("K3K/M7#^J0L,INE![+L=);H),635$0<4SIJ
M67N%9Y:<K+O%)WP(2)EG]4\>2?33_YVDA2P:B^UA*OCG;3X":CWAT9POU,8W
M2R^L VU=?-"]_>[QWM?W0>]V#P[VOKJWN'?4W7]]V*9A'W-"?X/%?OF!/3CL
M87?OU3<X,1SV69[XJGY\^%?6CU?^:J,%VMM;/Q/TP83A[VN4M@LPU_V;P<79
MQ77_<E 'P_HY()K-[G>+KW;$1]^)#-<>IH\ ZJ^"6M>I1,N,3[]%3,LHAJ0W
M@C$*VJ\,&>[I]'L/\E?$X.<?W2K.XZ]"* ,L 5OO2-O*7_VKX$(_#%.AOE[<
MM2YK6@^"X]U==LO!D.=S]CZ5=^+;4$7KX?"U4>'K4-#7H.4U1,H;$<Z3)&1G
M$MWZ9WWV^F#W:']M^?6+RV"=8GK/*$M^<2BWM S8UJ+WUZ^">7#%OFT1<WOK
ML_L?;L[/?SV'[3TS[/.] ^_77HWPHY5F+W47?Z[N F"LZVT>+W$I8HB;]'*K
M =VJ,C4LGK*%D!WV19T&U@"W6]5H +-5J-0=4U_J 7K\=^S2@U]*ME]*MMM1
MLNT53IJ,JI* *]*&JMEG+XTTOM,)?8VB^I>JY3]_"F=\)C/0N?^-#)[R)^,$
MEC,3@1RAFR5:5&J!J\6^KK[7?%,I#<9,K7)ZY9/4YN,6F0,4]/UXSBZ^K)9V
MI6O_<'YY?M/_V'9;I=?MM;2?Q47L:X_ 9@9$)%@,M6).:O)R*1T2.*#75>!I
MN=#/Z0]PH2E:W%'JXXAR)_&K6&''HSA8L*'(YD)4")_LFTJV=&;A5^D> (-E
M:1*M,W]82P9!GIJKGY?X<V[;SCGV6LLYM-0S59.K91155U"M:( 2K9_0A:0J
MV:L$+D8CS)O&I']'XT4A\\-:><=7R)O;K)7R\KU>8<0$R[4 . /Q)_C1\>YE
M.>LSKJCFX<<?#EZ=@HV%O$C&.7!#,9U%R8*\-92<#P_A%*@XHYQ>CD_PC_YH
M)",)F]50A-V:)/,QQHKPISL>Z83WTO*>SCI61FA[+26T3[$209[":5VYR@H\
MG=73G6FK0Q0&&!45!0RD/AOCQ] "S!=CA91/(WW$54"5/:*'9%0O3YE+JXS'
M2=U *ME$FD 02:E& M<!K,'6%?$@RWD$I*"QW0AY:Y]1/8C[3,_JK#.DQ=P=
M0E'>8DG.56# X(3YFQ)&Q]*:: ML.# QM"4-KXX%P  KA13 054&6 ,:V6\I
MC51KIU=+%[>%KEK4V1R6<1S13&N&B(-$0T/8VA01/08"&0FIZT*(+P,BSCSM
ME\]F$5BO^!A+[*26;CBZ*;>B^CG]KJTO4@8TC_B.-E,L.<0/PF0>VT%B@65.
M0(X3K 0C^WYK#=#UH*7H>E:2W&5)NUK4O5BB5HRMMD?H5U),7+->W;OQH8K6
M5!"/'G' Z5$>$=:#3@4O(ILUFH=Z3/58 \0[;"GB_:P9"PBR#O,J\>D@SM ]
M&47ZAT^H,?MOP&G?ZO-9+8("FT*.2+6_MLR1;&N>+HHR8%<%W%C1"(K\O:WH
M+;@A?.7Z3319$IW"C&A2LIN!11JR06+48 176#^+?']9"T7MN# Z3V95%%<@
M367%N.78B!82$*2[+%G")N6AL(Q_1H#)& 8ITSBN#VN<(Z%])%9DZ)5@K6\2
M@/+S['DE*5E;6T;0D8C2U<YY!KB0&0?LD*"$>(EQS\P,)K0Y$6BLQ'\Y?<D3
M?YDW=8@V&*XJR;.JHE?>L"FH=XJ;JP<OSK7C$*:Q"#@6R+40Y^"UF4@57K51
MJ(R4?$3!%!PBX$H0&(?PF^=?!H08Y2F93Z3:*F*A1*Y=P,4O05$8TFH$?D&Q
MQ2GM_C:*AL&L JX$0#Q9$^HOLW$9 PZ MK_LN+U#U@A7FN8!IOV2P=42J774
M4JEU@37T<5 /@Q$S,;K_:L72\QRC$O869R?[1RL[[$V^Q?K8V &Y,1!UT9$"
M:"Y"20H&L^&QHR2*DKENR2'\?@7(6)=),?\*A\((VG=&T#!'CH+\2GO=@=K)
MO84.<WF?+=CFT>X6<*0%+(ZX"4D:.SEQJLV18='\+I&A19 PR8>9:941"A[B
MWC&S!GMQ4%B;Q-]T%BV*+N4FFJHFP#I)I&!04*1@J=O,!'$OIC/:!-GR=D<'
MNZ_[A14?BJVRET^SQ%!$ -2TR<NW:;2##"]LPG"$\-HT:(>&G6J_:[TD6\"#
MBZR46]V!8A/$)PJ2X<+.1X<44XN0:8)I0IA9CD%/=-XAZ BBYO.$OB1//1F+
MWB.,EB3)9WP(X@X/FP1;*+3L%6%%G"YI&K+%Q!_H@;$69:GK7CF\@WH;F1C4
MD(3L8Z-X>9+?1P50S;0KJG#A.#6BT)S(C@'(Q&4T:L94:Z[7-4X<!J @Q@EU
M@I%^[,B #)06+6>I_0=J;PUS]- ^K;7O,2-HS&D>0+<$$8'0S5'PT!#W^1/)
MV6B#M3XT[D!-(YAB+V#!8>>>8C4-;5TTQNBM-;##)]^AU0+6.-2LT7>3>&>V
M5S^S,KF[U '0<H&A8*J-U2^= Q/X4!Z036+[W&A]$RV$/W*9BGHJ&CZBAC"5
MMB]X/-,D1SCESI3&]C2V/0\LR2.;D4 M. (]-$/DQY5%28!TR>^%LM,334=\
M;MI0T2)%%-:<4<2[^#V-K"G MBYJL!669^DJ'>PMP]%0D/&W:L9M62F^%<-Q
M>SRM4+[)$:B1MX'E/J#61V)<4^+Q?6*+C_!$RX$JSO _,;&'33,N0V9#+=16
M2)^NR4;!GE@:XS0BH&B&7QXY:M^*,D%U<Y(8^IZ*AH@2'GT>$8 +EW9J-E=M
M9+1$,3!@D)Y.IX'ZW#Y#WU\_?M52_?BLB&7"2;[7-+(H(+OZ- Y#-H9\"<F<
MJ6LL8V84F!GVHDMR!5++,%#,W4)U,8^-^-&C >]%=TH..RV4F-(;OBL%QD8)
M!O^!CX*"R97B+[<>B3L)K#O.$0DB"<5@Z2L%I(Z[>(!O.4Z*=YCAJAC)V()_
ME?0Q5-+X9T$/'&>1\ "  0(Q\'A:,Q"=E@/+'<DHLLX/\C\LB74OTT36P,%Z
MW%)2O-%^'-#!B.?IB]-63W_F C??)>0C*_J-4DTGY*L<%=H*H28@UYT$(46=
M[K#V0!6;JT5!)79&U%T2K3,NDJ"YF*L0[Q*2$F9PI"CS5Q3ODK ]5*166SVC
MVAD/EVAH04-^8=5R]THSC=1$M*K1.\& V(3A)!7;!K\E30@6E2(&T!LTC@''
M)G=$6WP.LC9- (HHA[7.8 P:I/5J')@D/8AP%N9E)FBM1-#'/>HV7VVAI0*:
M/[9#)>)W#&S*0^.'=@!VRH112?%IX?4S&R/K"&RQD@%%/WJ&"B78$:A\KSHY
MXD.MG3@N<U#6G=<Z%6X=<^&N!K^<W[#KFZO?+FXOKBY;G_NVW]K<-\]PAB>K
M9^]E0[YBALZ2N78^N6ZT#R6YZ9^0D238D 896YI'QF-$K*RT]TZEQZUFT-JR
M*$4A:#;-+EQ>;::C!60<FFG=:!U=AH*,"A3"Q*A&Q7JZK(^&;6#47M"=S-SP
M:[7MKI8(7JA(:9YHF',9>L"Q*)>-@M2>%J@[_&*:ANX!W!@-[-2$!5V!1IR6
M5F6">10P4L2QI\(ZPNIK,2!_EZ SS"W%AIM .$32>&A3$\339U+:;+T1L=Y]
M>:--:29>T^%Z')72JUK/0=J:U$>:RB4H7P,CT_$<5\](/,UP6,NYM]6..M<^
M=NH('\H(O5S+;(M]GPG\^,/AZ]-O?2@TX@D5_@1/V+O55CJ@P\W%W6H5]@XS
M;;B!ZGS??UQV0W<*GQKR4T\?++$0+]O,F-GVU(QIZD<(KEWH8>#B$90765SH
M&#<Z?Y<=]AHPB+9F- [X/<,TL3S*6J)DE#J7>_WW7==X_P5J$)^/R%C!0G9%
MWD6-JG_D:!NII2YB1%9;E%V.>Y0$T:;UJEN?K.VT7A9E.BMMJ[Z'4O5EPQ8P
M6R+0)R",Y]NXN^W/W%9N^I^%L#Q%-QPHXTQ]R7QH>>;#4BRT&%9W5C<BF7F_
M 9>D3KR!HUWHL&Q)3[3J&Z*6OAIC#1AG6W-KWQGUO!6M/4JYX'CDA2?,(D%5
MB_*]79C8R"L7%9=X(!4JX#TQODVBA31>,6,FU>EJ3D' &UM K&/0*2,!WQ1^
MTO40P*95DAJWF\*K1)RS:H;H+93)^ET#A&UK3F[?N>R43KN]=97FYQA2;4'X
MIFR5HFPOTD6K24$.>;&6'LWU0*9!/D5E 84^"%69/7RQC$M$J,ML'GR.DWDD
MPK%_74U3D7#A"(5!DU '6JR#PK>.40L1*5U-1!%L5?5?-OA'_J1+<Y54T-8<
M/YW NF)<[V-:@:Z#T8D/.EVH*+WTJKM+2%&I6' 6--<=38ON0EZ.5& :>Y *
M*Y ">+JHA@+*%S(5%9VIC)$D(GA_1(F_-C#2L/R&)(CE"RQ16TV1*3(6J*14
M?XR5])&@+DAEQ<:]K0,*JLO>+3!W32]1+ZZFX!<V[U''Q81A!0OB#45V<2CT
M56J"PAHCJN4OEC2B?/O,EI.48<$S/6+IP!U(4(&'K5#P17\TQ]@QF=AWDC,Q
MY3*BU!WW\]!%<^%#>KP)QYFGL:Y4G&44#2;?WY;Q1I+N#F]ODB()_\I ]\;@
M-P::M\C(IE_- 5."'F@*P:3T:RK&><33"($CK:Y@W)J8;H&A\(P"S-<X0V23
MM=> 4;4UV:*)&FX\U0E,PQ67<(T:K>(B#.I*2TPZQ!B=\:E+.#7\*$\EZ7=]
MG:=&S*C(&-(I11&?DR>0QUYIO![05%K0>UIN:F9"?:3L/6;6KJK7C!$U@IHP
M*F6DE>+,> 5?GB+5VU3>RIB44$&_S5-T:\4E%9<" UIM,!0/-B"F=>B:#C]B
M6X\!VTIZU&',%89K0%)M39J@ZP!6K>;2&@@=G/)G>L6,=,L$D 22$FVII)OD
M;:KIB"X#3'57",Z&7$DM@"I1%SV,N6ZPJ49M#5#H=4M1Z$-R)U*ZY_(CGZ_>
M8-*,T3!B8I7P#]>P4ZL:8UJR]B^5$*6#/31D2'W7J]%6@;7A06&)>#TI[7S+
M=%3@RSP-*0/&O$D)OJ@-32D)9&CRZYTD,%IF1&D_B+LC8/^Z;0%N< W0M;?;
M4GP]HR+_J;D:UQ.W@+ZKYH1/L[F7I0^DHE)J0QNUY@5 !-\J1*WVJS=<X5M3
M0JPS]OP^F/ 8E&7[8W'3:;]04 ".C<7"L%SXB^'L9E&V?MB[[]@SD#0!HH+D
M%8I:CX.)4W2T4+ N#VZ[G7!5@4%UA8,26$I7M)9?;;J+N8!ZU7BQ+3R70;V\
M*%IS=67MI^W69@<A\+7GZ397,Q$KZW?R*F=73./+T6YIXH>)'V,+D$B7/2.3
MH#04BVZE$@7M=4/:4 0%\X)?WYWIL >9!&E#O]G&!!T_*68ML@DZJSQKXMA^
M:B:5\[M#&GKJ;NGPXT2?:MV#:L]3&9TV*Y>#-W(F$P-&5"$[L>0E1AR88ODG
M(!.;\X5+&Z8P R6?6@.NDNK@B:EU8%AM34:Z+0=Z^CK0LWHMQ!K<%'"@1=GT
M=+2[3=JX=5I4_;%8A1;IW!8L69IAY2.-02&OI3+TH<#9PP$QKXKD26E3KN%P
M4]I44>U;X\-.UC^4B*@3U25E[T]H+HKYB7O0J8")JI)E0?]NWMPZD%5;4W@^
MNEBO\K4KOP3X"'.NU,I=ADU-=1)3C57JJ&,TT*1*<.2I:TAZ4/5.:+!G,Y2O
MR)-Z&Y>4CU(.1C,%E#+3%NC\IWP8$".1!_L2@57\F*:N']V6V!NM7'+?O%2V
MZ2I<]&A63.(R;G"4WM%P>[_ITRUM/Z'A8-R:.NSK<JO+B=.DEY=7^$R+X6L;
M"4LA]]+>I>U)3L HVYJR@WG0'+,=,VQ3X/<4NA&Z'YF:R-G*6>3$U+77$^+]
MOL&NW3>*>!+-9;&\*+H V#Z\90=R;+KR"E%4:=FFO$97KQ;=V0"-T8R\)KW6
M"XWA4=?BUVHDEA]:G9NYJK^GCF_;K-MJOE38SL;B'D,M6,6+$1?8&[;V2BC7
M8P+T($R[@Z)-ATV"TRW28%R>J83,)[=N:Q<$/%<F9N1Z!C[0_M@S,]=!G6EK
MGM(Y("N<;TORZ@8E3:'6\;N:*^R);*!.TT1-V<1-4E^PAE(':&26F[PFH??,
M"V(O)[_A5"K'@ARA*VHR5+3-9]G".#;1@B5 ZA9\1L&V8];*/QNZT366YUCM
M!VSGS)@3V*^F_1C>UAPDOZO3JK';]4 RJ<,5G[I%4M.Y*DYB;*ZD$U!T[RH1
M4ILK$2O:IVUDA8AD.W+KJVVTO&WN9\4VLV0L2 2Y!/CW K'?4L/ ]F#0J2A%
MP9U7](:1+504Q[EITV5JJS.7D^!5C3<4C7NE?]XD1>MY.ZR.96DWI9FB:'9$
MA<O6I&[W]4DM0</B%J5?C".S6H3TF*'8P)R;34??$USW^%8[4WD=PFP#M4H;
M["V+!@T&*(*UTS!+I6Q6ZT'->:HZ:PN1E !0:LL?@BZ7&.T&FUE-8SE:5!L!
M>7 C^Y^TGQ&7D7$^T2!;E3I<9V@6?8V>#&.<DT8RLR81=HK2E I'%X@PIRYR
MGIQTLW66OFZD4I8F7.?^Z"R@+=W,RO8ST5.:4EW7%'7I$5-6Q;)4G)';&QV_
MR0_4&7[:(BTZ$U6LZ3*/2YOZ ):,\LHGZR!8VYHS][%4]="804<&Q(JOD;'K
MLGGASJ;3UIQR=U 4=A584LH@./6NY,JZ=6U8Q0ISIT("#]&F&:41F>"SOIW"
MOULB=HIF33\D^M>]OI2[=()44;\!D<DUTAU^:5(B:P:_J0P,6DL[=I.QX4M>
M3Q78PSCETXXV%$-C_XEHI&].U8O!FRSJ60,>-Z6-.I:J=&\3>Q-&<;$&+#&4
M65*S;:F<I6S5UMK0&5CH(4SG:..\=Q"R2GZGN=:=K@#QVM' 68_II,S)%C+!
MNX#$K+/H2$L98 _LK3JUF59S5DHHMN?IM8)^)N-YN,OB4[N3/#S*BU.OI4U>
MSO_QR\6[BP%[]R4(@"4SH*VL2( 1GRS?+>'?D*),(V+UXP^'QZ=MWE[SR?@-
M$>U]-47GOB?O9X91CGB\'8E15NN.M-H#)(/A:)5651DX!TCCN*S7O=,!J8C%
M):ZH2 J\HM?>!:M3N>#=_:?CULM9O)S%RUD\A>>6^M[O[>D%K$;*E**=H-B!
MH'$W8Q17UE5;G.A<))>BRH<)7O!A^XU[?:+L329,3J>@]($"B1? E5KH@P&;
MHHX:8X]"Y57]A293G$#^Y'ZX[1%Q_2( ?^U@U>9M-*/(@QW?GZ=]O'"EYW&E
M!P-05.@(O$F*NY5'H @-V(LX6P?$.=,).,#5*<<@B5X0YP5QGH(XETF\?79Q
MMDV.#1%64YW5ZB_$^]K8U Z_SLXP"1?PQR2;1F__'U!+ P04    " "N@7U4
MQ"Q*K2\G   N[P  &    &%D=FTM,C R,3$R,S%X97AX,3 Y+FAT;>U=6W/;
M1K)^/[\"QZE-Q"J($B79EF2OJV1)2;1ERRE+6>]YVAH"0W)B$& P@"CFUY^^
MS P&%TJR8X=DK#S$(@G,M:?[Z^N\_-^S=Z?7__?+>3 IIDGPRZ^OWUR<!D^V
M=W8^[)_N[)Q=GP4_7[]]$QST=P?!=2Y2K0J5I2+9V3F_?!(\F13%['AG9SZ?
M]^?[_2P?[UR_W\&F#G:2+-.R'Q?QDU<O\1OXOQ3QJ_]Y^;_;V\%9%I53F19!
ME$M1R#@HM4K'P8=8ZH_!]K9YZC2;+7(UGA3!WN[>7O ARS^J&\&_%ZI(Y"O;
MSLL=_OQRASIY.<SBQ:N7L;H)5/S/)^IP)(=[^WN#Y_&^.-@].A+/1+1[&#_?
MBP[%<._I\__N[\,H=^!Y?DD7BT3^\\E4I=L3B0,X?GHP*U[,55Q,C@>[N_]X
M0L^]>CG*T@)ZR^%E_I/;:+<D\C$T5F2SX\$>M%3(VV);)&J<'M,$GW!3]O$H
M2[+\^+M=^N\%_K(]$E.5+(Y_N%93J8-+.0_>9U.1_A!JV)1M+7,UX@>U^D-R
M)_1QSN-_#NTD*I5V/H,]G,3Y?WZ^>'UQ'0QV^T?U&3QL[!$LO<R?+%V'SVCE
MKUZ"D[-_G[__]6WP^N+=]?GISY?OWKS[Z>+\*@PN+D_[&S>;TY]/+G\ZA[$'
MI^\NK]^_>Q.<7)X%5^<PQY/+T_/@Y*?WY^=OSR^O/VUF*HUA5L?[SV9?GU(/
M.B=V/5$Z.)V(="P#E0)G2(L\2P*1QL&5O)' F2(9G(QS*8FM;!43&7S_W>'>
MWNX+]RU]'KSH!=#45,22WJ;= @:DTB(+A@OZ;BB+N90I-' T>/'?KO_@E_T7
MP9;IX?Q61F6A;J3K 5LYB6%<Y31XK;)"1I,45FJLI ;*2J-^;82GV70FTH5]
M.PSD:"0C;# 0.LA& 3Z; )_411##/X&613#*\F*"(\8?-5">*,I<NL=G(B^@
MMV "L\.9R22;USH]=WV<09.V[\TC^??GIQ?7)V^N-HVB3]Q2__6]OYB). :!
MNYW(47&\=]#?/\!UN"CP:,C;&1 &'(EB(@JB)4.?P2C/ID$!PPB HNC?N4J2
M(,H %L0R9[K+M%9#E:AB@:0HTD!$OY>*<0,?L R>R^$M;C3+ _.%.]T1G^Y^
M$%Q#BZ\SD<?8UIG*86!9[FC<CLLG:WK:G4-X(1NGL"Z:9Z/+:.+&*VA(<,+F
M$F8A])+QJ_0F2\JT$#F<-9D#*. 78># .,J(/L"HX?#-L&7S<@2O#N$ !['2
M12[X,5@WQRR(2>!3D2BU]+Z'A]R2B@2ZQ [A>SF=)=F"^%LVF\'Q+U.%9[RV
M3A.81RQYG'8/%>TK#!$G.$0NHHCKZ:*UE#@F!5_K(HL^3K($QJ!Q0$)KX"YM
MDB "F @<-7R+&Z?2$OJ-9:PBL\#09#;\C9B-654WUS  :IBK8J(+> PA8&,/
M0O@"(2*12125>2Z1TT,;M)6P>L#]T^(3V=;J3__K]3G]3W$1*@("2:%@3?47
M(YU9GMT +7L$CAO.)PLE1T7R1#M!39H.GK_0/N%C)_#P-(,'4!+63LU4W*HI
M+ ,-ZT8DI6R.L9PA078 B2TZ-B,Z,R0K>RA@S:Q3^*' IIK3VSBR.]TLLIO.
MB$OS[BZA(^W@G]DHS;L<R;P02+@5R]8UWN/("V9SHR(6:AZMT$!D.J&VVV\!
MK< O2B3P/O EY&Q(G':4%6TSRHRR,A=C1J<U*0 ?<CG%D=)T_!'<PQLWGPN>
MK0\Y6@QT:L@F$C-5 +S] X4HD!!0E28U 78!2+-2-02(1<LYX-<KR9+^.;.1
MC=N2Z[;N('"NB(]&60)3TM]_]_3PQ:;-:[ ^I/;<KDH,Z)11Z'$)"Y3C>[ #
M0&UXM!V)K6[@3UX1MJS1NYX(@'Q#&#K@_RY%M:Y8LL0V/%@R:\:G2(\E%HO-
M94-0)"L>W:' $G-$B UM,Z>NC8H@Z!"5=@W-Z)&2\<8=O;V-(=&38OL# O]S
M!\Q63J-U'.HI6=''-)LG,AX;<KL37@)-X>M,XPZ1DOW$*I@"1@-S#XV.&7C
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MK,%^O+WO:@G(VO[1_NIJ;QLP >M= GH@;9U#_&'%G^[^PSY79(7 4EW3(6W
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MC.I85:6K\[YJY,%H"[%U'MSWQMH'Q%]=(AV7(#\QXQ)C/.%_EKKAVZHD#2*
M5#8NX9H*E9 C7XG@1ZX  Z>%1+)?Z@KUUI0RJJ*LS+' I3--!1?U5"5WUD)J
M'#I.S;*X*<#.8@>R4=2OLSC>!*N]F!?89.J+<DS(PLA 90I7^M4N+MHI5"YJ
M_D$CHU(FQN9,Y?SBWTN!%ROHT&UQJP6&:I5Y"C,(4RO\L,4WQ&W.).8/TH7%
MG^=-7^7=]+OKPQ<&]WI11@K7"^"MB_"XS-+M*[J"L5B];6CCL-!FJ8"U[5^]
M>* J<8AF@+M/LQAO8R$X@0P;N"^6/,Q4W(@A$PGRG$Z/A=R6MXI+E'")N8A2
M9'W]!?0!9(W%Q&HRYS8K:%D2*/*VB_3&L*T3C39PDDU>=J@M,W=?'JDK0%=+
M-AC*8BYK921MH,2?"F-Y5!$>J")0L;Z19$<()7N\-KKDBH\(&KJ!GET.2IOF
MN\P"#\AG]HOW5OXQ2A'P0BD0'V$U(LI*N,M+M;PX=SWK8&GVFV;Y0ZE")>;,
MPO=YJ0IV;"/(HEJDY$ W:=XVH2)T>7WTMBWI[1@ )Y!3*%^"EIUFJ"DF:F#V
MA&F%0"A=<FMN-8_;Z3\&=5&D";;FS1Y.<R)MJ1H_>->6H@T0WU)-\;SAW62O
M 8P3\_&:??9]YH"[R)GWT-U4?(294T*IGO!4+< F#$F.91RI*4);16V:B &3
MAHP_<58J[%DYI2]B"92-2M["A-EA9<PQ>3PE<)Z/.J3>J&9:EE=YJP3K(\3(
M'7'S166JD7Q+EY=E:?>2TIYIIPVZ=(P=/\SRC,KY4<'\4A< BED/Q?J-DE/.
ML%85I=N@UY$T#P$J:J1,?)G*8ZY9 8KHTK4M=;<K?MGY\JL$=,8_W'LPR1:Y
MY)!0\D!>S@I6K\M\R \8YK7\OFV?LG25/6=7#J0LG!D\278!T58:R53C=W8E
M0^\,W7723,$O:XS#-4ZQ13;<F2(6P*M&0N7)HH/0'[UME0QXMF'>ML?J%@^\
M':[,;]0-!P3]XJK:KX$YLGG+LF?U'NP:J*!I\++M:L\[;ISP2NK>Z8=O"UG?
MRH-UA1<U.V;AKD3@RO"*RIMZ19(H\Q610^'BU@A(_5;F2L?*!:F1;X%J_'($
M&H$5=[M0R_8/JX"A+[?D\."K%^*RBL+343:3+F'?E=JAK\K4GT"%UA(Q-ZLM
M"AY*:*:#O[H"1>X.#Y9:YG$3E^/&:ZK^&FV*S%RVK()Q3?":4.J2N36COK!L
MJ)F*6S4%&&!\1C-<UL*K[XJEY&MCWCAS[F"P,7:;,T!>&+7V7MH\AU6SB@QH
M1I<V.PY:3_C$XK7KV113LI$JO:2,F*=@R%90Q!QG%:0VA9DY0-U-N%0E-OY2
M=V:M!=+V$V*BD9HRP(PPC$=S-5/6Z:%_+DB632OLS1E]'*I&!X+'P+6B0NL3
M%:8"%P&O62X+C]\M&?P//JL+[PM3:CSMF" MZ$UE2T6FB&7"NXXH'D_XI[M"
MLC,"P3H,E:DZ$S+'-%F>]@=&@,&52(.W<,@S6/XRQ=S,4T!'L!JI$J&M9<8]
M_ZN,N;C(2=4V=?R6$N$4709$QG+8FXLTZJ/U9/_@:R?K4XO'JH!A1S4:?]Y)
MX_\Z>7NURC-&2]+SA(0G1W%LONC,RP25F-?F3#@R5MK?7Q3MD019A5<'9+XQ
MH76TYL**=U>7TM">]<1/[#D+JA)&!1=66Z"$)=7EMS(>TTGQ_(5T>0,.1")!
M]KF"NJ,UIO6J+J$K^BK*8F+*$Q@= F@WQEN."BZ!B!Z9A;DE0398#]>WX.&:
MD BJAFR%9X*%Y$!SXT"(RM XE*TSY14ZIN*!6I<82VRC=/WE!DY.0"KDJK8<
MR%#4IHL'76MS%$=\1G6MC'F6&O>95Q/* BNZ/;!S <EUPROVA_3F:Y,(T*V,
M7C.'(KR+">H70[G8$/\J&RWE1W/5KH57&,;048P?;Y/"?Y%B?ZBMS@BU;,SO
M)B#EYL278Q%>PY;I*:^*JA^DHNH;RT4V8,UCUKV;@[/6YG9]8:498YD@:JRB
M@5^;;.ZE2\.B8UB81&^5_E:F;)$P%$72S4 MVRA>6XXV%#S&5&9Q)JL(]FK3
M;<DW+F%4+=N]D>_+SS0ETKOSU'FNF9J-H0?7E"Y9P[5)L,P(6M)=V4L3E@"G
MXI3F*"Q:UH449#STA[UQT'!O8Z#A6V!^6*X]E5FIUT67W#AWQ29Y\?SLVA6K
M 9^9^+Z/!KS'8I-[1_W!T=U[_1/7BURUMC>1M;M1JNL<NJ-93:$;*U'Q+DHU
M8G3&-XL2KOG4VT5#(]-J?=GJV!&GA%3*$:>B>=I1IC5=Z"HX$])WJQ549JLR
M?85^Y*QY'ST".C/C#YO#V+)W5,?NP@7OEK]>QS )HI@X75,#>HJV=V.?7YI"
MWQB51/A$M>8!Y*&S'& QAK7RO4_41./BIT:#G\>K5WV&U^@0/^T?/KN/82/D
M8]B+-&_4W]6'7S1O[:N.0/.BOC9LQDO)+%XW,7BQO<;#3Q+VKVI;2M1.:['7
MP_B7+;GBLON(30^69^TN]T)WEK;0C6TQ(7Q^:8NNC,I/K751A;;1%2Q=E2\J
M%^48$Q30OM1=#,,%FBPA*1=> BV&I%O-*-S?)8G6><& KF&F7.4.ZU6E@/ N
MUY*L\7K2L*,RNW_5L'4.1[*ZR0ZO]4HX(T'=%DK"&F\]VUV_^I+;!_V]N^I+
M%I-5'M]>(VRU(\:]FT#NPFS?H'OU^?J[5U>T,IB4Y9WE"OYYUI@JX)HNZ*L%
M+\=<'M@>] 6><J9:$U[D%T;[#$+V+D5%9@DP*.9::'P[JB]1FI>EFUL!'_G/
M"OB/DXI5A41'66[+B)I\J=4"'QL*6M<(M>[UG]Y3->!J)B-V(=L(V4T'K,K/
MH:)@ 2X44X_F\^+SEB!$<QML!23=2MGH-8LAFP40?;"(T&NOM_6::X/[:FY=
MQ8N!+2S,C4O(VBR2Y/+Z[I)D+_6+JFLVKH6EH 5KP^_.']6>;3WE&RD]K1*7
M>J*&"@%I[8KNMGJY?&9<QK,:=)MON"G4T:97Y*2:4OUR89%CY!I5U!4]LX#-
M8!3@^<#N>]M4X\M*HBDA<K^@CW\]\<-9&Y:Z'?9J#7040)*BF  Q_VHOI^5"
M+"Y<KLY7NV?AN0))TUBZ]K::OG'%,)MU6EKK0ML.M: N1LEFD933&6SDM+87
M)@,H770Q]KB4W217;UUHS_?F=IRS S:3X:]/D<V]_7M-C1<>VC,71NL5>D&>
MO J"<_19=:!09R;HI"IK:[-5:*D,K&'E3A.]DS5OO'ULC0CO6?_IO0G:=%%[
M\%ZJZ1!X$D>0K]KD79/!7F2@/\9.<U6',=PS@16M&,N[S-T+&Z+0V6M=&"X?
MPAVZ4)H%256Q[0S4J.D0/NT/[$@:J1_N*V4OGC<BBG80TRA42B7%XK#AT#?/
MZ&HR##-2TV E[P7?K.*]#CK/F&SW(PK5\A;#!7"60XTWT,,WV%I8O^N]?<UJ
MO9'E;,3@#V\#&T5$I+T+B1-=:K==;YX;=*.RMCY@E%*^<J7$TT':51PJG=;$
MXX8<7!6;, L@GGQ,B-Q5&>0G(Q.31T_GM:<1J5.@E[TONY87K\8F^+D>"D(7
MPOE!02:[IE5XWRN YEKH\43-6* I$QN#ANV%U47<C9ID%C8AUXD2-J>.^5E5
M51#E[QTK9\*,,Z\CMYCDOXLI?U*X%3*7))H: ]V]N.E2.9PE3Q&K-\L U+)Y
MIWB3$B$^3/ 28[?MJY;Z'46*WN&5CL$;611RJ5RY__[8ZIH0#B\N5&[@:W4]
M2#V\'Q4?U./1#06OSCP 8<71%*LID*E"$OG'5>HTZWRD((L\1PE5>>]KW:)
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M%EJ+I'.""5G#Q<D/B_@E9M$2)?F=2C\J?IL\+=M+!@MGM-WK%9:-L5*8K,#
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MJM#[M^Q[X=G[O6!S+;]>V.\H9_\ 4$L! A0#%     @ KH%]5)KW0(B'90,
M_RH< !$              ( !     &%D=FTM,C R,3$R,S$N:'1M4$L! A0#
M%     @ KH%]5!*-F>A^#@  B(H  !$              ( !MF4# &%D=FTM
M,C R,3$R,S$N>'-D4$L! A0#%     @ KH%]5%T2532J(   DD$! !4
M         ( !8W0# &%D=FTM,C R,3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M *Z!?52 +P/D C,  $PS @ 5              "  4"5 P!A9'9M+3(P,C$Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " "N@7U4)R]#^$PR 0!4,@$ %
M        @ %UR , 861V;2TR,#(Q,3(S,5]G,2YG:6902P$"% ,4    " "N
M@7U4@T8.;G$. @!9#@( %               @ 'S^@0 861V;2TR,#(Q,3(S
M,5]G,BYG:6902P$"% ,4    " "N@7U4<SFK3R<7 0 O%P$ %
M    @ &6"0< 861V;2TR,#(Q,3(S,5]G,RYG:6902P$"% ,4    " "N@7U4
MTD?D*UC4  !9!@D %0              @ 'O( @ 861V;2TR,#(Q,3(S,5]L
M86(N>&UL4$L! A0#%     @ KH%]5,,A(QRY=   1&\% !4
M ( !>O4( &%D=FTM,C R,3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( *Z!?53:
MYU"*BA4  #Z:   8              "  69J"0!A9'9M+3(P,C$Q,C,Q>&5X
M,3 T8RYH=&U02P$"% ,4    " "N@7U4*T.RQ^P<  "R@@  &0
M    @ $F@ D 861V;2TR,#(Q,3(S,7AE>'@Q,#$Y+FAT;5!+ 0(4 Q0    (
M *Z!?52-LCS:-1T  *:(   9              "  4F="0!A9'9M+3(P,C$Q
M,C,Q>&5X>#$P,C N:'1M4$L! A0#%     @ KH%]5-(0))[,'@  0)0  !D
M             ( !M;H) &%D=FTM,C R,3$R,S%X97AX,3 R,2YH=&U02P$"
M% ,4    " "N@7U415]B-'T?   >E0  &0              @ &XV0D 861V
M;2TR,#(Q,3(S,7AE>'@Q,#(R+FAT;5!+ 0(4 Q0    ( *Z!?51,:SYQ/#L
M #V@ 0 9              "  6SY"0!A9'9M+3(P,C$Q,C,Q>&5X>#$P-&0N
M:'1M4$L! A0#%     @ KH%]5'F8V7M[+P  ;QD! !D              ( !
MWS0* &%D=FTM,C R,3$R,S%X97AX,3 U8BYH=&U02P$"% ,4    " "N@7U4
MMQ]:2,L<  #ZT   &0              @ &19 H 861V;2TR,#(Q,3(S,7AE
M>'@Q,#AE+FAT;5!+ 0(4 Q0    ( *Z!?53$+$JM+R<  "[O   8
M      "  9.!"@!A9'9M+3(P,C$Q,C,Q>&5X>#$P.2YH=&U02P$"% ,4
M" "N@7U4!1=;4!X#  "K#P  &               @ 'XJ H 861V;2TR,#(Q
M,3(S,7AE>'@R,3$N:'1M4$L! A0#%     @ KH%]5 ^VBV # P  % @  !@
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;,BYH=&U02P4&     !@ & !Q!@  ,,L*

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
